-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NLOFf1T1kLYxF1dwA0f3hEmT6yf+t+kd49HKRhL9Gw9z9fM7U0W8QTTQhmCgAxpW
 Fhh80J1zpsZRr3obDhRchg==

<SEC-DOCUMENT>0001193125-05-160978.txt : 20050808
<SEC-HEADER>0001193125-05-160978.hdr.sgml : 20050808
<ACCEPTANCE-DATETIME>20050808173833
ACCESSION NUMBER:		0001193125-05-160978
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20050630
FILED AS OF DATE:		20050808
DATE AS OF CHANGE:		20050808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NUVELO INC
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		051006871

	BUSINESS ADDRESS:	
		STREET 1:		675 ALMANOR AVE
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94085
		BUSINESS PHONE:		4082154000

	MAIL ADDRESS:	
		STREET 1:		675 ALMANOR AVE
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94085

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="21%" SIZE="1" NOSHADE
COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 10-Q </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="21%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>(Mark One) </B></FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="96%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="3"><B><FONT FACE="WINGDINGS">&#120;</FONT><B></B></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="3"><B>QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2005</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>OR</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="3"><B></B></FONT><FONT FACE="WINGDINGS" SIZE="3" COLOR="#000000"><B>&#168;</B></FONT><FONT FACE="Times New Roman" SIZE="3"><B><B></B></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="3"><B>TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>FOR THE TRANSITION PERIOD FROM <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> TO
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Commission File
Number 000-22873 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="21%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>NUVELO, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact Name of
Registrant as Specified in Its Charter) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="21%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>DELAWARE</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or Other Jurisdiction of<BR>Incorporation or Organization)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(I.R.S. Employer<BR>Identification Number)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>675 ALMANOR AVENUE,
SUNNYVALE, CA 94085 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices, including Zip Code) </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>408-215-4000 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Registrant&#146;s Telephone Number, including Area Code) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="21%" SIZE="1" NOSHADE
COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Indicate by check mark whether the registrant: (1) has
filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT
FACE="Times New Roman" SIZE="2"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Indicate by check mark
whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</FONT><FONT FACE="WINGDINGS" SIZE="2"
COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Indicate the number of shares outstanding of each of the issuer&#146;s classes of common stock, as of the latest practicable date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Class</B></FONT></P><HR WIDTH="23" SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Number of Shares Outstanding</B></FONT></P><HR WIDTH="132" SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Common Stock $0.001 par value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">On July 31, 2005: 42,126,540</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left">

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="toc"></A>NUVELO, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>FORM 10-Q </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>FOR THE QUARTER ENDED JUNE 30, 2005 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>PAGE</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Part&nbsp;I</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Financial Information</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx17073_1">Item 1. Condensed Consolidated Financial Statements (unaudited)</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx17073_2">Condensed Consolidated Balance Sheets as of June 30, 2005 and December 31, 2004</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx17073_3">Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2005 and 2004</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx17073_4">Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2005 and 2004</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx17073_5">Notes to Condensed Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx17073_6">Item 2. Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx17073_7">Item 3. Quantitative and Qualitative Disclosures about Market Risk</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx17073_8">Item 4. Controls and Procedures</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Part&nbsp;II</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other Information</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx17073_9">Item 1. Legal Proceeding</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">33</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx17073_10">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">33</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx17073_11">Item 3. Defaults Upon Senior Securities</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">33</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx17073_12">Item 4. Submission of Matters to a Vote of Security Holders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">33</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx17073_13">Item 5. Other Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">33</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx17073_14">Item 6. Exhibits</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">34</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx17073_15">Signature </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">36</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PART I. FINANCIAL
INFORMATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx17073_1"></A>ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx17073_2"></A>NUVELO, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(unaudited) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>June 30,<BR>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ASSETS</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">47,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16,811</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">43,968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">33,814</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">271</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Clinical trial supplies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,228</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,637</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,678</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Total Current Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">105,870</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">65,995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Equipment, leasehold improvements and capitalized software, at cost</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">29,216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,866</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accumulated depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(19,014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(19,818</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Equipment, leasehold improvements and capitalized software, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,671</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,671</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Patents, licenses and other assets, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Total Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">123,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">79,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accrued employee liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,044</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,337</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accrued clinical trial and drug manufacturing costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,524</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Deferred rent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16,381</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accrued interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,725</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,341</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Current portion of bank loans</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">693</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Current portion of capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Current portion of related party line of credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">204</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Total Current Liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">30,396</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">22,613</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Non-current portion of bank loans</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,262</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,907</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Non-current portion of notes payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Non-current portion of capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Non-current portion of related party line of credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,042</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other non-current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">336</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Total Liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">40,677</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">33,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Stockholders&#146; equity:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding as of June 30, 2005 and December 31,
2004</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Common stock, par value $0.001; 100,000,000 shares authorized; 42,049,297 and 32,228,732 issued and outstanding as of June 30, 2005 and
December 31, 2004, respectively</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">370,827</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">301,811</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accumulated other comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(206</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(287,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(256,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Total stockholders&#146; equity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">83,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">45,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Total liabilities and stockholders&#146; equity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">123,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">79,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">See accompanying notes
to condensed consolidated financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx17073_3"></A>NUVELO, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(unaudited) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>June 30,</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended<BR>June 30,</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(in thousands, except per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Contract revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">239</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14,486</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8,701</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,543</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,074</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,964</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,640</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Loss (gain) on sale or disposal of assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17,636</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">32,530</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,690</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(17,439</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(10,629</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(32,291</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(27,592</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Interest expense &#151; related party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Interest expense &#151; other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(271</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(531</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other income (expense), net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(911</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Loss from continuing operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(17,007</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(10,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(31,669</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(27,810</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Loss from discontinued operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(317</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(17,007</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(10,960</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(31,669</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(28,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Basic and diluted net loss per share:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Continuing operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Discontinued operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.03</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total basic and diluted net loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Weighted average shares used in computing basic and diluted net loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">42,027</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31,870</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">40,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">29,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">See accompanying notes
to condensed consolidated financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx17073_4"></A>NUVELO, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(unaudited) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended<BR>June 30,</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>NET CASH USED IN OPERATING ACTIVITIES</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(25,955</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(21,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash flows from investing activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Sales or maturities of short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,972</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">19,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Purchases of short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(38,031</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(59,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Purchases of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(407</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Proceeds from sale of assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>NET CASH USED IN INVESTING ACTIVITIES</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(10,452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(40,353</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash flows from financing activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Proceeds from bank loans</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Payments on bank loans</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(298</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Payments on capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,056</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Payments on related party line of credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Proceeds from issuance of common stock from public offerings, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">68,448</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">69,455</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Proceeds from issuance of common stock upon the exercise of options, warrants and under the employee stock purchase plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>NET CASH PROVIDED BY FINANCING ACTIVITIES</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">67,526</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">67,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31,119</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash and cash equivalents at beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16,811</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash and cash equivalents at end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">47,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">19,267</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Supplemental disclosures of cash flow information:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Interest paid</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">132</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">242</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Income taxes paid</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"> 6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Supplemental schedule of non-cash investing activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Acquisition of leasehold improvements under tenant improvement allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,787</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Capitalization of estimated future building restoration costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">336</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">See accompanying notes
to condensed consolidated financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx17073_5"></A>NUVELO, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>June 30, 2005 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(Unaudited)
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>1. Basis of Presentation and Significant Accounting Policies
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Basis of Presentation </I></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The accompanying unaudited condensed consolidated financial statements have been prepared by
Nuvelo, Inc. (&#147;Nuvelo,&#148; or the &#147;Company&#148;) in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (GAAP) for complete financial statements. The accompanying financial
information is unaudited, but includes all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The condensed consolidated balance sheet as of December 31, 2004 is derived from the Company&#146;s audited financial statements. Certain prior period amounts have been reclassified to conform to the current period&#146;s presentation. The results
of operations for the interim period shown herein are not necessarily indicative of operating results expected for the entire year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The unaudited condensed consolidated financial statements include the accounts of Nuvelo, Inc., Hyseq Diagnostics, Inc. and Callida Genomics, Inc. (Callida), through its
disposal on December 3, 2004. The results of operations of Callida have been reclassified to discontinued operations for all periods presented. All significant inter-company transactions and accounts have been eliminated on consolidation.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Use of Estimates </I></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Conformity with GAAP requires the use of estimates and assumptions that affect the reported
amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical
experience and on assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for the judgments made about the carrying values of assets and liabilities that are not readily apparent from other
sources. Future results may differ from these estimates. The Company believes significant judgment is involved in evaluating if there continues to be alternative future use for clinical drug material, and in estimating goodwill and long-lived asset
impairment, clinical trial accruals and stock-based compensation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B><I>Liquidity </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">To date, the Company&#146;s primary sources
of liquidity have been cash from financing activities, collaboration receipts and the merger with Variagenics in January 2003. The Company plans to continue to raise funds through additional public and/or private offerings and collaboration
activities in the future. The primary use of capital resources has been to fund operating activities, including research and clinical development expenses, license payments and spending on capital items. In the event that the Company is unable to
raise additional funds through financing activities, the Company will have to reduce its operating costs and delay its research and development programs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Significant Accounting Policies </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">During interim periods, the Company has followed the accounting policies described in its Form 10-K for the fiscal year ended December 31, 2004. An additional policy
regarding foreign currency transactions and contracts was approved during the second quarter of 2005 and will be implemented in the third quarter of 2005, a summary of which is as detailed hereunder. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Foreign Currency Transactions and Contracts </I></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Company has authorized the use of foreign exchange forward contracts, and similar
instruments, to mitigate the currency risk associated with the acquisition of goods and services under agreements with vendors that are denominated in foreign currency. These contracts may be designated and documented as cash flow hedges under
Statement of Financial Accounting Standards No. 133, <I>&#147;</I><I>Accounting for Derivative Instruments and Hedging Activities&#148;</I> (SFAS 133) at hedge inception, and will be evaluated for effectiveness at least quarterly. The Company will
only hedge exposures that can be confidently identified and quantified, and will not enter into speculative foreign currency transactions. All contracts will have maturities of one year or less. In accordance with SFAS 133, all derivatives, such as
foreign currency forward contracts, will be recognized as either assets or liabilities in the balance sheet and measured at fair value. The hedges are designed to match the critical terms of the foreign currency-denominated purchases at inception,
and effectiveness will be calculated by comparing the change in fair value of the hedge contract (on a spot-to-spot basis) to the change in fair value of the underlying hedged item (also on a spot-to-spot basis). The effective component of the hedge
gains and losses will be recorded in other comprehensive income (loss) within stockholders&#146; equity in the balance sheet, and recognized in the income statement when the transaction being hedged occurs. Any hedge ineffectiveness will be
recognized immediately as a general and administrative expense. As of June 30, 2005, the Company had not entered into any foreign exchange forward contracts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Recent Accounting Pronouncements </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On December 16, 2004, the FASB issued Statement of Financial Accounting Standards No. 123 (revised 2004),<I> &#147;Share-Based
Payment&#148;</I> (SFAS 123(R)), an amendment of Statements of Financial Accounting Standards Nos. 123 and 95, that addresses the accounting for share-based awards to employees. The standard requires companies to recognize as an expense the fair
value of stock options and other stock-based compensation to employees. The statement eliminates the ability to account for share-based compensation transactions using APB Opinion No. 25, &#147;<I>Accounting for Stock Issued to Employees</I>,&#148;
(APB 25), and generally requires instead that companies account for such transactions using a fair value based method, such as the Black-Scholes option pricing model, to fairly value stock options and recognize that value as an expense. The standard
will be effective for public companies as of the beginning of the first fiscal year after June 15, 2005. The Company currently accounts for stock-based compensation plans in accordance with APB 25. SFAS 123(R) offers companies alternative methods of
adopting this standard. At present, the Company has not yet determined which method to adopt, but regardless of the method, adoption of this statement is expected to have a material adverse effect on the Company&#146;s consolidated results of
operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>2. Stock-Based Compensation </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In accordance with the provisions of Statement of Financial Accounting Standards No. 123,<I>
&#147;Accounting for Stock-Based Compensation&#148;</I> (SFAS 123), as amended by SFAS No. 148,<I> &#147;Accounting for Stock-Based Compensation &#151; Transition and Disclosure&#148;</I> (SFAS 148) the Company has elected to account for stock-based
compensation to employees under the provisions of APB Opinion No. 25,<I> &#147;Accounting for Stock Issued to Employees,&#148;</I> and its related interpretations, and to adopt the &#147;disclosure only&#148; alternative described in SFAS 123, as
amended by SFAS 148. Stock options granted to non-employees are accounted for in accordance with SFAS 123 and Emerging Issues Task Force No. 96-18,<I> &#147;Accounting for Equity Instruments that Are Issued to Other than Employees for Acquiring, or
in Conjunction with Selling, Goods or Services.&#148;</I> The Company&#146;s pro forma information for employee stock options is as follows (in thousands, except for per share data): </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>June 30,</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended<BR>June 30,</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net loss, as reported</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(17,007</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(10,960</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(31,669</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(28,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Add: Stock-based employee compensation expense included in reported net income, net of related tax effects</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">178</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Deduct: Total stock-based employee compensation expense determined under fair value-based method, net of related tax effects</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(2,951</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(5,863</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(2,701</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Pro forma net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(19,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(12,710</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(37,354</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(31,339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Basic and diluted net loss per share, as reported</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Pro forma basic and diluted net loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.93</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>3. Comprehensive Loss
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The components of comprehensive loss in each period presented are as
follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>June 30,</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended<BR>June 30,</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net loss, as reported</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(17,007</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(10,960</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(31,669</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(28,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Unrealized gain (loss) on available-for-sale securities, net of related tax effects</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">95</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(292</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(16,941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(11,262</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(31,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(28,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>4. Financing Arrangements
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In August 2004, the Company entered into a Loan and Security Agreement
(Loan Agreement), with Silicon Valley Bank (SVB) that originally provided a $6.0 million term loan facility and a $4.0 million revolving credit line, and grants SVB a security interest over certain of the Company&#146;s assets, excluding
intellectual property. The Loan Agreement contains certain covenants and reporting requirements, which the Company was full in compliance with as of June 30, 2005. Proceeds may be used solely for working capital or other general business needs.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In December 2004, the Company completed a $2.6 million initial draw-down from
the term loan facility, the proceeds of which were used entirely to repay a note for the same amount that was owed to AMB Property, LP in relation to the termination of a lease agreement for facilities at Humboldt Court in Sunnyvale, California. In
March 2005, the Company completed a $1.5 million second draw-down from the term loan facility, with $0.6 million of these proceeds being used to pay off certain capital leases. On June 30, 2005, the remaining $1.9 million of the term loan facility
expired unused. The $2.6 million draw-down is being repaid in 30 equal monthly installments, plus accrued interest of 6.43% per annum, starting from May 1, 2005. The $1.5 million draw-down is being repaid in 36 equal monthly installments, plus
accrued interest of 6.78% per annum, starting from April 1, 2005. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">As of June
30, 2005, the Company has not drawn-down any of the funds available under the revolving credit line, which is being used to collateralize a $4.0 million letter of credit issued to the Irvine Company related to the lease for the facility at 985
Almanor Avenue in Sunnyvale, California (see Note 10). Any borrowings under this line shall bear interest at SVB&#146;s prime rate. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>5. Facilities Lease Agreement </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In January 2005, the Company entered into a seven-year facility lease agreement with BMR-201 Industrial Road LLC for 61,826 square feet of
industrial space at 201 Industrial Road in San Carlos, California at $2.35 per square foot per month, subject to annual increases of $0.07 per square foot per month. The lease will commence on or around September 1, 2005 and contains an option to
cancel the lease after five years, two options to extend the lease for five additional years at 95% of the then-current fair market rental rate (but not less than the existing rental rate), and rights of first refusal over all vacant space in the
building during the first two years of the lease. The lease contains a tenant improvement allowance of $8.7 million, or $140 per square foot. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">As a result of the entry into this lease, a review for impairment of leasehold improvements at 985 Almanor Avenue in Sunnyvale, California took place in January 2005. As
identifiable cash flows related to these assets are not independent of those of the Company as a whole, these assets were grouped with all the assets and liabilities of the Company for the purposes of the impairment review, and as a result, no
impairment of these assets was identified, as the fair value of the net assets of the Company exceeds its carrying value. In accordance with Statement of Financial Accounting Standards No. 144,<I> &#147;Accounting for the Impairment or Disposal of
Long-Lived Assets,&#148;</I> if the Company subleases or otherwise exits this facility, an impairment charge will be recorded based on the difference between the carrying value and fair value of the leasehold improvements at the time of the sublease
or exit. As of June 30, 2005, this difference was estimated to be $4.0 million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">The Company has estimated that it will incur future restoration costs for the premises at 985 Almanor Avenue with a current fair value of $0.3 million. Under Statement of Financial Accounting Standards No. 143,<I> &#147;Accounting for Asset
Retirement Obligations&#148;, </I>this amount has been recorded as an increase to both the leasehold improvements fixed asset account and the other non-current liabilities account in the balance sheet. Depreciation and interest accretion expense
charged during the quarter was negligible. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>6. Common Stock Offering
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In February 2005, the Company raised $68.4 million in a public offering,
net of underwriters&#146; fees and stock issuance costs of $4.9 million, from the sale of 9,775,000 shares of common stock, including 1,275,000 shares related to the exercise of an over-allotment option granted to the underwriters, at a public
offering price of $7.50 per share. The Company intends to use the net proceeds from this offering for general corporate purposes, including capital expenditures, working capital needs, current and future clinical trials of alfimeprase, rNAPc2 and
ARC183, as well as other research and drug development activities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>7.
Collaborative and Manufacturing Agreements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On March 31, 2005, the Company
entered into a new collaboration agreement with the Pharmaceutical Division of Kirin Brewery Company, Ltd. (Kirin) for the development and commercialization of NU206 (NU206 Agreement). The existing collaboration agreement with Kirin (Original
Agreement), which was amended in the third quarter of 2004 to extend the term to December 31, 2005 and expand the scope to include additional secreted protein genes from the Company&#146;s full-length gene portfolio, continues to govern all product
candidates other than NU206. The Company will continue to jointly own discoveries resulting from the Original Agreement and jointly develop and market the resulting products, while sharing costs, efforts and revenues with Kirin. As a result of the
NU206 Agreement, the Company will lead worldwide development, manufacturing and commercialization of the compound, and received a $2.0 million upfront cash payment from Kirin in April 2005. This amount will be recognized as revenue ratably over the
estimated performance period under the contract, starting from the second quarter of 2005. All operating expenses and profits related to the development and commercialization of NU206 will be shared in a 60 (Nuvelo) / 40 (Kirin) ratio. If the NU206
Agreement is terminated, or if Kirin or Nuvelo elects under certain circumstances to no longer actively participate in the collaboration, the relationship with respect to NU206 will convert from an expense and profit sharing structure to a
royalty-based structure. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On June 30, 2005, the Company entered into a
Development and Validation Agreement with Avecia Limited, a United Kingdom-based company, for development and validation of the scaled-up manufacturing process of alfimeprase. This agreement supersedes the Interim Agreement that was entered into
with Avecia on January 21, 2005. Under this new agreement, Avecia will conduct process development work and a process validation campaign for the manufacture of alfimeprase. This validation campaign is intended to validate the alfimeprase
manufacturing process under the U.S. Food and Drug Administration&#146;s Good Manufacturing Practice (GMP) Regulation. The Company is obligated to pay Avecia fees totaling &pound;10.0 million for completion of this manufacturing work, payable in
stages and upon completion by Avecia of pre-negotiated milestones (see Note 10). Milestone payments and fees previously agreed to under the Interim Agreement, of which &pound;0.5 million have already been paid, continue under this new Development
and Validation Agreement, and are incorporated into the total fee. The milestone fees paid to date have been recorded as research and development expenses, and future milestone expenses will be recorded as they are incurred, as either research and
development expenses, or clinical trial supplies in the balance sheet, depending on the nature of the expense. The Company is also paying certain related fees and expenses, including the cost of supplies, materials, specified subcontracted work and
equipment. The agreement does not cover the commercial manufacture of alfimeprase, but the Company and Avecia have agreed to negotiate in good faith towards the completion of a commercial supply agreement once Avecia has commenced the validation
campaign. The Development and Validation Agreement remains in force until the completion of the work contemplated under it, but may be terminated early by Avecia if the Company breaches the agreement, and by the Company for any reason, subject in
some cases to cancellation fees and penalties. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>8. Transactions with Related
Parties </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Dr. Rathmann, the Company&#146;s Chairman, provided a $20.0
million line of credit to the Company in August 2001, of which $11.0 million was drawn down, with the remaining $9.0 million having expired unused. The related promissory note bears interest at the prime rate plus 1%. In November 2003, the Company
began repaying the outstanding balance over 48 months with equal monthly principal payments of $0.2 million. Accrued interest will be paid with the final payment in October 2007. The remaining principal and accrued interest to date totaled $8.1
million as of June 30, 2005, and the interest rate on the note was 7.25%. The outstanding principal and interest under the note may be repaid at any time upon mutual agreement, by conversion into shares of the Company&#146;s common stock at a price
based upon the average stock price over a 20-day period ending 2 days prior to the conversion or, if in connection with an equity financing, at the offering price. As of June 30, 2005, 1,095,319 shares would be issuable to fully repay the principal
and interest outstanding upon conversion. Additionally, as of June 30, 2005, Dr. Rathmann continued to provide a personal guarantee of $1.5 million to the Irvine Company, related to the 985 Almanor Avenue facility lease (see Note 10). </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>9. Segment Information </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Company is engaged in the discovery, development and commercialization of life improving therapeutics for the treatment of human
disease. The Company has only one reportable segment since the sale of its majority-owned subsidiary Callida Genomics, Inc. in December 2004, and accordingly all segment-related financial information required by Statement of Financial Accounting
Standards No. 131,<I> &#147;Disclosures About Segments of an Enterprise and Related Information&#148;</I> is included in the condensed consolidated financial statements. Reportable segments reflect the Company&#146;s structure, reporting
responsibilities to the chief executive officer and the nature of the products under development. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>10. Subsequent Events </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In July 2005, the Company filed a shelf registration statement with the U.S. Securities and Exchange Commission on Form S-3, and such registration statement was declared
effective in August 2005. Under this shelf registration, the Company may, from time to time, sell up to $100.0 million of debt securities, preferred stock and/or common stock. The Company plans to use the net proceeds from any securities issued
under this registration statement for general corporate purposes, including the advancement of drug candidates in clinical trials, capital spending and working capital. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In August 2005, the Company entered into a stock purchase agreement and related registration rights agreement with Kingsbridge Capital
Limited. Under the agreements, the Company may sell up to $75.0 million in shares of common stock to Kingsbridge Capital within a three-year period. The Company has agreed, prior to selling any of these shares to Kingsbridge Capital, to register the
shares for resale by Kingsbridge, independent of the above shelf registration. The Company plans to use the net proceeds from any shares sold to Kingsbridge for general corporate purposes, including the advancement of drug candidates in clinical
trials, capital spending and working capital. In connection with the execution of the stock purchase agreement, the Company issued a warrant to Kingsbridge Capital, exercisable for 350,000 shares of common stock at an exercise price of $12.07 per
share, which is 130% of the of the average closing price of the Company&#146;s common stock during the five trading days preceding the issuance of the warrant. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In July 2005, the Loan Agreement with SVB (see Note 4) was amended to increase the revolving credit line facility from $4.0 million to $8.0 million and extend the
facility through August 29, 2006. The Company has yet to draw-down any of the funds available under this revolving credit line. The original $4.0 million facility continues to be used to collateralize a $4.0 million letter of credit issued to the
Irvine Company related to the lease for the facility at 985 Almanor Avenue. Of the $4.0 million increase to the credit facility, $2.0 million will be used to collateralize an addition of $2.0 million to the Irvine Company letter of credit made in
July 2005, in order to replace Dr. Rathmann&#146;s guarantee (see Note 8). A further $1.7 million will be used as collateral for approximately $16.7 million worth of foreign exchange hedge contracts that were entered into with SVB in July 2005 (see
below). The remainder will be used for working capital or other general business needs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">In July 2005, as a result of the entry into the Development and Validation Agreement with Avecia Limited (see Note 7), the Company entered into foreign currency forward hedging contracts to buy a total of &pound;9.5 million for $16.7
million, in order to reduce the Company&#146;s exposure to fluctuations in the British pound prior to payment. The contracts all have maturities of one year or less, and will be designated as cash flow hedges under SFAS 133. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx17073_6"></A>ITEM 2. MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>This Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations contains &#147;forward-looking statements&#148; as that term is defined
in the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including &#147;will,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;intends,&#148; &#147;estimates,&#148; &#147;expect,&#148;
&#147;should,&#148; &#147;may,&#148; &#147;potential&#148; and similar expressions. Such statements are based on our management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially
from those projected in the forward-looking statements as a result of many factors discussed herein and elsewhere including, in particular, those factors described under the &#147;Risk Factors&#148; set forth below, and in our other periodic reports
filed from time to time with the Securities and Exchange Commission, or SEC. Actual results and performance could also differ materially from time to time from those projected in our filings with the SEC. </I></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We are engaged in the discovery, development and commercialization of life improving therapeutics for the treatment of human disease. Our
clinical pipeline includes three acute cardiovascular focused product candidates, alfimeprase, rNAPc2 and ARC183. In April 2005, we began patient enrollment in the first of two Phase 3 trials of our lead product candidate, alfimeprase, for the
treatment of acute peripheral arterial occlusion (PAO), or &#147;leg attack.&#148; The second Phase 3 trial is expected to begin in the second half of 2005. A Phase 3 program evaluating alfimeprase in a second target indication, catheter occlusion,
is also expected to begin in the second half of 2005. In May 2005, we completed a Phase 2a trial with novel anticoagulant, rNAPc2, evaluating its potential use in treating patients with acute coronary syndromes (ACS). Based on the encouraging safety
results from this trial, an additional Phase 2 trial with rNAPc2 is expected to begin in the second half of 2005. In addition, ARC183 is currently in a Phase 1 program evaluating its potential use in patients undergoing acute cardiovascular
procedures. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In addition to our clinical candidates, we have a research engine
focused on secreted proteins and antibody discovery. In late 2004, NU206, a potent gastrointestinal growth factor, became the first compound to enter IND-enabling studies from these internal research efforts, and in March 2005, we entered into a new
collaboration agreement with the Pharmaceutical Division of Kirin Brewery Company, Ltd. (Kirin), for the development and commercialization of NU206. In addition, we plan to leverage our proprietary gene collection and expertise in secreted proteins
and antibody discovery to expand our pipeline and create partnering and licensing opportunities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Alfimeprase </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Alfimeprase is a thrombolytic agent, or blood clot dissolver, with a novel mechanism of action, that was identified through a research program at Amgen Inc. We have two
Phase 3 programs for alfimeprase, one in patients with acute PAO and one in patients with occluded central venous catheters. The alfimeprase Phase 3 acute PAO program, known as NAPA (Novel Arterial Perfusion with Alfimeprase), consists of two
overlapping trials that will include a total of up to 700 patients between the two trials. The first trial in this program, NAPA-2, which commenced in April 2005, is a randomized, double-blind study comparing 0.3 mg/kg of alfimeprase versus placebo
in 300 patients. The trial will be conducted in over 100 centers worldwide. The study&#146;s primary endpoint is avoidance of open vascular surgery within 30 days of treatment. Open vascular surgery includes procedures such as surgical embolectomy,
peripheral arterial bypass graft surgery and amputation, but does not include catheter-based procedures such as percutaneous angioplasty or stenting. A variety of secondary endpoints are also being evaluated, including safety endpoints such as the
incidence of bleeding, as well as pharmacoeconomic endpoints such as length of hospital and intensive care unit (ICU) stay. The second Phase 3 trial, NAPA-3, is expected to begin in the second half of 2005. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The alfimeprase Phase 3 catheter occlusion program, known as SONOMA (Speedy Opening of
Non-Functional and Occluded Catheters with Mini-Dose Alfimeprase), includes two overlapping multi-national trials. The first trial is an efficacy study called SONOMA-2, and is expected to begin in the second half of 2005. This study is a randomized,
double-blind trial, comparing 3 mg of alfimeprase with placebo in 300 patients with occluded centralvenous catheters. Two-thirds of the patients will receive alfimeprase and the remainder will receive placebo. The study&#146;s primary endpoint is
restoration of function to occluded central venous catheters at 15 minutes. The second study, known as SONOMA-3, will be an open-label, single-arm trial evaluating alfimeprase in 800 patients. This study&#146;s primary endpoint is safety, although
we will be evaluating efficacy in these patients as well. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In January 2002 we
entered into a 50/50 cost/profit sharing arrangement with Amgen for the development and commercialization of alfimeprase. In October 2004, Amgen exercised its rights pursuant to the terms of this collaboration agreement to terminate its
collaboration with us and enter instead into an exclusive license agreement, whereby we are granted the worldwide rights to develop and commercialize alfimeprase in exchange for the payment to Amgen of previously negotiated milestone payments and
royalties. As a result of dosing the first patient in the first Phase 3 clinical trial for alfimeprase on April 15, 2005, we paid a $5.0 million milestone fee to Amgen in May 2005. Additional future milestone payments under the license agreement
could total as much as $35.0 million, although we currently cannot predict if and when any of these additional milestones will be achieved. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On June 30, 2005, we entered into a Development and Validation Agreement with Avecia Limited for development and validation of the scaled-up manufacturing process of
alfimeprase. The Development and Validation Agreement supersedes the Interim Agreement that we entered into with Avecia on January 21, 2005. Under this new agreement, Avecia will conduct process development work and a process validation campaign for
the manufacture of alfimeprase. This validation campaign is intended to validate the alfimeprase manufacturing process under the U.S. Food and Drug Administration&#146;s Good Manufacturing Practice (GMP) Regulation. We are obligated to pay Avecia
fees totaling &pound;10.0 million for completion of this manufacturing work, payable in stages and upon completion by Avecia of pre-negotiated milestones. Under the terms of our license agreement with Amgen, Amgen is transferring the technology
necessary for the manufacture of alfimeprase to Avecia, and is required to continue to supply alfimeprase to us during the transition period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">10 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT FACE="Times New Roman" SIZE="2"><B><I>rNAPc2 </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">rNAPc2 is a recombinant version of a naturally occurring protein that has anticoagulant properties. In May 2005, we completed a Phase 2a
double-blind, placebo-controlled clinical trial showing that rNAPc2 has an acceptable safety profile and is well tolerated in doses up to 10 micrograms/kg in patients being treated for ACS, including unstable angina (UA), and non-ST segment
elevation myocardial infarction (NSTEMI). Based on these encouraging safety results, an additional Phase 2 trial with rNAPc2, a heparin-replacement study, is scheduled to begin in the second half of 2005. We have licensed worldwide rights to all
indications of rNAPc2 and all other rNAPc molecules owned by Dendreon, as a result of a licensing agreement entered into with Dendreon Corporation in February 2004. Under the terms of the agreement, we paid Dendreon an upfront fee of $4.0 million
($0.5 million in cash and $3.5 million in Nuvelo common stock), and have expensed $5.6 million for this and related development costs in 2004 and $1.0 million for related development costs in the first six months of 2005. We are required to pay
Dendreon milestone payments, ranging from $2.0 million to $6.0 million, for both of rNAPc2&#146;s first and second indications upon dosing of the first patient in a Phase 3 clinical trial, upon submission of a New Drug Application (NDA), and upon
first commercial sale. If all development and commercialization milestones are achieved, additional future milestone payments to Dendreon can reach as much as $23.5 million, although we currently cannot predict if and when any of these milestones
will be achieved. If rNAPc2 is commercialized, we will also be responsible for paying future royalties to Dendreon depending on sales volumes of rNAPc2. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT FACE="Times New Roman" SIZE="2"><B><I>ARC 183 </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We continue to pursue the development of ARC183, a direct thrombin inhibitor, under a collaboration agreement entered into with Archemix Corporation, a privately held
biotechnology company located in Cambridge, Massachusetts, in January 2004. In August 2004, we jointly initiated a Phase 1 clinical program for ARC183 for potential use in acute cardiovascular procedures. This program continues to enroll patients
and we expect to announce top-line results upon completion of the program. These studies are evaluating the safety, tolerability, anticoagulation activity and titratability of ARC183. Under the terms of the agreement, we paid Archemix an upfront fee
of $3.0 million in cash, and equally share all costs associated with its development and commercialization since our initial funding of these costs reached $4.0 million in the third quarter of 2004. We expensed $7.7 million for the upfront fee and
related development costs in 2004 and $1.4 million for related development costs in the first six months of 2005. Archemix is initially responsible for leading development and for all clinical development activities through the dosing of the first
patient in a Phase 2 study. Thereafter, we and Archemix will agree on leadership of clinical development and commercialization activities. We are required to pay Archemix total development milestone payments of up to $11.0 million, including $10.0
million upon the first dosing of a patient in a Phase 2 trial and $1.0 million upon the designation of any backup compound selected by both Nuvelo and Archemix for IND-enabling studies. We currently cannot predict if and when any of these milestones
will be achieved. If ARC183 is commercialized, both companies are responsible for paying any related royalties to each other depending on product sales volume. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT FACE="Times New Roman" SIZE="2"><B><I>NU206 </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On March 31, 2005, we entered into a new collaboration agreement with Kirin for the development and commercialization of NU206 (NU206 Agreement). In late 2004, NU206
became the first compound to enter IND-enabling studies from our existing collaboration with Kirin. Research to date indicates that NU206 acts as a specific and potent stimulator of gastrointestinal epithelial cells. Therefore, we plan to initially
pursue NU206 as a supportive cancer therapy for radiation and chemotherapy-induced mucositis in the gastrointestinal tract. In addition, NU206 appears to have potential clinical utility in inflammatory bowel disease and short-bowel syndrome. Our
existing collaboration agreement with Kirin (Original Agreement), which was amended in the third quarter of 2004 to extend the term to December 31, 2005 and expand the scope to include additional secreted protein genes from our full-length gene
portfolio, continues to govern all product candidates other than NU206. Under the Original Agreement, we have completed the initial analysis of 50 secreted protein genes in mouse models and will be testing additional candidate genes in 2005. We will
continue to jointly own discoveries resulting from the Original Agreement and jointly develop and market the resulting products, while sharing costs, efforts and revenues with Kirin. Under the NU206 Agreement, we received a $2.0 million upfront cash
payment from Kirin in April 2005, and will lead worldwide development, manufacturing and commercialization of the compound. All operating expenses and profits related to the development and commercialization of NU206 will be shared in a 60 (Nuvelo)
/ 40 (Kirin) ratio. If the NU206 Agreement is terminated, or Nuvelo or Kirin elects under certain circumstances to no longer actively participate in the collaboration, the relationship with respect to NU206 will convert from an expense and
profit-sharing structure to a royalty-based structure. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT FACE="Times New Roman"
SIZE="2"><B><I>Financing and Facilities </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In February 2005, we raised
$68.4 million in a public offering, net of underwriters&#146; fees and stock issuance costs of $4.9 million, from the sale of 9,775,000 shares of our common stock, including 1,275,000 shares related to the exercise of an over-allotment option
granted to the underwriters, at a public offering price of $7.50 per share. We intend to use the net proceeds from this offering for general corporate purposes, including current and future clinical trials of alfimeprase, rNAPc2 and ARC183, as well
as other research and drug development activities, capital spending and working capital. The amounts and timing of the expenditures will depend on numerous factors, such as the timing and progress of our clinical trials and research and development
efforts, technological advances and the competitive environment for our drug candidates. We expect from time to time to evaluate the acquisition of businesses, products and technologies for which a portion of the net proceeds may be used, although
we currently are not planning or negotiating any such transactions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In July
2005, we filed a shelf registration statement with the U.S. Securities and Exchange Commission on Form S-3, and such registration statement was declared effective in August 2005. Under this shelf registration, we may, from time to time, periodically
sell up to $100.0 million of debt securities, preferred stock and/or common stock. We plan to use the net proceeds from any securities issued under this registration statement for general corporate purposes, including the advancement of our drug
candidates in clinical trials, capital spending and working capital. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In August
2005, we entered into a stock purchase agreement and related registration rights agreement with Kingsbridge Capital Limited. Under the agreements, we may sell up to $75.0 million in shares of common stock to Kingsbridge Capital Limited within a
three-year period, subject to certain limitations. We have agreed, prior to selling any of these shares to Kingsbridge Capital, to register the shares for resale by Kingsbridge, independent of the above shelf registration. We plan to use the net
proceeds from any securities issued under this agreement for general corporate purposes, including the advancement of our drug candidates in clinical trials, capital spending and working capital. In connection with the execution of the stock
purchase agreement, the Company issued a warrant to Kingsbridge Capital, exercisable for 350,000 shares of common stock at an exercise price of $12.07 per share, which is 130% of the of the average closing price of the Company&#146;s common stock
during the five trading days preceding the issuance of the warrant. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In January
2005, we entered into a seven-year facility lease agreement with BMR-201 Industrial Road LLC for 61,826 square feet of industrial space at 201 Industrial Road in San Carlos, California at $2.35 per square foot per month, subject to annual
adjustments. The lease will commence on or around September 1, 2005 and contains an option to cancel the lease after five years, two options to extend the lease for five additional years at 95% of the then-current fair market rental rate (but not
less than the existing rental rate), and rights of first refusal over all vacant space in the building during the first two years of the lease. The lease contains a tenant improvement allowance of $8.7 million, or $140 per square foot. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Results of Operations </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Nuvelo&#146;s core business is to discover, develop and commercialize therapeutic drugs for the treatment of human diseases. The following results of operations include
those of both Nuvelo Inc. and Callida Genomics, Inc. (Callida), through the disposal of this subsidiary on December 3, 2004. The results of Callida have been reclassified to discontinued operations for all periods presented. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Contract Revenue </I></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Contract revenue was $197,000 and $239,000 in the three and six months ended June 30, 2005,
respectively, as compared to $20,000 and $98,000 in the corresponding periods of 2004. The increase in each respective period was primarily due to the ratable recognition of $62,000 in revenue from the one-time upfront fee of $2.0 million related to
the NU206 collaboration agreement with Kirin, and increased sublicense and royalty income from our MTHFR patent license. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our revenues may vary significantly from quarter to quarter as a result of licensing or collaboration activities. In the future, we may not be able to maintain existing
collaborations, obtain additional collaboration partners or obtain revenue from other sources, which could have a material adverse effect on our revenues, operating results and cash flows. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Research and Development Expenses </I></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Research and development (R&amp;D) expenses, primarily consist of R&amp;D personnel costs,
clinical trial and drug manufacturing costs, license, collaboration and royalty fees, outside services, supplies, depreciation and amortization, and allocated facilities expenses. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">R&amp;D expenses were $14.5 million in the three months ended June 30, 2005, as compared to $8.7 million in the corresponding period of
2004. The increase of $5.8 million was primarily due to the $5.0 million milestone payment to Amgen related to the commencement of the alfimeprase Phase 3 acute PAO clinical trial in April 2005. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">R&amp;D expenses were $25.5 million in the six months ended June 30, 2005, as compared to
$24.1 million in the corresponding period of 2004. The increase of $1.4 million was primarily due to a $3.8 million increase in R&amp;D personnel and outside service costs resulting from increased clinical trial activities, partially offset by a
$2.0 million decrease in license fees as a result of the difference between the $5.0 million milestone payment to Amgen in 2005 and the one-time $7.0 million license fees paid to Archemix and Dendreon in 2004. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">R&amp;D expenses included in the statement of operations for the three and six months ended
June 30, 2005, and since inception, for our significant programs are as follows (including license and collaboration fees): </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Program</B></FONT></P><HR WIDTH="45" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Three&nbsp;months<BR>ended&nbsp;June&nbsp;30,<BR>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Six&nbsp;months<BR>ended&nbsp;June&nbsp;30,<BR>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Since<BR>Inception</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="8" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(in millions)</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">alfimeprase</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">41.3</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">rNAPc2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1.0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6.6</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">ARC183</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">NU206</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.3</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We expect to expense up to $11.2
million of drug manufacturing costs (classified as &#145;Clinical trial supplies&#146; in the balance sheet) within the next twelve months as we utilize existing alfimeprase drug material in our Phase 3 clinical trials, or otherwise. We currently do
not expect to incur any other milestone expenses for alfimeprase or our rNAPc2 and ARC183 drug candidates in the remainder of 2005, except for those under the Avecia Development and Validation Agreement. We expect other R&amp;D expenses to increase
during 2005 as we continue to dedicate our resources to Phase 3 clinical trials for alfimeprase, as well as work to enhance our pipeline by seeking attractive therapeutic candidates that complement our ongoing development programs, while prosecuting
and enforcing our intellectual property rights. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The timing, cost of completing
the clinical development of any product candidate, and any potential future product revenues will depend on a number of factors, including the disease or medical condition to be treated, clinical trial design and endpoints, availability of patients
to participate in trials and the relative efficacy of the product versus treatments already approved. Due to these uncertainties, we are unable to estimate the length of time or the costs that will be required to complete the development of these
product candidates. We do not expect to generate any product revenue until we reach the commercialization stage for any of our drug products, if this ever occurs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>General and Administrative Expenses </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">General and administrative (G&amp;A) expenses primarily consist of G&amp;A personnel costs, consulting and professional fees, insurance, facilities and depreciation
expenses, and various other administrative costs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">G&amp;A expenses were $3.2
million in the three months ended June 30, 2005, as compared to $2.0 million in the corresponding period of 2004. The increase of $1.2 million was primarily due to a $0.7 million increase in G&amp;A personnel costs, and an increase of $0.3 million
in consulting, professional fees and other outside service costs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">G&amp;A
expenses were $7.0 million in the six months ended June 30, 2005, as compared to $3.6 million in the corresponding period of 2004. The increase of $3.4 million was primarily due to a $1.4 million increase in G&amp;A personnel costs, a $0.7 million
increase in consulting and professional fees, largely related to the Sarbanes-Oxley Act of 2002, and an increase of $0.6 million in non-cash stock compensation expense and outside service costs. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We expect G&amp;A expenses to increase during 2005 as compared to 2004 in order to support
growth in our general operating activities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">12 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Interest and Other Income (Expense) </I></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We had net interest and other income of $0.4 million and $0.6 million in the three and six
months ended June 30, 2005, respectively, as compared to $14,000 and $0.2 million net interest and other expense in the corresponding periods of 2004. The changes resulted primarily from higher cash and investment balances in 2005. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Loss from Continuing Operations </I></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Since our inception we have incurred significant net losses, and as of June 30, 2005 our
accumulated deficit was $287.7 million. During the three and six months ended June 30, 2005 we incurred net losses from continuing operations of $17.0 million and $31.7 million, respectively, as compared to $10.6 million and $27.8 million,
respectively, in the corresponding periods of 2004. The increase in the loss from continuing operations in the first half of 2005 was primarily due to increased R&amp;D personnel costs and expenses associated with the initiation and continued
enrollment of the alfimeprase Phase 3 programs, and increased G&amp;A personnel costs, consulting, professional fees and other outside service costs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We expect to continue to incur significant losses from continuing operations for the foreseeable future, which may increase substantially as we continue development of
our clinical stage drug candidates, alfimeprase, rNAPc2 and ARC183, and our preclinical stage drug candidate, NU206. In addition, we expect to incur significant costs as we further expand research and development of our potential biopharmaceutical
product candidates, potentially in-license other drug candidates, and continue to prosecute and enforce our intellectual property rights. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Loss from Discontinued Operations </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On December 3, 2004, we sold our subsidiary, Callida Genomics, Inc. (Callida). In accordance with Statement of Financial Accounting Standards No. 144,<I> &#147;Accounting
for the Impairment or Disposal of Long-Lived Assets&#148;</I>, the operating results of Callida have been reclassified to discontinued operations for all periods presented. During the three and six months ended June 30, 2004, we incurred a net loss
from discontinued operations of $0.3 million and $0.8 million, respectively, related to Callida. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Cash,
cash equivalents and short-term investment balances at June 30, 2005 and December 31, 2004 were as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>June 30,<BR>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">47,930</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16,811</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">43,968</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">33,814</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash, cash equivalents and short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">91,898</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">50,625</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Cash flows from operating, investing
and financing activities in the six months ended June 30, 2005 and 2004 were as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash flows from operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(25,955</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(21,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash flows from investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(10,452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(40,353</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash flows from financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">67,526</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">67,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31,119</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Cash, Cash
Equivalents and Short-Term Investments </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">As of June 30, 2005, we had
total cash, cash equivalents and short-term investments of $91.9 million, as compared to $50.6 million as of December 31, 2004. The increase of $41.3 million resulted primarily from net proceeds of $68.4 million from a public offering in February
2005, partially offset by the $5.0 million milestone payment to Amgen and cash used in operating activities during this period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">As of June 30, 2005, all of our short-term investments in marketable securities have maturities of less than one year, and have been classified as available-for-sale
securities, as defined by Statement of Financial Accounting Standards No. 115,<I> &#147;Accounting for Certain Investments in Debt and Equity Securities&#148;</I> (SFAS 115). These securities are recorded at their fair value and consist of corporate
debt and asset-backed securities. We make our investments in accordance with our investment policy. The primary objectives of our investment policy are liquidity, safety of principal and diversity of investments. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">13 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Sources and Uses of Capital </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our primary sources of liquidity to date have been cash from financing activities, collaboration receipts and our merger with Variagenics in
January 2003. We plan to continue to raise funds through additional public and/or private offerings and collaboration activities in the future. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In February 2005, we raised $68.4 million in a public offering, net of underwriters&#146; fees and stock issuance costs of $4.9 million, from the sale of 9,775,000 shares
of our common stock, including 1,275,000 shares related to the exercise of an over-allotment option granted to the underwriters, at a public offering price of $7.50 per share. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In August 2004, we entered into a Loan and Security Agreement (Loan Agreement), with Silicon Valley Bank (SVB) that originally provided a
$6.0 million term loan facility and a $4.0 million revolving credit line, and grants SVB a security interest over certain of our assets, excluding intellectual property. The Loan Agreement contains certain covenants and reporting requirements, which
we were in full in compliance with as of June 30, 2005. Proceeds may be used solely for working capital or other general business needs. In December 2004, we completed a $2.6 million initial draw-down from the term loan facility, the proceeds of
which were used entirely to repay a note for the same amount that was owed to AMB Property, LP in relation to the termination of a lease agreement for facilities at Humboldt Court in Sunnyvale, California. In March 2005, we completed a $1.5 million
second draw-down from the term loan facility, with $0.6 million of these proceeds being used to pay off certain capital leases. On June 30, 2005, the remaining $1.9 million of the term loan facility expired unused. The $2.6 million draw-down is
being repaid in 30 equal monthly installments, plus accrued interest of 6.43% per annum, starting from May 1, 2005; the $1.5 million draw-down is being repaid in 36 equal monthly installments, plus accrued interest of 6.78% per annum, starting from
April 1, 2005. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In July 2005, the Loan Agreement with SVB was amended to
increase the revolving credit line facility from $4.0 million to $8.0 million and extend the facility through August 29, 2006. We have yet to draw-down any of the funds available under this revolving credit line. The original $4.0 million facility
continues to be used to collateralize a $4.0 million letter of credit issued to the Irvine Company related to the lease for the facility at 985 Almanor Avenue in Sunnyvale, California. Of the $4.0 million increase to the credit line facility, $2.0
million is being used to collateralize an addition of $2.0 million to the Irvine Company letter of credit made in July 2005, in order to replace a guarantee by Dr. Rathmann. A further $1.7 million is being used as collateral for $16.7 million of
foreign exchange hedge contracts that were entered into with SVB in July 2005, in relation to the Development and Validation Agreement with Avecia Limited. The remainder will be used for working capital or other general business needs. Any
borrowings under this line shall bear interest at SVB&#146;s prime rate. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Dr.
Rathmann, the chairman of our board of directors, provided us with a $20.0 million line of credit in August 2001, of which we have drawn down $11.0 million, with the remaining $9.0 million having expired unused. The related promissory note bears
interest at the prime rate plus 1%. In November 2003, we began repaying the outstanding balance over 48 months with equal principal payments of $0.2 million. Accrued interest will be paid with the final payment in October 2007. As of June 30, 2005,
the remaining principal and accrued interest to date totaled $8.1 million. The outstanding principal and interest under the note may be repaid at any time upon mutual agreement, by conversion into shares of our common stock at a price based upon the
average price of our common stock over a 20-day period ending 2 days prior to the conversion or, if in connection with an equity financing, at the offering price. As of June 30, 2005, 1,095,319 shares would be issuable to fully repay the principal
and interest outstanding upon conversion. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We issued Affymetrix a five-year
promissory note for $4.0 million in November 2001, bearing a fixed annual interest rate of 7.5%. Accrued interest will be paid with the final principal payment in November 2006. As of June 30, 2005, the remaining principal and accrued interest to
date totaled $5.1 million. The outstanding principal and interest under the note may be repaid in whole or in part at any time, at our option, by conversion into shares of our common stock at a price based upon 90% of the average price of our common
stock over a 10-day period ending 2 days prior to the conversion. As of June 30, 2005, 735,800 shares would be issuable to fully repay the principal and interest outstanding upon conversion. Affymetrix has the ability to declare all outstanding
principal and interest under the note immediately due and payable if our market capitalization is under $50.0 million and Affymetrix reasonably determines that the loan evidenced by the note is impaired, and we have an obligation to prepay amounts
owing under the note to the extent that the amounts outstanding exceed 10% of our market capitalization. Moreover, we have registered for resale a portion of these shares issuable to Affymetrix on a registration statement that has been declared
effective by the SEC. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our primary uses of capital resources to date have been
to fund operating activities, including research, clinical development expenses and license payments, and spending on capital items. We used cash of $26.0 million and $21.3 million for operating activities, and cash of $0.4 million and $0.4 million
for the purchase of capital items, in the six months ended June 30, 2005 and 2004, respectively. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">In August 2002, we amended our lease on the property at 985 Almanor Ave. to provide for a rent deferral of $4.9 million over the subsequent three years, retroactive to June 1, 2002. We are required to repay the
deferred rent liability, plus interest, over a four-year period starting from June 1, 2005, in equal monthly installments of $0.1 million. In October 2003, we amended the lease for a second time, to provide for an additional rent deferral. In order
to receive this rent deferral, we pre-paid $2.7 million of base rental payments in October 2003 to cover the nine-month period beginning October 1, 2003 and ending June 30, 2004. The amendment provides that no base rent would be due for the period
July 1, 2004 through March 30, 2005, resulting in a $2.9 million deferral and $0.2 million of savings. The deferral amount will be repaid on May 30, 2011, the end of the lease term. Other terms of the agreement include the ability to repay the $2.9
million deferred rent in 36 monthly installments of $0.1 million, commencing on June 1, 2011 if the lease term is extended for at least 36 months, and early reinstatement of the original rental rates if we successfully raise $75.0 million in a
single public or private equity offering, with the remaining amount of rent deferred under both lease amendments up to that date coming due immediately. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">14 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Cash Used in Operating Activities </I></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Net cash used in operating activities was $26.0 million in the six months ended June 30,
2005, as compared to $21.3 million in the corresponding period of 2004. The increase of $4.7 million was primarily due to an increase in the net loss before depreciation and amortization expense in 2005. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We expect an increase in operating expenses in 2005, as we advance our Phase 3 clinical
trials for alfimeprase and continue to expand our drug development programs. We paid Amgen a milestone fee of $5.0 million in May 2005 as a result of dosing the first patient in the first Phase 3 clinical trial for alfimeprase in April 2005. Our
future milestone payments for drug development under current agreements could total $69.5 million if all milestones are achieved (excluding milestones under the Avecia Development and Validation Agreement), which would significantly affect our
future cash flows. None of these milestone payments are expected to be made in 2005. If we are successful in reaching the commercialization stage, we will also be responsible for paying our collaboration and licensing partners certain product
royalties, depending on product sales volumes. We do not foresee a significantly negative impact in our liquidity based on potential royalty payment obligations, as the majority of these payments are related to commercial sales, which provide us
with offsetting cash inflows. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Cash Used in Investing
Activities </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Net cash used in investing activities was $10.5 million in
the six months ended June 30, 2005, as compared to $40.4 million of net cash used in the corresponding period of 2004. The reduction of $29.9 million was primarily due to a $21.1 million reduction in purchases, and an $8.9 million increase in
maturities, of short-term investments in 2005. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Cash
Provided by Financing Activities </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Net cash provided by financing
activities was $67.5 million in the six months ended June 30, 2005, as compared to $67.8 million in the corresponding period of 2004. The amounts are primarily comprised of the net proceeds from public offerings of $68.4 million and $69.5 million in
2005 and 2004, respectively. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our future capital requirements and the adequacy
of available funds will depend on many factors, including those set forth under &#147;Risk Factors&#148;. We may not be able to secure additional financing to meet our funding requirements on acceptable terms, if at all. If we raise additional funds
by issuing equity securities, substantial dilution to our existing stockholders may result. If we are unable to obtain additional funds, we will have to reduce our operating costs and delay our research and development programs. We believe that we
have adequate cash reserves to fund our operations through 2006, depending on assumptions regarding clinical trial enrollment rates and the timing and nature of potential business development agreements. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Contractual Obligations </I></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The following table summarizes our significant contractual obligations as of June 30, 2005,
and the effect such obligations are expected to have on our liquidity and cash flow in the remainder of 2005 and future periods (in thousands): </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2006</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2009</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2010 and<BR>thereafter</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Total</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Contractual obligations:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Operating lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,149</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9,021</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9,292</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9,572</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8,822</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17,363</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">58,219</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Bank loans (a)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">886</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,695</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,420</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">126</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,127</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Note payable (b)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,089</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,089</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Capital lease obligations (a)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">50</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">76</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Related party line of credit (c)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,375</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,750</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,928</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8,053</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Facility restoration obligation (d)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">477</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">477</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total contractual obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,460</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18,567</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14,654</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9,698</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8,822</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17,840</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">76,041</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
</TABLE><HR WIDTH="10%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes interest payments at fixed rates of interest. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fixed interest of 7.5% per annum is accrued and due with the final loan payment to Affymetrix in November 2006. Includes $1.1 million interest accrued as of June 30, 2005.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Interest is accrued at a variable rate based on the current prime rate plus 1% and is due with the final line of credit payment to Dr. Rathmann in October 2007. Includes $1.6
million interest accrued as of June 30, 2005. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes estimated interest accretion at 6% per annum. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The foregoing table does not include milestone payments potentially payable by us under our collaboration agreements and licenses. Such milestone payments are dependent
upon the occurrence of specific milestones events and not the passage of time. Similarly, the table excludes contract termination penalties that are not expected to be realized. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">15 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Critical Accounting Policies and Estimates </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our discussion and analysis of our operating results and financial condition is based upon our consolidated financial statements, which have
been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of the financial statements requires us to make estimates, judgments, and assumptions that affect the reported amounts of
assets, liabilities, revenues and expenses, and related disclosure of contingent amounts. While we believe our estimates, judgments and assumptions are reasonable, the inherent nature of estimates is that actual results will likely be different from
the estimates made. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We believe the following critical accounting policies,
among others, affect the more significant judgments and estimates used in the preparation of our consolidated financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Clinical Trial Drug Manufacturing Expense and Clinical Trial Supplies Asset </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In accordance with Financial Accounting Standards Board (FASB) Statement of Financial Accounting Standards No. 2,<I> &#147;Accounting for
Research and Development Costs&#148;</I> (SFAS 2), we capitalize clinical trial drug manufacturing costs as &#145;Clinical trial supplies&#146;, a current asset on our balance sheet, as long as there are alternative future uses for the related
clinical trial drug material in other indications not currently being studied, (e.g., for alfimeprase, these include deep-vein thrombosis, stroke and acute myocardial infarction). We recognize clinical trial drug manufacturing expense when completed
drug material is shipped from the manufacturing or storage facility to the packaging and distribution facility. On a quarterly basis we evaluate whether there continues to be alternative future use for any capitalized drug material, and if the
material is obsolete or in excess of anticipated requirements. Any capitalized drug material will be charged to expense in the quarter in which there ceases to exist an alternative future use, or if the material is obsolete or in excess of
anticipated requirements, which may result in a significant adverse impact to our financial condition and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Impairment or Disposal of Long-Lived Assets </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Periodically, we determine whether any long-lived asset or related asset group has been impaired based on the criteria established in Statement of Financial Accounting
Standards No. 144,<I> &#147;Accounting for the Impairment or Disposal of Long-Lived Assets&#148;</I> (SFAS 144). SFAS 144 requires, among other things, that impairment losses be recognized whenever the carrying amount of the asset or asset group
exceeds its fair value. Intangibles with determinable useful lives and other long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable, and we
perform an annual impairment review regardless of any such events or changes. Our judgments regarding the existence of impairment indicators are based on historical and projected future operating results, changes in the manner of our use of the
acquired assets, our overall business strategy or market and economic trends. Events may occur that could cause us to conclude that impairment indicators exist and that certain long-lived assets or related asset groups are impaired, which may result
in a significant adverse impact to our financial condition and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2"><B><I>Goodwill </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We applied the
provisions of Statement of Financial Accounting Standards No. 142,<I> &#147;Goodwill and Other Intangible Assets&#148;</I> (SFAS 142) upon the completion of the merger with Variagenics in January 2003. SFAS 142 requires that goodwill and intangible
assets with indefinite useful lives no longer be amortized, but instead be tested for impairment at least annually in accordance with provisions of SFAS 142. SFAS 142 also requires that intangible assets with estimable useful lives be amortized over
their respective estimated useful lives, and reviewed for impairment in accordance with SFAS 144. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">The SFAS 142 goodwill impairment model involves a two-step process. During the first step, we compare the fair value of the reporting unit with its carrying value, including goodwill. The estimated fair value of the
reporting unit, in this case the Nuvelo business segment, being the only business segment in the company, is computed by multiplying the quoted market price of the company&#146;s common stock on the Nasdaq National Market by the outstanding common
stock of the company at that time. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">If the fair value of the reporting unit is
determined to be more than its carrying value, including goodwill, no goodwill impairment is recognized. If the fair value of the reporting unit is determined to be less than its carrying value, goodwill impairment, if any, is computed using the
second step. The second step requires the fair value of the reporting unit to be allocated to all the assets and liabilities of the reporting unit as if the reporting unit had been acquired in a business combination at the date of the impairment
test and the fair value of the reporting unit was the price paid to acquire it. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied value of goodwill, which is used to determine
the impairment amount. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We have designated October 31 as the annual impairment
testing date for our goodwill, although additional testing may be performed if circumstances warrant a re-evaluation. If it is determined that the carrying value of goodwill has been impaired, the value would be reduced by a charge to operations in
the amount of the impairment, which may result in a significant adverse impact to our financial condition and results of operations. There was assessed to be no goodwill impairment based on the testing performed on October 31, 2004. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Clinical Trial and Drug Manufacturing Accruals </I></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We accrue costs for clinical trial and drug manufacturing activities based upon estimates of
the services received and related expenses incurred that have yet to be invoiced by the contract research organizations (CROs), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or other clinical trial
vendors that perform the activities. Related contracts vary significantly in length, and may be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels
are monitored through close communication with the CROs and other clinical trial vendors, including detailed invoice and task completion review, analysis of expenses against budgeted amounts, and pre-approval of any changes in scope of the services
to be performed. Each CRO and significant clinical trial vendor provides an estimate of costs incurred but not invoiced at the end of each period for each individual trial. The estimates are reviewed and discussed with the CRO or vendor as
necessary, and are included in research and development expenses for the related period. For clinical study sites, which are paid quarterly on a per-patient basis to the institutions performing the clinical study, we accrue an estimated amount based
on patient enrollment in each quarter. All estimates may differ significantly from the actual amount subsequently invoiced. No adjustments for material changes in estimates have been recognized in any period presented. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">16 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Revenue Recognition </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii)
the price is fixed and determinable, and (iv) collectibility is reasonably assured. We defer upfront refundable fees and recognize revenues upon the later of when they become nonrefundable or when performance obligations are completed. In situations
where we have no continuing performance obligations, we recognize upfront nonrefundable fees as revenues on the effective date of the related agreement. Upfront nonrefundable licensing fees, including product opt-ins, and certain guaranteed,
time-based payments that require continuing involvement in the form of development, manufacturing or other commercialization efforts by us are recognized as revenue either ratably over the development period if development risk is significant, or
ratably over the manufacturing period or estimated product useful life if development risk has been substantially eliminated. Revenues related to collaborative research agreements and government grants are generally recognized over the related
funding periods for each contract as the services are performed. The terms of such arrangements may cause our operating results to vary considerably from period to period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Stock-Based Compensation </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In accordance with the provisions of Statement of Financial Accounting Standards No. 123,<I> &#147;Accounting for Stock-Based
Compensation&#148;</I> (SFAS 123), as amended by SFAS No. 148,<I> &#147;Accounting for Stock-Based Compensation &#151; Transition and Disclosure&#148;</I> (SFAS 148) we have elected to account for stock-based compensation to employees under the
provisions of Accounting Principles Board Opinion No. 25,<I> &#147;Accounting for Stock Issued to Employees,&#148;</I> and its related interpretations, and to adopt the &#147;disclosure only&#148; alternative described in SFAS 123, as amended by
SFAS 148. Stock options granted to non-employees are accounted for in accordance with SFAS 123 and Emerging Issues Task Force No. 96-18,<I> &#147;Accounting for Equity Instruments that Are Issued to Other than Employees for Acquiring, or in
Conjunction with Selling, Goods or Services.&#148;</I> Effective from the beginning of our 2006 fiscal year, we will be subject to Statement of Financial Accounting Standards No. 123 (revised 2004),<I> &#147;Share-Based Payment&#148;</I>, which is
expected to have a material adverse effect on our consolidated results of operations (see Recent Accounting Pronouncements below). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Income Taxes </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Income taxes are accounted for under the asset and liability method pursuant to Statement of Financial Accounting Standards No. 109,<I> &#147;Accounting for Income
Taxes&#148;</I> (SFAS 109). Under SFAS 109, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their
respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be
recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We record a valuation allowance to reduce deferred income tax assets to an amount that is more likely than not to be realized. Assessment of
the realization of deferred income tax assets requires that estimates and assumptions be made as to the taxable income of future periods. Our deferred tax assets are reduced to zero, as management believes that it is more likely than not that the
deferred tax assets will not be realized. Projection of future period earnings is inherently difficult as it involves consideration of numerous factors such as our overall strategies and estimates of new product development and acceptance, product
lifecycles, selling prices and volumes, responses by competitors, manufacturing costs and assumptions as to operating expenses and other industry specific and macro and micro economic factors. In addition, consideration is also given to ongoing and
constantly evolving global tax laws and our own tax minimization strategies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2"><B><I>Foreign Currency Transactions and Contracts </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">We use foreign exchange forward contracts, and similar instruments, to mitigate the currency risk associated with the acquisition of goods and services under agreements with vendors that are denominated in foreign
currency. These contracts may be designated and documented as cash flow hedges under Statement of Financial Accounting Standards No. 133, <I>&#147;</I><I>Accounting for Derivative Instruments and Hedging Activities&#148;</I> (SFAS 133) at hedge
inception, and will be evaluated for effectiveness at least quarterly. We will only hedge exposures that can be confidently identified and quantified, and will not enter into speculative foreign currency transactions. All contracts will have
maturities of one year or less. In accordance with SFAS 133, all derivatives, such as foreign currency forward contracts, will be recognized as either assets or liabilities in the balance sheet and measured at fair value. The hedges are designed to
match the critical terms of the foreign currency-denominated purchases at inception, and effectiveness will be calculated by comparing the change in fair value of the hedge contract (on a spot-to-spot basis) to the change in fair value of the
underlying hedged item (also on a spot-to-spot basis). The effective component of the hedge gains and losses will be recorded in other comprehensive income (loss) within stockholders&#146; equity in the balance sheet, and recognized in the income
statement when the transaction being hedged occurs. Any hedge ineffectiveness will be recognized immediately as a general and administrative expense. As of June 30, 2005, we had not entered into any foreign exchange forward contracts. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Recent Accounting Pronouncements </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On December 16, 2004, the FASB issued Statement of Financial Accounting Standards No. 123
(revised 2004),<I> &#147;Share-Based Payment&#148;</I> (SFAS 123(R)), an amendment of Statements of Financial Accounting Standards Nos. 123 and 95, that addresses the accounting for share-based awards to employees. The standard requires companies to
recognize as an expense the fair value of stock options and other stock-based compensation to employees. The statement eliminates the ability to account for share-based compensation transactions using APB Opinion No. 25,<I> &#147;Accounting for
Stock Issued to Employees,&#148;</I> (APB 25), and generally requires instead that companies account for such transactions using a fair value based method, such as the Black-Scholes option pricing model, to fairly value stock options and recognize
that value as an expense. The standard will be effective for public companies as of the beginning of the first fiscal year after June 15, 2005. We currently account for our stock-based compensation plans in accordance with APB 25. SFAS 123(R) offers
companies alternative methods of adopting this standard. At present, we have not yet determined which method we will adopt, but regardless of the method, adoption of this statement is expected to have a material adverse effect on our consolidated
results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Off-Balance Sheet Arrangements </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We have not participated in any transactions with unconsolidated entities, such as special
purpose entities (SPEs), which would have been established for the purpose of facilitating off-balance sheet arrangements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Indemnifications </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">In the ordinary course of business, we enter into contractual arrangements under which we may agree to indemnify certain parties from any losses incurred relating to the services they perform on our behalf or for
losses arising from certain events as defined within the particular contract. Such indemnification obligations may not be subject to maximum loss clauses. Historically, payments made related to these indemnifications have been immaterial. In
addition, we have entered into indemnity agreements with each of our directors and executive officers. Such indemnity agreements contain provisions, which are in some respects broader than the specific indemnification provisions contained in
Delaware law. We also maintain an insurance policy for our directors and executive officers insuring against certain liabilities arising in their capacities as such. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">17 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>RISK FACTORS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>We operate in a rapidly changing environment that involves a number of risks, some of which are beyond our control. The following discussion highlights some of these
risks. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>RISKS RELATED TO OUR BUSINESS </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Development of our products will take years, and our products require regulatory approval
before they can be sold. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We have three clinical stage drug candidates.
All of our other potential products currently are in research or pre-clinical development and revenues from the sales of any products resulting from this research and development may not occur for several years, if at all. We cannot be certain that
any of our products will be demonstrated to be safe and effective or that we will obtain regulatory approvals. We cannot predict whether we will be able to develop and commercialize any of our drug candidates successfully. If we are unable to obtain
regulatory approval and successfully commercialize our potential products, our business, results of operations and financial condition will be affected in a materially adverse manner. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We have not yet commercialized any products. We must demonstrate that our product candidates satisfy rigorous standards of safety and
efficacy before the FDA and comparable agencies in foreign markets will allow our product candidates to be sold. We cannot apply for regulatory approval of our potential products until we have performed significant additional research and
development and testing. We cannot be certain that we, or our strategic partners, will be permitted to undertake clinical testing of our potential products or continue clinical testing of alfimeprase, rNAPc2, or ARC183. If we are successful in
initiating clinical trials, we may experience delays in conducting them. Our clinical trials may not demonstrate the safety and efficacy of our potential products, and we may encounter unacceptable side effects or other problems in the clinical
trials that may prevent or limit the use of our products. Should this occur, we may have to delay or discontinue development of the potential product that causes the problem. Even after a successful clinical trial, we cannot market products in the
United States or in foreign countries until we receive the related regulatory approvals. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Our clinical trials may not yield results that will enable us to obtain regulatory approval for our products. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We will only receive regulatory approval for a drug candidate if we can demonstrate in carefully designed and conducted clinical trials that the drug candidate is safe
and effective. We do not know whether our current or any future clinical trials will demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals or will result in marketable products. Clinical trials are lengthy, complex,
and expensive processes with uncertain results. It will take us several years to complete our testing, and failure can occur at any stage of testing. Results attained in pre-clinical testing and early clinical trials may not be predictive of results
that are obtained in later studies. We may suffer significant setbacks in advanced clinical trials, even after promising results in earlier studies. Based on results at any stage of clinical trials, we may decide to repeat or redesign a trial or
discontinue development of one or more of our drug candidates. If we fail to adequately demonstrate the safety and efficacy of our products under development, we will not be able to obtain the required regulatory approvals to commercialize our drug
candidates, and our business, results of operations and financial condition will be materially adversely affected. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Clinical trials are subject to continuing oversight by governmental regulatory authorities and institutional review boards (IRBs), and must meet the requirements of these
authorities in the United States or in foreign countries, including those for informed consent and good clinical practices. We may not be able to comply with these requirements and the FDA, a similar foreign authority, an IRB, or we may suspend or
terminate clinical trials at any time. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Administering our drug candidates to
humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials of our drug candidates and could result in the FDA or other regulatory authorities denying approval of our drug candidates for any or all
targeted indications. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We rely on third parties, including contract research
organizations and outside consultants, to assist us in managing and monitoring clinical trials. Our reliance on these third parties may result in delays in completing, or in failing to complete, these trials if they fail to perform with the speed
and competency we expect. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">If clinical trials for a drug candidate are
unsuccessful, we will be unable to commercialize the drug candidate. If one or more of our clinical trials are delayed, we will be unable to meet our anticipated development or commercialization timelines. Either circumstance could cause the price
of our shares to decline. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>If we encounter difficulties enrolling patients
in our clinical trials, our trials could be delayed or otherwise adversely affected. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Clinical trials for our drug candidates require that we identify and enroll a large number of patients with the disorder under investigation. We may not be able to enroll a sufficient number of patients to complete
our clinical trials in a timely manner. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Patient enrollment is affected by
factors including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">design of the protocol; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the size of the patient population; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">eligibility criteria for the study in question; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">perceived risks and benefits of the drug under study; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">availability of competing therapies; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">efforts to facilitate timely enrollment in clinical trials; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the success of our personnel in making the arrangements with potential clinical trial sites necessary for those sites to begin enrolling patients; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">patient referral practices of physicians; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">availability of clinical trial sites. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay or terminate ongoing or planned clinical
trials, either of which would have a negative effect on our business. Delays in enrolling patients in our clinical trials would also adversely affect our ability to generate product, milestone and royalty revenues and could impose significant
additional costs on us or on our collaborators. In addition, prior to initiating our current Phase 3 acute PAO trial for alfimeprase, we had never conducted a Phase 3 clinical trial, and we may be unable to successfully conduct multiple Phase 3
clinical trials involving such numbers of clinical sites and patients as planned for our alfimeprase Phase 3 clinical trials. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">18 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We face heavy government regulation, and FDA and international regulatory approval of our products is uncertain.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The research, testing, manufacturing and marketing of drug products such
as those proposed to be developed by us or our collaboration partners are subject to extensive regulation by federal, state and local governmental authorities, including the FDA, and comparable agencies in other countries. To obtain regulatory
approval of a drug product, we or our collaboration partners must demonstrate to the satisfaction of the applicable regulatory agency, among other things, that the product is safe and effective for its intended uses. In addition, we must show that
the manufacturing facilities used to produce the products are in compliance with current Good Manufacturing Practices (cGMP) requirements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The process of obtaining FDA and other required regulatory approvals and clearances typically takes several years and will require us to expend substantial capital and
resources. Despite the time and expense expended, regulatory approval is never guaranteed. The number of pre-clinical and clinical tests that will be required for FDA and international regulatory approval varies depending on the drug candidate, the
disease or condition that the drug candidate is in development for, and the regulations applicable to that particular drug candidate. The FDA or comparable international regulatory authorities can delay, limit or deny approval of a drug candidate
for many reasons, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">a drug candidate may not be safe or effective; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the FDA or comparable international regulatory authorities may interpret data from pre-clinical and clinical testing in different ways than we and our collaboration partners
interpret them; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the FDA or comparable international regulatory authorities may not approve our manufacturing processes or facilities or the processes or facilities of our collaboration partners; or
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the FDA or comparable international regulatory officials may change their approval polices or adopt new regulations. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Moreover, if and when our products do obtain such approval or clearances, the marketing,
distribution and manufacture of such products would remain subject to extensive ongoing regulatory requirements. Failure to comply with applicable regulatory requirements could result in: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">warning letters; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">fines; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">civil penalties; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">injunctions; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">recall or seizure of products; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">total or partial suspension of production; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">refusal of the government to grant approvals; or </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">withdrawal of approvals and criminal prosecution. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Any delay or failure by us, or our collaboration partners, to obtain regulatory approvals for our product candidates: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">would adversely affect our ability to generate product, milestone and royalty revenues; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">could impose significant additional costs on us or our collaboration partners; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">could diminish competitive advantages that we may attain; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">would adversely affect the marketing of our products; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">could cause the price of our shares to decline. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Even if we do receive regulatory approval for our drug candidates, the FDA or international regulatory authorities may impose limitations on the indicated uses for which
our products may be marketed, subsequently withdraw approval or take other actions against us, or our products, that are adverse to our business. The FDA and comparable international regulatory authorities generally approve products for particular
indications. An approval for a limited indication reduces the size of the potential market for the product. Product approvals, once granted, may be withdrawn if problems occur after initial marketing. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We also are subject to numerous federal, state and local laws, regulations and
recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, the environment and the use and disposal of hazardous substances used in connection with our discovery, research and
development work, including radioactive compounds and infectious disease agents. In addition, we cannot predict the extent of government regulations or the impact of new governmental regulations that might significantly harm the discovery,
development, production and marketing of our products. We may be required to incur significant costs to comply with current or future laws or regulations, and we may be adversely affected by the cost of such compliance. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">19 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>If we fail to maintain existing collaborative agreements or fail to develop new collaborative arrangements, our
business will be harmed. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The success of our business is dependent, in
significant part, upon our ability to enter into multiple collaboration agreements and to manage effectively the numerous issues that arise from such arrangements. Management of our relationships with these third parties has required and will
require: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">a significant amount of our management team&#146;s time and effort; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">effective allocation of our and third-party resources to multiple projects; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">agreements with third parties as to ownership of proprietary rights and development plans, including clinical trials or regulatory approval strategy; and </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">an ability to obtain and retain management, scientific and other personnel. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In October 2004, Amgen Inc. exercised its rights under the collaboration agreement entered into in January 2002 to convert the relationship from a collaboration into a
licensing arrangement in accordance with terms agreed upon by us and Amgen. In November 2004, we entered into a license agreement with Amgen granting us worldwide rights to develop and commercialize alfimeprase in exchange for payment of previously
negotiated development milestones and royalties. As a result of dosing the first patient in the first Phase 3 clinical trial for alfimeprase on April 15, 2005, we paid a $5.0 million milestone fee to Amgen in May 2005. Additional future milestone
payments under the license agreement could total as much as $35.0 million. Under the terms of the license agreement, Amgen will transfer the technology necessary for the manufacture of alfimeprase to us or to our designated manufacturer. Amgen is
required to continue to supply alfimeprase to us during the transition period. On January 21, 2005, we entered into an Interim Agreement with Avecia Limited (Avecia), our designated manufacturer, for the manufacture of alfimeprase, and on June 30,
2005, we entered into a definitive agreement with Avecia for the scale up and validation of the manufacturing process for alfimeprase, in anticipation of the potential commencement of the manufacture of commercial quantities. While we currently
believe we have enough supplies of alfimeprase for phase 3 trials for the treatment of acute PAO and catheter occlusion, additional supplies may be necessary, and we are not yet certain that Avecia will succeed in manufacturing additional supplies
of alfimeprase for such trials. If Avecia is unable to produce alfimeprase in the quantities and with the quality we need, we may incur significant, additional expenses and our efforts to complete our clinical trials and obtain approval to market
alfimeprase could be significantly delayed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In our collaboration with Archemix
for the development and commercialization of ARC183, we share equally all research and development costs and revenues since our initial funding of these costs reached $4.0 million in the third quarter of 2004. We are obligated to make milestone
payments of $10.0 million upon the first dosing of a patient in a Phase 2 trial and $1.0 million upon the designation of any backup compound selected by both Nuvelo and Archemix for pre-clinical studies. The payment of $10.0 million upon reaching
the Phase 2 milestone is payable even if Archemix voluntarily terminates the collaboration, or does not meet its obligations under the agreement and we terminate the collaboration for Archemix&#146;s default. We have the option to lead
commercialization in which both parties may participate if we establish certain commercialization capabilities; however, if we do not establish such commercialization capabilities, Archemix, or a third party selected by the parties&#146; joint
steering committee, will have the option to lead commercialization. We do not currently have established commercialization experience or an internal trained sales force and we may not successfully develop such capabilities without incurring
additional expenses. If we cannot develop an internal sales force, we will not be able to lead commercialization activities on our own. If we do not lead the commercialization efforts, we are dependent on Archemix or a third party&#146;s experience
in commercialization and ability to perform and we may also incur additional expenses for a third party to undertake commercialization efforts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We are subject to a number of additional risks associated with our collaboration with Archemix for ARC183, including the right of Archemix to terminate its collaboration
with us on limited notice and for reasons outside our control, our limited ability to influence Archemix&#146;s conduct of clinical trials prior to the dosing of the first patient in a Phase 2 trial, and the loss of significant rights if the
collaboration is terminated because we fail to meet our obligations under it. In particular, if Archemix terminates the collaboration for our breach, all of our rights to ARC183 and other collaboration products will become the property of Archemix,
and we may not practice certain activities related to anti-thrombin compounds in the field of modifying blood-clotting times in therapeutic applications through the use of aptamers such as ARC183, including research and development, manufacturing
and commercialization activities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Pursuant to our licensing arrangement with
Dendreon relating to rNAPc2, we are obligated to make milestone payments ranging from $2.0 million to $6.0 million upon the first dosing of the first patient in a Phase 3 clinical trial, upon submission of a new drug application (NDA), and upon
commercialization for the first and second indications. If all milestones are achieved, total milestone payments to Dendreon can reach as much as $23.5 million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On March 31, 2005, we entered into a new collaboration agreement with the Pharmaceutical Division of Kirin Brewery Company, Ltd. (Kirin) for the development and
commercialization of NU206. All operating expenses and profits related to the development and commercialization of NU206 will be shared in a 60 (Nuvelo) / 40 (Kirin) ratio. If the NU206 Agreement is terminated, or Nuvelo or Kirin elects under
certain circumstances to no longer actively participate in the collaboration, the relationship with respect to NU206 will convert from an expense and profit sharing structure to a royalty-based structure. Under the original collaboration agreement
with Kirin, we will continue to jointly own discoveries resulting from this collaboration and to jointly develop and market the resulting products while sharing costs, efforts and revenues with Kirin. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our efforts to manage simultaneously a number of collaboration arrangements may not be
successful, and our failure to manage effectively such collaborations would significantly harm our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Due to these factors and other possible disagreements with Amgen, Avecia, Archemix, Dendreon or Kirin, we may be delayed or prevented from developing or commercializing
alfimeprase, ARC183, rNAPc2 and NU206, or other pre-clinical product candidates, or we may become involved in litigation or arbitration, which would be time-consuming or expensive and could have a material adverse effect on our stock price.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In addition to our existing collaborations, we will focus on effecting new
collaborative arrangements where we would share costs of identifying, developing and marketing drug candidates. We cannot assure you that we will be able to negotiate new collaboration arrangements of this type on acceptable terms, or at all.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">20 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We are currently dependent on third parties for a variety of functions and may enter into future arrangements for the
manufacture and sale of our products. Our arrangements with these third parties may not provide us with the benefits we expect. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We currently rely upon third parties to perform administrative functions and functions related to the research, development, pre-clinical testing and clinical trials of
our drug candidates. In addition, because we do not have the resources, facilities or experience to manufacture our drug candidates on our own, we currently rely, and will continue to rely, on third parties to manufacture, which includes
manufacturing bulk compound, filling and finishing, and labeling and packaging, our drug candidates for clinical trials, and, if our products are approved, in quantities for commercial sales. We currently rely on a number of sole-source service
providers and suppliers and do not have long-term supply agreements with our third-party manufacturers. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">We do not currently have significant manufacturing facilities for clinical or commercial production of our drug candidates and depend on contract research and manufacturing organizations. We may not be able to
finalize contractual arrangements, transfer technology or maintain relationships with such organizations in order to file an investigational new drug application (IND) with the FDA, and proceed with clinical trials for any of our drug candidates.
Until recently, we have relied on Amgen to manufacture our clinical drug product, alfimeprase. We have entered into a definitive Development and Validation Agreement with Avecia for the scale up and validation of the alfimeprase manufacturing
process and are in the process of transitioning manufacture of alfimeprase from Amgen to Avecia, but do not yet have a definitive agreement with Avecia for the manufacture of commercial quantities of alfimeprase. If our efforts are unsuccessful, we
may not have adequate supplies of alfimeprase to complete our clinical trials or to obtain regulatory approvals for alfimeprase on our anticipated schedule. Our drug candidates have never been manufactured on a commercial scale. Third-party
manufacturers may not be able to manufacture these drug candidates at a cost or in quantities necessary to make them commercially viable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In addition, if and when any of our other drug candidates enter the clinical trial phase, we will initially depend on third-party contract manufacturers to produce the
volume of cGMP-grade material needed to complete such trials. We will need to enter into contractual relationships with these or other organizations in order to (1) complete the Good Laboratory Practices (GLP) toxicology and other studies necessary
to file an IND with the FDA, (2) produce a sufficient volume of cGMP-grade material in order to conduct clinical trials of these other drug candidates, and (3) fill and finish, and label and package our material. We cannot be certain that we will be
able to do so on a timely basis or that we will be able to obtain sufficient quantities of material or other manufacturing services on commercially reasonable terms. In addition, the failure of any of these relationships with third-party contract
organizations may delay our filing for an IND or impede our progress through the clinical trial phase. Any significant delay or interruption would have a material adverse effect on our ability to file an IND with the FDA and/or proceed with the
clinical trial phase for any of our drug candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Moreover, contract
manufacturers that we may use must continually adhere to cGMP regulations enforced by the FDA through a facilities inspection program. If one of our contract manufacturers fails to maintain compliance, the production of our product candidates could
be interrupted, resulting in delays, additional costs and potentially lost revenues. In addition, if the facilities of such manufacturers do not pass a pre-approval plant inspection, the FDA will not grant pre-market approval of our products.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We are dependent on third-party contract research organizations to conduct
certain research, including GLP toxicology studies, in order to gather the data necessary to file INDs with the FDA for any of our drug candidates. These third parties may not conduct their research properly, or they may fail to complete their
contract research on the anticipated schedule. In either case, the progress of our clinical programs may delayed and our research and development costs may increase, which may in turn have a material adverse affect on our business. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our reliance on these relationships poses a number of risks, including: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">disagreements with third parties that could disrupt our operation or delay or terminate the research, development or manufacturing of drug candidates, or result in litigation or
arbitration; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">our inability to effectively control the resources devoted by our partners to our programs or products; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">inadequate contractual protection or difficulty in enforcing the contracts if one of our partners fails to perform; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">failure of these third parties to comply with regulatory requirements; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">conflicts of interest between third parties&#146; work for us and their work for another entity, and the resulting loss of their services; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">failure to identify acceptable manufacturers or other suppliers or enter into favorable long-term agreements with them; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">inability of third parties to manufacture, including filing and finishing, and labeling and packaging, our drug candidates in a cost-effective or timely manner or in quantities
needed for clinical trials or commercial sales; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">delays in, or failures to achieve, scale-up to commercial quantities, or changes to current raw material suppliers or product manufacturers (whether the change is attributable to us
or the supplier or manufacturer), resulting in delayed clinical studies, regulatory submissions and commercialization of our drug candidates; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">lack of all necessary intellectual property rights to manufacture and sell our drug candidates. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Given these risks, our current and future arrangements with third parties may not be successful. If these efforts fail, we would be required
to devote additional internal resources to the activities currently performed, or to be performed, by third parties, to seek alternative third-party sources, or to delay our product development or commercialization. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">21 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We may not achieve our projected development goals in the time frames we announce and expect. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We set goals for and make public statements regarding the timing of certain accomplishments,
such as the commencement and completion of clinical trials, anticipated regulatory approval dates and time of product launch, which we sometimes refer to as milestones. The actual timing of these events can vary dramatically due to a number of
factors such as delays or failures in our clinical trials, the uncertainties inherent in the regulatory approval process and delays in achieving manufacturing or marketing arrangements sufficient to commercialize our products. There can be no
assurance that our clinical trials will be completed, that we will make regulatory submissions or receive regulatory approvals as planned or that we will be able to adhere to our current schedule for the launch of any of our products. If we fail to
achieve one or more of these milestones as planned, our business will be materially adversely affected and the price of our shares could decline. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>The success of our potential products in pre-clinical studies does not guarantee that these results will be replicated in humans. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Although our clinical development-stage drug candidates have shown results in pre-clinical
studies, these results may not be replicated in our clinical trials with humans. Consequently, there is no assurance that the results in our pre-clinical studies are predictive of the results that we will see in our clinical trials with humans or
that they are predictive of whether the resulting products will be safe and effective in humans. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>We are dependent on key personnel and we must attract and retain qualified employees, collaborators and consultants. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The success of our business is highly dependent on the principal members of our scientific and management staff, including our senior management team. The loss of the
services of any such individual might seriously harm our product development and commercialization efforts. In addition, we will require additional skilled personnel in areas such as clinical development. Retaining and training personnel with the
requisite skills is challenging and extremely competitive, particularly in Northern California, where we are located. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our success will depend on our ability to attract and retain qualified employees to help develop our potential products and execute our research and development strategy.
We have programs in place to retain personnel, including programs to create a positive work environment and competitive compensation packages. Because competition for employees in our field is intense, however, we may be unable to retain our
existing personnel or attract additional qualified employees. Our success also depends on the continued availability of outside scientific collaborators, including collaborators at research institutions, to perform research and develop processes to
advance and augment our internal research efforts. Competition for collaborators is intense. We also rely on services provided by outside consultants. Attracting and retaining qualified outside consultants is competitive, and, generally, outside
consultants can terminate their relationship with us at will. If we do not attract and retain qualified personnel, outside consultants and scientific collaborators, or if we experience turnover or difficulties recruiting new employees or outside
consultants, our research and development programs could be delayed and we could experience difficulties in generating sufficient revenue to maintain our business. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In addition, we do not currently have a marketing and sales organization. As the potential commercialization of our products approaches, we
intend to hire marketing and sales personnel to enable us to participate in the commercialization of our products in the United States. If we are unsuccessful in hiring and retaining sales and marketing personnel with appropriate qualifications and
talent, our ability to generate product revenues would be adversely affected. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B>We plan to relocate our corporate headquarters in 2005, which could result in disruptions to our business and loss of key personnel </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Later this year, we anticipate relocating our corporate headquarters, where all of our employees currently work, from Sunnyvale, California to San Carlos, California. The
relocation could result in disruptions to our business, particularly with regard to information technologies, which could result in the loss of data, and with regard to laboratory operations. In addition, the relocation could cause some of our
employees to seek new employment with employers located closer to their homes. The loss of key employees could have a serious adverse effect on our operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Because we have not yet commercialized any of our drug candidates, our ability to develop and subsequently commercialize products is unproven. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We have not yet commercialized any of our in-licensed therapeutic product candidates.
Moreover, we have not developed any therapeutic products using proteins produced by the genes we have discovered in our internal research programs. Before we make any products available to the public from our internal research and development
programs, we or our collaboration partners will need to conduct further research and development and complete laboratory testing and animal and human studies. We, or our collaboration partners, will need to obtain regulatory approval before
releasing any drug products. We have spent, and expect to continue to spend, significant amounts of time and money in our internal research programs in determining the function of genes and the proteins they produce, using our own capabilities and
those of our collaboration partners. Such a determination process constitutes the first step in developing commercial products from our internal research programs. We also have spent and will continue to spend significant amounts of time and money
in developing processes for manufacturing our recombinant proteins under pre-clinical development, yet we may not be able to produce sufficient proteins for pre-clinical studies. A commercially viable product may never be developed from our gene
discoveries. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our commercialization of products is subject to several risks,
including but not limited to: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the possibility that a product is toxic, ineffective or unreliable; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">failure to obtain regulatory approval for the product; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">difficulties in manufacturing the product on a large scale, or inability to market in an economically feasible manner; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">competition from superior products; or </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">third-party patents that preclude us from marketing a product. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">22 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our internal drug development programs are currently in the research stage or in pre-clinical development. None of our
potential therapeutic protein candidates from our own portfolio has advanced to Phase 1 clinical trials. Our programs may not move beyond their current stages of development. Even if our internal research does advance, we will need to engage in
certain additional pre-clinical development efforts to determine whether a product is sufficiently safe and effective to enter clinical trials. We have little experience with these activities and may not be successful in developing or
commercializing products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Under our Original Agreement with Kirin, Kirin has
primary responsibility for clinical development in its territory and we have primary responsibility in our territory. Under our collaboration with Archemix, Archemix leads development until the first dosing of a patient in a Phase 2 clinical trial,
and thereafter, a joint steering committee will designate one party to lead development until commercialization. With respect to these arrangements, we run the risk that Kirin or Archemix may not pursue clinical development in a timely or effective
manner. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Any regulatory approvals that we or our collaboration partners receive
for our product candidates may be subject to limitations on the intended uses for which the product candidates may be marketed or contain requirements for potentially costly post-marketing follow-up studies. In addition, if the FDA approves of our
or our collaboration partners&#146; product candidates, the labeling, packaging, adverse event reporting, storage, advertising, promotion and record-keeping for the products will be subject to extensive regulatory requirements. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We, our collaborators and our suppliers, may also not be able to produce any products in
commercial quantities at a reasonable cost or may not be able to successfully market such products. If we do not develop a commercially viable product, then we will suffer significant harm to our business, financial condition and operating results.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We lack marketing and commercialization experience for biopharmaceutical
products and we may have to rely on third parties for these capabilities. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">We currently have no sales, marketing or distribution capability. As the potential commercialization of our products approaches, we intend to hire marketing and sales personnel to enable us to participate in the commercialization of our
products in the United States. If we are unsuccessful in hiring and retaining sales and marketing personnel with appropriate technical and sales expertise or in developing an adequate distribution capability to support them, our ability to generate
product revenues will be adversely affected. To the extent we cannot or choose not to use internal resources for the marketing, sales or distribution of any potential products in the United States or elsewhere, we intend to rely on collaboration
partners or licensees. We may not be able to establish or maintain such relationships. To the extent that we depend on collaboration partners or other third parties for marketing and distribution, any revenues we receive will depend upon their
efforts. Such efforts may not be successful, and we will not be able to control the amount and timing of resources that collaboration partners or other third parties devote to our products. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Our products may not be accepted in the marketplace, and we may not be able to generate
significant revenue, if any. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Even if they are approved for marketing, our
products, if any, may never achieve market acceptance among physicians, patients and the medical community. Our products, if successfully developed, will compete with a number of traditional drugs and therapies manufactured and marketed by major
pharmaceutical and other biotechnology companies. Our products will also compete with new products currently under development by such companies and others. The degree of market acceptance of any products developed by us, alone, or in conjunction
with our collaboration partners, will depend on a number of factors, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the establishment and demonstration of the clinical efficacy and safety of the products; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">convenience and ease of administration; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">cost-effectiveness; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">our products&#146; potential advantages over alternative treatment methods; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">marketing, sales and distribution support of our products; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">reimbursement policies of government and third-party payers. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Physicians, patients or the medical community in general may not accept and utilize any of the products that we alone, or in conjunction with our collaboration partners,
develop. In practice, competitors may be more effective in marketing their drugs. The lack of such market acceptance would significantly harm our business, financial condition and results of operations. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Even if our product candidates are approved for marketing and are accepted by physicians,
patients and the medical community, the size of the market for these products may be insufficient to sustain our business, or may not provide an acceptable return on our investment in the development of these products. For example, our lead product
candidate, alfimeprase, is undergoing clinical trials for the treatment of acute PAO. There are currently no thrombolytic agents approved for the treatment of acute PAO in the United States or overseas, and as a result there is currently limited
market data available for us to use in judging the market size for a therapeutic product of this nature. The number of incidents of acute PAO that are treatable with an approved thrombolytic agent may not be sufficient to create a sustainable market
for alfimeprase, if approved. As a result, the commercialization of alfimeprase for the treatment of acute PAO, or any of our other product candidates, could fail even if we receive marketing approval from the FDA or similar foreign authority, and
acceptance by the medical and patient communities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">23 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We face intense competition. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The biopharmaceutical industry is intensely competitive and is accentuated by the rapid pace of technological development. We expect to face
increased competition in the future as new companies enter our markets. Research and discoveries by others may result in breakthroughs that render our potential products obsolete even before they begin to generate any revenue. Our competitors
include major pharmaceutical and biotechnology firms, many of which have substantially greater research and product development capabilities and financial, scientific, marketing and human resources than we have. Our lead product candidate
alfimeprase, if approved, will face competition in the catheter occlusion indication from alteplase, an approved Genentech, Inc. product, and will potentially face competition in the acute peripheral arterial occlusion, or PAO, indication from
product candidates being developed and/or marketed by Abbot Laboratories, Protein Design Labs, Inc. and Genentech. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our competitors may obtain patents and regulatory approvals for their competing products more rapidly than we, or our collaboration partners, or develop products that are
more effective than those developed by us, or our collaboration partners. Any potential products based on genes we identify ultimately will face competition from other companies developing gene-based products as well as from companies developing
other forms of treatment for diseases which may be caused by, or related to, the genes we identify. Similarly, our products will face competition from other companies developing similar products as well as from companies developing other forms of
treatment for the same conditions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Many of the companies developing competing
products have significantly greater financial resources than we have. Many such companies also have greater expertise than we or our collaboration partners have in discovery, research and development, manufacturing, pre-clinical and clinical
testing, obtaining regulatory approvals and marketing. Other smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These companies and institutions
compete with us in recruiting and retaining qualified scientific and management personnel as well as in acquiring technologies complementary to our programs. We will face competition with respect to: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">product efficacy and safety; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the timing and scope of regulatory approvals; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">availability of resources; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">reimbursement coverage; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">price and patent position, including the potentially dominant patent positions of others. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">There can be no assurance that research and development by others will not render the products that we may develop obsolete or uneconomical,
or result in treatments or cures superior to any therapy developed by us or that any therapy we develop will be preferred to any existing or newly-developed alternative products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We face uncertainty with respect to coverage, pricing, third-party reimbursements and healthcare reform. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our ability to collect significant royalties from our products may depend on our ability,
and the ability of our collaboration partners or customers, to obtain adequate levels of coverage for our products and reimbursement from third-party payers such as: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">government health administration authorities; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">private health insurers; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">health maintenance organizations; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">pharmacy benefit management companies; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">other healthcare-related organizations. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Third-party payers may deny coverage or offer inadequate levels of reimbursement if they determine that a prescribed product or device has not received appropriate
clearances from the FDA or other government regulators, is not used in accordance with cost-effective treatment methods as determined by the third-party payer, or is experimental, unnecessary or inappropriate. If third-party payers deny coverage or
offer inadequate levels of reimbursement, we may not be able to market our products effectively. We also face the risk that we will have to offer our products at prices lower than anticipated as a result of the current trend in the United States
towards managed healthcare through health maintenance organizations. Currently, third-party payers are increasingly challenging the prices charged for medical products and services. Prices could be driven down by health maintenance organizations
that control or significantly influence purchases of healthcare services and products. Existing U.S. laws, such as the Medicare Prescription Drug and Modernization Act of 2003, or future legislation to reform healthcare or reduce government
insurance programs could also adversely affect prices of our approved products, if any. The cost-containment measures that healthcare providers are instituting and the results of potential healthcare reforms may prevent us from maintaining prices
for our products that are sufficient for us to realize profits and may otherwise significantly harm our business, financial condition and operating results. In addition, to the extent that our products are marketed outside of the United States,
foreign government pricing controls and other regulations may prevent us from maintaining prices for our products that are sufficient for us to realize profits and may otherwise significantly harm our business, financial condition and operating
results. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">24 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We may merge with or acquire other companies, and our failure to receive the anticipated benefits in these
transactions could harm our business. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In January 2003, we merged with
Variagenics, and we may merge with or acquire other companies in the future. The success of any merger or acquisition depends, in part, on our ability to realize the anticipated synergies, cost savings and growth opportunities from integrating the
business of the merged or acquired company with our business. The integration of two independent companies is a complex, costly and time-consuming process. The difficulties of combining the operations of the companies and/or our subsidiary include,
among others: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">consolidating research and development operations; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">retaining key employees; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">consolidating corporate and administrative infrastructures; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">preserving the research and development and other important relationships of the companies; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">integrating and managing the technology of two companies; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">using the merged or acquired company&#146;s liquid capital and other assets efficiently to develop the business of the combined company; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">minimizing the diversion of management&#146;s attention from ongoing business concerns; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">coordinating geographically separate organizations. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Moreover, we assumed the costs of defending against litigation claims asserted against Variagenics, and anytime we, or a subsidiary, merge with or acquire another
company, we will be exposed to similar costs. In addition, we may be exposed to a number of other risks in connection with future transactions, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">we may experience unbudgeted expenses in attempting to complete the transaction and integration process and exposure to unknown liabilities of the merged or acquired business; and
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">our stock price may suffer if the former stockholders of the merged or acquired entity dispose of significant numbers of shares of our common stock that they receive in the
transaction within a short period of time. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We cannot assure you
that we will receive all of the anticipated benefits of any mergers or acquisitions, or that any of the risks described above will not occur. Our failure to receive anticipated benefits of, and our exposure to inherent risks in, any such merger or
acquisition transaction could significantly harm our business, financial condition and operating results. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>We are subject to the risk of natural disasters. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Our facilities are located in Northern California. If a fire or other natural disaster (such as an earthquake) disrupts our research or development efforts, our business, financial condition and operating results
could be materially adversely affected. Some of our landlords may maintain earthquake coverage for our facilities. Although we maintain personal property and business interruption coverage, we do not maintain earthquake coverage for personal
property or resulting business interruption. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>RISKS RELATED TO OUR CAPITAL
STRUCTURE AND FINANCIAL RESULTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We have not been profitable,
anticipate continuing losses and may never become profitable. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We had net
losses of $50.2 million in 2003, $52.5 million in 2004 and $31.7 million in the six months ended June 30, 2005. As of June 30, 2005, we had an accumulated deficit of $287.7 million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">All of our product candidates are in various stages of product development, and some are still in research or in early development. None of
them are approved for sale. The process of developing our drug products will require significant additional research and development, pre-clinical testing, clinical trials and regulatory approvals. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">These activities, together with general administrative and other expenses, are expected to
result in operating losses for the foreseeable future. To date, we have not generated any revenues from product sales. We do not expect to achieve significant product sales or royalty revenue for several years, and we may never do so. We expect to
incur additional operating losses in the future, and these losses may increase significantly as we continue pre-clinical research and clinical trials, apply for regulatory approvals, develop our drug candidates, expand our operations and develop
systems that support commercialization of our potential products. These losses, among other things, have caused and may cause our stockholders&#146; equity and working capital to decrease. We may not be successful in developing our drug candidates,
obtaining regulatory approvals and commercializing our products, and our operations may not be profitable even if any of our drug candidates are commercialized. We may never generate profits and, as a result, the trading price of our common stock
could decline. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Moreover, utilization of our net operating loss carryforwards
and credits may be subject to an annual limitation due to the &#147;change in ownership&#148; provisions of the Internal Revenue Code of 1986 and similar state law provisions. It is possible that certain transactions that we have entered into,
including our merger with Variagenics that occurred in January 2003, when considered in connection with other transactions, may result in a &#147;change in ownership&#148; for purposes of these provisions. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">25 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In January 2005, we entered into a lease agreement for 61,826 square feet of industrial space in San Carlos, California.
In connection with our lease of this new facility, we are examining the potential to sublease or otherwise exit our existing facility at 985 Almanor Avenue in Sunnyvale, California, which is currently primarily being used for storage and for which
we have a lease through May 30, 2011. In accordance with Statement of Financial Accounting Standards No. 146,<I> &#147;Accounting for Costs Associated with Exit or Disposal Activities,&#148;</I> if we sublease or otherwise exit this facility, we
could incur a significant charge to our earnings based on the remaining lease rental expense for this facility, reduced by the estimated income from sublease rental, if any. As of June 30, 2005, the remaining lease rental expense for this facility
was $33.3 million. Similarly, in accordance with Statement of Financial Accounting Standards No. 144,<I> &#147;Accounting for the Impairment or Disposal of Long-Lived Assets,&#148;</I> if we sublease or otherwise exit this facility, we could also
incur a significant charge to our earnings for the impairment of leasehold improvements related to this facility, based on the difference between their carrying value and fair value at the time of the sublease or exit. As of June 30, 2005, this
difference was estimated to be $4.0 million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We will need to raise
additional capital, and such capital may be unavailable to us when we need it or not available on acceptable terms. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We will need to raise significant additional capital to finance the research and clinical development of our drug products. If future securities offerings are successful,
they could dilute our current shareholders&#146; equity interests and reduce the market price of our common stock. Financing may be unavailable when we need it or may not be available on acceptable terms. The unavailability of financing may require
us to delay, scale back or eliminate expenditures for our research, development and marketing activities necessary to commercialize our potential biopharmaceutical products. We may also be required to raise capital by granting rights to third
parties to develop and market drug candidates that we would prefer to develop and market on our own, potentially reducing the ultimate value that we could realize from these drug candidates. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">If we are unable to obtain additional financing when we need it, the capital markets may
perceive that we are not able to raise the amount of financing we desire, or on the terms that we desire. This perception, if it occurs, may negatively affect the trading price of our common stock. If sufficient capital is not available, we may be
forced to delay, reduce the scope of, eliminate or divest one or more of our research or development programs. Any such action could significantly harm our business, financial condition and results of operations. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our future capital requirements and the adequacy of our currently available funds will depend
on many factors, including, among others, the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">our ability to maintain, and the financial commitments involved in, our existing collaborative and licensing arrangements; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">our ability to establish new collaborative relationships with other companies to share costs and expertise of identifying and developing drug candidates; </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the magnitude and scope of our research and development programs, including development of product candidates; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">continued scientific progress in our research and development programs, including progress in our research and pre-clinical studies; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the cost involved in any facilities expansion to support research and development of our product candidates; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the cost of manufacturing our material for pre-clinical, clinical and commercial purposes; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">progress in clinical studies of our products, including alfimeprase, rNAPc2 and ARC 183; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the cost of prosecuting and enforcing our intellectual property rights; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the time and cost involved in obtaining regulatory approvals; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">our need to develop, acquire or license new technologies or products; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">competing technological and market developments; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">our ability to use our common stock to repay the outstanding note to Affymetrix and our line of credit from our Chairman, Dr. George B. Rathmann; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">future funding commitments to our collaborators; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">general conditions in the financial markets and in the biotech sector; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the uncertain condition of the capital markets and in the biotech sector; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">other factors not within our control. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">26 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We may face fluctuations in operating results. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our operating results may rise or fall significantly as a result of many factors, including: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the amount of research and development we engage in; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the number of product candidates we have and their progress in research and pre-clinical studies; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">our ability to expand our facilities to support our operations; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">our ability to maintain existing and enter into new strategic relationships; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the scope, duration and effectiveness of our collaborative arrangements; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the costs involved in prosecuting, maintaining and enforcing patent claims; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the possibility that others may have or obtain patent rights that are superior to ours; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">changes in government regulation; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">changes in accounting policies or principles; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">release of successful products into the market by our competitors. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Excluding our three clinical stage drug candidates, our potential products currently are in research or pre-clinical development, and revenues from the sales of any
products resulting from this research and development may not occur for several years, if at all. A high percentage of our expenses are fixed costs such as lease obligations. As a result, we may experience fluctuations in our operating results from
quarter to quarter and continue to generate losses. Quarterly comparisons of our financial results may not necessarily be meaningful, and investors should not rely upon such results as an indication of our future performance. In addition, investors
may react adversely if our reported operating results are less favorable than in a prior period or are less favorable than those anticipated by investors or the financial community, which may result in a drop of our stock price. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Our stock price has historically been and is likely to remain highly volatile, and an
investment in our stock could suffer a decline in value. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Stock prices and
trading volumes for many biopharmaceutical companies fluctuate widely for a number of reasons, including factors which may be unrelated to their businesses or results of operations such as media coverage, legislative and regulatory measures and the
activities of various interest groups or organizations. This market volatility, as well as general domestic or international economic, market and political conditions, could materially and adversely affect the market price of our common stock and
the return on your investment. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Historically, our stock price has been
extremely volatile. Between January 1, 2004 and December 31, 2004, the price ranged between a high of $16.50 per share and a low of $6.77 per share, and between January 1, 2005 and June 30, 2005 ranged between a high of $10.33 per share and a low of
$5.75 per share. The significant market price fluctuations of our common stock are due to a variety of factors, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the depth of the market for the common stock; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the experimental nature of our potential products; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">actual or anticipated fluctuations in our operating results; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">sales of our common stock by existing holders, or sales of shares issuable upon exercise of outstanding options and warrants, upon repayment of our outstanding note to Affymetrix,
or upon repayment of our line of credit with Dr. Rathmann; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">market conditions relating to the biopharmaceutical and pharmaceutical industries; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">any announcements of technological innovations, new commercial products, or clinical progress or lack thereof by us, our collaborative partners or our competitors;
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">announcements concerning regulatory developments, developments with respect to proprietary rights and our collaborations; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">changes in or our failure to meet market or, to the extent securities analysts follow our common stock, securities analysts&#146; expectations; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">loss of key personnel; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">changes in accounting principles; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">general market conditions; or </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">public concern with respect to our products. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In addition, the stock market in general, and the market for biotechnology and other life science stocks in particular, has historically been subject to extreme price and
volume fluctuations. This volatility has had a significant effect on the market prices of securities issued by many companies for reasons unrelated to the operating performance of these companies. In the past, following periods of volatility in the
market price of a company&#146;s securities, class action securities litigation has often been instituted against such a company. Any such litigation instigated against us could result in substantial costs and a diversion of management&#146;s
attention and resources, which could significantly harm our business, financial condition and operating results. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">27 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Future sales of our common stock may depress the market price of our common stock. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Sales in the public market of substantial amounts of our common stock could depress
prevailing market prices of our common stock. As of June 30, 2005, we had 42,049,297 shares of our common stock outstanding. All of these shares are freely transferable without restriction or further registration under the Securities Act of 1933, as
amended, or the Securities Act, except for shares held by our directors, officers and greater than five percent stockholders and unregistered shares held by non-affiliates. As of June 30, 2005, our directors, officers and greater than five percent
stockholders held approximately 5.75% of the shares of our outstanding common stock. Although we do not believe that our directors, officers and greater than five percent stockholders have any present intentions to dispose of large amounts of any
shares of common stock owned by them, there can be no assurance that such intentions will not change in the future. The sale of these additional shares could depress the market price of our common stock. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We have granted registration rights in connection with the issuance of our securities to a
number of our stockholders and warrant holders. In the aggregate, as of June 30, 2005, these registration rights covered approximately 1,516,792 shares of our common stock which were then outstanding or which may become outstanding upon the exercise
of warrants that were then outstanding. If these registration rights, or similar registration rights that may apply to securities we may issue in the future, are exercised, it could result in additional sales of our common stock in the market, which
may have an adverse effect on our stock price. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In addition, under registration
statements on Form S-8 under the Securities Act, as of June 30, 2005 we have registered approximately 5,520,839 shares of our common stock which may be issued under our 2004 Equity Incentive Plan, 2002 Equity Incentive Plan, 1995 Stock Option Plan,
Non-Employee Director Stock Option Plan, Scientific Advisory Board/Consultants Stock Option Plan, the Variagenics, Inc. Amended 1997 Employee Director and Consultant Stock Option Plan and stock option agreements entered into outside of any of our
stock option plans. Included in the 5,520,839 shares, options to exercise 4,648,120 shares of our common stock were outstanding under the specified plans as of June 30, 2005, and shares of our common stock acquired pursuant to these plans and
agreements are available for sale in the open market. Additionally, included in the 5,520,839 shares, we have reserved approximately 872,719 shares of our common stock for issuance upon the exercise of outstanding options under stock option
agreements entered into outside of any of our stock option plans. As of June 30, 2005, 3,930,263 shares of the shares issuable upon exercise of our outstanding warrants and options were exercisable. In addition, as of June 30, 2005, we had 2,967,410
shares of our common stock remaining for future option grants under our 2004 Equity Incentive Plan. Under our Employee Stock Purchase Plan, we have approximately 277,461 shares of our common stock reserved for future issuance as of June 30, 2005.
The existence of the currently outstanding warrants and options to purchase our common stock may negatively affect our ability to complete future equity financings at acceptable prices and on acceptable terms. The exercise of those options or
warrants, and the prompt resale of shares of our common stock received, may result in downward pressure on the price of our common stock. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In July 2005, we filed a shelf registration statement with the U.S. Securities and Exchange Commission on Form S-3, and such registration statement was declared effective
in August 2005. Under this shelf registration, we may, from time to time, sell up to $100.0 million of debt securities, preferred stock and/or common stock. In August 2005, we entered into a stock purchase agreement and related registration rights
agreement with Kingsbridge Capital Limited. Under these agreements, we may periodically sell up to $75.0 million in shares of common stock to Kingsbridge Capital over a three-year period. We have agreed, prior to selling any of these shares to
Kingsbridge Capital, to register the shares for resale by Kingsbridge. Should we sell securities under either this shelf registration statement or this stock purchase agreement, it could have a dilutive effective on the holdings of our current
stockholders, and may result in downward pressure on the price of our common stock. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">As of June 30, 2005, 735,800 shares of our common stock were issuable, at our option, to repay a note in the principal amount of $4.0 million held by Affymetrix. Affymetrix has the ability to declare all outstanding principal and interest
under the note immediately due and payable in the event that our market capitalization is under $50.0 million and Affymetrix reasonably determines that the loan evidenced by the note is impaired, and we have an obligation to prepay amounts owing
under the note to the extent that the amounts outstanding exceed 10% of our market capitalization. Moreover, we have registered for resale a portion of these shares on a registration statement that has been declared effective by the Securities and
Exchange Commission. If we decide to repay this note with our common stock, whether pursuant to acceleration of the note or otherwise, the resale of shares of our common stock by Affymetrix may also result in significant downward pressure on the
price of our common stock. In addition, as of June 30, 2005, 1,095,319 shares of common stock were issuable, upon mutual agreement, to convert the promissory note that we have issued under a line of credit with our Chairman, Dr. George Rathmann. If
we agree to repay this note with our common stock, whether pursuant to acceleration of the note or otherwise, the resale of shares of our common stock received by Dr. Rathmann may also result in significant downward pressure on the price of our
common stock. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We will need to raise significant additional capital to finance
the research and clinical development of our drug products. If future securities offerings are successful, they could dilute our current shareholders&#146; equity interests and reduce the market price of our common stock. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We do not intend to pay cash dividends on our common stock in the foreseeable future.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We do not anticipate paying cash dividends on our common stock in the
foreseeable future. Any payment of cash dividends will depend upon our financial condition, results of operations, capital requirements and other factors and will be at the discretion of the Board of Directors. Under our August 31, 2004 Loan and
Security Agreement with Silicon Valley Bank, as amended, we cannot pay dividends without Silicon Valley Bank&#146;s prior written consent, except for dividends paid in shares of our capital stock. Furthermore, we may incur additional indebtedness
that may severely restrict or prohibit the payment of dividends. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We have
implemented anti-takeover provisions that could discourage, prevent or delay a takeover, even if the acquisition would be beneficial to our stockholders. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The existence of our stockholder rights plan and provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more
difficult for a third party to acquire us, even if doing so would benefit our stockholders. These provisions: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">establish a classified board of directors so that not all members of our board may be elected at one time; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">authorize the issuance of up to 5,000,000 shares of preferred stock that could be issued by our board of directors to increase the number of outstanding shares and hinder a takeover
attempt; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">limit who may call a special meeting of stockholders; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">prohibit stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders; and </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon at a stockholder meeting.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">28 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Specifically, our certificate of incorporation provides that all stockholder action must be effected at a duly called
meeting, and not by a written consent. The by-laws provide, however, that our stockholders may call a special meeting of stockholders only upon a request of stockholders owning at least 50% of our common stock. These provisions of our certificate of
incorporation and our by-laws could discourage potential acquisition proposals and could delay or prevent a change in control. We designed these provisions to reduce our vulnerability to unsolicited acquisition proposals and to discourage certain
tactics that may be used in proxy fights. These provisions, however, could also have the effect of discouraging others from making tender offers for our shares. As a consequence, they also may inhibit fluctuations in the market price of our shares
that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in our management. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We are permitted to issue shares of our preferred stock without stockholder approval upon such terms as our board of directors determines. Therefore, the rights of the
holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of our preferred stock that may be issued in the future. In addition, the issuance of preferred stock could have a dilutive effect on the
holdings of our current stockholders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On June 5, 1998, our board of directors
adopted a rights plan and declared a dividend with respect to each share of our common stock then outstanding. This dividend took the form of a right, which entitles the holders to purchase one one-thousandth of a share of our Series A junior
participating preferred stock at a purchase price that is subject to adjustment from time to time. These rights have also been issued in connection with each share of our common stock issued after June 15, 1998. The rights are exercisable only if a
person or entity or affiliated group of persons or entities acquires, or has announced its intention to acquire, 15% (27.5% in the case of certain approved stockholders) or more of our outstanding common stock. The adoption of the rights plan makes
it more difficult for a third party to acquire control of us without the approval of our board of directors. This rights agreement was amended on March 19, 2004, to reflect our reincorporation under Delaware law. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We are subject to the Delaware anti-takeover laws regulating corporate takeovers. These
anti-takeover laws prevent a Delaware corporation from engaging in a merger or sale of more than 10 percent of its assets with any stockholder, including all affiliates and associates of the stockholder, who owns 15 percent or more of the
corporation&#146;s outstanding voting stock, for three years following the date that the stockholder acquired 15 percent or more of the corporation&#146;s stock unless: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the board of directors approved the transaction where the stockholder acquired 15 percent or more of the corporation&#146;s stock; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">after the transaction in which the stockholder acquired 15 percent or more of the corporation&#146;s stock, the stockholder owned at least 85 percent of the corporation&#146;s
outstanding voting stock, excluding shares owned by directors, officers and employee stock plans in which employee participants do not have the right to determine confidentially whether shares held under the plan will be tendered in a tender or
exchange offer; or </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">on or after this date, the merger or sale is approved by the board of directors and the holders of at least two-thirds of the outstanding voting stock that is not owned by the
stockholder. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The provisions of our governing documents,
stockholder rights plan and current Delaware law may, collectively: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">lengthen the time required for a person or entity to acquire control of us through a proxy contest for the election of a majority of our board of directors;
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">discourage bids for our common stock at a premium over market price; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">generally deter efforts to obtain control of us. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We face exposure to currency fluctuations for transactions denominated in foreign currencies, which may adversely affect our results of operations. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">To mitigate the impact of currency exchange rate fluctuations on our cash outflows for
certain foreign currency-denominated purchases, we have developed and implemented a foreign exchange risk management policy utilizing forward contracts to hedge against this exposure. For example, we have entered into $16.7 million of foreign
exchange hedge contracts with Silicon Valley Bank in relation to the Development and Validation Agreement with Avecia Limited, pursuant to which we will be required to make payments to Avecia in British Pounds. Although we use forward contracts to
reduce the impact of foreign currency fluctuations on our future results, these efforts may not be successful, and any such fluctuations could adversely affect our results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Recent accounting pronouncements may impact our future financial position and results of operations </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">There may be potential new accounting pronouncements or regulatory rulings, which may have
an impact on our future financial position and results of operations. On December 16, 2004, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards No. 123 (revised 2004),<I> &#147;Share-Based
Payment&#148;</I> (SFAS 123(R)), an amendment of Statements of Financial Accounting Standards No. 123 and 95, that addresses the accounting for share-based awards to employees. The standard requires companies to recognize as an expense the fair
value of stock options and other stock-based compensation to employees. The statement eliminates the ability to account for share-based compensation transactions using APB Opinion No. 25,<I> &#147;Accounting for Stock Issued to Employees,&#148;</I>
(APB 25), and generally requires instead that such transactions be accounted for using a fair value-based method, such as Black-Scholes, to fairly value stock options and recognize that value as an expense. The standard will be effective for public
companies as of the beginning of the first fiscal year after June 15, 2005. We currently account for our stock-based compensation plans in accordance with APB 25. We will be required to implement SFAS 123(R) effective from the beginning of our 2006
fiscal year, and we expect that its adoption will have a material adverse impact to our consolidated financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We have adopted an Executive Change in Control and Severance Benefit Plan that could discourage, prevent or delay a takeover, even if the acquisition would be
beneficial to our stockholders. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On December 14, 2004, our Board of
Directors approved an &#147;Executive Change in Control and Severance Benefit Plan&#148; for our executive officers and other eligible employees. The purpose of the plan is to provide for the payment of severance benefits and/or change in control
benefits to certain of our eligible employees, and the plan supersedes and replaces any change in control and/or severance plans adopted by us previously. All of our executive employees at the level of Vice President or above have been designated as
participants in the plan and our Board of Directors may designate other eligible individuals as participants. The plan provides that, upon a change in control of the company as defined under the plan, all Nuvelo stock options and stock awards held
by a plan participant will become fully vested. Such shares held by a plan participant will also become fully vested if the participant is terminated without cause or constructively terminated within one month preceding our change in control. If a
participant is terminated without cause or constructively terminated one month before or one year after our change in control, he or she will also be entitled to certain cash severance and continued medical benefits. The change in control and
severance benefits for certain of our employees provided for under this plan could make it more difficult and expensive, or less desirable, for a third party to acquire us, even if doing so would benefit our stockholders. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">29 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>RISKS RELATED TO INTELLECTUAL PROPERTY AND OTHER LEGAL MATTERS </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>The commercial success of our products will be dependent upon our ability to protect the
intellectual property rights associated with our products and drug candidates. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Our competitive success will depend, in part, on our ability to obtain and maintain patent protection for our inventions, technologies and discoveries, including intellectual property that we license. The patent positions of biotechnology
companies involve complex legal and factual questions, and we cannot assure you that our patents and licenses will successfully preclude others from using our technology. We could incur substantial costs in seeking enforcement of our proprietary
rights against infringement. In addition, to obtain a patent on a novel gene or the protein it encodes, we need to identify a utility for the novel gene or the encoded protein we seek to protect under patent law. Identifying a utility may require
significant research and development with respect to which we may incur a substantial expense and invest a significant amount of time. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We currently have, or have in-licensed, issued patents and pending patent applications that cover portions of our in-licensed clinical products. ARC183 is covered both by
a U.S. patent specifically claiming ARC183 and by U.S. patents covering aptamers generically. However, there are no equivalent international applications pending specifically claiming ARC183. International patent applications generically covering
aptamers are pending but we cannot assure you that such patents will issue. We licensed the worldwide rights for all indications of rNAPc2 and all of the rNAPc molecules owned by Dendreon in February 2004. The United States government may claim a
non-exclusive right to use rNAPc2 with respect to the treatment of hemorrhagic fever. We also currently have patents that cover some of our technological discoveries and patent applications that we expect to protect some of our gene, protein and
technological discoveries. We will continue to apply for patents for our discoveries. We cannot assure you that any of our applications will issue as patents, or that any patent issued or licensed to us will not be challenged, invalidated,
circumvented or held unenforceable by way of an interference proceeding or litigation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">The timing of the grant of a patent cannot be predicted. Patent applications describing and seeking patent protection of methods, compositions, or processes relating to proprietary inventions involving human therapeutics could require us to
generate data, which may involve substantial costs. Our pending patent applications may lack priority over others&#146; applications or may not result in the issuance of patents. Even if issued, our patents may not be sufficiently broad to provide
protection against competitors with similar technologies and may be challenged, invalidated or circumvented. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">In addition to patents, we rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop our
competitive position with respect to intellectual property. Nevertheless, these measures may not be adequate to safeguard the technology underlying our products. For example, employees, consultants and others who participate in the development of
our products may breach their agreements with us regarding our intellectual property and we may not have adequate remedies for the breach. Our trade secrets could become known through other unforeseen means. We depend on our collaborators and other
third parties that license intellectual property to us to protect our licensed intellectual property. These collaborators and other third parties could fail to take a necessary step to protect our licensed intellectual property, which could
seriously harm our intellectual property position. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We also may not be able to
effectively protect our intellectual property rights in some foreign countries, as many countries do not offer the same level of legal protection for intellectual property as the United States. Furthermore, certain of the patent applications
describing our proprietary methods are filed only in the United States. Even where we have filed our patent applications internationally, for some cases and in certain countries, we have chosen not to maintain foreign patent protection by opting not
to enter national phase or opting not to pay maintenance annuities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Notwithstanding our efforts to protect our intellectual property, our competitors may independently develop similar or alternative technologies or products that are equal or superior to our technology. Our competitors may also develop
similar products without infringing on any of our intellectual property rights or design around our proprietary technologies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>If our products infringe on the intellectual property rights of others, we could face costly litigation, which could cause us to pay substantial damages and limit our
ability to sell some or all of our products. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Extensive litigation
regarding patents and other intellectual property rights has been common in the biopharmaceutical industry. Litigation may be necessary to assert infringement claims, enforce patent rights, protect trade secrets or know-how and determine the
enforceability, scope and validity of certain proprietary rights. The defense and prosecution of intellectual property lawsuits, United States Patent and Trademark Office interference proceedings, and related legal and administrative proceedings in
the United States and internationally involve complex legal and factual questions. As a result, such proceedings are costly and time-consuming to pursue and their outcome is uncertain. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Regardless of merit or outcome, our involvement in any litigation, interference or other administrative proceedings could cause us to incur
substantial expense and could significantly divert the efforts of our technical and management personnel. An adverse determination may subject us to the loss of our proprietary position or to significant liabilities, or require us to seek licenses
that may include substantial cost and ongoing royalties. Licenses may not be available from third parties, or may not be obtainable on satisfactory terms. An adverse determination or a failure to obtain necessary licenses may restrict or prevent us
from manufacturing and selling our products, if any. These outcomes could materially harm our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our market success depends in part on us neither infringing valid, enforceable patents or proprietary rights of third parties, nor breaching any licenses that may relate
to our technologies and products. We are aware of third-party patents that may relate to our technology. We may be required to obtain licenses to patents or other proprietary rights of others in order to conduct research, development, or
commercialization of some or all of our programs. We plan to seek licenses, as we deem appropriate, but it is possible that we may infringe upon these patents or proprietary rights of third parties. If we do not obtain these licenses, we may
encounter delays in product market introductions, incur substantial costs while we attempt to design around existing patents or not be able to develop, manufacture or sell products. In response, third parties may assert infringement or other
intellectual property claims against us. We may consequently be subjected to substantial damages for past infringement or be required to modify our products if it is ultimately determined that our products infringe a third party&#146;s proprietary
rights. Further, we may be prohibited from selling our products before we obtain a license, which, if available at all, may require us to pay substantial royalties, which could adversely impact our product costs and have an impact on our business.
Further, if we do obtain these licenses, the agreed terms may necessitate reevaluation of the potential commercialization of any one of our programs. Failing to obtain a license could result in litigation. Even if these claims are without merit,
defending a lawsuit takes significant time, may be expensive and may divert management attention from other business concerns. Any public announcements related to litigation or interference proceedings initiated or threatened against us could cause
our stock price to decline. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">30 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We face product liability exposure and potential unavailability of insurance. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We risk financial exposure to product liability claims in the event that the use of products
developed by us, or our collaboration partners, if any, result in personal injury. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">We may experience losses due to product liability claims in the future. We have obtained limited product liability insurance coverage. Such coverage, however, may not be adequate or may not continue to be available to us in sufficient
amounts or at an acceptable cost, or at all. We may not be able to obtain commercially reasonable product liability insurance for any product approved for marketing. A product liability claim or other claim, product recalls, as well as any claims
for uninsured liabilities or in excess of insured liabilities, may significantly harm our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We use hazardous materials, chemicals and patient samples in our business and any disputes relating to improper handling, storage or disposal of these materials could
be time consuming and costly. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our research and development and production
activities involve the controlled use of hazardous or radioactive materials, chemicals, including oxidizing and reducing reagents, patient tissue and blood samples. We, our collaborators and service providers, are subject to federal, state and local
laws and regulations governing the use, storage, handling and disposal of these materials and certain waste products. We could be liable for accidental contamination or discharge or any resultant injury from hazardous materials, and conveyance,
processing, and storage of and data on patient samples. If we, or our collaborators or service providers, fail to comply with applicable laws or regulations, we could be required to pay penalties or be held liable for any damages that result and
this liability could exceed our financial resources. Further, future changes to environmental health and safety laws could cause us to incur additional expense or restrict our operations. In addition, our collaborators and service providers may be
working with these types of hazardous materials, including viruses and hazardous chemicals, in connection with our collaborations. In the event of a lawsuit or investigation, we could be held responsible for any injury caused to persons or property
by exposure to, or release of, patient samples that may contain viruses and hazardous materials. The cost of this liability could exceed our resources. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Variagenics has been named as a defendant in a class action suit and defending this litigation could hurt our business. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Variagenics has been named as a defendant in a securities class action lawsuit alleging the
failure to disclose additional and excessive commissions purportedly solicited by and paid to underwriters who are also named defendants in the lawsuit. Plaintiffs in the suit allege that underwriters took these commissions and in exchange allocated
shares of Variagenics&#146; stock to their preferred customers through alleged agreements with these preferred customers that tied the allocation of initial public offering shares to agreements by the customers to make additional aftermarket
purchases at pre-determined prices. As a result of our merger with Variagenics, we are obligated to continue to defend against this litigation. Currently we are in the process of approving a settlement by and between the issuers that are defendants
in the lawsuit, the insurers of those issuers, and the plaintiffs. We believe that any loss or settlement amount will not be material to our financial position or results of operation, and that any settlement payment and attorneys&#146; fees accrued
with respect to the suit will be paid by our insurance provider. However, we cannot assure you that this will be the case until a final settlement is executed. Failure to finalize a settlement could require us to pay substantial damages. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">31 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx17073_7"></A>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Interest Rate Risk </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We place our
investments with high quality issuers and, by policy, limit the amount of credit exposure with any one issuer. We do not use derivative financial instruments in our investment portfolio. We are averse to principal loss, and strive to ensure the
safety and preservation of our invested funds by limiting default, market and reinvestment risk. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">We have exposure to changes in interest rates on our cash equivalents, which are held primarily in money market funds and debt securities with original maturities of 90 days or
less, and that earn interest at variable rates. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Changes in interest rates do not affect interest income on our short-term investments as they are maintained in corporate debt and asset-backed securities with fixed rates and
original maturities of less than 24 months. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Changes in interest rates do not affect interest income on our restricted cash as it is maintained in commercial paper with fixed rates and original maturities of less than 90 days.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Changes in interest rates do not affect interest expense on our
outstanding bank loans, note payable and capital leases, as they bear fixed rates of interest. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">We have exposure to changes in interest rates on our revolving bank line of credit with Silicon Valley Bank, which bears interest at their prime rate. No draw-downs have been made on this line of credit to date.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We have exposure to changes in interest rates on our line of credit with our
Chairman, which bears interest at the prime rate plus 1%. Our interest rate exposure is mitigated by our ability to repay amounts outstanding under the line of credit with our common stock. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">A hypothetical 10% change in market interest rates is not expected to have a material effect
on our near-term financial condition or results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">There were no
significant changes in our market risk exposures through the second quarter of 2005, since our Form 10-K filing on March 16, 2005. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Foreign Exchange Risk </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Some payments to overseas suppliers of goods or services may be denominated in foreign currencies. In particular, on June 30, 2005, we entered into a Development and Validation Agreement with Avecia Limited, under
which payments for their services will be denominated in British pounds. As a result, our financial results could be adversely affected by future increases in the British pound exchange rate. The Company has implemented a hedging program to mitigate
the impact of currency rate fluctuations on our cash outflows. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We have no
investments denominated in foreign currencies, and therefore our investments are not subject to foreign currency exchange risk. However, at each quarter end we may have liabilities for costs incurred by overseas providers that are denominated in
foreign currencies. The Company has recently implemented a policy of hedging significant foreign currency exposures that can be confidently identified and quantified. An increase or decrease in exchange rates on unhedged exposures may affect our
operating results. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx17073_8"></A>ITEM 4. CONTROLS AND PROCEDURES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We maintain
disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods
specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required
disclosures. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control
objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, we carried out an evaluation, under the supervision and with the participation of our management,
including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the quarter covered by this report. Based on the foregoing, our Chief
Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We continue to review and improve the design and effectiveness of our internal controls over financial reporting in order to remain in compliance with Section 404 of the
Sarbanes-Oxley Act of 2002. There has been no change in our internal controls during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">32 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PART II. OTHER INFORMATION
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx17073_9"></A>ITEM 1. LEGAL PROCEEDING </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">There have been no
material developments in any legal actions reported in our annual report on Form 10-K for the fiscal year ended December 31, 2004. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx17073_10"></A>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Not applicable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx17073_11"></A>ITEM 3. DEFAULTS UPON SENIOR SECURITIES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Not
applicable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx17073_12"></A>ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">The Company held its Annual Meeting of Stockholders on May 24, 2005. At that meeting, a quorum was present and three proposals were voted upon. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Two nominees were elected as Class III Directors, each to hold office until the 2008 annual meeting of stockholders or until his or her successor is duly elected and qualified. The
nominees and the voting for each were as follows: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>NOMINEE</B></FONT></P><HR WIDTH="60" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>FOR</B></FONT></P><HR WIDTH="26" SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1"><B>WITHHELD</B></FONT></P><HR WIDTH="70" SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Dr. George B. Rathmann</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">36,407,475</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,714,109</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Mary K. Pendergast</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">37,986,475</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">135,109</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">An amendment to our Employee Stock Purchase Plan to increase the number shares reserved under it from 250,000 to 500,000 was approved. The voting for the proposal was as follows:
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>VOTES</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">For</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">19,125,992</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Against</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,273,607</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Abstain</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">293,017</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Proxy non-votes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16,428,968</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The selection of KPMG, LLP as our independent auditors for the fiscal year 2005 was ratified. The voting for the proposal was as follows: </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>VOTES</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">For</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">38,064,387</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Against</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">30,519</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Abstain</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">26,678</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The following directors&#146; terms of
office continued after the Annual Meeting of Stockholders on May 24, 2005: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Ted W. Love </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Mark L. Perry </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Burton E. Sobel </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Barry L. Zubrow </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx17073_13"></A>ITEM 5. OTHER INFORMATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Not applicable.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">33 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx17073_14"></A>ITEM 6. EXHIBITS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Number</B></FONT></P><HR WIDTH="42" SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P><HR WIDTH="61" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Agreement and Plan of Merger, dated as of November 9, 2002, among Hyseq, Inc., Vertical Merger Corp. and Variagenics, Inc.(1)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">2.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Agreement and Plan of Merger, dated March 19, 2004, between the Registrant and Nuvelo, Inc., a Nevada corporation and the Registrant&#146;s predecessor in interest.(2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">2.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Stock Purchase Agreement, dated December 3, 2004, entered into by and between SBH Genomics, Inc., Radoje Drmanac, Snezana Drmanac, Nuvelo, Inc., and Affymetrix, Inc.(3)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amended and Restated Certificate of Incorporation of the Registrant.(2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amended and Restated By-Laws of the Registrant.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certificate of Ownership and Merger of Variagenics, Inc. with and into Hyseq, Inc.(4)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Certificate of Amendment to the Amended and Restated Articles of Incorporation, filed in connection with our 1-for-3 reverse stock split.(8)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Nuvelo, Inc. Common Stock Certificate.(2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Rights Agreement between Hyseq, Inc. and U.S. Stock Transfer Corporation dated June 5, 1998.(5)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Hyseq Promissory Note, dated as of November 13, 2001, in the principal amount of $4,000,000.(6)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Registration Rights Agreement, dated as of November 13, 2001, between Hyseq, Inc. and Affymetrix, Inc.(6)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Pledge and Security Agreement, dated as of November 13, 2001, between Hyseq, Inc. and Affymetrix, Inc.(6)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment to Rights Agreement, dated as of November 9, 2002, between Hyseq, Inc. and U.S. Stock Transfer Corporation.(7)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Warrant to purchase 1,491,544 shares of Common Stock of Hyseq, Inc., entered into January 8, 2002.(9)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Warrant, dated as of April 5, 2002.(10)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Replacement Warrant to purchase 195,130 shares of Common Stock of Nuvelo, Inc, dated as of January 20, 2005. (11)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Replacement Warrant to purchase 200,000 shares of Common Stock of Nuvelo, Inc, dated as of January 20, 2005. (11)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.11</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment to Rights Agreement, dated as of March 19, 2004, between Nuvelo, Inc. and U.S. Stock Transfer Corporation.(2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.12</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certificate of Designations of Series A Junior Participating Preferred Stock.(2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.13</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Replacement Warrant to purchase 50,000 shares (pre split) of Common Stock of Nuvelo, Inc., dated as of June 7, 2005. (12)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.14</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Reference is made to Exhibits 3.1 through 3.4.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.5*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amended Employee Stock Purchase Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.41*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Nuvelo, Inc. 2004 Equity Incentive Plan, as amended.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.54</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">First Amendment to Lease, dated May 10, 2005, between BMR-2001 Industrial Road LLC and Nuvelo, Inc. (13)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.55*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Development and Validation Agreement, dated June 30, 2005, between Avecia Limited and Nuvelo, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">31.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certificate of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">31.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certificate of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">32.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
</TABLE><HR WIDTH="10%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Filed herewith. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc.&#146;s Form 8-K, filed on November 12, 2002, File No. 000-22873.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#146;s Form 8-K, filed March 26, 2004, File No. 000-22873.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#146;s Form 8-K, filed December 9, 2004, File No. 000-22873.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#146;s Form 10-K, filed on March 12, 2004, File No. 000-22873.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc.&#146;s Form 8-K, filed on July 31, 1998, File No. 00-22873.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc.&#146;s Annual Report on Form 10-K, for the year ended December 31, 2001, filed
on April 1, 2002, File No. 000-22873. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc.&#146;s Registration Statement on Form S-4, filed on November 27, 2002, File No.
333-101503. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#146;s report on Form 8-K, filed on February 19, 2004, File No. 000-22873.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc.&#146;s Form S-3, filed September 25, 2000, File No. 333-70134.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc.&#146;s report on Form S-3, filed on June 14, 2002, File No. 333-90458.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">34 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#146;s Form 10-K, filed on March 16, 2005, File No. 000-22873.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(12)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#146;s Form S-3, filed July 14, 2005, File No. 333-126591.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(13)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#146;s report on Form 8-K, filed on May 13, 2005, File No. 000-22873.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">35 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx17073_15"></A>SIGNATURE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV
ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Nuvelo, Inc. (Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">/s/ Lee Bendekgey</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Lee
Bendekgey</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Senior Vice President and Chief Financial Officer</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><I>(Duly Authorized and Principal Financial Officer)</I></FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Dated: August 8, 2005
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">36 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Number</B></FONT></P><HR WIDTH="42" SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P><HR WIDTH="61" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Agreement and Plan of Merger, dated as of November 9, 2002, among Hyseq, Inc., Vertical Merger Corp. and Variagenics, Inc.(1)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">2.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Agreement and Plan of Merger, dated March 19, 2004, between the Registrant and Nuvelo, Inc., a Nevada corporation and the Registrant&#146;s predecessor in interest.(2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">2.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Stock Purchase Agreement, dated December 3, 2004, entered into by and between SBH Genomics, Inc., Radoje Drmanac, Snezana Drmanac, Nuvelo, Inc., and Affymetrix, Inc.(3)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amended and Restated Certificate of Incorporation of the Registrant.(2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amended and Restated By-Laws of the Registrant.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certificate of Ownership and Merger of Variagenics, Inc. with and into Hyseq, Inc.(4)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Certificate of Amendment to the Amended and Restated Articles of Incorporation, filed in connection with our 1-for-3 reverse stock split.(8)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Nuvelo, Inc. Common Stock Certificate.(2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Rights Agreement between Hyseq, Inc. and U.S. Stock Transfer Corporation dated June 5, 1998.(5)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Hyseq Promissory Note, dated as of November 13, 2001, in the principal amount of $4,000,000.(6)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Registration Rights Agreement, dated as of November 13, 2001, between Hyseq, Inc. and Affymetrix, Inc.(6)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Pledge and Security Agreement, dated as of November 13, 2001, between Hyseq, Inc. and Affymetrix, Inc.(6)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment to Rights Agreement, dated as of November 9, 2002, between Hyseq, Inc. and U.S. Stock Transfer Corporation.(7)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Warrant to purchase 1,491,544 shares of Common Stock of Hyseq, Inc., entered into January 8, 2002.(9)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Warrant, dated as of April 5, 2002.(10)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Replacement Warrant to purchase 195,130 shares of Common Stock of Nuvelo, Inc, dated as of January 20, 2005. (11)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Replacement Warrant to purchase 200,000 shares of Common Stock of Nuvelo, Inc, dated as of January 20, 2005. (11)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.11</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment to Rights Agreement, dated as of March 19, 2004, between Nuvelo, Inc. and U.S. Stock Transfer Corporation.(2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.12</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certificate of Designations of Series A Junior Participating Preferred Stock.(2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.13</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Replacement Warrant to purchase 50,000 shares (pre split) of Common Stock of Nuvelo, Inc., dated as of June 7, 2005. (12)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.14</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Reference is made to Exhibits 3.1 through 3.4.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.5*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amended Employee Stock Purchase Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.41*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Nuvelo, Inc. 2004 Equity Incentive Plan, as amended.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.54</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">First Amendment to Lease, dated May 10, 2005, between BMR-2001 Industrial Road LLC and Nuvelo, Inc. (13)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.55*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Development and Validation Agreement, dated June 30, 2005, between Avecia Limited and Nuvelo, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">31.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certificate of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">31.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certificate of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">32.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
</TABLE><HR WIDTH="10%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Filed herewith. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc.&#146;s Form 8-K, filed on November 12, 2002, File No. 000-22873.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#146;s Form 8-K, filed March 26, 2004, File No. 000-22873.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#146;s Form 8-K, filed December 9, 2004, File No. 000-22873.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#146;s Form 10-K, filed on March 12, 2004, File No. 000-22873.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc.&#146;s Form 8-K, filed on July 31, 1998, File No. 00-22873.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc.&#146;s Annual Report on Form 10-K, for the year ended December 31, 2001, filed
on April 1, 2002, File No. 000-22873. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc.&#146;s Registration Statement on Form S-4, filed on November 27, 2002, File No.
333-101503. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#146;s report on Form 8-K, filed on February 19, 2004, File No. 000-22873.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">37 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc.&#146;s Form S-3, filed September 25, 2000, File No. 333-70134.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc.&#146;s report on Form S-3, filed on June 14, 2002, File No. 333-90458.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#146;s Form 10-K, filed on March 16, 2005, File No. 000-22873.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(12)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#146;s Form S-3, filed July 14, 2005, File No. 333-126591.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(13)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#146;s report on Form 8-K, filed on May 13, 2005, File No. 000-22873.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">38 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>2
<FILENAME>dex105.htm
<DESCRIPTION>AMENDED EMPLOYEE STOCK PURCHASE PLAN
<TEXT>
<HTML><HEAD>
<TITLE>Amended Employee Stock Purchase Plan</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">EXHIBIT 10.5 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>NUVELO, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EMPLOYEE STOCK PURCHASE
PLAN </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>PURPOSE</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">The purpose of the Nuvelo, Inc. Employee Stock Purchase Plan is to provide eligible Employees of Nuvelo, Inc. and its Affiliates with an opportunity to acquire a proprietary interest in the Company through the
purchase of Common Stock of the Company on a payroll deduction basis. It is believed that participation in the ownership of the Company will be to the mutual benefit of the eligible Employees and the Company. It is intended that this Plan shall
constitute an &#147;employee stock purchase plan&#148; within the meaning of Section 423 of the Internal Revenue Code of 1986, as amended. The provisions of the Plan shall, accordingly, be construed so as to extend and limit participation in a
manner consistent with the requirements of Code Section 423. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>DEFINITIONS</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Plan, have the following meanings. Wherever appropriate, words used in the singular shall be deemed to include
the plural and vice versa, and the masculine gender shall be deemed to include the feminine gender. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(a) <B>Account</B> means the funds accumulated with respect to an Employee as a result of deductions from his paycheck for the purpose of purchasing
Common Stock under the Plan. The funds allocated to an Employee&#146;s Account shall remain the property of the Employee at all times prior to the purchase of the Common Stock, but may be commingled with the assets of the Company and used for
general corporate purposes. No interest shall be paid or accrued on any funds accumulated in the Accounts of Employees. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(b) <B>Affiliate</B> means a corporation, as defined in Section 424(f) of the Code, that is a parent or subsidiary of the Company, direct or indirect.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(c) <B>Board</B> means the Board of Directors of the Company.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(d) <B>Code</B> means the Internal Revenue Code of 1986, as
amended. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(e) <B>Committee</B> means the committee to which
the Board delegates the power to act under or pursuant to the provisions of the Plan, or the Board if no committee is selected. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(f) <B>Common Stock</B> means the shares of common stock of the Company, $.001 par value. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(g) <B>Company</B> means Nuvelo, Inc., a Delaware corporation, and any corporate successor to all or substantially all of
the assets or voting stock of the Company. </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(h) <B>Compensation</B> means the compensation paid to an Employee by the Company during a payroll period
for federal income tax purposes, as reported on an Employee&#146;s Form W-2 (or comparable reporting form) for income tax withholding purposes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(i) <B>Effective Date</B> means the date the Plan is adopted by, and made effective by, the Board, subject to the limitations of Section 16. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(j) <B>Employee</B> means any person who is employed by the Company or an
Affiliate on a regular full-time basis. A person shall be considered employed on a regular full-time basis if he is customarily employed for more than twenty (20) hours per week. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(k) <B>Offering Date</B> means the date on which the Committee grants Employees the option to purchase shares of Common
Stock. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(l) <B>Offering Period</B> means the period between
the Offering Date and the Purchase Date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(m) <B>Purchase
Date</B> means the date on which the Committee purchases the shares of Common Stock, which date shall be the last day of an Offering Period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(n) <B>Participant</B> means an Employee who elects to participate in the Plan. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(o) <B>Plan</B> means the Nuvelo, Inc. Employee Stock Purchase Plan. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>ELIGIBILITY</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">All Employees of the Company and, if designated by the Board, any Affiliate, who are employed by the Company and/or such designated Affiliate shall be eligible to participate in the Plan on the first Offering Date
coincident with, or following the Employee&#146;s first day of employment. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>ADMINISTRATION</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">The Plan shall be administered by the Committee, which shall consist of not less than two (2) members of the Board. Subject to the provisions of the Plan, the Committee shall be vested with full authority to make,
administer, and interpret such rules and regulations as it deems necessary to administer the Plan, and any determination, decision, or action of the Committee in connection with the construction, interpretation, administration, and application of
the Plan shall be final, conclusive, and binding upon all Participants and any and all persons claiming under or through any Participant. Notwithstanding anything to the contrary in the Plan, the Committee shall have the discretion to modify the
terms of the Plan with respect to Participants who reside outside of the United States or who are employed by a subsidiary of the Company that has been formed under the laws of any foreign country, if such modification is necessary in order to
conform such terms to the requirements of local laws. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>STOCK</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(a) The Common Stock to be sold to Participants under the Plan may, at the election of the Company, be either treasury shares, shares acquired on the open
market, and/or </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%">
<FONT FACE="Times New Roman" SIZE="2">shares originally issued for such purpose. The aggregate number of shares of Common Stock that shall be made available for purchase under the Plan shall not
exceed five hundred thousand (500,000) shares, subject to adjustment upon changes in capitalization of the Company as provided in subparagraph (b) below. In the event any purchase right granted under the Plan expires or terminates for any reason
without having been exercised in full or ceases for any reason to be exercisable in whole or in part, the unpurchased shares subject thereto will again be available for purchase by Employees upon the exercise of purchase rights. If the total number
of shares that otherwise would have been acquired under the Plan on any Purchase Date exceeds the number of shares of Common Stock then available under the Plan, the Company shall make a pro rata allocation of the shares remaining available in as
nearly a uniform manner as shall be practicable and as it shall determine to be equitable. In such event, the payroll deductions to be made pursuant to the Participants&#146; authorizations shall be reduced accordingly, or refunded to the
Participants, as the case may be, and the Company shall give written notice of such reduction or refund to each affected Participant. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(b) Appropriate adjustments in the aggregate number of shares of Common Stock that shall be made available for purchase under the Plan shall be made to
give effect to any mergers, consolidations, acquisitions, reorganizations, stock splits, stock dividends, or other relevant changes in the capitalization of the Company occurring after the Effective Date. The establishment of the Plan shall not
affect in any way the right or power of the Company to make adjustments, reclassifications, reorganizations, or changes in its capital or business structure or to merge, consolidate, dissolve, liquidate, sell, or otherwise transfer all or any part
of its business or assets. Adjustments under this Section 5 shall be made in the sole discretion of the Committee, and its decision shall be binding and conclusive. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(c) A Participant shall not have any interest in shares covered by his authorized payroll deduction until shares of Common
Stock are acquired for his Account. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>PARTICIPATION</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(a) Each Employee may become a Participant in the Plan by authorizing a payroll deduction on a form provided by the Committee. Such authorization shall
become effective on the Offering Date coincident with, or the next Offering Date following the delivery of the authorization form to the Committee, provided that the Employee is eligible under Section 3 to participate in the Plan on such Offering
Date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(b) At the time an Employee files his authorization for
a payroll deduction, he shall elect to have deductions made from each paycheck that he receives, such deductions to continue until the Participant withdraws from the Plan or otherwise becomes ineligible to participate in the Plan. Authorized payroll
deductions shall be for a minimum of one percent (1%) and a maximum of ten percent (10%) of the Participant&#146;s Compensation. The deduction rate so authorized shall continue in effect through the Offering Period and each succeeding Offering
Period. A Participant may increase the rate of his payroll deduction effective as of any subsequent Offering Date by filing a new authorization form with the Company fifteen (15) or more days prior to the next Offering Date. A </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%">
<FONT FACE="Times New Roman" SIZE="2">Participant may, at any time during any Offering Period, reduce his rate of payroll deduction by filing a new authorization form with the Company, which
shall become effective as soon as practicable after it is filed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman"
SIZE="2">(c) All Compensation deductions made for a Participant shall be credited to his Account. Except as may otherwise be provided by the Committee under Section 4, a Participant may not make any separate cash payment into his Account.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>PURCHASE OF SHARES</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(a) On the Offering Date when a Participant&#146;s authorization form for a deduction becomes effective, and on each succeeding Offering Date thereafter,
he shall be deemed to have been granted an option to purchase as many full shares of Common Stock as he will be able to purchase with the Compensation deductions credited to his Account during the payroll periods within the applicable Offering
Period for which the Compensation deductions are made. In addition to the foregoing, any cash dividends paid on shares of Common Stock held in his Account shall be added to the Account, and used to purchase Common Stock as otherwise provided herein.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(b) The purchase price for the shares of Common Stock to be
purchased with payroll deductions from the Participant shall be equal to the lesser of ninety-five percent (95%) (or such other amount as the Committee shall authorize, but in no event less than eighty-five percent (85%)) of (i) the &#147;fair
market value&#148; of a share of Common Stock on the Offering Date or (ii) the &#147;fair market value&#148; of a share on the Purchase Date. Fair market value shall be defined as the closing bid price of the Common Stock on the largest national
securities exchange on which such Common Stock is listed at the time the Common Stock is to be valued. If the Common Stock is not then listed on any such exchange, the fair market value shall be the closing sales price if such is reported or
otherwise the mean between the closing &#147;Bid&#148; and the closing &#147;Ask&#148; prices, if any, as reported in the National Association of Securities Dealers Automated Quotation System (&#147;<B>NASDAQ</B>&#148;) for the date of valuation, or
if none, on the most recent trade date thirty (30) days or less prior to the date of valuation for which such quotations are reported. If the Common Stock is not then listed on any such exchange or quoted in NASDAQ, the fair market value shall be
the mean between the average of the &#147;Bid&#148; and the average of the &#147;Ask&#148; prices, if any, as reported in the National Daily Quotation Service for the date of valuation, or, if none, for the most recent trade date thirty (30) days or
less prior to the date of valuation for which such quotations are reported. If the fair market value cannot be determined under the preceding three sentences, it shall be determined in good faith by the Committee. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>TIME OF PURCHASE</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">From time to time, the Committee shall grant to each Participant an option to purchase shares of Common Stock in an amount equal to the number of shares of Common Stock that the accumulated payroll deductions to be
credited to his Account during the Offering Period may purchase at the applicable purchase price. Each Offering Period shall be for a specified period of time to be fixed by the Committee and shall be for no less than one month and no more than
</FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">twenty-seven (27) months&#146; duration. Each Participant who elects to purchase shares of Common Stock hereunder shall be deemed to have exercised his
option automatically on such date of purchase. Administrative and commission costs on purchases shall be paid by the Company. The Committee shall cause to be delivered periodically to each Participant a statement showing the aggregate number of
shares of Common Stock in his Account, the number of shares of Common Stock purchased for him in the preceding Offering Period, his aggregate Compensation deductions for the preceding Offering Period, the price per share paid for the shares of
Common Stock purchased for him during the preceding Offering Period, and the amount of cash, if any, remaining in his Account at the end of the preceding Offering Period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">A Participant may request delivery to him of the cash in his Account or of the shares of Common Stock held in his Account at any time
(subject to any limitations imposed by Section 16(b) of the Securities Exchange Act of 1934), and the delivery thereof shall be made at such regular time as the Company or its transfer agent shall determine. If such delivery is required at a time
other than the normal transfer date set by the Company or its transfer agent, the Participant requesting such transfer shall pay the costs thereof. All of the cash deposits in his Account shall be paid to him promptly after receipt of notice of
withdrawal, without interest. Shares of Common Stock to be delivered to a Participant under the Plan shall be registered in the name of the Participant or, if the Participant so directs in writing to the Committee, in the name of the Participant and
such person(s) as may be designated by the Participant, to the extent permitted by applicable law, and delivered to the Participant as soon as practicable after the request for a withdrawal. If a Participant wishes to sell the shares of Common Stock
in his Account, he may notify the Committee to sell the same, in lieu of a distribution of such shares, in which event all commission costs incurred in connection with the sale of the shares of Common Stock shall be borne by the Participant. The
Company shall pay administrative costs associated therewith other than costs arising from a sale occurring at a time different from the prearranged dates set by the Company or its transfer agent for making such sales. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>CESSATION OF PARTICIPATION</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">A Participant may cease participation in the Plan at any time by notifying the Committee in writing of his intent to cease his participation. If such notice is received
by the Committee the Company shall distribute to the Participant all of his accumulated payroll deductions, without interest. If any Participant ceases participation in the Plan, no further Compensation deductions shall be made on his behalf after
the effective date of his cessation, except in accordance with a new authorization form filed with the Committee as provided in Section 6. Upon ceasing participation in the Plan, a Participant shall not be permitted to reenter the Plan until six (6)
months have elapsed from the date his cessation becomes effective. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>INELIGIBILITY</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">An Employee must be employed by the Company or an Affiliate on the Purchase Date in order to participate in the purchase for that Offering Period. If an option expires without first having been exercised, all funds
credited to the Participant&#146;s Account shall be refunded without interest. If a Participant becomes ineligible to participate in the Plan at any time, all Compensation deductions made on behalf of the Participant that have not been used to
purchase shares of Common Stock </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">shall be paid to the Participant within sixty (60) days after the Committee determines that the Participant is not eligible to participate in the Plan.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">11.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>DESIGNATION OF BENEFICIARY</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">A Participant may file a written designation of a beneficiary who shall receive any shares of Common Stock (or remaining Compensation deductions) credited to the
Participant&#146;s Account under the Plan in the event of such Participant&#146;s death prior to delivery to him of the certificates for such shares (or remaining Compensation deductions). The designation of a beneficiary may be changed by the
Participant at any time by written notice given in accordance with rules and procedures established by the Committee. Upon the death of a Participant, and upon receipt by the Company of proof of the identity and existence, at the Participant&#146;s
death, of a beneficiary validly designated by him under the Plan, the Company shall deliver such shares of Common Stock (or remaining Compensation deductions) to such beneficiary. In the event of the death of the Participant, and in the absence of a
beneficiary validly designated under the Plan who is living at the time of such Participant&#146;s death, the Company shall deliver such shares (or remaining Compensation deductions) to the executor or administrator of the estate of the Participant,
or if no such executor or administrator has been appointed, the Company, in its sole discretion, may deliver such shares (or remaining Compensation deductions) to the Participant&#146;s spouse or to any one or more dependents or relatives of the
Participant, or to such other person or persons as the Company may designate on behalf of the estate of such deceased Participant. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>TRANSFERABILITY</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Neither Compensation deductions nor Plan contributions credited to a Participant&#146;s Account nor any rights with regard to Plan participation or the right to purchase shares of Common Stock under the Plan may be
assigned, transferred, pledged, or otherwise disposed of in any way by a Participant other than by will or the laws of descent and distribution; provided, however, that shares of Common Stock purchased on behalf of a Participant and left in his
Account shall be subject to his absolute control. Any attempted assignment, transfer, pledge, or other disposition shall be void and without effect. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">13.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>AMENDMENT OR TERMINATION</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Board may, without further action on the part of the stockholders of the Company, at any time amend the Plan in any respect, or terminate the Plan, except that it may
not: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(a) Permit the sale of more shares of Common Stock than
are authorized under Section 5; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(b) Change the class of
Affiliates whose Employees are eligible to participate in the Plan; or </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman"
SIZE="2">(c) Effect a change inconsistent with Section 423 of the Code or the regulations issued thereunder. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">14.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>NOTICES</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">All notices or other communications by a Participant under or in connection with the Plan shall be deemed to have been duly given when received in writing by the Chief Financial Officer of the Company or when received
in the form specified by the Committee at the location and by the person designated by the Committee for the receipt thereof. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">15.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>LIMITATIONS</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Notwithstanding any other provisions of the Plan: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
FACE="Times New Roman" SIZE="2">(a) The Company intends that this Plan shall constitute an employee stock purchase plan within the meaning of Section 423 of the Code. Any provisions required to be included in the Plan under said Section, and under
regulations issued thereunder, are hereby included as though set forth in the Plan at length. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
FACE="Times New Roman" SIZE="2">(b) No Employee shall be entitled to participate in the Plan if, immediately after the grant of an option hereunder, the Employee would own stock possessing five percent (5%) or more of the total combined voting power
or value of all classes of stock of the Company or an Affiliate. For purposes of this Section 15, stock ownership shall be determined under the rules of Section 424(d) of the Code and stock that the Employee may purchase under outstanding options
shall be treated as stock owned by the Employee. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(c) No
Employee shall be permitted to purchase Common Stock hereunder if his right and option to purchase Common Stock under this Plan and under all other employee stock purchase plans (as defined in Section 423 of the Code) of the Company or any
Affiliates would result in an entitlement to purchase Common Stock in any one (1) calendar year in excess of a fair market value of $25,000 (determined at the time of grant). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(d) All Employees shall have the same rights and privileges under the Plan, except that the amount of Common Stock that may
be purchased pursuant to the Plan shall bear a uniform relationship to an Employee&#146;s Compensation. All rules and determinations of the Committee shall be uniformly and consistently applied to all persons in similar circumstances. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(e) Nothing in the Plan shall confer upon any Employee the right to continue
in the employment of the Company or any Affiliate or affect the right that the Company or any Affiliate may have to terminate the employment of such Employee. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(f) No Participant shall have any right as a stockholder unless and until certificates for shares of Common Stock are issued to him or allocated to his
Account. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(g) If under any provision of the Plan that requires
a computation of the number of shares of Common Stock to be purchased, the number so computed is not a whole number of shares of Common Stock, such number of shares of Common Stock shall be rounded down to the next whole number. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(h) The Plan is intended to provide shares of Common Stock for investment and not for resale. The Company
does not, however, intend to restrict or influence any Participant in the conduct of his own affairs. A Participant, therefore, may sell shares of Common Stock purchased under the Plan at any time he chooses, subject to compliance with any
applicable federal or state securities laws or any applicable Company restriction or blackout periods; provided, however, that because of certain federal tax requirements, each Participant shall agree, by entering the Plan: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">(i) promptly to give the Company notice of any shares of Common Stock
disposed of within two (2) years after the date of grant of the applicable option, or within one (1) year of the Purchase Date, and the number of such shares disposed of (a &#147;disqualifying disposition&#148;); </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">(ii) that the Company may withhold, pursuant to Code &#167;&#167; 3102,
3301, and 3402, from his wages and other cash compensation paid to him in all payroll periods following in the same calendar year, any additional taxes the Company may become liable for in respect of amounts includable in his income as additional
compensation as a result of a disqualifying disposition of Common Stock acquired under the Plan, or as a result of the acquisition of Common Stock under the Plan; and </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">(iii) that he shall repay the Company any amount of additional taxes the Company may become liable for in respect of amounts
includable in his income as additional compensation as a result of a disqualifying disposition of Common Stock acquired under the Plan, or as a result of the acquisition of Common Stock under the Plan, that cannot be satisfied by withholding from
the wages and other cash compensation paid to him by the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman"
SIZE="2">(i) This Plan is intended to comply in all respects with applicable law and regulations, including with respect to Participants who are officers or directors for purposes of Section 16 of the Securities Exchange Act of 1934, as amended from
time to time, Rule 16b-3 of the Securities and Exchange Commission. In case any one or more provisions of this Plan shall be held invalid, illegal, or unenforceable in any respect under applicable law and regulation (including Rule 16b-3), the
validity, legality, and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal, or unenforceable provision shall be deemed null and void; however, to the extent permitted by law, any
provision that could be deemed null and void shall first be construed, interpreted, or revised retroactively to permit this Plan to be construed in compliance with all applicable law (including Rule 16b-3), so as to further the intent of this Plan.
Notwithstanding anything herein to the contrary, with respect to Participants who are officers and directors for purposes of Section 16(b) of the Securities Exchange Act of 1934, as amended from time to time, and if required to comply with the rules
promulgated thereunder, such Participants shall not be permitted to direct the sale of any Common Stock purchased hereunder until at least six (6) months have elapsed from the date of a purchase, unless the Committee determines that the sale of the
Common Stock otherwise satisfies the then current Rule 16b-3 requirements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">16.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>EFFECTIVE DATE AND APPROVALS</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Plan shall become effective at a time when: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(a) the Plan has been adopted by the Board; and </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(b) a registration statement on Form S-8 under the Securities Act of 1933, as amended, has become effective with respect to the Plan; and </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(c) the Committee has notified the eligible Employees that they may commence
participation in the Plan; and </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(d) the Plan is approved by
the holders of a majority of the outstanding shares of Common Stock of the Company, which approval must occur within the period ending twelve (12) months after the date the Plan is adopted by the Board. In the event such stockholder approval is not
obtained, the Plan shall terminate and have no further force or effect, and all amounts collected from the Participants during any initial Offering Period(s) hereunder shall be refunded. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Unless sooner terminated by the Board, or as set forth above, the Plan shall terminate upon the earlier of (i) the tenth (10th) anniversary
of the adoption of the Plan by the Board, or (ii) the date on which all shares available for issuance under the Plan shall have been sold under the Plan. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">17.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>APPLICABLE LAW</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">All questions pertaining to the validity, construction, and administration of the Plan shall be determined in conformity with the laws of Delaware, to the extent not inconsistent with Section 423 of the Code and the
regulations thereunder. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Adopted March 16, 1998, approved by the
stockholders on May 18, 1998, amended effective May 23, 2000, approved by the stockholders on May 23, 2000, amended November 3, 2002, approved by the stockholders on January 28, 2003, amended and restated on December 14, 2004, amended and restated
on March 23, 2005, approved by the stockholders on May 24, 2005. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">9 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.41
<SEQUENCE>3
<FILENAME>dex1041.htm
<DESCRIPTION>NUVELO, INC. 2004 EQUITY INCENTIVE PLAN, AS AMENDED
<TEXT>
<HTML><HEAD>
<TITLE>Nuvelo, Inc. 2004 Equity Incentive Plan, as amended</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Exhibit 10.41 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>NUVELO, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>2004 EQUITY INCENTIVE PLAN </B></FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">TABLE OF CONTENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Page</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Establishment, Purpose and Term of Plan</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Establishment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Purpose</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Term of Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Definitions and Construction</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Definitions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Construction</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Administration</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Administration by the Committee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Authority of Officers</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Administration with Respect to Insiders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Committee Complying with Section 162(m)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Powers of the Committee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">No Repricing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">No Restricted Stock Award Acceleration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Indemnification</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Shares Subject to Plan</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Maximum Number of Shares Issuable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Adjustments for Changes in Capital Structure</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">5.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Eligibility and Award Limitations</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Persons Eligible for Awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Participation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Incentive Stock Option Limitations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Award Limits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">6.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Terms and Conditions of Options</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Exercise Price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Exercisability and Term of Options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Payment of Exercise Price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of Termination of Service</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Transferability of Options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">7.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Terms and Conditions of Stock Appreciation Rights</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Types of SARs Authorized</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Exercise Price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Exercisability and Term of SARs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Exercise of SARs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">15</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Deemed Exercise of SARs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">15</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of Termination of Service</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">15</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Nontransferability of SARs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">15</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">-i- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">TABLE OF CONTENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">(continued) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Page</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">8.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Terms and Conditions of Restricted Stock Awards</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">15</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Types of Restricted Stock Awards Authorized</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Purchase Price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Purchase Period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Payment of Purchase Price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Vesting and Restrictions on Transfer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Voting Rights; Dividends and Distributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of Termination of Service</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Nontransferability of Restricted Stock Award Rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">9.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Terms and Conditions of Performance Awards</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Types of Performance Awards Authorized</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Initial Value of Performance Shares and Performance Units</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Establishment of Performance Period, Performance Goals and Performance Award Formula</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Measurement of Performance Goals</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">19</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Settlement of Performance Awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">20</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Voting Rights; Dividend Equivalent Rights and Distributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">21</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of Termination of Service</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">21</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Nontransferability of Performance Awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">21</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Terms and Conditions of Restricted Stock Unit Awards</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">22</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Grant of Restricted Stock Unit Awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">22</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Purchase Price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">22</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Vesting</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">22</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Voting Rights, Dividend Equivalent Rights and Distributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">22</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of Termination of Service</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">23</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Settlement of Restricted Stock Unit Awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">23</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Nontransferability of Restricted Stock Unit Awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">23</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">11.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Deferred Stock Units</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">23</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Establishment of Deferred Stock Unit Program</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">23</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Terms and Conditions of Deferred Stock Units</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">12.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Standard Forms of Award Agreement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Award Agreements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Authority to Vary Terms</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">13.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Change in Control</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Definitions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of Change in Control on Options and SARs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">26</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of Change in Control on Restricted Stock Awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of Change in Control on Performance Awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of Change in Control on Restricted Stock Unit Awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of Change in Control on Deferred Stock Units</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">28</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">14.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Compliance with Securities Law</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">28</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">-ii- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">TABLE OF CONTENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">(continued) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Page</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">15.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Tax Withholding</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">28</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">15.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Tax Withholding in General</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">28</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">15.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Withholding in Shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">28</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">16.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Amendment or Termination of Plan</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">29</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">17.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Miscellaneous Provisions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">29</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Repurchase Rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">29</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Provision of Information</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">29</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Rights as Employee, Consultant or Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">29</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Rights as a Stockholder</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">29</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Fractional Shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">30</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Severability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">30</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Beneficiary Designation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">30</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Unfunded Obligation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">30</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">-iii- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>AMENDED AND RESTATED </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>NUVELO, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>2004 EQUITY INCENTIVE PLAN </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B></B>1.<B> <U>E<SMALL>STABLISHMENT</SMALL>, P<SMALL>URPOSE</SMALL>
<SMALL>AND</SMALL> T<SMALL>ERM</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL></U><SMALL></SMALL> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">1.1 <B>Establishment.</B> The Nuvelo, Inc. 2004 Equity Incentive Plan (the <I>&#147;</I><B></B><B><I>Plan</I></B><B></B><I>&#148;</I>) is
hereby established effective as of May 6, 2004, the date of its approval by the stockholders of the Company (the <I>&#147;</I><B></B><B><I>Effective Date</I></B><B></B><I>&#148;</I>). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">1.2 <B>Purpose.</B> The purpose of the Plan is to advance the interests of the Participating Company Group
and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Participating Company Group and by motivating such persons to contribute to the growth and profitability of the Participating Company
Group. The Plan seeks to achieve this purpose by providing for Awards in the form of Options, Indexed Options, Stock Appreciation Rights, Restricted Stock Purchase Rights, Restricted Stock Bonuses, Performance Shares, Performance Units, Restricted
Stock Units and Deferred Stock Units. After the Effective Date, the Company shall terminate, and no longer issue any awards from under, the Company&#146;s 2002 Equity Incentive Plan, Director Stock Option Plan, Scientific Advisory Board/Consultants
Stock Option Plan, 1995 Stock Option Plan and the Variagenics 1997 Employee, Director &amp; Consultant Stock Option Plan. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">1.3 <B>Term of Plan.</B> The Plan shall continue in effect until the earlier of its termination by the Board or the date on which all of
the shares of Stock available for issuance under the Plan have been issued and all restrictions on such shares under the terms of the Plan and the agreements evidencing Awards granted under the Plan have lapsed. However, all Incentive Stock Options
shall be granted, if at all, within ten (10) years from the Effective Date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2"><B></B>2.<B> <U>D<SMALL>EFINITIONS</SMALL> <SMALL>AND</SMALL> C<SMALL>ONSTRUCTION</SMALL></U><SMALL></SMALL>. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.1 <B>Definitions. </B>Whenever used herein, the following terms shall have their respective meanings set forth below: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a)
<I>&#147;</I><B></B><B><I>Affiliate</I></B><B></B><I>&#148;</I> means (i) an entity, other than a Parent Corporation, that directly, or indirectly through one or more intermediary entities, controls the Company or (ii) an entity, other than a
Subsidiary Corporation, that is controlled by the Company directly, or indirectly through one or more intermediary entities. For this purpose, the term &#147;control&#148; (including the term &#147;controlled by&#148;) means the possession, direct
or indirect, of the power to direct or cause the direction of the management and policies of the relevant entity, whether through the ownership of voting securities, by contract or otherwise; or shall have such other meaning assigned such term for
the purposes of registration on Form S-8 under the Securities Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) <I>&#147;</I><B></B><B><I>Award</I></B><B></B><I>&#148;</I> means any Option, Indexed
Option, SAR, Restricted Stock Purchase Right, Restricted Stock Bonus, Performance Share, Performance Unit, Restricted Stock Unit or Deferred Stock Unit granted under the Plan. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(c) <I>&#147;</I><B></B><B><I>Award Agreement</I></B><B></B><I>&#148;</I> means a written agreement between
the Company and a Participant setting forth the terms, conditions and restrictions of the Award granted to the Participant. An Award Agreement may be an &#147;Option Agreement,&#148; an &#147;Indexed Option Agreement,&#148; a &#147;SAR
Agreement,&#148; a &#147;Restricted Stock Purchase Agreement,&#148; a &#147;Restricted Stock Bonus Agreement,&#148; a &#147;Performance Share Agreement,&#148; a &#147;Performance Unit Agreement,&#148; a &#147;Restricted Stock Unit Agreement,&#148;
or a &#147;Deferred Stock Unit Agreement.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(d) <I>&#147;</I><B></B><B><I>Board</I></B><B></B><I></I><I>&#148;</I> means the Board of Directors of the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(e) <I>&#147;</I><B></B><B><I>Code</I></B><B></B><I></I><I>&#148;</I> means the Internal Revenue Code of 1986, as amended, and any
applicable regulations promulgated thereunder. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(f) <I>&#147;</I><B></B><B><I>Committee</I></B><B></B><I></I><I>&#148;</I> means the Compensation Committee or other committee of the Board duly appointed to administer the Plan and having such powers as shall be specified by the Board. If
no committee of the Board has been appointed to administer the Plan, the Board shall exercise all of the powers of the Committee granted herein, and, in any event, the Board may in its discretion exercise any or all of such powers. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(g)
<I>&#147;</I><B></B><B><I>Company</I></B><B></B><I></I><I>&#148;</I> means Nuvelo, Inc., a Nevada corporation, or any successor corporation thereto. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(h) <I>&#147;</I><B></B><B><I>Consultant</I></B><B></B><I></I><I>&#148;</I> means a person engaged to provide consulting or advisory
services (other than as an Employee or a member of the Board) to a Participating Company, provided that the identity of such person, the nature of such services or the entity to which such services are provided would not preclude the Company from
offering or selling securities to such person pursuant to the Plan in reliance on a Form S-8 Registration Statement under the Securities Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(i) <I>&#147;</I><B></B><B><I>Deferred Stock Unit</I></B><B></B><I>&#148;</I> means a bookkeeping entry representing a right granted to a
Participant pursuant to Section 11 of the Plan to receive a share of Stock on a date determined in accordance with the provisions of Section 11 and the Participant&#146;s Award Agreement. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(j)
<I>&#147;</I><B></B><B><I>Director</I></B><B></B><I>&#148;</I> means a member of the Board. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(k) <I>&#147;</I><B></B><B><I>Disability</I></B><B></B><I></I><I>&#148;</I> means the permanent and total disability of the Participant,
within the meaning of Section 22(e)(3) of the Code. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(l) <I>&#147;</I><B></B><B><I>Dividend Equivalent</I></B><B></B><I>&#148;</I> means a credit, made at the discretion of the Committee or as otherwise provided by the Plan, to the account of a Participant in an amount equal to the cash
dividends paid on one share of Stock for each share of Stock represented by an Award held by such Participant. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(m) <I>&#147;</I><B></B><B><I>Employee</I></B><B></B><I></I><I>&#148;</I> means any
person treated as an employee (including an Officer or a Director who is also treated as an employee) in the records of a Participating Company and, with respect to any Incentive Stock Option granted to such person, who is an employee for purposes
of Section 422 of the Code; provided, however, that neither service as a Director nor payment of a Director&#146;s fee shall be sufficient to constitute employment for purposes of the Plan. The Company shall determine in good faith and in the
exercise of its discretion whether an individual has become or has ceased to be an Employee and the effective date of such individual&#146;s employment or termination of employment, as the case may be. For purposes of an individual&#146;s rights, if
any, under the Plan as of the time of the Company&#146;s determination, all such determinations by the Company shall be final, binding and conclusive, notwithstanding that the Company or any court of law or governmental agency subsequently makes a
contrary determination. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(n)
<I>&#147;</I><B></B><B><I>Exchange Act</I></B><B></B><I></I><I>&#148;</I> means the Securities Exchange Act of 1934, as amended. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(o) <I>&#147;</I><B></B><B><I>Fair Market Value</I></B><B></B><I></I><I>&#148;</I> means, as of any date, the value of a share of Stock or
other property as determined by the Committee, in its discretion, or by the Company, in its discretion, if such determination is expressly allocated to the Company herein, subject to the following: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(i) If, on such date, the Stock is listed on a national or
regional securities exchange or market system, the Fair Market Value of a share of Stock shall, unless expressly determined otherwise by the Committee, in its discretion, be the average of the high and low price of a share of Stock on such date, as
quoted on the Nasdaq National Market, The Nasdaq SmallCap Market or such other national or regional securities exchange or market system constituting the primary market for the Stock, as reported in <I>The Wall Street Journal</I> or such other
source as the Company deems reliable. If the relevant date does not fall on a day on which the Stock has traded on such securities exchange or market system, the date on which the Fair Market Value shall be established shall be the last day on which
the Stock was so traded prior to the relevant date, or such other appropriate day as shall be determined by the Committee, in its discretion. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ii) If, on such date, the Stock is not listed on a national or regional securities exchange or market system, the Fair Market Value of a
share of Stock shall be as determined by the Committee in good faith without regard to any restriction other than a restriction which, by its terms, will never lapse. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(p) <I>&#147;</I><B></B><B><I>Incentive Stock Option</I></B><B></B><I>&#148;</I> means an Option intended to
be (as set forth in the Award Agreement) and which qualifies as an incentive stock option within the meaning of Section 422(b) of the Code. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(q) <I>&#147;</I><B></B><B><I>Indexed Option</I></B><B></B><I>&#148;</I> means an Option with an exercise price which either increases by
a fixed percentage over time or changes by reference to a published index, as determined by the Committee and set forth in the Option Agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(r) <I>&#147;</I><B></B><B><I>Insider</I></B><B></B><I>&#148;</I> means an Officer, a
Director or any other person whose transactions in Stock are subject to Section 16 of the Exchange Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(s) <I>&#147;</I><B></B><B><I>Nonstatutory Stock Option</I></B><B></B><I></I><I>&#148;</I> means an Option not intended to be (as set
forth in the Award Agreement) an incentive stock option within the meaning of Section 422(b) of the Code. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(t) <I>&#147;</I><B></B><B><I>Officer</I></B><B></B><I>&#148;</I> means any person designated by the Board as an officer of the Company.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(u)
<I>&#147;</I><B></B><B><I>Option</I></B><B></B><I></I><I>&#148;</I> means the right to purchase Stock at a stated price for a specified period of time granted to a Participant pursuant to Section 6 of the Plan. An Option may be either an Incentive
Stock Option, a Nonstatutory Stock Option or an Indexed Option. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(v) <I>&#147;</I><B></B><B><I>Parent Corporation</I></B><B></B><I></I><I>&#148;</I> means any present or future &#147;parent corporation&#148; of the Company, as defined in Section 424(e) of the Code. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(w)
<I>&#147;</I><B></B><B><I>Participant</I></B><B></B><I>&#148;</I> means any eligible person who has been granted one or more Awards. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(x) <I>&#147;</I><B></B><B><I>Participating Company</I></B><B></B><I></I><I>&#148;</I> means the Company or any Parent Corporation,
Subsidiary Corporation or Affiliate. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(y)
<I>&#147;</I><B></B><B><I>Participating Company Group</I></B><B></B><I></I><I>&#148;</I> means, at any point in time, all entities collectively which are then Participating Companies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(z) <I>&#147;</I><B></B><B><I>Performance Award</I></B><B></B><I>&#148;</I> means an Award of Performance
Shares or Performance Units. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(aa)
<I>&#147;</I><B></B><B><I>Performance Award Formula</I></B><B></B><I>&#148;</I> means, for any Performance Award, a formula or table established by the Committee pursuant to Section 9.3 of the Plan which provides the basis for computing the value of
a Performance Award at one or more threshold levels of attainment of the applicable Performance Goal(s) measured as of the end of the applicable Performance Period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(bb) <I>&#147;</I><B></B><B><I>Performance Goal</I></B><B></B><I>&#148;</I> means a performance goal
established by the Committee pursuant to Section 9.3 of the Plan. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(cc) <I>&#147;</I><B></B><B><I>Performance Period</I></B><B></B><I>&#148;</I> means a period established by the Committee pursuant to Section 9.3 of the Plan at the end of which one or more Performance Goals are to be
measured. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(dd)
<I>&#147;</I><B></B><B><I>Performance Share</I></B><B></B><I>&#148;</I> means a bookkeeping entry representing a right granted to a Participant pursuant to Section 9 of the Plan to receive a payment equal to the value of a Performance Share, as
determined by the Committee, based on performance. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ee) <I>&#147;</I><B></B><B><I>Performance Unit</I></B><B></B><I>&#148;</I> means a
bookkeeping entry representing a right granted to a Participant pursuant to Section 9 of the Plan to receive a payment equal to the value of a Performance Unit, as determined by the Committee, based upon performance. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ff) <I>&#147;</I><B></B><B><I>Prior Plan
Options</I></B><B></B><I>&#148;</I> means any option or other award granted by the Company which is subject to vesting or repurchase by the Company, including specifically, all such options and awards granted pursuant to the Company&#146;s 2002
Equity Incentive Plan, Director Stock Option Plan, Scientific Advisory Board/Consultants Stock Option Plan, 1995 Stock Option Plan and the Variagenics 1997 Employee, Director &amp; Consultant Stock Option Plan which is outstanding on or after the
Effective Date.<B> </B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(gg)
<I>&#147;</I><B></B><B><I>Restricted Stock Award</I></B><B></B><I>&#148;</I> means an Award of a Restricted Stock Bonus or a Restricted Stock Purchase Right. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(hh) <I>&#147;</I><B></B><B><I>Restricted Stock Bonus</I></B><B></B><I>&#148;</I> means Stock granted to a Participant pursuant to
Section 8 of the Plan. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ii)
<I>&#147;</I><B></B><B><I>Restricted Stock Purchase Right</I></B><B></B><I>&#148;</I> means a right to purchase Stock granted to a Participant pursuant to Section 8 of the Plan. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(jj) <I>&#147;</I><B></B><B><I>Restricted Stock Unit</I></B><B></B><I>&#148;</I> or
<I>&#147;</I><B></B><B><I>Stock Unit</I></B><B></B><I>&#148;</I> means a bookkeeping entry representing a right granted to a Participant pursuant to Section 10 of the Plan to receive a share of Stock on a date determined in accordance with the
provisions of Section 10 and the Participant&#146;s Award Agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(kk) <I>&#147;</I><B></B><B><I>Restriction Period</I></B><B></B><I>&#148;</I> means the period established in accordance with Section 8.5 of the Plan during which shares subject to a Restricted Stock Award are subject
to Vesting Conditions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ll)
<I>&#147;</I><B></B><B><I>Retirement</I></B><B></B><I>&#148; </I>means a Participant&#146;s termination of Service, if as of the date of such termination, the Participant has reached the age of fifty-eight (58) and has completed eight (8) years of
continuous Service to the Participating Company Group. A Participant who terminates Service with the Participating Company Group and resumes Service more than six (6) months after his or her original termination date, will not have his or her
Service with the Participant Company Group prior to his or her original termination date count for purposes of determining Retirement. Notwithstanding the foregoing, the Board shall have the discretion to determine on a case by case basis whether
such prior Service with the Participant Company Group may be counted for purposes of Retirement. The Board will notify any rehired Participant if the Board has determined such prior Service will count towards Retirement, and in the absence of such
notification from the Board, such Service shall not be counted for purposes of Retirement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(mm) <I>&#147;</I><B></B><B><I>Rule 16b-3</I></B><B></B><I>&#148;</I> means Rule 16b-3 under the Exchange Act, as amended from time to
time, or any successor rule or regulation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(nn) <I>&#147;</I><B></B><B><I>SAR</I></B><B></B><I>&#148;</I> or <I>&#147;</I><B></B><B><I>Stock Appreciation Right</I></B><B></B><I>&#148;</I> means a bookkeeping entry representing, for each share of Stock subject to such SAR, a right
granted to a Participant pursuant to Section 7 of the Plan to receive payment of an amount equal to the excess, if any, of </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%">
<FONT FACE="Times New Roman" SIZE="2">the Fair Market Value of a share of Stock on the date of exercise of the SAR over the exercise price. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(oo) <I>&#147;</I><B></B><B><I>Section
162(m)</I></B><B></B><I>&#148;</I> means Section 162(m) of the Code. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(pp) <I>&#147;</I><B></B><B><I>Securities Act</I></B><B></B><I></I><I>&#148;</I> means the Securities Act of 1933, as amended. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(qq) <I>&#147;</I><B>Service</B><I></I><I>&#148;</I> means a Participant&#146;s employment or service with the Participating Company
Group, whether in the capacity of an Employee, a Director or a Consultant. A Participant&#146;s Service shall not be deemed to have terminated merely because of a change in the capacity in which the Participant renders such Service or a change in
the Participating Company for which the Participant renders such Service, provided that there is no interruption or termination of the Participant&#146;s Service. Furthermore, a Participant&#146;s Service shall not be deemed to have terminated if
the Participant takes any military leave, sick leave, or other bona fide leave of absence approved by the Company. However, if any such leave taken by a Participant exceeds ninety (90) days, then on the one hundred eighty-first (181st) day following
the commencement of such leave any Incentive Stock Option held by the Participant shall cease to be treated as an Incentive Stock Option and instead shall be treated thereafter as a Nonstatutory Stock Option, unless the Participant&#146;s right to
return to Service with the Participating Company Group is guaranteed by statute or contract. Notwithstanding the foregoing, unless otherwise designated by the Company or required by law, a leave of absence shall not be treated as Service for
purposes of determining vesting under the Participant&#146;s Award Agreement. A Participant&#146;s Service shall be deemed to have terminated either upon an actual termination of Service or upon the entity for which the Participant performs Service
ceasing to be a Participating Company. In addition, a Participant&#146;s Service shall be deemed to have terminated if, in the Committee&#146;s sole discretion, the Participant&#146;s employment relationship is transferred to an Affiliate or
Subsidiary Corporation and the Participant is offered a replacement equity award from the Affiliate or Subsidiary Corporation. Subject to the foregoing, the Company, in its discretion, shall determine whether the Participant&#146;s Service has
terminated and the effective date of such termination. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(rr) <I>&#147;</I><B></B><B><I>Stock</I></B><B></B><I></I><I>&#148;</I> means the common stock of the Company, as adjusted from time to time in accordance with Section 4.2 of the Plan. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ss) <I>&#147;</I><B></B><B><I>Subsidiary
Corporation</I></B><B></B><I></I><I>&#148;</I> means any present or future &#147;subsidiary corporation&#148; of the Company, as defined in Section 424(f) of the Code. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(tt) <I>&#147;</I><B></B><B><I>Ten Percent Owner</I></B><B></B><I>&#148;</I> means a Participant who, at the
time an Incentive Stock Option is granted to the Participant, owns stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of a Participating Company (other than an Affiliate) within the meaning of
Section 422(b)(6) of the Code. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(uu)
<I>&#147;</I><B></B><B><I>Vesting Conditions</I></B><B></B><I>&#148;</I> mean those conditions established in accordance with Section 8.5 or Section 10.3 of the Plan prior to the satisfaction of which shares subject to a Restricted Stock Award or
Restricted Stock Unit Award, respectively, remain subject to forfeiture or a repurchase option in favor of the Company upon the Participant&#146;s termination of Service. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.2 <B>Construction.</B> Captions and titles contained herein are for convenience only
and shall not affect the meaning or interpretation of any provision of the Plan. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular. Use of the term &#147;or&#148; is not
intended to be exclusive, unless the context clearly requires otherwise. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2"><B></B>3.<B> <U>A<SMALL>DMINISTRATION</SMALL></U><SMALL></SMALL> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">3.1 <B>Administration by the Committee. </B>The Plan shall be administered by the Committee. All questions of interpretation of the Plan
or of any Award shall be determined by the Committee, and such determinations shall be final and binding upon all persons having an interest in the Plan or such Award. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">3.2 <B>Authority of Officers. </B>Any Officer shall have the authority to act on behalf of the Company with
respect to any matter, right, obligation, determination or election which is the responsibility of or which is allocated to the Company herein, provided the Officer has apparent authority with respect to such matter, right, obligation, determination
or election. The Board may, in its discretion, delegate to a committee comprised of one or more Officers the authority to grant one or more Awards, without further approval of the Board or the Committee, to any Employee, other than a person who, at
the time of such grant, is an Insider; provided, however, that (a) such Awards shall not be granted for shares in excess of the maximum aggregate number of shares of Stock authorized for issuance pursuant to Section 4.1, (b) the exercise price per
share of each Option shall be not less than the Fair Market Value per share of the Stock on the effective date of grant (or, if the Stock has not traded on such date, on the last day preceding the effective date of grant on which the Stock was
traded), and (iii) each such Award shall be subject to the terms and conditions of the appropriate standard form of Award Agreement approved by the Board or the Committee and shall conform to the provisions of the Plan and such other guidelines as
shall be established from time to time by the Board or the Committee. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">3.3 <B>Administration with Respect to Insiders.</B> With respect to participation by Insiders in the Plan, at any time that any class of equity security of the Company is registered pursuant to Section 12 of the
Exchange Act, the Plan shall be administered in compliance with the requirements, if any, of Rule 16b-3. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">3.4 <B>Committee Complying with Section 162(m).</B> If the Company is a &#147;publicly held corporation&#148; within the meaning of
Section 162(m), the Board may establish a Committee of &#147;outside directors&#148; within the meaning of Section 162(m) to approve the grant of any Award which might reasonably be anticipated to result in the payment of employee remuneration that
would otherwise exceed the limit on employee remuneration deductible for income tax purposes pursuant to Section 162(m). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">3.5 <B>Powers of the Committee.</B> In addition to any other powers set forth in the Plan and subject to the provisions of the Plan, the
Committee shall have the full and final power and authority, in its discretion: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a) to determine the persons to whom, and the time or times at which, Awards shall be granted and the number of shares of Stock or units
to be subject to each Award; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) to determine the type of Award granted and to designate Options as Incentive Stock
Options, Nonstatutory Stock Options or Indexed Options; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(c) to determine the Fair Market Value of shares of Stock or other property; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(d) to determine the terms, conditions and restrictions applicable to each Award (which need not be identical) and any shares acquired
pursuant thereto, including, without limitation, (i) the exercise or purchase price of shares purchased pursuant to any Award, (ii) the method of payment for shares purchased pursuant to any Award, (iii) the method for satisfaction of any tax
withholding obligation arising in connection with Award, including by the withholding or delivery of shares of Stock, (iv) the timing, terms and conditions of the exercisability or vesting of any Award or any shares acquired pursuant thereto, (v)
the Performance Award Formula and Performance Goals applicable to any Award and the extent to which such Performance Goals have been attained, (vi) the time of the expiration of any Award, (vii) the effect of the Participant&#146;s termination of
Service on any of the foregoing, and (viii) all other terms, conditions and restrictions applicable to any Award or shares acquired pursuant thereto not inconsistent with the terms of the Plan; </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(e) to determine whether an Award of Restricted Stock Units,
SARs, Performance Shares or Performance Units will be settled in shares of Stock, cash, or in any combination thereof; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(f) to approve one or more forms of Award Agreement; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(g) to amend, modify, extend, cancel or renew any Award or to waive any restrictions or conditions
applicable to any Award or any shares acquired pursuant thereto; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(h) to accelerate, continue, extend or defer the exercisability or vesting of any Award or any shares acquired pursuant thereto, including with respect to the period following a Participant&#146;s termination of
Service; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(i) to prescribe, amend or rescind
rules, guidelines and policies relating to the Plan, or to adopt sub-plans or supplements to, or alternative versions of, the Plan, including, without limitation, as the Committee deems necessary or desirable to comply with the laws or regulations
of or to accommodate the tax policy, accounting principles or custom of, foreign jurisdictions whose citizens may be granted Awards; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(j) to authorize, in conjunction with any applicable Company deferred compensation plan, that the receipt of cash or Stock subject to any
Award under this Plan, may be deferred under the terms and conditions of such Company deferred compensation plan; and </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(k) to correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award Agreement and to make all other
determinations and take </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%">
<FONT FACE="Times New Roman" SIZE="2">such other actions with respect to the Plan or any Award as the Committee may deem advisable to the extent not inconsistent with the provisions of the Plan
or applicable law. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">3.6 <B>No Repricing.</B>
Without the affirmative vote of holders of a majority of the shares of Stock cast in person or by proxy at a meeting of the stockholders of the Company at which a quorum representing a majority of all outstanding shares of Stock is present or
represented by proxy, the Board shall not approve a program providing for either (a) the cancellation of outstanding Options and/or SARs and the grant in substitution therefore of any new Awards, including specifically any new Options and/or SARs
having a lower exercise price or (b) the amendment of outstanding Options and/or SARs to reduce the exercise price thereof. This paragraph shall not be construed to apply to &#147;issuing or assuming a stock option in a transaction to which section
424(a) applies,&#148; within the meaning of Section 424 of the Code. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">3.7 <B>No Restricted Stock Award Acceleration.</B> Notwithstanding any provision of the Plan to the contrary, no Restricted Stock Award may be granted which provides, or subsequently amended to provide, for (i) any
acceleration of vesting for any reason other than upon a Change in Control or after the Participant&#146;s death or Disability and (ii) vesting of one hundred percent (100%) of any such Restricted Stock Award prior to the passage of three (3) years
of Service (unless such Restricted Stock Award will vest in accordance with the satisfaction of any Performance Measure set forth in Section 9.4). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">3.8 <B>Indemnification.</B> In addition to such other rights of indemnification as they may have as members of the Board or the Committee
or as officers or employees of the Participating Company Group, members of the Board or the Committee and any officers or employees of the Participating Company Group to whom authority to act for the Board, the Committee or the Company is delegated
shall be indemnified by the Company against all reasonable expenses, including attorneys&#146; fees, actually and necessarily incurred in connection with the defense of any action, suit or proceeding, or in connection with any appeal therein, to
which they or any of them may be a party by reason of any action taken or failure to act under or in connection with the Plan, or any right granted hereunder, and against all amounts paid by them in settlement thereof (provided such settlement is
approved by independent legal counsel selected by the Company) or paid by them in satisfaction of a judgment in any such action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such action, suit or proceeding
that such person is liable for gross negligence, bad faith or intentional misconduct in duties; provided, however, that within sixty (60) days after the institution of such action, suit or proceeding, such person shall offer to the Company, in
writing, the opportunity at its own expense to handle and defend the same. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2"><B></B><I></I>4.<I></I><B> <U>S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> P<SMALL>LAN</SMALL></U><SMALL></SMALL>. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">4.1 <B>Maximum Number of Shares Issuable.</B> Subject to adjustment as provided in Section 4.2, the maximum
aggregate number of shares of Stock that may be granted under the Plan shall be Seven Million Two Hundred and Four Thousand and Eighty-Five (7,204,085), reduced at any time by the number of shares subject to the Prior Plan Options (which as of the
Effective Date equaled approximately Two Million Four Hundred and Fifty-Four Thousand and Eighty-Five (2,454,085)).<B> </B>Such shares shall consist of authorized but unissued or reacquired shares of Stock or any combination thereof. If any
outstanding Award, </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%">
<FONT FACE="Times New Roman" SIZE="2">including any Prior Plan Options, for any reason expires or is terminated or canceled without having been exercised or settled in full, or if shares of Stock
acquired pursuant to an Award subject to forfeiture or repurchase, including any Prior Plan Options, are forfeited or repurchased by the Company, the shares of Stock allocable to the terminated portion of such Award, including any Prior Plan
Options, or such forfeited or repurchased shares of Stock shall again be available for grant under the Plan. Shares of Stock shall not be deemed to have been granted pursuant to the Plan (a) with respect to any portion of an Award that is settled in
cash or (b) to the extent such shares are withheld in satisfaction of tax withholding obligations pursuant to Section 15.2. Upon payment in shares of Stock pursuant to the exercise of a SAR, the number of shares available for grant under the Plan
shall be reduced only by the number of shares actually issued in such payment. If the exercise price of an Option is paid by tender to the Company, or attestation to the ownership, of shares of Stock owned by the Participant, the number of shares
available for grant under the Plan shall be reduced by the net number of shares for which the Option is exercised. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">4.2 <B>Adjustments for Changes in Capital Structure.</B> Subject to any required action by the stockholders of the Company, in the event
of any change in the Stock effected without receipt of consideration by the Company, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend, stock split, reverse stock split,
split-up, split-off, spin-off, combination of shares, exchange of shares, or similar change in the capital structure of the Company, or in the event of payment of a dividend or distribution to the stockholders of the Company in a form other than
Stock (excepting normal cash dividends) that has a material effect on the Fair Market Value of shares of Stock, appropriate adjustments shall be made in the number and class of shares subject to the Plan and to any outstanding Awards, and in the
exercise or purchase price per share under any outstanding Award in order to prevent dilution or enlargement of Participants&#146; rights under the Plan. For purposes of the foregoing, conversion of any convertible securities of the Company shall
not be treated as &#147;effected without receipt of consideration by the Company.&#148; Any fractional share resulting from an adjustment pursuant to this Section 4.2 shall be rounded down to the nearest whole number, and in no event may the
exercise or purchase price under any Award be decreased to an amount less than the par value, if any, of the stock subject to such Award. The adjustments determined by the Committee pursuant to this Section 4.2 shall be final, binding and
conclusive. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B></B>5.<B> <U>E<SMALL>LIGIBILITY</SMALL>
<SMALL>AND</SMALL> A<SMALL>WARD</SMALL> L<SMALL>IMITATIONS</SMALL></U><SMALL></SMALL>. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">5.1 <B>Persons Eligible for Awards.</B> Awards may be granted only to Employees, Consultants and Directors. For purposes of the foregoing
sentence, &#147;Employees,&#148;&#147;Consultants&#148;and &#147;Directors&#148; shall include prospective Employees, prospective Consultants and prospective Directors to whom Awards are granted in connection with written offers of an employment or
other service relationship with the Participating Company Group; provided, however, that no Stock subject to any such Award shall vest, become exercisable or be issued prior to the date on which such person commences Service. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">5.2 <B>Participation.</B> Awards are granted solely at the
discretion of the Committee. Eligible persons may be granted more than one (1) Award. However, eligibility in </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">10 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%">
<FONT FACE="Times New Roman" SIZE="2">accordance with this Section shall not entitle any person to be granted an Award, or, having been granted an Award, to be granted an additional Award.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B></B>5.3<B> Incentive Stock Option Limitations.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a) <B><I>Persons Eligible.</I></B> An
Incentive Stock Option may be granted only to a person who, on the effective date of grant, is an Employee of the Company, a Parent Corporation or a Subsidiary Corporation (each being an <I>&#147;</I><B></B><I></I><B><I>ISO-Qualifying
Corporation</I></B><I></I><B></B><I>&#148;</I>). Any person who is not an Employee of an ISO-Qualifying Corporation on the effective date of the grant of an Option to such person may be granted only a Nonstatutory Stock Option. An Incentive Stock
Option granted to a prospective Employee upon the condition that such person become an Employee of an ISO-Qualifying Corporation shall be deemed granted effective on the date such person commences Service with an ISO-Qualifying Corporation, with an
exercise price determined as of such date in accordance with Section 6.1. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(b) <B><I>Fair Market Value Limitation.</I></B> To the extent that options designated as Incentive Stock Options (granted under all stock option plans of the Participating Company Group, including the Plan) become
exercisable by a Participant for the first time during any calendar year for stock having a Fair Market Value greater than One Hundred Thousand dollars ($100,000), the portion of such options which exceeds such amount shall be treated as
Nonstatutory Stock Options. For purposes of this Section, options designated as Incentive Stock Options shall be taken into account in the order in which they were granted, and the Fair Market Value of stock shall be determined as of the time the
option with respect to such stock is granted. If the Code is amended to provide for a different limitation from that set forth in this Section, such different limitation shall be deemed incorporated herein effective as of the date and with respect
to such Options as required or permitted by such amendment to the Code. If an Option is treated as an Incentive Stock Option in part and as a Nonstatutory Stock Option in part by reason of the limitation set forth in this Section, the Participant
may designate which portion of such Option the Participant is exercising. In the absence of such designation, the Participant shall be deemed to have exercised the Incentive Stock Option portion of the Option first. Upon exercise, shares issued
pursuant to each such portion shall be separately identified. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2"><B></B>5.4<B> Award Limits. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a)
<B><I>Aggregate Limit on Restricted Stock Awards and Performance Awards.</I></B> Subject to adjustment as provided in Section 4.2, in no event shall more than One Million (1,000,000) shares of Stock in the aggregate be issued under the Plan pursuant
to the exercise or settlement of Restricted Stock Awards and Performance Awards. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) <B><I>Section 162(m) Award Limits.</I></B> The following limits shall apply to the grant of any Award if, at the time of grant, the
Company is a &#147;publicly held corporation&#148; within the meaning of Section 162(m). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(i) <B>Options and SARs.</B> Subject to adjustment as provided in Section 4.2, no Employee shall be granted within any fiscal year of the
Company one or more Options or Freestanding SARs which in the aggregate are for more than Seven Hundred and Fifty Thousand (750,000) shares of Stock, provided, however, that the Company may make an </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%">
<FONT FACE="Times New Roman" SIZE="2">additional one-time grant to any newly-hired Employee of an Option and/or SAR for the purchase of up to an additional Five Hundred Thousand (500,000) shares
of Stock. An Option which is canceled (or a Freestanding SAR as to which the exercise price is reduced to reflect a reduction in the Fair Market Value of the Stock) in the same fiscal year of the Company in which it was granted shall continue to be
counted against such limit for such fiscal year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(ii) <B>Restricted Stock Awards and Restricted Stock Units.</B> Subject to adjustment as provided in Section 4.2, no Employee shall be granted within any fiscal year of the Company one or more Restricted Stock Awards or Restricted Stock
Units, subject to Vesting Conditions based on the attainment of Performance Goals, for more than Four Hundred Thousand (400,000) shares of Stock, provided, however, that the Company may make an additional one-time grant to any newly-hired Employee
of a Restricted Stock Award or Restricted Stock Units of up to an additional One Hundred and Fifty Thousand (150,000) shares of Stock. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(iii) <B>Performance Awards.</B> Subject to adjustment as provided in Section 4.2, no Employee shall be granted (A) Performance Shares
which could result in such Employee receiving more than Four Hundred Thousand (400,000) shares of Stock for each full fiscal year of the Company contained in the Performance Period for such Award, or (B) Performance Units which could result in such
Employee receiving more than Two Million dollars ($2,000,000) for each full fiscal year of the Company contained in the Performance Period for such Award. No Participant may be granted more than one Performance Award for the same Performance Period.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B></B>6.<B> <U>T<SMALL>ERMS</SMALL> <SMALL>AND</SMALL>
C<SMALL>ONDITIONS</SMALL> O<SMALL>F</SMALL> O<SMALL>PTIONS</SMALL></U><SMALL></SMALL>. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Options shall be evidenced by Award Agreements specifying the number of shares of Stock covered thereby, in such form as the Committee
shall from time to time establish. No Option or purported Option shall be a valid and binding obligation of the Company unless evidenced by a fully executed Award Agreement. Award Agreements evidencing Options may incorporate all or any of the terms
of the Plan by reference and shall comply with and be subject to the following terms and conditions: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">6.1 <B>Exercise Price.</B> The exercise price for each Option shall be established in the discretion of the Committee; provided, however,
that (a) the exercise price per share shall be not less than the Fair Market Value of a share of Stock on the effective date of grant of the Option, (b) no Incentive Stock Option granted to a Ten Percent Owner shall have an exercise price per share
less than one hundred ten percent (110%) of the Fair Market Value of a share of Stock on the effective date of grant of the Option, and (c) notwithstanding anything to the contrary in this Section 6.1, in the case of an Indexed Option, the Committee
shall determine the exercise price of such Indexed Option and the terms and conditions that affect, if any, any adjustments to the exercise price of such Indexed Option. Notwithstanding the foregoing, an Option may be granted with an exercise price
lower than the minimum exercise price set forth above if such Option is granted pursuant to an assumption or substitution for another option in a manner qualifying under the provisions of Section 424(a) of the Code. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">12 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">6.2 <B>Exercisability and Term of Options.</B> Options shall be exercisable at such time
or times, or upon such event or events, and subject to such terms, conditions, performance criteria and restrictions as shall be determined by the Committee and set forth in the Award Agreement evidencing such Option; provided, however, that (a) no
Option shall be exercisable after the expiration of ten (10) years after the effective date of grant of such Option, (b) no Incentive Stock Option granted to a Ten Percent Owner shall be exercisable after the expiration of five (5) years after the
effective date of grant of such Option, and (c) no Option granted to a prospective Employee, prospective Consultant or prospective Director may become exercisable prior to the date on which such person commences Service. Subject to the foregoing,
unless otherwise specified by the Committee in the grant of an Option, any Option granted hereunder shall terminate ten (10) years after the effective date of grant of the Option, unless earlier terminated in accordance with its provisions.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B></B>6.3<B> Payment of Exercise Price. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a) <B><I>Forms of Consideration Authorized.</I></B> Except
as otherwise provided below, payment of the exercise price for the number of shares of Stock being purchased pursuant to any Option shall be made (i) in cash, by check or in cash equivalent, (ii) by tender to the Company, or attestation to the
ownership, of shares of Stock owned by the Participant having a Fair Market Value not less than the exercise price, (iii) by delivery of a properly executed notice of exercise together with irrevocable instructions to a broker providing for the
assignment to the Company of the proceeds of a sale or loan with respect to some or all of the shares being acquired upon the exercise of the Option (including, without limitation, through an exercise complying with the provisions of Regulation T as
promulgated from time to time by the Board of Governors of the Federal Reserve System) (a <I>&#147;</I><B></B><B><I>Cashless Exercise</I></B><B></B><I>&#148;</I>), (iv) by such other consideration as may be approved by the Committee from time to
time to the extent permitted by applicable law, or (v) by any combination thereof. The Committee may at any time or from time to time grant Options which do not permit all of the foregoing forms of consideration to be used in payment of the exercise
price or which otherwise restrict one or more forms of consideration. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(b) <B><I>Limitations on Forms of Consideration.</I></B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(i) <B>Tender of Stock.</B> Notwithstanding the foregoing, an Option may not be exercised by tender to the Company, or attestation to the
ownership, of shares of Stock to the extent such tender or attestation would constitute a violation of the provisions of any law, regulation or agreement restricting the redemption of the Company&#146;s stock. Unless otherwise provided by the
Committee, an Option may not be exercised by tender to the Company, or attestation to the ownership, of shares of Stock unless such shares either have been owned by the Participant for more than six (6) months (and not used for another Option
exercise by attestation during such period) or were not acquired, directly or indirectly, from the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ii) <B>Cashless Exercise.</B> The Company reserves, at any and all times, the right, in the Company&#146;s sole and absolute discretion,
to establish, decline to approve or terminate any program or procedures for the exercise of Options by means of a Cashless Exercise, including with respect to one or more Participants specified by the Company notwithstanding that such program or
procedures may be available to other Participants. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">13 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">6.4 <B>Effect of Termination of Service.</B> An Option shall be exercisable after a
Participant&#146;s termination of Service to such extent and during such period as determined by the Committee, in its discretion, and set forth in the Award Agreement evidencing such Option. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">6.5 <B>Transferability of Options.</B> During the lifetime
of the Participant, an Option shall be exercisable only by the Participant or the Participant&#146;s guardian or legal representative. Prior to the issuance of shares of Stock upon the exercise of an Option, the Option shall not be subject in any
manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Participant or the Participant&#146;s beneficiary, except transfer by will or by the laws of descent and distribution.
Notwithstanding the foregoing, to the extent permitted by the Committee, in its discretion, and set forth in the Award Agreement evidencing such Option, a Nonstatutory Stock Option shall be assignable or transferable subject to the applicable
limitations, if any, described in the General Instructions to Form S-8 Registration Statement under the Securities Act. Notwithstanding any of the foregoing, the Board may permit further transferability of any Option, on a general or specific basis,
and may impose conditions and limitations on any permitted transferability. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2"><B></B>7.<B> <U>T<SMALL>ERMS</SMALL> <SMALL>AND</SMALL> C<SMALL>ONDITIONS</SMALL> <SMALL>OF</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL></U><SMALL></SMALL>. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Stock Appreciation Rights shall be evidenced by Award
Agreements specifying the number of shares of Stock subject to the Award, in such form as the Committee shall from time to time establish. No SAR or purported SAR shall be a valid and binding obligation of the Company unless evidenced by a fully
executed Award Agreement. Award Agreements evidencing SARs may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">7.1 <B>Types of SARs Authorized.</B> SARs may be granted in
tandem with all or any portion of a related Option (a <I>&#147;</I><B></B><B><I>Tandem SAR</I></B><B></B><I>&#148;</I>) or may be granted independently of any Option (a <I>&#147;</I><B></B><B><I>Freestanding SAR</I></B><B></B><I>&#148;</I>). A
Tandem SAR may be granted either concurrently with the grant of the related Option or at any time thereafter prior to the complete exercise, termination, expiration or cancellation of such related Option. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">7.2 <B>Exercise Price.</B> The exercise price for each SAR
shall be established in the discretion of the Committee; provided, however, that (a) the exercise price per share subject to a Tandem SAR shall be the exercise price per share under the related Option and (b) the exercise price per share subject to
a Freestanding SAR shall be not less than the Fair Market Value of a share of Stock on the effective date of grant of the SAR. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">7.3 <B>Exercisability and Term of SARs.</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a) <B><I>Tandem SARs.</I></B> Tandem SARs shall be exercisable only at the time and to the extent, and only to the extent, that the
related Option is exercisable, subject to such provisions as the Committee may specify where the Tandem SAR is granted with respect to less than the full number of shares of Stock subject to the related Option. The Committee may, in its discretion,
provide in any Award Agreement evidencing a Tandem SAR that such SAR may not be exercised without the advance approval of the Company and, if such approval is not given, then the Option shall nevertheless remain exercisable in accordance with its
terms. A </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">14 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%">
<FONT FACE="Times New Roman" SIZE="2">Tandem SAR shall terminate and cease to be exercisable no later than the date on which the related Option expires or is terminated or canceled. Upon the
exercise of a Tandem SAR with respect to some or all of the shares subject to such SAR, the related Option shall be canceled automatically as to the number of shares with respect to which the Tandem SAR was exercised. Upon the exercise of an Option
related to a Tandem SAR as to some or all of the shares subject to such Option, the related Tandem SAR shall be canceled automatically as to the number of shares with respect to which the related Option was exercised. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) <B><I>Freestanding SARs.</I></B> Freestanding SARs shall
be exercisable at such time or times, or upon such event or events, and subject to such terms, conditions, performance criteria and restrictions as shall be determined by the Committee and set forth in the Award Agreement evidencing such SAR;
provided, however, that no Freestanding SAR shall be exercisable after the expiration of ten (10) years after the effective date of grant of such SAR. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">7.4 <B>Exercise of SARs.</B> Upon the exercise (or deemed exercise pursuant to Section 7.5) of a SAR, the Participant (or the
Participant&#146;s legal representative or other person who acquired the right to exercise the SAR by reason of the Participant&#146;s death) shall be entitled to receive payment of an amount for each share with respect to which the SAR is exercised
equal to the excess, if any, of the Fair Market Value of a share of Stock on the date of exercise of the SAR over the exercise price. Payment of such amount shall be made in cash, shares of Stock, or any combination thereof as determined by the
Committee. Unless otherwise provided in the Award Agreement evidencing such SAR, payment shall be made in a lump sum as soon as practicable following the date of exercise of the SAR. The Award Agreement evidencing any SAR may provide for deferred
payment in a lump sum or in installments. When payment is to be made in shares of Stock, the number of shares to be issued shall be determined on the basis of the Fair Market Value of a share of Stock on the date of exercise of the SAR. For purposes
of Section 7, a SAR shall be deemed exercised on the date on which the Company receives notice of exercise from the Participant. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">7.5 <B>Deemed Exercise of SARs.</B> If, on the date on which a SAR would otherwise terminate or expire, the SAR by its terms remains
exercisable immediately prior to such termination or expiration and, if so exercised, would result in a payment to the holder of such SAR, then any portion of such SAR which has not previously been exercised shall automatically be deemed to be
exercised as of such date with respect to such portion. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">7.6 <B>Effect of Termination of Service.</B> Subject to earlier termination of the SAR as otherwise provided herein a SAR shall be exercisable after a Participant&#146;s termination of Service to such extent and
during such period as determined by the Committee, in its discretion, and set forth in the Award Agreement evidencing such SAR and thereafter shall terminate. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">7.7 <B>Nontransferability of SARs.</B> During the lifetime of the Participant, a SAR shall be exercisable only by the Participant or
the Participant&#146;s guardian or legal representative. Prior to the exercise of a SAR, the SAR shall not be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors
of the Participant or the Participant&#146;s beneficiary, except transfer by will or by the laws of descent and distribution. Notwithstanding any of the foregoing, the Board </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">15 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%">
<FONT FACE="Times New Roman" SIZE="2">may permit further transferability of any SAR, on a general or specific basis, and may impose conditions and limitations on any permitted transferability.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B></B>8.<B> <U>T<SMALL>ERMS</SMALL> <SMALL>AND</SMALL>
C<SMALL>ONDITIONS</SMALL> <SMALL>OF</SMALL> R<SMALL>ESTRICTED</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>WARDS</SMALL></U><SMALL></SMALL>. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Restricted Stock Awards shall be evidenced by Award Agreements specifying whether the Award is a Restricted Stock Bonus or a Restricted
Stock Purchase Right and the number of shares of Stock subject to the Award, in such form as the Committee shall from time to time establish. No Restricted Stock Award or purported Restricted Stock Award shall be a valid and binding obligation of
the Company unless evidenced by a fully executed Award Agreement. Award Agreements evidencing Restricted Stock Awards may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and
conditions: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">8.1 <B>Types of Restricted Stock
Awards Authorized.</B> Restricted Stock Awards may be in the form of either a Restricted Stock Bonus or a Restricted Stock Purchase Right. Restricted Stock Awards may be granted upon such conditions as the Committee shall determine, including,
without limitation, upon the attainment of one or more Performance Goals described in Section 9.4. If either the grant of a Restricted Stock Award or the lapsing of the Restriction Period is to be contingent upon the attainment of one or more
Performance Goals, the Committee shall follow procedures substantially equivalent to those set forth in Sections 9.3. through 9.5(a). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">8.2 <B>Purchase Price.</B> The purchase price for shares of Stock issuable under each Restricted Stock Purchase Right shall be established
by the Committee in its discretion. No monetary payment (other than applicable tax withholding) shall be required as a condition of receiving shares of Stock pursuant to a Restricted Stock Bonus, the consideration for which shall be services
actually rendered to a Participating Company or for its benefit. Notwithstanding the foregoing, the Participant shall furnish consideration in the form of cash or past services rendered to a Participating Company or for its benefit having a value
not less than the par value of the shares of Stock subject to such Restricted Stock Award. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">8.3 <B>Purchase Period.</B> A Restricted Stock Purchase Right shall be exercisable within a period established by the Committee, which
shall in no event exceed thirty (30) days from the effective date of the grant of the Restricted Stock Purchase Right; provided, however, that no Restricted Stock Purchase Right granted to a prospective Employee, prospective Consultant or
prospective Director may become exercisable prior to the date on which such person commences Service. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">8.4 <B>Payment of Purchase Price. </B>Except as otherwise provided below, payment of the purchase price for the number of shares of Stock
being purchased pursuant to any Restricted Stock Purchase Right shall be made (a) in cash, by check, or in cash equivalent, (b) by such other consideration as may be approved by the Committee from time to time to the extent permitted by applicable
law, or (iii) by any combination thereof. The Committee may at any time or from time to time grant Restricted Stock Purchase Rights which do not permit all of the foregoing forms of consideration to be used in payment of the purchase price or which
otherwise </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">16 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%">
<FONT FACE="Times New Roman" SIZE="2">restrict one or more forms of consideration. Restricted Stock Bonuses shall be issued in consideration for past services actually rendered to a Participating
Company or for its benefit. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">8.5 <B>Vesting
and Restrictions on Transfer.</B> Shares issued pursuant to any Restricted Stock Award may or may not be made subject to Vesting Conditions based upon the satisfaction of such Service requirements, conditions, restrictions or performance criteria,
including, without limitation, Performance Goals as described in Section 9.4, as shall be established by the Committee and set forth in the Award Agreement evidencing such Award. During any Restriction Period in which shares acquired pursuant to a
Restricted Stock Award remain subject to Vesting Conditions, such shares may not be sold, exchanged, transferred, pledged, assigned or otherwise disposed of other than pursuant to an Ownership Change Event, as defined in Section 13.1, or as provided
in Section 8.8. Upon request by the Company, each Participant shall execute any agreement evidencing such transfer restrictions prior to the receipt of shares of Stock hereunder and shall promptly present to the Company any and all certificates
representing shares of Stock acquired hereunder for the placement on such certificates of appropriate legends evidencing any such transfer restrictions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">8.6 <B>Voting Rights; Dividends and Distributions.</B> Except as provided in this Section, Section 8.5 and any Award Agreement, during the
Restriction Period applicable to shares subject to a Restricted Stock Award, the Participant shall have all of the rights of a stockholder of the Company holding shares of Stock, including the right to vote such shares and to receive all dividends
and other distributions paid with respect to such shares. However, in the event of a dividend or distribution paid in shares of Stock or any other adjustment made upon a change in the capital structure of the Company as described in Section 4.2,
then any and all new, substituted or additional securities or other property (other than normal cash dividends) to which the Participant is entitled by reason of the Participant&#146;s Restricted Stock Award shall be immediately subject to the same
Vesting Conditions as the shares subject to the Restricted Stock Award with respect to which such dividends or distributions were paid or adjustments were made. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">8.7 <B>Effect of Termination of Service.</B> Unless otherwise provided by the Committee in the grant of a
Restricted Stock Award and set forth in the Award Agreement, if a Participant&#146;s Service terminates for any reason, whether voluntary or involuntary (including the Participant&#146;s death or Disability), then (a) the Company shall have the
option to repurchase for the purchase price paid by the Participant any shares acquired by the Participant pursuant to a Restricted Stock Purchase Right which remain subject to Vesting Conditions as of the date of the Participant&#146;s termination
of Service and (b) the Participant shall forfeit to the Company any shares acquired by the Participant pursuant to a Restricted Stock Bonus which remain subject to Vesting Conditions as of the date of the Participant&#146;s termination of Service.
The Company shall have the right to assign at any time any repurchase right it may have, whether or not such right is then exercisable, to one or more persons as may be selected by the Company. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">8.8 <B>Nontransferability of Restricted Stock Award
Rights.</B> Prior to the issuance of shares of Stock pursuant to a Restricted Stock Award, rights to acquire such shares shall not be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance or
garnishment by creditors of the Participant or the Participant&#146;s beneficiary, except transfer by will or the laws of descent and distribution. All </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">17 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%">
<FONT FACE="Times New Roman" SIZE="2">rights with respect to a Restricted Stock Award granted to a Participant hereunder shall be exercisable during his or her lifetime only by such Participant
or the Participant&#146;s guardian or legal representative. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2"><B></B>9.<B> <U>T<SMALL>ERMS</SMALL> <SMALL>AND</SMALL> C<SMALL>ONDITIONS</SMALL> <SMALL>OF</SMALL> P<SMALL>ERFORMANCE</SMALL> A<SMALL>WARDS</SMALL></U><SMALL></SMALL>. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Performance Awards shall be evidenced by Award Agreements in such form as the Committee shall from time to
time establish. No Performance Award or purported Performance Award shall be a valid and binding obligation of the Company unless evidenced by a fully executed Award Agreement. Award Agreements evidencing Performance Awards may incorporate all or
any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">9.1 <B>Types of Performance Awards Authorized.</B> Performance Awards may be in the form of either Performance Shares or Performance
Units. Each Award Agreement evidencing a Performance Award shall specify the number of Performance Shares or Performance Units subject thereto, the Performance Award Formula, the Performance Goal(s) and Performance Period applicable to the Award,
and the other terms, conditions and restrictions of the Award. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">9.2 <B>Initial Value of Performance Shares and Performance Units.</B> Unless otherwise provided by the Committee in granting a Performance Award, each Performance Share shall have an initial value equal to the Fair
Market Value of one (1) share of Stock, subject to adjustment as provided in Section 4.2, on the effective date of grant of the Performance Share, and each Performance Unit shall have an initial value of one hundred dollars ($100). The final value
payable to the Participant in settlement of a Performance Award determined on the basis of the applicable Performance Award Formula will depend on the extent to which Performance Goals established by the Committee are attained within the applicable
Performance Period established by the Committee. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">9.3 <B>Establishment of Performance Period, Performance Goals and Performance Award Formula.</B> In granting each Performance Award, the Committee shall establish in writing the applicable Performance Period, Performance Award Formula and
one or more Performance Goals which, when measured at the end of the Performance Period, shall determine on the basis of the Performance Award Formula the final value of the Performance Award to be paid to the Participant. Unless otherwise permitted
in compliance with the requirements under Section 162(m) with respect to &#147;performance-based compensation,&#148; the Committee shall establish the Performance Goal(s) and Performance Award Formula applicable to each Performance Award no later
than the earlier of (a) the date ninety (90) days after the commencement of the applicable Performance Period or (b) the date on which 25% of the Performance Period has elapsed, and, in any event, at a time when the outcome of the Performance Goals
remains substantially uncertain. Once established, the Performance Goals and Performance Award Formula shall not be changed during the Performance Period. The Company shall notify each Participant granted a Performance Award of the terms of such
Award, including the Performance Period, Performance Goal(s) and Performance Award Formula. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">18 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">9.4 <B>Measurement of Performance Goals.</B> Performance Goals shall be established by
the Committee on the basis of targets to be attained (<I>&#147;</I><B></B><B><I>Performance Targets</I></B><B></B><I>&#148;</I>) with respect to one or more measures of business or financial performance (each, a <I>&#147;</I><B></B><B><I>Performance
Measure</I></B><B></B><I>&#148;</I>), subject to the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(a) <B><I>Performance Measures.</I></B> Performance Measures shall have the same meanings as used in the Company&#146;s financial statements, or, if such terms are not used in the Company&#146;s financial statements,
they shall have the meaning applied pursuant to generally accepted accounting principles, or as used generally in the Company&#146;s industry. Performance Measures shall be calculated with respect to the Company and each Subsidiary Corporation
consolidated therewith for financial reporting purposes or such division or other business unit as may be selected by the Committee. For purposes of the Plan, the Performance Measures applicable to a Performance Award shall be calculated in
accordance with generally accepted accounting principles, but prior to the accrual or payment of any Performance Award for the same Performance Period and excluding the effect (whether positive or negative) of any change in accounting standards or
any extraordinary, unusual or nonrecurring item, as determined by the Committee, occurring after the establishment of the Performance Goals applicable to the Performance Award. Performance Measures may be one or more of the following, or a
combination of the any of the following, as determined by the Committee: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(i) revenue; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ii) gross margin; </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(iii) operating margin; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(iv) operating income; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(v) pre-tax profit; </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(vi) earnings before interest, taxes and depreciation; </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(vii) net income; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(viii) cash flow; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ix) expenses; </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(x) the market price of the Stock; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(xi) earnings per share; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(xii) return on stockholder equity; </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(xiii) return on capital; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(xiv) return on net assets; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(xv) economic value added; </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(xvi) number of customers; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(xvii) market share; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(xviii) return on investment </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(xix) profit after tax </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(xx) product approval; and </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(xxi) customer satisfaction. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) <B><I>Performance Targets.</I></B> Performance Targets
may include a minimum, maximum, target level and intermediate levels of performance, with the final value of a Performance Award determined under the applicable Performance Award Formula by the level attained during the applicable Performance
Period. A Performance Target may be stated as an absolute value or as a value determined relative to a standard selected by the Committee. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">19 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">9.5 <B>Settlement of Performance Awards.</B> </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a) <B><I>Determination of Final Value.</I></B> As soon as
practicable following the completion of the Performance Period applicable to a Performance Award, the Committee shall certify in writing the extent to which the applicable Performance Goals have been attained and the resulting final value of the
Award earned by the Participant and to be paid upon its settlement in accordance with the applicable Performance Award Formula. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) <B><I>Discretionary Adjustment of Award Formula.</I></B> In its discretion, the Committee may, either at the time it grants a
Performance Award or at any time thereafter, provide for the positive or negative adjustment of the Performance Award Formula applicable to a Performance Award granted to any Participant who is not a &#147;covered employee&#148; within the meaning
of Section 162(m) (a <I>&#147;</I><B></B><B><I>Covered Employee</I></B><B></B><I>&#148;</I>) to reflect such Participant&#146;s individual performance in his or her position with the Company or such other factors as the Committee may determine. If
permitted under a Covered Employee&#146;s Award Agreement, the Committee shall have the discretion, on the basis of such criteria as may be established by the Committee, to reduce some or all of the value of the Performance Award that would
otherwise be paid to the Covered Employee upon its settlement notwithstanding the attainment of any Performance Goal and the resulting value of the Performance Award determined in accordance with the Performance Award Formula. No such reduction may
result in an increase in the amount payable upon settlement of another Participant&#146;s Performance Award. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(c) <B><I>Effect of Leaves of Absence.</I></B> Unless otherwise required by law, payment of the final value, if any, of a Performance
Award held by a Participant who has taken in excess of thirty (30) days in leaves of absence during a Performance Period shall be prorated on the basis of the number of days of the Participant&#146;s Service during the Performance Period during
which the Participant was not on a leave of absence. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(d) <B><I>Notice to Participants.</I></B> As soon as practicable following the Committee&#146;s determination and certification in accordance with Sections 9.5 (a) and (b), the Company shall notify each Participant of the determination of
the Committee. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(e) <B><I>Payment in
Settlement of Performance Awards.</I></B> As soon as practicable following the Committee&#146;s determination and certification in accordance with Sections 9.5(a) and (b), <B></B>payment shall be made to each eligible Participant (or such
Participant&#146;s legal representative or other person who acquired the right to receive such payment by reason of the Participant&#146;s death) of the final value of the Participant&#146;s Performance Award. Payment of such amount shall be made in
cash, shares of Stock, or a combination thereof as determined by the Committee. Unless otherwise provided in the Award Agreement evidencing a Performance Award, payment shall be made in a lump sum. An Award Agreement may provide for deferred payment
in a lump sum or in installments. If any payment is to be made on a deferred basis, the Committee may, but shall not be obligated to, provide for the payment during the deferral period of Dividend Equivalents or interest. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(f) <B><I>Provisions Applicable to Payment in
Shares.</I></B> If payment is to be made in shares of Stock, the number of such shares shall be determined by dividing the final value of the Performance Award by the value of a share of Stock determined by the method </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">20 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%">
<FONT FACE="Times New Roman" SIZE="2">specified in the Award Agreement. Such methods may include, without limitation, the closing market price on a specified date (such as the settlement date) or
an average of market prices over a series of trading days. Shares of Stock issued in payment of any Performance Award may be fully vested and freely transferable shares or may be shares of Stock subject to Vesting Conditions as provided in Section
8.5. Any shares subject to Vesting Conditions shall be evidenced by an appropriate Award Agreement and shall be subject to the provisions of Sections 8.5 through above. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">9.6 <B>Voting Rights; Dividend Equivalent Rights and Distributions.</B> Participants shall have no voting
rights with respect to shares of Stock represented by Performance Share Awards until the date of the issuance of such shares, if any (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the
Company). However, the Committee, in its discretion, may provide in the Award Agreement evidencing any Performance Share Award that the Participant shall be entitled to receive Dividend Equivalents with respect to the payment of cash dividends on
Stock having a record date prior to the date on which the Performance Shares are settled or forfeited. Such Dividend Equivalents, if any, shall be credited to the Participant in the form of additional whole Performance Shares as of the date of
payment of such cash dividends on Stock. The number of additional Performance Shares (rounded to the nearest whole number) to be so credited shall be determined by dividing (a) the amount of cash dividends paid on such date with respect to the
number of shares of Stock represented by the Performance Shares previously credited to the Participant by (b) the Fair Market Value per share of Stock on such date. Dividend Equivalents may be paid currently or may be accumulated and paid to the
extent that Performance Shares become nonforfeitable, as determined by the Committee. Settlement of Dividend Equivalents may be made in cash, shares of Stock, or a combination thereof as determined by the Committee, and may be paid on the same basis
as settlement of the related Performance Share as provided in Section 9.5. Dividend Equivalents shall not be paid with respect to Performance Units. In the event of a dividend or distribution paid in shares of Stock or any other adjustment made upon
a change in the capital structure of the Company as described in Section 4.2, appropriate adjustments shall be made in the Participant&#146;s Performance Share Award so that it represents the right to receive upon settlement any and all new,
substituted or additional securities or other property (other than normal cash dividends) to which the Participant would entitled by reason of the shares of Stock issuable upon settlement of the Performance Share Award, and all such new, substituted
or additional securities or other property shall be immediately subject to the same Performance Goals as are applicable to the Award. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">9.7 <B>Effect of Termination of Service.</B> The effect of a Participant&#146;s termination of Service on the Performance Award shall be
determined by the Committee, in its discretion, and set forth in the Award Agreement evidencing such Performance Award. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">9.8 <B>Nontransferability of Performance Awards.</B> Prior to settlement in accordance with the provisions of the Plan, no Performance
Award shall be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Participant or the Participant&#146;s beneficiary, except transfer by will or by the laws
of descent and distribution. All rights with respect to a Performance Award granted to a Participant hereunder shall be exercisable during his or her lifetime only by such Participant or the Participant&#146;s guardian or legal representative.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">21 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">10. <B><U>T<SMALL>ERMS</SMALL> <SMALL>AND</SMALL> C<SMALL>ONDITIONS</SMALL> <SMALL>OF</SMALL>
R<SMALL>ESTRICTED</SMALL> S<SMALL>TOCK</SMALL> U<SMALL>NIT</SMALL> A<SMALL>WARDS</SMALL></U><SMALL></SMALL></B><SMALL></SMALL>. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Restricted Stock Unit Awards shall be evidenced by Award Agreements specifying the number of Restricted Stock Units subject to the Award,
in such form as the Committee shall from time to time establish. No Restricted Stock Unit Award or purported Restricted Stock Unit Award shall be a valid and binding obligation of the Company unless evidenced by a fully executed Award Agreement.
Award Agreements evidencing Restricted Stock Units may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">10.1 <B>Grant of Restricted Stock Unit Awards.</B>
Restricted Stock Unit Awards may be granted upon such conditions as the Committee shall determine, including, without limitation, upon the attainment of one or more Performance Goals described in Section 9.4. If either the grant of a Restricted
Stock Unit Award or the Vesting Conditions with respect to such Award is to be contingent upon the attainment of one or more Performance Goals, the Committee shall follow procedures substantially equivalent to those set forth in Sections 9.3 through
9.5(a). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">10.2 <B>Purchase Price. </B>No
monetary payment (other than applicable tax withholding, if any) shall be required as a condition of receiving a Restricted Stock Unit Award, the consideration for which shall be services actually rendered to a Participating Company or for its
benefit. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">10.3 <B>Vesting.</B> Restricted
Stock Units may or may not be made subject to Vesting Conditions based upon the satisfaction of such Service requirements, conditions, restrictions or performance criteria, including, without limitation, Performance Goals as described in Section
9.4, as shall be established by the Committee and set forth in the Award Agreement evidencing such Award. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">10.4 <B>Voting Rights, Dividend Equivalent Rights and Distributions.</B> Participants shall have no voting rights with respect to shares
of Stock represented by Restricted Stock Units until the date of the issuance of such shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company). However, the Committee, in its
discretion, may provide in the Award Agreement evidencing any Restricted Stock Unit Award that the Participant shall be entitled to receive Dividend Equivalents with respect to the payment of cash dividends on Stock having a record date prior to
date on which Restricted Stock Units held by such Participant are settled. Such Dividend Equivalents, if any, shall be paid by crediting the Participant with additional whole Restricted Stock Units as of the date of payment of such cash dividends on
Stock. The number of additional Restricted Stock Units (rounded to the nearest whole number) to be so credited shall be determined by dividing (a) the amount of cash dividends paid on such date with respect to the number of shares of Stock
represented by the Restricted Stock Units previously credited to the Participant by (b) the Fair Market Value per share of Stock on such date. Such additional Restricted Stock Units shall be subject to the same terms and conditions and shall be
settled in the same manner and at the same time (or as soon thereafter as practicable) as the Restricted Stock Units originally subject to the Restricted Stock Unit Award. In the event of a dividend or distribution paid in shares of Stock or any
other adjustment made upon a change in the capital structure of the Company as described in </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">22 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%">
<FONT FACE="Times New Roman" SIZE="2">Section <B></B>4.2, appropriate adjustments shall be made in the Participant&#146;s Restricted Stock Unit Award so that it represents the right to receive
upon settlement any and all new, substituted or additional securities or other property (other than normal cash dividends) to which the Participant would entitled by reason of the shares of Stock issuable upon settlement of the Award, and all such
new, substituted or additional securities or other property shall be immediately subject to the same Vesting Conditions as are applicable to the Award. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">10.5 <B>Effect of Termination of Service.</B> Unless otherwise provided by the Committee in the grant of a Restricted Stock Unit Award and
set forth in the Award Agreement, if a Participant&#146;s Service terminates for any reason, whether voluntary or involuntary (including the Participant&#146;s death or Disability), then the Participant shall forfeit to the Company any Restricted
Stock Units pursuant to the Award which remain subject to Vesting Conditions as of the date of the Participant&#146;s termination of Service. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">10.6 <B>Settlement of Restricted Stock Unit Awards.</B> The Company shall issue to a Participant on the date on which Restricted Stock
Units subject to the Participant&#146;s Restricted Stock Unit Award vest or on such other date determined by the Committee, in its discretion, and set forth in the Award Agreement one (1) share of Stock (and/or any other new, substituted or
additional securities or other property pursuant to an adjustment described in Section <B></B>10.4) for each Restricted Stock Unit then becoming vested or otherwise to be settled on such date, subject to the withholding of applicable taxes.
Notwithstanding the foregoing, if permitted by the Committee and set forth in the Award Agreement, the Participant may elect in accordance with terms specified in the Award Agreement to defer receipt of all or any portion of the shares of Stock or
other property otherwise issuable to the Participant pursuant to this Section. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">10.7 <B>Nontransferability of Restricted Stock Unit Awards.</B> Prior to the issuance of shares of Stock in settlement of a Restricted
Stock Unit Award, the Award shall not be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Participant or the Participant&#146;s beneficiary, except
transfer by will or by the laws of descent and distribution. All rights with respect to a Restricted Stock Unit Award granted to a Participant hereunder shall be exercisable during his or her lifetime only by such Participant or the
Participant&#146;s guardian or legal representative. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">11.
<B><U>D<SMALL>EFERRED</SMALL> S<SMALL>TOCK</SMALL> U<SMALL>NITS</SMALL></U><SMALL></SMALL></B><SMALL><B></B></SMALL><B>.</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">11.1 <B>Establishment of Deferred Stock Unit Program.</B> The Committee, in its discretion and upon such terms and conditions as it may
determine, may establish one or more programs pursuant to the Plan under which: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a) Participants designated by the Committee who are Insiders or otherwise among a select group of highly compensated Employees may
irrevocably elect, prior to a date specified by the Committee, to reduce such Participant&#146;s compensation otherwise payable in cash (subject to any minimum or maximum reductions imposed by the Committee) and to be granted automatically at such
time or times as specified by the Committee one or more Awards of Deferred Stock Units with respect to such numbers of shares of Stock as determined </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">23 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%">
<FONT FACE="Times New Roman" SIZE="2">in accordance with the rules of the program established by the Committee and having such other terms and conditions as established by the Committee.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) Participants designated by the Committee
who are Insiders or otherwise among a select group of highly compensated Employees may irrevocably elect, prior to a date specified by the Committee, to be granted automatically an Award of Deferred Stock Units with respect to such number of shares
of Stock and upon such other terms and conditions as established by the Committee in lieu of: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(i) shares of Stock otherwise issuable to such Participant upon the exercise of an Option; </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ii) cash or shares of Stock otherwise issuable to such
Participant upon the exercise of a SAR; or </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(iii) cash or shares of Stock otherwise issuable to such Participant upon the settlement of a Performance Award. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">11.2 <B>Terms and Conditions of Deferred Stock Units.</B> Deferred Stock Units granted pursuant to this Section 11 shall be evidenced by
Award Agreements in such form as the Committee shall from time to time establish. No such Deferred Stock Unit or purported Deferred Stock Unit shall be a valid and binding obligation of the Company unless evidenced by a fully executed Award
Agreement. Award Agreements evidencing Deferred Stock Units may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a) <B><I>Vesting Conditions</I></B>. Deferred Stock Units
shall not be subject to any vesting conditions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(b) <B><I>Terms and Conditions of Deferred Stock Units</I></B>. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(i) <B>Voting Rights; Dividend Equivalent Rights and Distributions.</B> Participants shall have no voting rights with respect to shares of Stock represented by Deferred Stock Units until the date of the issuance of
such shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company). However, a Participant shall be entitled to receive Dividend Equivalents with respect to the payment of cash
dividends on Stock having a record date prior to date on which Deferred Stock Units held by such Participant are settled. Such Dividend Equivalents shall be paid by crediting the Participant with additional whole and/or fractional Deferred Stock
Units as of the date of payment of such cash dividends on Stock. The method of determining the number of additional Deferred Stock Units to be so credited shall be specified by the Committee and set forth in the Award Agreement. Such additional
Deferred Stock Units shall be subject to the same terms and conditions and shall be settled in the same manner and at the same time (or as soon thereafter as practicable) as the Deferred Stock Units originally subject to the Deferred Stock Unit
Award. In the event of a dividend or distribution paid in shares of Stock or any other adjustment made upon a change in the capital structure of the Company as described in Section 4.2, appropriate adjustments shall be made in the Participant&#146;s
Deferred Stock Unit Award so that it represent the right to receive upon settlement any and all new, substituted or </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">24 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%">
<FONT FACE="Times New Roman" SIZE="2">additional securities or other property (other than normal cash dividends) to which the Participant would entitled by reason of the shares of Stock issuable
upon settlement of the Award. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ii)
<B>Settlement of Deferred Stock Unit Awards.</B> A Participant electing to receive an Award of Deferred Stock Units pursuant to this Section 11, shall specify at the time of such election a settlement date with respect to such Award. The Company
shall issue to the Participant as soon as practicable following the earlier of the settlement date elected by the Participant or the date of termination of the Participant&#146;s Service, a number of whole shares of Stock equal to the number of
whole Deferred Stock Units subject to the Deferred Stock Unit Award. Such shares of Stock shall be fully vested, and the Participant shall not be required to pay any additional consideration (other than applicable tax withholding) to acquire such
shares. Any fractional Deferred Stock Unit subject to the Deferred Stock Unit Award shall be settled by the Company by payment in cash of an amount equal to the Fair Market Value as of the payment date of such fractional share. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(iii) <B>Nontransferability of Deferred Stock Unit
Awards.</B> Prior to their settlement in accordance with the provision of the Plan, no Deferred Stock Unit Award shall be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by
creditors of the Participant or the Participant&#146;s beneficiary, except transfer by will or by the laws of descent and distribution. All rights with respect to a Deferred Stock Unit Award granted to a Participant hereunder shall be exercisable
during his or her lifetime only by such Participant or the Participant&#146;s guardian or legal representative. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">12. <B><U>S<SMALL>TANDARD</SMALL> F<SMALL>ORMS</SMALL> <SMALL>OF</SMALL> A<SMALL>WARD</SMALL>
A<SMALL>GREEMENT</SMALL></U><SMALL></SMALL></B><SMALL><B></B></SMALL><B>.</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">12.1 <B>Award Agreements.</B> Each Award shall comply with and be subject to the terms and conditions set forth in the appropriate form of Award Agreement approved by the Committee and as amended from time to time.
Any Award Agreement may consist of an appropriate form of Notice of Grant and a form of Agreement incorporated therein by reference, or such other form or forms as the Committee may approve from time to time. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">12.2 <B>Authority to Vary Terms.</B> The Committee shall
have the authority from time to time to vary the terms of any standard form of Award Agreement either in connection with the grant or amendment of an individual Award or in connection with the authorization of a new standard form or forms; provided,
however, that the terms and conditions of any such new, revised or amended standard form or forms of Award Agreement are not inconsistent with the terms of the Plan. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">13. <B><U>C<SMALL>HANGE</SMALL> <SMALL>IN</SMALL>
C<SMALL>ONTROL</SMALL></U><SMALL></SMALL></B><SMALL><B></B></SMALL><B>.</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">13.1 <B>Definitions.</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(a) An <I>&#147;</I><B></B><B><I>Ownership Change Event</I></B><B></B><I></I><I>&#148;</I> shall be deemed to have occurred if any of the following occurs with respect to the Company: (i) the direct or indirect sale
or exchange in a single or series of related transactions by the stockholders of the Company of more than fifty percent (50%) of the voting stock of the Company; (ii) a merger or consolidation in </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">25 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%">
<FONT FACE="Times New Roman" SIZE="2">which the Company is a party; (iii) the sale, exchange, or transfer of all or substantially all of the assets of the Company (other than a sale, exchange or
transfer to one or more subsidiaries of the Company); or (iv) a liquidation or dissolution of the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) A <I>&#147;</I><B></B><B><I>Change in Control</I></B><B></B><I></I><I>&#148;</I> shall mean an Ownership Change Event or series of
related Ownership Change Events (collectively, a <I>&#147;</I><B></B><B><I>Transaction</I></B><B></B><I>&#148;</I>) in which the stockholders of the Company immediately before the Transaction do not retain immediately after the Transaction, in
substantially the same proportions as their ownership of shares of the Company&#146;s voting stock immediately before the Transaction, direct or indirect beneficial ownership of more than fifty percent (50%) of the total combined voting power of the
outstanding voting securities of the Company or, in the case of an Ownership Change Event described in Section 13.1(a)(iii), the entity to which the assets of the Company were transferred (the
<I>&#147;</I><B></B><B><I>Transferee</I></B><B></B><I>&#148;</I>), as the case may be. For purposes of the preceding sentence, indirect beneficial ownership shall include, without limitation, an interest resulting from ownership of the voting
securities of one or more corporations or other business entities which own the Company or the Transferee, as the case may be, either directly or through one or more subsidiary corporations or other business entities. The Committee shall have the
right to determine whether multiple sales or exchanges of the voting securities of the Company or multiple Ownership Change Events are related, and its determination shall be final, binding and conclusive. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">13.2 <B>Effect of Change in Control on Options and SARs.</B>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a) <B><I>Accelerated Vesting</I></B>.
Notwithstanding any other provision of the Plan to the contrary, the Committee, in its sole discretion, may provide in any Award Agreement or, in the event of a Change in Control, may take such actions as it deems appropriate to provide for the
acceleration of the exercisability and vesting in connection with such Change in Control of any or all outstanding Options and SARs and shares acquired upon the exercise of such Options and SARs upon such conditions and to such extent as the
Committee shall determine. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b)
<B><I>Assumption or Substitution</I></B>. In the event of a Change in Control, the surviving, continuing, successor, or purchasing corporation or other business entity or parent corporation thereof, as the case may be (the
<I>&#147;</I><B></B><B><I>Acquiring Corporation</I></B><B></B><I></I><I>&#148;</I>), may, without the consent of the Participant, either assume the Company&#146;s rights and obligations under outstanding Options and SARs or substitute for
outstanding Options and SARs substantially equivalent options and stock appreciation rights for the Acquiring Corporation&#146;s stock. In the event that the Acquiring Corporation elects not to assume or substitute for outstanding Options and SARs
in connection with a Change in Control, or if the Acquiring Corporation is not a &#147;publicly held corporation&#148; within the meaning of Section 162(m), the exercisability and vesting of each such outstanding Option, SAR and any shares acquired
upon the exercise thereof held by a Participant whose Service has not terminated prior to such date shall be accelerated, effective as of the date ten (10) days prior to the date of the Change in Control. The exercise or vesting of any Option, SAR
and any shares acquired upon the exercise thereof that was permissible solely by reason of this Section 13.2 and the provisions of such applicable Award Agreement shall be conditioned upon the consummation of the Change in Control. Any Options and
SARs which are neither assumed or substituted for by the Acquiring Corporation in connection with the Change in Control nor exercised as of the date of the Change in Control shall terminate and cease to be outstanding effective as of the date of the
Change in Control. Notwithstanding the foregoing, </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">26 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%">
<FONT FACE="Times New Roman" SIZE="2">shares acquired upon exercise of an Option or SAR prior to the Change in Control and any consideration received pursuant to the Change in Control with
respect to such shares shall continue to be subject to all applicable provisions of the applicable Award Agreement evidencing such Option or SAR except as otherwise provided in such applicable Award Agreement. Furthermore, notwithstanding the
foregoing, if the corporation the stock of which is subject to the outstanding Options and SARs immediately prior to an Ownership Change Event described in Section 13.1(a)(i) constituting a Change in Control is the surviving or continuing
corporation and immediately after such Ownership Change Event less than fifty percent (50%) of the total combined voting power of its voting stock is held by another corporation or by other corporations that are members of an affiliated group within
the meaning of Section 1504(a) of the Code without regard to the provisions of Section 1504(b) of the Code, the outstanding Options and SARs shall not terminate unless the Committee otherwise provides in its discretion. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(c) <B><I>Cash-Out</I></B>. The Committee may, in its sole
discretion and without the consent of any Participant, determine that, upon the occurrence of a Change in Control, each or any Option or SAR outstanding immediately prior to the Change in Control shall be canceled in exchange for a payment with
respect to each vested share of Stock subject to such canceled Option or SAR in (i) cash, (ii) stock of the Company or of a corporation or other business entity a party to the Change in Control, or (iii) other property which, in any such case, shall
be in an amount having a Fair Market Value equal to the excess of the Fair Market Value of the consideration to be paid per share of Stock in the Change in Control over the exercise price per share under such Option or SAR (the
<I>&#147;</I><B></B><B><I>Spread</I></B><B></B><I>&#148;</I>). In the event such determination is made by the Committee, the Spread (reduced by applicable withholding taxes, if any) shall be paid to Participants in respect of their canceled Options
and SARs as soon as practicable following the date of the Change in Control. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">13.3 <B>Effect of Change in Control on Restricted Stock Awards.</B> The Committee may, in its discretion, provide in any Award Agreement evidencing a Restricted Stock Award that, in the event of a Change in Control,
the lapsing of the Restriction Period applicable to the shares subject to the Restricted Stock Award held by a Participant whose Service has not terminated prior to the Change in Control shall be accelerated effective immediately prior to the
consummation of the Change in Control to such extent as specified in such Award Agreement. Any acceleration of the lapsing of the Restriction Period that was permissible solely by reason of this Section 13.3 and the provisions of such Award
Agreement shall be conditioned upon the consummation of the Change in Control. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">13.4 <B>Effect of Change in Control on Performance Awards.</B> The Committee may, in its discretion, provide in any Award Agreement
evidencing a Performance Award that, in the event of a Change in Control, the Performance Award held by a Participant whose Service has not terminated prior to the Change in Control shall become payable effective as of the date of the Change in
Control to such extent as specified in such Award Agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">13.5 <B>Effect of Change in Control on Restricted Stock Unit Awards.</B> The Committee may, in its discretion, provide in any Award Agreement evidencing a Restricted Stock Unit Award that, in the event of a Change in
Control, the Restricted Stock Unit Award held by a Participant whose Service has not terminated prior to such date shall be settled </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">27 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%">
<FONT FACE="Times New Roman" SIZE="2">effective as of the date of the Change in Control to such extent as specified in such Award Agreement. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">13.6 <B>Effect of Change in Control on Deferred Stock
Units.</B> The Committee may, in its discretion, provide in any Award Agreement evidencing a Deferred Stock Unit Award that, in the event of a Change in Control, the Deferred Stock Units pursuant to such Award shall be settled effective as of the
date of the Change in Control to such extent as specified in such Award Agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">14. <B><U>C<SMALL>OMPLIANCE</SMALL> <SMALL>WITH</SMALL> S<SMALL>ECURITIES</SMALL> L<SMALL>AW</SMALL></U><SMALL></SMALL></B><SMALL><B></B></SMALL><B>.</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The grant of Awards and the issuance of shares of Stock pursuant to any Award shall be subject to compliance
with all applicable requirements of federal, state and foreign law with respect to such securities and the requirements of any stock exchange or market system upon which the Stock may then be listed. In addition, no Award may be exercised or shares
issued pursuant to an Award unless (a) a registration statement under the Securities Act shall at the time of such exercise or issuance be in effect with respect to the shares issuable pursuant to the Award or (b) in the opinion of legal counsel to
the Company, the shares issuable pursuant to the Award may be issued in accordance with the terms of an applicable exemption from the registration requirements of the Securities Act. The inability of the Company to obtain from any regulatory body
having jurisdiction the authority, if any, deemed by the Company&#146;s legal counsel to be necessary to the lawful issuance and sale of any shares hereunder shall relieve the Company of any liability in respect of the failure to issue or sell such
shares as to which such requisite authority shall not have been obtained. As a condition to issuance of any Stock, the Company may require the Participant to satisfy any qualifications that may be necessary or appropriate, to evidence compliance
with any applicable law or regulation and to make any representation or warranty with respect thereto as may be requested by the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">15. <B><U>T<SMALL>AX</SMALL> W<SMALL>ITHHOLDING</SMALL></U><SMALL></SMALL></B><SMALL><B></B></SMALL><B>.</B> </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">15.1 <B>Tax Withholding in General.</B> The Company shall
have the right to deduct from any and all payments made under the Plan, or to require the Participant, through payroll withholding, cash payment or otherwise, including by means of a Cashless Exercise of an Option, to make adequate provision for,
the federal, state, local and foreign taxes, if any, required by law to be withheld by the Participating Company Group with respect to an Award or the shares acquired pursuant thereto. The Company shall have no obligation to deliver shares of Stock,
to release shares of Stock from an escrow established pursuant to an Award Agreement, or to make any payment in cash under the Plan until the Participating Company Group&#146;s tax withholding obligations have been satisfied by the Participant.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">15.2 <B>Withholding in Shares.</B> The
Company shall have the right, but not the obligation, to deduct from the shares of Stock issuable to a Participant upon the exercise or settlement of an Award, or to accept from the Participant the tender of, a number of whole shares of Stock having
a Fair Market Value, as determined by the Company, equal to all or any part of the tax withholding obligations of the Participating Company Group. The Fair Market Value of any shares of Stock withheld or tendered to satisfy any such tax withholding
obligations shall not exceed the amount determined by the applicable minimum statutory withholding rates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">28 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">16. <B><U>A<SMALL>MENDMENT</SMALL> <SMALL>OR</SMALL> T<SMALL>ERMINATION</SMALL> <SMALL>OF</SMALL>
P<SMALL>LAN</SMALL></U><SMALL></SMALL></B><SMALL><B></B></SMALL><B>.</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The Committee may amend, suspend or terminate the Plan at any time. However, without the approval of the Company&#146;s stockholders, there shall be (a) no increase in the maximum aggregate number of shares of Stock
that may be issued under the Plan (except by operation of the provisions of Section 4.2, (b) no change in the class of persons eligible to receive Incentive Stock Options, (c) no Option and/or SAR repricing as described in Section 3.6, (d) no
amendment to permit the granting of Options (other than Indexed Options) with exercise prices less than Fair Market Value on the date of grant, and (e) no other amendment of the Plan that would require approval of the Company&#146;s stockholders
under any applicable law, regulation or rule. No amendment, suspension or termination of the Plan shall affect any then outstanding Award unless expressly provided by the Committee. In any event, no amendment, suspension or termination of the Plan
may adversely affect any then outstanding Award without the consent of the Participant unless necessary to comply with any applicable law, regulation or rule. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">17. <B><U>M<SMALL>ISCELLANEOUS</SMALL> P<SMALL>ROVISIONS</SMALL></U><SMALL></SMALL></B><SMALL><B></B></SMALL><B>.</B> </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">17.1 <B>Repurchase Rights.</B> Shares issued under the Plan
may be subject to one or more repurchase options, or other conditions and restrictions as determined by the Committee in its discretion at the time the Award is granted. The Company shall have the right to assign at any time any repurchase right it
may have, whether or not such right is then exercisable, to one or more persons as may be selected by the Company. Upon request by the Company, each Participant shall execute any agreement evidencing such transfer restrictions prior to the receipt
of shares of Stock hereunder and shall promptly present to the Company any and all certificates representing shares of Stock acquired hereunder for the placement on such certificates of appropriate legends evidencing any such transfer restrictions.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">17.2 <B>Provision of Information.</B> Each
Participant shall be given access to information concerning the Company equivalent to that information generally made available to the Company&#146;s common stockholders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">17.3 <B>Rights as Employee, Consultant or Director.</B> No person, even though eligible pursuant to Section
5, shall have a right to be selected as a Participant, or, having been so selected, to be selected again as a Participant. Nothing in the Plan or any Award granted under the Plan shall confer on any Participant a right to remain an Employee,
Consultant or Director or interfere with or limit in any way any right of a Participating Company to terminate the Participant&#146;s Service at any time. To the extent that an Employee of a Participating Company other than the Company receives an
Award under the Plan, that Award shall in no event be understood or interpreted to mean that the Company is the Employee&#146;s employer or that the Employee has an employment relationship with the Company. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">17.4 <B>Rights as a Stockholder.</B> A Participant shall
have no rights as a stockholder with respect to any shares covered by an Award until the date of the issuance of such shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).
No adjustment shall be made for dividends, distributions or other rights for which the record date is prior to the date such shares are issued, except as provided in Section <B></B>4.2 or another provision of the Plan. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">29 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">17.5 <B>Fractional Shares.</B> The Company shall not be required to issue fractional
shares upon the exercise or settlement of any Award. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">17.6 <B>Severability</B>. If any one or more of the provisions (or any part thereof) of this Plan or of any Award Agreement issued hereunder, shall be held to be invalid, illegal or unenforceable in any respect, such provision shall be
modified so as to make it valid, legal and enforceable, and the validity, legality and enforceability of the remaining provisions (or any part thereof) of the Plan or of any Award Agreement shall not in any way be affected or impaired thereby. The
Company may, without the consent of any Participant, and in a manner determined necessary solely in the discretion of the Company, amend the Plan and any outstanding Award Agreement as the Company deems necessary to ensure the Plan and all Awards
remain valid, legal or enforceable in all respects. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">17.7 <B>Beneficiary Designation.</B> Subject to local laws and procedures, each Participant may file with the Company a written designation of a beneficiary who is to receive any benefit under the Plan to which the Participant is entitled
in the event of such Participant&#146;s death before he or she receives any or all of such benefit. Each designation will revoke all prior designations by the same Participant, shall be in a form prescribed by the Company, and will be effective only
when filed by the Participant in writing with the Company during the Participant&#146;s lifetime. If a married Participant designates a beneficiary other than the Participant&#146;s spouse, the effectiveness of such designation may be subject to the
consent of the Participant&#146;s spouse. If a Participant dies without an effective designation of a beneficiary who is living at the time of the Participant&#146;s death, the Company will pay any remaining unpaid benefits to the Participant&#146;s
legal representative. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">17.8 <B>Unfunded
Obligation.</B> Participants shall have the status of general unsecured creditors of the Company. Any amounts payable to Participants pursuant to the Plan shall be unfunded and unsecured obligations for all purposes, including, without limitation,
Title I of the Employee Retirement Income Security Act of 1974. No Participating Company shall be required to segregate any monies from its general funds, or to create any trusts, or establish any special accounts with respect to such obligations.
The Company shall retain at all times beneficial ownership of any investments, including trust investments, which the Company may make to fulfill its payment obligations hereunder. Any investments or the creation or maintenance of any trust or any
Participant account shall not create or constitute a trust or fiduciary relationship between the Committee or any Participating Company and a Participant, or otherwise create any vested or beneficial interest in any Participant or the
Participant&#146;s creditors in any assets of any Participating Company. The Participants shall have no claim against any Participating Company for any changes in the value of any assets which may be invested or reinvested by the Company with
respect to the Plan. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">30 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><U>PLAN HISTORY AND NOTES TO COMPANY </U></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="76%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,&nbsp;2004</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Board adopts Plan with a reserve of Seven Million Two Hundred and Four Thousand and Eighty-Five (7,204,085), reduced at any time by the number of shares subject to the Prior Plan Options
(which as of the Effective Date equaled approximately Two Million Four Hundred and Fifty-Four Thousand and Eighty-Five (2,454,085)). Such shares shall consist of authorized but unissued or reacquired shares of Stock or any combination thereof. If
any outstanding Award, including any Prior Plan Options, for any reason expires or is terminated or canceled without having been exercised or settled in full, or if shares of Stock acquired pursuant to an Award subject to forfeiture or repurchase,
including any Prior Plan Options, are forfeited or repurchased by the Company, the shares of Stock allocable to the terminated portion of such Award, including any Prior Plan Options, or such forfeited or repurchases shares of Stock shall again be
available for issuance under the Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,</U> 2004</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Stockholders approve Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">IMPORTANT NOTE: Implementation of Section 11&#151;Deferred Stock Units</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">The establishment of a Deferred Stock Unit program pursuant to Section Error! Reference source not found. requires that the Company determine whether such program will constitute a
&#147;top-hat&#148; pension plan under ERISA. If so, file notice with Dept. of Labor under ERISA Reg. 2520.104-23 within 120 days of adoption of resolutions by the Committee to establish the program to obtain exemption from reporting and disclosure
requirements of ERISA.</FONT></TD></TR>
</TABLE>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.55
<SEQUENCE>4
<FILENAME>dex1055.htm
<DESCRIPTION>DEVELOPMENT AND VALIDATION AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Development and Validation Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">EXHIBIT 10.55 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">THIS AGREEMENT is made by and between: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>AVECIA LIMITED</B>, acting through its Avecia Biotechnology business, with offices at Hexagon Tower, Blackley, Manchester, M9 8ZS, England (&#147;<B>Avecia</B>&#148;); and
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>NUVELO, INC., </B>a Delaware corporation with offices at 675 Almanor Avenue, Sunnyvale, CA 94085, USA (&#147;<B>Nuvelo</B>&#148;). </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">WHEREAS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">A</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia has experience and knowledge with regard to process development, fermentation and manufacture of recombinant proteins. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">B</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Nuvelo is carrying out research and development in relation to the Product (as defined below). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">C</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">In anticipation of entering into a definitive agreement to carry out a range of activities in relation to the Product (as defined in this Agreement), Avecia and Nuvelo entered into
an Interim Agreement on 21 January 2005 (the <B>&#147;Interim Agreement&#148;</B>) that set out the interim terms and conditions on which the following portions of the Project, consisting of (i) assessment and planning, (ii) transfer of process and
assays, (iii) purchase of certain capital equipment, (iv) replicate 15L fermentation and purification runs and (v) GMP consultancy preparatory to GMP manufacture, would be carried out before execution of the definitive agreement.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">D</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Nuvelo now wishes Avecia to carry out activities in relation to the API (as defined below), including validation work in respect of the Process (as defined below).
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">NOW IT IS HEREBY AGREED BY NUVELO AND AVECIA AS FOLLOWS:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Definitions</U>: </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Affiliate</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Any corporation, association or other business entity which directly or indirectly controls, is controlled by or is under common control with Avecia or Nuvelo and &#147;<B>control</B>,&#148;
&#147;<B>controls</B>&#148; or &#147;<B>controlled</B>&#148; shall mean the legal power to direct or cause the direction of the general management and policies of such entity whether through the ownership of at least 50% of the voting securities or
voting capital stock of such business entity, or any other comparable controlling equity or controlling ownership interest with respect to a business entity other than a corporation.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>API</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The polypeptide referred to by Nuvelo as alfimeprase is the Active Pharmaceutical Ingredient. In accordance with Annexe 18 of the EU Guide to Good Manufacturing Practice 2002, titled
&#147;Good</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Manufacturing Practice for Active Pharmaceutical Ingredients,&#148; an Active Pharmaceutical Ingredient is any substance or mixture of substances intended to be used in the manufacture of a drug
(medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation,
treatment, or prevention of disease or to affect the structure and function of the body.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>API Specification</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The specification for API attached to, and part of the Quality Agreement, which may be amended from time to time in accordance with the terms and conditions of this Agreement and the Quality
Agreement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Applicable Laws</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">All applicable supranational, national or local laws, rules and regulations, including without limitation the United States Federal Food, Drug and Cosmetic Act, the regulations promulgated
pursuant thereto, any applicable non-U.S. equivalents thereof, and any successor laws, rules or regulations thereto.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Avecia Default</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Means:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:2.00em"><FONT FACE="Times New Roman" SIZE="2">(a) A Failure by Avecia to use reasonable commercial endeavours to progress the Project;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:2.00em"><FONT FACE="Times New Roman" SIZE="2">(b) A Failure by Avecia to manufacture any Development Batch or any Validation Batch in accordance with cGMP,
specifically including any failure to follow Avecia&#146;s facilities&#146; Standard Operating Procedures that results in, or from which arises, a Defective Batch;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:2.00em"><FONT FACE="Times New Roman" SIZE="2">(c) Solely with respect to the centrifuge trials, a failure by Avecia to conduct the centrifuge trials in accordance
with Avecia&#146;s Standard Operating Procedures: (1) for the fermentation and harvest suite or suites which are applicable to the centrifuge trials in the reasonable determination of the Quality Team, a list of which shall be generated by the
Quality Team; and (2) for, as reasonably modified from time to time as a result of the work carried out under the Project, any equipment to be used in the centrifuge trials;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:2.00em"><FONT FACE="Times New Roman" SIZE="2">(d) Solely with respect to the Development Batches:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:2.00em"><FONT FACE="Times New Roman" SIZE="2">(1) A failure by Avecia personnel&#151;including without limitation lack of appropriate training,
lack of attention to MBRs or Standard Operating</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em"><FONT FACE="Times New Roman" SIZE="2">Procedures, or lack of proper laboratory analysis&#151;that results in, or from which arises, a Defective Batch;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:2.00em"><FONT FACE="Times New Roman" SIZE="2">(2) A failure of Avecia documentation&#151;including
without limitation inadequate Standard Operating Procedure or MBR documentation, improperly organized or lost documentation, or poor analysis of information incorporated into any such documentation&#151;that results in, or from which arises, a
Defective Batch;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:2.00em"><FONT FACE="Times New Roman" SIZE="2">(3)
Adulteration&#151;including without limitation adulteration from cleaning agents and/or other contaminants, or adulteration from using reagents other than in the order specified in the Work Programme or the MBRs for the Process&#151;that results in,
or from which arises, a Defective Batch;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:2.00em"><FONT FACE="Times New Roman"
SIZE="2">(4) A failure of Avecia equipment&#151;including without limitation poor maintenance, age of the equipment, computer malfunction, software malfunction or controller malfunction, equipment being out of specification or not properly
calibrated, equipment not being validated for intended use, improper cleaning, improper cleaning cycles or failure to clean equipment&#151;that results in, or from which arises, a Defective Batch;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:2.00em"><FONT FACE="Times New Roman" SIZE="2">(5) A Failure of an Avecia facility&#151;including
without limitation a cGMP violation in the facility, improper environmental controls, including HVAC system failure, poor construction or inadequate maintenance&#151;that results in, or from which arises, a Defective Batch; or</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:2.00em"><FONT FACE="Times New Roman" SIZE="2">(6) A failure of Avecia raw materials&#151;including
without limitation raw materials that are out of specification, quarantined, improperly tested, improperly processed or expired&#151;that results in, or from which arises, a Defective Batch;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:2.00em"><FONT FACE="Times New Roman" SIZE="2">(e) For the avoidance of doubt, a failure of a centrifuge trial or the
occurrence of a Defective Batch that is a Development Batch, that results from a factor&#151;other than any of the factors listed in Clauses (a) through (d) above&#151;which affects the Process or production of the API and was not known and could
not reasonably have been known by Avecia at the commencement of the applicable stage of the Project shall not be considered to be an Avecia default; such factors include, without limitation:</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:2.00em"><FONT FACE="Times New Roman" SIZE="2">(1) the Process does not perform as anticipated due
to a change of scale;</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:2.00em"><FONT FACE="Times New Roman" SIZE="2">(2) inability of the centrifuge to clarify the harvested broth to an acceptable level;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:2.00em"><FONT FACE="Times New Roman" SIZE="2">(3) failure during a centrifuge run of the pH
control system to maintain a specified range; and</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:2.00em"><FONT
FACE="Times New Roman" SIZE="2">(4) failure during a centrifuge run of the feed strategy to generate the expected product yield or quality; or</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px; text-indent:2.00em"><FONT FACE="Times New Roman" SIZE="2">(f) The occurrence of a Defective Batch during the Validation Campaign is, and is automatically deemed to be an Avecia Default, except upon the
occurrence of a Defective Batch which results from a factor&#151;other than any of the factors listed in Clauses (a) through (d) above&#151;which affects the Process or production of the API and was not known and could not reasonably have been known
by Avecia before the Defective Batch occurred, including, without limitation, a previously unknown factor not studied either as part of the Amgen programme transferred to Avecia or the Avecia laboratory work programme carried out pursuant to the
Project (the preceding in this Clause (f) referred to herein as a &#147;<B>Validation Process Failure</B>&#148;).</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Background Intellectual Property</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Any Intellectual Property owned by or Controlled by a Party (where &#147;Controlled&#148; means the ability to grant a license or sublicense to the
Intellectual Property):</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman"
SIZE="2">(a)&nbsp;&nbsp;&nbsp;&nbsp;at the Commencement Date of this Agreement; or</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2">(b)&nbsp;&nbsp;&nbsp;&nbsp;after the Commencement Date that is either: (1) acquired independently of the Project; or (2)
developed independently of the Project by any employee of that Party without use of or reference to any of the Confidential Information disclosed by the other Party.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Batch</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A quantity of API produced using the Process that (a) is expected to have uniform character and quality within specified limits, and (b) is produced according to a single manufacturing run
during the same cycle of the Process.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Batch Dispute</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The definition set forth in Clause 2.7(g).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Cancellation Fee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A sum calculated in accordance with Schedule 4. The Cancellation Fee may include, as applicable as set forth in Schedule 4 and in accordance with the terms</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">and conditions of this Agreement, the Development Batch Fee and/or the Validation Campaign Fee.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Certificate of Analysis</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A document, the form of which is approved in advance by the Quality Team, that is prepared and issued by Avecia&#146;s quality assurance department certifying analysis and cGMP manufacture of
the API and its compliance with the API Specification.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>cGMP</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Current Good Manufacturing Practices required by Regulatory Authorities with respect to the development, manufacture, storage and supply of any Batch, including current good manufacturing
practices as incorporated in Annexe 18 of the EU Guide to Good Manufacturing Practice 2002, titled &#147;Good Manufacturing Practice for Active Pharmaceutical Ingredients&#148; (formerly ICH Q7A) and as interpreted in the USA Federal Register Vol 66
No. 186 (formerly ICH Q7A), and subject to any arrangements, additions or clarifications agreed in writing from time to time between the Parties in the Quality Agreement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Commencement Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">21</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>st</SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"> January 2005.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Completion</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Completion of the Project as set out in Clause 4.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Confidential Information</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Shall have the meaning given in the Confidentiality Agreement, subject to Clause 7. New Intellectual Property shall be deemed to be Confidential Information disclosed by Nuvelo.</FONT></TD></TR>

<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Confidentiality Agreement</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The confidentiality agreement entered into between the Parties and dated 21st September 2004, attached hereto as Schedule 7.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Defective Batch</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Either:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2">(a)&nbsp;&nbsp;&nbsp;&nbsp;A Batch that has not been produced in accordance with cGMP, specifically including all Standard
Operating Procedures for Avecia&#146;s facility and the Master Batch Records for the Process, and for which any non-conformances from the SOPs or the MBRs cannot be closed-out in accordance with the procedures for close-out of non-conformances set
forth in the Quality Agreement; or</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman"
SIZE="2">(b)&nbsp;&nbsp;&nbsp;&nbsp;A Batch, other than the first Development Batch or the Engineering Batch, which cannot be Released.</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Development Batch or cGMP Development Batch</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A Batch manufactured during Development Batch Manufacture, specifically including the Engineering Batch.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Development Batch Manufacture</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The work to manufacture the development Batches and the Engineering Batch in accordance with Clause 2.3 and the Work Programme.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Engineering Batch</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A Batch manufactured immediately prior to the Validation Campaign for the purpose of re-testing the Process before commencement of the Validation Campaign.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Equipment</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Any equipment (such as, without limitation, columns, freezers, filtration skids, cassette holders, ammonia feed tanks) which is required to be purchased in order for Avecia to carry out the
Project and which is set forth in Schedule 6 to this Agreement or set forth in the Work Programme or any Programme Amendment Order.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Executive Committee or EC</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The executive committee established pursuant to Clause 2.7.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Expenditure</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">An amount paid or due and payable to a Third Party for the purchase of subcontractor services directly from the Third Party in accordance with Clause 13.2 or for the purchase of goods or
materials directly from the Third Party.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Force Majeure</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Any cause beyond the reasonable control of the Party in question, which for the avoidance of doubt and without prejudice to the generality of the foregoing, may include governmental actions,
war, riots, terrorism, civil commotion, fire, flood, epidemic, labour disputes (excluding labour disputes involving the work force or any part thereof of the Party in question), restraints or delays affecting shipping or carriers, inability or delay
in obtaining supplies of adequate or suitable materials, and act of God, but shall not include failure of the Product in clinical trials or failure of the Product to gain regulatory approval.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Handling Fee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A sum equivalent to 8% of the actual Expenditure for the Equipment or consumables purchased under Clauses 3.2(a)(1), 3.2(a)(3) and 3.3.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Hold Time</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Any period of time during Development Batch Manufacture or the Validation Campaign during which Batches are not being manufactured, whether by</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">agreement so that modifications to procedures, processes and/or facilities or review thereof can be undertaken or as a result of a Nuvelo Delay or an Avecia Default.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Intellectual Property</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Any Patent, trade secret, copyright or other industrial or intellectual property right.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Invention</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Any invention, innovation, improvement, development, discovery, computer program, device, method, know-how, process, technique or the like, whether or not written or otherwise fixed in any form
or medium, regardless of the media on which contained and whether or not patentable or copyrightable.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>New Intellectual Property or New IP</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Any Intellectual Property that claims or covers any New Invention.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>New Invention</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Any Invention directly resulting from or directly arising out of Avecia&#146;s performance of the Project.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Non-Manufacturing Delay</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A delay resulting from a decision by Nuvelo to delay the Project for reasons unrelated to: the Project; manufacture of the API under the Agreement; any Avecia Default; or any Process Failure.
Non-Manufacturing Delay may include, without limitation, decisions made in response to the outcome of clinical trials of the API.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Nuvelo Delay</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Any delay in the Development Batch Manufacture or the Validation Campaign which is caused by Nuvelo including, without limitation, unreasonable refusal to agree to any matter requiring mutual
agreement under this Agreement in a timely manner; but, each of the following is not, and shall not be deemed to be, a Nuvelo Delay: (i) any delay or refusal by Nuvelo to agree based upon or resulting from an Avecia Default; and (ii) any delay
resulting from Nuvelo&#146;s refusal to take a license under a Patented, Licensed Avecia Invention under Clause 5.2(c).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Master Batch Record or MBR</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A written description of the procedure to be followed for manufacturing a Batch of the API, including but not limited to the history of a Batch from the raw material stage up through and until
completion of the Batch, a complete list of all active and inactive ingredients, components, weights and measures, descriptions of drug product containers, closures, packaging materials, and labelling and complete specifications for each, within the
meaning of 21 Code of Federal Regulations 211.186, or its successor as in effect from</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">time to time, and also in compliance with Annexe 18 of the EU Guide to Good Manufacturing Practice 2002, titled &#147;Good Manufacturing Practice for Active Pharmaceutical Ingredients&#148;
(formerly ICH Q7A), or its successor as in effect from time to time.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Party or Parties</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia and Nuvelo are referred to individually herein as a &#147;Party&#148;, and collectively as the &#147;Parties&#148;.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Patent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Any: (a) patent, including without limitation any inventor&#146;s certificate or design patent, and any substitution, extension, registration, confirmation, reissue, re-examination or any like
filing thereof related to a patent; and (b) any pending patent application, including without limitation any continuation, division or continuation-in-part thereof and any provisional application.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Process</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The process for the manufacture of API communicated to Avecia by, or on behalf of, Nuvelo and subsequently scaled-up by Avecia under and in accordance with this Agreement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Process Assumptions</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The following: (a) requirements set forth in the Master Batch Records for the Process, (b) requirements set forth in Avecia&#146;s Standard Operating Procedures, and (c) raw materials and
consumables requirements and specifications. Any amounts of time necessary to conduct a particular part of the Process, also referred to as cycle times, are expressly excluded from Process Assumptions, irregardless of any statements to the contrary
set forth in the Work Programme.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Product</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Any product that incorporates or contains the API.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Programme Amendment Order</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A document in the form set out in Schedule 3 detailing changes to the Project agreed upon and signed by both Parties.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Project</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The range of activities to be carried out under this Agreement in accordance with the Work Programme, the details of which are more fully set out in the Work Programme, and any additional or
alternative work not set forth in the Work Programme that may be agreed in a Programme Amendment Order.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Project Steering Committee or PSC</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The Project steering committee established pursuant to Clause 2.7.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Quality Agreement</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The document, a copy of which is attached as Schedule 2, that sets forth, amongst other things:</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2">(a)&nbsp;&nbsp;&nbsp;&nbsp;the mutually agreed
quality standards applicable for the manufacture of the API under the Agreement in accordance with cGMP; and</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2">(b)&nbsp;&nbsp;&nbsp;&nbsp;the roles and responsibilities of each Party&#146;s personnel in relation to quality assurance matters
under this Agreement; and</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman"
SIZE="2">(c)&nbsp;&nbsp;&nbsp;&nbsp;the API Specifications.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Quality Team</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The Avecia Quality Unit together with the Nuvelo Quality Unit, as further set forth in the Quality Agreement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Regulatory Authority or Regulatory Authorities</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The U.S. Food and Drug Administration, the European Agency for the Evaluation of Medicinal Products, and any equivalent governmental regulatory body in any territory in the world, and any
successor entity or entities to any of the preceding.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Regulatory Filing</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Any and all correspondence or petitions to Regulatory Authorities for the purpose of registering the Product or the Process, or modifying or supplementing existing filings and subsequent
amendments and supplements thereto, as required by Applicable Laws, in order to develop, manufacture, test, sell or distribute Product or the API under this Agreement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Release or Released</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The process by which, in respect of each Batch:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2">(a)&nbsp;&nbsp;&nbsp;&nbsp;Avecia&#146;s Quality Unit:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2">(1)&nbsp;&nbsp;&nbsp;&nbsp;reviews and approves completed Batch records;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2">(2)&nbsp;&nbsp;&nbsp;&nbsp;reviews and approves all
campaign Batch records and buffer Batch records;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4.00em; text-indent:-2.00em"><FONT
FACE="Times New Roman" SIZE="2">(3)&nbsp;&nbsp;&nbsp;&nbsp;closes out all non-conformances;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2">(4)&nbsp;&nbsp;&nbsp;&nbsp;closes out all change controls;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2">(5)&nbsp;&nbsp;&nbsp;&nbsp;issues a Certificate of Analysis;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2">(6)&nbsp;&nbsp;&nbsp;&nbsp;Issues a Certificate of
Compliance; and</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman"
SIZE="2">(b)&nbsp;&nbsp;&nbsp;&nbsp;Nuvelo&#146;s Quality Unit:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:4.00em; text-indent:-2.00em"><FONT
FACE="Times New Roman" SIZE="2">(1)&nbsp;&nbsp;&nbsp;&nbsp;Reviews, and, if appropriate, accepts all Batch related manufacturing documentation;</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2">(2)&nbsp;&nbsp;&nbsp;&nbsp;Reviews, and, if appropriate, accepts QC Batch related analyses; and</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2">(3)&nbsp;&nbsp;&nbsp;&nbsp;Reviews, and, if
appropriate, accepts the Certificate of Analysis.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">For the purpose of this
definition, &#147;Accepts&#148; means Avecia has received written notification from Nuvelo that Nuvelo accepts the documents referred to in Clause (b) above. In the absence of such written notification that Nuvelo does or does not accept such
documents, upon the expiration of 30 calendar days from the date on which Nuvelo receives Avecia&#146;s written notification of Avecia&#146;s completion of the tasks referred to in Clause (a) above, Nuvelo is deemed to have accepted the documents
referred to in Clause (b) above. A Batch that has been Released may be referred to as a &#147;<B>Released Batch</B>&#148;. A Released Batch, or set of Released Batches, may also be referred to as &#147;<B>Released API</B>&#148;. If Nuvelo rejects
the documents referred to in Clause (b) above, the matter will be addressed in accordance with Clause 2.7(g).</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Standard Operating Procedures or SOPs</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written procedures requiring uniform performance of specific functions, or uniform use of specific equipment or resources to ensure data, analysis and manufacturing quality and
uniformity.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Third Party</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Any person or entity other than the Parties or their respective Affiliates.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Unremedied Breach</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A material breach of this Agreement which is not remedied within 30 calendar days after receipt of written notice from the non-breaching Party requiring rectification of the
breach.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Validation Batch</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A Batch manufactured by Avecia as part of the Validation Campaign.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Validation Campaign</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The campaign carried out by Avecia to manufacture three (3) consecutive Validation Batches that can be Released out of up to five (5) anticipated Validation Batches, intended to demonstrate to
Regulatory Authorities a high degree of assurance that the Process will consistently produce Batches meeting pre-determined acceptance criteria necessary for Release, as set out in more detail in Schedule 1 and the Quality
Agreement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Validation Master Plan</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A validation project plan developed by Avecia and reviewed, and if acceptable, approved by Nuvelo in writing which contains all of the validation activities for</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">10 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">the Validation Campaign, including validation steps, deliverables, a time schedule and responsibilities.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Valid Claim</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">A claim of a Patent that: (a) in the case of a pending claim, is being prosecuted, has been pending for no more than 6 years and has not been abandoned or permitted to lapse, and (b) in the
case of an issued claim, has not expired or been held invalid or unenforceable in a final binding court decision from which no appeal can be or is taken.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Work Programme</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">The protocol for the performance of the Project by Avecia, agreed upon by the Parties and attached as Schedule 1 of this Agreement. The Work Programme sets forth the timing and requirements
for the activities to be carried out under the Project, including the <B>Work Programme Timeline</B>, attached to the Work Programme as Appendix 2.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Interpretation</U>. References in this Agreement to <B>&#147;Schedules&#148;</B> refer to the Schedules incorporated into this Agreement, specifically including, without
limitation, the Confidentiality Agreement, the Quality Agreement, and the Work Programme. To the extent that there is conflict between or ambiguity relating to, on the one hand, any or all of the Schedules and, on the other, the remainder of this
Agreement, the wording of the remainder of this Agreement shall prevail. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Performance of Project</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>General</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia shall carry out the Project in accordance with the terms and conditions of this Agreement and the Quality Agreement with reasonable skill and care and no less than the level
of skill and care to be reasonably expected of a professional provider of such services. Avecia also shall perform the Project in compliance with all relevant professional standards, all Applicable Laws and cGMP. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The Parties acknowledge that, having regard to the fact that the work to be performed hereunder is by its nature developmental, Avecia does not guarantee to Nuvelo the achievement
of a successful outcome for the Project, but will use reasonable commercial endeavours to ensure timely success. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Laboratory work and scale-up activities</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Following the Commencement Date, Avecia shall carry out, and has carried out with respect to a portion thereof as set forth in the Interim Agreement, a range of
activities, including </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">data acquisition and assessment, process transfer, replicate 15L runs, process characterisation, fermentation and downstream process, assay validation,
process transfer and prep for large scale manufacture, laboratory based cleaning studies and centrifuge trials on two (2) 3000 litre Batches of the API, all as set out in more detail in the Work Programme. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Centrifuge Trials. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Obligations and Timing. Avecia shall carry out production of two (2) centrifuge trials on two (2) 3000 litre Batches of the API in accordance with its ABC5000 facilities&#146;
Standard Operating Procedures, the Master Batch Records for the Process, all Applicable Laws and the terms and conditions of this Agreement. Avecia shall commence modifications of its ABC5000 facility for the centrifuge trials no later than week
commencing July 4, 2005, Pacific Standard Time. If Avecia fails to commence the modifications of its ABC5000 facility necessary for the centrifuge trials before the expiration of the week commencing July 4, 2005, Pacific Standard Time, then Nuvelo
is entitled to terminate this Agreement in accordance with Section 8.2 upon 10 calendar days written notice to Avecia, without payment of any Cancellation Fees if Avecia has not commenced the modifications before the expiration of the 10 calendar
day period. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Process Failures; Additional Centrifuge Work. If neither of the two centrifuge trials is successful for any reason other than an Avecia Default, then the Parties shall meet to agree
to an additional phase of process development work, to include the performance of further centrifuge trials (all such work referred to herein as <B>&#147;Additional Centrifuge Work&#148;</B>) and commercially reasonable terms for the performance of
the Additional Centrifuge Work. The Additional Centrifuge Work shall be set forth in a Programme Amendment Order, such Programme Amendment Order to include revised timings for Development Batch Manufacture and Validation Campaign, as appropriate.
If, other than as a result of an Avecia Default, the Additional Centrifuge Work does not result in at least one successful centrifuge trial and Development Batch Manufacture has not commenced before the expiration of December 31, 2005, Pacific
Standard Time, then Nuvelo may either terminate the Agreement in accordance with Clause 8.2 upon a date that is 30 calendar days after December 31, 2005, Pacific Standard Time or call an Urgent Meeting of the PSC to discuss whether further
Additional Centrifuge Work should be conducted. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">12 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Centrifuge Trials; Avecia Default. If neither of the two centrifuge trials is successful as a result of Avecia Default(s), Avecia shall promptly reprocess, rework if pre-approved in
writing by an authorized representative of Nuvelo or re-perform, the centrifuge trials at Avecia&#146;s cost and expense until either (i) one of the centrifuge trials is successful or; (ii) the centrifuge trials are unsuccessful other than as a
result of an Avecia Default, at which time Clause 2.2(b)(2) will apply. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Development Batch Manufacture</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Batch Production. Avecia shall carry out production of two (2) Development Batches (in accordance with the terms set forth below) in its ABC5000 facility in accordance with the
terms and conditions of this Agreement, cGMP, Applicable Laws and the Work Programme, with the primary aim of testing and improving Batch records and operating procedures, clarifying any scale-up issues and ensuring operator familiarity with the
Process. Avecia also shall carry out an Engineering Batch in accordance with Clause 2.3(e). Whilst Development Batch Manufacture is intended to produce Development Batches which can be Released, it is recognised that problems related to the Process
that are not Avecia Defaults may preclude this. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Development Batch Failure. If the Quality Team is in agreement that neither of the two (2) Development Batches manufactured under Clause 2.3(a) can be Released, Avecia shall, at the
direction and option of Nuvelo, either: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">reprocess one of the two (2) Development Batches produced during Development Batch Manufacture in accordance with cGMP; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">if pre-approved in writing by an authorized representative of Nuvelo, rework one of the two (2) Development Batches produced during Development Batch Manufacture in accordance with
cGMP; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">manufacture another Development Batch; or </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">immediately stop all work, as a result of a decision by Nuvelo to terminate the Agreement in accordance with Clause 8. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Next Actions Upon Development Batch Failure. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Avecia Default. In the event that the Quality Team is in agreement that the second Development Batch or both of the two (2) Development Batches manufactured under
Clause 2.3(a) are Defective Batches as a result of an Avecia Default, Avecia shall rework, reprocess or </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">13 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="17%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">manufacture in accordance with Clause 2.3(b)&#151;within 10 business days after the Quality Team notified the PSC of the Quality Team&#146;s determination if
the Avecia Default is of a nature that can be promptly corrected, otherwise, as soon as reasonably practicable thereafter&#151;at Avecia&#146;s cost and expense, until such time as Avecia generates a Development Batch that can be Released (or could
have been Released but for an issue that is not an Avecia Default); but if, as a result of Avecia Default(s), Avecia fails to generate a Development Batch which can be Released within 3 months from commencement of such rework, reprocessing or
further manufacture, then the PSC shall hold an Urgent Meeting to discuss whether or not yet another Development Batch should be generated. Nuvelo is entitled to terminate the Agreement, without payment of any Cancellation Fees, if Development
Batches cannot be Released as a result of Avecia Default(s) before the expiration of the 3 month cure period provided in this Clause 2.3(c)(1). Nuvelo may terminate the Agreement during the 3 month cure period for Unremedied Breach if Avecia fails
to generate a Development Batch that can be Released as a result of Avecia Default(s) and is not using commercially reasonable efforts to generate at least one Development Batch that can be Released per month during the three month cure period.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Process Failure. If the first 2 Development Batches cannot be Released for a reason other than Avecia Default, at the request of Nuvelo, Avecia shall rework, reprocess or
manufacture Development Batches at a time and at a cost to Nuvelo to be agreed by the Parties in good faith and recorded in a Programme Amendment Order. If the rework, reprocessing or further manufacture results in another Development Batch which is
a Defective Batch for a reason other than Avecia Default, then the PSC shall hold an Urgent Meeting to discuss whether or not yet another Development Batch should be generated. If and at such time as Avecia and Nuvelo agree that Process scale-up
problems causing the Defective Batches in accordance with this Clause 2.3(c)(2) are or will be satisfactorily resolved, unless the Agreement is terminated by one the Parties, the Parties will agree to a revised timetable for manufacture of a number
of Development Batches to be determined, upon commercially reasonable terms, in a Programme Amendment Order. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Successful Development Batch Release: Pre-Validation Campaign Review. If at least one (1) of the two (2) </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">14 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:0%">
<FONT FACE="Times New Roman" SIZE="2">Development Batches manufactured under Clause 2.3(a) can be Released or if rework, reprocessing or further manufacture carried out in accordance with Clause
2.3(b) results in a Development Batch which can be Released, the Project Steering Committee shall review the activities carried out to date, solely to evaluate operability of the Process and Avecia&#146;s cGMP compliance in order to ensure that both
Parties are confident of success in the Validation Campaign (&#147;<B>the Pre-Validation Campaign Review</B>&#148;). During the Pre-Validation Campaign Review, the PSC, with input from the Quality Team, shall discuss readiness to carry out the
Validation Campaign, potential timing for its conduct and any other issues concerning the Process operability or cGMP compliance. This discussion will include a review and analysis of the actual performance of the Development Batches compared to the
Process Assumptions, and an attempt by the PSC to reach agreement with respect to whether the Validation Campaign shall be delayed, not be delayed, or not be carried out at all. If during the Pre-Validation Campaign Review, the EC, after referral of
the matter to it by the Project Steering Committee, is unable to reach a final decision in accordance with the terms of Clause 2.7(f) as to whether the Validation Campaign shall be delayed, not be delayed, or not be carried out at all&#151;solely
due to Process operability or Avecia cGMP compliance issues, or any other concerns which resulted in a Development Batch being a Defective Batch&#151; then either Party may terminate this Agreement in accordance with and subject to the terms
provided for termination set forth in this Agreement, including the possibility that the Parties may mutually agree to terminate the Agreement <B></B>under Clause 8.4. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(e)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Proceeding to Validation Campaign. If at least one (1) Development Batch is Released, then following completion of, and subject to either agreement by the PSC or a determination
made by the EC in the Pre-Validation Campaign Review, Avecia shall carry out an Engineering Batch and shall proceed to and shall carry out the Validation Campaign in accordance with the terms and conditions of this Agreement for the performance of
the Project in accordance with Clause 2.1, the Work Programme and any revised timetable for performance of the Engineering Batch and the Validation Campaign resulting from Pre-Validation Campaign Review. Development Batch Manufacture shall be deemed
to be complete when: (1) the Quality Team has completed Release of at least one Development Batch, and that Batch&#146;s associated documentation has been delivered to Nuvelo; and (2) Avecia has completed manufacture of an Engineering Batch that is
not a Defective Batch, and the Engineering Batch&#146;s associated documentation has been delivered to Nuvelo. <B></B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">15 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(f)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Delivery of Defective Batches. In the event that during Development Batch Manufacture it is determined by the Quality Team that a Development Batch is a Defective Batch, the
Defective Batch shall not be delivered to Nuvelo, unless Nuvelo requests it. If Nuvelo requests delivery of the Defective Batch, Avecia shall deliver such Defective Batch in accordance with Clause 4.2 and such Defective Batch may be used in research
or development internally, labelled for non-human use or destroyed. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(g)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Quality Team Disagreement. If the Quality Team cannot reach agreement with respect to whether or not a Development Batch is a Defective Batch, or whether or not a Defective Batch
resulted from an Avecia Default, the disagreement will be resolved in accordance with Clause 2.7(g). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Validation Campaign</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">cGMP Preparation </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia shall carry out cGMP preparation work following the decision that Avecia shall carry out the Validation Campaign under and in accordance with Clause 2.3(e) above. Such cGMP
preparation work shall include the work identified in the Work Programme, the Quality Agreement and any additional work agreed under a Program Amendment Order pursuant to Clause 2.3(c)(2) or otherwise. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia shall produce a Validation Master Plan for review, comment and approval by Nuvelo before the start of the Validation Campaign. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia shall conduct the Validation Campaign in accordance with the terms and conditions of this Agreement and the Quality Agreement. The Quality Agreement sets forth how the
Parties&#146; Quality Units will jointly review non-conformances, determine severity, assess their level of impact on the API and agree on actions which may include accepting a Validation Batch, failing a Validation Batch or declaring a Validation
Batch to be a Defective Batch, disqualifying a Validation Batch from the series of three (3) consecutive Batches or passing or failing the entire Validation Campaign. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Manufacture of Validation Batches </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Commencement of Validation Campaign. Avecia shall commence manufacture of Validation Batches following confirmation by the Quality Team that the </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">16 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="17%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:0%">
<FONT FACE="Times New Roman" SIZE="2">preparation work set forth in Clauses 2.4(a)(1) and 2.4(a)(2) has been completed and the Master Batch Records have been approved in accordance with the
Quality Agreement. If the Quality Team is unable to reach agreement on such confirmation and approval, the matter shall be referred to the PSC for resolution. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Number of Validation Batches. Subject to Clause 2.4(b)(3) below, the Validation Campaign shall consist of up to five (5) Validation Batches with an expectation of producing three
(3) Released consecutive successful production Batches and thus constitute a formal Validation Campaign. Avecia will ensure that sufficient time is scheduled in its ABC5000 facility to complete a Validation Campaign of up to five (5) Validation
Batches. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">5</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"> Validation Batch. In the event that the
Quality Team determines that a fifth (5</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">) Validation Batch is required, other than as a result of an Avecia
Default, in order to increase the chances of successful completion of the Validation Campaign, Avecia shall carry out manufacture of a fifth (5</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>th</SUP></FONT><FONT
FACE="Times New Roman" SIZE="2" COLOR="#000000">) Validation Batch on the basis that Avecia will meet the costs of operating its ABC 5000 facility and Nuvelo shall pay to Avecia, as an additional technical consultancy fee, the actual Expenditures
for any additional raw materials or consumables required to be purchased in order to manufacture such fifth (5</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">)
Validation Batch, plus the Handling Fee, in accordance with Clause 3.2(b). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Documentation Review. During the Validation Campaign, the Parties shall carry out review of the Master Batch Records, campaign Batch records and other relevant documentation
relating to each Validation Batch as it is manufactured. This review and assessment will involve the Nuvelo Quality Unit and such other of Nuvelo&#146;s staff as Nuvelo directs, in Nuvelo&#146;s discretion. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Completion of Validation Campaign. The Validation Campaign shall be deemed to be complete when the Quality Team determines that the Validation Campaign has completed three (3)
Validation Batches that can be designated consecutive successful production Batches that have completed Release, and all associated documentation and a validation summary report have been delivered to Nuvelo in accordance with Clause 4.2.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">17 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Quality Unit Determination </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Determination of Validation Success or Failure. The Quality Team shall determine in accordance with the Quality Agreement and by reference to cGMP whether the Validation Campaign
has been successful. In the event that the Quality Team determines that the Validation Campaign has not been successful, then, as set forth in and in accordance with Clauses 2.4(c)(2) and 2.4(c)(3) below, Avecia shall repeat the Validation Campaign
or Validation Batches (as appropriate) within 10 business days after the Quality Team notified the PSC of the Quality Team&#146;s determination, if the cause of the failure of the Validation Campaign is of a nature that can be promptly corrected,
otherwise, as soon as reasonably practicable thereafter. In the event of any dispute arising amongst the Quality Team, the matter will be resolved in accordance with Clause 2.7(g). <I></I> </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia Default. If the Validation Campaign is determined not to be successful as a result of an Avecia Default, then the repeated Validation Campaign or Validation Batches (as
appropriate) shall be promptly carried out by Avecia at Avecia&#146;s cost and expense; but if the repeated Validation Campaign or Validation Batches (as appropriate) does not result in a successful Validation Campaign as a result of an Avecia
Default within 3 months of commencement of such repeated Validation Campaign or Validation Batches (as appropriate), then the PSC shall hold an Urgent Meeting to discuss whether or not the Validation Campaign or Validation Batches (as appropriate)
shall be repeated again. Nuvelo is entitled to terminate the Agreement, without payment of any Cancellation Fees, if, as a result of Avecia Default, the repeated Validation Campaign or Validation Batches (as appropriate) does not result in a
successful Validation Campaign before the expiration of the 3 month cure period provided in this Clause 2.4(c)(2). Nuvelo may terminate the Agreement during the 3 month cure period for Unremedied Breach if Avecia fails to generate a successful
Validation Campaign and is not using commercially reasonable efforts to generate at least 5 Validation Batches that could lead to a successful Validation Campaign during the three month cure period. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Validation Process Failure. If the Validation Campaign is determined not to be successful because of a Validation Process Failure, then, if requested in writing by
Nuvelo, a repeated Validation Campaign or Validation Batches (as appropriate) shall be carried out by Avecia at a commercially reasonable cost to Nuvelo to be agreed in good faith by the Parties and set out in </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">18 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="17%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">a Programme Amendment Order. In the event that a repeated Validation Campaign carried out under this Clause is determined not to be successful, then the
Parties shall meet to discuss what action should be taken. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Quality Team Disagreement. If the Quality Team cannot reach agreement with respect to whether or not a Validation Batch is a Defective Batch, or whether or not a Defective Batch
resulted from an Avecia Default, the disagreement will be resolved in accordance with Clause 2.7(g). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.5</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Delays and Cancellations</U>. Nuvelo shall have an option to, and otherwise may as a result of an Avecia Default, delay commencement of, or cancel Development Batch Manufacture
or the Validation Campaign. The Parties also acknowledge that delays may occur as a result of Process Failures, as set forth below. In the event that Nuvelo decides to exercise such option or take such action, the following provisions shall apply:
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Notice. Nuvelo shall give written notice to Avecia of its intention to delay or cancel Development Batch Manufacture or the Validation Campaign (as appropriate), and, in the case of
delay, setting out the estimated length, or circumstances that would dictate the length, of the delay. Notice is deemed given at such time as either Party notifies the other Party in writing that the Validation Campaign will be delayed as a result
of a Process Failure, and in such case, the PSC shall determine the estimated length of the delay. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Cancellation Fees; Non-Manufacturing Delays or Cancellation. With respect to any cancellation or Non-Manufacturing Delay, Nuvelo shall pay to Avecia the Cancellation Fees in
consideration for technical consultancy into the effect of such Non-Manufacturing Delay or cancellation on the Project. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Process Failure Delay Fee. With respect to any delay of the Validation Campaign resulting from a Process Failure that results in a delay of the completion of the
usage of Avecia&#146;s manufacturing facilities for the Validation Campaign by more than two weeks after August 16, 2006, Nuvelo shall pay to Avecia, in consideration for technical consultancy into the effect of such delay on the Project, the sum of
&pound;212,470 pounds per week (the <B>&#147;Process Failure Delay Fee&#148;</B>) for each week beyond the expiration of two weeks after August 16, 2006, during which the completion continues to be delayed, until such time as Nuvelo has paid to
Avecia an amount in Process Failure Delay Fees that is equal to the lesser of: &pound;2,550,000 pounds; or the amount Nuvelo would have paid to Avecia in Cancellation Fees if notice had been given regarding a Non-Manufacturing Delay instead of a
delay </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">19 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:0%">
<FONT FACE="Times New Roman" SIZE="2">resulting from a Process Failure. Avecia shall make commercially reasonable endeavours to raise revenue by utilising the production facility during the
period during which the Validation Campaign was intended to take place but for the delay. Avecia shall refund to Nuvelo a sum equivalent to the revenue (net of raw materials and consumables Expenditure) raised as a result of such alternative use up
to a maximum of 80% of the technical consultancy fee paid under this Clause 2.5(c). For the purposes of this Clause 2.5(c), <B>&#147;Process Failure&#148;</B> means the occurrence of a Defective Batch that results from a factor&#151;other than any
of the factors listed in paragraphs (a) through (d) of the definition of Avecia Default&#151;which affects the Process or production of the API and was not known and could not reasonably have been known by Avecia prior to the time at which the
factor became known, including, without limitation, a previously unknown factor not studied either as part of the Amgen programme transferred to Avecia or the Avecia laboratory work programme carried out pursuant to the Project.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Delay. The Parties shall meet to discuss availability of Avecia&#146;s manufacturing facility for the delayed Development Batch Manufacture or the Validation Campaign (as
appropriate) in accordance with Clause 2.3 and 2.4 and, except with respect to any delay resulting from or arising out of an Avecia Default, Nuvelo&#146;s refusal to take a license under a Patented, Licensed Avecia Invention under Clause 5.2(c) or
failure of the centrifuge trials, if the delay is in excess of six (6) months, a commercially reasonable amount payable by Nuvelo to Avecia in respect of such later commencement of Development Batch Manufacture or the Validation Campaign (as
appropriate). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(e)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Effect of Delay on Project. Except with respect to a delay resulting from or arising out of an Avecia Default or Nuvelo&#146;s refusal to take a license under a Patented, Licensed
Avecia Invention under Clause 5.2(c), Avecia shall not be obliged to carry out the delayed Development Batch Manufacture or the Validation Campaign (as appropriate) until the Parties have reached agreement on the later commencement thereof, but will
use reasonable commercial endeavours to reschedule the availability of its facility and appropriate personnel. In the case of a delay resulting from an Avecia default, if Nuvelo decides to have Avecia proceed with Development Batch Manufacture
and/or the Validation Campaign, Avecia shall carry out the delayed Development Batch Manufacture or Validation Campaign in accordance with the terms and conditions set forth in Clauses 2.3 and 2.4. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(f)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Effect of Cancellation. Where Nuvelo elects to cancel Development Batch Manufacture, Avecia shall not be obliged to carry out the Validation Campaign, and except
with respect </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">20 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">to any cancellation resulting from or arising out of an Avecia Default or failure of the centrifuge trials, the Validation Campaign shall also be deemed
cancelled with effect from the date of notice of Nuvelo&#146;s intention to cancel Development Batches Manufacture and the Validation Campaign. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.6</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Nuvelo Delay</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">In the event of a Nuvelo Delay, Avecia and Nuvelo will use reasonable commercial endeavours to minimize such Nuvelo Delay or, subject to agreement by both Parties, to adjust the
Development Batch Manufacture or the Validation Campaign schedule to accommodate such delay. Any Nuvelo Delay which cannot be avoided shall be considered to be Hold Time in respect of the affected Batch. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">In the event that a Nuvelo Delay results in an inability for Avecia to carry out the Development Batch Manufacture or the Validation Campaign in accordance with the mutually agreed
schedule therefor, then the Parties shall meet to discuss availability of Avecia&#146;s manufacturing facility for the delayed Development Batch Manufacture or the Validation Campaign (as appropriate), and a commercially reasonable amount payable by
Nuvelo to Avecia in respect of such later commencement of Development Batch Manufacture or the Validation Campaign (as appropriate). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.7</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Project Steering Committee, or PSC, Executive Committee, or EC, and Resolution of Batch Disputes</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Membership</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">PSC Membership. The PSC shall have at least 6 and up to 8 members, within any case, an equal number of members appointed by each Party. Each Party&#146;s initial membership on the
PSC shall be as set forth in Schedule 5. Each Party may replace its PSC representatives at any time upon written notice to the other Party, provided that each Party shall appoint and maintain for the duration of the term of this Agreement
representatives on the PSC of equivalent or higher position within that Party as the original representative(s) set forth on Schedule 5. The PSC shall keep minutes of its meetings and submit its meeting minutes to the EC members for EC and Party
review. The host Party at each in-person meeting shall prepare the minutes for that meeting, otherwise, minute taking will alternate between the Parties for each meeting. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">EC membership. The EC shall be composed of 2 members, 1 representative of each Party. Each EC </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">21 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="17%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:0%">
<FONT FACE="Times New Roman" SIZE="2">member shall not be a member of the PSC, shall have obtained, and maintain, the level of vice president (or comparable title) or above, and shall be duly
authorized by the Party it represents to resolve any and all disagreements of the PSC. The EC representatives are set forth on Schedule 5. Each Party may replace its EC representative with another qualifying individual at any time upon written
notice to the other Party. The EC shall keep minutes of its meetings and prepare a report for Party review. Minute taking will alternate between the Parties for each meeting. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Power and Responsibilities.</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">PSC Powers and Responsibilities. The PSC shall have the following specific responsibilities and authority: </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to review and approve the overall plan for process development, characterization, manufacturing and Release of Batches of Product; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to review and approve resources and timelines for the Project, and any changes for the Project; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(iii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to evaluate and manage any changes or other incidents that may occur during the course of the Project; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(iv)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to serve as a forum for the sharing of information between the Parties with respect to Project activities and Project progress; and </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(v)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to evaluate Batch Disputes that arise at the Quality Team level in accordance with Clause 2.7(g). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">EC Powers and Responsibilities. The EC shall support the PSC in decision-making and support the overall strategy for the Project. The EC shall have the following specific
responsibilities and authority: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to resolve any disagreements of the PSC, but excluding Batch Disputes, in accordance with Clause 2.7(f); </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to review PSC meeting minutes and evaluate the effectiveness and composition of the PSC, providing any comments thereon back to the PSC for consideration; and
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(iii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to serve as a forum for information sharing between senior management of the Parties. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">22 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Limitations on PSC and EC</U>. The PSC and the EC shall have no power to amend or waive compliance with this Agreement. Any amendments that alter the terms of this Agreement
shall be implemented, if at all, pursuant to Clause 14 below. The PSC and EC shall have only the responsibility explicitly provided for them in Clause 2.7(b), and shall not have any other powers or responsibilities. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Regular Meetings</U>. The Parties shall endeavour to schedule regular meetings of the PSC and EC at least 30 calendar days in advance. The PSC shall meet at least once a calendar
quarter, and at least 2 regular meetings per year will be held in person. The EC shall meet twice a year, and shall decide whether or not it will meet in person, by teleconference or videoconference. Committee meetings held in person will alternate
between sites designated by each Party and each Party shall be responsible for all of its own expenses of participating in PSC and EC meetings. With the consent of the representatives of each Party serving on the PSC, other representatives of each
Party may attend meetings of the PSC. With the consent of each EC member, other representatives of each Party may attend meetings of the EC, or portions thereof. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(e)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Additional &amp; Urgent Meetings</U>. Upon mutual agreement of the PSC or EC, not to be unreasonably withheld, the Parties may schedule additional meetings of the PSC or EC as
necessary to appropriately conduct the Project, and any such additional PSC or EC meetings will be held by teleconference or videoconference and will be held no later than 15 calendar days after reasonably requested by a Party. A meeting of the PSC
may be requested on an urgent basis (<B>&#147;Urgent Meeting&#148;</B>) for the following reasons: Batch failure, excessive downtime in the facility being used to develop or manufacture Product, notice of a Batch Dispute, significant cGMP or
Applicable Law violation or significant adulteration of Product or a Batch. An Urgent Meeting shall be held no later than 3 business days after requested by a Party. Urgent meetings may be held in-person, by teleconference or by videoconference. If
the PSC cannot come to agreement on a matter before it at an Urgent Meeting, except with respect to a Batch Dispute, the matter shall be immediately referred to the EC for resolution. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(f)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><U>Decision Making &amp; Dispute Resolution</U>. The PSC and EC will reasonably discuss all matters that come before them. Decisions of the PSC and EC will be made
by unanimous agreement, with each Party having one vote on the PSC and one vote on the EC. If the PSC cannot come to agreement on an issue at the applicable PSC meeting, other than with </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">23 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">respect to a Batch Dispute, the PSC shall promptly refer the matter to the EC. The EC shall meet no later than 15 calendar days after referral of a matter to
it by the PSC. The EC shall have 15 calendar days after meeting to resolve the matter. If the EC cannot mutually agree on a resolution of the matter before the expiration of the 15 day period, then Nuvelo is entitled to make the final decision for
the EC on the matter, which Nuvelo decision shall not be unreasonable, with the exception of the following matters, which shall only be resolved by mutual agreement of the EC, Avecia&#146;s agreement to such matters not be unreasonably withheld: (1)
any matter which would require execution of a Programme Amendment Order; (2) any matter which would, other than as a result of an Avecia Default, adversely effect a manufacturing schedule&#151; which schedule is not in conflict with the Project
timeline set forth in the Work Program Timeline&#151;established for a third party by Avecia, for use of Avecia&#146;s facilities; or (3) materially change the Project timeline set forth in the Work Program Timeline. The decisions of the EC, whether
determined by final decision of Nuvelo or mutual decision, in accordance with the preceding sentence, shall bind both of the Parties, except that: Avecia may refer a matter upon which Nuvelo made a final decision to dispute resolution in accordance
with Clause 19.2 if in Avecia&#146;s reasonable, good faith judgement, Nuvelo&#146;s decision would (1) violate the express terms of this Agreement; or (2) result in a breach of Applicable Law. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(g)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Dispute Resolution for Batch Disputes. </U>If a dispute arises amongst the Quality Team relating to whether or not a Batch of the API is a Defective Batch, or whether or not a
Defective Batch results from or arises out of an Avecia Default (each of the preceding a <B>&#147;Batch Dispute&#148;</B>), such Batch Dispute shall be resolved as follows. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The Quality Team shall immediately notify the Project Steering Committee (<B>PSC</B>) in writing (the <B>&#147;Batch Dispute Notice&#148;</B>) that a Batch Dispute exists amongst
the Quality Team. The Quality Team will discuss the Batch Dispute in good faith to attempt to reach agreement on: (i) whether a Batch is a Defective Batch and, if so, what course of action shall be taken to address it; and (ii) whether or not a
Defective Batch resulted from or arose out of an Avecia Default. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">In the event that the Quality Team fails to reach agreement on a Batch Dispute within 15 calendar days after sending the Batch Dispute Notice to the PSC, the
Quality Team shall immediately refer the Batch Dispute to the PSC for discussion, by written notice to the PSC. Once the Batch Dispute has been referred to the PSC, the PSC has 5 business days from receipt of the referral notice to either resolve
the Batch Dispute or </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">24 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="17%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">refer the Batch Dispute to an independent expert or laboratory, with the expertise necessary to reasonably resolve the Batch Dispute.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">If the PSC cannot resolve the Batch Dispute or agree upon an independent expert or laboratory to resolve the Batch Dispute before the expiration of 5 business days after receiving
the referral notice, the PSC shall immediately notify the EC of its failure in writing. Within no later than 2 business days after receiving notice of the failure from the PSC, each EC member shall nominate an independent expert who shall not: be a
current or former employee, consultant or agent of a Party; have an immediate family member who is an employee, consultant or agent of a Party; or have any financial interest in a Party. Promptly thereafter, those two independent experts shall agree
on a third independent expert who shall use any reasonable information, materials and data provided to him or her by the other two experts within 10 business days after his or her agreement to act as the third independent expert, to either promptly
resolve the Batch Dispute or determine which independent Third Party laboratory will conduct the work necessary to promptly resolve the Batch Dispute. Such referral shall be solely for the purpose of establishing whether or not the applicable Batch
is a Defective Batch and whether or not any Defective Batch results from or arises out of an Avecia Default. The decision of the independent expert, or independent laboratory, shall be made in writing and shall be binding upon the Parties. Whichever
Party failed to accurately assess whether the Batch was or was not a Defective Batch, or whether or not a Defective Batch resulted from or arose out of an Avecia Default, shall bear the full cost and expense associated with the hiring and
performance of the independent experts and/or laboratory. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.8</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Programme Amendment Orders</U>. The Parties may agree to vary the Project and sums to be paid under Clause 3 as a result of a Project variation, so long as such variation is made
in writing in a Programme Amendment Order. The Parties recognize that any of the following will require changes to the Work Programme that may cause a change in payments set out in Clause 3: </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Nuvelo requires Avecia to carry out additional or different work to that specified in the Work Programme set forth in Schedule 1; or </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the actual circumstances encountered in carrying out the Project differ from the then current Process Assumptions; or </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">25 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">in the event that there is a delay to the Project for any reason other than Avecia Default or Nuvelo&#146;s refusal to take a license under a Patented, Licensed Avecia Invention,
including a Nuvelo Delay; or </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">in the event that Additional Centrifuge Work is required as a result of a failure, other than one attributable to an Avecia Default, of the centrifuge trials pursuant to Clause
2.2(b); or </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(e)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Hold Time, but excluding Hold Time resulting from or arising out of: (1) an Avecia Default or (2) Nuvelo&#146;s refusal to take a license under a Patented, Licensed Avecia
Invention. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.9</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Regulatory Matters and Regulatory Assistance</U>. <B></B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">During the Project and following Completion, Avecia will provide reasonable assistance to Nuvelo in respect of Nuvelo&#146;s Regulatory Filing activities for the Product and the
Process, including preparatory to and during Pre-Approval Inspection (PAI) and related quality unit support, as further set forth below. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">At no additional cost to Nuvelo, Avecia shall: provide Nuvelo with any and all requested data created in connection with the development and manufacture of the API under this
Agreement which is reasonably necessary to support submissions for regulatory approvals to Regulatory Authorities; and take all actions necessary to recreate or modify as reasonably necessary any documentation or materials provided by Avecia to
Nuvelo for submission to Regulatory Authorities that were not provided to Nuvelo in a form or format reasonably acceptable to the applicable Regulatory Authority. Nuvelo shall advise Avecia on the form or format Nuvelo, or the Regulatory Authority,
to the extent Nuvelo is aware of the Regulatory Authority&#146;s requirements, may require prior to provision of such documentation or materials by Avecia. <I></I> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Subject to payment by Nuvelo of a reasonable commercial rate for such assistance and Avecia&#146;s reasonable expenses, Avecia shall develop any data requested by Nuvelo concerning
the development, manufacture or quality assurance testing of the API which is necessary to support submissions for regulatory approvals to Regulatory Authorities, which data was not anticipated to be developed as part of the Project under the Work
Programme or the Quality Agreement. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Nuvelo shall be responsible for preparing and filing all submissions for regulatory approvals of Product. Nuvelo will confirm Nuvelo interpretations of Avecia data
in the Chemistry, Manufacturing and Controls (CMC) section of any </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">26 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">submissions to Regulatory Authorities with Avecia before submission to Regulatory Authorities. Nuvelo owns and shall own all Regulatory Filings related to
the Product and the API. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(e)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">At no additional cost to Nuvelo, to the extent Nuvelo needs to submit and make available any Master Batch Record in connection with obtaining any regulatory approvals from any
Regulatory Authority, to the fullest extent permissible under Applicable Laws, Avecia shall provide Nuvelo with any and all information necessary for Nuvelo to make the Master Batch Record available to the applicable Regulatory Authority.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(f)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">At no additional cost or expense to Nuvelo, Nuvelo shall have full access to and the right to use and reference, any correspondence, facility and engineering records and diagrams,
validation documentation, Batch records, reports, analyses, regulatory requirements and any other data and documentation generated in connection with the Project, and Avecia shall provide Nuvelo with 1 full set of the foregoing documentation upon
request. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(g)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will handle all waste resulting from or arising out of the Project in accordance with Applicable Laws. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(h)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The provision of data, information or copies of records from Avecia&#146;s work is included in the fees set out in Clause 3. In the event that Avecia needs to generate additional
information under paragraph (c) above or re-analyze data in an unanticipated way in response to a Regulatory Authority request, then that information and data shall be provided subject to agreement of a reasonable commercial rate based on the
time/effort required. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.10</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Quality Audits by Nuvelo &amp; SCAR Reporting.</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Nuvelo reserves the right to conduct, twice-a-year, comprehensive quality audits of Avecia&#146;s facilities, which may include a site tour, questioning of employees in work areas
and review of quality system documentation to the appropriate quality standards. Avecia will be notified in advance of the intention to conduct an audit and the audit&#146;s scope, and a mutually convenient date will be selected. During the audit,
any non-conformances will be noted and documented in a report issued by Nuvelo within thirty (30) business days. Avecia will be requested to submit a written response and corrective action plan within thirty (30) business days of receipt of the
report. Avecia will close all corrective actions that can be closed within 90 business days to the satisfaction of Nuvelo. Corrective actions that cannot be closed out within 90 business days will have a timeline for closure agreed with Nuvelo.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">27 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Supplier performance issues or non-conformances in the API will be indicated to Avecia, in addition to any notifications through the PSC or EC, in the form of a Nuvelo Supplier
Corrective Action Report (SCAR)/Memo. Avecia will be requested to respond to the SCAR/Memo usually within thirty (30) business days post receipt. <I></I> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Payments </U><U></U></B><B><I><U></U></I></B><B><U></U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Consideration</U>. In consideration of Avecia carrying out the technical consultancy activities pursuant to the Project in accordance with the terms and conditions of this
Agreement and in consideration for sale and delivery of API in accordance with the terms and conditions of this Agreement, Nuvelo shall pay to Avecia a sum of ten million pounds (&pound;10,000,000), to be paid, as follows, if and only if the
following terms and conditions set forth below are met: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Milestone</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Number</B></FONT></P><HR WIDTH="33" SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Anticipated/Approximate<BR>Completion Date</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Of Milestone</B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Milestone/Invoice Trigger</B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Amount<BR>Triggered by<BR>Milestone (&pound;)</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Done and paid in full before the signature date of this Agreement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy in relation to assessment and planning, paid on the Commencement Date</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">105,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Done and paid in full before the signature date of this Agreement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">In consideration for Avecia carrying out technical consultancy preparatory to GMP manufacture, paid on the Commencement Date</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">50,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Done and paid in full before the signature date of this Agreement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to commencement of the Project, paid on 28</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>th</SUP></FONT><FONT
FACE="Times New Roman" SIZE="2" COLOR="#000000"> February 2005</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">300,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Signature of this Agreement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">In consideration for Avecia carrying out technical consultancy in relation to transfer of process and assays, payable on completion of transfer of process and analytical methods</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">105,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Signature of this Agreement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to Process characterisation in the laboratory (Experimental set 1, based on RPN analysis), payable on commencement of the Process
characterisation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">136,250</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Signature of this Agreement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to assay validation, payable on commencement of assay validation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">358,750</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Signature of this Agreement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to preparation of the Project plan, payable on agreement of the Project plan, including the manufacturing schedule by the PSC</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">50,000</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">28 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Signature of this Agreement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to modification of ABC5000 facility modifications for centrifuge trials, payable on commencement of modifications</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">350,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">18-Jul-05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to preparation of a cleaning study, payable on completion of the cleaning study and delivery of a report on such study</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">10,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">08-Aug-05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to preparation of Batch records for centrifuge trials, payable on completion of such Batch records</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">160,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">14-Aug-05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to preparation for Development Batch Manufacture, payable three (3) months prior to commencement of manufacture of the first Development
Batch</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">420,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">12</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">18-Aug-05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to the replicate 15L fermentation runs, payable on completion of the runs and delivery of the associated technical report</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">54,500</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">13</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">22-Aug-05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy in performance of the centrifuge runs, payable on commencement of the first centrifuge run</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">200,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">14</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">01-Sep-05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to the centrifuge runs, payable on completion of the first centrifuge run</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">250,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">15</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">07-Sep-05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to the replicate purification runs, payable on completion of the runs and delivery of the associated technical report</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">54,500</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">16</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">26-Sep-05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to 100L labscale purification, payable on completion thereof</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">44,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">17</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">26-Sep-05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to preparation of Batch records, payable on commencement of Batch record writing (approval of Process Specification for GMP Development
Batches)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">88,500</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">29 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">18</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">28-Oct-05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to preparation for Development Batch Manufacture, payable on completion of the plant report for centrifuge runs</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">200,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">19</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">14-Nov-05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to preparation for Development Batch Manufacture, payable on completion of the Batch records for Development Batch Manufacture</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">88,500</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">20</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">14-Nov-05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to performance of Development Batch Manufacture, payable on commencement of Development Batch Manufacture</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">751,250</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">21</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">18-Nov-05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to assay validation, payable upon completion of assay validation for the first 10 assays to be validated</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">291,250</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">22</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">21-Nov-05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to characterisation of the Process in the laboratory (Experimental Set 1) payable on delivery
of the fermentation technical report</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">and purification technical report</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">136,250</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">23</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">01-Dec-05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">As a<B> first stage payment</B> in consideration for sale and delivery of a Released Batch of API, payable on commencement of manufacture of the second Development Batch</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">251,250</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">24</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">20-Jan-06</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to assay validation, payable upon completion of assay validation for the remainder of the assays to be validated</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">417,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">25</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">01-Mar-06</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">As a final stage payment in consideration for sale and delivery of Released Development Batch(es), payable on Release of at least one Development Batch during Development Batch
Manufacture</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">510,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">26</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">12-Apr-06</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy during performance of Engineering Batch manufacture, payable on commencement of manufacture of the Engineering Batch</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">424,940</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">30 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">27</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">12-Apr-06</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy in preparation of Batch records for the Validation Campaign, payable on completion of such Batch records</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">120,600</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">28</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">26-Apr-06</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy during Engineering Batch manufacture, payable on completion of manufacture of the Engineering Batch, as evidenced by commencement of post-Batch
cleaning of the facility</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">424,940</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">29</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">26-Apr-06</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">As a first stage payment in consideration for sale and delivery of Released API produced during the Validation Campaign, payable on commencement of manufacture of the first Validation
Batch</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">424,940</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">30</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">26-Apr-06</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to preparation of the Validation Master Plan under clause 2.4(a)(ii) of the Work Programme, payable on completion of Validation Master
Plan</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">50,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">31</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">26-Apr-06</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to preparation of the Validation Master Plan, payable on execution of the Validation Master Plan</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">99,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">32</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">12-May-06</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">As a second stage payment in consideration for sale and delivery of Released API produced during the Validation Campaign, payable on commencement of manufacture of the second Validation
Batch</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">424,940</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">33</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">29-May-06</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">As a third stage payment in consideration for sale and delivery of Released API produced during the Validation Campaign, payable on commencement of manufacture of the third Validation
Batch</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">424,940</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">34</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">12-Jun-06</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">As a fourth stage payment in consideration for sale and delivery of Released API produced during the Validation Campaign, payable on commencement of manufacture of the fourth Validation
Batch</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">424,940</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">31 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">35</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">26-Jun-06</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">As a fifth stage payment in consideration for sale and delivery of Released API produced during the Validation Campaign, payable on commencement of manufacture of the fifth Validation Batch,
if agreed under Clause 2.4(b)(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Payment in accordance with<BR>Clause 2.4(b)(3)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">36</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">16-Aug-06</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">As a sixth stage payment in consideration for sale and delivery of Released API produced during the Validation Campaign, payable on Release of the first Validation Batch</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">424,940</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">37</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">01-Sep-06</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">As a seventh stage payment in consideration for sale and delivery of Released API produced during the Validation Campaign, payable on Release of the second Validation Batch</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">424,940</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">38</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">18-Sep-06</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">As an eighth stage payment in consideration for sale and delivery of Released API produced during the Validation Campaign, payable on Release of the third Validation Batch</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">424,940</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">39</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">02-Oct-06</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">As a ninth stage payment in consideration for sale and delivery of Released API produced during the Validation Campaign, payable on Release of the fourth Validation Batch, such stage payment
to be the <B>final stage payment</B> for sale and delivery of API produced during the Validation Campaign, in the event that the PSC determines that a fifth Validation Batch is not required.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">424,940</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">40</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">18-Oct-06</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">As <B>final stage payment</B> in consideration for sale and delivery of Released API produced during the Validation Campaign, payable on Release of the fifth Validation Batch, in the event
that the PSC determines that a fifth Validation Batch is not required</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Payment in accordance with<BR>Clause 2.4(b)(3)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">41</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">01-Dec-06</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In consideration for technical consultancy pursuant to preparation of validation reports, payable on delivery of such reports</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">99,000</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Excluded Items</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The sums set out in Clause 3.1 above do not include: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Expenditure actually incurred by Avecia for major consumable items (including, without limitation, Expenditure associated with chromatography resins and filtration
membranes) intended to be used and not reasonably usable for other purposes by Avecia, or </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">32 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="17%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">actually used for cGMP Batches (including centrifuge trials conducted under Clause 2.2, Development Batch Manufacture and the Validation Campaign); or
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Expenditures actually incurred by Avecia for work conducted by subcontractors, subcontracted by Avecia in accordance with Clause 13.2, for the performance of the following assays,
which assays are discussed in more detail in the Work Programme: (i) intact MS, (ii) DNA or equivalent, (iii) USP/EP Pyrogen, (iv) EPA Copper and Zinc, and (v) DNA sequence for cell bank; or<B> </B> </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Expenditure actually incurred by Avecia in respect of other consumable items purchased for use in the Project (including, without limitation, disposable bags, tubing, hoses and
chemical raw material costs), or actually used for cGMP Batches (including centrifuge trials conducted under Clause 2.2, Development Batch Manufacture and the Validation Campaign). </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia shall notify Nuvelo of the Expenditure incurred in respect of Clause 3.2(a)(3) and Avecia shall obtain Nuvelo&#146;s approval in writing prior to incurring such Expenditure
in Clause 3.2(a)(1) or 3.2(a)(2) and, subject to approval in respect of Expenditure under Clauses 3.2(a)(1) or 3.2(a)(2), such Expenditure shall thereupon form part of the consideration for the provision of the technical consultancy services
(including qualification, quality assurance and quality control activities) by Avecia and Avecia shall invoice Nuvelo for: (1) such amounts; and (2) in the case of Expenditure incurred under Clauses 3.2(a)(1) and 3.2(a)(3), the Handling Fee. Upon
any termination of this Agreement, all consumable items purchased by Avecia for the Project that are not consumed or otherwise worn beyond further use by their use in the Project shall, upon Nuvelo&#146;s request, be sold to Nuvelo or Nuvelo&#146;s
designee for the sum total of &pound;1 and delivered by Avecia, ready for shipment, into the custody of a shipper reasonably acceptable to Nuvelo or Nuvelo&#146;s designee, the cost of shipment to be at Nuvelo&#146;s cost and expense, for
Nuvelo&#146;s or its designee&#146;s use and disposal, in its discretion. <I></I> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Equipment</U>. In order for Avecia to provide technical consultancy services work under this Agreement, it will be necessary for certain items of Equipment to be purchased by
Avecia. Avecia will be authorised to proceed with the relevant services for which the Equipment is required on the following terms: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Avecia shall obtain, from an independent Third Party, at least 2 quotations for each item of Equipment and send a copy of the quotations by fax or email to Nuvelo
and Nuvelo shall inform Avecia within 5 business days of receipt which </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">33 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">quotation Nuvelo approves and whether it authorises Avecia to proceed with the services for which the item of Equipment is required. In the absence of such
approval, Avecia shall not proceed with the relevant services. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">If Nuvelo gives its approval to the relevant quotation, Avecia shall be considered authorised to proceed with the relevant services set forth under the Work Programme or agreed upon
Program Amendment Order and shall purchase the item of Equipment for such purpose. Any Equipment purchased by Avecia shall be dedicated to the Project, and shall not be used for any other use or purpose. Avecia shall keep the Equipment in good
working order. The purchase price of the item of Equipment per the approved quotation shall thereupon form part of the consideration for the provision of the technical consultancy services (including qualification, quality assurance and quality
control activities) by Avecia and Avecia shall invoice Nuvelo for: (i) such amount; and (ii) the Handling Fee. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Following completion or termination of the Project, whichever occurs first, at any time within 12 months following such completion or termination, Nuvelo shall be entitled to
purchase all or any portion of the Equipment from Avecia for the sum total of &pound;1.00 in its or their then current, good working condition, subject to payment of any outstanding and undisputed fees by Nuvelo to Avecia for work carried out under
this Agreement in accordance with the terms and conditions of this Agreement and the Work Programme. <B></B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Nuvelo shall provide to Avecia reasonable prior written notice of its wish to purchase the Equipment so as to minimize any unplanned facility downtime and Nuvelo shall be
responsible for all commercially reasonable removal costs and expenses. If the removal of any Equipment is performed by Nuvelo personnel, Nuvelo agrees to pay for the making good of any damage caused to Avecia&#146;s facility as a result of such
removal. If the removal is performed by Avecia personnel, Avecia agrees to pay for the making good of any damage caused to the Equipment being removed as a result of such removal. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><U>Invoices and Timing of Payments</U>. Avecia shall promptly issue invoices for the sums set out in Clauses 3.1, 3.2 and 3.3 once such sums become payable in
accordance with Clauses 3.1, 3.2 and 3.3. In respect of invoices in respect of sums set out in Clause 3.1, Nuvelo shall pay invoices received by Nuvelo on or before the 15</FONT><FONT FACE="Times New Roman" SIZE="1"
COLOR="#000000"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"> day of each month by the end of that month and shall pay invoices received by Nuvelo after the 15</FONT><FONT FACE="Times New Roman" SIZE="1"
COLOR="#000000"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"> day of each month by the end of the following month. In respect of invoices in respect of sums set out in Clause 3.2, Nuvelo shall pay such sums within 30
calendar days after Nuvelo&#146;s receipt of the relevant invoice. In respect of </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">34 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">invoices in respect of sums set out in Clause 3.3, Nuvelo shall pay such invoices within ten (10) business days after receipt of the relevant invoice.
Payments shall be made in Pounds Sterling. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.5</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Bank Account Details</U>. All amounts payable to Avecia under this Agreement shall be paid by wire transfer, quoting invoice numbers of payment, to an account number specified in
writing by Avecia. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.6</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Taxes</U>. Any payment under this Agreement is stated exclusive of any Value Added Tax. It is the understanding of both Parties that the technical consultancy services being
provided under this Agreement are outside the scope of UK VAT. However, in the event that UK VAT does become payable, the UK VAT shall be for the account of Nuvelo and Avecia shall use best efforts to assist Nuvelo in seeking recovery of such tax
paid from the UK HM Customs and Excise. If Nuvelo is otherwise required to withhold tax applicable to any payment under this Agreement, Nuvelo shall promptly provide Avecia with the official receipts and such other evidence of payment as Avecia may
reasonably request and Nuvelo shall render Avecia reasonable assistance in order to allow Avecia to obtain the benefit of any relevant present or future double taxation treaty. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.7</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Financial Tracking; Reporting</U>. The PSC and Nuvelo&#146;s financial team representatives will review and measure the growth in value of the Project by tracking resources used
versus progress against the deliverables set out in the Work Programme. In respect of consumables, raw materials and any other items purchased by Avecia under Clause 3.2, Avecia will provide a breakdown by item and include copies of invoices for
those items of an individual price of greater than &pound;5,000, to the PSC and Nuvelo&#146;s financial team representatives. Within 3 business days after the end of each month, Avecia will provide a financial &#145;Earned Value Analysis&#146;
report for that month to Nuvelo. Utilizing the Payment Schedule set forth in Clause 3.1, the report will summarize the approximate value of services provided to Nuvelo for each Project stage that Avecia actively performed during that month. Upon
written request by Nuvelo, Avecia shall provide, within thirty days of receipt of Nuvelo&#146;s written notice, documented proof of purchase for all Expenditures and Equipment, or for specified Expenditures and Equipment, passed through to Nuvelo in
accordance with Sections 3.2, 3.3 and 3.4. Avecia will provide Nuvelo with a quarterly written report at each regular PSC meeting setting forth the activity status of its manufacturing suite(s) that are intended to be used or could be used for the
Project, for the six months following the date of submission of the report to Nuvelo. The report will set forth the times when Avecia&#146;s suites are available and when they are committed to other projects. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">35 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Completion of the Project</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Completion</U>. Completion of the Project will be deemed to have occurred when the Development Batch Manufacture, the Validation Campaign and any additional or alternative work
agreed in a Programme Amendment Order have been completed. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Packaging, Shipping and Delivery</U>. Deliveries of all material, including documentation, returned consumable items or Equipment under Clauses 3.2 or 3.3, and API will be made
Ex Works, Avecia&#146;s Billingham facility (Incoterms 2000), subject to the following. Avecia is responsible for packaging and labelling the API in anticipation of shipment. Avecia also shall employ a shipper, reasonably acceptable to Nuvelo, for
the shipment of all Released API and any Defective Batch. Avecia will package the Released API or Defective Batch in validated containers under validated shipping conditions. Until the shipping conditions have been validated, Avecia will package the
Released API or Defective Batch with temperature monitoring devices that are able to function properly during the shipping process, as further set forth in the Quality Agreement. Risk of loss for all Released API or Defective Batch shall transfer to
Nuvelo after delivery of the Released API or Defective Batch to the Nuvelo-approved shipper by Avecia, except with respect to any loss resulting from a failure of Avecia to properly package and label the API for shipment. Nuvelo will purchase
insurance to cover any loss to the Released API or Defective Batch once it is delivered to the shipper. Nuvelo agrees that it shall export the API sold to it promptly and in any case within 3 months of the final stage payment for the API and shall
provide evidence of such export within 3 months thereof. <I></I> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Payment on Completion</U>. Nuvelo shall pay to Avecia within thirty (30) calendar days after Completion any sums required to be paid pursuant to Clause 3.2 above which may remain
outstanding at Completion. Upon Completion, Nuvelo shall pay any sums for milestones triggered pursuant to Clause 3.1 in accordance with the payment terms set forth in Section 3.4. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Irrevocable Option for Future Manufacturing Period</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Avecia hereby grants Nuvelo an irrevocable option (the <B>&#147;Manufacturing Option&#148;</B>) to purchase, upon commercially reasonable terms to be agreed under
Clause 4.4(c) below, 3 kilograms of Released API (&#147;<B>the Manufacturing Quantity</B>&#148;), to be manufactured in the stream in Avecia&#146;s ABC5000 facility </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">36 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">in which the Process was validated under this Agreement, during the period commencing April 1, 2007 and expiring October 31, 2008 (&#147;<B>the Manufacturing
Option Period</B>&#148;). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Following signature of this Agreement and whilst this Agreement remains in force, Nuvelo shall use reasonable commercial endeavours to provide Avecia with an estimate regarding the
potential timing of the Manufacturing Quantity during the Manufacturing Option Period. The obligation to provide the estimate will commence on Release of the first Validation Batch and the forecast will be updated at each PSC meeting or on Nuvelo
becoming aware of a change in its timeline if earlier. To exercise the Manufacturing Option, Nuvelo shall give Avecia written notice of its exercise not later than 1 calendar year before the date that Nuvelo expects Avecia to deliver the
Manufacturing Quantity to Nuvelo. In the absence of providing Avecia with timely written election, the option in Clause 4.4(a) shall lapse. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">No later than 30 calendar days after commencement of the Validation Campaign, Avecia and Nuvelo shall promptly commence negotiations in good faith for the supply of the API by
Avecia to Nuvelo upon commercially reasonable terms (&#147;<B>Supply Agreement</B>&#148;). The Supply Agreement is anticipated to contain provisions related to anticipated volumes, pricing, forecasting mechanisms and quality control provisions, and
such other commercially reasonable provisions. The Parties shall use reasonable commercial efforts to commence discussions regarding possible key principles of any Supply Agreement after the first successful Release of a Development Batch. Nuvelo
shall have no obligation to enter into the Supply Agreement and may immediately halt negotiations at any time, as a result of an Avecia Default. <B></B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Intellectual Property &amp; Confidential Information</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Background Intellectual Property</U>. Except with respect to the licenses granted in this Clause 5, nothing in this Agreement shall be deemed to imply any license to a Party to
use the other Party&#146;s Background Intellectual Property. Nothing in this Agreement shall affect the ownership by either Party of any of its Background Intellectual Property. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Non-exclusive Licenses under Background Intellectual Property and New Intellectual Property</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Project Use License. Subject to the terms and conditions of this Agreement, Nuvelo grants to Avecia: (1) a royalty free, non-exclusive licence, without the right to
sublicense, under its Background Intellectual Property solely to perform and otherwise carry out the Project, and for no other use or </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">37 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">purpose; and (2) a royalty free, non-exclusive license, without the right to sublicense without Nuvelo&#146;s prior written approval, under the New
Intellectual Property solely to perform and otherwise carry out the Project. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Nuvelo Commercial License. Subject to the terms and conditions of this Agreement, specifically including Clause 5.2(c), Avecia hereby grants Nuvelo a royalty-free, irrevocable,
non-exclusive, world-wide license, with power to sub-license through multiple levels of sublicensees, under any of Avecia&#146;s Background Intellectual Property that is incorporated into the Process during the Project, to make, have made, use,
sell, offer for sale and import the Product or the API or any form, including any filled or finished form, of the Product or API. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Royalty-Bearing License. If Avecia believes in good faith that the Process would be materially improved by the utilization in the Process of an Invention or Inventions covered by a
Valid Claim or Valid Claims within Avecia&#146;s Background IP, then if and only if Avecia has previously, and continues to only grant access to such Inventions to Third Parties under a royalty-bearing license (each such Invention a &#147;Patented,
Licensed Avecia Invention&#148;), Avecia shall notify Nuvelo in writing regarding Avecia&#146;s proposal to incorporate any Patented, Licensed Avecia Invention into the Process, and shall propose commercially reasonable terms for a license to the
Patent or Patents containing the Valid Claim or Valid Claims covering the Patented, Licensed Avecia Invention(s). Nuvelo has no obligation whatsoever to agree to the utilization of any Patented, Licensed Avecia Invention in the Process, and Avecia
shall not delay or discontinue the Project as a result of a decision by Nuvelo not to incorporate any Patented, Licensed Avecia Invention in the Process. If a duly authorized representative of Nuvelo agrees in writing to the utilization of a
Patented, Licensed Avecia Invention in the Process, then Avecia shall grant Nuvelo a worldwide license under the Patent(s) containing the Valid Claim(s) that cover the Patented, Licensed Avecia Invention(s) to make, have made, use, sell, offer for
sale and import the Product or the API or any form, including any filled or finished form, of the Product or API, subject to agreement upon commercially reasonable terms. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><U>Ownership &amp; Protection of New Intellectual Property</U>. Any and all New Inventions, and any and all New Intellectual Property, shall belong to Nuvelo.
Avecia shall, and shall ensure that its employees shall, at Nuvelo&#146;s expense, perform all acts and execute all instruments necessary to assign to Nuvelo all right, title and interest in and to any and all New Invention and New Intellectual
Property. Nuvelo is entitled to, but has no obligation, to file, prosecute, maintain, register, enforce or defend any and all New Intellectual </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">38 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">Property. All fees, costs and expenses connected with Nuvelo&#146;s filing, prosecution, maintenance, enforcement or defense of New Intellectual Property
shall be borne and paid by Nuvelo. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Non-exclusive license under New Intellectual Property</U>. Subject to the terms and conditions of this Agreement, Nuvelo hereby grants to Avecia a royalty-free, irrevocable,
non-exclusive, world-wide license, with power to sub-license, but without the ability to grant Avecia&#146;s sublicensees the ability to grant sublicenses, under the New Intellectual Property for any use other than to make, have made, use, sell,
offer for sale or import, keep or otherwise deal in Product or the API or any form, including any filled or finished form, of Product or API. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.5</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Provision of Technical Assistance and Process Transfer</U>. If following Completion or following termination of this Agreement for any reason, Nuvelo requires Avecia&#146;s
technical assistance for the transfer of all or any portion of the Process to Nuvelo or a Third Party designee of Nuvelo, or other technical assistance, then Avecia shall promptly provide Nuvelo with all reasonable assistance necessary to transfer
the Process to Nuvelo or Nuvelo&#146;s Third Party designee, and Nuvelo will pay for Avecia&#146;s reasonable, actual costs and expenses associated with transfer of the Process, except that if Nuvelo terminates for Avecia&#146;s Unremedied Breach,
Nuvelo shall only pay Avecia for one-third of Avecia&#146;s actual costs and expenses associated with such assistance notwithstanding the provisions of Clause 9.1(b). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.6</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Limitation</U>. Avecia shall not, and shall not use the Process to, make, have made, use, sell, offer for sale or import API or Product for any entity, other than Nuvelo, in any
territory, without the prior written consent of a duly authorized representative of Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Warranties, Liability and Indemnity</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Warranties</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Each Party warrants to the other that: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">it has the necessary right and authority to enter into this Agreement; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to its knowledge as of the signature date of this Agreement, the use of its Background Intellectual Property pursuant to this Agreement for the purposes set out in this Agreement
will not infringe the Intellectual Property of a Third Party. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Avecia represents and warrants that it has not been debarred, nor does it intend to use for the Project any individual who has been debarred, under Section 306 of
the Federal Food, Drug, </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">39 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">and Cosmetic Act, 21 U.S.C. &#167;335a(a) or (b). In the event that Avecia becomes debarred, Avecia shall notify Nuvelo immediately.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Nuvelo Indemnity to Avecia</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Except as otherwise provided below in Clause 6.2(b), Nuvelo shall indemnify, defend and hold harmless Avecia, its Affiliates and their directors, officers, employees and agents (the
&#147;<B>Avecia Indemnitees</B>&#148;) from and against any loss, claim, suit, liability, damage or expense, of whatsoever kind or nature (&#147;<B>Loss</B>&#148;), resulting from or arising out of: </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">actual or suspected infringement of the Intellectual Property of any Third Party arising from the Avecia Indemnitees&#146; application of Nuvelo&#146;s Background IP or information
provided to the Avecia Indemnitees by Nuvelo, in the performance of the Project; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Nuvelo or its Affiliates, or their directors, officers, employees or agent&#146;s use of any results of the Project performed by the Avecia Indemnitees hereunder (including without
limitation API or other materials manufactured); or </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the negligence, wilful misconduct or breach of any Applicable Laws by Nuvelo or its Affiliates, or their directors, officers, employees or agents; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Nuvelo has no obligation to indemnify, defend or hold harmless the Avecia Indemnitees for any Loss to the extent resulting from or arising out of: </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the actual or suspected infringement of the Intellectual Property of any Third Party arising from any of the Avecia Indemnitees&#146; application of Avecia&#146;s Background IP or
information not provided to the Avecia Indemnitees by Nuvelo or its Affiliates, or their officers, directors, employees or agents, in the performance of the Project; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the negligence or wilful misconduct of any of the Avecia Indemnitees; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">any breach of this Agreement by any of the Avecia Indemnitees; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">any failure by any of the Avecia Indemnitees to comply with Applicable Laws; or </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">in respect of the indemnity under paragraph (a)(2) of this Clause 6.2, Avecia&#146;s continuing use of Nuvelo&#146;s </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">40 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="17%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">Background IP, following Avecia receiving written notice, and supporting documentation, from Nuvelo that use of any of such Background IP results in the
actual or suspected infringement of the intellectual property of any Third Party and instructing Avecia to cease use of that part of Nuvelo&#146;s Background IP which results in such actual or suspected infringement. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Avecia Indemnity to Nuvelo</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Except as otherwise provided below in Clause 6.3(b), Avecia shall indemnify, defend and hold harmless Nuvelo and its Affiliates, and their officers, directors, employees and agents
(&#147;<B>Nuvelo Indemnitees</B>&#148;) from and against any Loss resulting from or arising out of: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">actual or suspected infringement of the Intellectual Property of any Third Party by any of the Avecia Indemnitees&#146; or Avecia subcontractor&#146;s application of Avecia&#146;s
Background IP during the performance of the Project; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">any of the Nuvelo Indemnitees&#146; use of any Avecia Background IP or any results of the Project generated by any of the Avecia Indemnitees, or any Avecia subcontractors, hereunder
(including without limitation API or other materials manufactured) to the extent any of the Nuvelo Indemnitees&#146; use of the Avecia Background IP or any results of the Project results in the actual or suspected infringement of the Intellectual
Property of any Third Party, but with respect to any results of the Project, solely to the extent such results were generated through any of the Avecia Indemnitees&#146; application of Avecia&#146;s Background IP in the performance of the Project;
or </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the negligence, wilful misconduct or breach of any Applicable Laws by any of the Avecia Indemnitees; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia has no obligation to indemnify, defend or hold harmless the Nuvelo Indemnitees for any Loss to the extent resulting from or arising out of: </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the negligence or wilful misconduct of any of the Nuvelo Indemnitees; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">any breach of this Agreement by any of the Nuvelo Indemnitees; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">any failure by any of the Nuvelo Indemnitees to comply with Applicable Laws; or </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">41 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">in respect of the indemnity under paragraph (a)(2) of this Clause 6.3, Nuvelo&#146;s continuing use of any results of the Project, following Nuvelo receiving written notice from
Avecia, and supporting documentation, that use of such results of the Project results in the actual or suspected infringement of the intellectual property of any Third Party. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Indirect, Consequential and Special Damages Excluded</U>. Except with respect to indemnity under Clauses 6.2 and 6.3 above or any breach of intellectual property or
confidentiality provisions in accordance with Clauses 5 and 7, in no event shall either Party be liable for any special, incidental, consequential or indirect damages arising in any way out of or relating to this Agreement, however caused and on any
theory of liability. This limitation will apply even if the other Party has been advised of the possibility of such damages. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.5</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Limitation</U>. Neither Party&#146;s liability under this Agreement will exceed the total amount that would be due to Avecia if the Project was fully completed, except with
respect to any liability of Avecia arising under Clause 9.1(c). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.6</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Insurance</U>. Each Party shall secure and maintain in full force and effect during the term of this Agreement policies of insurance providing coverage for (a) employer&#146;s
liability and (b) public and products liability having policy limits, deductibles and other terms appropriate to the conduct of that Party&#146;s business. Evidence of such insurance in the form of a broker&#146;s letter will be made available for
examination upon request of the other Party. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.7</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>General Conditions of Indemnification</U>. Each Party&#146;s agreement to indemnify, defend and hold the other harmless in accordance with Clauses 6.2 and 6.3 is conditioned on
the indemnified Party: (a) providing prompt written notice to the indemnifying Party of any claim or lawsuit with potential for a Loss no more than ten (10) business days after the indemnified Party has knowledge of such claim or lawsuit, but the
ten (10) day time period shall not preclude indemnity hereunder so long as the delay has not materially prejudiced defense of the claim or suit; (b) permitting the indemnifying Party to have full conduct and control to investigate, prepare for,
defend against and settle any such claim or lawsuit; (c) providing the indemnifying Party, at the indemnifying Party&#146;s reasonable expense, with the full cooperation and assistance in the investigation of, preparation for and defense of any such
claim or lawsuit; and (d) not agreeing to any compromise or settlement materially adverse to the rights of the indemnified Party under this Agreement without the indemnifying Party&#146;s prior written consent. This Clause 6.7 survives termination
of this Agreement with respect to any Loss arising from the Parties&#146; performance during the term of this Agreement and with respect to any conditions and obligations that survive the termination or expiration of this Agreement.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">42 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Confidentiality</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The provisions of the Confidentiality Agreement shall remain in full force and effect, except to the extent modified by the terms and conditions of this Agreement.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The obligations of confidentiality and non-disclosure set forth in the Confidentiality Agreement will continue for seven (7) years after the expiration or termination of this
Agreement, and the Confidentiality Agreement shall not terminate or expire before the termination of this Agreement. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia may use the Confidential Information solely for the purpose of the performance of the Project, except that Avecia may use New IP in accordance with the license set forth in
Clause 5.4, subject to entry of any relevant Third Party customer or supplier into confidentiality obligations to protect the confidentiality of such New IP, which obligations are no less onerous than those contained in this Agreement.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The Confidentiality Agreement shall, with effect from the date hereof, be deemed to be extended to cover disclosures of information by either Party, together with any information
acquired by, or otherwise exposed to, either Party as a result of site visits, in each case pursuant to and subject to this Agreement. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Duration and Termination</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">8.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Commencement and Duration</U>. This Agreement and the Project shall commence on the Commencement Date and shall continue (unless terminated in accordance with the provisions of
Clauses 8.2, 8.3 or 8.4) until Completion. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">8.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Termination by Nuvelo</U>. Subject to Clause 9, Nuvelo may terminate this Agreement at any time with or without cause, cause including Unremedied Breach, effective immediately
upon written notice to Avecia. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">8.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Termination by Avecia</U>. Avecia may terminate this Agreement immediately upon notice to Nuvelo in respect of an Unremedied Breach by Nuvelo, where material breach includes a
failure by Nuvelo to pay an amount owed to Avecia under this Agreement within 10 business days of when it is due.<B></B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">8.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Termination by Agreement</U>. Subject to Clause 9, this Agreement may be terminated by mutual agreement at any time prior to Completion. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">43 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Consequences of Termination</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>General</U>. In the event of termination by either Party under Clause 8 above: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Termination other than for Unremedied Breach. Upon termination of this Agreement, other than for termination by Nuvelo in connection with an Unremedied Breach by Avecia, Nuvelo will
pay Avecia: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">all sums due and payable up to the date of termination but not yet paid, but excluding any payments (other than the Handling Fee) due in respect of subcontractors appointed under
Clause 13.2 or consumable items or Equipment purchased under Clauses 3.2 and 3.3: (i) that can be returned; or (ii) the ordering of or contract for which can be cancelled; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">all reasonable costs already incurred by Avecia up to the date of termination in accordance with the terms and conditions of this Agreement and uncancellable expenses incurred by
Avecia after termination which could not reasonably be avoided after a reasonable attempt by Avecia to mitigate such costs, including reasonable cancellation charges payable by Avecia to a subcontractor appointed under Clause 13.2 or the seller of
consumables or Equipment in respect of consumables or Equipment (i) that has been returned to the seller, or (ii) the order of or contract for which has been cancelled; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the Cancellation Fee in consideration for technical consultancy services performed up to date of termination and in winding down and cancelling the Project, if and only if the
Agreement is terminated by: (i) Avecia under Clause 8.3; or (ii) by Nuvelo in accordance with Clause 8.2, but excluding termination by Nuvelo (A) for Unremedied Breach; (B) due to Force Majeure affecting Avecia; or (C) in accordance with Clause
2.2(b). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fifty percent (50%) of the Development Batch Fee that otherwise would have been due and payable, as calculated in accordance with Schedule 4, in consideration for technical
consultancy services performed up to the date of termination and in winding down and cancelling the Project, if and only if, other than as a result of an Avecia Default, Nuvelo terminates the Agreement under Clause 8.2 as a result of a failure of
the centrifuge trials and a failure by Avecia to commence Development Batch Manufacture before the expiration of December 31, 2005, Pacific Standard Time, in accordance with Section 2.2(b)(2). </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">44 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Termination for Unremedied Breach; Avecia Default. If Nuvelo terminates for Avecia&#146;s Unremedied Breach, no later than 5 days after the effective date of Nuvelo&#146;s
termination, Avecia shall pay to Nuvelo, as compensation for Nuvelo&#146;s loss of monies paid to Avecia for work not performed in accordance with the terms and conditions of this Agreement, a sum equivalent to any and all monies paid to Avecia
under this Agreement, less amounts paid for technical consultancy work completed by Avecia in accordance with the terms and conditions of this Agreement and not affected by the breach. In the event of an Avecia Default in the performance of any
portion of the Project, Nuvelo is entitled to request Avecia to: (i) promptly repeat the applicable portion of the Project at Avecia&#146;s own cost or (ii) reimburse Nuvelo for the price for that particular portion of the Project. Failure by Avecia
to timely cure an Avecia Default results in an Unremedied Breach of the Agreement. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Currency Exchange Rate Losses. If Nuvelo terminates this Agreement for Unremedied Breach by Avecia, Avecia shall be liable for any currency exchange rate losses incurred by Nuvelo
up through and until January 1, 2007, as a result of commitments made by Nuvelo to enable Nuvelo to pay Avecia the payments set forth in Clause 3.1 in British pounds sterling. Within 5 business days after the effective date of termination of the
Agreement for Avecia&#146;s Unremedied Breach, Nuvelo shall arrange to sell all British pounds sterling purchased by Nuvelo in anticipation of its obligation to make future payments under this Agreement, and Nuvelo shall also arrange to sell all
contracts to purchase British pounds sterling purchased by Nuvelo in anticipation of its obligations to make future payments under this Agreement. Avecia shall pay to Nuvelo an amount equal to any currency exchange losses actually incurred by Nuvelo
in connection with such sales, as reduced by any amounts owed by Nuvelo to Avecia as of the effective date of termination on account of services completed by Avecia in compliance with and prior to termination of this Agreement. Avecia will pay any
undisputed amounts owed to Nuvelo under this Clause 9.1(c) within five (5) business days of its receipt of an invoice for such amounts from Nuvelo. All payments to Nuvelo under and in accordance with this Clause 9.1(c) will be made in United States
dollars. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Subject to Section 6.5, the rights and remedies set out in this Clause 9.1 in respect of the consequences of termination do not limit any other remedies or damages to which a Party
may be entitled in law or in equity. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><U>Acquired Rights</U>. Termination or expiry of this Agreement, for whatever reason, shall not prejudice the rights of either Party </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">45 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">acquired before such termination or expiry, including the right to payment for services actually performed under the Project in accordance with the terms and
conditions of this Agreement, pursuant to Clause 3. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Survival</U>. The provisions of Clauses 1.2, 2.9, 2.10(a), 3.3(c), 3.3(d), 3.5, 3.6, 3.7, 5, 6.2 through 6.5, 6.7 and 7 through 20 shall survive the termination or expiry of this
Agreement for the term set forth in the applicable Clause, or if no period is specified, the earlier of perpetuity of the maximum amount of time permitted under Delaware law. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Independent Contractor</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">Nothing in this Agreement shall create, or be deemed to create, a partnership or the relationship of principal and agent or employer and employee between
the Parties. Each Party agrees to perform under this Agreement solely as an independent contractor. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Entire Agreement</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">This Agreement and with the Schedules attached hereto contain the entire agreement between the Parties with respect to the subject matter set forth
therein and supersedes any previous agreements relating to the Project (including the Interim Agreement) and any understandings between the Parties with respect thereto. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>12.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Announcements And Publicity</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">Subject to the prior written approval of the other Party, a Party may make an official press release, announcement or other formal publicity relating to
the transactions which are the subject of this Agreement. The Party wishing to make such release, announcement or publicity shall provide a copy of the text thereof to the other Party for its review, revision and approval, not to be unreasonably
withheld or delayed. Nothing in this Clause 12 shall preclude disclosure of the terms of this Agreement as required by Applicable Laws, including without limitation the regulations of the United States Securities and Exchange Commission. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Assignment and Subcontracting</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">13.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective legal successors but shall not otherwise be assignable by either Party,
without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed, except that either Party may assign this Agreement without consent to an Affiliate or a purchaser or acquirer of a Party, or of the
part of a Party&#146;s business to which this Agreement relates. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">46 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">13.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">With Nuvelo&#146;s prior written consent as to the ability to subcontract particular work and as to the identity of each subcontractor, Avecia may subcontract certain analytical
work under the Project in accordance with the Quality Agreement, subject to inclusion in such subcontract of confidentiality and intellectual property provisions no less onerous than those contained herein, and commercially reasonable cancellation
provisions. Except as provided otherwise in Section 3.2(a)(2) or in a Programme Amendment Order, Avecia is responsible for all costs, fees and Expenditures associated with any subcontracted work, and shall not pass any such costs, fees or
Expenditures through to Nuvelo. Avecia shall be liable for any acts or omissions of any subcontractor as if such acts or omissions were Avecia&#146;s own. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>14.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Variation</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">No variation, modification or amendment of this Agreement shall bind either Party unless made in writing in the English language and agreed to in writing
by duly authorized officers of both Parties. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>15.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Illegality</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">If any provision of this Agreement is agreed by the Parties to be illegal, void or unenforceable under any law that is applicable hereto or if any court
of competent jurisdiction in a final decision so determines, this Agreement shall continue in force and effect except that the illegal, void or unenforceable provision shall be deemed to be excised herefrom with effect from the date of such
agreement or judicial decision or such earlier date as the Parties may agree. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>16.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Waiver</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">A failure by either Party hereto to exercise or enforce any rights conferred upon it by this Agreement shall not be deemed to be a waiver of any such
rights or operate so as to bar the exercise or enforcement thereof at any subsequent time or times. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>17.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Notices</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">17.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Formal Notices</U>. Any formal notice required or permitted under this Agreement shall be in writing which may take the form of a letter or facsimile and shall be sent by prepaid
post, facsimile, or hand delivery (including messenger service). The addresses for any such notice or other communication shall be those stated on the first page of this Agreement. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">47 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">17.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Other Communications</U>. In addition to the methods set out in Clause 17.1, any communications other than formal notices between the Parties may be made by telephone or by
email. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">17.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Change of Address</U>. Any Party may, at any time by written notice to the other Party, change the address or the facsimile numbers to which notices or other communications shall
be sent. All notices and other communications shall have been duly given or made (i) when delivered by hand (including by messenger service) upon delivery or (ii) when delivered by post upon delivery or (iii) when faxed upon receipt of a legible
copy by recipient and production of a satisfactory transmission report by sender confirming transmission of the fax in full to the appropriate number by the fax machine which sent the fax. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>18.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Force Majeure</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">Neither Party shall be liable to the other Party in any manner whatsoever for any failure or delay in performing its obligations under this Agreement if
and to the extent, and for the duration, that such is due to Force Majeure. Without prejudice to Clause 8, any said failure or delay shall not give either Party the right to terminate this Agreement except, and to the extent that such Force Majeure
continues for a period exceeding three (3) months. Termination as a result of Force Majeure shall take effect as if the Agreement had been terminated by mutual agreement under Clause 8.4.<B></B> </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>19.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Law and Jurisdiction</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">19.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Law</U>. This Agreement is governed by and shall be construed and interpreted in accordance with the laws of the State of Delaware, United States of America. Any proceedings
between the Parties shall be conducted in the English language. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">19.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Referral to Senior Managers</U>. Prior to any dispute, difference or disagreement concerning this Agreement proceeding to litigation pursuant to Clauses 19.1 and 19.4, the
Parties shall seek to resolve the matter within thirty (30) calendar days by referring it to the CFO of Avecia and the CEO of Nuvelo, each of which shall have the authority necessary to fully resolve the dispute. <B></B> </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">19.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Interim Steps</U>. Neither of the Parties shall be deemed to be precluded from taking such interim formal steps as may be considered necessary to protect such Party&#146;s
position while the procedures referred to in Clause 19.2 are pursued. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">19.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Jurisdiction</U>. Except as provided for in Clause 19.2, in relation to any legal action or proceedings to enforce this Agreement or arising out of or in connection with this
Agreement each of the Parties irrevocably consents and submits to the exclusive jurisdiction and venue of the federal and state courts located in the State of Delaware. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">48 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>20.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>General</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">20.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Headings</U>. The headings for each Clause or Paragraph or Section in this Agreement, and in the Schedules, have been inserted for convenience of reference only and are not
intended to limit or expand on the meaning of the language contained in the particular clause, paragraph or section. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">20.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Ambiguities</U>. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous
provision. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">20.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Counterparts.</U> This Agreement may be executed in two or more counterparts, including facsimile counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">49 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">IN WITNESS WHEREOF, the authorized representatives of the Parties have executed this Agreement as of the last date set
forth below, and upon its execution, this Agreement becomes effective as of the Commencement Date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">For and on behalf of <B>AVECIA LIMITED</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="3" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Signature</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">/s/ Kevin Cox</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Name</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Kevin Cox</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Position</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">VP Biotechnology</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">30 June 2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">For and on behalf of <B>NUVELO INC</B>.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="3" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Signature</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">/s/ Lee Bendekgey</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Signature</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">/s/ Michael Levy</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Name</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Lee Bendekgey</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Name</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Michael Levy</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Position</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">CFO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Position</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">SVP R&amp;D</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">30 June 2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">30 June 2005</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">50 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>Schedule 1
</U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>The Work Programme </U></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">51 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>Schedule 2
</U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>Quality Agreement </U></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">52 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>Schedule 3
</U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>Programme Amendment Order </U></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2"><B>(1)&nbsp;&nbsp;&nbsp;&nbsp;Project Title &amp; Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2"><B>(2)&nbsp;&nbsp;&nbsp;&nbsp;Date Project Started</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2"><B>(3)&nbsp;&nbsp;&nbsp;&nbsp;P.A.O. Number</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2"><B>(4)&nbsp;&nbsp;&nbsp;&nbsp;Reason for P.A.O.</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2"><B>(5)&nbsp;&nbsp;&nbsp;&nbsp;Amendment required and new milestones</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2"><B>(6)&nbsp;&nbsp;&nbsp;&nbsp;Impact on price, time frame, resources</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2"><B>(7)&nbsp;&nbsp;&nbsp;&nbsp;Amended payment schedule (if required)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">53 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Authorisation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT><FONT SIZE="">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT><FONT SIZE="">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">for Avecia</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">for customer</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">54 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>Schedule 4 </U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>The Cancellation Fee </U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">A.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The Cancellation Fee shall be a percentage of: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">in the case of Development Batch Manufacture, the total payment to be made in respect of Development Batch Manufacture for completion of milestones 11, 17, 19, 20, 23 and 25 under
Clause 3.1, being &pound;2,109,500 (&#147;Development Batch Fee&#148;) less any sums already received for milestones 11, 17, 19, 20, 23 and 25 under this Agreement in respect of Development Batch Manufacture at the date on which notice is given of
termination, cancellation or Non-Manufacturing Delay. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">in the case of the Validation Campaign, the total payment to be made in respect of the Validation Campaign for completion of milestones 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 37,
38, 39 and 41 under Clause 3.1, including manufacture of the Engineering Batch (or as otherwise agreed in writing), being &pound;4,618,000 (&#147;the Validation Campaign Fee&#148;) less any sums already received for milestones 26, 27, 28, 29, 30,
31, 32, 33, 34, 36, 37, 38, 39 and 41 under this Agreement in respect of the Validation Campaign and the Engineering Batch under Clause 3.1 at the date on which notice is given of termination, cancellation or Non-Manufacturing Delay.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">B.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The applicable percentage shall be dependent on the amount of notice of termination, cancellation or Non-Manufacturing Delay given by Nuvelo prior to the date for commencement of
Development Batch Manufacture or the Validation Campaign (as appropriate). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">C.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The Cancellation Fee shall be calculated as follows: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="37%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B><I>Notice Period</I></B></FONT></P><HR WIDTH="46" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B><I>Percentage&nbsp;of&nbsp;Validation&nbsp;Campaign&nbsp;Fee<BR>or Development Batch Fee (as<BR>appropriate)</I></B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Nine months or more</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">0</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Fewer than nine months but more than six months</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">50</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Six months or fewer but more than four months</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">70</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Four months or fewer but more than one month</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">90</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">One month or less</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">100</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">D.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Avecia shall make commercially reasonable endeavours to raise revenue by utilising the production facility during the period during which </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">55 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P>
<FONT FACE="Times New Roman" SIZE="2">Development Batch Manufacture or the Validation Campaign (as appropriate) was intended to take place but for termination, cancellation on Non-Manufacturing
Delay by Nuvelo. Avecia shall refund to Nuvelo a sum equivalent to the revenue (net of raw materials and consumables Expenditure) raised as a result of such alternative use up to a maximum of 80% of the Cancellation Fee paid.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">E.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Where the Cancellation Fee is less than the amount already paid to Avecia by Nuvelo under this Agreement in consideration for Development Batch Manufacture or the Validation
Campaign (as appropriate), Avecia shall pay to Nuvelo the difference between the applicable Cancellation Fee and the amount already paid in consideration for the Development Batch Manufacture or the Validation Campaign (as appropriate).
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">56 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>Schedule 5 </U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>Committee Members </U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Project Steering Committee Members </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Nuvelo</B></FONT></P><HR WIDTH="24" SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Avecia</B></FONT></P><HR WIDTH="22" SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Simon Allen, VP Business Development</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">Leslie Barnes, Director, R&amp;D Finance</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Dr. Kirk Hayenga, Senior Director, PSM</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Dr. Brian Kersten, Senior Director,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Regulatory
and QA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Dr Stephen Taylor, Business General</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">Manager, Biologics</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Steve Bagshaw, Head of Business</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Planning</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Dr Mark Carver, Head of R&amp;D</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Dr Klaus Neurohr, Head of Quality &amp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2">Regulatory Affairs</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Executive Committee
Members </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Nuvelo</B></FONT></P><HR WIDTH="24" SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Avecia</B></FONT></P><HR WIDTH="22" SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Dr. Michael Levy</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2">Senior Vice President,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Research and Development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Dr Kevin Cox, Senior Vice-President,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">Avecia Biotechnology</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">57 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>Schedule 6 </U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>The Equipment </U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="50%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Liquid Nitrogen Dewars (x2) and Data Logger</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Depth Filtration System</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">1000L jacketed bag holder</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Delipid filter skid</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">2x1000mm chromatography columns, hydraulic skid and spares</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">2 x Freezers (-30&deg;C &amp; - 70&deg;C)</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">58 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>Schedule 7 </U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>The Confidentiality Agreement </U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><I>See attached</I><B><U></U></B><I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">59 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Schedule 1 Work Programme </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>B2422 Work Programme </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Scope Statement </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Program to carry out technology transfer of the alfimeprase Process, Process characterization and validation of in-process and bulk API assays by Avecia and manufacture of two (2) cGMP Development Batches, one (1)
Engineering Batch and up to five (5) Validation Batches of alfimeprase in Avecia&#146;s ABC 5000 facility. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Contents </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Stage&nbsp;1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Data Acquisition and Assessment</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Stage 2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Process Transfer &amp; Fit</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Stage 3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Capital Equipment Specification and Procurement</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Stage 4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">15L Fermentation Runs</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Stage 5.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Laboratory Scale Purification Runs</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Stage 6.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Assay Transfer of Validated Methods</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Stage 7.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Assay Transfer</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Stage 8.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Assay Validation</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Stage 9.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Laboratory Process Characterisation (LPC)</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Stage 10.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Fermentation Scale-Up and Centrifuge Trials at 3000L scale</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Stage 11.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">cGMP Preparation at 3000L scale</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Stage 12.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Two (2) cGMP Development Batches at 3000L scale</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Stage 13.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Validation Documentation</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Stage 14.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">One (1) Engineering Batch at 3000L scale</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Stage 15.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Up to Five (5) Validation Batches at 3000L scale</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Appendix&nbsp;1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Process Assumptions</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Appendix 2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">B2422 Work Programme Timeline (see attachment)</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Detailed Work Programme
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stage 1. Data Acquisition and Assessment </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Objectives </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To perform systematic review and gap analysis of Amgen technical information regarding the fermentation, harvest and purification steps for the alfimeprase Process.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.1.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To perform systematic review and gap analysis of Amgen technical information regarding the analytical testing for the alfimeprase Process. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.1.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To perform systematic review and gap analysis of Amgen technical information regarding the genetically modified organism (GMO; Pichia) for alfimeprase. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Activities </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.2.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Review and evaluate all Amgen technical reports, laboratory notebooks, laboratory reports and previous process batch records to define the alfimeprase Process.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Page 1 of 11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Schedule 1&nbsp;&nbsp;&nbsp;&nbsp;Work Programme </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.2.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Review the analytical methods listed below. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Method&nbsp;number</B></FONT></P><HR WIDTH="54" SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Assay</B></FONT></P><HR WIDTH="20" SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Characteristic</B></FONT></P><HR WIDTH="45" SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0819</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Genotypic Verification (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">MCB and WCB Identity</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0662</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Microbial Contaminants (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Safety</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0359</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Viable Cell Count (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">MCB and WCB Quality</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A01382</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">AEX-Quant (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Strength</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0848</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Clot Lysis (validated)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Potency</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0120</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Absorbance at 280nm (validated)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Strength</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0829</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">SEC (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Purity</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0874</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">RP HPLC in-process (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Purity</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0831</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">AEX-Qual (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Purity</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0830</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">RP HPLC (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Purity</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0815</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">SDS PAGE Coomassie (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Purity, Identity</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0815</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">SDS PAGE Silver</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Purity</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0847</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Peptide map (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Identity</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0924</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Intact MS OUTSOURCED (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Identity</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0862</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Anti <I>Pichia</I> EIA (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Impurities</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A01339</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">DNA or equivalent OUTSOURCED (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Impurities</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0221</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Appearance (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Quality</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">USP/EP Pyrogen (rabbit) OUTSOURCED</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Safety</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0736</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Bioburden (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Safety</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0857</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">MES (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Process clearance</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0837</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Imidazole (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Process clearance</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A01102</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">EPA Copper and Zinc OUTSOURCED</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Buffer Monitoring</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0442</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">DNA sequence for cell bank OUTSOURCED (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">MCB and WCB Safety</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0719</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cell bank contamination (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">MCB and WCB Safety</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0404</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Polysorbate 80 (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Buffer monitoring</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0410</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Sucrose and Mannitol (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Buffer monitoring</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0225</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Citrate (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Buffer monitoring</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0302</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Sulphate (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Buffer monitoring</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">A0986</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Tris (V)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Buffer monitoring</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">EP Osmolality</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Quality</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">USP/EP pH</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Quality</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">USP/EP Conductivity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Quality</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(V)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">denotes analytical methods that require some validation work. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.2.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate a GMO assessment to work with alfimeprase at Avecia. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Deliverables </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Definition of a detailed work programme </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.3.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Project timeline </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Page 2 of 11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Schedule 1&nbsp;&nbsp;&nbsp;&nbsp;Work Programme </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stage 2. Process Transfer &amp; Fit </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Objective </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To perform a gap analysis to identify new facility equipment required to manufacture alfimeprase. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Activities </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.2.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Based on the technical data review (Stage 1), Avecia to highlight the requirements for new equipment purchases to support manufacture of alfimeprase. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Deliverables </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Scope of equipment requirements </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stage 3. Capital Equipment Specification and Procurement </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Objectives </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To purchase Equipment for use during Centrifuge Trials </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.1.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To purchase Equipment for use during cGMP manufacture </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Activities </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.2.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate a user requirement specification (URS) for all new Equipment. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.2.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Obtain vendor quotes and generate bid comparisons (as appropriate) for all new Equipment for Nuvelo to review. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.2.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Upon receiving Nuvelo confirmation, place relevant order to purchase new Equipment and management of supplier regarding factory acceptance testing and delivery.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>New Equipment for Centrifuge Trials</B></FONT></P><HR WIDTH="126" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Estimated&nbsp;cost<BR>&pound;000s</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Liquid Nitrogen Dewars (x2) and Data Logger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8.752</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>8.752</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>New Equipment for GMP manufacture</B></FONT></P><HR WIDTH="131" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Estimated&nbsp;cost<BR>&pound;000s</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Depth Filtration System</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">120</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">1000L jacketed bag holder</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">30</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Delipid filter skid</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">2x1000mm chromatography columns, hydraulic skid and spares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">303</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">2 x Freezers (-30&deg;C &amp; - 70&deg;C)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>469</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Page 3 of 11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Schedule 1&nbsp;&nbsp;&nbsp;&nbsp;Work Programme </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.2.4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">In addition Avecia would need to make certain plant modifications to ABC5000 stream 2 facility and provide items of a generic nature at Avecia cost. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="74%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Modification to fermenter control software</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Trace heating on glucose line</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Ammonia feed tank</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Various tankage</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">0.2 &micro;m filtration skid</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Small UF rig (Sartorius Beta)</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Deliverables </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">URS for each new Equipment purchase. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.3.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Installed and qualified new Equipment fit for purpose. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stage 4. 15L Fermentation Runs </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Objectives </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To demonstrate robustness and reproducibility of the fermentation Process at laboratory scale within Avecia (familiarisation). </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.1.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To demonstrate the fermentation Process comparability after substitution of several raw materials (comparability). </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Activities </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.2.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Receive alfimeprase working cell bank (WCB) vials. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.2.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate and ensure technical approval of laboratory protocols with Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.2.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform four (4) fermentation runs at 15L using Avecia preferred supplier raw materials. Presentation of familiarisation data set to Nuvelo. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.2.4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Receive the original alfimeprase raw material list and specifications from Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.2.5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Review and technical approval of a comparability procedure drafted by Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.2.6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform four (4) fermentation runs at 15L for comparability, two (2) using the original alfimeprase Process raw materials and two (2) using Avecia preferred supplier raw materials.
Presentation of comparability data set to Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.2.7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate familiarisation and comparability technical reports. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Deliverables </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Interim fermentation familiarisation technical report. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.3.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Final fermentation comparability technical report. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.3.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">QA review of limited data from familiarization and comparability technical reports for Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stage 5. Laboratory Scale Purification Runs </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Objectives </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To demonstrate robustness and reproducibility of the purification Process at 15L laboratory scale within Avecia (familiarisation). </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.1.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To demonstrate the purification Process comparability after substitution of several fermentation and purification raw materials (comparability). </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Page 4 of 11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Schedule 1&nbsp;&nbsp;&nbsp;&nbsp;Work Programme </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.1.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To demonstrate cleanability of alfimeprase in relation to proteins used in cleaning validation studies. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Activities </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Receive the alfimeprase fermentation diafiltered, concentrated, clarified broth (DCCB) from Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform two (2) purification runs through to final Product using Nuvelo DCCB. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform analytical testing of the purification Process using &#145;Nuvelo DCCB&#146;. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Receive the first 2 x 15L Avecia fermentation broth from Stage 4 familiarisation. Create DCCB and purify 2 x 15L to final Product. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform analytical testing of purification Process using Avecia DCCB. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Receive the second 2 x 15L Avecia fermentation broth from Stage 4 familiarisation. Create DCCB and purify 1 x 15L to final Product. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform analytical testing of Avecia DCCB purification Process. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Presentation of familiarisation data set to Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.9.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate interim familiarisation technical report. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.10.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform cleanability studies. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.11.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Review and technical approval of a comparability procedure drafted by Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.12.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Receive the next 4 x 15L Avecia fermentation broth from Stage 4 comparability. Create DCCB and purify 2 x 15L (one from each preferred raw material supplier) to final Product.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.13.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform analytical testing. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.14.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate comparability technical report. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Deliverables </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Interim purification familiarisation technical report. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.3.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Final purification comparability technical report. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.3.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Cleanability technical report. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.3.4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">QA review of limited data from familiarization and comparability technical reports for Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stage 6. Assay Transfer of Validated Methods </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Objectives </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To transfer the validated clot lysis and appearance analytical methods to Avecia QC. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Activities </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.2.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Receive appropriate samples, historical data and reference standard from Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.2.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Jointly review and ensure QA approval of analytical transfer protocols with Nuvelo for the clot lysis and appearance assays. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.2.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Execute protocols and report data. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.2.4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate validation reports. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Deliverables </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Validated method transfer reports. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Page 5 of 11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Schedule 1&nbsp;&nbsp;&nbsp;&nbsp;Work Programme </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stage 7. Assay Transfer </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Objectives </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To transfer the non-validated Amgen analytical methods to Avecia. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.1.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To transfer the non-validated Amgen analytical methods identified to be outsourced in Stage 1.2.2 to Avecia approved outsourced testing houses. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Activities </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.2.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Receive appropriate samples, historical data and reference standard from Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.2.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Jointly review and ensure QA approval of analytical transfer protocols with Nuvelo for non-validated assays defined in stage 1.2.2. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.2.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Jointly review additional work required on assays to prepare for assay validation. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.2.4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Execute transfer protocols and report data. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.2.5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate transfer reports as determined by Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">7.3. Deliverables </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Method transfer data and reports (if required) for each assay. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stage 8. Assay Validation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">8.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Objective </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">8.1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To ensure validation of all the analytical methods identified by (V) in analytical table from Stage 1.2.2 of the work programme, for API Release testing during the validation
batches. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">8.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Activities </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">8.2.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate validation sub-plan for analytical assays </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">8.2.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Jointly review and ensure QA approval of analytical validation protocols with Nuvelo for non-validated assays identified by (V) in the analytical table from Stage 1.2.2 of the work
programme. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">8.2.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Execute validation protocols in accordance with ICH Q2A and Q2B and report data. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">8.2.4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate validation reports. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">8.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Deliverables </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">8.3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Method validation data and reports for each assay. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stage 9. Laboratory Process Characterisation (LPC) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Objective </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To evaluate key operational parameters and ranges for critical Process steps. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Activities for LPC experimental set #1 </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.2.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Review and evaluate all Amgen technical reports and data from previous LPC studies. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.2.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform a RPN analysis. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.2.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform Fermentation Studies </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.2.3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Investigate degradation of seed fermenter media on sterilisation. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.2.3.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Investigate the addition of antifoam (heating to filter sterilise) for addition to fermenter. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.2.3.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Investigate seed fermenter inoculum volume. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Page 6 of 11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Schedule 1&nbsp;&nbsp;&nbsp;&nbsp;Work Programme </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.2.3.4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Investigate the change over to time triggers at a specified feed flow rate. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.2.4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform Purification Studies </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.2.4.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Investigate the SPHP step to determine the optimum UV cut-off range. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.2.4.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Investigate the SPHP step and reduction in gradient range during elution. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.2.4.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Investigate the temperature of operation during the IMAC step. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.2.4.4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Investigate the requirement for wash step #2 during the IMAC step. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.2.4.5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Investigate the pH of the load and buffer material during the IMAC step. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Deliverables </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">RPN analysis report </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.3.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">LPC Experimental set 1 Fermentation technical report </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">9.3.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">LPC Experimental set 1 Purification technical report </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stage 10. Fermentation Scale-Up and Centrifuge Trials at 3000L scale </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Objectives </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Release of working cell bank (WCB) for cGMP use </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.1.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To provide the first data on fermentation performance at 3000L scale </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.1.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To provide early definition of centrifuge operating conditions which can only be determined empirically </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.1.4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To allow greater chance that the first cGMP Development batch would make useful Product and de-risk that stage of the programme. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Activities </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.2.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform QC identity and purity testing of WCB and generate a Release Certificate of Analysis (CofA), approved by QA for the WCB. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.2.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Order all raw materials and consumables. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.2.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate draft manufacturing batch records. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.2.4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Review and technical approval of a comparability procedure drafted by Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.2.5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Carry out first 3000L fermentation and centrifuge trial. Analyse centrifuge performance data. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.2.6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Carry out the second fermentation and centrifuge trial with parameters to mimic the operation of the first cGMP Development batch or with refined parameters based on failure of
batch 1, if necessary. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.2.7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Supply 4 x 50 L fermentation broth for lab-scale purification. Store 2 x 50L of fermentation broth for future purifications. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.2.8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform 2 x 50L purification using broth from centrifuge trials to supply research grade material to Nuvelo. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.2.9.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate manufacturing trial summary report. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Deliverables </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">QC document for cell bank testing. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.3.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Release CofA for the WCB. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.3.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Draft manufacturing batch records. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.3.4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Research grade material. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Page 7 of 11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Schedule 1&nbsp;&nbsp;&nbsp;&nbsp;Work Programme </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.3.5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Manufacturing batch summary report. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">10.3.6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Comparability report. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Stage 11. cGMP Preparation at 3000L scale </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">11.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Objectives </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">11.1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To prepare for cGMP manufacture. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">11.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Activities </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">11.2.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate a Process specification document. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">11.2.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate cGMP manufacturing batch records. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">11.2.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate QC document detailing the Release Product Specification (refer to Appendix 2). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">11.2.4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Order all raw materials and consumables. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">11.2.5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Review and technical approval of a comparability procedure drafted by Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">11.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Deliverables </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">11.3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA approved Process specification document. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">11.3.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA approved cGMP manufacturing batch records. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">11.3.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA approved QC Document (Product Specification). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stage 12. Two (2) cGMP Development Batches at 3000L scale </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Objectives </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To perform two (2) cGMP batches at 3000L scale </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.1.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To supply cGMP Product from at least 1 x 3000L Batch for clinical use. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Activities </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.2.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Run the first cGMP Development batch at 3000L scale. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.2.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform limited analytical testing according to Appendix 7 of the Quality Agreement. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.2.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform full analytical testing for API Release of the first batch (to be jointly agreed and conditional on all limited testing performed in stage 12.2.2 being completed
successfully). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.2.4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform QA batch disposition for API Release of first batch if all Release testing was performed. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.2.5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Run the second cGMP Development batch at 3000L scale. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.2.6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform limited analytical testing according to Appendix 7 of the Quality Agreement. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.2.7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform full analytical testing for API Release of the second batch (to be jointly agreed and conditional on all limited testing performed in stage 12.2.6 being completed
successfully). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.2.8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform QA batch disposition for API Release of second batch. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.2.9.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate manufacturing batch summary reports </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.2.10.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Review the Process assumptions and cycle times as part of pre-validation review. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Deliverables </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Released cGMP API from at least 1 cGMP Development Batch to be supplied for clinical use. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.3.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Any material not Released for clinical use will be made available to Nuvelo for research purposes. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">12.3.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Manufacturing batch summary reports. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Page 8 of 11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Schedule 1&nbsp;&nbsp;&nbsp;&nbsp;Work Programme </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stage 13. Validation Documentation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">13.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Objective </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">13.1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To generate and QA approval of validation documentation to support successful validation campaign. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">13.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Activities </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">13.2.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate and approve the validation documentation shown below. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Document</B></FONT></P><HR WIDTH="34" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Purpose</B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Accountable</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>Function</B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Approving</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Functions</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Final formal Release by QA)</B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Validation Master Plan</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Defines overview Validation strategy for Product</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">QA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">QA,QC, M, R&amp;D</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Validation Sub Plans</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Defines specific Validation plans for Project relating to Equipment Qualification</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Cleaning Validation</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Analytical Validation</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Process Validation</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Electronic systems</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman"
SIZE="2">Training</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Various</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">QA,QC, M, R&amp;D</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Process Validation Sub Plan</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Defines specific activities to be undertaken in Process Validation programme</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
FACE="Times New Roman" SIZE="2">And links these to relevant technical reports and the Development Report</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">R&amp;D</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">QA,QC, M, R&amp;D</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Process Validation Protocol</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Document listing:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Runs to be undertaken in the
manufacturing campaign, the expected specification of material produced (and the acceptances ranges for this). Critical process control parameters and acceptance ranges.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
FACE="Times New Roman" SIZE="2">The results derived from the Process Validation Campaign shall be recorded in this document</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">R&amp;D</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">QA,QC, M, R&amp;D</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Process Validation Sub Plan Report</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Report detailing and analysing the outcome and data derived from the Process Validation Campaign</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">R&amp;D</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">QA,QC, M, R&amp;D</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Validation Summary Report</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Summary document reviewing output from Validation Programme and formally closing it.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">QA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">QA,QC, M, R&amp;D</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Page 9 of 11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Schedule 1&nbsp;&nbsp;&nbsp;&nbsp;Work Programme </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">13.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Deliverables </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">13.3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA approved validation documentation as listed above. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stage 14. One (1) Engineering Batch at 3000L scale </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">14.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Objectives </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">14.1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To re-familiarise with the Process after the extended hold period. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">14.1.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To de-risk the validation batches. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">14.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Activities </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">14.2.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Order all raw materials and consumables. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">14.2.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Run one (1) engineering batch. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">14.2.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform limited analytical testing according to Appendix 4. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">14.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Deliverables </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">14.3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Manufacturing batch summary report. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stage 15. Up to Five (5) Validation Batches at 3000L scale </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">15.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Objective </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">15.1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To demonstrate consistent successful cGMP manufacture by performing up to five (5) consecutive batches with at least 3 consecutive batches conforming to approved validation
documentation. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">15.1.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform Release Testing during validation batches. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">15.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Activities </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">15.2.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Run up to five (5) consecutive cGMP manufacturing batches as per the approved validation documentation. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">15.2.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Justify both Process and Product quality conformance for three (3) consecutive batches as per the validation documentation. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">15.2.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Perform QA batch disposition for API Release of all acceptable Batches. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">15.3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Deliverables </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">15.3.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Released cGMP API, from 3 consecutive batches, to be supplied for clinical use. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">15.3.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Validation summary report. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Page 10 of 11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Schedule 1&nbsp;&nbsp;&nbsp;&nbsp;Work Programme </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Appendix 1 Process Assumptions </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Cycle Times </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Fermentation &amp; Harvest </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The fermentation Process (from inoculation of the
production vessel through to harvesting of the last of the culture) is estimated to be completed in no more than seven (7) days (168 hours). Occupation of any one (1) inoculum vessel is also required for no more than one (1) day (24 hours).
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Purification </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">The Process is estimated to require no more than six (6) days (144 hours) occupation of the purification area for the process of each complete fermentation batch (including dispensing into final bulk containers).
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The total cycle time for each Batch is estimated to be no more than fourteen
(14) days in the ABC 5000 facility. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Occupancy times include time required for
key in process control tests to be completed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Appendix 2 B2422 Work
Programme Timeline (see attachment) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Page 11 of 11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">

<IMG SRC="g17073img01.jpg" ALT="LOGO"> </P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">B2422 Work Programme Timeline Wed 29/06/05 ID Task Name Duration Start Finish Predecessors
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">1 LOI signed 0 wks Fri 21/01/05 Fri 21/01/05 2
Stage 1 Data Review 9 wks Mon 20/12/04 Mon 21/02/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">12 Stage 1A Shipments to Avecia 8.57 wks Fri 21/01/05 Tue 22/03/05 18 Stage 2 Process Transfer &amp; Fit 10 wks Mon 10/01/05 Mon 21/03/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">22 Regulatory Submission Reports 64.86 wks Mon 06/06/05 Sun 03/09/06 23 15L Familiarisation 2.29 wks Mon 11/07/05 Wed 27/07/05 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">30 15L Comparability 16.29 wks Mon 06/06/05 Wed 28/09/05
43 Centrifuge Trials 17.14 wks Mon 18/07/05 Tue 15/11/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">57 LPC#1 2.57 wks Fri 25/11/05 Tue 13/12/05 65 GMP Runs 24.57 wks Mon 10/10/05 Fri 31/03/06 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">78 LPC#2 2.57 wks Wed 10/05/06 Sun 28/05/06 86 Validation Campaign 19.57 wks Wed 19/04/06 Sun 03/09/06 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">100 Stage 3 Capital Specification and Procurement 28.4 wks
Mon 21/03/05 Wed 05/10/05 101 Stage 3A Specification 7 wks Mon 21/03/05 Mon 09/05/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">118 Stage 3B Quotes / Order 25.83 wks Fri 08/04/05 Wed 05/10/05 135 Stage 4 15L Fermentation 22.79 wks Tue 08/03/05 Mon 15/08/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">136 Agreed scope of work with Nuvelo 0 wks Tue 15/03/05 Tue 15/03/05 7FF+6.2 wks 137 Receive R&amp;D WCB
vials 0 wks Mon 14/03/05 Mon 14/03/05 16 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">138
Receive RM CofA&#146;s 0 wks Tue 08/03/05 Tue 08/03/05 9FS+3.5 wks 139 Order Av RM&#146;s 1 wk Tue 15/03/05 Tue 22/03/05 136SS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">140 Order Am RM&#146;s 0 wks Mon 25/04/05 Mon 25/04/05 141 15L Fermentations #1a/b (Avecia media) 5 days Tue 05/04/05 Sun 10/04/05
11,137FS+22 days </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">142 Supply 15L #1 feedstock
to DSP 0 wks Sun 10/04/05 Sun 10/04/05 141 143 15L #2a/b Fermentations (Avecia media) 5 days Tue 19/04/05 Sun 24/04/05 141FS+9 days </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">144 Supply 15L #2 feedstock to DSP 0 wks Sun 24/04/05 Sun 24/04/05 143 145 Interim Familiarisation Technical Data 7 wks Mon 25/04/05 Mon
13/06/05 144FS+1 day </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">146 15L #3a Comparability
Fermentation (Avecia media) 2 wks Mon 11/07/05 Mon 25/07/05 140FS+11 wks 147 Supply 15L #3 feedstock to DSP 0 wks Mon 25/07/05 Mon 25/07/05 146 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">148 15L #3b Comparability Fermentation (Amgen media) 2 wks Mon 25/07/05 Mon 08/08/05 146 149 Supply 15L #3 feedstock to DSP 0 wks Mon
08/08/05 Mon 08/08/05 148 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">150 Review Data with
Nuvelo 0 wks Mon 01/08/05 Mon 01/08/05 147FS+1 wk 151 Technical Report 2 wks Mon 01/08/05 Mon 15/08/05 150 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">152 Cleaning studies 3 wks Mon 16/05/05 Mon 06/06/05 143FS+3.2 wks 153 Stage 5 Purification runs 26.8 wks Tue 08/03/05 Mon 12/09/05
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">154 Agreed scope of work with Nuvelo 0 wks Tue
15/03/05 Tue 15/03/05 136 155 Order raw materials 2 wks Tue 08/03/05 Tue 22/03/05 154SS-1 wk </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">156 Receive DCCB material from Amgen 0 wks Tue 22/03/05 Tue 22/03/05 155 157 Conduct Amgen DCCB experiments 10 days Tue 29/03/05 Fri 08/04/05 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">158 15L #1a processing and analysis 3 wks Mon 11/04/05 Mon
02/05/05 142FS+1 day 159 15L #1b processing and analysis 3 wks Mon 18/04/05 Mon 09/05/05 158SS+1 wk </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">160 15L #2a processing and analysis (#2b held in reserve) 3 wks Mon 25/04/05 Mon 16/05/05 144FS+1 day 161 Interim Familiarisation Report 5
wks Mon 16/05/05 Mon 20/06/05 160 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">162 15L #3a
processing 1 wk Mon 25/07/05 Mon 01/08/05 147SS 163 15L #3b processing 1 wk Mon 08/08/05 Mon 15/08/05 149 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">164 15L #3b analysis (comparability testing)&#151;external time?? 2 wks Mon 15/08/05 Mon 29/08/05 163 165 Review Data with Nuvelo 1 wk Mon
29/08/05 Mon 05/09/05 164 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">166 Technical Report
2 wks Mon 29/08/05 Mon 12/09/05 164 167 Cleaning Report 2 wks Mon 06/06/05 Mon 20/06/05 152 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">168 Stage 6 Assay Transfer of Validated Methods 28.5 wks Fri 21/01/05 Mon 08/08/05 169 Agreed scope of work with Nuvelo 0 wks Fri 21/01/05 Fri 21/01/05 8FF </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">170 Avecia receives samples 0 wks Fri 04/03/05 Fri 04/03/05
171 Avecia receives Ref Std 0 wks Fri 25/03/05 Fri 25/03/05 170FF+3 wks </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="1" COLOR="#FFFFFF">172 A0848 Clot Lysis 8 wks Wed 25/05/05 Wed 20/07/05 186SS+10 wks </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">1st Quarter 2nd Quarter 3rd Quarter 4th Quarter 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter 1st Quarter Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov
Dec Jan Feb </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">21/01 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">15/03 14/03 08/03 15/03 22/03 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">25/04 05/04 10/04 10/04 19/04 24/04 24/04 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">25/04 13/06 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">11/07 25/07 25/07 25/07 08/08 08/08 01/08 01/08 15/08 16/05
06/06 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">15/03 08/03 22/03 22/03 29/03 08/04
11/04 02/05 18/04 09/05 25/04 16/05 16/05 20/06 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">25/07 01/08 08/08 15/08 15/08 29/08 29/08 05/09 29/08 12/09 06/06 20/06 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">21/01 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">04/03 25/03 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">25/05 20/07
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">1 of 3 Schedule 1 (Appendix 2) </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g17073img02.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">B2422 Work Programme
Timeline Wed 29/06/05 ID Task Name Duration Start Finish </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">173 A0221 Appearance 5 wks Wed 25/05/05 Wed 29/06/05 174 A0120 Protein Concentration 20.7 wks Wed 16/03/05 Mon 08/08/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">184 Stage 7 Assay Transfer to Avecia 33.99 wks Wed 16/03/05 Wed 09/11/05 185 A01382 AEX-Quant 20.7 wks Wed 16/03/05 Mon 08/08/05
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">195 A0874 RP HPLC in-process 20.7 wks Wed
16/03/05 Mon 08/08/05 205 A0831 AEX-Qual 20.7 wks Wed 16/03/05 Mon 08/08/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">215 A0830 RP HPLC 20.7 wks Wed 16/03/05 Mon 08/08/05 225 A0829 SEC-HPLC 20.7 wks Wed 16/03/05 Mon 08/08/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">235 A0815 SDS PAGE Coomassie 19.7 wks Wed 16/03/05 Mon 01/08/05 245 A0110 SDS PAGE Silver Stain (not going to QC) 17.7 wks Wed 16/03/05
Mon 18/07/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">252 A0862 Anti Pichia EIA 10 wks
Mon 20/06/05 Mon 29/08/05 262 A0847 Peptide map 10 wks Mon 04/07/05 Mon 12/09/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">272 A0404 Polysorbate 80 8.29 wks Mon 20/06/05 Wed 17/08/05 282 A0857 MES 9.29 wks Mon 08/08/05 Wed 12/10/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">292 A0837 Imidazole 9.29 wks Mon 08/08/05 Wed 12/10/05 302 A0410 Sucrose/Mannitol 13.29 wks Mon 08/08/05 Wed 09/11/05 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">312 A0225 Citrate 8.29 wks Mon 08/08/05 Wed 05/10/05 322
A0986 Tris 8.29 wks Mon 08/08/05 Wed 05/10/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">332 A0302 Sulphate 11.29 wks Mon 08/08/05 Wed 26/10/05 342 A0819 Genotypic Verification (direct to QC) 4 wks Mon 04/04/05 Mon 02/05/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">343 A0662 Microbial Contaminants (ditrect to QC) 4 wks Mon 04/04/05 Mon 02/05/05 344 A0719 Microbial Contaminants (Cell Bank) (ditrect to
QC) 4 wks Mon 04/04/05 Mon 02/05/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">345 A0359
Viable Cell Count (direct to QC?) 4 wks Mon 08/08/05 Mon 05/09/05 346 A0736 Bioburden (direct to QC) 4 wks Mon 04/04/05 Mon 02/05/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">347 Stage 8 Assay Validation 43.71 wks Wed 29/06/05 Mon 01/05/06 348 A01382 AEX-Quant 9 wks Mon 18/07/05 Mon 19/09/05 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">353 A0874 RP HPLC in-process 9 wks Mon 18/07/05 Mon 19/09/05
358 A0831 AEX-Qual 9 wks Mon 18/07/05 Mon 19/09/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">363 A0830 RP HPLC 7 wks Mon 18/07/05 Mon 05/09/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="1" COLOR="#FFFFFF">368 A0829 SEC-HPLC 9 wks Mon 18/07/05 Mon 19/09/05 373 A0815 SDS PAGE Coomassie 9 wks Mon 11/07/05 Mon 12/09/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">378 A0862 Anti Pichia EIA 9 wks Mon 08/08/05 Mon 10/10/05 383 A0847 Peptide map 9 wks Mon 15/08/05 Mon 17/10/05 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">388 A0404 Polysorbate 80 9 wks Wed 27/07/05 Wed 28/09/05 393
A0736 Bioburden 9 wks Mon 14/11/05 Mon 16/01/06 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">398 A0857 MES 9 wks Wed 14/09/05 Wed 16/11/05 403 A0837 Imidazole 9 wks Wed 14/09/05 Wed 16/11/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">408 A0410 Sucrose/Mannitol 9 wks Wed 19/10/05 Wed 21/12/05 413 A0225 Citrate 9 wks Wed 14/09/05 Wed 16/11/05 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">418 A0986 Tris 9 wks Wed 21/09/05 Wed 23/11/05 423 A0302
Sulphate 9 wks Wed 28/09/05 Wed 30/11/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">428
A0662 Microbial Contaminants 9 wks Mon 21/11/05 Mon 23/01/06 433 A0819 Genotypic Verification (Cell Bank) 9 wks Mon 02/01/06 Mon 06/03/06 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">438 A0719 Microbial Contaminants (Cell Bank) 9 wks Mon 02/01/06 Mon 06/03/06 443 A0442 DNA Sequence Analysis (Cell Bank) (Outsourced) 17
wks Mon 02/01/06 Mon 01/05/06 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">457 A0359 Viable
Cell Count (Cell Bank) 9 wks Mon 02/01/06 Mon 06/03/06 462 A0924 Intact MS (Outsourced) 18 wks Wed 29/06/05 Wed 02/11/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">476 A01339 DNA (Outsourced) 18 wks Wed 29/06/05 Wed 02/11/05 490 USP/EP Pyrogen (Outsourced) 12 wks Wed 29/06/05 Wed 21/09/05 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">496 A01102 Zinc (Outsourced) 9 wks Mon 10/10/05 Mon
12/12/05 501 EPA 200.7 Copper (Outsourced) 9 wks Mon 10/10/05 Mon 12/12/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">506 Stage 9 Laboratory Process Characterisation 57.71 wks Fri 04/03/05 Wed 12/04/06 507 LPC reports received from Amgen 0 wks Fri 04/03/05 Fri 04/03/05 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">1st Quarter 2nd Quarter 3rd Quarter 4th Quarter 1st Quarter
2nd Quarter 3rd Quarter 4th Quarter 1st Quarter Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">25/05 29/06 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">04/04 02/05 04/04 02/05 04/04 02/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">08/08 05/09 04/04 02/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">04/03 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">2 of 3 Schedule 1 (Appendix 2) </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g17073img03.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">B2422 Work Programme
Timeline Wed 29/06/05 ID Task Name Duration Start Finish Predecessors </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="1" COLOR="#FFFFFF">508 Avecia review of reports 3 days Fri 04/03/05 Mon 07/03/05 507 509 Avecia/Nuvelo/Amgen LPC meeting 4 days Mon 07/03/05 Fri 11/03/05 508 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">510 Agreed scope of work with Nuvelo 0 wks Mon 16/05/05 Mon 16/05/05 508FS+10 wks 511 Order materials 2 wks
Mon 02/05/05 Mon 16/05/05 510FF </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">512
Fermentation 4 wks Fri 16/09/05 Fri 14/10/05 511FS+3 wks,14416/004/10 513 Purification (pre-work &amp; IMAC) #1 7 wks Mon 16/05/05 Mon 04/07/05 511 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">514 Purification (SPHP) #1 2 wks Fri 14/10/05 Fri 28/10/05 536 515 Technical Report #1 4 wks Fri 28/10/05 Fri 25/11/05 514 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">516 Experimental set #2 (scope to be defined after GMP
batches) 8 wks Wed 15/02/06 Wed 12/04/06 517 Stage 10 ABC5000 Fermentation and Centrifuge trials 32.37 wks Tue 15/03/05 Fri 28/10/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">518 Agreed scope of work with Nuvelo 0 wks Tue 15/03/05 Tue 15/03/05 136 519 Raw Materials Delivery 6 wks Mon 23/05/05 Mon 04/07/05
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">520 Installation/Qualification of liquid N2
dewars 4 wks Fri 01/07/05 Fri 29/07/05 120FS+12 wks 521 Receive GMP WCB 0 wks Fri 29/07/05 Fri 29/07/05 520 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">522 Complete cell bank testing (excl. DNA sequence) 2 wks Fri 29/07/05 Fri 12/08/05 521 523 Facility handover to Nuvelo 0 wks Mon 04/07/05
Mon 04/07/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">524 Completion of draft
manufacturing batch records 0 wks Mon 22/08/05 Mon 22/08/05 526SS 525 Installation and Commissioning of new systems (estimated) 7 wks Mon 04/07/05 Mon 22/08/05 523 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">526 Inoculum + Seed 2.5 days Mon 22/08/05 Wed 24/08/05 525 527 Fermentation 1 5 days Wed 24/08/05 Mon
29/08/05 518,519,526 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">528 Large scale
centrifuge trial 1 2 days Mon 29/08/05 Wed 31/08/05 527 529 Inoculum + Seed 2.5 days Wed 31/08/05 Sat 03/09/05 528 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">530 Fermentation 2 5 days Sat 03/09/05 Thu 08/09/05 529 531 Large scale centrifuge trial 2 1 day Thu 08/09/05 Fri 09/09/05 530 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">532 Lab-scale purification (2 x 50L) 3 wks Fri 09/09/05
Fri 30/09/05 531 533 Plant Report 4 wks Fri 30/09/05 Fri 28/10/05 532 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="1" COLOR="#FFFFFF">534 Stage 11 GMP Preparation 9.43 wks Fri 09/09/05 Mon 14/11/05 535 Documentation 9.43 wks Fri 09/09/05 Mon 14/11/05 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">541 Equipment Qualification (upstream) 5 wks Mon 19/09/05 Mon 24/10/05 531,130 542 Equipment Qualification (downstream) 6 wks Mon 03/10/05
Mon 14/11/05 541SS+2 wks </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">543 Column
Qualification 2 wks Wed 05/10/05 Wed 19/10/05 128 544 Stage 12 GMP Production 17.29 wks Mon 14/11/05 Wed 15/03/06 545 Batch 1 17.14 wks Mon 14/11/05 Tue 14/03/06 546 Manufacture 2 wks Mon 14/11/05 Mon 28/11/05 535,541,539,543,5 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">547 Pack-off 1 day Mon 28/11/05 Tue 29/11/05 546 548 QC
limited testing 1 wk Tue 29/11/05 Tue 06/12/05 547 549 QC testing (estimated) 5 wks Tue 06/12/05 Tue 10/01/06 548 550 QA Disposition (estimated) 9 wks Tue 10/01/06 Tue 14/03/06 549 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">551 Batch 2 14.14 wks Tue 06/12/05 Wed 15/03/06 552 Manufacture 2 wks Tue 06/12/05 Tue 20/12/05 548 553
Pack-off 1 day Tue 20/12/05 Wed 21/12/05 552 554 QC limited testing 1 wk Wed 21/12/05 Wed 28/12/05 553 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">555 QC testing (estimated) 5 wks Wed 28/12/05 Wed 01/02/06 554 556 QA Disposition (estimated) 11 wks Wed 28/12/05 Wed 15/03/06 555SS
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">557 Manufacturing Summary Report 4 wks Wed
15/02/06 Wed 15/03/06 556FF 558 Fill Finish &amp; Stability Trials (Nuvelo) 112 wks Wed 25/01/06 Wed 19/03/08 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">562 Stage 13 Validation Documentation 8 wks Wed 15/03/06 Wed 10/05/06 557 563 Stage 14 Pre-Validation Batch 2 wks Wed 10/05/06 Wed
24/05/06 562 564 Stage 15 Process Validation Campaign 12 wks Wed 24/05/06 Wed 16/08/06 563 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">1st Quarter 2nd Quarter 3rd Quarter 4th Quarter 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter 1st Quarter Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov
Dec Jan Feb </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">04/03 07/03 07/03 11/03 16/05
02/05 16/05 16/09 14/10 16/05 04/07 14/10 28/10 28/10 25/11 15/02 12/04 15/03 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">23/05 04/07 01/07 29/07 29/07 29/07 12/08 04/07 22/08 04/07 22/08 22/08 24/08 24/08 29/08 29/08 31/08 31/08 03/09 03/09 08/09 08/09 09/09 09/09 30/09 30/09 28/10 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">19/09 24/10 03/10 14/11 05/10 19/10 14/11 28/11 28/11 29/11
29/11 06/12 06/12 10/01 10/01 14/03 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">06/12
20/12 20/12 21/12 21/12 28/12 28/12 01/02 28/12 15/03 15/02 15/03 15/03 10/05 10/05 24/05 24/05 16/08 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">3 of 3 Schedule 1 (Appendix 2) </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>QUALITY AGREEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Nuvelo, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>675 Almanor Avenue </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Sunnyvale, CA 94085 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>and </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Avecia Biotechnology </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Biologics
Business </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PO Box 2 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>Belasis Avenue </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Billingham </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>Cleveland </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>TS23 1YN </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Name&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Name&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>Klaus J Neurohr</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>Brian S Kersten</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>Head of Quality and Regulatory Affairs</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>Sr. Director RA/QA</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Date&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Date&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 1 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Index </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>Quality Agreement</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">4</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">1.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Purpose</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">4</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">1.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Duration of Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">4</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">1.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">API</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">4</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">1.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Regulatory Compliance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">4</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>Manufacturing cGMP Compliance</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">5</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Materials</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">5</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">2.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Documentation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">5</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">2.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Change Control</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">6</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">2.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Process Control</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">7</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">2.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Training</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">7</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">2.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Calibration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">8</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>Quality Control</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">8</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>Stability</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">8</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">5.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>Quality Assurance</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Documentation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">5.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Batch Disposition</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">5.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Internal Audits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">5.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Audits by Nuvelo</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">5.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Regulatory Actions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">6.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>Dispute&nbsp;Resolution</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">11</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">7.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>Qualification</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">11</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">7.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Equipment Computer Facility and Utility Qualification</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">12</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">7.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Laboratory Qualification</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">12</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">7.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cleaning Verification and Validation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">12</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 2 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">8.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Revisions</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">12</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Appendix&nbsp;1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Glossary of terms</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Appendix 2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Responsibilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Appendix 3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>List of Contacts</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Appendix 4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Batch Disposition Roles and Responsibilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Appendix 5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Responsibilities for Shipment of the Manufactured API</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Appendix 6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Draft Release Testing Specification and Criteria for Acceptance for Bulk Alfimeprase API</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Appendix 7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><B>Draft Limited Testing and Criteria for Acceptance to Demonstrate Acceptability of Process Performance for Bulk Alfimeprase API</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 3 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Quality Agreement</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Purpose</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.1.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">This agreement defines the roles and responsibilities for both Avecia and Nuvelo with respect to quality assurance and regulatory compliance matters. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.1.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">This Quality agreement also defines how Avecia Quality Unit and Nuvelo Quality Unit will interact with each other over Quality related issues. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.1.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">This Quality agreement shall be incorporated with and constitute a part of the Commercial Agreement between Avecia and Nuvelo. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Duration of Agreement</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.2.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The Quality agreement will be effective as of the Commencement Date of the Commercial Agreement and will expire with the termination of the Commercial Agreement.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.2.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA will review, and up-date the Quality Agreement accordingly, in agreement with Nuvelo QA on completion of the centrifuge trial runs, GMP runs and prior to the Validation
runs. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>API</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.3.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will manufacture all bulk Active Pharmaceutical Ingredient (API) in accordance with cGMP regulations. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Regulatory Compliance</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.4.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will manufacture the API in compliance with all applicable EU regulations including the Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2002 Annexe 18
GMP for API in the EU. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.4.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will manufacture the API in compliance with ICHQ7A, as incorporated in the Federal Register Vol 66 No186 (formerly ICHQ7A) and those sections applicable within the FDA
regulations 210, 211, 600, 601 and 610. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.4.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will maintain all licenses and approvals necessary to manufacture the API and comply with all FDA regulations applicable to a manufacturer. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.4.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will test and release the API using validated analytical methods in compliance with FDA regulations and the most current versions of ICH guidance, including ICHQ2A,
&#147;Text on Validation of Analytical Procedures and ICHQ2B, &#147; Validation of Analytical Procedures: Methodology&#148;. The analytical methods will be validated by Avecia prior to the execution of the validation lots. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.4.5</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will ensure that it is in compliance with all computer and software validation requirements in accordance to 21 CFR Part 11. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 4 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.4.6</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will identify to Nuvelo in writing all raw materials in the product of direct or indirect animal origin. Avecia will source these materials from countries which are not
listed in 9 CFR section 94.18 and further, the materials must have supporting Certificates of Compliance as required by the European Union Directive R 999/2001. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Manufacturing cGMP Compliance</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Materials</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.1.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will use raw materials, packaging and labelling components that are acceptable to Nuvelo and sampled, tested via methods approved by Avecia and stored in accordance with
Avecia documentation and procedures. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.1.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia is responsible for ensuring that all materials procured by Avecia for use in the API are in compliance with specifications for such raw materials. Avecia are also responsible
for ensuring the raw materials are acceptable to Nuvelo for use in the manufacture of the API. Nuvelo shall confirm to Avecia the acceptability of the raw materials in writing. Raw materials are given an expiration date upon the satisfactory
completion of all initial tests. Avecia will hold the relevant Certificates of Analysis for the materials. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.1.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will purchase raw materials from suppliers that are acceptable to Nuvelo and approved by Avecia. Nuvelo shall confirm to Avecia the acceptability of the suppliers in writing.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.1.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia and Nuvelo will jointly agree to a list of key suppliers who will be audited by Avecia to ensure that they are in compliance with the FDA and EU regulations.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Documentation</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.2.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will prepare the necessary documentation for each lot of API in its standard format as evidence that the API was manufactured in compliance with current GMP.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.2.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will retain batch documentation for at least one year after the expiry date of the batch, five years after the records of manufacture have been completed, or three years
after the distribution of the batch whichever is the larger. Before disposing of batch documentation, Avecia will give advanced written warning of 3 months to Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.2.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will store the API under conditions approved by Nuvelo. Avecia will hold records of storage conditions according to Avecia&#146;s Standard Operating Procedures.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.2.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia and Nuvelo will agree on storage conditions, containers and delivery configuration. Avecia is responsible for packaging and labelling the API for shipment, and delivery of
the API. Avecia will co-operate with Nuvelo for shipping arrangements. Avecia will deliver the API in validated shipping containers under validated shipping conditions. Until the shipping conditions have been validated, Avecia will deliver the API
with temperature monitoring devices ready and capable of proper monitoring during shipment. Down loaded data from the temperature monitoring devices shall be sent to Nuvelo within 3 business days of the return of the Temp Tale.(see Appendix 5)
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.2.5</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Delivery of API - Nuvelo will authorise Avecia to deliver upon submission of a Nuvelo delivery request form, to a location designated by Nuvelo. Delivery records, etc., will be
documented and maintained by Avecia. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 5 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.2.6</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will deliver samples upon the submission of a Nuvelo sample request form, and Avecia will co-operate with Nuvelo for transit arrangements. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Change Control</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">These change activities will be documented in accordance with cGMP and shall be considered by Avecia to be records of the quality system, available for
review and audit. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.3.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Equipment</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">Avecia shall provide Nuvelo written notice of any proposed changes to the processing equipment used to manufacture the API, including: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">a) Design changes to process equipment. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">b) Major repairs to process equipment, excluding routine preventative
maintenance/repair activities. Replacement of equipment with identical equipment will be considered a major repair for the purposes of this agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">c) Scale up of lot size for manufacture of the component that does not involve use of alternative equipment. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.3.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Components</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">Avecia shall purchase components used to manufacture and package Nuvelo APIs in accordance with Nuvelo&#146;s requirements. Avecia shall provide Nuvelo
written notice of any proposed changes, including changes to the sources of, and processes for the manufacture for the raw materials, including packaging changes, to the specified raw materials or components used in the manufacture of the API.
Avecia shall implement and maintain an appropriate quality agreement and purchasing controls with each raw material supplier, to ensure that Avecia is informed in advance of any such changes by its suppliers to raw material composition or
manufacturing processes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.3.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Processes</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">Avecia shall notify Nuvelo of planned process changes in writing, prior to implementation and subject to Nuvelo&#146;s Quality Assurance (QA) and Process
Sciences Manufacturing (PSM) groups&#146; approvals. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">Prior to
any change being implemented, Nuvelo shall be given the opportunity to purchase components and API made by the existing process as assurance of continuity of supply. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.3.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Other Activities</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">Other activities, listed below, shall be documented in accordance with cGMP and shall be considered by Avecia to be records of the quality system,
available for review and audit. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 6 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">a) Adjustments necessary to operate equipment efficiently and safely for the manufacture of the API.
These may be recorded on quality documents; however, such documentation is only a requirement where it is specified on the Standard Operating Procedures used in that part of the processing. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">b) Changes to lots of raw materials to make the API. These will be recorded
as required by the quality system. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Process Control</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.4.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Inspections</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">a) Raw materials, intermediates, components, containers, and container closures for the API manufactured will be inspected upon receipt per requirements
of Avecia quality system. Documentation of those inspections will be retained in the batch record and appropriate samples will be maintained by Avecia. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">b) Avecia and Nuvelo will work together to determine the required in-process inspections. In-process inspections may occur during the manufacture of the
API. These inspection activities will be documented in lab notebooks, Batch Sheets and /or Test Sheets, whichever is appropriate. A copy will be retained in the batch record. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">c) Cleanliness : The API will be manufactured in an environment that is clean and meets current Avecia facility, regulatory
and safety standards, specifically including cGMP. The facility will be monitored on a regular basis during manufacturing according to Avecia approved procedures. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">d) Identification and Traceability Criteria: All materials for making the API must be properly identified and traceable.
Identification shall include part number and lot number as a minimum. The quality status of each of these must also be identified. The quality status may be identified electronically, marked on the container or referenced to a lab notebook.<I></I>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">e) Acceptance Criteria: Acceptance of the API is based on
achievement of the acceptance criteria in the API Specification identified by Nuvelo requirements. A draft Specification is attached to this Quality Agreement as Appendix 6. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">f) The specification will be jointly approved by Avecia and Nuvelo QA prior to use in manufacturing cGMP API lots and the
approved specification will be held in a separate QC document. In the cGMP Development Batches and the Engineering Batch identified in the Work Programme, a limited set of release tests to demonstrate the suitability of the API for full release will
be performed prior to performance of all required release testing. A draft of the proposed limited testing for these batches is attached to this Quality Agreement in Appendix 7. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.5</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Training</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">Personnel manufacturing and/or testing the API must be trained appropriately on the equipment and methods used. This training must be documented in a
training record. The training records will be maintained by Avecia for inspection. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 7 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.6</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Calibration</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">All equipment used to manufacture, test or store raw or intermediate materials or final APIs will be calibrated to meet the requirements of NIST
standards. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Quality Control</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">All analytical methods will be validated prior to the execution of the validation lots in accordance with FDA regulation and ICH guidelines. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The testing activities for the API that are to be performed by Avecia QC will be in accordance with the specifications agreed upon by Avecia and Nuvelo. Avecia will not sub contract
any testing without prior written approval from Nuvelo. All sub contractor analytical laboratories will be audited by Avecia. Avecia warrants that all sub contractors used will be FDA and EU GMP compliant. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will notify Nuvelo of any critical or major investigations and Out of Specification (OOS), Out of Trend (OOT) results related to the In process testing and final testing of
the API within 72 hours or next working day (Monday-Friday). Nuvelo approval of such documentation is required and will be shown by sign-off on the back-page of the copy of the original investigation/OOS/OOT form faxed by Avecia QA to Nuvelo QA.
Notification will be provided for minor investigations, OOS and OOT results on a weekly basis and no approval by Nuvelo QA is required. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QC will retain sufficient samples of raw materials and the API from each batch to allow at least twice the quantity necessary to determine whether it meets the API
Specifications, a draft of which is attached hereto as Appendix 6, excluding bioburden and endotoxin testing. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.5</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QC will retain samples for at least 1 year after the expiration date of the last lot of drug API containing the API. Avecia will inform Nuvelo of this date and give advanced
written warning of expiration of 3 months to Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.6</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QC will produce a Certificate of Analysis for each batch of API confirming that the API has been tested via approved methods in accordance with the Specification in the
jointly approved QC document. Avecia will perform release testing for the API within 30 calendar days after the last day of manufacture. Avecia will ship the API to Nuvelo/Nuvelo designated site within 90 calendar days of API release.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.7</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA will target a bioburden level of </FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#163;</FONT><FONT FACE="Times New Roman" SIZE="2">10 CFU/100mL.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Stability</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Nuvelo is responsible, where appropriate, for determining that a routine stability monitoring program is implemented. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will provide Nuvelo or its designee with stability samples within two weeks of the last day of manufacture of each Batch and of each validation lot. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 8 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Quality Assurance</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Documentation</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.1.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA is responsible for ensuring creation of the Nuvelo API specific manufacturing master documentation. Avecia QA and Nuvelo QA will approve the batch documentation before
commencement of manufacturing. Nuvelo QA are responsible for ensuring that the batch manufacturing records issued by Avecia QA for approval are done so within 2 business days of receipt of the final draft. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.1.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA will approve Standard Operating Procedures required for the manufacture of the API. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.1.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA will inform Nuvelo of any major and critical Non Conformance Reports generated during the manufacture of each batch of API within 2 business days. Nuvelo sign-off is
required on each critical or major non-conformance reports before closure of investigation. Notification will be provided for all minor non-conformances on a weekly basis. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.1.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA will inform Nuvelo of any changes to the master batch records, bills of material specification and equipment. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.1.5</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA will notify on a weekly basis via e-mail or e-room all Change Controls raised. All major and critical change controls raised will require Nuvelo sign off prior to
implementation. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Batch Disposition</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">For each batch of API, Avecia QA will provide to Nuvelo copies of the release, executed batch record, Certificate of Analysis, Certificate of Conformance, any deviation/change
control reports. Nuvelo will review and approve, as appropriate, the batch record and then accordingly forward a signed-off copy of the API disposition form to Avecia as confirmation of Nuvelo&#146;s acceptance of the batch.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA is responsible for ensuring that the API has been manufactured according to the Specifications attached hereto as Appendix 6, Standard Operating Procedures, Master Batch
Records and cGMP. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Reprocess/Rework: Avecia QA will not internally authorise any rework without written prior approval from Nuvelo. Reprocessing may be performed at Avecia with internal approval. The
details of the reprocessing will be included in the batch record. Approval from Regulatory Affairs (RA), QA and PSM management will be required for any rework activities. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Nuvelo QA must respond within 2 business days to any Avecia QA issues reported during batch disposition. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.5</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The release of the API ready for shipping is the responsibility of Avecia QA. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.6</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA will be responsible for ensuring that appropriate Batch Records are copied and dispatched to Nuvelo QA within 10 business days after final disposition.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 9 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.7</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Responsibilities for shipment of the API are detailed in Appendix 5. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.2.8</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Batch Disposition roles and responsibilities are detailed in (Appendix 4). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Internal Audits</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.3.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA will carry out routine internal audits for GMP compliance according to approved schedules developed as part of the Avecia Quality System. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Audits by Nuvelo</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.4.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Nuvelo reserves the right to conduct twice-a-year, comprehensive quality audits of Avecia&#146;s facilities, which may include a site tour, questioning of employees in work areas
and review of quality system documentation to the appropriate quality standards. Avecia will be notified in advance of the intention to conduct an audit and the audit&#146;s scope, and a mutually convenient date will be selected. During the audit,
any non-conformances will be noted and documented in a report issued by Nuvelo within thirty (30) business days. Avecia will be requested to submit an acceptable written response and corrective action plan within thirty (30) business days of receipt
of the report. Avecia will close all corrective actions that can be closed within 90 business days to the satisfaction of Nuvelo. Corrective actions that cannot practically be closed out within 90 business days will have a timeline for closure
agreed with Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.4.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Supplier performance issues or non-conformances in the API will be indicated to Avecia in the form of a Nuvelo Supplier Corrective Action Report (SCAR)/Memo. Avecia will be
requested to respond to the SCAR/Memo usually within thirty (30) business days post receipt. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.5</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Regulatory Actions</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.5.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA will provide Nuvelo information and support for any Nuvelo regulatory submission (e.g., CMC) upon request. Nuvelo RA will supply Avecia with copies of the submitted
information that relates to manufacture by Avecia. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.5.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Nuvelo will inform Avecia QA of any pertinent changes in the CMC section of its regulatory document. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.5.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA will inform Nuvelo in writing of any change of any kind to the Process that may impact Nuvelo regulatory submissions. Avecia shall not make any change to the Process
without Nuvelo&#146;s written prior approval of the change. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.5.4</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia QA will provide Nuvelo with advanced written notice of any FDA/MHRA regulatory inspections where possible. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.5.5</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will also allow Nuvelo representatives to be present at site during any FDA/regulatory audits relating to Nuvelo&#146;s API. All responses to any FDA/MHRA findings must be
reviewed and approved by Nuvelo prior to submission. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.5.6</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">During other regulatory audits (for non-Nuvelo APIs), if any findings are identified, Avecia will inform Nuvelo where their API is potentially affected. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 10 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.5.7</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia will confirm Nuvelo interpretations of Avecia data in the CMC section before Nuvelo&#146;s submission to Regulatory Agencies. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Dispute Resolution</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">If a dispute arises amongst the Quality Team relating to whether or not a Batch of the API is a Defective Batch, or whether or not a Defective Batch
results from or arises out of an Avecia Default (each of the preceding a &#147;Batch Dispute&#148;), such Batch Dispute shall be resolved as follows. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(1) The Quality Team shall immediately notify the Project Steering Committee (PSC) in writing (the &#147;Batch Dispute Notice&#148;) that a Batch Dispute
exists amongst the Quality Team. The Quality Team will discuss the Batch Dispute in good faith to attempt to reach agreement on: (i) whether a Batch is a Defective Batch and, if so, what course of action shall be taken to address it; and (ii)
whether or not a Defective Batch resulted from or arose out of an Avecia Default. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
FACE="Times New Roman" SIZE="2">(2) In the event that the Quality Team fails to reach agreement on a Batch Dispute within 15 days after sending the Batch Dispute Notice to the PSC, the Quality Team shall immediately refer the Batch Dispute to the
PSC for discussion, by written notice to the PSC. Once the Batch Dispute has been referred to the PSC, the PSC has 5 business days from receipt of the referral notice to either resolve the Batch Dispute or refer the Batch Dispute to an independent
expert or laboratory, with the expertise necessary to reasonably resolve the Batch Dispute. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
FACE="Times New Roman" SIZE="2">(3) If the PSC cannot resolve the Batch Dispute or agree upon an independent expert or laboratory to resolve the Batch Dispute before the expiration of 5 business days after receiving the referral notice, the PSC
shall immediately notify the EC of its failure in writing. Within no later than 2 business days after receiving notice of the failure from the PSC, each EC member shall nominate an independent expert who shall not: be a current or former employee,
consultant or agent of a Party; have an immediate family member who is an employee, consultant or agent of a Party; or have any financial interest in a Party. Promptly thereafter, those two independent experts shall agree on a third independent
expert who shall use any reasonable information, materials and data provided to him or her by the other two experts within 10 business days after his or her agreement to act as the third independent expert, to either promptly resolve the Batch
Dispute or determine which independent Third Party laboratory will conduct the work necessary to promptly resolve the Batch Dispute. Such referral shall be solely for the purpose of establishing whether or not the applicable Batch is a Defective
Batch and whether or not any Defective Batch results from or arises out of an Avecia Default. The decision of the independent expert, or independent laboratory, shall be made in writing and shall be binding upon the Parties. Whichever Party failed
to accurately assess whether the Batch was or was not a Defective Batch, or whether or not a Defective Batch resulted from or arose out of an Avecia Default, shall bear the full cost and expense associated with the hiring and performance of the
independent experts and/or laboratory. . </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Qualification</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">Avecia will generate the Validation Master Plan which contains the Validation Strategy. Avecia QA, Nuvelo QA and Nuvelo Process Sciences and Manufacturing
will jointly approve the Validation Master Plan which contains appropriate validation sub plans for the project which will be approved by Avecia QA. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 11 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Equipment, Computer Facility and Utility Qualification</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.1.1&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia is responsible for ensuring that equipment, computer, facility, utility and support systems for the manufacture of Nuvelo API are qualified according to regulatory
requirements including 21 CFR Part 11. Avecia will perform required Installation Qualification (IQ)/Operational Qualification (OQ)/Performance Qualification (PQ)/calibration activities. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.2</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Laboratory Qualification</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.2.1&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia is responsible for ensuring that all QC laboratories are in compliance with FDA cGMP regulations and are appropriately qualified in all of the methodology associated with
Nuvelo&#146;s APIs. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.2.2&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Validation methodology will be developed in compliance with ICH Q2A Text on Validation of Analytical Procedures and ICH Q2B Validation of Analytical Procedures; Methodology. The
degree of validation of methods will be agreed with Nuvelo according to the status of the API. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.3</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Cleaning Validation and Verification</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.3.1&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia is responsible for ensuring that a cleaning verification is conducted, and documented in accordance with cGMP and that a cleaning verification of API contact parts used in
the manufacture of Nuvelo API is carried out between batches of different APIs to prevent cross-contamination. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.3.2&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Nuvelo will provide information (solubility, toxicity, dose, etc.) to establish cleaning limits. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>8.0</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>REVISIONS </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Mod.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>No.</B></FONT></P><HR WIDTH="18" SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>DATE</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>REVISION DETAILS</B></FONT></P><HR WIDTH="77" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>BY</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">0</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">30&nbsp;Jun&nbsp;05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">New Agreement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">DH</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 12 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Appendix 1 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><U>Glossary of Terms </U></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><U>API: Active Pharmaceutical Ingredient</U>. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">cGMP: Current Good Manufacturing Practice. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">ICH: International Conference on Harmonization. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Certificate of Analysis: A compilation of the analytical test methods applied, specifications for each test and test results for a particular intermediate/finished API
lot. The certificate should be reviewed and approved by QA management. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Certificate of Conformance: Certification confirming that an intermediate or finished API has been manufactured in compliance to the cGMP&#146;s and that quality records associated have been reviewed and approved by QA management.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Commercial Agreement: the Agreement effective 21 January 2005 for the
manufacture of the API by and between Avecia and Nuvelo. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Approved Suppliers:
Suppliers approved within Avecia&#146;s quality system and qualified using FDA/EU guidelines, and approved by Nuvelo. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Key Suppliers: Suppliers that supply key ingredients for the manufacture of the API. Change to these Suppliers would impact the API quality. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">OOS: Out of Specification. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">OOT: Out of Trend. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">NIST: National Institute of Standards. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In-Process Control: Checks performed during production to monitor and if appropriate, to adjust the process and/or to ensure that the API conforms to the specifications
attached to the QA Agreement as Appendix 6. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Critical Non-conformance: A
non-conformance which would impact API quality. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Major Non-conformance: A
non-conformance which has a potential to impact API quality and requires an investigation to assess the impact on API quality. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Minor Non-conformance: A non-conformance which has no impact on API quality </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Reprocess: Reprocess is defined as repeat processing of a manufacturing step that does not affect the disposition of the API. For example: a 0.22 micron filtration when
the filter integrity failed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Rework: Upon prior written approval of Nuvelo,
rework may occur on identification of a non-conformance associated with the finished API (this applies to intermediate stages of API also) that may affect the API quality. Rework is only performed upon the prior written approval of Nuvelo as a
result of an investigation through the non-conformance reporting process or as a result of a change that occurred in the drug master file (ex: expiration date). For example: Relabeling of vials due to incorrect sample lot #. This would lead to an
non-conformance and then the change would be approved by Nuvelo before commencement of the rework . </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 13 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Appendix 2 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><U>Responsibilities </U></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Responsibility</B></FONT></P><HR WIDTH="50" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Avecia</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Nuvelo</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Formula</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">API Method</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Scale-up Procedure</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Qualification Procedures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Stability Programme</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Raw Material Selection</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Documentation for TSE risk</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Specific API Information (safety, transport etc)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">API ready for shipping</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">API Storage</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">API Specification</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Method of Analysis</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Method of Analysis verification</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Analysis + Release</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Storage of API QC Samples</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Manufacture of API</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Batch Number Assignment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Expiry Date Assignment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Manufacturing Documentation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">In Process Controls</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Audit of API Manufacturer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Deviation Management</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Change Management</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Retention of Records</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Shipping Study</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 14 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Appendix 3 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><U>List of Contacts </U></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Area of Responsibility</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">AVECIA</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Main
Phone:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">+44 (0) 1642 363511</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">NUVELO</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Main
Phone: 408-215-4000</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">QA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Ian Snowball</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2">+44 (0) 1642 364476</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">ian.snowball@avecia.com</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Wendy van der Linden</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2">Ph: 408-215-4348</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">wvanderlinden@nuvelo.com</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">PSM</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Kirk Hayenga</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2">Ph: 408-215-4344</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">khayenga@nuvelo.com</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">Mike Berry</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Ph: 408-215-4581</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">mberry@nuvelo.com</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">RA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Dave Theakston</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2">+44 (0) 1642 364034</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">dave.theakston@avecia.com</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Brian S. Kersten</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2">Ph: 408-215-4401</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">bkersten@nuvelo.com</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">QC</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Helen Bickley</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2">+44 (0) 1642 364483</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">helen.bickley@avecia.com</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Katie Reid</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2">Ph: 408-215-4544</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">kreid@nuvelo.com</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 15 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Appendix 4 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><U>Batch Disposition Roles and Responsibilities. </U></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Responsibilities for API Batch Disposition</B></FONT></P><HR WIDTH="147" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Avecia<BR>QC</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Avecia<BR>QA</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Nuvelo</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Final Review of all batch related manufacturing documentation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Review of QC batch related analyses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Final Review of QC batch related analyses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Generation of Certificate of Analysis (C of A)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Final Review of C of A</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Final review of batch record and acceptance of the batch</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Generation of Water and Environmental (WESRs)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Summary Reports for Manufacturing Period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Final Review of WESRs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">BSE free statement for the batch</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Review of completed Non Conformance Reports</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Review of completed Change Control Reports</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Review and Client Approval of Major/Critical NCRs, investigations, OOS and OOT results</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Review and Client Approval of Major/Critical Change Control Reports</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Final Approval of all Non Conformance Reports</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Final Approval of all Change Control Reports</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Final approval of Lab investigations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Notification of Minor, Changes, NCRs, investigations, OOS and OOT results to Nuvelo</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Compliance check against Avecia batch disposition procedure</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Batch Disposition</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Dispatch Instruction</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Copies of all batch documentation to Customer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#214;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 16 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Appendix 5 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><U>Responsibilities for Delivery/Shipment of the Manufactured API </U></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Responsibilities</B></FONT></P><HR WIDTH="55" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Avecia</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Avecia<BR>QA</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Nuvelo</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Provide Avecia with completed dispatch request form for shipment. Including, Batch number, quantity, reason for delivery, delivery contact and address.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Approve dispatch request form.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Agree dispatch time and date.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Generate shipping documentation&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Send documentation to courier for checks (if applicable).</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Provide all documentation to Avecia QA prior to shipment.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Arrange transport, packaging conditions/configuration and temperature monitoring devices and downloaded data.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Arrange insurance cover for shipment (if required)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Check dispatch batch records &amp; shipping documentation.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Execute dispatch batch record</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Inform recipient of shipment.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Return of confirmation receipts from recipient to Avecia QA.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Complete Final Product Log (SP3703)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Arrange customer invoice if using Avecia&#146;s courier account.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#252;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#134;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Documentation includes: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Cover letter (3 copies) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">MSDS (3 copies) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">c.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">CofA (3 copies) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">d.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A signed statement of identity which details the quantity, container sizes, an accurate description of the material and the usage of the material. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">e.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Customs invoice for shipments in EU. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">f.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">For deliveries to the United States. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">i.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A signed US Customs declaration, indicating that the material is produced by recombinant microbial fermentation (including the strain) and stating the material does not contain any
animal or cell culture derived products or additives such as albumin or serum. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">ii.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">For material that does contain any animal or cell culture derived products or additives such as albumin or serum, a USDA permit is required for US customs clearance. Obtaining a
USDA permit is the responsibility of the customer. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">iii.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A signed US Customs invoice stating the declared value of the shipment. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">g.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Avecia finance department will confirm the type of commercial agreement, as either technical consultancy or sale of product. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">i.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">For &#145;technical consultancy&#146; contracts, the declared value for all delivered material will be zero (0). </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">ii.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">For &#145;sale of product&#146; contracts the declared value for delivered material will be the cost of replacement. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 17 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><U>Appendix 6 </U></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Draft Release Testing Specification and </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2">Criteria for Acceptance for Bulk Alfimeprase API </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Parameter</B></FONT></P><HR WIDTH="33" SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Method Type</B></FONT></P><HR WIDTH="46" SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Acceptance Criterion</B></FONT></P><HR WIDTH="70" SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Appearance</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Appearance</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Clear, colorless liquid<BR>practically free of particulates</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle" ROWSPAN="5" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Purity</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Bioburden</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Report result</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">SDS-PAGE, Coomassie Stain</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Report % main band; main band same position as standard</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">SE-HPLC</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Main Peak </FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#179;</FONT><FONT FACE="Times New Roman" SIZE="2"> 95%</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">RP-HPLC</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Main Peak </FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#179;</FONT><FONT FACE="Times New Roman" SIZE="2"> 88%</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">AE-HPLC</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Main Peak </FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#179;</FONT><FONT FACE="Times New Roman" SIZE="2"> 93%</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle" ROWSPAN="3" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Impurities</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Pyrogenicity</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Absence of pyrogens (dose level of 10 mL/kg)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Nucleic Acid Content</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#163;</FONT><FONT FACE="Times New Roman" SIZE="2"> 10 pg/1 mg alfimeprase</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Yeast Contaminant Immunoassay</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#163;</FONT><FONT FACE="Times New Roman" SIZE="2">0.01% (w/w)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Potency</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Clot Lysis Activity</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#179;</FONT><FONT FACE="Times New Roman" SIZE="2"> 70% of standard activity</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle" ROWSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Identity</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Molecular Weight</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">22570 - 22583 Da</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Peptide map</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Conforms to standard</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Quantity</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Protein Concentration</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">9.0 to 11.0 mg/mL</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle" ROWSPAN="4" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Excipients / Chemical Composition</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">PH</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">7.9 &plusmn; 0.4</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Osmolality</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">315 to 455 mOsm/kg</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Zn Content</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">0.43 to 0.65 mM</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Polysorbate 80</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">0.005 to 0.015% (w/v)</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 18 of 19</FONT></TD></TR>
</TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><U>Appendix 7 </U></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Draft Limited Testing and Criteria for Acceptance to Demonstrate Acceptability of Process Performance for Bulk Alfimeprase API </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Parameter</B></FONT></P><HR WIDTH="33" SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Method Type</B></FONT></P><HR WIDTH="46" SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Acceptance Criterion</B></FONT></P><HR WIDTH="70" SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle" ROWSPAN="3" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Purity</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Bioburden</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Report result</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">RP-HPLC</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Main Peak </FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#179;</FONT><FONT FACE="Times New Roman" SIZE="2"> 88%</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">AE-HPLC</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Main Peak </FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#179;</FONT><FONT FACE="Times New Roman" SIZE="2"> 93%</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Impurities</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Yeast Contaminant<BR>Immunoassay</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#163;</FONT><FONT FACE="Times New Roman" SIZE="2">0.01% (w/w)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Potency</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Clot Lysis Activity</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#179;</FONT><FONT FACE="Times New Roman" SIZE="2"> 70% of standard activity</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Quantity</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Protein Concentration</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">9.0 to 11.0 mg/mL</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Excipients / Chemical Composition</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Osmolality</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">315 to 455 mOsm/kg</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date&nbsp;&nbsp;&nbsp;&nbsp;30 Jun 05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Modification 0</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Page 19 of 19</FONT></TD></TR>
</TABLE>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>dex311.htm
<DESCRIPTION>CERTIFICATE OF CEO PURSUANT TO SECTION 302
<TEXT>
<HTML><HEAD>
<TITLE>Certificate of CEO pursuant to Section 302</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT 31.1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>CERTIFICATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">I, Ted W. Love, certify that: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">1. I have reviewed this quarterly report on Form 10-Q of Nuvelo, Inc.; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and
for, the periods presented in this report; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">4. The registrant&#146;s other
certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">a) Designed such
disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us
by others within those entities, particularly during the period in which this report is being prepared; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal
quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">a) All significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
internal control over financial reporting. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Date: August 8, 2005 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">/s/ Ted W. Love</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Ted W.
Love</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">President, Chief Executive Officer and Director</FONT></P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>dex312.htm
<DESCRIPTION>CERTIFICATE OF CFO PURSUANT TO SECTION 302
<TEXT>
<HTML><HEAD>
<TITLE>Certificate of CFO pursuant to Section 302</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT 31.2 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>CERTIFICATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">I, Lee Bendekgey, certify that: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">1. I have reviewed this quarterly report on Form 10-Q of Nuvelo, Inc.; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">b) Designed such internal control over financial reporting, or caused such internal control
over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted
accounting principles; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">c) Evaluated the effectiveness of the registrant&#146;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">d) Disclosed in this report any change in the registrant&#146;s internal control over
financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&#146;s internal control over financial reporting; and </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">5. The
registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors
(or persons performing the equivalent functions): </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">a) All significant
deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial
information; and </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">b) Any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Date: August 8, 2005 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">/s/ Lee Bendekgey</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Lee
Bendekgey</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Senior Vice President and Chief Financial Officer</FONT></P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>dex321.htm
<DESCRIPTION>CERTIFICATION OF CEO AND CFO PURSUANT TO SECTION 906
<TEXT>
<HTML><HEAD>
<TITLE>Certification of CEO and CFO pursuant to Section 906</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT 32.1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>NUVELO, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>CERTIFICATION PURSUANT TO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>18 U.S.C.
SEC. 1350 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>AS ADOPTED PURSUANT TO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Ted W.
Love, Chief Executive Officer of Nuvelo, Inc. (the &#147;Company&#148;), and Lee Bendekgey, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">(1) The Company&#146;s Quarterly Report on Form 10-Q for the period ended June 30, 2005, to
which this Certification is attached as Exhibit 32.1 (the &#147;Periodic Report&#148;) fully complies with the requirements of section 13(a) or 15(d) of the Exchange Act; and </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">(2) The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of
operations of the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>In Witness Whereof</B>, the undersigned have set
their hands hereto as of the 8th day of August, 2005. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ T<SMALL>ED</SMALL> W. L<SMALL>OVE</SMALL></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ L<SMALL>EE</SMALL> B<SMALL>ENDEKGEY</SMALL></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Ted W. Love</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Lee Bendekgey</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>President, Chief Executive Officer and Director</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Senior Vice President and Chief Financial Officer</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">&#147;This certification accompanies
the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Nuvelo, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange
Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.&#148; </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g17073img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g17073img01.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!S0*H`P$1``(1`0,1`?_$`.0```$$`P$!`0$`````
M```````$!@<(`04)`P(*"P$!``(#`0$!``````````````($`P4&!P$($```
M!0,"`P,##`L,!0@'!`L!`@,$!1$2!A,'`!0((3$542()06$R(R14E-15E=46
MD4)2,S0E%Y<86`IQ@='24Y,U5M8G:*B2TT37F&)R@D-%9997H6-SI*4F*/"Q
M9'0:P:*$-F8W.!E9M!$!``("`0,"!`,#"04'!0$```$"`P01(1(%,09!41,'
M(C(487&!\)&AL4(C,Q46T>$D-`C!4F)RTN(E@J*RPF,7_]H`#`,!``(1`Q$`
M/P#]_'`5W3ZO.DU9,BJ75!T[JI*D*HFHGO7MJ=-1,Y0,0Y#ER42G(<H@("`T
M$.`^_P!+CI1_6<Z>OST;;_VEX`_2XZ4?UG.GK\]&V_\`:7@#]+CI1_6<Z>OS
MT;;_`-I>`/TN.E']9SIZ_/1MO_:7@#]+CI1_6<Z>OST;;_VEX`_2XZ4?UG.G
MK\]&V_\`:7@#]+CI1_6<Z>OST;;_`-I>`/TN.E']9SIZ_/1MO_:7@#]+CI1_
M6<Z>OST;;_VEX`_2XZ4?UG.GK\]&V_\`:7@#]+CI1_6<Z>OST;;_`-I>`/TN
M.E']9SIZ_/1MO_:7@#]+CI1_6<Z>OST;;_VEX`_2XZ4?UG.GK\]&V_\`:7@#
M]+CI1_6<Z>OST;;_`-I>`/TN.E']9SIZ_/1MO_:7@#]+CI1_6<Z>OST;;_VE
MX`_2XZ4?UG.GK\]&V_\`:7@#]+CI1_6<Z>OST;;_`-I>`/TN.E']9SIZ_/1M
MO_:7@#]+CI1_6<Z>OST;;_VEX`_2XZ4?UG.GK\]&V_\`:7@#]+CI1_6<Z>OS
MT;;_`-I>`/TN.E']9SIZ_/1MO_:7@#]+CI1_6<Z>OST;;_VEX`_2XZ4?UG.G
MK\]&V_\`:7@#]+CI1_6<Z>OST;;_`-I>`/TN.E']9SIZ_/1MO_:7@#]+CI1_
M6<Z>OST;;_VEX`_2XZ4?UG.GK\]&V_\`:7@#]+CI1_6<Z>OST;;_`-I>`/TN
M.E']9SIZ_/1MO_:7@#]+CI1_6<Z>OST;;_VEX`_2XZ4?UG.GK\]&V_\`:7@#
M]+CI1_6<Z>OST;;_`-I>`/TN.E']9SIZ_/1MO_:7@#]+CI1_6<Z>OST;;_VE
MX`_2XZ4?UG.GK\]&V_\`:7@#]+CI1_6<Z>OST;;_`-I>`/TN.E']9SIZ_/1M
MO_:7@#]+CI1_6<Z>OST;;_VEX`_2XZ4?UG.GK\]&V_\`:7@#]+CI1_6<Z>OS
MT;;_`-I>`/TN.E']9SIZ_/1MO_:7@#]+CI1_6<Z>OST;;_VEX`_2XZ4?UG.G
MK\]&V_\`:7@#]+CI1_6<Z>OST;;_`-I>`/TN.E']9SIZ_/1MO_:7@#]+CI1_
M6<Z>OST;;_VEX`_2XZ4?UG.GK\]&V_\`:7@#]+CI1_6<Z>OST;;_`-I>`/TN
M.E']9SIZ_/1MO_:7@#]+CI1_6<Z>OST;;_VEX`_2XZ4?UG.GK\]&V_\`:7@#
M]+CI1_6<Z>OST;;_`-I>`/TN.E']9SIZ_/1MO_:7@#]+CI1_6<Z>OST;;_VE
MX`_2XZ4?UG.GK\]&V_\`:7@#]+CI1_6<Z>OST;;_`-I>`/TN.E']9SIZ_/1M
MO_:7@#]+CI1_6<Z>OST;;_VEX`_2XZ4?UG.GK\]&V_\`:7@#]+CI1_6<Z>OS
MT;;_`-I>`/TN.E']9SIZ_/1MO_:7@#]+CI1_6<Z>OST;;_VEX`_2XZ4?UG.G
MK\]&V_\`:7@#]+CI1_6<Z>OST;;_`-I>`/TN.E']9SIZ_/1MO_:7@#]+CI1_
M6<Z>OST;;_VEX`_2XZ4?UG.GK\]&V_\`:7@#]+CI1_6<Z>OST;;_`-I>`/TN
M.E']9SIZ_/1MO_:7@#]+CI1_6<Z>OST;;_VEX`_2XZ4?UG.GK\]&V_\`:7@#
M]+CI1_6<Z>OST;;_`-I>`/TN.E']9SIZ_/1MO_:7@#]+CI1_6<Z>OST;;_VE
MX`_2XZ4?UG.GK\]&V_\`:7@#]+CI1_6<Z>OST;;_`-I>`/TN.E']9SIZ_/1M
MO_:7@#]+CI1_6<Z>OST;;_VEX!=%]4O3'.2D7!PO49L1+S4Y)QT)"0\7N]M_
M(2DQ,R[U".B8B+CVF0JNY"3E)!RF@W;I$.JNLH4A"F,8`$)WX`X"O/2,4OZ*
M73)V!_\`V^;,>H'_`)<XWP%A:!Y`^P'`%`\@?8#@"@>0/L!P!0/('V`X`H'D
M#[`<`4#R!]@.`*!Y`^P'`%`\@?8#@"@>0/L!P!0/('V`X`H'D#[`<`4#R!]@
M.`*!Y`^P'`%`\@?8#@"@>0/L!P!0/('V`X`H'D#[`<`4#R!]@.`*!Y`^P'`%
M`\@?8#@"@>0/L!P!0/('V`X`H'D#[`<`4#R!]@.`*!Y`^P'`%`\@?8#@"@>0
M/L!P!0/('V`X`H'D#[`<`4#R!]@.`*!Y`^P'`%`\@?8#@"@>0/L!P!0/('V`
MX"F74%D/5S";@QQ-C<089'MZ;!%C22@ML1<R2.8N%\F1U4$LBRK&%5!C13AE
M"D!72,W6=&!-RH0J10CZ5S?K^*[D6X[88FP,F]D48MSC;3&LF@GL4O.8TRQ^
M46<36YN/3K)ZUCS/WLJV.S$4VI3(M`=.3I*(`X,GR[KN@=S,U"#VQV^R_:B/
M?NB84NC(1;+(YMF#J#<,C/D%\K:*-P=M\Q69"8Y$!;&Q%RZ."A'[5!0-@C,=
M=.38VY8*XAM;MIF([FPX,)L99#*\9+M<[PR8E))619D67DU)R$SA!M%JH($(
M9^S,5PBX:\PH,>#8D]\NM6*R;%L6<=-..N%\GE6S`DW'2KV2QJ,($>W>3"\O
M+LI5=O$,89HL*Y73P6P/W131S=(5"@\.&SB-S^O&79F>+=.6V\`87,E'IQ\Q
MFZ!W_M3TY8W(%N0R%PV3CEF)R"HS*<Z^JF>U6TQ:`XHS)>LK+X+<&)F]O<4V
MER&%<;?!@V38_-P69(96F[F@)GRIHF;6.QC6K.$(*K<BRNNF<P$N5,':#9EM
MQ>OB-:$2CNG[;6=4=/6T6V=GSUDS?QK<JRC56?F42/C1[XSPI"+Z38B";;4$
M#`<""`@X\.SKK2<9'@T!FFRF"1F-SII1MEV=,,Q8.G^'D:1,DFP>JX\V>.$)
M5S(RC9!R4J!@0(BL#4U%*KE"+X/<GTD$0S26ROI^VRR!Q(/C)J)0V6Q+4^.Q
M@0PS)WG*HY*N2??M'<MX<#?FF9'KB#.!%4"2*3A`'5,YEUTH3F#^!;;XN_CA
MA-H@SUA(M\=CFJF0RT0FZW/-`3K;<"4<(1../1<HJ%7::JJX-2-#'1(LX=!H
M&.8^D+!]-L)/;K"#1Z>..3160L&L`"_C[24;+SBH0*^X!@?)$:-W+''$#.6_
MB)%D';\S3VU,@66Z?Y;?F5C\N_+UC\5"RB$\T'&3PZ<:W9+0KB'9*+-"M64Q
M/+**Q[X#ZKI5S1=54Q4TTR)!<%@J!Y`^P'`%`\@?8#@"@>0/L!P!0/('V`X`
MH'D#[`<`4#R!]@.`*!Y`^P'`%`\@?8#@"@>0/L!P!0/('V`X`H'D#[`<`4#R
M!]@.`*!Y`^P'`%`\@?8#@"@>0/L!P!0/('V`X`H'D#[`<`4#R!]@.`*!Y`^P
M'`%`\@?8#@"@>0/L!P!0/('V`X`H'D#[`<`4#R!]@.`*!Y`^P'`%`\@?8#@"
M@>0/L!P!0/('V`X`H'D#[`<`4#R!]@.`*!Y`^P'`%`\@?8#@"@>0/L!P!0/(
M'V`X"%=_0#ZC078'_P#6KIL]0/UB]K.`FO@#@*#]*W3[B$CTP=.,@ME^^B*S
M[8?:%XJDQZBM\XYDDHYV^QY91-G'L=P&[%BU(8X@FBBF1)(@`4A0*```3R'3
MEA0UIFF_HT&@TZEM_1H/D'^\;L'MX"+,KP+:3;MYGT[N/O!NUA&W>%81AN1R
M^495U4;U8_`P1)";SEB^?2<Y);EM6[9-V+5HB`**4,<B92!<8`-M/">$\S[D
M\MK^!]O:FQO>;VLD8\.#!COES9;SZ5QXZ1:]IZ3/$1/2)F>D2ADR8\..<N6T
M5QUCF9F>(C]\R28)@FTNY\G%Y%MUO)NWG.V608*WR&!RC%.JG>N>QZ5<&GWT
M:HY8SD;N4X;K@3E3HG("HV+(G(8H'(<`EYWP/F_;'E\_@/<FILZ'G-7)V9M?
M8QWQ9L=N(GB^.\5M69B8M',=:S%HYB8E\Q9<>;'&7#:+8K1TF)YB?W3"7_T<
M<+_KGO\`?\2V_O\`O&XU+(/T<<+_`*Y[_?\`$MO[_O&X`_1QPO\`KGO]_P`2
MV_O^\;@#]''"_P"N>_W_`!+;^_[QN`/T<<+_`*Y[_?\`$MO[_O&X`_1QPO\`
MKGO]_P`2V_O^\;@#]''"_P"N>_W_`!+;^_[QN`/T<<+_`*Y[_?\`$MO[_O&X
M`_1QPO\`KGO]_P`2V_O^\;@#]''"_P"N>_W_`!+;^_[QN`/T<<+_`*Y[_?\`
M$MO[_O&X`_1QPO\`KGO]_P`2V_O^\;@#]''"_P"N>_W_`!+;^_[QN`/T<<+_
M`*Y[_?\`$MO[_O&X`_1QPO\`KGO]_P`2V_O^\;@#]''"_P"N>_W_`!+;^_[Q
MN`/T<<+_`*Y[_?\`$MO[_O&X`_1QPO\`KGO]_P`2V_O^\;@#]''"_P"N>_W_
M`!+;^_[QN`:6%[#8Q,14@N_SC?U59KEN<Q*1PZDM^DQY*(S*=C8],P)[B%`Y
MD&39-.X?.$"A41'MX!V!TY84-:9IOZ-!H-.I;?T:#0!H/]XW8-!X#/Z..%_U
MTW^_XEM_?]XW`'Z..%_USW^_XEM_?]XW`-+"]AL8F(J07?YQOZJLURW.8E(X
M=26_28\E$9E.QL>F8$]Q"@<R#)LFG</G"!0J(CV\`[?T<<+_`*Y[_?\`$MO[
M_O&X#`=.6%"`"&:;^B`@`@(=2V_H@(#V@("&XU!`0X#/Z..%_P!<]_O^);?W
M_>-P#-S[8C&8+%W<G&YQOZB\0?P"1%#=26_2H:;W(8IBY()%=PSD$%&SDY>Z
MH5J';0>`>7Z..%_USW^_XEM_?]XW`8'ISPD!`HYKOZ`FK:`]2^_H":G?0/RC
M5&G`9_1QPO\`KIO]_P`2V_O^\;@#]''"_P"N>_W_`!+;^_[QN`9OY",:#<`\
M&.<;^^$EPU.6%(>I+?KS9`\VHS*H*_Y0]0+VY!`"W6C2M*\`\OT<<+_KGO\`
M?\2V_O\`O&X`_1QPO^N>_P!_Q+;^_P"\;@#]''"_ZY[_`'_$MO[_`+QN`/T<
M<+_KGO\`?\2V_O\`O&X"`=T]OH/"I1Y'Q.X.YPOC-]L9)I$9=U3[^Q23R&<[
MC.([<=Q'.T=X<?=E>L\&(LJF?5731723,+=81!,X5$D)_<5YMJ3(D$<X@\]2
MEI(4L'A>L?>F?<.$TL,QMQC$?-/LBZH(F-:8M-9^YE&\O*-UDY..C46Y4F8K
MG.KP&%<ZW+DGCE.'VZRF%C"P\;+1\OD7I`-^)!"7<HO@)+0,>E#=0*5[F9:'
MM8.CG33::9EUDUBB1$P68V+8XUFF'!)[R9-E^TV5+OW!H_%HGK@WUR95S"MX
MR),XEW;V1W84%#3EU'*`HIU(W!(+E#">O`3(7!NGLYK$]^MPU#B43@FEUB;O
M*J"0I!4,8J:>ZICF*5,!,(@'84*]W`4ZS)].,9UBMMY.9?GV,H8A*O7BN1=9
M&]^(,I;)&N59>5*$C,FBM^DU&DL$?%,61P=Q!&J`2;9R"S@$G"28,^7FL^90
MF`3;(^X$Q/RC]^68P6'ZP-XD$'*'Y2)YJLUR&2F.J3Q;&_#=GF;20BSQ195:
M1G53H.B(($.0H:U]G>[2J4\[C-M,EC21#PAXR+GNO[?YQ*Y4P=1"Y2MH\\7U
M`\G&/8><0U'*R@K%70.1LFB183K)!<_;;'MMI["8F5W*W&S+;[,15D6\]BD5
MUL[W3S*!6+*R)HQDYG9'=0JKN37AB(K*E,"8E$PE`@%)P&SR[%MBXW&I23B-
M^=QE'3068$40ZN]WWQ4A7>(IF!0A-T5R%$[?4$+@[BB(>Q&@52,]S-+/UX@[
M[(W6`NMXX^+;9@MUC[],)AOMDMDS4LZ]/C;'J37:)IQL`B^*TD2JJ*.3E;CR
M('5L(##-F6Z,$OE<7]4]RLZE&\=&N8E9SUN;J8BU;949O+&RK'XEE'=3TM)3
M^`Q#\L<A$RCLC.7?BJ\%9L4&Z1E0>N&Y%N%);A8Q#3V+R,;B,R_BI"7GT^OO
MJ)77PF$7''G$K&/V9M['Z.4ST&W4D-11--FS<'`H%)IM5#N0NP&$=/0I)K_E
M[W#*BL3515/UB;OD(LE>9/52,?=4H*)"H02W%J6X!"M0'@&!N!C^U\6PC@V_
MW>SC)\C?GR)"*@G_`%D;TM(J<ED,'RM[!1$A-,=SG#F(9O9]JV*HX1]M2``,
M4!$*"%6L//NA(0>3DSF3E82:\'@_J\3%^L3J!D9Q"43D\.0RWP^'?=3+Z$R=
M^>!E9AS$(G=-FRDE%D;JF,DX(;@&U#9]N:Y:8XQ';O/G;I:;>1$[DLYU\;OP
MZ3&(7>3),>R&>@\;ZCLB2AY<D)X6\F(]JL[;I.E';5HL<$DE#!,VPSY]EDU.
M,-Z59O;3'XR)10;99%==._\`**Y!D"JF.$;DCX"2WIETH1C(*G?*$!1TY7*%
MC4#&.DJJJ%I5<%Z?$#"1??K<-!0IC$.FOUB;O(J$.0:'(=-3=8IR'(/88H@`
M@/?P$0YY!8/%R,RUPC=K-IY9HCM%($BIKJWWS00<Q4OFN1-,X4CI..WGA5T'
MPX:W!PB<5'2111(8&ZHF*!@J_(3^Y+K;=IDC9OG$3GI7DJJ3`H7K$WGFC+N2
MX[@RF)0^4RV0]4D<QA\)E\ID9Y*9FF2AI2-;,VA$61USG!0/IQG>Y$D]D/`-
MN\JC(=%C%RT1(Y)Z0'?9V:?(68%"3@&2<+U!"BA)RL0JFHV=J*:,>8BIUD7%
M$TCA9S8YABN8X4C)[Q97EVU66N'JZK7%HCK>WUR,ZD*E&1(*2CQ])[L*J(&&
M6YH@H$JFU*0"F.<]QQ"7RX-T^'-8GOUN&JI8*@)H]8>[ZJHD*F*ICE23W5,H
M8I4@$PB`4`H5[N`IGDTAD#*73=8),Y9N!C+;$&[L_C_69OCAP361DELG,[C8
M?(8O?D$D)!-NQ9M%BOHM!%(7J*R9EBI+@8&E)SN?QK3;:73'<*??RZK0<DPZ
M$ZO]WV#95LKF^;$R4LI(S/5.M-P$I![91T*[@FL<24-)S3IPT=B1,AUFH:YW
MG>[RC63>L=L\ACS1DB5!K"2WI`>H!U*Y(R>0;HX*QKF,W]%DQ#'I]M:X4,#@
M9!(Z:**:*ASJI!=G;W'MK9["8.5S_<_+<)RPZ3DL[C<+UM;U3\;".%9"0<L(
M\^0O=UKY1\$0*1E%!L`]!%,A4P*``KRW%MC8Z"&1A]^-QE5T)O%FRBB/5WN^
M]2(W?Y+%M7J:X$W163(5:-.OVFH(%`Q@$+:@%3XM_FILV91$L[R#ZDO-U'<<
MIEYNLO?UI+I;=$FUSG=N,?8=2CYE%G2B@%%N\(J].X,@`@UN<$.4(_9YINY#
MHY+'.<&W.SF88I0;EBZ<=;VZN(@E**12XYI$)Q$5U-33ASB<5E:C6/@Y)<47
M[Y%1P=RA[E(J\"1]OYW/97<J`@,IQ]_%X:_?-)"3RUKUZ]13KZM0ZB$6_=Q2
MT0KO9)%R69ARF<MUEJ-6BZHW@D"+8^N%S@PCIZ%))8=^]PBHKD!5!4_6)N\0
MBR1A,4JJ)C[JE!5(QBB`&+4HB`T'@(XW%@-N(N/MVVW=S+*<K>0&;&QR`E^L
M?>IK"3F3L\8?KXQ&24Q'[J`ZC6;F;*F511%0BA2U$!J`<!6;&#[D/\>RPN82
M<]$3>E"?5@,1ZPM_I/(D2IY%B;++2LH.3ZEGT)DLP.*R$J\B"F<H-E9*/!%0
MJB2Z1.`:L%GVZ+UEBS!7;S-?$'3QS%9+DLSU][R,6$415S,!$3LM#8YU&SQH
M]VA#%C'4K'-EW*1'BSQHU<J%;$75";-@GKO+Y"?;[UK3VUT+&QC1LSR&,ZZ-
M_IEQ/SCA>$(D#.'D-YY5M!-':@.CD*=PY7]L*V*<QD%E5@M`I@W3XB82+;][
MA(J%,8ADUNL7=U)0AR#0Y#IJ;K%.0Y![!`0`0'OX"&L_A\.82,LAM_NIFN2C
M%H;9OEHR5ZM=]D$%HN1R?,&>6':2\5O-#JM'YXQ!N!%53.T2"F0"MU%#$X"L
M<O/[F+;<QF2L&V;L,[!Q,+*X#$]8^\\BF=V6-V_-B,/ET[/]4;5I!X5)2DID
M))B;8&4D8\&+,B+-14QTG`>SK.]R)![)CC^W65QL.V1BI6&>9+Z0'?9PXR)H
M:<.V?0+0D+U!*-F4Q)0BJ3A)VHH9".,58%47!B$3.$A8RP>9=C^$3F6OLQQK
M)XW=+IXFU\$C>JG>?=J&;6]2&QS-B]R5MDVX4Y'.#/UEW@@P724013*4#:BA
M14$.NG`'`4OZ4Y_-W?2=TZL%-LY%-!;8#:I@1RCEN+',HS_)_!M&\@B!G9!(
M+IJ!5RD,`&)>!3=H#P#:Z4,"4VCQ_,&F&QLOG2:61O<'DW*SS%8)RG+8)D66
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ML1RAGE:[)NFU!JHN4J`7F(W3;E\V7&H8[#N<=D2FQC?O=S$<3*#YS)X<RWLP
M*.]IDFZCJ49HS3#(HV3CV"T^^7D$DC@NHQ664;M#HH%!$@6LZ>L;S?!W&?S3
M7*]SMYHJ>?8]$QD9F>YF.Y,TP@N.1SIPLVA)4TFJ@[3E6^0-]1<!4<+@V+KJ
M*'*4Y@LK]:,Z_P#+!_\`^*\7^.<`?6C.O_+!_P#^*\7^.<`?6C.O_+!__P"*
M\7^.<`?6C.O_`"P?_P#BO%_CG`'UHSK_`,L'_P#XKQ?XYP!]:,Z_\L'_`/XK
MQ?XYP!]:,Z_\L'__`(KQ?XYP!]:,Z_\`+!__`.*\7^.<`?6C.O\`RP?_`/BO
M%_CG`'UHSK_RP?\`_BO%_CG`'UHSK_RP?_\`BO%_CG`'UHSK_P`L'_\`XKQ?
MXYP!]:,Z_P#+!_\`^*\7^.<`?6C.O_+!_P#^*\7^.<`?6C.O_+!__P"*\7^.
M<`?6C.O_`"P?_P#BO%_CG`-G%)#/(2.?M3[=+/!<Y3FDL"K3+,?TRIS.73<F
MDB;F3M5`602=%*>A3%N`:&'@*H.^E[<<,NR?)\:R[<K!&N991-3>31.#SV)X
MF>?C9?<&:W$*UF)&+EC.G63-G<\O$^,B8RX8^";(B9#)E<"$?J],N[.*OO$)
M'?#?]:;RN8&,2DD,\CR/TTG[QZNQ9-%S9$X3CR1:[PB+)18PL"JJ$*X;.C"V
M!`+<X#N<SQN&C,&04-DKZ#0:M><G-U\+GYU9*4FGD=$-GTJM/NWLFZ2=E!D4
MRIU')A(35$3GJ8'KB4CGL+&/6ZFW"[DSO)\SEP,WRS'1*D29RV:E$FZFLJ@(
M.&Z3HI%+;R7@-IA#@$N>YM.M<5EFF0[?2L>PGVZF,$7;9-C"S@760I*1C=-N
M4)!$H*B+@1`1.0`IWAP'.*/Z>,@Q:/ARM-WMZ(O;]XSRI.2@,-SF,A\9G6;:
M)*E),F[W'\M=GB(Z-8Q:1VX%.>0<%05.=TNHNX5.'0^'W<4C$&N-GQ225>PB
M:4"NLZR""+KO8F(>NGE7BTBX0741:0K@ZQ]=4"')88XG,4#!IY7<I_N7#R>-
MXUB*XR"88S+JA(3T4Q(FS#)(YR@)@$%ERJNT6MZ8"G04E$SB(%43$P2O]:,Z
M_P#+!_\`^*\7^.<!4;?#&66?9^WDIB/S/"\]B,(BXF$E(#/L.B5L>92F9#*"
M[BG+IT4WUCG1@E&I5$3`JW:@<Z9BG\XH1;![6S6+[B%RB;W"WWDV6#3A<E;X
MG,[C1A&\:[QB6.YE#*N3S"0Y`R>0>8IQBZ1RF-*(*`HN=TH4IT@NHKOF1%L5
MTKA[]-(7:+(Y3S<(5P@Y5CSRIR.FHK@X;%91R2BKHYR@1J"1P5$AB&``B_</
M$U.I#'UF<EATLK@V3QV(*K)Q>7P4=*/0PS<`N3"Q<F5(IRD=**QH-UCIG%P5
M,X@4$SC>0(-R#I!W9EW;@([>?J-AH2_'U8B!'=9C*H8TYQUTG(L)"$<.YH@F
MD6LDU3,W,\3=H))*KE4164Y)9@'VXZ4=^UHV/8)]0/44W4CV$HT,]2W(:"XE
M5Y&.C&B#V9$^5&!T>'58F*V(CRY!:&(5?6=@X?.@V9^F#?-PVE6SS>_J#6!^
MAE8-%6^YJ$:LP<Y"I/+1@F5890B=TPQMW-$<HI!HKJ+M4R<P1D5-FF%T(27S
M^'A8:(<8)-SKF+B8R.=34AE&*)/9=TR9(-G,DZ(F_4("[Y=(RIJ#VB:M`[@"
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M!+S.-1\--Y=E2\_)2DR]*CE[A@V8>.9*Z<H,6[5-N@`-DP`Q6;>@>&Z^Q^]F
MYN)84YPR>S3:G.MNY+<Z3QA7'\NQE;%99]G\LNT66RX\=(LY]V1AB3Z19MPC
MW3!PS=OA<IKZB*8`$U8=BFZ6*8]@,!,-<QW#?XWE<YD,[F.49;CQII^C,0V8
MQB#%@V5F'P)M84F0MF[=([BHMFPG45.N8YU`J-B_1[U%;<>#DP+?O>;D69,7
MBI*-G<BQ]0C^#@(_#\)1,HX^LLDV7E(W;3$4&B"JC05W,F4[Q5P15TN?@+6[
MA8;NWF\+G,%`)3VVYLKSO'\C3R2&D<8DI]&%@L<QEB1%@K]9(LL!D'CV,H."
M+@9^ARY3)G(;4&T&0RPW=_;_``/.D\MF,[W6G<Z?XTPULFS##X/'H%X^RATW
M13QN.E\O=M(.-#QULW%NDJJZ<I,R?A#D2D4!5O'M/OENMD"\K#YCF6V<0YQA
M7$U8''%,865-%RBX+9"HM*%S-F1V_=<DV!BN+9,S$JKHI@<`JB*`/G='#,[W
M09YGC2^,Y1BV/YOMT]VZDYO'<NQ)MEC2*EI,XS:D0HNL[9Q<C(0*RS9%W58S
M-94%2IJ"F`&"&<$V@ZJ\(W0V^R&4W.S#<?;O&6<XSGL8R&:B81](H_5[)6&/
M`+*'R13'9U^XF<@;K/G3TA$VR$,TY)L18[@Z@)L]Z<]X<V=XE/X[E>;[19'C
M^WK7!G+S#I7')!PJ5M/2,NL+*1>9.T38,I)*0!-P=HS92"FBF4S@R1"D*$B[
M28?OI@6,;8P>XIY[=+)8',I?()[*Y/*X7FET'^&9)`\G&I3&0/GCTY%WY79R
MZK9L"JJP-T&C4J+9((^Q3ILW6Q;+XR>;9AG2&/LY;#)*2Q&$E4H*,R-SAD['
M2BV29&DQW2299%GFX3)F*&4/WR*[:3%)N9%JT*#HKL'5NCLKN5NH@],W=[@;
M4337-)7*,=R'`\OQ9PY(A-1&,0K]K-1SY\WC91)2-AG2)$%B+)H*NDW29BKM
MT^`VF&;:;UXC`3$;.SN=;I+RDYMQ)L6F6Y)CR4;BZ6(9:GD,X2#?/<@R+)')
M9I!---,LB[?+%%NF!G%!,;@(NR3I@WH?9=.95AFZ&Y>VQ)W*,JGY.'Q!QC46
MSR)O/SF4Y#'I9BJCG)GLQ+PJN3C%IO&JS`2P;=%)$J+QNT?-@GN>@=V)>.RW
M'HN(?1$A.;785A!<P<RT!,ODW,:YRT)V47A5LN1D#GE&TL9-!8\F*Y%#BJ*A
MU$Q`0:6R^U>]NUT[-3N6YWNKNZ5X$NVAX'(\GQ]E!0\=)OV+Y!`&)\IDT%WT
M<=LH"3H2ZB:2HMT@30"S@(\S#ICW)RR.9NX/*=SMK,P=XQMWB.1R^&Y-B"[=
M;&,,QE[#2.,Q@+R+-VDQFY9\$@=85"%45;)%4;F*)P$'\XVAW*E=MU-KY\,T
MD4Y'9K,]K97<1MF4>VS)!SE3UNLWEHAQ(95-313PK)($6[EU+.)`-),RBJR@
M&5,#7V:V"WRVJSPN536ZN[NXN,D^L<JK@,O-XU'PLCE^5OLCFIN>?%2RYRR3
M:+S^5OG*+!!NDU;`+8I2FY)O0-9NAL9O=N3C&WS_``V>S':O.MN#YL$":!R[
M'UL3F4<]G&Q<@'*U(B7B\C>'2Q9%=LP/'/8URP=N#K$7$UNF$VXWB&Z$!BN`
M8O,-<QSY]C4_DLQ/YQE&5XV;(90F0P.>122;5N$LNDF2''*FR#9+63*1JV[3
M"H%3A57$NDGJ-VX>P2F&[\[R.XIJ]Q1">AI[(<=LF(2#)@>).A.O]8I-HI+)
M[48*A%(*F:E64D3J2"C@%UE1$+.9_AN\.;PF9PL&C,;:JY3G^.Y8,_"2.-3$
MTG&0&,8JT;M&+@V10P0LJ7*<4;+BM1ZBJP*H@9,#+7)@WL=VZWEQ/$<L99',
MYUNI/97,8I(*N,KRK'(V"A58S+74P[3QN/6R*7+`QZS)VW9IM4Q4U",DCJ'.
ML8YC@EW<VDWRW1REW-Q699GMS"/\>:XH[QC'%<94UH,[P'\T5Q*!F;4CF3D%
MT"IMG7+)BT:.G:1BK"HBH@#XW8P;.-VHS<#%',!EV'8_GV`M<"?SF*9;B+7+
M4(I6>>.,A1CEW#ATTB'$UC;Y9F1V7F%&BBPG*F82@(A$N![4]5V&[KX=E&0;
MFY=N7@,-%SK>>QZ<F(F$?2+I2)FFL)2*B\E6QJ36>RDVFX?.W10%J2):$8MT
MA4=F6#69UTY[R9F]Q"?QO+\YV@R&!VPQS;N0<X7*8T^<NDX.=7F'/)RC[)6Q
M6$=)`XM5%HT9/%C)IE7660(5$`DK:C$M\<&Q[::%W!)-[F9/C;[()')\MD,L
MAN;>KRT$^CU4HI*:R"2DGJ:"[G6]L722*8YP01:-@1;(A'.`]-.ZN#95"32.
M99X?'XR2Q&0?X=#RJ,#"SKG$0:-EIR89,MTBQ\WENX#1N"V3O)!)TE(OT$%4
M$69!>)O`<VYFR.YVYPF=LY#<+::>C<JR*<@)W`\OQ=PH9GDDA@SIZUFHU\_;
M1TC1GB"B*1%"*<JNZ(Z24!1`"G!PX1MOO-A\!(QD_-9WNFYD,IVTFV:>6Y)C
MI8_%V.'95'Y'.,H)R\R">R%X63.W4T!DGCYU81!)9T?3%8X1%.]+V];C*YW)
M\-W4W*V[0GLIS;(I+'L2<8_$1.0DR?)<JRB.#+C-,_)*2<Y%_6DT2I(,W4>H
M:%:-4VP-7C5L]2"P>20>ZN0L<\@8Z%?X^]R7;;#<+0RI26QR<?(FCY+,"3C]
M:*-E4:[06DX>=.#=?G3J(NAU*J:8U!G;.;5[W[92N0367YWNKN^K)ML@914-
MDN40+*"B&DQ*Q\FS*FQ/E,JB9_$"W<)I.[15*@YY<@$13(4`C;,>EW<G+8Y1
MW"97NAM9EDW&X3!93(X=E.).6CC%L3P+ZH.,3CM60CWZ$?)R@^*'5UDRG7*4
MIT!]GP&\R.$R_'6>WL!F!Y:1D,??=.44?))N62E)'(5PZM-GEUW![YO))5-)
MF4Y$4SOY!Z\63*45EUE045,'0;@#@*;=)4_N.'2OTV%)MS%BB38?:1)N<^>M
MP.NT2P*!3:.CD+CI@1.[;%(J*=3"F)[1$1"HA(N`9U)S268_4K;.&;!#[@Y1
M!Y4B&1OH4ZN8M18O)J1$DGA;#Q%.3"025(Z2U"K5&H@8!#@&#N7M;+[_`"VX
M&"9'*9_L[(+8SM9+0F;;-;J.<8S_`!F4A,HS]_'3$%D+*"49U,J51!PR?M'K
M!VV.<BR*A3T+NO`>;R>`\E7R./!J[58K:ML.SCC+AR5M'$UM6>)CYQ:EJWK,
M1-;0QY<<9:=DS:O[8GB8/V4D=N-O=OTD1CHP-N<-)C^-M$8Z4F)@(Z0@\@6@
MVK<SYJS?2:[^*F6HD>.5UC*\P105U#*7B-#>R[>?;OL[W=^JRSWVF8B.>^.Z
M)B(B(B)B8FL1$1%>.(B.$JQ6*\5_+'0UF^>].2K!\V+);5-VDD5BE)-WV0NH
MYP=HB]75C$G:,A!MGK:);.X@Q6Y3@1JE85,@`4Q"FJ)/M9;8V.BYI\2"QF:B
MY?%D=R5N0<9%D+-UC*#P8]DYQL48!RR3!.3=""+)B8BR:ZXGTRB>X0VF/[W;
M)8VU-'1608/C":JBL@^B7$K)Q2T2X*9E&K(S;-WCR0X^NU4T6H(.-$$Q2%(A
M0!(P%#<FZC]LT,HR+#I'*,;A)W%Y)*(DT)R5?1+<\BJ@NXY9@\>0:39\HDFW
M,)P(81#L'M`0$0]@ZC=I@,Z(MN)MPT%HH=-;G<S29EM(N9L"Z9G$8F51LJL4
M034`1*H%!*(@)1$)B1>2"Z22Z+)DJBLF15)5.3.*:J2A0.FH01CP$2'(("`T
M#L'@/37E/DYK\Y&^(<`:\I\G-?G(WQ#@#7E/DYK\Y&^(<`:\I\G-?G(WQ#@#
M7E/DYK\Y&^(<`:\I\G-?G(WQ#@#7E/DYK\Y&^(<`:\I\G-?G(WQ#@#7E/DYK
M\Y&^(<`:\I\G-?G(WQ#@#7E/DYK\Y&^(<`:\I\G-?G(WQ#@#7E/DYK\Y&^(<
M`@CEY/EU*1[40Y^5_P"T3=XR;P1#\`]0>`7Z\I\G-?G(WQ#@(VR_-,0C<CQW
M'LN"`:S?)S&90999^_2;MV^+-#O).2!^2%58(FCV15'%JJ@"!4#*`%4RB`1-
M$Y9TT2$J+.%_(ZI(*2&./BN(J623*_D<AG%64`+>09P1$9)5]/Q8I@0JARBX
M2H8+BC0+)QJ\GRZE(]K3Q"5[Y(W?XH\K_L'EX"%G?4/M*XRF6PZ2R'&&T[B,
MDY"10GG<I&-HR1BWH1AS\^^QTC`%TU'`G*8BA@Y<#K5TB&,`:F8W)V6B8S&L
M@7:8Z^AI5ADT7C<E`-LEG(QV@X41C\@A$S0N*NFQG4DJW*GRJH:BPH^:'F@/
M`+#;A;1MGXJ!&P)UWS^'*J^2C\G7CQ<KP<H[@WJC\N(&CRM7T.DY!)R4XI+5
M,4QA-<!0,#S7:S)7;I#;IM!C-H1<?(NV;<\ZQ?LX9[DI6R1W;65@60,N>=,@
M.0A@*LHU*W.!10%`>`F'+,P0PC&9W+\E2;,(#&XQW,3#T'3QV+6/9)&6<K@V
M913EVOIIE$;4TSF'U`'@(=;;W;(Y>1N]-D&W;H\K)^$-BR\PX9/GKZ,E)O'D
M$B-G^/I.#ID<@Z%(]+!:N"+@.BNF<X#G/=I8UWE3&0B8EFZB7N:RF0H2,=EA
M2G<MU<;#+WC8[K$1;O>=4GXT]K<QA=@J11(IRE$P!H5=UMBQBD^;BXA&.36@
MVI2OX7,$3B"C-R[:KGU\.!PLR8,XUR#]8UR:)6ZQ7`TN`P2[MY.Q,]"1<QA4
M>U#&W[!VO'@+J0:G$XS4@1^=9O)Q:$BDX/($4$Y5B%.!ZU"O`2)KRGR<U^<C
M?$.`->4^3FOSD;XAP!KRGR<U^<C?$.`->4^3FOSD;XAP''?TDGI@>E;T4>YV
MV+[JN:;BI(;WX+,-,(';;&D\S.*F`Y,R/D@RQ%GL(5@5)MF34Z'G'%8Q3EH%
M+@#\<++K:_9MFOI35?2>"]ZT#22DVGNRCL,;;A4<29]32LXC-/-XPR<,^#(G
M$'S*YWJ>-"H#,LTD985!8')&)AV2DOVGKT$4WE^49[-[>=24OE.:9'C&79(\
ME<`FI)H\R#$<!E-L8)TVA7NY*T#%(L\%R21CE&[-LW:NTW*JBZ:JJIE.`ZN^
MB"](;Z.CKF'=>+]'S@V:P*NR.,X-&9[]?HC(L?<-X3/\FW,RC%XII(3\SE"\
MWIY&A.*&$%#<HFHFD4V@5!,@=M1<2X`:V-:"(`>T!DSEN$`<"0!'P\;0,8B0
M#WTU#=]GG`B8N94693)1[57M="2^7$PF,5:1L*90J#XH5.D@4:*&M!4W8&F!
M3`M.XEPOLC6AZ:NG63,2^WGM&[\7FLU=%O7OMUS]^D&H&3KRP7V1K0U-2RLF
M<M]HO-*[\7FLU`20KWVZQN_3"\`R\L`FMCFA@`3VB,F<MP`+BP1#P\;;@(F(
M]]+Q[[?.!G9V]?H021UT&[)(<DPY/F"3?*F$5<OADB(ZBDOB11YJX$]/G#:@
MGLY=W7E5@>(+RU2W1K0*B6X0DSC:`F1`XA^+PK:4QQ#RV`'9=YH!5Y81+?&M
M"@(IWB$F<UH"+34$H>'ENTP46$.Z[2+W:@V!@CB6&R^-:%KI:ELF<]EW(ZMM
M8\M^F"SBG==H$[M4=,`CB6&R^-:$$=+4I)G/9<#+5M_%Y;],57%.Z[1)W:@Z
M8(UW4H"\:!X]J0YW0@)0E1MH+`QUN]!N944CF4M`$U;@3`PE)=<F"P'$O0*Q
MK0!H%0\4.-!$J8F"OAP5`#"8/7`H#ZM``%Q+T&D:T$:#0/%#A4;3B`5\.[*F
M`H?OB/J=H!G$N`&MC6AA`#V@,F<MP@#G3`1\/&V\4T@'OMU#=]GG@'<2X7V1
MK0]-73K)G)>)0>Z5WXN-9J"DWKWVZQ^_3#4!*#F3YUX";!N=0K=&B1Y02D%,
M%)KE5:`BL9,7)D4BGJ@2V\U#JZ5.`5F7E@$UL<T,`"I8(R9RW`47>F)OQ>:T
M5`30KWVZIN_3"\`5Y:HTCF@@`FH(R9PJ`&6`HB'AXT$Q2IB/DO'[GS@->6K_
M`$:TI6G])GK;=2M/#^^WMI^]P`"\L(A6-:!VEN$),XT`3(`80_%X5M*=00[J
MV`'9=YH(HUS)G:-Q!@V%,3"`G&5%0UHKMP4,`E2>E-8"BX@&J:ND4/-U!!,%
MA'$N-E\:T)72U*29CV7<CK6_B\M^EK.*=UV@3NU1TPR1Q+#9?&M"U!.^DF<U
MEP,M4"_B\M^F*J].Z[1+W:@Z88*XEQ`MT:T*(@2X`DSFM$0;Z@`/AP7`0QU0
M#NN!,O=?YH(W[F5*VJ>/:D#69W"66$H@)G38+0,9!D`U,80]F%U/8FK8(+!<
M2]!I&M!&AJ!XH<*B!51*`CX=V`8Q2`(]M+A'MM[0#.)<+K8UH:@*65DSE`P@
M#H4P'\7&MO%-$![[=4W?9YX!W$N%]D:T/35TZR9R7V@^TKOQ>:S4%)O7OMUC
M]^D&H&3.)8+[(UH:FKIW29RWVB^TKJ1YK-0$F]>^W6/WZ0:@(G+F3*\:%Y!M
M<(O-$/%!(582$<V@H44DC!<F1(W8DO:*A@\VP#F!:*\M4:1K00`34_&9P$0`
MRH%&GAXTN*4@^M<(?:]H&O+5"L<TI4*CXF?NN*`]GA_:(%$1_>IZO8`5>6&V
MZ-:``B2ZDF<1*`BV`X@'AX76`=40[JZ9>Z_S0"KRPV7QK0M13U+9,YK`,++5
MMK'EOTP57IW7:)>[4'3!&BYE!?JE&/;`;DHPRY0E1.")U%S@J"9-$PG`A#K"
M!A11U!1*%QKQT05E<2PV7QK0HCIWVR9S67`SU:5CRWZ8JKT[KM(O=J#8`#B7
MH6L:S`1`MU)0X@`B"`G`!\."MICJ`'=6P.Z[S0J[OPH[4G,7YIJDW$,HZ?;=
M)US(&KU6[*W`-6Z`EM-^[4.`MMP!P%.>DN:W)+TK=-MF"8UH)["[1D;J*;@/
M!45:)8#`$:N546^"N#)JN6Q2J&2(*HIF,)`$XA404[&[JQ^5(Y!';3;58O!L
M5F^.;H22:$W,XTRE5]Y6TAEA9PS9WMNP5+.R:R*JTFFNDDY*Z5$QRF$XG$/'
M<_:-WU"+Y]@&:K97MLLKCFU4S#Y;L]N[D6'Y[C$O`Y3G\C$SV-9E"8_'.HY\
MDY(=)5NL@Y:.6QSIK)JIJ&(&Z\!YS9]O>1KY'6Q:V>8I:EL6QBKFPY*7CBU;
MX[=)CXQ,3%JS$36T3'+'EQ1EIV3,Q^V)XF/W2=N0/]L\0VL.T<8[`RVU6+LH
M+#TH:.</YF.;$@IQ;&V[/54CG"BR,,^9"FZ774MJFH*JAANNH[]]S+MWS^0[
MIW,L_4M-NDS.2.^)XZ<<Q,3$<1'$QQ$0E6*Q6(I^6.G\R('DMT?2ZR3]W$;2
M,UFK]I,N$S.\@Q\5?;)!!HM.L"8C'E>P`N4%``CQ,\>*ND`A<=$#4TDB9-N;
ML?CF&MW$U$X2;"'&W\41FLBA+NX9S@&29)%XPTCFZX8>""S12;=-Q<,RF%9`
MA==5,I2W<`SLEFNF3'<FF,/R?;/;V,DHYY$MWIGD`Z)&.G*<",E'*).B8B)7
M#-M'M"I<T<I6G,B">H9034#<O]T^F.3DF4S+%V?5EN9=R",E*<X5TV7=Z_./
MGKUQA-K5!X*JHBLL<J*]IS`8P$$0#2JYQTC+IJ$5@]DG+1Y'1[=R/A+QS&C'
M1Z+<8Y)XH7;\[!$C`CA)(@*"4R)A*CV&"P`L`GO/B7CDUC`S.,-IK&DY,\RP
M<RLTRY%&%CDY:04UW6*(-5D6\88RY3)G,51)%4R=P(JV`SX_JHVCD(N`E@S?
M"F*&2Q;.7C&TI/2D?(\F^8@_1YUBXQD%V*P)5(8BH%$%R&2[5`$O`/C$MX,7
MS:<>8UC\G!O)YDP<2B\0$A+(2)(]JZ9,G#L[5[CC0Z2*#I^DFH!J*IG.4#$"
MH<!)6K*^\6'SFO\`17`&K*^\6'SFO]%<`:LK[Q8?.:_T5P!JROO%A\YK_17`
M&K*^\6'SFO\`17`&K*^\6'SFO]%<`:LK[Q8?.:_T5P!JROO%A\YK_17`&K*^
M\6'SFO\`17`&K*^\6'SFO]%<`:LK[Q8?.:_T5P""-5E>74HQ8_A\KWR:X#7Q
M1Y7NBQ[`'@&YF^X+';V+82^3%9LVDG/1&.-#D=2+F^2FES-VA5"M(1=1)$@E
M$ZAQ+:1,IC"/8`"$5N]SMO,BRU^VE<4C7LOBC/<?'Y&=F6,F:.@XK'VD:MGJ
M+F0<8RH9E#/&2[;VXQ"H/DU"`F8Y5"W@PH3-.E:4?Q\;`P^RJBC%7$AB58I(
M4V8J3.7R'U63CG33#2(+$'-6K@R87:*;Z\1$#@I0+9QBLIRRM&+&GB$MWR:_
M?XJ\N_[+'LNK3@(&W28[,X,K'Y#G&V>"*O,YRM&*6E3Q3=RX>RX1DM/+R$Z^
M+CYE18M8N%<JN%%1.!DRB2T]U@@V)W)MB'$1!24MM_BTG!'BMP$X=VUQZ?DF
MC.+@G2;_`#-`6['"E7#%-TZB".3%,D6\[8BA[#`F(ALG.;[+OLH2C'>(XHI.
MX5*A$QSP\3-BRC7T/C>2.R)QDJCA8LB-F<%CT@W3$#E2.)=!._4`I@]-K\QV
MFGW;]EMCAF.PDHSBHYXZ<-(5YC[M2*>Y.54&0NWF+QR[U('IBN3I$.J1`CE`
MQ@**I0X"Q$RR/,14A%S&/Q$Q%/FBS=_%/'1GC:0:J$$%6BS1Q$B@X(N7S1(?
MS35H/`51@\NZ;$VT!*#ANUN&NYEPE$0<7D+1."F=8SQ1BW12CB8JN5MS0N[K
MBF"YN8IE!`A`L#</<_V;A)'*8N0P*&9+-Y7<!YD2CC'I]1B[EU$HAWFRX.OJ
M:J@]<Y`DJU45,01YHQ2:E#F2`X-1#.NFQC&.O[N\381[F4Q5T\9N,7FT]5RC
M&KJQ,VLR-AAQ4:PC#'G"+IU:($!@HF(J`!0.%A-KY>%F,=B)+!(*.B\8=1[X
M\>P*H\C3-U23\FG)@Y8N(=)TU?'E"+&7(L0JP+";4"^[@)/U97WBP^<U_HK@
M#5E?>+#YS7^BN`-65]XL/G-?Z*X`U97WBP^<U_HK@*I[L=.VQW4)NNR0W]Z>
M-B][D,6V^9*XT3=W!,0W))C2DQE3Y*9/`(YEA\P2*4DFC!,S@R`I"X,U1(>H
M`!R!^5'=7TW_`.S8[/[D9WM9DWHV\'?91MQFV58!E(P/0MTUNHQ'(,,GE<<F
M_#WDCX2J^8C(L77+JZ1!533(8Q4Q4$"!63?/TTO[+SU`;29UL[E/HZ\@Q&'S
MR!<0R^6;4])G3]MKN-BSI0$5F.0X7G&*ST=-0,]"R!"KMU"F.@J*0)N$5VZJ
MJ!@:7HE_3<>@B]$5L=.;7[-X;UA9WN#N#*MYW>'>[)MIL"897N,_BC29,6C!
M8M=SEFN/XGA["460CXY`QR)J.'+DYU5W"IS!UE:_MD_HJ'"HIJX=U5,BVF$B
MSG;'%CIF,&J!$Q*RW!=K`8X@G]H(`!C=XE`#A^J+'Y9]+04;*L&315K),BR+
M,SB57*J=%X5XY:E6M:R0)F$HMP-150":AZ?>BE.&Z,M+A?8P8&IJZ=THN2^G
M/:-](H]FIIM[J76ZRE+M(NJ`9:7"^Q@P-05++I1<MP`+S2NI%&LO!-"[V5NJ
M>EVF&J`*TM4UK!@(`)[:RBY1$`%>RH!%&M$Q2I"/?03F#ML`3@SLZ=R*,&B=
M9-JR3'),/3YA*;5;''5RZ&2*C>:3P\!YD#`04^=-JWZ?+O*\JN#Q!:7[+F#`
M`\VZDHN-*BE?2L46ZTICB'=42E#LN$2@%6EQ$MS!@4!$EXEE%S6@)F@*6UBB
MW"0IUQ#NNTR=VH.F`1:7&R]@P+72U+91<]EW):UM8HE^F"CBVMM^BG6W5-I`
M%6EQLO8,"UTM2V47/;7DM:VL22_3%1Q;6V[1)6W5-I`B77E=>-O9,B',Y$!(
M666L$!8&,L':T;BJ*1Q4M#35N!,IA*2X3)`L!:7H%8^/K0*@$JN-!M3$0`?"
M0J`&$P!W5`H#ZM``UI>@TCX^M!H`RJX!6T]`$?"1H`F`H=W8`B/J4$`RTN`&
MMCX\P@![`&57+<(`XTP,(1)K0.8B0#WV@<P]M@`<`ZTN%]C"/-34T[I1<E].
M=TKJ1)[-04V]U+K=4]+M(-4$P+RG./`39LCJ%;HVI'E5BDTP4F>55&C584SN
M#)(@?V@EMYZ*+:0%X!49:6`36,&!@`5+!-*+EN`!=Z0F`(HUEX)H":EUNJ?O
MTPU`!6EJC1@P$*FMK*+@(@`K6"(>%#:)BE3$0[:"8P=MH"8#6EJ_@#"E>_Q1
M?NN`*T\*[[>W]WL]?@`%I;LN8,`"I;J2BXT`10O$`&*+<)2F4IW5$A>ZX1("
M.-7E#-4!!FR.03"`J#*K*'MUFX*&#W*\`XD`Z]`UC5TB!4NH()`L(M+C9>P8
M%KIZELHN>RO(ZME8HFIIZCBVMMVBG6W5-I!@JTN-E\>P+73OME%SVU!EJVUB
M27V"HXMK;=I$K;JCI`%6EQ`MT?'@(@2X`E5S6B(-[P*/A);@*8RH!W5`A1[+
MQ`@(WZ\L5K4[)BF&LSN,677*("+IL`@!A9LJU,(E]F%P?:FK8(+!6EZ#2/CQ
M&AJ5E5P`1`JMH"/A(T`3%(`CZ@&$>VT`,`9:7"ZV/CS"`'LNE5RW"!70I@:D
M2:R\Q$0&E;=0X]NF&H`=:7"^QA'FIJZ=THN2\2\[HW4B3V:@IM[J76ZQZ7:1
M=4,G6EPOL8,#4U=.Z47)=;SNC=2*/9J:;>[V5FLI2[2+J@C<KR@/&I09L@&K
MS0+XJL0JXE(Y`H*EY9,2U3*D8:).+1.8*!8!S@L%:6J-&#`0J-!&47`1"Y2T
M1#PH:")0((^03"'VH"8`%I;U6#``J'_:BXC2XH"-/"N\"B(T\H`'JU``JTMY
MMS!@`")+Z2BYK0$6^H)0&*+<)2F5IW7"0O=>(D`*M+C9>P8%KI7VRBY[:\GK
M6UBB7Z8*.+>Z[2)6W4'2!&BO*B_6*9FQ`>3C#+$"66.")U%S@MI$Y0UQ2D,N
M)3"BAJ"B0*C>.@"LJTN-E\>P*(Z=]LHN:T1!GJVUB27V"HN!>Z[2)6W4'3`!
M:7H%T?'@-"W4E5Q`!$$+P`?"0J!3&4`.ZH$*/9<($"KN_)W9YS%^;;MT!#*.
MGVW0='<@:O5;LK=43M&HEM-V>K7@+:\`<!3[I,D=S$^E7IM$F*8,HBGL'M%R
MYASW("*K-";?P`-%542;:KZ+E=L!3*)D%4$U!$I3*``&,&IZ?]Y,4W'F<[0V
M<VLVYQZ780FU>09@Y:NYG$SRS',</-(80F_7+M'&N)&1@L;:$9JH+`8\;8#;
MS0*`<!L=UMF2=1"V>[<;EL5\?;.\=VKF(V8VTW5S;$,PQR7@,GW`DX7(\5SO
M&H?%\AQZ?8O4C!5&Y-1N)TU=1)51,=UX#SV_[;\E7R?CXPWRQ6U;4S8J9L5Z
M7CBU,F+)$UO68^$QTF(F)B8B6/+BKFIV7YX_9/$Q^Z8/"8G=N\1VMU'.,XQ-
M;78NQ@<2:0,.W5E8)HV@)M;&F#=FW>Q9F@Q<`NPL,N<003(B8^H(%`1H;\[E
MMN^7R'=.[DGZEYM^:9R?C[I_;;NYZ]>J5>WMB*?ECI_,BIYG'2)++(/WT/M*
MV<1T@TR!0%6$W"J%7$\@V:24VW0P=HF^BM5-4H&>`JR!11.OG*HWU$DAS&YF
MT2$`BNYP[$YG&(?:];/HM=")!Y"IX*S<IQHM(\9#%VZ+%;5<%*5JL5NG035,
M`D4`H:A#=OIZEE$Y=W";?HRT\@R:*H3>.RP3SA86B+=G!KHJ8`Y4=R0MPT46
MR)UC."MU`1U"('$@:V&W$Z5F#0T7#L]FA:.GJNH0&KU\FZ=2F1C$',HZ<X,X
MYE)>=D@3*83F2(FJ4Q1!`2FX#8S&:;#0RV08]F.W>`XPVQ22=8\Y#(<?;C%N
MP:,\6%TO'JQF)RI3PX,\SB2F4<%;E,#PA1*(E4`@)Y/?7IO0=.YYVAMN\?RS
M8S"6D@B)1=ZO#3`)Q+I28<.,#364@G+5HF545!.15L*0@4Y%4[PW0YOL)(?4
ME='%]L))#/\`,76%8L^3A_<C_)6[":>N4%'+S"6Q2(`:5=MM8;DS/Y`S<!%9
M<Y1#UVUW*V@DLY/!X9A./8UESE3)L4;/6N/C%N95IA<@_:3"",E'XX4X0B$A
M`*`F+I1`JID2B0IC`4.`LQJ2WO6.^'N?HW@#4EO>L=\/<_1O`&I+>]8[X>Y^
MC>`-26]ZQWP]S]&\`:DM[UCOA[GZ-X`U);WK'?#W/T;P!J2WO6.^'N?HW@#4
MEO>L=\/<_1O`&I+>]8[X>Y^C>`-26]ZQWP]S]&\`:DM[UCOA[GZ-X!!&GE>7
M4HUCJ<_*_P"WN0[?%'E?^S1]7@$\U!H9&U28Y#C>,SK)%VW?(M)<0D&R3UH8
M3-G::+N'73(X0$PVG``,%1"M!'@(-2W%VE@,HG\2;8OBT+)(IY@ED2IX1[%L
MA:Q,2A+Y`23=?5`I7#64@XD5RTUD':+`:&,!4;P9\+NOTPS;YA&PL=L^Y,V4
MQ4T0NQBC<EJ3^6OV>-^%N4,%!(A1S)@M:>I$DGQ3&$P*%.)0M3&*2O+*4:QU
M/$);O?N>_P`5>W?]F^7@*ZR_4WLZOEN0X+D*\&25PUU,-)?ZQMI3P]@LWUX.
M1HN.,R"2:;F+>N#**![2$<*QU3E2`_`8F-T=F&L1`9BMBN)3#"1CLQ;8[(1^
M.R3MPHV5E8V,R^$0YK"&RC!:=DY)'7:+"CS]#*&`Y2"8`(S=O9QY.ORQV,8S
MXBM(QQG$TG`2)&TB\8XEDDM%/@EBX;53EL<A7Z#5582'$3Z"-VK00]-LL^VM
MRM[(LMML.@L?DF\7%/G2[>#4QTRT8ODP&Y)-7ZO,!=Z;Q<KI<B0J$1!X@92T
MZH%`)PS7,B8!B619KD+=L2#Q>(>S<J=HX>NG)6+!$R[@R#9&+.JNH!"C0I0$
MP]P<!6>)WDZ9LF7AYE*)VP+)+R7@\&XD8-TG)E7@L@?HM3,G*>"N`;,V[Y'G
MTU"JE*@T=(.E=)-PF8P;ISFFR47-98[>[;8E'S<*IN#X[)*XDMK2)V#G'39Q
MRTJAAJJ4JM-.,L9J+)"KKO!.<ZI/,,/`-Q/=?IY:1RYQVXQ1@R,]Q07#57#C
MIF,"3)Z\A951JGB!]1AC*4&\(9;M%NHS5*B!ZD%0)\VSG(C(,?AY?!X*+A<:
M=1SPK")(FK#"Q4;3LDUD45XQ.)1%@["215UDCD(J183:@`>X.`DS4EO>L=\/
M<_1O`&I+>]8[X>Y^C>`-26]ZQWP]S]&\`:DM[UCOA[GZ-X#B=Z4OTS/3MZ(G
M<?:N2ZD<'W3RTN^F!9"TPQOM'&X].JMU]N\CCUIPLZ;*,AQ!)DFY0S)ORQDA
M<"=1,P'`A?.X#\8+GTDG[.%)^D1E?2&S/15U=3$U-D5RJ1Z>97$MD)/8%QOA
M(R1'TQO.YQ)WN,H#Z7>:ZZXQ*UT*:6#Q$6X.%/:0ZC!^T^>@=[*^B\GJT"M.
MF;I3'MHG=01R4*@!A/3R@`>40*&/_P!)\]`[_P#ZO)WN_5FZ4^^T?_YD[KJ?
MO<!S;W;Z]_V;7J_Z[-A>IF>Z+NJ/;B3QR6BXK+]F,+V^V1Q_8G?:>2<-8[;E
M]N=B<#N"BFR;XT]T3281R29)YF0K=\DX32,1</Z7<6,FG'($:LHDJ*9%B-DR
MOW221")J/RMT2D*R=@BD0$VY:`8P$*8X``:92G#9'4F`OL:1IJ:NG?(NBW4Y
M[1OI%GLOL;74NMU%:7:9=4,&4F//L:1@TU++I!T6Z@O-*^D8:VX"M[J5MU%*
M5TRZ@9%28\ZUI&CVFMK(.@J%R]EP!&#:(E*E7OH)C=]H7@SLZ<2B4&D94&+1
M/ZQX@362EG:"GMN70R1$[@?8S4%[P*8G-B"@&$FBZ`>75!X@I,=ES2-#M+=2
M0=#0*I74K&!40**E.ZHE+W7#:`528\R]I&@`Z=]L@Z-:`BTU;*QA;K0,O;6E
MUB=:7FTP"*3'F7M(T*BEJ62#HUH"++6LK&%O$@'<VUMNTTZVZAM(,%4F!LO:
M1A:Z6I;(.C6B(,M:RL82^P3N+:TNTTZTU#:0(UU9C7C;VT:4QG(@<A9)W0P"
MP,*P%JT0U!3.*MH"12X"$$0()A,F"P%)F@5:1E:!4`D75*T3NH/A85`#"8`[
M.T``?5$``%29H-&D96@TK(NJ"-IZ`(^%]@"8"@(^01'U``0#*3/G6-(P>P]E
MTBZ"H@#G3N$(L;0,8J-:5H!STK84#@&4F`OL:1AJ:NG=(.BW4![HWTC#VWB1
MO=2MNHI2[3+J`EU9;G'@)MXXR@-T!(F>1=%(">I,\L<U&BMAUS)H@I1$H%`Q
MZ'5TR@(*S*3'GV-(T0#4LND'1;@`7>E?2,-;<!4+J5MO4I6PNH`*DQ4;6D;2
MIJ5D'0"(7+6"(!&#01*"=>^@F-WV@)@-28K^"1M*_*#JM+@[:>&=]OJ>7@`%
M)CLJTC0[2W4D'0T`10OH`Q@5$"BI3NJ)2]UPV@BC5)<6B%6\:8@B-3A(NCF$
MNLW!00JU<W&*4R]`U1J*:85+>8$@6D4F!LO:1I:Z6I9(NC6UY'6LK%DOLO<V
MUMNTTJVZAM(,%4F1LO:1@5T]2V0=&MJ#/5LK&$NM$[BVM+M-.M-0VF`529H6
MYI&`-"76R+H0`1!O?;6++<!3&5IW5`I.ZX;`1/U9@&M3-HTGMS.I@DG9:"+I
ML`@!@9M1$!,(A[,*A3L-42""T5)F@T:1@C0U`&1=``C:K;4?"QH`F`@#V=@"
M8?4`#`&4F:&M:1@C12RZ1=%`1`'6E<(19K0,)4+J5MO/2MA=0`RDP%]C2,-3
M4T[I!T2Z@/=&^D8>R\2-KJ76ZBE+M,NJ&3J3'GZ;2-&FKIWR#HMU!>Z-]L8>
MR\"-KJ76ZBE+M,NJ")PK+`\:`"$<'X9HD&1=%U1`CFS5`&I`*&F5(1HFO:8Y
MP"EH&."T5)BHT:1M*C;60=`(A52VM(P:")0((]]!$0]0!,!J3%0JTC:5"OXP
M="-+BUH'A@5$"U']T`#U:@`"DQ4MS2-`/,OI(.C"`"9OJ6@,86ZTIEJ5I42D
MK2XPD`(I,>9>TC0J*>I9(.C6@(L]:RL86X2`=Q;6EVFG6FH;3!&DK+B_6`S>
M._`HT5BA(NC:2AES@OIE%H('*!!7M,*2(G%-,!$;C:(*RJ3/F7M(P*Z=]L@Z
M-:(@TU;*QA;K1,O;6EUB=:7FTP`4F:%N:1@#0MU)%T(`-J%]M8LM0`PJ4[J@
M4O=<(%"KF_!GIIS%^;2:I#]:.GVP&SA5>O\`]5NRMUPJM6U`KW4K4.`MMP!P
M%,>E>7W-C>DKIV?KX_@!F$?T^;5.P4#,L@15/&--O(-5!54JV$Z#=THQ3*90
MHJ&334$0`YBA<(>'3]O.RW6=98\VOVDP+$G[.(P1YD#X\TT9&EV$O'RWU7:K
MR.*XD^%X,7%1^HT*L843QKQNY9F4:.455`V^Y>RD9U%+[@[;;S0$?X(^QC:R
M4;+X1GV<8[DL'+P>4Y])P&1XQFV-ML/RG%LCC)!`QDW+%PF<$ZIF,=-55/C<
M^!\]Y+VWY&OE/%6I79K6U9B]*9<=Z7CBU,F/)6U+TM'K6U9CGB8XF(F,>7%3
M-3LOZ?LGB?X3'6'EU);N[9=)NQLAFFX&WZ<_M9AC?;G$&6!X9`1TRJ1*1R%I
MBF*,8?'9<T?#)L(-11$0*94A4$$A,3M*4HZO/GS;.>^SL6M?8R7FUK6GF;6M
M/-K3,]9F9F9F?C*<1%8XCI$*M1G7KZ,W/%X5ZWRC:D[D\X#U)9;`L[CF[7)&
M@/$$D9^3:;:%@U7AS%=@VYAPLV=BV<';G5!$YBXGUZ0/I1/1[RCQD1KD..,9
M1?&RP[A/\F>9NW,/BS)XHM!0,FY@MO95(D7)B55VP8(*+E3*DJ95-`Z9R@#\
MR'KIZ/IK;_.]TH:(B]W6F`P&'9+D$7`[<SRF4+8GNSE3+'L2R=BEGV%XJR>X
MIF$FD=VA(<V#1\RC73I(ZI&BHD"/W?I(?1SH2T=&NI7;]8CW%4LK0EX_;;(,
MEB$%)+)M%IC(O,8V^G%%<NF)]HHY:M6Y%DGYVQED%E1`@F#>//2:>C[G0E#9
M%FV%BU$B\NHOD^W>X!@ED8Y3`$9&0.S>[8K2#=U$2$_#IN$GZ+9XB1F+H4P9
MM0<E#<87UV=!FXV5XGA,');>.LWSJ09X?!0"^W65.%7+F1EX[%T(YQ.,]M7N
M,(Q!LC>-(E1P+X6"4BJDT44*L($X",\.]*YT`YBW1:SG+8'*XID"SC&<4S3;
M*=D)P%`/CSF.S'$V&!XEG+=BVFW60(<FJ*C5\LH@N<$@(@93@)`<>D^Z"XXJ
M&1,LY@I1K"%>.G&48SMANG,L,5BW^,9WG"4\[FH_:P2,X3+('%)ES'N&QU?%
MRB=1`%4CJ*%#HU"SBN1PT3D,&K#2,+/1C"9B)!N\>"@^BY1JD^8/$!.P(<47
M35<ARB)0$2F"H!W<!L[IG^0C/A;KXGP!=,_R$9\+=?$^`+IG^0C/A;KXGP!=
M,_R$9\+=?$^`+IG^0C/A;KXGP!=,_P`A&?"W7Q/@"Z9_D(SX6Z^)\`73/\A&
M?"W7Q/@"Z9_D(SX6Z^)\`73/\A&?"W7Q/@$$<:8Y=2B$93GY7_:G7?XF\N_V
M/U#<!3S?'T@&Q/3KNLQV;W3E'<+F,I$;6RT88C4_@\E^5[=,=I<6CH^0<"W%
MW(,)Q-5_*@0@IQT.B9PH<3"DBH$3X_Z1OI`R_>K/]KB,$6^=[;MM[!S')Y?%
M4C0;:$VJ:+FW`D&.1,6$G)3L9D$5B[]9FDT07<2+.$7441(FFD*@:7"_20>C
MKSZ>C8'$\JVUDB'/M@;%9I'`,F+`RRVYVYD]@.%J0#P=NRJM$4]T\<=,EW3A
M)HT:21!$5KRJ&('32--+\NI:A&4\0EO]J==_BCR[_8_NJ\!RRF_29]!4?O?N
MWLWGL=%8SF^U,]/,]P9[+=N5'4*6;Q6;39K.5)."@<FE%P,U*K+IO5FY6[>+
M:K.5UD;+1#=[H>DLZ+,!PC`YR9AU\MP;<B+REUB9(+;624;KKQF5&Q-Y`OL7
MS#'L7F8J3G\EC5TT]9B5H!&8KO%FZ*C91</(OI,^C)GNNWVR1@U4LKG)=LWB
MYYKAK$V/9"6&QM12'GF.0-4#JN6!D9)I$0XJID=R#B7;)QZ*[94ZQ`D?IEZQ
M.GSJ-R&;QK9/!'6)SD7B<3E+QU,XE$8H@^A%<U!@K%QSR).Y-,N8UX];/GR;
M85F[$)=J#@Z;M91!,+NYA)>$XIDTMD4/'2\#$0,M+3$61-645?QL8Q7?/&B,
M:NR%%\NN@W,4B)NQ0X@7U>`YQX3Z1'H'R!GB+P'.$8;E653"V(ML)E<#E'6:
M0$S%+HE=1.3)X3A64Q6/(1"4V1PY57>E;1Z3@_,F15(X33#VDO2*=)F.Y+GN
M+O<#DF;S&<@WO89$[1PR`,QG<HVX0;/]PD&16ZQI.3ELKCD%G2)G#9$SQ".6
M,\,A80#A'++THO0@7',EF0V^?QD=B^0X3&99'+;7Q"3J*UH&=GHS)739JDNR
M>0F&L,*E"D6;JKN5S1X#$(ODW+!1T'0'IQW<PS?7:S"]U]H(5O"[>Y;#R:V/
M1+^/+CKUB6,RF;A9-%Y"1Z"S:+=!+1RXJ(U!4AQ$%"E4N*`3]=,_R$9\+=?$
M^`+IG^0C/A;KXGP!=,_R$9\+=?$^`+IG^0C/A;KXGP'*;TE7HQ.GOTJ6.R.Q
MG4;`),W$'AL'/[:;K8FNFWW+VHR-?+GZ<K(X?)2$2[8'8S\0S%M),'B2[)\0
MB5Z0*I(.&X6`V!]'-T<=-6T&!;'[7=+FQ#/"-OH1I"Q:D_A6/97DLD<HMEI.
M<R7*)_&WLUDF1S+]=XY=O'2QE'"YBCYA36)A+X=+73W0+NFGIR`:%K3:S"!`
M!M1OH(X>%0N%2G=V`7RC0#]%KI[I_P#VT].5:?\`E9A%*VC_`/R?W74_>X#F
M5GWH`?1X;@]>>`]?DAL=BT5F^#L`>O=HH!)G#[&9UN-#JH&PC='+\"9P9&*V
M38JDT)<BWT8Z2<`DY>MW"[<QG(=H&!YKDRV(Q1Q`75@B\>`43`M(Z8"/*KB!
M;RMP'M&@&4H'FE`P+CGFO/L;Q8_?=.]V[+6G/Z-]&)K;K6MU*VWJTK82\`YY
MKS[$(L0JIIWNW85`!>Z-]&1K1,!6]U*TN4I6TMX?E&ZL_P!KDZ0>DCJ2WQZ9
M,KZ9.HW+<OV'W0S/:O)9[&G6V:6-2LOADR_A7DA"J2F7MI,[!TX:%$@+MT5"
M@8U2U*`&"+<"_;"NC/?.9DL+CNE_J?QM>'Q#.MU%Y%T\VK6(M#[(XA.;Q9#%
MHIM]S(-09&:QS!G35H45]$[Q9,BP"@90P`R0_;;>B7LNZ0.J<.TMU)+:4:!5
M*^E<S"H@43T[JB4O=<(E#!?VV[HEJ6[H_P"J8`$27VR6TIA*`BUU+:YF6X2@
M9>VM*B0E:7FL`)^VW=$PV:G1_P!4Q:Z>I9);2GMKR6M97,R7V`=Q;6EVFG6W
M4-I`%_;;NB;S+^C_`*I@KIZELEM*:VH,]:RN9%OL$[BVMMVFG6W4-IAD/VV;
MH>5(19;I'ZK47+=1$Z+=)UM(LW<`JB5)V"KD=P&QD-`55#)^TK`K86NF)A$@
M8#]MNZ)J!7H_ZIJT"M)+:40`:$J`#]<PJ`&$P!W=@`/JB``#^VW=$U.SH_ZI
MJT&@#);2@%:'IV_7(>P3`7]X1\@`(!OVV[HFH:WH_P"J81H>RZ2VE*`B`.-.
MZF9&M`QBI5I6@'/2MH7@&_;;NB8+[.C_`*IAIJ6726TI;J`\TKZ9D>V\2-[J
M5MU%*5TRZ@?:O[;-T-$`KEMTD]6"SM9-5)PU77VB;MFY6RLD9B=!T3<-T9R9
MV11`5@%NCHB8X`*P$()@^#?MMW1-YUG2!U3#]\LNDMI2UH+O2NIF9K;@*A=2
MMMZE*V%U`R/[;;T2U&G2!U3B%36UD=I0$0JK8(A]<QH(E!,1[Z"8P=MH"8#_
M`/3;>B6O_P#:!U3TK\H[2UI<'J?7/OM_]/``?MMO1+V5Z0.J<`J6ZDCM*-`J
MC?2N9A40**@AW5$I0[+A$H9#]MFZ'&HE0:])/5>Z;$%.CEPXVC:.#@<6AU[F
MP;A2)2BD91P!/;S7@FF(V:A@2#Y)^VW=$PV:G2!U3%KIZEDEM*>VO):UE<S)
M?9>YMK;=IIUMU#:0!?VV[HF\R_H_ZI@J">I;);2FM$>3U;*YD2\""9Q;6EVF
MG6FH;3`+^VW=$WFW='_5,`T)=;);2C0;6^I;7,BW`!C*T[J@4G=<-@9#]MFZ
M'G(D1=])'5:U0,=(ZJ[9SM([6)I&36HFW-N!'`K>H02]JQ`M&HU[2B&!_;;N
MB;MIT?\`5,(T-2LEM*%1HI:`TS(:`)@(`CVT`1'MH`"`;]MNZ)O.LZ/^J81H
M>VZ2VE+40!UIW4S(UH&,5&ZE;0.>E;"W@&_;;NB;S[.C_JF&FIIW26TI;J`]
MT;Z9D:R\2-[J76ZBE+M,NJ'6;T3OI^MA?2\;H[G[3['[*[L[:3VU>WJ.XLT]
MW6<X>2,D(QWD9,::LHLV(SN1.CO`>/FJBHJII$(F90"B8Q2WAW/<GF`>-+4H
MS_;=$#.W@7B!'.EJ`5N``&D"(F\U2AC'I[$HF!:)YJHT0BZ5&VKMW6EREM?<
M7>)0)7UQ'R!4,W3->U",I4*^ZW=:7$KV<GVC;=3UZ?O!@IYFI;T(L`J2^UV[
M$0"K;4MJR"X0**UM:5$I*TN-:`0\UYFHA%AVIZECMV-`$66M95D%PE`SFVM*
MVIUI<:P$:)YGQ!8#HQ=.3C!6*5X\,)%!7.#C3`S8"F*!!7L$2D$PD3J/G&TP
M6%/->9>WBP[$]2UV[&@B#/5L$61;@*)G%M:5M3K2XU@8`\W0MS>*`:$NH[=B
M`#:AJ6U9!4`,*M.ZH`7NJ-H5>WX%\,YB_.$:$_\`FCI]L!LJLK7_`.JW96^\
M5440`*]U*^OP%MN`.`I/TNNMS6W2)T^N9)IMHI#M^GG;!9=-1W/&*I!H[=PI
MTRNROFK=GK*112ZX*'(AJ"8+@)V\`GZ=]W4MS3Y(EMAMWM[@[AECV!9#("5B
MP8-9N%R8F4,L>62?8:YDT79&!<87!N"M"J,ET7"`BW72.H$^XR.9CN-F/C9,
M63<_4S`+0BE)=9(4O&MQ=(3F>)(&!2[4N``$*6T[:\`\GL<XE'ZK2298_(M^
M39..6?LU'C?50=.A06!)P"B8*HF,(E-2I1[N`AK).F[88[[Z^S6P.ST[-8QC
M>3,V!T-M8"3DO"I=9"<GXN*BW#9%@X>3\A&(F/=:=98I;C]H\!4/9WJ=Z,-_
M-TFFT<#LUAL-E.8X?";B1H[@;5[=P3;*H>0PW;S+8E9!`TK(2LG(E99XW8IE
M%N>KV)D$DCF3:`H<(S@?2,^CUF($97-\.'!)G>G;_!LN=[<9GL!DF3Y7F6UL
M;(326V<E)X[B,-F42YQQDJ=X_C6IE!3;INSO$B>Z#*G!*S](_P"C*9Y)*/):
M&P'$="6<)L,YD-C$E"9+(9`NW2<O8LD#$2F7E-*@Q1%VH\9ME`%-,JX`8I0`
M'!E'I!?1HQ9IIMG+#!V.20SEW#+8?.].TTOE[XTA,95%MV+"*<8J85QG)+;9
M4BR1U"`S<@T1?\LN8")@\]M.O/H`RS,\2@\2+BD-N/N#E^.8U$1J&Q60I3:F
M2JSD5C&/GEY^$QIU$,`B)-2)04=K/@1C%';)-11,P@!`O1E&PFU.;-TFF7[0
M[/Y*V0-#&21FL%A9`I`Q^3A9F%1#F&"@BUC93&X]9-$?:@,R1\VB90`-DMLY
MMXY92,:XVMVD<1TQ).9B7CUL%@U64I+O/$!=RLBU4CC(/I)T,LZU%U2F5/S*
MMQAU#U"06K608MF[)FA"M&;1!%JT:-4%V[9JV;IE20;MT$K4D$$4B`4A"@!2
ME```*!P'O^.?+&?8=?P\`?CGRQGV'7\/`'XY\L9]AU_#P!^.?+&?8=?P\`?C
MGRQGV'7\/`'XY\L9]AU_#P!^.?+&?8=?P\`?CGRQGV'7\/`'XY\L9]AU_#P!
M^.?+&?8=?P\`@CO&.74H,93GY7U'7?XF\N^V^ZX"`NH7/=MME8)CN?N9A$#D
M2N19+@&T1'L?CN+2>3.R9?F#9+'HD5,HF8)U+0[#)7!'I8YHJ[=&7`56S558
M.`J-`=;'1G&[V97M4UVUBL5R;%D=_%)'/HS:_"I7"I&,VNQECD6[;J)RK;^;
MR.0DDY'&(<AWS7EBO0.S;M)%!NZ5:-U`T&'^D1]&ON%/0<#CDAM])-@<[6.<
M'R!38R<1Q^0>[F;K3V`8>[QQ=WC"+N*)';LXXY;.GBZ#-NRD2Z@JWU,`=58W
MQ?EU+?#`#Q"5]1UWA*/+O5]4U>`Y(Y'Z2'T?C/?7=_9S<O$XK'<RVHRJ63S[
M*<LV583<(ID^(9&@FA)ED(#ZS3KMR1)-6<;OEFA"MV#-58ZB2Q2)'"8LAZK>
MD:3VWQ;<(FV:6X>`R^WV_P#DT$HSV*1,LPQK:8T,YW?QYQCN;IXY*0S^73T7
M7)';D1DVS`ZZAK4DA.#=4ZS.ET^\,_A<9L@M.YA@^?1D%*YA%[<;:G!C*0&!
M9O)1.9QAG>7M<V>P\'A6#R;=H\;QXNB,A2*W3%LY2,<''TH]6'3=U`9/D$!L
M3M@G@&0,,+A\C?R+[;W#\03E8$<_=(JPC&3Q.?ECS1XB7F22+U)(5&S):;3*
MJ<CU5PBF%T-X]QHW:#:G</=/.VR#O!MOL0G<NS0C!@:270Q&#8+/\E?G8.G+
M9!VTC(5%=RX3$]3-TC@`&-0HARMP+TDOHWI)LR<0."PV)YF#O%L-BL$6Z>T8
MS,`3DLB<XTTBTGL.P=8K',,7R):21?-U91(&(MG1P()3`*@2U.=8?3#CN:;J
M*.^GY1T^VVE^H"-SK/X3`-GIU!>1V_\`J4VW6,1]$9\[R5X.5O,TB&+H7#9(
MYWRHM94&JS9P1$&8'7OT>P&#IY6]Z?GN/8,ZRO;&/:NV^U^T;R,=32&'L,R@
MI(B6/9W(M0>[58M&1ZI2&$)`@*1R<.D\,NU*8+W=,VY.'[N[3X=N#M+BS7!L
M$FV$^WB</>P$?B[[''<#FN18]D$6_P`?QU\_B(B20R**=<R@FJ8Z:]P*45O`
M`L/^.?+&?8=?P\`?CGRQGV'7\/`'XY\L9]AU_#P!^.?+&?8=?P\!':'C'Y6Y
M&HQ=OY.X&Z@/-2GULFM2WSK*<MJ4KVZEOVM>`D(OC?F7C%5HGJ6E=]]&>K94
MW8%W,6U]33K]MP`'C=`J,56A;J%=TK:C=2IJTNU*>M;Z_`%)NGLHJM!IYKNE
M;34^W[KJ?O5X`'QRAK1BJT/;4KNE;7&G=0W==I5IZE]/M>`0L/'.2+8,3=5U
M;4KVV_6D=.H"<36W\O=ZM-2GVM`7G\;]LTQBO^MTKRN__P`?H:EIO_RM]/(K
M3O)0`_C7GV#%TJKIWE=]U7NC?0P5&G+74_\`64^UX#D%NYZ#3H(WLZ^L.](E
MG>SN/R6\F+MU'LSB8I@&U6Y.?,%4OJANKN+AAFQFF0YWB+9JF5%43%;/5`(L
M]1<K-FZA`Z#[E8?AV'X7-9*EM_@**4.>+D7A8C%(U!^[8,9N/>N61#I-40,5
MVBWL.4YM,0$;O-X#\<+C]L;]'@10H-O1V[IKI>;>=>/V.;*77I@H!$TY%X0P
M67B`W]HT"E*CP'3[T3OIT^C_`-+7U"9)TZ;4=',MM9E.)[336[TO-[AP>V#R
M!6A(#*L$Q-Y%QGU:4D)%>57>9J51,5444"I)")CW`!#A^A@FU.$>UZFV^UO_
M`%6K9AL1_P#@-?3NC_\`\U97RI5[CU`)M3A'F7[;[6_]5J68;$?_`(#6LK']
MG;S5M?*E7N/4/!3;##TS,4"[>[8D27=$%VB3#XP$EM%@<:B4&-AA36,MIB<!
MH4Q?5NJ'N&U.$4"NV^UM:!6F&Q%*VIW4_%_=?=3UJ>OP`.U.$4&FV^UM:#2N
M&Q%*VJ4K^+^ZZVOK5];@`VU.$4-9MOM;6A[+L-B*5M=:5U(_NNT+J>I?3[7@
M`^U.$>?9MOM;W*Z=^&Q'?1]HWTC^ZO+74_\`6T^TH'D;;##E'"Z`[>;9*)MF
MY08IJXA%F20156FE$B`46`E(8[@43*@2@#500[1*/`>QMJ<'\^S;?:ZE5-.[
M#8CNJ\TKZ1_?;R]U/5U*?:T`':G!ZC3;?:ZE36UPV(K2JUE:1X=MNG7U[O6X
M`_)3@]?_`.F^UU*_U-B*TN#_`+O[[:_O\`%VIPBI;MM]KN\MUN'1%:7-[[:Q
M_?;JT]>SU^`3L]L,.=(I+N]O-L5U#G]M5/A\694Q"K-2F\Y5@8PF*B5<"U&E
M=/U+N`]R;4X1[7J;;[6_]5JV8=$?_@-?3NC_`/\`-65\J5>X]0";4X1YE^V^
MUO\`U6I9AL1Y&.M96/\`+S-M?*E7N/4`NU.$>;=MOM;6A+[<-B.^UMJ6UC^Z
M[6MKZEE?MN`3N=L,0:I$7;;>[8(.$UV8D62P^,(8AA<MRG$ADV)5"]YJ4'NI
MZ_`*!VIPB@V[;[6UH:E<-B*5M5MK2/[KK*^M=ZW`!MJ<(\ZS;?:VM%++L-B.
M^CO2NI']UVA=3U-2GVO`,3=+I;V,WGV\S7:G<W9#9W,=OL_Q^6QC*,9E\-8%
M9RL/)H2*!D%%V39J_9.4A,T42=-5D';5<AEFZJ:Q$3E"G_HTO1(]+/HI\$S?
M$.F/&`7G]Q<AD9K--TL\7\;W)R.-+(3;K$L/?SR#=H1#$<*9.VS9DR;)HI',
M#ATN"KQ=1<X=+'/C/.M+1BZ>[=*XKRMUCG2U+36TTM&[_E7T^UX!:/C51H,7
M2HTJ5W6ERMM:&#MLLKZ]WK<`4FJ]\72H5\UW6EQ*_;]]MW[].`"^-5+>,72I
M+[2NZTJVU+:F[[=:VOJV5^VX`)XWYEXQ=/:M2PKORL=:RIO)S-M?_55^VX!$
MB$WX@M>,73DHO6M*]`=37/S&E<<2VBGKV>K73N^VJ"POC="7C%5HGJ6E=TK1
MEK65-W5YBVO_`*NOVW`!?&Z%N&*K0EUH.Z5M0OMJ;NNU:>M;Z_`5>WXY[QS%
M^<Y01^M'3[8+4%@[?TK=E;K@5$0I7NI^_P`!;;@#@*4]+AMT&O2+T^.W;_;8
MT:WZ>=KW(IJPT[;X0EMW"JH).SOLF:,A6".*4JYE%$D!4N$1(3N#5]-&]LCO
M2EEBF`8W@.%G@$L=2EDEL318B]56-.1Q40'&LYDE56<4YA5DV:ZR::#UJH5=
MJ)DC<!8C&4\R#<;,0FWF+J.?J9@%IHJ-ET4M$9K<;2`Y7DJN;4*8#U$!H("7
ML`0&H/XI9;Q=7V^-KX:AV\HZ[N:<T"G/>7@/J6=2\;%2<CIH2/(1SU[X?'QX
MK/GXM6RJX,F23R98-%'3H4]-,JJZ*8G,%QRA4P!S/V3ZUNFG>7>C'-MXS;B"
MP3-)O'H'<O#9K.<)V_B'LJY?;;[:3L,6&"/S21EE,R)`YHG$((-]1Y6">%('
M*)-U5@8C/TG'1P>.ALFS'&6^.S\QC46XQN'C]KH+<_*5,*60!]A\8_/MEDV6
MEQ28&*<.U%\;D%6S^`4:.$7B*!E68O`1/O2C>CJN;)3#B/3?MYPD8TBG_37D
MB\RWR`D!*2SILA%$2</T)&-!J9BM1,#`[=)D()TSF4*&KR?TH?0PCEF;Q?U+
M#*,NPQTJPDE#;%L$7K[,X3(Y['YK$DG\O,)+IS<"F#MT+I821IB.%$0=%<F.
MB8+&]*_5UTS]268KXGMGA[7%=PFT$[R)*)G]GD<?7D<7P!UBT<I/Q&1QLB_C
M741C<GG<>V;D.JBZ05=E$B!4E"*'#H?9,>^(WX&Z^/<`63'OB-^!NOCW`%DQ
M[XC?@;KX]P!9,>^(WX&Z^/<`63'OB-^!NOCW`%DQ[XC?@;KX]P!9,>^(WX&Z
M^/<`63'OB-^!NOCW`%DQ[XC?@;KX]P!9,>^(WX&Z^/<`63'OB-^!NOCW`%DQ
M[XC?@;KX]P!9,>^(WX&Z^/<`@CB2W+J47C:<_*_[(Z[_`!-Y=_MWJFX"DO55
MU=;3;%Y9B6W&\F%2&3(Y&[P"3BI57!H+(<(CG>49?+XNWDWKV8RU%:*=8@6)
M6?.EE&1"E1603;*K.%A23"$<5Z\^EYIO;F>UT1MFSA9'&FN_RDEN5B&WNW^5
M8=-Q>SV/L\JW),RF=M<YR&6<FD(B.+S3-=!-T1ZFT9NDBNU2(IAHL0])QT&[
MA3V/PT0D@O'.W>U2^#9'*=/<Y&PLD^W+W9G-LL>=P@2W+/XHL!N?CZR+]TJ@
M@#%Q:L(A>F=0.LD:66%NI1>-`/$);_9'0]H2CP##^&AWF[>`Y"9/Z4/HXA=]
M]W]F=RL"D<<G=H\NDF.7YC-[-1F1P3S)<8R9NDPD&"T'/2\Z_<J-$U9MJN9J
M5<J+0Q2`+TR*"@.7<OTHG31MEA.V^4CA&79#C.Y,'G+O&V<9M1'0KY@K#Y0;
M"I:(E\:RC+H258MI>2;K&>NT6ZS!DR!%9\HD1TVU`3)>D]Z96>]".W#3;^?2
MR7))F,81^9,MM<:&.R%)/$4W>)R)G3/-5,A25G6[Z/CL?:O6R#R1;OR+-4Q9
M)+*D"2NDOK%V7ZD,IR''=I=KQV\F(["8?)W<G(XAA,.G+Q(;A/6*T(R?X3F.
M0C(>"2DL5Z[*<Q$$'<L=(!%VF](D%U=[-PFNT6T.Y6Z68,DIK#MOL+R#+\QC
MHZ%&3=J8C`QR\CE"Y(QW*MF\BFQ@4'"ZB`G`5DTS$*`F$`$.5\!Z53HLS`C4
M\IMU.Q&?*9)A41&X5DNPJ`Y`,T^S:4AHY7ZR!,KX@R<X?G(2YE`&3!PFX;NE
M695U3&`0=\OZ2;IJPG=7=G:<^USH,EQ=]O@KDTABN'[8S<1FLSMF.MFK=-]C
M^Y;H[K(9M..D#/6\F5NZ9*Q:Z<B"*J:I4@:47Z53I9DL1D%2[.90VAL-R[;&
M#=P1]LL"/&18S$,[F,9R.(=([A'Q:1:P26"'3AR,'"KR3%"-&*37!XSJ'1'I
M>W/Q[>C:'"=R-N<:98'B,[&3C2,PU>$C8M?&EL;S/(<8EXE>/QJ9?P#9PVFH
M=P"A6BZJ-]1*<U;A"QMDQ[XC?@;KX]P!9,>^(WX&Z^/<`63'OB-^!NOCW`%D
MQ[XC?@;KX]P$=H%E_P`KDC5>,M_)U`W49N[Q_P#FR:$]H\]:`"V!0H5`:*&*
M;M`HE,$A%)->;>YBQ["7VLG85&C34M`7YK0$2KVUK0#IUK8:\`"35`JYBQ&A
M:T9.P`1M2NI^,!H`F!2G?V"7R#4"R:I^$Q=:#_L+NE;1I_VAW74_>X`$DU0U
MKF+`:'MJR=B`#1Q9=1^%0`PI5IW@4_=<%H(F"<UR1;%XLAJNK0,Q>4`PK2.F
M)@%V@82@8S<1\TM0*I3V91("TY)KS]-S%A]]T[V3LU*\]H7T?ENMN;74I=8K
M2EY-,,G),^?8YC`^^:=[)T-*B\T;Z/RW6@9O=2EUBE*7EL#\?'6;^UW[8=(O
M5)OITM*=%VXV>Y)L5NUFVT\QD2.Y..X]&Y`]Q&<>PJ4O"L/`9M\#:5%!-0B2
MMIP*/>(F`"@R]M/VM-AU`3DO@P^C@WSA$XC!\_W26=HY8ED(ND-F</FMUU('
MD0VX`I7&5$P_PMLJ8+"/'B51(`WD#BCM1Z7GT7>SO4AU$]3^->@VSN5S3J6A
MY#'\NP_*LRA9[:W#H?*6*[+<QEMI@DAM:XA,61W7!XL>:*5(Y2E.9NR!JS6<
M-E@D7T>OIV.A3T8+?=,.E+T06^L%+[PY<_R/*\MRC=DF1Y>U@%I`KV"VO@L@
M?[;KR3';C"B*K)QK,RBBRIC%7>JNG(&6,'2<O[:#'^;?Z,G>P?87V[DHA6G*
MZEM=MS4NM6MK6EQ*UM->`7]M!8>;=Z,G>P?87V[DHA6G+:EM=MQI<)5K:UI<
M2M;37A)73=^V([2]0G4!LUT_ONB;='"<KW<WFVQV>Q^1#<7&9V/BIO<G,8C`
ME7^0-EH2#DF;:$=38KF303<+*E(*8@00$Q@_9D!)J@5<Q=:!6C)W2MJ=U/Q@
M/8)@-3R`(>01$`235!HYBZT&E63NE;3TK^,.ZZW]X!\H4`,2:H:US%@-#V7,
MG8@`B#G3NH_"X`,*-U*5`IZ4N+:`<DUY^FYBPKJZ=[)V-!$'NC?;(%NM$S:Z
ME+K%*4O+8"4"3(O7EB\84V@CIG,R=F+I">9Y8IP!TF!E$CF0%00.(&`IZ%)>
M40!68DS4UCB,`*J67,G0B`"+O2NH_"X2@9"ZE*V*4I>6P`23-1M<Q@!4UM63
MH1`+EK`&C\*B!13KY1`WE"T"R9K^$QE*^\G5;;O+S_?;_P"G@`"3-0N<QE*E
MNHR=`(A<A?2K\:")05IWT$Q>^T;@11B<P#1O<O&@4##<4&3LHV`NWO`+W20@
M8Q"KT$2=@G3'M`AKP6$)->9J.8L?O6I8R=EK3D=>RK\UMUKFVM;;TJUL/J!D
MA)GS+W,8(T3U+&3LM1`&6M95^:T#"5Q;6M+TZUL->&"DFJ%N<Q8C0E]K)V`"
M(`WU+:R`T`3`K;6M`,2M;1N!%()S7*C[?%F'69U#D7E!$'3:X0`KQ8P!4##W
M#0*5$*"/`+1)-4&CF+K0U*LG=`&U6T1_&':`&$E>ZH`;NJ%`#$FO.L<Q8=BE
MES)V-!$'6E<`2!;@*8R%U*5`IZ4N+8`<DUY^FYBPKJZ=[)V:E0?:-]K\MUHF
M;74I=8K2EY-,,F),^?8YC`^^Z=S)T:E1?:-]'Y;K0,VNI2ZQ6E+RZ8(G))CG
M&EJT;WO-(PLG8Z8B1R*8J4="!@TQ1`WG)U,4XA[(I2@M$DS4:.8RE36U9.JT
MN5MJ(/PJ(%$E?*(&\H4`LF:A5S&4J%?<3JM+BUI[O[[:_OB'D[0"DF?-N<1@
MA4EP%9N@J%6VI:(OQH(E!:E:T$Q*UM-<`4DSYE[F,'M3U+63HM0`66M95^:T
M3`5Q;6M+TZUL->")$DSX@L)UXS\"C`6,5D\+J*`N<7&F)G8E*42`O8`F.)1.
MF(^Q-J`L*2:\R]S%B/M>I:R=EK0&>M95^:VX2N+:UMO3K6PUX`$FJ%JYBQ&A
M;J,78`(T0OM`9`:`)@5IY`,7OM&X*N[\`]"<Q?G%&J@_6CI]L%LBLC3_`.JW
M96Z\%7"]0$W=2E/5KP%MN`.`ICTK!N>SZ3.G9ZK/8(5BVZ?=JG9"-\&RN2>$
MC4=O(-9ND#1KFH.)*038E*4Q$2%%=8!TR%N*4`UG3GOWF.^WCGU>B\7PXD/B
MNWL\9K.X%*1<L@WRQ/)FZ&.SL*UW"7>8[/8R?&5"*LG`5Y=P@LG[4J03!8'&
M4,O)N-F(3<GC3AS]3-OQ*>*@I5FEHC-;C:93IO,B?F%4IP/<8#`!@,4``!*(
MF!_%3E/&%?=4?7PUOV^'N>[FG-`IXGP#?W%R]UMSM]G>X3]!>98X)AN49F]A
M\?@G$E/2S3%X1]-N(V$CAF6X/Y=\BQ%)LCJ$U5CE+<%:\!RT3]*ET\,5W+69
MP><D,YA2Q\Y--MJ-N(_>#$F[E>-EBLI3'-W<<RIAAV5)(06/)IB\:K%,F)P:
M%`56KM)L'RV]*KT^-'V,OI;;3/,2P[),2RC+D<^F=HXQ)@R64FW*+B'491.<
M23UZ_P`XR>!<I,U6AETY20:IT$YG#,ZP;'`_2(]-.?,-_P"7V&VU7RS.=M-M
M,QZB\VA3;/-\%+FA,#;ML=D#&SH9B3AGN?.(!LB@W(Y,=V1%,&2XH+MW#=N'
MGF7I/-D]M9=&%S+:W+(C/I,DK'QD,QVO;R2<]EC%[G2.<Q$5D:61-R/,?CLK
MVW<-#31TDT'[DZ"XI$1,14P7JZ=L_P!M.H+"H7J+VQA8=J7*T,GQ!+(9C;PF
M,9OR.%9M-8M,8_)W2KF4;1[;)L;6,5N9<R9A(12T#4``L1IROON/^;W/TGP!
MIROON/\`F]S])\`:<K[[C_F]S])\`:<K[[C_`)O<_2?`&G*^^X_YO<_2?`&G
M*^^X_P";W/TGP!IROON/^;W/TGP!IROON/\`F]S])\`:<K[[C_F]S])\`:<K
M[[C_`)O<_2?`&G*^^X_YO<_2?`&G*^^X_P";W/TGP!IROON/^;W/TGP&OC4Y
M7EU/=<?^'RO_`&>Y'M\3>5_[3#O-7@*G[[]1DAMEGT1MVGM0^W$DY-AMM--7
MR:.,1T(H7,]V66W#9!B\G,L(Z4FL/F7368=IK-FS=.-$SE)R8S=<$@BP>MK;
M3'=TI7;\=M\CCGC",WZEE<T@]L&,OC<IC&S.![?[DR,K#S6,9?(HS)-S,9RI
M%>#8I*B^<A&&YM%N8S8B@1)B?I7.F'/9W'XMOC>X32)FWFU8X7DF2[`3L''R
MC_<C=:<VHCG+)M.3S)]'?5;/<?,614TQ79IJ)N!3!-1N=<.KT824Y96CJ/`/
M$);_`+/<CW2KP!'^DP[QKP'(K)_2Q;(XKOGNWLSN%M3N#CYMHLNDX*7S@^V"
M&2P$Q/PF3(-(=Q`E8Y*1_)KR,>FK*M`2(9\<[<&K9%=^J@@H$@;F^D1VRQ#9
M+&-[C;1YOE&(Y/CVZ"K*-?[<0,!*Q+G"LJQ#%9C%9]A.9VHK&*98YR%%VW52
M(X8*M&1S+J$5T4C@GA/2&XYE>Y$ABN*[&9'-JP^18V#G(C0>,,I88R7VQS#.
M8/,F>/*98M-&3'$L:72:(K*-W;A"0:@V!0KHI.`=?2=UOX?U293D.+8?MB]V
M\>Q6$PV7+24O&XV*4JU#<)_#+0[17$\FF1,2&?.P77,Z,W(+]\Z;H%569OCI
MAT:>)S`M'()&BWBG+K:;19DNFDZ/IFM;**'D%2IIKCYHF$I@`!J(#W<!RCC?
M2=;'%/MM&;KX/-X)NGN/+XZQB\`8;:N]SI&)1E<R=0N(3DED&.R*#9")6DW*
M[I)?2*"3GF$$=5V4R9PD]]UEXS%;]+;)DV:F/KN\G]U<9CI$N,X:BKE4YB+?
M"Y%XC#`EGJRAV&<P>0E?%?22\>S11CQ2?*).C)-^`CW(_2+;>X9@L3F+K8[,
MD(V5E-C5!B"85AS9VBPW+VEPW=;%IPI4MPEF2\ACC"40@63`3IR#W(V*;)D0
M2G;+&"Y72_NXVWZVBPG=7&L?:X-#Y+%SC9OB+ADS45@%L:S+(,5?L#+04NO!
M.;'\*J(*L55V:I1`R"JJ0E5.%C=.5]]Q_P`WN?I/@#3E??<?\WN?I/@#3E??
M<?\`-[GZ3X`TY7WW'_-[GZ3X".D$Y;\KDC5W'6?DZ@;@\.<@<?\`YLFA/:;Q
M02EJV!0H5`:',4W:!1*8)"*G,!;>\C!H!+[8UT6X0!KJV@,J>T#&*O;6MH')
M6MAM0,@G,4"KR,$?-NI&N@`1HE=0!E1I4P'$.^@&*';:(F#&G,4_#(RM!I^+
M70A6TU!IXJ'9=3L\E?W0#(IS'G6O(T!H:VL:Z&@B"]@FI*EN`IC)"(=E0*8.
MRX!(")BE+@S*";J-2&KJP#Q;OS3"M(:8F+SK(3`!SH"/F%N`BE!]L*8@+3IS
M`WZ;R-+75T[XUT>VO/:-])4E]E[:ZEMVFK2W4+I`'3F//L>1H5U++XYT:VHO
M-*^DJ6ZP#M[J4NTU*4U"Z8<VMQ?1(=$VZ?71@/I$<SV;P^5ZD=O855A'RZD6
MN&,S^1,SIEP_<;,,6+(%BLEW&V^8(%;0\JX(99NF8#&`ZK2,4CPOKG3>35@T
M2*F8O$_K'B"FBG$.ESAI9=#*D5L!ED]`0`H&,?E0`@%$^NU`.81#\V?I>_VE
M.%]$[U2H=+<STJ36]4ZXVQPO<]'+F&XK3`X9:.RZ1GXX8U-@[QK*7@KL5L:7
M`5@.9,YE`+0!3-<%`8S]L*W<F(^/EXKT0^^$M%2;1I(1\G&9]DSR/DF#M)JN
M@]CWK;9!=LY:/&XG.DJ0QR&*H0P"8"CJ`M+^U\;V>;=Z'C?T:67VYIEI;J<M
MJ6UV--;=:M;6MNH2M=,VH`7]KXWL\V[T/&_HTLOMS3+2W4Y;4MKL::VZU:E:
MVZA*UL-J!SO@_3"]/L7UR9%Z2Z,]`!O:EU..<<80S[(6N1Y*O@K')WJQT)'=
MDF.J;#FBX'>#(8X@L#SJ)`=+-B&_VA9XX<AT0#]KXWM[*^AXW]$:!6F9Y:';
M0M:!^0T:`)@-^X`AY*B#6RS]LQS?`F"$IG7HJ-U,+C';L(]I)99NG+XZP<OS
MH.'!&2#N8V89-UW9D&YE`2*83BFF<:4`1*'Z(/0X>E?:^E^Z?-QM_,6V??[&
ML=O=W'^T:V/Y%.IYJI+23#"L7S!69:2D<VQU$C,I<Q;("B*0J5;J")@U2`F'
M78Z<P-]CR-+74T[XUT:VH/=&^DJ2^P3M[J6W::E+=0ND"4$I7G78IN8\AQ;H
M`50\:Z,04]29Y8AJ/$KSH&41$X@L:X"GH1+4*8`5&3F*FL>1H`(J671SHPE`
M1=Z5U)0MXE*9"ZE+A(I2EY=,`4Y>IK7D:`5-;6.="(!5:T#"$H%P@44P'NJ)
M3#V7`!0-.7K^%QM*_)SJM+@[*^*4K;7]_P"QP`"<OYMSR-$*ENI'.@J%4+[:
MRHVB)2J`'?03%'MM$#@CC4I8&B%7,<0H"-2!&NB&`NLW%0`J[:VF,4J]!T@`
M!43&AK#"J"PB<P%FH\C34TM2R-=$NIR.M965/9?8YMK=;J)5NTS:H8*G,`!+
MWD880!/4MC710,(`SU;*RI[`.)'%M;K=1.MVF;4#)4YBA;GD8(T)?;&N@`1`
M&^I:`RHV@8Q5:5K0#D[[!$X(9!*8%K07,:I[>SJ4(QV-:.FPB(`#UV(4,`C[
M`:!3M+2\`6BG,4&CR,`:&I6-="`#16T1#Q8*@!A((AV5`#!V5`2ADR<Q0UKR
M-`1!2RZ-=&`!$'6E<`2I;@*8R-U*7`0]*7ETP#IS`WV/(TM=33OC71K:\[HW
MTE27V"=M=2V[34I;J%T@#IS`WV/(TM=73OC71K:\[HWTE27V`=M=2V[34I;J
M%T@1.4I87C00<1P]KS1.,:Z-HB)'-@JB#LX&#2,D4:*(7&(<0J!P(0%HIR]1
MH\C:5-2L<Z$:54M`1\4"H@42`/E$!'LJ`%`!.7KVNXVE0[`CG5:7%KV^*=XE
MN_<$0\E!`*G+U+<[C1"I+@+'.BB(`+?4M$90UHF*56G?03D[[!`X!4Y?S+WD
M:-!3U+8YT6X`%EK65E#6"<".+:W6ZB=;M,VJ"-)*6!^L)G,=^!QH+&+&.BZI
MRKG%?2,+T`(42`O:455A(*B8B`6&UP5E3F`LN>1@TT[[8UT6Z@,]6RLJ>V\2
M.+:UM!1.M=,VH&03F.RKR-$:%NI&N@J-$;Q"LJ-`$P*"`=M`,4.VT1,%7-^2
MO"SF+\VLU5'ZT=/M@MVRK>G_`-5NRMUP*NW5U3=U*4#R\!;7@#@*7]+R>Y47
MTB=/DJ3*\0<H1_3KM;)(,2[?28.5&C;;B#=-6`N%-RVR"CH&Q"I&6'1(HH`G
MM3`;2ALMA=W=W-[XQY,G1PW%8I&#Q&3:OOJK/2A59>>0EUIS&E+LT:,7:V.%
M9-5"OV#EY'OVSY%5!0Q3=@2]C;/*TMQ\Q++ST&^7^IF`"52.QAY%)`D,UN-I
MD,BXRB7.90A@.(F`X`8#`%H6U,#\*C*>+J^[VE?#6_;X:I2G-.>S^D:UKP#9
MW.S)_MCMKN)N2Y0-/M]OL%R[-UH*,CS$DII/%,?D)X\4P,=^<@/9`K#22J`A
M><.`YQR_I-4(S,I2+@]FG\MM8VR+"<0Q_J)5FHV`V4R61G-JVF[$C`QV6N#N
M&3C(HZ.>J1$1'L#R19?($A8*JQRRR`*A8+I,ZQ4>K5JJ^A=J=R-LX-7$$,UQ
MU[N?BT9!.)N,#=#<K;9($81EEDO(QKA-WMD>0*1VFW$S.1:G2$X`8>`MCC&%
M0^$QA87#8;$,2AB.7SPD3C.)LX&-*[E'J\E).BL8MRU:@YD)!RHNN<"W*K*&
M.81,81$'"+>3$2B+UB(E$1*(QBHB41`2B)1\2J`B`T_<X#Y*VDDR@1-ZP3(7
MV)"19RE"HB(T*$C0*B/`?6C*_*#/YM4^D>`-&5^4&?S:I](\`:,K\H,_FU3Z
M1X`T97Y09_-JGTCP!HROR@S^;5/I'@#1E?E!G\VJ?2/`&C*_*#/YM4^D>`-&
M5^4&?S:I](\`:,K\H,_FU3Z1X`T97Y09_-JGTCP!HROR@S^;5/I'@#1E?E!G
M\VJ?2/`&C*_*#/YM4^D>`01J,IRZE'[,/=\K_P!FJ=_BCRH_TB'>/`0CU'[\
M%Z<<%A,WEX]MDB<YN-@.WC:,1>1D`Y,ZSF=1A".FB\W+MF+QQ'D5,XT#+($.
MFD<5%44BJ+I!6W#^OISF.;[D8]%;42[K#]JE=^ULFSB%=M<B45QW8J)Q66)D
M<!C<8Z!M/I;CHYG')P[!I*JR2:BQB.4$CHN"(A&6(>ENV2S6<@XTN![YP\+D
M[K:U'$\CRC8R<Q]K,.]R=TI[:1$PL9K)V3Q@3$<P@OQE0%W39FNFZ%`$5&YW
M`=3(Q&4%LI1^S#\82P?T:IWA*O`$?Z1]4>`KEU0]0\YTXPNW,PCMOD6ZZ&;[
MA+8M,-\.B7+AWA.-P>WF>[G9'GK]DB=^M(M(6(V_522;%T1</7*">LE==P%5
M-U?2;1VVV'X=E"^SN4RQ\UCMYY`N'RSS%\0RZ&8[.96TQ.4>3$3-90X:K1DB
MY>IF449KNU$C+))MDI`3*F1"7#];ATYMI'EVBW"6C)>1Q9M$9(WQV.%K+Q^;
M;2;I;JX?,HQ"^6-LD;$G2[7GA4VCEHB^;R<HUYA%%$P',#9Z6.N]CU8Y-/XC
M&;93^W3B&PV&S,9.>-%2*,F!L]=8VZBFI862=BD$2L1(RJKPS36?*NVK8BXQ
MSU4H=#5DYI-%4Z#IBX7(DH=%N=FJW(NJ4@BFB=P#U84"JG`"B>P]H#6T:4X#
MEG%^E-V\9CMS!;I;=;@85N?N1*0+!M@6,X)*[GEA6F09:IC6+SDODS%[C::,
M.\=E,H"IF9*.$EFK?F'1`34"6)7KD6C-\&NQYMI,I<94_P`HW3PN"<$'&2KS
M4EMU%X9/H2+!@.8&%KB&9P^3ZC>4=N&S=FY9\L[!-<XE2"$)#TK4$SAGLR;9
M3-Y%&-E-DV4G'QA\<D)>%/N_MU'[D(1T]'$R0%(K-,?*_0C$(FJGB\PZ:-6[
MDCA5=)H%Y.FG>5?J)VIPS>&/A1PA#+(R;2'%7Y&\JXAE\:S'(,4=M1E(U\6*
MDTQ=0ASIN61UV*Z9BG;K+HF(J<+":,K\H,_FU3Z1X`T97Y09_-JGTCP!HROR
M@S^;5/I'@#1E?E!G\VJ?2/`1V@C*?E;D1&09B7\G<#<7PQ0!$`RR:.<0/XD-
MHF;E4('FC0QRF[;1*8)#*A+A9?(L34!.^D6J6X0!IJ"7\:&LO%-:G?;JE[],
M=0`$)>@5D60C0M:1:H5&U(#"`>)C0!,4X@';0#`';;4P&A+T'\8LJT&@^%J]
M@VB%:>)]H`:@_N!3U^`!0EZ&MD60"('M$8M4;1$'`$$0\3"ZPQTA'NK8;NO"
MP$3%M*@S*5)^S3[75@*1"@"4QEI$2&,0KB/`0`ZJ`C1,EP)'[1U`.0%IT)<;
M[)%D6NKIW1:I[+N>T;J29+]/5;W>QOT3^QU0T@#(2XWV2+(M=2RZ+5/;47FE
M=23+?I@HA7NNTC]VH&F&3(2PW6R#(M1/;6,5-0!%<2`/XS"X2E.F`]U1(8>R
M\+`9V=,Y!:#1(LJW>IADF'J<NE"'='#2RZ%5*KIFBLO`.5`H*"IR9=.R_F&8
M!S2`4YZT?1@='?I!YC9>?ZL]H<4W0F=A\T8YC@\DX8.HQZN@W71=2."Y.Y92
M95<HVUR)TB1:0@G@JL'2J21C$\TX*A>V/BW,6R8QL>I$,8V.;,V3-@PA.29M
M&+--B@BS9-D)`K=FV1;-U4TB$+8D4Y``*)4."HB,L%E\@Q-32U+8M4E]O(ZM
MM9,]FII.+>^W6)WZ0Z@8(C+A9?(,34TK[8M8E]O):UM90UFH*3BWOMUB>RTA
MU`2+(RVM'`9^U,8'-3B2*5!,0*Q$JMP"Z<BD*AP4$@ZB5NH4MQ[1*H"L$9>@
M5D&(C0*B$6L%1`J8"-/%!I4P&'U@,`>I40KQU5])NSW6ML3G?3AU(8EC^X>U
M>X,:9E+1#V+50?Q<BB54\/E&+RZ<B+[',LQQ^8CEA(-C$7;K)]@B4QBB'XC8
M3]ISQ#T;^6Y#Z-KI2]%:S:XGTU;J;@=/^&XY!;PS37(LUF<,S2=Q(,H=0+;:
M:<R&:S/<"49$DGIG"[Q^[=KGN65.H!RA:CHU_:Y<UZKNL78GI!DN@)7;?(-Z
M=[,5V<>S(;PRF12>`K9!D*T',3,QB3C:S'WKD^'IJ`X>MCKM!*1DOJ'1`PBD
M'[1^7D^<=BF]:D4,W1HJ>+.8FF*DSRR=071%0S<RJ(G]O/=8:B:.J!N`5&0E
MA$]DBR*`BI8!HM4UH"+O2`U),M]@*(5[KM(_=J!IAD49:HVR#(`J:@#&*C0!
M%:P!'Q(*VE,F`]U1(/=<`%`T):O](,J5[O#%>ZO=7Q+[GL_=[?6X#`(2P"%T
M@R$`$MP!&*A4`%"\`'Q(:7%*H`=]!.7OM$#`CC6\H1H@`/FA4P,(B0T4=(]N
MNW%0M`79@43@FO0=$M-4@T-IB*H+"(2X67R+(U-+4MBU27V\CK6UDSV:FDXM
M]E9K$]EI#J@%0EPLOD61J:>I;%JEOH#/5MK)FLU!37I[*W5)WZ8Z@!4)<`+=
M(L1$`)<(1:I;A`K<#B`#)FM`YB*B'?34*';8-X(G[>5,UH=^T.&LRN`D2H81
M$KIL(F`IG+T`\X!'[V-H?;%I>`+10EZ#219`-!H(Q:HT&U4"B(>)A6AC$$>Z
MH%$.RZI0#(2X@:R19%$04L$T6J:T1!UIB8`DRW6&41$>Z[2-W:@6`'0EQOLD
M61:ZFG=%JGLNYW2NI)DOTQ5;W>QNT3^QU0T@#H2XWV2+(M=73NBU3V7<[HW4
MDR7Z8*M[O8W:)_8ZH:0(W#>4%XT-SS6H"\T3>%',5$3$<VBJ;75$0!,Z1>Q5
MO<*9AJ:\"$!8*$M4:2#(`J-`&,5$0"Y00`1\2"H@4Q`$>RHE$>RZA0SH2U>V
M094J%?Q8K6EQ1$*^)=@B4!"OK@/J=H!4)8+;I!D:@DNI&*EN`!;B<`_&1K;R
MD5`.^FH7OL&\,$0EPLOD61J"GJ6Q:I+P+R6K;63/8*@)N+?96ZQ/9:8Z@)$F
M\J#]4POF@CR4:5<WA*A`6.FNH*ND?F"B4IB%7`"BLOIBL0:%L'7!65"7"R^1
M9&IIWTBU2W4!GJVUDS6:@IKT[[=4G?ICJ``A+T+618B(`2ZD6J`&$`0O$`&3
M&VXQ5!#OH!R]]HB8*N;\$=DG,7YIR@X$<HZ?;=%J9L!?_JMV5NK<Z<W5'N[J
M!Y>`MMP!P%)^F1+<N%Z/M@IM/+(652B^G/;&7;0\?MRZ6E'C5IMO"OF<.T*&
M=IE=R1VQ"-R&HF"RWG6DNM`/+IRWSW8W]3R4SYG$;?F@HK!Y5H#W#I%_XDGE
M4;*+OR44RYL"1(Z2C#I-SU#G&H$=I@9NY0.(3WC;#*D=Q\Q++Y)%R*_U,P`0
M58XRI%)@D::W%TTS)*S\H8YTS%.(FO*!@.`4"VI@?Q6\GXNJ'B2%WAK<1'PX
M.[FG-`_"_+P&BW`R.8P/`LWSA*/D\O6PS#\FRM'$\;B.9R')UL>A'TNCCT$V
M!R87,S,J,P;MDP"JBRA2^KP'&)?TQNXJV1)XIC/1=N=G3M9LH=GEN'$SB2VW
MF7#3\H[)\;'<D>;6QTM-1WCF*P:#18D:520;Y&5P@F8K,Y5PL/FWI&<WVGW"
MQ3&-W>EW=3$<.E-I-O<XS+.X6.5S-#;[<+.HZ6?+[3R+6+00@YA_C2T6#=R_
M0E4[U%R"5L`5`0ESI]Z[L:ZAMR(_;"*VOWZV[G)7!<AW!8R&Z6UK#%X52$@'
M^&M2H*/66<9`JVEY9IF[5R@V612.0J2Z2HD<('2`+T<O*?*:'S<'QO@#EY3Y
M30^;@^-\`<O*?*:'S<'QO@#EY3Y30^;@^-\`<O*?*:'S<'QO@#EY3Y30^;@^
M-\`<O*?*:'S<'QO@#EY3Y30^;@^-\`<O*?*:'S<'QO@#EY3Y30^;@^-\`<O*
M?*:'S<'QO@#EY3Y30^;@^-\`<O*?*:'S<'QO@#EY3Y30^;@^-\`<O*?*:'S<
M'QO@$$<WD^74I)(`'/RO_9P=X2;P!'\+]4>`H]U#];,IL!N]';5I[1YIN>1W
MBNV.3R4[@4//33C&&>XV]#':A:4R:$CL>=HL<6QF,5=S*[]!Z[4`(\S5RW9`
MZ9.EPT.%]<^8YIF^Y$/'['S3C!=L%]^W$UF4,\D9J6E\=V5BL5E8:9Q+&P@&
M,#D<CNH&9,D8R(2GRR31;6(Y3*9NL4@1QB'I6<1RN?AV*_3]U28OCV4N-KF>
M*9#EFQSW'U'[G<?=*=VE>A*1$GE#=:))A&00Y'4BFDH\?!%.DG@-@041.J'4
M6-;R@MU*22`?C"6#^C@[PE'@"/X7ZHAP'*'(?2K.,)WQW;VES/I<Z@&>.[6Y
M-,8JAN/C.$/<LBLS?M<A1C8)3&FBQ<8:2:<_"ZSI))J]<O%7I$H]JW=.7"?`
M2=GGI!YG%MHL2W?A>GG=B2B\JC-PW+F$RN&;8A,X9)X'E.*8TBSS1*'?YV1A
M$Y&CDBLBA(M><218L#W$,J>P@>.1>D%RS'LNP/&7'35NF=KN&[Q`N/R0QBO.
MKL<XQI2=A$SPC9!V+3)VCDY$Y&+=.6QF+)L^>'6$&I$7`;?I:ZX<@ZI\EG\2
M?[,Y+M.$+AT/F*,M.N%99K)N%,\<XR\B$4AB8A9B$=RJ7MSP&IGCXCYNT373
MC7#D0Z'\O*?*2'S<'QO@*#;@=9^XFW^[FX^WKGIRW&GL1P_,<.P;&MR\=9DD
MXG+)6<VYPS<C)Y5U'JC'+PV.8BQS$C`5FQY19W)(F1(F6BQD`;LIU\9;&3>\
MD.EL!E^0([436^$"RFL666F(K,Y39MGM!*$C&9ABVCB,D,EB]TW)C@!7:,>Y
MQQ^W!1V<"B`0T7TK&1CB\GDB72[N),J1,EM>@YB<6/*SKA=AN/`34L@5BL?%
M([F,I<R$&5E"1`IE/-&F8=51=@1_[2%^NF;>65ZC-I,'WF/C<CMROFL-*K+8
M7/-1=2D"K#99.X\HV=N3%CRN3JGBM4%$TQ1.0X"D=1,2J&"PW+RGRFA\W!\;
MX`Y>4^4T/FX/C?`'+RGRFA\W!\;X`Y>4^4T/FX/C?`1V@WE/RMR(C)H"'Y.X
M&I?#0\ZF631SC?SE2W-R'3`*#03@;[6TP2&5M+!9=)MS"`)WTC;;Q*#0%!#W
M8-MXI+"'?;JAWV><`#:6`"UE&XB`%N'PT`N$"I`8:<YV5,4X^M>`?:]H'+2U
M*>*-ZT[_``T.^TP5ISGW0@/[U.`P+:6$#4E&Y1$#VCX;6T1*X`@B'.!=891,
M1[JZ8]UWF@C8M)0K,I4I)%,*N@)J11"F*<RTC:8Q"&8%$"G61-0$RW`B/:.I
M<`+3MI8;[)-N2NKIUC;[+N>TJ^["WZ6LWKW7:!N[4\P`S:5&^V3;EJ*ME8VZ
MP#"]T@'W8%^D"J%>Z[1-W:GF`&;RHB:V30`!$]H#&@-H"+@25'G`N$@'3`>Z
MNF/==YH,[.V+]>"2(NY2>)AD>'J:!(5-T(&2R^&5(L*9X7+0+RMH*:G)ETQ3
MOYAI3FD0>(-I4!+=)MQ`!+<`1M+@`R(F`/=@VW%(</5I>'W/:`5O*A;=)MS4
M%.^D;;<!19Z@![L&W4!):G?;K%[]/S@"-I4++Y-N>FE?2-MOMY'5I[L&S5T7
M%.^W7+WZ?G@$;2P67RC<]-/4I&VWV@QU:>[#6:@HKT[[=<O?I^>',OTN77=F
M7HSNB3-^L+']LFF^<CMUE.W\4O@J[][B3)>.S/(8S$Y*8>9#'P&7N8E"*"04
M7`XH)I"8Y4SJ=P*!^4[:K]KM](9ORC-O-BO1(N-Y6..+LV\^XVJD=Z]QT8!:
M0344CV\XYP[;&51C7#Y-HL9(JVD*I2&$H"!!X"6O_P!)M],/VT]!-O%W#3_Y
M%ZGZ5H8`'_\`HWVT$0'][U^P*9F]+%U<#UBCU^A^S4Y@'5N&%&P4F[8[?=4(
MNBQXD7:DGQ@PV;+"&SXL,=.*^L(H^,C#$,PY@&I@2*'IB7I9>KG`NKC/NNW#
M?V:C+X'JLW,Q='%,MW6;;>]4!GCEH09`CV8CX<=F@AX;+LD9KM6LS,-$D9&6
M:LBI.%3$.<.`NDX_:7_3"H(-7Y?0+[XME)!%P4KUU@W4T9D^1:N9$C86`%V+
M;*F*R4<E36JX7*91(UH)"<0`$QOVFWTPPW6^@EWB+43VUP;J?-:`BYL`?[F@
MNL`Z5>ZNF;NO\T`?VFWTPW;3T$N\0!4U/_D;J>$0`15$H"/Y&@K0#$`?+:/W
M7F@?_I-OIAO_`/1+O'2O]1NIZM*UI7\C7W/9P#$W&_:O_2=;.XNXSC=WT-63
M[6X4R=,63W+]QFF_^#XNV>2"Z+=BS<9!D^U4;$MW4@O<F@0RH'44.`%`PA0P
M=X/01>F'SKTPVW&_>>3>P49T_1>R.98+AL<2-RM_N`QR]YDT&\GIVR7<8CA#
M)@ZAPCBU;(HKJ)(R:!E35`IE@[RD;2P67R;<]-+4I&V7V\CJT]V&LU=%Q3OM
MUR]^GYX!&TL%E\HW/32OI&VWB4&6K3W8:S5%%<0[[=8O?I^>`5M+`!;I1N80
M`EPA&@6X0!N!Q`.<&V\4U1#OIJ!WV><")^TE#-;3R2)@UF=UD40YA$KIL-P%
M.+XH4,41^]C;7V1:7@"P6TL(#24;@(@:@^&UH(E5`HTYP*VF,0?7M'R]@9,V
MEAOMDVY1$%+*QMU@F!V"8C[L"ZP541'NNTA[K_-`.VEAOLDVY*ZME8V^R[GM
M*ONPM^EK-Z]UV@;NU/,`.VEAOLDVY*BK96-OLNY[2`?=A;]/6;U[KM`W=J>8
M"-RUDC/&AO$4JASN@/A93E1$Y'-HJ'$53#:DHD7L50N%,1&Z^TH+!;RM1I)M
MP"IJ!X:`T`3*B7MYP*B4IBAZ]HCZO8&>7E:A^,V]*@(AX=WA<41"O.>J4!#]
M^OJ<!@K>5`2W2;<P`)!,`1MMP`9L)P#W8-MY4U0#OIJ!WV><`1M*A9?)MSTT
MKZ1MM]HLM6GNP;-4$5P#OMUB]^GYX)$6LF5^J89%$QN2C"N!\+*4JQTW!Q5%
M,X&(8H*)D6"T5EM,5RB!2V^V@K(VE@`E\HW,(`G>(1H%O$H,]00#G#6:@I+T
M[[=8O?I^>`#:6H%91N(@!:B$:`5$`0`X@'.#2XQ%!]6EX?<]H5=WX3=ISF+\
MTZ3<B.4=/MNFU!O93JMV5`U?;EK[A[?4IP%MN`.`IATHP&XJ72ATYKI[D-3%
M_(%M2Y:I*81'%*BV/@$&NR9J&0?*J*`S;&(B*@$$ZEE]MPTX!/L-N?OCNO-9
MYCN8L'6W#["HS;R3;R"V,D>1>0IYY"2,Z=!FC*L8*1:NH-JBV3<IJ%N2<*J)
M"!M.\0G3&8O)6VXV8DE,J)*K_4S`#%63@&4:!4C36XH$2%--PXO%,Q#C=4*W
MT$/-#@'\5K(>+JAXH-?#6XUY)MW<RY[.^O?P#8W/R6<V]VTW$SY@S?Y:_P`'
MP7+LO8XK%M"$DLF>XUC\A--<?CS-V<DX![,N&16Z6FW7/>H%J9QH40YS3?I"
MMTV^6R?U>Z<\CE=E!RK"L6QC?V5?Y7%8ID$A.;7QVX\Y&DQ:(VARC/ADS2+M
M7&8<[:-<Q[S(D2M'3EFJLFD(2MTA]:&:]4V3R\),[#[B;$M6>"AF[)+<E-ZT
MRKE5\^R+#HAO,0+[!H*):J9#'0!I1NFRE9%PU;'(+U)L#AF9R%^^4DOE8WP%
MMP&>5D?E4?@3?^'@#E9'Y5'X$W_AX`Y61^51^!-_X>`.5D?E4?@3?^'@#E9'
MY5'X$W_AX`Y61^51^!-_X>`.5D?E4?@3?^'@#E9'Y5'X$W_AX`Y61^51^!-_
MX>`.5D?E4?@3?^'@#E9'Y5'X$W_AX`Y61^51^!-_X>`.5D?E4?@3?^'@#E9'
MY5'X$W_AX`Y61^51^!-_X>`01S60%NI24$/=\J'X$W[PDW@"/?ZHA7@(.ZD-
MY9O8+!83,64$ZSMU,[C8#@A()J9Y&K$0S&=1B7DJ1U&8IEB:?@[50[DYGI6,
M>5-(PN'C<@7<!7#"^M+<K,<XW'BVFQ&4+8#MHXW\<2.51;N6>Y!D6/;.Q.*2
MF+R.&X\[V[C,=GYS=@V8-4&$,$\D_8KIN2+E,9LJ'`1UB/I0F^3Y!#LWO2SU
MAXCC>4N=K66+SV6[/)PCM=SN'NE.;42WC<,Z<E-$EP26B4I!^BDNZ>FAG23P
MJ`(*$.8.HL:VD1;J"$H(?C"5#\";]X2CP!'O]40KP'+S</TCNX&UF]V<;893
MT>]2<UA^(9>AB+3<O;G$S9DPR=>4=Q!H.0@V3B#Q^.>,W<-DC!4^G(J*&?F6
M8(E571$1#;3?I!\\:['8IO=!]-.Y\E%Y@.\)D(:344CI#&$-MMQ(;",=>9@E
M"85E;ME'9Q$RBTSS#5!V5DW9*)D*[$P*$#0H>D>W&7W088`?I1W@91\ID>/P
MK.7>-WQ9E-/*\(?Y7C97V,EP/32E)-VFU1520?.6T6R65>2#AJ5N=(0D#I2Z
MVLWZHLNRW"\CV"W$V63QC%,?RIKD>4I/7D%DSEYF!H9W'P2\CA.*J'1B!(1L
MJJN5$ZLJSDFZ"2J#'FE@OYE3Z9QW&,CR!H9::=P4#,3#6&0;HMUI9Q&1[AZC
M&(N"-WID%7ZB`)%."*HE$];#4M$.8&WWI0?K2RPN.FNFSJ63SG('YFV0QF&[
M=ER'$L9B2N2)AF*.83B>)(Y#BKE`%^569MU!?N&+E)H+@I4EE0^)WTDFX$/N
MYN3M8PZ8MR,L1PA7>QK#9=BYLA=1&5/]H2IJ!'Z$CM5&+Q2DJ5L[37<$,\8I
MK%;`R7D4WC11<&TU]*#N<XQ&9R@G2%NW(.8;)=O(GP*#-+RCJ6A\WQES+I2<
M.X#;!`5)N;G6`QF/Q#E%JZ?>)13J0-%(2!!(%_NF;=R?Z@MI,'W?E,7F]L9/
M,8:55>X+D*!',MCRT/EDY`"V=.5XN&.YUPBP6(J5N5)0BA3)F43$JA@L/RLC
M\JC\";_P\`<K(_*H_`F_\/`'*R/RJ/P)O_#P!RLC\JC\";_P\!':#61_*W(B
M,J(E#;N!J3D&WG6Y9-*'\^MQ;T2'3H'8&I=WE#@)"*TDPLNEQ,)03N]PM@OM
M!F"@C3V.H**H]G=K=GL"\``TDP``&7,(@!0$>1;!40*B!AIZEQB''UK_`%@X
M`Y.3I_2YJT$*\BU[[3``T]8P@/[W``LY,0-27,%0/:/(-1M$Q7`$'M[[!53'
MU]+_`)0\`ACV4D#(A22YR=KH"B:.9%,4QEI*TXD(V:)B)#+I#][`#:';6\QA
M!>=I)&U+)<Q+M6SW"V-IW\_I=_LM'F$._P!ER_;[,W`!VDD-]LL8EPJV>X6Q
MM.X7NF`5]EI`NB';[+0[?9FX`%I)")J2P@`B>T.1;#:!C.!(%1'ML!5,/7TO
M^4/`,S/6#U6!2!9\9TF&28>?0\*9.:"3+H8Y%;%(+(P`6H@"@'Y<HIF(!]9O
M373!Y`TD@$M9<QJ"6X.1;!<`&1$P=G=>!#AZU_K!P&2M)(++I834T[O<+8+[
M19BIW>QU015#L[M?L]@7@,$:21;+Y<Q[=*_W"V+J6<AJ]WL=7EU^[V/,=GL"
M\`$:21;+Y<Q[=*_W"V+J6`QU.[V.J+=;N]CS'9[`O`,_.,"AMPL;D<%SQE$9
MEAN71DKC66XMDF-PTWCN2X[,P:\9-PLY$R3!^R?1DLT463614M3.FN8AKR@!
M#!"W21T7;`]"^S<7L)TMX-#;5[91<K+SWA$8SYV0EIZ=<E=2<WD>022SJ<R6
M76L*@1R^77629HH-B&*@W13(%FA:25!I+B`T&@\BV&@B4X`-*]M#&*/_`$?7
MX`,TDA`ULL)1$#VCR+8;!,#H"#01\[3%5,>WOTO^4;@`[22-?;+"2[5L]PMC
M:=X/M/O'SM(7"/?[+E^WV9N`2`TD1>O0++*%,9!$Q#"P:"5,BAYDJ*1!Y<AC
M\N99(PW*J"84O8D`YA."LS22&^V6$EPJ6>X6QM,#"\%,.T?.T@72#M[]#M]F
M;@`6DD(FI+"`")A`.1;#:`F7$H=O?8"A`]?3_P"4/`9Y21K7Q4:5K3DFW==6
ME>_V/9P$>[K;/87OGMMFFS^[T)!;A;9[BX\^Q7-<-R:!CI.%R""DDT$GC-XT
M=$52OHF8Z*I0!1NN)%4C%423,`1WTK=+&SG1YL;@G3[TY8C$[9[38$S,TA,:
MBHY,Z[A91=JK)S602[M,DKD>3SKA!=9])O3*O7:[D5%%#B4@\!63TL/6MN3Z
M.+H7W7ZO\$VW2WUF=J7VWXO\`=J/X-D\@<FS?$L3R"<?S4%%S3R&90#&1<OE
M%Q;*()E,(*6$*!RA^/2&_;&NOS)L$S'=?&/1MX//;5[=OH2/S[<2)D]W)C",
M'>9"NV:P#',LQCL<-CV./9YPDHFU*[5;F<*+`5,HB!0$/T6>@4],=N]Z8S!N
MHC-L\V%A=AXS8_(]M,5AI7&9R:RV#SN7RV'R.4RAND_F\?AFS)[C*<"S44:H
M*NE449E$51*`HF5#OA(LI$S02FESC[<RK;',SB(E=-O.`JC9V3V11&M@VU[!
M+0#`"X6<F(#28,`B!@`>0:C01*J!1]>T3E'U[/7'@`S23$#6RYBU!2T>1;&L
M$P.P3'M[#:0K)#V]^CV^S-P`=I)FOMES$NU;/<+8VG?S^GW^RTN80[_9<OV^
MS-P&3M)(U]LL8EVK9[A;&T[^?T^_V6ES"'?[+E^WV9N`0N6<@9ZS,$J<!]W:
M5(]F8J0G(Y$HB8S94_M9%4RA11*[2[;KA#@%PM)(1&DL8*B(@'(MAH`F5$`[
M>^TIRAZ]GKCP!RDE7^EC=X=G(MNT+B"(?OE`0_?];@`K22`2W2PFH)+@Y%L%
MP%%L)P[.T+P24#L[M7_DAP`1I)!9=+B>W2O#D6Q=2P6.H'9['6!NMW>QYCL]
M@7@$2+*1+(K&&6.809195:Q[,I53)+G,J8IRMB'+K$25`2ZJ@$%<1*4EI;@6
M%:20`2Z7,>T$[QY%L6\2@R!0>SV.J*"P]GL=?L]@7@`K23`"W2XF$`(`CR+8
M+A`J`&'L'LO%,X^MJ?\`)#@*O;\(N4IS%^8>"[KE'3[;5NBA93JMV5`PU2[3
M7#VT'N]3@+;<`<!27IC@\ZC>C_8&6;[AY')*L^G3;*59P\=B^'`Y<E2VXAGK
M*%8`&/O%E%@3`C9(PE54.8`,8#&$0$-9TR;F[[[V(94.X4+N+LXZ@6.&.(]/
M(<>QA9"?/.L9568<1B[K!(=-5BU>,2`WM,HH")P.H%%$Q$+%XS#SC/<;,4I#
M+Y*85^IF`'*NM$X\R.4AYK<4"I6L8Q%,Y4Q(80$0N]L$!$0`M`?Q6COQ=4/%
MG=?#4!NY>.J/NISV?@5*<`BRP<IC,6R:2Q;4R')X_'YI[CD"[7CHMK-SS6-<
MKP\0YDRQ#TT<WD9%--$ZX(JBD4XFL-2T0Y2J>D@WK(]A6?Z#_5?<K#8EF>3"
M3!G"JD/B6=L93(H*&:)'PAL5QN7!XR$=X_&+'1;Q<FZ7:"N=1J<HAJH7TG>\
M,KX>0W0MU8HG1*W<Y*Z1Q%TLQ20=MVLFW;8@5[MQ$O,I<EAU%5EUEB1R")4R
MG)JZ@ID"5PZZ=VI[;#,\YQ_I=WTPEYCDWMC&QRV[N,R;6!D87.I.8C)_-O#-
MNMOLWW#>XWART*!CD90R[UPVDF+HR*""BQD`8TOZ3O,8.-RZ?D.BCK)1Q;`'
M.6$R_*'.%0L+%-8W%.:.YR"*;Y5`X]-R$&L@R55.JNT9*-DR"95,O;0&SDOI
M:7>)1C[)\DZ3^JW&,+AFD`,ME65X;%XY!+2&3(,%(AO"S,O`LV3YL\76.BU4
M,!3/E'3`I"$,X6*V#I-T^[IY'O=M^7-IS;_<_9I^:7>1_P!3=S8N#99*#,C5
MA(QTH9)FR%$J#YA))@<GLV[I-9`PB9(1$)PY)Y\KO/@\;\2X`Y)Y\KO/@\;\
M2X`Y)Y\KO/@\;\2X`Y)Y\KO/@\;\2X`Y)Y\KO/@\;\2X`Y)Y\KO/@\;\2X`Y
M)Y\KO/@\;\2X`Y)Y\KO/@\;\2X`Y)Y\KO/@\;\2X`Y)Y\KO/@\;\2X`Y)Y\K
MO/@\;\2X`Y)Y\KO/@\;\2X!!&LW@MU*2SP/=\J'X/&]X2CP!'\"'O'@*8=3W
M4GO+L3E>/PV%;`Y[O'CTM^3H'61XDZ.HX;.<OW"7Q">C"PK+;B;;@[QV(%M(
M$4/(%(JFX.98C=%L*JP,W#NJS?W*LYW(9DV"R_\`)UMXXW\<IS;=#(FF5YG`
M;5Q.*R.WJV$QN0[40N/S63[MKY8DW1B3OFRK%9J\+>MRHBH$;XCZ1C<G(9Z$
M;S/1)UGX5C.3NMK64%+9/MY%MI1!?.MTIS;+)C9)$-(-X2'#`1C$)ETB5=5=
M:#>).R!IG$4PZD1K-X+=0?%G8?C"6#L;QOVLH\"OX$/:-*\!R]W"Z\NH7;3>
M[-]O9?HAZC\PV[Q?,F^*Q.Y>UT6RR5++$I5[#J0\M!L9;$82'69*PN1-`./B
M9B^*)N6EX:!U0!?D77%O\RV#@=[,<Z3-UIEU/,=ZGY\$>K2#'+()/;;/(K&,
M+0DH1#:!Y(+N-RL>>N)-`"@B*:C8$$`=$5%RF"%#KNZAC[DIX2?HLW]4B'F7
MXM`IY(U8O%F^/0V4X#DV3Q\MF*Q]K$X9B[<9(QB8RQF\>,&*<BNI(/&:[4C1
MT#TZ4>KG>OJ+R_,,2W*Z<=Q]BXW',5QW(XK*<E;RJD)E,D[RX8M_&11\@VTP
MEP@$24I6PZY2KN'S%^9)([)-LZ<!?_*5YN#QC(YJ*._G)2(@9>4C84B;9$\N
M_CX]P[9Q9%6<%+.TCR#A(J0&2:N5"B>I4E#4((<O=OO2*[FY&TPF*G^D'JI^
MN4U(@CE:F,X`4N#8_`<PF4,QCLBR7&HL9J&=H%<@T12O7=.&*I2>U'065!5*
M]=O4+'YSG6)-.DW<^9;8U,[]0V/O6".9%6R,=I6K)_C<LHNOL,GC3>%S%MKI
M:S22?W.U6J3('>J43@PX_P!(SU0N\5R2</T*[UJ2./9/M[%MV#()\R&40V9X
M_(RVOC7-[*-IE2;D7S)DWCT'C)HU:&R&/"6<1XI/=(.A?3-N7F>^&TN#[HYI
MB&1[393E4/*J3&WT\W+XMC:\5E<Y"IMW!Y/&X%XNFZ;QQ'"2IFB)5DE2G)<0
MQ3"%A^2>?*[SX/&_$N`.2>?*[SX/&_$N`.2>?*[SX/&_$N`.2>?*[SX/&_$N
M`CM!F\_*W(_C=V(!MW`B)1;1M#6Y9-*FJ8&0'"]),R8T$/-4$0\X"F*$AE8O
M0MK,O3V@G<(MHP+Q(#0#":UB%-44%!&E*:YJ4M):&`8O0``&9>B(`4!$6T9V
MT*D`B-&(!4XIF$?^>-.P"T`Y%[3^F7O=2O+1G8-I@J'N&E0$0'R5#R=G``L7
MHW4F7I:@>@@VC!MN!P!1"K$0$2"J00K6HI%K4!.!@0Q[![R)`+,O25%T`"#6
M*`2B9:1`I@+X8D2I#.$Q"I*"+<E;KE!4!>=D]-?;,/"7:MMK>,'3OYZRV]B:
MNCS25MU:\L2ZMRMX!F3TU]LP\)=J6T;Q@V7B\$@%N8FKI<PF`5K7ER5K<I>`
M9D]$34F'A0$3"``WC1M`PN!*`"+$:@0%2`%:U!(M:U-<#,SQBY&!1%62<."!
MDN'&T56<6JG=];H84S6C"OQ`R!A`Q3`0!*8@#>3M.`/,&3T!+68>#02B("WC
M?.`ID1$!HQ`0`X)F`:4^^#2E"T`*R>ELK,/#VBG<`MXT+[!:"8#6L2TU0;J`
M-*4US4I:G8`1D]+9=,O#VZ5US>,#4LY&^ZQB6FMRJMUM*<R>VEJ5@!63TMET
MR\/;I77-XP-2SDKQ-:Q+36Y92M*4Y@]*6IV`A<,7@.(NZ8>G$CDPB86L5YUL
M>)3W4C#"35%(XB)3)TU3``T`I0!:#%Z`!69>C0``1%M&=H@5,!$:,0`!,)1'
M]TP^I2@'(O:"'C+T!H(`/+1E0$2G`!_`:>:)@']TH>I6H!F+T0-29>EJ!P*(
M-HP;!,#D"B%S$0'3%8@A6M=$M:U/<&3,GIK[9EX2[5MM;Q@Z=_.V"6YB:NCS
M*=*UKRY*UN4O!(#%X+UZ!9=X0QVZ!BJ`VBQ,F1129*DD431WG$:F7(8MQCB(
MI%N[#*:@*S,GHB>DP\)<*EH%;QHV7B[$@%N8FKI`X3`*UKH%K6Y2\`63T1&D
MP\"HFH`-XVA:F6$`"K$1&P%"@%?Y,*U$35`Y)[6OC#SOK3EXVE+@&GX%7N[/
MW/7X`!D]`0K,/!H):@+>,\ZT4!,`T8A2\$C`-*=BIJ4$"VAQ6]-UZ1??CT5?
M1=C'5!LIM5$[WN/RTXKM_G$5EK670QS#\-R:#RIV7+Y5_B$>T7BTQRK'X^*3
M5<BDU,O-`G=K&;%$/S8;.?M'_IN.LS;C(IW9+T1&(]2NT3UQ*8#ELAANT.^6
MXV`RRCB,CR9#ATXNQ?/X&3YN'>F(^9*7E%"0$JA`*9,`!M;-]<'IFNG_`*>I
M7I/VD_9N8/%.G/(DLJ1RK:?]&KJ*F,9S`F<J)FS#ZX)33I^ME)IQ$56QA?F<
M&28F2:D$K=JV32!]].GI,/3Q=).T.(["].'[/BZVHVDP=NLACV'XYL!U*E;I
M*O%R/).2D7SA^K)3<W+OA67=OWBJ[QTJN8ZJIS`!@"=&_INOVDERNBC(>@YR
MP[0RB8JE#9?J!B3',D*9T@+(2AW;!N8SA,/9I&NNM+0PE$`\1].#^TK"`T]!
MWE8"(&H/Y!NI'LJ"@`/:[&MHG*/_`$`\HU`-Z<']I6$#4]!WE9:@I:(;"]2(
MV"8'0$$*O!KIBLF(5K71"OLC5!F[C?M`O[0[M/@^5;E[E>AED,#V_P`+B'V0
M9;F.2;*=1D;C^+030KP[N:FI-T]!M'Q<6DY346<+&*DDFVO4,!!5$0Z->@"]
M.7U3>F"W/WYQ;=38/"-J,!V=V]AIY+<';9'*WT8\S;(<B6CH[$G[W*`E(EJZ
M4@SKO46X+"Z.6.O$#)BK<'Z?G+)X+UF(2[L+A>@2C6,'1$R;DQ1(8T:<WF$6
M(4*F"H)%K<(GN!<+)Z(C28>!43"``WC:``F4$`"K$1H4#@';V^8'JB-0`9/:
M_P!,/!"H#3EXWN`Q1$*@Q[A`HAY:&'U:"`!63T!+68>&H)!$!;QH7`46PF`;
M6("`*`B<!I2@*FI2A+0"LGI;+IAX>W3NN;Q@:E@LKP-:Q+35Y92MM*<P>E+4
M[`1(L7A9!<1F'AA*RBRGN:Q8:HIK*"<QC$C2&]N!!0#`!Q`O,'M`E""4%I6+
MTMETR\/;IW"+:,#4L!F!Q-:Q+35Y=01I2FN:E+4[`P#%Z`%K,O34`H"(MHP+
MA`J`"(T8A2\4C"-*=J@TH`%M"KN_"*Z,YBX+/%GE<HZ?;162:IB2G5;LJ`TY
M9!$!`PA7M`:#W<!;;@#@*';$1>Y4#T/;.9!B>9Y3DV2QO3%MQ,XSBY(S!V9)
M*1;[;0<A&X^@NA@$R\,54I"M$A%)98XB43&$XB;@/O:;-.I',=SIO$\UC]P<
M,Q%BVG5(S*'N+X^FE(+-)5-%HB#QYMBPAQ/&M@Y9<Q5A++++E=QUS))4>`L=
MC4-+LMQLQ2?9?-3*@X9M^<'#N/QAJH4AIK<8"HVQL"S2,1,2"8!$MU3B`B(`
M4"A&G5/N#NOL]M3E&?;08A*;IYU$J8<W8X<VAY"9>2$;*9.5C-JLHG%8%Y*2
M#YG%JJ*()B+9OK`45UTD@,/`<_Y?TGV]&).F$1FW0GU5Q$[+9!$XQ!MF,<R5
M:9;D$FOD!#8UA;F;VOA#3V2-&D6V='(!4XL6ZRX^(`=!%-V$_P`GU1=3"D:W
MEL?Z;MRB^)]);_?1#')R'EU,AQK=9')\>B&>T^2O(K;@8"6=.H*9>R2<9$K+
M90JG#+)BP14=-2"$+2'I$]_XG)4=NDNC?J/RS+7<4NMCV6PV!Y%BN#YZX88Y
M$R$K.8MCF<[71>91D'%2L\T%VUEE6B[9FH8G,*2`)LE@=&)=:W5CG,3N>*'1
MCO1MW.;>[09'ES%?<*+G5<4R_<EBC@AHG!\8>1VT$;D<XV*M.S`.!;1YUG18
MQ,S8UJBQD`8V->DGW^FF@M%>@KJUG9.+5=PF6/\`'L:BVN/Q621&%IS\TP=,
MIC"599J=225+HM&IIA8L:<:JJR@)Q2X/!CUM=62>;OF.3]$V^!-N%G:;/'\D
MA8.8?RJJJ<TH0\A-1I]JUG3-FZBP2",*5D!W+XY#/#Q;<55$`T4-Z0SJD>(E
MEY+T>?5BRB'35BK'Q+>%(ZRTZJ\>S=+H/D'6V,9&L'CAV=PBR14,5N<B)5'S
MN/.H5`0E/*.M'J&Q]IM<W8=$'4WDF3Y_B^634_%12<,,%MQ+XWN$MA;&"R?+
M3;;F96Y-#LUIQFJ5$C@6!VPBVHXU$P;`]7_6IDN+1.78#T6;H(`;=[,\?G,(
MW!TL9S%KM'A.WF$Y:OE.L^Q&(C&V7Y'D$Y*PT:W9DG&#J3B@;M5'I%%'B0;8
M>NC?-C-R,1/=$G55'MX5TX2EIB+@4\FCCMV:\2W?#`J0FUK@T^]9MWJTF!4K
M&KN)(ER;ES*'<Q+,-&IUX]3ZG(HQ_H\>K!5Y)P+3(&9)!SB$:U:H.IS)XKPZ
M><_4-VM#S:33&>:,TT5E2$?M+P(1<JG`?4-UX]34\_;-6WH^^JF":AE,5`2L
MGF8X_%M(Q@]?P+9[/\O"[>3[]]'1S1\]=',D0`%NW0$#"==9-H'5KDG7RN__
M`)F+^CN`.2=?*[_^9B_H[@#DG7RN_P#YF+^CN`.2=?*[_P#F8OZ.X`Y)U\KO
M_P"9B_H[@#DG7RN__F8OZ.X`Y)U\KO\`^9B_H[@$$:S="W4I+/@]WRH4!*+]
M24>`(]L</:(A7@("ZHMR=T=G-LVV6;585D&[>7.,UQ#'T<-C(:<DG#F,FI/E
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MDLD^O:\/(0RZF6X!B*;(4(TJ/*HI\XN[.U>.C:#0[`7(7&WGR#.<"VFW%SC`
M8.;W&S##L/G<H@=OXQ)AXOFSV!8+2GU5@BH1*ZBN0SR+4[6/)88%'JJ13`)1
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MJT0R7'8>>-%S$;'HOF:SMDS<.&KE-4[=$3Z10L)R3KY7?_S,7]'<`<DZ^5W_
M`/,Q?T=P!R3KY7?_`,S%_1W`').OE=__`#,7]'<!':#-T&[DB(RS\0#;J"J3
M2B[36Y9-*C<(1MX7IIF3&@AYBAA"AP(8H2&5BZ+;68D3V@2MR42%]@-0,)K(
MLM!5%N<34I05STI1/3`!B[``#QF1&@%`1%&)J80*D`B-(P`J84Q$:4"IS4[+
M;0.1=TIXS(]U*Z,37V(A7^C*5J-?W0\E0X#\&_6U^TU>E,Z??2';U]!VT_1Y
MM/EN48IOWDFU.SD'.X+NM*;D[IXZ[R!XPVLGXV#A\GAB2KG.H!TRD&JS)L+1
MTFJ0Z0:0F$P3C)^E?_:G(UXY8M?0WXHFBEVI@WP;.,A33,X277$4Y>'W:\,=
MF34>%&A`'3,@5-2IP6O!$;TM_P"U1FOIZ'#&B7:EMNUNYHZ=_-VVW[MFKI<P
M2VZM>7)=6JFH`;TM_P"U1FNIZ&_&277TMVMW.&RX70EMNW;-72Y@E*UKH$K6
MJEX`^EO_`&J,1&GH;\9+43"`!M;N=YH&%<0`*[N"/F`J4`K7[V6M:FN"1=L?
M2=_M*F>3TK#;N>B3Q;%<5989FV2QDD?%,KQ0CO</%L:D\@VGQ<9#)]U7#)8F
M;[G,(B$,DF4%P(_%4#IE2.H4(Z#TM_[5&`A7T-^,FI;4!VMW.`#4%(1`:;N`
M(`8""`T^[&G<6@!?2W_M486U]#?C)K;*UVMW-"^T6PF`UN[9::F@<!I2FL>E
M*)V`%]+?^U1ELKZ'#&3VZ=UVUNYH7V<I==;NV6FKRY[J4IS!Z4HGI@%]+?\`
MM49;:^APQD]NG6[:W<T+[.4NNLW;+35Y<]U*4USTI1/3"M?4O^T:^GVZ,L7Q
MS-.K#T9^V>RV,Y)D"<#B^6YKM[NO#XV_G4&!G;V!5D4]P9!D$O(Q3==9NB9=
MLJ8I%SIE5(B8J0?J;]"[UJ]0OI%NA'".JWJ&V[9;-99GN79HUQO'\8AI.+QV
M>P&"?-8['<RAB9>G)2KR/GED75CDBQFR^F)D?,MH'5T6+N@_CF0"H"%01B:@
M(@<`$*Q@A4!,`^2I0]2H"`9BZ&ZDQ(EN`X!:E$C9<#D"B6Z+-44Q7((5KVHD
MK4!/>`=BZ-?28D4[M2VU*)'3O!Y;9?%GKH\R2VZZO+IW5JKJ`D!FY,^>%"7?
MD,9LW.!RI10G3*LI,E32+?&G**;8RQ3$N`3"*);A.`J`<%AF3HPFI,2!+A4H
M!4HD0)>+L2@6Z,,(@D#@@%K6N@2ZM5-0`63H1&DO(%J)A``2BAM`QEA``K&B
M-"`H4`K4:)EK41-<&.2=?+$AWUIHQ7W5:?T;6E.S]SU^W@,@R=!2LQ(&H)1&
MJ450UHH"(#2,`:'!(P#2@T5-2@@2T&'E>VF);J;>9)MON1%L,YP#.H&5QC,,
M.R>'Q^8QW),=F$R,Y6'EXQW$JM7K&0:%534(8!['!Q"@E2%,-+L;L!M;TU;4
MX-L?L5C$;MGM1MQ#-8'$,)QB.BF<3&1Z"C9=P8XC'G=OI&6>$<.7SQ=11X]=
MOG#A94ZQRJ$"52L71;*S$B>W3NN2B0U+`9W">R++35Y8]UMM.84MI1+3`!BZ
M`"UF)$PE`@")DHGSQ*#<!$UL84*J"B81I3M5-2@`0"`AD&3L&H_CF0[%F85%
M&("H\TV"O;&`%1$*_NB-/4``7"Q=]OXYD0J!@`01B:@(E4`!"L8(5*)P$*U[
M2!6H7`8`S%T-U)B1+=?02I1(V7@Z`HENBS`.D*Y!+6M10)6H"I>"9_"EDV;V
M/?O5WD?(MGC)ZP=LX1VS<LWJ3]!=JX;.8E5%RV.B]*0R:@'(<J!`.!@,L"H0
M?TZ]*&PO2/MVKM/TS[=8ULIMVMDF39>MBV"04)%1R^39;(R$E,S#G\6K+O'9
ME7B**&L=0K5E'M&B($:H%1X";'+-R+UF`2[\HG%[9[5$B*5R;@P"G='"(Z95
MRE"Z[L2)6HB<3@M%DZ$1I,2`5$1``1BNP!,H(`%8T1\T#@`5]0@5[;A,!R3J
MH#XQ(=]::,50>THT'\6UH(%$/+01]6@@&2LG0"41EY`UHDJ`I10`>T6XF`UL
M840!0$3`-*=BIJ4$"6!@K)T6RLQ(GMT[KDHD-2P68FNMC"TUN6/=;2G,*6VT
M2TP1HLG(2#BLN_,)&<8!ZI1`"J*:R@F,I9&E,`K@V.!K;0`%U+`*()BF"PK%
MT6RLQ(GMTZW)1(7V`T`PFLBRTU>6.)K:4Y@]M*):8`,70`'XYD1H!0$11B?.
MM*B`B-L84*G%(PC2G:H:E``EH5<WY051G,7!5XX=URCI]H*Y&A!+3JMV5`:<
MJV;`-U*]M>WNX"VO`'`41V'A-P(+H>V:GL)S'-,BRN/Z8=MY?&,:<DP8C:0E
M4=M8-_'02*B>WCUSI*G*5HC>592P2W&$_MG`./:B6ZA<NRQ_&9V.=XEBR)]P
M4V\THQPIF[!UCLQ@K?&&!FSK;)!-XE*Q^0RA1D45>5D%(@RS5,J!PX#9[B;H
M[?\`3:_SO<7>O=R;Q?`8_'MJ6,QG>21L6O$8X>=RC<"(C%,A>X[A8,,>QX\F
MNFF>1?)I-&RJY06<$*<H<;?PG@O+>X]^/%^$PSL>1M2UJXZS6+WBD=UHI%IC
MOMVQ,Q2O-YB)[:SPQY,N/#7OR3Q3Y_[4VX1*O,MCHW)5"9+!$FX=&181\ZV8
ML9LL0Z>.EH=Q,1*L0V6A9)]&'2758K)D<LC*:"Y2K$4*%/>UHT]J^K%Z9+8Y
M[9M6>:]T?FBMHYBU8MS$7C\-N.ZO-9B4JV[J]W'')9N$\RG'<`SG(,02=9'E
MD%AV3S&+X\X3`R$[D4;"/GL)#K%AX*0EC)24FBDB8&K==P(']K34/0@U$G(=
MUZ1WJQP#&EI;=CH1WS(WC8B1E);-<>CI:`PUDW9,\=*TD9:*D]K\MG85E,3<
MD]11:-EYB:(W:HJ'8ZBYT$`FDG63U/R>V&(;FQ_1OOM`/)'=S(L.R#:>?A/'
M-R'6WL1B`3D=GL"KC>'I8W`>+3+@K5/QA<K)4S=1)!9915,Y08F9=;/6AMS@
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MR17@((/E"HQ*:IW3AM()*1A`Z5\DX^59#_0C?H[@#DG'RK(?Z$;]'<`<DX^5
M9#_0C?H[@#DG'RK(?Z$;]'<`<DX^59#_`$(WZ.X#YY!;Y6DO_A_Q#@#D%OE:
M2_\`A_Q#@#D%OE:2_P#A_P`0X`Y!;Y6DO_A_Q#@#D%OE:2_^'_$.`.06^5I+
M_P"'_$.`.06^5I+_`.'_`!#@$$:P6%NI^-9(/=\J'^P>I*/`KVL/5IP&P!BN
M'_:LC^^$</\`]\>/`5ZW7R[?#$LVAT,!Q%3.L$;;4[N9SE2:#?E,J>99A3.#
M^H6`8E,&8.<<">W#E)HR:*+QM0C9@Z6U`,5--0*48=UQ=7$Y.PH9-Z/CJ1P[
M%\C7VO;LEY!YC$A.P/UJW1G=OL^<92W@,.F6C8,#A&+/)!3,+5%Q#.RG*Z$X
MJE:AU+C&*XME/QK)!^,)8/\`8/4E7@5[6'JTX#D[D76IUSXEOCNWAK[H-W6S
M#:3"\FF8+`\\P,?=VX3,,@23QR6C.?Q:88D;/,;(J10RQ4&02:B)G#UBPUG2
M021/]3W6&?'=O9/%NEC*V.4Y-@>_.3Y1@.6AD,@3'9O;%JHK@,&7<3%]KQ@&
MDAN8Y*B2/8/V+=R_UU-)1`&H&=AIIGJIZTF&[\IAL?TK9=(X*EN5"8O!9"6#
MR4'DMAN0X_D3UGE3O(D\//@L0$5(MXM:446<%;L$7*S(P&?)^:#SZ6NH'JJW
MFR6>A-^M@9W9C'V.'Q$Y$3BD-DT>21R<,Z6B9"'<K97C4*W:`G%:(LV[<7R[
MD6CIZL9JU<1I%PM;U"Y+N?MUL?NKG>SV+R.Z>Z>*81/3F`;<&,B0N:Y2Q9*+
M1&.&.RC5':82CH"IB9,HF+6H=W`<]MN.N#K2GD\:8YSZ/K?>$F)B=?C-.F,C
M&1L-C.&JY;D9(22=>*8!))/L@#`VC`RK%%\916<!VFL6-8FC73X/>4ZNNO1I
MN;N!A\;T8Y;-8C`J[WML/S1).7CFLRMMZ85<'4DE9#$$V3IGF+9),C=2-%P$
MPN_`66D5@N#D-%']9?7\XQB2EE^B_+E9ACE6W3-M%HP68QJ,GBN2XZ[<3#I$
MLQAB$PAD3C*&*:`EY16,Q5C+-5)9TLNUDD6X7_Z;,PW/W0VKP[-]W\7E-LMQ
MYB.G$\FPP8Y[$IQ2T3F,_#,%V3')XAED2<9,Q3!!\U.^;,W:K9R0ZK9N<PHD
M"P?(+?*TE_\`#_B'`'(+?*TE_P##_B'`'(+?*TE_\/\`B'`'(+?*TE_\/^(<
M!':#!8-W)`?%9(:;=P-2U86&MRR:6&X`CP-YY4A3&@A[6H:E#6F*$A%CER@6
MLQ*'M!,!$WAU3V`T`1-;'%[5>6,)J4^_J4IYE@`1RX``>,2@T`H5'PZHV@D`
MB-(X.TPI"(^N<U*!;:&?#UZ?TO)]PA7\75"I1+7^CJ5J-?W0X#^=OU_^FE])
M%M5Z9/,]EMM.@7IDS'JCVKW&W`V`Z3\[RSIVS;(^HO,=E<UR*1'`GF/3C;.8
MHC^.S;&E4WZ;Y@W;LB-W#H2:*"[XB@7,>>D1_:]XU=9B/HQ=IS&2K4\;@*,R
MS*+@CA8.7D8_J.D&3C1%X4*`JH*9T"D/YP*E,$5;S>F#_:K=@-LLRWDW>]'/
MMCA6V>!12T[F66*[-9'+LL8@RJK).)F1;0.^$Q(H1,4#XBCAR*)D6J#8%ES%
M2(N<P=<?V='TK_7%Z6C%^I7.^I_;/"<`V[VN?;<XUM=GNUF&Y'C./9OETXGG
MSS<:$4D,NGLN:2\CAD>G`*BDR,ERA'J/,:@JA4/TPF8+C=^-Y(MPG$+0CO-N
M%P(`6L>/80%@`*U[$B5KYUP,[.VZC>"254E'ABCDF'$M75CT$A%7+X8A2W@I
M#F$1%0"E+KB)QH&FL(Z2@/`(]<!`1EY,U!*(@(1U#6F1$0&D<'88$A`:4[#F
MI3S;0R5@N42",O)&M%,1`P1U#V"T$0/;'E[%>5,!J4[%U*4\RP`D>N6RLO)G
MLTJWA&^V:?(W7VQQ?OW)GNI3\(5I3VO3#!(]<ME9>3/9I5O"-\_3Y*Z^V.+]
M^Y0UU*?A"E*>UZ80]OEL!M-U&[<RNR^_6'PF[6UN9BW;9/@^<Q<-,0,T2,*A
M(LCN6*S),`=-)*-3=(K)`"S=Q[8D*9BD,F$H1&,,,?B8N!@3GA(*#CF,/"PL
M0RAHV)B8F,:-V,?&1D<SBT6C"/8M&I4T4$B$223\TA2E`H%#8C'+B`AXQ)A4
M!"H>'5"I3E`0K'"%2B<!#URAZ]0#1RX@8`EY0MP'`!+X=4EX.0`2W1Q@JGS!
M1+6O:B2M?/O#!XY<U])>4)=JTL\.\S4!Z!;+H\WWGFRVUK^#IUK[9J`F!BJ=
MX\3"5D2&%NBI>0S`3D*NI,E(0I3-5"@FW%<!3JF`B*)+C*>>`@J-'KFOI+R9
M+M2@%\.\R\78@!+H\P^U<T4"UK]X3K7S[P!CUQ$:2\F6HF&@>'T"X5A``K'B
M-"`J`!ZR9:U\ZX,^'KUKXM)=]:?B^GL@&G]'UI0*?N>OP&`CUP$*R\F:@E[!
M\/H:T4!$!I'A[/1$!]90U*>;:"*-8K"T;G"6D1+<)K0-'F(($7;B);@:K&$I
M^5,`T.(T74I3VO3!:2.7+967E#V:5;_#_;-/D;K[8\OW[DSW4I^$*TI[7IA@
MD<N6RLQ*'MTZB?P[VS3!D`B>V.+]]Y0UU*?A"E*>UZ8!8Y<`+68E#4`@")O#
MJFM*W`1-;'`%3Z!A&E.U4]*>;:"-^P6(UJ:7DA`%F0#<,<6ONIL7M'DT0`3"
M%>\*B(]@]A>`6#'+B`AXQ*!4#!4/#JA4JH`(5CA[2BH`AZY"^I4!#)H]<P&`
M)>3)<"@`)?#JDO!V`"6Z.-VI"Y*):U[44ZU\^\,'CES7TEY0E^K2SP_VO4YZ
MVRZ/-]YYPMM:_@Z5:^V:@9/'+FOI+R9+]6EGA_M>H+ZVR^/-]YYPMM:_@Z5:
M^V:@(W+)7G&A?%9$!6%X!*&CP%*I'*E4@%J6X2%7`H7%4H5(E>V\Q@6#'KB(
MCXM)A41&@>'T"IE1``K'B-"@H`!6O80OJU$0SX>O4!\6DA[0&GXOH(`8IJ#^
M+^X;:>6@CZU`P6/7*)1&7DS4$@B!O#Z&M%L(@:V/+V'T#`-*=BIZ4\VT`L>N
M6RLO)GL%.MWAWMFF+(3`>R/+]]Y0UU*?A"E*>UZ8(T6*P/UB^+21A29Q@&J:
M/$5K%SF$ZI0:=AEP:F*82D3`064M&MFD"PL<N6RLQ)GMTZW>'>?I@S`1/;'%
M^^\J834I]_4I3VNP,%CEP`H>,2AJ`6HF\.J:T$`$34C@"IQ1$1I3M4-2GFVA
M5W?AL=O.XO>\=.Q-E'3[07(M_-MZK=E0\T&[=N%3#VC6O`6VX`X"AFQ&-[@0
MW0YL]-8!F.93^:M.F#;N6Q#'I-?%31[V=+MK"R,5!@)<6;J<HLN!6:6HH(E2
M,`F/<&H`.'%'/4A(;UN\,RSZW1FUJ<)GKUIG;3ZI`LZD(K.DXW"$2J)8HHT1
M&4PL.9=I*@151TK<@31(IIA-4'BHI[@9LPDLBR#(D7&$8&18)PT(J51NXF-Q
MDSM#HL(./;JM:)B-IR&J)S5$0M`LJVM2T7I,Q>)YB8GB8G]DP>OJD,L><)94
M@24F`!'(&^_-Q'M=.0[1,U$P]WJCZW=Q$:+<$^5P>`YQ-82#B=S.(P_)Y/$8
M1^!W#*7R=C"/G4!&.T(YNF_7;/I9)%(Y$#`J8IA`GG"'`<BU.OGKKP+&U97<
MSH$W,FFC"%?R[_+\3=RD%&-6K5ECB<>]D,.3PK<;+Q-,34@_*6/9$=32+-NB
M=5BFLHL@W"2LJZKNO&2V*9;C;?\`1AF.+;GN=PLYQ9/9W.5BYG*OL2AL!<3F
M,9NK-8ZGA$=BJ4CE*A&QT7?-)NBM5$&ZH.'"`@&OE>J;T@>,8IT^Y'(])>2Y
M5*Y?!23W=7#<-QUV=ZU?L\PR6+>)I33K(%S[2EBMOHJ/R%DC+1L^ZR-[*EB4
MDF"Z"RI`^GW6MUSA*1YXCT<>[;K'UY!*/=D?[CPC'($"R<ACI(J04+^3TT:U
M:(0KUX]>`0794!.W;K*-W2$BBV"?FV^'5'DFP;_<9ET]Y;MYN6V:Y<1UMQDQ
MV^;R$3X-NM$X;'Y#%1L0SPN5SU)3;<)7*T(9`8Q_+"V:L$%45'15.`K?(]8G
MI$(*#PEVOZ/S+\ID70SJF2IP6=-(U:5B8R)!&*G&\,MB,T7;E>9F'S5\K$/9
M&=DV[$5&:!7CM)THT#I7LW/Y_GVV^.9;N7A,SM#F<P$LI*[=N<EC<H>XX@VG
M)-E$)2$VR@8ABYD'\*V;NER((BB@JN*1%5RD!90).\.4^5)/^=;?%.`/#E/E
M23_G6WQ3@#PY3Y4D_P"=;?%.`/#E/E23_G6WQ3@#PY3Y4D_YUM\4X`\.4^5)
M/^=;?%.`/#E/E23_`)UM\4X`\.4^5)/^=;?%.`/#E/E23_G6WQ3@#PY3Y4D_
MYUM\4X`\.4^5)/\`G6WQ3@$$='G%NH/B<F'N^5#[ZV]23>!7\%]6E>`HEU);
MV=6VW&\>.8ELILS([F[;K06W<IE61GQ+('SYNZR'<E]`93&8OD$;,-\;D)R+
MPUF+P[631B6L9J-W2KUTDLH@V"/L.ZD^N69W/S")FNEN>;;=1,MU#?5)4\2\
MQN>RC',"QUK,[*O'&53$E(XW#R^Y,L/A3AL:./[>\(N@`)-'8$#3XAU@==<I
M/PY\P]'GN?B.*Y*XVN:MDOREX=.Y!BGUBW0GL%W)<9*M!XV^8.38;BC1ED[<
M@)L6R\:Z`@NQ7*HFB'4:-CU!;J#XG)A^,)4/OK;U)1X%?P3U:5X"N?4]D_4E
M@\-MT\Z<,)C]S)-[G[LFY,9D#LK0[#;6%VYS_*G9L==(G9I-LKR/+H"'@X]1
M<CINFM*7*(F*%Q0IWO/U+>D6PS%<1D]NNDD,KR:88;HKY/``L^R9CC3G'LW6
MA<-.C+12N,NWK-UBQ6S_`$C,2OISG3&:HM.272.&Q0ZD?2'*[CIP!>CI^M@S
MS,<28*9(:9A(U;%<4R?;_*9@CJ67?9&*.3R3+-"PK:3<138[6#;\\@LFX7%L
ML`/[I9WHZQMU,EGXCJ0V/-M)C3/#H>7AIEA$S$6=YE@9XYBG\8]/.24DV12/
M$D)R;=L9ZJH1DL^<J-47T<W.%Q=Y9#</$=I]Q,KVKAWF>[BXQA\[D.'8*NX:
MI?76<A6"TDSQ%LL?D46\CDIFPLFJJBJ:*3E=,Z@V`;@.9..]6_I)TTFF/9OT
M%33;)'F0XA%J9IC^8LG>#1\;*9B[Q?(90^/-8R>G'*"$=!.I1H<\DV*@V?,S
M/P;)#JK!)V-[]]>DSOK-;?R'3LA#;;!ENZV.XWN$^C9ENS"/QJ6CT\%R?))$
MS]6-'&)2&!85'+$AWLL\=H@T8MVS5XX*$?J]3_I)R1$DY+T?$-,1TSL^B:.`
MKTS9RUR[#QD,VB8UWXX49)2.R\&K4TT4",<=;21^>;O#Q;HZP7PZ:LEW9W#V
MIPW+M[L=<[?;I2D;.$RG%6+)[#L6)XS,<@BHEVPBY_FYUG'34&S;/FY7VB]%
M%P45T&ZHF03"P?ARGRI)_P`ZV^*<`>'*?*DG_.MOBG`'ARGRI)_SK;XIP!X<
MI\J2?\ZV^*<!':$<<-VY$?$Y0:;=P/FZK6PP$RR:7&XO*5$3@D*8C4/:U#AW
MB!BA(98U0ME964-:"8")E6OGV`T`1/1F%14Y41-2G:LI2E2V@!&J`!0\5E!H
M!0J*K6HT*D6IO<?:)M(1'USF]:@'AJE*>*RG=2NJUK[$Q:UY/O[:_N@'`1A*
M[!;23F[.,;\R^#XW);UX5B>08)A^ZSV`@7.>XOAV5.`=S^-P>3+19Y..B))T
MF0ZB*:@$$2CV457!4/P([Q^G]_:`&?I"]U_1_P"R&QFU\UNM!;S[B8+MKMJK
ML5,/LWF\-C)S(5\1RJ3E)/<%O"'AG>#F:RZDX8[6&%F0KL5"-;A$+:O>J[]L
MOD6KQA(=!.QKUA(-W;-ZP=X[L8Z9.F;U)^BNT<-G'4BJBY:G1?`04U`.4Y$2
M`<#`*FH#%VLW>_:Y]C,!@-J]E/1G],FTNV>*H/6^,8#M[@NP.,8GCZ,@_E91
MV2)A([J-29-`7D9=1<X@6JBQ0.<3',J90)#-U<_MG0B8?T%-EBU$XT+";(T+
M<*X@!:]28C0@+``5KV)EK4;K@?\`MOU3?M;\M.RC?>KHNV6Q_#D<+SZ0B7P(
M[+PX.-T8_#YM[LG`J.F_59!K'9Y1O$E!1;E(%A(HU=J`J72U#E"/PZN?VSH*
M5Z%-ES4$M:PFR/G6BD(@-.I,.PP)"`T]0YJ?:T`+U<_MG0"6O0ILN:T2"(&A
M-D*'L%J(@:WJ3*-%.6,!J4[%CTIYE@!>KG]LZ+97H4V7/;IUNA-D?/T^2NOM
MZDR_?>4-=2GX0I2GM>F`7JY_;.RV5Z%=ESVZ=;H39#S],&=U]O4F7[[RIKJ4
M^_J4I[7IA4_JY],W^U*=!F!P.Y_5KTM;,[5;?361ML;C<W?;60.5X^ED!F8+
MH0TS([<[TY(R@W$VV:K"W+(@WYHP+`V$3IB"8?J_]"'U1=7/7#Z/[;SJ8ZR\
M90P'<[<C)\O?XS'XYB3K!(2<VL;NF3?!LNB\?FGLW*!'Y&W2770=*+6/D#%7
M1#EU$3&#KB,:H("'BLH'8(5!5I4*E.6H>XZ5"^H>N4/7J`:-4,!@\5E"W`<`
M$JK6I;P=``EJS'M)S("6M>U(G?0UP!XU0U])64)?JTL5:A9J`^`+*LS4TN<"
MVM?O"5:T->"7D#G>/$@E)(AA;HJB8CAN)R@Y/-$(4J9B*%330UP%,=(E11)4
MREI@`%1HU0UWXUE"W"H(6JM0LO%X(`6K0>Q/F@`M:]B*=:T-<`,:H(B/BDH%
M1,-`5:T"XRPT"K0>PNL`!ZQ"^O4,^&J5KXI)]]::C6GL@-3\$K3LI^YP&`C5
M`$!\5E!H)>P56M!M,@-!HT"H'T!`?64-Y0H".-8G,U;J!*20EN$UO,-U2&L7
M;")1.)71C%/RA@-[:;L64`*5*!`6$C5"65E90]FE6]1J.II<C6^C,M=7DAOI
M2O,*TI4M@!(U0ME964/9I5O5:C?I@R`1/1F6HJ\F-U*5%=2E*EL`+&J%`H>*
MRAK0(%3*M:FL!N`B:C,*B?EQ$>[M4/2E0M!$^CSIMKC2LF(%69@-SALG6KIL
M3M.4C00$PA]V%1$0H:MH@L&,4$!#Q65"H&"H*M:A4JH5"K,:"74J'KD+Z]0R
M:-4-?25E"W`H`"55KYEX.P`259C04^:`2UKVHIUK0UP!XU0U])64)?JTL5:^
M9J<]2RYF:FESH6UK302K6AKP#QJA[Z2LH2\5:6*-0LU.>I95F:FESH6UK]X2
MK6AKP2.&)^;:E\3D@%?G`+1PV**52.5!%(EJ8'$@.`*%R:UI4B>Q$#&,"L8U
M01$?%)0*B;L!5K0*F5-0/<@]A=2@>L4OKU#/AJE0'Q23[!`::C6G88IJ#[D[
MAMI^X(\!@L:H42_C64-:)!\Y5K0UAFPB!J-`[#\N(&I3L5/W5+:`2-4+965E
M#V:5;U6HWZ8LA&^C0*ZO)C=2E==2E*EL!(DP.#]4GBDF84&48!P,X;&UK'!S
M:BR=A@*9<&8E.)4D@,"JE#&&W2!62-4*!`&5E#V`F`B=5K4^F#,!$]&9:BIR
M@B:E/ORE*5+:`$:H``'BLH-`*%15:U&T$`J-&8=I]$1'UU#>M0*N[\-C-YS%
M[G;MT)LHZ??PDZ1@+;U6[*AY@)(I``F[Q[Z\!;;@#@*%["89E\9T/[/2V!9+
MF<]G"?3%MY*XA#362G\+<Y";;B%DHJ),5J$18Q4<B5HD4ZQ2)HF"IJE`X`KV
MT2ZB)W=S(X+/4<UA=K4"9F3&LA2=GB99PI&3D&2"<2(FDIQD*2K)R[:)`02G
M?`ASI"%1.!2!87&<9\,W&S%`V0Y3)UPS`%-65E^:5+J36XH:9#)MT`!(FE4H
M"`T$QA]7@(XZI\@WKP':C*<HZ>L:5S[=&/4PXL1B[YM*382,8[R@C?("-8V-
MF()95Z$293144<$;H'$%%C$1*=0H4(D.NCKSQ1RRALG]&WN#+2\AD$9C42]Q
M?<62&'R"8?.,B%TQ;BRA,N;XVSC8V/:.#3,H^1@A#F"F=$$6VJ%G6NZ_6I.I
MM';/IJ88>VE.CS*]TFP9%G7UB",ZK&LE"IXQL3*I1^0XUD`8\YAWBZZCLT:W
M,NH`I\TV.@<B@,O`-[^MN0W"W/QG<#IWDHO'$,;W6<;0Y1!LI$863R_%XJ#E
M\&Q[+I%[G:KINUGDUWC4SXK-JQ?/RE2:K@0ACF!HXWU!^DFB6H8OE_1'`Y;E
MD/B&)S,MGT%O:YQ7`\BR+(H)*8E\?QV#7@LFF&HXK*2)(I85G2@BI&NUQ&Q9
MEK!X!U6>D4<FE8]#T<#MA(QS!FNE*/NHUHZ@9)TY:S2RH12;;%V[QVFDY;-4
M026.U6*?6,KI)JM3G!O,>KGTC+MSSSGT>LW'P48D[1>-U-QW9IB=7;,4RJ3C
M-$G,.(F$3D'Q#)QY&TC*NTVQP2K>(I!?OITS3>?<_#YN<WRV7D>GW)6N5/(^
M%P[\HR&?.'N+A%0[UC,2$S',&$<E)@_>.FBZ+<%6][7435.10*!8'PLOOZ3^
M'*#_`/?P!X87W])_#5/X.`/#"^_I/X:I_!P!X87W])_#5/X.`/#"^_I/X:I_
M!P!X87W])_#5/X.`/#"^_I/X:I_!P!X87W])_#5/X.`/#"^_I/X:I_!P!X87
MW])_#5/X.`/#"^_I/X:I_!P!X87W])_#5/X.`01T:`MU!YZ3#W?*A^&J?:R;
MP/)ZM.`HIU([L=6^`[P06+[([2/<]VZ<X[MV]F<E=X=/SJ2$Y/;G.8;*6*.0
MQ&ZN.\NU@MOV2KY]="J+1XG:*-BRIG2[=@&A3W2Z\H[>258#L;!YILH_A-\L
MCQ-VD:5V^SJ/+A4`Q<[68MEDF^W$S''1G-PLN,:.;J(,DA4CUC/ED&0MC-U`
M8N(]4WI`Y"?AULT]'GD>*XMDCG:QJ1DVWN@LAG\0"<W0G<+W.<3SR)*JQ?GQ
M7"VS')F@%1:-5V3D43.1<$42*'4*-C0%NH(OI,/=\J'X:IW%E'A0]3U0#@*7
M[[[D]6&U6Y$_);<[,/\`?O:9'!,(3Q[$\9=)8UF[O<K(Y#<Y&<,[S64RYQ%A
MC6/EQ7'$5TS02`-T\E,[.[,FR42,%<MS^I7TD2&W>VV6[9=%16&6Y1B^X+W-
MMOLARAYFSK")F"R\\+C7,SD3E>#7\WCJ2$B5BBR>+2?/*%;K)E8F,Y#=!OQZ
M18VXZ,0;I=9H8>^S3#HYJ)@?++-<7RG#)N2DGDMFJ&["D,S<X9.#'&DERQBJ
M`&!RQ0*LN"*RP2)TM;I=9^XV2S\9U-;+M=K<8:X=#2<)+PR$Q&+.<N#/'<:_
MCWX26<Y8W*FO$%)R:#47!])B=ZY4;E?LFP!:WJ$?;L8GL?NIDNP^/ESW>>$P
MF=D=L<+G'[@D-D^9MF2AX*&DSI2D&H1B]>@4BA@>-A`HB-Y>`Y^[;=4/I&WR
M&.QNX?H_GB$P^FI!WDDNPWC9P,5`X<[RW*%H-)NP$<O2D\K;8.W8,U44I$R9
MYE!PZ7!FR>,2<!(NX^[77KCVXF68]A6P,%EN*MD-Y1PJ=;NIM-"1)CL1BTSM
M7)9%(/,X8-&Y9Q1S)1;IF@4CQ]*`B9`C5DFNX*$&P'4CZ4I_CN0/)'H\B6DW
M%9MMXQA6RZLDS3R3#9R%>C,.^1-NXY5AY)[/-V`NUC.7"&*,Y50'*;]>.<)<
M!T.Z:YK=G.-JL.R;?7'EL%W6D8V;)E>-1I9.+CFIH_,<@C89ZPC):4F99BQF
MH!JU>HI.U^;(FX`%TT5;T2!8/PPOOZ3^&J?P<`>&%]_2?PU3^#@#PPOOZ3^&
MJ?P<`>&%]_2?PU3^#@([0C0#=N1'GI0:;=P(VB^4L&S+)I?SBT[1,*-@^5,Q
MB]QAX"0BQ12@0/$)4UFG[)^J83:8,P\\:><)^3"[RBHI]V/``110I[OE1H!0
M[7ZHUM*B6H^41T:CY1,;R\!^;;]I$](/Z0'T9FR&P>]_19CL-,8+,9?F^*]0
M.99G@[S<&%P11VRQ(FTZKPS::BS8TCD$FO,-RNER*-%G::"!SD54036#C9T_
M=>?[7_U0[0X=OKLSTS;5SNU^XD:>8PK(I[$-F=OW.00:IW2+6>C\=W`W?QC)
M2PLD"FJQ=J,R(/6Y4EVYE4#$4.#P7R;]KY'<YUO0TZ">D]GNXZPLNVJFY\;'
M=+#S./R>I3$CD!,&)FB_4)(S2V*H9'('?E8F=';D>ID.!0,6G`/<^^_[::>_
M_P"E+8TE^K[!7IE"S5Y[V%=_AII<Z%O?312[[1N`/OO^VF&O_P#I1V-+?J>P
M5Z90LU!>#YE=_AII\YYO?313^Y&H!M^/VTPPF_\`I1V-"X3C0JO3*`%O,X&A
M?[_^XFO0/("9/(-0D#;??+]KM6G90-[^F78J'PQ/#,]<1#LTET]1X*[I-\0F
MW.R<.9>&ZG,>>&9Y%O"2#C71#+'0.R=*E53.F)J!'X;[_MIH"'_TI;&C02CV
MJ],H@:TR(T'^_P"[C:-!]8YO+V`V<QZI/VS?`<2R/-I[I,VG<PF(0C[(I=+'
MH'83,)Y2,A6R#Y]X5BN*;VS&39(_%M'G$C*/:.7CD5#D12.<Y2\!93]F[]+5
MZ47THV^V\R'5%CV+*]-&TNU[A,^XV$;8K8,V/OLOEF!$Q[!G^0.9E\VE'RN%
M)3+UY'LVY56Y=-1P=(CA(C@/V$$BP)9[OE#6:0>>]4-=I<B`7U#SA4Y`+ONM
M57[L>`CS<[:+;?=[#WVV.[6)PNYFWV6E*PR3"L\8LLFQG(&;5!)TFUEH*7%2
M.E$@=1R:UJJ#@2J@*A2D-[84'XU@6C)JV9,W#YJS9MT&C1LW="B@W;-D44$$
M$4DBE(FDDD@`%*```!7@/;PHO;^,)7M`0_#U>RI3EJ'9V"%]0]<`\G`!HHI@
M,'/RH7`</-?*E$MX.@J40]B).:\WR"F3[D.`#Q13W^[Y4M^K[!^J6W5!\`V4
M]C9SPV_<Z27W`<`F\/(H[=H\])%'026,))%8%`%V>9)0I.9."2:0+CI413`!
M2)YQQ(`$!4:**:_W?*%O%0?-?*%MU!>#0G9YH$YP;?N033^X#@`8LHB(\_*!
M43#0'RH`%QES4`/4`NO0/(!2_<AP!X66M>?E.^M.>5I[(#4IY.RG[G`!8LI;
M?=\H-HD'SGR@UL,W-YP4[0-R]!\H'/\`=#P"2.CR*-D%0?25!,)@*$BLJ3VM
M=L-MQG3T3E-R5#55/V**!V7B``J)%%)9[OE3:>E[-\J:[2Y"E]?9ZG(!?]UJ
MJ_R@\`$BBDL]WRIK-/V;]4UVD#$//J'G7\B%WW6JK]V/`!8HI0*'B$J-H$"I
MGZHB-@-@\[L[1-RU3>43G^Z'@$CZ.(DVN%_)B!5F91ODED[JN6R?:H5TR-4U
M/Y0*B(]AZV&!6,44;O=\J%P&#L?*A2XJI:E[.P0U:AY!*7R<`&BBGO\`=\J6
M\%`\U^J6W4!V'F4]B).;&WR"FG]P'`!XHI[_`'?*EOU?8/U2VZO/5LI['3Y\
M;/N=)+[@.`R>**>_W?*EOU?8/E2VZO/"-E`\W3Y\;/N=)+[@.`2.(\@.VI!?
M20"XYPH?C%4@DJ5RJ(HD!TB`B7F:![6M84A*6V@;@%8Q91$1Y^4[1,-`?*T"
MXRIJ`'J`&K0/(!2^3@#PHH"`\_*=@@-.>5$.PQ34$!#M`;:#ZPCY>`"Q92B4
M>>E!M$@T,^5$#6"V&AO*!N6[?*!S_=#P`6**2SW?*FL%(?.?JFNTA8B%]?97
M\B%WW6JK]V/`)$HXG/*)@^DA%NSC0&LBL<RMBYC%.L072@7*`Q`IC:*6H!U*
MF/<($!46**2SW?*FL!(/.?*&NT@9!Y]0\X3\D%WW0JJ?=CP`$44`*'/RHV@0
M.U^J(FL*W+4WE$W+U'RB<_W0\!5[?AJ#:<Q<`<.U[LHZ??PIP9>VG5;LH6I+
M@J434[?*/`6VX`X"A6P^W^0H]#VSCW`)W,)'/#],>W4CB#&<SW+?!U<F6VWA
M9"*8+IM,D@-&-.^,5N0G,HI(HF`*@!`X#ZVQQWJ0D-Y\GB=Q(O*HG9A)ME9\
M1R9+<*80R)T\1G(LD0WF(YKN'DJ:#9M'"X2:*$*)GZ)A<+`B<I4^`=^Y^X^W
M_3&KG^Y6XC[=1_@L-C>U:622\&USW<J3QIG,Y3GT4$_(PN,)R^3?5>+753,\
M5;-7(,TSF7.0$P5.7=>`\#O>Y?)5\3XR</Z^];32N3)3%%YK'/96^2:T[[1$
M]L6M7NF.(GF8B<>7+7#3ZE^>V/7B.>/V]/@GG"EG^1QT;.34/.8H]EX9"1+C
MLC,2!YF'9.W;EQ&LIX`<"1KD"4>HGSS=,ZJ35V*B)%52D!4^OWL&'6VKZ^#)
M&;'2>WOC\MICI::?&:=W/9,\3:O%IBLSQ$JS-JQ,QQ,_!OLD;2$=CL^_Q]A)
M9#/,H25=PD";(G<<$W+MV*ZT;$C(.7R+=AXB](1'64.4B5]QA``'BJDYYP^Z
M_7>@A(XK)=-T1/9OA.)0JF33J.=Y/!85F.2'7:1SF0P*8=3*<=)LITAW$J6/
M*8CF(;M@:.C"X<)Z8/6$SSK7D3Y,ZG>G6%Q<D-ANXLGC\,WW6=9(&59;&+-4
ML$AE)]'*(T\8A(&Y@J@`P,#Q,I'&LSNY8`UV0;L]9,2$,=KTO.'GBLPTC'3=
M#<)Q(*0Q7KU5'7=+1N>KHKM&*:3<JKH00;B6047J0L:9)^#M2ROK`F,:P?\`
MN1A\+RS(,AR5EF":VY;K+(W"8&-R**;Q,B5<F40J<JY?XZH^53TBK%<K()#8
MW!8$R@AF,YZTRYME$'#]-N.(XBTR*3BL-S)[O6YD@R*#+(F:,,IEX9MD$:^Q
MM%",2-(&9&UUW8G3:%,W4$ZQ`39%F'7(TQ/;9/'>GO$I#,9K%G2NYKYQO4IX
M1@N81DJ=(K2*C599DKE\+D$4B"K=1%=HHF=4"J@B(#8'E)S/7>A@^,3,5MK@
M<KFC>0R/ZUXJ&7/XE"7A';/#QQ):)D'^?.6T)-0TC,28R"*BSE%VVB502.DL
MNVN#,YN'ULN6K?ZL=,D0S&1D7K9!U.;U)B]CXU5E*KQCY_%-YQ5LU=H*-$07
M*9PJF*JQ$R@)3G51"V&UJV9Y!@T/*[D8Z[PO,7"DJ64QUM/NWJ3)-O+OV\<H
M5=*;F"&%Y&)(K"`.5*"?[0?,*$@^%H^^)+YTD/C'`'A:/OB2^=)#XQP!X6C[
MXDOG20^,<`>%H^^)+YTD/C'`'A:/OB2^=)#XQP!X6C[XDOG20^,<`>%H^^)+
MYTD/C'`'A:/OB2^=)#XQP!X6C[XDOG20^,<`@C8Q$6ZGNB2_#Y4/Z4?^I*/`
M]1QZW`+O"D/?,G\ZR/QG@(JW*1W%9R.W"6WK)S)L'N=Q+7/3N)!PIR6&JB)9
M=SK+Y/"+,"MV1E5TUVY'ZXNT$$`;BFNHJD%5H?<'KL/E+X,CZ7L;B\.\9QF&
MC%8K?7Q^;4:&S7E,FR9PV"<C$4(U;!7I7+=(RAEF[]D=-1,Z:P'*%\(V,1%N
MI5Q)?A\J'])OP[I1X`=SCR!P%>]WU-^\9RQID&U^.O=QL13P]=FZP+ZQ1^/.
M769KS*:4;)ER21FV+YNS18KAS*8%%$B)#*@)CETE`8$A-=7LOM;#3L?MO"X/
MN(Y9[@DR'%1RM]FIXEU'S$<C@;J+>JYI!QSP9*(3>"ND)5RG5.BK5(I3-U`;
MIYOK8'(VMFW;%"'?9!CXC&J3;-TUAX&4C%#2+.3RI'=!!X\=8^HZ%5XZ;1-B
MKMCHMB'27(94'=LPZZGY#))1OOC`H16*DQF*/&/HQRFP4'+$LF:DD"NDFV<Y
M<JND\2<+),P3,B1)C'HN%A,N^%-`+C>%H^^)+YTD/_NYCMX"C#W(^L;$'C3'
MV6T?Y72N<RDA=YR_W#C<&91N#N=PYJ(A2>#14XJL[EF^$-&+U8Q4O-%X=4P"
M9$6@AO<\<]73',)9G@V+PDQC:AMP&^-NEY9RT;I(HP.-R&"S&0N7VX!W[E1.
M8"1CU&;=)H9XJLFX,9N@@8IP8*4YUT':OC-\#9G.U=XPHT5EEV#!W(HJ-LA0
M>1P1S'>-\V01DWB4&XE'@N0-$I/)%-JBY,U0`X3ACK3?>5V7CS3!Q@=]7*C%
M@^<WHK1;%JIN(O'+9`I"&R1=MX2CB`\^=D5^J\T2BB14[H0$086"->LZ)7)+
M[@Q>-YFT^IV&*CB,)FJ>+N#9GD68R+?+4SS)F#HB<=@.%%;.=,JIN:<B=%)5
MX)M5,/7!9OJSD$MLV^:[?DAIE9'=!SN4=.8;J8B*[!HZ/MW%14JRW#=Y#&&?
MRATD2K>'N4U&J"BJYTU%$4S`W]M-P.N"3RF'3W2Z9L>PW%IK,,;8KJP6]9,N
MD<6Q-6*D"93*2HI3;%N[<L)E!JLU!$J_,-7"R8IE603!R%\/"T??$E\Z2'QC
M@([0C$0W;D1YF3\W;N!$"C*/Q(-F632X7$%Q:81,B!1KWIB8@^:8P"$AEB4"
MV@#F4&P$P"Z5D#5TP:`%PF<#>)N3+=6MPG4K74/4,!$H``!S,IV`4.V6D1$;
M2I%"HBYJ(CH@(CZHB81]D-0@7J&7PI/`YG",PVCROJ"C<ZQG+D'6S\6WQW(B
M9U%P$(I*2<`^C,_R;'<4>I2P"DU30=.+%EUB`8+`,8H?G$]#%Z=/J6Z\=_NL
MO:C?GHKW"VWVVV(DYO(,?R3!&DBQ1Z>L:@W*V/\`Y#]]D<KEL;5D-P6C5@]>
MHJ1:"4BJNS>(EB2(MD#(AUHRW??T@$*[SV.QGIP@<D91&(9;+8E/0WUVG8Q^
M]A]]\UQE@_,HMN1#JY0IDFQQ6,[%P<8N206D2G37<,4SQZ0A;'I;S'??<W$L
MXD>H?;E7:K)HG<!Q!XY$1IIZ*2D<64P7$I=V]`7F69)XD,/G&33D.E)-E6[2
M12B4';=!$@I%*%G312)KZN9,+Q4$;91^6FJ+T1LM<!9;SQK:4ML3I32):&31
M:)A,(N9(+A.(@64?E`+S.##:`.`M`!<C2G<!2`'80M`9^<MDF,&BX*^?HC]8
M\/2O4FWK8@@YRV'0,D)S91C!3:X+"0$^9-J5`@-W50:J@[PBD0$!!S)C02CV
MRD@8!M,B8*@+@0$!T0KY0$U?9&J&21:)!((.9(;!3$+Y1^<!TQ:&"\#N#`<#
M<D6X!K<!U*UU#W`TL,VNP';F.>Q&`XS&89%2>13>7R<=C#<D&RD\JR>41F\F
MR.1;1H-T7LWD<PD9T_<J@99VX77.J8QEE1,#L+%($LHYDQLTJ72L@>NER5M]
MS@;[N0+=6MUZE:ZJEP(UXU!->-(#J3[7)@"Z8D;C:3`0`#`,BEK`8&H"8!(M
M41.82@)C'`%81*```<S*=@`';+2(B-"IEJ(BYJ(B"85\HB(]XC4#PE`0$.9E
M.T!#^E9"H5*<M0'F:@(`H-/((`/>`<`&B4#`8!<R@7`<!ME9`HAJ`Y`1*(.0
M$HEYHUM/8B4E/8$H&312![ZN9,+]6MLK($IJ\[=9:X"RWGS6TI;8G2FDG:"4
M(U!1X\1%U)``H(K&LEI`IRF=GF"&LMD#&13*#@=,"I)E()""4QA3("0*C12!
MA.(N9,+Q4$;960*`:@NQ&RUP%@%YPUM*6V)TIIDM`&*0$1'F9/SA,/9*R``%
MQEC#0`<`!0`5QI3N`"@'L2T`\*1K7F9/OK_2DA3V0&[N8I2H?8[.``BD`$H@
MYD_-$HA65D#`-@H&"X!<"!@$6X5KW@8P#V'-4$4;'(G:(*`ZDC><)@_&\@J4
M=-=N(`(C(O0.419%`P"H<!`Z@#V*'`06DBD"64<R8Z>E2^5D#UTN1MON<#J7
M<@6ZM;[U:UU5+@"Q*!+*.90;-.ETK('KI`R`+[G`WW<B6ZM;KU*UU3W!@(E`
MH%#F90;0(`5E9`PC8#<`$PBY$3";E@NKWB8]?9FJ"-_&()M1-S4F``LS+49B
M1)V"Z;)T$_B30:F`/Y3SA$>P]1*8%@Q*`@(<S*!4#!V2L@`A<54HT$'("`AJ
MC0>\!`H_:A0,FB4#`8!<R@7@H`VRL@40U`=`-MK@+!+SAK:4M$I*4TR6@'BD
M#WU<R8:FK6R5D"6ZO.W66N`T[>?-;;2RQ.E-).T`\4@>^KF3"_5K9*R!*:O.
MW66N`LMY\UM*66)TII)V@C<1R(/&A.:D0YCG`$`EGY!"XCE4=(H2*-!*+D:4
M34L*4@!8!"B`+!BD!$1YF3[1,/9*R`!YQE#=@`XH``*HT#N```/M0H`$4@`U
MYF3[P&@RD@(=ABFI3F.ZI.[R"(=PCP`6*0*)1!S)C:)!"Z5D#`-@MA"X!<#<
M`BV+4![P,<!]F:H!8I`EE',F-FG2Z5D#UTA9"%]S@;[N1+=6MUZE:ZJEP(T8
MU`'ZQ`=20Z#.-``-+R![K%CF*=0AI%0#&4Y`H&,*1!4`5`,92]0`!86)0)91
MS)C9I@%TK('KI`S`+Q,X&^[DBW5K=>I6NH>X,!$H`!0YF4&T"@%960$1M*@4
M!,(N1N$0;A6O>)C"/LC5"KN_#0C6<Q<"*NE`-E'3[^$NW#JEO5;LJ%2BX44$
M@B`=M.\>_@+;<`<!0S8O;F:/T.;.*;?SF7#GSCIAVY>8@67W#SLT07*%MM81
M[$MW#=#+HA-",-(F*B"8+)(HH"!0"PH%X!P[8;9[V.-P,@=[B3V=QF`M9'.4
MH".-N/)*.Y.,7?8J.$**A#YE./&RL:D6;*90[DIG+,6)ET4W7,``+MTL]P[I
MN6S_`'(RF(WGS#$X3&MK`GPP9IGN[&5P,?+Y3GT6MD8XQ#OY+,)+'84ZA%'Q
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M@*E8NA<JD8`XH&9ZY3GQ4D_LWMRDD^R7#RY8Y0W=R(5H;%Y=]((Y<>/8I9&9
M-5_BS*,37*/,.];Q5%-,KHS1<R@,;(&OI$(>=D&L/#X[E>.2TANDY8R3++H-
MG*8O%.HK,VNU;$J$Q+02#E]$2S>&=.B*)R!%R+F35=B&J5,'3E45UV?W=%P(
MN+"T>)2Y,[4SN<2).Q:1<_?0F,KR">,Y">$7G%-N,B9S<N2),HQ"1QMPS:>;
M()"`?&(H=;2><%7F8-Z^P1';.55\/S+*L'C9%]NBG'9"\:M5W>WN2O'#.&6R
M%./9,S)WI^$J"NZ$'93@((9G(>O]"5.E#[(X.ZBVK1M*@N?=1PL:2=NA6%UB
MR9E\_AUBDCDI!,".S(M;EHXQA.JFX`@!T)\,;C_ULB'K>+2G9_[WP!X6W_EI
M'YVE/C?`'A;?^6D?G:4^-\`>%M_Y:1^=I3XWP!X6W_EI'YVE/C?`'A;?^6D?
MG:4^-\`>%M_Y:1^=I3XWP!X6W_EI'YVE/C?`'A;?^6D?G:4^-\`>%M_Y:1^=
MI3XWP!X6W_EI'YVE/C?`'A;?^6D?G:4^-\`@C8QN+=2JLC^'RH=DK)AV!*/`
M#N=]]`_?X!?X6W_EI'YVE/C?`13N7';D%D-N2;=$<+QZF=Q)-P3+RY@TL*,8
M23!Q.^GHYRBFFR.JHD=B5P]%\FV)I\L=R<@50A,A]((;*7ZF2;&;8-L/&8QR
M*C48/>.?E9KPQ/,Q)DN3.2O\F@T$$'F!O;T4=5PNWDF(`#=9)<PE"^T;&-Q;
MJ56D?P^5#^E9,.P)1X`=SOR<!27<=7KDB=WLC/MWB&'9?L\G+)N<;"0RU6*G
M740^P+"VI(=TB?,H%9%6$W%AYQPN^%4#FCYQ$Q&[HT:5L[!T9(WZP5=OFCS&
M(#;YON8./;BI/(9[E^5$Q3ZR*,(U3;5\G)JY+*OTFD>[.Z(\;Z:A9!1,@F58
MI'$2@SG276_]:DCM8&*+C[S)854&)LABEHF(QM^Q.639/9HV;H9.\4@3/-1P
MNBQ%9R^9ID;$Y150P@ZMF&75*.22A-]D$2XD.,Q)8MPPD(IJLGEB.2LQ>G<)
MPV89"Y>$D$'*Q6H`FT1:Q[)J945WSMT5L%G\YB<B/A.8IX*\6;YNIBN0IX<X
M?R#YPQ0RH\0\)CRSQ!P_206:I2PHF4*<Y2F*`@(@';P%(\.D?2!"Y<I9?MCM
MR"+J5,^15+N!*G;Q4"C&-*PB3F+SYNZ>S$A+-%B)J*LM%JD\*N9=;2Y+@'_G
M+'K";Y1,-,"C<(?X@NMN.2&F97*9UI.1Q?JYB+G;(RT,I/K-9)JC.IS;9\H9
MRBLX46;',B@@D8RH1X1'KS,V?:,.P*=!WC:S%28EL:2?ODB-<D;/X\[>(W$=
MQR+)XZ+!NIIR*I'+4%)-.*36`C(3!.>,QV_9]FHWQ[DR[[I+1I93GGX)1;V*
M0W(5)(+\K!96XCHP9/`2G.BDE(.S,EE"7'<*)F*H#ZV-9;IN-N(E3?%L2-W(
M%_/A--H6<76BBM@G9#P86!F,Q()`S"(%`J5ZQW!DBE.N!5S*$*$N>%M_Y:1^
M=I3XWP!X6W_EI'YVE/C?`'A;?^6D?G:4^-\!':$8W#=R1-K2-2[=0-`&6E!+
MYF633@+BB[M-4Z``-0&I!,0?,.8!"0RQ38H%`%I(;`3`+I>5.(Z8-0+=<\&\
M1Y,MU:W7'K744N`"*;``!K2?8!0"LQ*B(VE2*%1%Y4PB"(5$>\1,(]IC5#FU
MU6SN;X3DV?[E85C^^N\&3;-[89ADV`;$;1YPE`3^X\R&##(+8Q##+).&[F7F
MUT"4,IS:Z9$AY-LLZ%-!8.)GH`NO'J5]))MUU:.=^^F+>#%2-]XLG7E]U=IY
M7']O=N<]D\N;KQ,EM=F+/+)G#<CE]R]LL609QCZ58.GCU6)28`]Y-XW;*.0Z
MAQ74UZ1R9A<UA8+I-Q=GE^WL#L$A(QZF>LLH5?9;F4+D3W=F-2B(3J#<RL+'
MM)*;A210OW:2L9%<X].K(*-$6J`=(NG>5W6S7;0)O?+&5\,SM7,-QXT8EB$S
MCB2V*1F<Y;%X3,^"'SC-58EU-8BJV=*$"27`%3$.E8FFW*F$YFBVYKZK207Z
ME;9>4)35%X)K+7@64YT]M*66ITII)V@#%MS"816DO.$XB`2\H4`O,N8;0*\"
MT`%P:E/8@!0"EA+0:&<M4F<&BX3=/TC_`%CQ!.\TU))D$'&6PR)DQNR.#((*
ME6$@$%<P&J!=%QV(*`[PBVX"`@M)=@E$*R\H(>:9(P5`7@@8!%$*U[P$P#V&
M-4`L6W+;1:2&P2"%TO*&KIBT$MUSP;P$69;JUN`R@#744N`+%MB646DALTJ7
M2\J>NER0EOO>&U+N0)==6^Y2ZNJK>`6*;$LHM)#9ITNEY4]=+DK;[W@ZEW($
MNNK?<I=755O!&O&-R+QI`7DJ<P8/.F)41-I,!`H&NDB"I4&I1,`E5N$3"(5.
M<W`+`BFP4#6DNP`#MF)4>XI"A41>5$:)A4?5&H]XC4`8IL("&M)=H"'9,2H#
MVE.4:"#RH#0X]OJ#0>\`H`:*;&`P"M)><!P&V7E2B&H5R4UHE>!:(`Z-;2EH
ME((4TR6@&BFQ[ZK207ZE;9>5)35YP#66/"Z=O/'MMI9:G;322L!*$<@=X\2%
M>1`ID$5A`LO)D,4SI28(I88DC>F0`<&L*4A"IB0@D$13)I@K-%MS7U6D0OU!
M&V7E"4U!=B:P"O``E.<-;2EMJ=*:2=H8&+;B(B*TEYPF$:2\H4/.,L8:`5X`
M%`!6&@!V``%`.PA:!GPMO6NM(]]?Z6E*=]W=SE*5#['9W<!@(MN`@(+27FB4
M0K+RA@&T43!4#/!N`>7+4![P$P#6\]P(XV.0,T;J"O(F$#":HR\F<!%-=N(`
M8!DG)3E'DB`("<P"!E`'L44`P+"1;8EE%I(=/3I?+RIZZ7)6WWO#:EW($NNK
M?<I=765O`+%-B646DALTZ72\J>ND#,"WWO#7UY$EU:WW*5KJJ7@!%-BVT6DA
MM`@!67E35L*W*`F$SP1,(@V+6M;A$XC6\]P(G\:W3:B(+R0469EJ,S*AV"Z;
M$I<,F@-1`.WSJB(CV&$1`P+1BFP@(:TEV@8.R7E0'SBJ%&@@\"@@"HT'U!`!
M#M*6@!HIL8#`*TEYX'`;9>5*(:@.BFM$KP+!`'AK:4M$I!"@IIV@'BFQ[ZK2
M07Z@#9+RI*:O.@:RQX73$O/GMMI9:G;322L`/%MSWU6D@OU*V2\H2FKSMUEC
MPNG;SY[;:66IVTTDK`1N8Y#G&A=>1`%Q>`<`EY,OLB.%!TP"13L$IG)K;2&M
M*!`"T"$M!:,6W$1'6D>T1'LEY0`[3*&&@`\``"JHT`.X```["EH!X6W`:ZTC
MW@/]+2@AV&*;N%Y2E2AV=U*AW"-0P6+;E$H@M)#:)!"Z7E#!Y@MS!<!G@W@/
M+%N`:W`)P&MY[@"Q;8EE%I(;-.ETO*GKI<F);[W@WW<B2ZM;[E+JZJEX)$8U
MN#]8H+R(@BSC0*4TQ*'[$UCF*90II(]YCBP(!C&3`5`%0#&/J*!P"LL4V)91
M:2&S3`+I>5/72!H!;Q,\&\1Y(EU:W7*5KJJ7!@(IL4`#6DQH!0"LQ*B/F%1*
M%1%X(F$00+41K<(F$:B<]P5=WY:)M9S%P3.Y/=E'3[7F'CMV(6]5NRH!:+I9
M82U#OI2OJ\!;7@#@*(;#[;/C=#NSAMN7V0,]P'G2_MRXQ->3S_<%:+2RESMK
M"/HP%T!S!JFUCU)02D$B9TDTD#"0H`D%@A\;98!U(J;V9$GN3XT38DS+,OJX
M*NYV1+9*+\T["*8N#P8C<!XLFT:1R3Y-K[695PS4(H],D[+IF!Z;F9ACG3TX
MS_/G."[S[BP4/C.UIIN)VQ:9CNOGD='263[@1KG(V>*>/.\KG8>#U"*O6T0D
M\>)MP463:J`140W'@O"W\_Y&OB\6QJZV?)6TTML9(PXK6K',4G+:.REK<3%9
MR36DVXB;1,PQY<GTJ=\Q:8CY1S/[^/7^9.>$HRLK&QLEE,$OC$S(PR+]SC83
M#IXYQY)Z\<NV<)*/6LBZ9/)N,:+$2?*-E%&IG95-`YT0(<U'=QZV':OAU,GU
M=>D\1?CB+\=)M6)B)BMIYFD6B+=O'=$3S"59F:\VCB?DV&<Q$^.$9D7`E-'.
M3XID1,,6?/W(LDLK/#O"X\J[YE=5ORR<N*(G$Y3$`H#4*<54E)8UQZ0K'G$I
M!O\`"MK<[8QB4NG!YDOF<JQD\F=F<S[B!&88L<IQ%C#QG+E9-G;A".%RW*4B
MI&KP[A<&(.&!D^N\38L$_MGM$5%]DN'?6Y9ON'EHNHC%Y9](HYB$8Q3R7EQ?
MXPQC45DC"[?:HRA$R%<BS5,X!FNL:](DRSZC+(<%E]O);)'IE>8DF:,KB^,.
M=T(^19BT$K9DO)2+#:N`=1?+J"L47>0)NQ<J*LA(`/&02ZTD):0CX2$:.H]Y
MD\R=S/9!DF.JMHZ$;9(JK&ML!8P^21$BVAGN%)HIHJY`E*2:DPHJ"Q6C8A%U
M`>6S33JT:3N+1N^$?A<K#/(C.E\RGL5R%^=*(FTY]I(;?-8(JC^%=O6*^,RJ
MD>^*M%'.5Y%:Y5P(L&L%L?"67D=?.$A\:X`\)9>1U\X2'QK@#PEEY'7SA(?&
MN`/"67D=?.$A\:X`\)9>1U\X2'QK@#PEEY'7SA(?&N`/"67D=?.$A\:X`\)9
M>1U\X2'QK@#PEEY'7SA(?&N`/"67D=?.$A\:X`\)9>1U\X2'QK@#PEEY'7SA
M(?&N`/"67D=?.$A\:X!!&Q3,6ZE0=?A\J'](2'<$F\`/]J\@<`O\)9>1U\X2
M'QK@(KW)C-QRR&W)=MKBQYL\B`W"%:12#_Y)J8LP!SR,@BZ(B#(RIDAC[GWB
M!6H4Y87(@%5828](>&4OU\EVHV4+B!YG'(N-9P&Y66OY@D0EF0_63)G1I3(H
M5!$'V!O1TT06=*-I)B2UNLDNH`!>^-B68MU*@Z_#Y4/Z0D.X)1X`?[5Y`X"O
MN\$;U`Q&4-<DV<;ERZ"0P]Q&K;>3.31T##.\L<3).2R!654*RR1/DF"P\P4D
MD"`MDS"FV5<`0B@0AE__`/D!DL"QA[C./X)B^XSACF"630\7D24WC<>N6?!O
MCCQ-?*LH.Z>ORXV4J[)-%PFU<.A5Y_EBBBDF"WE.NLV0,%!:P*<8]G,;7>L4
MYN"4Q^&AW\72?CU)`\PGESQ.!<NSF4722.X<OF:)4`!FJL8`>&S,9U3%R.4)
MOPHV=XB;&8E.,.S<P+99'+&^3-><65^K\X_<O2RB"Z_+AHM$&<:U97F</G+T
M&X7$"*9@(&`'-0$!"K]^8*@->T#.1*(>L(4X"C;\.MO%G[."QK&,9W,C'&8R
MCI_F^=YRC#O6&%.]PIUG$QC2'PYYB*#B3C=OTHYP=0S3S3K+'$[I=,&9PTTX
MQZ^/RAY$VQQ/$PV\6+N.ECS^7EHOFV3DRKY3;]Y8TFO$EXQHS:,4TDG"1G#E
MT]>F?"DB@UU`3)L>O=1L^TB1B)T'>,KQYYB3P_Q!ZF#7(FSZ/63AIQ6+3C5G
M)H-U.KB*;M(2RB4.4Q>1$0DY6/ZGD^GY#D/#7/4JD+!)564>Q+"*D&1-PW*9
MW3Y-C+2L%$LW.'VK+H-EWKA%&])%4[JQ0`9F,PG7%CTQCBD\OCFXR"V`<SDC
M%YEC'"<8:9X[F%E5F2$Q#1$IES@L=%F221(FP*S`$S'.Y7.H!$P<^-LNK-3(
M</+/(E3@`W"W&)E/-R6/%,KM^\8I!MZN[<P>4J/$'&/2:;@=%@V.ZDVYV@.E
MFI^9$H,C`9GTA2V3QZ^Y6U&S$=BLAE.$,G;'$]R<HFY&`Q891XGGLPLO*Y!#
M)NW9(=VU59%(#T3+M%TS-@*=,QPOUX2R\CKYPD/C7`1VA$LPW;D34=U+MW`T
M'Q&2H%F633@H"7F[!JJW+6H"(EJ4?-,8!"0BP[$@%`O.>8"8%K)R9OO0-"DK
M<[&X:,DZUK=YU:WGN`"'8@!0#G/-`H!63DA["E2*6HB[$1&B)>_O&H]YC5#\
MU7I\.KOJ9Z`-F\[ZA.D7:&4SO<1&2@\;G]R5W>0Y%`=/V(RV$+MGVZDSA+:4
M,G.%16(DP;K.D!A6#ET5=_?[4@X"X_2GU"=<>^'HR]F>HB"Z.8C8OJIW'?1>
M09+LM-.&T3!9`PG9QX]E]T&T)(9KADIB$9NPY?%DG"<N['((=C(KNQ)(+MVQ
MG(1EA>XOI8-'<!]';/X,&7.V.5KY3`M74?/NH/.X[!V9\$!1C*]1L&TC&.3@
M\BD4BM#N;FZLBY6$BT:P:JAW4;Q9'+1!203=)/%VQ#/$4Y62$B+A=)WS**1T
MWQ@*FDI(K%)::A0`EH^U)6`H-$,CB<3<YY^H)K9*2)]]%Z)[;'90)^'J4I2W
MS:4TT[0!B&1A,(\WYXG$:24D`5.9P8U`!V`%"KD]*4IYM*6EH#2S9FBSA$EV
MYW::GUCQ`EWB,@(6K9=#$.6TTJS*)3@J("%X@(#2Q0/:S`[0B&0"`AS=0$HA
M62DA[2&1,6H"[$![4"UKW]H#V&-4`L0R*)!#G/,%,2UDI(P52%H8E0,[$#=K
M%.M:W>=6NH>X`D.Q)9;SGM>E;=)21_O/(V77NS7_`-')5K6[SZUU%+PP2'8D
MLMYSVO2MK)R1OO(,0)=<[&_^CDJUK=Y]:ZBEX)E8MHDK'I$%V!!<=H#)21A'
M08B"0"8ST#&`.5)4!N`PW"(5,81!2$.Q``#W9V``?TG)#V`5,H=HNZCV)!7R
MC4>\1J`,.Q$!"CSM`0&DG)`-!*<O8(.Z@-%!_<[![P"@!H=B<#`/.>>"@&I)
MR1>Q0')3T$KL!+V.STI2WS:4L):`>'8GONYSVS5NI)R1?OW.@>VUV%G](*TI
M2WS+:::=@>'AC51TZ0/S>GH)K4+(2!!!1XI,$7$#$>`<I1*Y-:``!4QM$M!(
M2P%!HAD>\1YSSQ4$U)*2+]]%X)[0*[`"=KY2E*6^;2FFG:`,0R&HCS?G"81I
M)20=IS+&-0`=@`!5<U`#L#L`.PI:`>$,JU]UUK=_24CWW`;NYNE*AW=U.SNX
M`"(9%$HAS?FB40K)2(]I#(&"H"[$!"K8E:]_;7V1J@DCXUJHV16,+LQ[A-49
M&0I5-9L)*EYU0@A5@G4*B`^=7[XH!@5DAV)++><]KTK;I*2/]YY&RZ]V:_\`
MHY*ZZMWGW5U5+PP6'8DLMYSVO3`M9.2-]Z!D!+KG8WC^+TJUK=Y]:ZBEP!8=
MB6VG.>:!`"LG)&["`W*6MSL;AHU)6M;AN$:B<]P)7D6T1;W)B\`Q5FA0'Q*2
M'L%RV3$!J]+6I2^J/V:B`@J&'8B`@/.><!@&DG)!V'*J4W<["G8L;]P:"':4
MM`#0[$X'`W.>>"@&I)R9?OA793TM=A:-'JE*4M\VE+"6@'AV)[[N<]LU;K9.
M2)]^YZ^VUV6S^D5:6TM\RE--.P,GAV)[[N;]LU;K9*2)]^YZ^VUV6S^D5:6T
MM\RE--.P$J\:U!TW3#F['7-@L'B$AV@8KE8;!YTHI>V.CTM#L"T`H!"6@J&(
M9"(B/-U$3"-)*2#M,94PT`'8`':L;]P*!W`%`/"&0"`T=U`0'^DI'U#%,'9S
M=!"I`_\`N[A'@`L0R*)1#FZD$@A62DA[4Q;"6M78W=K0E:UN\ZM;SW`$AV)+
M+><]K%(2W24D;[SR0DNN=C?_`$>E6M;O/K744N!*E&-`>G3J[M;,XX$2C(R)
MJ`1<QRB>YZ;5,)H].X3%J<`,!A,"B@""DL.Q)9;SGF:8%K)R1OO0,P)=<[&_
ML8)UK6[SJUU%+@`AV)0``YRA0*`5DY,?8%0*6HB[$1&C<M:]_;7V1JA5W?AF
M@TG,7!$%O/RCI]J*KETY]CU6[*E`"\PLK;0.^E*^KP%MN`.`H=L+M4HOT/[.
MI[=NI2&S^2Z8=NE<6DI#+\Q<L&.5/MMX1_'.%4',ZNBV9^+G*!RID`J:!C$*
M73\P0^MM-I^H(F\F0N-QI-VYV4<I9J,'%K[A3CR?8K&FH`^*)Z\1)-5W!#-R
MR`H**&(=&/!)-R"CI0YDP=6Z.30W3\IN!G;3:W>'=>*A\:VL5FL8VH0G]QMQ
M$(R1RG/XQ]D$-BSW(BSV2,X$JI%W;&+YA[RQ5%4FRHD,'&Y\!X>OGO)5\9^J
MU-/)DK;MOLW^EAFT1S%+9.)KCF_$Q6U^VG=Q$VCF&/+D^E3O[;6B/A$<S_-\
M?X)YP=G+/XR,?9;`DQN>?0Z3Y[CK:5</S8Z#YXY=MH%[)H2#II*2D0V6(@\<
MMSBU6=$4,A[2).*&[CU<6U?%I7G+K5GB+S''?QTF\5F(FM;3S-:V_%%9B+=>
M4JS::\VCB6XS"$F5L1RE'"5FS+,UL;G$<2>RKAVK&,\F5BW2<"ZD$S"Z`S)O
M*&2.K[4H-@#YIN[BJDH?*POI"(Z/$,-+M[(M49R3>8^QW"F$I#,OJXC%%%I$
M[B9!C$A`8P^E5Y9RN=H,,Q2):V:HNG(%.Y<B$@9%"];QF6VLUCAMF!G(:*SQ
M[N=B#F9RR-QG+IB3YEMM[!03]1/()N*8XV1NDN_?<XB=<[D;45`2T3`W=SL"
MZZBYLCDFUF=[?KXZB\QLSC!IE9Q'P\FVC<8Q=3(D#2#F+G)N,9Y#E02Z:(I+
MG=MD3(&%4Q0L`)QV#Q[?B)936/[]R,%E7@\7@2.-YM%J%8S&4RJF*(*;B.IR
M,BU6\6Q2;9B*Q&`MVS(IV8D*9(3)ZRH6"\(8?R2OPMY\8X#/A+'^36^&//C'
M`'A+'^36^&//C'`'A+'^36^&//C'`'A+'^36^&//C'`'A+'^36^&//C'`'A+
M'^36^&//C'`'A+'^36^&//C'`'A+'^36^&//C'`'A+'^36^&//C'`'A+'^36
M^&//C'`'A+'^36^&//C'`'A+'^36^&//C'`'A+'^36^&//C'`((V)8\NI[6L
M'N^4#\+>!V!)O`#_`&CR!P"_PEC_`":WPQY\8X#2Y)!O5\=GT,9<#'9(O"2R
M./R"ZJSE%A-K,'"<6\5;N5%6ZR;5\9,XE.4Q#`6@@(<!4C*XKKB)FVV[3#$=
MC7&V[)C@$AN7*S\OFB6<R\BBB=ON7C\*T9J_5Y%!V%7,4Z`B`%<::2I01`XB
M%PHV)8\NI[6L'N^5_P!K>!V!*/`#_:/('`5^W?QO?IEE33+-F'$=.,&V(+0R
MNWV59#X5BSS)'4TF+7)7*S5@GD(+1C!<PK6294CMDA*1L=?3$0CZ1Q_K*F]K
M8==Q(83B.Z(L]P4<DCL*6&2BA6/,1H[?.8%;,)1TD+MO$-71%M9V@BIS0**E
M*HF5,@-Y3%NN(V2M%RS&,HQ;S(,==/&*,Y#N<;A89Y%J!/Q2:B^.MLPE&D$J
MZ5*#C5*[?/VS8Y"I-55@1!V[,8MU.QV1RI]])QK.XFIC,4UC$T'4$5=OE+?)
MVPN7HGQUM'*O!EDE7)B`9!NDQC4F"=5W:CXY`N,$2Q`0'35[!KVNW9@_?*9<
M2B'K"%.`HX_@^MC%'K2!PQ#`,\A%\RDI*1S+<S)Y`9YIA[_<.;2CH)A'8F7$
M&*KN)V^+''.HHA<!C.#`HY<@1,P)YK%^M%WFF9%QV9:PN*N9+<@,/7F)C#I9
MA'QV@V:X`*[9G!M<@4.[52.\3,N=8S`?<KHCX%3.T@T:6(]=ZC5^"60Q#0R+
MO%UXT9:8Q!W(N@(VR%L\9N58K&4(Q.)35<PCF=$$BO'"C233BSI$7:&`)TQ?
M&=\B[-1L9,S3`-\FZT<+^?D!8BVD(AMN0HX>"\;Q8O8ABO,8$F=$2-A5Y554
M--03D*?@*U.,0](:>3F3HS^/C!>+MWF+LU9G%$)DL:GDDJJG%95)M(7DU!69
M+H@Z=,FX:$:W0,FW=NE730H6YV#QW==CA3]IODZ)*98GE4T:.D$9!FHHZQQ4
MC([$[A*$3;L68`^YD$4@.J;E@34-H'4,U0";?!X_^25^%O/C'`9\)8_R:WPQ
MY\8X".T(AB&[<B?26J7;N!H;G'P@%F633DH"',6#[<V(/:`B(`)?8B8!"0BP
MT>0"`5-;VL$P+5Z^-32!H!*W.1K0&*5:UK0:UN/<$&;^-M[XO%(-;IUC,<D<
MH^LH)9$TRHBD@F.)CB>2I$7BN=S/$FR<HSRQ.'5$JCA0KEL19$2IBMS2`<@Y
M)/TFTGNPQRAOLUB60S,7MWM0CNGB+J0VW=PP3L^HRQG-"22TGNO',%&L[A\9
M)OG+*/82#>-:.T$FRCQ^0Q@"$.B3K@])#O?Z2S'MJ.I+HXSGIJV3D\(D<CEI
MAYFV73>-,<\1V,A)2,VN3B"20XC!!D*#I3,TX]VV^LD4=]R3Q8PMQ*'I%MCR
MG^AZZD^`UH\=^AB\>0_3S&6?_DLE?U7ZCCF>;_\`QW9W?3BN./P?5YM-/BGZ
MGN^K/?W<=G/3\D?AX_\`OY]>OR67VWR7TIRCOJ,5CMMH=MD1BXJ_BT<C1VV3
M=I3ZKJ.2=1,<TC>H:7@E\J:[8+E6.#EPWA'#Q=`J;HAV2G,>;KCIQTS&ZA)_
M#,N6ZH<=BH#,4]PYU#&&\":+8MW."K0$*H@L*>-9IF*/+-LHE9MHP4</"/EX
MU!JX<(-USB0H6/-#1Y[[DUO;-2ZCUZ6NJ+T3TM<!;49!6E*4J%*6$M`-#QYA
M,(IK><)Q&CQZ':H9P8U`!P`!4SH_=W5"GL2T!IYLP0:PB2S8BX*_6+$*B"[U
M;S39="BIYEZP4H8:C;0`[Q`.T`=@0T>`@()K>:)1#W:]'M(9$Q:U<=M!0+W]
M]!\HU`+#1Y+1*FMY@IB6KUZ/:D+,Q*U<#=06*5:UK0:UO/<`2&CT[+4UPT]*
MRKU\--'D=.MSD;J>&HUK6ZTU:WGN`)#1Y++4U_:]*VKU\:FCR()UN<C=3PY&
MM:W4-6MY[@2K13)-1@D1-?3%R`F]UO3#[G8B5&IQ7,:@<JG6HA<(#6HF-4%0
M0T>`4!):@``?AKX>P"IE#M%S7V*0?_81J`,-'B`@*2U!`0'W:^[A*<HT'F:A
MYJ@__8`X#!H6/,!@,DOYX'`U'KX/O@.BGI1R%!$'BE*=U0I[$M`R>&CSWW)K
M^V:M]'KXM=8'P*4M<A;7Q%6E*6U"E+"6AX#%LU73E`Z:PI:":U`=O"B*CQ28
M(X&\JQ3=I79Z!6A*A:!;2T#W-#1Y[[DUAO%034>O0`15%X)Z`#@`+47ZM*4I
M4*4L):&1AX\PB(IK5,)A'W8]#M.98QJ`#@`"HN#=W=4/(%`/!X^M=-:M:_AC
MWO`P&[N8IWAP&`AH\HE$$UJE$HE]VO1H)!0,7L%Q0>UL3]V@U]D:H)F,6S4;
MHK'36U+K_P`*>E`#)K-A)YFN!:`,>EV4H-!K[,]P*20T>G9:FN&GI65?/C4T
M>1TZW.1NIX:C6M;K35K>>X`D-'DLM37#3TP+5Z^-32!D!*B9R-U/#TJUK6@U
MK>>X`L-'E`H`DM0H$`/=KX>PA6Q2UJX&[S6B=:]]!K[(U02NXIDBW`R::UQ5
MFA0J[>G[.8;IB`@*YZ^8'?3U_7X!4,-'F`0%):@@8!H]?!V&*J4W:#@!#L6-
M^Y4/(%`#0L><#@9);SP4`U'KX*@J#LIZ4<A;4'RE*4I4*4M):`>&CSWW)K^V
M:M]'KXM=;G@4I:Y"VOB2U*4I<6E+"6@'AH]2^Y-<=35O]VO@KK<\*E*.0MKX
MDM2E+:EI2PEH)EXQGS3=,$UK'/-@O[J>#4!*Y6&TVM5+VQV<0M$O8(`'84H`
M"H8>/$1$4UJB(B/NQ[WF,J8?]H[.U8W[G[P4`"'CP$!!-;L$!_#'H]H&*8.P
M7%/9$#_[5X#!8:/*)1!-;S1((5>O1[4Q;&)6K@;J"T3[^^@U]D:H!(:/()!*
MFN`IBD):O7QJ:(LA3K<Y&ZGAR5:UNH-:WGN!,G%L^<.GIK6-F<<5`.;>]@)K
MF.6XPK>VB!F"5;A,(@40'L.:X%)(:/)9:FL%FG;5Z^-]Z!F!*W.1NH#!*M:U
MH-:WGN`"&CR@4`26H4"`7W:^&@)E0*7O<]M`;$[^^@U]D:H5=WX9-V<YB^@0
MY;\HZ?0,)UEUJV=5NRH``:RBEM`\E*^KP%MN`.`H5L+L\P>=#VSS;;YHU@<]
ME^F+;Q7&9A\[?/6L?EDEMO"OF4@LA)J2C1-'QE4#*>T'`J1C%`@E&T0V6VNR
M.]33=3)7N[#K")?;5TOEA\5C\0DY5NG'0[F7:+XNQEFC^)8SI\D91Q2I"Y3D
M%FMB;K4!0[A'1#?[FSC'81?/LTQ?93<C=YM%XYM8K+X1M*B3)-PU(J0RC/XZ
M3G<=Q^<GXQ7)3P:(D77CVC@':R"9S(IJJ%`AMSX'Q6#S?D:^.S[FKH]];=N7
M8FU,/=$<Q2]ZUM]/O](O:.V)X[IB)Y8\MYQT[XK:W[(]?YOBGC"6$L]C8QYF
M4#'0>1O89%[)0,>[._0QX[QXY=)0!Y0CI="8>PR"I6SEXD)4';A,ZJ1$TC$(
M6ANTU,>U?'HWMDU:SQ6\QQ-^.DW[?6L6GFU:SUK$Q$S,Q,I5[IKS;I9M\PQ^
M3=8EE+7"S1L;F#G')QOBDC*$,XC8_)5XMTE!OI!$Z+TJK)I)G245***M2%'S
M#=PU4E#I/#/2`1\;;A<EM2LV1G)-_C\9GZS6>RIMCZ44`-(3/LJB(F'BI^0<
MRSEPHT-&M&Q4@1:(NG"B?,K*!(>0X;UI/&VU\E`S^R$9-137,/RIQ(QDQ]7,
M@>9&Z-&XA]7VB[21D4V^W,:4LBH"K]N:6=&%`XE3[>`;.YNTG6UE&-XNIA6[
M.WF$YI'XWDL=D;F(@$B0DMD$MD`-X">:1LQ&Y$U:EQS%Q!8Z"I')'+DIB$!$
MQP6*$F;)8EU.Q&4B.]<C@,]BD]#9KD,HA`B0SG#,ODLX07P[",5>I0T&\EL*
M@,",9N9P^2%\J]3,JHLH"I4T0M5X-&>]"?Z2O\?@#P:,]Z$_TE?X_`'@T9[T
M)_I*_P`?@#P:,]Z$_P!)7^/P!X-&>]"?Z2O\?@#P:,]Z$_TE?X_`'@T9[T)_
MI*_Q^`/!HSWH3_25_C\`>#1GO0G^DK_'X`\&C/>A/])7^/P!X-&>]"?Z2O\`
M'X`\&C/>A/\`25_C\`>#1GO0G^DK_'X`\&C/>A/])7^/P""-AXT6ZE6A/P^5
M#V2G<$H\`/M_('`+_!HSWH3_`$E?X_`17N5B^=O9';@VW;AC'L&>>1+K/2.5
M6)`>X:G=XNT.20BI59TDNQUDTTFBC)T#Y1LMK@BBLFH%68>!](<AE3Z1R-/I
M>>8JO,8S&,(/'$,O1?-<?:9J+K(,@<O)D!(63E\$>JM%$2:H(/6B"R)3`=4G
M`7KC8>-%NI5H3\/E0]DKW!*/`#[?R!P%*]Q<)ZV6V[F13FV&1;4O]ISS"3[&
M\6RE$"RR3&0P3"8%>$?BA`HG\,@\WQJ1EBN`D#O%FV0O"!<=JP1*'WGN"]8<
MMCF*LX/(L/B,G1C,T/EL[AJ,&SBGCQ96)-B<8SQW+HB1<D6Y=1XF#].30!OH
M$O05.Y%9L",FW_6\;)FKI+*MIVV/.9Z%?Y%&/S&>(,X-WCDFU?P6#+-L,))V
M8[D$DFX<JRJ@N)@(]#179$4<)*`Y]F,$ZD83))1QO=D45DN*JXS$L8UN@K!"
MY:9,WR=N=P_`T!C^/<T,PDLZ..HDF1G'ECT"ZJX/%.`L[F^-24CA>81V&.F\
M'F$ABV0L<4FUDTW"4/DCR(>-X.540>(/FBI(^3426$JB*Q!L[2&#L$*687B/
MI`&#MRCE<OL'(-WDF,N+@6,B_1C8Y&.:($Q:,,U8X\[%20DV!CJN%TE`;MGJ
MATSG6(F0H+9S;SK(>9QE[O'<JQV'Q20D-RV6*1\RYQJ2:8_%+HMQP3($EV&(
MM9-_)J+LR$2CGJ+ANP2<N17<.U4DE'`:\NW772I'O2K9GMJ@)'^).<8*S-''
MGT8QO%S3"0BLZ=NL!-"2#TDTYC9&:<QJ9"23=JY;1Q&`J)F,%G-EL7S2*PC'
MHS=MPVF\_9L94DY+IBU`\DF;)98\.[<DBR(1J+I6&,@*J3<NBD>I"")0#@)A
M\%B_>:?^DI_'X`\&C`[FA`_Z2G\?@,^#1GO0G^DK_'X`\&C/>A/])7^/P$=H
M0\:&[<B<&9+B[=P-#W*U#3RR:=$#[Y3L7;D-^Z7R5#@)"+"11`(!6:8`GI@0
M+U?-T@9@GWJ=MH,$?]`/7J&2PL60``K0A0`"@%#J]@$*B0H??/4*@0/^CP$0
M8AC\03=W>54L>0IW3#;+64O<>WZ4+/($K<J)/:TC"7S0#UZCP$C_`%#PKQ=3
M(/JK`!/JIF25G0BV@3:B1FZS04CRP)!(&3Y5P=("BI0$S6AV=G%W_,_)3I?Y
M;.QG_P`NB>?I?4O]/U[O\/GM_-^+T]>OJCV4[N_B._Y\=?YU6]B]VM@-QMT>
MI3$MM-S=I=P]P\6RYJ.8X7ANY&-3^3P"D9B$1C:S?*X.$E7LEC`-YTSN/5,Y
M:HBFZ*HF8!43$`I)/SW>C=](%Z:7?+TL767T_P#4YT4LX#8'"@NE,7>2Y,8Q
MKIA(FSF2;;*8?NXI$N66^@;V1SU9PXTDU.?U3RD?X<P:K,SAU.R*4]+HKNKN
MLEB6UFWI=L%9'>UGM:OEN9[2IG;,RHQ:FT^0OW$$V=SDHV>.SR*+2+=,62Z2
M#TR\J].HBBW,%ANF5[U\GB\N7ZJ=JMJ7#H[3;CZ@,<2W"BTY0J:F-S26X#C.
M7,9B_@Z.6*3Q6Z[E"-,O#D6?*IQZIFR!#'"Q<R[SQPPI);81,(D68Q99)VUS
M4L\JHX+F$$<K<6:&&/3I)'`QS'6%.U$I1,)T@]M(#HP:=5R.5RJ"R#"$\4F<
M2<0NHBC/)9`R>M9EBG(,G39ZW;,#$42.Q$BB1T@$HD*("8#<!(Q86+()!*S3
M`4Q3$GG*>:*0LS)]Y^VP6"-/^8'KU#!(2+3LL9IET]*RAE?-T.0TN\_VGAB'
M\V'KU`)"11++&:9=/2LH97S=`&()4\_[0(Q"G_LP\HU!,K$1Z:K!)-F0$^8J
M(44-;R[$2(^<)5!(!0:IA[(E;0[1K0P*0A(H```9I@````%RO<4J9`#V?J%2
M*'[W`'@D4-0Y-/M`0'SE>XQ3E$/9^J50P?O\`&A(LX&`S-,0.!P-4RO:"@.B
MG^W^V!ZK_ICZU`#PD4I?>S3-J:M]3*>=K`^!6M#_`&X22]?_`&@^M0/`8F/5
M=.D5&A#)"@FK3VP`,J\4F"NC"<"E$QE"O5`$+S6W]@%[!$%!H6+/?<S(.H*@
MG\Y7SA6%X*E:'^V&06_TQ]:@`PL681$6:8B83"/G*=HG,N8P^S]4SDX_]+@#
MP6+K7DTZUK6Y3ON`U?9_=!P`6%C"VB5H0!*)!+YRO8*9FYB#[/[4S5/_`$?W
M>`2L(F/.W15.T("MU]1!0@@9-9L9,;+$*"`QZ(^P"NF'?41$%)(2+3LL9IET
MM*RAE?-T.0TJ>?\`:>&(?S8>O4`D)%)V6,TRZ>G90ROFZ(,03IY_V@1J'\V'
ME&H!82**!0*S3`"`0"^<KV`F#8I.V^OF@S2_T`]?@$KR'CDFX&29DN*JT`H`
M"AZ%YAL3V-J_<0H=MO92M0[P!4,)%#<`LTQN`P&\Y7M`Q52F^W]4JYP_?X`-
M"11[P,S3->"@&J93M!4'95`]GW&!\K_ICZU`#PD4I?>S3-J:M]3*>=K\]JUH
M?[?Q-?\`G!]:@9/"1:E][-,VIJWU,KYVOSPJUH?[<9-?^<'UJ`E7BF`.6Y`:
M$$CGFRN.Q0P&`Y7*P@)K3V7*NU![#$K>(=O8'`*AA8L1$19IU,)A'SE.T3&5
M,;[?U3+G']_@#P6+`0$&9`$!`0&Y7O`Q3`/L_4,0/L<`%A8LHE$K0@6"02^<
MIV"F+8Q/M_M19I?Z`>OP`6$BR66LTPTQ2$GG*>:*(L12[S]M@QJ%/_9AZ]03
M)Q$>#PY.4(!&K..(W^^`!"I.#*$*!K0OTSQZ(]ISTL#L"HW`H+"11++&9"V`
MD!*'5\T$09`G_P!9]J$>C_-AZ]0`A(HH%`&:8`0"`7SE>P"%;E)]O]J5JG_H
MAP%7M^&+5G.XN+9`J-^3]/I3"43C<!.JW94"AYQC!YH#P%MN`.`H7L1LKC\U
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M7^'S_<GG"F4L]CXUYFT+`Q^3O89%]+0\2"+R/@5WKMPY+CZ$B`6S!X))4K51
M\4J1'JJ1ERI(E4!(E#>KJ5VKTT+6MJ5GBMK1Q-XCIW]O]GOGFT5ZS6)BLS,Q
MS,J]W;'=^8[WL$Q<,GC=LV:LW*[1R@@[39LE#M5ED3IIN")NFKIL<Z)S`8`4
M24((AYQ3!4!J)*@[:;6=2N,[@`^SS),(SO"'^)LXF015<LV+Z+RY/$L&9N<G
MAHEGMTRCG$0,_`2BH-#*-ES+RZZQCF2!!L@#*Q_93K5QYM&XZ3=W9N8B6.&0
M";S*I_"7TKELIG*B#\^4.E#RB4HW)%A)+D%OV`F+9-(J:#:BI#AZK;6]=RYY
MYF.Y/3TT9)1#=+')6/V^`DX[DQ3<(KN)()#'I"(9*E!<5O,:*HBLBV`I`3!R
M58-9';<>D`YF2D7^5].Q%57;A&(B/!E%HIA'G>NW$<N[,VP1BZD%DBG12D*F
M(JNS2`K0[-<ZJAP=,EM?UIO\5S6`:;C;)P^0KY1MB?!\Y;X:W4<M,.CL@6<;
MH(RL$KBKB--/SN.)(H,S`!D".%5;0;E(10P(LIVLZT%G<Q%XSGFU9,>;,49/
M'IYS'QC;,WLZRW.<S:4/*V[:.<=0A93;AV$8Y$&BP%79I"F4-594`W>8;;]7
MC[,VL_@V5[.1,/`QCMNKBN2P#I7&<UEYO!L/3.\,I&1CR;@8O%<ZQ]Z9J4PK
M.'#6:="82Z#<IP;#_;SKU,AD16^6=.KAVF^GSX@X0QQY"MO#C*O&T,,^Q5QF
M?.ZD@;*MW*1"+E:HG3627!P)D5TP<N9;?=:;DA9'!\QZ?8QTMCV(-5\>F<*=
M/8QI/DA(<,XDV,DG$DD%P6R1-Z,>FL?1!BH0%"%5"I0:,+MQUVQTZV>3V3[)
M3D'(Y.J[G&<8R*@^C(DD2T8L6N--W.&1K1K#$R-'GA26<+/?"SJMUEW3H2K<
M!T$\(BODYE\&1_B<`>$17R<R^#(_Q.`/"(KY.9?!D?XG`'A$5\G,O@R/\3@#
MPB*^3F7P9'^)P!X1%?)S+X,C_$X`\(BODYE\&1_B<`>$17R<R^#(_P`3@-?&
MQ$6+=2L<S'W?*AVMTA[`E'@!WE'N`.`V'A$5\G,O@R/\3@*U[E[?;W/,RRZ<
MVSF\19P;W:6/@<9A<D2:*-8K<-MF)W[[(&30<7E&Z+M_B+I=MS+X9!N1RBSH
MT!(KK7""<8PCK\9/HB&R"0Z?'\<PD8%])9&2&!9>6A6$MAD?*P7-!`1[A*4F
MXE2??*.?"0!`R#-)-03+JB@%^HV(BQ;J5CV8_C"5#M;I#V!*/``/8]P`'`5\
MW?VTWA>96US/9J9Q)!=MAZ^-CA^<NY$F%.9=W,D71R9W$1T)(@H^BF:QQU`,
M"BR1-`"E$Q52!#4_M!UDY!AF+-UMP=M8+.$(_-4,L>X,P9P$*[4=3BB^,ECF
MTQA.1N5G(P1$6Y'(J,S,!*H82KJJ@JF"HNSO6..3M)%/<S:=I".)^'DLDB5X
M(91F,0MCDHQDX+"BGQ)L]@VD!.R171#/5GKF;%BU%1=@7F$EP=&S.U._V(Y'
M*O\`>+-(+,<77QF)BH]BDJP<NF>1-LF;+JRB81V$XDDKXPFJZ56,OJF;-C,6
M:)0!LNLL%Q31$9::V.8@:@VB+9&@&IYHC5,P=@^L/`4#PK:GK;AF,5`RF8[*
M/&#%VZD'F2S[-YE&62J1=55O"/3#B$='E3D)$+EW*!4008J:;9!`P$(B#RSK
M9[J7D<NGW&$;D8A$8M)K9:,$1_%08+XU'R>.MD8=F:-0V^6+*OV63HI*LW2K
MHPQ[5-QJ@^.Z`J0,HNRO6@I'ODE]U-M4[9#%76,(,XMFE+QC!A%3<>\B,MG'
M&`/&N5&1EGD?)R3M%HS-/<DLU31C4U@-P$V8MMQNPSV;C,/F<KA5-X&2T:N\
MS15M'22,C%--R%99=)^=?%N1,YF<*3,Q<<O'-R)*+&!MH6IJIAHLNVPW^?8R
MO$XYEL(VF&2NZXEFA'&8MQD;++)C(W.VB6NCMK(A!RFV\0I&H&.DW32=F!4#
M"H8"."A&T]TW]2SIM/R<=O=I2KO'$48W'T'IT8Q#)E,C9>*O&4JGCC$8^+>8
MM&B<J!VBRJ+N0609KQY4D7?`+\XVLZPIMG&(0V3[6PSEC!2+!1UBLHX@0?O'
M;'%FC9S-)3^V>6'?R+%XG*OBO&JC`%!3;-2H-BN'3D@)MQ,*ZXHS,LAG]LI#
M92>PYNW:!!XED<<R2D),L1CTV=-'31Q6)2CY#)<A>M"/G!Y?23!N*B":20@@
M`3EM7CN6L,H,UW2/BDSG#;#3\[*XQ$)QD0XCORCY.\QPS-D9(AVIDHMNT,H0
M1,8'"8F$QA\X0L`6%B"`0"1C$H$!,"4;(A:"0-03`OF]FF#%$`\FD3[D.``A
M8@H``1C$`*!0``;)=@$*D4H!YO8!2H$`/6('D#@*(;]XQO\`N)K+2=)9\+@M
MQ%=Q-I%<W>Y(QQM1DOMPE@^6MG";M&>A)<KQNE-'9B=%H+1^HW*J5!RB8QA$
M*]J89Z79:-Q'PO)]A$)+\FT8TRPN6H8>1NIEL;F8>-RIOJUMK*"3.,OPZTR*
M+8RF+Q@.Y%N;F%RL7HA4[(]V&'1OZ6;J6R6?VWZ:=CNEK<[IQQO+\KWURW)X
M/9Z1W2ZHWV5X)BJ<)E;]TXD(_+)G&]N'CE['@MCR+QT1]*#X@ZL.W3]Z^W/V
MP^X7W3\3C]M^V/;^YN:MI^M78\?XR=W;M.+]5W1>^/+3)&*TSV9(G^[K./7F
MW9W1.75[>[J:62<V;+6MO3B]^VO7M^<3'/R^/6?7X6(Q)#TINX&VJ>:X?GFR
MLZWR_#]BLHQ#)DH;!HYOE8O\2;ESQU'MI+;6K.!G9N=7DGZ[Q)T+R.34)!&;
M%=)&X\A]S>!W?:WN+>]M>1B8W]#;RZ^2)XB8OBO:EHM6MK]EN:_CQS:;8[<T
MOQ:LQ%_#EKGPUS4_+:L3'\8Y_E/Q]72[I]QW>9';)%+J<+MW+[MJY?N>O)N]
MO43*XA]4I'<?-GFW+"+%Y!8^],$9MQ,,6BXN6XNCK`J9=5=8ZJRFC94W#"Q!
MA,)HUB(F$XF$6R7G"H9P<XF\WMO,Z5$?**AO*/`-'-XAB6$1.VC$#+!DF'GJ
MA'E<J@!<NAE5%+$X#(CE!,MQS'Y<H)@`G%=L`"Y2!G8;!PY-W-Y5"Q;$IS);
M:")P;)U$48%Z*7VM/:Q1)2GW(>0.`E\L-$DLLC61=,4Q):V2"P4A:"D):%[-
M,6"`AY-(GW(<`$A8@EED:R+IZ0IVMD@LT>1%&VA>S2&-;V^30)]R%`"PL02R
MR-9%T]($[6R06:/)`E;0O9IA&M[?)HD^Y"@)%H>+(M'$3C692%<"-"-$K2:+
M$2(C4&JH)Z8-4BE&]+V!0N&@%$%80L0```1C$`````Y9+L`I4R@'L?4*D4/W
M"AY.`!A8@0$!C&-!`2B'+)=H"4Y1`?-[A*H8/W!'@`T+$&`P&C&)@.!P/5LB
M-P*`Y*H!JD[;RO%@'R@H;RCP`:%B#WWQK(VIJWW-DAOUN=!:ZI>W5"2<7>76
M/]T-03>$1BCMVDI'-#HF024$IVJ8IG5=*3!79Q$6Q2G47(]5`_MAQ$%35*6\
M1."DT-$GOOC61M05!/<V2&\51=BJ)JE[=07ZXCY=4_W0\!D8:)$1$8UD(F$P
MF$6R0U$YEC'$?-[S&<*"/E$X^4>`QX-$UKX:RK6ZO+)=]P&K['ON"O[O`9"&
MB2B`A&L@$HD$H@V2\T4S(&((>;V"0S5,0\EA?('`(X^)C1;(*'CF@*@(FJ+5
M,ARF36;F3&@M6H@)!CT!#S"_>2#VV@/`*R0L0G99&LB:>EIVMD@LT>1T;:%\
MW2\,;V^30)]R%`"0L0G99&,2Z>G9:V2"S2!F"5OF]FF$<A;Y-$GW(4`"%B"@
M4"QC$H$`@%`&R06@F#<I`"A>P"%:)`'DTR^0.`2/8>+(VJG&,[@5:``%:)&$
M"@Y;%H!0:N1H4A`^T[`#O+2X`5C"Q!@$!C&(@-P"'+)=H&*J4P#YO;<58X#Z
MQA\O`!H6(.!@-&,3`<%`.`MD1N!4'0*`;S.T#@^6`?+JG^Z'@`\+$*7WQK(^
MKJZES9(;];G05NJ7SM0))Q=7OUS_`'0U`/"Q"E]\:R/J:M]S9(;];G=:ZI>W
M5\2<7>76/]T-02N(F-%TV+X<T$BXNP<>Y4S%4`Y'*AM4W*JAYZKM4>TZ=14-
M[*HAP"L8:)$1$8UD(F$PF$6R0B(F,H8PB(E[1$RQQ_=,/EX#`0T2`@(1K(!`
M0$!Y9*H"!BF`0&WU#$`?W0X`+#1)1*)8UD42"02B#9(!**9FQB"`V]EAF:0A
MY!3+Y`X`+"Q)++(UD73%,26MD@L%$60I"6A?-TQCF]M.[1)]R%`2I0\8#Y4`
MC6A2(,XXC<0:)E*F5%8QTR)F!L0/:3,$!``4/:*1!M)0HF!42%B"6`2,8E!/
M3`E&R06`B#,J0%\WLTPCT`#R:)/N0H`$+$%M`L8Q`"@4"@#9(`*!"H%(`!;V
M6E;)@'D`A?('`5=WX9-&<YBX-6R#<#Y1T^W`BF1,#6]5NRI2U`H!6@=G`6UX
M`X"@^P^S>'Y/T/;.PF(0^&XWF61],.W3>&R4D%`.5XK)Y';:$<-II8'D3+D4
M50FC@NL)D%3B(&&EW`;7;CIIS/'=UL@R7<F0VJRG;]T?.58",A,4;8R=BWR*
M>A'N*0#S%3P[V),CAT/&K($D2R9GC@ZXU(0IE=4-WN?-+;**;@9;M/L!^6>0
MC,;VL</ML-OW^%8SELQ%.\HSYE.2>*%RI>)QF:R&'CQ!R6/<OH\7J*)B)K@J
M"::FY\!X[Q_EO)5T/);N+Q^"];<9\M+WQ5O$<UC)].+7K6T_A[ZTOVS,3->.
M9C'EO?'3NI6;S'PCU_AS_4GG!V,@I&1BV:LL73R=U#(O9AC!I-G$+#/'KQRZ
M/`Q;X[=!25:06MRA7ITD3O11%<4D14TB4=[]'^JO70[YTXGBLVZ6M$=.^T=8
MK-^.[MB9BO/;S;CF95[NW\7YFZR['0F,3RB(QTT?$9!*XY.1L'*I%:-5(R7?
M1CIK&R!'/ATGRYF;Q4B@'Y9Q;;724I8-1)SPE-GO2#0$+$PV'YIL9+$C(/*S
MA(RK?Q2;>2A6D>MBL?.2>7X!+O)@061=MS.2K-A5<.DG"@HMV@LG02_AVS_4
M[X7N3!9UN#@QEI+&FB^`9-!8W"!(0^9R4[*KR#9R[-C+,CC'X#'HR,1(<L8S
M%VZD7YB(-TTVI$@\8K9/J9C(+?6'3SW`7$IFF.Y"ELYF$TH[R"2VSREW+9@\
MB'\A!N,$8P\HP(AD+,"$0,@DP;Q39IR[P2J.U@53&P_48WVY)&8MO)C+G<V/
MR")EF63Y/BL&>%DV">TD!AT[#2T6SQ%9%-F[SY.5GF900<%;.'#<ZH.`2%`0
MCA38_KY4?,7B^]&PY^2F7+@6\7@3&&B7L*O(MP,P?Q+O;W(G:[H(LAC-E`D"
M\F)C(GYM0Y'R`;%+9#K>,T9,EMXMG2'8+0"Y9,^(Q3MQ(C#RL>[F$)EJSVQ@
M3.FV50[,612HN6PQKI5P\5&21<(1K`'_`#.S/45(R.[+3Z\X,OB&0<XMMLP;
MD3Q;((`BV88_+(0KO)L:V\0G(5`F+MY2-&01=2+@A7;<Q$05;G7<`PL.Z6^I
M!#/<?ELQWY2+AD1D&/Y))1L&[E9.9G"P;8"!B0E>PL%",\9<`4J#LZR3YU)^
MVNW`\PJF5L'07PF*^3(_X$V_U?`'A,5\F1_P-M_J^`\_#H7WC%_!FG\3@#PZ
M%]XQ?P9I_$X`\.A?>,7\&:?Q.`/#H7WC%_!FG\3@#PZ%]XQ?P9I_$X`\.A?>
M,7\&:?Q.`/#H7WC%_!FG\3@#PZ%]XQ?P9I_$X!!&Q\-RZE6,8(\_*][9H/8$
MH\M^T[@+W<`O\.A?>,7\&:?Q.`BO<O`LFR9_MPOA,G#P3"`SN)FLR05`K<LW
MB[8PA*10((0\DE,<\R,JV!HN=JB51P1WK`JT234"J,)LKUUL<H?S,YO1L%-P
M3B9QQ%IC+':\D$FQQB)S,9B5=&?K0<Z*\_-XB\<13@B:+<ICIMG";A$R9BF"
M^<;'0W+J58QE>?E>]LU'L\4>4^T[@#NX"JV[FT_4/*[FGS/9?,-N8G'5,*0Q
MT^,9V$E(1!9DKJ46&:904?C#Z,:/4%'C=91TJHZ<.TVH-"`S3.HL8/+(=D-_
M9;"<?C4MT,:+ET>3)4<BDXR&C,/;92TEGN/.XM`'T+ASQSCDA$-6#YHV?-&V
MHW1=@H9-PN4%`!E-^GKJP3GXV1-OE@GAPS,#(90R<8B:02FF7U8D8J<C<=CP
MC8YE@[2*FI,7S=-,7_BZK9J+@S0J2B2X.W9G9;>K;_(Y26W5W"B<XQIWC,5"
M,HT\BXDEF4ZVR5F[&5025Q'&T04ER*NUG2JZKI1,BK5BW*DW8:KL+B&CH<2F
M`C*+`X@-H\LT[#4\T?O8]P\!0/#=B>L>`9Q<&^W7VH<1+!V[D'$Q)PZ^:YA)
M>:JHUA9.3R+"FZ#AF\D!!1TY;E9"DV.+9HW;V$6X!Y9UL)O_`"^6S[[#=V8.
M`QF57RT8EJZCV@N\983&.-VT6P:1K7$A822[3)4$G#9XX7UXENBH5,'1GJVF
M#,_1TZLSL7Z"^^&%?AV*O<:;,H9RS>P+6+BIV,=PL[E"T"_=9VBT?/F,FX=K
M,F"F2KL!;NTF:#@XD":L9VKW(8;-QVWTOFL<ONG'K1KIQG!C)32C^,9;D*SQ
MFTB_?XTQ%ZYEL03&/>&2CF:8&6.#<B!`3,0-MLWM7NGB,B_>[J9[CF?%=L)]
ML1"'Q9KCT:@[>[GYSE$*[9Q9D';EF6/P6>BH4R9WSDH$B4K:F`ZRP6"\)BOD
MR/\`@3;_`%?`'A,5\F1_P)M_J^`^!C8<HT-'QA1\@M6H#]@4^`CI".A@W<D#
M`QC`.7;J!L,#9I<%N6S2Z=HV5"UTBF<*=RA"CW@'`2&2,@R@2R/BB@4$P3L:
M,P`H)E9@D!*)]@$*T;VT[@33I[$M``C(,`*`1\4``!0*`-&8```5$I`*`)]@
M`5),`]8I?('`0[B$1CH;O[S&+&PFHJPVR!P)6C#4/9"3R:8+43N&U`1*6[[3
ML#LX"8O"80X&K&11@->!O<30P&`X."J`;VL0&XKI4!\H*'^Z&H?CH]*GO5Z6
M;&_2M;%[:,.F#8K,_1I$@'.29"VW4QJ'G>FK/=LL;E(_)-W]T.J?<J<PAV;9
M_*]F7H$D84"-CA%"5!PS1ESR+MNX[C[=;OO_`%/>6A7[8['E-?WMFR_I]6?'
MY<V+<M?9B<%L6"<%JY9OGKDMB[*<SDB\TXM%IB:VW75MKV_6Q2=:(YMWQ$UZ
M=>9YZ=..?V>KL-M[G'4CU*[5[9[B]#VY6Q,GM!"Q^VF!OT8E_B^1XCD$YA2T
M\KN/*PV9O-JG3Z2@95#)F,9-,42-W"2L;(-V*[=PLJX5O?=SVQ[L]G_<OS7@
MO>VCN>.]QX]_+?)K[5;4STKEM]3'-Z7_`!UBV.];4[XB;4FMZ\TM6TQT,V#8
MT\>76M6^&:1Q->L=.D_L]?Z>GJLCL#M]U^1.\:SKJ"SK9_+-BTAW?;JQL9%P
M:6<3+Z5DL+-MG+$+$;;P3!EC$9'MLAM8G>^()'F%0?+R(\N9MYRMN@)HV%$3
M"9A%B(B>^YJT$1$YG`J753[1,9=41KWB<]>\W`-#-XJ-/"(\K%LE5@R/#U*-
MHQ!VL!4\NAE%%=)+&LH.!4>TYE.5+I``G%PTM%TB#-PR,@2[N;S&3CX<%!2V
MS$XD;,M2I(%YHB:TEP"44D[*_<EIW!P$P%C80MEC"*+:*8IVM6@6BF+,4K*)
M]@D,U;VT[A33I[$M`"1L&2S3811;-+3L:M"VZ7(:%EJ86Z?)-;*=VBE3V!*`
M$C8,MFG'Q1;-+3L:LPMTN0!"RU/S=,&36RG=I)4]B2@)%HN&!:.TXZ,!--S7
MVMDU$B=K`4VXU*S6*G:5!$I!O1["$`##0I#`K",@Z``1\50```HT9T`"E3*6
MGM?8`%(0`]8`\@<!@8R#$!`8^)$!`0$!:,Z"`E.`@/M?<)3F#]P1\H\!DT;!
MFOOCXH;@4`]S5F-P'!T"H'JGV@8KE<#5[P4/7V1J@'C(,]^I'Q1K]74O:,S7
M:@/@6ON3&[4!XYNKWZJM?9'J";PV(,[=@K'QQD5$$SCJ,VHI*++'F2O3"8S0
MI#JJ$=+`K[:<1!4]Q2@<PJ`I-&PAA.)V$483"H*@F:M!$PJ"]%83U3[1.9VX
MNKWBJI7V1JAD8V$$1$S"+$1$XF$6K01$3&7$XC4G:)C+*"/E$QO*/`8\-A*_
M@$56M?P5I6MP&_D^^_M_=X`"-A`M$K"*`0$HEHU:!02F;B02T3[!*9!(0\@D
M)Y`X!)'QL05LA?'QQ%2FKYS-JFH4Y%FIDAM%DS,4Q3-&PE]K*-4TQ"MI1X!6
M2-@R:>FPBB6:6E8U:%LTN0T-.U,+=/D6ME.[12I[`E`"1D&6S3CXHMFD"=C1
MF%NF#$$;*)^;8#-M;3NTDJ>Q)0`L;!E`H$CXH`*!`(!6K,`*!"MBI@6B?8!"
MMT0"G<!"4]B6@(WL7#BVM2CHPQM9F!2ILFIQM*Y;=Q2LG8VE3('VGFE`!J0`
MN*"P8R#$!`8^*$!`P&JT9T$!*J4]?:^X2J'`?6,;RCP`:-@S`>^/BA`VH"ES
M5F(&`Y7@*@>J?;>5TXNKW@HI7V1J@'C(,U^I'Q1K]4%+VC,;M3GP7ON3\[4!
MZZOKWZRM?9'J`>-A#ZFHPBC7ZNK>U:#?J\^*^I<F-VH+UU?7OUE:^R/4$KB-
MB3.FP^'QQB&%YS(\FV,0P*%=&/KFY-4*'6<K"-RB5QCG]D(F`05C&P@B-6$6
M(B)A&K5H(B(F5,:M4^T1,H<1]<QO*/`8\-A*@(,(JH"`@/*M*UN*("'F5K>4
MH_N@'`9+&P@"6UA%@)1()+6K0!*)!;&3MHG4!*9NB):=PD)3V):!@L;"%LL8
M11;-+3M:M`MTQ8BA91/LTQ9MK*=VDE3V)*`E2C(<CY0P1T:4A6<:5L8&;4I"
ME07$4B('Y,@6HG:MA*4JI[!32$"DH43`J)&09;+(^*+8">G8T9A:"8,@1LHG
MYH)@T;6T[@23I[$M``C8,`*!8^*```@%HU9@``4J`)@6B?8!2H)`'D`A?('`
M5=WW;,6\YBX,D&B`&R?I]O!JDBE4`ZK=E0*)@2*6M"A0*^H'`6WX`X"@VQ.V
M&"97T.[.X_BK3`L8RW(^F+;IC%Y,T@\6.\BLF?;;0IT9A431KS6<M)L0<+"9
M,ZAE"F$?/[0#9[<].<_BVZDME.>91M7F.#.E]Q%(Z'98A&XT1FPR:9Q=_A>/
MJ8L9"4A3FP9E$O$$Y0KTKEPFZ$ID*F.IP#@W,EI':];<#)=D]A\=WIFXW&MK
M73C:W%\@P7;^:GHQ?)\_9SKS&I+)$6N)/,HBHXX.$6<B[C4GJ:(I`[3.*0'W
M/@='Q?DO(UT_+[M?'ZEZVXSVQWRTK>(YK&2N/G)%+3^&;TK>:\Q/9,<\8\MK
MTIW8Z]]OESQ/\.>G]2=\'8/DHR,^NJ>*FRA>'1>3;>`1;&@8Q^]>.7:\+".%
M6K-S(14(9;E$7:R22[PB.LHFF=0R9:&[.G.U>-"+QIQ/%)M^:T1T[K1$S$6O
MQW36)F*S/;$S$<S*O=VQW_F/%['1#ID\:H<@T5=-'+9-TW38E7;'<(G1*NB8
MZ*I`52$]2W%,%0[0$.SBJDJ#MELOOOA>X))G*MQ\6W`PYWBC*"E(V?DI%5ZA
MD:&)X+&+YE$1:>,(PZ!5)O%7BOAHG*<ZDL[=G?"98&B(11B/3SUJ8JECAGO4
M5M]F,LW=XP3,)C(H<3QV2Q"<U+R>5H,L-/BCZ+QI^FPD4F,<XCW#595)N!W:
MAQ%,J(/%GTY]1'U0QUD^W^BAS'"$-S!Q^85CT9!EDKZ4B<98;8K;A)M(7'$L
MD:X[(1\B\<IN6KLY0?)H'4?BB=PN'P[V3ZR1Q\3,>I#;4,K"'61`CK:;!!QD
MTNJJ<"KT2P@)=,$&8@"2MYTRN@!91JJB`M#!J)_8OK76!$(/J.VVO>L6;284
M<X%BD2E'F!S(^*+8VU9[>28I.EV;M$&SA=4RK=5N!C:I3"3@%JFRG6>2$F&S
M'?[:MM*HL5&^-G5P'&7[5=T>A4',RZD,!=R39-BT`B8%`7ZKAX15V=0$G"<>
MS!U9ULQU)3.;DRS!=X=O<180S*1;1V(2>)J3N-9*[GL+Q1DZ=S[(BK)-BWQK
M,L84<1Z9$W2QV\L_$%FYSI@`-1]LOUJF2R--MOSM"Y6/(3BN'OE-OX"(3C8Y
M15\VAB3,:TP=^62D$V#E%8#F<':M'"!R*-Y`%DUFH.+,=I>K.113>8;OSM9C
MTB>`P]DYAWNV6)R6/)S;."AT,UEV#I?%5IPBTOD2#QPSUE5FR+9<J0M@,!3$
M!HP6RG67%SS5_+;Y;73\.]R562R..-"-&KD8Y.&;1T<WQU1##&R$+&HSC<)0
M8]'2,5$RC)P[D3&,[.'0?E83WO%?S+3^+P!RL)[WBOYEI_%X`Y6$][Q7\RT_
MB\`<K">]XK^9:?Q>`.5A/>\5_,M/XO`'*PGO>*_F6G\7@#E83WO%?S+3^+P!
MRL)[WBOYEI_%X!!&M87EU*MXJO/RG_4M.[Q-X!?M>ZVG[W`+^5A/>\5_,M/X
MO`5JW,VQW5G,SRW(]N,[Q['XV3VFC<3@(B661=,XC-V>9GEW.21T4XQ2<A85
M](8NZ<,5)-PA,GU.5$K$I&JA7809B^T77)%O(B.FMZ-FI2'BY&#?.9(<+A5)
M&6B(R3PUJ]QQT[7PT7HGF8-&?<.7(D%US:C`J3L@<R<`OS&M87EU*MXJO/RO
M_4M.[Q-Y;]K]S3@*^;Q;4;D3^4-<VV@S7&\:F&F'KXJ2'RM28D<,5</)E-X,
M^YQ5`7N.N):,9J*&27,RYI:T&XKI)'U$PC>8V-ZDI[:B(A9#>_$FFZS1GG[:
M6R7&8-OB>.31YN6C7.&**H0L(C),AQN-CSHBHV!%R5-TJ0%5%:.N`U#?IWZG
M$L@CY+](W&_#RS4!(Y*T<XLI(DR1H&,2,1.L(B-!:.C,";1DO)G?-4FI7J<H
MN@U,[!(&XD6!U[,;+;O[=Y)*2VYNYS'/L=>8S%0;2+=3+^7.RFFN3-'02K9&
M1@XLB:LHDHZ</%EEW:@<RW8MRH-8XAW07%,TAA`P$0BBGH-HZ+3S34[!I;Z@
M\!0/"]B.KG'6D7!O-\=N3PK!R\D%Y!_"%SC+Y`PE6,TAI2<RW%A!XP=OK5W3
MAN1B8B"@M6J"%A7)PW4WT_\`47*91ELE$[ZXYBN+SDQNIX;BS>.?3Z\9%Y(S
MB6^WTK%3\B5HXQ^3QHT0.K&)H.HUN=ZX5:G`XE``T8=./5">/>H..HC'3"9]
MB;['F;.,D6+C&4(J+G(IW"2>5'!](9\TCW,BSE%'+MHR6R5W'`A($10<'L":
M\8VNSV/V9C-NI;/VJNY<<M&NUL\%WXV\>QK'<A7(>4DI1[#1KB26E,43\->G
M(R:)FUE`131)9:$>-^G'>A\./I9;U#$>HL<ID9N>6QJ$-B2<Q&!F&[V10T*U
MCFL@Z6CFA(C,\?BW"8OE4A:8^D4I1$@&4!LM>GSJ?2V^A<32WZPJ/E(V?C9-
M2?%C.3V4KH(Y0J\>A+YG(J-!R-F:`6$0C`B8YFN\2324,#/526#ZR?:?K.0S
MO*)_"]W]H1Q"6R615AL4R#&XB1"*Q]X\09PB2)`PF/,P3@8D===$CUPNX<)K
M',X<"NFDW"V6T>.Y9`8%$1&[,_BN99TT=3P2>1PT5%1;&18K9!*.,>'D64/!
MLT'C;'E6J+C2:I)BX3.(7`-Y@]4&D)^5R1,#:)O#;N!M,"++4"F6S*B=HVW@
M`.DTC!3LU"D'V0%X"0B,X$+`(UB```2!.Q!F%`*#($0)0O8!2H-[:=P$3IW%
MX`!G`@``5K$```4"@"#.@`!40)2A>P`(1.GK`7R!P$/X@RQO\KN\HD:0(*"P
MVRY@4V\:"IJ0D\5+F1(34-1`1`E_<2H!V<!`G5/M9U:YA-Q<ITO[PX%M_&-V
M.((2&.9=#P3B)7E8S<$LKDLFX72P"?G7+&7PETZ:.6@/R)KBB5(A$`<.E508
MFQ^S76O";O+26\F\.U>8=.ZLUO!XEM^XQI@&5341E#5NE@R@*?D^@F,/"P0H
MOB*0QE5#W/7SA>0D"NDV[7)AS9=?+7/@M:F>EHM6U9FMJVB>8F)CB8F)ZQ,=
M8GK#Y,1,<3UB7#KH,ZA-^,2V8<](#O*^F[8OJKS_`*Q,L6VDP5]DP8T(;%8-
M&;<"P:0.%8IM-O+!3B$U@D?(^,Q;52/4)-GE49-2/5YY'C]9^Y?M3]VON/[=
M\O\`>GWUH^3V</C,UJ[^]J8='+AYR[6?\>WM3NTYS1DO%,<YHG)EUIU8Q6R8
MYQ6OHL.]H:F;'X[6M2)O'X:VFT3TK'Y:]OIQ'7CI$]W/$\NG$[M)Z6)W)L,%
M9=273[&9X]VEWB=?6='$Q=8@O*.LQR`F,9`\@W6SNLCDZ+;/(MNT,1PY:0K:
M(=BNUESR*AC_`)T\AX7PW^03Y[PN?;O3'NTU[TSX\..?[S%DR5O3Z6;+,Q'T
MIB>ZM8ZQQ/,3#;TR9/J_2R16)FO/29GTF(^,1\W:,64.`>Z&D2"I@$5A%!K0
MQS<P98?/(!A`QUEA&O:-QZ]YN.39S3S>.C%H1$K2/8+KER3#E;&\>V=JE!/+
MX8YU=(F.9.8H)#4XJ<J72H)^8:TYI$&;AK3'PW;WEL:P@*`EMH)A30CP6J$$
M\%'5$A-6H"1.R[NH6WN#@)?*S@@$EC6)`0%(4[4&8"`E%D*(DH7L$ID&UM.X
M2)T[B\`$9P1=/3:Q`6BEI6(,PM$GA^AIVE[!*+=I93NL2I[$E`P1G`A9IM8@
M+='2L09A;8$?H66E[+0;M;*=VFE3V)*`E580NK'&2918I).:B9-JT%-/W!8W
M&XK18J?FI(E(-Z784@`8?-(8%0,X&@4:Q%*%`*(,Z4`J8%`/-I0"%)3U@#UN
M`!9P-!JUB*"`@-4&5!"U0#5\VE+#&`?6$?7X`,S@1`][6($!!2^Y!F("!BNP
M5OJ7M`Q5E[J]X&4KWFX`.S@1OU&L0-VMJ7H,QK>#_F+[B]MP.'5]>^]6OLCU
M!/R4/S;L56<9HJ(IB)E&S7247,>:*]J<S4I3JB1POJAJG&BA[BD`QA4!29G!
M")[VL2(FU14N09B(WB]UKZE[;C+N;J]XG4KWFX`%G!")KFL341,)JH,ZB(F7
M$XFJ6M1.HK7US&\H\`<I!5_!HFM:_>6=;K@&OL>^^G[_```5I!`);6T2`@)+
M;46=0,!FXIVT+W@9-&GKE)Y"\`DCV,.FV0!1G&)K%-6TS9HFH4X+-#)>;RC,
MQ3`9!L)?:R]I$A"M"#P"LC."+IZ;6("W1TK$&86V>'<OIVE[+>7:64[K$:>Q
M)0,$9P(`GIM8@`*"6E8@S`"@0&`(:="]@%!NULIW6)4[B4`*S@0`MK6(```@
M$M09@``4K4$P+0O8!2I(VT[@*2G<7@$CUA"G;@1%E%G-JM+2)M6AQM*Y;"(E
M(#1WYI4R@-;.P``:EI<4%8LX$:W-8@0$#`:J#/M`2K`>M2]PD.I7UA-Y1X`.
MS@3`>]K$"!@4!2]!D("!BO`6OJ7M`Q5G%U>\#J5[S<`'9P)M34:Q`W:NK>@S
M&Z\)#7U+B]MP.'=]>^]6OLCU#)V<$;4U&L2-VKJWH,QNO&0U]2XO;<+AU?7O
MU%:^R/4$CAC#F=-S<G&&)5X#HW+-#%`%"NK^8/RBH%`ZRJU;E$KC&/[(1,'`
M*Q:00B(BUB1&IKA%%G6HF5$U:E[Q.<]?7$WE'@`&D%4!!M$UJ%*(LZUN((4\
MWON`H_N@'`!6D$`EM:Q("`IB2U%G4!*9J*0EH7L$IDD+:=PE)3N+P`1G!%T]
M-K$!:*.E8@S"@E%AH:=I>P2BW:V4[K$J>Q)0$J3&&(].<&<81/DXP&IP;-"D
M$B2_M(-S@T(`E241;6@54]HE2H4E""8%)&<"6RQK$!;I:=B#,*6`Q!&RA>RT
MJ#:VG<!$J=Q>`"LX$`*!6L0`4):!4&8!0"MP3MH7N`J:5*>H4E.X.`J_ONDP
M2G,8!DDS3`<HZ?;P:D0)6G5;LJ!+]$`J`%#LKZG=P%M^`.`Y\[$X=M1EG0_L
M_B\))[=8ED63=,FWL.WR:+)C#>3A<A?[<0H&EA4:&;NC/V$V',*@!RJF63-4
MP'[0#:[;;#-,/W2E\UR_?+;S/L*??E*Y#;YQ@N'P;2/'-I_")C'+I!#('S=R
M7`8_%W,:Q)RA"`V>J'("2JKDRX.3<G(9K`C[@9)T\;.X'O9DL7CFUKE7:Z*S
M+#-N762QA\GSYMD`X]D4HS5Q4F61\8L#ALA)K,FKHJ6D9TB)DQ'<^`T_#[_D
MJZGG-R=#1O6W]_\`2MFK2_'-/J4I,7[)G\-II%K5YB8I:(ECRVR5IW8J]UOE
MSQS^Z?3G]Z?<*;/&D;&IYN[Q5WE2D.B[G?`TVB<`SDGKMRZ=16/BLU9O'$'#
MJ*BU:+N$RNG"*)55P!4Y^*&[;4MM7G0K:NG$\4[OSS6.D6OQ,Q%K?FM%9[8F
M9BO2(2KW=L=WYFXRV*CIW%,G@XN3CH63FL=FXB/F&RY6KB*>R<8Z9-I%!RP6
M;O6ZK)9<JA3HJ$5*):E,!J#Q52<[Y#8?K6@X.&@,!ZF-M4&$/`Y01MXE",G$
MF67<,6)\68R,Q-8_D;K(&4>Z;.&QES`S+[N,[*V(#5LQX"7\.V6WM;Q6Y./9
MOU`1TLVR/&V7U.FHIDQ8S>-9M(3DL^G'G/-",))6"B(1E#LV:1%T`=*J22JB
M215T4D@21.P^\L3";YX^SWY@&Q]S<;R=AM_ECQ)_D&3;2Y))3&8/8J=C47[U
MI'2I2)940]A>3.R*P:M4S+I-R*B&J1Z<-YV&WLM!Q?4ORNXC?+D)S',Z=G=S
MJ#N-9X(MAAD9^"R-],M6S^:4=*R+I-`5XUO(Z+ELU3,@F7@&XMT]]7:S^/>N
M.LC''BL;-/7:)TL!QJ#9*P[N5:BM%OX.)9%:ORKQ"9A3,HMJ,3W(MU`(L*R8
M;)'I^ZHSM&$>XZMH4J46M`.&S_ZJ0L@^44QZ3C)!8)8%6K-2:;Y9'L_#79%E
MP%H4JSPAEUWJB;<'W-;*[M2K_=QNKO?"/\.S$'CG",8>@O'*8PJXR^!GTX57
M(,?/&Y(RAR0C!_%BJS>`MRLD`%(7E4Q4!AX=TE9]'[@060Y?U)33_%H&>Q[*
M3P4'-3*;Z<DH!EIM(5X\G)B53:8@V$I&JK4X/7<@V(911RBHL<G`=`JX^'>,
M-Y?]BX#/_P`O_P#<_P#[EP!^(/\`N?\`]RX`_$'_`'/_`.Y<`?B#_N?_`-RX
M`_$'_<__`+EP!^(/^Y__`'+@#\0?]S_^Y<`?B#_N?_W+@#\0?]S_`/N7`(([
MP'EU*^#UY^4]Y=WB;RW_`/9X!?\`B#_N?_W+@(JW+PMWETAMPZQO+H[&&N*9
MY$Y+D;=)TY;%GH-C>+V).E&/6C:1"0;WLS-WY5V0).U%],7"#<Q0JM#[!]5\
M9E3[(Y+K*QK)6+V8QE)+&U]J,/@8MABD'FOUC=MDSQQW2CB:E8!VZAW2P%0%
MTU.@83IJ(%,(7OCO`>74KX/7GY7WEW>)O+?_`-G@*J;N;/[N9#N@?/\`:3>?
M%L!:FPAOBRD)/1RF311W7.R:AI)"`5<$A6+MH,@1V#FU51VHU3;&(B03KB#;
MS;I]WFRK'L<@H_J:3@IB.Q[<F,D]Q6<;RF2J2>81[5CC[LF.P4G!8C)-H`%'
M8IF602D&BHM5F;I`[<X.`1*=.&\RF6)SR/5&E%QBF21,_.0[>&=2#/(FYH"5
MAY>#;,7^5`SPV*B'4RLYBTF(*HKK)-E)!-RHU2/P#FV7V.SG:_)):<S;>!/<
M*&?XS$X\A#R4M,2Y6<@SR=N\2E6OUA?R"K9=\FHY=/5#++&57?E;)@BU8-@4
M"X@^`T&TT.0U!M,')U*-.PW8(#YH]O>'`4%P?I\ZC,5914`;J?QU'&XYT]DQ
M*&.L\GR5VY$RQF<9)Y)EO/.I&)7>`5V\,4C=14JAVH`%#NEPV\UTZ;NS.4Y=
M-,^I1/%(#()G=0S7#X=O*R;-I%YBSB6V&R3"6E,G+(8[/XD,*0!;M@6C2BY=
M*,DF1E2E3#1ATP;V&CWJ#CJH%85WV)2$''(MIIBEAQ86*FH=Q#M\@1RX\UF$
M7$FE6\D@>1*1>9D(Q()8SA)4X$":\7VKR")V7C-KI'<T%,SC5HUZ.X"<@Y>2
M;EBPW(4RE-@_E%EV,G*&?P"01CTYQ3*Y354`Q-,PD$$&S&SN?8#F\G/Y]O8S
MW/C'D)E[($EF[V'%V]R3<A]FL.JXQI7()G&(HF%0KLT2S4CR(:S-0B1DDDVR
M0&"T=<?\L-]EEP!7'O+#?98\!G\0?]S_`/N7`1VAX!^5N0IX-?\`D[@+*<AJ
M5^MTQI6?]93G-&E.S5L^VMX"0B?5WS-/P6E$M.SD>ZC#0LM]2WE;*>II4^TX
M#!?JY0MO@E*%MMY&EMJ%EM/4LTJ>M;ZW`1!B`8O^5W>42!CNIX?MES`I^%:W
M]"3^ES>G[;]XK9J?]76WS>`F&S'SW!9#&[#WA:R-V"#H%+@H/8(&6`U?*>OV
MW`1#N'D<S`H8ECV"Q>WSK+<RE,EC&`YN\780K0L3B^7Y"9=VA"QJDF[2458G
M25!-,@$276.)C#V'#\A_HW-T?2^[&=7?I*NI/TG[/92&Z9=F9_,9#<'/LZQF
M8G\3P/<"1C<=;%)T>/=OL;RC,V.T<AMRSCS98<[<S(K-NBXE1+,(R9@O8/*>
M3UO'['B=;9SX_%;5L=L^&N2]<6:V'NG%;+CB8IDG%-[SCF\3-.^TUX[IYC-*
M6O&2T1-Z\\3QUCGUXGX<_'YNM.TT=U6]3AXK>O9SJJVZ<[=;Y;(;_P"7[5OP
MCYL92*@LOW@V[R/;SPS</)]K,?RM*(#'XM]&54Q]=K#)S$@[C3R**K5)OO\`
M#&?_`$%L3W3^G_SG6_#S;CG]+M\S%>.V)].9B>Z8Z3TB.<4\?JH^?TY__*KJ
M'TL;=;^[?8YFS+J?W>PC>3()?*(23Q&1QZ")"-<8QIEMGA.-3&/N4W39NI(/
M'F<P4W++O1`!>KR:R^FU!3DV_),Z=\V:Q3B#1!JVCEU?K)AYP*@U:.E/:\PA
M3G4!,L-.C[4("83@@`IT$VLW$-=,&=AZ./DW9WC."4&4PI;:A<0D:543!!NP
M1!42`"HF`P)Z=WD+;ZG`2V0,>J33"%K5+3LY&M;F&A9;ZMP-;*>KI4^TX`3#
M'?:]((6OM.EI@Q_[LY?3M_\`W.RG_J:?:<`)ACOM>D$+_P!3I:?(]U(WE].W
MUN3LI_ZFGVG`)520)E8XR18<R)'(4,F5B9,HF8`5M02HJ`01)H`2ADZAI@`B
M%I1!2'U<H%O@E*%I3D:4M2MI3LI993UK?6X`'ZN4&O@E*#=7D:4M4NKZE++Z
M^M7U^`#!CE#WA"4HIJ7<C2EKS6OKZEHN+J^IJ5^VX#*@8[[9JA"T]NU=3D?)
M)<QJ7>MSE]?_`%U?M^`3B2"*Z=F6)$`@9$MQE",@2,N4\X#\#&,B4IE2D%QK
M`*AQ`!4N*6IA,"@_U>JIJ>"UJMJW\C6M9#7U+NVMW-7U]75K]OP&3?5ZIKO!
MKJGNNY&MUSC4NKVUOU:^O?7U>`/_`)>K_P!C75[/P&MUP?OUO_\`3P`4,>J6
MWP:M266\C6MS;3MIVUO!&VGJV4^UX!)'D@B-T"F)$D6*;L*)61%`.*[(4:%T
M&P@83<H):$*-=*E?,$05)ACOM>D$+_U&CI@Q_P"[.6T[?_W.RG_J:?:<`$^K
ME$]/P2GM.E9R-*4CN7T[?6Y2RGJ:-/M.`"_5VA+?!:43LMY&E+6>E93LI9R]
MM/4TZ?:\`D>$@#M@*B6&.85F=A2%8GJ4'+8?-*"+BH`F`#['L"@U+V&`%9OJ
M[0;O!:4-==R-*6KWUKZEFI7UKO7X`.&.4/J!"THKJ7\C2EK[6ON]2T7-U?4U
M:_;\`*!COMFJ$+_UVKJ`Q[J27,:EWK<Y?7_UU?M^`%`QWVS5"%_Z[6U.1\LG
MS&I=Z_.7U_\`75^WX!*X)!BZ0/;$B0G.<V:UD)2@8'@'Y@V@H!`,N#BZXZ=3
M:E;AN#@%8_5ZIJ^#5J:ZO(UK<M?=ZM;]2OKW>OP`'U>KV>#5J%*<C6MQ*>O6
M^VGKT];@`H8]4E@0M:IV6\C6MS32LIZMP(6T]73I]KP&"!COM>F$+WHZ5G(]
M]8[E].WU:\I93_U-/M.`3)$@0?&,!(@"&91?*&*5D!3)E<`#<&Y@1+<4J@M;
M`*H8`$4J%+4@F!23ZN^UZ?@O<CI6<CW4C]#3M]2WE+*>II4^TX#`?5RA;?!*
M4)93D:4M;:=M/4LT;:>I93[7@*P[ZA'>.8P+#D:#E'3[J<GR_P"M9LI9?H=M
M+?8U]3NX"W/`'`<^MB$-I<EZ'=H,3B<YV]PJ9R3IDV]@`R:'F,=CI2!G7VW4
M*BI)`M&R,:]+(QTX&LJ4JZ2HN$Q`QBGJ(`MVTVQQO$-VI[/<EZC<'W)@YM/.
M"-\<EUL89HPS+)LAAIV$@V$<A./(4K7%B1RB"+M)!NL=L":1DQH900L;BDA@
M2FXN9&QU[AYVOU-P$IS0KF$,CKA,[B"L506!Q)K`0R=P#YUHDKV6\!(A7<)X
MNJ(NHJWPUO\`]<S[^9<_\KR<!JLU8,,EPS+L<C,D98W(Y!B^00;#(F;A(CN!
M>2\2\CV\RV,V>,G)5XQ5P"Q=-9(]Q.PY1\X`I8&P74,WFXUTVZYYHL&9*.2R
M!HX@\;</'Z;:.<H/DXLSIPY8Q'-R#MPH11%(BR1%4@$YS,FX\`YT.G_-7^+9
M#B6:=5F09%$9&.%)FY9&!AW$&VQ3-\7R-^WQQRBX749$G\>AW42X*N+I-1)[
M>J54""F<&^.PV_3H)]!_UHK-8Q>7EQQ2&C,=@DXV+Q617+RL-*@M(\_*K,&=
MZ2"I7"8H5*)!\P.`U+;I]ZAVJ,E&)=:Y4X5M"1S?$VJ&.Q(.V,^P6,H,O+2$
MC+2SQZ"R:Q[BBH<IW!4G!RG,F)#!A'8CJ=5G'D[)]:T>\4(1$D1&LX!.-B6J
M?(Q[203%J&0.])9ZJV46!U59PB)U$R&!-=0"A(LUL;F,[A$%'/\`J34E=SL2
MF\KR+&]S7;-DS79/LAVVE<8:HN<:A)J/@9"+ALZ?I3S5L[2=(-N51;D)[410
M`;,9L5OCKMG\YUI2RTJBU:Q3Q]%,(1FA,1-X.GYUX<SKP:,F1531;H.FJ!3D
M2155'VUXL!`Q#[+;_LYS`1E.KV*E<5QO,X^?RZ*+CS-@XS:"8/(B22QTP-YS
MEX)`JT<*`Z(G!4ERJNH+A=(0;3CIRWV82`*X9U<1V)P[C(9:;F(1LC.2"<ZL
M:96F(F0>R$QF\F^9OGQC((R;=@9FP4;-`222`KAP)PN3M4TE,5V[Q3'MRMQH
M/<7-8B..SG<U%..C!GUR.W"C=T=D5<Y4EB,5$DU!K50Y!./:8>`D#Q3&N_Q&
M"IW5YMA_K.`/%<9^4H+X9'_ZS@/LLCCIC6E?0IC=]I73$3=U>X#U[N`].;@O
M?,3_`#S/^-P!S<%[YB?YYG_&X`YN"]\Q/\\S_C<`<W!>^8G^>9_QN`.;@O?,
M3_/,_P"-P""-=P?+J5<Q5>?E>]9GW>*/+?MO)P"_FX+WS$_SS/\`C<`P<XQF
M!RYW@BZN1M8AIB&;Q^8O$F,JO'+S)8B,ETV$2=S'2D>')&FW;5=TDN1RW=-D
M%&YTA!83D"H$/L3U,QF5/<F?]=XY.@^F<83)CK[`,1AXAEBD!FOUG6CT?")3
M6<2\C#NW<0Y7'3!VR52OM40(?@+W1KJ#!NI5S%?A\J/:LS[AE'@A]MZH#P%*
M=QNGW=F:W<R'<G`NK5_@L-*3",U%;?KMC24+".7N"81@LP1(RV3@R5BRGP%G
M+M&(,B-RR#B0`W9)NE.`,^V!W&S+',4@%>IE9TY@XW-$9?)AEI7%\BGWV0K1
M*T.@Z4Q+(64(I",.6=D5168+.+%4"I+)I(J(N`2DZ=-U#9,VG_TO)!BV&>A9
M_(H^/9JJ,,KT\=E(.;BS1KS,E8_$H=BYFW#J(;1I2MDU@;F?)/5&J"A0=6R^
MR63[69)*SV4;W&W$C'^,Q..)0DI+S4HFS=,<G;OT)5J?),DGE6BSHBKET],!
MS&<.I(R8:;9FU)P%G<WBHS+,*S#%661H8X[R?%LAQYMD,4^(UDX)>;B'D8E,
M1SIF[9NV[Z,.Z!9(Z2J2A3D`2G*(`(!2?#.GK?O%W3KGNMU_+-)"3^L#\PP<
M;J+R*4>T8-(MNVEYZ;1C\?!>,;N7!$%"&<B*R`@5-4YA!\9]L3E^595)2T#U
M&/\`%H65>[@.C-V\U/N)&*99EBL'"Q^/1`%S)"';QD1/0_B;=8C=)PS/<DV$
M@*"=,(RC>EC=IJSG&SSJW?K$?Y'#9#!I$D<FICA64=(Q989I(#G*<L_@L*;2
M"*D2W=++B_=Q3=:5.YU5R<!8'%]LI2$V8C-JGF[2ILEC%8UZ7<-"6>FE%FD?
MN0KEJ,<\DE)=O+R?.0Z01CTZSCW8DHKJE,0YDS!#K/I:SI]D<)(YQUCY;F>.
M1DU-3CK&2,HW'TWSA[EV>Y?&%4=,LC=-N69&S)JQ42Y6TD?$-460L4TTBI`[
M=N]D<^Q#%(C$IKJ21D(N)F\>FTV3-NL245<0>Z$%FSLDAF;K*39%,,,DQ>+<
MP[UFN7EEDWYSK`X$J@N`9>3;.=3P9SD^6X/U?0<=%SV0R+IIBDK$-'T?&PCY
MTT;1[=('KN38-@QJ$`3)(-6K<J[EN)CJ@9VJ=,+]E?P*@7E?1*M1$!4YEDH)
MC4`1$QP.-3#6H_N\!'J#N#_*Y(`#J(O';N!M`%V6H-V73":=H77B`NU$BA3L
MU3$#V0EX"0B/(`0)8[AQ`P):=B[(0$#`R%&RANT#%7;6T[P.G3O+P`#R`$"V
MNX<0$"B6B[*@E$J(D$M#=PD43IZQB^4.`A[$'V,CN]O-8\Q_5*PVQYG3<1NL
M`#"3YDN:L/JA5`!$E_V@#3LX!M]3>'[@;C;;ML;V4W*B=L<Q#-\,EWF6IY3)
M8TZ:8Q!3OBF3-&3N!8RHO7[Z.9+IIM'S=>*6/=SB2R!5$%`Y<9=TO=<"2&RN
M+LNMR(Q7-%L.WNPN'R=^X?94XQB>=X_N5,1V8N6+F:QM7*LKDH5T=H^R)%)J
MI"C%%48LDDW3E$@2+O2TVOE=P^L5SF>.0V1-%8Q"+:O7>WTGE\.)V6T<JPRQ
MB9['P$S%,Q3>B\+((+'`^F9<RY1)J`?](>R=_P`CA^WFIA\3NX\%:[FY;/2-
MS7P6Z_III-\63-CO>)K6>V>V8F:\5GG\NHV:TG;M.2LS^&O$]LS\_28B30Q&
M(Z=0D=N&Q<!Q,")[&VIMD]DYX--JBOCB)M%LGA)Q+'(U=E,8E6Y!%P`U'4U/
M2='R/O2OLN^3#Y*]=3_,<';,>4UJTB/H9YB(_P"*K6L]L5XKQ%HK%>(B(B*4
M[4UOU'$T_%V3_8GGUC_PGSGF/[/.,)SEOBNWS(F5KXCEJ..'B]F<N82Z61K0
MV1)Q!V#\,/;GCY(LNH.FL*I!27U#"<!*<PQ]N^6]R8_<'C\GE_*4GQ-=[7G/
M&3RFI?'.&,N/ZL7I^IGOIV1;NKVSW5Z<=8B&;'AG%>,=)^IVSQQ2W//$\<?A
M]>5IM[-K-W)O<P<UQ3=M1;!'<MM@FSV]6G%`9XE*Q+#<7&9N<B\>;13B*R9&
M9E,L@70L9!4B:#R)YL'")TDK/Q0Z-SR]'/N1DC?KPZJME-QNK'(]Y\KVHV\Q
MR'S[!<LQ'<N';XQDB^2LW.-9(MEF4PC+")QYD$6HY<M%&LC("HW?\E%5B8E-
MPXG3%DRQ,XJVM$3Q/$3/$\<\3QZ3QUX^3Y,Q'J[RHO(!8"&0=Q"I3"F"9D5V
M1P,(BR!(""0P@(B99O;3U3)T[R\1M6U9[;1,6CX2^OHCF#&S3<10UTM.Q5H-
M;N0T++3=MPKM;*=]Z5.\G'P?!'D`;3TW<.-VCI6+LAN`X1_+Z=INVX'+2RG?
MJ)4]D2H)%G4$9:-,FYB#$!SYIB*LC%`5&'N>TP`8`$Z:J-E!+4#$H(@)0$%8
M/<?H`@[AZ4"@@NRI02IB6GGTH)#$$/6$/6X`%[C]!J[AZ`!A-5=E2EJ@F$?/
M[K"F$?6`?7X`,\Q\`/>[AP`H*">Y=D``!2NQ5$]3=@%*BO=7N`BE>XW`!WD`
M74U'4.%NMJWKL@I9X@+C4N-V6`V=WU[M-6OL3T!-S4(1V\45<114M!,IU%%6
M94Q604G!>E.<U`%1%-%?5`3")0*I4`H:H*CO($HGO=1`"45=2]=D`E$HO@7O
MJ;L$ID'-U>X2*U[C<`"\@0$P&=1`"`G`P"NSJ`E,N"@&J;O`Z:M?7*;R#P!S
MD#7\*B*UI]_95NN`*>RK6_L_=X`!Y`U+:ZB*B)`+1=E41,9L"8%H:M1,HC;3
MU3$IWEX!'&N80K5!,7$250#4`FJR`]YEVFD`%*"?G&,X:VT*`B)TO5,2H+$W
MD".GI.X@;M'2TUV0W7^':&G:;MOYEI93OU$:>R)4,$>0!K--W#C=I:=B[(;@
M.$>*%EINVX'#6RG?>E3V1*@%>0`@6QW#B`@2RU=D("4Q6HIVT-V@)54+:>H8
ME.\O`(WSJ".VM(YB#B*S,2@59D:H<RV,!@"B@"`$$H]W=3M#L'@%@O("@W.X
M>@`:ZJ[*E`*L)ZU-W`0BE?6`WD'@`SW'P`][N'``!74N79```4'HK7U/V`4J
M#FZO<!%*]QN`#O(`NIJ.H<MNMJWKL@ML"1YC4N-V6@V=WU[M-:OL3T#*CR`+
MJ:KJ("W6U=1=D%M@R/,:EQNRP6SN^O=IK5]B>@(W+F$%VV,*\2()<[S)A59C
MI%M=D4%8P@;3#617`U3%\XIP&H@8.`6"\@0$;G40`@)@-5=G4!`RH'K4U0$#
MD4`?7`WD'@`'D#4`!U$5$0I1=G41N(!:>=6MYB@'KB'`!7D`(E`CJ($3"G8!
M5V0B(F,T!*VANT3'50MIWB9.G>7@`CR`-IZ;J(-<*0)6+LAN$XQX(:=INT3B
MX:V4[[TJ>R)4$B+J#Y]0Q7$315E%\N8JK*BB9G`@WT3``"<@J.6UE#&"JB5`
M`3%J"HCR`,!--W#B!M(4[%V0@8#@Q%`26F[;BN&UE.\#I4[R<`%>0`@6UW#B
M`@2VU=D("!BMQ3MH;M`Q%4:>4#$\I>`J_OLM'JSF,"Q59J@&3]/MXM#H'H'Z
M5NRHDOT1&@6CV5]3NX"W'`'`4&V(D-JLMZ'=G<,1W,PS$'N1=,6W.-+9##95
M#QLQCTF^VWA&"K])Q&3<3((247*C>8A7""@KIB4QBFKP'KMGMYBN&;RY)N=,
M]6L;N9#Y`AF14,)RB<Q([''R95D4;/MV\.=A.IQJ3*)*P!JF`,2G!L@W(0Q`
M(IJA9#%\APM]N-F2L%.8L\:AAN`)F5B)*(<(@L2:W%,J0YV2QR:Q"*IB8!&X
M"F+7L$.`D`LG$^,*CXA'4\-;A7FFM*\TY[*ZG?3@%+UW#/&3QH:59H%=-'+<
MZ[>2(V71(LB=,ZJ+ELY0<MU4RF$2G3.0Y!"I3`(`/`4^VRV,G-LMPBY@WZB&
M^21;G$F.*34'DQ925=R*K3$\%Q_ZVH2LAN&\*RR-1?!43@0S==D5-RX,"0.7
M#ARL$<;?=+&XNWDK@+]EUJ9+D*N.R&).,W?9*,C+3.Z49"9=+Y1+Q&0*2.XT
MA&,&TDQEEHQORS0"-F)P$2J+)`J<'"3IRS=JX5;PO5>MAT0\>2;B4'$V3QED
M.3.9!R"ZN09)+R.XDDU?YE+("DD]?H-&R9"-4A9(-!47U0T+;IVZ@"22@.>N
MZ=:0#?+BO&B"30LC.2>%!%IQY8J3E'^5I-6$L07+I,JS9L<IC`@[4%1VF!P!
M"ETJ;I/GLVYR3KCR"6;2LH21203C;2-&[1\\=Q$65!]N"_8%;QH/3E!9)%)V
MX3$$'"JS9--(H/B$Z=9]YB\?BFXW4W.90CB&Y43F.&2)92/?22<+`[;3&-,H
MO(%<B6E%)1POGV2O)Y479WX%2:LFA#T;E6*"&,Z==U&\+'(/^O#<5WD[)JJ4
MDZD6$(R.[,S20;N%<>5G%HZ21:K)"L";L'&J8P@H8P5J&F>],F]:L7!IQW7K
MG".2,F)&4I+O4`=M70\W$.1590S3-8YBFL5*'(WU'17:JB*BQCF%5=90P/G`
M>GK<K$9S''DKU>9AD./XZ]A)`<<43,D2<&/DF+M['3T@^RV6<2+!\T2>I'4.
M7F72DF=9XHZ4;,]$-.TZ:=T&T]D64LNL3+\?E<J91T3+,8Z/@Y>&;Q^,QT^U
MQMU"(S;U12,F7DO/*RLNN(*@]7-RZ944"$'@"%Z>-\(Q7#G3KK1G)9YCF28W
M)S#E_!%66RF`BY""?RV+O@'-.19LY5"',P,HBV*9=JKK.P=/;G)P5Y-TZ[O2
M$N:3QGK:W`QYJ[R&4G)&&<-(R68+-W:+H&4(R,M.HN8B):"Y.B9-H9&J*NHG
MI.D&BZ`+-G=@-S-K\PQ>1G>J!_N/A,$ST%</FFSIF/.#&9:@K)!).\MR%Q*N
M',ADH&4%V)E54T$CJJJKHD4$+I^)P_RA&_"VO^LX`\3A_E"-^%M?]9P!XG#_
M`"A&_"VO^LX`\3A_E"-^%M?]9P!XG#_*$;\+:_ZS@$$;)1`-U`%_&A[OE1IS
M34.P91X(#]\[A#@%_B</\H1OPMK_`*S@(IW-Q5#-W^VCQIG4=C3+!=PXK-Y=
M%)PZ(YR%G$L9%%.$1?1V10Z<<FX>/$S.#+HOD5VQ%&YDK%C&`*I0O3?O/$92
M^RAQU^YID8R$SC)_`YB`Q9M"M<:QS-?K86$;(PD]'.%7SQD[=Q3ARHH8CF/<
M@15$QTDU"A?.-DX@&ZE9"-#\82H_A;4.^4>"`_?/5#@*3[C]-.79'NYD6Z.(
M=6V3[>H3,PE.-,(0N?0,*^>8)A.`S"K<2YG&:K5RVV]C9%LS%$C-*1*Z%1-9
M*0?$6!_.ME7<KAT=C,IU(Y=)R$?C>Z&.J95]873"9>&W(A&T>SDW9X7*8T%)
M##I1OSD<H)A50`QD$#H)&,!@;9^G%N^S.>RV7WW>/23&2)Y:T03>/4'<5*EA
MIYB'ASDV9+1S!C%24T1PQ0;,T$BHMDT'!7(")Q#VV8V#7V>R25R.0WK6SUH_
MQF*Q<L+).I9PFUY/)FDBUDVRD]FN4<DHH95RY>:!$C/7\FNHH?22:((!:#.(
MV(S3"LPP_P"L:<+]:\6R'&AF8R0(A(Q!9V(>19I1@LV>-'"+R/*ZU4SIJI'*
M<@"!RB%0"D>'=,6Y&).W!U^N+-)-J_E?K#(`9)LU</99*-:1S1O8MF3Y@W@D
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M=">6QHN,XQ)Y*"[1-K$MEB'%0B:B*/*)-`D';?I\R7!\8A\2?=1<I*0$+/8W
MD#:'8,6T4F+['MT8'<!0SF='('>82:4_$PZT.^0>2+ELZ0?JJN4W*EVJ&AW%
MZ9]P\MQS!\6PWK/W(VNB\9:S;?(%8)O!S\OEZKS*39-C[]S-Y7*2LFR?8X!N
M4$QU'1'S<I2K%$@"00L7M#CL_@F.RL3GF[*6Y\J^RR?GF4V^0)%J1<-++I+L
M<:00<3DXJHRAS%."!A6`2I'*F(")-0X+T).''=R1*$A&B<VW4#:4'343&NRV
M:0):&I4;G2Z9`IWJ'*'>(<!(9)2%-99(Q9@."8IV/&@W`H#04A)13M`Y7B`E
MIW@JG3V1:@!*0H@`ED8L0$"B40=M*"!BI&*(""G:`E6((>L8OE#@(>Q"8@#;
MO;S%)*0XJ),-L=<I7K(3IWPL\HGK`"EQ;D0$Q;N\H5#LX"81E(4H&$TC%E`+
MQ-5VT```@.!.)JJ=EI6ZHCY`(?[D:!"F73$`GG6Q2:LI#D6-E>>*E(H]8E5%
MNWVYST7:A2F5$VB@5NIJ"'84"&NI:-`;4=-0)<,ZG3>*Q!2MLOW,*['GF0`@
MJVP&-.[*Y'5`$U$"L'`J74$H(J":EAJ!LL+G8$V6[5`$Q$"/Z/S]Q0'[(1T"
MR>"%,MV*UT2BS7`3>Q`4E/N34Z_#CO\`Z!V<LQ/TI\QK1SQ/'/Z;:F8Y].>.
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M_"6.49_#1#KF]O\`(<>D,=4QL-PG>&HXHME.<QKII'<BY1!"&C#B(NUW"RWY
M?;IT&+)PIK`)(18W:5EKMH-VKR(HV44[=0'S:VG?K)4]F6H(UY2&,O&B21C#
M%,Y&T2NV@E,*C`3HVB"M#"H1RD):5J"A!#L$.`6!*0H@%)&+H(`(4=M*"!BI
MF+3VSM`2J%$/6,'E#@`92%`!K(Q8``"(U>-*`4"G,(C[9W`4AA'U@'R#P`:4
MA2W72,64"@<3W.V@6@0')E!-53L`A6RPFKW`F>OL34`/*0A+]21BR6:NI>[:
M%LT@>BM?<H%NF#%S=7NT5*^P-0$OB4.1X\.H_C2)E;HIG.=TU*0JK=2:,Z3,
M(J4*H@1JL*@#02@F>OL34!6:4ABW@>1BRB05`.!G;0+13%X"P'JIYHD,S<75
M[A24K[$U`!DX8!-=(1@"`F`U7;4!`2F6*<#54[!*9%0!\@D-Y!X`\4AJ_P!(
MQE:T_"VM:W`6GWSOO[/W>``DX81"V0C!$PE`M';41,)C(`0`HIVB8RZ0!Y1.
M7RAP"*-DH<6C<O/QHG$PE*7FF@F$YUVY4RE`%!$3'.\;@4`[1%5/[HM06$E(
M4]FG(Q9[]+3L=M#7ZO(Z-EJ@W:G/MK:=^LE3V9*@$E(4U@IR,6:_3T[';0;P
M5!D*-E%/.U`?-K:=^LG3V9:@%E(4P%$LC%F`P$$@E=M!`P'*V,F):*=H'*Y1
M$*=X*$I[(M012$K#<K4LC%C59F(4>-.T!=-C`(>V@`@)3`/[@AZW`+1E(6@B
M,C%T`#"-7;2@`4JIC"-5.P"E2.(^0"F\@\`&E(4H'OD8L`*"@J7.V@`4$P=F
M5OJIV`0K1<35[@24K[$U`#RD(2^^1BRV:HJ7NV@6:7/"M?50+=,&+FZO=HJU
M]@>@!Y.%)?J2$66S5U+W;0MFESP+7W*!;IBQ<W5[M%6OL#T!&YDH@'C01D(T
M`2%[K5=M0TP(FY34U:J!8!5&JQ35[C)G`?8FH"T9.&"H#(1@"`F`0%VU"@@9
M4I@'VSL$#)'`?7*;R#P`$G#5``D(RHC0`!VUJ(B8I0``U.\3&*'[HAP`63AA
M$H%D(P1,)`(!7;41,)Q;`F!0!3M$YG*(!3O%0E/9%J&"RD*:RR1BS"?2T[7;
M0;]460(V44\[4%ZVMIWZR=/9EJ"-&3AC/UK9",,"C.,,B)7;0=0BRQBH"E14
M1.50[QN!!#L,*J=*W%J"PDI"FLLD8LU^F*=CMH-VH#,4;**>=J`];VT[P53I
M[(M0`E(4:"61BQ`0()1!VT&H'*@)!`04[0,5=(0\H'+Y0X"KN_#IDYG<7%FX
M:N+<HZ?;Q;+)*VUZK=E1+<*1C4J`U"OJ<!;;@#@*$;#36U>?=#NS^"&W(QN`
M-D/3!MWB[^9B\A9Q\E`.G>W$'#N7J;EK(1SAL^C),_\`+)"*Y0*(U&@@Z=N,
M'VBP3/9_<*0WZ8;B2LI)[@2C%;*Y_#7LE!M=Q9;&)1["MI&(!D=7'8%3&TT(
MIL9$I&:+I4H"83UX":<7RW#Y7<?,EH2?@W[<,,P!(ZD:]:N$@62F=Q3J$.=N
M8Q`4(1<@B`C6APX"02R\7XPJ//M:>&MPKJE[^:<C3_T\`@RYO%Y;B>48KXRB
MQ#)<=FX$SY)5;49%EXQU'F>$Y1Y'N@,U*X%2J;A`X6^:H0:&`.><ITA[TQL+
M%8Y@'6W.XM"0<'E3.-BFD:^@VD=*2S1@,%RI,>SMF!XN)?1YTR)NRNU$FKQT
M<16?'0>-@E_$.G/((6*W+QS*NI#+LK@<XQIFQBSN)EXV>8YE;J=EI?(<I8JJ
MS3N2`IV:4,Q8H+R#M1-*/747675?.3'!-$=,\E#0.^^,1749)1<9O9CN20A'
M\2R51RK;F6FY?,95*?P[))#-958DBBIF[I5QS22RJKHJ1FZK-LDBT2#4I=)/
MA^!R^(P?4IFN/S:V4Q.48]G,9(NT\AB'47MS^3-=>355RQ16=E\CB555I-X5
M5F*KE856Z;58"*E!MJ](>XZC^/DG'79NV_=QDP[DV#V3>K@[;MG<@V<N8D$H
M7-8.#48O8UN"3@#L344`!;\LU,LS6#8%Z3\U39L(UUUI[F%81*^/.(VR3E#/
M&3C&):.EHU0%IC/I=F[&5%@DQDBN6ZY58],G)!'OE7S]Z#_FNGB0FI#=LSSJ
M"E9'&=RN=<1^$9&61R/%<6>/,PQ_+10&(?9R2/DL?+X(NR,R01CCJ,Y-RB9?
M1!ND@#`P_HAPZ!SR!S.?WHG<DC\;G\>RQEC;90D*@YR7&FP(Q#J1ES3TM)>%
M11B`DSCFAF;1NP2(W$JE5U%PZ`#-0X5K*QP4J`U>M^P2C00'VSLH/?P&?&8C
ML_&D?VUI[L;]M.^GMGJ5X#'C4/\`*L=\-;^2O\IY.`/&H?O\5CJ=]>=;_P"L
MX#/C,0(B`2;`PA4*%=H&-4`J(6@<1K3@#QB+]_M?YTO\/`'C$7[_`&O\Z7^'
M@#QB+]_M?YTO\/`'C$7[_:_SI?X>`/&(OW^U_G2_P\!KXV7BP;J5?M@]WRH]
MJI0[!E'@AW^L/`;#QB+]_M?YTO\`#P$5[DX7';A2.W,B3,PQ\NWV>1.:G30N
M4\5+%B8YHXBQ)..+'JOD@,V57.5T08]RZ1T:K`JD%583I/W"A<I?Y8/73O-.
M.I&8QM92,GG<4O#(8YC69&S!MCC9I$2<*L8ZP.WD<JNLJNFM&O#I+(+6IB4+
MW1LO%@W4]WM0_&$J/WTH=\H\$._UAX"E6XO2>]RS=[(]V\9ZG,]V[=STL2>1
MQ>*=G&#B9)Y@.%;>S;MH5MD4*^$)*(V[AW:*`J`R3?M#'50<H.WS=T'IG?2G
M]?,;Q3')7J!G)-OBT9F3967R5>9F,DE7F5*0ZJ"S[(HO/\;E?"8WD%P4CC*G
M;O".2$-8DV03*"F,Z4(-&=<S\_O3*9(\?2$3/*/W;>.:S!\CC\8EX9Q-H2",
MJ9I&J%E)<7[%&/:LT&()$;B59$*<!L]F>G./V/R.4R<F[#K+DI'&(K%3PSU%
MV5)!%CDS619/T3/LJR`C02&4<*N"MD6XO9.2>.G"B@':H-`L[G$9"9YA68X.
MYFN0:YCBN18LZ?,7`D>,6T_$/(IP]:J)*HJ)N&B+LRA#`<@E,4!N"E0"E.&]
M(F38<Z<J$ZR=UWS=_*&R&23\64CEY&;+%M8MHHXY/)R17A#8D8U7,V*R!1RJ
MB*:ZZK0YFO`;"<Z0T)[-LPS)7?F1B#9H_P!R3/FF.M7L6=&!SU%NFR@VAELY
M?0[1Q%*L6:KJ3:Q[:2DQ:)IZS=`RB)P^W?1SCSB`;QS?>%Y$S99""?.)N%9E
MC$E20$,XAXE!&/;Y*#J[%SS,@Z@5G+QVK&.3L14%TG'HIG"6,7V;BX#9J-V2
M-N&^72AU8V3:YBQ5>L'I$XO<A7.&+`%5\@DY%PB@+<C%8SJ0=*NT0.+@RMZA
M#!I-D>GD-G-P\ISQUOUFVZ".20TW'&C<Z<1KYS''G,_EL\YIL^BC,8U!JT<3
MBR":2,>WN%8PF4%,&R#<+7>,1?O]K_.E_AX`\8B_?[7^=+_#P!XQ%^_VO\Z7
M^'@(Z0F(H=W)`@/VHG-MU!6EU2U-?EDRV+3_`)SARF3_`)QP#U>`D,LU$GLL
MD&IM0$Q)14H@8%0:&3$/+>#]&GEU2^7@`)N($`$)%H(&`H@(*E[0.5(Q1_<,
M5<@A_P`X/+P$/8?D$&?=_>=,DJR,HW8;8\P0%BW(ZD+/+)Z@>I>B43!ZP<!,
M)IN(*!A-(M``H'$PBL4``"%<&.(]O<4K101_Y@^3@(1RS(X`,ZV(3-,QXJJ9
M7GKA(`<IG%1!GMUGW-J$,55<HD;`U4O\_LL'NI0`;<=D,%]3.ITWBS&UGE^Y
MJ3L=8M&RC/`(X[LBU?8F;DCEQ/Y`2-Y!X#8X5D4";+=J0++,3&'I\?N@`JP"
M(MBR>"`*X?\`J@%@L%?_`%9O)QV&'%DCV!LYNV?HSYC6KS\.Z-;:F8_?Q,2K
MS,?JHCX_3G^NJP1IJ)*)@-(-0$HG`P"J7L%,S@IP'URF:*`/_,'R<<>L&CG<
MDQ/`-]-ZW`RF38>FG[J30%0Y<MB`.F0QY.(!0U$C^8"HB:T0!-8?:CA2;KT1
MZP]V]D>IC:'H2WCVXVAW[:[+XZ]V]RW)<>>S,FGE.8RF7MW<='Y*CD*$=@DH
M_P`>QHK>+EE8F3&-?/R/#$$$B6A^='T%>X_7#AO35U$=$?5GO7,1G4C'93C^
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MO,RV3S1&S()&:=2&02\],'&7DGX+(I+O7)D$ETTBJ&*4H\`\G$[#BYBJ2;(-
M9R<J11<)E,L*D>*I`3**R9E*INDS=A3]ARC0/9`"\)N($`$)%J("`"`@J40$
M#%3,`AY:E5*/_2#@`9N(`*C(M`"@C452]Q2G,(]_J%3,/[P\`&FX@@&$TBT*
M!`.)JJE"T$P<F4$>WLL!DJ(_^S-Y.`#S<2G??(M"Z>K?58OFZ`/16KV_]6$:
MXKY-$WDX!&6;B"OWUTDS`$6[=-4.8((HJ-SS2BY5":IC)F(FQ6$:D+4$C=IK
M1`H+33422X#2#4M@J`>JI?-%(7A5;O)8,>O7R:1O)P`,U$E$P#(-0$HF`P:I
M:@)#+%.`_P#-,W4`?^8/DX`\:BJT\0:UK2FJ7ON`M/\`2&G[O``342:T"R#4
M;A(!:*E[1.9`I`#M[S&=)@'_`#P\O`((J<B%63?3DV:MYC$*)'*:@&,9PW3*
M`&*LN!A$[]$/9CVJ%#LK3@%Q)N)4LLD&IM32T[52C?K\CHV^74\3;T\NL7R\
M`%FHD]ED@U-J`D)+52C>"P,A2$OEU`DD*>75+Y>`"S<28"B61:"!P()1!4OG
M`H5L8@A_SBO$A#_VA?+P""2G88K,QSRC),FLR$3G<IID`#.VHEJ<RR`!<"A:
M>=VU#L&M!!>,W$A41D6@6@81]M+V`4JIC#^X!43B/_-'@`TW$$N$TBT*!`4$
M]5B^:"0.S*"/;V6`Q6K_`.S-Y.`#S<2G??(-2Z>KJ55+YFB#X5;O)IA&.*^3
M1-Y.`#S422^^0:ET]74N5*%FB+X%;O)IC&.*_P#L3>3@$+J;B"/F1#R3,AB"
M^$Y#."%-1%-RFJ($%8@FTCLU0-0I[=,W=2O`+QFHD!$!D&H"`F`?;2]@E,J4
MP#ZX&1.'[I1X`\:B1H'B#6HB!0]M+WB8I0#]T3'`/W^`"S4282@60:B)Q(!0
M!4OG"H+8I`#M[;S/$@#RZ@>7@,$FHD]ED@U-J"D!*+%&\5N2!("]O:*@R2%/
M+JE\O`(D)R'4D7!"2;,YE&46H0A7"9C"1TL<C<VF"QC%!<SY$"B)"W:A:":O
MF@M+-1)[!)(-3:FG9:J4;M4&8I4IWWA(H4\NJ7R\`!-Q)J"61:#<!!+14HU`
MY4#$$/+<5RF(?\\/+P%7=^'S-Y.8N+5RDXLRCI]$^D<#6@?JMV5,6M.ZX.[@
M+;<`<!0O8;)=LMQ>AW9[`G.X+&,1G^F#;O%I.5C9)5J_@E%]MX2#=/4G*:C8
M[9U&2!J%,*A"BL4"U&Z@A][<;:;:;=;V3V\!>I?(LU/-,<Y`^+9;D$3*-XLF
M=9)!3[PL>K$$C$"0T6\C$D&B:S)59!$44B.")DTU`L?C.:8M-[CYBO$3S"21
M+A>`)&.T5,L0BB4UN*=1,PE):4Q2N"#3R'#@'\67CO%U?=B=/#4.RBG>#IS4
M?8>OP"A\\B'[)ZQ7=ET'C1RV7$AEDS`@L@HFL8%$[%$K4C"-P&*):5J%*\!4
M#:GIP:[;9RVS_%=ZG\K&.\088I(Q;^,4F4YN-;XC@>,I9"2<6R-P*&3J_D^8
M'(Y22&/*W`R8,Q746=K!&FW?0['[<Y+MKD47U);DR[W;I:/*_D)QV^<Y'G)$
M)Z5GYQ+-)ME/L$I<ST919DW27:J-&<:JJB=!P(HJ-P<Z'2R<'2Z,'U+9AC$.
M=]*FDF&WR0X9+39GCLRPO\OGL?GT'639J^[$929>)G=N2-D`:@P$KD70:%KT
MH[A^+'UNMS>5.$0S0K^-B6>09$O)N<;+%HMOJK+3,AF#I<7Q$%G1$W#1)N((
MJ)K*)K/$B.B@E1Z*)=Q(3;K(NK?=J?+/RB<H*#E9TH<G)O7LE$1]DMD$U'KQ
M\$+U8S4Q6R;LFH8AES-K&Y`?F/\`2JR0QB,Q3/-[LZR^,Q3<F)S7!%'DL[5=
M8^TAMM)C!XJ)UYMQ,*.EQRS))'(#J+"L`N1;-``6S5(@!J6?2K+Q&-,T9?K+
MZ@UI6,8KE'+W&?3+,$E3,D4"/SQKN9=0:J;/2UBD>)NDQ.81/<`\`UWO2?++
MQ^/1[+KAWI:Y/'-6L2ZG7.83$E(2)WRL3+(),(Y7+TB1Z[Y&"0!,H\RHNU*8
M5!6,HJJH$A[?],,E@\WCC]3J:W>F83%W<(]8XL>:G6<.\-%R,>\<L9E$9YXC
M*Q#QLT<(:*J8J*A)NE'BKU7E#M`TK?I"`N13F5*=2N\;*4R=O"L<@;XW./,9
MCGC3#C.D\-,V4A%V,VW<-T)F56DP5>N$)-]**+&33T42E#1XGTG[GMY)Q)YO
MUH;TRI"+2J4?"X_D&31<6*'M9(28D3N9]TNM.+.$"R+]%($8X7IM!LB@Q`[9
M8'QGG3+/9;/R\]!=6F_N"'F\H>9`\CL?RN56BV[-=X[=,H*)CGSY5C#L(=-R
M5)N1NDF@<B10<(KA0H!K-LNEJ=VVRS&)TO4KGF20,,\D9&1PJ71EE()[)RV1
M%R1W)-3OLEEGQ71#`HP25?*R#P(YVNFJY6$Q1*%Y?%XWWVG]@_\`%X`\7C??
M:?V#_P`7@#Q>-]]I_8/_`!>`/%XWWVG]@_\`%X`\7C??:?V#_P`7@$$;,1O+
MJ5=I_A\J/<IW#)NQ#[3[D0X!?XO&^^T_L'_B\!%&YN&16X4CMB]7RE&&;;?;
MC1.>':C'BX4GEX=A)ILXE*0*]CW<*;F'(+G60,<RR2)VZI%&RRZ2@5:A.D/*
MH7*W^5)=:O4'-R<C+XTZ<,,BG4G\6CC6,YF?,V..-V$<I#JZ)EEWC$RRZBZ:
MD<\51616*!+`O9&R\;RZGNM/\/E?4/ZLH\$/M/(/`4GW$Z2F>9;P9'NSCO47
MN1M_-3\P2<+CL`^,G#14JXP#!\`GGS-)H_BI4'$GC>WT&X(F9?E$GC$BJB"Z
M"[MNY#TW`Z4(K-\>Q/&IS?'))%MBL9FJ/B.8&EI_(Y1WE!X9R#Q[DZ&60&0^
M&1?(+"JP!R+1V1T!5"@1NV*D"F+Z4,-;9`]G)S=J9R5^\DHB9<O9!C#)3RF3
ML,7FX=><-*HEHQ?"^DE9%D1B@S2CS(E1*4Z!+0#8;*].V-['Y+*9)&;GNLG&
M3Q:*QE2&<-5444F4?E2#ME()E-,RJ+4K97F#+<L@W%Y*2#]TY.J99!)J%HLZ
MC8#.<(S+"I*4.SCLOQ3(\8D'C4RB;EFPGH=Y%O':"@6::K9LZ,<IJA:):U"E
M>`I5A'1V\Q!T[59=6>];]H\ECY!*HDGW;!60R-.+9QS5P_\`"91K%*1[)O',
MUQ;<F"BZJ``NLJU,+;@/*=Z,<=G=QLDSI3?W,(UMDH;F-W^-1%K%IRNX*KIT
M^`RX2IP5D6CB0:%<.SHBLNUCH]$G+%35%P&DBNAS'62&0HJ=0N5.4YZ?QG(6
MC1%JDVB8"1C8N3B&W@$;XVX3CTXN)GA)C2:1BDA3-(]82O%FNHJ%A\4V<QV&
MV6B]E"9U(/8N'6CI-GE<=S;5PB$/N2KG#!BBHM*2KE1!DY:$9'%R]<JKI$-K
MG4,8X"&EV0Z=8K9C<;*\Y3WKS[<8V2PLRQ<QF>NF,H\8'GMP9G.SO$7T8VC6
MB#5"0FG"2::;%$3G65,HHH&@DW"V/B\;[[3^P?\`B\`>+QOOM/[!_P"+P!XO
M&^^T_L'_`(O`1VA,1OY6Y$G.IW&V[@;244J:_+)IJ0?86]J[DA/+4WDKP$@E
MFXH]@E>)#>"8DH"G:"H,S)_:?;`_1_G`]>@`3<4(`(/4J&`H@-%.T#%1,4?8
M>J5P3_2X"(,0R.&4W=WE1+)I'.U8;9ZR5%ZM]:%GER5`R8%#43`3>:(^OV\!
M+XS<44#"+U(`+>)AHIV`0K@QZ^9]J5HH/_0'@(4RW)H0F<[%(&EVXG7RO/'!
M"$456!=%CMUGW,J%435>)G!KRRE:J"(6C0`]B`-N/R2&^IO4X<95$089;N6D
MY/[?[D.QP"..X3,.G<`MBQRXC;4/:QI7LJ"_"\FA5,LVI(6514$W3](/0*&N
M-Z`2>"%,Y"Y(`$HBQ6#[KS![.ZO88<.2/8.SL=O]U/F-:O=T]8UMJ>/GZ3S\
ME>9C]5$?'Z<_UU6!--191,!GB8"43@;L4[!3,X*</8?:F:*?Z(\<>L*$]5&P
MN4[G9_&;EXUO^[VRCV&WA=KFL#%L9Q4ZF2Y+G<<\0R^6(]WDP;!,B8PX$1!"
M)=12JKA=(145>%%!HD$5;`])Q<#ZSMSMT<GZ@,TW)=0C:"S&$B9=]EC?1<[D
MI;IPC:.E3+;B3D-*14"PF7R*#(L4S8B4(Q4J!',=S+@(:WR!?$-M\`?AMGFS
M?)\:ZA=ALA\0B]HG$M)KJX]U`XIE4DM$/58^,:SK]]#M2J-T0DTSR1U46Z9C
MK&*D7]@Z?F?$>1]PSAV?-^/CPV[I;6M6,OD)QX8G9\9EUL5<O$Y/H4^KEBEL
MEL/9A_%>W;6.;:"V/)3%S7'?ZE;5GI3F>EXF>/3GI'ISU-W8#93.>M:21ZP,
M0ZMNI+;/!=P)?<%/\F^6;7[@[3/P+/XVMM](2>.0.5;HN1BW#('B2$9($BT6
MA6T>Q,@W%RFN\<^(_>;[7^0^S_W`W?8WE-GQFSN:TUM_P.[B\ACQURUC)3'?
M9PQ&*V6M;1WUKUKT[HK/2-CX[=IY#5KLTK>*S_WJS29XZ<Q$]>%Z>C/I,SGI
MAFMQ97-NI;*M]F^=P6W\3$PL^TR5M&X,.(*9&LNVQPF1;@Y^[+$/2Y@@FB0Z
MO,D11)KKN#4.'EB\NVXG8D7$7200#6<F*F03F(9858\5B`FF*R)EO,=)FH!%
M;0,`B!:7%!:$W%"`"#U*@@`AV*=H&*F<!]AZI52C^_P`,W%``B+U,``!$1HI
MV`!3F$?8>H5,WV.`#3<46X3/4@M`XF[%.P$P=&/]I]J#)7_0'@,GFXI.^]XD
M73U;Z@IYNCSVK6A/M/#5_P";'UJ@C";BB/GPFD$*(MT$U2`<QC(J('FCK`HD
M"IS)"!&*HU%(EP)C0QZ4*"PTU%D$X&>)@*8J`>H*>:*0O`4KYGVHQZW\V/K5
M`&:BP$P"\3`2B8#5!3L$AERF^T]0S8_^B/`'C476G.)UK3N4[[@+]Q]T/``3
M4680`'B8B82``44[1.9N4GVGVQG28?\`2#@$,5.12K-OIR""UYA(4Z:AERG,
M=PV3*`*E6=E,(G?HE^^&H)P#LH(`"XDU%J66/$S:FE90JGG:W(Z5/,^W\30I
M_P"U#UZ`$FXH]ECQ(VII64!3SM8&0I4J3[<))"G_`+0/7H&"S<48"B5XF('`
M@E[%.T%"MC$^T^V*\3_TP]?@$,C.Q)6@G-(H)%UF7MASF1(`'=-K:J&6:@%X
M*``!>%:TH:MH@N&;BB@(B]2```PB-%.P"E5,;[3U"HF'][@`TW%$O$SU(-,%
M!/V*>:"0.S*5\S[4&*O^@/K<!D\W%DOO>)ET]6_L4\W0Y[5K0GVGAJ]?_9CZ
MU0#S46G?>\3+IZM]2J>;H\]JU\S[3PQ>O_LQ]:H(74Y%$>LR&D$"&)SHF3%0
MQ3F*B1RFJ)4]9(RVDHT4K1-6VP1\WV7`+AFHL!$!>)@("("%%.P2F5((>P[P
M,B8/^CP!XU%C0.<3J(@`=BG>)BE`/8?='#[/`!9J+-:!7B0WB0"]A^T5!;%(
M'L/MA>)?Z8<`%FHL]EKQ,=33LH"GG:PL03IYGVXR2'\X'KT!$C.11Y%<A)!`
MYCLHM0B93F,<I'2YR(',D"IC)`N9ZC:(I)W7AYQZ"!`6DFXH]ECQ(VIIB2@*
M><"P,A3$/,^W"11_G`]>@8+-Q1@*)7B8@8""7L4[0.5`Q*>9]L5TG_I!P%7M
M^'S1[.8ORJY5@)E'3Z)K;O-OZK=E1*(W`'L@X"VW`'`4)V&R3;+<?H=V?P"5
MR&13CLBZ8MO<3FWD?"S_`#<<1?;>&@I!V@L>'.D19@[$=-4P&2%0I1\XHA4/
MK;/;?97;W>.?W:AMX]P,FE)?\H)I."R0[Z9;MWN99#`RTJ3F&N/,W249CSU@
M"+1HJ!N6YLI#J&TVY2!9'&<SQR;W&S%>,D5':),,P%$PA'RJ5BB4UN*<Y1*X
M9)"'FN"B`]PU[.X:`_RR[#Q=4=96GAR`4Y1YW\RY[:<OY!X#6YBC!93B.58S
M)O%6L;D6-SL'(NN26/RS"6BW3!XY$KEL=L((-ES''4`4Z!YW97@.>3[HMEI+
M'(A/!.L7=_',4CX+*B1)8-"2/CK)_.LVG+R\*O`SD*F2.A'L;4A'"SQ<S-P\
M(9US+D[TH3%C'2Y"XG`;F0N2[P[F9+B&<XHT8N6F0J2A&F,S?C4K/9+FK%9Y
MS+%)T^0"):M@63-R#.%((JK*.'*J@)X+I6QQ/&]YX6"W<SM+$.H+$\A@Y,<:
MBT47$&CD<IETLC/8)D964BX9O/\`YXD%5SG,Z2=.UQ7("!;42AJ1Z,\!CL`E
M\&BMT=R<8.\R*-R?'<HA2J061P2T'MV&VA51?QK%@K+/I3&EEB2[ZY%P_P!<
MYS&35.HJ<&JIT0LEY5FNOU5]1TG)Q,X\E62TSDTQ+3;#GY1K).HU%58"II-)
M&.::;M(6XI.E"$6,F!"G14#;H]$\>BVBXIQU%[_%CH]Q"&A&C:6F&J\>\Q1]
M&S<(>*4<%>)D<&-#D;R)124*]B6K=L4J&DLJX"09/ICA9"7W8?'W4SL\;NB=
MT]-BLHQ4GL5QZ6=9C`9H+AMCTPDZB'S!.1@=/E%4"E,@_>$,82K%*D#,P[H:
MV@QC.87,Y'*LPR1#'9J&RB(QQPU"'B1RF%1`64Y)#!L&*SD8YZ0AF3)N+2-0
M;HI(J-UP)>(7Q\8C_P"55^"//B_`'C$?_*J_!'GQ?@#QB/\`Y57X(\^+\`>,
M1_\`*J_!'GQ?@#QB/_E5?@CSXOP!XQ'_`,JK\$>?%^`/&(_^55^"//B_`'C$
M?_*J_!'GQ?@#QB/_`)57X(\^+\`>,1_\JK\$>?%^`01TNP!NI554?=\J/X(\
M'L&3>"'^S^H`\`O\8C_Y57X(\^+\!%&YF%XUN%);:R$G.OHI3`L^B<QC4T(P
MJYI.0B2J.T8]%5XS45CW#CEK5%VUKDS`SIN`Z3A40"KL/T5MH3*W^5->J3JE
ME)Q_+XO(NV^2Y?)3;%+'L9S4V;16.-XWPIF",:22,[;IJ*BJ`LG:Z"A54Q`I
M0O5&R[`&ZE55?P^5'\$>=PRCP0_V?R#P%)]P^D'",\W?R+=>+WEW7PO+,@FD
MYH\/BK[EHN.FC8#@V"3TBP:(1J,LG)R>(8)CZ@B+DR:+B-:+BD=/427#PW+Z
M,\"W`QC',+FMUMSDRPD7DK%L_F5GDWDD@VF'K*7D$U9N30)/IQJSA,_B235P
M@+QNJ1,RB9441*&A<]$FVCG-,<RHV\6XI)7'IR+E'8(IL&TI/R2<`6/F%9Y\
MRB6JSV2F63!UH"=,4XUD\?)M$4Q,DJV"0ME.GC;W9#)93(\6SJ2FW4KB\5CC
MB*5CF[5`8N.RI`\>]T(Y$J*9(]1!4@F212UY)Y(N5S*K.;40M#G,?C>;X3F.
M&3CERC"9;BF18S,K)-W":B,3.P[R+DEB**MC))F29.CF`Q@$I:5'LX"EF$=$
M^,XFZ=.(CJ"Z@'S5:6&;E4D\@?M57N4I1K)FS>RBT%'Q[1=*/:L6+A-J=O4S
MALFHJ=1*B7`?$YT4[:9#N%D^X#O=//6WU@-N2SFH2*;-6$<5#<$[YY*-71TH
MTPKOD7,LF9RY<E4=N6[&/1$Z:2*@.0;\5T,;5LT,A`V\&:.T\CR'&)\J*<?%
M(Q43+I1<E%MSP$22,5CHHX0V3*HXX1L1,L(4C%5N55=L590+$8KL[@\9LM&;
M*-LDE9'%(E>.DX^=8-%B*ME(7<I7.8UFSN3D4R-8F49IM2@=18X)(B!C">H\
M`S-H=AMKNG[<W)<^3WBS+()/)(28@W4=N1,,WCQ$^6;CR^X#A<79(^)4<J*9
M%,N"-A51,Y.9=4%%EJID1"WS/*(&1;`]CY%-\S,=5(KMDDX=-3*H+';+IE<(
M(J(BHBY3,F<M:E4*)1[0$.`6>+L0,4@G<`<R9U2E,Q?E,9),2`HJ`"V`133%
M0H";N`3!7O#@#QB/_E5?@CSXOP$>(3#`=VY$@+*U-MW`4)RCV@WY9--2F$>7
ML#VYR0.T>P!$?8@80"02S4<>VU58;P3$M6;T*@J#025N;A2H/DJU[JC6EIK0
M`FHX0`056H8"B'N-Z'8<J)B][?L$2KE_<J/D&@1!B&0Q:F[N\B)72YS-H_;/
M43%C)@".K"SRY*"=H5,^HF%?,$U![!H/9P$OFFHXH&$55?,`XF]QO1H"97!C
M=S<:T!J?N[Z!3V1:A"N79'%)YUL6@9^H=1;*\[<%!)M).4UTF6W.>BX,#A('
MZ`BARYZ%,M<(A0@5$"\`VX_(HOZF]3:G.K"#'+MRTES@QE!Y<[+`(XZY"^X[
MU-$L>J("D!RFM"P3"<EP+\,R2*4RS:HH/%SB;I_D'EO(2H7(A)X(47'GLBEN
M,+%4+1HH-`\WSBW=?APWCV#L[';_`'<^8UJ\\QZQK;4\<<]WI///''[>5>9_
MXJ(^/TY_KJL`:9CRB8!55J43@:C-Z-!(9P4U*-QKVM3]W?0*>R+7D%@SLZFV
M)()&Q\+4PY)AY-515Q&%$#Y=#)'2!TK.XF0PJA4NES9M8!L!N[NY58&U!9%%
M+[U;CH)NESJ-MN]GTU$A8R1`2.XR'=Q5,`,JT(D;4([3$1()@"H@:@E,`!^8
MK]JRVUZT=\]CNEK!>CG-MZ99"9WUQB(S/8G9O!)UVYRC+)>3B'6S^X6:[@XV
M[0GL-B,*RED)X])\@G"'DC`[5=(/F#,IPZ?*=*O4QN7L_P!-O3-OAUQY3-[N
M8%M+'9MGF]>,;:OL4R7*LN:,([`U7K0T)E>-IK'=)Y<LV=.7Y7"[I`RQU4$G
M+DRK8-B3T9&9IS&T4R?K;W@$VW#3:%G)-_`LG*AFA-KLDC)2*CWR0[D&;L8-
MY'HL4RMU$W:Z<@59XY<.R**-2!UO7FHXR\8(.3E!5T)"$,B[2.L*L>94A2I&
M%`RM".2&$--6SM$2E$ICD!8$U'"`""JU!`!#W&]#L,5,P=@MZ]RI?_L`T`\:
MCJ".JM0`$1]QO>XI3F'_`&?U"IC_`/80X`--1Q0,(JJT(!Q-1F]'[V#DQZ4;
MC6@,U.[OH%/9%J&3S4<G?<JJ&GJWT9O34T>>U*6MQNIX<M2E:VA2MY+@2^,Q
MY'KT3.#B5)!$BA"HNE#IG0/-&6N0(*AR`8K!2TVB0%;0`IU*E`H*C3,>03@9
M5:I!4`U&;TWWH7@*4$K<0-06"M*5K0*5N)<`,S'E$0%57S1,`^XWHA4AEB&[
M0;B`T,W/^[0/*%0/&8^M-5:M:?@;WONM[^7IWCP`$S'F$H`JK4PE`*LW@>S%
M`I:U;A2HN2=_=4:]PT!%&3,<=H@!71EA,82`H1)VL0QCKMB%`%@.\*:AGZ0"
M.J:VHUI8<"@M),QZEEBJPZFE95F]+76Y#3K<W"VOB2-:TMN&M+#VA@DU''L$
MJJPZFG;5F]"NJ#(4ZU;A;4)%*M:4N&M+#V@%FHXP%$%5J&`@E]QO0J"@-C$[
M!;@(5!VGW]U1K[$U`1OYN.!K=S1T@%9G[8H@\;E`#NFU`,H8S,"W@H`4%0*B
M-MIO8""P9J.`!$55:`!A'W&][BE5,/<W[>Q$W[M/7"H9--1Q`.)E5@L!0349
MO1H"0.S'I1N-:`Q5[N^@4]D6H!YF.)?<JK[7JWT9O34T>>%2EK<;J>&K4I6M
MH4K>2X`\S'IWWJJAIZM]&;TU-$7P*4M;C=3PU:E*UM"E;R7`B<S,>5XT`7)R
M"GSHG3%%V4Z@)$<IGTTKDA<Z9FAQ\U-:@``^:!BF$%HS,>`B`JJU*)@'W&][
MRF5*:@\O0:"B;N\GKA4`)F/$::JU:@'X&][Q,4H=O+T[SA_]@'@`LS'F$H%5
M5&X2`'N-X':H9L4E:MPI47:??W5&OL34`+,QY[+551U!2`M6;T*ZW(@G6YN%
MM?$4:UI2X:TL/:"1*9CS/U2E<G,*K*,5(D"+L3$(Y7.FD91$3'%N*IGB7LD4
MA$*U,8"'T@5%FHX]EJJPZFG95F]"NL#(4ZW-PMJ$@E6M*7#6EA[0`FHXP%$%
M5J&`HA[C>AV'*@8M:M^SS7)._NJ-?8FH%7M^'K9Y.8ORZASV91T^B8#HKI4`
M_5;LJ)1#633K4/)6GJ\!;;@#@*%;&9!MSGW0UL_@V1+Y86#G^F#;K%Y]VQP3
M-U%6;5SMM"0S]ZT<J8HZ:"9FJ83I+B51`1*4X7$$!$/K:/`-E-O]T,HW*QC,
M\_FY*7>YN61A5MOLE4C(9]-Y.:;G&C1=MA192,.C,RRJLFU%P"3N2<)N%TBK
M)H@4+)8UEL-,[C9BNP-+G2)AF`(F!UC>2QQRG3FMQCF]IDHEHH)!!<*&`!*8
M:@`B)34!_%E&OBZHT>T\-;A3PR2[P=.>VG*>OP&CS]IC>68'FV+9&\D(S'LE
MQ#)8">DDFKQDI'0LQ"O8^5?)O'3$[9H=HP<**`JH42)B6XP"`#P%*L9Z0MH$
M%)')\,WNWX3P3).97C(7',WG'>")QTL^R9X_CV+A.,?,I:*?3N0$=@HJHL[,
M\:^<X4(X<)*`K@.B_#H<9YH\WXZGLI3G]O=P\&DH#*\HGL@QU=MN,WG(MUE;
MO%Y/'W3)UD4<PE--!50.3,NAJBA>=6X&'/\`1;MH\GU$"]2V\V,3F5H3:$#!
M0KN,Q_E)0[^2D\P?;?XU'XXQ0B5TY.37$Z4>@'AZ0@B(VE#@))W#Z*]N]SLZ
MG\VRO<_J%D4,@E&$F;!G<Q/.]O80R*4>E*H8UC:^/&+#)S@LC**B18QDE%CB
ME86A>`V&4=&F!3V0QN9PFYN]>&9<RQS'\6<SL`^5!:=A\:Q9?$(8T^1[CKA6
M0E(R(E)$S9WJ$737DES&$Y;$R!II;HBQ:4D?$U-^.I-9PA%),(Y.6RJ8F6K1
M=%]/'3=*M'405NX*6$F_#!*4J2AVB0WJ&.NX,H%[FSYHW;H-[Y-?0121UW,?
M)JN%M(A2:JZHLP%192VIS4"IA$>`]O%&GW+WYLD_BG`'BC3[E[\V2?Q3@#Q1
MI]R]^;)/XIP!XHT^Y>_-DG\4X`\4:?<O?FR3^*<`>*-/N7OS9)_%.`/%&GW+
MWYLD_BG`'BC3[E[\V2?Q3@#Q1I]R]^;)/XIP!XHT^Y>_-DG\4X`\4:?<O?FR
M3^*<`@C91KRZGFO?P^5'^C)+N&4>"'^R>0?WN`7^*-/N7OS9)_%.`B/='$L/
MSB2VQ?9#,R40OA>X4/E,`BG$@<\S-Q159!I$MC2$2Y<-W3@6-3J,13>'9%<H
M`;177`0JQ#=$F'0F6/LH8=0?54_R![,XM*ODLBS"=GVJ4'CF;&S>%QY"+=8X
MFDTB"3*;M%%0X'-RKER@(J)")"A?.-E&G+J>:]_#Y4?Z,DO5E'@^]._M_>'@
M*/[C=(^TNX.\62;G-]T]UL4SN>FTY5W$8D_!!BPGB;?X#ALX_8QB>.JR:,S(
MX/B&-**G,X,+=6/CW($`"@54-QD72SL_),,9QO(\TW!=,XG%-R\?:(9."TM.
M2,5F<0Z9Y`\1EY^!<RJ811I=5XN*!@155.B+HITT4B@#2R+I#V2R+=%MG3K<
M[.V62L\U^LSV+CRLV3Q].R<<NO-MI51''B2[IW,,F+H4`7,H:/CEGI&A$@,5
M5N#RV/V&VCV;R:5R'`LVE)V1E<5BH%U%@PCT4%(2-RQ)&.?F:P<0R(9.+<1Z
MK8AR$*4\@M(KJBHY=*V!:C/&.,9?@V:8GDZCQOC63XED>/9"X,R>-P0@IF&>
MQTNL*[ED=LB"4>Y4->H`D+2I@$.S@*1X1T3[8XR\=N(+>?J!DD/%_%95%.=D
M`5<98E&L6S-]+N8/'&)55(UFU8N$6BJ8`#A!%<]X4+P#OE>FC91S*9L:8S')
MVS_/E]UW4FU29,XAV,/N"^Q6<RMB)28Z1V_0BI*"8K*.E]18R(HI.CJ)E2``
MBR*Z*]@6K;(%/RL9D^1R?(L5FC"1M`DBF$X[BI*.9#!1B.,FB8IS)P>5.$<>
M3:II^$HF9JL2BLW36,%CL3VEVU8[)16SS&>E9?`HUQ&2$7.,6-PHN(?<U3-(
MEC'Z$:[8)-HB?9I-4"`4YDR(@2NH%0"/,9Z4^G9V[@A+D>5YZ^Q+(\@S..>S
M+\DMD23K(LOW5G9TDAD,9!,9V4BWN8[@N3+INEEBK+PC5)85`2=$6!RX-TJ8
M1A6.16+AG>Z,M!PLOC,Y&X\X2(VQ2/E,/W*@-RX&1CL>0QL46DBW?8V@R%?5
M.<&*BJ26D44BHA[XMTN8KB^_+K?\N[74'.SRK_,'#+#<CRV9D]MX>.S<I0E\
M?B\5-")(H0C=1HR49IF4.9JHP2,0U3+:@6T\4:?<O?FR3^*<!':$JU'=N1(`
M/JFV[@J!X7*6^=EDTW`1-R=A:*."UJ(4)<<?,*<Q0D(LNS/;0K_SP((71,J3
M[X#42W7LBV#1X2M:6B!P&FFI:`$NS$`$"OZ"!1[8F5#V14C!4!9`)>Q8M:]P
MU`>TIJ!$&(3;(^[N\B8>(B*##;.\HPTT`%U(:>6+IF/'@FK4I1KIB:AO-&AN
MS@)?-+,RW5*_\T#"-(F5'L(#@PT`&0B8:-C4`*B8;0"HG)<$+9=.LD\ZV+1,
M:1.<^69VL&G%33E,Y&FW.>BI5PD@^1U"@W-80RMYQ$H$+YQ"\`V8^=8_4WJ;
M,(R(@TRW<M-40AIL1(9I@$:=4$@\/N<%`K%2P4@.501(!!,*J0'#889/,399
MM24!DC5Z?I!R`#"S@`9,)/`RB?SHX"Z@BR/0GWP:D\VBB=W7X<=O]!;.;B.V
M?,:U?6.>8UMJ?3GNXZ^O''PYY5YG_BHC_P#G/]=5@!EFA1$!*^J43`-(J4-V
MD%<IJ"5F(&"K8U*5J%HA4#DNY!8-+-I-(\(D"*KIL<,BP\!55(_B4[#9?"HG
M3,]6F,33HM=9IB\'6`UG+NP/RJP-J%F61MZ-QB7/2BAMWM$D<%8N61(0YY[=
M]P`%479)I*%T5P,82&,4@`:X0$A[0_*;*>C[](#L;Z=G<CKUSGTBSEKT^S.W
MTQD\(S6D\0BMS=RMNEW+L<;Z(X;9O.%X;;1E`XQ+G14;3J^E&E4!*1O1FE7Z
MS+HO#>T?=?N+#?9\!XW?W=;%;MO?!@R9:UMQSVVM2MHK/'7B>.G5BR;&##,1
MEO6LS\YB/ZUYNBS&$.NK=G(NL&9<=4NS`;CL\Z;1>/[G8XRVWRA]`8.&<=.$
MK(AB^&3.5XMIS$+FX`,LN[;KLI*!(=DS%DD#T^HWM#>\9M6TO)8<NON4BLS3
M)2U+Q%JQ>LS6T1,1:MJVK/'%JVBT<Q,2G6U;U[J3$U^<=717HUZ'8_I*S3,,
MP;[X;A;GES7"\:Q0F/Y)`.8R$@4HF;?S+5U"-4W3XC%JY//G-HT`P.UWZRBJ
M@&TFE1)?Q>7:"O&B`OB@HY$H%-'2B1CZK`RA`TC)H&/:#@HF`2*V"!KBE%,Y
MDP6!+LQ`!M?T$`$*Q,J'8)2&#L%E4!HH'9W@-0[P&@'BS2@C8_[`$1I$RH]Q
M3F&@`RJ(T3']T:!WB%0#2S,MPB5_YEXC2)E3?>P<B:T"LA$_8T/2E;A$H!43
MDN#)I9H2^I'XV:@FMB94_P!Z!Z)[;&1KZ\@I;;6^I+:ZJ5X)?%&I'CLQN=$I
M&Z)!(2/DU3E,@I,BJ;0(10X$.#(]AP1(5;S`(=6],`!4:6:$$X"5]4@J`:D5
M*&[4A=@:T2LQ`_:R/2E;JDI743O`&6:`)@M?^:)@&D5*&]B98HT$K,0,%4#4
M$*U"@AV&+4#Q9I6EKZM:?T5*4K<!>_DZ4J/?W4[>[@`)9H(E"U_YPE`*Q4H7
MV9D"A6YF%H5<%K6E`N$>PA[01QLJU,T0#W:H81$MX1\FH41.LW*7VX2NRB4!
M>DJ(JF`M#UMTE`("PDJT/9:1_P"V:5MT3*D^_<C9?>R+IT\03NNI912ZFDK8
M&"RS0]@@1^&IIVW1,J3[Z#,2W7LBV4!^G==2VA[J:2M@!9=F8"B!7_G`00K$
MRI1\\&XEN`S(!*-'1*UI:-P#02'M!&_EVG+=G/)U69^<:.E40`#.FPT$XIL[
M;BGI03A4:EH;M((+!EF@`(B1_0`,8:1,J/84JIAH`,A$1HD-`#M$:`':8M0#
M2S,H&$2O_,`XC2*E3#[6#H36@5D(G&C,]*5NJ2E=1.X,GEFA+[B/_:]2ZV)E
M3_>N=OLL9&U*^'J6VUOJG;752O`/*M"7W$?^UZMUL3*G^\\Z![;&1M2OAZEM
MM;ZDMKJI7@C<2K4'C3M>AIB\$Y>0DRB<$R.2#II@5+FA`S4X@!$U_-$I@M`Y
M#&!8,LT"OFONP3`-(J4$*E,H4:"#,0$*I#3RA00[#%J`$LT$:`5_W@']%2GJ
MF*4.WDZ4J<.WU`J/<`T`++-#"4`*^J82`%T5*%[3BW*6HF9@!>UT2M:6@!A&
M@$/:`65:'LM(_P#;!3`MT5*%^^BS`MUS,+*"_3NNI90]U-)6P$:,LU,_6`.=
M'59QBA"#'2E2`NN<A!52,F;EC&%V2ZY)(0`IQ,8P)*:0*RRS,UE"O_/TQ+=$
MRI/OH-!)=<R"SL?$NK2VAZTTE+``EF9J4*_\X"B%8F5#L."!@J`L@$HT<%J`
M]H#<`T$IJ!5W?EVBZG,7%(%PMRCI]$07:NFH^=U6[*B%`<HHB;L\E:"%!X"V
MO`'`4+V/R#;7-.AC:##,S2RXN*S72]MQC>3N0V\SLJ;>,<[:P<1).V[UUA[I
M@)6PG%1%S:JCYI5BB8@`;@-OM*PZ<,(SZ7F\+R+,)C,7+O=MRXBSX9DBJD<E
MF^889*Y^Q;1$3@4>X:H167XJT%P`@*B<B\<J.Q4<N1,`3WCV6Q,GN+F+EJED
M`)%PW;Y`2N\2RR.7O),[CJ"(-)&$:NC(T5"B@$%,35`#7`(`#^3E&QY90X)2
M-IHU```T1+$.`@[<@(&3.R*H7]\`J'`*7\G%\@^&0!RDP!FZ,^4=1<@1LFS*
M@H+H[@R[+1!$J`&$UWFT[^`Y]P/1YTTY@F,WC>X&YF8X<[C,2QXT%&32>4X"
M:(PW%H/&H^/8,4,3?QD2LZCX9$SE9D9NY,1RY1*<C9TJB8'`OT6;-*J*HQN=
M;ZQ[LL2]CY`I)!S*JJEFD)%L>9<-9O"I1-K/K(.#()R"9$G(-$C-R'!(ZQ3A
M]RW1-L1-8=AV%2D_O.M(X7CD_!XUEQ)6>9YJFC/9(&23TNNY:XV@SE)-=^Y!
M(RZ[54$45`M`BIM40:.(]#.S"*;]D^W5WOSAJSG)AM*1:\@Z69E:K2KF4:XS
M/@AB[F16=(1;U%E)G6<$7EF3=H@Z`6K5DW;AT!QQM&8QCT%C3$LHHRQZ&BX-
MFHK#O2JG:Q+%!@W.H5I&-VI5#(MP$02333`?8E*%``-SXFV_DY#YIE?B7`'B
M;;^3D/FF5^)<`>)MOY.0^:97XEP!XFV_DY#YIE?B7`'B;;^3D/FF5^)<`>)M
MOY.0^:97XEP!XFV_DY#YIE?B7`'B;;^3D/FF5^)<`>)MOY.0^:97XEP!XFV_
MDY#YIE?B7`'B;;^3D/FF5^)<`>)MOY.0^:97XEP!XFV_DY#YIE?B7`((V2;@
MW4JE(?A\J/\`14H/8,H\$.YF/J#^]P"_Q-M_)R'S3*_$N`B/=+'\$RZ1VO7S
M"<D8<V*[CQ.48Q%FCFI$<KRF+82:T5"*)3$`^?O3MS`9^DC'*-W>LS(I>)$S
M%$*J0G0ILE"9;(9#%[F=2BN4.);%Y]^$OFV29!HQL'FJF;8]$$BIG&7C:/@$
M\C9.^7.5(JP)JN4"+:1CI\!?>-DF_+J>U2'](2H_T5*#WRCP?49CV]O`4;W%
MZ3^G/<K>7)<^=YWN'#;ESDT5[*0^)32"16>0,MO,`QN:=-<>5Q:4<M9]WM]"
MXNHY5-<Y;%:13Q(43IM5.`W>2],?3NW@H6&RJ>R]ECN.XGN)#E1RA0ARKP67
MQ;MEDK]W*9'BZSM!.*&:6=G51510%RN51X"P$2*4&9D?2_TM9'N@SRZ1W'RM
M',6&9FGU89G,Q+1X\R678'D)=K)(I8L$^[>9(QBW"QR**F709&=E9BW0.>P'
MQL;LYL!M?DDOD&U&;2&1S,IB\1#OHUNK`.6ZN.1N4(,(Q^LTQC&8E1R6'<PR
MD>W5.)DDW!7QJ"[<O%#A:C/F^)Y+@F:XYF)W+7$)_$<DALJ=.F;MDV;XW)PS
MUE.KN'CUB9FU12BUU3&45`4R`%3`(`(<!1_!^B+IWB'+QWC6>[T3:;:9%W+$
M3R!S(&^M:,6Q3;/)=]%XBB^&2C&(,7+9LLJ"*"Z3=T"6K:H(.K-MB>F+-\OR
M.>E<SDXZ2E'.Y`Y?#PSV*C2NU)^!QB*S:/F2_5M272CHDL7&R#UFHL")9#EW
M#PIZ)!P$9QG21TD-&\^[)NEDKY/+L@QN6=NU);%C1X3T]%S#*--#M&^')P\>
M]RV!RMXC%D;I%%JV<)&B2MS(H*%"R&+;;;-LMDHG;".G'\SM4Q<1$A#3Y`9*
MHD>1FYILLA6<8ZC()&#;-XO*VJ+9FDV;D!`J)$DZ*%*;@&5M-MQTW].N72T[
M#;E.4):4:/<?&%R9[`M4(PDQ/-TS1T7'L<;AGT>@62PT&J#$IP9HNVSTY$"N
MUWJB@6C;[J;>.X=MD+7*XMQC[R03B&<Z@996&=RRSWPQ&+;2A$18N)):1'ER
M($4%4ZWF`43=G`;1EG&+R0R81TF,@,(]6C9H&#"2>##239))PYCI8&S-08U^
MW06(=1%:Q0A#E,)0`0'@-HUG8]ZBFY:\^LW532617)#R^BNBL342504%B!%T
ME"=H&((E$!`:]H<`PD)-N.[DB4$I#SMNH*@^$R@%"[+)IN%QA9@4M#K@(U$*
M$`QQH0AC`$AEE6Q[:)207@00NAY8E-0&HENO9%L$`>$NK2T2G`::2EH`2K80
M`=*2[0*(5AY8!\X$C!4!9`)1`%@J`]H"!@'M*:@0_B$RU-N[O(0$):J3#;*X
M30<T4@WPL\J&D<S`"+4*%#6":TWFC0W9P$P&E6Q0,(I20V@<1MAY8PC8"XC:
M!60B81!L:E/9")0"HG)<$,Y5*)&SG8X@-YA6S*LY<JJIPLTX0210V^SE$17=
M$;NT4S&5(!$RF5N4,<@$`;R%$&G'ST87#NIDHK.KD<RW*:F)X9*ZHN6^WT4N
MH@@ER6J[5%%H8Z8(E/JE,F*=P*I7A6?],&(P#J>V.VARO:'=J'P_(>F:0R6+
MZCW[7#V>PCB/;IX.]?L`GG66(Y2.3LI)L@R&,+$F=JG?M5TR':*"X)^C_;7V
M?R^YOL!Y#WYX/S?B=GRV#SVMAOX7'&Y?R_=./9K3)]&FK.#]/?'WY:YYV(QQ
M&+)CFT9XKBMJ,WD(P^5IJY<>2,<XK3]2>V,?K7ISW<\Q/3CCGK$^G5>;&=\=
MI,SF`Q_$L]@,DFS-7;XL5".%)%\9DP5*@]>%;M4E%#-&RRB93J`%A162[?;4
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M*F8_&.J7*&U8]RY?)1F^>>;A8>A&SA8DKZ%>LY##-V2/'S9"42<-ET"$%0`2
M<G2Y3[B>1\;Y3W1.UXC-3/HT\?X[#%Z5O6LWU_':FOEBL9*8[]M<N*]8FU*]
MT1W1'$PSZE+TP=N2)BW?>>.GQO:8].8])AK&_HK]LPW-VGW3-O;OBZG=LY?9
M&<!![!0Z;?+7^SRN.%B@R0[;$F"Y(]W'1<<B@S3,DTB%#2:R2>HZ>"GQ"RZK
M+RK<5XP03D@`[DQ:&BI9,1U&!E"@9,R*)J%!P6ZI#@02FN`HIG$@+?%6P@`Z
M,EV@`_T/+`/G%3,%0%EV#10*U[A`0'M`:`>*M@`1T9+L`1_H>6$>P#F[`!D(
MB-$QH'>(B`=XA4`TJV+=5*2&T#B-L/+&K8#D1MM9#>(@U-:`5N$2`%14)<`>
M5;$OJE)#9J5LAY8]=('@FLL9&U*\B>VVM]R=M=5*\$H2;<CUX8R<@)2-T""4
MD9**&N04F3*&*B1%0PD.#,P$."12K")`(=03IAP"LTHV*)@%*1&P5`&V(E3@
M.F+L#6B5D('`19'MI6ZY.E=5.\`91L`B`I2/FB8!I$2HA4HK%&@@S$#`(H#0
M0[!`2B'88M0/%&U::4CWT_HB5I[("]_)]U1[_)V]W``2C8:>U2/:)0"L1*A[
M,4`"M606@`N"U$>X`,(]A#T!#&2C<S-N&G(B)C"6X8R5.%3KH%*(JBDX+:'.
M$N$5!`H%4K0$E`("TDJV/91*2#4T[;X>63IJ\E;?>R+ITY\EUU++5+J:*M@!
M95L>RB4D%^G2Z'EB4U09B6^]D73ISQ+KJ66J74TE;`"RK8P%$$I(+@((70\L
M40O!N8+@,R`2"`.2U`:6B!P&@D/:"*0EFX-:@G)%JLS[?"I9.@&=-AH)M%L)
M1$#T$+@[:@(&H)1!:,JV`!'2DNP##V0\L(^:54PT`&51$02&E.\1*`=IBU`-
M*MBW"*4D-EXC;#RQJZ8.A-:!60B>H-#6TK<)B`%143N`-*MB7U2DALU*VP\L
M>NESMUEC(VI7D#VVUON3MKK)7@'E&Q+ZI20V:E;(B6/72YT#66,C:E>0/;;6
M^Y.VNLE>"-S*-RO&@:<A1,7EX!&2GGZ9'!!TR`D3F!N;&$`*16I1(8*`<AC`
MM&4;`(AI2/8(AV1$J(>:90HT$&8@("*0TIW@(#W&+4`)1L(@&E(]HT[8B5IV
MF*7M'DZ`%3]_D`1[@'@`LHV,)0!*1"X2`%T1*E`+Q;@%PF9@!``7):UI:`'$
M:`0]H8+*-C642D@OTZ71$L2FJ+,"WW,@TZ<\2ZZEEJEU-)6P$:,JW-(+@"<C
M11G&'(!HN5"T%UE"%U"&1'0-5V2\#)IB4"G$PB"2FD"PLJV-91*2"_3I=#RQ
M*:H-!+?<R"RG.DNNI9:I=325L`"5;"`""4EYP%$*P\L4?/!`P5`60"40!P6H
M#[$0,`T$AJ!5S?ETDYG,7%,CDEN4=/M>89NV@C=U6[*B%H.D41-2O;2M![^`
MMKP!P%#-B\BV^RSH:V>Q/.XG-&N'RW2_MUCV5NGV!Y>T9I0Z^VL)$R3M)^M`
M+-=`$S"HBY)>0"6K%&P+@#TVH@^G+#MU9[*\$RC<&=R]]^4!1UA88O).8Z)<
MR^7LULZD(W&XO`(Q['R#'(TDVC]8%!4!R=07>H\7<*J`[MSC[L9\ON`WZ?,W
M7VCW-:XQM:\Q_)-P=HI7*L3<^&Y1GSF1@,JQ&76Q68?8YD$>HHW.XC7[%\W5
M$%45A%)1(^Y\!M>$U/)5R>X=7)N>)FMJWICR_1R1S'2^/)Q:L7I/$Q%Z7I:.
M8FO6)C'EKDM3C%:*Y/G,<Q_&$K,)G$-F,3;K9SF*D7#0D9%MY_/]PWK2'"7G
MYF452<3$Y*..2AFTGDT\Z,H"*`(MDU5RH-TDTP32+1WMK];M7V>RF.EI_#2O
MY:5CI6E>>9XK6(B)F9M/'-IFTS,RK7MK$>IWS_U5W"P^?QQX9_*8SF,!-8Y(
MKQ+234(ZBIEBZAY,C*19M52%5T%U"`<AA$AP\H<5$E#]T.E3I8F)_)IK<_>;
M<6*S$N$R.2YI*2VX$/B<DCAOB+-![G<Q"%QJ*@\?@&CB+(T/((L&<:4R*8'$
M5V[<Z(?<_P!'G2U+[>O<B@LXR."A)V'@7<%N6$XA/XLT072CD&\ZP5E8Y?#9
MAAFAP3/(E5U64VHY,*Y505$HAOI#I$Z=,_21W(1W`W)>-GF)PL:CG&,9*U3C
M5<?@<"8;>/I*.R1IC+E)LG.8O#$"0=H.@'4)K)G1,FF9,-&U]'UTR2S1M)Q4
M_NZX;/$I!TSDH*=,2,<GEWS"2/*L6<5B1,<!V*L<01<(-RF=G'6<BNX(DLF'
M1/Q=J`?>93L#Y%F!'_\`X:B/`?02J`@`E;R0@/:`^&/PJ`^K0S<IO_1P!XHE
M[VDOFU[_`*G@#Q1+WM)?-KW_`%/`'BB7O:2^;7O^IX`\42][27S:]_U/`'BB
M7O:2^;7O^IX`\42][27S:]_U/`'BB7O:2^;7O^IX`\42][27S:]_U/`'BB7O
M:2^;7O\`J>`/%$O>TE\VO?\`4\`>*)>]I+YM>_ZG@#Q1+WM)?-KW_4\`@C9-
M(&Z@"UDOP^5'^C7GVTF\-ZB(^7@$<]G.*8HS;R&533+&(]Y)QT(T?9$L2%:.
MYF8<E9Q$0U7D3-TW$G*/#E2;H$$RJRI@(0!,(`(1/E;O9C>-]M<DIG;*5<1&
M4,]U,&CL8E(IZKEJ^!R!`,_8D(QDY"7Q^#F5$@>+1ATM-4H(K+`F=1)0*UP'
M0;TPP^82\K`3^[P9FG,XMDLTFKGF2SK]BVCLP-G.+QSB(G&,JE#P)\FC7"S,
MQ$$%J"Y307*0RI>`OO&R:0-U/<LE^'RH_P!&O/5E'@^HB/EX"C.XG3)TG;J[
M\Y3(R^6SK3?.58QV=3^&8YER!<D810X_C^W1LR'`58Z5=QS2<A,6BH\\L9J!
M@7C&2K9=%VT;*I!M]Q-ANDJ+P."VRS[)`PF#BX[+Y/&_K'DK+'Y5M'.9#%)/
M*Y5@KD[+3>QK"8BXQR]$Z2S,'"Q3.RG%8`,#5/T_]'7UUC$E-S7/UQB)M@B$
M&MG4"IE3J73QWGIN+?*KQ9\X-(9M!0RKZ9*1RF[?,2.2W$8*N45`>^QVV?39
M@N22V0;+YXGE\_(XK$1TDPB9_%Y[5Q=EE*$3%2;EOC,2R>NVL0[QLT2S6745
M;MSM712`#M:057"S^XKK"'^`9K';AN2PV"2F*ST3F,I-UAXEEC4K&.8Z97D)
M60(FQCVI6#D]RJH@F0!J/9P%*\`Z)>E($R9%A4WGF5Q7B\J<7[+*763QZ^5P
M3EUBDB[6G64.Y>N)O%Y2',T%L9V*,=*1]^@F^1,H`9R/IPZ.GVY&3Y7D6?O&
M^6ST=N,7)()QFT3%IJ8XZ?/Y++F+Z'+&MI`L)ATUFJCMP94PB@X=MO$%%BH,
M2(@W8CIOZ(D(^==LMV5)!AEN703N1D?RAXNX8+YMG$2[*4K+E(E.(;9#NE`9
MFL5%)),'!F4BF$05HD1II!97!-N-G)'9R'VQQ"0<YGM0'*R\#-0ZL7)LEEX?
M<-SF#4D.^QN*;8\@S@\G9`FW29MTDFA&X)D`IB5`&;"=%6P$%D<!D*,5GT@7
M%9;*)W'H:;EIB9CXV8S&;R+(YZ0,_D&BV42BCB:R5=PF1](NDD%2@=,A3'7%
M8/IIT;[0,\42PY.5W?-#)BV*+12==#&<JUR!/(TFK3%BPA,*A;':14DW$?&-
M'K=N6Q%=,1,80^LYZ.=G]R,=G\=S&2W:D"9+N6YW2EIF/F7&,S[J:<Q+F%\%
M6D\5@X0SK$4&CFY./7*JF"J9#B(B`U!_;%=/FVW3N;(B;>FS\['(8O#84T;D
MCV0GV\7&8''R$5C[>.=.H\LLJHG&R&BLN\<NW"Y44A,H)BB)@?Z$FD.[<B'*
MR?;MW`A<,8]`@7Y9-(!<<4:%$#+@8:]R93&]B4P@$A%E4364:2@7@F(71CTM
M-0&@A>!D0$@EYPMU?8B12OWL]``ED1`!Y24[0*-!BWP"%Q4C!4!1"@@"P5\@
M@8/M1H%&MT>L[I8Z4MS]PI+J;WVVWZ?H[*VF$HXF_P!X,HBMOV>6+P6/R+R;
M;XNMD;I@$^YAT)!N+E-J"AT3+IE$*G*`A%@^F\]$4`"/_P#D3Z3_`#0,/9N]
MC`B-I5S"``#SSA$&XTIWB)0#V9:A`.^OI9_1!;GP37:C*/2"=+KO%\ZA-T\'
MS-]"[PX7)$B,?S#;?-(1R]!ZF]EH\5U"K:3:H+%,Y51+:-Y2&#F.ZW0]"1*8
MUOTE)>E'VU76>;_;P;O8K%/M^MO)H)!7+\.:%EV,,]>X4:09-\IF(5%,7C4'
M3])JT(R:N3(.CD7"N/I)L[Z%.KG8OH%VEZ??3@;>]-K?I7VDR7#<IR+;K>G#
M3Y3F)G\#M#%P<1D2:6]&P**[>,+MN_43.37*5P9``;I`L53CJO;^EXW<T\^/
M>\Q3QF2,N*:TOCV+TRQVYHM>9P4R<7Q3-:Q%J?BIER3%HF.V^#+:];1-<??'
M$]>8YCTZ=>/7_LA"7HUWG2YT+[Z9QN]N9Z?>%ZCH69V'S[;2,Q/--Z=NR(Q>
M19-E&WSII)Q`2F__`%!`)EXS%7R:JB,8Q721%`Q'7G:)^Q\1X3V_EV::$^:U
M_)?J<]:3@[-W'7LC'FM;-:^2=;'WXND8JVM?NODMTB(_'7R9,L1W?3FG;'KS
M6?C'3IS/$_']D.L.U>3^A6@([<O$ML?2C[99J\W!PQ9')8)3?7:>(80<)CD%
M.)9QG,#'LH>*AX6.PK;A[,N6[$A/!81@+MURJI2C3R..8B(GK*^L;TD^DH]#
MGTJQ^1;28GZ278#(<+C8O'WT!D^;;V8I)RS]>;RS<>9DXYW*$;QA7LA$GF$#
MNUU!77<*N3.5E`45.1/Z+AE]-WZ(LUM/2*=)X7B0`NW>Q<M-06H!=<\"P`YL
MMU:6VGK33/:$8F]-1Z)M3>=A,E](-TL^%!M>^C32)MV,9(Q(_=99CKE%DHY,
M\`A'8MU]04QH8I$U3#0$E+0EEAZ:[T2<FNDV:>D2Z2M54"F+S.\^',4BE,#,
M:JKOI%N@C:#TE;S%H)5`'M34M#H=&Y?"9)'8OD4`NXF('(&S*8A9:.:.G4?*
MQ,Q#)R,9),W*)=%PQ>,WZ:I%`N():C]J(@&_"61$`'E)3M`![8M\`]I4S4$!
M1`0$`4"M>X0$/4'@`99$`KRDIW"/9%OA'L*<U*`A41&SL\HB`>J'`!I9$H&$
M6DH-H'$0+%OC"-@.1$"T0&X3`U&VGLA.2GLRU`/+(DOJTE#6:M;(M\:[2!Z(
MV40&^_D#6T]EJ)T^^$J"4)1(KUX86LF($;HIT+&O3"86YYDYS$(4AKR*`T$"
M&`M%!.F`":\@<`K-*I%NJUDQL%0!MC'IJZ8O`&VB(W@;DC6TK<!TZ??"5`&5
M2`3!RLF-HF#LC'H@-IEBB)1!&A@'0&E.\#%'[8*@>*I5IRLGWTKX8]I[("]^
MCW5'[';P`$JB:WW+)A<)`[8QZ%+S(%"ZJ/F@',!41[@*81]B:@(8R52,T;EY
M64J)A+4T:_`*G7;E`3&.0]"ASI:B)NP"*"-`3/0%I)5(]E&DH&II4OC'I+=7
MD:7W(A99X@6ZM+=-6M-(]`"RJ)[*-)0+P2$+HM\2FJ#(0ON1"P2\\6ZM+=-2
MM-,]`"RR)@*/*2@7`00NBWP"%Y6Q@N`4?-$.9"M>X2GK[`U`12$LERM0:2O:
MLS[HQ^!J&=-A^U(F:M#T$*]]0$!H(<`M&61"ON24&@&'LBWPUM*J80"B/:(Z
M0T\HB4/M@J`:61+=5I*#8"@C;%OC5TP=B-H`@-XFY,UM/9"=.GWPM0#RR)+Z
MM)0VGJULBWQ[M('PC91$;[^0-;2MVHE3[Z2H!Y5$E]6DH.GJULC'I[M(7P#9
M:B-]_(&MI6[42I]])4$3F53*]:!RLH()B]$UL:^$#Z9'*?F6D`%!,+81+0#5
M*8@AV'*(@N&52`1#E9,:"8.R,>B'FF5+V>T]H"*0T'U0$H_;!4#Q5+L#E9/M
M$`_HQ[ZIBEJ(Z/<`F[_(`CZ@\`%E43"4.5DPN$@!=&/0`+Q;%"X11H4`%R%:
M]P%.(^P-0,$E43V4:R@7BD`7Q;XENKR0!?<@%EG/%NK['34K][/0$:,JD:06
M#E)0`591ARWQCXH$UESD`%+B6IG(+PMX"4HD`B@F'VLUH+"RJ)K*-)0+].ET
M8]+;J`S$+[D0LMYTMU?8V*5^]GH`$LB-/<DH%P$$*Q;X*7E0,`#5$+1#F`K7
MN$I@'V)J!5W?AV5U.8N)$7:0%RCI]_"6JS:MW5;LJ-":Q""82@/;3NX"VW`'
M`4'V,RS`L@Z&=H<=W!@,R8X0]Z7]O(/+WTMB<S%QJ4"IMM"Q$F]"3<-003:F
M1,*J+@@B`)B58*%"X`6;4Q/3SC6XTCF>`/=Q)K)W,ANV4T"G`O%8]O(O,JQ=
M+=$\5"L<:C52K0&1(QK22%(Q@3>N`.^U'RYESA8K&LH;RNXV8N$H?*&90PW`
M$A)*X[)QBPF)-;C&O30>(I+*HF!2@'*427%,%:AV@U=_]FL'ZE,#G]I=P$<M
M:XS.AC4BN\QLC5A/,GF.3PS#!>-?2<5+IQKPCE`MK@B)72%=1!1)8$U2ASPG
M_0R]+CV01>P>8=0F)QJDY&2F0Q3++4E&;V`A3S[U&`AW*D,@ZQ1V9U/.!-.-
M3C/Z*JZ)7@%=.=4)SA.C+I`R+#X88B?R>?PF9Z4(+IK8.X_.616>2;'/)9'-
MH67/D<,U9RTF]?'0.M'/BO.19-UG!XU%L*RQS`S)CT:_0RYGIAE((Y8S9Y'C
MTM'8_MP3,TVV*83C<5/8_-9:&"8V9GK1+7QJ*I*N5U'*B9)%VV.HFBX,D`-R
M6]%#T2R31"&=3.["$"QF'LNGCI-P(T(TKUSCS[#%V;T74$O)/X=HPRH4F\8Z
M<+1[([H$D$$DW2R2X.W%O1W=&6S.9X[O`,UN.UE<*R.'R'&W^5[B'-#14[CL
MW"+WHD,T9`_<GDHD&*P+*+K-F#I:*0%O'F(S3!#(>B_Z,D'C%[)OMU&;"`B6
M:&/P3O<$S*#QIQ`P./QTSE$6T4CT5RY'+,\:1=RSYPJN<ZRSI7VHKI<%`O'M
M'%;8;"[(;=X%C&022FVNW&$8]CF-9'E<NE).5L8C&K>.AWTGD*A&C5X4Z&F7
MF`*FEW``%`*`#J-O5M85&$<#G.-<ODWBX8ZN$U&&1GAQ\"#.EAU2NQ3DCPQ%
M"F=%1$XMR#<<"AV\`Z9',L?AV:TA*OB1S)N58RSIZ)&R"8-TU%G%RBIREN02
M1.<X=Y2D,(T`!H&Q;S;1VB1PT3=.VZEVFX:H"X0/8<R2@$61,=,PIJ$,4P`-
M0,`@/`>WB1?>4E\"5X`\2+[RDO@2O`'B1?>4E\"5X`\2+[RDO@2O`'B1?>4E
M\"5X`\2+[RDO@2O`'B1?>4E\"5X`\2+[RDO@2O`'B1?>4E\"5X!!&R10;J>X
MI+\/E1_`E?MI-V;_`-%>`AWJ#V1P7J7V_+MEN*GF*6)*9'`Y#)L8`C-H:=+`
MNC.B0$P:2B9=)QCLJ)M-Z@0B:BZ-2:A2F,!@J'$^C]Z2]K7>UB$CD6Y[7ZN[
M;[C=.&V<5DV<MV2;G'=X&&3'R3&H--I$Q+UQ-*MIF269)M%":`B0Q4C<JT!`
M&9BGHN.B7"9W'QQJ:WC8Y-B*NUDSJO=W9J;F9`F";M9#N5MPYG#Y$$HY6,;,
M'3Z/3<IZ+IY'(E8"J9-LB5(.J$9)%!NJ')27](2P_@2OVTH\-_Z*\!2SJ&Z>
M^FSJ!W%>8YG^49SC>Z648#BB:S#",I7Q3*7VW.#2.Z3%(S?28NET(A\IN].,
MGSA,2+!K(&140<((+%"N6Y?HXN@T=K-N]O=P,LW!@\-VVQW/VF./I;<MJ24D
MF$QFBN4S\K*R4U&OCSRN,9'DZR(6D%L7Q+3>I.%!;B0%X]%_02VW&([-N'D:
M.5,\VPN1DL27W)A1=/\`)\0Q2;:-XJ82<QI\NULB8KR#^72*\2</EE5BF,5N
M<6XA(_2ETZ=(NQ^3Y#/=.N9S&79%+X;!Q$ZV2RF!R9)3&$<Y<'BI.13QZ*CE
M'BS-]%J1K!1VHL1JW:+%;$34<2"SH+E[T[9X3O\`;3;A[*;C1$\^P/='$YC"
MLN9L.8CGKJ`G6IV4DW;/R%.=HJJW4$H*`%2UJ'`<S=J?1F=`"K2"R+;F:W/R
M&$Q')':,0H3<J2D(]IGD=DTRYE7J[I1DF_?90WS.974TUUE2L)D5EVJ3=\[D
M%782SN5TL]%.8[@9C/9=E[^-D9Y+>F9S/#V64XW&X^22S.$PV"W.RZ29##*R
M<'.PC-I&"HYYMORJCY4%RG*_<D7""XGH&]&HT@)YHUW#EW+'*<JVX>RTH?=6
M!+KS_@D\C&LD"M6#:(8N]S(W+9M>0%%NFZ<&E'2C51L*2`M@Z#=/<%LUL;LO
MAF,[:9(L]V?@FCMMB^53,G$K,'2F69[,.4F3*1CVL-`(LULGFS,8MFQ;-V:)
M!0:-$BD*D3@)AQG=O;K-'CB.Q#+(7*)!HU4?.F4!),95VV9HR;F%5=+MV3E9
M5)$DJS50$P@`:B8AZG`/7Q(OO*2^!*\`>)%]Y27P)7@#Q(OO*2^!*\!'2$D4
M=VY$.1D^W;N!"[D5=,+\LFD/./\`:B45KQ\B9#&[BCP$A%E2FL]P2I;P3'SF
M"Q;=0&8T/7V(DYP+O(*:GW`\`!*E$`'D)4*@4:"P6`0N*B:@AZ@AK4'R"4WD
M'@/S<>G.]$4Y]+[@V68UM_DLG@'4)T^OL9RO9=[D[-ZWVURX<TQH6F7X;F2[
M9L]>,&T@UQQF=K*-DE58]XA89!9)90"A4[H[_9;?0VOMJAV^W(ELMZJ>H39^
M74P/J.SC#-WLNQ%C`[N\@CD$OABF#X;D+=GAB$(PD6Y&C5Z*D@=J=%5PJ914
MP%"0\X_9K?018WF>`0;G:S+H=*8?9>\R=N/4ON8=I%XWC>-9FH>1DG;K,7*D
M4P)D>.`@#E15-,SI,S<3"<;.`307[,MZ$_(,6WSG(;9#=2;';G+,_P`;8+16
M_.ZC[EG>)8FTE18`1MD9B.%TWUU@*E,9772"IBG+P$I8G^RM^A7F,4QJ8=].
MV\P.I3'8F3=%/OAO"DKS#J-4=+E.BGDA2)JF4;F\PH`%5$P`//#@-7N/^RU>
MA@Q'#)[((KIXWD-(1B2!FPI;W[P.37JR)&1SE25R0Z:A-,#&[0$+#%'U0X[+
M[?UB_O#2K/T^)O?_`!+6K3_"OZVI:EH_9Q:.9XB>8F8FOM?\O;U^'I^^$G0O
M[,UZ'[:!P]RC!]@=UFDU*Q$UMT[7>;U;R/4!Q3=6.=;:9VS(D.0."IK2N$Y1
M(-$E[;VQG!5DCI+$363XU815%?LM7H7GVY>98NITZ[TIQD'B&W<LSU]Z]X$4
MCO\`)9?/FLBLW=?634<H@WA&A#W&$J1T5*``W"(/TO[*1Z$\XD#]'C>$MXIA
M4V^N\A0+J"S`!/7)?-`G.!=]R":GW`\!'G_Z+;Z&`V[#/#R].V]!(I?;MQDI
MSJ;V;OD;>(_6:!BDB\V;(M<KANVE3"JE=84A#F$*D$>`H1U9_L;VPV==1^PT
M]TB[C9;LETRR+Q-CU*X-F#N:SC-X&+C4&[]O.[-3T\606?2^7\V6,=-)E0S>
M%7*=^F9VDFI'E#]IV&0,#MYB&W>`8S&3J&.8-CV/X9CR#QN\>.T(/'<9:0\2
M1Z\5*)UED&"29555!`QE"'$>T!X![!*E$`'D)7M`!H+!8!"I4S4'R"&I0?7`
M0]3@`94H`(\A*C0!&@,%A$:%.:@!ZHC90/7$/+P`:5(6[W!*C:!Q\U@L-;`=
M#0O9VB;E1M\HG)]T'`9/*E)?[@E36:OL&"QKM+GO84]E?R(V_=:J7W8<`D"4
M*5Z]-R,H;3;H)B!8]<1.*!YHXF3\T"J$5!M0@E$;A4('9>6H*S2A2B<.1E#6
M"H'FL%C`;3%X'F4]D!^3&VG?J)_=AP`,H4!,'(R@VB8*@P6$!M,N6I:=X&T*
MAY0,7[H.`/%"UIR,IWTKR"U/9`6O[G;7]S@`)4HB`<C*!42!VL%@`+S-RU$?
M4`O,5'R`0_W(\`BC)0HM&Y>1E0J825/'N$Z7KMBW&`Y2&*4.=`1$0[`34'[0
M>`6DE2GL]PRA;]+V;!4MNKR-+Z^PLY\+J^QTE?Y,W`!)4I[/<$J6_2]FP6+;
MJ@R$+Z^QLYX+J^QTE*^P'@,%E2F`H\A*A<!!\Y@L`EO*V-0U>X2\R`&\@D/]
MR/`(I"5)RM>0ENU9D/9'.#&"KIL;V)2'-V7=O9V4&M*<`M&5(`"/(2HT`P]C
M!81&TJIJ`'JB.E0/*)B^7@`TJ0M_N"5-8"@^:P6-=I@['S*!YPGY00+Y143^
M[#@,GE2DO]P2AK-7V#!8UVESU;*>RU.0&RGLM5*GWP.`#RI27^X90UFK[!@J
M:[2YZME/97\@-OW6JE_*!P")S)E!XT]PR@Z?.CYL>X,!],CE.A#`42B)^6$2
MU$+BG((5N#@%HRA0$0Y&4&@B'8P6$!H94M0'N$!TJAZQB^4.`/%"]GN&4[1`
M/P!;U3%+VCY`NK^X`^3@`LJ0UON&4"X2!YS!8+;Q;!4W9YH%YD*^0"'^Y'@`
MLJ4UGN&4+?I^R8+%MU18AY]?8V<\%WW.DK]P/`(T90II!;W#*AJ,HPP71[@H
M$UESEM.8Q0*!D^<`3@`B)`34K2P>`6$E2GL]P2I;],?/8+%MU09"%]?8B3G0
MN^YTE/N!X#!94I@*/(2H7`0?.8+`(7E0-0WD$O,4'R"0WW(\!5[?AV#J<Q<0
M;NT+<HZ??PIN=`#7=5NRHT)?VF$M>WR<!;;@#@*$;$YCBDKT.;01.?X7F;/!
M%>F';R(R]_--(R`B_JX;;B%B)1Z:4>S[+EF3AJ<54EBG*H")@5"V@B4/C:='
MIBA]WI[+]ML7RV8W=4:[DH2RK.1&1>,X:1SF'9YVP)C[;)$X--BPSO'$&RBO
M*F<%?(+@94ZO,F$'ON9%;F[JJ[@1.T.?YKT[[B(XUM8_QS.WNWV,9HV;+Q>4
M9^Z<1T_@^0R!&>38I.LC*M7223N/=E$UZ+E)1,HFW/@-_P`7X[R5=CS.E7R'
MC9K:M\,Y+X;3%HXBU,M.9I>L\369K>OK%JS$L>6M[TXQV[+_``GCG^>/C"><
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M2;K[@Q[DCZ.S%VT:S[9BK*9`Z64?M>7;LR#>H)`(0%2G6\\0U.1]%/2O)#C"
M+Q?)8H[6=:.X8#;CPBSB85CG+E92%!>8E'SJ4!4F1.DES`<[T0D+S*ZR;-5N
M#@@>GCI"Q^!Q.+AD&A\>VGG,AR:+9AN/%RR3&3R%_C65N#RRALF=OGIFRYHA
MPW!0XJJ$4;ZHK`O[:"5'I$Z.LIW)R[*6.-#+YQD^0N\SS)DUW#/+DE9-:84F
ME%%(0^4OT6<<A-%*<S9BF@W'2307*=$A4N`<LYT+=+^0Q>W4-*;63ZL9M/`R
M>+X&S3RK)$D(6`E)%>5/%J)DR2R5;,7[@QVG.`X%L(`"8@`!P&XDNC3IRE\+
M98#([8RZN.QSYW*LDF\S)QCQM,2+7$V,G+H2$5,L7;>1E&6&,T7*B9B\P@HY
M2.!DW3@B@-AYT$],DGX>I+[?9C+O&,HK,*2$AF$^J]?R#EK(MG;AV<DZDDDJ
M]/)"LJ=L1N<RR*0W`!;1"SVVV%X]M1AL5@N(PT\C`0ZDDJS3?*H/'0'E9-Y+
MNA4<&<$O`7;X]O8%"T#M'M$'UXBI\ER?\TV^-\`>(J?)<G_--OC?`'B*GR7)
M_P`TV^-\`>(J?)<G_--OC?`'B*GR7)_S3;XWP!XBI\ER?\TV^-\`>(J?)<G_
M`#3;XWP!XBI\ER?\TV^-\`>(J?)<G_--OC?`((Z0.#=0/#),?=\J/WIMZLF\
M&GX5ZE:<`O\`$5/DN3_FFWQO@(FW/0VZE'^VZ^X*KR(=,=P(-;"D5YII!DG<
MP16"1@X(Z1I)`LR5:4C&[I-H-05=-$>_V!PJE#]%O11C^6/GV/8TK#YDK-8K
ME<DNUW3<+RJA_KP;(L7;'2D<R>@WB7N=02JC5!$B8\VFJ5$2F.H!@OO&R)P;
MJ4C),?=\J-=)MWC*/!$/PKU![.`KSO#C&QFZ^6L]N=PU9A+-GF'+R;.&89(Z
MQN46PDDTFE*.4UFLHU;%8NW:)FC@]X+:2PE*)1,4P!%LQM9T=[:;:8]MG./8
MO$\/CV&Y$AC2DOG<&+D&<O+-'N=O&[V3FG:$H5C)(H)GUB+Z:B12B!E0,(AI
MQVUZ+BY(RA?K0092*R#'4AQ8V[:+A)W-PL2>1:-91HOE"SJ0=RJ</SSY114R
MSU<AM50Q7*J:X/+9+&^F:&R67F=D9PN39,IB\,VE@C,P8949/%E<G1CHEP]Y
M>2<*:20XJG',!7.()M(VB!0O<*+!<[Q%2M/#)+O[Q3;`'[HB+OL#@*)/]A^D
MC?AZSS\Y9;(V\1FLB9`4\\>1L.3.VNY4UD$V16)?3C0KF6-FDZ\8*IF(8J8G
MY=(I%4RB0%F<8YT<95FV0/,OG8(F2LGF?.,MB#Y_$Q0$D'&-Q<+F"DXV3GF[
ME`D7#1:2AFXJ$:E70,X,D==L"B`,U/;[HA=-7[UUG))8LF[Q:&<2LCN^U57!
MQ/M,D?(Q*3KZQH@B;.V.5SIGY>PYT)%Z0HH)DL1"><4A=BDMDXK'XAPA(;(.
MUHIW#S;G(8Q"*?R4AN6>4A2L9M.2CV=CS.ED46"3<2$44,DBB40,0!".MLVG
M2-L[E,ANMB>8-B9'NDBYCWLW*9ZQF7.9J2.8/D5I<K-6646D1\=@EF@/B)BW
M(G'KGN`W.K*!:#']Y=O,JCXB5Q[(XN6CL@GW6*P#MK*PVE.Y&R8O95Q#0HJR
M28RSXL1&KO2D;@IJ,DC."7(A?P#D9YI!2$HZA&#IN^F&,>SE7D6RDX1X_;1L
M@Z?LF3Y9HUE%5R-73N+<ID.);1.@<*U*/`;KQ%3Y+D_YIM\;X".T)$X[MR(>
M&2@5V[@0N%%OIEORR:0&XP.ZU("VH-`'VLAA[P`I@D(LFH:S\52I;P3&ADFH
M67@S$0/1V-!3YL0-2O:BI2M"W`RG&\&V3*?4Q)_G6&1V6HNF[!SBC_,L1:9,
MUD'<";*&\>Y@EIPLF@_5QM-20*B9(%#,DCK@`I!>(<D^H;;S;+K$WYF)QKUA
M[H;/8ETP2VT'4FI-=-6YV,1TOD,&RVBZK-N<H23G8)Y..VT&/BR@R;DK9\18
MD,JP!$AU%%TKOC?';OF/):_B/&XYR^2VL],.*D<1-\N6T4I2)F8CFUK1$<S$
M=>LPC>]<=)R7GBE8F9GY1'JYI^@R]$2T]&UUB]1F[61=8VZV[SS>F5R;#MI,
M`)C.X>'1.Y>)`5]GH[@=0ALTA6,1D>]485D_!F@@Y%-F4SQZ5PMX@9NSZ?R/
MV^]U>+\;F\MM8=>=#7K6V2V+;U,\TK?)3%6TTPY\E^V<EZ4[HK-8M:(F8Y8:
M;>"]XQUF>Z?3FMH^'/QB/A#H/NGTM>C[RW</&,@2W;QV/BLF)NH.6'Q?=G9P
MN.8@PR++]W]Y8[,#'03&'*6*W6D)-&&+D2,M!--5PU3;%66?'6XM86GZ4-K]
MJ=E-E.KJ%V;DY+,<7E-WMT7KIZSDL2G0;RN*;+8#MRG"-U<:.P9&=1L%MRP:
MJF<%!\Z>G%=VH=PLNH`7QP"54'`<*.$1,A7#\>.":C=J18+8:H$.GSH@54>4
M`*5$*K)A7M-:#;WME#DVPRVL3,J`#=D6B#9LJ<WXZ;$`Q"<X03%'1`WJ"!#E
M'R@'8_;^GU/>&E3NK7F]^MIXK']U>>L\3^Z.GKPK[737M_#^N#CSEVHX@TDO
M"Y+LR/$#U,R(Y)1'+8=03::#.:4``*G<!]``)V&%5``%9/CE@V8*644WJW')
MX+.):>W6SY-1=JT(@L"F0[N&U&ZA7QQ531Y@04$0*)3)G``&@"(2L624-9^*
MY0MVG[))L%EXLP&^CL::?-B)J5[$5*5H6X(?-*G/O['I>#39!'9Y\H*RC9H#
M8-?-<:(*0K`^,;F&_-"90H%$`(BH("-"@8)@))J'LK%2A+]*MZ38+-0&(C?1
MV:FESHW4K305I6A;@1+R*AEXPPQ4J41<CYHMVYA)JL!,)CF*LJ5,$N8$IAN)
MYR9P`3=@'!8$FH(`/A4J%0`:"DUJ%2IFH/NL0`0U*#ZY1]:H`R:@`/XJE1H`
MCV(MJC0IQH'NOO&RG[I@_>#)I-0H&'PJ5-:!QH5)J(FL!T(`6KL*BIRP`6M.
MU4E:5-:`>34)?2*E#V:M+$FPZFD#X0LJ[+75Y,+:TKKI5I4UH)`D3D>/#A%R
MAQ*@BE:5NA4_+GF3E.F<RI"*$7Y<`)10PU63N*2X1X!6:24+?^*I0UHJ``E2
M;#?IB\`!)5V%04Y0!+6G8LG6E36@#)*`)@\+E!M$P5!)M0;3+EJ7W6`B!M$!
M#UCE\HT`\24^2Y3OI]Z;?=`6OX7W=M?W.``DE!I^*Y0*B4.U)L%MQFY:C[K[
MBZXB/?V)G\@5!%&2!P:-R>%RA0N$M3-T$P+>NV`3"0RB!RE)S8B/F`-$5!"M
M"B<%I)-0]GXJE"7Z5;TFH6:O(5OH[&FESPWTK3EU:5H6\`DFH:S\52A;]*MZ
M38+-0&(C?1V--+G!NI6F@K2M"W!@LFH8"CX5*EN`@T,DV`2W@V$0-1V-!)S`
M@/KIGI6@7`C?R)S-:#$RM!69B(<NW4$/=38WL"K+B(ENH-"C00'M``NX!8,F
MH`"/A4J-`,-`1;5&TJHT"KL.TVG0/7.7UZ!DTFH6_P#%4H:W4]BDU&_3!V(`
M2KL*ZG*@!:TJ*R=:5-:`>34)?2*E3V:OL$FPWZ8/A"RKLM=7D@MK2NNE6E36
M`'DE"7_BJ4/9JTL2;#?I\]2RKL*ZO)!;6E==*M*FM!$YD3@\:#X7*&TN=$+6
MR)@4L(Y3\PX*'*05.7`Q;CIW%5)WB(@4%HR2@"/XKE!H(A4$FU!H94M0]U]P
MZ=0]8Y?7H!XDI4`\+E.\`KI-J!4Q"U'W7W!=7]P!X`+)*&$H>%RA;A(%3)-@
M`MXM@$34=C0"<P(F]9(]*T"X`DDH:RL5*$OTJWI-@LU19`-]'8TTN<&ZE::"
ME*T+<"1&1.+]4?"Y0NLSC#&$S=`H)"HN<HD44U0*8Z(.Q$X%.I:"2G8'FZ@*
MBR:A@(/A4J6\$Q\Y%L`DU`9"('H[&@I\X(&I6F@I2M"W`%DU!`OXJE2U`@T,
MDUJ6XJ`T-1V/:37$!I7M3-Y`J%7M^')G,YBXF:NVHERCI]['2:9+KNJW94?-
M%-54!$O</=3@+;<`<!0?8_-(%3H8V@:[A[>YBWP#]&#;J-R]]+/<)A(L^,'V
MVA8R4>J22^>L#LV#IB<RI%-1)8J1P-0AP$`#SVCE^G9#=F=F-L,0S&1W+6-N
M0K-,VF38E**DT<P8P6;JFC/R@+($0B,JC2QP'(72%=)8`%54BRA0?.YV.;D;
MNN<[@MM\VW*Z<L\1QW:N4QW/XV#V\R5Y'.H?*,_=F;2V)9#*3&.97BLXW,HT
M>,ECH*'()C)JHJ$34XW7@?):'BO(QL^4TL7D-":6K?#DO?'W1:..:Y,<Q?'>
ML\36T<\3'$UF)F&/+2UZ=M+32_SCB?Z)]83M@T0RPZ,C<9B6DX^;0T0DS6D)
M*1C)::E9$KQR>5F,AE"O4_$LCF)(ZKI^N8`.L[64.8`$1#BAO;6;=V[[>>*U
MO>>>VL=M:U_LUI7^S2M>*TCTBL1$)5K%:]L>D-CGCK'%L'S-+.XMR7"%,3R(
MF9"\<-6[0,5-#O`R$7+AK*).D$`B!6O.F8JA2U$H@-!XJ)*%+[%]"V[,8ZF)
M(GUF=99)/'N13T]NJ$?F&53]B^-H.LK+-9G&SQY2&4PM1!F@N@B5`8PY"I"F
MFH40?,IL1T;YKB&$X@;'853%\8DF$3B#6)W%AV)%7BF0CE+:%;N&^;)JS)9>
M>G4W6C<KS9ED!+<&EP$?QV#^CXB,:C=MF&.L6,-@;W/T6+)6>R`'^+JO)58F
M:Y$K.O\`(C2D9$!-LQ;)SRKDD?S;<K9LZ%5,J8!HL$V)]'D&0KLH''C+9#A&
M(R4S),LKRR8B76-XX\<,DW\O+)Y5D$3X0XCUYA$#ZHI.&7/)"8B8&0$H2GM=
MMAT9;*Y?"YO@DC"164&:90K%R#[>G'Y8TDRRX3/II;2DMP'*<BS5\&66*80,
MD4Z:JO:H6\H6H)O=MRHZ(R2R2$7=J+O&Z;9OD^(.%E%(]HZ?2!B$1R)03-V+
M9BN*RP>U)&1.0Q@.4Q0!$WZ@-I748WF4<YP_PMTTCWR+U;.<!:I"TEBKFC%E
M0=94@HW!\#54$RJ%(8QDCEI<0P`"B0WUVSB9N:QR7RF`AYO'&V-/)R/E\IP^
M*4C6^8IS"V+'<*R&1-F]T\CC[T[8A3F.<C8YJ6T$06#O+MV"FB;*<8*J#I1D
M*8YM@0*`\1D48A5H)/K5=S*4LX3:F3I>5P<J8A>(%$)#%\N`B'A4B-![P-'4
M_>_&'`8YY?Y*D?LQWTAP!SR_R5(_9COI#@#GE_DJ1^S'?2'`'/+_`"5(_9CO
MI#@#GE_DJ1^S'?2'`'/+_)4C]F.^D.`.>7^2I'[,=](<`<\O\E2/V8[Z0X!!
M&OEP;J?BJ1_#Y4>^.]64>#3^D/4K3@%_/+_)4C]F.^D.`B/=$^W[F4VL/GYY
M6-?,MQHQY@#+QYM%-9K."1\DA%,'K`DPBPFR`DX4,@B[*=(CP$3IVN00'@*@
MPG2YT#0F6OE\9Q2`A<T5G,4R>27C=VT`EUW3C.QF,6:J&7W%<#X>_P`_Q\YV
MS-(``7Z9P3*510;PZ%QKY?EU/Q5(C[OE>VL=ZLH\$0[9#U![.`KCO1#[#;D9
M6TVZW1830Y4\PUQ+MFJ4W)8P13#4II-*4_'S.;C(1--T[2%LX2%R5V9NL8``
M"'`W`0/E6S_0UC>W>(X-D#)&,P!NEFIL79M<^*^C91=M.N,@G=16-RB0;Y#)
M8[-&7%LW<\PJ4^ND5-0=4O`>Z>-=#IIV+B4)8JCJ/F\80:P)-T7;F&=RL/#F
MDHI)XF;,5H^3%^A$%>.UE%%!>.B@"ZACNCIN`?&Q[7I>0RB8?[&/5)[+28I"
MEF`:96?(E6V)OLF;,HA5\5W-N@036#%T&;#6$#!'QR(H!HF%18+K<\O\E2/V
M8[Z0X"@LMM-T:[T/F6>3$0\D31>;R";0L[FLCBC0N=M=RYR4F"_5S)<HA3NI
M1SG4R^CSW-SD,*AFJ-!(4"AY9!#]'!\US5?+LBDG,^:4W)=9G!Y+N6[4BV<A
M*,V[W+BN8]_E`,F1HJ-9%"-%,Q3-&315NQ$&S99),-"2!Z%EVT@\=Y`O(>(N
M\8AGDA+[HR2KX%9MGD\B6,UW>6D=-6^5L9O(33(4*0$GDDFX,@5-4B(3YB1-
MA2[(0[:#%)[L5).(AW"S#O(F:,=(RLON:9W#':S3B;9'4+(Y^Y239E3.4BJA
MTTT@$AB@(0IA&R?0_NE*R[/`H=7),E<PK6<GI&`S66"3?8JIF,VC&B\59Y*D
MP"*'(8M^@P633373T%%FJI3^WB%FL+V"VMP(C0,>P>:3589F?/FCI[-JOW2.
M2#%R,(DX*JXGC5;(14LND"(@*:AU3KJ@HY446.#9V@Z3>GW8?,IG<':G:1UB
MF8Y"QDHJ9G4YV2DW3Z*EI1O./HM0LQE,B@2//,MBNB)$(4B2XG,0"BHI<%F.
M>7^2I'[,=](<!'2#Y<=W)$OA,B`#MU`U.(QMA;LLFDAN_&-WF$5%0:`/F)FI
M4UI3!(99!P:VL/)DN`E;C1GF7@U$P&MDC=J8N#`:E>U`]*^UWA0;<7T=G3GN
MKOP;J+S+'=SW>X"D_$9`=!KFC2/QRL;B\7BRL/X0T<D.$3+1[(@OBE6UUS`N
MD"H-5U$%0YT;M^A9V3W7>;Q8CMUF/4)M=DT!`;<A"S6/;F+8ZOD7AN*[ROL>
MQF;F86:$"0KW)LX1;2K@D<55:`:J1Q2#S;AV>[XV-"WD=>OE+Y<?C)ST^M;%
M$6RUQ=T?4MCK::UMDBG,TBUJQ-N(F8CJC?N[)[.)OQ/'/IS\.?V.0FROH=F'
MH4>H?;S?';+>F5WAZF=RL8W0VQV!Z;=PNH_;?:++-YYB0Q4Z\DGM>[<8D1E.
MY5C2C%FZ)&/Q3CI0JJ<>93FG+=)3W/[5>&^R7D/>^EXWWQ[GW/%^WMG)6F7:
MS^'C;UL43>)M^HQXMR<]<5Z1:D9]>MLV'):N2*]L6XUF]D\E36M?6PUOEB.8
MK&3MF?W3->.?CQ/28Z.T>7=)?2+@KO92#Z@,ME=LLUW,QB;>93BF=[U[72DM
M@3[5RO-W&0XMG,M'8"\'('&Z+QLQ<3BD4X9SPIM&RX"BT1TO%/.:GB=#S.UH
M^!V\GD/"X<]Z8-F^']/?8Q5M,4S6P3?).*<E8B_TYO:U8GBT\\PV6*V2V.ML
MM8IDF(F:Q//$_+GB.>/GPMATZO\`ISV=Q'J;V.VQS^'E\DF-VMX31V#O=P,'
MD\T?2L#M#B3!2!@80N6JR#EMCN(XU'IA5)%;0M<O`!47BX:I-T*P"1<C@6%&
M\%E0$<0QTVF88D%`$(8!`@@$J)`.;EBA[*E5TZCV*:8-O>V0<%VORW\3RB@`
MW9![4,6(F`)IJ0#%`\FG4H@D!NV@VJ%[*W`7L?8%8O[OTJS:M8F]^L\\1_=7
M]>(F>OIZ>O[.JOM?\O;^7Q@X\Z66=P:2!H=^8`R/#U:G:LWQ`Y?+X5;4T&\;
ME2H6`E>"G*`"5`.*[2T7*/'+!LP4FY/O5N.0T%,)`GMUL^0%%1A])4%,AW=,
M91$4I=502(BL('N*4;DCV@8+!,$K%?N#"2L1)$N%,!$QHVA+Q:@83VR)NQ+F
M3":E?O!Z5]KO"'S23D^_T>F,'+I@.SS\XK'&(T"BMFN-%.D)B2QU=9L#DQE`
M`@EM04M,8=,#A,!7[@UE8>2)=I5N-%^UZ@,KK[)(_P!YYL]UM?P=2V[VO4!$
MN]7.O&G&'DBB#D?-,6..8FHP-<8QR.7!$P1%<2F'42J*9@*8X"0J@+`D'%`'
MP>3"H`-!-%U"I2"(#23'M*)Q`?4J4?6J!S[B@CX/)C0![+HNHT*<0`*R8!41
M*`?NF#U*T`-(.`NI#R9K;Z`4T9Y]@.1`"W20![8*!0+6G:L2M`OL#)G[@M](
M>2/;J4M-%A?I@]$H$ODB=JW*$MNI^$)W4]LTP2@\7(\=J%B9!0W+HIVD"/*<
MX-U)DR9RJ*.4DSD<:)03#6,8HKDO(D`G-P"HS]P43@$1)'M%0`$IHRA[!=@4
M27211HKRQ1+6G8NG6GMFF`+]P`F`(B2-03``@:,H:TRP`);I(!H8$@$*T[%"
MUH-UH'/N*T\(DN^E;HRGL@"O](UI0:_N>OV<``_<"):Q$D6HEJ(FC*%N,@`B
M:V2'L("PB-*]B9J5\VX$<:\7*T03\)D2A<);A+'I%*!UVX"84S.&ARE3YHXF
M]J*(@@I0#53%0%A'[@UE8B2)?I5O-%^UZG(W7V21_O/-GNMN_!E;;O:M0,%?
MN#65AY,EVG4#&BQT[P9B8#V21_O7-'NMK^#J4K[7J`%D'`@41AY,MP$J!C1E
M27`W$0-;)"%4Q7,`TKVI'I4++P1OWJYVUHP\D%5F8C4L:K2CIL?M(1R\$;1&
M@B!!H)1&I0H<`6"_<``CX/)C0##0#1=1H540`*R8=IA3``K3M.6M`N$`#/W`
M`:D/)FM`]`*:,J>P'0@!;I(H54%N4"UI]^)6GME@9._<%OI$21[-2EAXOVS3
MYVVR^2)]^Y0EMUOX0G=3VW3`._<%OI$21[-6EAHOVS3YVVR^2)]^Y0EMU/PA
M.ZGMNF"-P\7YMH;PF1$41>"6A6!M6A')`!,^NH5(5`0*8+U$*@J0.T;RD!8+
M]P%?Q1)#03!4#1G;0R@`(5D@&A@3`0]8X5IVT`!^X$:>$20=H!431E.TQ0K_
M`$E6@`81_<`?5I4`K]P(E`8B2+42`(F-&4+<+<!$ULB8:)@N81I7L2/2HV7@
M%?N#65B)(EPI@-QHSVN\68&$]LD;L2YHXFMK^#J6U]KU`2)/%Q?K&\(D2BJS
MC!.)@C@T1,NH4R:B@.0*H9N#HQC@158`!$]``13U@5%?N#65AY,EVG6XT7YE
MX-!,![9(WWKF3@:E>U!2E?:]0`'[@:?B>3"H%$0$T7YMP("(#22$*D%80&E>
MU,U*A;<%7=^7"B\YB^HS=-+<HZ?:`Y%J-U>JW941`O+.7':4>P:T]:O`6UX`
MX"AFQ^;P[7H8V>-N'MOF!,`0Z7MN6N7N7\A@3..<8L.VD(PEG1UR;A-G:,>\
MC3G4`:I+@B;M*13S0!/M/+].H;NR^6[8;09^INA.&W&AYG(T'["1;R:N'92P
MB<ZBUY-]N.\QI53%,A=(M4TBG]S$7M;>U*B)@>^ZF*;@[Q+9]CF#YANOTZYL
M3&]K)/'-P<6+MQ*3L,^ALGS]Z07F/34ED^(Y7C,LF*C1[&OR6KI&,(:2A4E0
MW7@/*:?B/)5V_(:6#R&EVVK?!EF]:VK:..:WQS6^.]9XFMZSS$QZ3$S$X\M+
M9*=M+32WPF/]D])_<G3`XR.Q2+C<:@(Z3<,(*))%F<.I:+F)5X_:OG2<K(3T
MN:2,K*Y')20*N)%RL87"[U511414,;BAO[.QN;=]O9B(RY)[N(CMK$3'X8I7
MTK2*\12L=(K$1'2(2K$5KVU](_E_.V^<+X^XPK,$,ZB%/J2MBV0I9B#]S'I,
M1Q92(>%R`'BJ,HFLDU&)%8%#%,4Q25$!`>WBHDHN?:7H"?RTO/O,&Q7$IS*V
MKV.G8.<S$-K)H[#(/&&DC!R6`3F<8K+P$;D!$5[V!V#9!VDT2.5,Q$4C%#SA
ML!]'@QB\.RZ(A-LD(^-F\;E,/G?RDP0'=3F#3\^E"NF0N=P=>671GIEZ1?S%
M2OA$@+ZI$&^F#E=P'10ZR+,8^57C&>1-\JG=N<TCYW>5S!N'TM+>'[AR^V:[
M:9W,8)S>,MWN<H2J<(U!>(9/WZ@I))N#."\!LH/%.C)YD,BX8+XKE>6;A1S7
M%)->5WSB<SR#,49:3BUVS)09;=65?2LC+R6%-2)F(!EU?#02(-B9B<!"K[!?
M1QY#(S$DZV_?+NABR*31"&W*;LXF`B'!WL9+O(\DTDQ@\=EY%$WA+\R:+*9>
ME.FR4<K@H7@'YA</T),MPY3(,;Q5MBF<;2X@D$XED<ID.!M<%QB9A(F%/XQ$
M9MDD%`Q2IH>48MW!5D@<(BNCJ@502CP&\<[?]"2<F=R]B=L@=I-BI\D[W9Q0
M&C4)66;,U'J44MN6#-N_FI9LV:JN@2!9THW01$YA3(4`S(0G07.Y([RZ48;1
MKY2O&HFD)9]N7A323>PD&TA(*-=/P6W#;J2$)#,,6:(QRZI5&S9$IQ;&*5RL
M98&?M?T^]!+3-!B<7:8OG>X#@CQ./;O]U<7R6?90QHZ2B&>/P<;$9HF7PS&,
M?@7;)JDD@HZ9,FZFH?O.(='N==?)#_\`G8OZ2X`YUU\D/_YZ+^D>`.==?)#_
M`/GHOZ1X`YUU\D/_`.>B_I'@#G77R0__`)Z+^D>`.==?)#_^>B_I'@#G77R0
M_P#YZ+^D>`.==?)#_P#GHOZ1X`YUU\D/_P">B_I'@$$:\<@W4I$OQ]WRHU!6
M+[QE'@B';(AV@/9P&P!XZ$0#PE\%1[Q5BZ!ZXTD1&@<!6O(MUNGS.I-L,_,,
MWCG:QR^W`5=+9(U@8G'SX5E2N-23V<D_K%%PCMOCV9128+,7BJI$W:#5P9&G
M+*B%><6V/]'6DZ;97AN';9QDCDF4XX^2F87=&&C)65R=[.1V8XY#K&)N4A('
M<OI]HW?(Q!RA>Y"\&^H(\!T*C7CH&ZE(E^/N^5_ZV+]64>"(=LCZ@]G`5RWI
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MEXZ00(KE;3&7L_D^5N98I6I-5\Y:ZR()"T*)`#534ET/ESC+R9*[55RXRNZ\
MQED//Y[E;IJ8!=L$]RWW@DCF*L*=JQ=MT4$%&J0IMP9\O'B4C0R2((U&O0FD
MQ=/7I3.R23G&XF0=26=Y5)RS566CLFR!O#R@.\Q<S$`24AY"<=SS=P5L`-7;
M\\J4B:JU0L?MC&;0YCM9"Q>WL$XG]H)Y!6>A1-)NW))-P3-I#('$CSTK.>,+
MD4RA,[@ICJB4U``H"D(!P&_P+9+;7;+('^4X7@\Q&3LDRD8]X]<9(^EM5M+2
M;26D0!"7RA^V36=NX]J!E"D!32:I)@8"$`.`F#G77R0__GHOZ1X`YUU\D/\`
M^>B_I'@#G77R0_\`YZ+^D>`CM!ZZ'=R0`8E^`#MU!5/JQ=I;LLFDAN`)&[S$
MU#*#0!\Q,P!4XE*8)$*]=&MK#R)+@)4#*Q(V7@U$P&MDS`(I<P<#4K70/2M4
M]0,`^=B`#X-(A4"B("M$U*(E2$0&DF(5**@@-*A4AJ=EMP5'BNHK9K'.I/>#
M;3(MPL+Q_<`Z&T;1OATUG&"QN1NW4MBN1S$>W;0KG)R2@J.&*-Q=1%.^\EMP
M*$$P?G\])+Z'WI+]+'UW;'=7^)];#]BWVJQQ.:ZA]NMNMTX?,LB>[2;1R4D>
M&G]AEXK+7B^T4T;,F(1THZ;(\@15Z632(G)@H$A8U-7+O;>+2P<?7S9*TKS,
M1'=>8K',STB.9ZS/2'RUHK6;3Z1'+I7NZQZ1>JC.MO)Z0S_.?JULE@&2IY_+
MH[CR^+X]";7+PN2Y*C,RLT_S*$BQ7GY3"4F<XY?,GZTG&"JP?G(U4>%4WWF_
M:?E/`:F+=W;ZE\&7+?''T=G!GF+XXK-HO&*]YITO6:S/$6B>:S+%CSTRVFM8
MM$Q$3UB8]?WPT6V&%=">*Y7N[NWAN>XRIFS?J#W29X#&0V\L']7\GW(D]FW<
M2R@(S''6Z$]&Y!DLA%[DRKI$""S.J]RY5<S5"^QMS+,ZS;/9E$YAM'MCEF)F
M)DN,Y'M[B$Y`3L'*X[*Q,U$R./(O(^0C)-A-N(]\S?-R)'2525.D<KA,0-0%
M!("/>Y\[+M?EUL-(J4;L0"U:("X`FFI;@OE"4*)4BF[:#10O94#@7L?M_6M_
M>&E6UHK7OOUGGB/[J_RB9Z^GI_1U5]K_`)>W\OC!QYT=P\@T43PKLQ0R3#E?
M;6["1('+Y?"K`KRR$3EZH"EI:@*<D71H"@N&=HND..6#9@9%Z?>O<@AX*31*
M3;G9\I%3KPIB+`?(=WC'.0$I=10I415,!KBE,(I&M`0$@G"5RO70VUB)`EPD
MK<K%#9>+4#":V3-4$P<'$:5J"!Z5JGJ!#QI!X;?^/3-!R:9!V>D#BN=>%%,I
MU<UQHJB0E3ECK7MBN#F.(%$H@@>P3"*8*!,)7KHUE8>0)=IW7*Q(Z=_)W`>R
M3-71YD]UM:\NI;=5+4!$N[<G7C3C#OP$'(B)3&BSF3!1@:\PG(Y<$("(KF*8
M=1(1%,P%,<!(54%@/G?9^)I`*@`T%:)[*E((@-),0J43"`^N4?4H(@"^=T$?
M!I`:`(T!:)J-"G$`"LF`5$2@'?WF#U*B`!GSH+J0\B:@'H!58D+[0<"4"W29
M0`5!1*`5I05B5H`'$@!GKHM](>1/;J6VJQ(:EG.6V7R9*:W+$MNI3F$[J45T
MP3`Z<$>NU"Q+Y0W+H$`I#1A3G*@I,BF8%5'"*9B.!2+845SF)KD$Y$?;#<`J
M,]=%NI$2![=2@E5B@OL%T!1+?)E$-7ER"6M*:Y*THII@"]=`(TB)`U!,`""L
M4%P%,L`"%9(!H<$RB%:#10M:"!K0.==5IX0_[^_6BJ=]*_TE6E.W]SU^S@`'
MKH:5AY`M1*`U5BAM`10`1&DF/L`5,(TK][-2M27`BC73DC1NGX0^*%1"X!C$
MR%`ZS>IM,5V2@%(#DXC[241T#T`U4A5!:1ZZ-96'D$[M.ZY6)'3OY*Z^R3/7
M1YI2ZVZO+*6UJEJA@KUT:RL/(DNTZW*Q(Z=X,Q-=9)FKI<R>ZVM>74MK5+4`
M!\Z$"UAY$M0*(@*L3YHF!N(@:V3-VD%8P#2O:D:E0$EX(G[MTHUM&&?]J[(1
M`QHM4"T=-C]I".'PB)!]4$QH):W%"AP!:+YT%?Q/(#0##0%HFHB!5!``K)@%
M3"0`"O94X5[+A*`9\Z"ZD/(GM`]`*K$A?:#H2@6Z3*`"H*!`"M*"N2M`!02`
M&>NBWTAY$]NI;:K$AJ6<Y:!+Y,E!6Y8EMUM.83NMHKIAD[UT6^D1('MU+;58
MH-2SG+;;Y,E-;ED[;J4YA.ZVBNF"-RZ<"\:'\(?&%$7@D[8PPJC8X3`$CBNJ
M5+4*B4P7JMZE6(`B80.0@+!>N@$0"'D!`!$`$%HJ@@!E``0K)`-#`0!#UCAZ
MMP%`YUU7^B'X=H!76BJ=IBA7LDA&@`81\M`'U:`(!7KH;:Q$@6X2`(BK%#9<
M+<#":V3,(@F"QA&E>Q(U*B)+P"O71K*P\@2[3K<K$C9?R=UUDF:NCS)[K:UY
M=2VZJ6H"-)TYY]8XP[\NJSC;Q$T8`I"*R@'354!P4%#-P=',8"++@`(GM`HF
M3UP6%>NC65AY$EVG4#*Q(V7@T$P&LDS5%+F#@:VM=`]M:IZ@8!\Z$`_$TB%0
M*(@*T3YMQ41$!MDS!4@JF`:5[4S4J`DN"KF_*ZJTYB^JS<-*91T^T!<[0XGK
MU6[*B-O*N7(!:/8-:>MP%M>`.`H;L1FK9CT.;/K[C[:S;?;]ETO[=I98X?36
M$K,'F*EVVA&4DN=-KE8.09OHDYEC$/I*%0,)1`%0L$-CM/NGL,IN1D<'M7@,
MJKNA*&S^4G&QI_&G4R]3QW,8S%,Z53>RN=OTR,(_*6#5H!$CD;BFS3*W`6Z*
M=`WNZ&#YEO:KN!B<1D^[W3UE!L:VLDL?W`VVR7"$<R@)&&RC<!^W=D:O%LKQ
M#(8&0`IVCZ+EFCIJ[;G.!D@,"2I-UX#RV'PODJ[NSIZN_K=MJWP;%;3CO6T<
M3UI:MZ6CI-;X[5M68Z3QS$X\N.<E.V+6K;YQZ_[)_=*=L&CHO&(R-QO%HQ8\
M/CT0G")":;:S#T7,6]=,Y!28EEWSEW*SZ[]%120=.%5':[TZIUS&6,<1H;VQ
ML[>U?:V^F?+/=/3MCBW6O;6(B*TBO$4K6(K%>(K$5B$JQ%:]M?2#CR(K"3QZ
M>CLG@@=8V_A95GD#5XJT6:.H1RP<(RK5RBFN8ZJ#AB=0ARAWE,(<5$E+,,P_
MHFW2GYV"QG$V.>S[S&UWTZ:9FLJGG3^"G83`Y^1F',OEF0+B\?R\'E..G>O=
M8SYPD5HBNH861$VX:3;S'N@#)'+"<V\)B<BYG7<0SC9AON5/)?6>1R7*LL;Q
M$>TDY;-$$LHD<CSK`Y9SRY%'*SN9CC/%"F=`DL(.:3AN@B8?9.^?M-AUY',3
M9`GE[DF<8(DZR%Q+/\F?9$ZGN7RL@R#]X\?20+.5P,L<@"D!Q332(4-%MSA7
M09ME+A(8_+;9R&<,7K-[)9;D>[>+9!FCV9;Y)"2[21F7[O,#F4E39%*Q8`;2
M3,H86:(@)4T2$!Q0^&]$N0O?"H=#!Y*6DDI5)U#([KE/+2#1A'FFW<-,11\^
M!Z]CL,9IJ/F4<Z3.WQU1-5PT2:JD4.4-2GC_`$%RXR4,E^3O+7F\*N.XE(M2
M[I$S2=S1[,OL=F((IEASF8F59:5D,7BWBDB4Y'*RK%!9=<3)E,`-9]MAZ.1=
MU*S4@UVFD6X+QSU6&_*G$/H9A-,Y[)C#+16--,V4;HY1.3<Q)-'BR*)GDCK*
MM5+R+JIJ@ZIS&N@"?8*QDW%;-.V4FMCLFZ1/FN.-SMG$HR2'%'KQ5OEB+F$<
M2+6-3(Q.<R!U#D(1.IS``A/T)TY[,8QE6.YGCNTL=#9'B()EQV0C))RS0C2H
M8^\Q1`4HQ*83BUM+'7RC0FJ@<2I"%*"0@E"<^<??)+CX2Q^,<`<X^^27'PEC
M\8X`YQ]\DN/A+'XQP!SC[Y)<?"6/QC@#G'WR2X^$L?C'`'./ODEQ\)8_&.`.
M<??)+CX2Q^,<`<X^^27'PEC\8X`YQ]\DN/A+'XQP""-=O0;J4BG`^[Y4?PIC
MWC*/!$/PCU!X!?SC[Y)<?"6/QC@*V9UM]T_X^]37S3"`BWN[,XG@:+EK(3R!
MYC),JRM3.D$TW<)*IHX[.2F8LTW*4KJ,W`.TFR1'`"1NF`5\Q_;3T=[7-#,\
M=)M>;(XSZN."0[+=>)=$:2,[F^/,<=<MCES99<TL_P`PVVC6";9-<UAF9&^B
M4KDY5PZ#QKM[RZE(IP/N^5_VECWC*/*_[1Z@\!5#=O.^D3.,OD-L]X7N)N<N
MBGB^'2,1D,VICJC1PU@<!W"=0:TN:3A6@-74#N+"+*!S'+O4GYVU5;':)`:D
MEA_0Y&8'CT>K"8H7;>.Q/=Y3'DL>RZ4D,6/B;=S&S.[QDU,6R=VQD4F"R+4R
MX*BJNBF0J;8`3*)`#Q71Z&VN5E@G,+CL=D&-9/$P#>"5DIV-B/K)A4-(R#6,
MCXH9=OB\Z3'8W#UG#TJ";EJ@X9IG=B#D41,#EV6E^EN1R65#8A@5;,&&+Q#J
M43(ZRE-=CB<_DC,60G:Y4]%NS\64@VID*)D74BVK"T>1*Q#@+8Y'EK/$<>G\
MLR1NM%X]B\)+9'/21SI.BL(:#8.).3>"V9&<O''+LFISV))G.:E"@(CP%7WF
MYW1WNE+2DC*3>UT[.)2L%C;YU,9)C47*K2#!D]#'X]J:3F8YV^02;9VY*@9O
MJ-S*/%2W"<AP($>9`?H32S;),CR;'(GZWL'^X3?(I261RX[5-XW2FU,T9BLN
MY-`.$RB_EE&:"%Z1EAD#QY15!T(!J6<EZ/CDYUPSQC%6I5\@@<<RU^E%9$PG
M9+)FL')9$*69/0,ADLI*-,=>/S9&[DS*&(T,\1F%;`<)@%DMN<ZV>QK:R#S3
M`U08;//-/P.85=R;OFY/,L^=16JH>;<.IU=::S.5$FHX,/GK@(B"?:4$DAU@
M;#QKZ)C5,M.Z>3TU)8]!EC(N2E&TS,PL_-8O-,(J18-5XR17B)S'G:+D$5C@
MD"93C[6LB=0'9CW4/M?E.*1.;0TX"V-SLO#P,0]<$!BN]E,ARAEA<$@G&/3M
MY0B,ME$DW9HKG1*W%14MQREJ(!]!U&;-CD4QB1]PL+0R2`?.HR7AW>9XBR=M
M)%@W;.I%A1Y.()KO(Q!VF+I-,QS-A-:J!3`(`$N\X\^UBUSE^U.5TRM,'J&+
M5<!H8.T*@'`1T@[??E<D0\(<`4=NX$!/S<?YMV6329JDYF\;$E#J#0*43$/9
M"4!"0RO7X@2Z&<D$P)W`+N/&P3@T$X#:Y&ND*Z@#2M=`U*W$N#`/9`0"L,Y"
MH%$0YN/[!$J(F`:.N\HJ&#R#8/E"H<[L@Z/=D-X.J+=O=7=O!9C(9>`DMA,M
M@UW^:2R,7$O,&Q3*$(PJ;$F:&8,81B\<&>JL46K!DX?@#I=)PK<L(,3%<9]'
MCLWB^59KM=NKB,`ADNV:FVL9/R>^#W+\5B87J0CV>68:+*.DLMFV3!',H+!X
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ML1U&]'&RVS&WVS^+;M;;8_![-;7M\>-`_79)V7&XO;%K%8S/L#/9N>FI)P>&
MD7+5(J:SUVZ52=)J$,LF!U2\BSI3R+?#;?>;9[<68V@RF`W,B\??QN/S4AB<
M[%/F$?,J_5^?+&KOQ<%:`]+"S#-P=(#B=(')2'`JI3D+V/V_BEO>&E7):*4[
M[]9B9X_NK_"L3/6>G2.G/,]%?:_Y>W'\NL)JSH[QY!)(GA5#%#),.5#6*R?$
MJAE\*J13ER0N5&`4S)@<%.4+HTU-=J).92XY8-J"?R9MZMQRJ0#M$A=NMGRI
MK&D(E0%RGR'=P5%`22>&51!`RQRB!P`3:0B6H&+4)6*]?B)+H=R4#"G<(NH\
M;`.+,#B-KD:Z0+J"-*UT#4K<2X(?,^DS;_1Y#P+I-(=GGYA<C(1)B@JKFN,E
M6;Z!'8N+FI%U#&/;88$#`41$Q`,$P$>OS670SDEVE=5W'CIW@QU+K7(W:/,J
MUI6O+&I6].X$:[I^=>,.,,L`E=#<4SE@8Z8*L#7G*8H."AHF6.4P@HB(Z8VF
M,!BD."L'L@(`(PSD!$`J'-QXT$2IB(=CJ@VB80_Z(^H(5#(O7]!_$SD:`-`Y
MN/[:%.(!^%=XB4`_Z0>0:`&>OP`U(9R82WV@#N/"^TKH2`%70`&H**8!6E-8
M*TM/:`=Z_+?;#.3VZMH`[CPU+`?64N=!;K"V2I6E.8+6EJEH)0<OB/7BA8A8
MXBW13(4KAB4YR('FC)'%0X)EM<&33`A=902:X"8B=#B8%1GK\+Z0[D]HJ6B#
MJ/"\""\`@A<Y"FJ#=,0K2FN6M+3V@"]?@(@$.Y,`":@@Z8!=0RP%'M<@(`<$
MRCZVH%>XU`SSK^O]#N>^E>:C^P+@"OX3W4[?+P&`>OQ$M8=R%1+4>:CQMN,@
M!A&CD1&P%3B-._3&G>6H(XQR^(T;IC#K$`#"43%<,"D*4R[<#&LM9&H0KA01
M#1*(Z!J5N()P6$>OS670[E.[2OJZCS:=_(ZE;7(W:/,JUI6O+&I6].X`CU^:
MRZ&<DN!.ZKN/'3O!E>`VN1NT1<JUI6O+FI6XEP`/7X@41AG)1$""("[CQM$P
M-A,`T<B`Z8K'`:=^D-/9%J")^ZD%&MO@J]169#0[F/.4!!TV.-P%!Z/F#7M!
M,:"6M2]AP!:+U^`"(0SD1`#"`<W'@(B!51``JZH%PD*'_3#R#0`SU^`&$L,Y
M/:![0!W'@)Q*#L2`%SH`#4%!,`K2FN6M+3V@'>ORWVP[D]NK;1U'EU+.>TZ7
M.0MUN62I6E.9+6EBEH!WK\M]L.Y/;JV4=1X:EG/:=+G(6ZW+)4K2G,EK2Q2T
M$;ER^%XT,$.L;1YP2"+AB)E!L<ID!(1*J">H1$AJF50[%@`;A`Q0!8+U^`B`
M0[D0`3``\U'A<`&5`!"KD!"X"%'M^[#U0&@9YQ]6G@[D`J';S3#L`3$`1_":
M]@&$?^CY:<`%>OQ$H##N2@(D`1%U'C:!C-@.(VN1$=,%CB-*UTAI[(M0P1Z_
M-9=#N27"E=5U'CIWBR`XC:Y&[1!RJ(TK7ES4K<G<"-%T_P#$%3C#K%UF48*@
M\PP$R)A7.55-4P`34%N5RH;S5E@HB:A2B<FJ"PCU^:RZ&<DNT[JNX\;+P9B>
MMKD:Z0N%0&E:\N:GLB7``]?B!:PSD*@6H<W'C;<5`3`-'5!L%4X#3OTQIWEJ
M%7=^%G"TYBXKLE&E,HZ?;046;JB>O5;LJ(TT%5+;1[.VE?4X"VW`'`4)V(S<
M\9T-[0OMQ-LGY<`C.E_;WZTF<S6.RC>1Q-#;:%:R*HQ\:^<O%V\A#"9<Z(D*
M<J)C%-[8%@@AVHSSI[?[T9$IMEM,Z1WJ52SM&<=KS3%&7D6\%EB$'E"1W4GD
M+AHX2:3#4"L2C0J<>F(L[69R:@2!N;M[D&^R^?8<O+[M[&S1L;VLE(/.=I]P
M8''\^QV3A<GW`?LI*.>IIY#C<G&N1*=J\C)=D^8O&ZARJMS5(<FY\#YC_(O(
MUWYU=3<Q=MJWP[./ZF*];1Q,3$36]9CUK?'>EZVB)BWK$X\N/ZM.WNM6?G$\
M3'\OE/1.N#,8G'(N-QO$(I,L#C<0GCK1%&>2F%6ZD(]=1KU"1E7+IX]DIE-Z
MV4YY=RLJ[5>:IG!S+BH(T=[/M[.W?:W>?U.6>^>:]OYNL3%8B(BO$QV16(K%
M>(K$5X2K%:U[:^D'F]DEVK)XY>QAR,VS1RX=&!<BX@V00.JM:@U(LX6.*9!`
M"D(8QA[`#BHDIOM:]Z4<PW&3<;98RF;.('#&#MJ];K95"))[?GQ3`W#2/12D
MG+"/5Q`L'E<,<8\Z0LN=.H<4A>(N3)@RL'RGH#RIKL[%8#"8",1&3>&K[-!#
M1LSCN/MYR"S'<QQ@X0#KDXJ*540SF'R4[4ASG3/("<3`*BZ&H'C'P7H](^()
MCI'.T[Q!JY!RZ6D=QS/Y9RZ:F528J3$LO.FD72+)W&(FB4UU!;-W31@:/*15
M&/$H>:^.>CC=24JDNCLBM,&?OU)Q(-P$C2AI64D\80DC2Q$Y_FS2,A./H\BP
MK`*JKYTJ!JK*N[@<./P?1'D.;8Q*XFK@;;*(:`R^!;8SCV;I1:#N+?8UEI\@
M:Y)CS"21;29X+'<DR(R`N0,#,7<D9'VU)<4@2X:?H%B)+;-OMXAM6XF8_(8E
MIMRWQ')E)63-+Y7*-):/"QA(N7#]@O-@V=J<_J-&KY-N=73<$0H#<7@_1MIX
MXI$BQV4<0<9..IX[%OF(.EPR-[(HQC@#"E,'?N9)Y+P:*'*&,83+I(AI^<D)
M@/`/1T@B9!TWVB?FD127?KN,S;'<MC9YD619RS"1Y660+$KSV033X$T0(DJ.
MH#42`D0B10Z.BZD`$0"*,(`-`$KQM0:>J%PE&@^N`#P&.;D/DD_PQK_&X`YN
M0^23_#&O\;@#FY#Y)/\`#&O\;@#FY#Y)/\,:_P`;@#FY#Y)/\,:_QN`.;D/D
MD_PQK_&X`YN0^23_``QK_&X`YN0^23_#&O\`&X`YN0^23_#&O\;@$$:ZD`;J
M?BHP^[Y4>QZU[QDW@B'?Z@C3@%_-R'R2?X8U_C<!$VZ4C@+=SMJIN7`KKG4W
M,QIK@9Q\5=LFVX3DS@N+K/S0Y3L&Q?$"E*V4D:-"OQ0,%%@2,4*AP$;Z-A7+
MY&&Q.+Z=TLQ),XQD4F.+9%CS:3<SDWG016/)NW\%(D6?+NMP81%,[$YSIE?@
M@*R0&.F)@Z#1KJ0Y=3\5''W?*_[:U[QE'@B'>'</9P%&-RISH6E=Y<DAMT8+
M`4-X/%B8]D\G.IOH:4,\A-N\*R,K5[DA"L43QBNWNYD>W44!<6;UFN[9J&53
M;/DD@>>1;D=(V'[>,)R00PP^W*L!N*I%O8-NO.P2L*BRBL5W":MEH1N];IBY
M82;1FH@8Q%'*)PT2G(4YB@RG66="DAF2*\MC&`N\N^M,<2`?S\`[74=91!0$
MK-*/L'?2[`[0RL?#02IY=Y&&*D*@()OU#+K-R'!T[)9-TRS.3RC?8['#L\M8
M8M%/Y$B[3*X=5MBV09*Q<-R)MLJ(@BF>3Y%BN`))@KX66-N$&H,2`%I<[FXB
M)P?,Y;-XB[#(O$\CDLN(I61(?&&,,]=3R9H]@DY?/P4BDE2Z**9U%:VE`1'@
M*+X._P#1UG<N#8C%[/1*D=,'QDC11^2%:*S,O$LTE5(R-?KMF+YZ^A9LC91^
M@F=3E`.D=4$$3@0%<[F_0Q%[AY:;(H6+:9TDGN+]922;/,P3E&YG<@OFB;9F
MNF,-/M)*2Q^16;$:)KIKN8QTHU#42,;@-4URWH-%M,F'$6]$)J"Q>;))PV>.
M)9I(1D/*92\9/6C]%:;8QD)'$E%\F4,0C+5"1+)F45,\*8+!XIDVQZVR<9/P
ML0D78^6<QQF*<DE..U%YJ<W-59M5Y!G()/,B*Y=Y^\*HHH[`!0.?46%-,AQ(
M%=L<W7Z`L9R9"5Q3$<<ALB649/$HZ'Q.98,X\9G(\WA$I@^.)L4,=@G"LK-S
M1S*F;H.C%D1H!CNDB*!(VW\ST=,L75S;$L1Q:,:(S#6*6DG[!VKG#IRQW*Q-
MXP6<DDBO<Z?1;/<9]"KBLL!F[!P*',"@")BIAH,@P7H.SG>`^W<G';9S&]>1
M2^4OW&+-<\*YRM64@';+(LPAW$0WG%_"SF(^.NNP!%&K9=VJD0I1<*`%^^;D
M?DD_PUK_`!N`CM!U(#NW(@,2<"CMW`U/SS3S;LLFDSA8`W&L0.=2H=@Z=O>8
M.`D(KR2&RZ(.6X$[@YYJ-EP,Q4#L'SA3%=4.SOT!I[,O``/)(0"L.<!$"U#G
MF@T$2HB8*@/;:)S!Z]GKAP$08@]EAW=WE`\"HF0C#;+25\4CU.8K"SQE*)$-
MJ-Q25"SS_9UN#LX"IVZVVWH\H%>(V5W788/CLJ[9;*X)#X2]W`RJ+FACEG&?
M0>RT*FK&9*A(,FN0(P&0QJ:QUDRR#'GFKQ11N=8A@Y#=9'29Z._T@6W,#T08
MEN3A.(;<-.H=]NIC..X-O>CA@)R<5@.:)9!CF`QF5167-&"&1;J[V03U-,D6
MFV>.)OW$HHD8B0^I^,U=/R?B?$>*RZVQGU/TV[L9HT]>E\]::^>;9=G+DFDY
M)PXJ6[<TQ;MQX:4F8B*<Q1O:U,F2\3$6YK$=T].L=(B.>.9^'SG][E[T7]`?
MHHN@_J)VXZP]G^H0LGF>TT;N-,PL)EW63TC2C679Y=M+NU@ZL8[QQ;(\1E&4
MBJUG43E37<I+ME*)J$$Z2VITGEO8WVTU=7:UM#S.&WF*5FF+OS9)Q1EC)BB9
MM;'I3&2LU[JUFEHI-LD9(OV1$1BQ[.Y:U9MCGZ?K/2.>.)^=NG^[CU?I"C<=
M]&+C&VFV6Z6Y)HC`V_4+LTXSF%0R3=_<LL=D.+YW'8W*2<M"0K#/9?'(F2$B
MD2>*5CP3?L6C%#D#IH1%6GC'EO'7\1Y//XO)EP9LNOEMCM?#?ZF*TUGB9QY(
MB(O3F.EZ_AM'XJS-9B9V&.\9*1>(F(F.>)Z3_&/@DN/S[H7V=@L\V0V`RO#D
M,[S?*H+'E,$BLVR#*)::R>!9Q,:@@Q=SK^?23CHN#BBF<N45RL$W`JZJG-&5
M`>B^W]*W]X:<6M%*Q]6TSQ,\1CP9<END=9_#6>D=9^#%M=->W\/Z9B'0W/%'
MSB"224B"B3ZR8<>JJK1T6J67PRB9P1&(G:&`Q"F`^@`I>S!5`2ZR?&K!MP3Z
M6-O5N.52!413+MUL^5)896/5!P0^0[N"JH"*8ZK?0,JH6A^T^E4O88.`E8KN
M1$271)R@84[QYUJ-@&%F!Q[!\[3!=4>SOT.SV9>`A\SV6-O]'D/`G32'9Y\8
M7(RD><`55S7&BN$.6*;7$6I%E37TL/HB`=IB\!+Y'DD:R^(.2[2O]W-3:=X,
M=2M!\[1%PM6GLN7&GLR\`B<.I(SB,,,.("#H;P%ZU,9,%(\VH8H@BJ`Z1E5"
MCYZ0FT^P1`P%$%H/).@?B<X"(`(ASS3L$2IB(=@]M!,8/^CZX<`"\DJ"(1!Q
M$`$0#GFO:(%.(!41H%3%`/\`I>L/`!GDD`&MB#F$`4M#GFH7B4'0D#M'S=04
M4P[>[5[?8FX`.\DBWVQ!SVZMGNYJ6^P'VF':/FZPMT>_V/,!7V!N`2`YD2O7
MIRQ%YN71(0`>-2F431/-&0.8YD2`4%SII@!14.)-:HE):83`L.[D@OMB#GM%
M2SW:U+>!1>`F/:/FZH()#V]VN%?8&X`%W(@)J1!S4$U!YUJ%P`98"CVF[+RI
MD'UM3UAX`!W(U_HDP!6E>=:]UP!7O\G;P`#N1$2UB#@`B6H\ZU&T!%N!AH`]
MMH*''U]/_E!P"&+<R)6C<AHBP+A`1(\:V%*9=L!S`4$&HT(5=4::91'0'OO*
M(@N(\DC:=\0<EVE?[N:FT[^0U:VCYVCS*W=[+EQI[,G`8(\DC671!R7:5X"^
M:FT[P9:@>:/G:0N%N[V7+C3V9>`"O)(0+=#G*(@2X.>:#:)BMA,'8;ML%50.
MSOTNSV0<`BD'4D=K3P8>U9D-#O6@E`>::F&OM#KV(B/;8/:6M2]A@!:+R2`!
MI$'$0`P@'/-0J(%5$H5$>RXQ"AZU_K#P`9Y)`!K8@YQ`%+0YYJ6\2@[$@=H^
M;J"BD';W:W;[$W`!WDD6^R(.>W5L]W-2ZEG/Z=*CYNMRZ/?['F`K[`W`9.[D
MBWVQ!SVZME'S4NI8+[3I</FZW+H]_L>8"OL#<`B<N9'G&A@B1-I\[8(O&M5!
M`CDA`((H*:>H1),PU.E0%:><)3!P"T7<D`C2(.(`)@`>=:A4`,J!1[^RX"%'
MUK_6'@`'<C4*Q)@[0J/.M>P+B@(]_;0HB/[W`!7<B(ENB3E`1)</.M1M`PM@
M./8/;I@JH/9WZ79[(O`!'<D:RZ(.2X4K_=S4VG>+'4'L'SM('"W=[+EQI[,O
M`(D74EX@L8T1:"C*+%00>M1,D8RYRJIG$$27\N5PJ;L4.`@B-`*)RW`L*\DA
M`ET0<EP)WASS4U@F!D*@=@^=I"NL'9WZ`T]F7@`'DD(%K#G*(@01#GF@VB)4
M!,%0-VV&4.'KZ?\`R@X"KN^ZSE6<Q?F&8M*91T^VU<(KWUZK=E1,'M0C;:/9
MV]_J<!;?@#@*$[#YI+0W0[L]*9YMM&FP6)Z8MO%<C(\R0LZC)8FVVWA4'IUH
M>)QN4=O$Y"&JLHV!(]$S&((B(4,'EM#N;LQE&Z,ZYVGVJQAWN,U'-6$QDD?*
MNR',;ZRHM<BCQR1[C96`GEY+'-5HCK%%PQC#'0+RZ10X![;F[7RV_P`OGN#9
M"^W$V?D#XYM9,0F:[/[IGQ;/\9EH/*,_?QLS!S["+<L3%.H"B#EC(-'C%VW.
M<BR"A3A;NO`>;R>`\C7R&/!J[5.VU+8MC'&7#DI:.)K:L\3'PF+4M6]9B)K:
M&/+CC+3LF;5_;$\3">,'9P\#&1N/83&QI,:QF'2QF-;,IY6229!CSQS#N&"T
M@Y([=O7[)TS.DZ5755<&<E4%8YE;QXH;^7<V-N^SO]WZO+/?:9B*\]\=T3$1
M$1$3$Q-8B(B*\=L1'"58K%8K7\L=#Q>R#QJR>.G<:ERK9HY<.;72[HPH((G5
M6`C9I'.'+@YDR"`$3(<YQ[``1&G%1)3K:_(.E[.MQ4AV\P?'B9O`X>QGH^4-
M$SN/&0P93$\$4:DCE)&%8VXN6"RZ*3%IID9B[!8NF+ELYTP:.W6Z_0YFA=LV
M>!0FV;.):2&,-]GWR.,3&'XT\EVV799%8U$86\<XC$1[MRAF;^3T&Y?:E'SH
MYR`=43B4$T>X]'W&PY,;;);&K1[!T=XJF_G)*6?"Z5,Y:,W4K+2<:\E7@*N$
MTBQ1W2YR&<`P%C57D!X#X<.?1WNI"29.&G3NXE$'[XLPT-)@J^1E'\EBS"4+
M)MPB1<$D'DRYCT'(*AJJ.U%B'JH+L.`<$"?HGRW-,:E,=;;5?7"$@<MA8Z'A
MLBE8EN2%?XSEBN4,)['(IFVQR90:8])Y""1GR+DJ`FE`:&!0CNT$N'9-T)MI
M#;1CMXPV5>2[/((AKMNUQ$'+Z1:RV5239TT7;F8P!U$V0S3ENLY6=&Y9I(:&
ML*;K0#@&ZO(>CG2QM2+\*Z>',#$3CF9+&MU0<`3)7<@G$."IE"$%0\LZDXE!
MN=N)KA,5N!B@4Z(F`,\]'D"1T'$?L2_+(BDI(JO9523<-#9WDF1YR1*2<.HY
MPZ9K3V52[\RC8!U066%NHF5,@)D"?<TZQ-E\!RJ5P:?R$ILNA(EYD$IC\-%Y
M7/O6<!&SC'&I*;5&'Q=XV)'1\Z^!HH85`,+A,Z9"G4*!1!4KU?[$M(V`F9/<
M3$H2&R?'%\HA):>D96&CW<<TDAB';4[B1@&Y6<XVD2BD,<MIO3"4PD2,!3"`
M?$?U@;'RD8_FVF<8Z:$BE,?0DYE1Y)IQC1UE'UK+!LP>'@P2?O7J^%OT=%J+
MA4BZ94S%`Y@+P&ZG.J79#&I=.`G]TMMHF:60C7*$8\RZQXY;S#*$DHE5JD6*
M,+D)*.R1BX0!.X5$7`'`+2G$H:TG5]T\J-9-\GO+M0HRATW2LB[3SA$[9`&2
MZ[=P0JQ8P4W"Y#MQ,5)(3J'2,10I3)J)G,$RXGFK'.()IDN*&CYJ"?*ODF4F
MRDC':.P8/W,>JLU5.Q)KM55FIC)*E`4UDA*H03$,`B#CYB4^3$/G$/BG`',2
MGR8A\XA\4X`YB4^3$/G$/BG`',2GR8A\XA\4X!!'.)/EU*1J`AS\K_VB'>,F
M\$0_!/4'@%_,2GR8A\XA\4X")]T9?"8YWMHMN+C+9^JYW*QV-P9RLA)RC6*S
MV1YAOC3QTM'Q3EM%@=^)4F[AW:@1Z=`0$%`(8H5,A,D]'1)9:_QS&&73`ME3
M6:QC(9`F,G@DWJV13><!CT$9T\AH(BKJ14SJ)01615,8I'8MQ7*`G3$0OY&N
M)/EU*1J-.?E>^1#O\4>5_P!D[@'@*/[D9[T3.]XLCQ7='&ML`W82F$X+)9/)
MH!TC*&<8_M_A.9(`_P`F#&Q%>%)@VX[-,%N8,S6;>(-CF,FT?D2#:YYNCTG1
MVWD`YF,7Q7)=NITN2EQY?$<:G,AB0=1)HU*719+0&,'/$2*IF#84C@*!C$;D
M6*<J1"J<`WR;A]#S+)V$8MA^U+2>1GX2$Q0\ABICM'LSA6-R3]BKM^^7Q9:,
M<M\4@8`R;A]%G!LB)FR*BHG<-B*`[ME,WZ=,CR648;+88QALI8XO%2D@/@60
M8NLEC<]DS-\FW1)/PL<4ZDB/(O%"($,<L>M&BH)4A9D`+1YU/1\#A&93F8Q#
M=?$87%,BELI0,*\L"^.1L.\>3:(Q36-=.9+6C$52\NFFH=:M@%$1IP%'L(SK
MT?CARY7Q2'V+A5H^5-B*1/"_!&KB0DXMFNN$4W/C*+%X9Q#S0$7=I%$Y6952
MJG!ND>T-YEF;=&N-Y_DB.4X;@Y<\A_RER^1&?8Q..WZ*IF4.;.G)2N<7.#U:
M>:3!00,U*J#X#.N7$U7`F!K--R>B%-K+I_D\@$",YG'L;F&<EA65'DFKO'XB
M1RA=-U&N\:6EF\+B#..DE9YP*16)'*$@1T=587)3!/\`BV:[.J;+1N61&.Q[
M?9F1<1Q6D:_C)MP/C$ON6M&-U9*!7A'TTW=JYVZ*JN9VB4S50PK.!2*F<Q`K
M6\W$]'\K+I,H[%-M\PR#*9IS"KM<?9/IB0EG),QR_$72TF[<1J#=Y'2DQ@TD
MTN56.66B6:*:97+`S,APEC`<KZ3)'&664XOA.WS`F134="D8O(:_.C+Y;N!B
M6&18R</X(_RF-Q]WFC*$:ZCDJ3*.%JV36Y8&NFB'TGG_`$60N\&23BS;8G'=
MXV$X]\<S"0:,8/(W601C`S:65;Y<[QIJ:5>1[)THU<JH.5`[5D!,82+$*%TN
M9DQ[2QR!BCVE,$A0#!Z@@!F8&`!#R@`\!':#B3_*W(@,8B`#MW`W&"2*(E`<
MLFB'H3E`$UK<YU*U"HD`OVU2A(17,L-ET6@41!.^DD!K!,#,5`#W&%VF*JP!
MW7:(=U_F@`YEJ`(Q:`"(%J'B0#01*B)@KR@5M,<X>O8`_;=@1!B#N9'=W>4#
M0K<A2L-LM)7QDBFO6%GS'JD#`IF^DJ`$[1->`W!3NX"'>J?;7I4?-(O=_JDP
MB%49XS-8(RC\O?26=F+$R4+,Y2;"AD`P@E[2'CI3,GRB[AXF$<B1X=1X<$D2
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M^WM'Q&/!Y#QN_P".V]3:RY*QBULN;)DP3CI@R3&6,^OKV[+_`*B(Q7K%ZWG'
MEKWS;%:9LX,MLDS2];UM6(ZS$1$\S,=.)GY=8_;'S31O)E7HLMO(&?W<C)';
M^%R7%]QS,VD['9#N>,-'Y[LD_B8:82/&(MWV)MF&-&E4D%5S-0C5IJ2,*:JD
MJN*A_OL"<<>[].,D]L6^M3GB;<?4ULV.9B(F.9[;3Q\(GKQ/'!M<_I[<?L_H
MF)=6G^91NX&V^*9KBW*3&(Y@MMOE.-S%[A`LG"3<_CTK"ORQTM!E?-1>-7"1
MP(L@DNC?4=,Y:AQT3$QS'I*P^8%W-&WKW'*K"MT4R[=;/@DL$R185TS9#NX*
MJ@HE8$,W%$ZBI0*)C7Z8#4`/V?1*Q7,J-ET8@6NG?22`UEPLP4I[D"[3!580
M[KM$.Z_S0A\SN9-O['E4AFZ:7Y'WQA<!,D.(*J9KC17*(-N0*<0;D56,"EU%
M-("T*)ZE"8".98;+XM`EVEJ4D@-9<#'5I[D+?I:R].Z[0+W:GF`A<.947$6)
MHML4W-&N#Q,HB0#1YA5$H\@-XIG44+V"2X$P&M#T`%H.9:@5BT`$0"H>)`-!
M$J8B%>3"M#&,'KV@/J]@`N9:@TBT!&@T#Q(`J-IQ`/P3LJ8"A_TO6[0R9S+`
M!K8MN80`XE`9("W"4'0I@(\F-MXII`/?;JCWV><`=S+!?9%H'IJZ=9("7V@^
MTJ^Y#6:HHH5[[=<W?I^>",'$H#YZ)8MN8X-T"IAXB4HJ))GFS-SF-R-2"NHF
MD`EJ8":HC]H-X+#.94+[(M`P`*EE9("W@47FF(^Y!MU`21$>^W6'OT_.`%S*
MU-2,0$`$UH^(@%P`9<"C3E!I<4B8^M>/W/:!S,K\F(=]/Z1#NN`*_@GW/;_Z
M.``<RHTK&(!42W?C(!H`F;@80]R=MI3J#ZE=,`^V[`0Q;B4Y-N`Q;<I;A`1+
M(E$"D%=N!S``,4@$2%56&E`J*(!_UE2@N(YEALOBT"7:5])(#67<AJT]QA?I
M:[BG==H%[M3S`".98;+XM`E=*^DD!K+@8ZM/<@7Z0K+T[KM`O=J>8&"N980+
M=%H%$0)<'B0&M$0;"<`'E`NL%14`\NF'=?YH(I%Q+"T&L4V$=9D-#21;:\TV
M$0J+!0/-,(@`V^I7LKV`M%S+4&D6@(T-0/$@"H@542@(\H-+C%('JTN'R=H9
M,YE@OMBT#4U+*R0%NM!V*=?<8VZ@I(@/?;K#WV><`=S+!?9%H'IJV5D@)?:#
M[2K[D-9JBBWKWVZYN_3\\`[F5"^R+0/35LK)`6^WGM*ON0;-71;U[[=<W?I^
M>"%TXE.=9B$6W-:+W2$9$I1.($<E3"@L3B34332,/G!;J"';9YP+A<RM1I&(
M"%1I^,0"H`94"B(<IV5*4@^M<(>IV@<S*U#\6(4J%1\1#NN(`C3E.VA1$?WJ
M>KP`5S*B);HQ`H")+A\1`;0$6P'&G*!=85140\ND'=?YH!',J-E\6@2NE?22
M`UEPLM6GN0M^D"R].Z[1+W:GF`B0<2HR"]\6W)>RBQ5$)(IA3,9<X+$#W`05
M`0*JL(#=0^D%`+J=@+"N980)=%H%J"=X!)`:P3`RU0#W(%VF*R].Z[1#NU/-
M`*YEA`MT6@41`EWXR`:")4!.`>XPK88Z@>I73#[KL"KV_"KM2<Q?FFA&PAE'
M3[;8Z!Q=7JMV5N`:(I6VC^[7@+;<`<!0K8S,,CQ[H:V?G,RV\Q1[A4+TO[=/
M)YJOE<S.>)XLTVUA`>@Y@XS;:67=<Y"E,HLV*FL4H"9,3&`+A#.RNX>V>4YY
M*N=I=G]LF.9+*;H)/9Z*DYV)7E`Q/+,3C,X4\:/M.T;+HN)O)HY9N158BJ[5
M7613!$U3`\=SMHG/4*XSW;_.5,IVY46QS:N9A\KV?W<R3$,\QB7@<IS^1B)_
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ML-_>A=EE,9-,5-HXS*FB#)K!2A83+(Q^HT7A4XYC$8^N;;M`[UBK"L&Q2,FM
MZ"@+LQ*0QW38500(Y_T0QT-(9OC&VFUC]3;1_MI+EC\2Q-6/DXB8-E41B.WK
MV"1<8A!P#A[!9+DK9$KEJZ,FQ,K>90H4$00H9[T!X_#FQ,F-[/F1A)&8![#.
MHS()J299`R(NV?,YR:?X:^2"7*HX!-H9Z_TSJ`@=JH8"('*"8=Q_1\/VIWCS
M$MD".%6A9R0CGN//CRK1G.J,@<RDHW1PERFF1T>"2!T?4.<RQ10/<X7%)4-J
MXW+Z$W&X$$]0C]M5,NQ:)FX!B7'V^<-H=M&9;`ODWT/)P\/AC;'LC<2T%EKX
M&K59L^<IHO7RB)$R<V<H9<;O=$6W++::<B<)VL2@3Y'-M<#RO&X,B,3B3V+D
M,45EYM>0>XS%O&D0#O.HI^5TW(Z(LBN1^F!DDM<@(66?>CME,=:1S''NGUYC
M:$FXR)FU2QB849DE%UHUF]DT2#MQ4532IF,:N8*E"55:QYZ/%4&Y@L7B6Q'3
MMFF(P^40VRFW<M`9I#FR!B\GX1^,F^C,PGI/<)R=VAE>.I9`R\4G\G=/%V[A
M-%2]P9,Y`(`)E!_2FQ&U<W+O<@F=H=NI:?D))I+N9R2:(/9@7S!Z$FR40DW,
M*H]9HMI.KHB*)TT0='.M9J*',8,K[$[5.L::8<YV=VT<XPP3TV$(XC62S%B4
M'KN1*+--6",+4Z;]\LL0Q!*8BBIA*("(\`HCME-L8@'Q(O:#;1@G)2L5./4&
ML5'HMUIB#*]"'D@;DQ\$$G<8:3='1.0I135=+'"AU5#&#QR#8O:O*UD'&2;.
M[:3*[6/+$H*OXQBNHG&$1AFR<>!A@:F9IM<>9(E3&I"HMRI@`$J403EV`V?)
M#+8\39+:DD(N>95/&E@XHK4JF0LW,=-*($#'0%L>0CG:C<XIB000$$PH0I2@
M$BX[`-\2BDH/&\>AXB(;KOG*#!I).BMT59%ZXD'>D0\8?33.Z='$I"B!$RB!
M"`4A2E`-YJROO%A\YK_17`&K*^\6'SFO]%<`:LK[Q8?.:_T5P!JROO%A\YK_
M`$5P""-5E.74HR8B'/RO?)+AV^*/*A_18]@#P"_5E?>+#YS7^BN`B#=3(<.A
MY/:E+/L4C)E[-;EQ$1@3IPFYD&4!FZT?)KPTL]D#PYFD$45&PMVSA4;CR*[9
M)$IG"B0<!4"!W;]'?D&6/\6QJ-Z:WN3,)W&)N0)C\(AK#DLSG)<6B%G3N*P(
MJBDHCFT>V2=:P@5!91L=<0*<AN`Z'QJLKRZE&+'\/E>^37#M\4>5_P"RQ[*\
M!1+<[>#HS+O)D^#;HX7MNMNDSE48C(Y3(\.=O)!8^/;?87GS5X\R!OA;]ZYQ
MY##,]3*FZ$YF@I,Y5%02HL7M@;#-]SNDIGA^-Y].8=@TSC#B&S>+Q.2@L9R%
M<PL@D<3CLEQV/*WPEB>.<Y%)N(@&S=44`D!2172$R2.J0-(3>?H]:90PCD=L
M<&%WXM#,XC(@P,QL7;KX9"B$#*P^0K8?X6S:0Z)6T;'K-Q(HY=NVK9H58RA0
M`'ILAN/L%EV32D9L_MU'8KDS/%XN7>.5,;?XDHIC\UD[&2Y%LH]@F0O57'.L
M)!RFW!4&[1['<P*9C((D"U&>3[7&\&S/(LLAF;_%H#$\CFLD8I&<S"CV!BH=
MZ^EV:<26'4-)G=1Z"A`;@4PK":P`&M.`H?A.\W02_=N'6*8QLM$JLY4^'-UT
ML-?1K-X[>1362=$BE&6WJD>X1\'ES&=K@)3HLTUSKB1JD8_`.O-=[^EYOGN5
MI9UMQ!JYA@SC*FTW-2N#R<@F=ZY@7C:1192Q<1<I3,EE&.XW((M2%$[A5M'N
M"&!(BB7,`QX[>_HF593:3/;'$Q+$9##XIDD8I@LFM(14GAK"7FY%&28GQ-9P
MG&[>%QV3"96+<V*[;.DP%TJH8%0L5B^?[3GV2CLUC,0CHO:)ZXCT$L<?PLGJ
M,I>3W,5A"JR^-)X\_D(]VEFSD'#OF$"JLCW+.=(4E!(#6V+W(Z:=VLI.KM)M
MQ@R4]$QN0RZ&0-,'1Q\Y4GLBD&1(-Y<V(LG!'DJWS=M)N$#"51=G.HK*%$RZ
MI2!/L%M!MYC")$8#:K;N*`BC=0%6L>R*[$[.<:9*RO>F@3/%"LI^/;O$`,H(
M(KMTCD`HI)V@T)[ICV/R>2?3,YLCML]F).34EY&7Y?EI5\^7?H2;I1W(M(I!
MXNB]>H7.$3'%%<JBI%"&(LL4X3SJROO%A\YK_17`1T@K*_E<D0%BP`OY.H&X
MP2:XB%<LFBGM+X4%UK<RAP[0J<I2=@&$Y`D0JTN(%N81X"()W@64<&M$0:Z@
M%K$DOL$ZUM;;M,E::@Z8`+2]`JPCP&A;@"5<"`#:E<`#X0%0`PG`![*@4H]E
MP@4(?Q!>;'=[>4#1D:4A6&V6B<)EP85:PL\)[R>"%T;%:%"ACW%&[L'S>`WN
MYFU^+[P0++&-QL-B,I@XS(X'+X^.=9#-L$D<EQ1^>7QJ4U8EJS<"O%RK9NNF
M!C&3*KY]IA2)<'/W?/I:Z.-OXW;+(-Q]B]M$]IX1SNY&YNA-,I/.HR1BLQQ#
M.)24=93$.\2S#(LE='FD0>%D@6%[&N';I8AA*=43AR+])MT7^B3](MO9']5'
M4+O"9Z^9;>2>T&/&Q]COUR;*(V0RG<`^0+*!@<0S;"F_R?,V[=BLNB<LFY7;
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M8^-K-T?2#>@ZR/",LBHG(>F`)R8R[\H!I*+ZC.GIG*N<S,]<@YGFPM]PWK5J
MHJFES)&J#4&;=V=-RW11<(-ER>;>R/:/MW'[LT\]_<'A;8HO>>R*>3MZXK1$
M=-?'>>.Z/7+$])[IMQ,3;V<^:<%HC%DYX]?P?/\`?/\`4Z_[/=7W2_GW2CCF
MY&RDQC;/ITPO+XW;?'\GQB;)G^%1<;M6V9Y++N"95@!LRA0Q^"@(!9%=^YD*
M`^1.U,91Z=%!QY;YSP^MX7/BP:F]I[^#)@C)&37G)-:\VO3Z=XRX\62F2O9S
M-;4C\-J6B9BT+V+).2)FU;5F)XXGC^?I,QPU27I&>E2!W6E9B?W)9PT7GN";
M.1>(NWN-[F(GE)Q3-MV8=QBKMHOMVW6@LVCGZCG7A78IR*+9@Y<JI)HMW)T-
M*R.EFK*W``LF%MQ`$P2;@1`HF:@<P%&*"HE*=80"H5%,@5#4$4PATR\T._\`
M'E4C(TB/Y'GYC+$F7!S@J;-<:!RF"`PJ8"5%,ZYB'O#4%,@"4FH84PF`JLN-
ME["/+73U+91P>VO):MM8DE^F*CBVMMVDG6W5-I`A<+2_,1=S".`PN3`8`E5Q
MM`6!A5L$8H@J"0QE0`*><!"B-MXV`N!:7[*L(^M`K25<#0;25`!\("H`83`'
M=4``>RH@``K2]!HPCZT&@#*N``1M/0!'P@:`)@*'=V`(CZE!`,M+T-:PCQ$`
M/9=*."W"!7(IW"$2:T#F(D`]]H*&'ML`#@&5EPOL81YJ:FG=*."74YS2NI$G
MLU!3;W4NMU3TNTBZH)`5E0?/+&+`QP;(`0II-8H&2*I-"V.<P1AS)F6.1(#E
MM$"`H<0,?3`#@L,K+!?8Q8&`-2RZ4<%N`!=Z5U(D]EX$0N[[=4_?IAJ!@59:
MHT8,!"IK:RBX"(`98""(!$FM$Q2IB(=M!,8.VT!,&=66K^`L*5[_`!1Q6E?)
MX3WV]O?W]GK\!@%I:H7,&`!4MPA*+C0!%$#B`#%%N$I3*"'=6PO=<-@(8M:5
M%FWJQC[1$:F+*+'$"BNW`Y@`(NTQBE.N(!=VBD0!$-0VF"XBLL-E["/+73U+
M91P>RO):ME8DFIIZCBVMMVDG6W5-I`%5EQLO81Y:Z=]LHX/;4&>K;6))?8*C
MBVMMVD2MNH;2`!:7\VYA'A4"74E'!@*(E;B<"UB2W6F,J`=U;"CV7C8""16E
MP:"(L8X!UF5?QLN`5YIM4+AB2]EPB`>J(`'94:`"\5I>@T81XC0U`&4<!4;5
M+0$?"1H`F`@"/J`81[;0`P!EI>AK6$>(@![`-*."W"`.M,#"$2:R\Q$0&EUH
M*''MTP!0`ZLN%]C"/-34T[I1P2X0YW1OI$GLU!3;W4NMU5*7:1=4`ZLL%]C&
M/-34LNE'!+J<[HW4B3V:FFWNI=;JJ4NTBZH(72TJ#UE:Q8#07NE646+>()N`
M(!P\,J2Y,J0C0#VB<P=H$`3@O%66J-&+`0J-!&4<`(A<I:(AX2-!$H$$>^@F
M$.VT!,!JRU>UBPI4/^U'`C2XM1IX2':!1$:>4`#U:@&"JRPB6Y@P`*DN$)1<
MU`$6X*"4!B2W"4IU1"M+K"]UXV`%5EALO81Y:Z=]LHX/;7D]6VL22_3!1Q;6
MV[2)6W4-I`B16EAD7`&8QX59Q@JVRJYQ3,990%@(`Q91.5,IUQ*(@2\4B!YN
MH;2!:567&R]A'EKIWVRC@UHB#35MK$DOL%1>VMMVD2MNH.F&`6EQ`+F$>`T+
M<`2K@:")41.`#X2%0*8R@!W5`A1[+A`@5=WY.[/.8OS3=N@(91T^VZ#I1R!J
M]5NRMU14:-1+0?W:AY.`MKP!P%#]C<QRC$^AG9[)<JP'$);$L?Z7MN).78%R
MV;F5I3&V&VD&H[(XA2;9.B+G=0Q#'6;>WI@813$QRU4X#.RW4!B&<YW*XKM=
MM)M]&SQ'.Y#V1EHV96A4UWD1DL#%9;(/#([8-)PB>62)&3I)TX;$)(I-D3J&
M`X(%$'AN=LRAU$N<^V]W-:2>*M5L<VJF8J?VJW7S'$\WQF<@<GW`D8+),5SC
M'H7%IR!F63M-0HZ=R2B(F25*JDLHF&Z\!Y[=]N>1KY+0K@ODBEJ6IFQ4S8LE
M+QQ:F3'DB:VK,?..8F(F)B8B6/+BKFIV6YB/G$\3$_LF%A<=@TL30BL7QN$A
MHF`QW&8B$A(IF\<H,XR(BRF81S!JF,>J)$&C1L1,H"(C0O:/&KV=C/M[%]O9
MM-]G+>;6M/K:UIYF9_;,SRG$16(K7I$-O-"NI#RZ<K"Q<I&'BY`LC%J*KR*<
MDQ,T6!U'J1YX=4CY-Z@)DS(B0X*`:VTU:#A?5-=NMS.F_=3.VT%`;/8.RRJ-
MPN.SZ%DLFPR(@E%<2''<,>LY6#<.,7/)BS9L<X;L2G*D1$KID\;D,/*&J#<V
MPZPND_-5L-)AT#C$"RW#>8XSV[E9'#7F/QN9RCS/%<>@VD)RN&K/VZS'.(!L
M8BKUNS027,T634$QB&*'HVW_`.B1EXV5K#;1-0D9)*3R(4ML\J1(]E)IZV39
M2,P?\CY2.74_(.FA6:RHF,_5>LP0%07;75#7AO[T'-Y7(V?A&Q[:65%;'LJ#
M\G$^W<+C'2T3%NH>67_)$GKA&S$BW361.80;JHJB<"\HX%$''MUEG1=N#DC/
M"\,VWV47R+)R*%"&:[8KM0=<G'S#\H.'Y]L&N/*-13PZ0(W<<V9LY6BW1&RB
MRC=0H!;D^`8JI'J1*FW6WYXI5NJT5C#QD<:/4:+##F6:J,S8X+8[=4<>CQ,0
M2B4PL6]0]I3M!DPG3SLSCCI5]";';21[Q:71G>92@(HRR,JVC6L.V=,U%<;4
M,PY6-9)))$0TTTP+4I0$1$0EF/9KQ+)K&14-!QL:Q1(V9,&+I1HS9MD@M2;M
M6R$.FB@@D4*%(0H%*'8`<`LU);WG'?.3GZ*X`U);WG'?.3GZ*X`U);WG'?.3
MGZ*X`U);WG'?.3GZ*X`U);WG'?.3GZ*X`U);WG'?.3GZ*X`U);WG'?.3GZ*X
M`U);WG'?.3GZ*X`U);WG'?.3GZ*X`U);WG'?.3GZ*X!!&J2O+J4:1XAS\KWR
M+D.WQ1Y4/Z+'L`>`7ZDM[SCOG)S]%<`S\V3BD897*<LQ2#GF^`IO<VC]5N:<
MDHN0@8YXY"2Q]LI!KKISB3;4(@9"B]QZ$&H\!2W(]]>B+$\PP#`LDQK9*'SC
M<R3V_P`CQ?&5\+*6:7D-P#MW>#Y*^*CMV9NV6D)-)!`KL5CF3?6)F,!@&T+Y
MQJDMRZE&D=_2$KWR+D.WQ1Y7_LL>X>`HIN;U$])$;O+DVVNZ."X.ON'%2B3#
M()3)<$+.F7"`V^PW<>-EW,DUPZ<E74`ACF9&(U=G3,BDI$2P'TDF*J@AN<TZ
MBNGIAA&.O5-M8W/\-RQIEPQ$5C&#+RQE$87PAO/)K8A-8G#339J^!RTJY!D+
M(4]`ZZR2:C8R@:5MOCTT2$^D>'V7Q696B9J`;1^4Q6+8DK'V0>-R4A#9-`/%
M(]"3DX#%L;A%#-W3)NJ9%J5,[4AT;3@#IV0W>V2S_)92*VKVJCL(R-MC$9-.
MI%3$X[%#.X21R9A)*1#21CXHHR2I#S3&3>MT#JIM"RK07.FY4%%,+3YWD2>*
MX/F>3Y)"MI3'L;Q/(Y^=BVAU)1U)0\/#/9&2CV\8O&D1D%GK-L=(J)Q`JHFM
M'L'@*)X/U+]#TXY7>XUBFUD4Y;RRF'M'R6V\@F21%2(;3CHL9)06VD@T-$I1
MLHHJZ%15(6Z*2ZRY"-RZI@=;W>/IGA)G.'[W9[%F4UC+[=V1G),,#8*N9E_"
MRT%#[COXZ0;8PL>1DLNE,C`#%6,B[DRHNE5R`F%Z@1]&]371V9#(F3+9C&VR
MD%.X_`Y1$EV[A$UFCO&8R8F1=NM&".QD8S;0,2?HN%D5EP0>,C(L@<J*(@J%
MDL9W.VW-LI&[A16!-(';!PXC6"6$J8Z6/<Q$M(;FJ8S=)XFUA5$HERSR]QS3
MP%$RJM#`==8"J$/0(4A>JKIMPP@YGM_M=$(P<HXFX-]N)@4+BD?#)(1&XF98
MO,#/22",7*Q,(ID>&R[]%=\@@U=MFQG"9C&\T`MEM!O'';U8N\RK%HI=BT83
M\ACSQA/.>2E6KUBW8O2B[8H-72S$7;"20<)I+@DOHJD,)``Q:A*FI+>\X[YR
M<_17`&I+>\X[YR<_17`1T@I+?E<D*M(ZS\G4%<(2+D3!7+)HI[2^%`!K6PJ&
M"HA4Y2E[`,)RA(A5)@;;F<:41!.^V3=&M$0:ZMM8DEP%,9>VM+@(2M+S:88!
M29H%6<8`T+<`2;H0`:)7``C$A4`,)P`:!4"E'LN$"A#^(*SGY7MY;F,0!`8;
M9:`EEGICG_$L\)]8@PA"I6K4`MICU+VC0?-$)@%28H:UG&"-#V@,FZ`!$`7L
M`PA$FM`PE2KWT`QN^T+P@#<N*/E,YM!C$[C^-9!B\]D.X;";BI5^NY:2C=QM
MEN*T"-=M#Q$@W<Q[QNX`C@#*#:!S4(>P"F#3.^CCIL<HG0-TZ;06ER'+<L0.
ME')L7">29DP>1D]-(NV<(1TR?R3%!DG>D?W(!""A:+)L)@H7Z0CT*72SZ1B9
MV<=[T8/C:\#L)M_(;=;7XLTFMS<<BL7@WCDI]"-3VUS?;Q(C06<-%(%;N$W:
M;4C<01$I2F!QU'AM_P!IZ^G.'SWCMK:V_J]U<F';C7_!,5CZ=J6U\\3Q,3,6
MCMG\<Q//%9KAR5SS;G%>M:\>DUYZ_/UAS`W"_93/1R8EA\[D,7M7C?.QJ:*C
M45L_ZG`(`+R0MA$P&W[=EN!LX3H`D.%P"';;<IW_`+&\C]NLGNO3I'BO*T_%
M;\4>0PVF.,5O[,Z-8GF8Z_BCB+3,>D0J;--N,%OQTG_Z)^?_`)G2S:KIPZ*_
M1K[)X1T5N(6'0PJ,S7)=_P#;Z'R&"W,GL-QYI-R+?#<Z2;YKE\KD;1Q).XC*
M95)RUDLA,L+&962!LJ@=!JX\Q\WM>$VL^*?!:F73U:88K:,F?Z]\F3NO,Y)O
M]/%6O-9K2*5I%8BD3UM:TS=QUR5B?JVBUN?A''$?+UG^LST=R?17Q^[><XYF
M6#;81>`;:8?B.%Q.191MED,9M?MXECF6[J9#FCU7,Y/;>&B86"7RC'7A7<Z]
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MN#*LI7"\]QR$RS&Y-526CEWD).LHU^T<*1TG!,W[-86[E>J2Z:2A3)D`P%%0
M^D#F<*R^O&7-8TAS.1`2!)N1`0%@8RUHC'HBH*9A5M"PUP$*(@6X13!8"DQV
M59QG<%:2;KL&U.M!\)"H`83`'E``'LJ(``*DQ0:,XRM!H`R;JE;3TJ/A/8`F
M`H=W8`B/J``@&4F/.M9Q@]A[+I-T6H@#G3N$(DUH&,5&ZE;0.>E;"@<,F4F`
MOL91IJ:FG=)NBW4YS1OI$GLO$C>ZEUNHI2[3+J@E!64YUX";:..H#9"U,TDX
M(72U)GE3G$K%4Q#KG(B!PT@`@&/:=73`#`J,I+^?8SC1H*EETDZ+<`"[TKP"
M*-8)P(A=2MHJ*4NTRZ@`J3%1M9QHA4UM9)T`B%5K!$`BAH(E!,1#MH)C!VV@
M)@SJ2]?P..I7O\2<UI<%>SPH.VWM[^_L]?@,`I,=ES.-`*ENI).AH%4+Q`!B
MBU$"F4IW5$I>ZX1("*,5E3,VX\K'&((C4X2;@QK=9N"A@`&"Y3&*!EZ!J"`B
MFG42ZAM(%I%)<;-1G&EKIZEDFZ/;7DM:RL22^R]S;6V[33K;J&T@"J3`V7LH
MTM=/4MDW1K:@SU;*Q)+[!.XMK;=IIUMU#:08!28\VYG&`-"74DG1J"(-[[:Q
M);@*8RH!6E0(0>R\0("*05EP:B)FL83VYE40E'(``BZ;5`!&/;UJ81`/."O9
MV#6W@%HJ3%!HSC!&AJ5DG0`(VJV@(A$C0!,!`$?4`3#VT`#!DRDP`&M9QHB`
M'LNDW10,(%=:=U(D]H&,5"ZE;0.>E;"@H`=28"^QE&FIJ:=\FZ)<(<[HWTB3
MV7B1O=2ZW44I=IEU0#J2X7V,XTU-33ODG1+J<[HWTB3V7V-[J76ZBE+M,NJ"
M)RK*@\9@#:.`:O-$II-P75$$W-@*!R)1+[45(PVD6M,<X=Q`,<%HJ2]1HSC1
M"HTK).@$0N4MJ'A0T$2@01[Z"(AVT`3`:DO7\#C0"H5_&3H1I<6H_P!%!V@6
MHT\H`'JU``JDO4MS.-`*DOMDG0B`"+?4MK%%N$I3*VUI<)"5I>(D`*I+C9>S
MC2UT[[9-T:VO)ZUE8DE]@'<6UMNTTZVZAM($:*LL,@N!FL=7DHP5BEDW)A3,
M9=0%M,HL*G(4HKV&%-*\4R`(^>;1!8528$"7LXTHB"=]LFZ,!1$&FK96))>!
M!.O;6V[33K;J&TPP"DQ0+F<8`T+=23="`"((7@`C$A4"F,H`=U0*4>RX0(%7
M=^3/#3F+\VBV1'ZT=/MH-G*KD!_^JW96ZX56C6VANZE:AY.`MKP!P%#=A\NS
M3#>A[9W*\HQ/"I?%<:Z8=NIB3CV,Y/R+R3QR-VUA%UDE(Q?"SHJ.%H5,3K(B
M*J>I<2X2#J`'AL_OOA>X&Y4G%[:[1[<Q&9+GW':O<M(?P==^KA^40Z&3-WKU
MO@;3*"$R%]/(RC4SI!,D@B(KCY]0X"S&-+9@IN/F(S,?C+5Q]3,``J<7,2T@
MD*036XVD<RKN"C#%4,83@8H$$``"B!A$1``?I32WBZOM,;=X:W[.9==W-.:=
MO*4[^`4O7<FS9/'BS-HX2:-'+E1NU4<KN7!$$3JB@@B+4H*K+`2TI?5$>`IS
MMCO7L%N/N(C#8[MEC<#F*&),=R8>:R/%H*`?N\?6Q+!!1F(9X6-7ESG;PN6M
MHO4(4"@>,=MBG%-J%P1;M[U<](>Y61[9!CFV$2DKGRL4YVWRZ2VRCV[-9S!9
M&_QF!<I.&<,_G\;+$Y"F1%FY=-6J2`OD%$U"IJW\!O&/4%T,Q,,2"80>V;6"
MAWJBA8XFTF5A&L'V0"XBR/!*KM?RY7>5#/%035J*K\)=$M3@\)>'FXZE^A'Q
M"1BW4=M/SL0]?,)!)UM/D)"M7[.0QF$DVIUG&UY4!79/C,47(`8=$(\XJ"4C
M,YDP?>`[O=+.YFZ.!CB<'ARNZL4TG6^$/B83DC!_"I2L-D:LT2,GC8:RA46L
MHRQN:;$<D="@Z,Q?)MU%!!0IPN==,?R,;\)=?%.`+IC^1C?A+KXIP!=,?R,;
M\)=?%.`+IC^1C?A+KXIP!=,?R,;\)=?%.`+IC^1C?A+KXIP!=,?R,;\)=?%.
M`+IC^1C?A+KXIP!=,?R,;\)=?%.`+IC^1C?A+KXIP!=,?R,;\)=?%.`+IC^1
MC?A+KXIP!=,?R,;\)=?%.`01II?EU*(QH^[Y7_:70=OB;R[_`&3[JO`+[IC^
M1C?A+KXIP&DR68<0..9!.RL>V?1<+"2TM(LF8+OG;QC','#QVT:LCMBD=N'*
M")B$2$0`YC`7U>`IYEW5CTIXWG6VN&9>?"FNX^X<9M\UQ&#?8E*NYQICNX:1
MRX49V^)AR[&.@'+I;DQL='1;NE=,P%"\2A<^--+\NI1&-_#Y7_:77?XH\K_L
M@_;<!1_<GJFZ7H'>#)-J=S\2@3YM#2R+.>D9W!DY]H<D)@6%[FQ,^HY:P<W+
M.(-&(RM0K-V9`=%U`RM02(SU%`1;F=472[!8QCN79#MU%9OCTI$9&A!K,]ND
M7SY-NK(L(YQC[>!RR!A)XJN9/T$0100:G1<D125<"FF9N8X>).LWIIA\OB(E
MMA*+22RI_'1,+DL?B<4,?,M(V"12B)()!@W/)I0;1O+L8Q@HX12UE)1NDT*H
MDH)@![;*;W;0;EY+*P^V>V#;"<A;8Q%S;J3=XM!X]S\0]R=I(JP[64@B./$U
MFRN0M)1Z@FHHFT/+HZ]CM19),+1YSD9L1PG,<KG8I"5A,8Q3(LAF(M@4\@^D
MXR%AWDD_CV;%TDW;/'3UJV,DFDH<I#F,`&&@CP%'L)ZN^C7)73A_!0F'QSQ&
M3/B#.0+MM)JGE&_AC7(78Q\GC^$RJ/@3-E(K+N@651Y=-!PLHF5,`4.#[R_J
M0V4P#(\I@IO;<&KYE)[AJ3SUOB3`&DSD\)`8W,Y"T;NCLD5)S(\OQR03<-ZE
M%1\RC7"BQB)-[N`BN*ZN.E`4<B:QVT,>S/`SV/0F2QB.!8FAR[G&8Z7EBR)U
M6Q#1,K&[;*8<\;Z[9=P)'S,B,:#E0Z`'"QF+[KX`?9:,W*BL%)`;;N%XV+3P
M;ZN-(Y_"23_<I3$CA)8RU;^'Q:K#*7`N7H>S;@"BIPU""`@U-KNH#8#J,R^:
MP'$L3@,B>1S>?RTSV:Q>/5@993!]PY;"Y&69*NF*CE1VTR>06<MG"R"9U"/S
MG((+"Z32"U,'CS;&&:D=C6-XICT>JZ7?*,8-JG$LU'KH0,Z>*-F$:W0.Z<B4
M!44$MYQ#M$>`W-TQ_(QOPEU\4X`NF/Y&-^$NOBG`1T@:8_*Y(U1C+/R=P-U'
M+O4__BR:!2T.4L$`;"H(5$!U`*'L1$Q0D,IINA;T(L!HG?:Z=B`#1IJVU9A<
M`&%>VM*@5.M+C6@`::H%4(NM"W4=.Q`!M2OI5F%0`PJ4[J@!?*-`A_$#3_Y7
M=Y;D(33Y#;+0L=R`J_T+/ZG,@=B"9?;J`6P3>9VC0>S@)@$TU0UJ,77S[*NG
M8`(VN-.ZC0:5,"5:5H`G[Z!<$*9<>?'.]BA1)!K-_K7G=ZBCR1Y@S@-N<]!H
M5$")OT=&I4P6$RPF)4UI?-`O`36<TUY]B$6/WW3O=.PK3G]&^C,U+K6MU*TN
M5I6TEX!S353V(18A533O=.P$0J]T;Z,QM$0*WNI6ERE*VEO"+=[33@[89:"2
M,.`Z#*T5W3ZRSQIM2\$F9CWBD"?=4+A-Z@`(]C]O_I_ZPTOJ]WT^^_/;QS_A
M7XXYF(]>.>OIS\5?:Y_3VX]?]\&CO!LQM=F+TN<YWMAMGD.4NF.-;9.,ER&+
M82,B\P*:SJ.5=8.]<23W&P?8W)/))4RL>H[51<'7.4&CPR@M5^.6'-/>G<CT
M2FX4YOSL#NQM'@WC4PPW28[SHMMHIJ'G,G@=O)&$;Y_'H99!8LTFG\=EBN!K
M-D2,'B9Y0(9T)3$-14P.KIJW+Z;LLVNWZA-N6L'NSMSA^/;*=/\`.;+/=KGV
MU^/X[C60Y=EL+CF"N6LZ:2BWQ8!_GTG#R!&S-!JS-!@DBD40N-['G\Q@^Z.S
MX_VO@P?Y;7!.YM9,ULD[$3-='!.7MQQCQ36(IXZ)QU[K3WY)BUYB(F-?&.=*
MM\\SW\]M8CCC^U/'7F?C?K^Y"&;XHBUW\QCJ&WI'I\0Z,E(;<[!T>F=ETDPV
MZV]K3>39;']PDIG'&NXV,XO(0'U-7P#9B45@%'$2UGGR3=G$(B511-=#A?>'
MMC+[2\S_`)7;+^HU[:VMGQYHI;'7)CVM;#M4XK;K%JUS5I>(F8B\6XF8XF;.
MOFC/C[^.)YF)CGGB:VFO_9T77P[TB/1MB$IM/L;ACX<?2R-3:?!ML\>QS#LA
M'%"'W`8XD;'H*)EHV%&`!''&.61XR1R*BBSY]J!CF.=P#;EF=T.7/,@O&7DB
MR',Y$#$*[=VJ!X>8RP$J5N)Q3/JB4!36J4I1$I:F,F"P#3=`JA%UH%:.G=*V
MIUI[C#LNN_>`/*-`!--T&B$76@TJZ=TK:>E?<?==;7UA'R!4`QIJAK48L1H>
MRYT[`!-:ZT[A!H-`$P(W4K0#'I6TMP!S37GV(18_?=*]T[+6@/M&^C,UMPE;
M74K2Y6E;2W@E`\QSCP$R1AE`;HB1(SIT4I$M2:Y0YP`%1`ZQR(`I1%,`"^AU
M;"@`*C&FO/L0BQ"JFG<Z=A4*O-*^C,:")0;W4K03*4K:6X,B:9J-J$92IK:N
MG0#2Y:RM&8T$2@G7R")N^@5`NF:_>8RE??+NM+@]3E.^W_T\!@#350N1BP"I
M+J.G8B`7(7TJT"H@45:>40+Y1H".-/+BT;C;&*IB8:J%=.C")-=OJ"6O.@)B
ME%Q3VTP")$_8W&`@+"&FO,O0BP^]:ECIV-*\AK659EK;<ZMK2MJ5:7'L`*::
M\R]"+#[UJ6NG8TJ#+6LJS+6T3.;:TK:G6EQK`"FFJ%N0BP&A+K73L0`;6VI;
M5F%0`PK4[J@!*]YK01/SS(-:F)%I>W,@$_-NP`!%TV`0K:R$;C"(`&H%0IYI
MJV""T33=!HA%5H-*NG=*VJV@-&8]EP$KZPF\@5`,::H:Q&+$?;++G3L`'S7>
ME=1H-*F!"ZE:`92E;2W`'--4/IH18C[;IWNG8`-.>T;[69J7"5M=2M+E:5M)
M>`<TUY^FA%C]]T[W3L*TY[1OM9FMNM;74K2Y6E;27@C<GEP>-``L841%[H)B
MZ=%UA`CG3U`#2I:D"0FHDO0QCTM`H&,"T33-1HC&4J:E73JMMRMM0Y3OM`E?
M7$WD"H8`TU4*HQ=*A6CIW6EQ:T]R=X%N_?IP&2FF:EO1C`"I+[7+H1`+FVI;
M5H%1`HK4KWB!*TJ:T,$-->9J(Q8?>M2QT[&E19:UES0+K0,YMK2MJ=:7&L!(
MB>8\05`Q(L?<489=,KMT(I*&7."XIE$IKB&3U[#"BB)A(F`B:IM(%9337F7H
M18?>]2UT[&@T9:ME685H(N+:TJ!4ZTN-:`!IJA;D(NM"W4=.Q"MJ%]M685`#
M"K3R@!>ZHT"KN_`O1G,7YPC0@_6CI]L!LJLK4?TK=E;[Q512H%W=2OK\!;;@
M#@*%;#Y9G^%=#NS^7Y!CN$S6/8OTP;>3CJ+BWTR\?RL#&;;0KGEC-).,:,>:
M5A4Q,J0RADA5`2`-HW`&OV<ZD,2W)W6D<+P'`,!A-Q0;;L/G<BO$RD.X6C,+
MS7$8;(W3Z63Q9L]*?,9G*$)!NW,)W"Z38SAT1$3-Q6"T6,GS,VXV8C--\60<
M_4S``*2*>R[I(4O&MQ=(QU'C!F8J@FO`P`40H!>VHB``_P`HR_BZOFQEWAK?
M[=UW<TYI_P!7P"AZYEFC)X[.V9N2-6CER9LUU5'+D$$3J\N@1<S=$RJ]MI;S
MD+4>T0#@*8;7]0.RVX^Y"./1NW>.XME?U68[C0<ODT#C47)2$8MAN`N$GL8L
MT4>2!Y1O#Y:G&`5$QU`+$.TZ@@DB94(PV\ZV.F;<G)]KQAMKQCU=QE8A;;_*
MI?`L:173<QL[+8IC[AVV9/W^3XWRLDJ!&"BS9,Y&\B1=,I6Z@J"&P-U9]#V+
MP$A&MXO"6&+8?DDOCZZ++:-ZGC<?E*KR0@I=JS.ECX1RTC(L9%V[641N.O%+
MK+G$0.<A@\W_`%>]&C)F5Q*8UBJ"S6'4FIM@MM*Y4=0J;1%@29C3B6`.WDIF
M!=1#)N^1:*+$;Z")SJ`DFF8`D;,-]NF;#,^8S&50&+M,RP!K;C&7-,'5D7<5
M'YMCD?+NU<>EF+`SQDWE<>E53+66"=!NZ+VB=(C@/%]Z0WIVBR.SRN2S44#.
M,<S)BRF`YG'J.(M`QDF[UB1U')F=I2SHAD68%\Y58MI@)4HF!!(^D9Z>V<HP
MB&L])23B1AOK`BNCBN0MFA(1PDZ-$S"@OFS9X,;+N$$DTC)HG4*5VW6,F""@
MJ%#?8IUU[599&Y(Z:H9$VDL8Q?)LS<P*V.OU7\ICN&PT7-Y2_@W+=52)=A`)
MSC%LZ!5PW`CYZW2*)@63.8-&3TC'3P\.U+#9!,3)5ED@<+-\*RQFFR8G5GDA
MDS)2;%D]D&@FQU8I.21='.JNW3H4ZI@3"4\&ZL]M-QIU]C^+/WBSN*CIA_+&
MD\;R**"-4@W+EG)1R[9RSYY20:/8N0;J$32.4J\<L4#"4R!U@:^6==&QF&Y!
MEN*2N2/%\AP:?5QS)(^.Q'+7!6CUB:)&<<-GRT:VCG[#'6\P19X=)4RFFDIH
M$7,!"J!HQ](7T[$QXN6JY---\9.W17)-N]O<Z9L#G62,N5BFH[B$16D000<'
MTB`8#E:+B0QK2WAMGO7!MC%/HF/E664(N)O#L1S6.)'8I+3QW<5FK5-Y$\NG
M"B]4.+9)4I72AP3214,4I3'J(@"9CUMXIE;0DQM;B.5;GXT)Y=F?(8.,/"MP
MEX/)<2QQ[%HQ^6+0<LZ5<GS-BHR.F@8CPZY42#J$<<N%S1&8J-"QHA4:")G1
M1$/4$2@0P`(AZE1X#%9G[F,_G'7^KX`K,_<QG\XZ_P!7P!69^YC/YQU_J^`0
M1HS'+J4+&#[OE?MW8=OB;R[_`*O[JO`+ZS/W,9_..O\`5\!&NXFY2>`.L!BI
MB,1E%MR\XC=OHEHQ78BJ#V692#Q1XNQDWS%U(QS!E'J+.R,TW2Z+0BBQD]-(
MX@%28;KRZ2<OS)YC<?(,)"5ACXWC`R[O;/*&S%)_.9@I@B>,(2<KC[4$S0DL
MZ;G>)U!%!B^3<%N2%02A?&-&8Y=2A8RG/ROV[H.WQ1Y7[0?5X"C.YO5[T^8G
MO!DFTNYN&HFR2"F&S69F9/"64[&*(1V!X3N5`Y'K%YV1<1!T<D=MV2HHZY'^
M-R0%3+I-Q<`XLSZB-FQP2$S0=LPSJ"EHG.AAF2N!,T'22<(ICC>>B749E9(Y
MU'_6)I*-7"92I'2=-&XF5$IB)IG"/'O69T[M<YQN&5VU;NI":GHAMBN6,\0Q
MQ\T=<A!HIXWDC)=)V:?C(XZ<RP80RSALV6=%DT@:%,D(\!(>Q^_FVVZV42T)
M@>V;7!YQKBT5/.))W"XW'FD8UUE:#QS#-I'%GLH1X>.<9"V?/DA5L;NY04SA
MS1714@M3G61NL0PC,LME(M&9C<6Q3(\CD(>.3%U(2S.#AWDFYBV+9ZHT9KNY
M!%J**9554TS'.`&,`5X"C.$=:W2GE3URZBL;:1S].1-B[!Z3;%=TM*1A(YK/
MO'C5W!Q[]1''6"#UPLY%<4BI\LN:TQA(4X;3+>LC9F#W&G\=G]MG,ED^,.-R
MX5GD;#'\6R-&9?8A%Z^9PL#,L)=XY2=K,88Z4@@Z%H+4Z*"#X$E%"ID!GQ/6
MATZ*(9&A'[/)-C8_/XO#9`R;8E@Z;8#X_'2C]"6;OD)<(6;C<'=8<X9L%6JZ
MYG+Y!LC&`N=5$.`L?B6\.)+[(1>ZD;@Y83!5UXZ+#!6<)&HOH1Z]W+5PY?FH
M9LX0AT3Q>0+B[>`BHH8A2*'3!94"@<-3L/U)[>[WY<Z2P;$"P\Y(8E*3J\W)
M1T&RDG49!Y8E'+1$VG'23O)(MYK9*WDDF[]!(#D?F,6IP5$`MG69^YC/YQU_
MJ^`*S/W,9_..O]7P!69^YC/YQU_J^`CM`9G\K<C4L79^3N!NH=WJ?_Q9,ZEO
MF6"'*ZE*]NI;]K7@)"*,WYEY8JM$]2T[OOHSU;*I]H7<Q;7U`3KWFH``SE`J
M6*K0MU#NZ5M1OI5/NNU*>M;Z_`0_B`Y#^5W>6\L'I\AMER^F>1UOZ%GM3F;T
M]+[]2RS[3O[>`F`1F_.M+%5H>RIW??1QIW43[KM&M/4OI]K4(4RT<A'.MBQ2
M-`JH?6O/`.=123%P9R&W6>@S!&U=\D"`""8+7JF,`76`%`*`38<9OVS3+%?]
M;I7G=A[_`-#4M(-*T:WT\JM.XE0##->?86+_`.MT[CN^WM>Z-]$QIV<M=3RJ
M4[BU"+-[1G?R7Y;I%AJZ#*T7!W]EGC3:E^BG?=I:?=V7W>I3CL?M_P#2_P!8
M:7UN_P"GWWY[>.[_``K\<=W3UXYY^'/Q5]KG]/;CUZ?UP<6=+2R$&BHJXC6:
M?UDP\@+$=NFIQ%7+X9)-'5'(L3*8JXG*0R0NS`N!A2Y=W?RRW'+"J._DATF=
M-[M#</<[8;!'>2YDGNM-EF\,V(8Y?E&0R#3#764[CH.I*-QA9PYR3,\:CWA-
M)TX(M,B4Z9C'("YDPJ_^E3T&'R"*Z;-I(F#VIRW>7,-E(7'9S;79V(:8QD<[
M'JX9EN".5)*`:QT+DF-8RD\BF2JYU1:IDFVJ;10Y%7!V_0^U?<$^U_.8O,_1
MC8I3'FQVQS>:=U-C!DU\D1>L3-;13+::VB)XM$3,3'1BSXOK8IQ\\=8GGUZQ
M,3'],(RB,4W^VZW<WEW`SJ6V7W<Z1X*+W>6?[/3FW6/0N>2^?0F:[CEW`R&0
MRMSA>217U5&/R+)D(=H=<T@9F_3:.WQ$#+ZO[/\`<6/[5_<;V#X+V;'C=_3^
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M$E>8(V@^KR@,Y0*EBJT"M#O*5M3NI[6'9=?3UJ>OP`(S=!H6*K0:5.[I6T]M
M?:ZTOMKZU?6X`,,W0UI8JM%++CNZ5HZTKJ)]UVC=3U!/3N+4`XS?GZ98K_K=
M.\[OOH^T;Z)^J/+74[JJT[B5!*!IGG7H)FBS'!!$4TCG=@5-(3S0-3'`%U/;
M%#E0U!!%,*`<`.I:4"`K.,UY]A8OO4T[SN^ZKS2OHGWB'+W4]45*=Q:@",U4
MUI8NE36U.[K2Y:RZB??;IU]>[UN``&:KVEBZ5]0[NM+@_P"1WV_^G@`!FJEN
M+%TJ6ZAW=:5;WVU3[[=6GKV>OP"*,&9%HW$QHM8MPU4*H[$QB:[;4I<X?U,4
MG,`'MQ@J"?<`F`H+2#-^UZA8K_JM6P[L?>&OIW$"M*NK*^1*O>>@8(,WYFH6
M*K[5J6'=CZC+6LN3#U>9MKY$Z]YJ`%&;H6XL56A+[5'=*VMM2VJ?==K4KZEE
M?MN`1/QFP:C4T2E[<S`3ZCP`*(N6P"'8NQ$0,83``:@5`0"A^TA@6B,W0;2Q
M5:&I4[NE;5;:T3'LOLKZUWK<`&&;H:PL56BEEQW8!6CO2NHF-`NT+J>H*E.X
MM0#C-^?IEBO^MTKSN_\`\?HWVI]G:#6ZGE5IW$J&3C-^?IEB_P#K=.\[L/5?
M:%]$QI4`;74\JM.XE01.1F0>-`*:++7G=%,RCL-40(YT]0`<(A0B6B)J)+^<
M)Z6`!3""T1FJC:6+I4U*G=UI<K;6B??;97U[O6X``9JH5+%TJ%:'=UI<6M/,
M[[;OWZ<`%&:J6\L72I+[3NZTJVU;:IAVVZUM?5LK]M0`@S?F7EB^]+4L.[[J
ML=:RJ8=H!S-M?(E7O-0$:(S7/J@8T6;W%%F62*H[]K.*YP<"D`N%`$AR%7L$
M44A$2I@)C^=I@K*,W0EY8JM$]2T[NE:,M:RJ?=7F+:^1.O>:@`#-T+<6*K0E
MU%'=*VH7VU3[KM6GK6^OP%7=]^>\<Q?G0:!_\T=/M@-16'M_2MV5OO%4I0I7
MNI^_P%M^`.`H5L-DVY&#]#^SN:2R.&2D/BO3%MWD)HB&AIA]*2$-%;<0CPC,
MI)7)(9@=Z:'2JH)U2)F6*(``%,%`QLYU/26Z>X<WMYB$#C,&\9JY\\<2<IC,
ME$MY"5Q;*V<'*E.Q;9"M*)/YE-T62U'*2=4#)@<QEC&(F%D\9)F0;C9CXVXQ
M8SGZF8!:,2SER)"B,UN+I`<'CXY@5`P'N$!H("7N$!J#_*66\75]NC;O#6_;
MRSKNYIS3LYNG?P&ISC)WV#85F&;/DD9!GA^*Y#E+MA'LEE'[YOC\0\EEF3)-
M5^DF=VZ3:"FF!C`%Y@J/`4?Q_KAV+D7[YG-XQ)XIN9`N7II'&9+::>4D(_)X
MY.>BF\:&0)H)$;3+O'<56<)<P1LX3BTC`<A10622#VC>NKIKRE2<7Q0B\_E6
M.X!FFY[!@]VBR#'5I+'MIXS(':S]EDV0<G#,"I\D[;L5%G*8I+**)T(<%BE!
MNO>OKIEA22D+EL4VB7L.,A+YA'L,$BLF@(UVPDY"/6E&TS%SXL,K2?NHT5F;
MI@FNLZ;JI+V%*?S0W6>=8G3IMOFN5[6-</=Y1FL)*NV.6XYC6T2B9>?RERWR
M`IC2L](PT!-I96]F0=@*+M8[A143V&,(T#:9-U@;$XUF[:(S7&#PI<DQ['LH
MB\WF=N6RD5.M)'$&^8*,C+A,+R2$[C+2$AT';1PFFJ5=S'Z.J4@F1#2SW6MT
MJJ9.P7<QP3L^6!<LQFG6S,H@K&XY+/95L_C/%L@68)E;.<IQ8&+IMJD2YLE3
MC1NL*07J;XS$O.1ED(3#E#Z#-:/>FQA--TDW2;B5@*1E#@X;:#982D+YHIE,
M)0IVAP'I]4(_Q-2:\#Q#Q=6)=02DEX`3G5(5\LU7>Q)W.MJFCGBS!`RJ(CIJ
M&13$P#86@>B6*,D%`50A,/15`0,"J6/))J`(*/%@$#D4`P""T@X/W^R74'O.
M:H:V(V\QV`R*<RZ#Q7!HC*LF.FID.1QN,H,YN:.DW;-4QDI-NHF\>`1NR2*`
M'.8/,#U>`W2D`591TLK'8NJL^62</55(0#J/'#=-)%!=T<RXF<+(I-TRD,<1
M,4I"@`@`!0/(^,-E&)8M2'Q(\80B29(X\`F9B1-"F@F5H946Y2(T\P`+0OJ<
M`I"%."@*@SQL%000:@H$.(*`V:W\LW`X.+@0;ZAK"5M)<-`"O`90AU&I3$;-
M,<;D.NLZ.5"(,B4[EPX([<.#%3<%`RZ[I,JISCYQE"@81$0`>`V-LQ_+1OP5
MU\;X`MF/Y:-^#.OC?`%LQ_+1OP9U\;X`MF/Y:-^#.OC?`((TLORZE%HW\/E?
M]E==_B;R[_:_NJ\`OMF/Y:-^#.OC?`-G+ESQ4#)Y-*1D=.%Q&.DLG;-$(E%[
M*"YAX]R\`(4).49-$999-,R:)S+H%`QZ&4(41$`J+E_6;L1BN:[:[;Y,UD/K
MEN,&W.1P\07:B;DVL,SS\HGQK*)B<;+N8%@VCI,"MG3H'(@P6JHH8B*9U2A=
M&-++\NI1:-`.?E?]F==_BCRO^U^J/`4AW*ZU=HL#W=R/:'<#&I1*6QZ9;M92
M;6PII,0AVB&"X/N-!Y(DMX\+I>/=FR%\S9@*0.O$<:?$33$_)@Y#UW#ZS=M,
M:PS'L@5Q.2RJ!RV+S1^,(MB\/%3#.*Q-6)0EI&6Q/)LH92A\?5"7:&6=)-UT
MD2.$2J%U5"I<`UE^NG:,F9XS#+[?S?.9+-1"6.3A\*A#.:*P":D!,NV!<H4R
M"".Z"?91\:1RBBX<A(CRX&3*<#!(FR?4?B>\F32V.8O@P8A*,L6BLC5?2$7C
MZ8/VB^5HJ.8EL[QC(9DBQXI:=;N7I5%"%1?2"J``9P@[TPM)G.12&&83F.8.
MF:<TVQ3%<BR5Q#1C(59&71@HAY**1;!-Y)M69WD@1J**0*JIIB<X7&`*CP%(
M<*Z\]@,O?.5&43,,'I9+ZOQ[D=L57;B3B4V#2;>2J1XV9<.FN.QJ3IRHN98"
M)@9HJ!;UC$3,"R6ZQMML9SC+L?5VY=EEX%QN6BYEH[&\9<.,AEL4753E(J/*
MRRA5^,UDJ$`]=J)/^3T63`BKLQ-9N0P-N.ZZ-I#I3J+?;&3;+P,MBK*;:M\6
MQ(S%-LS933B.F$)E#+@@)=M#GPI1*$(V<+.).Z.%@0W.(``6'Q/>R(?[*Q>\
M+'%5XK&72T;%#AC"%C592'=N]RE<(<:S-">:0IAB)98SIV+9PK[6FH*',*6`
MH#;Z?.IK;?>S*76/X%C+S'L@+ACW+7ZDI@W@*2<0GG$C#HQ:\HA)'(ZF5G;L
M9-RS2U08C(%*N8KDZA`"WELQ_+1OP9U\;X`MF/Y:-^#.OC?`%LQ_+1OP9U\;
MX".T"R_Y6Y&JT9;^3N!NHV=WT^MDT*EH\W8`"V!0`J`CJ"4?8@)3!(12S5"7
MKQ8C1.^UJ[`!$`::ME7@T`Q@7MK6@&3K6TUP8`DW0*KQ5:%K1H[I6U&^GNT:
M`)@4IZPE\@U"(,0+/_E=WEO7A+.0VRT!3:2&K_0L_J<S>_%,?;J"2P`H3L&H
M]O`3`))KSK5XON/;5H[&@VN-.ZCT*@!A2KY0`_=4+0A3+@R`<ZV*%)U"'1'*
M\[`YE6DB9QS'Y.<^!H9(Q9ATEHD,*8*E,<QC`4UNG4"D":SEFO/TUXL/ONG>
MT=C2O/:%]KPMUMS:^E*VJTI<2P`Q9JI[%XL`]LT[FKL1#M>Z-]'@74`S>ZE*
MVJ4I<6P(MWM+.!MAEPI+0XCR[*T%VSZRSQEM0#BB\`]X)BGW=@F`WJ"`!V/V
M_P#I_P"L-+ZW=]/OOSV\<_X5^..>8]>.>GIS\5?:Y_3VX]?]\'%G1Y5"#245
M>L&Z?UCQ`EZ/-LU#:V6PZ)$N8#*,>"BHJ%*8FN8%@$4]!Q?H*<<L%F3X3#YQ
M'C$YOC6#YA$G3=(JQF3XPUGX\Z$BT&-DT19RYGC84W\8Y<-U2B00415L.`D$
MP&#G%N3U4]$FSO40RVISC9F&9[H8[D>!XW$YS"[(X)-Q3')F.WBV9X'%1&2Q
M$V\R."GHF`>+M8J/6:M91F1^FX1;EBU!>J!`^%]0FQ_5'C_4U#;5[@;I,?JC
MMAN3N[FV-36W6VS%PG$YPOD\Y/P&/Y,N^S!N:>`DJHNB*R;QLQ1DH\%@6.F[
M;J>^>P?N+L;ON_V_XROCM.?)1M^-UL>:^7;BG."VMKX;Y,6+/CYB(QUG)7':
MEK<V[;5MVS75[6I%=?+?OMV=MYF(BOQYF>)F)^?3GEH.G/(X3I<VES_=7KH=
M;?[X[DK=9<_MRRSW">G;:^+?PCYM`.LKQB08J1T/AL[(G@\3=2FJYTU7Z:RH
MM8QH*8D17W__`%2YOMUM>[O"^0^VGA+^%\+N>V=#->N79S[6?-FBMM>]\M\V
M;/Q%?T\4Q5K>T_2BGU+VR<\8O"1MUP9*;F2,F2N:T1Q6*Q$>O$1$1\^O3U].
MA_\`_P#DDZ!-FQQK<*%VID,%?Y'AKG()67PW8S"XG(8N/ELIR(,CPW+7F/9>
MT>LIF/RV$FI"99G,\9MI)J*+@X2ZS1!S^9&Y=F;9G[5Q&"7LH(LW8"(43[1+
MSHT$1N[*]@"`>H(B`))J@T7BZT&E6CNE;3TK[M[KK?W@'RA0`Q)JAK5XNOGV
M7-'8@`VNM.ZCT*T,*-U*5`IZ4N+:`<DUY]B\6`^VZ=[1V-*@^T;Z/0NM$S:Z
ME*VJTI<2P$@!,"]>E(YC+]!$R93-G8D(D8\R#6\@2@U4U`1U#`FF!RD.`"-2
MZ0*S%F?/L7BP"JEES5V-`J\T;Z/`J(%%O=2E1*I2EQ;0!+-5&U>+`*FMJU=B
M-+EK*B#P*B!13KY1`WE"@9MF:]J\92O;[E=5I<'_`.,[[?\`T\!@"S52U7BZ
M5+=1J[`1"Y"^T1>#01*"M.^@B7OH-P(XP)@6C<1=1BA+AJ8K9V)C$!=L"@`8
MTJ\\ZPK@"U4/03)U]B8#`L(6:\S47BQ^]:EC1V%:<CKV7/#6W6N;*UI<E6MI
M[P"%FO,O7BQ[$]2QJ["H@#+6LJ\-:!A*YMK6ER=:VFO``LU0MR\6(T)=1H[`
M!&C;4MJ\&@"8%K:UH!B5K::X$,@$T#41%U%D'59A>#5X'G"Z;`-*2S0:&-4`
M#4"H"`4-VE,"X235!M7BZT-;5H[$`&BMM:/0J`&$E?*`&\H4`,2:H:Q>+`:'
MLN:.Q`!H[T[@!Z%0`10NI2H%4I2XMH!RS7GZ:\6'WW3O:.QI7GM&^UX6ZVYM
M=2E;5:4N)8`<LUY^FO%A]]T[VKL:5Y[1OH\+=:!FUU*5M5I2XE@(W(3'.-`!
MS&%NYW1(+=WYPV.13U`"41!0")"E=[6IYP'$++BB4%@EFJC1>+I4UM6KL1`M
MRMM:/`J-HDKZX&\H4#-LS7M7C*5"ON5U6EQ*_P"V=@VW4]>G[X!2S-2W+Q@A
M4EUK5T`B%S;4M$7@T$2@M;WT$Q*UM-<&"%FO,O7BQ[4M2QH[+4`%EK65>&H)
M@*YMK6@F3K6TUX(T2S//K`9U&&HSC!6(5L["A]<X+F3*,JJ!2JD(O8(I$$!%
M.IE+#!P"PA9KS+UXL?O>I8U=A7L9ZUE7@TJ)7%M:T`R=:VFO``DW0M5XNM"W
M4:.P`1M0OM`7HT`3`K3OH`E[Z#<%7=^`>A.8OSAVAQ^M'3[8+5)9*G_U6[*W
M7`JLM4*]U*>OP%MN`.`H9L5/[GX-T.[.9J=YA\TTQ;IBVXR)*#BL*EEY60C8
MO;:$?)QR0R.Y,2Q6D#1B5ICF42(HL`B4@`8"`&HV8ZH9_=K=R=VSA82"QV9A
M6F=NEIR;VPF(M%V7'<S0Q]PW1,GN*X<B]F%">(.DA$>2`S<C@PKK`4@6JQI#
M+B;C9B$U*8TY<_4W;\2GBX"59(Z(S6XVF4Z3O))`VJ4X'J8#T,4Q0``$HB8'
MZ5.5\85]UQ]WAK?M\/<TIS3GLIXI_P#KX#TE!R!O&2*[$8A^]08/%F;%RV=,
MVSQVFW4.V:N'@/78M4'"Q2D.H"2HD*(FL-2@A0&/Z]<34(#1[@>4);D'@L,D
MY3#XK#DG`'6R_'XK*(N!B<NG\FQ-CDTJR8Y6B51!%(%"JJ+J%(+1!R[2#;J=
M=6U;$%6[R&RB(CUHB5FDSRFVJ4.A(1J)I)9^LW3DLW9M7:D@\;JD(T*J:1<'
M,HL+7E4UG)0;\_UK8;&8WM_GI-JYJ9VVS3'LBG7^4L]NW;ASBN.XQD)\3@SR
M4*BZ=)7S;HA1;MUWC/13,!4Q5,`E`%D9Z0K9S)B`6$B\TGGO.':LXAKM@V-*
MNI1E)+Q2#%!HZW"1Y:21EHY=-5-<43QJ:23I[RK1VP<.@O-!.SY?C$#.E2C/
M#\AAX:>;LI"'36412?LVTBS3<D;S;YB+AJ54H52553`Y:D.8*&$-LM$JN=87
M"<"X%P@#5P*T&977;`HHL#=;4D3:J`*JF-8:I;C"-*B/`+=.6]^1WS:Y^E>`
M-.6]^1WS:Y^E>`-.6]^1WS:Y^E>`-.6]^1WS:Y^E>`-.6]^1WS:Y^E>`-.6]
M^1WS:Y^E>`-.6]^1WS:Y^E>`-.6]^1WS:Y^E>`-.6]^1WS:Y^E>`-.6]^1WS
M:Y^E>`-.6]^1WS:Y^E>`-.6]^1WS:Y^E>`01J<KRZE'<<'N^5[XYR/;XH\J/
M]*!WC]C@%^G+>_([YM<_2O`17N7N6[V[?[;1:R#"5=[E[@Q>W\<@D1%JNW6D
MF,B_7DTVSZ<;>)(Q3.-47<(D.4XMB*&()E`315"IL)Z0_:+(,J?8RA&;@M",
M)7',8\<FMFLA@H5S/3^8CA3B#;/9K(6*"RT*LZ:O7!4C*G/&NA72(H5)2@7W
MC4Y7EU*.XX/=\K_V<Y'M\4>5'^E`[QX"CNYG6UB>W.[F2;39G@^2UQR9;-7>
M4(X>A*0#AB?!L(SR`GVZ[C)6*2R4G(SLG&-&]_.C)8XNFDFHLY8)+AX[C=9F
M,8SBV)Y8?`'^1I9%%YQ)I0<OCD5`Y5#1.)J1"$G*.8*4RAZ[6@W(334RZC36
M73(ND4&ZRPJ(I!H7/7=C*6:8S`+[7Y-KY3.0[:%E5,38C)H$D<?(Z@I.6A?K
M,:7A7TD:=:,XYLH/,.47:ZJ8@DW5`P2)LEU,--Z<GEL7C\')AKQCBT5DII!T
MC#NROBGRM%)W%(&@9Q\H7PA672,[,Y%N3Q-P[:H@LJR>*$"U&<Y!,8;A.8Y>
M5HCD!\5Q7(<D)`Q[`Z;^;/!Q#R3)$LCN)8&Y'<B9J"*8G$"`<X5&G`4;P[K]
MVXRY^Y(EAN;Q[WQ`8J..;;0'+R1@46#:7>3YV_UP:R;''X\576H=1(4CK-#I
M(F5='(W$'QG'5.PP3,9S&E]OW,C/PBFXMR4?%0(3DLABD!BDVYF8B.^MQWCN
M#R1.:;MC.#'3526;AJHF(FN9L$91W7GCR[>;30VHF$C0$SBS.3*TA8=>%.U7
M92Z["7C)]+(DX68,*N)%2QYN@H=Q,`\BA1!`SPB:06'Q+>\\MLI%;S-,368L
M7B\;%*X3%,(Z1?Q2[C<I7!GAP4:9$UA'X1#M0[QP=FX634224Y8S@PD%0-)T
M^=4L1OE.J8KCV(Y)BJZ&*RN9+K3F$/XJ#1!/-7>.J0Z4N65&,D<G$=-[(MFQ
ME>04=@@JH9P18I`MMIRWOR.^;7/TKP!IRWOR.^;7/TKP!IRWOR.^;7/TKP$=
M()RWY7)"KN.L_)U!7`$<Y`PTRR:,>TWBH@6YL"A0J`T.8INT"B0P2(5.8"VY
MY&F$`3OMC'1;A`&NK;66/:!C%7MK6T#DK6PVH&`3F:!5Y&"-"W"$8Z`!&B5P
M@`RPT`3`<0"HT`Q0[;1$P1!B"4Y^5[>6Y]$B06&V6B!8IX4Y?Q+/`?6,,T<J
MM5:"6TI*%[!J/G<!+XIS%#6O(P!H:VL:Z$`$07LN`)8MP%$R5>ZMINZX+`A7
M+4YTV=;%&3D(G2^MF=@8%(IZJJ*P[<YZ#4Y50R`Q011JGJ$$#&/88"F3N`"!
M-9DY<;['D:6NIIW1CHUM>=T;Z2Q+[+VUU+;M)2ENH72`,G+^?8\C0KJ671KH
MUM1>:5])8E]@';W4MNTU*6ZA=((LWM3F?R7Y;IO(L/<[*T%(QV<`+XRU$`-;
M+IB)@3,F%0IYQ3#2A@`G8_;_`.G'O#2^K%IIWWYXF(G_``K\=9B8]?V>G\ZO
MM<_I[<>O^^#CSKQ1."2,=\R*3ZQX@4=%L\:*""F6PY"$URY%'^:83%`Y1.(*
M%J44U`-IFXY8/`$YCLN>1HAYMU(UT%>U*^E94:5*"@!WT$Q1[;1`P<PMT>MG
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MI*#+'87%;;XACY9!"%Q<Q7$J5R989%<JR""#<`2-^C_^HGS7VX^YVO@]U?;_
M`,-D]M:?@O":>K&G$Y,^/-'UXIDR3LY_(;66O&7/><.+Z?%,,16^7)EBUIU'
MB<>YI3.#:R1FMER6MW=(F.G2.(I6/2.L\^OI$0\)_KNZ2L=C7J#[8HJ2&VV'
ML'I\;-MALJB\@8IUO!([<_5M6/7W7(VVX9I[B[>GDDUY,644NBT2<(K*J-!,
M/X[=`O-TL]46)]7.WTSN-MLUR&%A\?SB;P"199UB1X"9"9@X^"E%EB1Z&2R0
M)-EF$\@82**%<-EQ4;+IIK(*%X"R8IS%!H\C*T&@C&.J5M/2H>+=H`82CW]H
M`(>J`@`9.8\ZUY&!V'LNC'1J"(.=.X`EBW`4QD;J4N`AZ4O*)`R9.8&^Q[&E
MKJ:=T8Z-;7G-&^DL2^P3M[J6W::E+=0ND"0$Y87KP"/8\#<N@9.Z/='(1,RD
MR#<ITPF"W*)G%$5#`!`4!,X!2XND"LR<OY]CR-"HJ671KHUH"+O2O$)4MXD`
MZ%U*7"FI2W4+I@"G,5&UY&@%36UC70B`56L`1"5"H@44P$>RHE,/9<`%#.G+
MU_#(ZE>[PUS6EP5[?%1[;>SN[^WUN`P"<QV7/(T0J6ZD:Z"H50O`!&5-01*5
M2G?03%[[1`X(HPDL+-N)GL>8M1$WXO="82@NWO`#FFE_.$I%P`1$P`*B?8.F
M8%`6D3EPLU'D::FGJ61CHEU.2UK*RQ[+['-M;K=1.MVF;5`*G,!9>]C34T]2
MV,=%NH#/5LK+'LO$CBVMUNHG6[3-JA@$YCS;GD8(T)=2-=%J(`WOMK+&M`QB
MJB%:T`Y`[;!$X(I`DP#0:OHT!UF85".=E"HNFP&[II(:&-7LN[A`/.[0$%HI
MS%!H\C`&AJ5C70@`VJVB(!+!4`,)!$/5`#!V5`2ADR<P(&M>1H"('LNC'1@*
M(E=:=U)8EP%,9"ZE+@(>E+RBF`=.8&^Q[&EKJ:=\8Z/:(\[HWTEB7V"=O=2V
M[34I;J%T@#IRXWV/(TM=33OC71[:\[HWTEB7V7M[J6W::E+=0ND")R26YQF!
M7L>%W.Z0#'NJ`-C@4Q4`)E,%@(F9(!\WM,0XA;>%@+13EZC1Y&@%1I6-="(!
M<I;4?%0J(%$@#W5$!'LJ`%`TY>OX9&B%0K^+70#2XM0_I4>T2U"OE$!]2@@%
M3EZEN>1HA4E]L:Z`1`!;ZEM94UHF*56VM;1.2M;!`X!4Y<++WD::FG?;&.BW
M4Y/6LK+'LO`CBVMUNHG6[3-J@C1)+^(+@=['&`&<9J`6.=%J?6/KF3`9I0$@
M5*FN!:DJ43IU,IIF`X+"IS``2]Y&F$`3OMC'10,(`TU;*RQ[`.)%[:W6ZB=;
MM,VH&`3F*!<\C!&A;J1CH`$0!"\0`98:`8Q5!#OH!BAVVB)PJ[OR5X6<Q?FU
MFRP_6CI]M%LV5;@'_P!5NRMUVJ[=75'NI2GK\!;7@#@*(;$S.ZF$]#NS69,G
M^)Y$?&.F';;(6./,,$F0DY)M%[:P;]"+266W*;H+R)V".D)P*F"JWG%3"H)\
M`OV;WXW@W>R^5@6L+B^.Q4)([D14G)S>"98SE&+K",DA(2/,O&_71:+`,O3E
M3N$T22)W#0S-=-8EY.`EE?*OJ)GF1/-Q]Q-N<<2E83;"!BI279_5*+?2\M.[
MD(P\`U&<S9<KN<DG)5"H))KZBXT(1(3!4;6IH[N_>V/1PY<V2E)O:*5M>8I7
M\UIBL3,5K\;3TCXRC:U:];3$1S\3^PS)R9RQ89;C\HS>0<Y$)/(24\'<(M)N
M'.^=C&ST64TPJ9>&FV8D=,E[K7+15-8H`4Y>&[IY]#9OI[,1&SCGB]?C6W]J
MEOE:L_AM']FT3'K!6T7KW1Z2VN8SDMB.(97E940G#8QC4[D)(6,B7"DE+GA8
MMU)%C(],),XJ/7YFVDD4`$3'.`<54E$I+T@N-8LX>,\NQ+(GR[)@ZET<CVMQ
M"5W"V]FX]FI&LE'F-9G*R>"GF0%W(G1`4V6F!DP*)[G#8JP;R3Z\,;AV,I+S
MF`;HQD'$-8IXYEI/;F,CV#1&>016AW,E(2FYK*(C&4FU?H#S!W0I,04.$@9E
MIGX#79CUX?4&8=J9)M7GZ^W*T9`.\;SK&L'DIY2=7G<+VYS<6BL":8CV,>DQ
MB]P@1.<LFX,=W'JH)IG553)P&UP7K:PW+I+'8C!]OLZ<AD^0XZB9VVP3&HZ!
M8H9SE,)&/LND9QGN<]CU8<SO)".P>M^:+-'(XY$SH[9X+<+X`C*@``#V/``[
M``(Q<```[@`/%>`-*5]_,/FQ?Z5X`TI7W\P^;%_I7@#2E??S#YL7^E>`-*5]
M_,/FQ?Z5X`TI7W\P^;%_I7@#2E??S#YL7^E>`-*5]_,/FQ?Z5X`TI7W\P^;%
M_I7@#2E??S#YL7^E>`-*5]_,/FQ?Z5X`TI7W\P^;%_I7@#2E??S#YL7^E>`-
M*5]_,/FQ?Z5X!!&I2G+J4?,:<_*]\8N/;XH\K_VH'8(]W`+]*5]_,/FQ?Z5X
M"*-SMQY3;V0VRC",XV;=;C[B16"-DQ(JQ4CP?L9%^YF4BJO3MGOA36/.LH@H
MNTU4BF*DH=R*#=<*I0OI!<3FLI?8ZIMQO5$,6<WC6-I9'D6RLK!0[W))O-!Q
M%U&M5Y7,6R2_@@.&<F<Z!UU%XY<ZJ*1Q;J%$+ZQJ4KRZE'K$/=\KWQJX]OBC
MRO\`VH'8(_8X"DFY'6NKMEN[D>V&1;6YRO&X[+HLSYM#XLK*03V->8)A67P4
MRT6=3</'*J3$[-S$*DR!WSG/P%B1%EY!DW,"?<;K7?83B^-90VVES2:0R-C.
MN0AI/'T<=R"+/&2#".25?L@R.=8DA$T9`CV5>\T`1$<<BBB:BACHIAJG'72_
M1SB"Q0=H\L6:Y)*M6<-/IX_(BH5"3A$9''EI2#661E(F5RTTHV"*8GJJLR!Z
M[<&:I,5RB#]V6ZFYK>O)9;$W6!FPD[#&(G*"2#E0LHD]7-E#>/?1:96SA!9N
M,.=VDDNJY*@"LF5\U;`OX>Y6X"T.<SL_B&$YCEK%FCDCW%\5R+(F6.LV:S9W
M/.X6(>23:&;.3/W!4'$FNV*@0XIGM,<!H/=P%),,Z^8_+'3EHKM5NO%NQDS-
MXY'\G.LX>8^C&-I!UD[ME)9G!2T=%LU1=HB(ME4UEFNB@HLZ4*V`%\UUK3$5
MFV;8>UVQ?Y&?#I;.(1C)8\"L@;))3"V<HY?MF$8=5!VP!D>$61E%51%"/5=Q
MX)'>`[,*`-F,Z]Y.28SJR&SD^57'<DA(9ZF5FX4CWS!_'2+E+)8*3(<$)*.G
MI&)*SQ9,Q$7&1&>L%0(S1=$,4+#8KOA/9%LS%;T)XBND[D5XN)=X3'IIRSN.
M%?<E3!I!RC(-I--C+)0Q#'?**-3*).$$3`@=2XAS!HMA>IN2WLRR4Q(,5:8P
M[AL:?3\L*COQ%6->(Y:YQYK&*D072CY,DDV0.Y*ZCW3Q%)9)9!?2.5(RX6RT
MI7W\P^;%_I7@#2E??S#YL7^E>`-*5]_,/FQ?Z5X".D$I7\KD@(OF`E#;J"N*
M$8N`C3+)HQZ&\5$"W-RJ$#L&ASE/V@42'"1"HR_FW/X\1`$[[8MP6X0!KJ6U
MECV`<2+"7OMU"5KICJ!@$9B@5D(\1H6X0BEP`1`$KA`/%AH`F*<0"HT`P!VV
MB)@B#$$)K\KV\HFDXT2F8;9Z1`AG!12I"SP'O.,T?6N5H8*%):4+>WV7`2^*
M,O0ULA'@-#6UBEQ`!$%[*@$L6X"B9*O=6PW=>%@0MER,T;.MBC)R4:1(,LSL
M#)GAW2IS+&VYSWEE-89M.Q-`3)B<EHBI88`,2X+`?VX&6GVZP7-]P9A8'4-@
MN)91F4FTC(8SJ47C,9AYJ;<MV""\\R0=/SM6J)4R'51(JHF8!.F"H"B'+&.]
M,QL1)X?DV8I81NJDVQ/*\<Q:8C0QG%7CU,L_#STJI/QKAON26+R*";KPJK"+
M48KK*Y4^12)#IN2R3,P!5?TIWI-L%QCT=6S744TZ@=P^CW$^H;=5S@V-;C1N
MU,?N3F&/R^,*[@.G&,9+@B;+/HQ^UG6V`NTE1(*!FBZ1%.8*-6Y_<?L#[W^V
MGV\][_ZI^Z7@J>Y?`X<%J5\?:^?#]3)D_#&2NQ@S8;X;88_'$S.2MX[L<X^;
MQ>FM\KK;FWK?0TLOT<LS^?B)XB/AQ,3SS_#Y\_";&]'7I-MM.KGH5G^IO`)O
M)]T\!VJW5A=I7&1M<;7B]P=R9?!X3;'*IR=&`RM?;%#ZR2#O)3IJ,VS=%LY5
M1,*!2(J41\[]Z9_:^YYJWDO:47Q>.VOJ9;:\XIQ5U+VSYN-;%SFV+9,-,,8K
M4R7RVO,7[;S-Z6M-O7C/7'V9^)O7B.>>>[I'6>D<3,\\QQQ\FUG_`$SVQ&.8
MMCF6N\#W8>Q^2,)]PU)%8]A3\R4A!SG@_AAG#7=%=L[2%(I'4@_9F=L8!!ZV
M"0416-HFY)G=6F./Q$DY99<A&8FI(ORL)9*:-B:))A348M$$'(R!GYGA'01A
MUD2'$PF335(7M*F8JH:?(=KH?(<1RW#3-X&#C\UQ"5PB:>XUC;:)DP@YEJ[;
M/$F3CFW"21D5)J37;%53621</`.)#B57F-KX'S&S[>\YI>?TJTMN:.WAV,<7
MB9I-\.2N2L6B)K,UFU8BT1:)F.>)B>J&7'&7%;%;GMM68G^,<&%BFP#_`!W+
MH/,)/=7*\O=0"\@\8QLWCNWT=&E>RL8I#O79S8CBF-2BJG(/WA$BJ.5$B&7(
M<Q#G3,97L?+_`'$OY/PN?PFMXOQ^EBV:XZWOBONWO-,>2F2M8C8W,^.L3?'6
M9F*1;^S$Q7B(KX]2*9(R6O>TQSQ$]O'6./A6)^/S2B\Q&,7<@=U#8:Y6F$3Q
M<NLKB#50\E&"B#MQ'O#JO55%V:[U$ZH)J&,0#&)4#"014\Y6V^8Q*\8D=".&
M"CT5G+EZNBP@3,T5GSY;FG[U1)&4*4SEZ\4455.-3G.>IA$U1,"L49>@T?QX
M#0:#X4X$`&TX`(AXM40`PE'O[0`0]6H`&1E_.M?QX5`]MT4N:T1!SIB:DL6X
M"&.D(]UP)F#LO`2!DR4N-]C^/+74T[HMP>VO.:5U)8E^F*C>ZEMVD>ENJ72!
M*"4H+QX!'K$J@MT!(8\:X.0J9E)D&Q!($J2Y1$YD14,`EU`3,``2\HI@J,E+
M#?8_8%J*EET6N:T!%WI`:DL6^P#H74MNTSTMU`TP!1EJC1^P`*FMK%KB(`(K
M6`(^*A<)2F3`1[*B4P]EP`4,Z4M7\.84K\EKUI<`TKXJ/;;V=W?V^MP&`1EN
MRY^P$*ENI%KA4`%"\`$94UHF*52G?03E[[1`X(XU*5Y1`1>L;+A$2^&N+A+K
M-Q.4#C*C03%(N`"(#;JD[!TQ!0%A$I8++W\>:FGJ6Q;@E].2U;*RQ]/4TW%M
M;K=5.MVD;5`*E+A9>_CS4T[[8MP2Z@,]6VLL>R\4W%M;K=4E;M,VJ&`1E_-N
MD(\1`"74BERW"`-[[:RQK0,8JHAWT`Y0[;!$X(WZ,N#4:OV`^W,ZVQ;D.WF6
MP&$*2PB`":HT\@T]3M!8*,O0:2$>`T-2L4N(`(E5M$0\6"H`8Q!$/5`HAV7`
M)0R9&7H:U_'@(@>RZ+<&M$2N@3N`)8EX$,=$1[K@3.'9J`*8!TI<;['\>6NI
MIW1;@]HCSNC?26)?IBHWNI;=I*4MU2Z0!TI8;['T>6NI9=%N#VUYW1NI+$OT
M]1O=2V[24I;JET@1N4I7FV@%>L@$PO-+\6N!!.J;D2"J`2@`J!2'2`?8U$AA
M"EX`0%@HRU1H_8`%1H`Q:XB`7*6@(A*A40*)`'NJ)1'LN`"@:4M7M?L*5#L"
M+7[KBB(5\5'M$H"%?*(#ZE!`*C+`);G[`P`)+P"+7+<`"WU`*/BIK1.4JH!W
MVB<O?8('`*E+!9>_CS4T[[8MP2ZG)ZMM98]FH";BVMUNJ2MVF;5!(BE+<^M<
M^8C:SC05I&."@<X+'%8R=94P)`H0BX%#SA(*A!$3:8@H"LJ,N`$O?QYA`$[Q
M+%N"W"`--42UECV7BFO;6ZW5)6[3-J!@$9>@72$>(T+=2*7`!$`0O$`\6&@&
M,500[Z`<H=MHB<*N[\D>$G,7YMPW7$<HZ?;=!JHV`M.JW96X37NW5UP_N4#R
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M!QBVJ^HBT:LUG#M0A4$4S*J$`:$S-I[K3S:4U&%_3-;*PRGA^7[1]2.,3Q)2
M.@U(8^U$6_4<S<J]G6;2`@E%,ZC'61Y44(8BJD*U;&F"I.@.5J<C=V9#X)M#
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M;-JEA2N&D;Y?*1.;S4_(95$*0[65@\,<+BS3;NUB.EDV21G#H%$R`AAO2.2>
M:85N#N)@'3?O7-8O@KW:.%;HSF-(0.3Y;/[MY=G.!M6F/X_&/LI%:/Q'*X*$
M0FG.N88Q.9<F=IMSQ#M(P1G,^EYQQ@;)%XSIWZ@I>)@SS,%'R9MOU(U"=SB$
MRR2Q=>)07</U8UIC;\(\KAA(BY5>/SN46:,>9ZH1`P?:'ICMK7#I\D383JJ(
MR+'3,G"RZNSL8E&RS6!=S,?(NWSI?/46V-Q(O8<13?.U.6*S5%VN9NV1743#
M6YCZ7&0V]W#@L2ROI*Z@U<8DML-M]T9/-\2Q!]DS>'C]Q=KH_.DX(S%1G#QJ
MD]C>3RS>!D".)-FFWJH\4,F1(R/`.J+]+'CA1D39ATV=46*H%R9YC^.G9;6,
M,N<3Q(U)N23$S&(RY%ZRR1E(+"B$$FF[DW@5%F1R=!ZFT"R/21UIPW5PXS6-
M@\$W'VXEL'CH"<>$SK&8PD-,P679!G</C3W&\AA\BE8Z:6798.9T[(G:DW!V
MD"*KI$Q')PNIR\I\IH?-P?&^`.7E/E-#YN#XWP!R\I\IH?-P?&^`.7E/E-#Y
MN#XWP!R\I\IH?-P?&^`.7E/E-#YN#XWP!R\I\IH?-P?&^`01S>3Y=2DD@`<_
M*_\`9P=X2;P!'\+]4>`@3JAW[D.FG;-KN(.-K[A+O,VQ##FN+1:IXF5?JY3)
M<B8T4H5A,HNI%LD!E$T7`LVI[!UG3=.JI0JIMEZ2(-Q&FV#Y397/8=+/-H=Z
M-U9Z-9,ULBR;#G&SZ\BHGAI,=091KJ=DLXA(PSR.?*'CHX5'3)IJJ.7B"9@T
M.(>E;P?*YZ&8J["=4N,0&5.-KF>)Y#E>R+O'SR3G<C=&=VE>!)1,ID35:*)A
M.10Q7,DFFJ\>EBG*3P&P(*(G6#J)&H28MU*22`?C"5#^C@[PE'@"/X7ZHAP%
M=.IO?G-NGR'VZE\>VNR/>,,QSYWC>1L\3;G1>X5B$'MQG^Y.29NJU3;R(S`L
MV.""Q:L;VG./WZ"0+D,8`$*\Y5Z0#)(",PU]'=/V<S$KE^,=1V5?49^Z98]G
MD5']/:STBY%(XZ4OCDFKE9&92H$;2QUQ6<I`Q2DT2.5VX+6?7MD3W=/-MN4.
MGW<9>.Q#.66&IY<U;ZA)1*;VUW/W!Q.<\`7:-735KF*NW2#!@1-PY`/'&B[A
M1#[R</3I:ZXYGJIR6>Q%SLWE&U'@N&P^9HRT\Z\7;2:RF>.<8>1"")(B*59!
M'<JD`K/.5,[>E?-VB;@D:X<B%K>H/<[(=B]D-U-XH[&)7<U_MMA,]E[/;W&F
M8HY!F3F&9*.T<=AE2%D3$D9,Y`22$$%?/,'FCP'/W;7TL6.YRECC28Z;^I[&
M,BR.;D6I8E+:DDHUA<9+EF21,%F60.Y/(\7DXR*E\3A$)<2&C[S++N(UD+]W
M'/`3#SD_2E2\;NQN)M23IBW8DGF#!O85E.QK-VXB\F=;/+K@$>U'P0J;)[.,
M(]RY<T5<I11%&114<J/T2\`UX'TM\I.XYD,^ETJ[MD/C6;;>XF\9IHO5TY!A
MG,*^D4L@@GJF-M?$22$E&\ECS8R2)\@&1C%S'8HOR&3#H=TU[PR_4-M3AV[R
MV/N-OG.6QTV5SA\@=.<6AG&/9ED.,+$)-(I1K2::NE(<5T'C5,[-TBJ55NJL
M@9-4X6"Y>4^4T/FX/C?`'+RGRFA\W!\;X`Y>4^4T/FX/C?`'+RGRFA\W!\;X
M".T&\G^5N1$9-$0#;N!N($:4+@#+)HYQ`_-B)1,W(=.E!H*@&^UH8/Q)[R_M
M?_4AMQU0;G=+F)>C?C,^SC;_`'GS?9N)B&>Z&;_73-I7$LO<XLP4C<'B]J9*
M70ELC+%J+IL$N;4(9T0A#*`G<J#V#]IZ]+%0+O0-;ZB(`6ZD)U'@`B!4@,(!
M^CV(A<8IQ#M&@&`.VVI@9,)^TN^E789KG4ZEZ#/>QZ\GVV)I.8=.!ZB"N(,L
M/'R+=NHZ.3811=8)0SD54[TT;2IB4HGK<`/8?VGKTL5#6^@:WU`1`UHC"]1Y
MJ"(.+!$`Z>RW`4QTA'NJ"9NZ\!(#4S+]I+]*\EF6#*/?01;^8R\Q27GWS+'9
MK'>HL)64>R^(Y''IMP%?IZBUR"Q93!7ABIMS&51;FK84]Z8.M3]IY]+`<%2A
MZ!??.TX+`4BL)U'JE`#\^"150#I[3U2D!9N!@"V\$5/8ZH:0:XG[3#Z4A$AT
MFWH`-WVZ1CLU"IDQ;J(*0#Q5X0ISE3Z>DRG/$E;L@1&A=/E1T[+D]$*_=1'I
MP>M_JIQC&,,WP_9TMS,WQ3#<A=93C>.S^V^Z>5P+"<=1,Y">)?5_/.DS+H`7
MR,?-J`1PFU27(85!(<I5C%#>^$\Y_DMLW=IZ.YCS4K6:[..V2*]MHM%J36^.
MU+=.+<6XM69K,3#%DQ?4X_%:LQ\IX_GZ2ESHG],'UH[=1N8[)[8_L_>Z^S^W
M;QMN1ORYC<=VZW4Q^">;A;?[9MIK',?9X[B?23`8LQ>;F2FVD+C:)TF`.59*
M2(J45G*A$SP\YYJ?-YL.2-32T\>##].M-;'..LQ]3)EFU^Z][7R3;+:.^UIF
M*5I2.*TK#[CQ_3B8[K6F9YZSS\(CIZ<1T_GYGXG(/[3!Z48R1&ZG[/\`;NG;
M%1=-N7'%>H?2!M(';GDFY$S=/)DR(R`I"*I:"50U@G`UE#:5D1UNA^U[==>Q
M*$&]WT]$#.[/,,@=+-H5UNAEF[VW*$^M'EC5I1K!N,PV3C$7[ELW4.)RI"J9
M$'*1C@($]L#]3_HB^O7./2:]$F`=7V3[8-MCG.=91G,*TP9!](92S/%87E`8
MXE-Q^12,7C2LDUFSQ3LQ3D:`FD=73`R@H"8X=,2-I8++Y1`]NEJ4C0+?:#'5
MI[K-9JZ*].^W7+WZ?G@E5;R0*L"J2"2BO,`(*%C@*0H$8B5>XH+*TUC$4$//
M);J`%36@!@4@VEJ!640$0`*CX:`5$"I@(TYP:5,4P^M<`>IV@"VEJ#240`:#
M0?#0&@VG`!_"^VAA*/\`T?7[`R9M+"!K91N41`X%$8T#6B8'0)B(<X%U@J)"
M/==I#W7^:`=M+#?9*($KJZ=8T#V7`^TJ^ZRWZ0K(5[KM`W=J>8"?EY$SIT5-
M^DFJ*"8ZQF`')IJ*3(-4@)JD`1:&52$PZAA4TQ["7\`H,VE1OLE$"@(J65C0
M-8!A>:8#[K"[3!5$![KM$>[4\T`6TK4U)-``$36AX<`V@)EQ*%>;"MI3IAZ]
M@_==@'+2ORFAWU_HX.ZX!I^%_<]G_IX`*VE0$MTF@8`$MWXN`*@!FXG`!YL;
M;BD4#U::@#]KV@E8-Y'ET1(_332N$=([`!/:"S85"B<54!`5`27H-@4UB]@Z
M?G@J(VE@LOE$#VZ5](T"WV\AJT]V#9JZ#BG?;KE[]/SP"-I8++Y1`]-*^D:!
M;[08ZM/=8V:HHKT[[=<O?I^>&"MI8`+=*(&$`)</AH%N$`;`<0#FQMO%-40\
MFH'?9YP)G;>2!`-6025("S2XA(X"F$0<-PN`=9Q0`.`F]B/9V5"EW`*1;2U!
MI*(`-#4'PT!H(E5`HB'-A6TQB#ZE;1\O8&3-I8;[91`M=2RL:!K;@=@G7W8%
MVF*J(CW7:(]U_F@';2PWV2B!*ZME8T#V7`^TJ^ZRWZ0K-Z]UV@;NU/,`.VE1
MOLE$"5U;*QH&LNY[2K[K"_2UF]>Z[0-W:GF`F7;R',MP%^F)S\V#<X,`M;B)
M7)@,H&J?5HDHD7V:=13$>V^TH*1;2M1I)H`%1I^+@&@"942@(\WVT*8@>O:(
M^KV`<M*U#\9H4J%0\.#NN((A7F^RI0$/WZ^IP`5M*@);I-`P`)+@\.`+@`6P
MG"O-C;>5-4`\FJ'?9YP!&TJ%E\H@>FE?2-`M]HLM6GNLUFJ"*].^W6+WZ?G@
MF2;R/.F]WI7D9QP.3^'@!7!RN#"H*8:P`B!TTE@I>I:*X#0+`O!05M+`!+I1
M`U`3O$(T"WB4&6J(>ZQMU!17IWVZP=^GYP!6TL`%NE$#"`$N_%H!40*@!Q#W
M8-+S$4'U::@?<]H5>WX2=ISF+\T[(Y$<HZ?;;&H-[:=5NRMPC196ZX?W*>OP
M%MN`.`H;L&?=7$>B#9W*X;(6V82<%TQ[=3T#BK3#TF+F549;<PDA'P)5VSZ6
M<N'!F1`:D,F@*BRUI[>T2""3:+?K?3<S=.5V\F,0G,&BV2&X"K?*I;!%@:WX
M9EL?`L4G@+/B1Q3S4<^*N!$72HE6,*91.""P@$O3^X&/[-95D^1;S[OX?B,$
M]A]JL>;93E+>(PO'DY>?R/<1C!Q#J2DI11@@ZDG]4D#JKI%454*F%3"0!V'C
M?$^3\SGMJ^)U\NSM5QVO-,=9O?LI'-K16L3,Q6.L\1/$=?2$+Y*8X[LDQ%>>
M.J5,*R,N=1T;ET'(/"PF00S>1A'+Z*0:J2L*L[=GB)Q!J*QEV["<8'3=M2K`
MFXY=8@JII'$R9<.]IY?'[5]+/-?U&.>V\1//;:/S4F?29I/-;<<QW1/$S'6?
MM;1>L6CTELLM`L3!2642357(C8?&RN3,6$?CC:7G#NXJ,=N`3QYH!%W*DTZ2
M*9%`B(`JJ933*/G<54E"(;K^F5&CR)GNGS>E+<G$<2B)W<_!,?B(24>X1+O'
M+**>QJ_..8UZYASS+S\620H$1E8]%=XF4J2)J@\(7K1GI]7)5F_3_OO"1V(X
M;N/ETFEE>(Q\-.RIL$79MV<+CT:FY?,EWT\NNJB87#M`6CE`R0%7``4$-5+=
M<D5B98T3[([SLDLEGTX]N`82PB5E9J7?JMDO$VCOE5T)5XL@`*I'*9R5R]CD
M3`8SZY`'DGU893,XU@\MC>QV\:4UGV09'`1V/Y?B[6!>0/U9R.*@WDIE)&9Y
MA6-:':2"KPR=NH@1FX*:NG>8$,QUC3T?FF3X,QZ=NHU^_P`=R&2QAG..<!CH
MO%LL?LI`\6C(8E+K2"X2^.JK)'<KO;4R-8T@NA*<#)D."3(^L/-H'$=MY='I
MKZAY;)MP\6=SRN/L\!0%G@LK#R9XZ:QC/Y4KE53'I%,C=1=L<&ZZ;E$2&3O$
MP`(>$IU8[QQN#8MFY>FG<Q^61?9&URC'HEFK,3\&Q9M<0<XI/1+%E!BK/1>1
MKYB@W7*8K1=@9NZ6,0Z+1<Q`^YOK5F&S-LKC?3YU%Y$I)R3N,AWA=ND6<0^,
MFSE7L>_27.[._<,Y)&)4.!$FYUDTZF,6ZPB@6MVOS5]N?A$/FJ3"=Q,LLI*)
M^!9)%MT)=H,9+OXH3N$BB0"D=<EJD[/8'#OX"0.5DOE0/@*/\?@#E9+Y4#X"
MC_'X`Y62^5`^`H_Q^`.5DOE0/@*/\?@#E9+Y4#X"C_'X`Y62^5`^`H_Q^`.5
MDOE0/@*/\?@#E9+Y4#X"C_'X`Y62^5`^`H_Q^`01S:1%NI24``Y^5_V%'O"3
M>`(^S]4>`7\K)?*@?`4?X_`17N3F^4X/([<,8J'<9,GFV>1.)22Z#5V08./D
M;B.)4A6$3*HJJQY!%VH5VHQ:\BT<CS`*@BDJ%6X?K=R&2RI]"O>F?J:QV#0F
M,9QIIDV1[;MHYD_GIK-1Q:4*V32>O%5HN(BW;673<$`P.V8KE):JB)3!>F-;
M2(MU*2@![OE?]A1[PE'@"/L_5'@(^W8R+<C$8*&<8!`?7G()C+L?Q[PT4F[1
MO'1DDX4&5GWJZCELB5K$,4#G$#K(@8PE`#"82D,$"3'4IN>VB\6>Q&S63N9?
M),<W8R4<-G6\I"3[%MMY#A*1#([Z/Q;(L?/)9.LJBV2;"Y*\456$6R#A-!<Z
M8*T>HC=)7,<BQ\FSN2+Q$5DH0S"600E0?NHMYB6:Y!C\XYC5\528)IY+)XZP
M9(II/U"-0DKW2B2J96ZH>>S._NY6[61RF-Y9MJ_V^9L<9B9]K+JDE'S=[*_6
M=NPD8DP2^-8THT",!<C8ICDJ[?LY`$:H-2JK!<3E9+Y4#X"C_'X"L^XN[^[&
M#[@OX*,VLR3,,(:X_B:B.5P#%JX75R?(WV6J2+-1B=TBMX5C4%BQ%5SHI+F4
M</VZ5Q#'`!!I2'4;NBW?;AMHK:&;R-GB,QNC!P3Z*3G4E,AE-O%,,39,G$?(
MX6T7CDLD+D$@=%XF9RT4+%&%D9\FJ5;@-(_ZH-W&6,LYU+9"??K+26.I"FR+
MD*K&1AI?'1DQE8=4V"DDS.)N?*2)AVJ[1(557C95ZHR*98B(.5UOWN"PZ?6N
M^!]M99_F:SJ(B'FV<8"RBZ/,[EJX<^<LY$T0+I^U:1H&>H*@U(#P"E`A0U"A
MP&WV/W3W^W%R(&>X.U*NVV.J;=PF9IRKP4%7))C)9Z<9QV)+-5797!)./@X0
M';P-$%$1=)D<)M5!*DH%I.5DOE0/@*/\?@#E9+Y4#X"C_'X`Y62^5`^`H_Q^
M`CM!M)?E;D1&5`2AMW`U)X>AYUN632A_/U+BWH$.G0.[4N[RAP'Y8XKTIOHI
ME/VAY_M:GTVF1ZHEH%OTK!UKC@$CSK_?QI-IPC[;\<`Y#Q!DT78('@`W%!MX
M@H0WAYC!CA"/Q#OYD_6P3%M[,\V8#;++\J';_),1Q&5R_$I#')5$L_F.Q6=[
MV0L=)8N<[*?BW\JG@A(IL5(CUL=S-LCG72J=$@,KHNZLG?5)N9O`Z:8)F>WC
M8-OMI<Q8K9(E"R,0JG(Y-O-@3J'BY2/63-)2$:_V\,Y>B=!N5!1V#8H*"B=0
MP=%Q:28@:DL`5`]H\@@-HB5P!1^^=M@J)CZ^G_RAX"&\Q;S`YWL=R\XHU:GR
MK."*LSQ3945UQVYSWE7!US%9'3!H90I@("5%+.T>T3"$RG:R8ZEDJ!+M6SW`
MB;3OY_2[U`OTN80[_9<OV_?#4`,UDQ$]LJ!`-J6!R")K`,+T4^T5`NT@71#_
M`)6AV^S&@`M9,;J2H!43V^X$1M`3.1('WSML*HF'KZ7_`"AX!J9JT?#"I:SD
M[U/ZQ8>?ETHTJAO,R^%5!402ALB4`K8I;[^6*!++Q6;@`KI@ZP:R8"%94!`!
M+4.01"H`*(F#[X-+@(</6O\`6#@*U]5W1ML)UP;/2>PW5-@<!NUM?+2<--K0
M4PP%F\CYN"=,G3";QV?C7+6=Q>:3!)RCS<>X;N#-7JS<QS(**)J!..&X+#[>
MXKC."X.Q@L1PO#H6'QO&,4QG'(R#QZ`Q^$:1;".A82(CB(,8J,9LF"B2**)"
MIHIK`!0HF6H.(C23"RZ6`]NE>/((%U+.1U>X_F:N@OW>QYCL^]EJ"99H_!6/
M!22%14KD!*J5@@!2@5B8J]Q026MUQ(>@WI6ZM*FH!3`I!I*4`!E@$:!4?#T`
MJ(%3`1IJ=EQBF'UKO6X`%I*4[)<`&@]OAZ`T$2G`!^^>H80'_HT]7@`S24$#
M6RP%$0/:/AZ`V"8'0$&@J>=8*J0^OI?\H>`#M),;[)8"7:MGN!`VG>#[2[SA
M=I"NAW^RT.WV9J!X<J_%TZ!.1%-4R"8ZXL43%TSJ3`-42@*1`-R8K)F$15.)
M]/M*0#B)@4&:R8WVRP$J*EGN!`U@&%X*8=JGG:0+(A_RM#_EC0`6LF(FI*@`
M")J!R"`V@)EA*%=0*V%.0/7L_P"4-`.5DZ_TJ%*UIR"'==6E;_N>S@`K63`2
MW2P&H)+@Y!`+@`R`F#[YV7E3.'K:G_)#@$K!J_!LB))$4T@,(Z)V"(&L!9L)
MR".BT$-0$5NW3+37]6P!$%1&DF%E\L![=*_W`@74LY#5[CC9J\NO_P`WF.S[
MV6H8*TDPLNE@/:"5_N!`MXE!CJ=RGFZHH+=WL=?_`)!:@%:2@`6Z7`P@!+A\
M/0"X2E;`<>Q3LO%)0?6U?^2%02O&DAH!JR0JD!9I<0D>A<80<-O.#VIY2TY1
M-[`:`/>6EP`J%I*#6DL`5`U/Q>@-HB54`'[YVVB8H^O9ZX\`&:2@@:V6`M04
MM'P]`;!,#L$Q[3^=IBLD/KZ/;[,:`':2A@/9+`2[5L'P]`VG>#[2K4_GZ0N$
M/)=R_;]\-0,G:R8WV2P$NU;/<"!M._GM+O.%^CS"'?[+E^W[X:@)5VK\73?\
M8")S<V#=0&*(E;"8KDP"?VI2^B2J9`JHE44J^<)A+P"H6LG4:2H``B:GN!`:
M`)E1*'WSMM*8H>O9Z_`'*R=?Z6"E0&G((=UQ1$/OGJE`0_?KP`5K)@);I4#`
M`DN#D$`N`#-A.%0/V7E24#UM7_DAP`1K)@)+I8#VZ5X<@@6^T6.K2A_,U006
M\MNOV>P+4$J35^#TX^(B)R,XXKA06"`%<F3<&,<2B"1-.\B2P"4%5+.8J`%M
M+>"DK24"RZ6`]-._\7H%OM!D"@]B@VZHH+#_`,G7[/8!4`K24`"UE@,(`2X?
M#T`N$"H`<:`IV7F34'UM3_DA4*O;\).DIS%^9=@ZKE'3[;1LFA8(=5NR@&&I
M#&NN$*T'NX"VW`'`4)V';[H8KT.[/95C^53.8S<)TQ;>9!CV(,<?QJ.<3#AG
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M<OZ5NHQEF+\&$9F<7`8]`2D%`9%X/*O)9&+G%(Y%3(H*.?PK@"O$4A*=F!%B
M@8ZJ"*P/+'^I_,II7.&7Y#-]!D\/A<?GF**6,LVK/,&T_F!,=.QQA[,P$8F^
M>Q$.Z0E#B-H.&NH(%1,0Q`!F-NLO/91GCAHOICZD`E,E7Y=O'O<:A41B3^%)
MR22\VNI%MF;1E*ZM62A5S'.U2667(@HD#=0'CC/55DV1[@XUA*VP/4=C4?DC
M_'6A,NR7$(5C%1+?),<E\B:/9EHWCG;Z/*U3CTV[DB@$Y1P=4C@R)T;5`:L5
MUD9U/ODXN%Z9.HY:0-$LY9;Q/'HV#C6Y%9I]#OF9I:1QE-JY=L@3;+DY?62<
M)+*"0_M!A,#38=>>6RD2ADT5TR=2$OC<I$24C#OHW&XE05%H>/DI*0:/E7$&
M@B1RF5-LW,FW!P)'1'92&7!%$7`=&6!7SYBS>A(234'C1NZ!L\8,D';<'")%
M=!T@HR3.BY2OM.0Q2B4P"`@'=P"KDWWRNY^"Q_Q7@,\F^^5G`_\`[JP__4VX
M`Y-]\K./@S'XOP!R;[Y6<?!F/Q?@#DWWRLX^#,?B_`')OOE9Q\&8_%^`.3??
M*SCX,Q^+\`<F^^5G'P9C\7X`Y-]\K./@S'XOP!R;[Y6<?!F/Q?@#DWWRLX^#
M,?B_`((UH]%NI25<![OE0_!6/>$H\`1_!_5'@%_)OOE9Q\&8_%^`BK<K+LPP
MV1VX90,3)9,CF.>1.+S:[9JJ(P41(7$=2Y1C\;F&Y#QJ9A>',].R9\HT7**X
M+F034"K$/UD;AR.5/HB0Z5>J+&\?0F<8QQEDT_AT,@V?R\OFOU:F%6[=C'2#
MA2'BH1VUET7(%!-TW!PG<15("&"]L:T>BW4_&K@/=\J'8U8^I*/`K^#]X\!'
MF[4UN9C$!#+;;PRV9Y%+9=C\$JQ52CT6L9#2#A09F?>**"Q1!O%,4#&H=PB!
MCB4H"8PE3.%;,PZE=[<?QN#GH7IXW/R23F,?SV6^HS=H0F4IR./HJFQF)UFV
M)/89$KXX(GD%%EDEP1<`$>W?+IF1$$KKJ:WK1RI*'2V0S56+>9-"1<<8\9D*
M4XO#3T>NNRD7:?Y-CXW&O0.J@Y<(JR(`R9HN2KF*LD8J8.G9C>W=O=#(Y3'\
MZVVF-OHYGC$5.-)=5M*K-7LT&3MF4C$J'GL+Q<6@1Q'!6R7FJF>/&#]1,"MD
MD#KA<;DWWRLX^#,?B_`5DW&W1WFPW<1_"PFU^3YE@*&/XF=MD\"WC5'9\HGW
MV6J2Z*C91(RQXG&H/&D5%01;J&5=2+=/62$P`(1I,=2N]\?E.48S&]/>Y,^W
MB7NY[:)RB.:+%QMTMA8-QQ6(DW*^%%<-Y3,&J;EYS#=->,(@9JDU</'*JB2(
M-Y+JHWW5:OED-B<ID3,'>+@==E'Y@W9.F<LUR$%T&993:=G)JS$Y(P[$L40&
MXMDF^0,E7ZR`).;0M+LME68[B81CV7Y='/<,R658RJ4OCAVP&3CUXK)9:*3Y
M5:2B8QZ[9.4&A5D5U&R`KI*%4!,@&`H!,/)OOE=S\%8?%N`SR;[Y6<?!F/Q?
M@#DWWRLX^#,?B_`')OOE9Q\&8_%^`CI!H^_*Y(B,LX$H;=0-2<HP\ZW+)I0U
M3\M>%Z*9D^P:`"@C[("B`1(AT1=-#?JI5ZVR;486'5.XV];;8.=Y`QN(+E*^
M*(&;@8#*%:@V)/N621V"DL5,)0T2H$?S'))IH%"SP,GX``#,.1$`*`CRD?YP
M@5$#"-&P`%PIF'LI2\?(%`_,?Z27T_6S_HLO2%8CTV9OMWN5N,3=AKM;D&\6
M70,"UC_R7[?2D3D4#`R^"QJL.1WO!DJDZ)'+QHV4(U19MU&J#A1_>U1#J!U$
M>D?8['3^/1.-;&]06\\?E&T;K=:,D\)VLW(2DDFQ,C<PIFLEC:NTCR0AHJ%9
M)"YE'CLR;IBJO&H@Q7!\=5`(MQ'KY>[M]7&RFR#7:+<K"&)-[-VL&:91E&.Y
M#$&?MV/3[O#GL+DYXJ<VG@F,81Q%P*"ZK?Q,^DTFX90YEE7KA!J'8([)^:^V
M8<IW:ME&L>;3OY[3I<V&[1YE*E:UY8M:WJ7`&9/S">V8<DNU+0!JP'3O%Z)`
M"YL-VD#A(`K6O+EK6X]P!F3\1-28<E`1.(`#6/&T#"X$H!5L-;`5(`5[](*]
MYJ@T,XCW2D&D"KEQ(D#(\/4Y48UHZ`-/+H94JVFEBV3*!R@`"@*<L72%,#BX
M:@47*0/`&3\*5F'(T$HC[ECPN`!1$P#1MV7@F8.SNU!IW%H&"LGX"2Z8<F`H
MIW`+6/"\""S$X#:V"FJ""@#2E-<U*6DM`(R?ELNF')[=*ZK6/#4LY'4K:V"W
M6Y96M*4YDU*6)V@$9/RV73+D]NE=5I'AJ6`QU+K6P6ZW+*UI2G,FI2Q.T$BS
M)X"T=?*.E3D<U!3DV%``K`2*B:V-5`FN*9^T#HT%80`PT*005`RD```&9<B(
M`%1Y2/"H@5,!'L:T"X2B/_2'U`"@9%D_H/XY<A4!H/*1_94IP`?P7O`3`/\`
MT0\HU`,R?B!J3+DHFOM$&D>-EQ70$$*M1`=,5DQ"M:Z(5K<>X`[)^:^V9<DN
MU;1!I'CIW@^LI<U&[1%RE2M:\N6M;E+@3<D\%V[LDW*:AT$AUP:,!\Q0\R""
M!1-'%*<K(S@A@JJH813"XI0.8504F9/QOI,.27"I:`-8\;`.+P2`%S8:Z0.$
MP"M:Z!:UN/<`+)^(B(3#DH")J`#5@-M3+"4.UL(B!`4*'KZ85[S5#/)/Z_TP
MY[ZTY6/[0N`:?@W=3L\O`8!D_`2UF'(T$M0Y6/"ZTR`F`:-@$+P2.`T[M0:=
MQ:`DCF3PK9`2R;E,@&KHBS8$["KMC'((>&,C`"H(*A73((<P80]B00!61D_+
M9=,.5+=*^K6/+J6<CJ5M;!;K<LK6E*<R:E+$[0",GY;+IER>T$[JM(\-2P&5
MXC:V"W6%LK6E*<P:E+26@`R?@!0&9<F$`(`B+2/"X2@V`PC1L`!J"B<1IW:H
MT]B6@(WK%[RU#RKI8NJSJ4&<>81$'+;SZ!&.^T#%$WWN@5[R`%Q06"R?B`TF
M7("(&`!!I'C:(@J`"%6H@-HG*/;]P%>\:@&9/Q`P%F7)+@/:(-(\1()@=@00
MN:B`Z8KIB%:UT"UK<>X`[)^:^V8<DNU;:-8\VG?SVG2YL-VCS*5*UKRQ:UO4
MN`.R?FOMF')+M6RC6/'3OY[3I<V&[1YE*E:UY8M:WJ7`D<,G@NVP^).1,87>
MDH#-B8&HG*Y,`@88U;N(L0@7*)U!(*WB8P""L63\1$0F'(`(F$`Y6/&T!,J(
M`%6PB-H'*';]P'JB-0SR;ZM?&'(A4.SE6':`&((A^#5[0*(?]+RTX`*R?@)1
M&8<F`!((@+6/"X"F;"<!M;`(:@(G`:4IJC3V):!@C)^6RZ8<GM%*ZK6/#4L%
MD)P&UL%NL#94!I2G,&I2U.T$J3)Z#Y01E'(B5G&E54,S8`#DR2YC'J8L:F`:
MA45`$I53V\R80*G0@B"HC)^6RZ9<GMT[JM(\+[`9@>MK8*:HMU1&E*<P:GL2
M6@`R?@!:S+D:`6H\I'A=:5`#"-&M`O%(XC3NU!IW%H%7=^$7",YBX+O5'E<H
MZ?;=1%LE93JMV5`PARZ2=UX]O;6GJ<!;;@#@*&;%QFY6/=#>SN18CF.793D\
M5TP;<S>,XHC'X(Q"5D6NVL)(QN.-G"6W<V[]O`A6:(BBNL<1*)A$XB?@)#P@
M-_Y#.'L+EN1Y,TQ!<^YJD)D[:$PQ@Y2;X=E.(8[B[:;B'>WCAN5SF#:2EWS5
M=)\4KEDP26(W(54P%#2[M97M!M/^4*5ZGMR(5#:>5QO:K&<AF]U8;#OJ&D;)
M<JSZ,B8W,%!Q0N+L(%Y*&33YJ5(FS(NL0BBP"9(.-Y[=\9Y_RGDZX/;%,^3S
M-*VR4C!,QFXI'-IQ]LQ>UHKS/;3F\Q$S$3$2Q9;XJ4YS3$8YZ=?3K\_]Z?\`
M!YL^9QL9E+4^114?/0R,G$(3+-BSEG$*[=N%8:1?QSJ+(\B5I6,,DYY-RFD[
M:E5!)PFFN51,NNWM2=';OIVM6^3'/;::SS6+1^:L6CF+16W->ZLS6W'-9FLQ
M,SK;NK%OA)P9*ZD(#',@G6OUBGW,-"2TJV@H9K$KS$TXCV#AVC%1*`QEJTG(
M*(@D@0>PRIR@/9Q4246;=4'47'8]B_UIZ2M]#YDL$?%YNSQD^)R&-PV0>$RB
MTRO`2#?'Y9S.8TVE(98$G*8*`=HHB*9UG"S=NN#R@NH;=^6/G#13I]WI2?8I
M#0$Q#'48,HF*S4TSF"<$]BH%_D.`Q8@^A,?=)R@ZQ$U5T2*E619'(8A09C7J
MLWXD6>.&9])F_P"WDLB7,W.RD4(ALGCUL8D^1=3SQW@4='(LI)9:U`4W!U4D
M4E1=D:NBI,EP>&+]2&[&0;@XQB,ATW=0&*X]D;_'FRV;SK#'?#X)ID./R4X1
MY,M([$GQ&0Q:C5%H](=R4&;E11-8Z9TTBN`:.WG4#U7S>38EA6<].&9X[(9$
M_P`:?RV:H`P;8)B^)2Q,1>3";TP0N0+N<JAFTO(-]$72`<RW1%5)(.;3:A[8
M;U&=24CF<3BF2]/^;-F$KG,9!FS1K$Y%'XU&P#C)F["4=N$7NV[ERY/$XZY%
MR#UTO#LW"K=P%J($;E=A?WDG/RM(?S<5]&<`<DY^5I#^;BOHS@#DG/RM(?S<
M5]&<`<DY^5I#^;BOHS@#DG/RM(?S<5]&<`<DY^5I#^;BOHS@#DG/RM(?S<5]
M&<`<DY^5I#^;BOHS@#DG/RM(?S<5]&<`<DY^5I#^;BOHS@#DG/RM(?S<5]&<
M`<DY^5I#^;BOHS@-?&LW(MU/QL_#W?*]R47ZDH\`1[8T>T1[>`V').?E:0_F
MXKZ,X"*=R\BSO%Y#;EIB<5+Y*VRC.XG'LG<H,>9&`QY\(I/IC4CL=?-H[PY(
MYGAG#\460I-#H7@X7;@(50A.JS?J0RE_&2O2)U$8[C2$SC<`RR*20Q=T+UY(
M9IX!/R)&4'B\N["!C,:>-I=!RHF@@LFDY14624*F!@OK&LW/+J?C9^'XPENY
M*+]24>!ZL:/:/`1[NW([H0,!#'VMCSY1DDGEV/P[I"12C>1BL>>+JFG9YS:2
M+*(1K%`1(!G"93*F*'G"($,%:<SWVZCHO&,5D\:V9R<V23K#-9&7QJ<ALAE$
M<=;0+F*1AN:FL/V]DFYY*00DKR,5$D5Y`4EM$R*:!U3`B4Z@NI+ZQLV26Q6;
M!#24]`-6*3J!EDIM*!GHTRZ;J8DF^&O,-B91@NZ07?E,].WCDF[ELH<[D2&*
M#NV8W7WVW!R.5@]S]MIC`89KC43+,)GP>:;-W>0%R5HVDHI9QD6)P:#<&:+H
MJ#9-(72KU1@[>#HM%66L%Q^2<_*TA_-Q7T9P%8MQ]P=^<4W#?QN+[;36:;>(
M8_B8-)N*\+2EE,HFGN6K3YS@HQ<%7B<:A<>:`*";4IEWDFB472(5`0BN<WZZ
ME&.;9?!0>R^3Y%CT6_W(B<5ED\?R2)=34AB2+=6"=2:\K@C:"9XO+`@Z(G(M
M7#L\HNJV(Q;&2$[DP:<G43U0G;/E$=B<I?G8N\:'7)CN5Q3=ZS?-<C(_:LV<
MMM^C**2<O)1,=RJ@)F:0S:=2-)G*9B\X"=<7SG=^5V;C,_DL)DF^Z#A>,CY3
M`A0=PY4&AMR%,<E7S$LOBIYPS5KC&I)M3N6+8SM,A#*$;$4$4PB)QN]U?_7&
M-Q..VC2?LY&?=@;+#1,G&Q<;A;93(5VL_*)2K5G&-Y:8:Q:*"<:234>M5S:B
MJ)B.&R8AOX_>7J*;XEMZ?)-GLP;9]D"^V;[+FD=`MW>'PT5G&22,9D$''R$.
M3)I9IE>#P3,K]ZM*)-8Q,ARE44(LHF@8&;,=5F_D5F&:0I>D+J$<XQB*LS&M
M,L13QIXVR^5B\F:P[97&6<-B\O*.X.:A^:D&;KE1(=-N4B@HG7;@J'03DW`]
MOBL@%>VFE%]E?4[8T1[.`CI!FY#=R1'Q9^(!MU!5(*450UN632HU$(T#!>FF
M9,:"'F*&$*'`ABA(96+HMM9B1/:!*W)1(7V`U`PFLBRT%46YQ-2E!7/2E$],
M`&+H``!F)$:`4!$4HFIJ`D`B-(L`J84S"-*!4XT[`*!0I/D_2=L)OEU.$W3W
MBVWQ'<O<'IZE,!R[9'+,OQ3%9::VTR*0QJ?8O)'&WZT'S)+U=-ZFBN99!O)-
MT'B)$W3=%5,.7_IN_3NP'H?LJZ=<"_(_N'O!E&\,TWRG*7@M6^+X9`[,PLRM
M%9F&*9D]QY6$R?=LYG"?)1!#F18)E1<22B"3EL1X"S<CTI4+N;N5LV]Z=>GG
M?3.I+93-,BD\E9[I[3YULA(QKG<3HSW%W.QY%DYG]D9A6`9HQ68QC5]XB>*.
M^=`'(-9=%NLZ(%S8GKWW>E]UL4P,>E;<V&QS*\EV5B$LJG4LSBW[2&W=!L5_
M.K09]D'41'JX<$NNY59/IENJFSQJ0,].T5332>!T_,R=&OI,2)+M2EJ42.G>
M+P2VWQAJZ7,DMNK7ET[JU5U`R+)T(FI+R!:B>@`E%4+<*X@`71@B($!4H!6O
M8D6M1$XF!G9U'K*0:(*.7<B0,DP]3E%F$>\2JEET.J5844<0R)4!:"4%`4Y<
MND*8'%PUM%TD#Q!DZ`0K+R!J"6H"E%4-0R0B`TC`&A@3,`TIV*#2@@42@%9.
MBVUF)`]HDK<E$A?8+43`:R,+0%0;G`U*4!<]*43TPP1BZ+968D5+=.ZY*)#4
MLY*^^R,)36Y52ZVVG,J6VT2T@"L71;*S$B>W2NN2B0U+.3OOLBR4UN54NMI3
MF5+;:):0(UV+D%XT#2C]42.3#J';Q0F+8P$AQJ2$.1,5Q2-<-R/:L<"FI80`
M6<BZH'XYD1H`!448GM$"I@(C2+`/.$@B-/5,-.R@`!R+J@_CF1`:"%01B.P1
M`X`(5BQ"H"8!\E2AZE0$`S%T-U)B1+<!P"U*)&RX'(%$MT6:HIBN00K7M1)6
MH">\`[%T:^DQ(IW:EMJ42.G>#RVR^+/71YDEMUU>73NK574!*#)R9X[`LF^2
M,9NB8%R(1E]JBDP":`'4AA3.FR%P4R8"=0U4RWA0Q]8%9F3HPFI,2!+A4H!4
MHD0)>+L2@6Z,,(@D#@@%K6N@2ZM5-0`63H1&DO(%J)A``2BJ%`PK"`!6,$:$
M!0H!6HT3+6HB83`<DZK_`$Q(4K6FE$]UP#3^C.ZG9^YZ_;P`#)T%*R\@:@E$
M0%**\ZT4!$!I&`-#@D8!I0:*FI00()011K)P5HA23?)E`PCH@WC$R4*L@8Q+
M1A6AP*J#<]:$(-'!Q`>Q(Q`6$8NBV73$BI;IW7I1(:EG)7WV1A*:W*J76VTY
ME2VVB6D`5BZ+968D3VZ=UR42&I8#.X3V19::O+'NMMIS"EM*):8!6+H`+68D
M36@0!$4HD!/:#<#":V+*`"H*)A&E.U4U*`!`("-^P<BU$#2L@K[:S\TS>*/4
M0=-O/M+".>THE$WL*`(UJ0``Q06"Q="`_CB1"H&H()1-0J54`$*Q8A4HG`0K
M7M(%:@)@$`S%T-U)B1+=?02I1(V7@Z`HENBS`.D*Y!+6M10)6H"I>`9BZ-?2
M8D27:EMJ42.G?SMHDOBSUT>:3MNNKRR=UU5=4`[)T:^DQ(DNU+;4HD=._G;+
M+XP]='FD[;KJ\LG==575!(X9.!=M/QD^$3"\L4Y>,,9L)R.#`*1QA50*)2K%
M(%YRW%2+6\1/>"P63H1&DO(!41H`)15`J900`*Q@C0H'``KZA`KVB81`!DZJ
M`^,2`]M::4500N*-/Z,K00*(>6AA]6E`"LG0"41EY`UHDJ`I10`>T6XF`UL8
M40!0$3`-*=BIJ4$"6!@K)T6RLQ(GMT[KDHD-2P68FNMC"TUN6/=;2G,*6VT2
MTP2(L7)7ZPC*/A$K.-*=06\6!G`I+',;5.6%3*(J`@<#`100*#DXE(D.D8`5
ME8NBV5F)$]NG6Y*)"^P&@&$UD66FKRQQ-;2G,'MI1+3`!BZ``K,2)J`4!$4H
MFIK00`1&D6`5.*1A&E.U0U*`!`*%7-^4%49S%P5>.'=<HZ?:"X(T():=5NRH
M#;RK9L`W#V]M>`MKP!P%#]C(?<B$Z&MGIW!LSR_(\O8=+VW$OBF,N&N`(-9"
M80VT@Y"+@$E4MOW#@$5U"%9I"IJJ6&`3G$]5.`<>$NNHM[N[)XAEV2Y>C@0L
M,XE(G)T<#Q*(%-I#9<UQO%6CV:'&9>$<3DVW9/G_`"Q2HBK%JM7-$#G,VX"7
M6.&(2.;Y]!Y3+O\`-HJ2P/`VS^/RF+Q%XP>LW$UN*51B\CF>,L(]XS]J$;%4
MCW"<UUP`4"Y<.;-KY:Y]>]L>>L\UM69K:)^<3'$Q/[8E\F(F.)ZPDTK%;Q=4
M`DY`OXN0-_L`][EP%*G8F,/=ZH\8GTGR5:3@\<R":CB3^12$1!RTFP@(P(CQ
M*;>L6#ATUB([F&)6_/R*Z144=003U#A=YM>`YXQW4#URIO,+83?3++JR#E[$
MQ&?L(DT<FVC9!K&$0G7>,98N=YB3N'R;(1<+13ARX!M%1K(`D%SKO6H<`YL2
MWMZNIK%YV2S/9N=VXDXZ;V[8ID1Q)QN`Z;1\[@\I+Y>Y2QB!79N,K&-SJ.:Q
M2*D;(Z#-G+ING9Q,S=IE#<P>^W4U(-\@":V`S/'%,:QEW*K.S`695G)EGEN(
MQ@PT%",,-(D[4<XA*24LF5I)2(FT4&Y3G=%>MFX(,BZG-^VSW)OJCTP[PY+#
M0*N4%BY15>.C5<K^K$R_@S%;1Q]N%'<.67.W3<,P,5V\5)>0S5,H:P!?)J@Z
M<-FRZC^4;*+H(K';K$BP60.HF4YD50+'6@HD8UIJ=E0X#WY)Q\JR'^A&_1W`
M8Y%?Y5D?L1WT?P!R*_RK(_8COH_@#D5_E61^Q'?1_`'(K_*LC]B.^C^`.17^
M59'[$=]'\`<BO\JR/V([Z/X`Y%?Y5D?L1WT?P!R*_P`JR/V([Z/X`Y%?Y5D?
ML1WT?P!R*_RK(_8COH_@#D5_E61^Q'?1_`'(K_*LC]B.^C^`01K%<6ZGXUD?
MP^5#NCO4E'@5_H_U:5X!?R*_RK(_8COH_@(;W8R3<_%)7:9E@&/R67,,MW-A
M\:W`?`@DJ;#\(>,9$\CDZ1FT4J@@K'NTT#"=T!6PI`<E=4Z)3!6&$ZE.J1YE
M+YE.='^[6/XHG-8W`1TVME>$RSMVX>9D,-D,T9C!8?(N"0++$WB$JV553;)"
M9LY0672,9(W`7RC6*XMU/QK(_A\J'='>I*/`^3_5IP%%LRWRZO\`$]P,]CV'
M39D.<[?X_+*,<2EL8F8"/E,L;J34`V;O$32,=+%:MO"<L0$#';"47$1(F6.@
MV*18@>4[OEU7CB./3./;/2;#(YE3<QR_Q^>QG*YEG!P^+RS!ABIGLE!8<QER
M3\TU='5(R&*!.2TE3-UTD4TE70>BF]?5O];8UDGLE-$QF2F8Q'37B#?6"/BY
MR%%Q$IR$NU:.\,3?-9%VFK-.#.4V<.W9.6Q><>K-2'!Y[,;C]1.;9)*0^[N!
M.,,@$,9BY*/EVL%)Q8.,D3R9HUD6#A6;8<HDBFDX%!FF@JZ6=!'+OU.7:NV"
M:@6.W-?YCBVWN9Y-A$?+9IEF/8Y*3D'A[;PHCW*GL4U4?%QR,.LT0;DEYM-`
MS9F94Y4BNE4Q/YEW`4;:]1/6>Q:-HG(^EG)E,G72,FO/PDNR7PID_9Y+(XBN
M!&;'$LAF7C"9<0:LI'J'<-M.,E&!WO+(@Z>)@ZYK>7JR;YKF\)CNT$G.XY%2
MN;Q>&2KW'GT"M-ACS24/'R<F^=M58<D.H]C6R;=5`U^0$ER':D:\BN"P>CK=
M3J^;8^WGFNVP3!G,A!MR1(8D^AI4K8T,N]?N!CUW\B_01R:6>Q;)JHY2;#CI
ME7RDBFX28&.J$LXOEV]<GLU&9M*8HJENXJM&,I;#2-'$.S\/#<E2#EGT8SG(
ME&922+B`*2#(7B+=182IBJ1(IS%*%6X[J,ZY'@N@D>G&8AR-7;,Z!T(&0EEI
M=B,Y)H.6[-$[6,292:K$C9LES2J;4JZ3EXLNBP59*+!,^';L]3<MBSP\WL[D
MZ.7(2SG0=BU@\>PYQ%-,KP:.<,$&<R*V<K2RN.Y')N&CM2/;L%EH<XC[08JB
M@-/*=_>K;'L"Q>3@>F#-]R,YR5[F#-Q%PDQBV&1.*FA%XHD*;(6N7Q1Y`C66
M<2BC1)R1P"+KPY=\71:JHEX"S^S6:YMN-"9%(YEA&9;7/H;+G\!'1>2*1Z[J
M<B&T7#/FV1M3?5:#*5FY<2*S>TJ:I"K-5+5E"T$`W2#%<-W)$WBTB(!MU`U(
M(1MAK<LFE1N_%UWGD2%,:"'F*&I0UIBA(98]P6VLQ)GM`E;BQGGV`U`PFMC2
M]J@MS":E.U<]*>UV`!'N```\8DQH!0$1+%U&A4@$1I&!VF%,1&E.TYJ4\VT(
M@Q"-<EW=WE-XY+FU&&V5I#A#BFA;"SQ!T`+$%.&H8;S7F/YP!2A?-X!-O3TQ
M[&]1K3!V.^^W.)[LM-L]P,?W4V_0SK&\=R!+$-PL64=JP&50A'\2J1M)1YW8
MAV@9-8A`(J50@G*<$.78TS-N9L?.D4,VF%<CS./6D4HK&PD%FR>W>XIF::L@
MOC99(4HX\BH9!,IR(@(B)RJ7J"H%<-Y^KC>?;?J"3VFQ;I]S+<#!B3&U\;*;
M@X]'YPJZ8H9^SRM22/%L/R0KXGD+C'5VK,[E5K/+-8UH057IRJ@HT.$=[0==
MV^&X.6Y]B.X_2_N9L\GBVS^<9\VR`D#G65MSY+`Y<7&X_'%"N]I\9:()EYQR
MB5;5<%D74`^5::K!(KQWUGMCVML^>W=3ZE]?%X[/OTUYMEV,.&9G\%LG;&2]
M;3%:7KS:(FL6O2O/=,0P9L\8JVXYF\5YZ1,_N]/W)>C=PM^G\5&2"F[&-)*O
MXIC(*)I;2Q8II*/6)WATTA/N&H?33.I:2ZX;2IU$P@<5O6MOVE[`U]S-K4\;
MOS3'FO2)GR'7BMYK'/\`\?Z\<<_MB?3GBM"N?:FL3WUZQ']C_P![YELOWA<M
M2HS.X>/3C3Q.'639%VJBD"I/&<XW=LGQA'(\GU$H]TS(J)102["5YIH(<TGI
M_(^V?9?T*SJ:&[BR?5Q\S.]W\UM>D6KQ^AIQ,Q:8BW,]L\3VV_+.2F;8Y_%:
MLQQ/]GC_`/8FR/='?;&H*7GQW/QN2"%:F?C'GVMC68/DVRQA.U,[2SMTHU%P
MFWMU"I*"2XX@01M!/?>*]E>PO*>1P>._R_?Q_7O%._\`7Q;MF8C\7;.A6+<3
M/IW5YZ1W1ZSBOL[5*3?OK/'_`(?_`'&YNCUC;YX!U'O-E\6Z9<_W,PMAD&%8
M^&Y$(TSAJDY>9/B,5/.&P'7V:'"W!(YR^UW,DWG#PS=@TD4%'24LDFP2_.<-
MND/I/Z@=^]_7CUSN1L=)[,8TQQ1M*\S,N\I1G%\G4S:>QY/'48[+=JL)2D&I
M8K#G"[]=$Q%&JCI,2)G;O&:Z877*P<%LK,21[=*MQ8OVS3!E=?9&D^_<H>ZV
MGX0I;;[7I@C68+E6CBC*2"H@Y$=0Z488Y=-B8IA`Q8<Q4]<4C7B`I5UC@`TL
M(`*PCW%`#QB3&@`%1+%U&A2`(C2,#M,)!$?4J8?6H!R#B@AXQ)A4![;8NH5*
M<`$*Q@A4!,`_NE#U*U`-'N!NI,29;KZ"4L9YEX.0`2W1HA[6*Y1+6O:B2M0O
MO#)F#@U])B2)=J4M+%C9J`]`HDOC3]J/-DMNK^#IW5]LU`2\DN9X[*$D_3$S
M=$P+D3CM2U929`B`'/$B0R;,7!3)@)CF`4R7A03ZH*C,'!A.(2\D2X5!`"EC
M*$O%V)0)=&F&B7,E`M:]B"=:^V:@`L'`B80EY(M1,(`!8RA;C+"`%NC1&A05
M``K7L3+6HW7`<@XK7Q>2[ZTMC*>R`:?T=6E`I^YZ_;P`#!P`EK+R1J"6H"6,
MH:TR`B!K8T.PX(B`TIV*&I3S;01QS%<&J!@DGY``PCI%2CB)T(NW$26^$-C`
M53EC`;S2C1=2@UTQ("PC!P6RLO)'LTJWEB_;-/D;K[(TGW[E#W6V_A*MMOM6
MF&"L'!;*S$F>W3J)BQ8:E@,P,)[(TGWWE3W6T_"%*4]KTP"Q[@`*`S$F:T"5
M$Q8RI[0;@(FMC0"J@H&$:4[53TH%E@(WS!<&W;*2"U%F?F'2C#@(@Y;!<)2P
MZX5*);JV4`>VI0`!*"P6#@0$/&),*@8`$"Q=2U!4`$*QH]I14`0K7M(6M0NJ
M`9@X$#4F),MP'H)2QE27@Z`!+=&F"J8N"B6M?O)*U]LO#)V#@U])>2)?J4L)
M%^UZG.VV7QI_O/-DMNN_!T[J^VZ@!V#@U])>2)?JTL+%^UZG.VV7QI_O/-DM
MNK^#IW5]MU`1N&*XNVOXR?B)Q>`132CC&;7$<&`43C$*6"!5RD"XX5*D2MPW
MW@L%@X&OXWD@J)AH!8SLJ900`*QHC0H*``>L0*U[:@`P<`-?%Y(>T!H)8RG8
M8HT_HVM!`HA^X(^K2@!6#@!*(R\D:@D$0,6,H:T6XB!K8XHT4!`P#2G8J>E!
MLL`*P<%LK+R1[13$;BQGME@LQ,![8TO8KRIP-;3\(4MI[7I@D28K@^5_&<@(
MILXTIU!2C0,X%-<YC"L<L00#"H#<X&`IZ%!PI:5,13$`5%8."V5F),]NG6XL
M7Y]@-`,)[8TOWWECB:E.U=2E/:],`&#@*?CB3&@%`1$L7YUH(`(C2-`*G%$1
M&E.U0U*!;:%7=^6ZB$YBX*.W+L391T^T%R#8!+3JMV5#S>6;-P\X>T:U[>ZG
M`6UX`X#FUTK;D;+,.F/IV9ONKF#CGK?8_:HCN-=;J[/HKQ;GZC08K19T',6#
MEN$8H(H%35JJF5,"G$3`(B$]_E4V+_7$QO\`.SLU]&<`@3W"Z?TI-Y,)]7^-
MED'[&.C72_Y7=GAU&<4O)N6"6D,>*1-!:8<#<4H&-J4,(@4M`6?E1V)`XJ?I
MA8UJ&(4@G_*QLS=803&*6OAE:`)Q&G`??Y5-B_UQ,;_.SLU]&<`?E4V+_7$Q
MO\[.S7T9P!^538O]<3&_SL[-?1G`'Y5-B_UQ,;_.SLU]&<`?E4V+_7$QO\[.
MS7T9P!^538O]<3&_SL[-?1G`'Y5-B_UQ,;_.SLU]&<`?E4V+_7$QO\[.S7T9
MP!^538O]<3&_SL[-?1G`'Y5-B_UQ,;_.SLU]&<`?E4V+_7$QO\[.S7T9P!^5
M38O]<3&_SL[-?1G`'Y5-B_UQ,;_.SLU]&<`?E4V+_7$QO\[.S7T9P!^538O]
M<3&_SL[-?1G`'Y5-B_UQ,;_.SLU]&<`?E4V+_7$QO\[.S7T9P!^538O]<3&_
MSL[-?1G`'Y5-B_UQ,;_.SLU]&<!@-TMB2@($ZPL8(`G54$";K[,$`3KK*+J&
MH6+`*F55$?6[NX`X#/Y5-B_UQ,;_`#L[-?1G`'Y5-B_UQ,;_`#L[-?1G`'Y5
M-B_UQ,;_`#L[-?1G`8#=/8DH"!>L+&"`)U5!`FZ^S!`$ZRRBZAJ%BP"IE%1'
MU@[.X`X#/Y5-B_UQ,;_.SLU]&<`?E4V+_7$QO\[.S7T9P!^538O]<3&_SL[-
M?1G`?)]T=B5``I^L+&3E`Z9[3;L;,B6Y(Y5""(#&4&TY`'][@/K\JFQ?ZXF-
M_G9V:^C.`/RJ;%_KB8W^=G9KZ,X`_*IL7^N)C?YV=FOHS@#\JFQ?ZXF-_G9V
M:^C.`^?RH[$7BI^F%C.H)`()_P`K&S-UA1,8"W>&5M`QA&G`?7Y5-B_UQ,;_
M`#L[-?1G`'Y5-B_UQ,;_`#L[-?1G`'Y5-B_UQ,;_`#L[-?1G`'Y5-B_UQ,;_
M`#L[-?1G`:XN?]/I996<#J^QL)-:.0BE''Y7=GZ&8-G+AXBCH^'Z`"1P[4-<
M!;QNH(T``X#8_E4V+_7$QO\`.SLU]&<`?E4V+_7$QO\`.SLU]&<!I66:=.\?
M,S>0->KV`)*9$G%)2RYMX]I%4UR0J#AO'%2:JLCM6FDDZ.!M$A!4$:GN$`$`
MW7Y5-B_UQ,;_`#L[-?1G`::0S3IVE).`F'G5WC9GV,O'S^&,WW>V>9-VSN2B
MWD,[5.Q91[=DZ%2/D%B`"J9P*8XG``/YW`;TN[6R!0`H=8N+T#NNW0V/./[Y
MCPIC#^^/`-E[E/37)2TI-ONK'$G$G-8TEA\HX-NOLTF+K&TG,D\+%B1"-2(B
MD9Q+KF,=,"*'O`#&$"DMV^#SOE=;1P^.P9>W4U]R=K'';7\.>:TKW\S$S/3'
M3BMN:QQTCK;G'.*EK3>8_%->V?W=>G]*,$L&Z,$4DD$>K!\D@BD1!%)/J[.5
M-)!,ATTTDR!F``1,B:AB@`=@`-`]3CJ;_<_WADO.2^31G):TS,SX[QW,S,Q,
MS/\`POK,Q$RP_HM>.D1;C_SW_P#46ML4Z-FQS*!U5)NQ,`!9,=443D#<ABK%
M7*NDSGL@DV:#Q)0M4G!$RN$##>D<AP`P4]K[@^Z=S%&'+DU*TB];?@TM'%/-
M9B:\VQZU;3',1,UF>V>(YB7VNI@K/,1;^-K3_7)&I@W1<N04G/54J];G$FJS
MD>K%&28.2D.131>,'^5.63YL<R87I+)G24"I3%$HB`W*?=#WEBM&3#FT\>6/
M2U-#Q]+UGB8YK:NK%JVCGI:LQ,>L3$Q#Y^BUYZ3%IC_S7_\`4G4N[6R!0`H=
M8N+4#NNW0V/./[YCPIC&_?$>//UI@V[.QYPH;K%Q>E:^;NCLBF/^DE#$-_Z>
M`\_RJ;%_KB8W^=G9KZ,X`'=38H0`!ZPL6-0P'*8^Z>RAU"&`IR525/$F51$2
MJ"`V"6X!H-0[.`/RJ;%_KB8W^=G9KZ,X`_*IL7^N)C?YV=FOHS@#\JFQ?ZXF
M-_G9V:^C.`/RJ;%_KB8W^=G9KZ,X`'=38L1`?TPL7`P$!.\NZ>RA%#$*=0Y2
MJ+$B2JK`4RIK;S&MJ-*5'@#\JFQ?ZXF-_G9V:^C.`/RJ;%_KB8W^=G9KZ,X`
M_*IL7^N)C?YV=FOHS@#\JFQ?ZXF-_G9V:^C.`/RJ;%!['K!Q9,/4(CNGLH@F
M'_-20B4TB5]6A0J/:/;P!^538O\`7$QO\[.S7T9P!^538O\`7$QO\[.S7T9P
M!^538O\`7$QO\[.S7T9P!^5/8KLKUA8N>ABF`JNZ>RBZ=Q#`8HBDO$J)&$I@
M`0J4:"%0[0#@#\JFQ?ZXF-_G9V:^C.`/RJ;%_KB8W^=G9KZ,X`_*IL7^N)C?
MYV=FOHS@#\JFQ?ZXF-_G9V:^C.`/RI[%>KUA8N(AV@8VZ>RAU"=@@.DJ>),J
MC<`T-88MP=@U#@#\JFQ?ZXF-_G9V:^C.`/RJ;%_KB8W^=G9KZ,X`_*IL7^N)
MC?YV=FOHS@#\JFQ?ZXF-_G9V:^C.`!W4V*$0-^F%BX&`@$O+NGLH10Q"G4.4
MJBQ(DJJP%,H:V\QK:C2E1X`_*IL7^N)C?YV=FOHS@#\JFQ?ZXF-_G9V:^C.`
MCK<;<'8UXPQL(?J!PW<#+I;=_IK@HA@KN7M_+2AT#=2.UCY5C$16.G8*.EW2
MR!3&#264'3`"T"H"%[^`.`Y_[&)YK"]-73N^P_:_#\R@T.C'"9Q-LK',6LX_
MW+88CMP7&X;GE7A4U(Z7AGLDL<@-!5,LT*',$$Y2F!];,N=[<ASE=KNWL]A.
M*8@ZQ&7FD/#\:C`4AIH<G9-\7A!G2Y++^.NWV,*NEGY/#V0LUVZ8=H*A<%J/
MJKC']7('YGC_`(OP!]5<8_JY`_,\?\7X`^JN,?U<@?F>/^+\`?57&/ZN0/S/
M'_%^`/JKC']7('YGC_B_`'U5QC^KD#\SQ_Q?@#ZJXQ_5R!^9X_XOP!]5<8_J
MY`_,\?\`%^`/JKC']7('YGC_`(OP!]5<8_JY`_,\?\7X`^JN,?U<@?F>/^+\
M`?57&/ZN0/S/'_%^`/JKC']7('YGC_B_`'U5QC^KD#\SQ_Q?@#ZJXQ_5R!^9
MX_XOP!]5<8_JY`_,\?\`%^`/JKC']7('YGC_`(OP!]5<8_JY`_,\?\7X`^JN
M,?U<@?F>/^+\`?57&/ZN0/S/'_%^`/JKC']7('YGC_B_`'U5QC^KD#\SQ_Q?
M@#ZJXQ_5R!^9X_XOP!]5<8_JY`_,\?\`%^`/JKC']7('YGC_`(OP!]5<8_JY
M`_,\?\7X`^JN,?U<@?F>/^+\`?57&/ZN0/S/'_%^`/JKC']7('YGC_B_`'U5
MQC^KD#\SQ_Q?@#ZJXQ_5R!^9X_XOP!]5<8_JY`_,\?\`%^`/JKC']7('YGC_
M`(OP!]5<8_JY`_,\?\7X`^JN,?U<@?F>/^+\`?57&/ZN0/S/'_%^`J=O%*;T
MXCNA"M]M-D<;SW;=?%&QY<Q(&&;NHZ>6FGJ,A(JR"LHW7?HQ\:1H"3!NW(X.
M=<Y_;DM11D$.2VXW6C&LU8EOT7;;R<VC`1+A+*&>1PJL#(S[ZBRL>3'Q50=L
M4DC&Y!=560%-FN47HZS00)P$C83F74-D^7SD5.=*.*X1B#S%<OFL2RN<D,?>
MNF,Y&-&#3%H&?QV,7%=T:9E"K.50YEB<&SDJ91`6RBB@:#=;/.I'"VD!+8=T
MQXEFZ&/X=`Y;NE$,XUFD^>'=X;-HR^/X$9%X\4DY]CN`Z:+"T13>J$B(AT0!
M4</V0@#=@=XNJK(GZ+!IT,XU'M3Y+.8\[G\AR%A!L(U*+5,S9S9HYS#J24I%
MR*12R8';^U`FH,<50[I(RI@?&VV8]24]GK=AG_2EB&*X1)3<;&.I)O(XXX<X
M;'$@)9Y+2KA4'2RF9@.1MV3%,6C=HGHOM<H&*T7U`E#I^<Y[E\9-GW@VNQ_%
MG[863F+(.$M<==`F_?Y`12'DF7C>61RTE%QC!BNJJQD'36K[2*HH9(QS!8?Z
MJXQ_5R!^9X_XOP!]5<8_JY`_,\?\7X`^JN,?U<@?F>/^+\`?57&/ZN0/S/'_
M`!?@#ZJXQ_5R!^9X_P"+\`?57&/ZN0/S/'_%^`/JKC']7('YGC_B_`'U5QC^
MKD#\SQ_Q?@#ZJXQ_5R!^9X_XOP!]5<8_JY`_,\?\7X`^JN,?U<@?F>/^+\`?
M57&/ZN0/S/'_`!?@#ZJXQ_5R!^9X_P"+\`?57&/ZN0/S/'_%^`/JKC']7('Y
MGC_B_`'U5QC^KD#\SQ_Q?@#ZJXQ_5R!^9X_XOP!]5<8_JY`_,\?\7X`^JN,?
MU<@?F>/^+\`?57&/ZN0/S/'_`!?@#ZJXQ_5R!^9X_P"+\`?57&/ZN0/S/'_%
M^`/JKC']7('YGC_B_`'U5QC^KD#\SQ_Q?@#ZJXQ_5R!^9X_XOP!]5<8_JY`_
M,\?\7X`^JN,?U<@?F>/^+\`?57&/ZN0/S/'_`!?@#ZJXQ_5R!^9X_P"+\`?5
M7&/ZN0/S/'_%^`/JKC']7('YGC_B_`'U5QC^KD#\SQ_Q?@#ZJXQ_5R!^9X_X
MOP!]5<8_JY`_,\?\7X`^JN,?U<@?F>/^+\`?57&/ZN0/S/'_`!?@#ZJXQ_5R
M!^9X_P"+\!#>^N.X^TPS'G#6"AFSA+>SIL,DNA&,4EDC?I%;6!<FHF@4Y#``
M]X"`\!8+@#@*(;=_HR_D_P`&_)Q^E?\`D\^I^-?4/PG]/WPKZF>"LOJOX9K>
MV^'>":&A=YVE;7@'C_<Q_B^_S\<`?W,?XOO\_'`']S'^+[_/QP!_<Q_B^_S\
M<`?W,?XOO\_'`']S'^+[_/QP!_<Q_B^_S\<`?W,?XOO\_'`']S'^+[_/QP!_
M<Q_B^_S\<`?W,?XOO\_'`']S'^+[_/QP!_<Q_B^_S\<`?W,?XOO\_'`']S'^
M+[_/QP!_<Q_B^_S\<`?W,?XOO\_'`']S'^+[_/QP!_<Q_B^_S\<`?W,?XOO\
M_'`']S'^+[_/QP!_<Q_B^_S\<`?W,?XOO\_'`']S'^+[_/QP!_<Q_B^_S\<`
M?W,?XOO\_'`']S'^+[_/QP!_<Q_B^_S\<`?W,?XOO\_'`']S'^+[_/QP!_<Q
M_B^_S\<`?W,?XOO\_'`']S'^+[_/QP!_<Q_B^_S\<`?W,?XOO\_'`']S'^+[
M_/QP!_<Q_B^_S\<`?W,?XOO\_'`']S'^+[_/QP!_<Q_B^_S\<`?W,?XOO\_'
M`']S'^+[_/QP!_<Q_B^_S\<`?W,?XOO\_'`']S'^+[_/QP!_<Q_B^_S\<`?W
M,?XOO\_'`']S'^+[_/QP!_<Q_B^_S\<`?W,?XOO\_'`']S'^+[_/QP!_<Q_B
M^_S\<`?W,?XOO\_'`']S'^+[_/QP!_<Q_B^_S\<`?W,?XOO\_'`']S'^+[_/
MQP!_<Q_B^_S\<`?W,?XOO\_'`']S'^+[_/QP!_<Q_B^_S\<`?W,?XOO\_'`'
M]S'^+[_/QP!_<Q_B^_S\<`?W,?XOO\_'`']S'^+[_/QP!_<Q_B^_S\<`?W,?
MXOO\_'`']S'^+[_/QP!_<Q_B^_S\<`?W,?XOO\_'`']S'^+[_/QP!_<Q_B^_
MS\<`?W,?XOO\_'`']S'^+[_/QP!_<Q_B^_S\<`?W,?XOO\_'`']S'^+[_/QP
M!_<Q_B^_S\<`?W,?XOO\_'`']S'^+[_/QP"![^C[S6,>/?I-Z7U_VW\%^M_Z
E;OU:^NOU_P`:_)[XS]9O_EGD_KYX;7Q/\75IS7M&IP%S>`__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g17073img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g17073img02.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!T`*H`P$1``(1`0,1`?_$`.````$$`P$!`0$`````
M```````$!0<(`08)"@,""P$!``$%`0$```````````````4!`@,$!P8($```
M!00``P,##`H.!0@&`!<!`@,$!1$2!@<`$P@A%!4Q(@E!46$R(Y345975%@I2
MTC-3)%0E%]<8<8%"DI/3-#56EE>76)B1T;9W.&*"0W-$9*1%\'*BXR8G*!FA
M8RFQP659&K+"A*4V.3='M\=(>+@1`0`"`0,#`@0$`P4)```````!`@,1!`4A
M$@8Q$T%1(@=A<9$4P5(5@=$RDE-"TN(C8]-TE!;_V@`,`P$``A$#$0`_`/?Q
MP%=@ZI-3JNYEHP9[EG0@,ERG$)*0QCIHZD<J@OI#A61RF(Y0P89'C>IY2`F"
M1&20KIH==FY7;G50-8H8M!$/I^L[K;^CG4'_`)2>JS]"_`'ZSNMOZ.=0?^4G
MJL_0OP!^L[K;^CG4'_E)ZK/T+\`?K.ZV_HYU!_Y2>JS]"_`'ZSNMOZ.=0?\`
ME)ZK/T+\`?K.ZV_HYU!_Y2>JS]"_`'ZSNMOZ.=0?^4GJL_0OP!^L[K;^CG4'
M_E)ZK/T+\`?K.ZV_HYU!_P"4GJL_0OP!^L[K;^CG4'_E)ZK/T+\`?K.ZV_HY
MU!_Y2>JS]"_`'ZSNMOZ.=0?^4GJL_0OP!^L[K;^CG4'_`)2>JS]"_`'ZSNMO
MZ.=0?^4GJL_0OP!^L[K;^CG4'_E)ZK/T+\`?K.ZV_HYU!_Y2>JS]"_`'ZSNM
MOZ.=0?\`E)ZK/T+\`?K.ZV_HYU!_Y2>JS]"_`'ZSNMOZ.=0?^4GJL_0OP!^L
M[K;^CG4'_E)ZK/T+\`?K.ZV_HYU!_P"4GJL_0OP!^L[K;^CG4'_E)ZK/T+\`
M?K.ZV_HYU!_Y2>JS]"_`'ZSNMOZ.=0?^4GJL_0OP!^L[K;^CG4'_`)2>JS]"
M_`'ZSNMOZ.=0?^4GJL_0OP!^L[K;^CG4'_E)ZK/T+\`?K.ZV_HYU!_Y2>JS]
M"_`'ZSNMOZ.=0?\`E)ZK/T+\`?K.ZV_HYU!_Y2>JS]"_`'ZSNMOZ.=0?^4GJ
ML_0OP!^L[K;^CG4'_E)ZK/T+\`?K.ZV_HYU!_P"4GJL_0OP!^L[K;^CG4'_E
M)ZK/T+\`?K.ZV_HYU!_Y2>JS]"_`'ZSNMOZ.=0?^4GJL_0OP!^L[K;^CG4'_
M`)2>JS]"_`'ZSNMOZ.=0?^4GJL_0OP!^L[K;^CG4'_E)ZK/T+\`?K.ZV_HYU
M!_Y2>JS]"_`'ZSNMOZ.=0?\`E)ZK/T+\`?K.ZV_HYU!_Y2>JS]"_`'ZSNMOZ
M.=0?^4GJL_0OP!^L[K;^CG4'_E)ZK/T+\`?K.ZV_HYU!_P"4GJL_0OP!^L[K
M;^CG4'_E)ZK/T+\`?K.ZV_HYU!_Y2>JS]"_`'ZSNMOZ.=0?^4GJL_0OP!^L[
MK;^CG4'_`)2>JS]"_`'ZSNMOZ.=0?^4GJL_0OP!^L[K;^CG4'_E)ZK/T+\`?
MK.ZV_HYU!_Y2>JS]"_`'ZSNMOZ.=0?\`E)ZK/T+\`?K.ZV_HYU!_Y2>JS]"_
M`'ZSNMOZ.=0?^4GJL_0OP!^L[K;^CG4'_E)ZK/T+\`?K.ZV_HYU!_P"4GJL_
M0OP!^L[K;^CG4'_E)ZK/T+\`?K.ZV_HYU!_Y2>JS]"_`'ZSNMOZ.=0?^4GJL
M_0OP!^L[K;^CG4'_`)2>JS]"_`'ZSNMOZ.=0?^4GJL_0OP!^L[K;^CG4'_E)
MZK/T+\`?K.ZV_HYU!_Y2>JS]"_`'ZSNMOZ.=0?\`E)ZK/T+\`?K.ZV_HYU!_
MY2>JS]"_`'ZSNMOZ.=0?^4GJL_0OP!^L[K;^CG4'_E)ZK/T+\`?K.ZV_HYU!
M_P"4GJL_0OP!^L[K;^CG4'_E)ZK/T+\`?K.ZV_HYU!_Y2>JS]"_`'ZSNMOZ.
M=0?^4GJL_0OP!^L[K;^CG4'_`)2>JS]"_`'ZSNMOZ.=0?^4GJL_0OP!^L[K;
M^CG4'_E)ZK/T+\`?K.ZV_HYU!_Y2>JS]"_`'ZSNMOZ.=0?\`E)ZK/T+\`?K.
MZV_HYU!_Y2>JS]"_`'ZSNMOZ.=0?^4GJL_0OP!^L[K;^CG4'_E)ZK/T+\`?K
M.ZV_HYU!_P"4GJL_0OP!^L[K;^CG4'_E)ZK/T+\!,F(Y5!YUBF,9MC#M9_C6
M8X]"Y5CSYQ'R40X>0>0QK:6B7:\5,LX^8C%G#!VF<S=VW0<HF$2*ID.!B@&P
M\!7GIB__`(<9-_\`[#=7'_\`U9N?@+#<`<`<`<`<`<`<`<`<`<`<`<`<`<`<
M`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<!6WJ.PO?.8M->#HG.8_"7\
M#FR4SE@R,BYC4)R`1C7J:46HHA`9$1RW-(G3%5)5N=(2><)%!*!!"OZ.K^O1
M%"/%?;F)O6P,\=4+%-\C\+EH61C1V$^GV;[*'.I9U'-&&0N)N'CR/%&+!1HP
M8E<=S5=I"+D'N=U-UM*/]:/\3WSC$>P@,"QIEGD)D:`R:F2YXP/-O9I^1\SQ
M`@GB'2K*%9D&J"JS56045+SC)"8'1CKSK=E(S/VN4;BUPR'+-9NX#$_`(F1;
M2N`9X246\)R7Q9E%1:4PFKCSD22/)29F/)$!1J"#?EI)!K&9XSZ0#!8A-IKK
M.\)VN@Q*TCF"T['0<+ECI`5A9M7LJ>28H12J[=<&KF0<&>*J'BRO44TE7ZC5
MXD#ZCB7I!E)&:*MM;2+6-9#%KXXL7&7;E6<<%A44Y9I.HACZ`Q<0K.H"HD#8
MYW9$5U"\TUB8@&W8=AO6&EF31AL;:&N,AU:[QW+FLXMCL&^QW8!9B1;$;8\>
M*D8]DQ8QY(PX@JFNF'-(//O!03-Q0#1":RZ[L:QLD=B.Z];RCR+QJ-9,0SN/
MELF=S,^&-1#><EYK(7,,E)"NKDWB#AD5,"-4R"V!5$4P51$/S]!O2%Q\4H>.
MW!I!],N9EDX<I2V-33F/3CGL@=W-G8?D]%PT48)D1;LFMYD`9"N!CBY,BX('
MZS'6'7>WV!G>2:ZWKKLV(/Y557`<0S*%=O4H2-6FL??D),=Q@FJCM1)E/9&V
M.0':@=VC(8$S`L=THF'PR+6W7)+X;"-&VV,:C,V*_P!F2,[,1$RV911T)#PA
M/`\:;19M8GYL/RT7@&=E5;R$6F9("G>.3G>)!\3:MZ\4\PQB4+O##'D(D^A7
M.9QRB0-HN1$T"Q8R`0,:AAA7L5'0TD,FX[L=VL,PLY8F.=HFS.FH$DZ)U[U.
MXGG3J0V_LUEF^''P]6(;QYI%)TZ0R-"8;N2SC=%AA^*HWS5SU93GBMW%DJS8
MH@/=UEUPM]P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!
MP!P!P!P!P!P!P!P!P!P$*]-G_#KH/_<KJS_8:"X":N`HOH3IYT-EV(YKD>4Z
M9UAD>02O47U;+R<W-X/CDG*R"Q.J?<B!%7K]Y'+.7*A44BD`3F$0*4`\@<!O
M<%IGHGRB9EL<QG6W3=D.00);IN$@\:UW*RT04%00,,E'L6J[ID!%S`0W,*6T
MX@`T$0#@-1V;J+I$U2X7S?/M3Z1Q+6N%:HVUGF=3DI@&+HPL)C^(KX#+RN02
M94X=03)0\4@NI4I#*`2X"`(FH,MP/!<QY1SFS\:\>VV7><]R&ZQ;;;8,4=V3
M-GSWKCQ8J1\;9+VK6L?.>LPQY<N/#CMFRS%<5*S,S/I$1&LS/Y0@O4&0^CRZ
MD(QKL_4N`Z@-KW`Y?.H#:2^6:B9:Y5PZ3A</QS+`3S.'SC&L?>Q*".-9/&RB
M2SA,$192"2H&#SP+[+[G_:7SS[.\Y@\>\_V==IO]ULZ[K!-,V#<8<^WMDRX/
M=Q9]ODRXKUKGP9\%^V^M<N')68Z:SK[+?[7D,4Y=K;NK6W;.L3$Q.D3I,3$3
M'28G\IA;5IT_](#^,C)MEJ#I_=PTT6/-#RK?#<$6CI4LOW4(H8YZ1B9N]\3%
M\AW?EF-SN<2RMY:\W;C\L-!='LJ^?1<7J3I[DI.,>O(V2CF&(X"\?1\C'%:'
MD&#YHW9*.&CUB200%9)0I5$@73$P!>6H/:?2[TOK`44="Z65`Y3'(*>O,/.!
MBE-88Q1+%C<4I^P1#L`>S@/K^JMTS?X?]-_W<8E\U<`?JK=,W^'_`$W_`'<8
ME\U<`?JK=,W^'_3?]W&)?-7`'ZJW3-_A_P!-_P!W&)?-7`'ZJW3-_A_TW_=Q
MB7S5P!^JMTS?X?\`3?\`=QB7S5P!^JMTS?X?]-_W<8E\U<`?JK=,W^'_`$W_
M`'<8E\U<`?JK=,W^'_3?]W&)?-7`'ZJW3-_A_P!-_P!W&)?-7`'ZJW3-_A_T
MW_=QB7S5P!^JMTS?X?\`3?\`=QB7S5P!^JMTS?X?]-_W<8E\U<`?JK=,W^'_
M`$W_`'<8E\U<`?JK=,W^'_3?]W&)?-7`'ZJW3-_A_P!-_P!W&)?-7`:)CG3'
MTY.,QV*S7T1J%5JP?XV5DW4UYBITFI7.-,5URMTS18E2*LL(G,!0"IAJ/;P#
MPEH;HY7R9UA2.INGI;,6,<E+O<43Q'`3Y(TBEC)D2DG,(5D,DBP4,L0`5,D"
M=3E[?.+4%ZW3ETF-W3=BXTMH=!Z\*Z,T9JX/A";IR5BB1P],@W/'@JJ5F@H4
MZHE`03*8!-0!#@'$G2STQJ7"GH+3!P*<R9A)KK$36G(-IR&I%#0Y![!#R@/`
M:-CO3'TY.,TV(S7T1J)5HP<XP#)NIKS%3HM0=0"*S@&Z9HL2)`LKYQK0"XW:
M/;P&^?JK=,W^'_3?]W&)?-7`:Q#:,Z-,B>2,?`:KZ=IM_$/G<9*L8G%-?R+R
M-DF*_=7K!^V:,UEFCQFY]S534*4Z:GFF`![.`?6?3'TM2+<KN/T5I%\U.=9,
MCEGK_#7+<RC9=1LX3*LC&'3,=!RB=,X`-2G*)1H("'`?B2Z6NFI".D%D=`Z=
M3519.E4E"ZYQ,#$4304.0Y1"*J!BF`!#@-?P'I>Z;GF"X6[=:%U`X=.L2QQR
MY<+:[Q159=PO#LU5EE5#Q8G4554,)C&$1$1&H\`KR30O1WAR#!UEFI.GW&6\
MK(DB(Q>>P[!(E*1E5&SIZG&L3OV*!7;\[-BNL"2=R@I(G/2TAA`%+GIXZ1F9
M5#N]-Z#:D2,R(J=SA6"H$3/).Q81Q#G58%*4[]\4440$:JJ^86INS@'G]5;I
MF_P_Z;_NXQ+YJX"/\WZ<^F*!D,%=/=*:6AX0N23+F>=N\$P]A&IQD;KO.)%5
M>4<+1R39-@R,V!<YU1!-/E@<1"VH`^QNANCF9@2Y3$:FZ>I/&3M7;XN0L,1P
M%W""RCU%$G[OQ1!DHQ!NQ51.18]]J1B"!Q`0$.`>4NF/I:73251T5I%9)<I#
MHJI:_P`-436(HH5(ATCDC!*H4ZIP*`@(@)A`/+P'[#I@Z7!MIH?28W``EIK[
M#AN`4U%0$OY,[0%)(Y@_Y)1'R`/`?0G2STQJE`Z>@M,*$$3`!B:ZQ$Y1$IA(
M8`,6*$*E,40'UA#@(HVSTXZ`B6<`T@=(:PC)2?=9/"1KB)U!B\^JE+.M?Y>,
M4[7B`Q6;:NVT>](5<W>FB[0HI@*I!+V"%.8_I]>RR.;M9/1^E9".4)"Q>&!B
MW3'%XW(/!A\GQ(<Q0E,H#23MQBV034/'SD4F]3.JG'.5BKF004(040C&-U?G
M3)7",3G=0]&\.]<2TACDP[=]-I9S-)``*YE#)Q,=(Z8QPN391B^/3T2D+A-J
M@A(NVRKM9LBDZ(@D%@M`ZBA8A]*FZA-.=/LG!OR%QC%$<$Z2C1<U,3S15F=Z
M,[)L-=,F9WB!H1R*C5!!JF#SO(V%33121"S$?KWHIESF3B-#8'+*$;-GIRQ?
M3K*R(D9O5GK9D\,++`5RE9O',:Y316KRU3MU2E,(IGM"LVX=/:P4>R*>NM/Z
MQP]K![/CAFY7+.G^->0[*.D]?XU%1466*F]63+&53G,L?D3*V3>,#G56*JCS
MEC(B4(NFNGN<3PG.9+(M*Z4"48S<>\@B8[TZ(Z\CSXW&XKFS4JIITG3YDLG`
M<S*7L'*29%6TF5R6-=MP.FT<HM#`P(:@V/,/4<>-J+H[C'B.*RC-^]Q7I3:3
M.1N,KQJ/A&KV78P4GJ9XVB4'F4.2]^173>)Q+.4;I'+WDI14"S^A]0X+'L)N
M+ZA]&:*=Y._4"8@X;7'29)P+-I`QJKY-P_?J&P,5Y-P!I5!(H`-4$^60Q!7,
ML8P3RAJ;I`=HI.&?3ABKM!=)-=NLATTS@H.$%2E.DL@Y/K\C95)1,P&*8IQ`
MQ1J%>`HKDNBE))*!G=9:CT^R@)C5V*0T>QS'IJB<BE)7-6,4Z7?.8%:0TS)*
MQ+[N2QU3N'9Y=NZ%JF8$S)IK)H@AGM"3K#-8)]@VC>GJ9CY5@,$X0S;0"R4!
M(S377L3'C%1N,1^B!3BYJ$S^$G)Y]*^)F4>1PBP.V(<$NX@P1^DMLS,?%R\/
MJ+I#>.!EYR&E&37H]1G,6;LXF=*S3=#)QNL&D@\REHX;.V$F@FX;MFPMSI@B
M5T-R87U3P;HVC&,8WRW2^N232+G'L-?.W73FM#DD<Q=0,>\:PT?'DP1$@24@
MR63609H$$>6<H$`?)P'RSG572BRQ63?,>G/'&BK52-.+HO3=-1YT$AE&?/."
MKO`VOF"W`X&M$>P:#Y0`0J/C^D6+;>4RUR+$>G3(\;CIJ:R%SKN*Z2<=/--L
M#R/*E7./IRL435:>4QSV"Q!P@BF\5>F27>(EYAO=UJA&OYD]C8JWR2+9:1Z5
M%U3M\/7BY'8FBC3$B$N\1-CDK*-'!M#8ZP0A]C9\];>$028+FC$D%4$%SBZ0
M1:!+.M=$96&Q\9?Y-J#IJD=8+K,)V8=1/1NBVG2)G91L@[B<1DFNN&#5&(1>
MHJIL73@SMXJV.H<3F6.V!(+9M<.Z&WK^,B&VD=<KS,S`(97%0:/3^\7FW^,.
ME#HML@;P[?!U9$\0NJF8I5^6!*@(5X!ASS3_`$VK&QZ+Q70.-0LI.J95&,'Q
MNFU5-(DDXP'+"1BJS*>UXO'N^Y/;5^6Z;+H43N.0Q`'@*O1G3Z_E4LT:2ND=
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MMQZ>U>I+2!-=:AUCAK*!SZ+-/RN6=/\`&/(9DPE,*B8B(CBQ$[JV782J<UE#
M\A"HD>,#F54(HD"ZIDA($7S?3U/$P7.)+(=+:3),Q\XVD84,>Z<T=?1)<9C,
M-RUL5<\X7I\R23A4"9<YB9:207:R7>DX]RWYI&JZ30X,J.H-CS#]/'CZ@Z/(
METCB\@V>N<5Z4VLUD;G*L:CX)%[),X.4U,\;Q+9_D+Y,7Z2Y'A8EE*MDC!WD
M"F4"SVAM08(PC):*ZA]%Z,>97)K&EX.'UQTF24"Q;P$099)T^>'-@8N)1TFM
M,HI@`#[BD=$@DYYU1,$\M=2=(+]))=CTXXF[170!TW73Z;)@K9PW%$7!%F[M
M;`4FBQ%4?.3$IQYM0`EPF`!"A^3:(<22$-.ZSU+IUC`36K\0A8MGF/35$Y%+
M2.:LHEPJ^=P2\CIF24B'@M'!U3KNS3*#HS1,Q2&3*JFB'PR/0D['9O$26":,
MZ=YB'F6B\&+?-=!F""?3#?#8J)1BF&+16C%?H_-8]G<%.S$A(J20K/F!^Z';
M)^X"R#78[26V9AC%RT1J+I#=KC*3,+,,FW1VE-XPT0A9H[#O(2,9K%K(O,I;
MO&SEE*($<(-VAFQTRH%<7"0+]&P+HWAVC!ME^E=;I3#9[`X6^=N.GGPU*0S!
MQ"L'+6&CFC;""MU'\@T535;MFI3E%,Y03J%.`29SJKI098K)/F73ICC15JM%
MJ&=%Z;IJ/.@EXJRYYP5=8$U"T6X'`U!&H#00[0`0J3":18MM\33;(,1Z=<BQ
MAA/S&2+ZZC.DK'%)U'7F0909:"0EHPFJB95'/X3%'"21'RCT45WR114'W=8.
M`C3\RFQ,71R**8Z2Z5EUG#+%7,1([#T0>7D!EE4`Q^;FF2IM"X]'LX38&=2;
M08J`)W@8M)!1%%<XNT46@2MKK1&6_G%QE_DFH.FF0UDNXC)Z:<Q/1JDC-II&
M:Q,@_A\0D&NMV+9*(3=(+I,';@[MXHW44.)S+':E1"VS7#NAIZ_BXEMI+7"T
MS-P"&51,(CT_O%YN0QETH=)M/MH=#!U9$\2LHF8"K<H"5*/;P#+G&G^FE97$
MH_&NG['(IY+S4Y'INOU;ED4Q76UYG!6?.:3VOE(]Z5L\L7Y3ENLW'EWJ$,0I
MN`JQ$=/DE))9:RF-*Z3D8OPR$A\55Q?I?BH*4D9")E]?ES0)7)"Z1<J8Q.S+
M.*R:,0?(B9.-=/4W!FJ1D4P2"-V&KLYC?H9C4SIOHXA5ULD>XS).)3IS"?S%
MVDX*^EF\:Q;/],8P.699B^,3\0F#E-JV)+.V:CM5NDD[Y*02_I_1B?C,>VW1
MJ/IX>0KG*<<QN`6Q/I>8XA(2<@C(PS>44RS)1P.#A$#B,8\369I)M4SOUE2@
M0$RH(I!T7Z8FK9CTU]/3)DW1:,V>CM3-6C1LF1%NV;-\"@$4&Z"*8%(DBBD0
M"E*4``I0``X"<>`IWTZK[*0P3/%F2&%*PB'4-U>K19#&GU9I9LCU.;B4Y+I`
M"HLN^K2)5"!RU+`2$H]I@$HA6[2&1XSB>S8)[@V$O(Y;;[E5_C,A/Y4$AC\/
M*[GP/'=S90W#'BS[K)8J3DH_&,?"5(=)ZBP449`BHFFZ'GA:3:^NI[<"KS56
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MMFLNGV:;M[D,L$Q)()YYGK=DD](K!+-56:;`T=(D2CU\98*I(]\!-0[1(%N8
M0A2ASYMJ-9KDO31L[+<AS);#I,<B=9Y)&R$V/YI.8N3+LJ9YA)L<=D?`9J<:
M#,+;`@(\CZ&=,6X.'\(O&QYE`<+M60!.FH)K4>H5]@[_`-?Z\+`*8AIS(5AC
MV4])S4'DF-ES]U"(Q6O8V-DYB`D\GRG+L*1;-BM5V[9RX>)7*G5,H8@36'I(
M=,%8B_6SS%4TR1:4JJ5/$]GO+$%GAXE)%,[+'7"3ARMD"*T:0A!$>^MU`-8F
M!53@YCZ0S3X).'`9_B*C5I/,\9<NTL2VJ=LE-22#AS%M+@QCF*GDT&QC(E3*
M=2E.84@C3@-YP_K"Q;.LPQC7^/9%C)\OS*0RF(Q^'?XKLN/46E,*C5Y'*6;]
M5Y`MVT4:".U4:N#.%$P[VF9-/F>:)PLG=MO[SKGWSDWP3@"[;?WG7/OG)O@G
M`%VV_O.N??.3?!.`+MM_>=<^^<F^"<`7;;^\ZY]\Y-\$X`NVW]YUS[YR;X)P
M!=MO[SKGWSDWP3@"[;?WG7/OG)O@G`%VV_O.N??.3?!.`+MM_>=<^^<F^"<`
M7;;^\ZY]\Y-\$X`NVW]YUS[YR;X)P!=MO[SKGWSDWP3@-:B8K:C*=RN43/KU
M5>;>12CEN8V2ID:BPAFC)($EP34%P"R9;AJ1.P>SSO+P$*;/Z55=OSCK(<P5
M9)R#DXKIIP.8Y=#LXY\XQ\N(2TC')M61%$GL]AY`C'1E#*%*WJ=`J#CW?@*T
M;?Z/-7:?Q/-=O2.+`[09)XP@XC(#(YQP6/:J2F+XNU48L95DHP)"1+=%N[?H
MNBO6Z[9F/.;N+$R%!QQ;JDZ?>E[(9?I]@9C&X>9BG<Q/95'-8;<>1IQ;Z,P2
M%EP7DIA[C2XR$GDV,1*3ILL1RY-*N3"-PN5B@L%W<,<9U.&?9[C$AKZ6B,_C
M<3R&/54)DK5/PQ?'&2L8NBI1<RZ;QFX*H`B1(0`>T.V@!!&W^M%OHW9#+6.?
M,HIO+N,:1RYW+1D;D4A`QD$X)D3Y!P[71`S\RR\#@F3R":23=111MC+^@7E1
M*L%"<E8=->SBY7L:-8S.3-'FR,7<NG$'/Y'B#J6G]CRN1Y`C%8M!ST?BTH^3
MBY'$I`[ULS0+).URJ**"Z(07"86(P?K+Q+5&O\9QO$==MHG'DF3N81A&->[X
MP_R;,\HD)W'WB)5F2[0,.5:2JTHH@@[9QR;,J2CD[EP@FJ$V8OU>N=A["9:I
MB(*.0=Y$^R:'9Y&Z1?'@10B8^95;2)N[/SR+<F1F@W@QR#I)JY7:I%="0J"R
M!U0LOC##:L-CF/1"?YOG+>*A(F.3<"?(TUUT6+!NV*MW<4S$(JJ1*ZSFB`"-
M+O5X#FWD'6WHC>3''T<_CF,>C!969?#O&X/8/,<91,X=DN.$7C28LTDSHK'Q
MC+P,V<N3MTTE)1JH`@8#G0"$9QATS0,MK=>5UTH6)R'&]5Y`B5/))Z6QMDQV
MK'10XTTV%!$DGLNSDI(D:@\=(';E&8<HN'`=[Y!S@%M8'K_@VW,Q)KBRC*1Q
MK%&[]O$2";HSARU0,T;1<4C*JRIX]2:&'(N^?IN7"*D0V9+FD>['()>`DV"V
M.ZZJ<-R7\B1C.`QQ_D<!,03].8;RN31N1:MR2+=FBW3"0Y3>/?I3[A!LY344
M%91J<Z8E()#F"@&R(71DLXBLE<Z*\-+*XXG(8VUPK)V3%":2R;5^&YL\2=X.
M]EWHNI2'QIY%#+`NP>($<395W`N5G#80#<>GWIXT3O,F4XYB.+.8UAB[C!\R
M.25V)D\D$UXXM*R;%PSEDC/9=6-C7;)U&N$E'%%G"//7($F@1RF%F8WT>."Q
MHM2A'LWS9N6&2.PD<RRM=B[;P39)JR;.&Z+!ORDCHMD4E3-Q054:)=R$_<%7
M#58+0:OUGE^GL*C=?X0UPI+'(EY/OV:4I*Y(\<)+9'D,KDKY%(Y(]%-%D@^E
MU"-T2EM21*4H>3@/ME'YT#93K#O2.`#3*Y@4R-WF2I*'K@67E6*"QF*A4!%N
M8UI[#B4]OFB%>`@+'NB9E";&:;2?2\CEF5-9"-FC'R3-)`[!UD$9E"V7HY"L
MPBL2C&9)E26>.0%0B8)D2>."D3#FFJ&[Y[TU/=IFG5LZ;XPX?2C/.XN-D8&?
MRZ"?8_'[#A<,AIY2-6;H'NEBIX2W,DNI>C8HHF=`Q#&N#3=>:)EM%3&(:RUX
MCC8L)N?RS;KQ]DV03<BZ*]QAGC^.K1Z8,,98*2*\FOFXN%'CU=5T4J()"=1(
MC=)$--9>CKP2,RJ.RV-(Z9N6&1$R)2*)GN0J0LCRGLC(HP#]HKCYU1Q=-W-/
MC=P2420-WY>X!`_8$G;WUI,9?A6PV.Q8;%9_$,FSC7TBM`1>7Y[B#HL@U=X?
M`8VX6R6%B^_*CC\V1O+)"W2*0SUFB!P$H'3X"JF;N\']'IKISBF82&3YA-[G
MQ+($Y++(Z$F,VEWB>L(;O+UV;%<=;PXQH.PRM18ZR+<K,[Y51Q)O"N'?/6"G
M.WMT]#TAO%S)Y'E\]BT]E^=C,S.P(M_E:NLXXPX4OM:1R)@X(S(RE,8G$L'B
MD7*3!PU=3SM1@E'G=7"<OJ_$?#><\XW]N(\;PWW/-3;!3%@I&MLN3<;G#MJ5
MBTS%:1WYJS;)>8I6.MK5CK&#/N,6VK[F:8C'UUGY1$3:?SZ1Z1U7+UOMS8^8
MZSQ)WJ!'76=ZU2UID&K<)W'';X>&R;/8J)G!Q]/;S65-K++X5=_E+_$#RI`5
M[^FX!Y583")TQZ?S?V1_^4Y&_C_E^^W_`!WE6WQX?W6UOQMN_;9LN'%FM@R=
M^ZQW[\/N^WDUQU^NMM([=):6/DO?I[NWK6^"9GMM%_6(F8UCZ9Z3IK'7T(-9
M8KGNH,F;9GC>J,/DYF&CS14$.1]1V4S#>"@4V4LS\`BVC73(+FC%`DSJ*$$K
MARX62;B8R@MT"\0MOMKX_2EKSS.ZG2)G3^FS&O3TU_>SI^>G\=,G[S+_`*=?
M\_\`PD'4[O776N&6C]/[[R;)L/>Q>/:_RYC-X`QR<,.CI/,IWZ%XC,Y2]>XT
MYGX%UC$TR750\1:,4Y!-9=L1J^6379$X]'IU]4@W#IGZMM/9UG>O.E344JK]
M*]6%RW(6D;F,5F+=:2B(!IDF+NG+O*)%F1)5]D#N>DG3$.6L\5+#NS.&R!`(
M=2HW.0]'<U:LHEC@F726&,HK(X[(BQ#O+\FS6!5>=_4?Y*][AD[-RZ"<R=R]
M>O!='<JI,9AX>1;($<)HBF%A-C]/N1;:8OH_,W<&V26V%&[#8.\2FYW'Y>-D
M(["8[">YLYKPEY*QPN&+)0YG;!9D\*584BG`E_,",]7='DQHW'MDQ&%9`QDD
ML^-C:!?I;)3,P:"C8!HR;D9HJQ\&TE)4[F1(NZ`5U10:=X,FV10(94RH;#LS
MI"2VSE#K*LM79&<.I1>=&'9S0F@49J2Q+'<&R!\5H_PUXN]+.8OBC!#DNU7*
M4>LW([8@V?%*Y`-]RC1<QG$(XQ#,(K`IG"5L<P;'/`1>Y"U,=#7V5L\M@EG+
MMJP2`0%]'H%.5NFV.027I*$&@`&@ZBZ/VNEL@C,GQ5TXDY6'CI".9_2;8&4R
M#9T#^,3C2/9]%"%:DR:78D%R*#Y^#A\FD]5;E6*W(U3;`@V%T<*;7BH..SF6
M3$T/AF"XB(8QDTOCK1=?7Q,K0@LB("6/N99-\9AG$JU7:*/5XUPW=#S4%%")
M*)A)F&:<S#6\3@&*XPMC*L!B&19#-)FF9*?>SKWQZ*R1FY17G&<&VYCM,LY<
M,@](Y?NU4Q6=+.'*JBIPBG'.B9E`[%:;1>S$CE>5-)",FA4R3-9$[!SD,7E"
MV7DR-9A%XG&LR33F8>.KU")@D5)ZX(1,I53!P&^9WTVOMHA.GSIMB[EY*-\[
M81LC!3^703['F6PH#$8&<5C%VR!C#,)HX>B9%PI>B!53IF0,41N!NU?TORFE
MX1'']>KX^E'_`$\:Y\\^D<K,2SEQ(MF+AH9`'+.'B55E'*CI151V[%V[,`D1
M$XH(MTD0BE/T=N#-\L:Y<R*Z9ND,D/DCB*2SW(E(22$\A*RO@#YHM`'5'%BO
MY^14%@DHDB89%S<`@H-`G;8>BYS<$?L#%-@M,5D,/S&<Q>9=1$5D6=8\\(ZQ
M-G&+8^=6<B4(]XN:+F8YO()"W.B7OC5(5`,0#HF#2-3=)^0:=U]F>'P$_$Y#
M.Y_`,X+*,SRR0E7+IV#!G,MF[QO"Q,3$QK)4Z\XNY<<JT[QTHHX<J+.5E5C!
MJ6?=!&.;`S:<V.\/X-F&03R&3OUX?-,D3AQF$U8-R]*E$J0_X-'3KK&(PTBF
MW506=%CT"BJ427<!-L!IO9<!BN*XDVRN*Y>,:G>:P+EI96;4SE\Y?-\?!QG*
MTQ*QDNQ4R162@A>*`X:.D5UUS<P#%J!@T[5_22WU)E3',L<,E)S<,Q4BL>')
M,SR*1:8_#'CY=B6#CD"02(!$":9.LL12]9PHBA>K1!'E@[91T_YAL;`M>8CD
MV0-8Q#!`9R,<OA\Y+097<TR8MDH:8>-93&9-V#V`<IG6;E%0J*G..DX142,=
M,P;EB6ILOP+%M;83BWT5+CNMY%60:#-3>22\S*G<,\D:NA=RIXU`2N5U,D.L
M*ITUA%0G:`@:A0JI+>CL:DCV,=@^82>&-6>0-,A&-<Y?DN:0:K]5XN[R>2&.
MR9DX<>.9.XD7ST7!W*B+*9>FD6[<CE-`4@L5LS0&0;<9R$=ESF$9M%MAQNPX
MMQBT].0LY%/8W#F>%E9-Y\(5>29J+QS=03/8\T>\*"QDR'*03@<(KU?T<R^C
M8+8\9A.0,I)+//HXV3#+92:F304;!MH]$&B2["$:RDLHZDD5G0"NJ*#3O!R-
MD4"G7,L&R;,Z0D=LY0ZRO+%F7>'<JK/FAV4T8T$E.R&(X[@D_(@TD,,>KO"S
M>*8JQ;`@[4<HQZR!'C(K=^0CLH;UD>B9K,84F'Y5&8!,803$\4Q$8!1UD#<S
MAEAF2Q630JCITT8H)@'>X5`JA&Z3<P4$R1TQ`H`&@ZCZ/6NE<AB,HQ1VYDI:
M"92#)@.3;`RF2;.N_18197F0HHPK4N4RK(BCDR#Z0!R^23>*-R+%;IM$FP)-
MA='"FUXB#C<YE4Q&'PK!L0,&,9-+8\T<+Z])EJ$!D1"IX\ZEDWP,<ZEFR[11
MZO&N6[L0605.1(Z827A&G<OUE$X%BN+JXPO`XGELWD28SDE//IMZ,S!93'.&
MSF::0;<7+@I)VXT@^*Y?.U4Q5=+N'*IU#A%4#T3,8;8[3:;Z6D,IREK)1TV(
MY%FLD>.<Y!&90OES?(%V$7B<8U"7&5>.`YA2`F1-TN!2!S3B(2!G73G(;0\>
M-G37%7;F5)FC>,?P<_F$$^QQOG>*XKB<TXBW#1&_QE)GBJ9V[DXF33%8Y11,
M':(:?K_IQ2Z?8V`@L8.R''9G;F&3\N+Z7?RTN9\DY.BF9LJ$+$IN5G#MP=1=
MP],Y="D)$"J`W;M440L'TV?\.N@O]RNK/]AH+@)JX"G?3N39:>`YXXCI#"BQ
M*?4+U>K1357'IM_+F12ZGMQF!!VH;+(>/7=KORJ`!BB@D5,Q:]H"(AH&*]1L
M]DV9:MA'&)8_&+["=P".`3RFN'[]O%2.1:0>[8DF60OV&>.4<+E87$$HZ.<)
ME5<"[4E6Y6XK().C-PLVDCG1=FXMXY(XDL`X1GW=_"H:9;&*`3>N>=S>]SSH
MIQ,826B%*`!J@-0$H2(X)+>)1M7,=7E/Z#W%U0/-;UJ'B';7@',"2]0JZCJ5
M[:,7-:>K3\H^7@.0;'TIG3;FN0Y!`1^L<ORF0Q9YL^*>V:VPY5TK!ZOR(K>.
MR>)CYS8L=)R>"YIC<2GDD8^02.BC'BP(N5-\\:-3@^0?I.=.J!NF)QK6&0B?
M1^![,V(]:P$+KN5B\L:ZQV"WQ%^TPQ;#-F3_`(BM)9([**+HJ'=BR"+EK>9X
MA8<-9=>D.Z-L'1:3^;Z?R?6><2YY5MDV,SW32LTR^%>YG.PJ>Q$YI<)9$DDU
M))/%7,XLBHMSPC5$U"'=J,FKD-RPOTDO27L(F3GQ:`GY,('",EW&FF'3_--C
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M'>2/5YK6^1X]"]WCY&"823)I.O)-6,DI./\`I1&JJI-U%"@F](('$Q%B)A<B
MR8_&8WWBZ^<>`+)C\9C?>+KYQX`LF/QF-]XNOG'@"R8_&8WWBZ^<>`+)C\9C
M?>+KYQX`LF/QF-]XNOG'@"R8_&8WWBZ^<>`+)C\9C?>+KYQX`LF/QF-]XNOG
M'@"R8_&8WWBZ^<>`;FA);OLK1S'5[PVJ/<G7;^`MZ4_*'9P&E;?V.73>K-B;
M8R):,5@=<8;D.:2Z0JQL*52/QV,<RCHAI?)<DAH"-*9)L("L[=(()AVF-0.`
MI+KST@F#[ZCHIAC.L<GFW$WO+&=*R.$9)'Z])D46K+1QLA<9M*8Z?9TBBM!8
M<WBGKJ3:E4-)M$(TZY6YP.WYH1S.^EFZ.2SF104BXRJ41B?SP0^:23KI^S,C
M*/R72$/%3^982_1F7#5>7F@AEU5&Q$"KHKJL^[D.9=5!,X=,<"GFV78Y#Y7B
M;^)<8QD^/XQD6..$(MPV0<0,UC\?)0ZR#8LB)6Z*L>Y3,4@"-H"`<!1/JJ](
MKJ+I7VVVU/MG"\UD7#W!H[-GV68_KI/*<98XM*#FC=/OZB>3$E5%@B,,REP9
MN1J<`:Q3JX2@LGS`;,>Z_.G3+L/S_-\,P>?RC"-=[)U?AV0R4?IYA'N!R+-&
M*K*%R!+%L@RR&R;D8J1FG'K`HS)*D4.F1LV4;B57@(:?>E9Z;F^*8?+&U),K
MP,OJ<-A-6R^,:LC6<)"(Y*JTR#%VR,[M",3DY#'I#%G"CHD:1PU/)M6;1(ZC
MQVT*8)LUQU_ZBV?U(L-$0.NYR/S5_F6=XRUS:6Q/$6<:F_Q3!YB3))"NQSJ4
MRADZRJ`Q%V1D@NS1=#$(-G2P)M'C$5@Z0L"RP1[(PN8X"`S;"-&+D1`H($$?
M_,0`1`/V.`XN:S],STB;;QT\I-X1L'$#=ZB8N+QK*-*%R*8F)K(<$QA[)0L6
MPQC*)U$[V.D\Q6Q5V(F!(7S)S<<K`R3A4)*S3TFG33AFU\"UZ\P:7?O<X::6
M=XUF*&NL9:1[2%V?B\-DN*R3]E*9PSRV%90$'E<<0@+,4A675>-V8**1SPJ8
M:7%>EKZ<Y>8S**)J/,VF0XQAN<Y/*,G^#Z]17>(-IV/;Y%!.)`FSE6,>]>,G
MYY.>!^LW1B2LGB<F*3AJJ0H73Z4>I7#.I_'\DR;6^+.,*88YG3*!D&,_CL1$
MOI==]K6$R*/G3-L<R:::':+0\JBU1%5?GBFU`;2I<JH6J>XLTD@2+(Q.(ORH
M)N44"O<:3=`BD]:)L'B20+NU`33=L4BHJE"@*)%`AJE``X#[QV/EB%'"L4QQ
MB,5>)LTG:D=``Q4=)QS<&D>FX.V>)F738-"@DB!J@DF%I:%[.`=;)C\9C?>+
MKYQX`LF/QF-]XNOG'@(]RXDU]+-5VNHJGTJGJW1[P35_-YF5EM),H``'H)J@
M-0[`IY>`D$R<S0UKJ,`:'MNCW0@`T7Y=U)(M0`PI5\E0*:E+@M`,G,^?8ZC`
MKS.7='NC6U!YRKZ21;K1,WNI2ZQ2E+R\L(GR%.>'=>MN2[ABICKW<=_.C7ZB
MH`,WJ[NO+%.623J10[;FW`-Y4U;;14(*0>3SJX^M\Z_Z5NJ'?72XMT1Y_G.2
MZ*W-L+3;Z?9[0@X=EDTC@V436+I3$1%CC$J_(VF5V2"J2)QYEAA"MQR@0*[;
M$^N!DR;$'<6T]&1O6->24[!2:CN2S4@QR88_D<)*-4"G;:Y:N':KA&+32.)C
M%$BAO-$2B4I`29G];>UEL5=BYS_T.N=9TXBF4S%Q2^9R./Y0O&QF0"V"=CF*
MLUJ-Z=HRFR1K,'B28D3<]V)S"FL(!0T[+?K3^@,Z8RT=E?H5\NDT9R,3AI-V
MG)PT=-JQB.//L00:M\AB]4LYUAW3$I9Y&(';N$CH,72J!!*DH<AI;@>=Y;QC
MF=KY#P6:=OS.SSTS8<D5K::9<=HOCO%;UM69K>L6CNK,1,1.FL,>7%CS8[8L
ML:X[1,3'SB?5HF+?6?<1P.$;8G@'H[^I#!,(C7LROCV$XV]P5K`8I&3<_(3Y
M\=QYNGJ5NDTA(E2:=H,4N6`(MRH$&ZPXJ=(Y?[R<YY%R%N9\EV>WY#GLM,49
M]UGS[NV;<7Q8L6'WLUIS3-LN2,47RVU^J]K6Z:Q$:F/C\>&GMX;33%$SI6(K
MI$3,SI'3TC7I^#?\2^M#GS3*<9P]3HEZH&/TLGX3&E7R[W#5FK,)Z1C8MP[6
M;EU0Z46;MROG9Q)RU!,44@$I[5`5B[?<?NI-)XC8Q$QIK&7=:_#TURS&O3Y?
MP7_L_P#J6_2O]R2=G_6E=38ALO)<2R;T0.6;`G]7S'YL$LZE#8PXE96-U9D:
MS.$79N7FD6;J/C6LFB^?QS8J#9)@L[*9-%(P*`;FK<:DG];XT_@4DMG@^B+R
MG#9@SN5</LS3R#%\;DCO\M6A#Y,NMD7YJ&KH'>4.HDHNC'6$[PZ+;FBH*(7!
MWN]"_P"F_P`=],D/4`7"M#Y!H[]7Y#5IIE7*<DC\O;Y(XV9],@20BE8EO$&9
M^$?01T)Q6*85"NT1``Y:@&#ND"<S0*NXRM`K2/=``C:G=3\IC0!,!J>6@"'K
M"(@BD4I@S-8!7C%*BEYGAKHU?=2_N>\/:VFH/W,W8`^U]L4%IDYFAK7<8`T/
M9='NC``B#CEW4DRU`IC)5I2H%/2EP6`&3F?/L=Q@5YG+NCW1K:@\Y5]),MUH
MF;W4I=8I2EY>6`=.9&_ENHPM>;R[V#HUM>_<F^DD2^R]M=2V[EJTMYA>4`=.
M9\^QU&!45.7>P=&M`>^\F^DD2X2@=O=2EW+4I3F%Y8)'*<L+EH/.CC""K@4#
M]P=#R!%!]:*ONRUP"B9(HT4;U,!O.$#`F`+!3F.VCJ,\HTJP=#V7'I7\I!40
M*):^R`^N%`.7,=E74;Y0K^`.O)<2M!\2\HE`U/9$/6&H!4YCS;G4:/:2^U@Z
M"H`+;F6B,D-HF*5:VM:"8E:VFO#!4YGS+W48-.7S+6#HMU!9<ZRLD:RX"N+:
MW6\Q.M;#<P$;1*7!R\$RT:`BJT%<Y8YT3GF!M&`L9(173H42$7*6JCBT3IU-
M[F8A@6%3F?,O=Q@TY?,MCW1;J`SYME9,UMPE<6UK;>G6MAN8`5.9H6YW&"-"
M7VQ[HH"(`WYEM9,U`,8JM*UH!B5K:-X`)S-`J[C*]E:1[NE;25I^4Q\IKOVA
M#UNT`4YF@T=QE:#2L>Z$`&U2E?RF%0`PEKY.P!]<!`$C%*7"/9E37C4J,T2E
M(>.=>88&ZP%J0'#"A04%(1+R4O-*<+2B8+`5F3F?/L=1@5YG+N8.C6U![R;Z
M21;[1,WNI;=RU*4O+RP#IS(W\MU&%KS>7>P=&MKW[DWTDB7V7MKJ6W<M6EO,
M+R@#)S/GV.HP*\SEW,'1J5%YRKZ21;K0,WNI2ZQ2E+R\L$<BG+"U5`RT<JF)
MR>Y^'N3&$O>%!3"O.?`)B`*0B/)-42''S;@%,%O+F/QJ-I4?^P.O)<:@?SEY
M;:?M@/K]@8!.8[*NHRE0K1@Z#LN3N`/RD-!$H'IZPB'EH-0"IS'FW.HP>TE]
MK!T6H`+7F6UDC6B8I5J5K03DK6PUX!$YGS+W48-!3YEC!T6X`[ESK*R1[1,!
M'%M:V\Q.M>6;F`C63E^=&<Q>,.<KL!.<L>Z`"D!A:X$@"X<BF94P+@0PJ)6`
MHF`B>TQ5@6%3F?,O=1@TY?,MCW1;J`SYME9(UMPE<6UK;>G6MAN8`"<SYMSJ
M,'L)=2/=!4:(<RVLD-`$P*TK6@&+6MHW!H6>EDP2P\7*[!1+\X.&WE1:.$5*
M^)I]I#G?+%`+P'RE'L'UPJ(,O39_PZZ"_P!RNK/]AH+@)JX"GW3NCL<FO\[<
MQDWAA(TG4)U?+13!?$)E[*`1/J?W**;=V]'/8ABZ<*OBF&X$VR8)F*4:"`G$
M(DUOUDYKL+8T!K@F+O(60R"3Q6-)*.]1Y*YA(<<DT[-;646R:7C]ENV$`:,<
MP_@A4UCWOG:H+-[D"*&(%MTVV;)[.Q;QN:Q5V`X1GW(\*QF7CS$`)O7'-!;O
M>6R8*WF$@E$MEH%,`@:X!*'QW9L"1U%K?.=J*,$,E#7>"9AF(8^S!K#N)H8*
M.3>^&)RDQ-MXN.%WR[.>N<J:0#<-U*"',UGZ:GIT;L"J9A#;,Q"6+`ER!RP5
MUPG*1R;`"8N=1TG.'SN)3:LW`9*)F!I1"*7E",U"MD3N%6K=P%F-;]9V-[A#
M3&2:WP>4?X7M&3W+C\AE^788M@$IKB!T\Q[WD&23>,S\P,B]P^3DF;)D447"
M:Z#IVU(LW`Y'!&P5GPWTO'3<^@X.8G\'V5K65R!NDY=0,OHV0)(PL-+;<6UQ
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M)'621D&QD<;9SZ2+I4RJ32+5.JJ[4:-D':Z`6BZ8>L?6?49F^P-:8!&RL!DN
ML(IK*SC:5P$T1#>$2^6Y9CD2:*F6>2NV3UR]#%>_*()E!(K=Z@=)5P0PJ<!=
M?EROX['_`"8Y^=N`.7*_CL?\F.?G;@#EROX['_)CGYVX`Y<K^.Q_R8Y^=N`.
M7*_CL?\`)CGYVX`Y<K^.Q_R8Y^=N`.7*_CL?\F.?G;@#EROX['_)CGYVX`Y<
MK^.Q_P`F.?G;@#EROX['_)CGYVX!M:)RG?97\,CZ]X;5_)K@:_@+?R!XJ%/_
M`*O`5(ZO>K%ETLL<")D6*L<U0V2IG\<@V++XQCR+-7#<(D,QK*(Y7DS$AH*2
M+'BS</B@=M'JN$.?VK))JA6!AZ3[`PW%K'4L%IO-7"VT'?3\A'YE$8?%*8_`
M.NH)BDE'MLA!AE2KQE+8@\N9R;6G.33BI153DHL$A=@CG_2T]/3.5R*$D<#W
M$[BL=6W1#Y;)O^G>?8QS/+=,1,7/9/BA4YW)V3*7>3,<X7*Q7(OW9Z];$;(&
M657(!0Z?8#D1,UQR'S+'GS0T#EN/XOD\*=:%<M%#Q$]CT?*1ISLQES&:',S=
M$$4A,84Q\VHTX"AG5CZ0[&>EK;"6J\\U#L?,(UU@3+-Y7-L/P$V48VPQR3^F
M?-:OD@GD55'B<)@&2NE4#6I$0C?=E$RNT3"'QQ+TB6`9;B6Q\[P;6.Q9;&-?
M[*UK@N1&1UI'PV2/97/D133GD\.D,\:9#9C*K9!JLU72),*G41.DU[H9-R8(
M+D/2Q:V:XIAT^.B)Q6'G-2I;%;I/(_#XMK&,F65#&3>)Q0RV4-"S[F`D\?,4
M%8],[5Y,^&,VO,5?MEBA-VMO2!XOLOJ5C]`LM29#`STEF.P<60SR9AH)HU26
MQ?!I#(&T@HP:Y*_R9H]RV#Q0RB2"J)`;PYHQRY6(618H'#I0Q)+!',S$=1YS
M`R;B5,8]P6X00(($Y@R@@6X>RM.SUN`XR8WZ8G3#U1T;-]'[HUXXCDYGPA23
MTP,FD]=Q4<F^R%L66)E<;#X^W1CWD2*KUXZ09)DD"J.U6K9LX7(&W9)Z4G`<
M?S;7.,RVC<\=*9U"=/T\G.,\-AY-7&4=RXM%Y3CR,C$-\J5G3JXNVS($$5$D
MP0=+,YP$5$@C%N<$K9?UQ1F&0V9S$YHC*VKK&83>"[UJYQ_"@1DEM3[;@]=Y
MM$JR[/8$BV91TM])/I.J^<E!@$&DNNL<7"2R"82WTF=3<9U28_DF3XQACS7:
M.+Y\U@'<9/1<<1_+*R.MH3*&LZL2`GY!B@*K&;3;E05<"](FW*=9-$#II\!<
MGEROX['_`"8Y^=N`.7*_CL?\F.?G;@#EROX['_)CGYVX`Y<K^.Q_R8Y^=N`C
MS+TI?Z6:JM?1H!]*YZZL4Z,(UUYF0$H(3!0`"GH(]@U#L[/+P$A"E+T-:^C@
M&AK1&+<B`"(+V7`$P6X"F,G7R5`AO)>`D`,E+C=8^CBUYEET6Y-;4'?*NI,$
MOL$Z%U+;N6I2WF%Y01-D*4V.Z]:BC(11$_S>[CN*K#NU3B!IO5H-@*<DXB4!
M2.HW%2I1Y@)*`%G-**(>`?KL],OT$Z7],MLK<D[Z)8=K=8G2[L_/M`Q>P2;?
M3@,?V)E^"98]Q/"=QNM7M];SS>7V='LF"*,&_<'<O$&BQ+5%%T(U9@%PMB_6
ML>HN=PI1M_\`2:^HV`\9GH:0)-2D]FYH@Q\<R2"D$&K50FAHTSY=3N*#=416
MN(HH%.PQ$RAM0_6XNHVHT]#!U#`%1H`Y9G0B`54H`C^8$*B!1*`^3M`1]4``
M#_\`&XNHVH?_`&&#J&I7M_\`BS.@&E2UI_\`($:#;4/V:#[`@!];BZC:A=Z&
M#J&$*ENIEF=`(@`H7T$=`C03`52GEI<7RVC>#WC'UKKJ&S?(\>PIYZ''J!B6
MV7S</B[N65R/-W2,8WGG\=%.I%1FKT^N$W"31)PX5Y9B*%,`D`0,!#`J'VRS
MZU/OW5F5Y)K*,]#SO[)8K7.0RV",,A8Y)F+%ID$?B$D3'T)IDT9].K%DR;3#
M:,57232;I)(E<)%*F!4A*H$'[F^L\YQU$ZLS726\O03;FV9JK8\"XQK-\*R3
M(,Z<Q,Y%.RL^<6GY@P<Q[YLNBHX9.VZB;M@Z!NN@J19N50X0)T*^GJC_`$<F
MBXSI[Z6?02]0N(84VDW<_/2TCFN=2V:9UD\B+8'V3YODRW3Z5Y/3)FZ/=D3'
MHBT9IH-T$TT40(8+E!];BZCJ!7T,'4-6@5$,LSL`K0EU`_,$/8)@-3V!#UA$
M0^[;ZVAU&RZZ<=_])8ZE'7>+O<(W(LW>O3BD0ZP<EJKT^K$4M,F4QJE&A`,(
M4&@@'P-];BZCO.M]#!U#`-#6W99G9J#1>RZF@BW`4QDJ^2H%-Y+@L#2\U^N5
M['UNV9OMB>B?VEK]A)N5FD:]S7:L[C+9ZY33=+&;LUYS2,:B^<MT3H'.FF:X
M2IG'S04**8>DST0GI,5/2R]*4MU20NJ%]&1[';F9ZK:8E.2XYLN]'$X/'9;Z
M0HS;1OC"*S1ROEB+<4BMPM48+A?54O(#J:9*6&^Q['%KS++HMR:VHN^5?28)
M?8!T+J6W<M2EO,+R@1N4I,7+(>],!'G..288M<P(B+=[0R@]\5$P<HR91M4;
MU,4PW"!P3*"P4I:HT>QP!4:5BW(B`5/0!'Q<*B!1*'J5$!'U0```2EJA5['4
MJ%:1CD!$*DJ`#XN-!$H&"OJ"(#ZE!`*E+5+<]CA"I+@+%N2B(`+?F6B,N:T3
M%*K3RVB<GEL$%`"I2P67O8XU.7?;%N2W4%IS;*S![+P(O;6ZWF)UNY9N:")H
MC*`Z>B9W'U%5ISS%BG!.<8K6-!4R8]^3$I3$37*6Y1P)!43J:B1B'!:5*7"R
M]]'&IR[[8MR2Z@-.;968/9>)%[:W6\Q.MW+-S0`2EZ%N?1PB`$O$(MR4#"`-
M[[0&8-:!C%5I6MH')Y;!$X'*EZ!^'1U:!7\EN:5M+6@>,=@"8##[`"`>I40P
M*4O0:/HVO;2L4Y$`&AZ5#Q@*T,)1'R5`!#LJ`@"1@C*A'LRIO(Y,`9(%*4T2
MXH0P-U0"I"/V``4IS)#:"2780P4+>'+!89*7&^Q]'%KS.7=%N3VU!YRKZ3!+
M[!.WNI;=RE*6\TO*`.E+#?8]CBUYG+OBW)[:]]Y-])A.^SF-[J6W\I2EO-+R
M0#)2PW6/8XM>99=%N3VU%WRKJ3!+[`.A=2V[EJ4MYA>4".11DS-5@,Z8'()R
M>9X6N8PE[P<2!47CPHF(!DJCR35$AA`"W@*8+.5+5_EL=2OQ6YK2IJ!7Q?RV
MB`?L@(^K0`R"4M4*O8\0J%:1CD!$*IW``^+C01*!@`>V@B`]M!`P8*E+5+<]
MCA`!)=;%N2B(`+;F6B,N:T3`5:E:VWDK6PW,`*E+!9>]CC4%/F6Q;DEP!W/F
MV5F#V"<".+:W6\U.MW*-S01KHRG/C.8[CSG*[J8Y8IP!;08"5Q8!GSD43*F*
MO8;F)V`H0HBI88JX+"I2X6WOHXU.7?;%N2W4!IS;:S![+Q(O;6ZWF)UNY9N:
M`"4O0MSZ.$:%N$(MR4!$`0O$H#,&M`PE4IY:`<OEL&\-!SY.1*EAXN'3)5/\
MX.&W%18+H'$?$T^TJAY)R4H75&@E'L&GJ5$&3IL_X==!?[E=6?[#07`35P%/
M^G9EL(F`9T\C,HQON`=0G5ZO%Q#C"G;EZF5/J?W(";1Q*!G,<@\.H^(8W,Y+
M8+#@3S;>8(1!KOK`V7L#9V/ZV4Q!#%O&U<?;N9R;PEZCX:YR#6".PB,R10;'
M6?/G<<].I'.`(04TTT1>'.1`Z=P6Y(PS)'9N+>,9-!2`&PC/A0"/Q)U%"F`3
M>N06!4R^52W-YAC$$M`);8(>==YH2$X0D_$8\IG[4P'1D"B`QIK1+:WJ4P=_
M[0'@$\]B4;E<<:&RJ,QG)H91PR=JQ,]C#.7CE',<Y2>,'!F4DNZ:BX8ND"*H
MG$@F24(4Q:"`#P'*Z$]*RVG\BR#&X;ISW$X=P+G:CCEN\67Q]Y-XI@DX(8WG
M^/1^2.H=29Q#86%&1G4G*)S&9FDH]@!73EZ44P85O2XQZ>Q)S7)]#Y,>3A<L
M2Q%*:&8BR8UD4B;;K;630F+SRQR1DJNX1=DD$[ED6:+A-RS7<H=T<NTPV#+/
M260>%[\RK545HB69S7YW)35<AM3,8I[K/#<OA\'Q!-P.?,LI>Q$D?(L=C<^;
MY#BK=(AUQ37A%G*:G*<I)<`BE?2T0V/8'I7863Z(VMB[#:\.XFI7'<@PW(XS
M,<8.3*X?%RX/CL8Y8DB]F;7QU.:&1R>"9/FB6-LHV1!5XNX;IHN`42/IA-(I
M%S`N)ZUZ@L\/A<:Z?K+XSI=NG"R#1)&C)>/G)/9+)IX?*O3M445;1'E.TG8I
M]RO<$#K2W\0<H(N4WS0".$4EB587B!%2`H0!.E)J)'H!_*4QBCZ@B';P'U,W
MDC>V>LS4K2Z-.-*@)1\K_P!4IA#]@>`.1*?C[0!]?PT__P!U_P"SP!R)3XQ:
M_)IOA_`'(E/C%K\FF^'\`<B4^,6OR:;X?P!R)3XQ:_)IOA_`'(E/C%K\FF^'
M\`<B4^,6OR:;X?P!R)3XQ:_)IOA_`'(E/C%K\FF^'\`<B4^,6OR:;X?P!R)3
MXQ:_)IOA_`-S1"4[[*TD6U>\-J_DTU/Y"VI3\/KP&A[HV$OIW4>R=K27ATLQ
MUUA629DZC7*:T:B_1@(IU(*,U'Z/BJ[4C@J`D$Z31TJ`&\Q%4]$S!2K47I`I
MG=*4(GC&D)J.R.0WICNH)+$\@EF"$Y"P4K!N)Z<V,+B)4F(1\SPJ-8/UWS`K
MM)-5NBB9N]55>MT#!H$SZ6_5D3,3\<ZT]U*^$XLKN6&R::>Z"E8EJTRO341%
MS<MC3'QC,647*ER-@[<I1CWOJ31Z_02:MQ7.XJD'2[!<B^G&/1.:PCX21&80
M.,Y3%E?PBK)Z$=D&/Q\JQ!VR4D#JLG(-G1>8B<QC)GJ41$0KP%%>JGTA@]*N
MV6VM,CT7MK/H,V"L,^E=@Z_P]QD,'%PST^8+*M%FZ;UND>5:0VN<@=JI*.4$
MDDV*`+*I%>HG`/QB_I&8O.,2V%G.'Z:V[*P&NMBZWUY*M'F$M(;,'J^?I*"Y
MF6>&N<P5EB)8PY!)!9BJ)))P+A)<J!&BB;@X0F^]+FQ9XQB64!T^YJ,?DFJT
M]F?AKEK%IM#M<D7Q^;Q>*6=E_P#B5W$.XX[=%TU("$C+.XMFU!0)))RF$SZW
M](8;9748RZ=R:9S+&5I7+L]Q(F=32;9NP1+B>'2V71C]>"(Y7F&[O*(V#,Y(
M@<.0QC'D8Y<NBJR;1J8.C+!*3+'LC#(-A*5FW,(!'&K:"!!H'X=Y:<!QCU3Z
M:#$=@P@/\NZ:.HW`)AX\AHJ$Q;\VA,EEYN6?8AB$M.L&@/<HQ%(Q,>R_)W,"
MLZ3YS,GAQI%VJR8N$3B$HYOZ4R"PW:F!Z[-I/9TFPSU'2[YAE_T:.Q\&B]Q8
MS&Y.S=SV/#(/7K!S#M)Y)JFV!P=21?,9A%,4PBE3K!H\5Z7E*3E<S@%NFO:4
M9+X?A>8Y8N@];(=Q<+X=.LHV6A7DF146\1X#%+.W,^[."J,&ZC';(Q7"R93'
M"Z'2MU0K]5D!D&3M,)F=:#B&=-<9-$Y*BV>/Y(DCKJ'RYM+G&.?*LV`F1R#D
M=S.L9ZD1(JCA-$5B)`%O^1*?&+7Y--\/X`Y$I\8M?DTWP_@#D2GQBU^33?#^
M`.1*?&+7Y--\/X"/,O;RPY9JNV3:%IE4]4HQ1C7".O,Q`HW>(E$MAJ"(4&X.
MSL\O`2"+>7$#6R30!$#VB,8<;1$K@""(>(!=:8Z8CY*@00[+JE`,WEAOLDFA
M:@I9=&'-:)@><H34D2W\L54*^2[DF\G,"P(GR%K-&W7K8R,PS1(&O=QU3-#"
MN*@'F]7`W`5?%$A3[L=9N8P@4>;R#AYO-`4P\`G7KZ;;IVTMZ978NP3^B"P;
M:_6?TO[0SKISPK;3[:F1Q,EL23QK*GF+Z^V235$=JZ49R6QU(M-JECT@L>2D
MVS%R1-JY/1B=J%JL^^M`^D8F<1.W7]"-O7&D9&;AGQ,@=+[N%B9S!9%"2#9F
MROZ=X\@J**-6S96KA4YCK=@%O(0`V<?K5'I'ZC3T&^Z0"IJ`*N]1$`JI:`__
M`$/H5$`$M?7M'U^P#_\`&J/2/U#_`.P;[HI4*@"V]>T*EKV_J^C0:`(?M^QV
M@!]:H](_V5]!QN@>TMU%=ZA4`%&X`_\`H?1H)@*I3RTO+Y;1N!\Q7ZT+Z1+,
M,EQS$93T)NY(2.RB<AL<D9M0^[Q1B&<T_CHU[*J$<=/2R'*8H+.%A`Y3$`!+
M<!@((*!]\P^LZ>D%UOE^3Z\QST+&XLNQS`LCE\,@\I:*;H3;91"XK)E@X_(&
MH1O3RG')MYUC&G<I`@0$2%<IV!:G10(OS3ZW)USZSQQWF.R?0V9Y@.(QAV*4
MIE6:Y/MW$L<9*OG4>Q:INYN>T4RC&1Y!\H=%`JBH"95PF0MQBT4#MCZ"_P!-
MOEGIEFG42\?=.C?I]::`'5+4TBWS)_L6+S23V&CF"L@T:/%\6PU&'7@"84*A
MD+GBIDI1$3"0$@%<._X(2W9619CV%K^3%``1`J8&'^<1I4Q3#[%P!ZG:"*10
MEP9JTDVI1JEVEBS&'[J4/(9XL`]HA^Y'L`?)6H`M,A+"!K9%F41`]M8Q0P%$
M0<`01#Q$MP$,=(1\E>6/DO\`-"K_`%B]%^CNO+0^7=./4UB4-GVLLM%%UW91
M@=E/8Q/,#/SPN68;D*+WQ#&<KA3.DP1>MC$.9(%T%`.W=*I<!)>E-%8!TXZG
MP?1VC<9Q;6NJ];8^WQG"L/QV`!M&P\8U*_Y9U+9`JTC).W+E)R^>+F.ZD'8+
MN%U#K.3G*$JF0EAOLDFA:BIR[HPYK`,+WE74D"W\L%4*^2[DF\G,#E@B=-Y,
M73/\H-JBLYY(^&7`D(H/A`3B+HQC6I'3+V&2J)!&M#6@"T4):O9(M`"HT#PP
MX]EQQ*`CX@%1`HE#V1`1]7L`!"6KVR+00J'9X:<.RX@B%?$/*)0,'L"(#ZE!
M`*A+!;=)-!H)+J1ARW``MN8`?E`UMX$5IY;>87RV><`5"6"R^2:&H*?,MC#E
MO`HLN;;60-9S`27IY;><7R\L>8"%HVE0=/!-)-3""K,%Z10DYIR-HSFG((.P
M,4%2)+E`!,K8*I>T03M,"XC>6"R^2:&H"=](PY;[09<T2_E`UG,%)>GEMYQ?
M+RQY@8*WEP`MTDT,(`2X0C#EN$`;\P0#Q$;0.8BHAY;04+Y;/.`!O+T"LDT$
M:!4?"SA4;2`(T\1[*F`P^Q6GJ=H'=Y:@TDFE:#0?##]@B"@%'^<.VAA*/LVC
MZ_8"-@WE?#V8)R+0GX&B!;HH?--W=8"B)"O&Y:%.=(;0(2H)F"@7^8"P[>6&
M^R2:$J"O+K&'/8)@>\H3?E$M_+%5O7R7<D_DY@<L`[>7&^R2:$KS>76,,>R[
MOW)N_*!;^5SF]?)=R#^3FARPR="6&^R2:%KS+*QAS67"\Y5WY0+?RP50KY+N
M2;R<P+`123>3,T6`T@U$@G(-OA8G&WO"@D`;G2Y3"0#I`(V#7EF'LO"P%O(E
MJ_SBTIV]GAA_LC"';XAZA1`/VJ^KV``A+5"LBT$*A7\F&`1`!3$P`/?Q`*E*
M8/)V7!ZW:`5"6`27230P`)+P",.6X`%KS``?$#6W@FL`>6WF%\MGG@%0E@LO
MDFAJ<KF6QAR7VBRYMM9`UG,!)Q3RV\XGEY8\P$*[>5Y\5S)%J<Y'@&.8L4)0
M,4L>!7`%N=K"B*QB+B40,%@+%"IK!!0%I6\L%E\DT-0$[[8PY;A*#/FB6LB:
MSF"DO3RV\XOEY8W@`WEP`MTDT$0`EPA&'+<(`W`X@'B`V@8Q%1#RTYA?+9YP
M:%GJ,B1+#S.'S=9,-@X=<FFP,B8X^))@`@H+Q:P`/4WD'UO9X!FZ;/\`AUT%
M_N5U9_L-!<!-7`4\Z=8O8'T#SQ[&YC$E8FZANKU>*AE</(==N"?4[N,B3)>5
M^D"8.BJ2"9E#*B@F:Q2P``2@?@(FP'J<WMFFSL8U]*:_>8>QG2X_XCDTCAKY
M1M#/,AUK].DH<C=:9:&D).*>!R'P$\UFU.FJMRE#F13"VB<9F#?9N+>+Y9'2
M8&PC/A0*TQ4L8*8%F]<@J"AS3D@*G,,8@A0"VV"';=V!(CAO)>)1H#))U%)_
M0?#R4#S6]?\`M%>`<@;250NDDQ+4*@#`A1$/5`!%<P`/[0\!Q:R_TMN=8SXV
M#?HOWV_-%Y%FT>Q2D,:RW'5YW$XK+4([`-CQB;_7JR*F)9UA;MI)KJ&5`T7(
M2\?'%[X995P@$Y/.NS=C!IL9%;I-V(\F<1U!N/:V(N(=OEKO$-C.-:;5A]6X
M]@4/D4KK>!789EG*L@K+%9+M>]-(I-)8J+E-<5$0:=9]>O45FN)[#S*>Z(]J
M8Y%8//Z>Q&/8LY-F\R/,,LV%G.OL-R^$@(3)8G##*A@#?-EY%5\98(DR44ND
MY=LQ'F$#3<%])GN&9@W63[`Z-]I:UA93"=DY!K8)$\G(S6PLTUYCC:;#5;2!
M2PQM)1.39&Y5,W9.E2'9.#%.5L9RJBLD4)F5Z])J'=:C92FD]F9RGM/'$9H,
MGT3B60[`PJ$,;84Q@)G/B.80>L,AE8EP+!M(->5%E?NF;TJB+95`@.%`TAAZ
M5##9=ID,I#=/O5?,PN,YBZP>0FHG44#(LEY]MDL[B_AD8DTSU5])3QY'&7J1
MHI%(T@B^[JP533>OFJ)P_"7I4\-5D&#']7OJS%)\XPUJ$JAIV%=1**V;I3ZD
M<0':&=&[T,>K`BV>BB4Z;1ZHJBL=/N3TR(=`]-;&'=6J=>[:AV>1XK&;$Q.&
MRUGC6:XX2&RV!1F6:;L(G(8L'JY&<JQ%04U2D443$Q:D,8H@80DONTG\9I?)
MY/A'`'=I/XS2^3R?".`.[2?QFE\GD^$<`=VD_C-+Y/)\(X`[M)_&:7R>3X1P
M!W:3^,TOD\GPC@#NTG\9I?)Y/A'`'=I/XS2^3R?".`.[2?QFE\GD^$<`=VD_
MC-+Y/)\(X!O:-Y+ODI223J#AM7\GD[?P%O\`]XX#1-S9W*ZCU+LG:!4TL@/K
M_"LCRXD'W.52&74@HMS()QP*8]#9=/`+LZ`$`&47(NA$U$FZQQ*0P4IU%US;
M/W$E"-XKIZG,8R-[O/']6S&,Y3,3**T3AC^$/.Y+LA">8X`ZQR1-AS%@\569
M=Y18/4P:%;RAEWJ2)0T::]*<TAYJ<:J=*?6(6"Q57<L1D4[(Z41B"?2K4,3%
MS014"+K)31,O#YL@NZ:Q$JH];-'LBF@@AS@7.H@'2G!YU7,X"+S"-7?Q['*X
M+&LE9L9N"-&S#-I.P$?*-FLK&KK%<1TDW1=`1=!0+T50,0W:`\!17JGZ[L]Z
M8]LM<!+TR;DVYAY<&89Y,;)UGCSN:CHQDY/F#EU#@R)&&CU)MA":ZFG2J:LB
MW31$(\BITPD43%#&,]?F29MBNQ,UQ/IKWBO$Z_V-K;`58#(\9;XWG\REG"!S
M3$]'8HFI-E/]$WAD4C,N]"JX2<)N3'0;F(<X0>^]*EGS7%\2R@G2AL0&N2:I
M3V,ND_5R9D9"3;9*MCTWB<09MK*3\<5:N6G=63L0:DE)*3BTD$Q;/1>(A-&N
M.O'.MA]1K'03_IYSK#8B2R[/<6_./-=_*S;-<8PN4RV"D',(MBK,47.3,HLC
MDY"O%&<<PE8HRSL7;\C-,.C#!"2+'LC#))B4&;8PE!@2X0!`@B`#SQ`!$/8X
M#C5J7TNV4YI"@[V!T1]56`Y`^>0T7`8M%8$.1O)>47P_$)/(TN]Y*77B2$?C
MV<9"\ASO2%7:E91X2C@[9NX(F4),SCTEN3XCM7!L!:],.Y9?'LX2TL^+EY\?
MF6;O&XW;F-1^2'/D>/,L8F6363@0E18ILTI199W(0TRF?NI&!%'`:+%>E2V3
M(2N9P3OHYVW%2F)87FF4`=R2?/$NW^&S[./E89U)EUV3N26/Q1GJDT[02>IL
MI",<,FI7YC(**A=#I6ZD,HZG(#(<CF=;Y!I]QB6=ML:;P>3$._>R320UU#9:
ME*J*'C8=)DN4\^=N=F('<H%2*9<$3J\D@6_[M)_&:7R>3X1P!W:3^,TOD\GP
MC@#NTG\9I?)Y/A'`'=I/XS2^3R?".`CW+VLJ.6:KI+)%_P#BJ>`2^&)FN$=>
M9B!!N%R`DY9NWL]MY!X"0#-940-;*I%$0/:/AQ!M$2N`((AWD+K#*)C[/+'[
M+L`,UE1OME4B5YMGY.3-9<#WE?\`:`NY0K("/V7('R<P;0BC(6<R;=6MC)3:
M2)`U[N.J0PZ"W,!2;U>#<.<9V0Z7=3KMS")0'F]W$!H"@VAX`.O'TYD+ISTR
M6R)QMZ)/2.VNM'IFV=GG3%J?<<A/;$2V!G<<RR=[CF`9.RUI%XPZ0E,[F851
MF3'G])*30C'YVS!T+=RF)0MEGWUBOTS\QBBS)UZ"S=^-%6FX1XYG'&O.IL6B
M;N+R.'D(EDU37U"T(W5<*MFK<X'75.L=6I`)S"D`-H'ZR+Z;:HT]`SN4`J:@
M#J[JH$0"Y02@(_FJ"MI3%`?)6T?7[`S_`/C(OIMJ_P#[AG<U*AV?FOZJ/)<4
M1[?S4^42@(?MU]3@,%^LB^FV"V[T#.Y1H)+J:NZJ"U`!0O`/_E4-MP$4IY:7
MAY;?.!\Q;ZQ3Z:#)<DQW&\B]!EN#'X&?FX>$GL@6UKU.LT(2(DW\:QEIE9R_
MU6+%JC'LCN5S'6]R3`P">I4QO!1F'UAOTR."9?D^$X;Z#W;N9X;AN1R^+8KE
M[+774L^:9;C..R:<3#9(S?Q&K%8EVVR&+CC.DEFICMS%=D,F)B$`5`K7U&?6
M4?26MM*9XQZM/06OHWI\R*&#$MG'W;@O4#`:QDH3)5&$,I#Y-(YEK-MCK=";
M=+'00!=0!%PY1!.JA"WATZ^JP==F)=5NB=YZ0TCT:8)T::3Z8'VNO`T\)R#*
M]AALG,=J&S"0RZ3RG-<LC8V1F<LBV^'MA54=.9%]W.0:IG.D@V;%4#U9`UE:
M!652$0`M1\.)VB!4P,/\H[+C%,/L7>QV@ADVLIW%;\K(AVH]HQJ1@^[%_<F<
M@7M$0_T>SP"XS65$#6RJ11$#VCX<F-HF!R!!IWCSK!42'V>4/V8T`.UE1OLE
M4B"(*65CB&L$P/N6(U<!?RQ60KY+N0/DY@VAD[65&^R52)=S;*QQ#<N[O_*K
M^$!?RN>WKY+N[CY.8-H!FLJ-]DJD6HJV5CB&L`W?N57\("_E`NA7R7<@?)S!
MM!$Z;2?>F7Y42"Y9T"58](>68R#XQ1J+BI[$CD+V4K8(C[80`%HMI2HB$HD`
M5&@>'$&@"8X@%>\!6A3%#V;:^KP`#:4J%91(0J%0\.(%0`Q!$*]X&E2@8/8N
MKZG`!6TH%MTHF:@DN_)Z87`4S83A_*!MO*FJ'L<T/L`J`5K*A9=*I&MY5](X
MA;[18\VGX0-G-!%>GEMYX>7EA<"%HUE`=/+I5(UJC(%0"-2+S#D;1@K&J#D3
M$YQ$E@`!K9S@$*V!<"TC65"R^52.(`G?2.(6\2@QY@A1P-G,%%>GEMYX>7EA
M<`5K*@!;I5(P@!+A\.3"X2@V`XT[QYMXIJC['-#[`*@`UE:!652$:!4?#D^T
M;2`(T[QV5,!A_P"=['``M96@TE4@&@T_)Q!H(E4`!_E/;:8Q1]FWV>`11[64
M&.9V2R(59(@40C4J`86ZP%/:5R!:%.HF-`[!Y8A^Z[`6G:RHWV2J1*\RRL<F
M:RX'W*$?P@+^6*R%?)=R!\G,&T,G:RHWV2J1*\WEUCDSV7=_Y5:N`OY7/;U\
MEW=Q\G,&T`[65&^R52)=S+*QQ#67"]Y=?P@+^6"R`#Y+N0/DY@V@BDVTGW1<
M1E$@)>00*,<D-"BY4$I1$SB@VE43"OJ\L1[+NP%O=I3XT3\H_P#EQ/)<80#^
M4>H40#]KV>``:RM0K*I"`"`B'AQ`J`&3$P5[P-*E*8/8N]CM`*UE0$MTJD8`
M%.X`CB%N`HM14`![P-O,!)4/5MYH?8!4`C65"R^52/04KZ1R9;P*+'F@'X0-
MG-!!>GEMYX>7EA<")=M*`O%`>52,8KP!./AR1>84D<`+D+5R/+%8R2Q@$*B4
M%@#M`GG`L*UE0LNE4CTY5_Y.3+?:#+F_]H&WFBBN(?8\\/+RPN`*UE0`MTJD
M80`EP^'$"X0*W`X@'>1MO,FH/L<P/L>T-"SU"0(EAYEY!-=,-@X:!TRL2)"<
M?$D@KS`6.)//`3=@>QP#/TV?\.N@O]RNK/\`8:"X":N`I-I)KF<1JG:F4-LY
M?!'QN\NLV:CL>98G&NE4"1G4CNA9..279P\_-R0KOFIE!Y3-R[4!44TDC&L`
M0C+6'4'U"9UFN$8S.XAD^)Q63NUVLGD)H!-T2&KC$E,Q2AVTC@<&@<991BF[
M,4K@XL8]RF1P)78*))A;U*%RAGLW%O%,U<3`*83GPI`,!"L!1`DWKD%"@=LD
M(G!43E$:A4+.SL$>`D5PT?!)1H>++5%)_0>Z,:A0K?R>X]E>`<@9OJA66<"%
M0J`-6("(>J`#W<:"(>P/`<6\L]*7NS'S316/0QU%/C1N2YNPCDY&#RJ'7G<-
MC<P1C]>[$87:9>,2P.784Z9OGR2C@CB,EI=G'I@[`'+E`+%8CUJ;6G\5VME$
MGTW;+:(:_P`&W-DN,H02>23;S964ZSS!KC&-Z_QR'E--8QD"<OGI91KW94S0
MYR.B.TN[F*U44X"#L;]))OV?>F2<='^U(`Z6:Z!PN3QR9CLT1R['FVS\'AIS
M:V=R<:AIMP*F&Z%R]Z]BI%02(#(I1QUD%"JJ`V*&TK^DRGL<V/FN'9OTQ=2K
M.,APO@5,9UIE,]D[-09V0B8N)SZ/<Z[BL583F9P48IDD4ECTSDB*,&(!(*LW
MAD6ZP7/Z6-[3O4OK1;9;O7FRM-MEY\8Z'Q;:,&WALQ<1?T9QB8&4D8E2+:IL
M@\4F730@)*.4E`:<P%*F,FF%CD8URW3!)"1.@D!CF!-%C'II@90YE%#`0C<I
M0,HH<3"/JF$1'M'@/IW-_P#&Z_O1C_$<`=S?_&Z_O1C_`!'`'<W_`,;K^]&/
M\1P!W-_\;K^]&/\`$<`=S?\`QNO[T8_Q'`'<W_QNO[T8_P`1P!W-_P#&Z_O1
MC_$<`=S?_&Z_O1C_`!'`'<W_`,;K^]&/\1P!W-_\;K^]&/\`$<`=S?\`QNO[
MT8_Q'`'<W_QNO[T8_P`1P#<T:/A>2H>++!1PVJ/=&/;^`MNT?<.`T7<V93.J
M]2[)V2Q2>9*]P7"LCRIGCR#"266FW4)%N7[>+20Q3$LSR9=1ZJ@"8)Q\3(O#
MB:U)!0X@40I3J+K-W=MQ*$;-^G/)\,R-WO.`UM-8_EDKD**$9KYY"'F\HV*U
MR<FET<??N<3:,71P;<U.,D+F:2$EWAX5),-&FO299)$3,X@/19ULDQ_%C[EB
M)R;D=8P<>#C*-41$7-1[7'1`'4;+8WGY%G3*(EE'39L\D2H))7D5451#I3@\
MNOF$!%Y8U5G8=OE$%C61(Q,_#MXV=C$IN!822<?-1SEF@YCY9D1R";A!0A#H
MK%,0P`("'`45ZI^M;;_3=MAMA,+TJ[LW9@J>#,<YF=D:RCADVD<BN?+W3V`2
MCR8>ZCEIR/A->RSA8BDDB5(Z\60]/$4Q*&,9ZY-C9MBNQ,SQGI8W\BRP/8VM
ML&3Q7+HUCC6P9]AF;<YLAR&,Q]OBDXP7/B;P[<G=DWJB2[=P5RHZ;IB!1"#W
MWI,=UM<7Q+)4^C_:8)9!JE/8#UL^^F:"R,ZUR1:!F<0B"1FAIH9`R:[8C:/<
MN>Y&DGTM&<M$&:ZKM$)HUQUK[:SWJ-8Z-F.FW8V$XM(9?GN-'V7-&E#,VL?C
MF&2F58Y(.XQQK&(8)K9(VC4EUA2DEF3!M,1:9G*CURHU1#HPP:O@CV1O%7%`
M9MC6E:LJB`($&THBW-VC^WP'&K4OI5-P99"@YV1T!]6^$9&_=P\9C^-0>+%F
MSR4FIAV'OLE%>0RG#\$19Q$#GL\_C!>V'1\+CR22@IE<=W3"3<Y](AL_%=JX
M+A$=TE[VF,4S1'2SYQEJD/,(R&*L=JXW'9%($R&&C=7S,*A+8XI**1Q6B,LL
MJH_@I<K@&B;=`[@-%BO28[W?2N9P;[HGW-%/\6PO-,D0=+CDRL*]EL0GV;&0
MAG$B72":A$(&)%\,HY9HOP&1C56L>1^"K918+H=*W4!G?4=`9#/YAK#+-+O<
M8SMKCS""R8IWCN3CGVN8?*2RHKOL1Q?D.B.IU5LJU!(ZC<$B\T2*',F0+?=S
M?_&Z_O1C_$<`=S?_`!NO[T8_Q'`'<W_QNO[T8_Q'`'<W_P`;K^]&/\1P$>Y>
MRD1RS5=)E<H?2N>J'<H\UPCKS,0*-QD*EL,->SRCY>S@)!%E("!J3#@HB!J"
M#1@-HF!<"B`"W&M@JD$*^7EA7RFJ`9E(#?;,+DN!2VC1@-@G!Z!!"Y`:\H7"
M0A6M>06M;CW!$^0L90^Z];"E/+H)_F\W'>D$=&*W\R;U>"``LJW,HEW4[E$P
M6]JG=B@:H'4N#P(==WIQ,OU!Z9;8S>`]$UHG:G6KT][,SSICTAMB59[+=[?S
MK$7&22$5KN;A\$B(LH2V5Y3CKUFI`R"23YZE%OU&[!P+5ZIS0M5L/T\7I\9G
M$'#%[Z#G:6-@M.PCI[-+ZGZCW#=N\89)"OX1@BR<X@B#!1PNBU;VK*JF<&5*
M8@%$]!#;1]/U]8.J/_V"+:`!4U`_,MU0=@"900"HXOVV@8H>S;[(\`!Z?OZP
M;7_]Q%L\0J`T_,MU0>2XHB%?HOZI0$/V^`"^GZ^L&@):^@BV@8`$EP?F6ZGP
MN`#-Q,%0Q?LO!,X>QS/^2'`/6,>GC]/G/9'CT#E'H.]F8]C<S-0\3D60JZ@Z
ME8]*#@W[Z,:3,TJ^?8VBQ8IQ\>#E<RJQR))`<3&,!4P'@%.7>G9]/%A^79+B
MF">A&V1FV"XMD4MCV'9@TU/U)2K7+\2@I)*-@<E;2T5!/XV1;Y'#QW>B.&RZ
MR"I7MZ:AR%(80K?U%?6&O3%XWI//G75;Z#D8?I]D((V.;3>;FU%O^.U@YQS(
MS1\&ZC,P=95C),=1C)Q9<[:UV/*,H\*0*F!,!#IE]5EZ[6_5SH7>&HM7='&O
MNCC0/3)):\88836+S*LHB<_S;9`99,9\ID&6YFQ,\G,MB&^-QZ[E1=X^D0:R
M[<JYRI)M+@]50,I"@`,RN(@``(]S8=H@5,!'L0H%PD,/_.]8`X!%)M)`K)8?
M&EBT%'SA:1_9[L4/W9$2]HF#]T'D]7R""TS*0$#4F7!:WVB#-@-MP.0*(50&
MO+%4@A7R\H*^V-4,F92!K[9AP2[FVT:,!LO![RQ"Y`;N2+A*E?+W<M:W'N`.
MR?FOMF'!+N;91HP-R[^_\NES<;N3WE&E:U[L6M;U+@#LWYA/;,+D`W-M`&C$
M>7>+WETN0&[D]X2I6M>[EK6X]P(W35_WIF`2ZI>8JZ!,!:L:IB*#Y0HDJ4@G
M%--0I:"52H)@(@`B8W`+19OZC^5UP`1$0#NC'L`3*"`5Y';0#`'_`#?9'@`&
M;^H?E=<0`0$0[HQ[0`Q!$.Q#LJ!1#_G>P'`8*S?@);IA<U!)<`M&(7@46PF`
M:(!3F`BH`T\G.&GM2T`(S?E$ETPN<"\JX!:,0YE@LN96U`+>=W=6M*4[P:E+
M26@A:-'X.W@&F5C@FHS*H'=8\!4,1M&&4,>TAA(*Y$%`$`*2G/,)0\T@@"XK
M*0"RZ87/;RKJM&`7V`RYE;4`MYW=U:T\G>#4I:2T,%92``6LRX-2RX19L`NM
M!L!A&B`4Y@I'$:>3FC3VI:!D&4A2GC"XC0.WNC#MH4@"/W"E1$HC_P`[V`X`
M%E(4$`F'`"(&`![HP[!$J@`(!R*>:)@'_F^R/`(H]H_/'LQ+,KA<R1`#%:1Y
MO.%NN4%`&Q8IJ&63-[8P"*0=H@8U06G92!K[9A<EW-LHT8#R[P>\NER`W<GO
M"5*UKW<M?;'N`.S?FOMF'!+N;;1HP-R[^_\`+I<W&[D]Y1I7R]V+6MZEP!V;
M\PGMF%R`85+0!HQ&R\7HD`+D!NY0.$@"OE[N6OMCW`BDFK\K18_C"Q0O3&AF
MK`"@4SA2TM3%1]J"Q``;P$>4'EN,`@M[F_K_`#NOY1[.Z,?)<80#[AZ@"`?M
M?L\!D&;\!"LNN(`):AW1B%:"F(AV(5`#`0P?\[V`X#!6;\!+677,`"03`+1B
M%X%%K>`T0"G,Y*E:>3G#3VI:`$9ORV73"Y[>5=5HQ+S+.X\RMJ`6\WNRM:4I
MW@U/:$M!&NT?E7BBFF%C"#P!.)FK`IE2I1X`JG0")TYYFZAAM*82\XU``"$$
M@+"LI`++IA<]H)W5:,`O$@,@.(VH!3FBW5$:4ISS4I:2T`&<@`%K,+F$`(!A
M[HQ"X2@W`P]B%`O%(XC3R<T:>0M`T+/6SQ-+#S*R2K@@;!PT#)';-"`<?$TP
MK>DD0Y1N"O8/JT\G`,W39_PZZ"_W*ZL_V&@N`FK@*4:3C,LC]3;3R..SO+`*
MSWCUF2\9CD3CF+R(I*1_4INE1"+CD4,)R#(I0[IXV$X)E3>/%3JBFD0PV$X#
M5\)S_J8G,BUC'9+$Y[`0N7+MR9%-$@8-SX0@\UXVR9LNJR=Z?B$8`Z&3*+,7
MJ3YX86P(@FF=RN<03"S*<%.,=FXMW_-YR:!3",^%,'<9BC7N]DYKD#@F:-Q]
MF)P6%0HFONH)`MI4U0D-PS=!)1H>+/AJE(=HHQE0\QOY/R?3MX!S!DZK_.S\
M?8Y47_\`<CN`XL97Z1+K&AAFBQ/0#O\`>'991G#&(3D(+)$3SF%,\O(AKK.F
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M:IND49%BBN5)8M!5):LH$H]R=?&[_P#@8OYNX`[DZ^-W_P#`Q?S=P!W)U\;O
M_P"!B_F[@#N3KXW?_P`#%_-W`'<G7QN__@8OYNX`[DZ^-W_\#%_-W`'<G7QN
M_P#X&+^;N`.Y.OC=_P#P,7\W<`=R=?&[_P#@8OYNX`[DZ^-W_P#`Q?S=P!W)
MU\;O_P"!B_F[@#N3KXW?_P`#%_-W`'<G7QN__@8OYNX!N:,W7?94/%GP4<-N
MT$8RH_@+?RUCQ#@-%W-DV2ZZU+LC/,::S669#A^%9%D<'C#"%?SCZ?E8F,</
M6,0SA</Q3(LIEG,@Y1*D1LP8N72QC`1,EP@(!274G5%U4;01A6LET[9)KS(E
M]YX[@L]%Y2VS!*%8ZJ<0JLQE^?,<P?Z;@HMQ)XZDP<`U`R81LDLX8M2+IKKJ
M<D-`FO2!]0<5+SI"]`763]'<9/N2)D)5YC6,%4E\@UG$1DOC+C&?"\<E4G^'
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M9HV&;8,4A6?$?$;!T:8-'01S,P2K_L9-Q`H(Q@^1`G8'Y.$:\!QBU5Z1OK%R
M&%!7:'HY>I_$\G?.8>.A(''HI1PT</C8=AZV3.I&6R36<4C&P$3L*6DVI':A
M25@V2+TA%UU%6B(2AFW7#U-XYM/!,1A>CC>$UA.7(:8?R^3FAIA65PYGL7&X
MR=REK--XK5+['!F,5D)9>+%!*1.+5WC\@9^#=-=B*@:-%=?766\E,RAI+H<V
MQ&+8[A>83L=*]RR]S`R,_C4\R;*Q!GA=)IN'K6*A1?E7-'I/%IB18`6(*Z1=
M-CG"Z72MN;;V]8'(9K;&J\KTC+X]G36%AH"<;.^=*0K[741D7BG>)_"<365>
M(2<LY:KIHM3H-Q1*F*IU05`@7`[DZ^-W_P#`Q?S=P!W)U\;O_P"!B_F[@#N3
MKXW?_P`#%_-W`'<G7QN__@8OYNX"/,O8NQRS5=)F0+3*YZH`A$#6[7F8E`1$
MT8(A8(U"E*B';4.S@)!%B[&ZDS(%J!J"",3YMP+@`A=&B`B052B%:]J1:U`3
M@8`S%V:^DR_)=S+1*A%#R[P>`42WQIJBD+E,2W5KW<EU:J<P(GR&/?*;KUL8
MD])(%#7NXQ%--M"F*;FS>KBI`)EHE50H-1=)F)0P7"V3ON`RH*!X#.O3TW/5
MGJGTSFP,'UOZ,WIGV!UAZ5V1L'ICZ=]C9)J?9N1[^SC5^09.^)KEY`Q\3D<0
M9_(YABSUNZC7[5NI;'2"Y&JA&CUX5R%I<_\`2V?6?)3#P1G/0_L8F/D9N(7<
M/V>H=M.7J$C&9)".X=H>-4V,_6AB.'Y&B*97*%7137D$:G,(;(/IB_K30B/_
M`-AN9!41[`T+NZ@5$X@`5V0(T`#``5^Q#V:@?_3B_K37_P"!M9#V_P!@N[O7
M`:=FR?)0*?L#^QP&`],7]::"E?0W,C4$M0'0N[O.M%(1`:;(`:'Y8@-*?=#4
MI0MH/V*>EW^L]3>3XW"Y;Z(1G!8K+3L-%Y-.CI+<48,/`/I"/:34N,B^V>T8
M1XL8X%EA665212N.8QB%*04P^^8^ER^LS8WE^48]K?T1S++]=P&23,-@>5#I
MC<LT&4X7$R?<<8R`TRQVK(-);QZ#8I.3.47"R:_>SG34,44C$"N74-Z<?ZQ-
MK32NPLLZFO1"Z]A="M<>7B]IR6S.GG<CW7H8I/\`=("1;9NW?9Z[BC8Y+][%
MLZ!VGW0Q7AR'H44P('3_`.JP==><]8O3_NO7D3TF:HZ3.G;IMD->X_JO\QN/
M90QQ#-<SS?Z73VTD)&9S1YD)IW)H@T;&/'ARNUGQ"3I!=*&N;&`/58#%W0/R
MS(#0`"O(B:C0$P$>R-`*F$@B/LG&G90`!%)-'9&2IO&GQ:"D%13BB`%5BEK<
M+9H`=I@_Z0O:`>6HE$%IF+L0-29D"U`X`((10V"8'`%$MT:-13%8HA6O:D6M
M0$]X!F+LU])F0)=S+;4(H;+P>`02WQIZ\GO*=MU:]W)=6Y7F!D[%V:^V9?DN
MYMMJ,4/+O[]9;?&FKR>])VW5KW9.ZMRO,`,Q=FOI,OR7<RVU&*'EWB]LMOC3
M5Y/>4[;JU[N2ZMRO,!&Y:N@<LR^+O0%59R!/<XPHIB*#U0.444$N8)"*%*`&
M(OYJ11$H#><06"R=U'\L/PJ(C3DQ5``1.(`%8X1H`&`/7H4/5J(@`R=U#\L/
MQH(#3DQ5!`!((@-(X!H(%$/7H8?5H(``R=@):S#\U!)4#(Q5#VF;B8#6QQ1#
MF`B8!I2@+&I00)8`5B[+968?GMY5UR,4',L[G?=9&EISN[*74I3O![:6I<L$
M31HZ[T]*,R^.**K,IZIQ0BH)&L:<YE2E;*<LRY4#@(%(@%'!Q*6H)G*"PK%V
M6RLS('MY=UR$4%]@,P.)K(TE.=W92ZVE.\'MI:ERP"L78`6LS(&H!`$10B@O
M$H-P,)K8T*"H*)A&E.U4U*`!+`.XNZ?SS(5H`5Y$3VB`$`1[(T`J(E$?V3#Z
ME``,BQ=C7\LOP[!"H(Q794#@`]L:(5`3@/[)0]2M01,6;M6/9F+-/BWLT:'(
MG%*!4S=4`4`QFKT#B!EBF`>8H`BD7M,`GO!89B[,!Z3,@2[F6B5"*'EW@]LM
MOC35Y/>4[;JU[N2ZMRO,#)V+LU]LR_)=S;;48H>7S._667QIJ\GO2=MU:]V3
MNK<KS`#,79K[9A^2X5+;48H>7>+P2@6Z.-7E`Y3`M:U[N2ZM5.8".1:NB-5E
M!EWH%`Z8VF)&$(`&<'H6_D-#`!.<4`]U`1Y1:W5.!P6=Q=_'#_RB-.3%>2IA
MI_-U:``@'KT#UZU`!D[`0K,/QH("("C%4$`%,1`:1P#0P$$!IVT.-.T`$``8
MNPMK,/S6B01N1BO/`HMA,!K8XM.8"!P&E*<X]*4)8`5D[+9=,/SV\NZY&*#F
M6"RO`UD<6G.[LI=;2G>3VTM2Y8(UFCHB\60TR^.(NPJ8R<40RH(Q_NB8E(U;
ME,5P+8YC@4B@@*QQ*!`*F9$%96+LME9E^>WEW"9"*#F6`S`PFLC2T%46R@FM
MI3O![:43Y8`,786UF9`U`*`B*,5YUH(`(C;&@`"<4C"-*=JIJ4`"6AH6>M7*
M26'G4DWC@H;!PT!252CRD/\`E-,M1%!BBH`W!=V&`*B/J4``9>FS_AUT%_N5
MU9_L-!<!-7`4KTI%90PU%M3(HC.,V%=IN_K/E8K&XF$PV5(FY9=2NZSMHR*9
MFPJ0G9,[EVWN(B99==5542$&@D*`19J_8O5SE&>89"YC%9W`XE*.T6653)\`
M:0SR+77PA2?(JS\9U<$,$8A+*)-W3EP]2[NZ!9@@5Z=-)XY"X98"68[.Q87F
M:Y+-<S",^%,)!IB"`-[)S7`&!/PC%HP3`MS`$U]]!(6VGG7!(+ADOXE&AXK(
M"(I2%!MC:AYC?U`CJ#7@',&3@!`?%I`?8$D90?8&D<`\!Q6RKKE](C%FF"0?
M0'LUT=KDV:HPI'\<\>^,8']+4AUIEQUL:@I1FPE76`N6A9N%653DDIQ^<44T
MV<6_X#?\5ZL^O'(E]M)NNE6=AH_&=2[+S76\_*8OL"*2R+-,6S]AC&(X9/XW
M(8$&2+/<H@7+J00:PR3YR\9QY'8':@^*R:!J^"]8OI`LAF%$,NZ4\OPB%^F6
M!1#=XZU+GTI).(*7UXVR*;4.SBB/(]FZGLW55AFL@=V,7B94N;.&->%`>LDZ
MH_29+YRI`8-T1.FF-MY#+W9)S/<KQX3OL9QS+,[C&J3QQBP.H>!R61QV!C%V
MR3-;("2+E\4S4AVBQ5T`M#T];RWAMC9$E#YOK?-=;X,76V.9%#+Y5JW.L8F7
MV1NX'`7N1&=9+DN.Q&+QZ;++L@G8-''E&_CA28[XH<YV+]J/`76[BX^-I']Y
M%_-O`'<7'QM(_O(OYMX`[BX^-I']Y%_-O`'<7'QM(_O(OYMX`[BX^-I']Y%_
M-O`'<7'QM(_O(OYMX`[BX^-I']Y%_-O`'<7'QM(_O(OYMX`[BX^-I']Y%_-O
M`'<7'QM(_O(OYMX`[BX^-I']Y%_-O`'<7'QM(_O(OYMX`[BX^-I']Y%_-O`-
MS1DOWV5#Q60`0<-NVR,[?P%OY:QPAP&B;GG\PP/4FR<TPEG.9=F&+85D4]C&
M+L(!7)WV03L9&.'<7#M,=QZ/)-SCF0>)$2(U:G267,8"%43$>84*2ZCZ@^M/
M8R,*SR;0CO6>1J;TQ[$I]O/X_EA\71TV>%6ELRS&,RF5Q;&:3D2,<LG&N5&B
MC*0=/630S9(X.E40T"6ZX.LAA-3I$?1X=1RF/8ZMN2%5=GGL+>O,DG=?Q,7*
M8+*8T$#A,RY/AFSG?>XV/<F8JK&=*(+*%;H)+"<.F."/I+)L>BLC?H9)B\AD
M$#C,V^QN;0C49O'WDKC\>^<PDP@,2B"$K%++F0<$`A`*LF8+2^3@*)]5/4CU
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M8NQQ`/%G$>T[\^3>&0*YF6\6U;JNV4DLW#HZP9N`CV9@E)$:,FX@0"1G;1`@
M@`5CA'MX#C!JCKQ](=+P@'VQZ./;T1E#]["QL1&XO*H1L01P&(8?]*)&7EIC
M`<C3CX!IL.0E@;K+BW7&`;-U$$9!\+ANF$GYMU>];,%M/!<<QSHUV7,Z\R=#
M2[[(\@&/>/YC#&V>8U&3.<Q[Y[&8DGC;J7Q.7DW48-HE2C%H!=60M))QI>`T
M>)ZS_2'N97,X>5Z(\OCQ@<,S&7AIM&+R1S"2648[.LDRQ93?1$KF99-((D@F
MBFP`7>3OFJ*T2'<WB(\!=/I4VIOK<<!D$MO?5LWI6=A,Z;16.PCE@^;EE,?>
M:ZB)Q21%SD6/0[B0?-9R2>-'!FS86")D0037<*I+G`+@]Q<?&TC^\B_FW@#N
M+CXVD?WD7\V\`=Q<?&TC^\B_FW@#N+CXVD?WD7\V\!'F7L'(Y9JNDS)EIE<]
MV%)%4&[7F8E`1K%B-2"-0I3M#MJ'9P$@BP<#=28DRU`U!`D7YMP+@`EK&"%2
M"L40K7M2+6H7@8,F8.3`>DQ)$N!0`$I(H1)>#L"B2^,-44N\D$MU?N"=:U4Y
M@1/D,:Z4W7K8Y9R71`->;C]S2+#\LW.F]6E(!P5B%3B#879#)T,':V3OO`50
M5#P*]>'IK_2"ZJ],WG^H]6>CQZ9,UZL=7;"V#TV],6>Y/HC8&0=0^::4RO*9
M)SKYS"2#3-HA-ZTS'&'*,@C(LVR+0K%RXY8I-7+\JX6QV#Z1#ZV+)X@HAD'H
MM=51L6_G(115Y'8JX=R*4BPR2$<PS56/_6)DE(Y-:3!HDF!VR8+IC<`FJHH(
M;4/I*OK<8B(__2J-6!41[`P-[0*B<0`*]0HC0H'``K7L*%>VHB!_],J^MQ__
M`(*C5GE\GT#>]O:4:?\`$+6E`I^P(^K00`#TE7UN,*5]%1JP:"6H#@;WSJ"B
M(@-.H4/;<HP#2GW0U*4):#UC'I'/K8$ED>/QN8^B[UE#XD_FHECE4REA3EJO
M%XZY?1Z$Y*).3]1C--NLSC"+J@<54BD$YAN)1,4P49=Z1GZU3#9;DT3K#T8F
MLLIUI%9#+1VO<D<XB_DU\DP:/D@;8I.N9,>I%^>06G(!DDX47[PL*IG:A@4'
MW,Q`KAU%>F"^LZZ/TIG^R.I+T7FE(C1<'`+-=H2>4Z>R'*\31Q.9!K"2I<QA
MH?=DV97%7Z+@Z$@==L+(B#M7G"1*P4PZ6?59NNW='6GH#=.)RO2_I[I>Z;^G
M9]K[$](%Z?,"R+#L!RK*,H/F,]M>/5=Y9,Y6A.3T*LTBGKT[98'"9YXQG1CF
M50,0/5.#!R`!^6),:``5$D54:%3`1'\F4J82"(^R8:4"@`".19N",U3#,R):
M"EVUC$O*J4O:<K9D(=I@_P"D+40`.WM*8%@L'`W4F),MP'H($B_,N!P`"6Z,
M,%2"L40K7M2)6H7@<,F8.37TF)(EW,I:2*\R\'EHDOC#_<N]$MK7^3IW5JIS
M`#L7)KZ3$D2[F4L)%>Y\SOMME\8?[CWLEMU?Y,G==57F@&8N37TF)(EW,I:2
M*]SO%Y;9=&&^Y=Z);=7^3IW5JKS`2.6BX.69?%I`!66<@7MCBBG5!ZH'*)R$
M2JB0JA2@!TW%"I%&T#7J""ON+BHCXO)!41&ED70`$QQ``K&B-``P!Z]"AZM:
M@=Q<5`?%Y(:"`TLBZ"`&((@-(T!H(%$/7H8?5I0`K!P42B,O)&M$@B!B1=#V
MBW$0-;&E&B@(&`:4[%3TH-@D`*Q<ELK,21[>76XD5Y_+[G=?9&%^[=U/=2G\
MH4MI1/E@C:LU^\O"^+R)Q15:$/<,:;F"1M&J"*I`;JE1,L#<X&`B;<!!PH(%
MKRSE!85@Y+968DCV\NMQ(KS[`9W">R,)]U[J>ZE/Y0I;2B?+#`,'`6UF),UH
M$J(DB_/M!N`B:V,*%3BB81I3M5/2@6`0,@P<@%/&),>P`J)(JHT*0*_S92HB
M41'V3#ZE*`"P<#7\L205`0J!(OLJ!PJ'Y,$*@)P']DH>S4$;%DX58,S%F9(M
M[-&AB#&*]IFZI04!11L_YA@%8I@$550$4B^<8!/>"PS!R:^DQ)$NYE+217N=
MX/+;+HPWW+O1+;J_R=.ZM5>8`=BY-?28DB7<VEA(KW/F=^MLOC#_`''O9+;K
MOY,E==57F@&8N#7TEY(EW,I:2+\R\7@E`ET8;[EWH@%K7^3IUK53F`CD6BZ;
M5909:0MO(-HFCDB`!W!Z%YA461P`O/*`>[%$>40!NJ<%`6=P<5_G>2\HC2R+
MI[8PT_FSR`!J>O0`]FH`,'%0'Q>2&@@-!)%T&@IB(#2-`:&`@@-*#0XT[:"`
M!6#@+:R\D:T2"-Q(OS[!;"8#6QI>Q0$#`:E.Q8]*4)8`5BX+967DCV\NMQ(O
MW2P6=P'LC"_=>ZGNMM_E"EM*)<L$:S-P1:,(:8D3#WL*F/X80RH(L//3,1-L
MV(H5P+4QC@":H@*QQ(!`!,R(+"L')0)68DCV@F`B8D4`GL!H!A/9&%H*O=CB
M:VGW=2E*)\L,`P<!;68DS4`H"(DB_.M!`!$UL8`5.*)A&E.U4U*!9:&A9ZT6
M22P\YY)\X*78.&@*2Q6`)F'Q-,M3"@Q14K4!'L,`5'UJ``,O39_PZZ"_W*ZL
M_P!AH+@)JX"E&DH"<8ZGVIDT3E^?.'J&\.LZ6B\9C"0$@V!\SZDMU`SC8B-&
M!3D7G/>-BG3;G=B95PH)1/::T`C?6N9=7&0YYA4)F\-F,1ALN1B3*9U#&DH-
MY$NWV(2\DHU1\1QEXQ2)%2K5H=TY57*@4[H6"`NG"1CG"VZ>,.XW9N+<_,<N
MF.;A&?"4LHX@[4>7-ZY`P)!'0,>805YH":X3=I"TI0:A(CB/.$E&AXE)]J3_
M`+><AV4(W_[MVUX!R".,`@(R,D8`$!$HKI4,`#Y!M0*:@^P(#P'%O+^M#TF4
M0$X$#T"9&Y.VR'-C0*;XJTMXMK\^6(JZSR1=?&,@>HL<B#`W;)O-PJ@E?GFW
MJZR*;9G%/"'"?9#?G7.WE=KQGZO3!N7%]0;8RK`I-O'9E.14_L#$MSSF(8%"
MR+M@T26D66:ZJ08SB4;$(/)=5WWF[NK<68.0@N$ZN?25OI2$&0Z0I!I"N<NU
MW'3Z"^O\I8Y!%0,[#PZTX,2<,YD\?FW<B]=O5Q>KN8Z.Q1%B#:2.Y=N$R@$G
MYEU"^D@Q#)I<L7T@1^Q\-6W7M*`Q=?&\GC(7(2Z7P\V8XKA>5Y*G+Y`NS;36
M>9N^Q%^U40()C8UX\N>.0[JT<*!KNL.J3T@>526U4,FZ8)6.CL1T%F.9:N=2
M.O,MP%QM[;T)D&6M(''3MI?*LH;X-#S<%&1JR<7(N23*RCL1`Z8"!4P>UNLO
MK!A#>&DZ&=S;1[N2,!OF\&FKJ)AEA)%LX=-GS;7680F;S6#+2()\E-E)33D8
M]9LN,PO$@O&D?`@D.N#K4AU@9R/HUMU/':<;*R;A;&-GQ<]#BFRF("/8LV4B
M?4\:NYE91D]D')6QVZ0D[H@`GY:ZJS4)(U'U5=56>[DQ3!LSZ(MN:VUYDLQF
M$+*[+FLKA58O"R8FIG(L9Q^B&-M'TRPS=M#Q!F)10C4FYWRH`X=&!%-0.C/A
MI_C.3_AD/@W`'AI_C.3_`(9#X-P!X:?XSD_X9#X-P!X:?XSD_P"&0^#<`>&G
M^,Y/^&0^#<`>&G^,Y/\`AD/@W`'AI_C.3_AD/@W`'AI_C.3_`(9#X-P!X:?X
MSD_X9#X-P!X:?XSD_P"&0^#<`WM(\XO)4/$I(*.&W;SD.W\!;_\`=O+P&K[.
M<9KCFM]@9#KIBIENP(+"LIF,(Q64>'0CLERV-A'SS'H%ZLQ:'>)-I>612;G,
MD`J`"GF]O`4MU]NOK5S6:=0<YHQOKQ=AU*,,*"4G82=?XU-]/"4"C-Y+GK.9
M+,1*D3E3)9NYCV#A1N[9/Y)1!,K$&PG><!%\OUG=<C":G!0]')MLV-XZON:%
M%8VS<2DG^4S&#1$7):YG<?/`XE)/&^';,?@[C6IS1KEV599%PJ5LB@J"P=*,
M&=2&30$7D4HQR/$I.>@L:FI+%Y9=L,MCC^4@(]\\@93EM2I^)1#A<S=>T`)S
M4S4``H'`47ZIM_\`6_I[;+6$T9TJ/M_ZC;X.PRB7RB+GT(K(#SISY@]DL/CR
MKG7(9^UBL'%/F$8NCB[R***DBN8'"8AC%^H_K2RW$MAY.7I%G,,F<5V+K?&L
M:UWE^373^5XE.(G+GL^SR)MCT;CJKN!=JH';K(`K&)-#G,LNHY35:I!"#[J]
M](XCB^)3:'1M()R$IJE/)IJ*4Q?,9%V38++)%XF2QILPCY8CW'V$NDW;)QJ,
MF'?B(2Y9-WR6T:_;"$SZXZ@>M?)^HQEK?/\`IM7P[2KS+L]B7NQ$V60+OV.-
MQ^&2L]A+Y26Y_P!%3@^=,V)7[\I@3,\F4XMJS47CY%TD'1A@P.#!D<)"2,(,
MVQ@)SD:&HB0;>QN`T'R<!QJU-UM>DN?P@!M[T<66-LKD7L+'1#/%,U1QV";J
M)8CAY,KE9J1D8+/@:P:6P'TNJU,J=JY"`1;E01D9`'"90LFAU`=93S936+3Z
M89*,UR>"T7.2CZ2?.G&21/YP(9@]V-#,I9HS3QW(I[!)R0=,%D"-F@,$X11R
MX%4)-BD0*_1'5WZ2MQ*9E$S'1.X8%A,*S.5A)ULRR)Q$R&58Y/,TRQQ41DQ<
MSC!M")2*#1%H9%YE+UNV<Q_(9O"V!='I7V5U!;;@,@D^H75KO3.10V=-HO&X
M9JC*MD9/''>NH>:6>'7GTP7D9!GD$@\:KJM4NX)&2!!)9PHBLH(6]\-/\9R?
M\,A\&X`\-/\`&<G_``R'P;@#PT_QG)_PR'P;@#PT_P`9R?\`#(?!N`CW+XPX
MY9JO\JRQ:95/!0KAN!37:\S$M3@+01$25J7M"@^OP$@FC#F`P>*2A:@<*E6;
M@);RN"U+5J/:3G@(>RF3UAJ`:,.:_P#*DH6_F4M6;A9S`>@%E6HTY??`$M:T
MY*=:T-<$3Y#$G5W5K8WC4XC37NXQ!-!TU(B?GS>KR@"Q#,5#*`V[\!DJ&+:9
M!(1NM,!@\#'7?Z8[TLVK_3)[!Z=-0=%?3AE_4OANP,_T=TFYEE/31.Y#U$97
MT]Y=DTS*X0Y@<V2SR(;K8AEN-\J6=/VB;.*131747[ND1\00LUL+K'^N"26'
MK-LB]'YI**BW<["J.)&)AL&7EBR;;)(5Q!MCLQZI9;P]$90S1),"M$@53&X3
M&&]3@-K'K;^N3"(C_P#2\M(A43#0,6P&@7"J(`%>J$>PO,``]@A?9J!^NW]<
MF[/_`+'EI$:"`T^BV`]M#%&@_P#T4-:"!:?L"/``=;?UR8!*/_TO+2)K1(-!
MQ;`:&M%N(@:G5"'8?D"`TIV*GI3S;0>\7ZT/K@#S),=99MT`Z8C<-<S<,VRZ
M30QS!6[ECC"C^+3R!\BNAU3M545T(INNH!B*)F*94XE,4;!3!3F'6A];ICLP
MR=EJKH)TSD6KV&22[77$Z]@<+?.I[`6<FFEB$L]>N^JER]>.)?'F"*RRJBIU
M5#.U3"<3"02!SIZO/3Z?6-^BV:Q#6_6;TD=/V!'W!$/F>+8WEFCY7*(#9<>H
MHR@IB`92&(;FR*`G'RBBA$GL45<78)20<Q`J;EN/`>Y;T<.OY;".A'I/A<@U
M!`=-66K:/U_D6=Z(P#%&>O\`$M9;`RJ"C,FSO%8O#2%=K8^1EE;YX"K9===T
M1957GJJ+"8_`75",.``'BLJ-``*BLWJ-"IA41[KY1Y=1]DP^Q0$4C'&*S5$T
MK*@`"E6UVD@/:L4.Q5/N1R]I_44+6@!V]I1!<:,.8#!XI*%N`_:59N`EO!R%
M2U:B`"3O`"'K"F3UAJ&#QAS`</%94EX*@%BS<!)S`>@`DJU&@I=\"VM:<A.M
M:&N#)XPY^9^5)0E_-I8LW#E\WO\`3EU:C3E=^"RM:<A*M;37`'C#FO\`RI*$
MO%7VBS<+.:+X0LJU&G*[X%GEIR$JUH:X$;F/-WIF`R<H`K*N2EH[2(!*H/E1
ML3#DE4$H+``7)KVE3*-`$!/P"P8TXB(^*2@5$1H"S>@5,<U`_!?(%]`]@H?M
M@!&G`:^*2GE`:"LWH-#$-3^2UH-E!]@P^Q0`L:<HE'Q24-:).PRS<0-8+81`
MU&H5`_=Q`WD[%3^2H4`+&'+9^5)0UG*]LLW&_E"R$;Z-0KS>YC?2E>>I2E2V
M@B:1Q@=.P\4E3"@HS(:]VDH"G+;QBE5$QYI4S+=U$#VIH`8%E!M$3`<`6$C#
ME`@>*RI[`2`;UFXB?E@R`1/1J%15[F-U*5YZE*5+:&2QAP`H>*2AK0(%3+-Z
MFL!L`B:C4.T_=Q$U*=JI_)4*!@(PX!_.LJ/8`5%9O4:%(%?Y+Y1LK^R(\!D8
MPX@(>*2@5`0J"S>H5*H6H5:CVA?4/9*'[8(V,<92/9B64E2@=DB%P.TE35,W
M6**@*J@].<]SBX!%53M3)YQ@`;@6'C#GO_*DH2_FTL6;A9S0?`%E6HTY7?0M
MK6G(2\M#7`'C#GO_`"I*$OYOM%FX6<WO]+*M1IRN_!96M.0E6MIK@#QASW_E
M24)?S/:+-PLY@O1"RK4:<OO@`6M:<E.M:&N!'(L#%:K'&3DP"\AK2NTT0"]P
MH(%!0@LSE*7O``'NI:@F0!N[0,"SPP_QI*>41ISF_JB8:?R7R!=3]@`X`"-.
M`@/B<H-!*-!60H-IDS4'\&[0-RZ#[!A]B@!8PY;?RI*&M%,?.6;C=8+41`U&
MH5!3NH@;R5!4_DJ%H!(PY;/RI*'L%+VZS<;^6+$1`]&H5YO<AN\E>>K2E2V@
MC7CS$6BR#*2AC`\*(&,[2**H(1X`9-0A00(L1?N8F.`D5&Y502@6I3)@L)&'
M+9^5)4UG+]NLW&_E@R`;Z-0J*G<Q$U*5YRE*5+:&"QARV_E65-:!`\Y9N-UA
M6Y:FHU#M/W<1&E.U0_KA0-#SUB9%+#U!?R"X%V#AH<M=5$R9ORFD6IP(W(81
M[*^4/.']K@&;IL_X==!?[E=6?[#07`35P%)](XM+(ZJVID</D^P7DI^?'K-D
MHC&HZ2CU6?B;7J1W0E'QL/'JDA[P6>M2'306D$4U'"@@HL5,PT"/]=.>LB7S
M?"([8>/Y#CN"/@C$YR>C9^%5DWR3W!I)\^?.VA#NU<.<PN6I))+,UT3E4"PC
M=PO>:@6O2Q12+V;BW,RO,);FX3GQ@"5E6RQ4N7-ZY*()`VCFH@"G-J8!$:B0
MH^IVA(CB-`)*-#O\GVI/^WO8]E"M_P#D<`YA&@`@(OI(P`(")1>&H-/4&TH#
M0?8$!X#DK$[U])_)Y!D4>[Z3('&HYLOM:7Q9U,SK24;3>((3?BFI6SR2Q[;*
MI8C.OH@X91<DP60!-[-.';P@LVC`6RX2!,;1]((CD.YX=OI3&F\7C>LMOS6J
M\F:H2\K'9+F6/[?FL>U8B[01V&K*.U,GU6W;23J)3:)+]Y'GIKE*J6.*$%0N
M_/2K.I.#5D^FELUA5\PURTR%@OCC=M,-,>E(B&/.I0,FUWG+1\FK*/'#]P\>
MOFT4VQONJ314RZC@5$`E#,MI^E`Q7)Y4^-]-^!;+PY[NS:<?C:#',4,=R*-T
MEC/TSQ77LMDR\MG+2/"=SG*)3$YM-1H1RJGC[">(NT:KJ,!2#7M7;K])%DDK
MM1OFFD#XU#P&@<QG=13$SA*\,YV#N2-R#+$,=2R3'XG;N7'Q>+?P3.+5"&%\
M1\J=<]%ZCY@)X'J1])O&0#^8F^AP^>*A`Q0146SV3!:WE33#;%\BR":F7S1[
M/Y@JI#RRT$FQ:,"I(2B$E(LTE4BE5<]Q#>]A[L](:EKO5V98)TNQ$;FL]DVP
MV>8:D?9>[SAU'0L*C'-L!>2.:-Y'!(K'DLD<=_?NA%)<R3%)NDF;OQNYN`-6
M]2'7SF6PL<C<PZ&97`]=R.2L8+(<DE=N19)*$@/I<WA'F;,(E-)ZZ?*G@IDD
MD,8N"0)MXET!'*JKE!,@:N^ZI?2+(X^[6@N@Q;(I1Y'OCXU*.]H.,<;^,)P;
MQWX;D^(R;%&:B4F4Z444UP=@@_:,#@55%R_8EX#8<_ZL>LIEL[8^L-8=$V:Y
MFTQ%'%$(G8[[*Y7&\=EW668<O-`Y8CD..Q6/RY8F6*?GI-990C1-H+1\HV>O
M691!)"=6'7#(3\U@60=#LYA^8'TELW8V&S'T[GLOP:3S+',4&6P3"9W((7%V
M./PSZ;RA1&&?,UY9L^57.9=B"C4AE@#ZYOU"^D!/K+'<PPOI"DX;-1VCD6,2
M6O7D^QS=U,P<>QQ=7#5WT@.6Z]+@F)91*RTLSE\G(2=&&)!E=-8J12D&Y2A8
M;I3SCJ-SM*=9=0>(2F'R;#&L1F$%PPY[@J">13$GF3++,69`;8>RX[)8W&7$
M(@BUD4G;5=XU%-XHT22>-C*!</PP/Q^3]]C]IP!X8'X_)^^Q^TX`\,#\?D_?
M8_:<`>&!^/R?OL?M.`/#`_'Y/WV/VG`-S2-J\E`[_)]CAM_VP>VK%N/V'`:O
MLXN<0^MM@2VLFQ<AV/%X5E,C@,!.NW7@LYF;*$?.<8B)7N;V*=>'R4TDBBKR
MW3<UAQHH3VP!5J'G.LU[*1#!]$8]'DDM^Q#-9VYPYZ2-B>G9GCK1YF+N8?M]
MPNSIYTZR1E(LH)XW073526CUG48F51R"(0%-]3OI'6$Q.+M/1Z.C8UCRFY89
M`I=_8_,/\PD,3B(N0U5E44:*9@_BL4V++)NH[NQF#J0;`X(Y7*B1N9-<.E.#
M*2T_`14W/QLWB4[,06-2LWBKN41>.\:EY&`8.Y*`=NVIEVKEU#O%3MU%$CG3
M.=,1*(E$.`HKU3[5](#K3;+9GTY=.<%O'3K3!F.12LH]R]''<F=90!\O?R>(
M1ZCC)FQRG0C<,0;@J2,<F4=9.PY15.[.@X`QG<O7ME6*[$R%QTN1>!Y)C^QM
M;06':ZR/.U)M;)\(DD3EV),)YHRE("+%[&NE4%6KKNA&J#45"&1<.2'*0(1?
M=0?I1DL8Q.6;]+4<G*OM5)3<Y%!%N9=T;9++)5HUY#`BGN:%4QN,GT$F16*#
M@KMPT92JL@Z4+X8NT.$SZXVOUZS?48PPO9&B8O%]#.,NSYA(9I'F=K2K+&6V
M&2LS@SKQ<N>RD8Y3%\WC4W[ON*!W$C+*L6[0"1CEV<.B[".HP9&![)&$&;8U
M@O#`!AY)!M$0*40`?)V"'`<:M2]3OI:/!>3N'H&A'F5R;N&CXOZ-[398ICT;
MW7#\0:91.3+@,AV*L6(5SYQ,2#9(3HNQA`;M$B.'J:RAPL5M#;W7?`SVIE\#
MZ<6$]BV7->GZ0V!&EGC2F18"[S!OLE7>>*NI<V80,8\<8"O$8^1C))L@:"5V
ML*H+&.F5,([B-I^DZ<8SFL]+:6PIC,8_#9RE$XJG!R"JTW/14]`)P+V!?EW8
MJ>=8)0R&1$3;*I1XSAFL0NBNS"261:A9WI7R_J3V#`9"^ZF=?):NR:.SILPQ
M>,A%7:+-]C3G74-*N55#/9[(%7C]CDKQ\W672.#2I`22,J*1U3!;[PP/Q^3]
M]C]IP!X8'X_)^^Q^TX`\,#\?D_?8_:<`>&!^/R?OL?M.`CS+XL!RS5?Y2ERT
MRJ>"TKX2D-=KS,2U.7EC<)*U+V]@]O`2",54#?E&5"X#!V/!`0N*X+YOF=@E
M[Q4/6$A/L>`R>+`]_P"4)0MX*>T>"6WF`]#S/,\T4^^^;ZW*3^Q[0B;(8CF[
MKUN?Q:=1IKW<8\IO(\I!3GS>KRT63Y)A4!OW^Y(*A89%(>VR@AX"^O7TL?IL
ML$],=L/I1T;H+5<CON%V+L35725.2'3'BLYNW*^F[-,KD9S#7<3L:<=G:FU]
MD./1K:3DI%%5C$MS1ZJKT6XM')4@M'G^S_KERN)'+D^AM*(11YJ%\06CY#I;
M&1\4#(X93'B.$V^X5@:$"55:%3[J1(ADPJK6AS<!M([3^NN"(C^833`5$1[%
MND"@5$XT#_YM]@!?0/8`/6X#'YTOKKE:_F%TSY0'[MT@4[!*/]K7D[*?L"/`
M`;2^NN`(#^873(T$HT%;I`$!M%$>W_YM!4#<KM]>XWK\`^XKL[ZYBIDV.)9W
MHW3K7"#SD.GF3M-QTG%5;8J+^/+D+DAXO;R,F55*(06.`MSE7J8W+$#"%`KQ
MUO>D!^M6=$N';#WWE^KL!@>D_%<Q<L<:SV,P?2FRO!]>/YKN>OYW+&6+9WF6
M9140_B6S-->2E$P(1R\`CE<%ERW!W$]`UOGJ?]*ET=,>IGTDVI<'F9?$>HIM
MEW2=D#G5<;C,8K&81B..L6&X<'9RAY1X2=:9BXFV2$ZU,@41[P1L(`!AX#T4
M%B[;?RC*#:!`\YX(W6`U"IO,H(G[KYWKBH?[+@,!%]@!XC*]@`%1>#4:`F%1
M\SM$>7V^R8?7X!#)18`R5K(RP!5'VLBJD;[J4.Q1-1L<OMO4.%:!Y?((+C1=
MP&#Q&5+<!P\UX("6\'(5*-G8).\U+ZPD)]CP`>+OO_*,J6\%0\QX);>:#T*D
M\SS13[[YOK"DG]AVAD\7?S/RC*EOYOM'@ELYO?\`[GYGF\OO_F?8\E+[#M`/
M%W"<?$)0M_-]H\$`+S1?#Y@6#;R^^^;ZW*2^P[01.8T.],P\0E0%55R`6OU"
M`6Y!ZJ-I"G3(82\ZA:E4M*0M`"V[@%HQ8"(CXA*!41&@/!H%3*&H'F>0.90/
M8*'K<`!%T$!\0E!H(#07@B'8)![0L\@V4_8$?7X`"+H)1\0E!M$@]KP1`UAF
MPT-YG:!^[4-ZX*'^R[`"1=HD'Q"4-8*0^>\$0-RA9#Y_F!<"G<O.]?FJ?9]@
M(FD8!73S\HRQA149$$#R"BA3\EO&J7'3,=0A3*]UH>TJ=X*J5`1/=P"TD6!+
M/RA*FLY7MW@C=R@9!Y_F><*G<O.]?FJ?9]@!8NT"AXC*&M`@><\$1-85L6IA
ML"HG[M4WKB<_V7`8"*```/$97L``J+P:C0I"U'S/*-E?V1'U^`R,74!#Q"4"
MH"%0>#4*E4+V>9Y0YE0]DH>MP")A&`>/9TD98`,S1"[Q!10_G(+E$_-4.X.8
M]7-P")S]I"=HV]H+3Q=]_P"490M_-]H\$MG-!\'F>9YO+[]YGV/)2^P[0#Q=
M]_Y1E"W\WVCP2V<WO_M/,\WE]_\`,^QY*7V':`>+`]_Y0E"WBJ/F/!+9S1>C
MYGF>:"???-];E)_8=H(I.-`&BQQD)4//3-0C]1*E[A0;0,FHW,4I>\T``.'8
M0@=M*""WPS_[X2GE$?Y6/JF,:GM/)YU/V`#UN`R$900'Q"3[!*-!=B(#:9,U
M!\SM`>70?8,/K\!@L7;;^4)0UHICYSP1NL%J-#>9V@?NOG>N"A_LNP`D6!+/
MRA*&LY7MW@FNY0L1\_S/.YG<?.]?G*_9]@(EHP"+Q9?$94PD>`8!-(*!S`0C
MP`2*D*=(BY%>Y@8X&*I4RB@@`":XH+218$L_*$H:P$_;O!-=RP9!Y_F><*G<
MO.]?FJ?9=@!8NVW\HR@V@0/.>"-;`;A4WF=HF[O4?7$Y_LN`T+/6'(2P]3OL
M@K;L'#0L6<\Q,WY32+4Y+`N'S:_^MV\`S=-G_#KH+_<KJS_8:"X":N`I-I/#
M'`ZHVI/Q,QL!].*[RZS)"*@8[+Y1!HI+-^I+="$;'1$:,]CL>@1=VU3$B)WK
M-`ZYS"HLF4QC`$::OBNKA[G.*1FR8S+6>)2+UHYGI]ADSQJUAXH,%77<1+U(
MNSY*7">'+!2,+ILT<L%5#G1L;)(?A06\2Q!M$;-Q>R=RY_S\(SX1++91+2!4
MQ2F]<E#E%77'E@?G#<`=AA*41]J'`2(XC4@DHT.\R7:D_P#_`#)[ZA6__P!>
MKP#F$8B`@/>9(>WR#)/J#[`T7`>W@.+>4[G]+PW/,E@.DG$DBERC-G$`*N8Q
MTT1?73_,4G>O5Y%PSWJS4:YSC>&.F47)LBME$)-^H_D$SM4&:2"P25K;:/I*
MY5AL53873G%PN2Q&EMH3&$8ZRF8]/&LAW:EF!8S56*L<X_/N_65@DXU93Q@\
MA&1B"K%LF^:O53.#MT`5X)MGTF,KDNGH7/ND[$,3QZ1G-?0FX,KC]KFFWT<D
MD7&FFT,C@XAGGBS",@E)`)EU$E!:57&-(V3.'>E.`U]+8/I6,<9R2,YH'6^:
MN\I1S=QAK_&\W>,/S?+I)9&3!8?/HUUG+9*8=2+MBU6578N>YM6:R:2ZYW*A
MC)`^--P^DH?QVX85]TBPV.Y)%Z+VQE.K,N;;9:3V+RNZ\<BH-EK'!BPJF9L9
M*1A<[FPDGIE7JT:=DWY"*JE1,H`;/H3/?2"S.X->0&Y-&L(O2KN%S%#/MC!D
MD?$Y.SR%UB6)2^OGS'&&FR9=P6)C\B@,EC98G<!464G8A1(J*3-V=4.E7A2/
MXU)_*C[^/X`\*1_&I/Y4??Q_`'A2/XU)_*C[^/X`\*1_&I/Y4??Q_`'A2/XU
M)_*C[^/X`\*1_&I/Y4??Q_`'A:/XU)_*;X?_`+:_`9\+2_&9+Y2>_P`=P!X6
ME^,R7RD]_CN`/"TOQF2^4GO\=P!X6E^,R7RD]_CN`/"TOQF2^4GO\=P#<TC4
MA>RH=ZDJ`X;4_*3WU6+<?OW`./A:/XS)?*;W^/X"ENY)_J_@-XX+":IU]`Y7
MH^8R?3#7*\I6?R'TD@H69G=AL]Q]\!UL^`(FW@,=C(1\R?-HUPHBNX!OW5\+
M@YV@5RG-[>DZ93$\Y8]!^.&QN!4W-#1Z*74@TEY','6-Q$8^U#F3/NTDT>0V
M/9[-).6"S$S=>09).0<K%)W?E+!TLP4):9Q^*ELEBI7%<CDX+&I+(,75GE9!
M7')Q]`1[F6@57[1\[:/E(A\HHW,LDJJFJ*=Q3F*("(4"ZDMB>D6P?J)91V@.
MGW%]L=-B&$PDW,9#(9F$+EYLH)"[::9-CC));8D4\7,C-K8;)->5%&%PV92+
M$%06>H+M`1S>V?2*OM5O)J*Z58;"MKGV=B49C>(&V2ALV`>8#(M,J'('6;S"
M6R->GQDD:^@V7,D8WQ94I)=NFFP.!'3EL$29#MWTM+2)P)]CW3-B<JI(8ZQ7
MS%F\EDXZ8:.&^<OX^4D2MB[W?L8C))3%$(M1K!%4?M$/%7KE:2#PL&K@)PUO
MG'I`I3J+C\:V=IS'<=Z?ULMSQK)Y1$2:Z\JRQ@F&2DK@ZI)7\ZTV5\W0DD8Q
M!ZY\*;KNY.3<MDFZ;:-,Y7#HVPC4_#V9@<2)C=S;B!?$GH`8>00:=BY:`(_L
M<!QEU/O'TPB4*#?;W13@$IE4DZAX^/<0&X4,7QZ)(TP[$(_)9^8%ML7-G)H]
MSG9YB5:MBF*Y-$F08$JY1.X5"7\[V?Z1EKLK`D<!Z>8AY@<C&Z'=;"B9R;HK
M!2N6,'3S<L3C.P6FY+9AIKPQ3HJNG>/L16<@U(R3=D,X6$(UBML>EI-*YE&S
M73;A2;&/PO,G6-9"QE+D7F70\^R.U(A$GWVJM*LU(EM(,X9NJM'GFC&9/')H
M]-5<B`72Z5ISJ9R^!R%UU280SU[E+3.FK7%8_'9%T5@ZQA?74/(.A,`YEF"K
MAXQRAR^15<`X(B<Q>6D4Q4Q4.%O_``M+\9DOE)[_`!W`'A:7XS)?*3W^.X`\
M+2_&9+Y2>_QW`'A:7XS)?*3W^.X"/,OBD399JO\`#)4*95/!0LJ_*4;M>9D6
MIB@O0PE`:EK[4>T.W@)!-$HF`P=[E`N`X#;*/BB%Y7!1M$%_-$`<"(4\@E((
M>T+0`T2B>^KN4"\%`&V4?%MYH/`&RU<+!+WTUM/:V)TIRR4")\AAT5=U:V,+
MZ:3_`/E[N,1(A-2*"1^\3>KRF!1)-<I3@EX@84@_Z(R:0EH*2=H;4\U3KY_G
M4;M!YBT2YV3"XU-X;"Y\LT1/F$/B61R!)6<QJ*R(Q!E6$')R;=NX6:I*E1.L
MT;G$MR"0E#1-V1"2NOLD)WZ;1YN8:Z,*C:;DVZR?,SC$*@W5(YJW*'/&@$M`
M*%I[4*!-0Q2(B(]ZDPJ)A[)-\`!<94P@``OV``JB`>L`%`/:AP!X4B`U[U)^
M4!IXF^$.P2FI]W\E2_M@(AY!'@`(I$HE'O4F-HD$*RCX0&PS<P7`*X@8![L%
M0'R@8]?;FJ'\]/-/2Q_6-)KTJ>8>COP['V[/(87;>2`UP,-+X6DJKTXQV3=^
M8;-E<WF3*L2X>[UJW07).IOT472SD$4C&>."HF"W^T87ZX'ELEL7&,/P7065
MZ"R9[E<!BV/96ZZ/9&,R33\NX6CX.'R.)RG)C2;YE,X85!%ZWD2"NLFNL1R`
MF55`0UN`A/KHV*0<'B^+8+T^XWC.,Q,7`XYCL(^Z)XV$@H*$9L(^(AHF-;90
M1JQBXUA&I((()E*FFD`D*`%,("&E[?VM]<^T?K#-MN9CB.OY'$M=X^[R?)$,
M'BNE3865$@XHC=63>16&8A-3&49$HP9MS.%D&35PX%$BI@(:IJAT;^K,^D)]
M)GZ2C&^H/:G6F1"3T5BB6&XMI;8L+@D9KMEE^?IOIY38K%DZB%&HY03'HU&-
M(Y500!HU<+BD)^<*A"AZFY.)1%DL'>Y;RI=I):1(;[L4.PR;DA@]MZ@AZGK<
M`N-$HF`P"[E`N`X#;*/BB%X.`&T07`2B'>1I3VHE)3VA:`&B43WU=2@7@H`V
MRCXM.:#T!LM7"P2]^-;2EHD3I3EDH`>)1/?5W*!S.;6R4?$MYW?KK+5PLL\0
M-92EG+2I3E)V@&BD3B<1=2@7BH(VRCX@!S1>B-EJX6`7OQK:4MY:=/N9*`C=
M1:0NF0]ZE`YBKH!ME'X%+>@]4$2@5P!2"45Q`HT\T"E`*6EH"T8I$:CWJ3[1
M,/9)O@]L8YNP.?V`',[/6``#U`X`"*1`0'O4GV"`]LF^IYIB&[0YU!`13[0]
M4!$/5'@`L4B6VCJ3&T2"%TH^-6P6PA<`KC<`]U"M?;`8]?;FJ&"Q2)!((.I0
M;!3$+I1\<!Y0LA"^Y<;P-W$MU:W<Q2OW0]01-(I$KIY^%RP\I1D0H'E9`Y3`
M@VC3E$Q3N#%.8XLPY@_NP.H!J\P]06DBD264=2@V`G2^4?'KR@9`%]RXWB;N
M);JUN$ZE:\P]0"Q*)0*`.Y0;0(`72CXPC85N4+A%<1,(]V"HC[83'K[<U0`B
M40``[W*=@`';*/Q$:%(6HCS^T1`G;ZXB(^J/``Q*(@(=ZE.T!#LE'U?.*H7L
M]W[!#F#3UA`/6#@$;")1-'LP%W*A5FB41\6D+_.06*(W"X$X'#O0B`UJ`E((
M=I"T!8>)1/?5W*!?S0&R4?$MYO?@&RU<+!)W\UM*6\M*E.42@!XE$]]74H',
MYM;)1\2WF]^K9:N%EGB!K:4LY:5*<I.T,FBD3WU=287\RMLH^);S1>B:RU<+
M+>_&MI2T")TIRR4!%)1:7=%C=ZE`J=,WFRD@6ESA0P@6QP42E#O(@`!V`!2!
MY"%H"WPI&M>]2GE$?YT?4[3&-3[OY`$_^@`#U`X`"*1`0'O4GV"`]LF^$!H*
M9@J`K4$!Y05#U0$?7'@`L4B42B#J3&T2"%TH^,`\L6HA=<N-P&[H%U?;7GK[
M<U0P2*1)91U*#9RJ7RCX]W*[B(7W+C??W`MU:W<Q6M>:>H(EXE$CB*`'<J/+
M=@8+I61-=R8\"E!7\(HL0_<BB<#@8#F.H(]JAQ$%I8E$EE'<H-@)@%TH^-=R
M@9@%]RXWB;N1;J^VO4K7F'J`6)1*!0[W*#:!`\Z4?&$;"MRA<(KC<(]V"HCY
M1,>OMS5#0L]CTVZ6'J%</U!+L'#0M7D':R9ORFD7STU53$./FU[0\O;Y>`9N
MFS_AUT%_N5U9_L-!<!-7`4KTIA?/U'M*9AG&</,D<;NZSG43%QVPLLC6J\PG
MU*[K0C&<;'&RZ"Q^.Y[E!,"E%5FV!8PG.H2XZG`1/J7">L8^=XTRVS'SS;##
MRQ5YJ<B=JRJA4<?)A;G\GRS%#;KZ34GU<J51!1Q'("U%P10R:2+,I$E@N03$
M(R)V;BPMWN4.>=A&?";Q3,\NF`(*4YK@I>2$I-NP0N!8;@):!Z%$U1*6@2"X
MC&WB<:%[Z@I/_P#S64]0C?R#WRH>7@',(QL`@('?U`0$*RLH(5#UP%X(#P'%
MG*\M],Z09LF-:.U4B8<GSAWCQTL\@)E(,"ELM)*X%'RB\EMB`.EG^%XBNUA7
M94VZD7**DDGXN"G3CTE@F^*;^DTEL6W!,343KC$\R1P?:334F#1N1MYK&W&<
MO=C*)Z=E3YLZR%65[M`:S:&\<"3CP;/GKM!9%LD9%=J8(OD]E^EPQN6)KPO3
M7I_.)=O$SZ;#<$1L3)B89DRF-X_AQ?I%(PC[8>(#C+F?GL@='91J@H+/U6*K
M<J+-H1221"0-3YQZ3Q[MK'8;;/39KJ+U$[(UCLERN.W(!9R&5C<:R9XYG(YI
M%YY,+39\JG#11#$,R9(QAR*M")+$'Q0P1[DNY_2U8E&L7#OHQUEE)W!P+(O,
M&W#,RRD2,H_C8:(;HXR[VLRE)IW'OG)G3LP+M6)F)S'4=,BM55%`ZV8NUE7N
M,XZ\RF/7@\F=P40YR.%99+*2K.(G5X]NK+Q;23!T0)%K'R!U$DUZ!SB$`]`K
MP#YX6U^S?_*LI\,X`\+:_9O_`)5E/AG`'A;7[-_\JRGPS@#PMK]F_P#E64^&
M<`>%M?LW_P`JRGPS@#PMK]F_^593X9P!X6U^S?\`RK*?#.`/"VOV;_Y5E/AG
M`'A;7[-_\JRGPS@#PMK]F_\`E64^&<`>%M?LW_RK*?#.`/"VOV;_`.593X9P
M#<TBVW?97SW_`&.&U/RI*!_V%N/:/?*CP#CX6U^S?_*LI\,X"EVY?URF&\,%
M9Z?@,6F]$2&2Z93S22>2*C;*86!=3NPV^Z><I*[,BC.6;/&6\"Z8N&,>9ZB]
M4!%)N\(HZ.W"MLOL+TLB$U/.8_I1TP?'H=;<L/"L6W4#)R+[+0B(>-=Z7S4X
M/,K@E89CEDZW<,WT:*X.6#1T9=3F*)))F#IA@J,Q)X_%2.71+K',K?0.,O,G
MQY'(7DBE`Y"Y@(]::A22324=M9$D7(G40!=-95-4"7%.8!`PA0+J3F?26X[U
M$L?U;M8:ZV!TTM\+@Y*4'(LQ0B,S<Y@E$;889)`LDWFQ,9>.459>3Q"4:5%F
MFL$.[8&>-R2!G;4/@XRGTFDA@C"2+H36&,;`#;V'D4QB/VXXR&&<ZC<,<M+D
MS>=R"3S5L,8\;S,9$=YDXYL[>H,)506D6[7:'!0-0CEO2P3P8.QF<9UMKYY(
MX`R2S68@Y&(RV)@-BDST(F6E"(RVTB2#V$'$E$)-K'-VZG.8`\2.\0DBM$SA
M(&MWWI%''46RCMHX9B+'IR'+L]2E)6'EHGQ9/$5<.F'6#*D>CL^9FW3=A,HQ
M:#D`B$GKN5>OZBA&L6JCP.C3",;A'LC%,^$P,VPE#Q63`!-R""`4[Y0`KP'&
M/56:>FK80@--L=.^C,DR9^[AF+>4C]ID@H*$;,L0P^(R"?DFL+M%9XX2E,U2
MF9QLR1!=4[5PE&\QF"!7BP6BSV1Z]6TGKAWAV!8\K&34;T\/,YA(V9CY4<0R
M!^GLIQU(P,O/91NG''4OC,65EC;:&?0[)1Z1P[$Y2.42NCIA7J+FO3"`_P`K
M;2VM]5*QJ.(9R;'I9I.Q;=Z&6QDY$*8\,9$FW"Y0FB3<:23;PQ)%>*;F:]Q7
MEA;.5')$0N;TKFZI)6!R$_5GC\3CN5IYTU#$$<7ED`CCXJMKJ(7>I%)#YKF)
MU%666FD$SN7#M-1<U0(@D@1(3A;[PMK]F_\`E64^&<`>%M?LW_RK*?#.`/"V
MOV;_`.593X9P!X6U^S?_`"K*?#.`CW+XEH;+-5B)Y'S<KG@"DO+E`+]>9B0:
M@5\`"-![*UM'M"@]O`2",4U$#`*DC0P&`:3$L6@'!<HVB5Z`EH#@U*4M$"B%
M!(2T`T4U-?521\_F5MF)8E.:#L#6V/BV4[Z>VVEE"6TY25@1/D$,S6W5K90Z
MDI4NO=QB'+G)M$@"YF]7$4J1&033,`!(*65`>4()B2T44A($L&BFI[ZJ2(7B
MH)K9>6)3F]\$UECTO+IWX]MM+*)VTY25@0MNV':N->Y$DH>3`JV8:Z$11F9I
MLH/,SC#Q-RUF[Q!8A0%<P%L.(%H4`$+"E*$TC%-1$1%20J81$:2TJ`5,90PT
M`'H`4*JC0`[````.PI:!GPIK6M\AV"`_SM*TJ`E-Y.^T$*E\GDI4/((\`%BV
MI;:*2'FB40K+RINT@MS!4#/1`P"+8M0&H&`3`-0.>X*D]8^%[(8:&W+L#IBQ
MF/==4C;6[6`P7(3-(U_E4A!Q.2Q4^_Q%*2GP<#),E6+=\JVCUS*(*OUSF*05
M5SB</#CTW=7/UI/KVVOU.1O1-M..1T]H#<F9:R0R#-\"T-@N&1ZV.9.XBX7!
M(.9S/7J;W)<AA8"&:JOT"$55:)*E,\Y1GI2KA<8NG/KJ)+:;VTD-G+I=+=+1
MZ\L&@%NOUV:^O<B775NJI=7FJWADNG?KJ)+:;VTB-EE+I7I9/6P$`+<!]=&`
M]0;%K6MU35K>>X.?76AU$?6K_13Z<Q#8>YL]PK%-%K9(?&$9+3&L^FC*<*PN
M=F'@/V++*X["M;MOHFAF,L\6!LY41(W>2!E$Q5!RNF58/9]Z(O(^M'9WHZ]&
M[&](4UGH_JCSMOD^4Y7'RD>TP^8:XI,YK-.=:$F<0Q9-E&XU*GUXK'*+LCM4
M7K<YJ.TTW152E#J&:*:F`P"I(^<!P&DQ+%'SP<`:T2O@$@@#HU*4M$"B%!(2
MT`\4U/?521"_F`:V8EB4YH/`-;8]+93OQ[;:643MIRDK`#134]]5)$+^;=;+
MRQ*<WOM]ECTO+IX@I;;2RB=M.2E8`:*:FOJI(^?S+K9>6)3FB\$UMKT+*=^/
M;;2RB=M.4E8"1S&-Q<L_.?""JKD#CXG*#:!D'J@BF8'!N[C>N8`$IDQ`+2@-
M"$*`*QBFHB(WR':(CV2TJ`=HG-V`#T``*G'L#R!0/(`4`"*:@(#?(=@@/;+2
MHA4!(8*@+V@A4@=GD$*AY!&H9+%M2B404D/-$@A=+RI@\P6XEN`ST0,`BU+6
MM;@$P#4%#W!@L4U+9121\SEVW2\L>O*%F);KGHWU[B2ZZM]5+J\U6\$;6+;%
M<O//D*)JM"D$TK+#>5%M&F**@F<E[P:YD0#&,903@)P,-%%"F!86*:DLHI(C
M9R[;IB6/7E`S`MU[XU]>XDNNK?52ZO-5O`"*:E`H`I(T*!`"Z8EC5`@-REN$
MST1.(@V+6M;A$PC43GN`\):4`.9(=@`'\[RU>PI2A4>^U$:$#]D:CY1&H8&)
M:"`AS)'MJ'9+RP#V@<HT$'M0[%!IZPT'R@%`2,8IL9@T`QY$HBS1()2RLLD(
M`*"Q!H4KI`2&`')J"!2B`@40H)"6@L-%-3WU4D0OYEULQ+$IS0>`:RQ\7ET[
M\>VVEE$[:<I*P,GBFI[ZJ2(<SFW6R\L2G-[[?98]+RZ>(*6VTLHG;3DI6!@T
M4U/?521"_F5MEY8E.:+P36V/2V4[\>VVEE$[:<I*P$<C&-^ZK&`[\3"<AJ>)
MRIRU.X4,;W/O"Q;0[R:@6"!0`M*`F2T%GA36M;Y#RU_G:5IY3&\G?:`%3#V>
MM0/(`4#(134!`04D*@("%9:5'M**9@J`O1`0JF%0'L$*@/88U0"Q34HE$%)#
MS1((5EY8P>YBV$MP&>B!P$6A*UK=4]:\Q2X,%BFI+**2(V"F);I>6/7E=S$M
M][TW,KW$EUU;ZJ75YJMX)%XML1>,*4\@()NP.`FE9900%!A82\YG*HF*;N9+
MP,8H*")[KA54!0%98IJ6RBDCYG+I=,2QZ\H&@%NO?&OKW(EUU;ZGNKS5;P`B
MFH`4`4D:%`H!67EC#0@(`%PF>B)A$&Q:UK=4U:WGN#0<]CV[=+#U$SO!,78.
M&@`+2,@X)_.:9?.3<.E4S#0OE$!&O;Y1'@&7IL_X==!?[E=6?[#07`35P%+-
M)X,BOJ7:<S!AEB^5O-W]9SJ*:,MA9=$MEYP.I3=36+18M5,A2QZ(YJZ*0%$$
M4VZ:H\TP7"8PAIN`:FZE6F3ZW=9OE>>R.//E$B[&CUMGG5:1"#+`^8X,5&-F
M6<DZ5G,TE^ZD[DY4*@,1WRA$7@,40M`7#86)V;BPM#Y`ISL(SXQQD<ORZ8`H
MI3>N2DY02TX]*A4%S76`6_LNJ)2T"07$4T\2C0_"Z"D_J/B,B(AYC?R#WNH5
MX!S"*:%$#!WNH"`A61D3!4!KVE,Z$I@]@0H/`<<WZ7IFSKY6G%0&@&QUC[6E
M,,4D<^57A&<)/RBTYK+'IQRWC!G%,_U[%.6D$B9-HK!2IFK]W(.CF49'$-QQ
MR*]+'(PFRFN4?F=@WR^I]J(:ODX[+2JSK;=2V9X277KJ?:!&2N--\"8XTMD`
M1JGX<Z58HLU)=H:0,HD(?%Q(^E@Q&:@XMSAND=E0>/OL3Q"3RIE-Y)!*[&-E
M$W@V/2FQ7,0QS(74`TP*-D92??))MX5)P5BXCT6BG,8O.`3.\B]+Y.0<O'-M
M-].N#S1\5S0S+(T\ZR7(CHY$QCLN-A1XF&=;958*/LCE6<4BNT?F%A%H.`<G
M>/#*KL8\$89CZ8M>:;K)]/G34R@TWL3'JL7>SLJ.X>,'YL1/+9&Y<-=KNE8U
MS#$)+`1B@9R4HN;04>]R06D0E[7;3TB@]64RCL5IAB?2478.RR0*\;,P:^3'
MUX&-/T]?>)E+)J9$+X9Y.-41.0H.>:M*$>E*@E&J*!T7\)9^N\^4I+X7P!X2
MS]=Y\I27PO@#PEGZ[SY2DOA?`'A+/UWGRE)?"^`/"6?KO/E*2^%\`>$L_7>?
M*4E\+X`\)9^N\^4I+X7P!X2S]=Y\I27PO@#PEGZ[SY2DOA?`'A+/UWGRE)?"
M^`/"6?KO/E*2^%\`>$L_7>?*4E\+X!N:133ODJ'X70'#:@^(R("/X"W\H][[
M>`CC>\;LY+36S3Z&(DIN;Z&3I=:!+2?Y/+F!V2I(=5P29?H0ZO(<F`Y$W:B3
M50Y0*J<B8F,`4/.EZ3M_MG52C.)QN"U<D_T`TW(PF9W"9!!^V,FX+U"S&%RT
M1DA\MCFB":1C1K99JLX>.W+3DFCV[1V5\#/,3_I>T9J=?1FFNF%:#BE]S0V.
MP[/:.>/'&4MVT3%KZ0S24+*Y=`J1JTKD#19O*QB<DW*SCW:J@G<KD;@0.EN"
MM9I_C\4]S2++!YB[@<9<Y9#1LY(OV$3DJ^/QZL[&,I$'ROB#2/DSJI)KWF%4
MA`/4:U$*!=23?TFT7U&,)+IEC-59)TUL\+@WTCCV93A6F52.:-8?;$?D<0UN
MGL<D'+.0D9[%)1J`RT4F=SCYV1WC5M(.ETP0S3OTHTKJITHA@^H<0W"KLS$0
MQ]'"\P<Y#B$?KQ5IEOTI+GQ=@YB=S.-&KN.BA.K!J1<LJ62$C<A`:JJK!$^0
M-O3)DB<$=8PPUDL]'&V/TVC)>>Q`LF=VSSI^5Z)WK>8"$;9[.8:6*`18E4QI
MD@I,*$35>DBD3A.&MH_TC@=1<>&U2X8;IQ-EF>&F$8.2@#/$\4=X;+.<*(VD
M#S*F5+,X2>\+:"F9D$@^DE)1==PA'(1Z3H.C3&):C'L[3/$SBR;VF+(/QL-R
M"4,!#.3$&T>V@@(>N'`<=L=6]-3C`2(9#AO3=LE)VE*I-%PS&7AWT,$;'E<Q
MCYC'QV488RE)";>RQT0:NGB;=4\0FF=>.3>*/4PLZOBG7:\+K<_TO@8@R>$]
M.4AL%O%FA%BJ9['16S7_`%,0"ZLPYE3O(#*I&/Q>.AEHT8Y6,/(+.4E54VZJ
M:@5FB6/ID22N9,IE'5R\,3"LQ3Q2993&*I/SYBRG&3N(=LV!Y?DCXO&LWC*`
M0D0!HDS>M'$T<KQ%P00NGTK1_5.>`GPZN"P_TL^G3<V'J8R_8(,"XJKKN',_
M:D0@9F5YA6F7!(%!T[73<NC"80;-FY4"F"WWA+/UWGRE)?"^`/"6?KO/E*2^
M%\`>$L_7>?*4E\+X`\)9^N\^4I+X7P$>Y?#,C97JL1!Z-N53P`8)25"T%->9
MB0U;7H%$3%'LK40'M"@\!(!H=B8#`/?:&`X#24DR]AP7*:EKP+>QR>E/(-M*
M6EH&30[(]]W??/Y@&MDY,OW7O@'MM>!8/X>I2E+?,I3EIVA$^00,>ONK6ZJA
M'YC)Z]W&(')+S*14Q=SFKDU1$B#]-(;BR*H%N*/+&P26BDD)`E@\.R/?=WSW
M3FW6R<D3[L+X3VV.RV?S@K;2EOF6TY:=@0ONV#8NM>Y"@JB],FOF&NSF!*1E
MVRBHJYQB`GM7:KM%Q*45C`%BAP)0``2@0I"!-`Q#(1$1[Y41$1I)20=IC*&'
ML!V``%51[/('9ZP4`\(9!3^6=@@/\Y25*@8IO)WN@A4H?M=GD$>``B&1;:=\
M\T2"%9.2-]S%N):@9V(&[6Q*UK7SJUO-<'\\7(^K+ZS9DWI;,V]'[BF?YU#(
MQ.S,CS9G$O\`6NI":_:=)9,T,X@MAR&R'&M,@*\P1[AD>WCD'_,=OW,J<\:*
M:LJHLT,%[9[HZ^MM-<IRYSI+K!Z:<+U5*YCD4_@&.H$U3!+,,5E)@C['$I:.
M-TML''C!(9HS*[%TD#A18%><%ZJP'!K)TB?7+264Z[.G7S.6!;IC5Q_N7<P+
M=?TTFOKW%.ZZM]3W5YJMX4,U!U8?6C\8]*=J?T>NX]E9SD^4?3C`\MV*@PUO
MIY774STVLLJ@PSG:L5LUAKJ';IZ\<8ZS7:#))KMWI901CP(26.+4P?T0)C#<
M8R*-6ALAAVT_$.3-3N8J<,M+QK@[%RT>LE%V,BJY;+*-'K%%9,QBB)%DRG`0
M,%>`^\C$,Q:+#8[4&J?F"^DE0&JH!]SO=`-+Q'[F-.P>R@"`+#0[$UP#WSS@
M.`TDY,/N@.`-2CP+1HZ/2E*>;2EA+0#P[(]X&[Y[IS+J2<F7[J#T#VVO`L_E
MZE*4M\RE.6G:`>'8GON[Y[IS;K9.2)]V[]?;8[+9_.*M+:6^9;3E)6!DT0R/
M?=WSW3F":V3DB?=1>B>T"NRV?S@I2VEOF4IRT[`2.(IF+AKYCHW.5<`H?OLB
M8Q`.@^4$4U+E1;7'<F"I3H]EI0$0*4G`*QB&0B(CWSM$1&DG)`%3"<P]@.P`
M`JH/9Y/('J!0`(AD`@/X9V"`A^4Y+R@8A@_[7V]J8?M5#R"-0"Q#(HE$.^5(
M)!+63DC?<Q;&+6YV-W:T)6M;O.K6\]P!8AD2RWOGN?+$MTG)'^Y"R$EP&=FO
M_F].MU;O/K7F*7@C:Q#(CEU0CHO)4:%3,+Z1J<J+>-,05#F.GWD2F8I@)C'6
M$0N*8:'4((*R0[(E@%[Y[GR[:R<F;[D#("77/!O_`)`G6M;O/K7F*7`%AV);
M0#OGF@0`K)R8_<P;@6M7@W#1J2M:U\ZM;SW`!#L0"@=\I0`_G.3'L`I"A41>
M5$:$#M\OE]<:@##L1`0'OG:`A_.<F'E!0H]H/*@-%![?V/6"@)&40S.P:`<C
MM,19(IF(1_)-[0%NLD(`F11IRS6NC^1-,0&T;2B0EH*SP[(]]W?/=.;=23DR
M_=@>@>VUV%G9(*TI2WS*4Y:=@!X=B>^[OGNG-NMDY,GW;OU]MCLMG\Y*VVTM
M\RVG*2L#)HAD>^[OGG\RZV3DR_=1>">VUV%G\O4I2EOF4IRT[022$2T!LJ<"
M.E#7D-8+V16((G74,;W$3.B&`.\G$`Y8@7S:6V$$H*_!V7_?/*(_SG)4J)C&
M\G>Z4J<>SR>IY`#@`(AD`@/X94H@(5DI(>TIDS!Y7?;VI!^R%0\@C4`L0R*)
M1#OE2B00K)21NU,6IBW`9V(&"K,E:UN\ZM;SW`%AV1+*=\]SY5MTG)'^XBR$
MEU[LU_\`-Z5;JW>?6O,4O!(M$,R*QI"$=F*F\*<#&?22IB"W8<M(15.HN8I3
M`S3`U3I@H(FN$PJ'*H"HD.R)9;WSW,$P+63DS?<@9@2ZYX-_\@3K6MWGUKS%
M+@"P[$H%`.^4*!`"LG)F["%;E+43/!$W8V)6M:C<(U$Y[@T//8UJW2P]1+O-
MQ-@X:!>8^?+%`/$TB=J:SE1,PVE\H@/;V^7MX!EZ;/\`AUT%_N5U9_L-!<!-
M7`4GTEKF*=:HVK-0L4_<YA);QZS7<<0N53<<@[R`.I'=#&*%,KEZ[A8PQU6R
M`%4%H=%(X<T4S"`U")]3:?ZMVVP(`FV'Z$EKP9%HXEUF68-R2#>,3PAXW<Q4
MBR9*E7F%764.$#=]9KQYD%VYU`0514*4H7(2P;&H79N+'CV3THK81GPJ&<S<
M](``I3>N2)B0)"3=$2&UP<!M`+J]M:!0)$<1+#Q*-#D&H*3^H\]SV4*WIV\[
MLX!S")CP$!Y`]@U[5G!@[/7`51`0]@>S@.+F5XWZ:4QY@,=?:#;\_)<SF8(8
MZ;QY^@RPG),N0GL4PZ3#(\(CG*N8Z]Q]XW@DGB8F8/6+&1=NE73Y=@;@)48:
MZ])N]UMN)VZV7B,1M9766RXC3S!XVUXZQ+\YTQGG>=<9=)-(S#5WD-'X5AL>
MHV,U<R4NVEV\@BLY0;O$54BA`[+!?35!'Y<YR'+]>*9`[C6$EB$?ASK588O'
M23G8N32SW%GC_(\8:S)6\;AKN)C"R1FSLPLV:[CE.'J@HK!W$+$LA*45&]#B
M`"<".'(D`XA4P%'F%J4#>3L#L]0.`_7A$?\`>#>^'/\`'<`>$1_W@WOAS_'<
M`>$1_P!X-[X<_P`=P!X1'_>#>^'/\=P!X1'_`'@WOAS_`!W`'A$?]X-[X<_Q
MW`'A$?\`>#>^'/\`'<`>$1_W@WOAS_'<`>$1_P!X-[X<_P`=P!X1'_>#>^'/
M\=P!X1'_`'@WOAS_`!W`'A$?]X-[X<_QW`'A$?\`>#>^'/\`'<`>$1_W@WOA
MS_'<`W-(AAWV5_!S?RAM0>>Y[?P%O_\`7J=G`1YO&$V&MIW9B>CS,VFX#X5D
M(:V<22K0[(F8^'+^!`X\;[Q#)%4?6E!1VDLW2,('434(42&"A9H#TG3S;6J7
M";K`8?6K%_H%EN9@L[P>2A\C;M4G).H>=P=9*+0SK&V+TJ)S1#)PH\<.'+QL
M8JL:BS72=@V3BOI?B34Y(Q>#='AX:*5W+#8U"1^09\X5R5D$3%JZ0S2<3F9R
M,.SE5\B9JIR\8A)M6S:.=+B!W*X-Q2#I3@S&7=X_%.LVB(^*S)Q!8TOEL9#2
M#Q[$1V3JP$>I/,(MZHJ!WL>SE#*IHK&`#*)E`P]H\!0+J1Q[TF#7J+83W3$\
MTU(=.+'"H1U(89G2S<F32F;LX?;,;D#!N;D1DBX82CS)<8DVH&G(U/OV-D:G
M7;LWSTX@VY$Q]*E+ZN4/'Q73CBVW?SEX\ZC$,2E)5;$D]>'A<U;R\1DSO.C9
M8X?MV^2-H%TY=1[9I)JL73I%J0BB!#K!#D]C'IG/HKKY;'Y?3_TG)AD8AG;-
MVZP,J:V1L<S>!(O1.?'EVA)^?QD(PUC)8(=BS\5*4'#[P\QPG_6^,>D50ZBX
M]SM68P%[TY_2S/%9:+@S8J1X7%7^&2J^&I-7A(QME9FN/SYHIH5`X'>O7X2K
MIPZ28ECVRP=&&,.P-',P!(Y#"R;T,5=<1((H$H8`.H8HB4?4$!#UPX#CSCT+
MZ:;%`D0F0Z5]F)/49=%NJ]=24=(0Q(Z/*YB7D6TB%<$CWDM,/I59$$7JZC4Y
MXIN111DDZ7=$"=\NQGTAC1OJ=3&);$)5VIC/3679K9LKA3!G'YK&Q^R%.I==
MT:<BEGD_B>4/?HVC'(Q:\6]9'.JX;*`F@JU>!J.88=Z4)ODN8LL1R[6DIBH8
MSLHN(32S?$(N4,_2V!.2.O@-&.X-XFCFCK`$(V,26<G5@$CK+N'J"BY2FX"Q
M?2M`=4+6!R`G5LZQR5RM3.FRN(.<8&':LD<7/KN'"09$;X\4B9T6V7$?V.71
MBNG)C&-R&Z`($$+?^$1_W@WOAS_'<`>$1_W@WOAS_'<`>$1_W@WOAS_'<`>$
M1_W@WOAS_'<!'F7PD:?+-5F,V,(ERJ>*!N\NPM!37F8D,'FK@7SBC3MK['`2
M`:%C3`8!;F\\#@;\)=!4%"N"F\BX4J#H_P"Q7V`H`:%C3@<#-S#S`4`_X2Z"
MH+`]!3R+A2X)!;R>2X*>U+0(HR''8EQNK6ZZK(ZATM>[C$JH.GY>4+R;U@DN
M/N;DB?NQ)1<OG`-+PMH)2"4)8/"QJE]S<P\SFW_A#H*\X7PJ>18*7>)+>3R7
MA2EI:!"V[<>BG>O<B;+1W.3<YCKPZI`4>I&<"KG&("<QE4`:K*4%<]!*JK;Y
M`,4"@0@32,-'&$1%`PB(F$?PASY3&4,/9SJ!453?Z?8#@`(:.`0$$#=@@(?A
M#KR@8I@_Z;[(@<`%A8TMH@@8+1()?PEUY4Q;&)7W;MH+1/R^6WV1J##+XGCO
M=I22+"LU)08)Q'`_%N+B148()D70CC.#-9)TNS*NV(8$!2<)F,)O<CB<Y3A^
M</AF*>*XK<S.W42QZ`JC1RSY!T(V&L2[D$;CI6O)&+1#E>'L0)RQ+W=&IDP#
ME3Z;YGU[P'H_\[S#T94AD\5U)Z_R?$LR40PQM"SV9S.L(`JHYU$8GCF5Q>01
MN338LFC-P2/3;F?/$VBA&H*N3E16#R)]!FL/K7WI!],L^I?6?6:KJK!9EZ[@
M\*G>H"2@L!RC.H>/7;]^F,080NC,OFU<(2E6(($<.>YMG;E!06Y5BE.?@+NA
MZ-;ZWX%*>D[TKV``!_\`-63\@`0H?_XN^LF'_H(\!]4?1K?6]C*%*Y])_HE)
M$;@,H_V3+OVI:D.!>:T2Z4)!143'-0H@B>PX@;S0+<4*;]*6;?6@(_TM.LNA
M?=FZ-R9#&87L'`=A[]E)".PAWI>>Z6F.:MAS/.8392F`,P6Q;-\>2D(N+,R.
MTF%957N/*;/D%DVX?T1SPL:>^Y`X\SFW_A+H*\X'H*>1<*7!(K>3R7=GM2T#
M)X6-4OO0,/,YM_X2Z"O.[_S/:K!2[Q-;R4I>%*6DM`/"QI[[D##S.9?^$N@K
MSA?"IY%@MN&16\E*7]GM2T!(YAHXSEH(M+Q45<@H<3N#F("B#Y0]BEBPM[U'
M1ZB51&M0+<(`!!!6,-'"(CR#5$1$?PAT':8RAA\BWKJF_P!/L!P&?!HZH#R#
M5`0$/PASY0,0P?\`3>NF7_1^SP&"PT<42B5`P"02"4>\NAH*8MC$\JPUH+-/
MR^6WM\HU`)"QI++4#!R^79^$NAIR18BGY5ANM&.1\M:V=OMC5!&UA8XCIV)6
ME@I*,RIG`[DICD0;QADKU!(D+CE'CT@`3'7I:)1,`"8G`*R0L:2RU`X<OE6?
MA+H:<D&0)^5<:VA'(^7RV]OMC5#)86-+:!4#!:!`+^$NAH"8-BE\JXUH#1/R
M^6WM\HU#`0L:```-S4```/PEUY`*0H?]/ZR8?^@CP`,+&B`@+<W:`@/X2Z[0
M,4Y1_P"G]4%#?Z>`2LH6-,P:%,TY8"R13%,BCE`I2BW62,4$B$9`F-CM0*<I
M(0$WM2B```*C0L:>^YN8>9S0/^$N@KS@?`IY%@I<$BMY/)>%*6EH&3PL:I?<
M@8>9S;_PET%>?W_F>18*7>)K>2E+PI2TEH!H6-/?<@8>9S;_`,)=!7G"]%3R
M+!2X9%;R>2X*>U+0$<C#1PME3=TYIA.0UASN%RF,=PJ8PBB9-Z4WG.U!#W(U
MM0$+;2F*"SP:.^\&\HC_`"EUY1,8P_\`3>N<>``AHX!`00,%!*(?A#KL$IDS
M!_TWJ&2+_H]D>`"PL:6P2H&"P2"7\)=#04Q:F)Y5NV@LD_+Y;>WRFJ`2%C26
M6H&#E\JS\)=#3DBQ%/RK#6T8Y'RUK8-:W&J"-:%C2+1A2M*@B[*H0PG<*&2,
MW8`FB8JIB+G2\UDD`^>D![:&,:XQ%`5EA8T@$`K<P<L$P)^$NAH"(,@3\JXU
MM"/1\OEM&OMC5#)86-*!0!`P6@0"_A+H:`F#<I/*N-:`U3_9M]D:AH6>Q;%N
MEAZJ*)BJ)[!PT"F%9P>T!DTT_(=4Q1\T*=H#_IX!FZ;/^'707^Y75G^PT%P$
MU<!2;26L8"1U3M64B(!LMF,SO+K,78KNIA^P;N,@/U([GCHI=5=9";91H%.W
M0#G!'N2H"7F@@H8+3!%NJNG/J5B,]QM?9N2XWD.OD7C-S--VT];-D3)ATHV>
MQJS5OB3-&:8&R!^S107(\8.2#''>*D75=@"`7"2P/%(39V+'BX<K<5\(SX53
M&=R#@!%*;UR5,0!R[6*02E7.'8`5N[?4H$BN(B.\2C0[HG04G]>U3U"MZ?N^
M`<PB(T!`>Z)=G;VW"'[8"80$/V>`XM99IOTR#L9L(#;?3TQ[WDN<3L&:/&,,
MA%XGE68HY'C^"/6TSIE5T]F->Q;I&%CI,CI--:(C7:CL'+Y\BJB$TP6D?2"!
MCNV)23W%C:6:.L;S>-U)`RCO")K%6\[+;,83&)S62.X31^*/&JF+81$N6*1T
M2+)/6TR4J[5)PS(?@-*G==^EY4(D#+->DIRHHX9)*N(>!F,;5;LCY!'O7A"-
MI.&RED:D5%"W4=4.X!"1<`BCS2(JE#](8SZ8*6QYQ'2JO1[CLT_CF46,K"-Y
MIP6+<.(O)TY+(F"[F&7Y#EJ9RP!)NHS>$))M4UP,HR7<-$0OMTX0F^4]8M"=
M4J.K5MLEGLE!XIJ-M,-</''@EW(8SR2S"HO5GHQ0$%10Q4C&*);R`H!ZA/'A
M$;^*)_Z3_;<`>$1OXHG_`*3_`&W`'A$;^*)_Z3_;<`>$1OXHG_I/]MP!X1&_
MBB?^D_VW`'A$;^*)_P"D_P!MP!X1&_BB?^D_VW`'A$;^*)_Z3_;<`>$1OXHG
M_I/]MP!X1&_BB?\`I/\`;<`>$1OXHG_I/]MP!X1&_BB?^D_VW`'A$;^*)_Z3
M_;<`W-(B-[[*_@B?8X;`':?\1;C]G[/`1YO+%\\EM.[-C-+.XZ#VT^PG(6^N
MI:1%H#%CEZD<N$&LY4DF$PP02[]8`JJM')$:WBD>VT0H6?5WI)GFVM4R@YYK
M2'UW"/\`0#3;T2DXQ.5ALZ90*3HF_P"=QJ+'4\5E6'&RI-(WA<>,L^N<OTU#
M+LTV1$3@V3>&>EV\9G96-G^BD\9'J;FB,4@(_'<S1\9B7T3%FTGE62EED%"%
MRB-R-@89=FW=H,BQ[EPFDHJL9)1(.E.#14J>!BS9O'0C?,Q@\:'+D,?5<+0*
M.4#`,!GTH1==%FNO$IRO-!L<Z*1SH@43$*(B`!0+J2U=Z1Y[U%,<SZ9=C:8C
M^G]AA4(9YK3/V2"LS+9S'0VVHF;33<EPI\Y"-FU,Q@)%`5)=%-*4QAH4Y09K
MODW`-V1:]]*)-ZP.V0S#IDQW;@[-Q^6C)#"XM_&XBQP,(7-&<KC\Z&78CG+N
M;CV^0%Q]\KR&K60=MS/4$UT;$A4"&IW2_I@U<5U[X!M_2Z&4,\+BV.<I.C8L
M5L_GH[,W:SMX*AM-O>;.Y!C@Q@K.&ZJ#!DV;2;<B#EPX;..`G[6^JO2`1O46
MPR#:.Q]>SO3ZGEV>/I3%8<F/H.CXS+X7*?15LS*VUU#3Z:&,Y`M%-$&JL@NJ
MNNVDW[AR*;ADT3#HTRAHX\<T+W8I1,R;A<437%$R!`N+<)@N"O94!#@./..Z
MH],IAOB'>-I])^S$9!&90+])<>?MI&(291@K0;J%-#XKB\<G-R4E*N4Q%XF]
M:%/&LN<3DJN1X"=\NU;U[)-M3FQ;/\*?O&N,]-C?9:0JX9#L$LUQ>/V/^L7+
MI)O=1R\AEF-;#?.L<2;,TW<,NVY:[ELHVY`LWH:AF.F_24!DN8HXAN+7#S$E
M\9V2WQ)_(L<,BYY%XML"<FM?H*LT=1.V#3*PP@D;$!**&<QK-,5U'#%\YHX,
M%B^E;`^I/&8'(6W55DN+YIE3W.VSS%9'&RQJ+5IC7YN89M(1H-X;',9:IM4<
ML;/SI'52%RN*AE#@F0R:90N!X1&_BB?^D_VW`'A$;^*)_P"D_P!MP!X1&_BB
M?^D_VW`'A$;^*)_Z3_;<!'F7PD4;+-5F,Q2,)<JGB@814\T%->9B0X!0X!YY
M1IV\!()H2*,!@,S2$#`8#=JG:!RN"G`?/_=%=*?OOV.`#PD4>^]FD;F<P#U%
M3S@6!Z"@#Y_[L)%;^$'V*!$V0X[#.-UZV66C455$M>[D$JHBM5,7DWJ])P/F
MJ`7W<DHX*-0'[J-*#2@2R>%BU+Q.S2-S!5$]14\X5N_<VOG_`+OQ)>O_`%@^
MQ0(4W=CL,ZU[DB"\6@JDZS#79UBB10@N3*9QB',,HHDFV55[5S]O,5MJ(`8`
M"PH36,+%F$1%FD(B)A$:G\IC*G,/M_5,L8?V^`/!8L*#W-.H"`AVJ>4#%,`^
MW^R('^C@`L+%E$HE9I@)!()>T_8*8MS$_=_N1:)_O0]G@&R8@HH8:4($>D</
M#'9"IB0ZP'`C5N"9!1,VD`6#\GHA:*"]U@!RSU$I@0X="QR>)XI5@FBHGCN/
MARP1,UY)T(V'L(#4L7CY6W)&,0`$P8,@)R@#NZ/:F`<GO3EX+UTRGH^LZE/1
MJ3.88WU)8'E6)9RFAK>4*PSW)-<XVFX#-<9Q%HX0=IY%-.&*#-PE%E`'$@#'
ME-P5<F206#R/^CVZ0?K0GI`]%-^H3&_2%Y]TXZ\F)9=A@##?.RMDX7D&<1D<
M9-N]RK',1P_7.2JQN)$D&)6[9P\*S%\=$ZB"9T+5E`O6'H7_`*T<%*>F=PKL
M``#_`.=O4!V`4"%#_P#DAZ@)A_HX#]D]#-]:(;CS7'IF<%51(`@9-;;>]Y=,
MUQ3)EN8/-&*-UZ&4J`F`;!\\.TH#P%$NEC!_K,./^ESU?T6[EWQU$93C6`;&
MUWL_>&=2>7OI+1F7]+,/G2"^49-%['D(%)65QK8$*C(Q+",3!"56E%CLUFS9
M=NY%L']&$\)%'O`[-(W,Y@'J*GG<X'H*5H?]V$BO_"#[%`#PL6>^]FF;F<V^
MHJ>=SN_\VOG_`+OQ->O_`%H^Q0`T+%GON9ICS.9?45/.YPOA4KY_[L9)?^$'
MV*`C<PL69TS$6")Q.JZ`YQ3,<Q2JH/E%**"@L9$%%'1ZT41K=2HAYH@L&%BQ
M$1%FG41$1[5.T3&4,(^W]4RIO]/``0L6`@(,TZ@("':?L$HD,'[OU!2+_HX`
M+"Q9;;6:86"02]JG8*9FQB?N_P!R9FE^\#V>`"PL62RUFD'+Y=E!/YO)%B*=
M//\`W`QJ'\&'LU!$TA(I-T\,2/1(*:C,A#E(8AC$;MHTR("H"*(K`B9@C01.
MM3E@%0[2@"TD)%$LL9I%Y?*LH*GF\D&0)4J?]P$:A3_JP]FH!82**!0*S2`"
M`0"]JG8"8-BD_=_N09I?O`]G@,!"10```S3H```=JGD`I"@'M_4*F7_1P&1A
M(H0$!9)4$!`>T_:!BJ$$/;^J54P?M\`B80<4,>S(,>@0.Y(IBF5,R)2E%NLF
M8@)$19%3J5VJ`@"2?MQ\T/(`+#PD4>^]DD;F<R^HJ>=S@?`I6A_W822]?^L'
MV*!D\+%J7WLTS<SFWU%3SN?W_FUH?]WXFO7_`*T?8H`:%BSWW,TQYG-OJ*GG
M<X7HJ_N_W8R*]?\`K!]B@(Y*%BS-5A%@BJ)CIF$ITQ6*8QW"AS"*1D'A3><[
M4'[F:EU>R@"`+/!8O\33\HCY5/*)C&']W]D<?]/`'@L6`@/<TZ@("':IV"4R
M9BC[?U#)%']K@`L+%DM$K-(M@IB6@G[!2%J9,0\_]R+)+]X'L\`$A8M.RQFF
M7E\JR@J>;R18BE3S_P!P,:A3_JP]FH(UX2+*O%@6/0$$'@*)F%,QS(&;QX)(
MF(H**QDK2,42]ATKK``3&J)#@L)"11++&:1>7RP)05/-!$&0)@'G_N`CD?X,
M/9J&`A(HH%`&206@4"]JG8!"MRE`//\`4!JG^]#@-"SV*CVR6'+(-2)J)[!P
MX"'*)ZE`9)-,?*80[2``=O`,_39_PZZ"_P!RNK/]AH+@)JX"E>B]98;,ZNV:
M\;XKC3C*IO>_639(/4&:2Z\PMU+[HCF+AR_<Q<X#4Z94D2@L+-URBD`P(J4L
M,$6:FZ6MZX_EN%.]ES&M<DQ:->N'&6%9^&=^>LTL>F8^,9-XLFJHM-X!CO61
M'BJDDB8[Q@K($`578)M@MZGA.%0>SL6-#XW!1PN,(SX5A:,FR7-,E-ZY!(3V
MEH)DRK*`7U0`QO7'@)%<1D2$G&AW%A04G]0Y"';0K>G[GU.`<PBX@!`08,*@
M-0_!T/4_YO`<<)3IY]+>X4RXL3U"]-L8K*J;;D\2>*8V#R/QEIG,PM/XAAKR
M*<:A5=/WNN3/&\1"SPN52MXF-44=L'SI\(H!,<KH+KL5G]R$0W9AB^*SVL=M
MP^J56K+$8:?QS-9W;<Q.:O?.46^FC,6LABNK'*$4K)<UR0PD(F+4[@@RA@U'
M']8>E3;1L)`R65](R*49`)1*V4GBYS(,@DY@T,X!OD,XW?X*U;/6\:LJ1)PW
M241</Y)%-UWA-J*[94/Q.ZZ]+6216+C.6=$JT3XA,$25G<-R0'X1Q,RQI:)=
M`C'P"+<Z[S%DI-/NICE[H@JF4[ET[`%RAI$AT_>EVQ_:>>Y3AV_>FC+,!ELE
M77P/!M@P#@C'&\=GLEPN8EVTDE!:L9OGBN.1./R,;#@61,HFUF53K***II&*
M&X2FF/2PN6R)&V[>E%%=A)M%T'$?KIQ'+R+)@V;JG3DTW>(S#!0)YV_>-72)
M4BD0;-6BS<Z;D53<!<3I?PGJ-@H#+5NJF<U=DF4RV0-7.,-=;QYFT+!8ZVB&
M;-5FZ[SC\"*TB\E45G)C$3,3EJD+V&*:H6?\+B/Q!A_`(?:\`>%Q'X@P_@$/
MM>`/"XC\08?P"'VO`'A<1^(,/X!#[7@#PN(_$&'\`A]KP!X7$?B##^`0^UX`
M\+B/Q!A_`(?:\`>%Q'X@P_@$/M>`/"XC\08?P"'VO`'A<1^(,/X!#[7@#PN(
M_$&'\`A]KP#:TBXCOLM^`L.QPVI[@CV?@+?_`)/`5[ZE];;IS+'H9+0.816&
M2C)ML%+(&2P8S&FGRS6M<IBL-/'Y!,ZYV(M!2N.[#6BGY%4VQ43()+`L1:B9
M2A4T='>D2?;6U/.J;1U?`X!CSSI_;;7QYN[@,AB]@,<71<DWS+1<2?1&-S&+
MO,U33$L<T3EED3.'_/5.@5FU13!GFM1^EE-,3TM&[2Z,C1[-3<D5B4`RU]DC
M(DA"RL/&AI;(\F-)0DBB;+\?R1@*DNW0438G8+KHHG,HH15(.EN#1,@2`BTL
MW8XR.9I06-)Y<./I7P(Y.2`8%GO`SNF;%R>'\4!7NPJ((G%&VY,@U*`4#ZD]
M(^D+GNHAEGW33N33>-Z*8X3")N=59W"MW#^6SB,AMM0\PH1X37<\*$9._3B%
M?IG5?'30EL78'.W.U%XW=`US^FO29S&KUH]/:_35#;:-LR`G8V<P[%58/%8[
M"$H3,V4MC4FWR'`,R=S\:C.GQ^0,CR$';XA7S?OB!.2!@A^=Z;_2UK8MKU.!
MZ@]+M<GC<-C(O-A<(0H,I.:C<Q>NUWIU1T4[7>S4_CQHP'+Y,S9!JDS?M"-5
MS/2.B!/NM](==T)U%,<NV7MW7F1Z$0RW/)*4PN*;0S1=7&YO"Y5+&VC-FTU7
M!R2">,3Z\8U:M%9=<@BRD)%=951ZW:M@Z,L8F)/',R]R9%$S)N%Y$4`.410(
M%Q1M&A@$:@/K\!QW@.G_`-+]AXO_`/Z('I:V*B_1F4`#+<'71?QB#:-$\$M"
M.8W`HU@TFWLE*.B'6=-7[5(6+`RR+A(7*1@V_(>GWTFI\TUW)8QOC3C?&8:"
MT.VSF*E8>(<L,EF<>Q:':;E=]Q1U&WE4RY!D[29<$43D4RR"<RP#D,/"1*X"
M6LPT/UJF@\N9X?O#$7#][$;C8XRZF(#!HQ^Q6D=IP&4:?>ED(O3BB#*<8:Q:
M2&,/G2C=ZU9BZ2>@T>N4U%E0DWI7UKU#8-`Y"QZH<QQ+8F326=-9+%Y:!0CB
MH,<>+KF'82,4"###L,:-FB64LWJJ)>[*+J`L9552IP(F%O\`PN(_$&'\`A]K
MP!X7$?B##^`0^UX`\+B/Q!A_`(?:\`>%Q'X@P_@$/M>`CS+XB$-EFJA/'1IA
M#*IX"B9LW$0`^O,Q(<`J7R&((@/L<!()HF%,!KHZ.$#`<#5;-Z"!RN`.`^90
M0,5PJ`^N!S>N/`!HF%-??'QQK^:"ES9N-P*@]!:ZI>V\'SBZOEYJE?;&J$39
M%"0"V[-:*+QD4HJ77NY1(91LV,<!<S>L".Q+<6HBLG(N@/ZX+*5]L:H2T>)A
MCW\R/CC7BJ*ES9N-PJB^%:ZI.WF"_<W5\O.4K[8U0A3=\+!+Z[R--U&1:B"V
M8Z[,L59JVY:QE,YQ`53*B9!,%!,=PK43&4[3F[>T2@$UC%0PB(FCXX1$3"(B
MW;U$3&5,81&VM1,J<1]DP^N/``14,`U"/C@&H"'X.WK4#%,`AYOEN*`_L@'`
M!8F&+:)8^."T2"6UNW"T2&;"F):%[!*9LD(>L)"^L'`-DM$PP0\F"<='5"-=
M`F4K1L;VC9OR@*3NKH#6BR;VARE/N2?F&M*'`(<.BXL,4Q0QXYB18N/8^(@+
M-LB=-1*-AN6'++'18)&2-'MJ%!LVL%%,`23M*0H<J/3?ZFZW=@>C_P`\3]&U
MDT]A/4OA&38IG\:EKR<+BN=9?@V*I.!RW"<.>(I6/YZ2CTV:S6..HEX@9@FW
M2,9<R"9P\D_01Z.?ZS)UR:,8[^D/2.;AZ6L:R*4<(X/BF^-K;KQ_.<GA61D4
M5,L1P[&\?E%\9QUR^9E28@_!JY>$;\]-#NIFZRX78#T$GUD,*`'INF]``H!_
M\Y.I/L`H)E*`?_!?J`F7_0'`*6?H+?K'3-PFX=^FZ0!NG<![=G=0TX/GD42)
M^2Y'#DV;H+U?W9@L[3AYQ0X!.?T$WUD(;K_3<LQ$X'*<YMP]2',,10'`'(93
MZ$\P4S@Y5J6MHW&[.`IUUT^C5^LQ=%F@<DZA8STEVU>IN$PIP1UG&%:.W!NR
M2V#"8NL60!_F+?&LD@8<V30T0L[4"018F7>(-W"C@4#-TW*B0>J#T#NK.NC"
M_1_8V_\`25Y3DV<=0^R\[R?9C-KLV9-DNP,)U?E$#`M,1PK,U72!1AYQ$R$K
M(+QEZIV`2YT5^6Y[R@D'9P\5#'OOCXXPG%45+FS<1.*HOA6OJ3M%07[FZOEY
MRE?;&J"-S%Q(N6GX`P$%57(+_@R!KRG0?*'!0>[J=AUG"@C4Q*F.;M&H@(+!
MBH81J,?'"(B(B/=V]1$3',(^U\HF4,/[(CZX\`!%0P"`A'QP"`@(?@[>H"!B
M&"GF]@@8A1_9`/6X`+$PQ+;8^/*)1()*-T`M$@M13$M"]@E,U1$/6%,GK!P`
M2*AB661\<42"D*=K9N`D%(6(HV4)V"F+!M;3R<E.GM2T!&TBH@KIW;'1Y>4H
MR*@)6C<MA$6\89`$Q!NGYJ2C)O;0Q[12)00M*4H*RQ,*0"`2/C2@GRN6!6S<
M+.4#($;*$"G+!@WMIY.4G3VI:`%B84H%`L?'`!`(!0*V;@!0(#8$P+0M``I6
MJ-/6!,OK!P`$3"]@!'1M`````;-Z`4"D*```$\@%(4/V`#@#PF%H(#'QM!`0
M&K9N-0$JA3`-2>02J&`?8,/KCP"-C$PYH]H"D='=K-(IBF:MR^:9!<ABB3NZ
M``42.E@$+"!10_8%1#@%AHF%/S+X^.-S`5YES9N:\%0?`M?4@U!0'[FZOEYR
ME?;&J&3Q,,?F<R.CC<SF\R]LW&_G=_Y]]2=O,\0=75\O.4K[8U0P>*A3WB>/
MCC7\SF7-FXW<T7HK7U+VWB^<75\O-4K[8U022,5$=U6,$>P,<3D,-&J!S"8S
MA0R@B`MUZB8SE41\T>TYA[*B/`+/"H81KX?'5J(_R=O6HF.81]KY1,8P_LB/
M``14,`@(1\=4!`2B#9O4!`4S%$/,J`@9(@A[)0]8.`P6)A2B42Q\<42B024;
MMP$HIBU%,2T+V"06J(AZPID]8.`"1,*2SEQ\<6P4A3M;-PM%(6(HV4)V"F+!
MM;3R<E.GM2T!(M$PY%HL$XZ/*1)V4Q+6C>U,R+`I&QBB#<_+%,K)N!!`R8@"
M1``1H!1!66)A2V61\<6SE`G:V;A:"0,@1MH7LL!BWMIY.4G3VI:`%B84H%MC
MHX`*!`+1LWH`$*W`@!YE``I6Z0!ZP$+ZP<!H6>Q\6W3PY1LS9(JEV#AI2'11
M13.`>))EH42%`:6%`/V`#@&?IL_X==!?[E=6?[#07`35P%*='8'@<WJW9QD\
M9P-;+)C>W62W&0?Q\,@_7EW/4ONABR5D94(R0D4503Y)!6%)=5-(I1`AZ%*(
M:A@72SFF-3>LGF63^N<BA8!9N[SE,S".2=NP::^2QOPMF)<(:(Y0QDLF$T@Y
M6E#HK<T!73`JRA00"S26,8%%;-Q88/'L0CA7PC/N\#%14,T%4R4WKGD\WNB"
M8G,F552VO:`&-3L$>`D5PRAO$HT`:1=!2?U_!VGV+>G[C@',&4,`@(-(L!`:
M@((-`$!#R"`V>7@.-<MTD>DW=N,@$.JW5CII*3F>S$.C$*3N"*8Y'Y]E262,
M\3(LEK/-%I5GJTKP6>/OS'05-&0R+%=N"4J_.B&^XKTK]=[,-L*9!U%XL<<M
MU?L;'<$8J9*^R=+"\WF-BMYW"9F+D0TYA;B)72P8'4<^ECHRCB-<ND_"639J
MT304!K6Z:/2511<R5PGJ2TS$M)#$D6^"8OFS`=I)8EE#=HC'M/%\[RK3WTLR
MMBW2<*N73]9-)>3<LVU[5#G.E#A9KI5U?U:X/-[#-U3[8T]M7'9$D8;7*.$8
M4PQ^8AG!IK*)"=-/ND<7QI%RW,PD8]JS2*"X(MVA""/,(JX>!<_N$)^)17O9
MI]IP!W"$_$HKWLT^TX#/<(0/(SB@_P#T=I]IP!W&%_$XOWNT^TX`[C"_B<7[
MW:?:<`=QA?Q.+][M/M.`.XPOXG%^]VGVG`'<87\3B_>[3[3@#N,+^)Q?O=I]
MIP!W&%_$XOWNT^TX`[C"_B<7[W:?:<`=QA?Q.+][M/M.`.XPOXG%^]VGVG`'
M<87\3B_>[3[3@&YHRAN^RM6D70'#8`_!VG9^`MA&GF>SP$;[WPK+LTTULS$]
M/ST%@^T,CPV<A\%S!V0C9'&\B?LE&\?+B[:Q<NY9J,E#WIKD:.3(J`!P24MM
M$*)'Z9NN^0VQJK*EM_8%C^#8H]T`ELC%8N7?SD9LJ,PE-=/=3Y3&7VI(=.!E
M=BHARV:#>6[L51ZLX=BLHUCB-089CIX]*4M-3TO&]4?3(5JDON6+P^%3TV2+
M:%QW(XB,)IZ7R8RV.9"S>YGA611P.9$Y6BC5RT57;(`D#@Z@!TPP2+?-<>B6
MF;AB[[,FD#C+;+7D&T12A'63H8_'ISSB&27:M%THE>4*J9N4Z21BHB4!(4>P
M`H%U)]-_77F?46PV=TZ=2FOM?:=887!-#ZARJ#*^0D\VBHC;$))2"C@V%93&
MM8Z>0V%'.Q,NA()MY;&8QT=DY3;J-'(-,]TY^D6G=7+0JO4OI./VF.R8#)H[
M+<6P-+$H*(Q!K"9K'RN+K1C7"Y)QDL469=0$D5@]\Z0.V>(+/D4%$2D"(Y[H
M\])\[Q?`&L)U@:ZC\EA,.C87+W*YI(6,W+168/Y(7HN2ZL6>2DI.X^:.(]EU
M4VRY0CG#$C84)1=R@$_:VZ;^LW&>HIAL+8/4)B>6Z2:Y7G<Q)ZZ;F5:%<P.1
MX?,-(-BVA$<`CTD/HOD#B-09,SS!V+=O&N9`X.7TH*;`.C#%A#'CF9>ZQQ1,
MR;A<1%L50!,@0+BG`MQ3@(]@^4!X#COC?2=Z57#A?BSZS-(YJD_3E$#)YSKA
M)V\9H(L2C`FA9%QA,VSBI121DWP+.U&#Q)$&T>HLUD4T562@;Q+]*_I`CYC@
M,S#=36`_1_'8#12&403\7K>-RO(L-Q"*A]IO)2+C]<`[>1V4Y.26E0(C)L#S
M"TFS(][NWATVSX'/+^E3KI=9+F)L0ZI,=1P^1QO9$=BR4TBT9Y%'.9?8$[D^
M",UU(75_AK!_'XRI&PRF0H`L^C62*Q46;Q0_/,%C.E?4>\]70$_&=2&R\=VW
MD,SG#:7QR99B#@8N#3UY$Q4A$`FIBN(M(]C])H]VX0;I-ESVKBLLZ666.5(+
M?=QA?Q.+][M/M.`.XPOXG%^]VGVG`'<87\3B_>[3[3@#N,+^)Q?O=I]IP$>9
M>P@ARS58F90XB&53UHF;,A,`&UYF15+:DN`#)B(&IY0'M[.`D$S""$#`9E$B
M`@<#@9LS$!`P.04NJ2@@8JRU:^4#'KY3<`'800W@=E$B!N;S+VS,;@.#X%[Z
MD[;RN7-]?*"BM?;&J$39%'8XINO6PN&$$=7\WFY!**[6.,M56;UB5V*8JIBH
M`J)O'8*V^V*JM=V&/4)9.P@S7\QG$FOYO,O;LQNY@OQ6ON)VWBZ=75\O,5K[
M8]0A?=["`4UYD17;&%.V/F.N^:5VVCSMSF/G.("L*Q5TN48QCK*W75$1,:OE
M'@)I%A!B(B9G%"(B:X1;LZB(F5,:M25$1,<XC[(F]<>``80=>QG%5`0\C=G6
MH&*(?N/*!P#]L`X`*Q@P$MK.*`0$EEK=F`@)1;"G;0G8)3(HVT\@D)3R%X!M
MEF$(6'D^6RB@$L:ZY=C=D%+&S?DV>Y&`+1;-K>P0#EI=GFEX!!A[*('%<5.=
MI&<_Z/8^83&;L^8"A8V%%,:E12"\IFC6VA2T%)*@!:0`#E)Z<30G6-O'T?>?
M0/H[LVG=>=2N'9-B>QX`-<Y@_P!=9OFN+X@14^28!B62P3A@HG.3<>9HHS:K
MKHMGJS)!N8Y#&2,`>1KH!]#;Z?\`ZV-$,-^[%])5U'=(S+*)1T7","W%MCJ(
M7V/.P+(Z2"F62^*L<IC'6%QCY^U*1@W?`1ZZ10!QR4VYFJBX7?#ZMOZ:X*`'
MIUMA@```!3/NICL`"I@`!_\`'_D`I"A^P`>L'`15O#ZO?Z>K6FI<]S[67I@=
MH[PSC$L?=SD%J6)W)U`8?-9\LP#G.,=@9_(LX6@&D^]9\T&)'ID&R[FQ)1=`
MJ@JD#HK]5PTEZ32,U?OC?OI&<^W7-8CM/Z(XIH;6G4IEV;9!L/'TL%D\Z1S[
M,5L1SY9P]P:(R9W+I,T"K`B]DRL55SI`U%JLX#U@F808WWLXD;N8*ES=F-;N
M_"K?4G;=WER)J^7F*U]L:H!V$$:_F,HDUP*@I>V9C4#A(`L![B=H&!VZNKY>
M:K7VQZAD["#-S.8RB37"KS;V[,;A4%_SN9<3M$XNG5U?+S%:^V/4$CEE#]Y:
MAW2,M45<]X]P:4.7DOSFYU4QN**ZJHC7]V8PCVB-05BP@ZB(LXJHU$:MV=1$
M3*"81\SU3',(^R(^SP`#&#`0HSBJU`0HW9UJ!B"40\SR@8I1#V0#V.`"L(,!
M*)&<4`E%,2"5NS`0$HM12$M"=@E,@A;3R"0E/(7@`C"#+9RV<46T4A2L;LPM
M%,6')LM)V"06K6VGDY:5/:DH"-JQA@<NK6<6`)J,P;4;LPL3(WBS(@A1,+2$
M4;-Q)3L`R:=/:EH"LC""+9RV424"\KEV-F86V`QY-EI.RPK5M;3R`FE3VI*`
M%8010+:RB0`H)V6MF8``%!J"5M"=@%*@C;3R`0E/(7@#N$$`4!E$T``I^#LZ
M``%(!?W'D`I2@'L`'L<`"P@A`0%E$B`@("`MF=!`2J`:OF>02G.`^P(^N/`)
M&3"%,P:<YG%&$S-$JG,;,QJ46ZY3`:J90$HIKK`/8`"4Y_4$W`*SL((W,YC*
M)-=S>;>W9C=S`?\`/YE2=MX.G5]?*"BM?;'J`=A!&YG,91)KN=S;VS,;N9XA
MS^9<3MO[V[OKY>:K7VQZ@'809K^8RB37<WF7MV8W7B^YU]Q.V\SES=7RBHK7
MVQZ@DD&4.#94Q&D8"MY/.*@TYEQG"O-&O+,-QA76N]<3GKY3<`L[A!UJ+**J
M(C7\'9U$;CB/[CRW&,(^R(\``P@P$*,XH!J42T;M*U*9(2TH3R@8A!#V0+ZP
M<!@K""`2V,HD!**8DM;,P$!(+04A+0G8)3((6T\@D3IY"\`$809;.6SB2B04
MN78W9A:)!8<FRTG8)!:M;:>3EI4]J2@)%6,*56,!)G%E3*[()`3;LP(4Z3`H
M-!*`)T`R96K<$Z4$`33IV%*'`*R,((+`(RB0`O*Y=C9F%H$!B"%E"=EA6S:R
MGD!-*GM2T`*P@@`MC*)`"@2RULS```H-@3MH3L`I44:4\@%)3R%X#0L]:1*2
M6'';-HY)4-@X:"9D$6Q%`#Q),M"&3*!@]S``[/W(>MP#1TV?\.N@O]RNK/\`
M8:"X":N`H[I&`UA):QVDB=GK1++I+>_60R</I-.#;219=]U*;F9M%)9^V!.;
M16[LJ@!CE.#DJ%M@^UX")-4],60X?FF'36;;.U3DN.P+IN>:8)2\FX=2[%EA
M;R";(N&DN*T,^=N)J2,9\JJF1!T@T;+)H-GO>%EPN2UCM:L]FXP..L<%:BIA
M&>`Z&%:X^@8YBS>N^[@L+$A3&,4AE;*^0!/3LNX"2W!('Q*-H6'IRG]?-8_8
MMZ>IY>`<@+`@("`1`"`@("`,@$!#M`0$.T!`>`XMY-T1^D'EE)WN'I`H-CXG
M.YWE$0XC(S)<=#'#Y[E*66?048U&7FD)S#\(?/3MX1R99F\:Q,,TC4B(-9"1
M``W7571CUCPI=P1VX.ME+8L1GNFMF8/AAXYYE..2V`[#R3(G$MAVPHA]#R,2
M]8NX<5>:8R+CG,6W+BVM6R)G+D)BPWIZZJL+VEKF:1ZIL6R/4<%+M66;:_RG
M&HV9E)C`(EEGC&'A(W*)&,?9&XR(H3$*Y=S#V0/*2#UBL=VZ<(BBW3#H79CP
M?N88!_88A_\`<X#-F/\`V,/_`*&7^K@"R`^QA_WK+_5P!9`?8P_[UE_JX`L@
M/L8?]ZR_U<`60'V,/^]9?ZN`+(#[&'_>LO\`5P!9`?8P_P"]9?ZN`+(#[&'_
M`'K+_5P!9`?8P_[UE_JX`L@/L8?]ZR_U<`60'V,/^]9?ZN`+(#[&'_>LO]7`
M%D!]C#_O67^K@"R`^QA_WK+_`%<`WM"0/?)2I8>G>&]OFL?Q%M7U*^7@(UWS
MAT]GVF-GX3JW,8G7>Q,JPJ>@L.S@BW=%<7GI%BJV8S"#V-35?Q[AHHI5-RBF
MJHV/10J:@EL,%#3]*_6(_P!M:JS)WU58_"XAA3_0*><XS`S^7NHK9\3KI-R3
M:[B;Q&7;*0K&9V@D4B)`:N4&R8/7+AZ5^X18';`V3/31Z1UQ-3LY'=>.J*)K
M;FC,,A2Z,PV%CV.,9C$1:&K%I_DQ<U&2V8:\GHLCUP^6CG!':1E6J*;=)RN)
M@Z6X,T79X_$L\TD,7FLO9P6--,IF(EFS814KD;:`CT9R1BV)@`[*.>R9%5$$
M1^Y)F`OJ<!S_`.I/I?ZO,^ZC&&W]!]8,/J?7,7A4''DTS*1`RD#)YG#0^V81
MU,.>\(S./MVF0,]EH*K"XBI(B$G`13\S9R=@F@H#9D73+UT9'J\^-ONM7!T]
MD&V5CN6,L\Q_7\9@K.#QIE"YK%RF-HPV&MHI3(HDDA(P<DG'2:ZR+US'.$W*
MX(KD*D$-SO1#Z01]BNOF,1UZ1<9DN/87&0.4OC/\N.UG9*)S-Y+)K*KI`DM*
MO)6"78ED)AP@G(+&AQ9))H-)1T=`)_UKTP]46)=1L?L_->JEGF^I6N79Y.R&
MM%9&:;L'L-E&&2K",8$QXR1XA`V.Y`]8HL&I701K%E#F>`@O(RCA1J'1UBG`
M&CFA3!$A<R;E$2]S(<*H$`1*<M#%,'J"`U`>`XZ8]T:>D;P@)`(#TAV*9,C)
MI2Z#EMG6NXR:<)-4HXHXZC$2T^TRX8*0&4D9#GOD6IC)%!BJHB_(T[HH&[S'
M2+UG*YG@4]#=8\2G"XO`:&9SL*_>9&2+R>>P'$(Z"V1*3<$R*5O+,\LG6TC*
M@@1TQ4EG<V09-51"&:-G(.>8=(?5H^R7,5L2ZRU&6(RV,[)C<<CY>1F0FXMU
M/9_.Y=A4:H_BBH-V@1<,XCX=6?;$":81S4Z#0!*H(\!8SI3T_M?3\!D41OC<
M<?NN;G,[;3<#/.WKE^XBHA+74-"OXLGB39BE&,%<BBW3E!FBFK8"XJK.7"ZR
M@D"X5D!]C#_O67^K@"R`^QA_WK+_`%<`60'V,/\`O67^K@"R`^QA_P!ZR_U<
M!'F7DQP<LU7>2#K]*I^V\L??3\W>9<RRX+J<NMU.RWR]G`2`<F.4->2$I12^
M\K"E+70*W5#R6BO=7U!/7]UP`=/'**<PD)2BPJWE8TH(2'/YEP>00,[OKZZM
M?W?`11D2>+_GJUN+DF.<W\WNY;1<EBN?49O6G?>3S@YU13.]YUG[@5[^SF<!
M+"B>.^Z<TD+V\[F\PK'MJ,EWCF7!VU$[R^OKK5_=\!#.[R8Z;7>0E>D@!:_3
M'7W,*^"+,TN-G.)"YYQ71C(`(G,M?>!:F$]0J(B(3,9/'JFN)"UN-=<5C6ZY
M:^ZH5NO%2OLW>SP&03QZH4)#5J%*%8UNN+;3LK6\"T]FG`8*3':EL)"UJG9:
M5C6MS3E6T#RW%0MIZH)T_<\`W2I,?")D11+#`<L:Y%$4P8%$I@;,Q;BF8%$0
M*("1I8(')2B-!"A!`$&(!!FQ;%3J!$G<&Q_'S"<QF*JQEAC8,4C<PJ[OF*"<
MK.TP*JU$$1`YO<Q$.4_IONG/JPZE?1_9YAGH_=CR.M>I'%LFQ'96+*X'GLCK
M'+,U@\/(96;U]CF9X[(12L9+Y$P=,S,B.7"+!TX;-D%E$2G(LF'DOZ`_0+^F
MNZP=%LMY[\])QU.=&#_*)1Q]#=7;"SG?.8[,?8ZT,W0^DV7P)=P82K@/B#Y$
MA6,>Z!5^JW3(NJDW3.WYH7=#ZKMZ2R@4]/GO.@`%*-]\T``*F!:?_1.>0"@2
MGL`'L<!$^\_JU7I?==:DSO.-+^F>W7N_9>+0+J9Q?4JV;;NU@MGKMD`JKXY&
M9O);^R.)A9R09@J1CWQNFS6=B1)=PU2.=PF'17ZK]TN>DHUIK+>N]O2/;"W)
M(Q^W"8EBVE=/]1N>9OF&Q\+CL"E,Z3S'+Y+&L\DY)77S+,'DP5N@U."+]^@P
M,Y62*V.U47#U8*MX`H'%=&'*4W.Y@JIL@`P"60%>\3EH-2*.A/7U#*U\I^`_
M*B>.^Z<TD+V\_G<PK'MKXGWGF7!ZMSV^OKK5_=\`*)X[[IS20OE6YO,*Q\HC
M)=XYEP>41,[OKZHK5_=\`G<%A.>@4"Q-AE7/?`_`@*8G+D!-W@+BW%[R*PC<
M!O/OKVW#P"@28]4:DA:U-6I6-;A,I=7L\HG$]?9K[/``)X]4*$A:U+2A6-:W
M)VT[/+>!*>S3V.`R4F/5)82&K5/EVE8UJ!F?)LH'E`Q6]M/5!.G[G@,)IX[[
MGRB0OE1Y7+*Q\H#&]WY=H>4!*TLIZH(T_<<`E:E@A<+E`L1811GW(`!D)2I\
MB)%#NP`8UI.<5K9:!0N!*@5L'@%)$\<]SY9(3LY((V%8]E`CN[\NT/4`K2RG
MJ`C3]QP&2DQRA+"0E*)V6E8TH!6G*LH'D`I4+:>H"=/W/`8!/'*!0D)2@4H5
MA2EI+:4"E+`+3V*>QP`*>.4&I(2E#5J5C2EJMU>SR6B>OL7>SP"9H6`,Q:BY
M+#F,+-'F"L#$PB3NSD#7F,92XO)%>M3&"T5.T0NX!4=/'!YG,)"=O.YMY6/:
M`A)=XYEP>J!WE]?76K^[X`43QT>9S20HUY_.YA6/;7Q/O/,N#U;GM]?76K_T
MG`!R8Z/,YA(4:\[FWE8]HB,CWCF7!V]IG=]?76K^[X!,^+"%05,D6)!<#@("
M0&0*WBNN"W:!TS7")E[NT.T5*_N@X!39CM1\R%K4:^:QK6X]:]E:WW?MU]G@
M`$\>J%I(6M2VT*QK6Y&VE`\M_+I[-OL<`%3QVI+"0M:I\NTK&M0,R%&R@>4#
M%;6T]4$Z?N>`")X[5/EDA:^X\FPK&O8,;W?EVAZ@D9V4]9&GD)P"50L""D:"
M!8@$1=I4!(&()B<K!(65H%,4!,4I6O*H!A``2M"E@@"DB>.`"?+)"4`$>585
MC2@!'\CEVAY``C2RGJ`E3]QP`5/'``MA(2E$[+2L:4M:<JV@>2P$+:>IRZ?N
M>`T7.B0H)X>+,L6"X;`PWEBV*T!6WQ)(/<Q3"^G+IY/W/L<`U=-G_#KH+_<K
MJS_8:"X":N`I%HW\V:VL]H,AD=;QF6/=[]9+!T[?NX=G)-I1_P!26YF;=667
M8O(^>15!FLC>)%T77(ML.7S1`(IU;H-_AN<85.Y/U`ZZRC&\?(R">@CY#,.'
M4TJPQ.;@$U1/*Y8]B#E<J3**+U)=FHDZ3C$'*16BZRY!"X39QKD-FXP./+X.
M`AA&>`Z&&5@+@,:<USW<%NY&NJ)04LKZEU/5X"25W,&,C'"5>)$H)OP,(*LQ
M`!L;4`?.\O;P#F#F$`0$KB*`P"`E$%6@"`@-0$!`U0$!X#C9+]$_6L^7RDY_
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M+&L4VS*.)-RJ*KD$$4TTD04L(4I0``#;^_8[2O?(6GK]X8T__+X#'?\`'/QV
M$]\,?M^`R#['1\CR%']APQ'_`//X#'?\<_'83WRP^WX#(/L=$:`\A1$?(`.&
M(C_HOX#(/,?,(`#J&$1\@`NR$1IY:4-VTX#]]X@OO\3_``K/[;@#O$%]_B?X
M5G]MP!WB"^_Q/\*S^VX`[Q!??XG^%9_;<`=X@OO\3_"L_MN`.\07W^)_A6?V
MW`'>(+[_`!/\*S^VX!N:.(0'DI5>)H+AM;[JS_$6]?W5?+P$%=06KLHVO&P#
M37F[9G3SJ,8[/8R3O%9EU'C*CF^I<SPG&WRI8M^Q'Q+!LWFHN?8KF$QD5HT0
M3L44*H0*L91TQ=3N0[ZPC9S?JU0P[`L4RK2SR8P7'<BSTT3F^+:]=R*F=1^2
MXS+9*[Q,)C8[`R#(RC))FU2(Y=K.DGS@&JB`:?-],_I`7<U.3\?Z2;'^<FKN
M:-PR*_,]@T-'Q&+9S$Q;;6J<N+$SZ/F<LUK.Q2<@:4<,'`O0!1N1)NBX<`<.
ME>#%788_%,<QR#'\BRME`XTSR;(6*#2.8SN0M8"/0FIAC'F77,P9R4B119)$
M3GY1#@6X:5X"@/4GTN=4.P^HMANC2'6\OIC"XK"86,;Z:.T=26+R.80<-MJ$
M5GG2:DTMCZ"$]'[1`7',B'PHR$-%R'+67C6Q`!MR/IGZS<GU<?$Y/T@#)7/S
M[+Q_,FFPXC#V&$!`03&%S6)D\>80N`3&-&F(@CR6A9)&-D73ADX>1:I7(F2<
M@5((:G>AOK=D<5U]'QGI%WL5D6,X9%X[D<D$OGAV\Z^B,S=S38ZQD<S;#(K2
M$*Y9ED)1TB,FZ4A4VJ0MF<@Z*D$_ZUZ8>HC$.HR/VOEG6$\S[6;3+<[R!]K!
M[-9.$6_BLLPN4C&;`(%SD+Z`;G@I]^S28()`G',(^$(L1NI(2+MPD'1MBM!C
M'LR&7BRU9-RC:LU(<*H$`1*8IP,0P>H("`AP''?'^B[KXP/Q`,7])RO+)R:,
MRV?-,WPV/R%7NI(T`QUI'2>22N5N()TG*24B*SUHDDNB4[-6QSW,B!PWG(^D
MOJRD,TU=D.-];Q,?B\"Q31$'D<::9SF1C]E36N\5?1&P\HS#''>7JPAW>5SC
MDC]NBQ%@5P85/%3/C"D9('#+^D/J6DLES%SBW7/D,9B<WC&R8J!B)7(LP<2T
M4XR3/YW,\/B5)5AES0$641&NF$4K,-2)3K6.9F;LEDD5!*`6,Z5-1;)TO`9%
M#;EWL&]):?SMK/P\_+R<A(.XF-0US#P#Z.(>;?.C,&+B<B'+E%FC<5$%A.HL
MNNJJ8`N!WB"^_P`3_"L_MN`.\07W^)_A6?VW`'>(+[_$_P`*S^VX`[Q!??XG
M^%9_;<!'N7N8#Z6:KN7A:CE4];<JPN$`UYF1E++C74!,!$U/W/E[.`D`SF`H
M:Y>'H`'ON594``*Y%2ZIO(!2+75]0#U\AN`#N(`+Q47APH"O-$ZK(*`4'_.O
MN-V``).KJ_8JU\A^`BC(%\;_`#V:V*LM`<_\WNY`(5=2,[Q<$YK'O@(@J;G"
M8"(N^=9VVD6N[`/P$N'/#!?S#Q@?=>9>9J'D[[SKZCZ@E<W5]92O[K@(4W>Y
M@1U[/I/','R"YAKVJ;Y>-[N40SG$#.>81TY41(('*H)[BI]H&$2B-3&K%;6C
M6(F8@3(+W'*C5W"UJ:M5V-:W*75J?RW`>OLU]GB_V<O\MOTE36'V!2%-02GB
MQ[0$!`S0>VXM*"`^6^G[=.,:HYD*6T>9%A42`4;F@5,8S<$P+V^4QS)`7UQ$
ME/W/`-<JZ@PB)$R+F)*8(UR*)TW#),0'NS44#)J`[96#55J)!!9*ER0@<M2&
MX!!B#J&/BV+&5<Q:C@^/P!C'.Z9N%E%E(V%%,PK^*3(KJ*'7:"4X/'=XG2$%
ME;B','*;TX'2EU$]9OH_LZU=T6[2+K7J!Q_*,1V=A2\#G+_7DEFR6'$54>:\
MCLU@96)-C[[*64JV!DJZ5+'*.R-4W!T$5`<HAY*.@GZN/Z4KJIT:RW1U/^DC
MWQT;9/E$JX^BVH\BG-F;*V']&V@M&R,_G2?Y[<'3PV2E794A:Q9N]NRM`05<
M"@=0B!0NN'U3WJLH%/3J;LMH42TPK8]*"5(24_\`HJJ4L$E/8M]C@/VG]5'Z
MKF1@=?\`T]S>K;E_].TPK8HN"7@=/W._JT9$\X#&`:JE\T3>7R"&N9O]5+ZW
M&N+91(X9Z;W:V4YNTA)5UC4!E,7M3&(.>GFS.05CXB<RAKU'90]Q^.D'*:J*
M[TD<_,U(913NZMIB"$X?5C_1]^DKZ>=N=0_4!Z0;/]BPN(-L6RSI]P'2^X-J
M3NP966RF.SR)F,GVQ%,)#)YS&X?$V:.(/V$7))7JSC=^[<-S%8`"SP/90=Q`
M!S.8O#A3G<V]5D%+?$>\<RXW9;R7=]?)8M7R'X#)W$"',YB\0%HJ\V]5D%!*
M,AS^9<;L$!2=7U^Q5KY#\`F<.8<KAL4'$84@JN>]EYS0I1*5)^!N>7O"=Q2N
M"*UN*H`'*>H`("8`4BX@:C5>(J`C6JK.H#<H!J^=Y;P/7V0'V>``<0-0HO$5
M$0I15G41N3`M/.\MXDI[(A['`!7$"(DL7B!$13LM49B(B)F@)64-Y1,HA;3U
M3)T\I>`".($>7RUX@;A2Y5BK(:B88_D<NTW:(BJULI]DE3RDX!(U=0IG#@H.
M8HQ+V?<R@NS,4$SH1?([N4'"MI#K+-K+2I@)CIB`"(E,8%1'$`/+Y:\.->5R
MK%67;<##D<NTW;<"S6RGE`R5/*3@`KB`$"6+PX@($LM59"`@8K44[*&\@E40
MMIZAB4\I>``<0%`HO#TH`A15E2EI*4\[R6"7]JGL<`"Y@*#5>'I0:U594I:H
M)J^=Y+"GK[`#[/`)FCN$,Q:G<.8HQQ9I&4,JNS.(E!NXN$YS.'-Q0236J/,.
M%I3^<(`8>`4G<P``IS%X<``%N;>JR```H2'/YEQNP"@BZOKY+5:^0_`!W$`'
M,YB\.%.=S;U604M\1[QS+C=EO)=WU\EBU?(?@,G<0(<SF+Q`4%4%;U684$HO
M^>"EQNP2BBZOKY+5:^0_`)7SF'*W5%)Q&%6`Y`J1=H10#`X6*J%P.6Q@$!(N
M!O/#M`X=OG!P"KO$#7[O$5J-?=6=:W'K^ZK6\#?M@/``.(&H47B*U+;15G6X
M3)6TH;RB<Q*>R)?8X`*X@1$EB\0(B*=EJK.HB8S/E64-VB)E&]M/5,G3REX`
M(X@1Y?+7B!KR>58JR&MPQ_=^7:;MJ*S6RGV25/*3@$JCJ%YD:5!S%<I1VF`%
M279@10XL"&9@4I7"8*&$JK84P`J@T,F(%"I3`"DCB`&P4UX<:@ERA(JR&H&!
MAR;+3=H""K6VGV25/*3@`KB`$"V+P]!`EEJK*@@(-A2MH;R"4Z-M/4$E/*7@
M-$SM:(.EAX-%8TZWYP<-$@-SM3*V^)I=I`3$3TL$/)^Y'UN`:.FS_AUT%_N5
MU9_L-!<!-7`4BT;+ZO/K+:$.YRC6\-DKG>_65&R"TE*0R$A'OY#J3W.W(K,)
M-)B%G"G(Q<)&.4KIJY,W$MBJ=2G`(PU?I."P?,L*G9SJZQ78,)C(Q@KXG,R$
M2@1H2(PN7Q!M$X^]:9R+<L*X&6Y[LDFRD7CI1(!,Y"Y0#!*74`RP+8,'-8EB
MK+&\[-.:MSN,D,7P^;Q9O(S#9UE>K1.P[T.28RT0,NU26$H+2+,IP(8I5`'C
M)BS9-OEKGPV[<M)B8GY3'I/7I^JDQ$QI/HU/H;UM,Z@Q#*H#*HEOB,<_S<K_
M`!/&I!EC#%[%1#;7.!0TJ9P_@MH;11F22N7QDD]145=M%6R#DC7D"5`KA>1Y
M+>['>X=M?!AR4Y.,5_W66V3OKN,MLV2U,E,<4K&&M<%L6&:1-XM?';+K'N=M
M;:5M69B9CLU^F-/2-(Z3/QZZSK^.GP7R"0A:A:]B[JA;1RTK6O92AZUKQ%+W
M->:Z.=A22;M%#K3RNKS('N2]_7[VWDF3B>R9YG&1XZR")SMC%AB+_+I15^U;
MJ-3NV+=BP8)N1:HGO"4W73G,'G,VDT^H^7=1F58C*8\VQN9DI63BRNI#;JVS
M"%E5U<U"5<P:&-B.-&;M'#-8\6^>"59,3I%3#3X'IQW7!L'K(_71,@W108I8
MK#Q^.P45!0;)N5H@:)401R,9)W&FADUV*:A7*:Z?/!Z0Q'B*2A0:E>GOJ0/*
MLXY+K95##;I-607=D))S;I[D"\L^DW"<>\DCMEF:9%F,>PCG+YQ'LVR;I<B(
MJKHD;!).4:+SO(<1P]DCU6R4!F>.1&<Q\GF$>D"X9:_FCJO<+EG[&0RY<C%?
M"YP"NP32,<BI#J-D@00!$$PUT.G#8"4@PR,>LK(I'*6K1JT<OY1)LFQD6HNW
M"\LV\/A\JBT(P)%#NR)7#0J3I%-J)2J6KK`8&=CTZ;W;O).4>]=THYF'[IR5
ML[+`MBMHJ,</WSYLC'Q;G-W+!%2+5=$.1,2&;O`231>%<(I)E*&T;`T'L+,(
M_%X*+ZL9.&90S%DUDYA=<[V<G!C\VF,G:&?)LLEB49$_A+EE&K"Z671=I,KE
MT%#&+8'P9:%W$VFQ=2?6UD4]CP2^,R3:$>MVT2NDE!?1]V_0&7QW*(EVY2R-
MW%.4'"*W-:%9O!$$A6`RB@/;O2.:O8[9,5)=2R&2PV4Y&UR'%X#*"2,C"Q+-
MIF[[*QQ'(>ZYVPE9;%G$>Z+&*HLG4:*K:A%.8BDB@4%.AM'Y)J:1A762;OA-
MBBW;.R9%/./'6F1YDY<-'W)3R`9;.\IB7C*!7>HM8H$T473.+BVR2RSM0QU2
MA<0LC!&`#%?1)BC6ABNF8@-!$!H('H-!"G`9[_"?CL5[Y:?;\`=_A/QV*]\M
M/M^`._PGX[%>^6GV_`'?X3\=BO?+3[?@#O\`"?CL5[Y:?;\`=_A/QV*]\M/M
M^`;FC^%[[*U>1=!<-J5<-*#^`MJT\_MX!Q[_``GX[%>^6GV_`1CN;%3;+UCE
MV"XUM%UJB9R1@BQ:9[C"T>>:@@*_9N5^ZE4=LS"G(MT#-%N6NW7!%<_*525L
M4*%9M@:$W!E6RLASO'>N?)L3QUPA-I8GK=KC^)*P&,CD&-IPSHKB80E6DO+`
MQEBC)QYS<M1FX(FG55`%DEPMSAHI1<,PC)[)XS))J-A\?82V1F[LS\?DVD(R
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M=FYS-_`MW;9W()-F8MV"*3**C6R")`5.Y66"X,>_A`8,0%Y%@/<VU:N&E?N)
M/+Y_`4(;]+NR(;,)Z>A^MC+HV&R"6E`/`'2(J:$QM]FN89XG"Q+QWF3A$\BR
M=[!EXU)XLW$R$4LR(FF16*CU$@V3)^GG+I[*H+)6O4RJ1./:8`C*E>+SPNY9
MSA,7&-W$@B,/L6(@V#AS-1BDB418+B8\S)(KBJ"C91J&IM>DC)&;F1%+JDES
M,I&#F8!1%R_R%XY79N7C*5BRG>NMB*.(]W*R\<F\G'4<+%P_`Z[9`6K90A40
MGW1VL5M1-):/G-I!L4<BRQ"=2>2CETLM&BCB`1"[4KJ9R'(7@-!.Q*1N@58J
M*""1:`*AU3F"QO?X3\=BO?+3[?@#O\)^.Q7OEI]OP!W^$_'8KWRT^WX`[_"?
MCL5[Y:?;\!'F7R,"&6:J`SZ(`1RJ?$MSED`B!->9B92VIZT*0!$WK!Y>`D(9
M&"`#7/HD`*![ZN68``%*X%2ZI^P`*BL(U]0AZ^0W`!Y&"*!^8^B2@7FBI>Y9
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MV;`:!>:\V0QQ37.#EREW@V<,\8"'T4O'RX9&MCV0MH((E\CJUFJQDPE2(@W6
M(LD9)4I3%.40`W'9O%.<\\P>3\7GYGE][_2:<CM;9_=Y>M\?LQFQ3F]RD\A:
M+8_;[^^LUM%J]T36>L(_/BVLX;QCQU]R:6TTQ]==)TT^CUUTT3_M_0G5/EO4
M.KL77G5&PQ+5"^1ZRD4->FS#-8T8N*Q:',TR1FRAHE5;$GQIF9`3JH.T%FLJ
MUE5R.2I.6,4[;?#+TI1TJ]/_`%,:BVG)9-NKJP/NS!'.$Y)C<=BTIDV02/)G
MGN;8Y,8YE!(Z6$&*$LO&)O%':AEW0-33"$9'$;L&*9W87[E9*%\(DC(R$4!O
M#71DC)O6B8@)FS843)JE?QXD$1=-A*8'"%.8D(*$N(;@$.(2,2?%L6%60CE7
M"F/P`F,>0:NEE5E8V&$AA<#-9`=RHJ=ZU$#]_?"H*R0@X6O(H<'\DC!&L%-]
M$C=RN78Z9C=S`8"A9:?MO!VUMIY>:E3VQ*@%D8(UHE?Q)K@3$@E=,QN`Y6@I
M"6A^T#E<(6T\H'3IY2U`"1@A`*/HD0H40HZ9TH)4S%IY_D$IR"'L"'KAP"-_
M)0I6BIB2$60P"D(&*\:)F#W4*B!P>,Q#S0-_TA:A7R]H""PTC!%NO?1(`4#B
M>YRS"T"E="H)JG[`*5!:ZOD`AZ^0W`!Y&"+?S'\2%H*\R]TS"T$P?<Z^X_8!
M`:.;J^3EJU]J>@!Y""+?S'T26WF\V]RS"WE^(<^^X_99W-W?7R<I6OM3T`/(
M01;^8^B2B3F\R]RS"WEB_P"=?<?LL%HZNKY.4K7VIZ`F<2$0#AL`/HT"E5<]
MY`';4I0*1%\4W/+WM$!*1=%4!N(J`'(;L*)1,4%0R$'4:OHJH"(#5RSJ!@,H
M40'S_*!B&`?9`?6'@`)"#J%'T541``HY9U$PF3*`!Y_E$QR@'LB'KAP`60@S
M"4"/HH1-8!+7+,1$3F:@D!:'[;C.$`+3RB<E/*7@,$D(,UG+?1)KN5R['+,;
MN8+'D64/V\P7;:VGEYJ5/;$J"1K(PYW#D`?QABF49BU`';4X"FJWB^2*!0>+
M`!%573>VTB0&,JG0#"8IC`K)(P1K.6^B37<KEV.68W`H#'DV6G[;P=MK:>4%
M4J>V)4`LC!"!;7T2(&`@DM=,Q`0,5J*8EH?M`Q5T1+3R@<E/*7@`)&"H`@^B
M:4`0HY9TH)2"`AY_D$IRB'L"'L<`#(P0`-7T2`4&M7+.EH%4$U?/\@%(>OL`
M/K#P"5G)0O<6IEY"+N[FB90RKQH8;2MUS&,<YGCNXH)H+"(BJIYI#C<(`8>`
M5'D8(M_,?1)0)S>9>Z9A;RP?\Z^X_98#1U=7R<I6OM3T`/(01>9S'T26SG<V
M]RS"WE^(<_F7'\WE]R=WU\G*5K[4]`#R$&6^]]$EM%7F7N686BF+X%KZG[!(
M9JYNKY!35K[4]`2OY&(*W5Y;Z-*L4Y0\QVU(H4Q5U04"H/&ABF`4%@-[H7VA
MP&M#%X!7XA!^3OT36H@/X2S\H&,`A[?R@8I@_9`>``D(,1"CZ*$1$H!1RS$1
M,)DBE`//\HF4(`>R8OKAP&"R$&-MCZ)$3"F!+7+,;A.+0$K:'[1.9P@!:>43
MIT\I:@$D(,PDY;Z),)^5RK'+,1,*@L`0LH?SKQ=M;*>7FI4]L2H)59*&%6-Y
M4A%BFJ[(!>6\:`10ZC`AFA2@5VD54QRNFPIA:M4%$Q`H5*<H*B2,$8"<M]$F
M`W*%.QRS$#`H#$41)0_;>5TVMIY042I[8M0"R$$8"VOHD0$""6URS$!`P-A3
MMH?M`Q5T1"GE`Y*>4O`:%GCR)63P\C5U'*K#L'#1(1!=LHH(>))&J0J9A-3E
MF`:AZ@AZG`-'39_PZZ"_W*ZL_P!AH+@)JX"E6BLNU\YUCL[%ELSP^)GU-[=9
M42]*^?-P<13MYU*;H,"TDV;R<1(6MF3I-90".FR@H^19/L.4(VUGI?&<"RO#
M,AD>L)MGC+$7,&[3QR<F(I1LT:X]A&286:"Q@&.9@6/QUZA/D7<I2*$RZ,JT
M(87-YCG,$D]0:V%;2@YK$,?2QK8@2^K,]CY'%64QCJ2<NT=95JP56#QU*RD3
M#HI.6R*M`=.FZ2EHE$X5XR8LV7!EKFPVFN:DQ,3'K$QZ3"DQ$QI/HT[H8UM*
M:9P_*H&?CXG$XV2S<)+%L691^OF"4)%--<8#`R=7FOLPS-A*^,Y3$/Y`IW:Z
M#EL1V#4J0H()**2/);_:;[#MK8\%L?)4Q7C<YK9;9)W.6V;)>N7LF(C#V8;8
ML$TK,Q:<4Y9F+9)B+:5M69UG6FO2--.V-(Z?CUUG^W3X+ZA+QAA`I7S8QC"`
M%*"I1$1$:```':(B/$4O<WY+HER9Z*AD^L//1!7)765@Y>ID4=IOY[(WV;91
MCY2QN71$6K@LSFTRO*I1BK4ZS91I&M^]*M&AT'(/$/T;3++%LNQB7ZH<DE%L
M@Q!MC$-EB)).-RZ%?H[#C]BKY$]D?S@NV<])NGL84H?@[7DBX=B0>4Z51$%.
M-]*FP<8CI",:]9^<N"/W\U/*KJ]Z9N39#D#B6E94RIHW/6A#04E/2W>CHE*1
M^W213;,WK5N4"`#0KTD[8,R<1R/7-F:*$A+/GLE?%J.U7L=,2,C(S+`JCS8B
MZ[,LF$H=L*:)R,4T4454VQ78*N5@D?*^GK*YC+,IR/%.I177Y<GR%S-/GL!$
MKGR]RU=I&*QB)?(E,^2C)9ABB2BK:#1-&)M&;-<X+(.G";=RB&K%Z7-FEFWB
MGZ\.STL5=^*G&"2D)`9D3O':#F,-]*G>>.G2`0J;4B!>[(-^\(@8%;C**&,'
MW?=-&U#)QI(7KAS^)%.:-(32AFK)WXFP\TOA[-!/*V;2+75[R\,X<<M8SE=T
M190HJMD#%!YANGG8<`78;<O5OF&0,,R@QCH%ADCQ[(.,7D/I4QFTY5I)R67R
MX'.6";*11R)M4BK(*@H<!,!P5#1F/2-LF.9S?AO7#L:+EIDJZQWT>O)+-6T@
MKDIIEPN#*=V'.JNB=Q<.F-ZRYWA2J)B#@$VR"!`W93IVV"KCDA'FZN\N4R-S
MD6.32.3FD,G2]P@8C-8:1B',8RVBT2:M,M)EB;E^G&*1C=%VU(HS1;<IB#(&
MK..EB:S'+XK*%M_PKM)FUB5)R/R;%'TP.=O8G#,7Q((#-%(?9^+L7^L#24$O
MDQ8)NU;*)Y0][X#P4DSMG`6WUTP3PO$6..S&7,<@>LG^1+^)G>6W-)/(Y:6C
MF1"NGCM<B43&ODFA"F4/:1```:`'`;QXS$4KXI'TI6O?&]*"(A7[IY*@(<!C
MQJ'^-8[]P'\M;^50;4P^Z?NS=@>N/DX#/C$7\8-/4&H+$$!`>T!`0$0$!#@#
MQB+_`!]K_"E_U\`>,1?X^U_A2_Z^`/&(O\?:_P`*7_7P#<TEXL'LJ/?VO:X;
M4]U+VT8MPK[/`./C$7^/M?X4O^O@(SW)BGYU]99=KV&V7-ZRD<GCTF*.;XBX
M9IS\(4KYHY6[H9U1/DR2*!FC@"G25,V74*FJDH)5"A67/NFW9N7[,R+/X3K>
MV1B4*]1FDL7UVP:X^KC&+?2#'$H1^7O;63C9J3*VD2C)L#<]NHR=E2*4QVY5
M45PMSAIRP<.QAIG*$LCEHJ'Q^-D\C6*#57()!C",F[R;4;BZ>\@\JX3,N).>
MM:*E+STN$*X[^Z>I/<N90>8XUU$Y5J7PF(@XYY#8ZHHI'3;K%LI6S""?O.7D
M<*HW.UE%0(L*%BR[:J8JE`2B0&X_3KE;[%$8"5ZJ<OF99+,8#,B9$]."SF)6
MA&V4LBHX\T/E*J3(K-&<8+L@>FD&A7\*W<O6[]19SS0T9WT<9*YAF,:EUA;,
M;2S3$W.(+9BFX:GRE\S\7EY1HW>'4GC0QFDF653":$C,DA)*1[4Z+MF0ATU`
MWS%>FYQBVVH_:SC>LMD23&=RK(5L;?FDG"$JIE<1+-I0RI%<T=P9'Q',@FDW
M62C"@TB8YJS0(D)7#AP%O8^8BPCV(=_:A1FV"G-+V>XD]G@*%-ND7,HC,,@R
M*&ZR-BQ,9D,O)G7Q]-=4@16./\WR[/RP$2]+F*0$=,Y/84TR2>.4'!T(MX@D
M@FBM'1SAL&TY+TRS^0Y5!9.AU'2B?AC3`$)$'R<R]?R[C!8N,:@_*^C]BPS%
M@Z<3,4:23.#151)>5E"*F7*[3%N&I->C-\R=2'(ZE<A!E)P<SCZS1<\RZ<.H
MYT\92L:FY>.]B+&25>3<:B]G5X\D>ZF5#+)%5:ME2HI!/.D-5AI5K+1TALQ?
M/?I'EB,\#N2%\*T>JCB/@RS?O,ID>3.^0<K$A4$"+(MFS9),B:5X*JJA8SQB
M+_'VO\*7_7P!XQ%_C[7^%+_KX`\8B_Q]K_"E_P!?`'C$7^/M?X4O^O@([S";
MARY9JH#R+,!-E4^)0%4O:">O,Q.<0]3S2`(C['`2$,U$%N$T@T`"@<3"*I:`
M!`<&.(C_`,D&JHC_`.H/K<`&FH@EXGD&A>7S+[E2A;R@>BK6OV`1Z]?^J-ZW
M`5"ZI\7G=KBPUGKS9IM89SD^N-D$A,S8R$_'.(?P/.].RLNF>1Q.=QK)8]O)
M1\&\8K+,G[9PFFJH)3^:("%8W_1+U;.&T6BIZ2/.S2D9G.RL@7R\8"4CWK>!
MSB);)MF!L28;*1Q&1>8I)0TBS8HN4PBHZ/>KK,VC5^S07*&M]4F-1N`X+K:#
MW%,-MHRN"ZBU'@TOL?(<.>98XR3,L>SS7J&59&JV<M-@2D+)Y3X.J^<%56!5
M<36'5<G`#CW?[<<CO-OX;NMIQV[MM\T\KCODK7<>QW8_9M6EK_\`.Q1>L7F8
MKKW=LS,_3UF8S>4K.XK:]=8[)TZ:]=?RE\]F1NG9/7NR(K%L#Q/Z42.#YO&8
MT6,T\G&R/TB=P&1L80L=(EUVQ\/>^*II%07!='E*%(<%"`!3<=>\4Y[RC:>3
M\7NN8Y7>?TK%R.UOG]SD;WI[-,V*V7OI.[OWT[(OW5[;=T=T=MM9B8_/BP6P
MWKCI7OFEM-*:3KI.FGT_-.NW>F'J"SKJ#4VQA758_P`-UZXR#6TJEK@)G9C1
M*,C<1B#LIIE%-8/8T5A@C,RUJZA'<,Z;2#:5>HNTSK$CG;/XJ>C??I9Z7=X:
M+VC)9IL[JSR3=V)N\+R7%&6+9),YE(IH2<MFV/3<!DA$<CS#(F2,T>/;.57Z
MQ"C<YF^Z,RM(YFV1.%])6:BC1,D*4BU`QXYT*1@<E1[5&S?E&*KWR.Y=1D$!
M`W>$*<TH\PE0,`(,0F(X<5Q8JDBW47/C\`!C&>`[.JJM&P]IA=#+Y`+HRQI-
MN(*=_?<P5BCWA:[F&#8"340I8))!H;F`D)+52C<"P,12M]?F!(MZ>OS2^N'`
M8+-1!@*)9!H('`@DHJ7S@4!J*8AZ]X/$1#_K"^OP&0FH@:"$@TH(`(#S2T$#
M`F8H@/LE5*/[8<`C?S$6+16R1:%-5*@]Y(E0.:`CYXNF=OFE-_TA:T'R^006
M&FH@H&$T@T`"`<3U5*%H)@Y,H(_^J#141_\`4-ZW`!IJ()>)Y!H7E@J*E52A
M:"(/15$WK6!'.*^MRC>MP`>:B$^9?(-"\OF\RY0H6<CO_.N];E^&.*^MR3^M
MP`>9B"7WR#0O+%4%*JD"T4>_`J!O6%,8YQ7UN4;UN`2N):,[PU$'[4"HJN17
M_""$M*1%\D83D%RB)P(LV4`?,6H)!&A:7`"H9F)`1`7[0!`1`0%4OE`RA1#]
MD#)F#]H>``F8D1``?M!$1```%2^43)E`/V1,H4/VPX`+,Q!K;9!H:X2`6BI1
MJ*@M2IT_]8SQ(`_ZPOK\`$F8@]ED@T-S.4"=%2C?SA9`E;Z_,&1;T]?FE]?@
M$C68BS.'(A(-3%<*-#MP!P4]R:S>,(D)"=Y6Y9557Z-H6(W"J4:&K>8%99J(
M/99(-#<SE"G:J4;P6!D*5OK\P)%O3U^:7U^`"S408"B60:"!P()1!4O:"@-C
M)B'_`*P.TA#_`-<OK\!CQJ($`'Q!H("`"`\TM!`2D,`AZX"4Y1_;#@,C-1`5
MK(-.P!$1YI:``%4,(B/L%3,/[0\`E9S,4FQ:\Z1:7%9HG.87)%>PK=90QA4[
MR\O`"-%1$>:IV$-YPT$>`5'FHA.\3R#0O+!43W*E"T$0?"K=ZW+".<5];E&]
M8>`#S40G??(-"\OF\RY4H6<GO_.NKY.7X8XKZW)/ZW`!YF))?>_:EY8J`I54
MOFBD+T%;O6L&/7KZW*-ZW`)7\M&F;JID?M2J7D+_`"@J0@8BZH*`)^],[1*+
M14!#F%K88.WVH@J&9B?(+]IY1`0YA?*!CE$*>N!B&#]D!X`"9B1$`!^TJ(E`
M`YI>T3&2*4`]>IE2!^V'`!9F)-;:_:#>*8%HJ6IA5%J5,`]DXO$:?]87U^`"
M3,0>RR0:&YG*Y=%2C=SA8@E;Z_,&2;T]?FD]<.`2JS$6HK&G2D&HD.[*0*."
M%Y@N6)3MBE)WE$5A4!\@)0`BWW0HVAV'*"HLU$'`@DD&A@4Y8D$JI1NYH,A2
MMIY;PD$*>OS2^OP`$U$&M$L@T$#`02B"I:"!P;F((#_R@=)"'_KAZ_`:#GLG
M&N4L/3;O&ZJA]@X:)")G`QC!XDD>I0#U+#`/['`,_39_PZZ"_P!RNK/]AH+@
M)JX"E>B\XP9[J[9^'+YA#,)@=Z]94*^3<D4>&BEWG4INA<5'C(#MN<BT9/"+
MJ$YJ912K4Y0J8`C?6.E-;ZXRO`LJ-U=9[DX8F\A)%GA\ADF-#A<F$%K7--?(
MQ+.()&NIQ+&F</E2CMHT&0<F;+-N<HJNH852A(G49+81L['9W&&9L5SIB_U5
MG[27QR8D(1K!R3%QE.K#+LIASDYF^.),W3=NH`@].1LH(6'$`-QEPY,V'-7+
MM[6KGK:)K-9F+1,>DQ,=8GY:=5)B)C2?1I'0=@2>IL*RJ)4-C$/"RN=!)8[C
M&)M=6I0V/,&>M]?X^_20<:D>2$2]--Y!#/)01>F*[;B]%N0.ZHMQXD>3W^#?
M8MM'[><?)8L=XW&:<F3)?=9+9LN2N6];],=J8KX\';3Z;1AC);Z[V64K-9GK
MK29Z1I$=L:1&D:>O76>OST]%_0EXXP@4KHIC&$`*4"*B(B(T```$ZB(CQ$LC
MG_"]%N(L)1^MD.[\KSN#EY"5E)>&S)G$R2RKO*,R#,<_CX]^EW5",Q[+,ME9
M%T=L5J=RR>N6IT')#,D0,#E/=(F(Y&[V`LEO#-8YEF^*2&+),XQ^=0^//7N[
M%-N-)E@^<R#I8[S'Y%L2*C4/<TFR'>1$%%'*@`#;C'2-+8O$R$;#]6^VA8OW
ML_.JK%E99@<^4S+B8DYUZN;',H@V:T7)9#+J/GS<$B/;TRI(/6J!03`&1UT=
M9,FR/%GZT-L,D9J;>+O$55GB@S3>;?RDW-Q(A(Y2X5.I.>(N4UDD3%8J-$DS
MBS,Z(L\7"1LQZ=5I/*LKR>$ZB9S6Y<ER566E'>+QJ<+EZX2E$$8B>S=M/,WT
M\W@EUNZX\V=(BRC&;A1$6KE?NKEL#`ETCY.G//7"75_O9#&'AYAPKC+3*,L0
M>J+23ENZ8K+Y-]+E),30I&J:2)DB(G40+:J8]Z@G#]R72OEAB1:<7UE[N@S-
MYX'\P<)EZH:8;K'*5.*313FF3>+77%1[S%TTSJNUW9EE@471143!]@^F*>@?
MSC-OUEMHST+G,0,>A"9%,9')!`N#Y6PR`\BTE)'))%9!XK#M5(@5D$6ZAF:U
MZ@JJ$J8-6:=(814QA[Z0ZC\FBL9Q5YB+AMK[&(./P?`I2<QV?:/&DT^@V\FY
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M>EBXW-ZZC\D2E9#)@;(KNLU?.IEJEF:F#-V__P`%%<-4D\65,)DRN2F.F<+@
M86DVQ?$L<QQY-C+.H2&81B\BH5S<[49MR(F4#G"JMR_-H2\QC6@%1$:CP&S^
M,QGXV3]ZK]IP!XS&?C9/WJOVG`'C,9^-D_>J_:<`W-)B-[Y*5=DH+AM0+5?Q
M%N`_N/8X!Q\9C/QLG[U7[3@(RW)AD;N'6.7ZV^G64X&3*HU-BIE>$N6['(XI
M--ZU=G[HXD(]^T[J^!OW9VF=/W9HLHF!B"<#E"M&?]+&29IL^?V/'=86]\52
MDTIE+%\$BYE,,.Q(,AQQ&`ER1K9F:,FET16(,@VY;Q!1D^!(R1P23%)0+<8<
M8D!#L8.5R-SD4C#1$!%OL@D$E2/IYXPA635U-/"56L=2JZ1EU`O/YYQ\X?+P
M%;=_]-\?N[-8'-&.\,YUB_A8F!C#QV)KB@QF'.-Y4OE^+OI$`<LGY58[(5`$
MHM5FZQR7$*J41`Q00..F9T[Q5ICLWU'[,F9`F:X[F1,BFGSN4D8Z3ADLJCTP
MQ-.8E'Z<"Z;(Y&U&-.879&K^'9NETGKCGF7#07?11"NX9A%%ZGMN-UFF'.L3
M^EB4A"CFCV(&9E).,:NYA1B>*7@W2DZ4LR@#`%9M9JR4.X1,D)50WS%>F>"Q
M#<,=MDFWIF7?LI_+)L\)((N5%)9WE4)*%G"NCDG?#W$HJZD[@<FCSJMHABR8
MH`@1!19<+B1\Q&@P9`+LE0:-@'S5?+R2?\C@*#L>C,\9F>0Y+CO5/N"':Y'+
MR+F2@(N6>L4V6/R.=9?L`,<BG</+QKALFAE&?3Z2;ET5XH@QE%$6Y4%VS%RT
M#8<OZ66D_EL!E2N^)UNYBD==MGHS+!:6EIISA,='Q[)TI-GR*/>-9!W+0A9!
MJJF45F[Y]*U,N215(0-5:]$^-LG,J+7>N1I1\E!3T"Z8F;.%^]Q2S]F_C&LJ
MHXR-5JY;HSD>W?3JK=!F\GGW,!9PBW6,V`)\T7JB'T@TF8IKG[O,4LARY"=7
M4>I/`/'.R8<2+42,=U+3BI>\HLTA113.V:-V:2"2+<HD467"R'C,9^-D_>J_
M:<`>,QGXV3]ZK]IP!XS&?C9/WJOVG`'C,9^-D_>J_:<!'N73D67+-5E%\0HF
MRJ>,!;5O.!/7N8G./8G3S"A7MX"0#3<44#"9XF`%`XF\U7L!,K@Q_P!Q^Y*U
M4_>_L<`'FXHE]SQ,.7S;_-5\WD@]%7R$_<!'+?P8^Q4*@=5.(J;C\/U+CVRW
M6L<BS+7.R4HW+F">0G7COH[G&H)R31.&-9%ATYW208X^[9N.ZRK%;D**6J^0
MI@K"^Z!MUK-8Q);TB^\E)>(SK9N4!EZS!RADK6,SZ+0;+QS5O'9FSQ(TC`.L
M=>MFBJ\6K'LXE\Y19,6CHC=XD"?J.P%;!L!UW!98.0;@#7FI=0ZVD-EO,$F,
MP?Y!E.+;`UXUFIR51;L\W?P\SE/@9WJQ#K"=98P%%5<]B@]M\`YG%L_$,^PQ
M[_'M-U;E<>2U+;F-O-L<8+4BVDY,<7BMIF/]KMUF>D:ZQNZQS;<1>:3:O9,>
MFO77\I.>T,0BIK7.RH/'M/3BD_+X)G,/`)-M'S+!8\V_Q[(HZ(2;R"F",D62
MAI`$BD6%9$B5"'O(6TP=0\2\LG8>4<5O^3YW#''8.1VN3--N2K>(Q4SXKY9M
M2-S:;1%(O,U[;3;K';:9TG2SX._!>M,4]\TM$?1\9B=/@D3;?2/L78O4(KN;
M'>JO(,,QEQD>M9HNN46FQ5&S!#!8A6-<,H=S"[AQC&F:LE)*=Y!1:#<I'1DY
M-LZ2<@Y15:_(2??7I7Z1,TZ>MI2&>Y3U49IN2%>X3DF%L\3RL<P>)-CSF:X[
MDL3.D<9%L++FB,ND5LX5D%6[5`S^1G')RB@S19LT`OS*S4:I$R()/4P.I'.>
M4-RJ/G*MFX)#S169<NHR"'G<Y&WF`-Y*"8`3X<^0-B>+`=P"BIL=@KCBJHY%
M0YXR-J?O)G\N9Q>9XG507;JX3U%90:G$-@&19%(505RV'%$I36G$!%<6Q40J
M!?\`I!>)4_\`7#V>`T(-S:B&E-H:^\ZR@#F$``^Z`V$@4%^`@)@>)?P@>OQ/
M_P#RGE$^G&\A_P"OF_W&+W\'\]/U@]0>PL$RA91MC.8XUD3A%,BJR$%-1\NL
MBDK:*:BR<>NX.BFI>%IC``#7LXTM]PW,<92N3DMIN=OCM.D3EQ7QQ,^ND3>L
M1,Z?"%U<F._2EJS/X3$G:5D62+!=55VDW(0J:AEEE!;)D("Y0$QECK-2D+4H
MA45"U'L[?(,:O*%9B-0,<BSHB9DP,)RB16I0(1PH:H`0?(1HH/\`S1]C@/P>
M;BB`<3O$P!/F"?S5/-Y(/14K0G[D(Y?^#'V*@'FXM.^]XF7E\V_S5?-Y'?\`
MFUH3]QX8O7_JQ]BH9--Q9+[GB8<L50/YJGFBB+X%?(3ML&-7K_U8^Q4$SB58
M"NW.#Q,"-E'!G`7*%H4J+U$1LYB0J@15L<!H16EM:!V&`%(S46`B`O$Z@(@(
M6J>4IE"B'M/4,D;_`$<`>-18T#O9.T0`/-4\IC$*`>T]4RA0_;X`+-19[;7A
M!O$@%\U3MY@MBD\I.RX7B7[\/9H`6;BSV6O$QY@I`3S5/.%86()>4G9>,DA3
M_K`]F@)6TO'"NX-WQ,2N3M5&X7*&$R:R$:FF:SF*<H%%'Z0!4B5>8`T'M,(*
M23<4I98\3-S.590JGG<X&0I4J3]V$BA_"![-`"S<48"B5XF-X$$OFJA4%`;&
M)Y2?N@>)?OP]G@`)N*$`$'B=!`!#S5?()2&#]QZI5"_Z>`!FXL`$1>)T`!$?
M-5[`*50PC[3U"I&_T<`F:3$<@R:E6>IW$9HG.:JBH4!NLH8>8!W('H1HH/W0
MX^8/:/E$%)YN*3O$[Q,O+YHG\U3S>3W[FUH3]QX:O7_JQ]<*AD\W%I\R]XF7
ME<WF5*KYO([_`,VM"?N/#'%?^J'V*@'FXLE][Q,O+YM_FJ^;R1>@K6A/W`QR
M_P#!C[%02O9:/40423>)@J)REH)CI4%-=4%`$XJM0+3NBH>W"MM.VH`(*O&H
ML!$.^)U`1`?-4\H&,40]I]D0?]'``348(@`.R"(B4`\U7M$QDBE#VGJF6+_I
MX`+-19A*!7B8B<4P+YJO:*HM2ITJ3]T+U+]^'LT`+-19[`*\3'F"D!/-5\X5
M^X\JE2?N_$D*?]8'K#0$JLO'*J1RJ;Q,4S.R$]L<EYG3`#-R@05$A4O!^B-+
M%*7@(@%!,4%))N*/9:\3'F<JSS5?.YP,A2\I/W82*/\`"![-`"S<48"B5XF(
M&`@E\U7M!0&YB4\S]T#M/]\'L\!H6>2L>Y2P])!T11138.&B4@`H`F`)--3U
M2`'M1`>`9^FS_AUT%_N5U9_L-!<!-7`4JT9G&&/-7;0Q!W-.&[\-[]9$)(B7
M&)B838'>=2FYECJ&;JPSJ,DD6K)Z54Y1YK<Q0$IZ@!@`(SUCH;36M,PP+.(S
M=6S<A?8Z6+.Q99#'2KZ&.V881+8P2/P]LVQ]J:"QYW$.+Q:G4D2D;-?<CD.9
M9<P25U%3F&;"Q^<@2?1J?CE]5Y\E,1>>$''\/=,%,IU:JNCD,EE4`]@6\8JW
M:J`<SMNLW$UI%"T-QDPVS4RUMMYO&>+1VS69BT3\.V8ZZZ^FG52=-.OHTKH1
MPMAK3"\K9M)?#EX6;SD).$@]=N]?S.*8VT8ZWU_C;MJQ=ZPQ#%XWFSDM".)9
M<CQ)9PFN_.5-0&I4$DY+D]]3=XMMAMMJX>0P8[USYN[+;+NLELV7)&7-&2UH
MKDICO3;Q%(K6<>&EK1.2;VFRE9K,SKK29Z1TTK&D1I&GPUC7K\9^2_82S$1`
M`.N(B-``&3T1$1\@``-ZB(\1+(YMONB'5K1.7,ON_/3-IE]/R3UQE3*!F'C2
M<R?)7DOFSN'E7<&S7AR36<9#(2IFZ0V-<C7:N2]K1)`P;%B_2'JW#$\^?I[>
MS-JCD^MI[#6SIKRHUM@@.LO1R2,S>#5>-I%-&<PK(H)JO'*NS+-VTBF[4,4P
M.3HI@UR?0[C$W-LI",Z@MU,<308FC8;#HU9=2$CDCLI1E(NH8[5HBB$JX93+
MTIUCI+@<KM8%R+$$A2!O:728Q1Q?%\;=[NVW-2<!+9^XCLQRR):Y9F#-IG3S
M'I838G(9+!22.*Y9C#C$6RD9+LD068\YZ9!)(7!3(`WPW1[BF-X@ZQ]WM;/<
MCEG>18_E\ED>QL=8YR#QUCN'9)A:_B$/ED/(,I-F2#R==9MWXSKN#QJS6JJ5
MORU`$ND)=VV592/4UU(RF/NTI-RC'(3D^S+XC(,CL6<P61:I&<+=V3%-^9&O
M<UY@RSKED25*U2#&7=(,+D4ACDL]W3M3'HG#H7'FK%*$3EX@S-;%<`:8029"
M56.NFT<*L6J[I584Q7256,9-9,0.<X?O".FO&XG+XJ;_`%CMN;`183SK/(G'
M<GR>:R)!M&SGCR4:BP`KT`#'E8J46*544E".%VJ2Y#$Y:B:@?!QT<1;C5X:V
M5W9L.3,SE57D'/91"HYB:%9N<(=X&LBUB,F0D6!95K%OU%6+XG*.P<I('3)4
MBO/#:<1Z4<$Q%/#%$<D=R,MK^8C7>+SZ^%QL?-IQ<;*8(N<D[*PK&-DLJRJ7
MAL-7:R,S(K.'#Y:6<+J)^:BF0+C>+,?OBWO-Y\'X`\68_?%O>;SX/P!XLQ^^
M+>\WGP?@#Q9C]\6]YO/@_`'BS'[XM[S>?!^`/%F/WQ;WF\^#\`>+,?OBWO-Y
M\'X`\68_?%O>;SX/P#<TEF/?)7W5:@N&]`[H][/P%M7_`+/V5X!Q\68_?%O>
M;SX/P$8;GP;'MSZPR_64SDF88M%99'I,G\[A9E8W(6+=N^:R!NZNG<1*,^[.
M1:`BZ26051<-5%$CA:<>`K5L'I"9YWLN>V2'4CU,8\^FF\XCCN(Q>43"6$8H
M7(L;1QZ>+`0248U>@V=E*+X"D=%,U?\`+61,GRDR@%M\-31QN&88\ZF9>=<0
M41`0RTU+LW7BLPM&0K)DM*R8)M$TPD)%1$5EK2E+S#C0`#@*V]0/3/@^]<T@
MLQD-F[$P6;A(B!BDFF'*@R:29X/*E\IQ%U*)J1:K]5:,RI0%&X(+MSF,`D(8
M#&J`,DSTG8W)8(?"<@W+N"1\1R:'GU)[(W#Z:DV\NUCLLQ\@XN&0L9!MC[].
M.RU-*-.@4ZC%>*CUB@JLB<RH15(>C^UK(8Q`8D?<.PTG4#!)QI'Z<<49$\9#
MY!*2[!B@HHW-+L\8C%<A6!=F#HY73M"/7=*J&:%(J$L8=TQZ\P;;<3M"/V+D
MDA/QTYD[\L;)L$Q=RS_(X"1-D24@Y:-F8R$L_=RQW:RZK=1=./;LVB0(MVI!
M,%S(^68@P9`*BU>Z-O\`L;S[R3_N_`4&8]$N%M<RG\HQS>V\HSZ0RTH]F8."
MF'S%HA!2^<9GG:F-1BT$PCWK"+^F>;Y)118[E0K:9?MDQ3-R56X;!EG2;A,]
MF&/Y4KM;/(W(L=0UX@P?KLN^9"$AB<2UQQE*JR;YIWM_*2C:$.9H5X1TW:O7
MDJNDB=5\H*8:(WZ&]/M9A\\;;8S1LU=8]DL1X`@W:$BG$>HY8E8JSK,S$Y)]
MO!/&#=:2YQ2A+R-Z[XQCJ6@%C=$ZIQ'2+29B,<RR4R1O/9:A.OP>LEB"QD/H
M:FQ/<FB18J:SY!!-0A"<E!)F5NFDB4$Q45"R7BS'[XM[S>?!^`/%F/WQ;WF\
M^#\`>+,?OBWO-Y\'X`\68_?%O>;SX/P$>9?-QY,LU645EP$^53P@4&,@-P)Z
M\S(YNTK42A:4.RH@(^0*CP$@C,QY0,(J+T*!Q&C%\/8F#@QJ`#81&@-3^3RT
M"GMBU`-,QY+Q,HN'+!0348OC4!('HGI:V&Z@1ZM*5NH%*WDN"*YV;8$W7K=O
MSG0'4U[N$O+)'2JA3BVGM7"I>=%F=$@$&.5M$YB@<0*!+A43`P2V9^V*)P'G
MU3`PF`&;PU`(+H!'S4!J`BS4H(>VH6E;R7!6CJ/VMK?!,+D&F9Y_BV'OI+)\
M'=QC/(IMK#OWK2+S?#O$G;!B\73>NFK0$3"HHDF)`+0PC0P",UQGC7D7-;?+
MN^&V&]W>UPVK7)?#@RY:TM?I2+VI6T5FVGTQ,Q,_!COFPXYBN2U:VGTUF(U_
M5N(=3O3D)K"[VU(8]PD`A=@XN8PG`RA+2@63$3&$R1@``\M/9#B?G[8?<F(U
MGQ_F]/\`P=S_`-IB_>[/_5Q_YJ_WIG*_;G`#%!S:/:`BR>@`A4H5[6X=GG!V
M^2G;QX9LOR:1:D`!-W@H&,0H"+)YY5#($)7\'[*F<$\ODJ-?:FH#3*2[):)D
M2I*+WJQSD$JM'R7G+-FX)5.9)#EU&02J(G);41$2V'$H<UMT=$^9;WV%K7;.
M.=5>Q-/?1W&-/)?1#'8/)):*DY'!)-+(6RLHLGGT5&/F2CJ?1,W3,V4%%==V
MHY6>I*`BV!\Z=NB2>T7OYUN5UU2[/V/CKJ*SV)8ZQR:+R@\2V3SR=QN9;2CJ
M1DLRFT7<^W(@U!\Y[B@1VN4%$4F)"+HFI,>@UW7\"^@\#P&!E-)[`3DX7",,
MA9-(NK47*:<E'8[CK&02!R1N9%=,CITH`J`(E-54>VU6[ZT\C\@X_D?(N1Y'
M9\]L9VFXW^YRXY_=Y:S-,F;)>D]LQ$UF:]G2=)C2L=-([8+#BO3%2EL5NZ*Q
M$_3'K$1JWN$UU(;#9;>Q5O#9=J-#/M'36O$,ODL&?Q"K*6R%5<B#Q%C%/(&2
ME`C$I`RJJ2;]DJ('.1-PBH)E2\W^X?*;/<^+8./IR.WWNZCD9R=N/-;+V4]K
MMUGNT[8M,1'3UB(UZ:1&YM*6C/-YI-:]FG6-.NJ!3^C7S)/%5,?_`%UMR*B&
MP(#.$))!IF\5+I*M</9XED!B9`79*\Z6<?EB&KF,7,Z-'0AD#$;QXF745'BB
M1=&NG[!!T;I776IIC/<@V5(X!C2$$]SB>BW[:3GU&AWZQG)V8*20LFC=-(R#
M5OWA<4&J*2?,.-IC!,AYF/)?<HN'+YHFHQ?&IR0>BI2UL-U`CU:4K6@4K>2X
M`\S'IWW*+AR^;?1D^-3D]_YE+6PW4\-6I2MUI:5O)<`:9CR"<#*+U3YM]&3X
MU.2+T%*6MANH,<K2E;J%I6\EP)W$FT%=N<%%;6JJYEP[L[*(%!%\CYI.645Z
M*MS=A0/V``TH)1$%(S#`!$.8OV"(#^!/O*4QRC_V?UTQ_P#00X`"88"(`"B_
M:(`'X$^\HB0H?]G]=0/_`$`>`"S#`PE`JBXB<2`7\"?!VJ"V*6M6X4J+M.M?
M)4:^U-0,$F8\]EJBX\P4@)5D^+7G"R!.MS8+:C()5K2VIJTL/:"9M*,^>X/S
M51*Z4:J(!W5X(V*H1J1+R"D(H"91\GV&`E`$1$*%.(`I),QY[+5%QYG*$M6+
MXM><#(4ZW-@MJ$@E6M*5&M+#VA@LU'F`HE47\\""7\!?A4%`;&+6K8*=CM.M
M?)4:^U-0,A,QX@`@HO00`0_`7P=@E(8/*V[.PX?^@#P`,S'@`B*B]``1'\!?
M>0`4,/9W:OD2'_ZGKA4$S259-V34BRJUR;-$QQ*U>JA0&ZR@B!R)*WC8U/Y#
M&$1``[1,6H*3S,>2^Y1<.7S;J,7QJ<D'HJ4M;#=0(Y6E*W4+2MY+@#S,>G?<
MHN'+YM]&3XU.3W_F4M;#=3PU:E*W6EI6\EP!YF/)?<HN'+%4#T9/C4Y(O04I
M:V&Z@QZM*5K0*5O)<"9[)M%4%$4U%05$Y"A<V>)%JFNJ!ZJ&32*`?@BG;<`#
M0*5N+<"GQAA6G,7J`B'\B?>4#&*/_9O)4@\`!,1XB``HM41`H?@3T.TQDRAV
MBWH':J7_`.KZPT`+,1YK0!1?SQ(!:LGP=J@M2DK5L%*B\3K7R5&OM34`),QY
M[+5%QYG*LJR?%KSA8@G6YL%M1D4JUI2IJTL/:"9649JJ1RJ:BO+[VF0:MGA#
M"+MB44/<S)$,:O?DJU*($J-U+#B4%)9F//8)5%QY@)B6K%\6H*@R$E;FP6U"
M02K6EM1K2P]H`3,>8"B"B_G`00JR?!V*`W,6M6P4J#HGE\E1K[4U`T+/91FX
M2P]))143GV#AHE`[5VD!@\334H)E4"$`;1KVB'^G@&;IL_X==!?[E=6?[#07
M`35P%*='YQARVJ]HXM)/YELJ3>G65$RKA'",BFFS$CKJ4W.LNX+S\9DX&4;M
M&+L%#@<KAH(`8BH&`#EX"%-;:4Z:-:[#UEGL/NC;,G/QB#(<=B)U">>8[D+4
MF&.\?:DQ>%^AR'=HT84X';IM%5TT69%"HV@LNH<+![J/';?1<X3C48QR5],:
MVSMEX%FT+D4'C4F57*-7N3M)5S*X3/H=S6;LE`-6/>IW6E.F('"MU+WQWC)C
MM:N2)UB8F8F)^<3'6)_&"8B>D^C5>E+5<ITWXCF;;/G<-`QLCDJV6MXV(>1K
MO#\/QZ%UU@^+2"S9[$:IU4VBVLC(8TYEWP.FSGENGJQRN"H"F@A([_D:;_;[
M7%^WPX]SM\5Z9,U9R3EW5KYLN6,NXF][1.2E,E<%9I%*^UAQ]T3?NM:RM.V;
M3K,Q,](Z:5Z1&D?ATUZ_&9^"X[#*H.59-9*+<N9..?-T7;*0CHN5?L7C5PD1
M=NY:.VK)5NY;N$5"G(<AC%.0P"`B`@/$8O42ANC#1^,Y`8DAF>PIXF6/9J47
MQ?-F#";7R*1EI\^:;`+'GDL0"7&(R^9DY.0F6#4W=^]21G)`1.@W%($,#T3Z
MB.SV:[B]@Y_*M=LPR\%,J1D&T)C[)RPV$SS$5(",@L;;1$0BPFH3NZK)H"*)
M%%G@T(=0A6X-SCH5UW%MX%,N].H.#88_W*/Q]3Q!Q'KP[IY'J8T@2!?DQEH6
M*>@1[RXH$"@HU</'5O.%X<H!\YWH]UUDCB"D)#J8WV.0JIR&4-IYMD[EM*2P
M2+CQ![(P8HQ)0C,24BA,B9O'`FV[N@V.*GX/50-ZS+I4P#+\,QO72FV-M-X8
MA<H.51XO+SN19(WRLF*NI0`DI1@L9XW`^,*/RU17(5ZZ,X"@)@00;'W0_ATB
M>2`VZNH@T3+X^?''^/RT_-OX5=%PVG6[^0+%OHI-L22.2<JW4(0"-#`J"9;%
MC$*$AONEW$)#(]H3JV>['!IM)@_0E,:Y!E\<C9%^ZQM^I(,HEY#N63IN#S&D
MS'9.DUFJZ:ZZ2I3IJ&*(-FINE/'-39"SR)CL#)Y]V&636;2PRF"8PQ</I[(D
MW9)=*.D<?Q:)D,>QH""V39PS50(IFB18I4#&53.W"Y'BS/UGGR;)?!.`/%F?
MK//DV2^"<`>+,_6>?)LE\$X`\69^L\^39+X)P!XLS]9Y\FR7P3@#Q9GZSSY-
MDO@G`'BS/UGGR;)?!.`/%F?K//DV2^"<`>+,_6>?)LE\$X`\69^L\^39+X)P
M#<TE6??94?POM<-NSPV2J'X"W#M#NG97@"4RW'H1H9_,R`13$A5S*/9%J]9M
M$RM6JSUR91RX;IHIE;LFRJQQ,8`*DD<XT*0P@$1[?B]9[TP3,=+3F9S<6CD\
M=%MIDN%/EX[,8]FY>L92,42*:-D3(M9@S=,ECALJW?ME#)"51-00$*_["Z/\
M(SS:$]L-SO3J8@LBR%ED)X3$XO+\B0Q+&VLQ`,L6RA7&\5-!%6)'N0=)N%@!
M8Q6LBLBND9%0C>T+?X8BUQF&88X:2G9D8&'Q^%\7F(]Z:7E?"X1DR&3E11CF
MR7B+\4>:N)4TRBJ8P@4H=@!6#J$Z>=/;RSV`R+*-CYSAN61$1#0[*,Q-\C&>
M*#"9.3)\77D6#J">R#YQ$93(HK-BI*)#S%2E#M5"H-+[IIU8RQAOB,[M_:AU
ME,WQ7)#RF2RKEW-ER9!GET3%)8^>9AU1QJ6>1F1J(1*C`J3QB:*8J-#`JTO,
M$=O>CCIO<X[$0A]T[-;QB6"EBV4XGD40GDLAB0SSMS`.!R<<4OD,31>Y?R%V
MXD4C9EPHQ.]!PNDD8X23B'3UI?$=S1^R8784X[S1ED>8.DX5XC']_D9>>@'\
MAED:_.VAVDM(2CI6?-).S+\UT1B5D@'+:-D`X"Z<?*L^X,0H\$>Z-@[(V2&O
MN)/)1IV\!STA.C724KE4_F6%[IW&LG/2SJ0GH[$\A.K%)0^39%D.TD<;9+X]
M`).XN&D9S8\T_2$RRBJT?DCU-,X(NB'(&VY-TL:KR#,XB65V/FK>;QYAKEL\
MCGD+%3$R_1QJ,8P>/N9:1EL7<90@M*KX@W=,U4W"(DD47YD!,1\_15#1FG21
MTY,EY@[':TZV9/,=R./D8]N6!*T5QV+DVI&J<ZD$"*$M"8=D,>W7D#.R&[]+
MI"I(JJ&5624"QNAM8:_TTSF8G",GE\C9S>7H34J5PS`Q6$L?"T$37(QD<@BB
M[DV(H.;;2%!F9L5-,$B%,<+*^+,_6>?)LE\$X`\69^L\^39+X)P!XLS]9Y\F
MR7P3@#Q9GZSSY-DO@G`1[E\PR+E>JP$7H797/"`!%RIJV:\S(YJB5D)0$"AV
M5$*CV!4>S@)`-,,B@81![YMXC2+DS>T!<QJ`5F(F[&QJ4K7S:5O+4,GEV1+[
M@>^Y@H)J1<F;[D#P3VVLQO\`Y"I2E;O,I7F)W!3OJOUS&;\29:67RB:PWZ<:
MWV.E](8_&I>:,S^CF=:>R%5):-339HR3*0^CBC99`[EN#ANL)2'$RJ0*!5Z1
M]&-&NTXM!?J^ZI'"T-GNT,R)E+U1@]V`@CLN)29Y`PBLE;XVUBFTH$ACBX%D
M3Q;HYXB0=QY$BD>(+$!RW[KW(]4ZZUYC,-"[-VC!Z]U1I[4JN:,(F*=3LI)X
M)GNO&9)3)6KN5QT_B.0H1!G`':)KH'<B-!3`R9A[%X/RG"XO$L^PWV_VNTWM
M.3QYHIF]_6^.<,XYMCG%@S1/;/\`CBTTGMGZ8OUJC]S3).>+5K:U>R8Z:>NN
MO768;)LUCL7+-=['Q2*TKN49/*,&S?&XL'<+AR+(9"=Q_((A@#E<NPE.2T%R
MY3O.!1M3H8`I:`=*\4Y/Q+AO)^+Y?><[PW[7:<AM<^3MG>S;LPYL62_;'["-
M;=M+:1KUGIKUUG3STSY,-\=<63NM2T1_A^,3'\QUV_T*MMJ]1*V_$=X9GC)G
M62ZSGU,/0PE^_:MQUS$*1+9O$3I9:,?0ZSAX*3MNX03*=IWF30.#EI*.T!^4
MTX4=*70K"=+NU9#9,?N;86>IR.$9/@J./91`2Q4&[#(<WQS+(]X+QQ(2"";Z
M/%@)WJJ#9JM+R\I)2#M0UR+9D%KMP]1&B--QD4AN#;^NM4*YV9]!8439F60^
M!_2R:[LP`T3COTI7C?&)%/QIM>@W*JJ3F^<7S3``5OB?2;>CEQB,B\8R+KOZ
M08/(<?81\%.0LKU$:ICY*'F8UO'Q\C%R3-YDC)PP?1[U;E+I+)(G1435*<A!
M15*F"XOI5?1EGLIZ0/HT\_EVW=2.HR?=.Z"6Z_+"V4[Z2MU+:'K3EJ6@%]*K
MZ,LUM/2!]&OG`00KU(ZC+[<&XEN`V6`):`Z+6M+:&K2P]H'_`--5]&7V#_\`
M3`^C7M`!"O4CJ,/*!#!6N6=@T4"OK=OK#0$[GTIGHT7:!T&_I`>C,ZIK!*`]
M2FH2!0AP4,(F/E@E"A$Q'V>P/*(<`H-Z57T99;J^D#Z-?-OK3J1U&;V@+B:V
MW+!N[&YJ4K6I:5O)<`;TJOHRRW5]('T:>9S!&WJ1U&;[GWH36VY8-XCW,]M*
MW5)2O,3N`-Z57T99+Z^D#Z-/,YEUO4CJ,_W+OEUMF6&OKW%2VVMU26UYJ5X!
MO2J^C++=7T@?1IYG,K;U(ZC-]R[V!K;<L&^O<CVTK=4E*\Q.X/FKZ4GT::IT
MG*?I`.C,R#!5071_UE=/@)`42>MT^63Z6"9<3JH&H!*C2ANT#%N#ZCZ53T9@
M#0?2!]&G8(A_Q):C'R"<HT$,LH(5(/[/9ZX5`#TJGHS!&@>D#Z-/*`?\26H@
M#M$A0[1RR@!4X?L=H^H-`P'I5/1F#:`>D#Z-/.$@!7J1U&7VXMP+6[+`M"KD
MM:TMH:M+#V@%]*KZ,LUM/2!]&GG\NV[J1U&7[J+0"W798%E.^DNK2VAZTY:E
MH?%'TI?HTB'5<'](#T9@B^51,V,/4IJ#S@!"-2,"A1RP#('(=Z2X#T$H7"-`
M34L!0EZ5+T9RYTDTO2`]&YU%S)$2('4?J2\YUQ:`F2T<K`P'$7J8"`T$HWUI
MRU+0M+K/=VHMTXJVSK3VQ\0VKA+UV[8-,PUS-,\UQ=R^8*H(/V2$_C:DE%*N
MF"[DI%TP5$Z)P,4X%$AP*&_A+LA`!H][0`>V+DP&@E(8.P6=0&AP[/+Y?6&@
M`R[(`$:/>P!$:1<F/8!5#>0&=1&B8_L]GKA4$K.3:H,FI%`=W)LT1,!(V24"
MA6ZR@TL9><-K4_8`5$;0I4Y`,"H\NR)?=WWW/F":D9)F^Y`]$]MK,;_YO4MI
M6[S+:\Q.\`\PR)?=WSW/FW6QDF?[CWZ^VQF:_P#FY6VVMWF6UYJ5X!I=D2^H
M/?,YEUL9)G^Y"\`]MK,;^UBI2E;O,I7F)W`E?2395!1$@.N8)R%"Z/D"%JFN
MI?[H9F)`"C4]!\@^;3VY*@J\795$*/*@(@/Y,D_*!C%_%/)4@]ODIV^00X#(
M2S,1``!YVB`?S9)!VB9,H5JT[.U4/+Y`J/D`:`%EF9A*``\\X2`%8R2+VJ"U
M`MPF:`!>UX2M:6^=6EA[0P679'LIWSW3EVW1DF3[J+("77M"V?S@G==2WS[J
M<M2P$JLHU55CE"`[L[T4!NCI(A@%RQ#DB)#LP,`?AR=PC:"?GW"`IJ`4%1)=
MD>RT'ON@)B6L7)E^Z@S$EUS,+/Y<G6M+?/K3EJ6@%EV1@*(`]\X""%8N3*/G
ME;F+4!9@)>QR6M:4\X!H)#VAH6>R35PEAZ2?>KS[!PT2\Q@_0+3Q-(_G*+-D
MTR#:8.P1#M[/+V<`R]-G_#KH+_<KJS_8:"X":N`ICHW+\94U3LW'I7Z7LT2[
MSZRXZ4DFFOLLDF31LOU+[J4<O&<BOB,OC4DFV:.+@,)7345"BF<A[3I\!H^G
M=;=+6KLAQ^8PR?V?-2\F?'9F$1GH;8$ZSFWL'@V4X_`S,!'J88FT;(EPR=D#
M-T(DK>.Y!`521`J0&`+1!E\7+;-Q8&C3)B<C",^Y@2&&9?#@/-G-<"44QEX-
MB"X!RA`PDNL$2@:EQ:A^]NX9C6X,$RW5>4)S">.;$P[*<.FE6L)WATE'3C)%
MFY5;MIB%E8Q=5-,XB4J[99*X`N((=G`<M\C]#IJT\4Z:ZWZC^IW`99VQ:QIG
M#I^E.X\L19UBBD[*2N.QV.XB:<R%\EB+8S)V]>K$B7::3END!T$P`)MP3HZZ
M:<"G]!3$9O3;4[DW3C,]1$Q@TEF&>,<OGGLEL]TECFR3Y*[F\9>/WYL'EG2#
M8Y41;%:2"@%?E456,4X0/">C=Z-,3CH#',/ZKNH;%H?'?"XV`B(S>$0?N<LU
MW>KGZSDAGV)NUG4[,;B=R22P*\SFR<FZ:"F8Q4$$`W?'NB#I>U9AVX=49QU-
M;3EL4VGB.-:K:-\_V8I&YMK[*\?EY?;+_*L1EGQ$(R(VF[-D>/2#<6T0U\.B
M\>AE"-S$%1=P&L9'Z-#HMR25EG*^_-U,'&WY_,V&'0<?L3'"P7<EFH1DYJ_6
MN,NL%=Q\SB&,1,/W-6%*F_*DFW,+LJBH'/P#VW]$CTXQ1I*3_/'U7A(N>^J+
M3\EE#=5TTCCR,C*)Q)E5M:)LOHS'^*.1!BJ068JJF<G(+@`5`+]].FA\%Z8\
M)E,#PB;VCD\9+Y0ZRY]*;(F)S-<B6FGT+`PL@N>;>1K=RL62&`*\<">\RS]R
MX7,83*B`!/GBC?[Q)?),E\%X`\4;_>)+Y)DO@O`'BC?[Q)?),E\%X`\4;_>)
M+Y)DO@O`'BC?[Q)?),E\%X`\4;_>)+Y)DO@O`'BC?[Q)?),E\%X`\4;_`'B2
M^29+X+P!XHW^\27R3)?!>`/%&_WB2^29+X+P!XHW^\27R3)?!>`/%&_WB2^2
M9+X+P#<TDT`>RH\B1[7#;R14D(_R!OY0[KV<!6;J<Z5-6]5OT!6V!)[#AWFL
MUL\=8L;'&[=:).YV)@,YKB>5R'$\LQ/*\0R;E8[D#@&HO&*BC50YA3.4JBI5
M`T=ET>=..&3&L,AGY/(GN682[T9C.N<FRIEC+;*%0T.PS4FN\3823+!HA],.
M7</DS\D@1*Y_)-VR=QP*@/`5]F?17]-,E-3:ZFY>KEODN3CN9_'D=;8R:3<P
M^.;7B8K&LOQ[%HJ8Q=V=KA6+)J,C1B293#$OCMU^=S^0<`Z98-'LL.@(K$V[
MO)IEMC$%C..MI>>9O'D[*H0L`PCDI*;=-XQDBXEWI&X*.3E11*98QA!,@#:`
M4+ZJ.AGI-ZI-S,\UV3GFQL4W`;!HS`82.P+-`Q>928)LMH2T9(L,?\!?2SJ:
M>`\>21CA<1T7$6AQ3,A&N"F!E6]&STWQ^"Y1@L]L/=TKCN>;9P'9&3.MA'QS
M+93(G^$04MC6/88_G\VUC*2#V(>(S1@.KS?'5"HH-2/BLRG;*!!.0^C,]'^I
MC6M6LQOS846VPG%(H^,Y.[V1A3=_+LF.:R.10F6^-2>&*$=1K.=S%TW:HMC%
M@^<Z:'[N9XRCUD`L)K'HIZ3=<=2$?N_"]E98^VJQR_/Y-GC+N;Q1V=W/9/A,
MJ7,\?=H-\/:Y?(+*-LL7G7J*KP[PQE&(KF%@QCT$0Z3,)%N:/9)\F1"YFV+<
M$7)``7($"H&[K0*5\O`<7-0>B-Z',<@QB-0;FZA9'%$G4$[G([$MGLY6/DF0
M85AD1BL-*.\8P@BC6`6UKC\0S1;I*(ED<?Y"2@K-.2`!953HAZ7H?9$+FTQG
M&POIRSC=&XYC)\DDXD\^G,ZG@6>-X?+,GLGAA<ED\IR^#PH$W-ZZO.%"048I
MMC.Y$5@@J&]&[T+Q!,T5A]PYFBPFL.S6'GVS;)-?C'1^,&R6+,BM+D2P'E2,
M)K/)<?9%2)+B[9GEFYU94KQXY=F7"WW2%TZZ,Z6L9R7#]&9;EN88_D6QE<LG
MO'99ME+F&R)[A#%!9F5>&A(WNWB#!%!X5)<ICIH+I$2L:$;))A='Q1O]XDOD
MF2^"\`>*-_O$E\DR7P7@#Q1O]XDODF2^"\`>*-_O$E\DR7P7@(]RZ6;AE>J_
MP>4[<KGA[(>5,`6:\S(XW"5F(%$0"A0'M,/8';P$@FEFY;O<),;0,(VQ$H:M
M@+F&T`:")A$&YJ4K41*`=IRU`-*MRWU0DQL!01MB)0]>4#L36`1H83B;N1[:
M5N$R=*\U.X(GR&9;([KUL0S:7-77FX_.1@YE=,.[3FKC'O418G(0#@P."=1]
MU,=("7"LE>$LGE6Y+ZH20\OF5LB)0]>4+T#66-!YEW<#VVUON3MKS4[PA7=L
MLW;Z^R-8S67,!,PUU4K>"F%U5.7G&($,**:$8"CD!%L:@D%8!"VAO.*7@)J&
M5;@(AR)(:"(#2)DQ"I3*%&@@TH(52&@AV"`@(=A@J`$JW$:<B2\H!VQ,G2HF
M*7R]TH`5-Y?)2H^0!X`"5;F$H`A)><)0"L3)E`+Q;@%PF:!:`"Y+41I:!3B-
M+#VAPT].9Z+B0])YIS2,MK_+'^,;CZ4-G)[AUY`34*]+B.QF3IQB9\PP6<=&
MAWCN$EY2+B6YHIZ":S=%ZD=%TB*)EEV@<B9SZM5Z';3N%CN'TCG4KE6([#W5
MLK-,M?YI+[=@>GS5P36>S+S-8S7N&,LPQ5@9VMC&/RA2*J+G2>.SM7;D6K-)
M([5J$/%]#E]4N-;3T@F+!?RZ7=>6IR"'-[F);P/%%%.G?B774LM4NIRE;`P7
MT.7U2XUHAZ07%O.`@A=UXZG+2\&XA<!HD!((`Z+4!I:('`:"FI:`'H<OJEP@
M`_\`TP7%NT`$*]>6IP'M`A@J`Q0"`T4"H#Y!J'E*-`E;4GH`_JS6]<I:X9HK
MJ?F=XYL[:OG[+!M;=8.(9QD3]A&IBI)O$8/#L<D)U5I&(>Z+*)IV)@`7B`#P
M%L#?5"_0ZENK'=6(V@<1MVNY-6PK@PVVZ\&\1[L:E*W"8@![<EP!_JA?H=27
MUCNK$;.96S:SD]>4#P366:\&^[N)[:5ON3I7FIW!D_U0KT.I+ZQW5@-G-K9M
M=R>O*[]=99KPW,N\//;;6^]*VO.2O`-]4*]#J2^L=U8#9S*V[7<GKRA>@:RW
M7@WW=Q/;2M]Z=*\U.X,'^J(^AU1_!_!>JI4RRAJN3;:D>:V(V!Y>#8$=?"U6
M[P=O00.`B)+#$'SRWAD?JA7H=0$0\.ZL.P1#LVNX$*@)R]@AKR@A5,:#Y!`0
M'R"%0`^J%>AU$0#P[JP[1`.W:[@`J(D+VB.O*`%5`J/D``$?(`T`+]4*]#J8
M2@$=U8!=8`7;7<%`+S-BA<)M>!;0711-6EH%.(TL/:`7ZH5Z'4]E([JP"_E4
MNVNY)3F]S`M]VO`LM[\2ZM++5+J<I2T/RG]43]#JO^#A"]5:)D3)"#D-LR15
M7)'A(XR97(+Z^!JB9L9Z`"!``2%!05!JD<$PH'Z1#ZG=HB1TLVG/1HY5L>`W
MMC\LU<.L&WYE2\OA&QL;DE8AL[8(9*3#XQW@^20!'W>VZRA7+1T1-PV632.4
M'#</3IZ)7H,A_1A=#6INDA#-)O94YBZL]E>;YD?')&,BY3.\[DR9#DR>-1PL
M2NF.*QKV2*V8E=&.[.@@*BXE4YB:8=)?%F]*\B3\@#_-$H`]I2&\@M*@(`<*
MAZ@U#R@-`/%6X`(\B3[`$?YHE!'L`YNP`:#4:)CV>J(@'JA4$;"4;I1[0#-I
M,+&B0B4L-*U"Q!8PE!,(Y`UU&Q@`O+((B)``H"<@""PTLW+?5"3&SF5MB)0]
M>4#P366-#7W=Q/;2M]R=M>:G<&3RK<E]4)(>7S:V1$H>O*[]=98S-S+O#SVV
MUOO2MKSDKP#2K<E]4)(;.96V(DSUY0O`-9:T&^[N)[:5O`R=*\U.X$4C)(&:
MK$[O)&&],*>$29P$2.%`&E(YR!@_!C"`@40$!((#YY!$%OBK>M.1)>40_FB3
MIV&,7R]T\E2^7R4H/JAP`$JW$0#D205$`[8F3`.TR90J(M*`%50J(]@``B/8
M4:!@LJW-;1"3"X2`%T1)EIS!;`%US0+``71;JTM`IQ&G+/:&22K<]E$)(+Q3
M`+XB4)3FBR`MXF:`"=._DNNI9:I=3E*6`B7DVZB\68&\EYSN@70TJ42<]@`E
M,I=&GY!2]^(!S&,D!!*H4QJIJ$`%A95N:RB$F%X)B%T1*$IS0:"6\#M"B02]
M])=6EHE4K3E*6@%E6YK1!"3"X"B%T1*%I>"`A<`M`$H@#@M0'R"!@'VAZ!H6
M>R"+A+#TR)/BB;8.&F`RT<_;I@'B:1O.47;)IE&AO((AV]GE`>`9>FS_`(==
M!?[E=6?[#07`35P%*]'9E"?FKVA`2T=G$>R1WIUEL9.=;8;+JQC9BMU*;I</
M)5A+.HE]!NF[-HX,8%#E61YJ9B&(<0$@A!NK=5]%&,['P+,]>91L&9SC'GC5
M:!:A)9)D*&0RQ=?.VR)T(1Q#K1[1TI@<@#D&T(G'(%8@F)$BMC6'"[R>7M)?
M9N+`A"Y<UY&$9\!AE,4G(DIN;-ZY$HI&D6;8%@+R1`UM;1,6OM@X"1'$D09*
M-'NDEV)/_P#L#CU2M_\`D\`YA)$$0`&DC41`.UBN`=OKB)0``]D>`XW->A#T
M<6*3N23,KN.7<GR"0VVYR&+S;<F*2[(^=2^5%B-NY8F;(8U:6A\MB]FS[D\H
MBU<MV+#)I03+-".TV0-@;T^@WT>;_)\RW.AO^;=G<RD_FV>OT,_TNZPM*,Q7
M8\/G&9-9B,+KQ6!@<0B,D.R93()%:$11<<IRJ5P]75<!MK3I'Z"-B;LR7>F$
M]0N226S)'92&W<I4Q7;^#YO&AG&UVC;",2DW&-9!C^91T.C-XVZA,;@T4$FZ
M;MC&1;8H+JEN6#56_0YZ.K,L"PS4^"]1.9-,9TEA)\7)'81OW')Q[%ZRQ6?Q
MC8\;#2IY>/R@V%P6'2F,1,@M*0Q(20?`T36EWKXQU5%`40OHQ>B':K2;FTMX
M;WW(TV=`*2(2OYWH;*(N2C9-=U%.\D@6V.XBCCZY9)1N_CU%B(*MN0JZ8%(5
MN'=TP[$MY9@V;H-R$?B1`B;4AAC')!$4N6W`HD2;))$4%02EM*4H`8P%``J`
M<!]@G&0C0$WPCV!0(]X(B)C'(4``$>VXZ9@#UQ*(>H/`?0LJB<I3D;2!R'*!
MB'*Q<"4Y3!4IBC9VE,`U`>`_7B9/Q.2]X./M>`/$R?B<E[P<?:\`>)D_$Y+W
M@X^UX`\3)^)R7O!Q]KP!XF3\3DO>#C[7@#Q,GXG)>\''VO`'B9/Q.2]X./M>
M`/$R?B<E[P<?:\`>)D_$Y+W@X^UX`\3)^)R7O!Q]KP#<TDB`]E1[G)=KAM3\
M`<>HQ;_\GR\`X^)D_$Y+W@X^UX"N?4+K736V76B3[<FI/&U];[_P#:&KTDY=
MGC2V3;5PXDM)8KBY>_M5GN0(/1(LX5BV)DW+TC2T3"B"J9PI)-^BJZ/GL_,D
M>9YU%LLHS4VZIUHU7V_//'[7&]H1,1B^?1&+0L_%R:"&$8VV?,2L42-U$H5V
MX;K$.1<43@'37!HQEA>/Q6(,3Y+*,<6@L:QME)S22K^9D6D'`1\8W?S#U-LV
M([E7:+8#N%`23O6,8;"UH`<[NI?HCZ)^HCJ:C=D[0V%E6-]0JV$P&$0N,XYL
M2!@I9:*8P&YG>./T<`E(>75FWPXE,9R)2N6SIF^AB2Z2Z"[$C],0V^+Z$^E'
M6VM9S7DKD&QOHUEFPL&RY>9V'FRLC/!L?%9*2?8Z_A\BR.,YK;*9)"4%DH=(
M1>N8]%)`I@33#@(!@>C7T:NNHW7CN0W<S>0>.:SCXB'-FVU=8N(;+]=);`#(
M&$C)G<0+)M(XJJ_FW$&(,3-H9Q'R9VZB)W`-ED0E?6'2?T3X-U+LMNZ_V>_D
MMV,<RV&[:8@EG.#R3I7))W"Y93.L97AV>/I9DN"33,G,^^9G>"N#ARV5<B=F
MSC&[4.E["03-'LR"TD@`S-N01[BN%*H$"M1+0/V>`XH:7]%)Z.7Z/J,=*;2V
MCE.(L'4#(SC3"MRQ.40CMFYP;"@Q.+FG<!`NS-,>=:OBX5-NU16:H2>-G;)K
M@Y8"W*4++;1Z-NC+*,BU8RSC,9['\VU^TZ;<3QG_`.-H:!SG)#:1_.4IIUC.
MN7T2.33LMD)Y^9,H*1DUY<(X2)>YH."&"OD1Z/\`]&@T>9E/1&Y'8@MA>>Q\
MZ9GMK7IHG',86R&$CG,P_9MH`(Y1MK.;QV-8-'$R1XV0=-2A(@[=KN5'`7=Z
M2=,=/N@<<R/'>GK*I+-,=FL^;362G3F\>R="(R9'6\)$D:G/B<3$LVTA)X^R
M8OW!W1%7SH7)53JF1,@4@7+\3)^)R7O!Q]KP!XF3\3DO>#C[7@#Q,GXG)>\'
M'VO`'B9/Q.2]X./M>`CS+Y4A<LU7^`RQJY5/#<6-<F*6W7F8FH<P%\T34H4/
MW0]G`2`,LF`&'N4J-H''LCG(B-@.#4*%O:)N[C3UQ.3[(.`#2R9+_P`"E36`
MH(VQSDUW*!Z(V4+YXG[D-M/;<Q.GW0O`11D$P1+=6MB^&SBO_P`O=Q@*B$0Z
M613[O-ZO,(K*E+:F"_<!!(>WF&52`/NA:A+!Y5,E_P"!2AK.;6R.<FNY0O@&
MRA//O[@-M/;<U*GW0M0A;=LHFAKW(U0CIE<2YAKNJ32&>+.%>5G&($N1*#1`
M'0'[N-HE46[!+YP5`A0FD90@"(=RE!H(A4(]P(#0RI:@(%[0'E5#UP$OKAP!
MXJ2H!W*4[1`/YO<4"HE#M\WR>=_H`?6X`+*IFM_`I0+A('G1SD*7BV"IJD\T
M"]Y"M?(!#_8CP#;+R2:T/)D[A*&YT8Z+8>*<J5YS9N6TZ/<9`3T[\%Q>[K_<
MU`Y9[#%$/.;]8HZ5.FKJV]'3KG`M[=46NNC[-\'R.&S'IWS+=4]&X%JW+MJQ
MVNWD>;6>4K2T-CRZ,?D.-S+HH*,&#5[%*-3.NXG0:.61@\]?2!Z+SZL3B&@\
M%C>LKTD&J-N]1KUBE+;(R'7W4>IA.OH>8E$X]4<1PV-CV1'#Z"QD'A4/$GH@
M[D%DW#@R35.C1L%F`]'3]3H$"C^N7BX7`00KU?3("%X-Q"X!;5*)>\A=6E!*
M>OM#4!#)^C?^IY/HR09L>MW'X9Z\8.FS.7:=7#QP[BG3EL*;>2;-I.->QR[E
M@JL50B;A%5$QR6J$,6XHACZNAZ.'HBZ9>NW9^X(#TE'3EU7;1AVFPL)Z6M5Z
M$S*/ELIR/5D@R9JY)MG9V(<B1G(V>3@1,S"&9)NV,>H"SD[YP!V_*#WG&EDR
MW?@4J-MX^;'.35L!R(VT)YUW=A`M/*)R4]L'`!Y9,E]64J:P%!&R.<FNY0/1
M&RA?.$_<1MI[;F)T^Z%J&3RJ9+_P*4-R^;6R.<FNY7?ZV4)Y]_<!MI[;FI4^
MZ%J`>53()P[E*&LYO:2.<F`W*%\`V4)YU_<1MI[;F)4^Z%J"1S(IBY9B+*2$
M4%7)OYL<GNM0>HCRE`9K%`3<D1#W1*XIRT$UP%,"L90@"(=RE!H(A4(]P(=@
MG+4/-[0'E]GL"'K\`!*D$0#N4IVB`=L>X`.T2!V^;V`',[?8`?6X`+*$-;^!
M2@7"0/.CW`4O%L`"81+YH%[R%U?(!#_8CP`253.)/P*4+>*7:>.<%`O-%D`7
MU+YMG?@NK[7EJ5^YFH"-K))"Z=B#*3*+A1FIYT4[3M!5O&I%!50S)$HG3[T%
M_NBPI@FI42\LQ"@L)*IGL_`I4M_+'SXYR6WF@R$+ZD\T2=^"ZOM>6I7[F:@8
M++)F`H]RE0N`@^=&N0$+RMC!=4GFB7O(`;UA(?[$>``EDQ`![E*]H`/;'.0'
MM`AJ"%O8(7]OL@/K<!D95,`$>Y2@T`1[(YS7L*H;L\SRCRZ![(AZX<`C8R::
M4>T*#*4$$V:/82+=$]HW6,)2I"S9F*;\%$H%Y*=1,0`*%Q0X!8>53)?5E*&L
MYM;(YR:[E`^$;*$&^_N(VT]MS$J?="U`/*IDOJRE#6<WVD<Y-=RN_P!;*$\^
M_N`V4]MS4J?="U`-*IDOJRE!LYE;8YP:[E"]`;*%&^_N(VT]L"B=/NA:@CD9
M%,[59,64D(7D`1&+=*E]S<*!6TK-Z)BCW41`03-V'(/8!@,`+/%25$.Y2G8(
MA_-[B@T,8M0\WR>;_H$/7X`"4((@'<I3M$`J,>X``J9(M1&WL`.;4?6`#>L/
M`!94AK?P*4"X2!YT>X"WF"U`+JE\T"]["[U@(>OM!X`)*IGL_`I0O,Y5+XYP
M6WF]Q`+ZE\RSOP75]KRU:_<S4!&M))J+19^Y28"+L`*!XMT)B=XCP\\YNYK%
M;E3!\`',8Z-!(H6X;#$,"LLLF>S\"E2W@F(71SDMO-!D(7U+Y@D[Z%U?:\M2
MOW,W`9+*IF`H]RE0N`@^='.`$+P;B`&J7S1+WD*^L)#_`&(\!H6>R!'"6'IE
M:2"8FV#AHWKLET4R_E),_GJ'*!2^VI_ZW9P#-TV?\.N@O]RNK/\`8:"X":N`
MI3HW-8U'5NT8:4@L^9Q[3>O64VDLA90*[:/1CS]2>YW;V6BYM4_=!29-%S"5
M;U%DC%`HF+00AC4,/T=8_F.(/]:3N<2\\SG6#N!AVBZ;MI/9(QUW)ND3*L6C
M!J26G4L.R)>04$AN])-W"2(B1D1NT(%U$<N3E]FXN!,<R]AR,(SX!&6QYU'$
M/S9O7)@%(S@Q04`G)H:E;1,7U^`D5Q(UDHT>X278D_\`^R^N5O\`_7.`<PD:
MB``PD:B-`JV``[?7$R@``>R/9P'#;-.AKT4+@9YMDFV'4,$EE6?RF1,W_4HS
M5%SLJ`S5/&=J3[I+))Z471RN/V%+R#.;:IV-&\S,.^8U(Z*@9L%D&_3UZ/+/
MC;(GX_)XK*EI_3&Y->;6DHS=@2Z;O5.1[>+L':4IE3-IE;B.8EB=A0ZK=:=,
M@BLV0(=H=P*:9"IAH6):0]%'B^.YMK:&F-;/6.Q\DTI*Y-XGL>-FG\TFD\U_
MN32V`Q\T\F%P-C64LL1A)-C"M5!/.,3$6,5QSBJB"S!NA/T=K97)=2:MDWD3
MD>`X[F&N=MQ.*[.CG&;2.#[4A0AY?7^R7#YS(RZ&-=S:"5FW;BQ-'.RJBF=-
MPHXY@35)]%O2_NF8P;+<FE=A;;R?3)PQ]IEA]D*.94LZ?*"[:4?SCS#'$0V9
M90Y=985=)RQ(P50C7Q4VO)0,0.`C*,]$ITE-6.0(RL?N"=E<ER]YE3[(G.8.
M6,RU2=Y)D>0#`1#J,1:&C&@I9(=LK(D_^(%S-6;Y21&39-'R`93]$CT@IOF,
MIX9N@9*/<8@X0=DS=5L(?0IO-,8IN#5FP;,$&KN.G%4'Q$4D@>@*BJM5WD@L
M[#H#IS7F+Z-U5K_3V$L\I/B&M<5A\-QHT^X/,3`0L&T391Y)"24Y9G:Z;=(I
M;K2A0``"@```!)7B7_<)+WK_`.\X`\2_[A)>]?\`WG`'B7_<)+WK_P"\X`\2
M_P"X27O7_P!YP!XE_P!PDO>O_O.`/$O^X27O7_WG`'B7_<)+WK_[S@#Q+_N$
ME[U_]YP!XE_W"2]Z_P#O.`/$O^X27O7_`-YP#<TD?PV5'N$EVN&W_9?68M__
M`*YP#CXE_P!PDO>O_O.`KAU#X3H[8SK0_P">J07A%\*Z@=?Y_J1NYR!CBRF1
M[BQ4DM(X5CS?O*Z3K(CK+D4=!%MS`=X=H4I@.F!DSA1N=]&+Z/56=FVCY3,H
MG)L\-NO+!15W8^5=>";*B(G%=G(0L5/3<E%M\.C(R7:(-VW=SLX<[E-1`$E!
M(<`Z?8'&1N&X[$8C"H3SN&Q>`QC'8AW(K#+2#J+A,?CXQ@X?RAE3'DGRS5L0
MRJYA$RJ@B8>T>`YT]3W2EZ/S?'4PQRO=N5##]2#G!8+#X>"1VO&XQ.?1YMC^
MYY_&I`F!2,@HPE#(XPTSERFH]9.6CF+9RR:Z:S(CQ(0V^'Z-.B'4FM)_`3J.
M(7"\NV-@LG*/,GVB@>07VAC4C(R^*E;9+*S02#?-7B<L=(0(L$DYCB)I`/(2
M(!0@3'.G[T6VKH[74B7<<$G$8]K"/"!4R+>6*KQF4:Y;Y\7(&$],("_;M)3&
M22LJ\AQ!(J,0:,DG+)1$2`3DA*NKM`]!.+]3<?L+6NPD9'?;#,-BJL</8[2Q
MJ<D@R-WADHIG^/J8X@LMD0-F2&9R$[(,A5*3Q*2!=R!RMF*30.FS"0NCV9!8
M25!9MRC^#`7RH$#RBH`!^SP'$/37HW?1/ST`(:9RE7+L/AW$+,S#?'M]L,GQ
MYRW?X)A,]C"$PX\8>@C`CK)&$73:I*H-7>/+-B.BKL!03*%F]H],?0=/9#JG
M&\]R)I"9?@#+IKQ/#(L=GP<+E\LTU.&RE-#QDF!Y$,@EC3:LM-*(G`Q#S0Q]
MH&43;J$$*]Q'2-Z*5-]F>30VU88ZR6%9XVG73'?&*J-,2QA7((:'7F#$;R(M
MVJ>MI.&B8V)6?@X28BR0*H595591<+Q=(NM^FS4>-9)#],N0GS#%I'8"#[)U
MHO*87,V,5E+;7$''D8&=0!B-$9)WCJ#%\Y.OS7[H[H%5E3E,D!`N?XE_W"2]
MZ_\`O.`/$O\`N$E[U_\`><`>)?\`<)+WK_[S@#Q+_N$E[U_]YP$>9?)TRS5?
MY-EC5RJ>&I&52%MUYF)J'-S0M$]*%[!J/`2`:4M`P^'2HV@<:%:5$;`<#0ON
MG:)^[]GKB<GK]@!Y2R_\G2IK.9[1I==RP>CYGNGG<SN?F^OS4_LNP(GR&7Y6
MZ];$\(G5JZ\W'[JWCP50)W><U>:JRHKDY8..X6I#0;S+)!V7U`)9/*67_DZ4
M-8*OM&E;^4+X*D]T\X%.X^;Z_.2^S[`A?=TF#?7F1+!%S+@P9CKP#(LXP57*
MO)SC#R`=$HIM2N04!OYH@JKV&*`F+[0@30,I01#PZ4&@F"H-*@-IE2U#W3M`
M>74/8,7U^``DZB`>'2G:(!46G8%3%+4?=/(%U?V`'@`LG<)0\.E`N$@5,TH!
M;S-PJ8>9V`7O%1]8"'^Q[0;9>1YT/)D&,E*+1KL@E48<T/=FJ!;5$>[R7,`O
M??.+W=Q7E*!RSVVF#SK_`%A_IHZ3.J7T=.O]?=2W4MAG2#EV+3\-E'37L+:4
MDEBVN)G<,9KUTT)@&5-#0D*N>!R+&I9XBJ+2-9O8H6YGB3,Q&BK!8//IT>=!
M/U4W7?3_`(%C_6#UM:PZ@.HI=@E*;,SJ!W7N/`<.9STHE'K+XKA4%AKB`;J8
MIC!G7=T7SY,\A('27<J@@4Q&;8+.!TB_4M3`4?ST8`%P$'MZGNI0!"\&XT-_
M\3=@E[QV^M8?[$>`0R71W]2]?QK]DTWWAL*Z>L7+5M,1W4UU!JR,0NY;\M&2
M8HS$O*Q*CU@HL"B9735RW%1.BB2A+B""3ZNEZ/\`]'=TV]<^TMJ8)Z1_3'5O
MN!)'8.']*>LM22BZ&1N-..V;1UDFR]GXJZCE9$<U/"%,Q-%M".(J-*19UWER
M==`&0>\$TI:!OR=*C:!QH5I436%<C0ONG:)^[4+ZXJ$^R[`#2EM_Y.E36`J/
MFM*W<H'HT)[IVBIW+S?7YR?V78&3REG,_)TJ>SF^T:`:_E=_^Y^Z!=S.X>9Z
M_.2^S[`#REE_Y.E#6<WVC2MW*%\'F>Z!=S.Y>;Z_.2^S[`2N9`!<M#"PD1%!
M5P<H=Q,<5*(OD1!$X(K%*801N"JB%Q#EH)KK!!5XGVC^3I3L$0_DG8-#'+V>
MZ>0;*A[`AZ_`9\3[0#P^3[1`*]T[`J8A:C[IY`OJ/L`/K<!@LG=;^3I0MPD]
MLTI;>+8/.]T[+>\U-ZP)G^Q[0"2=]GY.E"W\KV[2VSFBR#S_`'3S>7WWSO6Y
M*GV/:"-K(!WET8(Z3*+E1HH:Y@*?+YC>,2`%E!11*8Z8.JGHHO85%3S@ML`%
M992ZS\G2I;P2'SFE+>:#(:']T[!3[[YWK<E3['M`+*7`7\G2H7`0:&:4$MY6
MPT-[IV"3O-#>L*9_L>T,^*=@#X=*=H`/\D[>TI#4'W3RA?0?9`>`P,I0!_)T
MJ-`$:`TJ(T*H-`]T\H\N@>R8/7X!*SD018-"ECY,X$9("`)L#)AYK=8PD*D=
M%B8IJMK0#DI=IR!:6Z@`K/*67_DZ4-9S?:-*W\H'P^9[H%W,[EYOK\Y+[+L`
M/*67_DZ4-9S?:-+K^5W_`-I[IYW,[AYGK\Y+[/L`/*67_DZ4-8*@>8TK?RQ>
MAYGN@7`IW+S?7YJ?V78"20?@HV52,PDJ7D`3"Q%8GN;A2AK"H/3&`PMJEHD;
MVY!\VMQ05C)T&GATIY1#L:5#L,8*_=/(-M?V!#@`).H@'ATH%1`*BTH`5,F6
MHCS.P`YE1]@H^MP`64N$H>'2A;A3]LT``+>+4/.'F4"SO53>L"9_L>T`DI?9
M^3I0M_*]NTI;S18AY_N@V\OOOG>MR5?L.T$BL@"BL8H,?)%'O9``JC`PF)WA
M@%3F,"+@J!4.^6J"*B-!34`#&ML."HDI?9^3I4M_+]NTMMY@,A\_W3S>7WSS
MO6Y2GV/:`64N`H^'2H7`0?.:4$MX-QH8.9V"7O';ZPD/ZW:&AYZ_YZ6'I]RD
M$;M@X:-Z[;EID_*29O=#7C;Y:>KYW9P#-TV?\.N@O]RNK/\`8:"X":N`I7HS
M,B-M7;/C'^'Y^6)9;UZR4I#(HX8>(9^'!U*[H=OY.)F5<GC7C0K1NJ<".`Y*
MI%TAL[0*(A"&KHCHO:;!U_DNN<>R.7SF&?%0PHS7-8*754D76"O)!PV)'CG:
MC=63=XRJL]6*9,');N1YB5K7@+MI90ZE=FXL!\/RZ)Y6$9\`#+-(=`JP*3>N
M3"9(S>;=5!+E`!JT&IRTKVB`2*X?+>)QOY+D>Q)_V48]OFM_^_=E.`<P?+"(
M!X7(]HT[>X`'[8]^[.`XAY?TH^B#3-.-\CR>!A`?93GCC(F+GJ<>)I.]DXAF
MB>&;)FY%A([,=D'-X;-W[^.E`L`Q'\I("9+GF.HD$VPN-^C<0Q/<\2SV'`3\
M1,:YW,;=L@;?9)F>'5>4YQ');:^D<TPSPT\RQ\D_!MXQ9=-1-<B1A*503NSJ
MKA&NMM#^BJ?#,--:9BS=Q$!EV@MC.(&-Z@9`8S%\PQ,V,X!T[3B#IUG1)9-S
MB[F0A8B(;KNUT&;L[1%5(K@Y0,#2ET]^BCVSDN0S$!LE62/C6+9#/N(#'.IV
M8:8O@>OD)%[L/8<GCL4.P2L\<PN=RU\>?R!ZU,#=U+-RJ++5;<M,.B'2#J[0
M>E](8]C?3%%R"NI)5=6=A7@9&ME`/G)&;#&G*PR4S,.GJ2K=/'$VZK<W+[NJ
MB8@ID.!B@%GN_K?%<C_X'X=P!W];XKD?_`_#N`._K?%<C_X'X=P!W];XKD?_
M``/P[@#OZWQ7(_\`@?AW`'?UOBN1_P#`_#N`._K?%<C_`.!^'<`=_6^*Y'_P
M/P[@#OZWQ7(_^!^'<`=_6^*Y'_P/P[@#OZWQ7(_^!^'<`=_6^*Y'_P`#\.X`
M[^M\5R/_`('X=P#<T?+=]E1\+D>UPV]1CV?@+?\`[]V\`X]_6^*Y'_P/P[@*
MU]1T)H3)SZ,5WZ)(L,6Z@=;Y9J`LID3/'$9/=\4[=I:XBD52R[0)AXYFGA3-
MHXY^6\>)HE$JG80P4>GO1Y^C#&8GV3[#XF%R//#;IS1]9N]1%VX8[$AXS%]M
MN&320V(YC6^->"S39L9GR>X1R;H#())"-P!U`P.-B\3QZ)Q;&XV7/CN-P&,0
M$"9Q(H3+@T+#8_'QT6+B8=2SMS++BQ;DO<J*JJ+FJ<QS"81$.>/4YT_^CFW!
MU(,Y?J!=0+3J45P6$QN(8O-QI8=DS?%D(+<.6XS(-\3'-8^,4[E`XSFL@W=N
M&:J9FD=(@<3H$73$-J@>F#H'U)K7(,&C8;',7U_E&P\'1G`>[?8)=\V;`R4C
MD.'QXY`\S_Q-',55)=8Q4B."OG#.THW()$`H0?C6M?15ZMC]=RT=L'%V49C^
MLX^2QE=]OUN]8S>O4,]+D,=DTPR#-S-I:&;3[UXP`ZR0,DXU\]8F3!J)TTPE
M+6>K?1^0W4I'Y3K')8A]U",<OV$K'8O&;B8Y#*H9,EALJ7/8H,3+EL@X091S
M3,Y25?-0(5L67EW#A8#+E2!`.E3!ZJ,<S*,7(B`LFX"/X"7L%`@5J+\*=G`<
M3=2=#_H=LG@@=ZB3PS*<2A',1D4B2(ZA@G\>6!YA.%YMC:LN+[8[M%2*;:]<
M0L@@W`Q6O@[E`%B':F3(`6)V5J7T=T[EFK-<9Y(XLUS;`FG3EBF`X>7;44QR
M=PQUPTSR3T%#F8-<Q\6F$Q;3TJ]3,-RCY%))1P<Z)$JA"45H/T2)G^7Y-#YC
MABSQEAN=IS<BRZA8Y8V)XNZGH>&>R;15+/#&B"80_C(F.@U!$0C$F;0K8.V]
M0+L])6'],F`X]DC+I8?-\CQ1WG[8V5.('.([.H]AE3+6\*R0C1D49Z100??1
M@C%TXN.=RLHXYBQS&,`%"Y7?UOBN1_\``_#N`._K?%<C_P"!^'<`=_6^*Y'_
M`,#\.X`[^M\5R/\`X'X=P$>9?(K%RS58>$2IJY5/#4I8\2A;KS,34,(R)1`3
MB%"T`:B/;0.W@)`&17`##X1*#0#B``$?4UH+B`%K(!VG%$`"M.U0M:>=:&32
M"Y;Z1$F>WF4M"/\`/Y8/*`2Z0+]U[J6VM/NZ=:>?8$39#*+)[KUL0(2:6KKW
M<8`H@G&F2+R)S5Q@%0RDHD8@.>YE!*A1$3.$KK0Y@IA+)I!8M](F3/9S:"4&
M'NG+%Z!;+GY?NO="VUI_*$ZT]TY80KNV150U]D:H0LPL)<PUT'*:H1QEU^7G
M&'E*=$%';0BH*@B%HF4,(`<H"):&(F$U#(+`(AX3)C03!4`84-0R@`(5?AV&
M!,!#V#A[-``D%A_\IDP[0"H@P[*F*6O8_$:`!J_L`/JT`0`D%A$M8F3+<)`$
M1!A0MXMP$34?B-"<\1&E>Q(]*^;<#9,/UE(:4*,/)T4C'8"4R<<K3F-4`,4Z
M7/?`I8#LUQ>2L`\A0`(?S"J!YT/K$6B^BGJ%]'7K?7W5_P!1$=TD3L=D4+-=
M,FT\I9R:N$GW7':Z=I-\3R^!QR!!XMB4]C,B^0>&3CV+B-*W,Z01$R!63D.`
M?1KT]?5%].]/^"X?U4]2&#=4._A9I2FS-J/9/JNPF#4R.32CE'N/85C6"?1:
M/987C1W(MVBKI%:1><A=PLH45$VZ06C+B'U)0P%'F:Q+<!!\[/NN,!+>#81N
MIE(T$G>!`?\`JC^6@7!]DM1?4K<]36Q''I77D3-Y*CX!$R$9L[K&CIMA)SA2
M1L>[A%,CR1U#FEVCQX4R'>$'"`+$`54SIU`P7I]#9]6YQST6W4[N#JDSG:TY
MN/)&+G*,#Z:F$3&MH)M`:HR<K0KW)]G->\+I2^S)%F4T:+-H`Q#)(AW1155=
M)DC0]59I%<MWY(E#6@>@%"/\ZP'`@!:R`=I^0`!6G:J2M/.M#)I%<M](B3/8
M"@A:$?[IRP>B`$ND"]JO="VUI]W3K3S[`#R*Q;Z1$F>SFTL!A[IR^_6V7/R_
M=NYEMK3^4)5I[IRP#2"Q;Z1,F>P50"T(_P!TY8O0`27/R]BO="VUI_*$ZT]T
ML!&Y?*BZ9CX5(B**SDQ/<V)N:((/DO<CBNH"8F*D!@N.C4JA0J(W$`%@R"U1
M#PF3&@B%0!A0:"<*A^'UH($`0]@P>S0`)!:H!X3)A40"H@PH%1(%1_#ZT`#B
M(^P4?8J`$@L(E#PF3+<)`$1!A0EXM@$34?CV)]X$34KV)'I7S;@"R"QK*Q,F
M2_E5N!A[GS!9`(GM?F^Y=[-=2OW!2E?,O!$T?JBZ>#X1)$%95F<]R;`O+%1M
M&D$%3E<$YAD0<F$UIUJ`@H`#[0I@6ED5S65B),EX)B-P1_N?,!D(@>V0-VI=
M[-=2OW!2E?,O#!9%<UOY(E"W`2MP1_FW@W$0-20'M3YX@:E>U(]*^;<!XBM2
MOA$IY`&E(^H5*0:?SAY0$U/V2C[%0!D5P`1\(E![![`"/J-`.-`_*%*B)``/
M9,'LT!&P?JIQ[,"Q$F8"LD1`I$X]/VK=8W+`@N6@$,(H`4`Y:855)V%"ZP%I
MY%8E](B3/;S:6!'^?RP>B`$N?E^Z]T+;6G\H3K3W2P`\BL6^D1)GLYM+`8>Z
M<OOUMES\OW;N9;:T_E"5:>Z<L`\@L6^D3)GMYE!($?Y_+%X`"2Y^4?=>ZE$M
M:?=TZT\^P$4D^5,U5(:*D1+>F`F%-BH00(X4`#6<]R82GY!1#W,:`J01M\X2
M`M\06^*9/RB%:,/4,8*_R^M!`M?V!#V:`!(+"(!X3)A42A4084"HI@(C1^/8
M6\1'V"C[%0"R"QA*`Q,F6X2`(F!A0EXM0$34?CV)]X,)J5[$3TKYEX!9!8UE
M8F3)?RJB8&'N?,%D!K[7YON7>S74K_)U*5]SY@(UGZIUXLPQ,D01>`%#IL#&
M2YT?4YSF*X7!,J'>C%.)3$&J*@%$P6%5!8217-96(DR7@F(WA'^9S`9B('MD
M#=J7>C74K]P4I7S+P`D5A`H^$29:@01`0CZEN!N(@:C\>TG/$!I7M2/2OFW!
MH6>O%%DL/(>.?MP-L'#1YBP-.64?$TS6GY3Q4X#VB'M1"H?L#P#+TV?\.N@O
M]RNK/]AH+@)JX"EVC,M4:ZLV:Q?X+GRT,SWKUE$?3D2[QN,17C0ZE]TN7SZ'
MD"YI%SC0R*"AR)JE(W<D73$4Z"!#"$$::F.BF*S7$OS18CDWTLE<F(^Q^/C\
M]CG24UE[7!)F746>0CK:2D:_R)KBDT^=K@Y0%RV5=*$/RU5.4(7B3R20DMG8
ML"^%Y7#\K",^`HRHXP!5[YS7`F%$8_)I`?<>6`&N`HU.6E0NM"0W+UQXG&#X
M5(?<I#LOC*CYC?R?E&G9P#F#UP(@'A,@%1I43QE`]D:20C0.`X:9?I#T,;+Q
MU#)'.,0J;C+<\2R5F&]LL1;.=DX1FGT$V#)2S`NR5VZN>1>8*2#!TJ9/O+A5
MY*+$!4#.UR!(>/XWZ*=NZW_(LYZ*R%Q(Z[V*OU"(9!N')\I..!O,J@"YU)Y5
M&SN=/U14.[90[#O":9GSJ*,R*F*S9VFHX!SP@_HFF,-F&K,.QG7;UCF^?ZE+
MF>.A&R$P_FLD8?1':6K<4EEI!=W('P_'F&(Q,BI#'4"!AV*12OT6Z2IRG#5)
MO%O1`ZA2;ZQ=/<)UNO$GV%KW(X:`V=,0\U)1^5KR.NLZP?:TOC^9FEI#&5'V
M(K1R;:><@S9+M"]T%(QR&4#HYIO:.H`<-]*Z\RK(\QG\7Q-CF#LL]D\IG>0J
MPN5%C,F:RT]G&03,L:0EY9GF3&0[HN^%X@PDFBG(1:+-JA8/OSCXID?W\7\Y
M<`=^<?%,C^_B_G+@#OSCXID?W\7\Y<`=^<?%,C^_B_G+@#OSCXID?W\7\Y<`
M=^<?%,C^_B_G+@#OSCXID?W\7\Y<`=^<?%,C^_B_G+@#OSCXID?W\7\Y<`=^
M<?%,C^_B_G+@#OSCXID?W\7\Y<`=^<?%,C^_B_G+@#OSCXID?W\7\Y<`W-'K
MCOLK^2I`:N&U0OC.S\!;>6LB`<`X]^<?%,C^_B_G+@(:V[D^IH9]J(^VCHQ;
MQWMN!8ZH:R\PRCDIK;,A"9)%XS%MFQ)MNSEY%5I(.Q9H.P.@5^""I`!TFV,4
M.;4YT<^B0)+Y$Q?8?K2$G\T-NS.)A=OO5DQ740SF$C,=W,\%P?:YXJ,B'&/3
M*""[$W+:-6JQS(($(54Q`ZJ8"RA\:QR'QW$XF0^BT#C^+PN-AXJTFA+`16/Q
M[&'`TR[G'SJ6$(Y!/\)47747]N90XFN$.<_5'K7T9FP^I-FMU*!B;/J7/@D%
M#1?C6UGF$9#'X>2#W'FF,2:+1'.X3'F*<=#8-F<BVD5TP!$D<[`RE#`FH&S8
MUIKT=.L-9Y%AV-PN!0.M<AV)@L+DB$?N",>-5]G14G)9)A,*]F6NS'<FRRL[
MF6<+IHBX3<K-C!?<BF2T(4Q:,]$WKB.UU-8]/12,=!:RCLAQ)5#:&6SZ4CKM
M'._I+&Y-,Q;7+WX231GDAWJ)3/D/<(QQ(-13+']Y3($IZOQKT=37J9CW^K)"
M,==1S3+]AK1>/1VRY::?-\FC,/F6N?($QM7+G\8A%QC3*Y=T[`$BL`G)5\H(
MF?WE2#IHP>+C'LBC$R`E%DV`1OC0"@H$J-?$@$.S@.'&I^G#T)&50)9/5+35
MDKBD*YA\E>4WZZ1@G!W>$83L3'WLDCE.U&R4BRC,$E(6232H9NR8N4B+$(4>
M44)]S33?HU8W8&"MLK-#0V;H1^@X/"(1/=3MM=&-X4T%I0S&/C]BG9(-<QA=
M4M6Y7_N83*>-M"+K*@0H*A$D3@?H>'$CEN00\SAZ\FQPS.!FG[7<<RH]QS%9
M.>@XF0=PXAG0NHH\`[;0[3'@9ASF+)LQ-&$!`$E#!>'I%BNEJ`QS)2=)9T9O
M$5-@-VV7.H3+E,OCVN6QFN(5JWBTY*3R&2(1PVQ<S!5<B:IC<Y8PK&%83@`7
M0[\X^*9']_%_.7`'?G'Q3(_OXOYRX`[\X^*9']_%_.7`'?G'Q3(_OXOYRX"/
M,O?N0RS50!#29JY7/5$#Q-"VZ\S$P`-TH4:G$+0H`]H]M`[>`D(7SD`,(0\D
M:@&$`!2)J:T%Q`"W2A>TXHE`*T[52UH%]H9,^<EOI#R1[>90"J1/GV`[$H$O
ME"T%7NQ`+=3[NG=2BG+")LAD72>Z]:D+!RRP&UYN/W1)2%`A>3-ZM,03<Z81
M.`.1:D*G0H]KE.^P`5%()9,^<EOI$2)[>9;:I%!S+.^6V7R9*<WNI+;K?Y0G
M=2BO+"$]VR#E'7V2J$@Y5<Q,QUT`)('A@57LSC#BE,GS91NF(*`D6T3G`0!0
MM;:&`@38+YP`B'A$B-!$*@>+H(`90`,%9,!H8"`(5H-#A6@W``'?G%?YHDO*
M`5OBZ`%2A7^<ZT`!KZ]`'U:`(!7SD;:Q$B6HE`1,I%>;<*`")K9,1H0%C"-*
M]B1J5\R\&N9?.!AI6Z&D0`T8\N*8\0:E[5$#`<HR"Y#<OO)[@M.`\A2@&JF"
M@><KZQ3K;H'V_P"CEUO@W73O"3Z8'"F10DATR[@1Q;*LRB8K=\=KIX=K$Y#B
M&`1$H[E<2FL6>2*#])5HS%%)`ZK8Z;A-LFN'GEZ/6/U/C1V@<%P+J)V,MU3;
ML;LTY'9.Y,JUGUBXPG-9/)IQZDC'XQC&(,H.*@<,@5%3MV"!DUWATFRBJZZR
MRI3*!9P-I_4D1MKKK&RU`E0'#^NOS;@0$0-:_,%4^<8!I7[D:E:DO#FKDVIO
MJN+CT@.NNHS7W6YFFN^DG'DV&8Y;TH,-(]2LFZ?[+QA[%KX_$8OLB6Q5_D$-
MK+(%$S.YELNHYDD5FQV[)TFB]3/&A[ANE?TY'HT.NS9K'1/2[OUSLG;4S%34
M]&X4IK79&*/7,1BZ!9&;?`_S7$H*#339M2W6G<@H?]P4>V@=:A?.0`PA#R1J
M`80`%(D!-:#@0`MTH6@G%$H!6G:J2M`OL`,^<ENI#R1[>92U2)\^P'=H%OE"
M4YO=B6UI_*$[J45Y89,^<EOI#R)[>92U2*#F6=]MLODR4YW=26W6_P`I3NMH
MKR@#/G);Z0\B>WF4M4BO=+!>6V7R9:<WNQ+;J?RA.ZE%>6")T]7[VQ_)+\;%
MG0D\Z*'FB5N](`)"+\1*)RI`8+A3\U0M1K>4H+!?.*C^2)(:"(5`\700`3@`
MA63`:"!0'UZ&#U:@``/G%0_)$D%1`*B>+H`")`$1I)B-``PCZ]"CZM`$,E?.
M1$M8B1+=943*15"7"W`1-;)F'W,%S"-*]B1Z5&P#@%?.365B)$EW+K<I%>9?
MW.Z^R3-7D]Y/=;7^3J6W52Y@(6CUP+M]6'D27JLS&$3Q/N8J-8TIBJ"21J8R
M`.#":T5`H@>T1JF!P6E?.36UAY(EW+K<I$^9>#2X#62AZ\KO)[J5_DZEM:I<
MP`'SD0*(P\D6H%$0%2)$2W`W$0-;*&J)!6,`TKVI'I4++P._N:?S/)!V`-+X
MJH5`@B'9)TJ`F$!]DH^I01`%^Y`!'P>2&@"-`/%5&@'$`"LF`5$2@'K5,'J5
MH"*.?.2QS*V&D349HB!2GB"UH@J8"%`9%(H"842E#L*%525H`'L!:9\Y+?2'
MDCV\REJD3[I8#RVR^4+3F]V);=3^4)W4HKRPR9\Y+?2'D3V\VEJD4',Y??;;
M+Y,E.=W4EMUO\I3NMHKR@#/G);Z1$B>WF4M4BO/L%V!1)=)EIS>[$$MU/Y0G
M=2BO+!#)O5^Z+%&)D!+>F%;HHQ1M<'`I@*9^<:'Y)1"I:@"I*T$#V`M[\X^*
M)+RB%;XOUS!7^<ZT$`KZ]!#U:@`9!\X$0#PB1"H@%1/%T"HI@(C23$:%`XB/
MJT(-.VT!`*^<C;6(D2W"2MRD5YEXM@,)K9,W8F"YA-2O8B>E:DO`*^<FLK$2
M)+N76Y2*]SO%G<)[),]>5WH]UMW\G4MK5+F`A7>N#.(H1AY$@F=T$#GB!%(%
M(^IS'$LBI0$!<G`]@U$4%+;@%/F@N*^<FLK#R1+N74#*1/F7@T$P'LE#5%+O
M)P-;7[@I;6J?,#`/G(@`C#R1:@41`5(JI;@0$0&V3-VD%8P#2O:D:E?,O#0L
M^=K*I8>0\:^;@.P<-'F+&8"F4?$TS6F[N^74K41#L*(5#UJ"(,G39_PZZ"_W
M*ZL_V&@N`FK@*8Z+R1^AJS9C*2U[F+S'F^]NLE-Y,1,QBC8'\5^LQNE9ZYB^
M1F4=DC18$SJ))B";=T58EQ+0L/P$*:M7Z,V>P,%EM9Z/RQCG3U9K(X'+G64;
MMY)UD&+STHBX:R4UL,\*_<S,+$2"ZXK&4.J]14.L`O.T0NH6>FG^S<6[WA&0
M0O+PC/K!D9'$5@7`\YK@3BD$3DLF8.2)"@:^RO,"VM#4"07#QYXE&CX2["B4
MAV"XCJCYC?R?AM.`<P>/!$`&)=@`B`5%>.H'LC1Z(T#V`'@.)&5X+Z%"*\<^
MDL+K.)3)EF;Q>2-V^<9RR:J[`P#+?S?9PO+M(;,R-G6>,,I;/&9WJI324B0\
MHNBJX;*22Q@EJ'B_1=8HMM20B!B32$+I3:1-H3_YR-B91-0>FGVY9:,V@9?)
M7><S$K')NMTXF[:*@S<EDU'D<*3<!;I%``CK#T/1`XM/1<%A3?Z-9%D.880P
MAXZ)RG>L"\R#))7"F$1%QL>0,G9DF(B3PATT9Y0V3%6*,BHBC/D!0R91#=$6
M7HA(K8,TB;"]%P&>XOFV?:EEVLK'-\="'S8T3N3/,TBD$)9ZP@B+141B>:J(
M2S8!:QQ(]RR9.DC$1;<!(&B-K^C[USDV5O-0Y3DL//XGI=;.,\:95F&ZWJ.-
MZIQ4[/#5<OS.%VKD;J/CYV,8:Q:0Y';]`,D-$PC5HF)F**"?`6S8=6&@GS9N
MX4V5B$&NN,<0\+F>58K@&61[B7%^$4QG,*SJ<QS,,=DY$8IUR6K]BV<*@W4$
MI!`@CP'Y9]7/39(-D7L?O'3;YFX,N5N[9[EU$Y;+F:O(>/=%171SHZ2IFS_(
M8]!0"B-BSYN0:&63`P/F/]2&ELKR9GAN-;'P6=RF3.X1BH2*SS!)%],.61\B
M3D6,*FQR9R,U(Q)\2D@>MFG/78]R5%P1(I:\!,'?7GQ0\]\1OPW@#OKSXH>>
M^(WX;P!WUY\4//?$;\-X`[Z\^*'GOB-^&\`=]>?%#SWQ&_#>`.^O/BAY[XC?
MAO`'?7GQ0\]\1OPW@#OKSXH>>^(WX;P!WUY\4//?$;\-X`[Z\^*'GOB-^&\`
MW-'CP'LJ/A+L:N&W8#B.J'X"V\OX:'`./?7GQ0\]\1OPW@*[=01NG]ZXT:GU
M"1<?WAOOS`9'1S><DU&I%]^1Y95?7@QY(V7;-74NBY!8S--^)F0O>34!7Y'`
M43E^GGT/:,WD#.0P_IZBY[+5MUY]D+QKMZ`B%E5,KA8R%W?*/IR/V@V:PJ4G
MCLPBE(-#+MTQ8'5%-'D)N!('4#`V<-CN.Q$!AD,HGA\)C^,0^*(M)9G*-T<;
MC<?CV<&DA)N)=\O(HIQB*0%7.NN98H`<5#B-PASVZF<?]&'EG4C'M>IUCKMO
MU,'PF`CHUUE.;RN&Y)&86:(VYF^,OV\XTR['X2`;1\9K?+I!K*"NW59*QZMJ
MZ:ZC<JH;9B>O?1SX5KZ6PG!X#4[37>4;'U]A$U$XIL6'G(Q[M$DV_G-=XO(K
MPN?RCECDR\S,KN&S=51(RH*U4`4P+0(>B1]$]JU+7[^$:XZS2@]90&;X.I#9
M#L;,"JZT?Y<AG^-9:X;Q613X3#=2>54>M7,@19XG'*/2%MCC/2<!(6LT_1P_
MK(QY=5HXZMU)H9;L!>(BHW+,P=O4,K@<1FXS.W",&ODKG%B,HN*R&7(LL"`Q
MQ)A_)BF;Q15\(ATE8.W0Q[(IHEW:+-L!C=XCK;10(`C_`"T!I3@.)^IM9^@Y
MRR"\:U;%Z#-C,*\@\F65<[8=XM#*.GF'X;L^`E'C',=CPC:;+$X?.PTFGS4G
M!(<CDI3`V6%4@!:+94)Z.Q\]UMBFQ(3#'B^$1O3/&:^C29-(OH^&@&SG8;?I
M=54=X[E3B)#&G4@O/!#/I!46+ES;SEC'[IP%?HIKZ&QW)97,Q*>NW$RSP[-E
M9UVAFF;#+1>)3\Y!QDX:!3-E@/HXXOU(DD&6(*1XV8)L#PP$9)-CE"ZW2>/2
MLCCV0J](C:.D<2)G;:,S%U`9#+SS%+*XG74.@RBDWV33LF*9H_$EH^Y!JH""
M*AS7E!R9?@+B]]>?%#SWQ&_#>`.^O/BAY[XC?AO`'?7GQ0\]\1OPW@#OKSXH
M>>^(WX;P$>Y>]?!EFJZ0KTP?2J>J(.HH+1#7F9&*%IGX";F&"T*5H(]M`[>`
MD`SYZ%U(9Z:E]`!S&!=:"XE`+GP`%XI$`*TH*I:T`#6ADSYZ6^V&>GMYEMKF
M,#F6=\L`MSXM!5[NG2M*=X)6EJE@1/D+^1)NK6P)P+Y<GYO=Q@90CV'3`G*F
M]7"B/+6D4U%`=&:I%+:`B47)!/:!513"6#O7I;[8=X>WFVVN(P.99WVRV]\6
MG.[LG;6E.\DNI:I8$*;L?R!-?Y**,$]<J)YCKDJ:17L,CSP+F^(6B11:3*1/
MF`F40!3EC[J6H>V$`FL7KT!$`AW@T$P`(.(V@@!E``0J]`:&`@#V]OGAZPT#
M/?7E0#P=X`5`*]XC>P+BA6G?:T`!$?V`]>G`8*]>B):P[PH")*B+B-&T#"W`
MPC:^&M@*G$:5KRC4K4EP-<R^>^"RHFAGA?R6\$USJ*`"7-4+[C&D2$]R[PI4
M;@#\'/V^<G<'D*]/EU?>A?ZF-)Y!Z.WK!ZFLQTKU*Z,6PC,<'R'&M1[7SA#5
MNT975L',8Q(SJ6)P$ABV<87D6&9\"<DS;OU5BMSG%%5!ZDW-P'+OHSV-]4'Z
M<^G[!M:;I?#U3;;:M$I+9&Z]D].W4'XADN622$::62Q^$9PR+/%\,B%5#H1T
M>F"JA$&IU%EG+E45UPM*'5]]2[$"UT)KTM0((@/3=U$5)<#<3`:V.,`B05C`
M-*A[D:E:DO!NENJKZEQ.Q,E"JZ0PZ-3F(]W%JR$3T_\`4C$2L>20:BU.\C95
MDP([C9!H#@3HN$3`HBJG>0:@41"V'U=/T3O0'J+)=Q>D8Z4]_9CU=X[*YKGN
MH>G3)9?$YC5X:MP*L.IDT7E,'EB6,/<OV:N@^3CW$KW1I%"R"]JV(JX4!`/8
M29\]"ZD,]-0#V@#F,"\2@X$H!<^"G,%$@!6E.:6M*'M`,^>EOMAGI[>9;:YC
M`YE@/1);<^+3F]V3I6E.\$K2U2P`[UZ6^V&>*6\VVUQ&!S+._66WOBTYW=4K
M;J4[R2ZEJO+`,]>EOMAWA[>9;:XC`YE@O;!+<^+3F]V3I=2G>"5I:I8")T]>
M`[8@$.\-:JZ$@]YBPY@E;O2E*0#2!3`*A$BF"H=@*!6@@:T%HO7H"(!#O!`!
M$`'O$;V@`G`![7M:"!0'UZ&#U:T`!Z]J'Y'>``B`5[Q&]@")`$1_#O4`PC^P
M4?5I4`KUZ-M8=X6ME1%Q&C9<+8#"-KX:\L%CB-*UY)J5J2X`KUZ:RZ'>$NY=
MUSB,'EWBRO$UKXU>5WE2MM:]W/2MR=X(&;YX9X^`89X2Y1D*@F<Q1@2,HVC0
M.0P)R*AQ%`K@YC4+000/;=<G>"\KYZ:RZ&>DNY=USF,'EW@R$]UKXU>5WE2M
M*U[N>E;D[P"OGHVUAGI:@2X!<Q@V"8&XF`;7PUY8K'`:5KRC4K4EP`/GM`_(
MST.P!H+B,J`B!!$.Q\(5`3"'K5*/J4J&!?/0`?R,]&@"(!WF,[1`%!`.U\`5
M,)`#_G!ZPT!%'/GOAK,0AGIJ,D1`H.8FIA*@L)2@)9$Z=3BB0`&X0]V+4:`>
MT%QGKTM]L,\/;S;;7$8',L[[8!;GQ:<[NR=*TIW@E:6J6`'>O2WVPSP]O-MM
M<1@<RSOUEM[XM.=W5*VZE.\DNI:KRP#/7I;[89X>WF6VN(P.98+P"6W/BTYO
M=TQ"M*=X)6EJE@(91Z\!FO\`D=X(`=,+N\Q90$`<'`I@YD@F``<$B"%1`?=2
M^J!@*"[OKVO\SO/*(5[Q&>2I@K_+O((%`?7H/KUH`#UZ-*P[P*B`"/>(WL`3
M)@(C1[7S0.(]GV`^J(5`*]>B):P[PM13`1%Q&B!`,+4#B-KT1$$P7.(TK7DF
MI6I+@"/7IK+H=X2[E77.(P>7?W*^ZU\:O)[RI6VM>[GMK<G>"%=\]%Q$W0ST
M@J.[3`+F)]R`\>!E#'I(U,"`N%`,!`.(BW.(`("F)P7%?/3670STEW+NN<Q@
M\N_N=X&M?&J*7>%*TK7NYZ5N3O`*^>B!:PSTM0)4!<Q@B6X&XF`;7P@(D%4X
M#2M12-2H"03!H6>NG2J6'E4C'+<@[!PT3*JKL3E)^4TQH)472IS#<-.P!\E?
M)V\`R]-G_#KH+_<KJS_8:"X":N`I;HF=G_S8;.CGNNI9_C26]NLE%:299%%E
M6EXDW4IN==Z>/8QCL<A0=+"HJV13(0KD5B@)1*!BF`(SU_M3IM4RC4^,87JN
M:BY]\Z+/:G2?/9.+93TBXUVN07[=])27<)Z2:X5CQDCB_,NLU5*!C6++<PX6
MU2F\F?;-Q?Q'"7<,">$9\"9G$]!.P7`\WKD5!*5@Y<'+RC$*`W`%>94/(/`2
M(X=2'B4:/A8U!)_0._-NVI6]?4]3@','4B(@`Q=H"(`)A>H4*`CY1M*8U`]@
M!'@.'>6LO0E,0GRY#BNIV23?+<WQ+)"Q*&TFS,^P,!RT=?9:$K]&4",W.<&G
M89ZDA)*":1F6))1VU7<LE9!90+#P.;^C?V"XS[,\<+"2J3W3.]IG+LNC5=K1
M6/+:DC=@ER;>\K!9`1".QY-Q]-%6\B_6AUBS"J"C19(3-!;#P$<XEB?H@I%S
MKW'L-;:=DI78[_5<M@F%1>QLQ>3+UU/Q&+2FO45L-'(5'F.-LCC96(?/6#]L
MT1DEP0<2**SE$IR`KD=B>B)VZCE<EDL-HF54U[F.U<TR#Z6P+Z`F?IWD,L3/
M]G9)'-)J+BY;,,CGUL:YZCAD1ZNNP*9FD/=5SME`<\0BO1381!;DS3#%-6.H
MU31VQ9#<:D;L_+LXDLPT:Q9DS#8^2S,$MDT],;`C&(9T"CJ5(W?/T';X4"K%
M7]S`&W$-;>BHWOGV.X;%X/C6;;.V#!9?.QD1F,]MIQEN4Q."PVN'&>+SCS+Y
M0SN36E(;8.-GEBR*QULF301.X!\$.<S$+%S7HU^B3(7RLE+=+F'.'JT8^AU%
MD9[)&-6$D\;R#],J;#(6J)%W3IJF8RQ2@N($`M]OF\!M^!="G2CJ_/X#:>!]
M.N)X[L+%I3)YF`RQM*RSF6C9#,C2Y\E514?R[M,Z,FK.NU!1.4R"2BMZ1"&*
M02A;SO4C\5#[];_ZN`.]2/Q4/OUO_JX`[U(_%0^_6_\`JX`[U(_%0^_6_P#J
MX`[U(_%0^_6_^K@#O4C\5#[];_ZN`.]2/Q4/OUO_`*N`.]2/Q4/OUO\`ZN`.
M]2/Q4/OUO_JX`[U(_%0^_6_^K@&YHZD.^2@A%C47#:H=^;=E&+?V/6X!Q[U(
M_%0^_6_^K@*Y=0TAH(CG1*?4/%PHK*=0.O1T:G.+RRZ'Y_R!*_FY6:!"IG9I
M2J3LRH,E)*C$CXR(U!?D"`4,F=>>AE1G<@8OXSI-93>2K[QS[*9*+V1#L#IO
M)>#C66]W\WDD'D:">.OI/%Y(@2C-5RV45C2N#`D*"+@2!U+P)K$0>.0\-A$2
MS+AD3C^+QF(IQLPF^CTL888]'-8!)B\55<*NVA(I)($U3**"H0`-<:MPASMZ
MG7'HPY;J7C8'JCBM9-NI9SA&/,XR5RV0RF`GHO"G45MW,<8>M<UC5(V%QY)D
MWUCD[EF^(];N64@@DFFJF\=L2+AL,!DWHT=&:_7?82[TA":X:[2P&,DW>O,B
M5S*#B-FX6^F]H8.I.&PQ?(S0QL9=M'\QWMT"3!N5)4ZZ@%*(`$5J[C]$S`N-
M<9PJXP5@K]"<.<Z_E@8;2%J7&5,X:/L);*()12C`)IKE&/K*LF[]/Q1!BSD+
M"%8`]J$A:REO1QN.I6-8:JC,:-U(?2_8*\,A&GV6E=E6-X?D$%FTFS!\B7!U
MF+*)=S;4KLES`\LO+]V.:15D3&#I8P<OQCV131=""S;@8QGJ%`**)`$1M`1H
M`>MP'$/43+T&.80(Y%K5ATX1..P3Z!R4QYK*)_7K!>1DL0P[9L#(*Q.:2./$
MR!Y$8]/Q+Q$#H.3Q#Q4R!00>E72`+4['F/1XM)K56+YNIB;:1QN#Z>T]8HPF
M0;!1B4,-[CM%CT^/23.%KEQZ5P1%B^R4K1T]<KQ2'>;G9R&6:"8(9<M?1'0T
MQECM;%<&;3J.,[,93ZA&6VCR;"+?YP;"LYQ^&(1F9S&9*GE\*#*-C8L$I9LW
MC$ABDB,F:)D@MWTER72T]QW(W72)'Q2^)H9XTB<P7B7F6"W+E$7KB&3CXY$^
M:E[R1M&XBNP(5%I1HBH)PM!P+C@+E=ZD?BH??K?_`%<`=ZD?BH??K?\`U<`=
MZD?BH??K?_5P!WJ1^*A]^M_]7`1[E[N3#+-5TAQ,'TJGA$WB+4MHAKW,1*%@
MA<?F&[*A[7RCP$@&=R8`:D0)A`#VAW]L%P@5P)0[0[+Q33#V.9_R1X`,[DPO
MMB!/;S;?PYL6^P'O+\H>;S101#M]KS^WVAN`B?(7LN3=>MBI0)G!!UYN.Y8)
M5BB"8)S>KQ;B**@<U7O9VZ!0`OW/O%3=B9N`ED[N2+?9$B>WFV?AS8M]@ON5
MY0\WF@W1\OM>\=OM#<!"N['TH77V2"A!G=K)9CKLJ;?Q:.;@L`9QB`IB"RRZ
MI&W,`A#"!RIB',\@T$Q@FH7<D`C2)$0`34'OS8*@!E0*-*=EP$*/L7^P/`'>
MY*O\TC2H!7OS;R7%`1I3U"B(_M<`%=R0VUB1+427?AS8;0,+8#CV!VV`JH/L
M\K_E!P#7,O9(L+*'/%"G2+=F./B+0G+JU;BH/,,X9D*"0++#<*R0>X>W+>40
M#S7]:GU;'I.](1UGZ2ZW<VFLJQJ.DH?#G/5'K6!E"N(_J(3Q+#<3@\$=1^0D
MG)%YKY?PR-2CIY5@Z?>*Q+`@-%&CY0TBL&Z==71_]7V]&YIR!WMU9=`/3[A>
MM)[/(+63"8Q[2A\[>_2^?@Y7((]@M$XX@]E@0/&8W*',Y%,42F9@4Q@,ND!@
MX^AZ17ZG0-M>CS`2ULK_`/0?90(%N!J)ZT:U'EBLH'9Y>2-/;$J%*NO+>'U3
MOJTT3(:\T?%Y#T8[?92#2;P?=6INE;.DRQSY($TWT+G.),U&#?-L2E&:RA#M
M^<V=-G*::[=P0"J)KAU8Z`_3T_5]O1S]+.!])N@=F;W1P_$N]RLUE63:4V(_
MR+.LYF#).\JSG(UFK`A$Y/(GK0@%;M4D6C-`$4$4R(I``!U[Z.OK#GHV>O'?
M>'],W3=G&Q\GW%GC?*76,X[/ZLRW$6+MMA^,3N7SCAQD$VR0A62;>"@%E2@H
ML"B@B!"$,I0@AVS,[DPOMB!/:"MGX>V+>)`>\L.T/-YHH(^7VO/[?:&X`.[D
MRWV1`GMYMGX>V+S+._\`*\H>;SN[H>7VO>.W[F;@,G=R0">R)$]O-L'OS8O,
ML%]RZ5#S>:""/E]KS^WVAN`1.GD@#ID7PLU>:ZY5)!H4JPD0?`4H@9=(]3II
MD.%"*VWT$`M$P`M%W)5&D2(A40`>_-@J`&4`!I3LJ4I1_P"=['``.Y*H5B1`
M*A4>_-NP!,0!'R>H!C#_`,WV>`"NY(;:Q(EJ)+OPYL-H&%L!Q[`[>6"J@]GE
MY7_*#@`CN2$27Q(DNY5X]^;&Y=XL>96@>=R@76\GMN1V>W+P"%H]D3.WA1B3
M%$5&0K5D&ARHF4;1@*D`I%E#B*)%E3>T3OY/8`WE,(+B.Y,;+H@27<J_\.;&
MLO!ES`[`\[E"NMY/;<CL]N7@,%=R8@6Z($M0)<'?VPVB8K83AV!YU@JJ![/*
M_P"4'``.Y.@?D@0&@"(=_;=@B4@B%:>H81#]KV>`!=R=!I$"(@`T#OS8*B!5
M!`*T[+A*4/\`G>P/`(H][)#',S$B3'JR1,6L@T$3F[NN8`O*LZ(-YTDP`W,.
M'NM:C:/`+3NY,+[8@3V@K9^'MB\RP'W+#M#S.:+='R^U[QV^T-P`=W)A?;$"
M>WFV?A[8O,L[_P`KRAYO.[NAY?:]X[?N9N`R=W)%OMB1/;S;/PYL7F6B]Y?E
M#S>:""(]OM>?V^T-P"*2>2!6BU8LX$`Z87ED&A!M[RH4AJJ+M2A>":8T$X?=
M:=HE$!!;WN2^*1\OX\V\EQ@KY/L0`?V^``=R50K$B`"(5'OS;L`13`1I3MM`
MQA]FWV0X`*[DAMNB1+44[OPYL-H&%J!Q[`\[E@LJ/L\G_E!P`1W)&LOB1)=R
MK_PYL:R\6/,\@>=RN\+>3VW=^SVY>`1+/)$5XJ^*,F91X!3%"0:"!"GC@.N8
MWNR0J]W,JJ%I2*";D5H`&*8`6%=R8V71`DNY5WX<V-9>#+F>0/.Y0KK!V>VY
M'9[<O``.Y,0+6($M0)<'?VPVB)6XG#L#ML,HH'L\O_E!P&AYXX?*)8>5>-%N
M0=@X:)E.^-U;!\32&@D)YQZF$2]GK5\G`,W39_PZZ"_W*ZL_V&@N`FK@*5:,
MF<G'5VT(]WK8)C&$][=92"JX9*V46GX@W4GN=9\FA#,(]Y*`X>"HLU3;E`RJ
MAP#M`#@(!$>JMV]-V891@T3K73D:.1XS/MX[%W"2;]@..9)D.N%GJ;64EG$(
M5%"2DL5P@S0PO%%!5>1H=HG1!8H7(2E\L>;-Q?Q3#DX>S",^Y)OI*P?@L4TW
MKD5!M;M0,04C%(%!]M?7]R-0D5PXDO$HT1C$J@D_H'B!/L6]?^S<`Y`XDQ$`
M&-1`!$`J,@6@>R-&PC0/8`>`X:99L7T+D>,\YF-9:6'P?+,XP">7Q[6N8B@7
M.=>9<3!IYJ]<8WAI&KC*I)_BCM6.D3F,[FX=F_=MG"[-9R=<),QW,?1=XU$[
MHG<+U-A:V$L-2[;1VK.8_@.;/=99)K#6.T6D)LK$!<K8Y]#,CCF&>O4$6T<0
M#(/&`@#(%(U,P$#YXCM[T/L,PQ386+FZ8\3=XD[:YWC\9'MG4+EF&2[<D5E;
M,#8-&8V$Q#2,<\79"V8=SM3?D00;)BNFBF`;GCN9>BUW'F6&Z[AH_ISD,V:Q
M"C7"\:%4,=D7C',VV:9#D6,1EL3&H3QW0,Y1QD$;S'!"/#$*^)WH42`&M1>:
M^AY%?*<FB)'I)(ZV+B.P-990[93@).<NQ3,4F<AL#%56:<21:3)E*:Z)ER))
M&7>BG:F)Q1,!`NSK;IBZ:<7FL6VQK31^KT\E;,V<MB&SHL&TODGALCC$C`MG
ML/FCU%[-+1\MBN0+HF$KD4W;=8HG`]J8E"S?>9/XL2^4"?!^`.\R?Q8E\H$^
M#\`=YD_BQ+Y0)\'X`[S)_%B7R@3X/P!WF3^+$OE`GP?@#O,G\6)?*!/@_`'>
M9/XL2^4"?!^`.\R?Q8E\H$^#\`=YD_BQ+Y0)\'X`[S)_%B7R@3X/P!WF3^+$
MOE`GP?@#O,G\6)?*!/@_`-S1Q)=\E:1B5>\-J_E`GXBVI_V;@''O,G\6)?*!
M/@_`5PZB,FT;".=#EZ@(*!=*RO4'KV*TGXVC*2K9GOIZ67;ZZ?MS1L6[:QDH
MD\5529.GEJ"+Q9(0,57EF*%"IJ>]#2:=R&(>L^CKQB:<;SS;+I.'>1:2K:90
M@XPV^'609#!1";B%R5_BKX%)A!19)TXC4'!E"BBBK0.IV`DAX_&X9C@D3#IX
M2SQ[%VF')0DB489'%6^/1Z./)1`BU+6-3B2)`@/D%("\!SIZG]A^C2;]3,;@
MG5#B>K#=1<C@^/H1T]F&-3ZDVRPB8B=N9+CAF6?Q^.J(1"*1]7SQ6AF[U-TV
MF%&2"-KV08%6!:B7T8,WK)PQQ_$NGC,-51FT\'Q>1C<$CGF6XLTV1)FR=GA3
M288XKCD@S(S?&RR8;E7=%\*5,\=-U3F.<R0A7K)-C>AT:XIKIME.K]>IXZYP
MF%=X2@_UYL9R9C"YGES^0CHQ^[0Q9PM'YA)3#:7=N&CY8LPFR1ERKE*B=ZDH
M%AM8;!]'M*]2L9C^J\(Q1OU!+YCGPP\C%XGFT*W4R?%<)G<;RB:933['(_$G
M34L''3D8T<I'.DN]3EP;56._4.'3)@XD1CV8#&HV"S;@(FD"TMY!*B:UL(TI
MY:`(\!P^T_M'T(6:00Y3@&-=-.+0N//H*>(:?QB8UZFI,3^(X=L>&<EB)S%X
MHTQ-Q\?D,;R2'16<,)H%F:($D$7"10MALK(>A!Z[UU#99K#%<V1@('IK+@;S
M'\#S+*<?@L&S)78\=TZ/VD]"XFK#GP&K+(3(G(LNQCDKUGI426'`(YS;;'HS
M93*LUELQP3$)',38YLR-RUPZUMLHDT^+(;"G\6SW'"H&P=LZ=9U,YLO*';((
MD\6<(\YVS,+4>:(66Z2,KZ9\GQ[)'_2AC,-'8LUSQE%92,8PR''4E\@8ZVA?
M"R-V6413!]X6QQ-9B@AR$R,RG34*F',!41"YO>9/XL2^4"?!^`.\R?Q8E\H$
M^#\`=YD_BQ+Y0)\'X`[S)_%B7R@3X/P$>Y>YE0RS5=(E$P?2J>J;Q,A;1#7F
M8B0+>Z")^8;LJ`A;Y>W@)!,YE0`UL6B80`]H#)%+<(%<"0!'NHTO,FF'JTY@
MC^Y[0#.94+[(M$U.9962*6^T'O*K^"C9S!10KY;></EY?G!$^0NYDNZM;%2A
M$5R#KW<=51F44.4"<WJ\6XBB9D<ZO>CH-RB!1#E=X,(U!(0.$L'<RH7V1:)Z
M<VRLB4M]HON57\%&SF@BA7RV\\?+RQN"%MVO98NO<C%"'([62S'79"-QFF[<
MJA0SC$!2$%5`=%:\PH$,8IDTJ<P:%-2\X32+F4J-(M$0`34'Q$H5`#*@4:=V
M[+BE*/L7"'J=H`.96H5BT:5"H^(E&@7%`1IW4*T*(C^U[/`9*YE!$MT8B4!$
MEWY1*-H"9N!Q#\&"ZPJB@^I7EA]EV`US#R5)#2ASQJ*5L8[,<X2J:8I?@J`J
M&!4QHTI.4"JX@87#</<`'F)WW$!#ASR15Q3%5"-$G2*N.X^<KP98CDRZ:L;#
MF.YYQ7^0@X$2N%S7!(/N9R0'O"O-!3@*6^DCZ"].^DIZ3LZZ9^H''7:<#(@A
ME^'9;`2Z*>3ZSV5`1JR6.9YC2B[<K-P_A23,@W6;N`%L_8*+-E`*1T)DP\3_
M`$3]9_U4WHTT'BVG,\TE*]7.R6HGE=C[UW9T=0V8Y'E>7.R,49/P1EFIWZN$
MX='V&2CH9F8R3=%&]95R\67<K!;0/3`_5*J!_P#8^=8AV`(A^H'J[L$2IB(?
MR+U!,8/^;[(<!^%_2[_5*'K=PR-T!ZR9D>-G+15P7H&UTD=-%RW616Y2\>U2
M>MUCI&$I%$C%43.8#%$!+7@*->C4ZR/JV/HU^KW;O5KKO.^JK-L@GW<ZTZ=\
M>S72TLHQZ:\*R>)>-,KQV,D6\Z]?9ID,QWA:-;3+TG>&D`N5J8%'!GKQR']$
MK5^T8W<6L->;>P9@L[PS:6!8KLC#EY)4T7(.L9S;'B9/C:K^/6;&5CGCF*?,
MQ51.(F0.N8HU%(;@WT[F5#F61:)[>;RZR12\RWO_`"J_@HV<WD-Z^6WO`^7E
MC<`=S*A?9%HGH*ME9(I;[1?<H1_!1LYH(H5\MO/'R\OS@1N7<D5RS+X<2[G.
M>2`2:92K"5!\`%4*(HF"Y)-,X437M$XU`MM_`+!<RM1I%HB%1H/B)0J%QP`:
M=U[*E*4?^=[':`#F5KVQ:(!4*CXB7R7$`1IW7U"B8?\`F^SV`%<RHB6Z+1*`
MB2X0D2FM`1;`>@=U"X2`HJ/J5Y0>2_L`*YE1LOBT27<J^DB4UEPLN;3\%"_E
M`LO3R7<@/)S/-!$T=R9G3PHQJ8#S&?/`91-0J!U&T9S4TREYIAY1%EC=J:%_
M*"A1YEX`L(YEA`E\4B2H)7@$D4U@F!ES0#\%"_E"LO3R7<@/)S/-#)7,J(%N
MBT2B($N`)$IK1$&PG`![J%U@J*@'DKRP\E_8&`<RM.V+1`:!7\I%'MM((A_)
M>VAA$/VO9X#(N96@TBT1&@T#Q$H5$"J"`5[K0*F*4/8N]CM!&Q=RAH]F=.,3
M4JR1,43RB8B<W=UC``J%[\40.HFF%W-5[%1&XUOG`L.YE0OLBT3TYO+K)%+?
M:#[E5_!1LYHHH5\MO/'R\L;@#N94+[(M$]O-LK)%)?;W_E5_!1LYO(;U\MO>
M!\O+&X`[F5"^R+1/3F65D2EOM%[RZ_@HV\P$4*^6WG#Y>7YP(Y)W(D:K":.(
M5,#D"\DFFF>WO"A2&`3F9%*)P(E4.:7[H(><):&!9WF5^*T:5'_S$ODJ8`'^
M2^J``/[?L<``YE*A6+1`!$M1\1*-`$R8&'^3=MI3&'V;?9[`"N94;;HM$M13
MN_*)36@86H*"'X*%W+!540\EW*#R7^:`1S*C9?%HDN%*^DB4U@&%CS:?@H7\
MH%EZ>2[D!Y.9YH(UG<GSHN^-3(=1X4IB%DT[2E-'@=P(U[N984#*+6E!-6[D
M`:TM]Z8+".94;+XM$E>7?22*:RX&7-`/P4+^6*R]/)=R0\G,"T,%<RHVW1:)
M:@2ZDD4UHB5N)P#\%"ZPRB@>I7EA]EV!H>>KR!TL/*O'IH)CL'#;E"OBK"0?
M$TAIR^02\!,(AV"'K\`S=-G_``ZZ"_W*ZL_V&@N`FK@*5Z-E,P+JS9S9;7N/
M3V,)[UZR2'([RQTHO/Q'ZRVZ%'S9?'VV%2IN8],99L5J!W'-"E1\^T`@'474
M#TRS^RL-QS6FE-8Q&PY&5%ICAVR$M"R3"43PI_+O05DC:K0(S4;1J3AFY.96
MT90QBB8YS\TP7K2D<Q<[-Q<)C%X:+MPC/N09IEBTIS0-.:YYMY1QE@*0IB4@
M![8#`81J%M#!(CA:4\3C:L6=>4_I^4E:>U;UK^3>`<@5E/Q%D'L^)+=G_P"K
M.`XE9!U`^AWIE+N>UKTYE;8I*[,P?)94-1+BR;Y%JS(QQB:Q\S^.UL8C[(,B
M<82LM`<L5%YV)CUEVISMC"*H2WC_`%=>CD1Q?<#;$<4U.A$PFJ<WVGMK#H36
MCJ%6D-78=ED0H_FYR"5U_%QTA&91,;%9R\45R8H2C24[^`<L5#E#376Y_1/[
M/SC'=B9+C^A3YUG,-DDPH]S*$G8-8SG+8C"F$RGG$:_PU"$/F<BC'1\>T7=)
MN'19!LNU9K@Z.J14'EIOGT3NN72>UL88]+K/(H:.G\BB9?!,7=2.9."1./SS
M3(F>-LX'7*LP_E&V/1KQ9Y'MRBJD@L1ZNF0CI)PJ&J9OL3T-F8/V$!E[#I+-
M)-DHILU>MF4ICKJ&*$MBDS'PCG*H3!HI?'U74C.M>8P6=(&63"0063%-O))I
MA=+7O6YT\Y%N=;I6P9\FEL/#\AR+6JF*QV.99'X]`2>`8Z^E'$0C+#B#3'F<
M8$9CDDA'&*J1%PI#NTT@HD3F!<SG2OX@R^4EOFW@#G2OX@R^4EOFW@#G2OX@
MR^4EOFW@#G2OX@R^4EOFW@#G2OX@R^4EOFW@#G2OX@R^4EOFW@#G2OX@R^4E
MOFW@#G2OX@R^4EOFW@#G2OX@R^4EOFW@#G2OX@R^4EOFW@#G2OX@R^4EOFW@
M#G2OX@R^4EOFW@&YHM*=]E?P%G7O#:OY25I_(6]*?DWMX!QYTK^(,OE);YMX
M"N74+G.FL.<Z*#>F.XU(JY+O[`<6TVK-Q[Z>:Q.\9LDLRU_)MEDL=?I0$J#I
M95NS?G`G(<N"6F*(W%"B,UO+T1+B;R"`?LNCIY)R"^[<KR]Y&0$4X%M/X_"Q
MC[>"N22L3K\7C+,5\8>`XETU!!ZXCVS@R]2)&`0ZBX">*)CD.3!HO'&^%%Q_
M%RX>W@'@MH%OBQ<?CPQ]"$;H1""*$0E$@D5L0A"$*B!0`H`%.`Y[=66\O1VX
M%N]KBO59A&H#[?D\"8*HY-G6OW$Y(-]?23Z39,:YR&#R)HV)!TA*K()D=$4*
M,<^52)<V.(`Y8YOWH/:8=/(:KP'6^6X*RV/J7!I9OI_6TKD>-O<ZRV0E9K6`
ML4\?U\6.G$6<^=P*3]ISFS"47%+F%=&.0H0C+[>]&6_B,0BI+IDQ>;Y6NV\_
MC6,_J_9!*34?B&39@M(,FJ;4<!4,>5RR:9.I5NW366=RS4R[A+GE=T<!,>LM
MU=!V0]24=B&M=980PWZZS#/6\9D<?K.:QXPY-BV$S&/Y+,MLP=X1%1+@KB!Q
MF8AVBZ:YU'BD?)D0*9,KE4X=*F2\F6-:#X>T.4&*`VA(*F,<`;D&T"^&]IC!
MV4]?@.*NONI3T-4ZY*..8=TO8B]@'2\K&LYK6'T.>O9L;W;@F/1*NM47>0Y.
MW/$-E$D6Z*SLSARS!L!UW*13!8F<ZM>B&"GM/8YD&'X[&N<^PK2!-3/WNL<I
M3@#X/G6,9>UU4Q83HZ^\-A8F#QG-)=KW<ZB18U.7=HD+47I4@B)YU?>C#SO(
MLKD977^`S68N<$S9::\8TWE1,GRC%,GGF)LDC8U)]K=.0R1SF[K/6\D5-'F*
M.FLKW@YB<Q0`"X?2;L'IUV!C^1R72[AN-XWC$?G3.+R9*)QR3P5.0G4M;PR\
M8Z3BI3&(9ZXC&^*N&39NN5`&PB@<B(F`AC"%R>=*_B#+Y26^;>`.=*_B#+Y2
M6^;>`.=*_B#+Y26^;>`.=*_B#+Y26^;>`CS+UY<,LU7;',3`.5SU1&56+00U
MYF0D"WPHUP&.``(U"T.WM\G`2"*TO0;8]@(T-:`RBQ:B`+V`(A%&MN,5,!\M
M`.;RV`!P#+RX7V1S$U.99646+<(`\Y5WY*-9>*:%WEMYIZ7<L.8$3Y"XFR[J
MUL",7'*D'7NXZJ'FED1*!)O5PMAY80JW,%<R3<#A<'*!8XA?R@!4)8.M+A?9
M'L3TYMETHL2ZT7O)NI%GLY@)M[O;6\X_MN4'-"%]VN9@->Y'R(YBX63S#794
MT59I5!,Q0SC#Q1N5!B_%L*A03,8O)3M$YJ%/0%%`FD5I:HT8,1"IJ",FL`B`
M&4`HB'A8T$2@01\M+A#MM\X#G2WJQ[&E0K246$:7%`1IX6'D*(C^R`!ZM0`*
MM+#;='L0J)+J2BQK0$6]XA^2RW"4IU:>2HD+Y+Q$@-DPYER0\H<[%DE;&NS'
M4),+$%*C5`53D5%O&6BD!UQ*87#?[D0>8ES!,D#3C$E()X5CK\6S9XW)BT*[
M,Y\84<KN40B8I95<%A<9$1RJH11P8##)O@4%(@BY5YHJD#RPSOUR?T6,:[5C
M2ZZZL9I,I11>*L]:X.FW(J!TD7344I;9<>NM95;MY8%.!2>2\P)AYP]"=9'U
M8K1?6MM'J\_5DZM-C8SEMC_6/3%L+4>H,ITCI?))HBWTZEHO'9K9[QMES!ZJ
MY-X!'R95V>/$%4$DSF,R-'!U;#ZQ%]6RH%?1;L:T"H!T/=)`@`T)4`'Z0!4`
M$3?L@`>OV`NCOK#'U:UZ\2;K>C4C<;(>\1F%>AKI>5(T$A#G`MD)/'DQ%P)0
M3]S"GGC=YH"`ATXWW]7S]&1Z3F;Z/.M+!M2L-`X+,8A@FS,IUOIZ'@]2X]OO
M4>78NEFN%8KG6,8I!-F&$90D,JR(_EHFV15CE73$ZIU",7K,/2)C./-,'QC'
M\+PS%<?QW$\/@8S%\3QV)=#'1$'CN/1RD5C\+&LF\2*+".CHY@S;I)$`2HI&
M,!0$$B\P'TZTN%]D>P-3F\NZ46)?;W[DW4BCV<SE-[O;6<X_MN4'-`,M+`)[
M(]B8`%3EB:46+>`"]Y0FI%FLY@)M[J76\T_MN6'-!*Y7DP<M`[FT`PJN.07Q
M10I5A*@^H54.[HB4!2(F;L3<VF,8+0`@*""L5I:HTCV-*C01E%@J%QP`:>%C
M01*!1]BHAZG:`"TM4*Q[&E0J(2:PT"X@"-/"PK0HF'V1``]6H`%6EAMN8,2U
M$EU)18UH"+:^VL66X2@=6GDN%,ODO$2!@JTL(DOCV)0$4^8)918U@"++FB6L
M66_E@HXMK;=RB>UY@\H$;1Q*&<NP,R9@/-:<\OBRJA4#';QO-(B7NRHF`B:B
MY@JFVO%,GF^ZB<@+"K2XV7Q[$HCR^9;*+'`MP,^;:(Q9+^6*B]OM;N43VO,'
ME@%6EQ`MT>P`1`EP!*+&`HB#>\`$8HMP%$ZM/)<!"^2\;``6EZ!6/8`-`J'B
MJP]MI1$`'PKM`#"8*^L`#ZM``%:7[:1[`1H-/RHL':!3B`#^2NP!,!0KZE1'
MU.T$C%Q*F8,S),F2H"R0,4RDLL(G,+=40N.5K(5*90J07<U7L4,-3"0+P5F6
MEPOLCV)J`KR[I18EXE![R;J19[.8*;>ZEUO-/[;E!S0#K2X7V1[`U.;R[I18
ME]O?N3=2*/9S.4WN]M9SC^VY0<T`RTN`GLCV)@`5+!-*+$NH+SE":D6>R\$T
M+O+;S3^7EAS`22*\F5JJ)F;,B8'(',+*JD.!>\*`0>UNQ*`G`J50YQ:<PP>=
M8`*`LYTO\7L:5'_S1;R5-0?YK]4H`/[(B'J5$`%I:H58,0"H5$)18:!<F!J!
MX6%1`HF$/)6T`[*]@!5I81+='L0`1)=246,)0$6W,M`8LMPD`ZU/)=RR^2\;
M`P1:7&R^/8DJ*7,ME%CV@867.MK%EO%,%'%M;;N23VO-'E`D6<2G.C`49,TS
MG=@4Q"2JHDM%@!W':+5L*PHF,O87EJ7\DAA`EXF1!65>7&R^.8EKR[Z2BQK1
M$&?-M_)1;[!47M\EW*)6WF#RP"K2X@6Z/8`(@2X`E%S``B"%]!&*+<!3'4IY
M*@0ODO$"!H6>JR)DL/!PS:(ICL'#;SI/U5SE'Q-,:`F:/0`X75#VP=G;['`,
MO39_PZZ"_P!RNK/]AH+@)JX"EVCY++T-3[/*O@N(3^+H;SZRQ.A(YB]*M.Q!
M>I?=*CUH_A%,"D&"0O!%5N*!W"Z1R4$QJ'$I0@C3?4-HS,<\Q>)UUTZ:U@<P
M-,1L?'2*;9""D<;?RV*Y0\CU';Y#5Z;Z.2=ML3DX\ITQ,55RA4MS=5%PH%Y"
MO,R7V;BWB^/8Y'`7",^Y`L,LD);F@,YKCF\PJV'Q/(%,0);03W@8U;;0N"07
M"DKXE&U:1]>4_I^47-/:MZU'PNO`.8*2U0JSCJ5[:2+FM/5I^2_+P'%4O6'Z
M,>0E,G#%>GS6V?SV./-L:TGVF$Z5PZ8?K#KZ:4Q#(\=JZQR.:S#3,H[$%'4$
M@"BHS<0R3!(G,79MG`;7!]9'H^H5/?D;"Z(Q;'I71>M-I9IN/%PT["0DXVQ1
MEG48?.L:(W-C2#:?D,JR1K&S!XU-<[=='N;ET9$X)%*&N2_6IZ+K/$VF?Y3B
M6O29-F6<ZJR*4.ZU]D9=AN<LCI?",[PB1S-WB.$/WCGZ,2V.L)1VQ<O%S<G'
MW+H[5=JQ55*#W(=2_HF,(CY269XSTQNFCF+AHV<>8MJMY+H#CFX&TRZ%Q,S#
M74?A3>`R+'LAE'\JLY=$3&).Z5<U2`P"$R=/0>CAZCWTVWT+J7IES)YBQ,6R
MF65A-4A$BR7<(,#X[(=\GM50"3F59(Q37FD145=,A!('!4C*$O"Y,7HG4D'G
M2VT(;2>HXG9"\G.S2V>QV-PC/,%)C*&I&622A\B;XPG+"_GFA+'BO-O<%,>\
M37GN"6>9+?B<=\I.?FK@#F2WXG'?*3GYJX`YDM^)QWRDY^:N`.9+?B<=\I.?
MFK@#F2WXG'?*3GYJX`YDM^)QWRDY^:N`.9+?B<=\I.?FK@#F2WXG'?*3GYJX
M`YDM^)QWRDY^:N`.9+?B<=\I.?FK@#F2WXG'?*3GYJX`YDM^)QWRDY^:N`;F
MBDKWV5HTCZ]X;5K(N0I^`M_(/A8U_P#J<`X\R6_$X[Y2<_-7`5OZB=EZEUTX
MT1^>O$X*=5S3J"U]@>HG#^*-D;?'MTY.27C\#G$UW$$X^CCXKE15JWD4BBX;
MJN@$M"\Q0@4(F.KGT2KN<R+&I",Z791ZJ[WC.9HX9:P6D"M<JP:%BY;=C;(C
MLM1GF%,Z4QET9U)D*BL[<,V2_>#`)4R*!U/U^[BG.-0KG`V&,)80XQW%E\.1
M@%U&,"CBJN/1ZF/)0;-"$:HM8<D29(&R9$DBIH@4H$*`4`.?/5!U<="&#=14
M=T_]2N!X+,[:R+"L<60D\KUD.:ME,)RB!WH>&9$GD<+GIMRS,.,9##D8M$5U
M_%,I9LTD3'F!J'ZQS<GHZLGP];+L&P30N485&[XUKXG-XSK5V6%Q_<60'DL1
MP'9,D\=ZOBVC!"/`[YB7*B&,U9"+IOWD%!53$$V/=570OF$'KG<&/:IQ.8BG
MVLV\]KW,V.H'KH\5@6.;0TOAQ89C*-<!5\!-AV=YWB;E:.!1,8A%(KLX(D:B
M8H??6?4=T1Y3U-,]?Z]TYBT9O9WFNP(IAG+75[:#2^D^+85.P\[-HYT?&6)S
M'G,>PF7B6!@.#^01B7O+1[D4SA0.F3!64+'LA%I'VE9-A$?$7-:`@0?)X6/`
M<0M?]=WHA=UXX^R)+7NE(6,:G8,E&^9Z+<,9!V]V'@>%3;B*0CX'5\^NM,O&
M4VP@G#92QRYG8Y:.;%<+,^P)VS_<WH[\6SG62&6Z9U`\R'8$1TZ2&N<M_-*B
MK"O<2RZ"S\FC)MGE<GKY@R:8WB,!K^212\\#0I%&S9-(%'":/`:E#]37HZI;
M',US..Z?,-(U^C.R5\B37T8DRD\GA9C+,%CLWB&YEL)(REWV<R6W85^X9*."
M+*L9`%WY6Y4U"D"TW1SNGIPW7BV29#TJX=B^,XI$[#-C^4)1&+_0)*2RF,P=
MBV%SX4GCL:N[;14<DG%%<F1*F*T>JDB)TDBJ'"[7,EOQ..^4G/S5P!S);\3C
MOE)S\U<`<R6_$X[Y2<_-7`',EOQ..^4G/S5P$>9>I,?2S55K*,$/I7/5K*.@
M$!#7F8B2@!$&`0,>@#VA0.WM\G`2$*LO0U&4:(T-;63=%`1`%[+J1!K0,8J5
M?+0#&\MH`<,F5EPOL91IJ<RRZ3<EN$`=\J^D0>R\2(74NMYBE+N67FA$V0JS
M@;KUJ"+"*.G^;W<=QE9=XD<`+-ZM[M:0D(L415.1L"E3!RP55$+Q2*"P2R92
M7"^QE'&IS.7=)N274[YRKZ1![+P(WNI=;S%*7<LO-"%-VK37YO<C[NSC%5BY
MAKH$DUY=VDE:&<8>*5YR1KTR`J%Y8F`J1;1.:@'H!U`FL5)>HT9QPA4:5DG(
M");E+1$`BAH(E`HB';01$.V@"8#F2]?Y'&TJ%?RDYK2I:C3PKM&T1&GK@`>K
M4`"J2WFW,XX`J6ZV3<C0!%"^T!B2W"4IE:>2HD+Y+QL!LF%I<L/*',UCTA+&
M.S&.26=%%,0;(BH8BG<H\0%.Y<2FYR%>6GYZ?,,9$&_$%I)?$L7$6[%T@OCD
M")EUI5RX4<)*QD2*JJAC^.@X.<BK@:F?O.8*:=5U.:91,.'6EOJY7HX-+=;F
MS>M&-TCC64*9PQ37Q'0.9IQF3:'U%E\Y>&P<KPO"97&5V;H\\1VJ$:Q?`LP@
M1!46*2(.&Y8P.GQ>AGHY\V[HKZ1`["7VZ.U::@B#;F`6NN2W`4QEK:TN`A*T
MO,"8'ZC/1U0*]%?2(`T"O_R.U:(5M3N`!_-T%0`PFIZX`'DJ(`',7K:^KO>C
MEZR]O:,W9E&DL8U0^U#-MCYMA^DD(?6V&;YPEJ9R[C\%V1$8[CT.@BFVG54C
M#+1QFDLI&G<,C+&*9J=H'<O'X-#$<?A<4Q3&<:Q[&<8AH_'L:QZ&6&*A8."A
M6(QT)#14<RA$VD;%QK%HV0111(":"("4A:)E`X5-](!UQX+Z.CI6V/U=;DQ3
M(\GUSK)WB#2;AM?*L)#+WA\WS6+P2%&,8SIX")5Y<SD+`[CFO$N6W,N8G,,D
MF1</-JO]==]':FHL1#IGZQW!"&6!%48/3*)5BE%[R#F*;;QCI`KRVUP4$2<U
M3VW*+S@_!OKL'H[POLZ8^LDU.9R[H32Q+J"\Y5]-P'LO`C>ZEUO-4I=RB\X/
MT/UU?T<RI%%C]-O6@DX:GO9-RXYI<Z+WF=[1.5TN7=J(,P31Y2@>Y.0$YC%`
M`L*H<+%])?ULOH8ZP>HW373)@.A^J#&<[WCL3'];8E)YK#ZP;8PSE\C=BS8O
M)QY`[(GI%K'IG$O,%%JNH`B(`4U*B'J*!27J%6<;2H5I).1$`J2H@'A(5$"B
M8:>J(`'JU`,E4EJEN91P!YEULFY,(`(M^9:`Q);K2F5$*TJ)"`-+Q$@!5)<;
M+V4<6O+OMDW)K:]SYME8@E]@'<6UMNY:=;>8;E`B:K2PN7@&:Q_8JTYQ0E'1
MP1,9M&BJ5(!8G`Q2D.N8M2-[Q(2I?=#'("PJLN-M[*-+7EWVRCH]M0:<VVL0
M2^P3KVUMNY:=;>8;E``K+T+<RC0$0+=23=&`!$&]]M8@MP%,96GDJ!">2\0(
M!S)BG:RC:T"OY3=4K0E0KX0'8!A,`>N``/JT``5)B@T91HC0:`,FZ`!&AZ`(
M^$C0!,!>WU`$?6`!!&P6EACV9B-(]419HB!E)5U4YN0J);C@P>B)3'*D`FYB
M@T.8:F$H7@L,K+A?8RC34YEETHZ+=0'G*OI$'LO$C>ZEUO,4I=RR\T,F5EPO
ML91QJ<WEW2;DEU.^\F^D0>R^QM=2ZWFJ4NY1><`926"^QE'#3F672;DMU!=\
MJ^D2>R\"(74NMYBE+N67F@CD590&JU6S`A+R4.63<E.!>\'`@T[FT`#&`J50
MYH4O.'G6@"@*^9+_`(G&TJ/_`)DZ\E34'^:?+;0:>N(AZE1#(*2]0JSCJ5"M
M))R(@%4[A#\DA40*)A`/5$`#LJ(E`*I+>;<RC@J)+[9-R:@"+;F6UB2W"4#+
M6UI<)"5I>84P"J2PV7LHXM>7S+9-R>VHL^;96))?8!W%M;;N6G6WF&Y0(UU9
M;GQE[6/(8SL`.4DHY$MHL+G%HBP;BJ*1C+V%$AP.":8B!!.8R(+"JRXV7LHT
MM>7?;)N36B(-.;96()?8)U[:VW<M.MO,-R@P"LO0+F4:`T+=23=&`!$$+Z5B
M"W`4QE:>2H%+Y+A`@:#GQY(R6'@X;,4TOS@X;<9%\NNH`^)I]A4SQS<I@OJ%
M;@[`KZM`!EZ;/^'707^Y75G^PT%P$U<!2W1C[-FNK-GJN<:P26Q)MO3K+6%N
M_P`ADBO)6(2ZE=TK.V<I'/,7-#(F>+`J@<IW2C<$!`QS#4Q`""-4=7&E<TV7
M@V!83I7!,=SZ9=&+CASPPQBV/*(X=(I@\=R$;@-T&W[C!J0B:A5"BK1)-(#M
M5$3G"\)%LZ4V;BWC49B3,`PC/N1X7.S,B90HS>N>;S0=8Y%E2$A@);03W`)J
MTH%0D1P:7\2CJI1E>4_M#O#OM\UO7M[MV4X!R`TQ4+DHT"U"X07=&$`KVB!1
M;E`1`/4J'`<6Y'TFOHU,8EG^0-,`QQY-X=EF8:M-/8QJK$74I'2NN\Q:X^TC
MX^222;/B061)8*G/02R1@:J0T0W<JBV5[B@J&Z-NLOH?9X)NO8##IG(VP7`M
M/[<S+:4FTTWK=,97!,:SUI&9CA\OCK1X;)%9'8<])EF8Z+EV+1MD#4%7EQE$
MS@`0ZR](MZ-7+XC)YN)Z9([*,5P.*9-GL^71FKQA4\72SZ7Q>->QZLLNUY&'
M$<:W\;2<K%;LD8MNS<F%-2Q,@=<2=/\`I?N9VB&BM&^'.<@;Y>9J77N*`T7R
MALI(+L\H4;EQL4%,@04F'9TWH@+@AG2PE/50XF#;\4U[B^!I"C@VO]=X8B+9
MNR%+%(&.QU(6;5)%!JT%.'AV1>[-D6Z9$TZ6$*F4```*%`W&Z9^]1GOAU\%X
M`NF?O49[X=?!>`+IG[U&>^'7P7@"Z9^]1GOAU\%X`NF?O49[X=?!>`+IG[U&
M>^'7P7@"Z9^]1GOAU\%X`NF?O49[X=?!>`+IG[U&>^'7P7@"Z9^]1GOAU\%X
M`NF?O49[X=?!>`+IG[U&>^'7P7@"Z9^]1GOAU\%X!N:&F.^2M$HRO>&U?PAW
MV?@+:G_9>`<;IG[U&>^'7P7@*\=0&V]8ZI<Z-_/%C$=.J["WY@.L=6.AQ]#(
MTL;V[F)):.PV=,YD&IE,;5YPJM"2#0IW:'>QH7E"L<@49F>O7T6+F<G\6DE]
M)3JB;S=C_-5"::FYADQRO6,/%SNW8C(F9]6J2K_-@QYT=V\12:.EET&*Q5SE
M4Y":P=.<#D8V5QV'E,$)C1L)DL?QB0Q`88J[*&^B[S'X]QC_`(0T2CVR+:+\
M*42[NF5-,I$K0`A:6@'/[JRZQ>B#1^Y6VL^I[7^,/\YF\`92SK)9[54?FT43
M7LZYR-@DVD9A2%EIAQ%.FV.Y`J+!-NN9=O#R%B)Q(!50V+".LCHPFL=R&7UO
MC^,O\!QO9FHL&FLEQS6CJ(P]MEN=2KM?!I]920Q6$,6`QB?*L#F8,@",9("<
MB9C+@<`"#9'TI7H_X##,.FB82NO@678.&8PKF'U7#KP;#'\ORI4\LQE6:9$B
MQ;Q>6P1>2E4@2.@"\.F1909(S!JN$JZSZN.CC/>I%CK3`M2QL?NF2S#/8B/V
M";56/0Z'T@QS"IAK+37TW[LWFD5LGQO`I&+8E.4DI(,H901;A')HKG#I&Q/,
M!',Q[O''*#)N-A5W`G.`($\TH';E*)C!V!40"OE'@.,.#^D7]%3DCNA,)USA
M$K!KO%8)MD>A"H2SV9<$3-*Q^+(XM@^2.`G%DT8XIB"+<[Y1^P21%=54J9`G
MO.>M#HOBE]*,<^US%BGL'&.G7+M8.Y_5T8XA(3%]H0NS)G4DH66DHOPW'6N%
M,L3FDUBHGOB'#XB#4JBCLQ>`43W53T@XOC69EE]'I,(MDQWF^R3&W.FX=CX\
M\@]LX_J;<T*=D_C6D1)3F4YMDC)Q(D<JD1D8U0)!ZJ5$+N`F3I1W;H_>&/Y%
M/=.V"QV$0<3G+*-R-HKA;#`%IZ7<:WAI.*R$D;%-4UI2-4Q=VS9-GZQ`*L1D
M*:!CH(IG,%Q+IG[U&>^'7P7@"Z9^]1GOAU\%X`NF?O49[X=?!>`+IG[U&>^'
M7P7@(]RXTW]+-5VHQ(A]*IZMSEZ!J_F\S*RRC,2B`GI=6E`\E>`D$QINAK4(
ML1H>VYT[`!&UQ9=1F-`$P)5]8!/ZP5`.:;H>Q&+$?=.7>Z=@`]CSDWT:#2H@
MWNI6ERE*VEN")\A-D'YZ];\A&$%+\WNX[N>[D"K"`3>K^Z<HJ3`Z0B90&O-N
M,`%*96VX2D`X2P<TUY_+1BQ^Z\N]R["M!?<F^C0;:@#:ZE:7*TK:2X(6W::>
M_-[D?=DH4RP9AKL$"NW<B1O;].,0%+G&0:N%2"8O+$P$(``(F\M`,8)I$TS4
M:(Q=*FMJY=UI<I;6C2@#;97V1'U@J&0-,U"J,92O;1RZK2XM:?@GEMN_;IP&
M`--5+<C%TJ2ZCEV(TJWOM`6@5$"BK2OE$">2HV@VS!YL(>3$4HLHA&.Q,8CM
MZ`E'NJ',$ABHH&`2U<6C>0?-3\XMQA("'$#RQL5Q8Q2,5$C8]`#S573PZYR&
MC8<53G,?OPG5$#.1`3+K"82IU4-<<Q0V`IIKS+T8L/N7,M<NQI4&/.LJT"MH
MBYMK2MJ5:7&M`*::H6Y&+`:)WVN78@`T:\VVK0*@!A6MK2H%)6EQK0YB^E2]
M*GJ[T2>CL%WUO?7V;[`Q;/MI1VI(R)U4:#=9`UR*2Q'*,P1?.D<LE<9CAATV
M&'/$SF(Y%<%3HT2,4RADPX!C]=BZ#G7N#GI3ZNFB!_;N&S?3KM8EERA+&P[4
MC@/>H0I1]V):4PCYU+3`&^NU="]#6])75D(T/9<;3Y0$0!SR[A#8QK0,)4;J
M5I<>E;2WA$'4!];M]%MU1:=V#H+>_0CU-;)U)LZ!=X[E^(3Q-0]TDF)U'#EB
MX1<-]E)O8F8BY%HQ=LGS51)Y'/4P<-U"K-TCG!A^KG]6WH9'6UFG03TF='FZ
MI;;>YU]C[`G-Y]76-:2RZ:F8W`X;*\J@L8D)7&YF=-$0V.8X@BS8LXV-104<
M*.7+B]=0ZJH>TTW3EI+S[.G_`$(/W7EW:XQ(*]K[DWTQ<:5`&UU*TN5I6TMP
M84T%IYN'<&^C='HLI!81<LT]>XN1N_.S)(*L1>HDQXB2@-@,0Y1,56PYCV@%
M`,(<O-`^@*Z`NF[KVSST@6MM41;38>1F)*X%K5TJF?4>D<V?B_#+L^U;BQ(L
MH0V09,#@AD$U#JLX(RC@(Q)J51,J(=JP-,U"J,92H5HY=UI<2M/P7RVW4]D`
M]<:!@IIFI;D8L`J2^UR[$0"K;F6U:A40**UM:5$"5I4UH!#37F7HQ8?<N98Y
M=C2HLN=95H%;0%S;6E;4ZTN-:")H::[T[O3BZ<QGS@*Y>#8<6\;SP2N0,4Q`
M(9P).Q.IBIU#SC"4%I#37F<Q&+#[ES+'+L:#1ESK*M`K01<VUI4"IUI<:T`I
MIJA;D8NM"7VN78@`T;<RVK0*@!A6I6E0`E:5-:!=-T#W&+K0*_A3NE;25I^"
M>2Z[]H`]<:`":;H-$8JM!I5R[`*VJ6U_!!H%UM?8$?6"H(V!IKP]F)$HLP]R
M1$!,Y>@!CBW6$M1%!8UHJ`C4;C#03C41`MP+#&FO/L1BQ^Z\NYR["M`?<F^C
M0:7"#:ZE:7*TK:6X`YIKS^6C%C]UY=[EV%:=_P"1?:T-2ZUK?2M+E:5M)>`8
MTUY]B,6/:KR[G+L*A5[R;Z-!H(@#>ZE:7*4K:6X$<B:9[JM[G&%)>G0W>7EU
MO>%`((@5%*AA*"5?.``$3^4`"X%MTS]YC/+^,N_)4W_=/+;3]NO`8NF:A5&+
MI4M?PEW6ER=U/P3M$"WT]D`]<:`%-->;<C%^5.^UR[&@5:\VVK0*B`"O;6E1
M*2M+C6@$--5)>C%@'N7,L<NQ$.UCSK*M`K0!<VUI6U*M+C6@C7--<^+O3C"F
M%X4%2D<O!**8QX"YL'DI@8Q%!7L`Q3`8"IB-HF,)`6$--T)>C%@/N?,L=.Q`
M.QGSK*M`K01<6UI6U.M+C6@`::\VY&+K0M]'+L:#:WOMJT"H`85:5I4`)Y*C
M0-"ST904L/[RG'E2_.#AMXHKN3J5\32]H4[<A1\^OE$.SV>`9NFS_AUT%_N5
MU9_L-!<!-7`4IT:]S6/U=M%_(EP#Z$,-Z]93U87S/)I5^>`:=2>YW$BG*Q3-
MLL1\JHHFN4R3<JMZ`E`J:AZD,$,Z>ZJ<'V3D6NV.!:NP&'<Y6ZB1Q24<0$%%
M.H95_@,TNU<.(YA*K9!$J-(_&UX-0R2`\I/DT$S-PV.L%TDASP=FXMXZ7#R!
M]",^[N,4::5,)?&]<\X%0=D1*`W<NV@CV75[:<!(S@)?Q*.J:-NY3^WS'5/:
MMZ_])P#D`3%0J>-`*A403="(!ZH@`J@`C3V0X#ASF/I2O1YMU)I65U$SRM3'
M,AS35[A5#4>N9-8Z."Y:S@8@(]&3R5&0=X3FD1B*&00KA)(S0L2R8"Z!HZ68
MMCA.N.==/3D&*[?>Q.AW4-KG76+9QD.QY".Q33[S'5VN.;0:8R[C'T9B.P9H
M7SC,)K+7,W&G51,RD44I)3G=Z153.$83_I#?1H)#S7.OL8E%E&L?&%1E>F=:
M#?JM&^5QJ+)$$,O@H@?H_&2+A>2[R8P,T/#7!BCW@J9%`F4?2_\`18XQIYDL
M'LF5R!NWB49%HUCM;9LDK(N'2$V+&%3=/VK2+CY=P^A.Z&2>+MP04>LUE!*T
M<IN>`NCH+J"P+J<UTSVMIG(D,EPA]+34(WE'N.Y+CJJDC`/CL)`J;">:L'BK
M7FD`Z*Y2"DND<IBCY0`)II,_91G\&Z_C.`*3/V49_!NOXS@"DS]E&?P;K^,X
M`I,_91G\&Z_C.`*3/V49_!NOXS@"DS]E&?P;K^,X`I,_91G\&Z_C.`*3/V49
M_!NOXS@"DS]E&?P;K^,X`I,_91G\&Z_C.`*3/V49_!NOXS@"DS]E&?P;K^,X
M`I,_91G\&Z_C.`;F@3'?)6AHRO>&U?,=_B+:G_24X!QI,_91G\&Z_C.`KGU"
M[CP/3[K1'YT,90R-79G4#@&IM<NVN,L\@+BVSLW2F8[%<C6/)O6Z\*F@<%6Q
MWK(JKQ!)R<P$Y(+&*%$YWTD?HVUIO(,6DT\9G4&;O=OTX<'Z=LF>L(_,M21$
M5/[/QF88R&+I/YC,%8)PHX.1!!SWD61TCJ<X[=-4.H.OY>/R'&86?P=7'U,,
MG<=Q:9Q)6-9+LHY3&)/'HY[`'CV:1DTFC$T4LD**92E`B=````*`%!NK3KPZ
M7NG?;S;4G4)@#R7FI?`8_(WV2AJ^.S?'4<%FASB-30D%U'KB:=(*Q$%EZHL4
MV:O,9QLD`%'F@58%FO>MGI(GX;-\EU9B+=WAD/N'4&'Y=E4#J-'&8QSG6PET
MF.+9G*QTN;'\A688D]CDFSN169&?M7"1"-T5;`$H5ORCTHG0<ECN"YG+:5>S
MV/95@+7,(64_,[KV15A(.7SIRK(1#]DYRHT@S<1V48>O(2(-4W#)&69-43K>
M)N62*H3QK'K3Z7]B]3+#4N'ZB"*VS(9EL""9;"?:WPN*1),XY@LF+V6-D+2?
M<96R=Y=C.!.V3-%=NA).HN,2551)'J,U50Z7L?&0CF9B^''HR;B4A2.0,800
M((%`3JE+41]<0#V>`XM0/I2O1S9R6289AK]/%CHMYYJSC<WZ>DYD9]V[BDVN
M40;`F.-\H:(.)"'/%MG'?3M6[M.39HF4,43@D$Z9UUT=*V/&T>RSG5ZQ66R<
M6Z;\RUX_E]88NZQ['<;VY![/E]:/#OEYQ9*"/@C7"Y9LNDDF4[-S()I,`<<]
M42`_9KUJZ!B(#,W>8:=GSI0\+O`TY#3NN<*$9@<%VI`:CVKCIU'^7GB%%YJ=
MR5M(O#O5D8Y:"$SQZNG8HF0)3Z2-]:FW_CN2Y#HW!6NOX:&SUI'3C!YB$+B#
MJ=E'^MH2:CLF%CC4B_1?-'./OVS-!TN8%%4V5"50(B8P7-I,_91G\&Z_C.`*
M3/V49_!NOXS@"DS]E&?P;K^,X`I,_91G\&Z_C.`CW+@F_I9JNTT13Z53U;B/
M;Z_F\S&RRU2VE]+J^IY.W@)`,$W0UIHJM#V7$=TK1Q9=0X=EW*K3U+_8X`,$
MW0]AHJONO+N([I6CWDWT/Z_=[J>LI3REH$49"&0?GJUOR#P8)?F\W)=STY$5
MJ>-ZO[IR125!*H'[KS;_`"E!6V@B2@2P<)OS^6:*_P"EY=Y'?KON3?:<*T`6
MUU/+16GE)0(5W:$_^;W(^[&A`6^F.N^[B\3DA;6?3C$.5SP;J$5$0#EW<L:5
MN]@`":A":J-IHNE36U([K2Y6VM%/+;97V;O8X``)JH5-%TJ%:$=UI<6M//\`
M+97]NG`!0FO-N-%TJ2ZTCOR5;<RVI^P;>=2OJV5_=<`V2X3G@\G4T6)O#'5U
MB;T:F[LWY@$`IC'[?PBV@"/:GY:&J"+$`EPQ7%@`6`)!C\``@J1X"X$"-A^:
M!P/RS`K0'-+BE$!%*H!0X"#^0)OS+S17_1<RPCOUF/.LJIZH@YMKY*I5\AZ@
M%";\RXT56A+[2._+1KS;*J>2[GVU]025\AJAP)^L;=1?21H+H"2A^NWIZGNH
MK3N\]EL-1Q41KIY"PV<:^V$ZP;-,OQK9^)SN3.FR<#-XP&)NP;N6YSJ&,N""
MR+AFL[2.'FEZ&OK(OHSNA_1.%]._3MZ+K;Z>)XDFHK)YJ_G-9Y=LC.<L<M">
M-YOFTV:$;*RN3Y$=`G/`BJ+5FU`K=HBBT00;D"TYOK@/2!0UOHL,^KYUESC6
M%/(O9=3$_7Y5:?\`*]C@$,K];WZ+W\;)L9;T4V8/8AZQ?-))G*GU2XC7<<Y;
MOD73:3;N<0.V78KMCIE7(H44S)BJ`@(4X!I^KL=9GHE9_P!(CGN`=%O0IMO2
M^^NIQ'963Q&:[0S'#\[P[2>`8OBTIF,IJS5IF"C?(,8P^;DHA-51,J2[M4RI
M6ZKHS1HT23#WG'";\^PT7Y5>7>1WY*ON3?10.T`[M=3UE:>4M`1N@F>],[1C
M*<USRJD>=@\A[RQ5M-:)>5RP'M#SKJ>H'`+*351H:+I4:>8[K2X]*^Z>6VVO
MLU]C@``FJA4T72H5H1W6E25I[IY;;OVZ>SP`4)JI;S1=*DOM([K2K;F6U4$*
MV\ZVOJV5_=5`($WYEYHORI<RPCOR58\ZRJ@]HAWFVOKI5\AJ@B:!-]Z=WC%T
MYC/G6D>A4_=XSO`I7FM`E@.`)Y?.Y=?(8!!80)OS.8:*K[ES+"._69<ZRJ@T
M[>\VU]=.OD-4`H3="WFBJT)?:1W2MK;F6U4&@";G6U]2RO[K@``FZ!4T56@5
MH1W2MI*T]TK2^[]JGL\`"$WVT-%>0:5([\M%+:^Z>2ZROL5]C@$C$)OP]I:,
M6!NY(@`&(]H"G=UK;JF*>WF\FO8`TO\`5MH"LX3?GV&BO^EY=Y'?K/N3?13U
M!%M=3RT5IY24#)PF_=.6:*_Z7E7D=C^/\CF6G"M*M;Z>LK3RDH`<)KS[#1?_
M`$O+O([]=[R;Z'[>SNUU/64IY2T!%)!,]U6H,8);R4"QY=9WA2RMAC#=;RJT
M"E0/ZE*`MI-?91?E&GF._)<:G[ORVT_;KP``350J:+I4M:$=UI<G=3S_`"V7
MT]FGL\`%":\RXT72I+[2._)5KS;*G\MO/MKZHDKY#5`*$WYEYHNGN7,M([]=
MCSK*J=E0!S;7UTJ^0]01+A-\^+O&+$W?"\T2$>VV>'AWBSSAH85`7LN$`H*=
M>T#5!84)NA+S15:)<RTCL`K1ESK*J#V5[Q;7UTZ^0U0R4)NA;C1=:$NM([I6
MC?F6U/Y+N;2OJ65]7@-"SWQ3E8?WD8\4OS@X;S.25R"E?$TZ<L3G$@>?7R_N
M?9X!FZ;/^'707^Y75G^PT%P$U<!3#0K_`&##ZUV3-`]PY'&8G?G6)*-RIXWE
MD]D!8R.ZF-RNW!%8Z+E$U9624<HK`1)HF)SD,0I$SJ>:8()UCUL!M#8>LL;B
M=?Q$5.;+4[[$3$UA2K5]CYR8*YD%CY0FCEKB4@)4"M?"DT3AS7#11-RD)VAR
M7!=Q(F=ALW%_'76('+]",^[OX4PFDS@'C>N>=S>]R2I1$3"G;2E``U:U"@2*
MX++>)1M5HVO*?T_!G7V+>O\`VO@'("R_JKQH!ZH@U=#3]KO@5_TAP'%#(O2V
M]*2/TP5E-19;-IX27:L&X!+4<%)2$I":UG$RXY)P<0ZRA.5=:]V1C^-M)^/E
M12)$1K(8WQ!5LNX;)@$XN.OS6,)*;IPB-TM/MI/5>N]O;$R"!6QO7L$CDA-8
M;HGM9S<>W3+L-9H*62Y.DM*M9)Q^!+$='(<_B(*M>`U&*])[T79/$P1W+,KW
M(74(WRE_A[/3:T_)X^^8-G+\C$#&D6R4C.)R*0%CT6I3/G9%R/$40:`NX1!N
MDO2==`F'R81LA'JPLJUDWC-%!OTV31UR2N/3D3@ZJ#<T8JO;)1J&:@)T0$'+
M)FJNBN1%P(MC@R(>F4Z:\'V9G^I,KP;8.L&6OLHDX:3R3\V[=SCDG+2V68?'
M0#Z'BL;R=S,/@SHF9NIBXK45T&\6\,Y(56PIPW^3],!TXL$&RZ,9MUX/BC.-
MDVRFF9N*<Q1EFZ#R0.<9;)6C-VO`,)*/=O$4UKNZ/B&1%94BB!0N!TS]5.&=
M5L+F&2:N-('@,0R%IC:\ED&.N809%^YA6,TJ:/;>+O16;-4WY4C*`<2"J4Q0
M&XIBE"S-LQ]^C?>SKX7P!;,??HWWLZ^%\`6S'WZ-][.OA?`%LQ]^C?>SKX7P
M!;,??HWWLZ^%\`6S'WZ-][.OA?`%LQ]^C?>SKX7P!;,??HWWLZ^%\`6S'WZ-
M][.OA?`%LQ]^C?>SKX7P!;,??HWWLZ^%\`W-"RW?)6BT;7O#:OX,Z[?P%M3_
M`+7P#C;,??HWWLZ^%\!7+J%W=`Z3=Z()F>,J9.?;/4!@6F<1<Q6.H3)L5S3/
M$9EE"9.[3>R[5RS8L>2JFX<-0.N@U655&B1%*A1;(/2J=&*<OD6.2<'E<I'P
MSC=4?FCU[TZ9,G',<QTW$1>09OB3IO-K-`F)U]$N%CH&1YJ3QPT!N0ZBZR)#
M!U`P&?;9;C<-E>*.XE;&,GQ_%\AQQ9*-<LTEH&:QZ/DH=1)H5Z8C5(\>Y3$J
M8"($#L]3@*$=6?I"=2=,.VTM3[<UGE^0]_P%CF$GET#KIOE^-,\/F`S5N=O(
M",X616.,+AF5N%&H-S)@UC'`*&*5PG>'ZPKK^T=E6-;#S'6&O<IGL9Q':FK,
M&R!Y$:PA\;D9/+=A%*VAYY;'LBS+'YM-/'7C)NR7,]11DR+&1,FW%K:XX",I
M3TEVBE]2X%NN2T?E#[%,WQ;()R&?R6"8(@W9*8OL?6D)EF/JOYS/68INF^0Y
ME'RC)8$RL9A5LB#58[Y5NB(;YK'KVU%L[J6C=)0.I)6%SB2S'/\`'&V>S.)8
MC')(/L<P-_*C(+F99;(9?'/\NQW"U2-VSAJBY"(;L7#D4VSQ@54.E[()D(YH
M)%(TP@R;B0G=W(7""!!*6X7=`J/97@.+\'Z7CI(R<LBUS[5F>85W=M/MX]ME
M>BRS*$RZ3B`'*8HCR.G'L/%)+0[R*2<.)!PU9'1E$>\JI-TEU$PL"WZ\M43F
M089CKK6+QVUD<'Z;=A(R1(774REKZ.WK#RDIK\F60*>QC9/B[C'VYE4B<IBJ
MH8RRAVY.[F!=4&'-_2,ZQQF2R_&<EU#/*2^/8IM^7R#''K'5:DP5O@FRG>K\
MK1F8;\Z;M6/Q7)W#%W(!-.K8I6,:N#.3D.W=)H!/O21U(X;U+X]DV2:UPDVO
MX_'=@-8>2CI>!AHE],OI+6L'D;3(U$,8GIAB9-S#RJ#5,5E^]"FU*)B$3%(!
M"YMLQ]^C?>SKX7P!;,??HWWLZ^%\`6S'WZ-][.OA?`%LQ]^C?>SKX7P$>9>6
M;^EFJ[5XFGTJGJW-'HFK^;S,K+!*]`H`!Z75`:AY*>7@)!,2:H:U>+`:'MN:
M.Q`!HXY=U'H5`#"E7R5`#^2H6@&)->?8O%A]TY=S1V-.QYR;Z/2UH)F]U*5M
M4I2XM@1/D)9_\]>MN0XA`2_-[N.[GLI`RU!F]7]TY1DI!-(!*H9KS;BC<4BM
MMHG()`EDY)GS[%XP/NO+O:.AI7OW)OH]+=:!FUU*5L5I2\M@0KNPD[^;W(^[
MJPQ%QS#78HF=,I$S<Q1SC$`1%8J+ELJ<2!RP,)%#`(E-VEJ!2!-0EF:C1>,I
M4;:M70C2Y2VM'@5$"B2OKB`^N%`+9FH57C*5"OX(ZK2XM0#\,\MM?VZ<`%+,
MU+<O&"%27VM70"(5;\RVKP:")05I7R")*UH-P-DPG-FAY0HJQAQ&,=@8I63T
MPG$6R`*%(0JKLPWT<`4.4J/GI^8>TP'!#AZ4L3%<5(!F"*1,>@"\E1D\273(
M6-AP42.0Z<2*2I2E<@`"T;6B9,!2)8<@AL!235"7KQ8C[ES+6CL`&@,>=95Z
M:VX2N;:UI<E6MIKP"DFJ%N7BQ&A+[6CL`$:->9;5Z-`$P+6UK0#$K6TUP5KZ
MN>D7477%H#/NFOJ/Q#',YUIL&+%H\:KLG*4KCTT@0#PN8XE*@[%WC^6XS("+
ME@\0,4Z9P`A[TCJIJ!IW1_T-Z+Z!NG'"^FWIRP?&\;P7"VB!G+]W%F?Y7G&3
MN0;DGL]SF;`IW$]EV1N$2JNEQ3!)(A2-VR;=HB@BB'+#TRGIW=:^AXV#J77&
M:],DSNV8W#@D]G,%(XQ.P&(Q$6E!Y`M`+1DH>6CI=THX,<Z"MZ*9@M$P"`"8
MH@'(-'ZXABV8P2JC+T3FV,IQF<:/V9E$<QCIV"EV*P2#%TU5,EJAS'R+13S4
M5R><0]JI!#M`"ASOZ(?3,]#7H[]L;UW5TN>A+W[B>>[WG'C]\_D]@+2J.ML7
M>#WM;5VJ"+ZJ.?$-<KSJ"<BJS1$%%53`@8XM&L>@T#I3-?7.F^.Q[F7G?1@;
MQ@HIL)2JR<ULDD;'MA<++H-"N7KS6#=LF*JZS<@5,6\]P%[3E`H=D/0V^G1P
MSTR4WNZ'P30>4Z1D=`Q>`2\TKEN31>81\R;9"VP&3%M&KPT?%K)>')X;<H98
MJ(JBJ(%#S:"'>@2S-1HO&4J-*M'5;;CVU_#.T0+;7V0'UPH!;,]GN\9Y0K^"
M.O)4EU/PSL$2W4]D0]8:@%+,U+<O&"%27VM70"(5;<RVKP:")06MK6@F)6MI
MK@"$F?,YB\6/:GS+&CL*@`LN=9<]-03`5S;6M+DZUM->")H2:!T[O5C`#F-.
M<8K-X453@VC.>*5RY2E)85P!/.5H)DZCYABF!84DUYEZ\6/W/F6M'9:T!ESK
M*O36W"5Q;6M+DZUM->`4DUYMR\6/82^UH["HT;<RT!>C0!,"UM:T`Q*UM-<`
M!)J@57BZT"M&CNE;25I^&CV":[]H0];M`$DU0:+Q=:#2K1W2M%+:AWVHA=;7
MV`'UPH"-B29\/:`16,3$&:(%*=F\\TX-U@"X!7:F``4%(1"P@T*<*`(EM!88
MDU0]B\6`^Z\NYH[$`J#[DWT>ENM$S:ZE*VJTI<6P`Y)KS^6O%A]UY=[1V:E>
M_<B^CTMUMS:ZE*V*TI<2P,G+,^?RUXL/NG+O:.QI47O)OM>!=0#-[J4K:I2E
MQ;`12))@6JOND:<EY*$[H[$XD[PH)*VJN*B4HI5\P?:G]K4!*"VV9K]WC*5&
MGX([K2XU/^V=HVV_MUX``LS4*KQE*A=1JZ`:7)W4J\'M$H'I[(AZPU#!23-2
MW+Q8A4E]K1V`B%6O,M$7HT$2@M;6M!,2M;37!DA)GS+UXP?N7,L:.@K06/.L
MJ]-;<!7-M:TN2K6TUX(EB3//B[U8PQ@>%%4Q&CP`!,&``YLJNK890X+@03&(
M!0,F`B82F*H"PI)KS+UXL1]SYEK1V6M`9\ZP!>FMJ)7%M:TN3K6TUX!235"W
M+Q8C0EUK1V`"-K?F6U>C0!,"M/+0!)6M!N#0L]+*`EA_>58\Z7YP<-O!%NY3
M4N\33[2&.Z4*`7U\H#YO9Y>W@&;IL_X==!?[E=6?[#07`35P%--"KY[$ZQV/
M-HSF,$@8S?/6-*-F+?7V49+D)63#J:W0Y40*VBLV9K3TFHX14%)%JU346`Q$
MB$%3SC!I."]4>=9Q+ZL8E@XN`/M!QCQV),FUZ\AIB+^D6I?SC%<JPI]L.95T
MI!"8T))@":9FCDMXW(*(BJ%G2-LU3V;BWC<UBSL!PC/N[^%XQ+QQB`$WKCG`
MMWO+I0%;S"02B6RVTP#=<`E"0G*<IXG&_AC"O*D*?DUQ0/,;UJ'BO;P#F"<I
M4*O(\0KV@$:X`:>K0?%1H/`<99/TQ.JV+Z<1;ZIS<7N.RVP\>;K9!#0&#!,1
M>-96WAL/G,>6RW+8QQ)8IM^#*SDX=PB0R/.DXABM1R_3%(-ZQSTG>'YA^=LR
M&I9=5'6^I]E;`7?MG&"91&9E%Z_V.CKR<@V,GC&<S;*.C4Y&2(ZD)&2.A&MT
M@='0,^0;*N1!F4]*[H_'C9=]+M>Y7&?0'%FN:2V08+AV-[+P5]&MXDC%P]P_
M-(//(Y#)V+11VVC63YNW*WD`?MB-S")UDD`LUTL=8VINKN;V)`:^Q_)8B8UP
M5BODK?.]6&QQ,R609+DB#$[)^ED\PR?K2+K%/$%4P.51(5D@5`'2;E)N%U%8
MUPO3G#"K44*J'-A3J45(-2*!?*#10@]H#Y0X#)HYR<HE.:&,4U;BFA5#%&H`
M`U`900&H`'^C@/V@R>M4BHMEHELB2MB2$.JBD6XQCFM33E2E+4YA$:!Y1$>`
M^W+E?QV/^3'/SMP!RY7\=C_DQS\[<`<N5_'8_P"3'/SMP!RY7\=C_DQS\[<`
M<N5_'8_Y,<_.W`'+E?QV/^3'/SMP!RY7\=C_`),<_.W`'+E?QV/^3'/SMP!R
MY7\=C_DQS\[<`<N5_'8_Y,<_.W`'+E?QV/\`DQS\[<`VM$Y3OLK^&,*]X;5_
M)KBG\A;^0/%0I_\`5X!RY<K^.Q_R8Y^=N`KMU`[W;Z*<Z-1G,=?94?<F^L$T
MA"+P4$5Z;%I_/49AO'9/(MEYQ-R,1'"T-WQ1#SV[,RJQA`B9@,%')WTN/3NR
MELA@W^)[B=1F.K;FALLDGO3]DK".899I>(C)_*,1`DYD3%I+/I6,<K@Q636[
ML]>-BMD3+++I@`=-\#R,F;8]$YGCT@S5@<N@,8R>%56AW+916)G\?CY6.4.U
M&7$S8YV;H@BF)C"01I4:<!1#JN](IB?2MM='56?:KV1E+!S@C'.93-,/P,V3
M8RPQR3-F%Z#U,N0)+G>)PVOLD=*H&`J9$(L>:HF5TB8058%Z0S7FPX7,LGP?
M!<^?8OB6V=3ZOR&26UPA$2997:*J<>GDSC$'.:$RWPW$EBHHO6IF9IQ6],[=
MBHV.DN<*\9!Z8/6N/XI@L\?0FV',#EN!QF:(1A\)@V$OCR(9@ZQ9]!OL5=9C
MXHJ[Q>2@SH.3M$5D$9A>,8`(*/DUD@G+6WI"\4V;U(L.GYCJK*8&?D\PS_%$
M\UG(>`9M&Z^*X3)9&W?.(YIE<ADK-[E4/BRBB+=9N3N\2,<Z<JD)(L45`Z1,
M22P1S,2.H\X@R;B4@Q[@MP@@02D$_B@@6X>RM!IZW`<;(/TR>D)<7R6?Z?W3
M@9FZ$VE'%GM.JR[:4<QD7WO(F)I,F5-86$:I1<C&`J[?.6[$B<F!W:K9L@X6
M($W9EZ1;$,"<Z:6G]49TU:[KQ3IYRF,R%+$8=S&0L-OJ%V/,Q;*8589F\EC2
M^%GULHT=LNZD4<NGS?NMZ15E4P=\RZ[HO$HC+IO(=)YL@\Q:$W.LY;OX/"3$
M?*Z=VI`ZORZ(-,-=CR39@P=H9$7(3/G%D>ECZ*ZRJG/26;IA*W2AU01753`9
M)E&+XC(8"CBN>M<>=1V1QD:#^44D=;PV5-9M0D!D4FR0*LQG2-RHJN!>%(@4
MZJ:15$R<!<7EROX['_)CGYVX`Y<K^.Q_R8Y^=N`.7*_CL?\`)CGYVX`Y<K^.
MQ_R8Y^=N`CS+TI?Z6ZJM?1H!]*YZX!BG1A$1UYF($H(3):`4]!'L&H!3L\O`
M2$*4O0UKZ.`:&M$8MR(`(@O9<`3!;@*8R=?)4"&\EX"0`R4N-UCZ.+7F671;
MDUM0=\JZDP2^P3H74MNY:E+>87E!$V0HS8[KUJ*,A%ID#7NX[BJ0[M4X@:;U
M:#8`.6<1`HHG4;B?S1Y@)*`%G-**(2R9*6&^Q['%J*G+NBW)[0'OG*OI,$O$
M@';W4MNY2E+>:7E!"N[D)D=>9'W=[&HK'S#70I++0[I5*WZ<X>"5R9))B9<4
MR\L#&!8X&$AJ"2H$2":A2EJC1['`%1M`8MR(@%5+0$0EPJ(%$@"-`J)1'LN`
M"AGE2U?Y;'4J%?R8YK2I:A7Q?L&T!"OKB`^I00P"4MYMSV.$*ENI%N0J`"A>
M!:RYK1,4JH`/;03E'ML$#@V3"$L>'E"&=QZHFC'93$)#NCBK5JB"A2)=\DA,
M*MJX%+R'%.:F'+5Y9BK`AP]O)HXIBJ0*LFR:6/0"?=3Q#ENJ@1.-B2G;F2$F
M/`W4(5)P4"C',N6*B8"V2Y1DCAL)4I<++WT<:G+YEL6Y)=0&?-LK,'LO$CBV
MMUO-3K=RC<T`$I?S;GT<-`)?2+<EN$`;\RVLP:T#"56VM;0.2M;!%0.0?IF_
M2KNO1!]..O>H:2TR??;+.=RQ&H%<<B\A4P(81:7PK,LN2R%S-.([+4E&Y3X8
MHV!N+<ACG=D$%/<Q!0//!K[ZXIN+<93%UUZ(O:^QHWORT<X<ZUVADN=JIR#1
MF6348@G#:!?M1>HMCI+*I&,!TT#7T`!*/`4TZ]/3HXSZ2K6L!JWJU]`IN?.(
M;$<IC\NP^?C-G[)QW-L4D6CHBLDS@LLB>GAM,,87+8]NFPF&A%2HO6M34(Y3
M:.&H6PP[ZU]M736O8'!<`]"#L;6NL-<8PW@\7QN%S/,(#$\,Q/'F#E&/9-6K
M?IS9Q\?$Q#!)"\0!,EB*IA$O,`4@OQZ)WZSZIZ4;K'PWI$8]'+G3CW+L6V+E
M*N>#M@VPXZ":8/C$QD*!'L,C@6'JJIR*Z+1H*HN42E5,-*BL0J8>G_:VIL.W
MCKG-M0[<QC#]AZQV)C\IBV983E6.*2L%D$#*)/$E6$BU5EB@>P#MCE53%-9)
M9`543I*&2,@%5^A3T=G31Z-K4+;1W2C@[##\8?Y),Y3D4]+(N\AS?,,@D?$C
M(R6:Y:Z7-)3PP\4JWCV"9U6R35HW`B?W0Q3!><4I:HT>QP!4:5BW(B`5/0!'
MQ<*B!1*'J5$!'U0```2EJA5['4J%:1CD!$*DJ`#XN-!$H&"OJ"(#ZE!`*E+5
M+<]CA"I+@+%N2B(`+?F6B,N:T3%*K3RVB<GEL$%`"I2P67O8XU.7?;%N2W4%
MIS;*S![+P(O;6ZWF)UNY9N:"-JC*@Y>"9VPJ*K3G&"*<D!8Q6T:"ID1%ZG:4
MQ$UREJHYL%0E3>Y&(<%A4I<++WT<:G+OMBW)+J`TYME9@]EXD7MK=;S$ZW<L
MW-`!*7H6Y]'"(`2\0BW)0,(`WOM`9@UH&,56E:V@<GEL$3@<J7H'X='5H%?R
M6YI6TM:!XQV`)@,/L`(!ZE1#`I2]!H^C:]M*Q3D0`:'I4/&`K0PE$?)4`$.R
MH"`)&",J6/9E3=L$Z,T2E*I$N:D/R%0"X@/V%`*<R0B7E)#0A@H43ARP6&2E
MQOL?1Q:\SEW1;D]M0><J^DP2^P3M[J6W<I2EO-+R@#I2PWV/8XM>9R[XMR>V
MO?>3?283OLYC>ZEM_*4I;S2\D`R4L-UCV.+7F671;D]M1=\JZDP2^P#H74MN
MY:E+>87E`CD490S58!=,3D$Y/<RQ;@Q[>><2!7OCT!$@&2J/)-6PX^;>`I@L
MY4M7^6QU*_%;FM*FH%?%_+:(!^R`CZM`#()2U0J]CQ"H5I&.0$0JG<`#XN-!
M$H&`![:"(#VT$#!@J4M4MSV.$`$EUL6Y*(@`MN9:(RYK1,!5J5K;>2M;#<P`
MJ4L%E[V.-04^9;%N27`'<^;968/8)P(XMK=;S4ZW<HW-!&NC*\^,$[M@<Y'8
M&.<D4Y`@%!@)7%`%\Y%(RI@6L,*B8$!4@"*EABK@L*E+A;>^CC4Y=]L6Y+=0
M&G-MK,'LO$B]M;K>8G6[EFYH`)2]"W/HX1H6X0BW)0$0!"\2@,P:T#"52GEH
M!R^6P;PT'/DY$J6'BX=,E4_S@X;<1%@N@<1\33[2J'DG!2A=4:6CV#3U*B#)
MTV?\.N@O]RNK/]AH+@)JX"FVA39Y%:QV/-LYZ$6B8_?/6/)L8-IKF;R#(3(L
MNIK="P,$`89XQ//R3AVB<4DD6S<ZUY42@!O=!"/L,ZI]NY3E&G,;?X&KC`;<
M28*B[G-:9%&J8D#[5<?L-9*8:/=AI.32$5,OS0J[:Q-8%&JKJT$`[`M*5EF2
M6S<6\8R+'7P#A&?"@$;B4A%"F`3>N05*J+G,)@%;S&()1`"6VB`W75*$@N$9
M3Q*-J_9UY3^@^&J4#S&]:AXCP#F",I4+G[02U"H!'*`(A7M`!\0&@B'JT'@.
M+>3^F#&#/.%0Z6-SRIX6<SV/*BZQ.9@7TSB<!E*,=AFP,?CIADF]G,1V5B:S
M.40.U(J=H]F(J.$K@[L[AL&Z:I]*'/[A+N%MB_3)L&`GM7::V7MQA&YTRDH!
MOG7YN,B<Q2N&1<A'QDVK'S<@Q(4ZIE&ZI6DJ<\:!%UD5U$PF+#.OII,[1USI
M_+]/[-PS(]ARK/#H^9)@_C.!-<N18YVOD#3Z2#D<5(CAT:^P%PT92JT8V7?J
M*IJG8-6QTEE0Z&=WD@$3%>,"F&@&,6+5`3``F,`"(R0U`#'$?V1'U^`SR97X
MP9_)JGSCP!R97XP9_)JGSCP!R97XP9_)JGSCP!R97XP9_)JGSCP!R97XP9_)
MJGSCP!R97XP9_)JGSCP!R97XP9_)JGSCP!R97XP9_)JGSCP!R97XP9_)JGSC
MP!R97XP9_)JGSCP!R97XP9_)JGSCP!R97XP9_)JGSCP!R97XP9_)JGSCP!R9
M7XP9_)JGSCP#<T1E.^RM'[.O>&U1\-4[?P%OY/REZW`./)E?C!G\FJ?./`5Y
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M[`=-&<:49>`<3LLUCI;'!CDE7IIESB<E8P<N&IQ!2<>1C4B0)/#/&H2IK7T@
MTCLCJ/8=/2FC<PQ,\IEV?XH7/)M`K=HV)B>%R>61KYS"$.M(MWN31T+W@$1.
M9JQC'L6X7>`M)-FG`='F*4L$>S,1ZR.(,FXE3&/5(!A!`@@05._FMN\@C0:>
MMP''*!],)$+!(%V-TM]1^`F12ERQ9C:K7G6$@Y@HTLI/IOI>2R'$XF`C6D=)
MQIC/EUC-$B/5579VK9HNN`25/>DQ6@,@PB'>Z<DED,HQ/ILRZ3Y,B)LGQ7]8
MEN1PV@5L+%`9*<R3"VZPN'3=DL<3,6CI=<65K0CT-^S#KKR_#H++I28Z?,V(
MXQ:'W*^.S,6/78OWNFMI0.N9EFI*1TK)!'Q,G!3HY021,@H@2#:N+2++I'3*
M$H]*G4[(=5$!D63EP.6U@?$L\;8T,1DB";V0DDY#7,-EK>76,R=@T8J"C/\`
M([F=4SQ$B1#N"("J5$H7`Y,K\8,_DU3YQX`Y,K\8,_DU3YQX`Y,K\8,_DU3Y
MQX`Y,K\8,_DU3YQX"/<O0EQRS5=))D4`RJ>J`Q*AKA'7F8@0;O%"V@0]!$*#
M<'9V>7@)`%"8$#6R+$!$#VB,4J8"B(+V"(>*%NL,=,1\E;#>2\+`#(2XWV2+
M$HCS+*Q:IK;@><JX`E"W\L5$+O)=RC^3F!RPBC(6\V;=6MA1EH](@:\W'5,\
M*JN)P/-ZN!L'-"91Y?=SJMS&\TW-!$X>9S0%()8.A+C?9(LBUYG+NBU3V7"]
MY5U),E_+!5O=[6[DG]KS0Y80ONYK+CKS(@;R3)LLIF&NS$74A#N$RE'.,/*B
M(I`]8"Y%,O+*8W.4J*8T,2H)IA-`H2U1I(,@`1&@#&*B(!<H)0$?$PK0IB`/
MKVB/97L`!"6]6094J'_EBODN*(A_.?E$H"'L5KZG:`5"6`2W2#(P`)+@",5+
M4`%O?0?$QM$P$5`/+2\OEL&\&R8;2YX:4(=\R5NC'93D+#J*"K^"H`J0J(KR
M8'%4$UP`HMW'W8@<M3EB54$.'M9)'%,52(X:-44L=@$P:&AU&ZB":4;$%.W%
M(&V-E;G*5%P4"^&L03%4@=V1Y0I&#82H2X67R+(U.5S+8M4M]H,N=;63-9S!
M3<6^VMYQ/;<L>8`5"7`"W2+$P@!+A"+5+<(`U!02AXH:V\2+"'EMYA?+8-X5
M[ZJ]!ZVZE.G;;>F-\X1C>V=89EA,TVR/")>$<F+*"S8&?,'$2Z;27B,+D4=)
MM2.8U^S,1ZP>$260.55,IA#P(]&'UI*?T7@^M^BSH6]#A$H8SBK!U%8CJ'7&
MW,]SK9$[*LD',EDD[(H0^DI7(\ORR17:J/Y9^Y:.'BQBJG5.``!B!>TWUI'T
MI?G6^@HW('MK;F'42:E07LNIH,MUHF3KY*@0WDO`2!^5?K1OI2%DU4C^@EW$
M=-4BR8IJQW40JF8BA792D5(.@@*J2BB('#L`X)J!V<PO*#E=HKZPSK_T9>[-
M[Y#K_P!!K@?3!M[?DR&8;/C9O:VQ\-R]!G)I+OHF"QG'\TU`DM@6N7$H9.3"
M'BVK*+<.A54(F4@M2LP_I):@S+(]H:DUALI^R0Q.0V)KG#,Y=XN[CW;ASC+S
M+L:1GU8!TJX<Q[APO!K2B+=0QT$#J&:J")$Q5`J0;VY;R8N6@]]:B8%G(H&"
M+.8J(F0>VF5$5UA,`)'3)V*-KC%,-PW@F`*Q0ENVD@R`*C3\EJB(!<<0`1\3
M"M"B4/9$!'U:``"$MV5D&0]H5_)BH"(7$$P?SF-*E`P>Q4!]3M`*A+!;=(,A
M`!)=2,5*)@`6PJ``^)FMO`BH!Y;>87RV#>`1"7"R^19&H*?,MBU27@7N7-MK
M)GL%0$W%OMK><3VW+'F`C:MY0KEV(OFEPJM.\&\).F5<Q&T8"ITC=X2$H'32
M7*%5'-@J$\[W,4S`L*A+A9?(L34Y=]L6J2Z@,N;;63/9S!3<4\MO-)Y>6/,`
M*A+@!;I%B(@!+A"+5+<(`WY@@`RAK;Q(J(>6WF%\M@W@`A+T"LBRKV5'PM4*
MC:0![/$QI4P&']L`]3M`%"7H-)%B`T&@^%JCVVJ`41#Q0*T,)1]2H%$/5J`(
MV3>5*P9E2?,T@!D@4I5(E0!(?NZQ0N3*YCP`I5#I#;R4NQ,P4+>%@+#(2XWV
M2+(M>;R[HM4UEP/>3=23+?RQ4;W>UNY)_:\P.6`="7&^R19%KS>7=%JGLN[]
MR;J29+^7S6]WM;^2?VO-#E`&0EQOLD61:\RRZ+5/9<+SE74DRW\L%$+O)=RC
M^3F!RP1R+>3.V5`SUH=,3D'EDBCG.)>\*&(`7+OBB)`,E4>2:O+,/FW`*8+.
M1+_&+*G;_P"5J^2XPA_YGZA1`/VJ^KV``A+=E9!D(5"M(Q4*A<F)@#\IC01*
M!@#UK@'MIV@%0EP$MTBQ$`$E](M4HF`!:BH`#XF:V\I%@#RV\POEL&\`J$N%
ME\BR-3E\RV+5)?:++FVUDSV<P$W%OMK><3R\L>8"-9O*\Z,YCYHHH1V4QCDB
MC@2PK"QSV"Y=&1%8Q5K#<Q*SFD*(J6"58%94)<++Y%B80Y=](M4MUH,^;:`R
MAK.8*:]OEMYI/+RQY@!4)<`+=(L1$`)<(1:I;A`$+Q`!E#6WB100\M+R^6P;
MPT//4I$J6'BX>M5DPV#AMQ$F"B!C#XFF%04,_7`H75'VH]E`]D09>FS_`(==
M!?[E=6?[#07`35P%,="H9W&ZTV3/-,J3<Q3+??6+*1^-QF`EEYT4F/4ON90(
MIB<F1M3S;]V];G,D0$T3K"J"0"4:'X"+M8=4VX]C99A6-.\1'#PRMS`L)5*;
MPW)V&28?)RVMG^<RD;+0,RUBB+K8N_;H,G:I%P;*%=%.DH95)V@V"VZ<9E[?
M9N+^,9;'R8&PC/A0!IBI(L4@+-ZY!4#G/-2`J<PQB"%`+;8(=MW8$B.&\CXE
M&@,F01%)_0>X)]GFMZ_]/P#D#:2J%TF40J%0!BD`B'J@`BJ8`$0]6@\!QPE_
M2O9<P7RANATE[?;'QYSM!PR-EL3EV'%R?%<0FQ#7V78\#S7+[OT;M?$#LW34
MM0[E,SD7%B=QWA9XV#;,*])?FV<QNTG;/IMRF#D-=:=SW:R,'DDO*P<G*+8C
MEL/C4=C;[QS`X:.B5Y$)1RF_52<O5(>4A)%LX0%L1I(.PU]?TOF'Q;?`59S1
M._6RF2(1;#*4VNO5FP8UF.0A&*8SC,*;+'.)FRP^2LUW+I@(E8/'K<C46S5<
M[TA2!AUZ76.AF48GD?2AU:L,E)C[7)<O@F&K&<FVQJ,=%2.@+"6-.LQR-Z^3
M>M3MFP-VBWNBR;@K9PT71*'577^4.=B8%A&P&*<UC[+.<0QK+VD#E$(VCLEA
M6^2PS*91BL@CT'[U!A-QZ;T$G2)%EBI+D,4%#@%PAMW=I/XT)[P2_CN`.[2?
MQH3W@E_'<`=VD_C0GO!+^.X`[M)_&A/>"7\=P!W:3^-">\$OX[@#NTG\:$]X
M)?QW`'=I/XT)[P2_CN`.[2?QH3W@E_'<`=VD_C0GO!+^.X`[M)_&A/>"7\=P
M!W:3^-">\$OX[@#NTG\:$]X)?QW`'=I/XT)[P2_CN`;FC:2[Y*4DR`(.&U?P
M!+M_`6]!^[<`X]VD_C0GO!+^.X"OF_-V9!I!SI!NRPN>V(&XM\8)I1T;'FH@
MKA+7-4Y8RN=R35!J^4>0>-A&\]\!C-4D61553+E%,I%`I3-^E3B(::G&BG2[
MU@!!XJMN6'R*>D-($AT297I^(BYLT/!B^R@(B7B<T;N'3:(E3OVK1[(I(-V_
M/YYCH!TGP:=4S6`B\QC'+]C'Y9!8UDS)G,08QLLT9ST`PE&S:3CEU@<1\@@B
MZ*59!3ST5`$ANT!X"BW5-UYYITP[::Z^-TS[DVSB88,PSR7V1K7'G4U&1C%T
M?,'+F)[FG&@P/-,(774VZ536D&R:-C$JITPD$3E#2W_I,WJF$9=GN/=/6V3,
M<8VWKS5+'&<Y@WN%YOECW,L;G<CEW,+"145F[5B_QQ*#,0C60=,TGA%4U.\H
M\YHFZ"+Y?TM6<QF)X)EJ'1SN&6:YC@3#,7+!@63&2C'2F9.L0E8R/;FPL?I"
MRCGC--%)VD**CQ]+Q2:3<6KI5\V">];]>V8[$ZC6'3^^Z?,\PN.D\MS[%_SA
M38N2M&;?%<-D\MAGKN$-CJ(HN\E918.#$([68Q["3BSJO!=2";,H=&&+>4\/
M9B213$>YMQ*0629"B/()0HG!0XE`1\HT&GK<!QYQ_P!+?-D"0#9'1EU38,9-
M&8")58:^//Q[QWCT<66FO%969-A;*#B6K&2C3]]$7"*1'#A1QR$&2RHAON4^
MDIRS$\RU;BKKIMV!*-]C:_T?GC^1A"3D@\PA7;L8:0D,,R*)2P@44LTQN\.Z
M-#/$B2J+1\<RC([0R1@DK+^MO96'0>72<ATUYR9WB\1N5ZFW0?\`?6$@_P!.
M[2@<!>HJ2,;C[U=C"SF+3)\L0?E;./R2S<)(H.5DC<!)O2OU)9'U/P&09')Z
MYR#42^)9TVQI&$R4OB#V2:R&NH?+494ZO<(Q%BN4T^=`[(;W2!4B'<%1.KR2
M!;[NTG\:$]X)?QW`'=I/XT)[P2_CN`.[2?QH3W@E_'<`=VD_C0GO!+^.X"/<
MO:RHY9JNV73*'TJGJE&,1-<(Z\S$"C<+@!)8;M[`&[R<!(!FLJ(&`LJF41`]
MH^')C:(E<`0:=X"MAE$Q]GE_\H:!DS64&^V53+7F6?DY,UEP/>7_`-.%W+%9
M&OV7('R7C0(GR%G,&W7K8R4XF@0->[DN2&';K<P%)O5X-PYQW)#HBU.NW-4H
M#S>[B`T!0;0E@[64&^R53)=S;*QZ9K+^_<JONX7\KGH5\EW('R<P;0A7=K*5
M-KW)`0F2M%E,QUV8C@89LY*D4<WP\$:(J"U*Y%,#$*(F44KR_;%K80)K%M)B
M(TE$P`1,(!X>F-`$51*%>?VV@8H>S;[/8&.ZRE0_*J=*@(AX>GVA4HB%>?ZH
M`(?M^QP`5M*`);I1,P`)+OR>F%P`9N)P^[C;>5-0/8Y@?8A4&R99RAH:4(:3
M(H!HQV4Y0BT5!4_!6X*%!(Q'Y3<T$5@`HH+A[N'F'L`I@08<SD$L3Q0A'I&R
M*>.X^0K3PM%OR4THV&`S<$B,8(K>A6ZY;08LP3YX`""7*!/@-B(UE``E\JF<
M2\J\0CDRWV]QYHA1<;.;R%_7MYX>7EA<`5K*`!;I5,P@!+A".3+<)0:@<0#G
MC;S!25'U:<T/L`J`#64[*RJ8T`*_D],*B!4P$?N_94Q3#[%WL<!X>/2M^DAT
MEZ!3TG6Q\FT+Z-C566[DZL]-X3M+/^H=]F$W@:DPO(Y+F,/DV-8?CB.$9+C<
M$I)3&*LY3(W44LV4FY!9-:024<$3<"""&^LX>F*R:&B\CQKT&>UIW'I^-:3$
M#.PV"=3<M#S$3)ME'D7*Q<FQU*JRDHU\U<H+(KHG,DND%Q#"50!`',WUE7TT
M@WV^@=W06O,LKK7JE-;=WOEU_P#E`6ZP54:^2[E&\E_FASQZT_33[_S[.](=
M7?7+]7N:1F3=,V2]XU3M[=..]0.#8Y!S,N:3-C\#E4IDVKXG'LSCHV=60DH>
M+ECKHM)=L9TT3375.;@/61Z"_P!+;L[TP>D-R[CRW149T^M=8[(CM=PQ8:?E
M\XA<P7<XRK/R;YI+R^/8PFDO"GDV22S5+O)DP`ICG+SP*4.WCII(BZ9#XD6O
M-=<D0C43%1$R#X2F.82*G\U-1,@441N$@U$;K.`6BUE*C243`*B(!X>GV`)E
M!`*\_MH4Q0_YOL\``VDZA643$*A4/#T^T+B"(?=^RI2F#V+O8X`*UE`MNE$S
M4$EWY/3"X"BV$X?=QMO!-4/8YH?8A4`K64"RZ53-04KZ1Z9;P*+'F@'NXV\T
M$5_7MYX>7EA<")HTDRNG@C*%$>8S!8?#$"%6.FVC.:<ABE2.'-(BL7M.M9S0
MH(<L"\`L(UE0Y=\JF>WE7B$<F7F6@RYE/=QLYHHK^O;SP^]A<`5K*A;=*IFH
M!+OR<F%P@5L!Q^[^;>9-4?8YH?8A4`&LK0*RJ8C0*CX<F%1`"`(TY_940,/_
M`#O8X#(M92@TE4P&@T'P],:#10`&G/[:"8H^S;[/`(V#22"/9E2DRI@#)$I0
M/&H@)#=W6*`B0@,R@!#J)B!023[$J6A<-`6':R@@>R53()N;8(QR9K+N_<H1
MJN%_*YZ'K7<@?)S!M`.UE!OLE4R7<VRL>F:R_O\`RJU7"_E<]O7R7=W'R<P;
M0#M90;[)5,E>99^3TS67"]Y=:KA=RP61KY+N0/DY@T!%)-)$[58#2113%0@V
M$C43FM[PH8A0O*\*:P%$P$12-7E"/FW5*"WNLI\:I^4?_+T_)4P@'W?U`$`_
M:]G@,@VDZA643$`$M?R>F%0`R8F#[OV7%*8/8N]CM#!6LH`ENE$S`'+N#P],
M+K1:BIV@OYO,!)4/^3S0^P"H!6LH%ETJF:T4KZ1Z9;P+W'FT]W&SF\A?U[>>
M'EY87`C7:27.B[Y,ISIO"F,8(U&TQ2QX$<`-06,B*YDUA`Q3I6\\`J8"`4X+
M"M90++I5,U.7?^3DRWV@RYG_`$XV\P45J?8\\/+8%0"M90`+=*IF$`)<(1R9
M;A`&X'&G/&V\4U!]CF!]B%0T+/4'Y$L/,O($73#8.&@9,K)-(3CXFD`#S`6.
M)*&`3=@>QP#-TV?\.N@O]RNK/]AH+@)JX"F&A(W,V6M=DSS3,9UTQ;;[ZQ9.
M-Q2`Q;%5Y8Q674ON4R4+%N90ED@^>OFYA3%P=/F'6!,3IE`#E"'=;]1747FV
M?:YQ.9UYL#$8W,.Y-\KDI7$CLW.N)=77'TN?P\TC-ZY@VLH9E.KI,RNVJPM%
MTRK@4X*H+`F%R$H7)V>S<6\3S5S,`?",^%(IH"$8BB!)O7(*`!VR%3@J)RB-
M>T+`IV"/`2*X:/@DHX/%EA$4G]![HQ[*%;UI[AZO`.0,WU0K+.!"H5`&K$!$
M/5`!%N(`-/8'@.,61>DXZ@XIW)-H_H0ZAG)&F6YE%LUI*#R>+%[@;+-$([`M
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MIKVXQ@,SQ7:.8/\`'9#&LO6V.#;#LWR;&<>QB(A8#5<Y`QF6*8U#-,CF0R&0
MA6#:+?!W%P_.F81#497TGF6PYHQZ\Z(>M-/'Y,@`V=!KZ,<3[Q=3*,?QILE'
MXW'Q#X1(JF\DY`3/'3+\GL&ZI0/WX@(@ZI^D;V2$BS1=]#762S8'1DW3TY<*
MQU^^2CV)4WI)%L5B@JQ6.,6PD1[@94K]=V5H@BF<7(F(&MN/2D9B$`VRIET,
M]:*L"*&4K/%Y+"(.'?B.+XQ-SYD8F+<1BKI^M.NVL>UCN\]Q([%ZL)3`LU%N
ML'6*"<O)V$AYQ-W+QR<S%1\JG'RT6V92K$DBT1=E9R;-=HDLTD&I5K%DCE*9
M-0HE$`$*<`Z]S?\`QNO[T8_Q'`'<W_QNO[T8_P`1P!W-_P#&Z_O1C_$<`=S?
M_&Z_O1C_`!'`'<W_`,;K^]&/\1P!W-_\;K^]&/\`$<`=S?\`QNO[T8_Q'`'<
MW_QNO[T8_P`1P!W-_P#&Z_O1C_$<`W-&C[ODJ'BR_8X;5'NC'MJQ;?\`UC@'
M'N;_`.-U_>C'^(X"OF_-LYQJ!UI!#&<$R?9Q-J[XP3461&QU-(B^`XWEZ<L,
MGL>01;X]+D7A,2)'@Y>\XS-`C4J@BN4_+(<*3SGI)\[AYF>1'H?ZU@Q[%C[F
MB)F:?ZY@V??<FU5$1DS$I8V*+=['RF+;#!1VQB)91=NW=2!4")W)J*JHATJP
M>6=9?`Q>5HGGH1/)H/&LA)#Y!$-XZ>BB34`PDBQLW'N63=S'RS`'/*<(*)D.
MBL4Q3%`0$.`H%U)=<.Y]`]1+'4\9TH;IVSK`<*A,SF-T8#%O'T-%D>0VVE)N
M'502P5_#)R./9%BV+IK@>2*<(J>=O`3$T>1N[!S9]<.Q,BQ.$R*"Z9=\XI)S
M>\M9ZI8XUM_'7>*/Y+'<_>3S-YFZ"^(8'L!O`-\9-C;E5YXWX9'(-S(&4>E5
M=-6ZX/:?5?OA3%<7R?\`5?SX@S>MPS&7AU)MT25QS)F&9:.QK)L(59_FB,Y?
MK1D1MF4DF#D2-E98N*O$RMD""=P@&NZ\ZS-TYOU(--'3?39L+#,.>9EL#&5-
MHR@2ZK%M&XYATKDV,R;ADXUA$Q!3Y*A&H.%E$91PQ9-YJ,1[PJ]66;(!T68-
M7P1[(WBK@0!FW-:5JQJ(`@0;0'NX]O[0\!QIU-Z4??.50H.-E>CXZLL*R5^Z
MB(R`QR"QD\N$A)'P[#WF2J.I+*,(PU)C"P>?3DA'B]$ADO"&"<B:G/%LD$W9
MEUT[3Q_/<8Q^(Z=]C2V-3L1T\3,BL[B\[9YM!?GN.)YO'EH*.T=,X?(93K>.
M4,[E$6^0&:LT62R;E=!RLW;B#1$==74.]P?,<HDND+9,1(XW$;+<L8P[^?<D
M>3FN\GU]%OX5^F&E491%NT@<QDG2SMDWD`>NL9?H1:3],47!PL'TE]0NQNI3
M&LCR+/-.Y]H"4Q78BF+,L8SEL)Y&7C/H.PFDLA14?8GC5&\@XDU#()E3.8C,
MR`K<M<ZB*87([F_^-U_>C'^(X`[F_P#C=?WHQ_B.`.YO_C=?WHQ_B.`.YO\`
MXW7]Z,?XC@(]RYE(#EFJZ33@H?2J>J4&4<-PCKS,0*-QFXF+RS#6@>4?+V<!
M()F4@(&I,N"U`]!!I'C;<5P!1"K8:B052#V^7E!7RFJ`=E(&`]LRX)=S+1!H
MP-R[P>64N;B!N5WA*E?+R"UK<>X(GR%C*'W7K84IYP@G^;S<=Z(1T6K?S)S5
MX(`"RK8RB7=3.43!;VJ=V*!J@=2X)8.R?FOMF'!+N;;1HP-R[Q?64N;C=R@<
MI4K6O=RUK>>X(4W8PDC:^R4$)URV55S'71DUO#8E?D`;-\/`@$258E(ORRJ%
M`!4,J/N8=OE+P$UBS?B(B$PX`!$P@'=&`V@)E!`*]WJ(%`Y0_P"8'KC4,@S?
MU#\KN!"M1#NK#M"XHT_D]>T"B'[?['`8!D_`2UF'!J"01`6C``,!1;B8!HW`
M0O!(X#3R<T:>0M`;)EB_&%E"FF'!_P`ENP-^!1QN91J@!ZD,Q<$'F\A6H"F<
M/P@WFC:0`!!AK)V7$\4LD544BX[C]K8C)@FFFFG&0]42E)',03*)6RI:`BC:
M#@UI"6)E(&Q%92!;+IAP>WE7B+1@',L!B!ZVMPMYPME1&GD[P:E+"6@%92``
M6LPX-0$[A%HP"\2@U`XC1N%.8**@C2E.<-/:EH`#*0[/RRX&@`'\D8=H@5,!
M$:-_*82B/_.'U@H%4^J;HAZ:.L-CK,O4SJC#MQ_F8V##[.UL;+\>C'ZN.99%
MK)"4Q#]U,:0QZ4Y:02<.Y!>)E2MT0>-U@13L"U?<'I2<M*551(4IB)$39L`(
MD6UP5,I"BWH!4@53H'_UD*^4U0R9F_-?;,."7`K;1HP'EW@]!,0N;C=R1<)"
M%:U[N6M;CW!_/OZX?K*O6)F74=U,^C%E_1H:AW\S>[=VGTVEU!DL+M7(LPVY
M`L<IR"#Q1=O@<<B23&4R*$2CY=DHT34.2Q%VU4+YBW`2/HGTK_IT>F'4F%Z'
MZ??J\N1ZLU'KJ&+!87AF/:%ZGRLXIB4[]4SAVZ69&>S<V_=/"N7\@[.J]DGA
M5'#E119=4Y@FE/TY_P!8H7:/G:WH(]@]Z:*(#''_`#1=130$3NCODU?R4\B%
M9.:$&RA"U:J)<CE7JW%.(<!5K??UK/TN72=*XS&=4?HN<5T(YS!K(2.+,-LX
MSO/7#G)V$6X(WDUL>6RHK9.2+%K/$".!1(KR143O`O,+4/9YZ/3J"V=U>=%7
M3AU-[1Q$=39SNS7,;GTWKQLQ=IM,>3EWKL\4DS^D+-&948R<&BW=HJK%`547
M0')4@D'@+DE9OP$M9=P:@D$P"T8A>!1;"8!HW"G,!$X#3R<T:>U+0`C-^6RZ
M8<'MY5U6C`.98++F5M;A;S@;J@-*4[P:E+26@A9L7Y7;TPS#D]%&0*`+*-(5
M4R;:,%0]Q&*:E5R-U"F\XX%YYK;;2`4%Q&4@6RZ8<'MY5U6C`M]@,@4$;6X6
M\X6ZHC2E.\&I2TEH!64@`%NF'!A`"7#W1@%PE!L!A&C?LO%(XC3R<T:>U+0#
MN4A0/RRX[`"H]T8=H@4@"/\`)Z!42B/_`#OV.`!92`@-)EP`T'M!HP[!$J@`
M/:W$/-$P#_S?9'@$,<Q?A',BEF')?P)(H"+*-`2F%!<H&`I&*"86&6((!RRA
M[B`"'G&J"XS*0-?;,."7<VP0:,!Y=X/@)2YN-W)%RD(5\O=RUK>>X`[)^:^V
M8<)W<VRC1@;EW]_Y=+FXW<GO*-*UKW8M:WJ7`&9/S7VS#@EPJV4:,!Y8'%Z*
M8!<W&[D@X2`*UKW<M:W'N!#)LGQF:WY7<6B=,;09QQJ`+E0Q2@"C%P`V`J0`
M$2F'W(!\HF$07]S?_'#CRU_DC#R5,-/Y/ZP@'[7[/`8[F_J'Y8<"`"41#NC#
MM`#)B(5[OY#`0P?\[V`X`*S?A;=,.#6BG=5HP"^T6HG`:-^SF`BH`TI3G#3V
MI*`$9/RB2Z8<'MY5P"T8!S+!8BI6UN%O.!LJ`TI3O!J4M):")PQ?`XB;I=R<
MR;P#&'N<;10I(\"JE/\`@)S)\\4%1$2&3$HN#``T*0H`M(RD"@2Z9<'MY=PB
MT8%YE@,[ZVMP`O-[NK6GDYYJ4M):`#*0"VLPX-0"@81:,`N$I6X&$:-P`!.*
M1Q&GDYHT[`+0-"SUL\32P\RLDJX(&P<-`R9VS0@''Q-(*W))$.4;@$>P?5IY
M.`9NFS_AUT%_N5U9_L-!<!-7`4RT+#Y@WUILB;CLSRIVFCOOK%D(K$8&&P)-
MVH=IU,;F%O"13^?AE4U'3]\@(IJ/5P)S%K3G(F`"4(JUCMGJJR_+\&ALMQ+8
M&%1>1$Q@<G4?X0D*F(NY7`\@FLCBG$VMK!KC#M3%<KBV:!G0.2-GC62231N=
M).`2"W:4%/L=FXMXAF\O-`IA&?"F#F)QAIR`)-ZY`X$-'PS83@L)RB-U1"P*
M"`"8!"1'#-WXG&AXJ\[4G_;R(VH4*W\GX#3MX!S!FZJ%99Z(5[0Y,:%?8_D'
M`<5<O](1UN0H3G@WH_\`>;T[')L[:0R;^!R,RDYA+7+B$UOFR1H36,JR;*RV
M!+-3S,2JX3DF<W)D113.W8/U2!/+GJIZNFV2;3@ENE#."M,,U%M7/,6FX]Q)
M3,7DN4X3NB0UWB&,<[\UL4\DULVP)`F4HL8MJZE56B"R;9-856HJ!'F,^D$Z
ME'[=1O)]`O5U*.85-H,UD$)B$3CL-D"!@Y*TQA&-Y7CHY*=N_76169L7ZB3@
M&G/,LH11`J:X,\AZ37;&/G,SR?HRZC(J6D'$2OC$4GW%9[+P$A,:PQ`LJ[C'
M&JF>3,74QFVT&K:%:$C5UI!FV=++@R78R#5H$QP_5IU.9/JC.,SA^DS<D/GF
M$Y;@.-IZTS2/"%F\K8Y\]6@QR.!Y6#.(Q2(PV4?L'TPHW?R`-H,CU=44%DB(
M&"/ISKBZOWL!(/\``N@W?I)*,R4F.J$STL>P0D4RSF31SR9B6&-X1+22L:RC
M,;[P8ZAB)F</6R!#G25*\$$LWZ0;J23)%L<9Z"NJ>0F9&)E))XM+XZZCX7'%
MF.4(XTVAY59'52P/\B>@H9R5HQ769\M,:/Q0$KL0D/&.MK=61M\]>272%U'Z
M[AL/U_FN5MLISZ/AXZ$?3^,H/7K'&EVI<(1DR)*,V1ROW:(*IHO4CHLP?MS(
M/E@BZ4Z[^L",B';%AT4[ES3-UV<O,-#X[B>61&$8N:,FX&.<8%DDED^N&,KE
MN6Q;=\ZYLOCB3O'GYP;JL%5D!=F:`^9SUT=4VN-S;;PJ1Z)M_P"Q=>8KDNOL
M?USENK,6E)"1RQOD>$QV1Y3-OG$C@AL67CH&7>+,B&:NDR$.T435/SQ(0P2Q
MH'JVWIM+;*VN]E=,.W-$L5)YQ%P\SG)&:[/(8QK@4M/2F00$@TP]G'2,5CV7
MXZI&.E%CLCJ$FHE5%%0%'%@=#>YN_C9[_`QGP#@#N;OXV>_P,9\`X`[F[^-G
MO\#&?`.`.YN_C9[_``,9\`X`[F[^-GO\#&?`.`.YN_C9[_`QGP#@#N;OXV>_
MP,9\`X!N:,W??94/%GG8X;=O(C:C^`M_+^`\`X]S=_&SW^!C/@'`5ZW]L7:6
MLG.D$=>8#DNT$MC;WP766=&A4$17U[@63IRWT@V8\[MCL@U1B</(R(Y=*.S(
M-^2`I@?FJI!P%(9GKYZE8R9G4T_1]]71L=QI7<D.]E',5BQEIN?UO$1LOB;S
M&`B<8EP>89LU47<?%2)T@*L]%`P@F@"QRATPP61D<IQ^*R9PGD>-N<B@<9G7
M&/9!',F,_!+R\`P?JPTZR7BVZS.8BU%Q0<I&33,FL0Q1*40IP%`.I3JYZJ-*
M=13+7.#](FUMS:7^A<'E<ON'"FCURW8O'4-MD)['>0PU_D#89.$R6#Q$QB)"
MZ<J1$M(JI-EG35JV<@F?]9O4JYU\VS&%Z--_0,PIMG%,--B&=Q*JTPXP2>C,
MO<OLU!I@6M<ID8QQ&RN*IM%$U&Z[1L239KJK^[`B`:]CO61UC3(X:<>D;.#,
MY_6C3,I1VLRSG'%6TJ7.6T!-1Z4;.Z3[]$/XG&5"O2P4F5O,.';M,B8BS:NW
MQ0V_7?5;U399U.M=+99TL;$P[5+S)-A1:NZG3246A6,5C^-24MB!'XKZ]BH<
MDCDY&;9VH\1?*QB1)1O'IJ*22#Q-(.D#%H["/9F\5>C1DW-:5"-[:($&TOX`
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M`^A+*32R)%U)XKC_`'DC^0>.#$*BB8C9N9)!8W?$W*:87*[F[^-GO\#&?`.`
M.YN_C9[_``,9\`X`[F[^-GO\#&?`.`.YN_C9[_`QGP#@(\R]B]'+-54F7Q0#
M*YZH`WBANNUYF12B(FCQ,%AAN"GE$.VH=G`2"+%X(&`)E\6H&`!!O%B)1,"X
M`(71X@(D%4HA6OW(M:U/<`9B],![9E\2[F6B#>+'EW@\`@ENCQ`>2+A,2UK7
MNY*UN4O")LACY`^Z];"G//T"?F]W'<F1G#'`X*S>K@1"]:-44)W4SI(Q;1`3
M"V(![@,J"@2R=D\-?;,O27<RVUO%CR[Q>B2V]@>O)[RG;=6O=R75N5Y@0INQ
M@_/K_)2HSKYNH?,=="14C2$6%`#YOAXE*1-:.5(;E@J4"\T##1,HC6IK@FP6
M3P1$0F'H`(F$`!",H4!,H(`%6`B-H'`.WU"!7M$:@`R>>K,/1[0&G(C.T`$H
MT_D%:"`"'[`^O3@`&3P!+68>FH)1$!0C`N`HMQ,`T8`(7@B<!I3[J:E*$M!J
MFF3P(65NFGH@6+>7"="(*!K&J(G$XF8$3*"@-U+JT*'>#^2U.P$&&M7)\2Q-
M0DJY(D..8\<J*2<4HB!`C(<13(HFU5`Z2A6R@5*<0HY.)3>:D)`V,C%Z6RZ9
M?'MY=US>+#F6`R`]UK`M.<+92ZVE.\'MI:GRP"L7@`6LR^,(`0!$6\6%XE!L
M!A-;'E`.8*!Q&E*<XU*4)8`#%X`!69?"(`%1[O%]M`3`1[(^@7"01_9,/J4`
M`02;%YW%;\M/B]J/G=WB.SW8H?\`21XI^40\OJ@'[8+Q8O!`U)E\41`X`(-X
MOS1,#D"B%T>("*8K$$*UKR2UK4]P!V+TU]LR^)=S+;6\6/+O!X!+;V!J\H7*
M8EK6O=R5K<I>%=%NCGIU7ZFT^LLVKL0#J@0UTZU2WW/]'H8V8M\(=.GC@(U-
MX=B9$7S=)R1HF_,07X1R/<A6%HJNBJ%BS,GAA/29>DN%2T"MXL>7>+VP"WL#
M5Y/>4[;JU[N2ZMRG,#QD^FS^L8];/HP>N3+>E[`>F7666X0.)Z[RW4>QMD1V
M>(N<R;Y5CK=?*CQR$&]AHO)6T-E3IU$)&9*D%NLQM6YJHG`0J+OGK?\`3V=:
M.'X!%]1?U?;66[<0Q/,,5V]@,;GNC=NNDX7*X10LI`2Z;.3V&D\12606!!_'
MN2`A(,S':/4545%4C!9%/TO_`-:)1(FDEZ%F$222*0B:2>J]N$2323Y8%2(0
MNS``B8$):`!2@#V>0*!!'41]8C^L&=(^!(;3ZEO18Z_T[K<\Y'8X;-<VUMN2
M-QI.<DB<Z/C'LLEL)=K'.)4D>N5'G&3!4YS%((G`@`'HM]!%Z1CJ)]*=T>9'
MU.[\U?!::=H[IR77^!LL+BYQOC&;X7B^.8&\<9='/,N[^YDR*9:_F(I99FL9
MJ19HLD4062,"0=FV;)X#M]69>GL59%4`4(GW4R;6-,<Y^6Q*<IG!6YP,'FT!
M<PE`M$Q("XC%Z6RZ9?'MY=US>+#F6`S`]UC`M.:+9034I3O!Z4M3L`*Q>`!:
MS+XU`)41;Q876@V`PFMCRTY@HG$:4ISC4I0EH'<7E/YY?"-`[1;Q?;0"`(C2
M/`.T2B/[)A]2@``+%X(#29?`(@-![O%]E04`![8^@VB<!_9*'J5`00QS%X,<
MR`)I\%62(`8J$0-!%!8H'+;'BF-HK$,'E+5$M:@)[@7'8O37VS+XEW,MM;Q8
M\N\'H$MN8&KR1<IVW5KW<EU;E.8`=B]-?;,OB7<VVUO%CR[^_66WL#5Y/>DK
M;JU[L2ZMRO,`,Q>&OI,OB7<RVUO%CR[Q>"2V]@:O*!RF!:UKW<EU;E+P0RC-
MWW-8WC#T"WIC;R(JT`%R<0+51C2A`6(`5&ON1:U$3W`N[D\^.'WJ]G=XOUS#
M3^05[`$`_8#UZU#(,G@4_+#T:"41`4(SM`!3$0&C`!H8""`^P<:=H!0,%8O`
M$M9E\:@DJ`H18`>T6PF`;8\!`%`0.`TI3G&I2A+`"LGA1)69>GM%.X#-XL.9
M8+*\#6,"TYW=E+K:4[P>VEJ?+!"X9/"N(D#3+TXE>5,)D(D!5!..HH4P`P*(
M`N+=0364$.\'MH!4[`7%8O2@2Z9?'MY=PBWBPYE@,P.)K8\`#G"W4$U*4[P>
ME+4[`"L7@`6LR^-0"@(BWBP$XE!`!$;8\`"\4C"-*?=34I0EH:%GK5RDEAYE
M))TY*&P<-`R2J+`I3?E-(*B9!FBH`W%KV"'E$/)3@&7IL_X==!?[E=6?[#07
M`35P%-=#063I:QV/-1.8YPY7)OGK&?16)PZ.MT"J.6_4WNCNL-$O<BQ%<$U'
MSM&J:C]V=,BRP\PX)!0H0OK?:G6%DFQ-:XWF.";,Q7&,G9Q*^>S;C'\3(3`)
M)S@S^5E\?&4#6BD--J1^6H()IR**Q6"C-?D7=^(8G`7-)C\JPV=BPO,UR::!
M3",^%,)%KB*((63FN0,"?A&+Q@F!;F`)K[Z"0MM/.N"0W#-?Q.-#Q20$12?T
M&V-[/-;U_P#+Z=O`.0,E_C60'V!)&]OL=D>`\!R";=7WI!<BG)G'87HSRW#W
M1)?8J>+36P(B5>8]-XXEDZ:6G)N3?8S$@QQY:=Q5]'ER1FY=DD(Q^]<+HMCM
MHAZD<-TR[J<Z\(1WNR+A>DV5G7V!:8W%FNMWK!Y)N\?V)LG!=T2>`:ZP0LHO
M@T0<2[2P)!'(44VB*CEJA>H8PHJ(U#6-7]:_6UD96K3/>@O<^/3$W-O"PB3=
MRC$133'7VP&^/XZ&02[_`%W/1L9.1>&2*$Q.F>KQK1,4ETV'?1(H5$&%3K_Z
MRDU9]\'H\.I%:&C8I&6BF;9BZ4GY6R-G.]QARNM41Z*+EQ/(,FR!D$'+M/\`
M"CJ,3,NXR+P).ENK'JXC877.4GZ6=GI-LEQ39V43V")XCD&09JF_Q_.<D@<,
MP=27Q?#I.#UW-AA4?'Y!(/)AJ[3F2/#LX5LN[(1(X:7)]>W5S&=P?G]'3U.N
M8=\2B35@^BY+*%%U,I@H%$5(QCJ-6/ADBQ1Y64,$@Z;5:(,@,=%9RNBT!S)U
MM]8Y7[0COT>W4"@QY,HZ?`SR3&Y)?N#1,CUNNU>?FQ8HA,G91SU(D69N;O3U
MPR(#Q$AU3E!@5Z_.L)2%;Y"R]'#U,D9`EE*KJ-DY-BWR1P;'<:F9=BUCH-KI
MAV\1/E$JG'-&"KPB`'%9T55-%1!(K@)`V;U>=3V*9I(ML-Z:]GYGB4#B3?(3
MPL;AD],[`RZ??:WP3-4\#9R4/B7T/UO)QCW,';=1_-E<-'ZT(Z8-"'D:)%#1
M<AZPNOQ'6[S,\?Z+LW1R0-Y8AA<;@4W'2<I-*ZIF\,SC(YG,'A\>QT"I2D5/
M8_%PPNP*$6W<2I57!2D+0`4M^N_J[DWV,*,_1\=2,+C<AL1MBF23>3.(=%W`
M8FID;^%?;"4Q\FN6,F&.P\&9I-K6`X>K-R.F;9HLN#=54.FVK9V<SG6>O,UG
M4I/&YK+\'Q3)Y?'U4VI5(.3G8)A*/XDY7<0V=%-'NG1DA!5--0+?.*4U0`-[
M[DX^-9#]Y&_-W`'<G'QK(?O(WYNX`[DX^-9#]Y&_-W`'<G'QK(?O(WYNX`[D
MX^-9#]Y&_-W`'<G'QK(?O(WYNX!M:,E^^RWY4D/Y0V[;8WM_`6W_`-[^`<NY
M./C60_>1OS=P%>M_9YM[73C2*6KL"G=G)9]O?!-=;&.P12.MK[6N2$E2Y+LM
M=1M"KLVC'#RM4W"RKLQ4#E#D%`RRZ5`H]+]<O5_'S<ZFW]'CU+JX]CB^Y819
MZI)X<Z=Y%.Z]B(R5P>3QH(+"YEPKAFSW7>XZ.=F9**&=G054*@@FL8P=,L$?
MR.3X_%9(^;Y)C#_(('&9M]C<XWCV\W`.Y;'X]^XA)EN:*1%O+12RXH."6$M6
M3,%H4IP%`.I3JGZQ=.]1C'7^M>D;/=UZ-^A<%E$MM7%>\"Y:R+F(VPGD.-)(
MQ^'9$)Y*(R2)P]4"MF4@[5B9"3Y#1P]29-U@1ONKOJV=Z]:Y=#]&6X\;GS[8
MQ3$U,/S$"9!*+Z]FXW,7$IF1V^":]=/(9[%RN+H-E2F3>L6B,HT756,*@H$!
MAQ[JRZYI<<.45Z3,E*SF]:,\OF7+R*S/%G+2;#.FT),QGA<WKAP[Q^5C\3.5
MVEC\@(R+IXZ`47*K!DY>G#<-==376'D_4ZUU#FO2SF&(Z7>9)L*-7W0HVD5F
M+"'A,;DI3#"/#JXHQAQ=Y&#1JY7DDG!HTAY-.*2*>19O1('2!@S<!'LC!*2`
MT9-A`H$C>VB!!M#\G>KP'&#5'7QZ0:9A+]K>CAW1"Y0^=PT;$QF+OR,HD'08
MAA_TG?R\O-:\FD8Z`9[#D98J"ZXMUAQ]JW501?OA<-DPE?+^K[K/AMK8-C4%
MT:;2EM;9*SU!(Y+E)6+A_.80EG.)Q\]EL6]*QPYOCLI,8_/R:\,?EN$DH56"
M<N9*A)&,2.&JL.L;KX43GT9'HZRMO)Q^-[+>LT&V/9TLP1F\,F,4")%Q**:_
M29Y%&2L-(SC=JUB3+24\^@B.(\G<I)F)@MITD[?W[N_&LAF]]Z9RGI^R*!V$
MI`X_C4NG>>:QL<)92*60IO)&`C`?"^DG3@U$$A29I&(T4.9XW=@4+E]R<?&L
MA^\C?F[@#N3CXUD/WD;\W<`=R<?&LA^\C?F[@#N3CXUD/WD;\W<!'F7L'!LL
MU728DRTRN>["EBJ#=KS,B@)@-&&$1((U"@AVAVU#LX"018.!`0"8DBU`U!`D
M74MP+@`A=&&"I!6*(5KVI%K4+[@P9@X&^DQ)DNYE+2Q8V7@\`HDNC3?<N]%$
MM:]J"=:^Z<P(GR&-<J;KUL<LY+H@&O-Q^YI%A^6;G3>KBD`X*Q"IQ!L+L@IT
M,':V2OO#F@J$LG8.#7TEY(EW,I86,]SY@O;0)?&G^X][);6O\G3NK[IS`A3=
ML>X6U]D:99N50,.8:Z$%6XQ`JH7YQAYRE3!9@[3("7.+:!TP$0(41`U3&4";
M!8N!$1\7D0J)AH!8R@5%00`*QHC0H*``>P0*U&HB&`8.`_\`-Y(>VM!+&=OG
M%&G\VUH(%I^P(^K00`!@X"VLO)&H)!&I8SSK10$0-;&E[#@B8!I3L5-2@V6`
MUS#)PG"RIAF9*B<8\,)SC%)_<VJ(F,=3NK(J8'[J>X>:B`<]00.2B9DP0X:V
M66Q+%'!9=Z<BF.X^L'+4C7"*A1C(@_FN`&8,NFL#4]3@]="8'*@@L?W(Y`V(
MK!P6RLQ)'M!.MQ8OW3E@R`PGLC2T%;NI[K;?Y0I;3W/E@%8.``H#,21K0(`B
M8L74]H-@$36QH!504#":E.U8]*4)8`#!QV?EB2&@`%1)%]M`3"H_DRE1$@B/
MJ5,/J4``023%P5DL(S,D4`%+M'PHE/=BA6X6;<`&IOLP[0#R]H""\S!P(&`)
MB2+<!P`2EBZEN!P`"6Z-$*IBL40K7M2)6OGW@&8.#`<`F)(EP*4$I8L13O!X
M!1)?&G[4N]$$MU?Y.G6ONG,`.P<&OI+R1+^;2PL7[GS._6V7QI_N/>R6W7?R
M9*Z[W7F`&8.#7TEY(EPJ4M+&>Y\P7HE`ET:;L2[T2VZO\G3K7W3F!X/OK$?I
M<^JGI"](;@>DU.B3IDW%C&K7FN-S]&&W]^Z5S/-LN3S6<QALSS*3UQ*1>7P,
M'-/8C-WPQQ4&S8QVCR-9*J)G>)-G`!N[/TG7UN:09M7[?T6>NR-WS9!X@1UI
M[(F#DB+I/GI$<,9#?K=^R7*FJ4#HKID63,6TY0.!@X!4'I+_`*W9_P#@M=9C
MV@-!U3+]M!(-.SJ#`:"!1#]@P^K2@4_ZZ/3`?6)-7=.&:GZ]_1C=/D?TPYTF
MWUUL$=G:'R_(-?2"63"FFQBLG&)W7*IQ!)%VRL:.U^[@F_43!!4CKNMH>E[Z
MNIU>[ZZX/1\1FU-PZ2P+IRQ?$MB/]4:"PS3>"2>`:RF=*8#B.OVL5.8M$9*^
MR)=U'DROQJ).Y9.",A.T632(11(3%#NJT9+@Z>!XQ(G%%5F4X&\,'FB1M&G,
M94I69K#+@W,!K2HA1=02E`>68H+2L'!0(`S$D>WEU$Q8NJE@,P-?9&E^Z]U/
M=;3^4*4I[GRP"L'``4!F)(UH$`1,6+J:T&X")K8T`JH*)A&E.U4]*>98&.X.
M*4\8DQ[`"ML74:`0*]D8`5$2U]:IA]2@`&18..W\L205`0J!(OLJ"@5#\F4J
M`G`0]2I0]2H""*/9+J1S,2S$D`'9H@!B^%GI<@J4%"G%DY`Y@%8I@&]0!%(G
M:8!/>"TS!P:^DQ)$N!2EI8OW/F`]`HDOC35%'O1+;KOY.G=7W3F`'8.#7TEY
M(E_-I86+]SYG?K;+XT_W'O9+;KOY,E==[KS`#L'!KZ2\D2[F4L+&>9>+P2V7
M1ION7>B`6M?Y.G6ONG,!%),URM%CC+2`%O3&T?#2%`#N#VEO[JW,`$YY0#W0
M!'E$K=4X'!;W!Q\;R7E$:6QGJB8:?S;6@`:G[`!ZM:@`Q<`(#XO)#00[!+&4
M&@IB(#2-`:&`@@-*=AA]6E``8.`MK+R1K1((@)8SSK!;"(&MC2C13D&`U*=B
MQZ4\RP`C!P6RLO)'M%.MY8OW3E]RN`]D:7L6[J>ZVG\H4MI[GRP1+LER+Q91
MF)$P@[`1$_A93*@C'^>0Y2LT0.5?NIC'`I#"`K*"4"`"8I`L*P<!968DSV\N
MMQ8L+[`9@83VQI?NO=3":E.U=2E/<^6&08.```&8DC4`M1$D74UH(`(C;&%"
MIQ1,(TIVJFI0++0T'/6BR26'G/)/G`%V#AH"FL5@!##XFF6IN0Q14K4*]A@"
MH^MV<`R]-G_#KH+_`'*ZL_V&@N`FK@*9Z&QS(T]9;(FX7+<X>/OS]=8SZ(Q-
MB[P9DR5?M^IG<Y&4/'/9G$77<DWKQ`HE4>+K)IJJB9012"P`C76^6=:,_E>"
M1.S,+S77T+,AB9,E>(K:FR9!,'VN)N6S5VC,8Q&OT\5^CNPV;9DT;OTE3/&*
MQ1!8RXV@%L"8V_CMFXL+C,\KF>9A&?"0),<;*5"R;UR!@2"+QN-$06Y@":\3
M]I"TIVW!(3A@J$E&AXI)=J3^@W,^RA6__<J#7@',&"H"`C)R(@`@-!,SH/L#
M1F`T'V!#@..4GU:>D]16RU&(Z#YEZY8_G8DL.9.YG$&Y)W%&LHK):@F'\V&9
M$A6&0IX<LP;3V.J*HRLE-.W`,09I,%DE`WUMU(>D#?&W:B_Z89+#7V&:VV[D
MVNXQ]CR&7_2/(8'9Y(#4T<ADN)Y>ZQG-93)=;BK*RD(S4BG)72*8-79B.12;
M!%R?5EZ59H[?(.^A57(&/BD`]QZ7@I/'H129P:.DM:2&?.IR!R/+BN,.S=_@
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MC/4&LQ%8AL7!T4FZD[FTD>#*S:MH/.&:L;#:K,P7E9#Q8]F1J*M1;-VY#K)`
MYQ?6=UQ/FL+$CT*;#=Y`VF1Q;,Y^/RB(2QMK/0\%K3*YJ0BXM[A8*I8G)QF;
M/(U!T,H[79ST2]:E1?E:&55#:)WJAZSGD?IF3@.F7-<26S##,6RG96*2^*J;
M'R;$<DEI#8S%SKEFK%NM;0S0'3O#XM%2??+$0@D)]N\?LN2!B%#2%.JGTC\[
MKO;.9171I)X%.PF(:\EM881E*Z6:R\O/S6Q<.QO.XZ8/CR>-O)8N-X5)RTRF
M@U8LE_P(I`%QV<X$<AUI>D7'&9P\%Z-_8C_*\<3A4!3?[)PR&8Y=*'B,;>S*
M.+1CS&N[-F*DPO*,4W#J;,W9IIMG(JO*K(%"2]C=2?66SQ_&G6M=$S$A*RGY
MSG$B>5P;(9LR1<5S+,\<P-@EBZ"^&RC#Z8N82"9OG;IV0(QODOC14%8Z.<E,
M&KGZU.MY.8;@/HZ]P+PBI(F,<M4,^Q\N0,\C3@LO>9<X3=K:Z#&7^(Q.31,;
M&,GG>&YY!!TH^;E73,@B8'QEUD]8L@V6,3H`V[&J1<(,O-O9K.XYM&@5=]"M
M8TN-,V&HI+)\G6<1TP:478I,$I5FT9N&RK4LF0&(A\<9ZN.M;)MD8#CDUT39
M_JG"I//2P.7Y3E,\US4P8RXV#$X4WDHOZ(XE&,()=*-D%)5PL]<+H"V3`[<%
MFP.';<.I/AZOQK)?OF7P+@#P]7XUDOWS+X%P!X>K\:R7[YE\"X!N:,%>^RH>
M*20"#AM4;F7;^`M_4[EV<`X^'J_&LE^^9?`N`JSL')NJ)EN.&Q+7F-X\OK-Q
M-:6%]FLY%.I94^/9"\V^XW8BX<-9>#0@)?#H'!8((=<&TFBO)9(W2<("D)U$
M`J5-=8G7O'S,X=MZ.S91L:QU7<T*"@[4P64?Y9+X3$1<CK7(8$\%ACYZSP[9
M<B5W&H71CMZFHLDX6*V105*L'2G!G4KD<!%Y!+,\@Q.6G(+&IF5Q>45CE)3'
M)&3@(]Z]@9(R#$&YI"(<K&;K"F`$%1,;0`*!P%`NI'J'Z[]4]1;#$M/]*K[=
M73REA4)DLUL*.DFS&?3F3PVV4LEQEL":4L[.[C<@:8:[1!K"2+A:,4E4$4%W
MJC$I`^$GU/=<CS7K3)XKHVRO#LK/M?$L=5P_()^(V([7UK,1N8J363+ABD-B
M00TO&3..,D5#`J_9-FTNW5-S3<U-(-;QSJ1](G+#AJKCIB;H,Y?63;*IU23@
MY?&WS7(T<]:P\Y#JQSJ3E!QN=;8@J19O!+JR!G+URHNC)KL&"BCD-PUYOWKJ
MR#J<:ZPV!TU*8QH%YDNPH]UMQL10SJ/AXK&)"7P9)4W>E&#@TR5)BL[ER)I-
M.]R1HA%L+I@Z<"'1Y@Q6"/9&"2DAHS;F`ES.@T0((%_D5>WR<!QHU+UF>E"=
MPH%W!Z/&<3RN1>0T=$-\5S:(QJ!:*(8AAZ652\T^>PFPQ;P9-@/)=PU%0[5U
MX`DV302?R!7!0"R:.^.MAYLIK&I]-KN+UP>"T9.2KF2<H.\DBOI]#,'FR(6/
MFF;=O`9%/8).OW;!5(K)H5BE"&<KBN$HS22"#HGJD])@L;+VTUTE(M'43B&;
MOH)=A"2KADOD^+Y!&%*5T+B813FX=6"-)-HIM&KFDLH?LDG2)8YB\0$0MQTE
M;,ZE=NXWD4IU+ZB=Z*RJ$V&I"XU`-54EV\QBIL(82*$[WQP#D'KEW(NG!E`1
M`$&=X,C'5<M7)Q"Y/AZOQK)?OF7P+@#P]7XUDOWS+X%P!X>K\:R7[YE\"X`\
M/5^-9+]\R^!<!'F7QJILLU7^5Y4M,JG@H4[`"C=KS,BU,`QYA$2"-2T$*"'J
MAV<!((QRPW?E:4"H'"H&8^;<#@`$M6(A4G/`0K7M3)6OG7`&CEC7TEI0E_,I
M:9EYG,!X`67,34Y7>RB6M?N"=:T/>$3Y#%+*[KUL<)N:1IKW<8@F@K'E1-SY
MO5Y"@J4\:H8X-N^E,E0P4,W2$UP`<%`E@T<L:^DM*$OYM+3,O,Y@OA"RYB8?
M<N^%MK7^3I5K0]X0MNV-47U[D:034R@)LPUW55JZ8@NAS,XP\Q2(\UL]3;@F
M"X6@*1!$"%$2FJ)U`FH8Y41$?%9,*B8:`9E0+C*#0*L1["@H`![!0]FH`1RH
M#_.LF/:`T$S*G88HT_D5:#;3]@1]B@!8Y4HE$9:3-02"(&,RH:T6XB!J,0[#
M\@0&E.Q4]*>;:#7,,%4H:4,,Q*`"48[,)S+LD1]R:H")S+`6.Y5W<S"8P.&]
MO/4$%$_,,F"'#FJCC$\4=!+R"I5L=Q]<!(Z:.TE0&-AU*@Z%WD)G*:X-#54\
M0>B<'"@@X5J10`V$D<L6RLM*'L!(!O,Q\_E@R`1/:Q+VJ]S-=2GW=2E*DL`+
M&K%`H#+RAK0(`B8S&I[`:@(FHQ#M4[N(FI3M5/2GFV@!&K=GY6E!H`!43,>V
M@)A4?P&E1L$1]DP^Q0$4BP4(S5,:7E``!2[><R2\JI2A[H"3,2]I@_Z0M1``
M[>TI@6FC5A`P>+2A;@.%2G95+>#D`$M6(T$G>`$OE[4B5KYUP!HY8U]):4+>
M"@!:9CYG,!Z`"2YB;M2[V6VM?N"=:T/>`>-5/?26E"7\VEAV7N?,[]2RYB;[
MCWTME:_R=*M:'O`/'+&OI+2A+Q5I89CYG,[[0"7,3?<N^%MK7[@G6M#WAX.?
MK#?I;NOKHO\`2,X5IC&>F+IXV1KO%%M<[:Z+-C;PZ=)?9>:(;*EL4;0>8S>G
M\E:Y5&1CS*(7,9U>+Y+=D=\S439C:"@MEU`D*/ZS?KF,HP92;;H(TVDVD6C=
M^W2D,4U/$/TD'B7>4DWL5+=2#*5C':::Q2J-W2*3A$Q;%"%.!PX!8'5_]<X`
M0']0O1X]H#0832]!`#$&@_\`T3-:"!1`?5H8?5I0-/S_`'[];[VQ@^4ZSVEZ
M-GIJV+KO.(-]C.9X1F6':,G<8RG'Y-%%M)1$Y$/.I8[1\Q>H)G*<AB]G.,);
M3%3%,''$^I7ZXA@F,XWA>%>CJZ=L4P[#X6'QO&,5Q[$]'0^/P./P+.,CHJ$B
M(IAU+(-(V+9L(P$4D$"III)K'*F!`*D"0;,/5O\`7-46S1<.@K01Q54."QDV
MVE'+Q91KX84P24>GU4*J17-3;#8'(:@L1TJ<EU$S)!3_`*N_36_6CN@;#L:V
M+U;]+6E-38%DDZ3&XK+Y#4\)EF-+3Z39H\3A9B8UYNC)F>/OY9LQ7.W3>J,S
MO`,Z[M=R?<`]:?H4NIWJNZV_1\:FZF>L+'$L!VOLR7S"4C8K'\0<X)!RNN6T
MZ#3`LIBL?G',U*%C<HA&0.T7*BXIODG(N$`!!5`0#J]X:M0`\7E.P`"MS&HT
M*0M1_`:5&VH^R8?8H`,<L-?RM*!4!"H&8]E2J!4/P&E0$X"'LE#V:@D8L%58
M]F8LO*%`[)``,19DKVF;K%YA53(O;S5<`8!%54!%(GG&"ZX%9XY8U]):4)>"
MH!89CYG,!Z`"2YB;M2[X6VM?N"=:T/>`>-5-?26E"7\VEAV7N?,[]2RYB;[C
MWTMM:_R=*M:'O#)XY4U]):3)>*E+#,@LY@O1`"58F'W+O9;:U^X)UK0]X(I%
MBH1JJH:5D@*!TQMY[1$H7N%!`O,*1F8H%[P`![J41!,@#=YP'!9X<K\;2GE$
M?;LO5,8:?R'R`!J?L`'LU#(1RH"`^+28T$!H)F5!H9,:#^`UH8$Q`:4[##[%
M`"QRI;:RTF:T4Q&X[+SK!:B(&HQ`:*=V$#4IV+'I3S;0"1RQ;*RTF>SE5O,Q
M\_EBQK?:Q+]U[F:ZE/Y0K2E26`B68*)K191EI,X@\*-QUV915!&/\],Y"I-R
MK%7[H)C@!%!`55!*!/-,D"PL<L4"5EI0]G+J)C,:GY8,P$3VL2_=>Z&$U*?=
MU*4J2P`(Y8+?RM*#0"!43,?.M!N`B:C$`J?D"(TIVJ'I3S;0T+/62B*6'G-(
M/W`%V#AH<M<[7EF'Q-,M3@DU2,/DKV"`7#^UP#-TV?\`#KH+_<KJS_8:"X":
MN`IAH3$I0NMMDST5D.<R<FIOOK&?Q6*(Y2QAXE:10ZEMS(,(A@Z4B5/"6SIX
MV(8#JF63354,=0#DJ00C_3Z/6#E.0P;?;#?(\"8`OCJ^5),'T&_C6C1UK9VZ
MR.)CI9*6=N'$JRV0B@#5TU[^S&/=\I4>>V5$X6F2Q,\7LW%K\JS"5YV$Y\8`
ME99NN5+ES>N2T2!"/:B`*<VI@$1J)"CZG`2(XC:24:'?Y/M2?_\`;!]0K?\`
MY'`.81H`("+Z2,`"`B47AP`0]81*4IJ#[`@/`<<)?J3]*0BME)&_1PVB$V;O
M:,GB!U3(YGX]BP3PO],-I`^/;IC@A<J<XZZC(B>;J%$2R+Q])IIH-(H[-P&_
M:[W=Z2#()?9K/+>FJ`A8['=3;1R[`GY',E%AEVR<4SI!M@6NB!*YVO0N>XB#
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M`.O<^#M7ANF@N#YB[V+DD$_:1:>0;@)!ZYA$M4"EF49&,LBP%++9R1;99DCY
MDQ/(18.T\>!H4.]G%,X-D7U!^D>R.<REN/1T3!(/'\`W4>%>SV71\X_S+8N(
M8=+2.J#$9Q6:(M,>B-@Y4@S;JL$W4L1NDX%,)6XAU2AJ.,=57I-%,91B9KH!
M>269-<1)+/LR'9;+$,8D)=P^RXJ+"(PYT^R&6%^2(9PRO=G4FT$7+ER1<6@%
M2#@+Y],&<;HVC@;R9WQK24TOG;%[CS)_A02+IZG&/7FN\(G<ECF\^*[J+RUG
M"YG+R3)&5CC"Q=)(%*7W1-7@+(^%A\82GOT_VO`'A8?&$I[]/]KP!X6'QA*>
M_3_:\`>%A\82GOT_VO`'A8?&$I[]/]KP&?#`_'Y/WV/VG`'A@?C\G[['[3@#
MPP/Q^3]]C]IP#<TC:O)0._R?8X;?]L'MJQ;C]AP#CX8'X_)^^Q^TX"ON^\AW
M=AKG2*>E<+#8*.6[XP3#]M!)/'9#X;IR73EAS7/&+A*3BVS1WC*#9)<AE@=%
M74`K<J!SKE,0*4S?5+Z1-A,SBS3T=\J.-8ZIN:&1`-\P$N_S"1Q&(BY#5>4Q
M)HF/,_B\3V/*D=1P(&CW4@W[P1RL5`C<Y%PZ3X.K*9!`Q<[.QLYB,W,P6-2T
MSBKV32=/<:EI*`8/)&`>.6QEFSAW#NU3MU3I',F<Z8B41*(<!0/J0W7Z0#6G
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M1@H]ENYMTS2$@K%I,P.P6=G#HXPCJ1[(W?9,U&;<UG?#`!O<2#;4I2B%?)V"
M'`<;-2=4_I7CPH);A]']&N,JDG</'Q88SM%MBN/QPML/Q!KE$W-.%)K8JI(<
M^?.)A\U3%1!V,&5NV2(Y?)K',$I9CU`>D2CML81%XSTCHOM53373S_-'Q\@\
M0R/$%,LQ-G*9W!Q\R3,XF)R!_!9:ZD(M=P>/9MXAO"I.E!>#+MDD`U)AU`>D
M[$F0-I+I?A2R++&=GN62C.)E0BD9O$YO%?HZX;/5=RJFRQO-1JF0LF$<B2/=
M3"L='OBK-&TD*34+9=)>==3NS<:R.0ZI=3I:5RZ)V&I$XO"0<HN\92V(FPA@
M^;RYG:TY.]Y>.9)PN=;EB1)H=3N5RJK594X7(\,#\?D_?8_:<`>&!^/R?OL?
MM.`/#`_'Y/WV/VG`'A@?C\G[['[3@(]R^+`<KU7^49</_BJ>"A7QBE&[7F8E
MJ<O+\X25J7UA[>`D`8H!`P>(RH7`<*@],`A>#@/-\SL$O>*AZPD)]CP`:*`U
M_P"4)4MX*!YKTQ;>8#T*D\WS1)WWS?6Y2?V'`1/D,/S=UZV/XM.HTU[N,12;
MR0I(*=XF]7EHLGRC"H#?O]4@J%AD4A[;`X"6#Q8'O_*$J6_F^T>F+;S1?#YG
MF>;R^_>;]CR4OL.T(7W;%E7U[D2(2LVW,.8Z[$5F<JHDX1YN<8@<"(&,JZ(U
M`@./-`$DNP"C::EY@FD8L!$1[_*!43#0'I@`+C*FH`6]@!S*!ZP%+ZW`'A85
M`?$)3L$!IWTU!H8AJ#YOD&RG[`CZ_``18`)?RA*#:)![7AA`UAFYJ&\SM`W=
MZ#ZX'/\`9<`V2\:",/)G\2E`Y48[->:1.E3DM6YKC+`ZCA3N[EYQN\("'-4'
MF$NN*"'#V8.<5Q5WXE(J\['H!Q>62,Z25K&PZEP.!E<A%R1;N51/X@^Y@+*C
MWA;F"H8-@)%`2S\H2IK.5[=Z8U_*!B'G^;YW,[CYWV7.5^S[`"Q0%`H>(RHV
M@0*F>F$36`U#SO,\X3]UJ;UQ4/\`9<!D(L```\0E1H`!47IA$:%3+4?,[1'E
MU'V3#Z_`(9&-*1FJ8TC*4`4NWQ%1'RJE+]U3<,3E[3^HJ6H@'E]J(+310&`P
M>(2I;@.'FO3`(7@Y"I1L[!+WFI?6%,GV/`!XH#W_`)1E2W@J'F/3%MYH/0\S
MS/-%/OOF^MRD_L.T,GBP/S/RA*EYG-]H],6SF]_^Y^9YO+[_`.9]CR4OL`J`
M>+`]_P"4)0M_-]H\,%G-%\/F>9YO+[]YOV/*2^P[0\)?UA?TIOI+.C'TAN"Z
M>U]T[Z9SW51GNN-A]$&?;0Z>7.V,T#;C[%D,;S-WI[(D9[NZFP8[+LI=Q16B
M3(THV0<-`33`B[=58-Z8[_\`KI4DR9R"72=I%ND_;(/4D'Q.FJ.>H)NTQ<$1
M>1[W?:#QBY2*N!3HK$(JD8MIR@8!#@%0;S^NG`(#^JGH<:"`]KGIAH-#$-0?
M_H@/(-E!]@P_M!6OJL])9];7Z(M12&^NI/IYU'A6I("2BHW(<RB\'U)L-ACZ
MLHNV;QSO)FFMML97*P4*]>MRMA?ND$6)7+LJ)E2JKH%$/1_]7\ZO.M[KZZ'7
M?4OUQ8ZVQ+),LVS.---+8YAZNOH+,]+Q.-8$,7F;"'=R,K(2+27S5&;;D?G4
M30>((F%`G*,"JH=N6L<4'+L`D)0PMU&:8W2*BG,Y3>-4`54S.%RD.IW6AZ)H
M7@JH(E-?>(:;LS2^L]T8+-ZPW!B,+M'7.3(L6^28-GT;'Y3BN0(QKR)DF:<S
M"2S5RPD"H2,*BX*"A#6KW*!0P@(!O#:#;LV[9HU=/V[5H@W;-FZ+@J*"*#9)
MHBBBDBDD1--(B;0``H```!ST`*]@?7PH.S\HRO8`!_+3=M"D+V^9Y1LJ/LB/
MK\`#%@("'B$J%0$*@]-4*E4+4/,\H<RH>R4/6X!(RC2JL&ABR$H4#LD0J214
M4'SVZQ1."IW#XQC5<W`;G*]I"><-H5!6>*`]_P"4)4M_-]H],6SF@^#S/-\W
ME]^\W['DI?8=H9/%@?F?E"5+S.;[1Z8MG-[_`/<_,\WE]_\`,^QY*7V`5`/%
M@>_\H2A;Q5]H\,6WFB]'S/-\WE]]\WUN4G]AV@CD8\I&JJAG\G2\AA+X@HB7
MSW"@VWD<,C%*`N:![J7L(0.VEH@L\+"HCXA*=HB-.^FH%3'-0/-\@7T_8`/6
MX`"+`!`?$)3L$!H+TP@-#)FH/F]H#RZ#[!A]?@`L6!;?RA*#:*8^<],-W+%J
M-#5+V@?NM#>N"A_LN`"18$L_*$H:SE>W>F-?RA8CY_F^=S.X^=]ESE?LQH"-
M:.*FM&$\0E#"#PHE,>15`Q^[L`J0Y`70(X*L#*XX&36J*BA@*6X3D!62*`EG
MY0E36`F'GO3&NY8,@J?S?.%3N7G>OS5/L^``B@`"AXA*C:!`J+TPB:P&X5-Y
MO:)N[U'UQ.?[+@-#SQ@""6'J`]D%;=@X:%B[H5$S_E-(M3D$OG#YM?4\[MX!
MFZ;/^'707^Y75G^PT%P$U<!3#0N$JK:UV3-QDKF4A,N=]]8CR,Q\VP\BQ^"6
ME$>IC<K>/C458]0_@4>Y=-DQ.=))0$CJ'4$AZB40A_445UHR>98G'[DQ:8Q:
M!<O&`Y3)XMLAY,0C%HC@!SRB)7*FRW4\1T]S@2G;"BR>()D-R5%;$KG07'2Q
M!M$;-Q?ESF7/^?A&?"(2V4R\B5,4IS7(!RBN'!N6!P6&X`[#"4HCVE#@)$<1
MJ024:'>9+M2?_P#F3WU"M_\`Z]7@',(Q$!`>\R0]OD&2?4'V!HN`]O`<7LFV
MKZ80@SX8[TO:^;G1R#/WV+HO<V8RC64P9_EB;[6+"5E&>ZFZ\-G$#B[MA$RQ
M>X.&3Y89213,@5JT;KA)T'GOI-WK+8"C[0N)H)QVO]FRNO7$AD;*&G9W9,9M
MG$8W`L0FX%GN_)XN,@Y75SB8>HO4W[@BXIH"Y5:N4S-W`,*V^/2DQ4L5H_Z%
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MS2.QI!T1"'R:*4Q=1"&?FE%7G=9-N=`@J&[N1NNFH'4SPI'\:D_E1]_'\!GP
MM$/^U2?RF^'_`.VOP!X6E^,R7RD]_CN`/"TOQF2^4GO\=P!X6E^,R7RD]_CN
M`/"TOQF2^4GO\=P!X6E^,R7RD]_CN`/"TOQF2^4GO\=P!X6E^,R7RD]_CN`/
M"TOQF2^4GO\`'<`W-(U(7DJ'>9+L<-O_`#)[ZK%M_P#7N`<?"TOQF2^4GO\`
M'<!27=TYUE0.\==0^G]?X[E^C9G--*-,XR5S*.VN28WB<M*[.:[K75%WLJ)!
MRK!Q$=C;R/6;1@BF9PLE8[.>B85ZF]T^E%:3,ZY9=#^%&QN"4W-#1S=#J/3E
MW^8+X]$1CW3V9MN5+Q[N&@\ZFD7+!Q'G26?L4'/>50`4`25#I9@Q9:7@(N5R
M>*D\5R62@L:D,BQ@T^K(GQV=>P#!S+01Y!F_>-'YXA^HHW%9)95)44[B',40
M$0HGU4Y;Z13#-LM@Z8-,8+MG3;7!F$U)*Y'G"N-90\S$%,N?2F+L5ELVC3D0
M28XBP:D6"/4YKG*4!(<"L7)@#47&S/22RV&Y3*H].L%@6;DV_KC&L+Q<,F1V
M5`!KUU`3;S8.599/?GDP*0<PB$P@R32=Q[5.22%P5L2,4`'#]`(LEMH^E^1Q
M[6\C&]-N!+RLEB44YV!#AE#91Y&2B.:/6<RX;/%=RM&C?)9#%D8LS:*!!>/1
M"3D'"KX#1J31P$\:WRWTA,CU%Q^/[0U/C<#T^+9;GJ$ID</+)K2C+%PPR4DL
M&.24_.M..'[=K*I1B#Q?PALY=RDB[0(BDTC0<.0Z-L8LAHYG:[D2G%DWM,,B
M],!3"@2AK>>`"`#ZG9P'';'MO^E_Q\7X9OT?:RS5-PWF4HYUB^Y/H^:(/$1@
MOFLJO&&SR://C+N)5-))@+F/,L>(62*NB9VBJ0-\E]@^DR8Y?@[-OHZ&=XR]
MQ[0KC+G4:XC)%%CDLOB<;([I8.91SU"0\BPCF.4FF(Y-1G&2)H\S.)52%ZW?
MO5V@29E\YZ0*(@\O''\!P+(I9K$;C)B[B.6EVIW$EC>TX!+5LF,9*[L*@_',
MM+JR2I(Y1=D4<A02[R[9-U@02"3^E:5ZG,H@<A<=4^'LL%REMG35#%&6.22A
M8]SBZ^NH=\[`2HYIF2B[ICE*[]%5P9R0BABV)$Y:8'.%O_"TOQF2^4GO\=P!
MX6E^,R7RD]_CN`/"TOQF2^4GO\=P!X6E^,R7RD]_CN`CS+XI$<LU7^%RH4RJ
M>"A99^4HW:\S$M3%*N`&$M:E$?:CVAV\!((Q*)@,'>I0+@.%0E'Y1"\K@HVB
M"X6B`.!I3R"4@A[0M`#12)[ZNI0+P4`;91^2G-!X`V6KA8)>^FMI2VQ.E.62
M@1/D,,BKNO6QQ?32?_R]W&(D0FI)!(_>)O5Y1!1)-P4BA4O$#"D`A[F9-(2T
M%).T)9-%(GOJZDPOYM;91^2WFB]$;+5PLL[^:VE++$Z4Y1+0A7=L2@OK[(T^
M_325^8:Z$3MIR3062%3.,0.)4#IOU#-0#O(T`A4@``+YHVE,(34,4B(B/>I,
M*B8>R3?``7&4,(``+T``%4:>L``'[D*`>%(@->]2?E`?YT?"'88IO)S_`">;
M3V0$0]4>``BD2V_A4F-HD$*RCX:V"W,`&`5Z&`>[!6OE`QP'VYJAY_?3\=5'
M7_T5:OZ8MI]%;9937,INMI@75/E#_%6F?(X;A66/<*A<,EWX23]%YC$8]E"O
M6BLJ0R2"3ITF19=%1PD)PXJX?L_ZWUO<N4[%Z<T,-::)<[%V!!ZE7V'#],N%
MSDS@>*9@]@,;FD(G8;L^7/X.2CH1(S21>'7\60,9T1=RDY[PL&VEB?KL1;:.
M-*C992Z8Z,C5Y?=0"ZYV-]W="W5K=<>M>8>H!8GZ[$6W\(TJ-H%`+ICHR-6P
M$`"ZKL;A'NX5KY:FK[<U0`B/KL04#O&E>P`#MF.C$?(!`[1%W41H0.WUQ$?*
M(\!]VT3]=5YQ`D7NB$68W`LK(S?2,DS*(D4!/FGA'8291%4Q0+RO*>V[S*\!
M\1B?KL0U_"-*!=<`TF.C(*7`L`T$'86B'/&E/)0M/:EH%)]0>E6^LRP_I-=9
M^CMW4U*_VS*[$PM+8.!)Z6U8=LGIM[,HO<QV=!YUB3!ICYL%:X6X>N"3Z#]1
MD@=N"0&!TB")0_HJGB43WU=R@<SFULE'Q+>=WZZRU<++/$#64I9RTJ4Y2=H9
M-%(GOJZDPO%01ME'Q+>:+T1L`JX`0"]^-;2EMB=/N9+0TG+M9X'F4M@\AEV-
M163R.$Y2IE^$2$^W3E'V'98C$3L<EDN*.7JAEX*>2BYUXU*Z:@"Y6BYT@$$Q
M&@;L,6B(B/>I,*B(T"3?`'G&.8:`"X```*@T`/(``'D`.``BD0&O>I/R@-!D
MWPAV&(;R<_M`1(%0]4!$/5'@&/)<$Q;,\;GL.S"*2RK$LIAG^.Y-C.1F/-0.
M0P$LT(PEH6;BI$7#&3BY5B4R#E!8ATUT552'`2J'`060V*0F/141!0+=2'A(
M".C8B%AXUPNRC(N*B&\:SC8UDQ;G3;-F+-I%I)$2(4"%3$Y0"AS@(?II%H@Z
M>`#N4,*"C),`-+R"@""+:-4+S"'?K%N4%H6\1(F*@'4N`W,.8X+B12)+*.I,
M;`3I?*/CW<H&0!?<N-XF[B6ZM;KU*UYA[@P6)1*!0!U*#:!``32C\PC8#<`$
MPBN-PF!L%U?;"8XC[<U0`B40``[U*=@`';*/Q$:%(6HCS^T?,J/KB(CZH\`>
M%(]OX5*=H"'\Z/PI4%`&E%^P0Y@T]80#U@X!&PBT%(]F/>Y2AV:05"8D3F&]
M!8HF!47SDPF_"A$#<PX@)2"!AL*(`L/%(GOJZE"W@J`V2C\EO-!Z`V6KA8)>
M_&MI[6Q.E.42T`\2B>^KJ4#F<VMDH^);S>_5LM7"RSQ`UM*6<M*E.4G:&3Q2
M)[ZNI,+^96R4?%MYHO!-9:N%EO?36TI;8G2G+):"*2C$0:K'[U)AYZ9AI+/T
M@\]RH(@`D?-;2AWH0``.4``I`[0(4.`6^%(UKWJ3]7_S1_3M,8WDY_\`RJ?L
M``>H'``12("`]ZD^P0'MDWP@-HIFH("O00'EA7UP$?7'@`L4B42"#J3&P2"%
MTH^,`\L6HA?<N-P&[H6ZOM@.>OMS5`+%(DLHZDQLY5+I1\>[E"R$+[EQOO[B
M6ZM;KU*UYI[@1+1:*:\64'<H-KL!"^7D1$_(8``%4*+],'!3]Q*)RG(L!A,H
M(E`5#FX!86*1)91U*#8"8!=*/SUY0,P"^Y<;Q-W(MU:W7J5KS#U`")1*!0!U
M*#:!`[91^81L!N4+A%<;A'NP5'U1,<1]N:H:'GL>FW2P]0KA^<2[!PT`*M(.
MUTQ_*:1?/355.0_M:]H>V[?+7@&7IL_X==!?[E=6?[#07`35P%,]#8-WO6>Q
MY:*?Y0YGWF^NL5S&13G96=X_C:DL3J:W,VCFAP@I(PP44LY03%4S1N8R8F.J
M5,YQ$#!&F`ZSZND<OU,\S^:E5<6?L&;7<41%[3G5TH.>9Z\CE7LMB<A](6,H
MIBTQGLB\3(U4(_?HFC4//*T<J&(%L4\081&S<7%"3RMWS\(SX3!*YAD\L4G*
MG-<`7DA(2K@$+N<-UM`.(%K6TM`D-Q&(>)1H`M(T%)_7\JR8_N&].WO=0X!R
M",;AV\Z1_;EI/X7P')"&?^EL?9'D#:9UYJ;'(0KK:LOBKTF9)9,Q7@)"<&<U
M1BN0&0V-CTTRS?&\?7:X^Z<-V[B(=K)R,DLL<2,$5P:)M]Z7$F3@GBF$X>\Q
MPF=3"%^82>%Q":^"!MF%2QIXHXQW=<[*MWY]<NI(9,A&RBA(]DU,V$TJZ5!L
M"O,5_2VQ>T)]W@&$X!E6I8[:N0&3@\NRW'(+)YW5P[=[CCZ&O9N&V`J5!1+2
M8M7YE,F0:R"TV$DW."27ARO`/KA_Z3L--:KCIK#82/WBLWV:IMZ1UC.X]D\:
MJ6,S2"+K=37WYQ,UQ?"&3F0Q6:*5\A,+(&418R:B/X2DQ*Y!+^<3TLJ+^)4/
MTGZ=>M&Q8:'R"-;;RD&;>5EDG:B6399CN2+[5</HO$'"2B1XQL\AU93D$6.X
M1*L"+=4'9GL3TI#QL*2W2CK"(<,8>?DW4F\W2X>A-K)0R*F,0\)CD?N8_A^3
MOI<JW?6KR6\*;`"*"<LJ111\@'S89SZ4!]GV*-<DZ>-?X1KA'9:J&0SN-[,<
MYU.2V`=Y;QL.F]BW&R2J8TK)NGB+EVX9MY4S=L+F\6I&!594.JWA;?[](_*T
MI\+X`\+;_?I'Y6E/A?`'A;?[](_*TI\+X`\+;_?I'Y6E/A?`'A;?[](_*TI\
M+X`\+;_?I'Y6E/A?`'A;?[](_*TI\+X`\+;_`'Z1^5I3X7P!X6W^_2/RM*?"
M^`/"V_WZ1^5I3X7P!X6W^_2/RM*?"^`;FD8@+V5#G2-`<-J?E63#_L+:M1!W
MVCP#CX6W^_2/RM*?"^`I#N]+K58[RUXWTK#8O.Z(D,RTH38+R1F189/"8>M*
M[-;[Q%-64S]DJ^.A#)8PYCE&3$'*2QE4DTW-ZQD@KO,9MZ6I&:G74=TR:+4@
M(A;<L-!1[;?.0/WF6EC(B-=:5S9<)#+L?4AVN3SS9PTD(SO9%F#-T=8XJJI(
MIB'3+!$)J1QZ*?9?&.\=RM[`XR[R?'V^1/9)""R)S`,%IN&1DF\FZ0D4HR2.
MH@5<BJI%2D`P',`U$*(]52OI(X/;;9UTH8?K'.M/-<'CY)[&9SF+J`R&2SDI
M\N>R6/MG9\GC548WN^,1+--401!9;*#'YZ!8\ZI0U):9])_+X9E#P^K,,P;/
MS[<UU#X9#0F70N<XJRUCX#.K[$R;)WF0;FQJ4GXH\TDQ(GW0\3.`9;D-V0))
MJR)PBV5E/3,)P&NG<5K75:LVXQ.+'8D0;,H)15M+M<T?DEU&<HYV0RCD\PEL
M10C`21;MUH!LFZEEN89TVC6BX3OK13TC*W46P:[3QC$6/3F;+<["6>0DY$J2
M3?%%\.EW6#=WD#[$DLB>-(J<2C&R]8A)^]E'<@=0S>-9LQ>AT=8Q:)HUH!7$
MB0YF+<"G"4D1L,+<@`8""ZL&T>V@A3@..>.9+Z9W'!?_`$KT9HC8:3A.519+
M1FU'<"ZB/#F'>H^12BR;`AF\XYFG<KR2LEG[-)4T/RSN8XCWOB8;Y*/O2CML
MOP=%E@>-/<75Q[0RN8KQT]B*K9ODRN)1;W>+=TM,;EAYPD6.6^+L0\/;K':I
MA#+QYW*9I4`"2\N8^D+CX3+B8NWP*?EDXG<:&*.FZJT4Y4D(G:D`MJ&3!I-;
M:7BW#W)M,FDFXLG1VS1*?317>N&[=0R"(2CTJ)]4[Z!R$_5I$Q<+E9<Y:AAZ
M>+R[8(X^*+:[B%GJ()0V8Y:=11EEPR"9G3ETDLX-6QLBW*B*@7!\+;_?I'Y6
ME/A?`'A;?[](_*TI\+X`\+;_`'Z1^5I3X7P!X6W^_2/RM*?"^`CW+XEN;+-5
MCSI/LRN>#S9B6*%#Z\S$@W`5X`&$`'L$?:CVA0>`D$8IL8#`*TD%P&`:2\J4
M?/*N4;1!X%H@#@U*4H(%$/:$M`-%-CWU6D@OY@#;+RI*<T'8&L$KP+!#OI[:
M4MM3I3E)VA$^0PS9;=6MCF7ERB77FXQHC.3**8]XF]6D/>FB^(0P$"0/RZA[
MD8J0DM%%*P)8/%MCWU6D@YG,K9+RI*<WO@FLL>%Y=O?CVVTLM3MIRDK`A7=D
M0W7U]D:1EY8H*YAKJHHSDR@H3F9QAYC`BHC(E40`!<&H!+`+0M`\TH@$UC%M
MQ$1YTCVB(C26E`"IA4,-`!X``%5!H`=@```'84M`/"V]:\Z2[!`?YWE*5`2F
M\G?*"%2^3R4J'D$>`P$6W*)1!:2\T2B%9>4,`V"@8+@,\&X![L6H#[8!,`UO
M/<'GL^L);LZ^^FO2G3WGG1M'J2FG93;!L`ZS59+#<>VE'QFI\V6P['H-YD4+
MEZ$NXC<3=.2OFDA(H)D00,[*#I4A7%Q@X[X6A];WWRGE&R-&[3PC`M*OMAY[
M%:BA]KP6@L,RA[KG&LM=0V(398'(=>3&1#`2L1#('8NY%4SB3:U=7+(N^>X#
M<2Z2^NDEMIU%]/\`YEE+I#IN/7E]UMNNU0-]>YDNK6ZIZUYJEX`:2^NDEMIU
M%]/_`)MH!60Z;C>T!``N$VJ!N$>[EK6MU35K>>X`-)?72`I_]$7T_P#8`!VR
M'3>/D`A>T1U141H0/V1J/E$:@NCM%_7.73Q%"4ZFNFR,8J<P%WTP_P!%>'(6
MHJBD+CZ.:>>S-5%K2$Y*1O=#%OH0#&`$)M)?72#75ZB^G\+KJVR'3>6EX+`-
MMNJ`MH"YJ4I2A:4L):'.W5/7#]95QWTMFK>BG<Q4\AZ@'<WBD#G#QMH;1:AG
M'2R]S1C.Y[F<!M^!P:*(AIT\:#AT,BB_300E$$FY2IRB"38@?T?#Q38]]5I(
M+^96R7E24YO?;K+'A>7;W\]MM++4[:<E*P`T4V/?5:2"_F5MEY4E.:+P366O
M`LM[\>VVEEJ=M.4E8"-S&H=Z9!SI$.:LY`X!+2@=AD'JHV`#XH)B!EQH)0\T
MH%`*`0MH+!BVXB(\Z2[1$>R7E`"HB<PT`'E`"IQ[/(`4#R`%``BVX"`\Z2[!
M`>V7E!"H"0P5`7E!"I`[/((5#R"-0"Q;<HE$%I(;1((`:7E#!YAFY@N`SP;P
M$6I:UK<`G`:\P]P!8ML2RBTD-G+I=+RIZ\KN8EOO>#?=W$EU:WW*75YJEX(F
MD6W*Z>47DAY2C,A0-,2QP$$FT:<MX'?G!0QA9EO$0`3@90#5YJEX+2Q38EE%
MI(;.72Z7E3UY0,P+?>\-?=W$EU:WW*75YJEX`138MM%I(;0(`5EY4U;"MR@)
MA,\$3"(-BUK6X1.(UO/<!X4VI3G27D`/YXE1'L`A0[1>5$:$"H^J-1\HC4`8
MIL-0YTEV@(=DO*AY0.'8(/*@-%![?4&@^4`H")A%MSQ[.Y>3\YFD`B$Q+`/G
MH+%$0,#\Y@-1R80&X1`0((#4A!*"TT4V/?5:2"_F5MEY4E.:#P#66O`LM[\>
MVVEEJ=M.4E8`>*;'OJM)!?S:V2\J2G-[]=98\+R[?$#VVTLM2MIR4K`#1;<U
M]5I(+^96V7E"4YHO!-9:\"RG?3VTI9:G2G*3M!'(QJ`-5C@O(@-Z9NR6E`*`
MG<'$0``?)@4*N34`!```"`'80@`"SPMO]^DO*(_SO*>J)C>3OE*5-Y/)2@>0
M`X#(1;<!`>=(]@@/;+R@A4!3,%0%X("%4PJ`]@A4![#&J&"Q;<MM%I(;1((7
M2\H:O+%L)0-<\&\![J6ZM;@,>M>8>X`L6W)91:2&SETNEY0]>4+,2WWO#<RO
M<2775ON4NKS5;P1KQ;<B\6`+20@1W4+IB6-=R6`%("ES_P!V*;N1!.!P.!Q,
MH)@$55!,"PL4V)91:2&SE@%TO*GKR@:`6\3/!O$>Y$NK6ZY2M>:I<`$4V*``
M"TD-H%`*R\J8?,*@4*B9X(F$>[EJ(UJ(FK[<]P:%GL>B@EB"A%7QA+L'#0HM
M(R#A,0\32+YR:[E1,PT*':("->WRB/`,G39_PZZ"_P!RNK/]AH+@)JX"FNA<
M#:NM9;'EH<9@V4/]\]8R\:B]V%L.'Q\\R/4SNAI'%<-X6;.G#QIED4N:9BU`
MZ7G*ID%7M$(<U)K?K8)GV,$W-(LUL%(TATLH/BVT\P7!S,FQ1,N1*I)N\F;2
M1,3\6$XM.40)(TM:)BIQH6<!<@F&0D1LW%A:&GU.=A&?&.,CEV6S`%%*;UR0
M@I%EYQ\5#L7-=8!;NRZHE+0)!<13/Q*-"CJ@I/Z_E"0[/-;_`/>NRO`.813,
MH@8`<U`0$*OWY@J`U"H"Y$!#V![.`XUY`Q],3)/D4L;1P:"15CG^.'-(9!KQ
M*,;RS3&H1BMLAQ*E6R^7/'RV6IO'<-%)1(G39*7R)$SD)'G!XS##/2[JY4[Q
MO$]B:[2B5]<ZFBHS8Q&>'L<59[$9YJJQW%ELKCTL.29J9*6PMBF_C6"#-9D!
MWIVX=U5(4Z(27L1/TEF%;(RZ9P!/5.UM>Y!DV%8+KO!)Q2>@58!H3441,9IN
M.<R&&F8V1A8#\Z,5+,2PCZ0EEW*$@TY"S/NX%>!'&=[5]+7C>1-\:Q?I?TGF
M8RK[*V<)D[/-\O9XP9"#A3O6,ID2[G<15L7CI13DF8`X$SN2D5EHL[=@W:DG
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M=B)T4UQ,!1KVE`.`5^$LO6=?*$A\*X`\)9>LZ^4)#X5P!X2R]9U\H2'PK@#P
MEEZSKY0D/A7`'A++UG7RA(?"N`/"67K.OE"0^%<`>$LO6=?*$A\*X`\)9>LZ
M^4)#X5P!X2R]9U\H2'PK@&YI%,Q>RH4==CAM0?$)#\1;?]Z]3@''PEEZSKY0
MD/A7`4YV_']72&YL-3U,9BZTL^R[19,D.FM`)RD#C"<OM0^_3S8Y+E+24EF+
M^`0Q5.+\'31D6KYPHLGSDD7"#@*SS&3>EZ1FIY[&Z/Z95H.*7W+#8]$M-JYH
M]<Y2@TB8MQI+-9`LIEF/J1AIC(&J[:4C"R*`,F#M54QG"Z;<I0Z68,VF)&`B
MGV9Q)8/,'<%C+G*X6/FWS]C$9(OC\>K.1;.0(^6+(-8^3,JBFN!S\TA`-<:M
M1"BO5.T])-&;::R'24PU)D>GV6#1[YWCVPIYQ%34KGB:F8/Y*%2=DD&3M.)4
M2QN%9)G[RUYI\E<'%PW*P*J`:>X=^E*E\,RAROAVOL*V"MM[7,9AS#$YZ!RO
M$HK5R<!.*[#R+(`S'8;26RF-<S1&)2HH.H2<!1446R22")WC@(OEO_IT1,?U
MRZBH/4"D\;$XH=C1)LAQA02R[3-GH2H-)-Q-M6),SF<1+&%*+5$V.-45)A4J
M9WB<4@H$[:V:^D>'J+8)[6:X4'3@;+,\&8+!R&/&?)XF[PR6=821M(FR!?*E
MV<+/!%M#$,P+(/I-63667;QK>/3=AT:8Q+48]G:+LAQ9-[3@_?&$AN02A@*=
MP8@B4?4$!#UPX#CQCLAZ:G&0?AD>ONG#9*3I.52:K)9M)0KZ&+&QX.HU^SCF
M65X@QEW\V]E3(`T=/46ZAXA-,[B-3>*/4PGV':^D-'+,64DF^-DQJ/P7IU6S
MAB\>XRJPR7.746Y_6):8A*Q68-\CQQO&2BB9FRCUL[;N@+8Q*W*D95V$%Q37
MTQZ;W+&TNCJ9U&%P[.B8_)-WV--9(N6QT[#KXTXA&9,E59/C9#'(2;>(++]U
M9M6"S`\N!GW>A2"YG2LSZJ%X#(/UN6\*EE89TV-AQL8>QR#`N**ZZASOVI4(
M"=FA4!IEX2!>].W";ET83"5LW;E0`X6^\)9>LZ^4)#X5P!X2R]9U\H2'PK@#
MPEEZSKY0D/A7`'A++UG7RA(?"N`CW+X9B;+-5B)78B7*IX`$).4+2_7F9$-4
M"O`*(B4>RH"(#VA0>`D`8=B:X![YYP'`:2<F'8<'!34H["WL<GI2E.RE+2T`
M/#L3WW=\\\%`-23DB]BH/`/;:["WL?J4I2WS:4Y:=H11D,#'+[JUNJH1\8Q-
M>[C$#$EYE(I!=3FKTU1%-%^FB:XLDJ!+BCRZD$EHIIB0)8/#L3WW=[]TYMU)
M*2+]V%\)[;786?SBK2E+?,I3EIV!#.[H9D[UYD#99-X=(^8:\$2IR4LW4,*V
M=8@=2U=J[;N``#.#6@4]"4``H!2@4)F&(9"(B/>ZB)A'\I20=IA4,-`!W0.U
M4WD\@4#R`%``B&0#7\+\H#_.4D/:!BF#L%W00J4/VNSR"/`!8AD42B'>ZE$@
MA62DA"I!;F+4!=B!@JU)6M:^=6MQK@\]/UA/87I#-$Z8Z==G=#+R<;ZLC-N&
MQKK.)'8SBNQN7IK+C8A",)/(L:S>#RM4<'9G:O4)A\S1#N2+OF.A!LHNH4..
M^+Z9^MZ[Q')MEZFZH<:U'J69V!G26I\.W`AI_#\S2UM"Y>YC,(DW.,NM$3\N
MQAY:!@VBS$9-0CYZS-WA5,2.S'7#92='?US(@$`O7?HWW/E@6[(=0G^Y`R`E
M]_3:;F5[@G==6^JEU>:K>`7H[^N9%MIUWZ-\P"`%V0ZA-]S!L!;KNFT;QHT)
M6M;A$XC7F*7!\ENC[ZYHB@JHGUT:2<G21.<C='(]-@NX,FF2Q!([GIS00!5;
MDE*`J*$)<(B8P`)AX"/?05=7'U@'J4])'D>FNLG,=JRVA.F1;-H?JUA-@ZWU
MI@S;%<O=XG-1^O,2"?QS"(*0E\BD<K=,9-DVC':I'<0D=\!U&5AU`]X!H=D:
MX![YY]]:2<F7[H#DIJ6O`M['9Z4I3S:4L):#8?#L94F!R$\.V'(!BW$)X\`K
M%FPA73IP^7B"2Q50D"1AWKD5N0"@)`J5,X%`R28D!S/#L3WW=\]TYMULE)$^
M[=^OML=EL_G%6VVEOF6TY2=@!X=B>^[OGN@JB:V2DB_=N^B>VUV%G\X*TI2W
MS*4Y:=H)EXQJ"[<H`ZM<*K@L/?GXC047JWN9^>)D*J.#=I!)V4+Y"E``4^$,
MA$1_"^T1$?RE)`%1,<PT`'=`[5!_8[/6"@'A#(!`?POL$!#\I20A4#$,%0%W
M0>U,/V>WUQJ`6(9%$HAWRI!((5DI(>U,6QBUJ[&[M:$K6M0NK6\]P!(=B2RW
MO?N?*MK)21ON(LA)=<[&_P#F]*MU;O/K7F*7`E;1;0'#DM'0%;*-2(B+^0J)
M4F\:H7F&%P`N!`[).HG$XF"X!$044`P*2P[$EEO?/<^6!:R<D;[D#("77.QO
M'\GI5K6[SZUYBEP!8=B6T`[YYH$`*R<F/8F#8I:U=C=V-25K6[SJUO/<!X.Q
MI3\,[``/YSD_4*0H?]K\M"!V^7R^N-0!AV(A0>^=H"'\YR8#004*/:#NH=B@
M_L=@^H%`3-(MHNR:F5!V!CLT2F`K^11\K=9,:%(Y3L&UT?M``$!M'L$A+04G
MAV)[[N^>Z<VZV3DB?=@>@>VQV6S^<%:4I;YE*<M.P,GAV)[[N^>Z<VZV2DB?
M=N_7VV.RV?SBK;;2WS+:<I.P`T0R.)Q-WSS^8)K9*2)]U%Z)[;'90)_+U*4I
M;YM*<M.T$KZ-:IH**D!US+R"%7S]0M5%U!-[D*ZA!#\+/0+:%\VE+"6@J\(9
M5K1WZO\`YE)>J8QOQOUSC_Z`'``1#(!`0[W4!*(?E*2'M**9@K5WV]J05KY0
MK7RC4`L0R()1+WOS!():R4B;[F+42UN=C=VLR5K6[SJUO/<`2'8DLM[W[GRK
M:R4D;[B+$277.QO_`)N2K6MWGUKS%+P3*Q;5)2.3(#JSO9##<_D5#`+9B`(U
M4.X.:GX$G<`B`*>==<*A[P4$AV)++>^>8"8%NDY(_8D#,"77NS7]C!.M:W>=
M6O,4N`"'8E`H!WSS0*`5DY(>P@-P+41=B)NQJ2M?+YU:W&J&AY[&M6Z6'J)`
MYN)L'#0#F/GRQ0#Q-(E136<J)F&TH>4!]?R]O`,O39_PZZ"_W*ZL_P!AH+@)
MJX"F6A-=QCS6NR)B(;N`RR3WUUC+L#R>5YLA`C-FZE]S,(U5XPBYQ(K*/*=!
M'F=S32.0`%1.BOG<!"VJ]*=:C#8^%*[<S+&9[7#=!DWSMK`YKEX/I25#!#M9
M"2BU%%HL[?&_I*>]-N#<CT[\"J!R6GF@%SD\'QV&V;BQF#>4]VPG/C*"\R/)
M9,`,E-ZY(02!)2[LB7FKF`;0"ZH5K0*!(CB(8>)1P<E40%)_4>]/.RA6].WO
M'97@'((A@40,"2E0$!"KIV8*@->TIEQ*8/8$*#P')6*PKTMSC(<A).YGI2(A
M%U=JSV*KP4C'S;9G'Y%-AD6ML!R!M+X+%R9IK!F+IOCJ<HV44:K,&3YX[%X]
M<,U4P><WPKTH26PW!<4S7#7VO%,F=@Q=L'6"1L@SQ5;?TT_B%I*(R#$'SB4D
MXG18LVKUL@^9%D#$*1-RW?"N],'ZE\9]*+&[/V?,:\=ZND,"D-B9JI@^*;HR
MAE-0L;KZ/2C`P-OCDEK6`PK,F#C+GC)VK)'FU91Q!-GZ3=`LBHU,Z<`Y;&A/
M259%C&MB8>KB&&Y>?#57.P1Q^2Q5I%$V"K(9PSB2`MEYME`&(PSSZ*/I5JT(
M9U)083*+1R@_%HF(:^9]Z7T)<CY+7_2D:-60C(U?'U\DR\&31:,Q?-D9W*&,
MVCE03`GR3-?!W+&.62633BRE;JJM%S.EP!^9O_2O.D7'B.ONEJ'"*A6BPJ,9
MS-9F2RR5=S\&"K>)8NL]BXK'W41ASYZHN1X[4:KS;'D(K=R6(Z$/CAZ?I3WN
MS=>K[0@-"P>MF65&^F#'4\K(22\KC[K8L-'F+,N<^G'<B#2(UN#]XW-&I-W+
MI<43+E(L!F@AU$\'C_O2OOMY\(X`\'C_`+TK[[>?".`/!X_[TK[[>?".`/!X
M_P"]*^^WGPC@#P>/^]*^^WGPC@#P>/\`O2OOMY\(X`\'C_O2OOMY\(X`\'C_
M`+TK[[>?".`/!X_[TK[[>?".`/!X_P"]*^^WGPC@#P>/^]*^^WGPC@&YI$,.
M^2ON*M`<-Z#WMYV_@+:O_:.VG`./@\?]Z5]]O/A'`5\WYCN^'3G2/ZOTC"1:
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M-7:BBJK8I"`0JI@BR2PCTIHZDPUS$9QK\FT"X_/L\LA7KG$#+#+(9YKQ7!IA
M3(T\0-C:\LYP<LZED231@A'&*!O#TTW2C99$-QUKA_I%VO45'/=KY5@DKT[!
ME>>+S,/!K8^DY'&)'"Y-7$$62A85ME)6<!D)XMJFW557>NGI)1VX>%9^'M3A
MT981#$(]D8J*EX,VXE`73L2W<D@@`@*XA2O`<:M28SZ;C%X4(W9,YTK[!G))
MW#M!R257ERM,=CHG#\/QZ6F0B\/)KWODCD60L)7(2,['*(OGPL>:R8HH&X"S
M.Q\;](`J_P!>2.#RV&$2>Q?3TMGT!$24"RA,=RE@ELMSU%HH*9?#S60Y/A&0
MK*XTUBT6\@PE&@`HY1<>X*MGP:3F>$>DL2G<JC\-SG&GT.GB>U@QK(W3C`62
M3Z54V6\D]6-"P2^)*OH;+FNL&:4:I(.%Y"$4>/"*.6-Z"SA<+`]*^-=4+"`R
M%+JUE8&>RM;.VR^)/,;7CD&;?&#:ZAR2#`B$$@T3%NVRY)^*;AR)73DQSF%%
MNCR4^`M[X/'_`'I7WV\^$<`>#Q_WI7WV\^$<`>#Q_P!Z5]]O/A'`'@\?]Z5]
M]O/A'`1[ET)'&RS59A06$2Y5/`!N^/PM!37F8D,'FN0+YQ1IV@(AZE!X"0#0
ML<8#`*2H@8#@;\,>A7F`X*;R.`I4'1_)Y*A3VI:!D\+''ON26'F<P#4>/2UY
MP/04I:X"T1"05I2E+@I2PEH11D&/1;C=6MUU&JZATM>;C$JA7\F0$N^3FKTE
MQ$J3PB0\TLFL`7E&RX++1(02A*YX:.4YEZ2H\SFWT>/2UYPOA4I:X"VOB*U*
M4I<%*6$M"&=W0<>]UWD#1=HLLBIF&O#"F1U(H'5%;.<0.J/.;*-5S!<N>EJA
MP+Y`$`*!2A,XP\>(B(I*U$3"/X8\#M,90QO(XH%16-_I]@*!CP:/`:\I6H"`
M_P`L>>4#%,'9WBGE('_VO)P`6&CRB4025"P2"7\,>#02"W,7RN!K06I*U\M!
MK[8U0:9S'XA:!F&J[$KQLM$/FZS-V9P_;.D!9HIF;.63@K]%X@L1DF4Z1T%B
MJEN*8AP.<IP3XC%-!Q;%U54%DU_`(%10@J/&UBR<=$&M,U%M$\D2GC4JD%HV
MI:8!2)<<@@_$AH\EEJ2P<OE65>/34Y(,03K<X&Z@1R-:UK:-:WGN`+#1Y;0!
M)8+`(!?PU\-`3!J!*U<#6@,T_+Y:#7VQJ@!#1X```DM0*`'X:]_<E3*'_:/6
M2+_Z"-0A_>6&Y6ZTMNMKI/N6/[ER'6V<-M=3QU$FQ4-G.,0D(K`YJ5<NF,LV
M6\+G.Y#SG35V1))$MQ#$(!>`_G2](KWZU_UR=0>\M#8[U0;JTYE73R_<8_NC
M)]UNHG6FN<0RPH&",P]O)XIK:>3R#(LBCWHOV(0[-XW7C#)OQ7*V5:K*ATV-
MZ+?ZW(:ZOI6-2>??=3<N<!]T!T!J4Z:`M['BE*4M\VE+"6ADWHN/K<I[KO2L
M:D\_F74W+G!?NO>[Z6]-`6_RY2E*6^;2EA+0Y@[IEOK8O3OUKZTZ(WW4IN_8
M6UMU('=ZLS#`W6/9?I;,\?*01R[)4,UR?7<9'8_%:["7..0*2K1@XAB"DL8G
M(68JK!_2DBX,S2,QYG*7NI+N#=M,.@=OG//?)QS@[U8CI6]8G.>KJFON1,8#
M``B-`+P#Z,-'B(B*2O:(B/X8]I4QCG'L[Q0/.4'_`$^P'`'@T>`@/*6J`@/\
ML>^4#$,'_:.WM3#_`-!'@`L-'E$H@DMY@IB7\,>CVIBV,2M7`UH+-/R^6@U]
ML:H!8:/)9:DJ'+%(2U>/1IR>XBG6YP-U/#D:UK6T:UO/<"5M$L@7<EY*@%;J
M-2(CSW8")$D(Q0EZ@BF+BP[!+M,=7L*)1&ACE$%)(6.)8!4E@Y?+MJ\>C3E`
MR!.M7`W4".2K6M;1K6\]P9+"QQ0*`)+>8!`+5X]'L3!L4E:N!K0&B?E\M!K[
M8U0P$+'``!REJ```'X8]\A2D*'_:/*!4P_\`01X#(PL<("`I+=H"`_ACWR&!
M0H_]H]94W_H`<`F:1+%=DU,J@H4QV:)#E*N[0``%NLD(`F0S;EC8Z/Y$R"`C
M6@"4M`4GA8X]]R2P\SFWT>/2UYW?@4I:X"VOB*U*4I<%*6$M#)X>/4YER2P\
MSFWT>/2UY_?^92UP%M?$UJ4I;<%*6$M#!X:./?<DL/,%034>/2UYHO1/2UP%
MM1D%:4I2X*4L):"9]%LTT%54T5#*7D-0RSI8HB==43B*)N\D,'X6H(!RQ`*A
M2EI1*"GP:/$:\I:M1'^6/?*)C&'_`+1ZYQ_]*<`!#1X"`@DKV"40_#'@]I13
M,'E<=M!2+_H]D:@%AH\HE$$E?,$@EJ\>#04Q:F)6K@:T%DG6OEH-?;&J`2&C
MTQ()4E@%,4A)5X]-3DBQ%.MS@;J>'(UK6MHUK>>X$RL4R34CDB(*"0'9#U%=
MVH8@M6(%0'F&%8Q`_`4@'STP/0;A->8IP4DA8XEEJ2P<OE@6KQZ:G)!D"=;G
M`W"`1Z5:UK:-:WGN`+"QQ0*`)+4(!`+^&/1H"96Y2>5P-:`U)Y?+0:^V-4-"
MSV,9MDL/5124`Y-@X:!1,Y=*``#)I)U$JBQR#YI0#M`?7\O`,W39_P`.N@O]
MRNK/]AH+@)JX"DFE-5P$SJ;:[V)BT&N8S^\>LXS&76<NU"(Y`OU([HC(J3,U
M=*NHXIFAT$#%J@9,!3`UHCY0U33?3[O>,FH)SMB<QF0@V<JR&=BV;\L@I,01
M<(S>-(F@N&/LWT9*(Y"ZQUR^`KQ0KB0:OED%B-#HMA"SJ6"8G";-Q8T9#)MQ
M7PC/C*B+I^X`3(S>N2IB`.72Q2B4K@X=@!6[M]3@)$<0\;XE&@#-*@I/Z^W]
M0K>G[K@',(>,`0$&:-0$![0,(=GK@)A`0]@>`XV0_3UZ5YSC^0+N.H_7D!EB
M&'9YC\$WE8;%<AAI?-<UE,FA\>SDZ[37WY`B-4P4O&S;!L+1V>2D(8&*[4C=
MXX4,&\[7UGZ4*:>X(MJK.=2X:];:EU>PSP7[[%IK!W^Z$"R@9]-QL3(:<6R]
MOA+&:!FY72!\+F>B%EFK<D.Y;)*N@D7#]2]=#K"(53)=DXY`;(@]';O@A,Y=
M83D^*Y5N2?>)J:"R7+6D;J"#621U_%OE4IM:-%LUDG;)$Y6!D5%2'"'YJ-]+
M-BA<=C=?XEH/+,?.JBF*^T,CB\PV!&-$X;))<@9YE.-06GL>FG"\VT0C':D-
M"E.FW<QX("JH63D`"1]&QOI0I7*<8>;WB^DS&]?'@FTA.Q&-P^0OMAC)GQ;*
ME4H*1>-)UUBD?)ES%2+3D58\SQD2/2JS54546$`C*/P+TL48E*.X:;TS)O,F
MQQE&+DV?(8T\2P[(Y!NJ\C<LP^#PG`&+6+3PJ+MBYV-?R>0HS\Y:_9*M&13H
M*AL\:S]+>R!,\AC'1O.H,7TH/(56R2(E9^$*]C>XD=K,D7,9#9(#10Y45$07
M9+`F[57*@<[%!,%[R&]+6V2@"1R71+)R*IX)SDJ\A"9RRQ]JFNEDRDS$Q2+.
M3\;7.S?%CT3NSF+>S$BJ*7/[PD`6@Z3<9ZBH_`)UMU6+0,ML$V7.WD<^@2P!
M(OP"0B(9\DRCB8ZUCTDV$3).'#0I7*7>0605H=5N*"J@6D\&C/Q-+_V_MN`/
M!HS\32_]O[;@#P:,_$TO_;^VX`\&C/Q-+_V_MN`/!HS\32_]O[;@#P:,_$TO
M_;^VX`\&C/Q-+_V_MN`/!HS\32_]O[;@#P:,_$TO_;^VX!N:0\9WV5#N:5`<
M-J>W_$6P_9<`X^#1GXFE_P"W]MP%?-^8?NV6<Z0'0LMC./H1F^,$E-U$R)NS
M71F]%-4Y?\X$''=[C)1R$W(H'139`V%JJ5V9-0RY$DU"G"E,WBOI>`FIR5C)
M/HI-%QRNYHC%8&/A<U(,W%/(F+/I'+,D)+D`"9,PR1B?QABW?-V)(YRX(FHL
ML9%1$.D^#Q<JK`19\XC(-MFAH+&C9<W@%7"\$WR@T"P-/H0KA=)JNXB4I452
MMSJ))G.B!1,4HB(`%`^I+6OI(7/44QR_ICSW2[+I]883"'>:WS]DV4FY;.8^
M&VU%3B22Y</<NQC9E7+\>D6_,F6R:<IC#5,X%9.'Y%PVF&PGTB$OK>?2S#*N
MF_&-JAG6%R^*.\`QN36Q`F%I24BWS7$LC)ED=//WB*D6FS=MWC5-J^4<'60O
M33*4Y@BV3U-Z3H^I,-\)VGK5':"$!/L<KC'J>$*)*R*6>Z[=X)+CE9=0'8/9
MLF$MIQOD7(C&L<Z*82LFZ+A9%TW#<-:ZP](+&]14=-[4V%KJ>Z?$\LSQY,8W
M"H8ZU<J8W*X7)?11!B1#`XS(4&V.Y`I%M46BL@Y76<-Y-\X=BDLR:E#HVPAX
M[P]F(,T;^YMQ"ZX0NY!*7`(B`A7R]G`<:=2ZN]-/A\+X5G^S.DS8DQ)NH=HK
MD\]".G!<>C(?#\/QJ2EF\7C6(X$D[F,CF8V3R#NXE4;A*2!VQCHL$T"$"S.Q
M\`Z\7;_7LEA.4:\0!:+Z>E=@0<6IB\-C\+E<(CLQ?J&4C$LAUOE&093A>9.'
MF--8]F,I'/VB:2KE%RF*!FK\-)S/5'I&/'<I98=LW#W$)]%-JI8UD#XVNF*S
MJ2>;+>3.KV2F/%TZH:#R:,UHT0B5)<[J2CA<NP47CE#ME'#P+`]*^$=2N/0&
M0-NJW(,6S#*G>=MG>*2&-DBD&K7&_P`W4.WD(XK>%@,=;E:H98W?'2462%RN
M*AE#E2(*290M]X-&?B:7_M_;<`>#1GXFE_[?VW`'@T9^)I?^W]MP!X-&?B:7
M_M_;<!'F7P<2;+-5&,P1,)<JG@*8>9YH*:\S$AP]O3SR#3@)!-"11@,!F20@
M<#@;M/V@<'!3A[?]T#I3]^/`9-"11[[F21N9S+ZB?SN<#T%:^=^["16K_P!8
M/L4")LAQV%<;KUJLM&HJJ):\W()%1%:J8O9O5Z;D0M4`ONY)1P4:@/W4:4[*
M!+)X6+4O$[)(W-%43U$_G"L+X51'S_W8R2]?^L'V*!"^[X")>:[R%JYBT%T%
M\PUX<Z8IJ$YXJYSB!E3&432;J*U,NIV\Q6E1"X*6%":!A8LPB(LDA$PF$1J?
MM$QE#&'VWJF6-_IX#(0T6`U!FE4!KY3^4#%-7VWV1`']K@,%A8LHE$K)(!()
M!+VG[!3%L8E/._<BT3_>!P#=*PD82)DN6P2,8L<Z!,@)G6J*;9ORR`CW:0YO
M;'H4+W=>[E@'+/42F!!B$,P+BN+&48$27)C\`)B&0.U,DJC'0XE(+48N`[L9
M$\6@'+[@RLY0!W=&@I@#^2$BD[`(R2+R^5903^;R09`E3S_W`1J%/^K#V:@%
MA(H@%`K)(`(!`+03]@)@U*0/;_N09)?O`]G@`(2*"@`R2[```]OV`4J92A[;
MU"I%#]K@(JWKA^73VD]NP6HWS/&MKS6L\XA]89&Z-:VQ[8<GC,JQPJ=<'5BY
MY-)&'R1TW<&.9DZ*0J8F%(X!:(?SK^DW3WUJ_K.ZA-]:2-U5;QZ>YG0$FICV
MW,_W1D\CK[7),O%N08;&L=E,#P:=-L"6R&!?$D6CN*:O&`PRJ#I1T1)RR[P'
M2PWH;_K3Q[@-Z8[7XW@H!O\`YU[R"H*@Z!3R:%"EP/5?W_L!0`WH;_K3Q[[O
M3':_&_F7_P#SLWGV\WO?,\FAOW7?U?W_`+`4#F7NK5/UK;I]ZUM5]':/5!O7
M:V:[I:.76M-PX3E#K*]%O\=(4@Y].2F=Y?A#(V#,M?\`BUT\G(LF;Q$JC<Z"
M+@'+`5P_I)1L`5I'8^SE$T7TD1B@UEWWNSCO;Q./<"]<]X6;J+`#IZX5.)C'
M0,?F=HC6P0?!A8L1$19I"(B(B-3^4QCF']WZIE##^WP`$+%@("#-(!`0$!J?
MRE,0P?NO4,F4?VN`R6&BRB42LT@LL$O:?L%,6QB4\[]R+-+]X'L\!@L+%DLM
M9)!R^5903^;R18BE3S_W`QJ'\&'LU!(VAXTKAR`,42E0.T(@8$S$$$T$(U1(
M`4Y"(J@DI'HT$5%J<L`J%!(`*B0D40"`1DD4$P3`E!/YH(@R!.GG_N`CD/X,
M/9J&2PD44"@5DD`$`@%[3]@)@V*2GG_N09I?O`X#`0D4```,DJ````5/Y`*0
MH![?U"I@'[7``PD4("`LDJ"`@/M^T#%4*/[KU2JF_P!/`)F<-&*L6O-8(@)F
M:)#D!,R(``MUDC%Y946=E2.U`$.4G[<?-#R`"D\)%*7@=DD;F<V^HG\[G`]!
M6OG_`+L))>O_`%@^Q0,GA8M3F7LDC<WF\RHG\[G]_P";6AOW?BCBO_6C[%`#
MPL4I?>R2-S.9?6_SN:+T5*^=^[&17K_U@^Q0$K^(CBMU5",43J7D/VIF6J)U
MU3'$4Q0>`:HNU1^YFI<(]G8(`J\%BZU[FE41$?*?RB8QA'V_JF.(_M\`!"Q8
M"`@R2`0$!#M/V"4R9@'VWJ&1+_HX`+"Q91*)620"04Q+03^:*1FIDQ#S_P!R
M9DE^\#@`D+%IV"1DD7E"D)*"?S11%B*0AY_[@8U"G_5A[-02JP\:FK&IIL4;
M".R'`>68XI&:L`3;F*H**QDK`8HEK>E6P`$PUL."HD)%$LL9)!R^6!.T_F\D
M&0)>4_;8$<C3_JP]FH8+"110*!620`0"`7M/V`0&Y2![?]R#5/\`>!P&A9[%
M1[9+#U4&J::B>P<-`ARB>I0\233[*F$/:``<`S]-G_#KH+_<KJS_`&&@N`FK
M@*3:6U1BF1:CVLJQQS'D,NR/=_6>DVR%W&L5G*4X[ZD]U1<=*K+O8V72YC(2
M(B4QVS@I`2`>4>EHA$^L.DW?<!L#`9G/,GU3.8+#JORYGC+:+(\>SJ9H!W%P
M;QN^<8/'.BK1B9TBO$#.02DI0#2M6_F,2A<I/!<,@]G8L,1B\'&BXPC/A6%I
M'-D>:*,WKDJ0G`J=#"F5<X!ZH`8?7X#Y;MPW),FUMG6-:R?L\3V)/X%F,5A&
M2)BRCU(3)GL<DC$R:3Y>#R!%DJS=&`Y5C,G/+$+@((@'`<L9767IDL$QP2X]
MEG3/M46T/'M$(U:.B/I@I+.E<1;I*-IC)\-Q&&\'Q\K.14DEY)Y)2,DV<K<B
MQUW91$+)8QIGKV?/M!R6P]JZ,:N,=E-^%WQ&X!B1X[&LO@LAA7[32">.,93&
MW<D,IBLX=NX765<M2HM$Q*8CM<3'.$0OM1>EH>26OEHC/.DG&8G$\4US'3\=
M*$F<U5SC-8C#YR`V!DV7OR:=Q-Y(8QD^2.VTN$6P/$O$S()D1?-Z*@J"Z2T]
MZ65W$P!&&W>DJ*DEI&;4R$Y,&[RXCX%K!P8XJR:.W&M%6$ODTGD@R'BSL&;%
MBDS*D#5J!U#&2"1]::]](E%YQK93;.5=.^185(YVNTV.QPO!&!3X]K6.Q7*)
MP)9M,R;3&)*0S3(\^:1,(W0:QZC)I`OEG"PB]:`L["/\>Z</29Z]Q"%C87J7
MT/M3)%SXI)3;K:VM5"LHJ7<HY..<QC.1B8A>?R##&CUO"'9I"K&OG(.I$J*L
M6DFR1*'[/JWTL7/O;[!Z.$V`EB$T6C_"Y-]+((FUSD328<2,PRPF)CI&3;[(
M78.R$;QS)LY;(`D`MB&6O!\S/07I!,D>8E*P6W]6X7D0:JTZSR-U"KMSX%$[
M,QR0+(;E(EK.3TW*AG$7L5R5(K&55EH=>,8)JM2,R\P55`UPFK/2Y'BUG9]B
M]$#?(3YXS.SB@PC)G>,--?&<9B[EDY![]"V<Y)S(%5A6C$B(LK$$UE5UE50'
MFA]F.E?2HN)]^U>[KZ9(W")6.25*NI@C:6SJ!?*PF-INHR,DHG7.*0*@(S#1
MYRGBK%0:.7"O++5FBU!A?Z9]+M*"6*';_23!PR!\A3/,P>,OOI/+-E\K8GQI
M-;Q/6,@UA@88D#E%TLW44=.3"0Z9VRXB<@67Z>M=]<L5L)>6ZD\WZ=I_7(0L
MLP;XOK7#GC*</-KR1G#2>5FG^/10D9(D1Y31D`B*,>L5-TH\>)&>+!>3PF(^
M+H_WJW^TX`\)B/BZ/]ZM_M.`/"8CXNC_`'JW^TX`\)B/BZ/]ZM_M.`/"8CXN
MC_>K?[3@#PF(^+H_WJW^TX`\)B/BZ/\`>K?[3@&YI%1(O94!CV`@#AM0!:H"
M`?@+?R!9V<!5#JIU!U";#>ZY+T]9]":ZCHICM1#/$7;Y*&"7>SV$'8:XD&ZK
M7!\JD%5\8S-))R8"+-400,H*B3HW**D#(CT_]0[784#D++<R@8;!OM,0TGBD
MZ?$\@0SK&<*/F,?M')YM,=1QZF.YCL^,5@'AFT2Z;-F\@W=@"P(J@4P5YFM+
M>EA/+SLM&[IZ.S,FI]R1>(P+36D]'INX29B(TNF)_)C/\?EVZN8XUD<>*TLD
MC:Q48KKH('N5!5,.EV"P\BG`1:.;LL95S-&"QE++CP#>Z!/DY(!@6>/!BZ9,
M7(Q!I0%1;"H@B<4;;B$&I0#1^H?66<;'U)D6%:=S5GJ7/)V5P=)GL)"-1=NL
M=@&>>XQ)9RHP:D1$SB3D,&9231J2]"YPN0.>W^[IA4"=T!U[?1E)E`[RU*ME
M+;;V'3;&8=8T6.BT]60H9ZUD<<G8H,.EW>0"]*[QQU(MB.V3N7.U>I!*L@.D
MJ(1)+],_I1%('&44NHW5+[)F&LE("=?Q)8G%(B2V(QRMVZC<O79.-!9*LY;R
ML4:.</TD3,03;L7D8B2U_P!]2"7]<:&ZYH+J,99GL?<^!9+H5OE^>RLE@L:C
M'-5E\;GL-ED,<9M(]KJR&>H$Q:?7BVS1FI,K)`5@^D5E%EY!%LS#HRQB(D\<
MS+W!D43,FX7D;(`H410(%Q36"('#R@/K\!QWQ_IQ]+KAHON7U*],VPT9!"70
M$N7X&L1_&H-XZ^"5@WK3`4&#&;=R,H\*HX<LG[9$64>=9!VD#AN8)^RC0_6P
M*>I#XUMS"W:\5CG34SV<FX6QZ!9+Y;@K+8H=0.01:)-&3KW+HC:[N2QY(D>\
M=18)D;+N$CLSI)MW(1#'=-7I/6[3(V,AU)Z<D(Y?%MGQ<&8L"Q:YA])9'(L$
MEL*R,V2%U(>*BT7<?C<TQ0;%CW!<69Y")?RVJV152"UG27J[J5U_C>11O5CG
M^"[6RR2V&I)XE.XG%MV+-CB'T(8LDH5=DEBN+((*,9)HMS#`BJ9VX%5V8Q.\
M`@B%R?"8CXNC_>K?[3@#PF(^+H_WJW^TX`\)B/BZ/]ZM_M.`/"8CXNC_`'JW
M^TX"/,OAX8V6:J$T9&B(97/`41:-Q$+]>9D0X!YG9>01`?7#@)!-#PP@:Z-C
MA`P&`U6K<0,!RKE.`U)V@8KE0!]<%#>N/`!H>'/>!XV/,"G,!2YJ@-X*@]*J
M!JD&O,!^X`WK\T]?;&J'CZ^M28MZ3#$3=,>^/1]YCNV#Q3%\8VCAVX,<Z=)?
M)VV>H*Y?E>`,X?*GN-8B@,M,8^^DYXD:LY;<U9JZ=DYA"IK&4`*@:?\`0?\`
MUE+9.K\+SK/?2\YGIK+,O@&T[-ZKRW?G4#.Y3A"TJ#U<L!E$AC+:0Q]2?0;2
M*G?4VCARB@X762!52ACF#9=B^@B]/ZSPH3Y!Z;F6G&*<[$(2\2[V1U(D:"]F
M,EA&D0]*_&/7<3@H/I$BYQ52+W8R8E3$PB:@;,/H#?K$HB-?3D28B(B(UW+U
M.U$3&4,81_)?E$RIA'_UA]?@#_Z0;]8E`0'_`.GD2=0$!`?SR]3O8(&*8!_F
MOR@8H#^UP`'H#/K$H6B'IR),+1()1#<O4Z%!(9`24I%]@E,V3I[)"^L'`/V)
M>@D^L$8YE&,S^2^FRE)W&H&>A)>?@B;8ZDY,9B"B9&+>R<26,?0;ME(=_819
M$0062525M(0Q#%[.`^V8^@P]/YE^891E^"^FEE,,PO)LDF,CPS$0VKU*0PXE
MBTM*)R>,XV6)8XU#LHGZ/Q*+%J5LBT:I-^Z)D(BD5,I"AK1?0&?6)"66>G(D
MRV<OEV[FZG0MY7<P2MI%]G+!BA;ZW*)]B'`9+Z`SZQ(4"@3TX\F`%L`M-R]3
MOF@F#8$P+^2^RPK5*GK<LOK!P&`]`9]8D```/3CR0`````&Y>IVE`*0H!_-?
MJ%2*'_-#@%;'T"?UAANY25D/3F3*+,MX+*-]G=2DZJ6Y-1-.R*=L6[=T`J*`
M`W'+8`B<*B6@@G/Z`[ZQ,<#W^G'D1YEW-'\\?4V!E;BN"F%8X1(&5$2.50J8
M1&AS!Y!'@/P;T!GUB0]]_IR),U_,`]VYNIT;N:#P%;JQ?;>#Y>[U^:?[(>`#
M^@,^L2'OO].1)FOYE]VYNIT;N;WWFW5B^WF>(.+O7YRE?;&J'Z-Z`[ZQ*8#7
M^G'D3";F@8QMQ]39E*+"\%<H*&BA4*587RXG`!`#<T]:U'@%:?H%OK#1&;]!
M?TYTV5T].@#9$FT.I5XBXM4>KNQ=2BC(CF(L!PH)>6FH#@ZAB'$O94$8^@-^
ML2B(B/IR),1$1$1_/+U.]HB8YA$?R7Y1,H81_9'@#_Z0;]8E[/\`[.1)]@@(
M?_.7J=[!`2&`?YK]0R91_:#@`/0&?6)2VB7TY$F6T2"40W+U.A:)!;BG2D7V
M"4S5*G_5E]8.`P7T!GUB0EEGIR),MG+LMW-U.A;RNYBE;2+[.6+%"WUN43[$
M.`I%Z07T<7UD3H0T&COV!])9OOJCQ_#Y5!ML#&=&;1WFOFV$Q+M:-"*RPD),
MIM9'.<7;.F;-)Z9H59>+$$SF0%JFNN@'KC]!WJ#K3UIZ/;6+;TBN29)F74OE
ML]DFP),NQ)Y?+,^P[#\E6AG.$87ET@^(92/R&$C(I!1Q'D44\-4.1N<P+(G(
M0.NA8>&+:!8V."P"`0`:MPM`A6X$M\SL`A6J0!ZP)E^Q"@'@\-2GAD=2@!3N
MC?R`!"@'M/(!4RA^P`<!D8>'&H#&QX@("`@+5OV@('*(>T\@E5,'[!A]?@$;
M*'B#L&@*QC`1%FD0Y3LD"C0R"Q#D,06;2T!(Z5`0Y2?8H<+0J(<`K-#PQP.!
MXR.,!^;S+FK<;^:#X%KZD\[F!(.+J^7G*5]L:H9/#PY[[XV/-S.;S+FK<;^=
MW_G7U)YW-\2<W5\O/4K[8U0#P\.>^^-CS7BH*ES5`;A5%Z*MU2=O,%^XNKY>
M<>OMC5!(_BHONRQB1S$51.0U2LT3G$QUU#*#0&;P1$PNE1'W,W:H8>RHFX!6
M,1#B-1C8^HB)A'NJ%:B8QA&MGE$QQ']D>``B(<!`0C8\!`0$!!JWJ`E%,Q1#
MS.P0,B40]DH>MP`6'ARVVQL>42"026M4`M%(6HIVT)V"0S1&GK"F3[$*`$B(
M<EED;'EY?*%.UJW"SE"Q%&RA/-Y8Q[>VGDY*=/:EH"16(B2+1I4HQ@4B;LIR
M@1DA:F9!@4C8P"#14$A2*Q;E(-Z-.40`,-"D,"HL/#DL`D;'E!/E@G:U0"P$
M@9%2`M"!3E@P;@7UN42GM2T`+#PY0*!8V.`"@0"@#5N`%`A4`(`4)V`4K9*G
MK`F7U@X#0L]C8UNEAZK9BS05+L'#2E.BW13.4/$TB4`Q"@(!80`_8#@&;IL_
MX==!?[E=6?[#07`35P%'M,:[P/(]2;830A\,:9?/[OZT&09"O'P02S6:?=26
MZHYC).7SF-DEB.V:9D1*=1%<2$(7W,X`!1#1-/=)>08UD./RVT,OU_DS*$D6
MKY5E$F=*>)MVV,Y'"HQ<@DX81$>[0YDK'&>J+(J%DGD1X@"+-9ZNW3"<MDM8
MK7\@;(=5ZOP;,LOC]6[+D8?`D9;&,!2S:2CIC7"S+'C90]CGD5$/'XF.DT7>
M)]U(X4*"JB29CJDWN,P;+=<AAV_)9YVNQO>*WS=DY/;K/3OFD36UHKZVBL]V
MFND3.D3;>;5I,TCNM$=(UTU_M;/J"8ELMQ6`S+/L1A]?2^5$=SB>M7"N,OY;
M748\;-/"\6RN5@7+^&D,U09E36F.Z.'#)J_74:-EW2#=-VXV.:V_';/?VV7%
MYHW.WP_1.>L6BF:T3]63'6T1:,4STQ]T1:U(B]JUM::5MQS>U>Z\:3/P^7X3
M^/S3.!,:`0$"08"`U`0*P`0$/((#3L$.(ED4&=].FZ)91E/RVXX<LC#8I@V)
MGP*#S/(8##\\)CTB_4RO(,GRV,@D,GQ>?S%JNW5[S$LS/6JS;DF=.&ZAR\`Y
M;,U=U6+S42^U3N+3\=CI"8XUEL6F\6Q@CP"(,<*C9]U&Y7+8+FT@=1P[;S<@
M0[Q)RH'-21$#W@9L#0.G.L(0BY`_4'J`\HPD6*;N+0P;$&6+RL6#UFXG7;Q`
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MG&O%6DJ@\R=YC#*#:X[(/#2T>F=HW(^D%E&X*`?G"8A@5#3LJU9UL)$C/HCN
MW2KQ[,O`&:-)8-@[*%PNY)LNJK$H?0)W+Y+`I"5VV2:+K)R`JJM%SO+$'*#L
M+/Z2P_/L4AGZ&Y=@81L*:>=P60=PF,8UC;.-62[ZD]:MTHJ'B.]-%4.[&`ZY
M3JBX!<Q>6D=-!()MY>,_>X+]['_ZN`.7C/WN"_>Q_P#JX`Y>,_>X+]['_P"K
M@#EXS][@OWL?_JX`Y>,_>X+]['_ZN`.7C/WN"_>Q_P#JX`Y>,_>X+]['_P"K
M@#EXS][@OWL?_JX`Y>,_>X+]['_ZN`;VJ..`[DQ,E"6"X;V")&%HT9-KK1I3
ML'R\`X<O&?O<%^]C_P#5P$7[EQ-]F6N9_&]?3\%BF62"D,,;.>(##]U393L8
M_?IC)131[(-0=1[55+W-(U]]AJ%,8P!5W.=-=6TEL:<R#">HO3D-K]%G)HXE
MA3W5F/$DN\2N,-X\JV0Y`+"6:K*0>4`:09G[BZ**!.[*)F%4RR87&PUFDTA(
MYKE:^+/\E;0\`VR"0C6[%O%OIUO",DYAU&(F0;"BP7D`.9(G+3L3$`M+2@`D
MV9C*&7Z[SK%,5R"*P_)<EQ+(8&!RQH#4KO&I:6BG3%A.M3("1<KF*<KE73$@
M@8#$"@@/;P%:I+1NX"PIXJ%W;C(NFF:8W(8_+R4>@BYCL2A&F5L0C9M./:E6
MS`W/?1$@[:/'`>-K,5FSIXF@N44@CB1Z<.IA:%CVWZQ>*RD\ABKN">S+=60P
MAFYE4Y2;<1V1>#1<=D*1I)T#^.=.CF5\P(<8U$"LY!P=()!PW2.XX';,3F61
M[C@\BPEI,Y-(RN*DD54&4@VGH:3(@1#'0@NZMRP3UTT91[)-^1FW;L3OCE7>
M/#D0"X[!+&P8L@,G!@8&C<#`)6%;@1)6M0K6O`0AN'5\]G<YA\Q@VRV.`)XK
M"9LFHP;MV#R/F\DGU\03QV3EXQ<B\7)-<;81<F*:3I!PD*[L@BF<H'#@(<F]
M&[\<9'"RF.;WP6'BX]IJL9N+D<?---,H/B1\94R^'(P*M')8NADCV+DW*\H@
MHZ>2:,N#%RDF@T14,&GH=-_4.@==J'4!!JL?#,I8]_<3TFO)R1G9X-S"*BW\
M`(UQQ^]D85=59XT464AVLLNS9)JIH(*"$_Z+UUF6OF4PSVCG,+G[F6RQ"4B7
MIWY9-2+8%Q+N"\811U#PJ;*.1>MO<$03<*J'!1TLY45<F31"QW+QG[W!?O8_
M_5P!R\9^]P7[V/\`]7`'+QG[W!?O8_\`U<`<O&?O<%^]C_\`5P$>Y<AC!LKU
M6848`UN53H`(IQPB4%->YB0X`(A4`.4:#3R@-!X"011Q@UP&2@1`P&`U21XW
M`<%RG`U0[0,5RH`^N"AOLAJ`9'&#W`=*!-?S`/<2/->"H.@5`U0&[F`^7`U?
M+SCU]N:H>:/ZR?LOTBNK-*Z9R#T:N+HO\E<267,]KY?K6&C\OWQB>+O,NU5X
M2.`X<K#RAG4!D.7OF[.??-$G;Q%H],DHB5DZ>KD"]>OLB])=LCI_Z4H+9$9T
MVZ6ZPY2'A]D;^C\?R8F28BO!02BD/DL%E$"MKZ;325GWF;-'4E&P4P'*?`];
MLY<$"@LN$<[8U+Z2EAK^`=YKN[3TF#/&M'Q.PUX5IC;&$G=FQ.X\+;3&4.&"
MO3M)R4XQR6(H]>D:!')D2<N6"+=(1*N8.W`I8R(B)DX(3&,8QA$D>(B8QE#&
M$1$*B8QE3"/KB8?7'@#E8Q6O+@:@("`V1]0$!*8!\GE`Q`']D`X`!+&"VB5.
M!*)1*)1`D>%HD%`Q!+0.P2&:I"'K"F7[$*`W2C?'#14BF@A"&4&/=)HII(,%
M#B<K=$J*:216CT3F`S%`"E!%;M13`"&M*7@$&)(8^CB^,%70AD72,!!%4(HW
M8MED%V\=%`!#H#%PAFRK<\:@`$[FS%,6Z8<E+EE(0'\J.,$LL2@2V<NRTD>6
MSE`T!*R@!;R@CT+:>UY"=/:%H`5'%RVVI0);`(!;21X6@F#<J8%H'F@0K1(`
MIY`2)3VH4`!'%P``!*!``````)'T`"@0I0#L\A2I%`/6`H>L'`)7K7'EFRB:
M#>%55,*=J:2#!4Y@*H`FHF5LZ$P`035]S-0!'R>4`5&1Q@UUR4":\#`>XD>-
MP'!<IP-4/.`Y72H#7R@H;[(:@&1Q@]UZ4">_F`>XD>:_F@[!6ZH#=S0?KW5]
MMSE*^W-4`R6,'OO2@3\SF7W$CS7\[OO-OJ`W<WQ%Q=7VW/4K[<U0#)8P>^]*
M!-?S+[B1YK^:+L5;Z@-W-&07NK[;GJ5]N:H?!="`.LW.1&'.D*JP.SE28F3M
M61>G#O!^[J@`*KN%!\XZ=QU#=IA,)3!]Q2Q@1$13@1$1$1$21]1$1.81'L[1
M$RAA_9,/K\``EC`"`@G`@("`@($CZ@("0P"'9V"!DRC^R4/6X#)4L8*)1*G!
M%$E@E$I(\!**8MS)B6@=EAFB0AZPI$^Q"@8*EC!+;$X$MG+LM)'ELY/=!2MH
M`6\H6"%M/:\A.GM"T!.W;X^DLY.*$,FD*C<C4XHL2)BFV0CA*1N;NR0&(W58
MH4H=0"&1)02B0I2@H*EC!;;4X$MG+`EI(\+.2#0$K:!YO*!@A;3VO(3I[0M`
M`1Q@MH%2@2@4"@6A(\+0("!2`6@=@$*U2`/6!,OV(4`Y.+@%`2@:````61]*
M`!"@'D\@%(4`]@`];@`4<8&H"E`B`@("`DC^T!`Y1`>SR"50P?L&'UQX!,U:
MXZ1FU2=-X4JH-$2*IKH,"'`#MU"B4Z1V[82@=-VH`@*9.Q4P6@!A#@%)D<8/
M?>E`FOYE]Q(\U_-!V"M]0&[FA(+W5]MSU*^W-4`R6,'OO2@3\SF<RXD>:_G=
M]YU]0&[F^).+J^VYZE?;FJ`9+&#W7IP)K^8)[B1YK^:+L5;J@-W,%^N)J^7G
M*5]N:H)WB$`J@H""$.JN<Y3%!)%BJJ8PK***&`I6[HQA$'*IC#8;[H<>RX1X
M!1RL8\O+@:U$?:1_E$3&$?)Y1,81_9$>`R"6,`(""<$`@("`@2/`0$HIF*(=
MG8(&2*(>R4/6#@,`EC!;;4X$M@D$E"1X6BF+<R8EH'FBF+1(2T\@I$I[4*`%
M2Q@EEB<"3E\L4[21Y;.4+,4K*`%O*&/;VT]KR$Z>T+0$ZK;'@48&1;PH(-G1
M#G,FBQY3<4F7+:&$Q6ZA413%B@5,;DJ<D@`;S2D$%!4<8):!$H$MG+`EI(\M
M@)`U!("T`+>6#%`"T\G))3VA:``CC!:`5*!*!0*!0`D>%H$!`I`"@=@%*V3`
M/6!,OV(4#1<Y2@BDP_N*<25P&P,.`G=2,P6`H228&`G*#F4!,@5I^Y#U@X!M
MZ;/^'707^Y75G^PT%P$U<!SDTGD$%'P&P4%>E7/LV<?K(=69G.70V&:@>1\^
MM^M!MX@/$7L]GL3,N^4B0B%[ENFI[E0`M`H\!,/TN@/\%NTOZB:*_2=P&`RW
M'P,!PZ+-H@<H"!3A@FBK@`U+@`WYSJ@`T[>`_0Y?`F&INB[:8C2E1P710C3R
MTJ.SZTJ/`8^ET!_@MVE_4317Z3N`/I=`?X+=I?U$T5^D[@#Z70'^"W:7]1-%
M?I.X`^ET!_@MVE_4317Z3N`/I=`?X+=I?U$T5^D[@#Z70'^"W:7]1-%?I.X`
M^ET!_@MVE_4317Z3N`/I=`?X+=I?U$T5^D[@#Z70'^"W:7]1-%?I.X`^ET!_
M@MVE_4317Z3N`/I=`?X+=I?U$T5^D[@#Z70'^"W:7]1-%?I.X`^ET!_@MVE_
M4317Z3N`/I=`?X+=I?U$T5^D[@#Z70'^"W:7]1-%?I.X`^ET!_@MVE_4317Z
M3N`/I=`?X+=I?U$T5^D[@#Z70'^"W:7]1-%?I.X`^ET!_@MVE_4317Z3N`/I
M=`?X+=I?U$T5^D[@#Z70'^"W:7]1-%?I.X`^ET!_@MVE_4317Z3N`/I=`?X+
M=I?U$T5^D[@#Z70'^"W:7K__`+":*_2=P!]+H#_!;M+^HFBOTG<`?2Z`_P`%
MNTOZB:*_2=P!]+H#_!;M+^HFBOTG<`?2Z`_P6[2_J)HK])W`'TN@/\%NTOZB
M:*_2=P!]+H#_``6[2_J)HK])W`'TN@/\%NTOZB:*_2=P!]+H#_!;M+^HFBOT
MG<`?2Z`_P6[2_J)HK])W`'TN@/\`!;M+^HFBOTG<`?2Z`_P6[2_J)HK])W`'
MTN@/\%NTOZB:*_2=P!]+H#_!;M+^HFBOTG<!@<LQX1`1Z*]HB)1$2B.!Z)$2
MB("`B`_G.[!$!I^QP&?I=`?X+=I?U$T5^D[@#Z70'^"W:7]1-%?I.X#`9;CX
M'*H'19M$%"`8"*!@FB@.0#@`'`IOSG7%`X!VT\O`8'*\=,?F&Z*MH&/02WC@
M6B1/:(W"%P[.K01[?V>`P;*<;,%INBG9YBB(")38%H@0$0H(#0=G4J`E#_1P
M'[^ET!_@MVE_4317Z3N`/I=`?X+=I?U$T5^D[@#Z70'^"W:7]1-%?I.X#`Y;
MCX@(#T6;1$!`0$!P310@(#V"`@.SJ"`AP&"Y9CQ"E(3HKV@4A0`I2EP/1)2E
M*4*%*4H;.````#L#@/U]+H#_``6[2_J)HK])W`'TN@/\%NTOZB:*_2=P!]+H
M#_!;M+^HFBOTG<!@<MQ\>P>BS:(AZPX)HH?_`.YW`9^ET!_@MVE_4317Z3N`
M/I=`?X+=I?U$T5^D[@#Z70'^"W:7]1-%?I.X`^ET!_@MVE_4317Z3N`Q]+<?
M[!_4LVCV>3_X$T5V>IV?_,[UN`S]+H#_``6[2_J)HK])W`'TN@/\%NTOZB:*
M_2=P!]+H#_!;M+^HFBOTG<`?2Z`_P6[2_J)HK])W`8^EN/\`:/ZEFT>WR_\`
MP)HKM]3M_P#F=ZW`9^ET!_@MVE_4317Z3N`/I=`?X+=I?U$T5^D[@#Z70'^"
MW:7]1-%?I.X`^ET!_@MVE_4317Z3N`P&6X^```=%FT0`.P`#!-%```'D``_.
M=P&?I=`?X+=I?U$T5^D[@#Z70'^"W:7]1-%?I.X`^ET!_@MVE_4317Z3N`P.
M6X^(4'HLVB(>L.":*$/_`.IW`9^ET!_@MVE_4317Z3N`/I=`?X+=I?U$T5^D
M[@#Z70'^"W:7]1-%?I.X`^ET!_@MVE_4317Z3N`Q]+<?&@CT6;1$0[0'Z":*
M[.RG9_\`,[L[!X#/TN@/\%NTOZB:*_2=P!]+H#_!;M+^HFBOTG<`LC\_CXIX
MC(1?1WMZ-?MQ,+=\PP[2+-V@)R&3.*+EMM)-9(3IG$HVB%2B(>0>`WWIB7,Y
MZ:^GIR9LY9F<:.U,N9F\*B1XU,K@4`H+9V1NLY0*Y0$UJ@$44(!@&AC!01"<
M>`YEX'E&'.?H^(]16N-<#KKJ8ZW7F7XS([#:PT_(/9?J,W$TQQN^A_I;'1+A
MC'K.#.7#258.#+D,GR56X"KS@5ZU&)Q?/L/S?-NNC6^;#&.YQUD\8KM%DUCY
M1J[Q)3&8F`:0H9T&+#&H/E"2RKE6/!X#UN4"G$IS"4+E?K":#_MPU!_>7AGS
MUP!^L)H/^W#4']Y>&?/7`'ZPF@_[<-0?WEX9\]<`?K":#_MPU!_>7AGSUP!^
ML)H/^W#4']Y>&?/7`'ZPF@_[<-0?WEX9\]<`?K":#_MPU!_>7AGSUP!^L)H/
M^W#4']Y>&?/7`'ZPF@_[<-0?WEX9\]<`?K":#_MPU!_>7AGSUP!^L)H/^W#4
M']Y>&?/7`'ZPF@_[<-0?WEX9\]<`?K":#_MPU!_>7AGSUP!^L)H/^W#4']Y>
M&?/7`'ZPF@_[<-0?WEX9\]<`?K":#_MPU!_>7AGSUP!^L)H/^W#4']Y>&?/7
M`'ZPF@_[<-0?WEX9\]<`?K":#_MPU!_>7AGSUP!^L)H/^W#4']Y>&?/7`'ZP
MF@_[<-0?WEX9\]<`?K":#_MPU!_>7AGSUP!^L)H/^W#4']Y>&?/7`'ZPF@_[
M<-0?WEX9\]<`?K":#_MPU!_>7AGSUP!^L)H/^W#4']Y>&?/7`'ZPF@_[<-0?
MWEX9\]<`?K":#_MPU!_>7AGSUP!^L)H/^W#4']Y>&?/7`'ZPF@_[<-0?WEX9
M\]<`?K":#_MPU!_>7AGSUP!^L)H/^W#4']Y>&?/7`'ZPF@_[<-0?WEX9\]<`
M?K":#_MPU!_>7AGSUP!^L)H/^W#4']Y>&?/7`'ZPF@_[<-0?WEX9\]<!7?J!
MRG`MIH8(?7O5WJC6<OB&3^/#*$V+C\@U6'NX(HJ.X)IE\9'3_<_/`C9X()B*
MHFYA2E.DN$$NV.8I#'N,>])?KR)!P[=2>40C_)\"R)D\<&B@CV\9"S<O.+S$
M-%*((@DJ*)4U"N%CR"8$<ID((??#6^88_D&N9"9])/JR8@\+>8Q'SD)XUA"B
MV;8A"NW3V3:3<E*Y9)'\<F2+D9*NP3%P=NB545N=6H;QLDV-YEBB.%8[UVX9
MAC9_DFRYB6S!CM2$=Y;&QV4;(C-@8?$PBB^9!S4\5CX\^/EYS@B1(ARJFBD0
M+"$"%(D_4"\%4^0>DNT-`JK-L<>'/CTSKZ<0+(DG9-UE<2T;3:C,C.,>-BLG
M39<PK*(B"D:4@-!.NJ&X.8W)S9*69:^DRUYR8^&<Q\(9_-:_>&:KR?@ZD@L_
MA4<I98])KHO(]V=NZ61.X30DA;EL3:)"H$XXAFF%0.Z,QSZ5ZK-126'9*M*'
M98FEMUJLSCF@L,::PS<8><S"7B6TDDZ9/5EWC#N:1DQ11(V+[J<X6)_6$T'_
M`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_
M`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_
M`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_
M`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_
M`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_
M`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_
M`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_
M`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_
M`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_
M`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_
M`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_
M`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX`_6$T'_
M`&X:@_O+PSYZX`_6$T'_`&X:@_O+PSYZX!OZ95T'/3=T^N6RR+ELXTAJA=NX
M;JIKMW""N!P"B2R"Z1CI+(JIF`Q3E$2F*("`B'`3?P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
9!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g17073img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g17073img03.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!S@*H`P$1``(1`0,1`?_$`/P```$$`P$!`0$`````
M```````$!@<(`04)`P(*"P$!``$%`0$```````````````8"`P0%!P$($```
M!0,"`P,"#0T,!P,'!!,!`@,$!1$2!A,'`!0((3$542)!,E(C,R14E"55E1<)
M8=&2TE/3U!;65Y<86(&10D.3-#75EM?8"G%B<D1%5IBA<R>"8V0F-S@9\,%E
M=;9'=[<:L48H>"FBPJ-TA#9(.5D1`0`"`0,#`@,#!`D/"P,%```!`@,1!`4A
M$@8Q$T%1!V$B%'&1,A7P@;%"4F*2TE.AP=%RLN(C)#1$9%46%P@S0V.35)34
M)45EE?&BH^'"<]4F_]H`#`,!``(1`Q$`/P#]_'`5V3ZONDQ9,BJ75#T[*I*D
M*HFHGO9MJ=-1,X`8AR'+DPE.0Q1J`@-!#@/O];KI0_:>Z>?TT[;?E+P!^MUT
MH?M/=//Z:=MOREX`_6ZZ4/VGNGG]-.VWY2\`?K==*'[3W3S^FG;;\I>`/UNN
ME#]I[IY_33MM^4O`'ZW72A^T]T\_IIVV_*7@#];KI0_:>Z>?TT[;?E+P!^MU
MTH?M/=//Z:=MOREX`_6ZZ4/VGNGG]-.VWY2\`?K==*'[3W3S^FG;;\I>`/UN
MNE#]I[IY_33MM^4O`'ZW72A^T]T\_IIVV_*7@#];KI0_:>Z>?TT[;?E+P!^M
MUTH?M/=//Z:=MOREX`_6ZZ4/VGNGG]-.VWY2\`?K==*'[3W3S^FG;;\I>`/U
MNNE#]I[IY_33MM^4O`'ZW72A^T]T\_IIVV_*7@#];KI0_:>Z>?TT[;?E+P!^
MMUTH?M/=//Z:=MOREX`_6ZZ4/VGNGG]-.VWY2\`?K==*'[3W3S^FG;;\I>`/
MUNNE#]I[IY_33MM^4O`'ZW72A^T]T\_IIVV_*7@#];KI0_:>Z>?TT[;?E+P!
M^MUTH?M/=//Z:=MOREX`_6ZZ4/VGNGG]-.VWY2\`?K==*'[3W3S^FG;;\I>`
M/UNNE#]I[IY_33MM^4O`'ZW72A^T]T\_IIVV_*7@#];KI0_:>Z>?TT[;?E+P
M!^MUTH?M/=//Z:=MOREX`_6ZZ4/VGNGG]-.VWY2\`?K==*'[3W3S^FG;;\I>
M`/UNNE#]I[IY_33MM^4O`'ZW72A^T]T\_IIVV_*7@#];KI0_:>Z>?TT[;?E+
MP!^MUTH?M/=//Z:=MOREX`_6ZZ4/VGNGG]-.VWY2\`?K==*'[3W3S^FG;;\I
M>`/UNNE#]I[IY_33MM^4O`'ZW72A^T]T\_IIVV_*7@#];KI0_:>Z>?TT[;?E
M+P!^MUTH?M/=//Z:=MOREX`_6ZZ4/VGNGG]-.VWY2\`?K==*'[3W3S^FG;;\
MI>`/UNNE#]I[IY_33MM^4O`'ZW72A^T]T\_IIVV_*7@#];KI0_:>Z>?TT[;?
ME+P!^MUTH?M/=//Z:=MOREX`_6ZZ4/VGNGG]-.VWY2\`?K==*'[3W3S^FG;;
M\I>`/UNNE#]I[IY_33MM^4O`'ZW72A^T]T\_IIVV_*7@#];KI0_:>Z>?TT[;
M?E+P!^MUTH?M/=//Z:=MOREX`_6ZZ4/VGNGG]-.VWY2\`?K==*'[3W3S^FG;
M;\I>`/UNNE#]I[IY_33MM^4O`'ZW72A^T]T\_IIVV_*7@#];KI0_:>Z>?TT[
M;?E+P!^MUTH?M/=//Z:=MOREX`_6ZZ4/VGNGG]-.VWY2\`?K==*'[3W3S^FG
M;;\I>`/UNNE#]I[IY_33MM^4O`'ZW72A^T]T\_IIVV_*7@#];KI0_:>Z>?TT
M[;?E+P!^MUTH?M/=//Z:=MOREX`_6ZZ4/VGNGG]-.VWY2\`?K==*'[3W3S^F
MG;;\I>`/UNNE#]I[IY_33MM^4O`'ZW72A^T]T\_IIVV_*7@#];KI0_:>Z>?T
MT[;?E+P!^MUTH?M/=//Z:=MOREX`_6ZZ4/VGNGG]-.VWY2\`?K==*'[3W3S^
MFG;;\I>`/UNNE#]I[IY_33MM^4O`'ZW72A^T]T\_IIVV_*7@#];KI0_:>Z>?
MTT[;?E+P!^MUTH?M/=//Z:=MOREX`_6ZZ4/VGNGG]-.VWY2\`?K==*'[3W3S
M^FG;;\I>`D#`MX=I-U5)=+:_=+;G<A7'B1RD^G@6;XSF"D&G,#(%B#RY,>DY
M$T:25-$N@;"M8"XME;+M,]`D;@*Z](9"?JG],7F%_P#=[V8_@A^;G'/J<!8B
MPGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_
M8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];@
M"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2
M_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];
M@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ
M2_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A];@"PGJ2_8A]
M;@"PGJ2_8A];@*_=2<AOK$[>MG73O"QLWG@Y-%I.&DDG%';A`"UDCNSTEG;-
ML!5))-HDJ)3"J5NJH8E@AJD"N1L^Z]SB@)-I,::Q3UQ(@G)+-,7<Y'#O3Y_!
MMH]GD6+H;HDCC8PTPHD@X,[BY*1>.2*))6HN$Q64!=-9/U[JXYM6^P_`<'<2
MLX?)C;F1^6-X"$DL0;?CFU@,62*W8YW)Q;J3)C&4>..Q9N7[4R>+N&R9C+2#
M81!TXQN#UGS60M_']B<+QG#W&-9T@=Z&51SC(F67,H=N_P`(>.(?QERW5@Y2
M:!>,5(1QJ$!(CLP@DY`C0&1);G]<VU^&M7>7;087N<\81)G\W.829X]?(ZC=
MH]>E-C<8X8OIEYC23]0A$(]D0TTM'G12!KKIN0#8Q>[_`%T32T<BETQX1!I2
M6*P^1GDIW,"%:Q,@^>N.;Q1XR3ED)1>8;1:[=0YA2;D07273,4P&3,`.['MQ
M^LQ7+L)C\IZ><!9XCD62LV^43<5GZ"S[!L:5CUG+U5TU%9UXY)MES`0JJ!2(
M*';BG8',D41#6?C!UNXNY>,V>`89NDS1E<D>)2L_,8[A;U]#H9AEK3&H.-0@
MW9F;!X]PZ.B7"KUVFJ4CB0/<D&D=(`;,?NIU_>"RD\\Z:,!5?#%$D6&)#G\8
MV6*Y(W:LQBFK\KY14SPSI=616Y@H%%%OR:(ZBA7/`+\VS3KW8Y%!2.%[0[<R
M^(K[>0&0Y!!N9Z.0EF&?/<1E)F=PAE*N9QJLZ8PF3X66)YSDAYG\<FBR8@2,
M=FX#Z3W#ZX9?%I9ZKLWB^%Y<IEV!Q6/0Z7A&80;.&<Q.1/<QF<BD3Y_C\A(P
M:;U",(*K)!N^1,Z,U(V-I+R*8,Q]GWTBI,=QR09[1X0,LYC&Q9J&-X&Y=-T4
M<BEDI&84?!FC1JAE+J#2B`:Q9$#LO;S]95PF9FDBH$IXGE'6,XW9@FF7X+CC
M/;!QDTR2<-'-84CN.AG<8_<P*:$Z&72RL@T@T"LC/%@CT%GLJNNW1`C=N158
M+KV$]27[$/K<`6$]27[$/K<`6$]27[$/K<`6$]27[$/K<`6$]27[$/K<`6$]
M27[$/K<`6$]27[$/K<`6$]27[$/K<`6$]27[$/K<`6$]27[$/K<`6$]27[$/
MK<`6$]27[$/K<`6$]27[$/K<`6$]27[$/K<`6$]27[$/K<`6$]27[$/K<`6$
M]27[$/K<`6$]27[$/K<`6$]27[$/K<`6$]27[$/K<`6$]27[$/K<`6$]27[$
M/K<`6$]27[$/K<`6$]27[$/K<`6$]27[$/K<`6$]27[$/K<`6$]27[$/K<`6
M$]27[$/K<`6$]27[$/K<`6$]27[$/K<`6$]27[$/K<`6$]27[$/K<`6$]27[
M$/K<`6$]27[$/K<`6$]27[$/K<!"L"4`ZC-U*``5V4V!K0`#_P#+KJ5\G`39
MP%`.E/I[Q:2Z7NF^16SK?E!5_L-M"\518]0>\;!DBHYV_P`>6.DS8,\S09L6
MB9CB":*1"))$`"E*!0`.`GS]6[$O^?\`J#_ZCM[/RXX",\@VQVVPF7S>4SG>
M7>3$<"Q#!,7RJ8R/)^J'=N!@L?2=2^:M)*2E)N3S]JR8L3(12`'.LH5,@IA0
M0$PUS^+XOD^;Y'#Q'"[?/N^6W.2,>+#AQVRY<M[3I6F/'2+7O:T](K6)F?A"
MF]Z8Z3DR3%<<1K,S.D1'VS)#A>W^UFY<GC4]MQO?N[G6VV2X7,SD1E&(=4F[
M610$N[83\3%BJRG(K/G;1<&HJK(G(53S%B*$,`'(8"W^<X'F_&.6S\#Y'L]S
ML.;VU^S+M]QBOAS8[:1.E\>2*WKK$Q:-8ZUF+1K$Q*G%EQYL<9<-JVQV])B=
M8G]N$M?JW8E_S_U!_P#4=O9^7'&I7!^K=B7_`#_U!_\`4=O9^7'`'ZMV)?\`
M/_4'_P!1V]GY<<`?JW8E_P`_]0?_`%';V?EQP!^K=B7_`#_U!_\`4=O9^7'`
M'ZMV)?\`/_4'_P!1V]GY<<`?JW8E_P`_]0?_`%';V?EQP!^K=B7_`#_U!_\`
M4=O9^7'`'ZMV)?\`/_4'_P!1V]GY<<`?JW8E_P`_]0?_`%';V?EQP!^K=B7_
M`#_U!_\`4=O9^7'`'ZMV)?\`/_4'_P!1V]GY<<`?JW8E_P`_]0?_`%';V?EQ
MP!^K=B7_`#_U!_\`4=O9^7'`'ZMV)?\`/_4'_P!1V]GY<<`?JW8E_P`_]0?_
M`%';V?EQP!^K=B7_`#_U!_\`4=O9^7'`'ZMV)?\`/_4'_P!1V]GY<<`?JW8E
M_P`_]0?_`%';V?EQP#-A-AH![EV;1*^X?4"9E"_BWR"8=16]13)^(QBKEU<<
M,W`REZI`$*B-/0X!Y?JW8E_S_P!0?_4=O9^7'`'ZMV)?\_\`4'_U';V?EQP!
M^K=B7_/_`%!_]1V]GY<<`SXS8;'W6;99"J[A=0(L(B%Q!TS2#J*WJ*8J\LMD
M_.J'4#-KSBH5@D``(B``3LI4:@\/U;L2_P"?^H/_`*CM[/RXX`_5NQ+_`)_Z
M@_\`J.WL_+C@#]6[$O\`G_J#_P"H[>S\N.`/U;L2_P"?^H/_`*CM[/RXX!G[
M?[#8_/X5C$S);A=0*K^1B&CEVJ7J+WJ3!18Q*'4L3S8I"B<0J(``!4>`>'ZM
MV)?\_P#4'_U';V?EQP!^K=B7_/\`U!_]1V]GY<<`?JW8E_S_`-0?_4=O9^7'
M`,_,]AH"':0:C'<+J!3._P`PQ2(<F'J*WJ4JQDIIJV>D+?FQ@(*C<QBW!VE`
M1$!#OX!X?JW8E_S_`-0?_4=O9^7'`'ZMV)?\_P#4'_U';V?EQP!^K=B7_/\`
MU!_]1V]GY<<`?JW8E_S_`-0?_4=O9^7'`-#-ME,.Q*(9S*^Y.^C%F3)L19/W
M<GU)[T(,46$EDT4Q>%<+K9XDFBFX07%(3"8HA?V"!J#P%)$9?."RTECSPTLB
M,=A63/VN6FZU=]$8J>SI*$RY?%L?2C5>HD5H1FK/Q<:@Y,JLY(5)V('<(J&#
M3!C--R-Q8QE),$=NMX<]=1F5N&<?.S/6[N-@$M-88+J,;LY>>Q2*ZA,B;8K/
MK+!+`5(JJJ7*,6KA9)NH\.V;A*VU,WD4[N$?%]S&LEB&%M@FA=[G1G7KODX:
M+I`7(BQ)8'&93=V0.Z5.*+),55U@L!-5R9(H+H)(A:X^#;`)"(*=1.XB8A;4
M%.K_`'*((7@(DJ!MR0$+@*-/+3@(2W=B\5Q^/GDML-W=QLIR(8?"G,)'K]4V
MZDFU(>4S,K&9DW*;;>K%7*D6QQ\17="@Z573:E,=!!=6Q,P0NA-YU)O<D82/
MXP88VB</3?,Y:)ZV]Y\P/)3+W)L!3=*0J,EO]"-7,KCV(2>1`C$N=(KZ5B43
M'<IMWJ"7`-:%W)W'58XPU/MIN9(KOY5XPD,JGNO#='&6?XOJOYAMCN5RD1";
M^Y(A$/C101CR99-7+YNU<+.FC=<YTTC&"9-B'\IFT_)PN\`9%MG#,XM1%CF<
M3UV;V2RN49`W''3"A"8O(;MR@,&#LKEZL)CN'2C=,B:!AU`.H<+,EP?I^.<B
M9.HK<,ZBABE(F7K`W*,<YCB`$*0H;E"8QC"-``._@*P[CJ*0LU");6YOF&XS
M,N89;&Y&PG>L#=W'&+:#;P\"$,Z-EC+>J./'*M95V)BI>'/1>$45#42%,I5`
MBV<RC/8W'<$RA`^?OI.2>R)YW"8SJ]W419BU#<J;CUV>29#.=2S=]AQ(;:)!
MA)1ZS-&35DYMT+==-!,HDX!,^W(W252G7D5M9ET>WAG2"\8QR#Z0'>E63S&-
M=Q2PIM(H8O>\S-@^CY<@*N7!S+)F:F(@FD#@QE$PN#MK![<Y/A4',[C;F9IM
MKF#XDBK(X9%];6[62HQ;9*6>HQJJDT_W)!9\L^C"H+G,4A$TQ5!,`J41$'R3
M!M@%5-)+J)W$45H<=-/J_P!RSJ43*8Z@V%W)$WF$*(CV=@`(\!23)I'<E*9Q
M@F`RKO),*=8EMP[=9=D76KO4W?R,\Y;9"_SYO)1\/OM"&QLA&[>,;MC<@J0%
M5U%+CBJ5-`/G*LIRO&=RG;2#CMS]PL,D&\CX;'L>M/<B#;1X%A(1?%5(S+G7
M4.,CDDU,Y&M)-9=LM&-6L:V;$625$$Q%X#=^<7=X4(:0+M9.B$DL\CGF-N?I
M"]\8Z7BUV+H$PG7\H;>)ZT:QDPF8"MF@-U5D!*=1980`"\!?AG@^QBS-!=[U
M`9XV>:"!I!!CU@[IJL6;U1`BR[9NJZW+4<BW2,8=,53"H*=!,(B->`T668ML
M?'8O.R4/U#[BK/V,>JJWT^KG<MU8J(6D$4B[D'`1[Q"H=X<!`,B^E8_=./Q5
M5_D#S`I#,YD9'<%#K/WT:$AL(+D#5M#)FA`W^45\8<P3O7,X("A!,F<XM$40
M*4P0HQW"W3AD,C8N\&W2SV8;,X-_$.C=:VY.&-AE7$,LZS&%:1K#J/GG<KAL
M'/K,6<+,G,B[E$'*ZJB!B-"+NPD/#,LSF0W#@(/)\5DX;#960BWDGEW_`,0+
M?,Y,/A71,?7?13YDIN\Z)DV10P.7:*HI@T;N7)B%3)I-U3+A<HV#;`$`IC]1
M.XA2G)J%,;J_W**!DQ$"@<HCN2`"03"`5#L[>`BG=>&V]QV%7<[?[T;G9-.N
M,3S5W"0[;JKW)DSRL['L6P0B#9-7>3&D%EN=.<"D-(-B&,40$PVVB%?VTUN.
MXEFT&Y;O&)4L4S&4')4.N7?9>(F<A88?DBF'P[EG(;\L'>)A(9DRC!=%6%<3
MLY(2D.CR;E8P,]IN5N%&QT@BUV^WAW"Y++7;"&R66ZW-Q,`>Y%B**\2D,E+X
MY$=0V2L,=GRKFE2D22<+D!DT9N7"+<[PZ"`2QM5-9+/[ACB^Y#*4Q/"6ZLJF
M]W/B>O7?1TT4!4F2^"-X3&Y/=N0,]>+&;L4;UUBCYJKD42E7121"UJF#]/Z)
MS)J]16X:2A#&(=-3K`W*3.0Y#"0Y3D-N2!BF*8H@("%0$*<!7?=Y!ACBCA':
MC<?.<]E&.98D@X@Y?JVW88LU<<=0<JZGB.)YIO3`+01"JD!4'>E(6J(%1T0U
M`$`A?(LAW'1PV3R)B?-6V2,<LREC#XA"]8&Z\T28+'0N#EPF*G9;(.I6#)#8
M3D^0NLC\3R-O>]9LX]LJV8'!8I%`^W.XVX$@]D"0&VN:1L.V:QDG'2^3_2`[
MQ*&G$239F\K`LT(G?`4$IF4ACIJ-%U%"I,#`J=PDL!4TU`LGLHVQ7.,*2FMW
MLNS#9S)EI-1)GB\;UQ;OY0HZC0B(A<\@Z>R>YACMEO%#NT@:D`1;IH^><YA$
MW`2V&#=/YE"HEZB=Q#+',4A$@ZP-RA4,<X@!"%(&Y-QC&$0H`!4:\!3W<];,
MXYQ$-=G<FE\TB#K;F,IS*,HZS-XV[N,E6>YR,+A;48"*WQQ=<\4VQ1-ZNJ[*
M1R"P$3$PI@B;F`T^;9+E.-Y)A;Z'+N%E,%(Q^.%RC&X+K/W2&+9*N8^9-FKT
MF;RG4,RED,@A)U*.0B(M*.<HOVCDQE5@4/>U!MN-QMW.46D4=J<F8F8S:L4K
MC4M](-O:$U*M'!2+-IEJ_9[TKL8Z/A4ZINA$CH[U82F0!-/O"[>&8IM/-8M`
MR>7;R9OB64O8AB^G\5BNM'=6<9XX_=)@*L667=[E&7D1:*52.X&TBJI3"0"E
MH4`W3G#-@R-7BK7J(W#67;M7"Y$R=7NY:PW))F,6Y,FY)C"6^@#V>CP%2LNE
M\B@UX0N)2629Y#SS/$3M\B<=9&]\2XA&:F&-G^0RDU%M]^HY*657R1)=!,&Y
M&-H&(1-%<]Z@`UIC+\RQO<#*XF/A]T]Q\75/D!L:=MNLW<K&&+06F9O&>*%@
M9(W4:[E,UC9;;1F>6F%G#2//'3!2,4!4USIL@21N>;L.GV.<WMO+LF>1-H\)
M!JY^D+WU;+X*Z`LVC**9%(!N\Y1D$UE6K=V@BB@B*+3UDZIW#@AD0O!TUP$=
M$;J[H2,;D^894C/[1[)OBR.6;@99N"4S=MN;U1L6)H9_E4U-K-&"K)`@VH*`
MFKV'&INW@+J<!038G=!?#.AO93(,VPN?QO%(?IMVI0D9\DWB;PQ&3C!<;AF;
M]DV9S:KLZKP7::J29B%4+<!3!J!:(1UTASNW>V>0S6VV#Y).;F9G-X\9\E$*
M)8ICDE(P>'9/..'N932SC+GJ.4SSYSN"DS\:*9)%_$L&)&Y3IMC*F!Y]56RB
MW5SA6[FQ.7X/FL)%Y?BNQLH#Z&R#`%7T=+[=;MY#N7BSYTR>Y!X=-0A\HQ1J
MF_CU3D*^9:R!C)Z@*%Z5](?J?S/T;^H6P^HG`8<&XY+8UW-/;RZ]M\6[VN;9
MYXBT?>Q9/8W&3V<U/O8<O9EK$S32</?[+'R&TMM,LS%+:3K'SK:+1^6-8C6/
MC'0R]G>DN,P#8Z=V#2Q)YDL%E&3;K9OFKANIMI'1;?<'<O>]?>?*V>/82VR*
M7@\1Q6,R.361C8LCET>-;`DD8ZARF6&]]8/J9R_U:\S_`-KN7P3MKUXWC]EA
MI;);-DC:\;LL&PVLY]Q>M+[K<6P;?';/N;4I[V6;WBE*S%*^<?L\>PV_X?'.
MOW[VF=-([KVFUM(_>QK,Z1\(^,ME&]-N_P!'YC'9?+;V[Z247CV;#G,3B99[
M#6<"BDA*2+XN).2/<VDVY<36B)9U&N$VZ35<6*H))K(HI)IEY>S5=H:,@94(
MG<';GJMW`PK;G/9R7R-&"4WCVSQU27#*LFS;)I>$B7<QN%C>10S1[+YLZ6;M
M5FQUHY?SV8(%,FFF%EMB,T0V^R#.9J5WLS#=.!7Q7'G#.!SG>7:>6;X7"QTJ
MY8+Y0E(2.XX.',9-RLN@W\07`3G7.5$[A4O*I(!/Y^K3;`C1*1&4Q@T6J=PG
MXLGNWLDI$I*-#-R.".9,FY!F34R:KI),=0Y?7%2%[S``A]2?5AMM$8^_REZZ
MA1@(U21;NI%EN9L])I`]B8]S*OXM!.,W!=KO)A"/9J*<FB11R<"T*03"`""N
M7ZH]OL?E%8+('6/0,Z@L5LYA)G=;92,F&KDX-1!NZC'NXZ+UNXH]1$2'(4P`
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M#2F;LLJS*8/MG,J(S8X\5%!+(\,%RV&,C#MU.:`\\1$-850,2PZE0K=:/9P%
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MLN10@":H`)1$-_D&YDQBD!/95DFW<]$X]C$)+Y'.R:L[AJY&$/!Q[F4DG0H-
M9]9PJ*+-J<P%(41$0IV=_`<H\EBT921S_=;;_?7<C;!ME>6M)^1_%21QQ1]!
M&SZ9_&V-99!#LMRW4@I)N6>-G76Y](S1A`-CJ`W:LCN5%0M?MOU,[8[382WQ
MMY-YKG!$'&X>2_C*^R-GGTD]9LLSS!.>.ZG@RB></`CYJ"E&K7UPA'24><S-
M,S<@&X"58_K#VWE<NA\$CF$LZRC()LF/0K!-]C1T)*4&+7F5DF4BE.*L'B#&
M.1`[I5%14C4RJ2:@E5623.$AX)*9OC^&XW"K[9S+I:.B&C=1PSR3##-E3`F!
MA,B9Q.MEA+YU/.(4:\!67>#?38_=Q5#:G)I,(U[B^<NIR7B'>=;=XLF\?[49
M0K!S,*_>Y+D+5`C5+)+`,D=,%':"8J)%,C54H5<RB'Y9&$9J;_;^24,_Q!&8
MD6F,Y+%9FQRG!I)QDV,JC$O\)R=XUC6+HS@46[-J=1-GX0=T@U(JFJN0+G8S
MU=[9XQ!1N+R#G*Y1UBK"2@9+(L@DX1<[]U@D+*.<@D'^2OYT&<HN+?%I,W-<
MPIS[F.>)I&57;KD(#HAM^(7?47<5MS`2TF]P;),(D\K;OG\%$N8<CUVN]08.
MFKN2!TC,`A'K`HT5(DJW4+8MIF&G`<ZL,88@I!;=XYL1OAU%8K&&7PYFY3QZ
M?5EH7*YC(54\59S$TRC9*-;8VGD4Q/17BO*BUY-N^;KJF;.GC*03"P,1TH=0
M\'`2./QW4)U#IMW#!".B%395"7XNV:HQ*:*,&">Y1!TU4F"C14SPSMP#(Y3H
MJHR7,R3H-RGTV=2:9ERAU!]0*B"@/4T@6R/'E'*`.)V5E6CPJQ=Q4T32<2A*
M`5$12Y)51L@FY:KL$^0$+*[0P&YNUT1D<1-H;F;GA+Y8\GX=]EV78Q)26.PS
MB)A8]#&4Y.7S61>OVS=Y&KN@.(I%O=F`J8=HB&\W$R?+EHB$*IMA/(@3/=NE
M0,ID6$"!SI9O`J$2`"9$<PG6,4"E[*`(U$0"H\!77+]ENI'*MQ9?+6N[.Z.'
M8S,R4VX=X;A;?$H5$[%6/AXS&4P?*;OO@0E(EMC[0SIT@D@#M3F`(1%-TJ3@
M-5O9F^VV5[G*8)G.4IX7D,-/[)OOQ13W$VJC<JE9F4<[D8_@4(^C9C(W+54N
M2Y#EC)=LU*D[.HH@G>1$JJ"Q@KIL?NM%E?S&`L>I&5ZI\YW=JS@X$,NP=8Q9
M/;E,DKEDV*9]QY"!BX^*@<;+11LW;JN.;3,HH[0.Q.E7CK%\E<<VBO=:(UG7
M2-?C/;%K:1ZSI69^43/0GI&IGYOGL5E!L3ZEL&ZK]R]I,2ZA'>;9;MA%2#C#
MWC1K!P3+#76Z"T-$$W/$9>$$=K8@2II-W2;8R[FQ`"2:QQVWD?![GQ?F<_![
M_+M<NZP36)OM\U,^&W=2MXFF6GW;QI:(F:ZQ%M8UG1;PY(S8XRUBT5GYQI/[
M<+'Y+U-;,3;60V_2W8(G,Y)L9C^UJ,[&[@;>2.YJTEN#!J/<>R&.;N<K.=;)
M<@AU2NF:RYQ,5^Y:ZZ93.6Y5M)WT^<?G7-$B=,^V^_NW+D<@S+,]TMS\3"!5
MA\`Q.7E\-;$3QE4N/!B<WERQL^?,%<UB\;B^4<%CD$(Y9995R)3N%3JC4&GN
M'TR[U9J]Q+(\7S_=G::;Q_;7`L35A\:DL3DL>3RG!H'/\<99.T.EN9CZY1/#
M[HS**J94DP=+%CW"P&/'-R@$Z;;8YOECD!A;+<1KE.Y&0P.Y&39&^R-]+8&W
M61Q=?',JQ7%V+%!.>1(XD&\=)M%G93@F47)W`@JIYIC@PL<VAZC&68L,AR+=
M'<]]`MLM=9J\PW'&V'8[#/I23GV$Q(PPF<[MS;LF&`@R530C3G5*4\@Y$YSI
M@BDF#UDV>YNX&#[IXYCN.9%@:^89W.-AR)M([?Y#(,8EN,7C<YX>E%[CQA(V
M<.2*<J,5CN3F:+@D9PV-ZZWX#RQ?!]YX#;C<#&LG+ENZ&5YS++R83DP\PK'V
M,4@6#QZ"8Q#-H3.,A539II08KJ&`WGN%U#6A=V!&FX&Q_4=(YEN7G^V6YFZ.
M'/MR3Q+Z1PU^IM^ZQB-=8O%Q<7!,,7DF>:I26+-I..AR-)1QHOE%!=N':*:2
M^D4H/60V[WARO;.&PO+\>FE,E4V/9;>Y5F#7)X5\J]RS4QI[+2*)U<VBYV1B
M7[R)7(=1R]*X725JN12]0A@8VTNRW5%MSNC`Y#D6ZFY6X^VL/#2*"F#RY\*A
MR*O1@$8*&CVK"+W`\"0B&@CKG.LFY.0S1`4DR+JO'"X;7-]E]T]Q,2VS;11,
MIVWG<-QI&-0G89SB$Y*PC].1@)DLUA4DVW,@&D3(2H0IXJ246;/!<0[Q9)(4
M3F$Q@ES#,:W,Q6!P&#EH/,\T=XYF^495+Y+-9+CZ\BJVR2.SM!*.8A.[A9-)
M+-X17*D&[8B[X:,VX!<`E`!"O."],V_6WZT2PA-[-^E,5AQQ-!K%2+O!)23-
M"8]&8KC\CCKV5E-RWR$LE-8_".4DY)RV4F&*ZC54KE04'(/@E/<W:K<3<QD^
M9)0.080L;=);/&$Q'/,2F)1F@XVT4P9*0B11W`QQ*(S3'I)QXE%.UO$&C=RW
M2,JW6`1(`:3"]M-_,)P+<*#S;)MP][I#)H!O&Q;[,)'"848=<BTL=P!02W!D
M(@K187J9@4*S(]$PG(JX6;I,T6P>VZ>U741N#N$CEF/[A[B[9XZ56`8NL7P]
MKA[9U(8O%LYKGHI_-#NR#=:6=R.3OQ2D$F3<Z"16ABIZ[8%3@Z\WVSS//\;A
ML)GX//U8MK@D!BD_EJ60X(3+,A<PV68!D4DX6(KE#AJF.4-\3<H.U3J+4YH1
M%)4!,7@([P?8[?7"\QS/)I+.MU-P(.?Q[*\<AL$R%]A4?"PL3(.I-7$XE,L?
MN">!Y;'6LL9,RX1/-"+=,$#MT%'""H:#<[INWOSK(([+<0W%W=VED66*XO&)
M0&/2&(R6/LLFQK&<HP]+)&ADMS8-2]>`S:23.CI$25<<HX4*91FEP$^P$/NG
MCC;:N-DH?,,XG<5CLO+/9QDDO@:<I,2\ZV6'Q$L03,E2\FW=.O6VB:Y$V[8I
M42"4I2CP$%;&[`=0>T&9QYY3<W>+.MK<1,?\5L0G)O##S.0HOH:7YQIGDBEF
M[>%63C<LFUGS11DQ3<+I$11=**IH)$*&WW8V"W6W1/B\C$3NYNT\EC<ON,Z6
M:XK*XA(Q<\UR;=R"W>Q=633)N'CRB;V#R3#(DZIDPO5:"^8ZG+O5A,#BVNP'
MJ)Q##YC'-QY7,MX7P9GMA(8W*STK@[)5IC6&2>+SLZH]'\9';@\Y+S3)^<A3
MJN@%$&I3+@)3VAJ\MV@ZC,HS3*)YKNEN?B.-9-/&EE,8PYKAT.=DTC(I6$QM
MDQE5-VWBK-0S(6ZLPJBFF61=,4C)IMB'7(H$T2/SG.WVZ@P.$24'(Y1"0T=`
MS;U]A4VDP?,HN2;E=RD$TSJ#<KMSJNBW)IOFZ@E$PD4*(`/`,3:/;S>/;5IE
MZ>42FX.ZRDOC6.XAC24ZYP>()`0V,HY&1LNY6#/YD)"9E#SI><<%31!30)0O
M93@(^RO8O?J9G(3-,*SW<_:W(VNU&.[3R$'%AMQD>&IQD(WD%23L:R=9K$N0
MRUO-3#ARD^4$45$TFR"S4Q$C"<'CA.&[^);=8-C6Y4',9!F,2MN>7(<M99E%
M2"R37,B9>PQXT2_D\L89`\<PD5-,RF$7+(4S(F*W.F0B5`AO!NG/JEP+,MN'
M<?O!N2_VWQB4BG$[MXH7#HN+\'BWKJ3-"PJ4;N.7GR/U%>544D552F;N%CKI
MN5$F0-@E[</:_<3=#"%,:1@)[#'B6>;C3K65;O,.GQCBY5(Y2C'Y)"HM-Q,<
M+'Y_AOBR;V'=+F=MF;],14;J>:)`WF"X+N]AN'24!/)YWN=,RN>X/EJDUDN2
MP1.09XL[P7G&#`DON-E:K<K]/%%WNDB9!L#]XI:FF0U0")'O3?OPQRG*YS!-
MY-\,1C,DE<IGV,*NM@N0)8M,Y%EV<YN48L9'<\&DKCS>;S#3\*D4'+5%D15%
MH+6YJ+()>W#V]SW.XG*H`,.EF[>89;2H-I/(GV*Y*,F?;G*'<X^2R>,B]P,1
M=/4IMNH4IC(R*1M8PG$*%M,#5VBVJW^VPDYMYE^X>[V]<,X@YR+B8;-W^"LE
MH[FUHWPYR=W';A!%/71&3,Q7*KEBL<JA0,T,T*L\(Y!!N!M;U%9S!;<(83F&
M7[-K8=@^/P8#C+3#)EXXDR/(%YD"KN4-NI%QTM#O&^,L4FS=1@&F`N@4.JFX
M`B8/V4V^W'?[=PNW3EGN/-J-XO<B(D-P9K)<,<9@BAG&/9E"1CQN<^9+*/W^
M.)Y&W(FHHY2,9-L`UNH`A&.)=/F\.$[J8_F$+GF\*VW6*BDS@-IG[_!$XAC!
M&@XAI)19W4-G\-%2*DM,P_,**/(QRF0CI0Y$BNR(NBA*?3N1=/<#,2NFXM'/
MS,;/F7:&517,U5/N]U6'4;F6;F.W5,@8UHF3,8AA"I1$*#P%O^`YW;09H$7T
M%[./MT-N73;;V/Z<=HB3:R.9)`[?19<1Q5C'*L1Q@0F&SN0.=!8@$41.B!K3
M'`Q:""797+NF<FYS=ALKM-`1^Y+?&)0D:C&3"\6"F(I.&9"I0ZC]%."<0(M?
M/AA;B9L$:586`E;&.!PEW<G`,EWT-N5@KR6W+V.F'^%[7O('/]I]P8J&S_%9
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M#"`@(!7MXPU3GO'!]&YF>)X[EZ4/TW,,9S!U%R$`$I(PN$@Z<,U\J-&MQQ]^
MA".8M`KG+)8PM%FZ*!SNU1.01H(!M'$_T(;?!D^?JM]OQ?)X_%QN5O2R^1YA
MD<ABK_,L7!O+3$,*<W.3,>;+XJ,7?2"K=59,[8JKI0"%$W`>:.+?1W_B@!#P
MG3TPQA%DT?B:1RB,CW"3#"Y[*4V+WF':Z4OI0\S+2J21RG$1*L=(MR0E+P"9
MS,?1\8EMYD,\TB-GV.`8ODDUN%DK?$EG2K8DV_Y:$D<CD(3&6AW$XRF5,98@
MF`HN&CI9"/6(4R@LCB&TW#9=`FX>5+Y#G,ILFXRR!F5$I>4#<=.#>F>"M)G>
MQT\ZCWC!.0BW9WSI%T18QVJR3L[943).Q26#?XKC?19._BO^(<-MID_)YU`.
MX)QA^4R<_H9GX3^-F,+/G<6NZU"M(7;<O)E=G.U:H1!&9"I@B"!0DW;?JZVA
MW9;#(81)/Y*';Q#F<F,@<0F11V-XVP;Q[F83/DN0O81&&A3OH1DL\0!9<`.@
MD-1*I:007#U==.)$4%U-\-GD4G*9EFXN=QX)JHJD5ZC'&.1!R9%Q0'RY4_25
M[S>D*<Q0V&.=46R&5K1#6#W,P)R^GW<4QAHQ7)T&<L_=3KI-G"(HQ+QJA(E5
ME5UT02(=(JE7*`'*4RZ('"<>9D_BLGO]+[SP!S,G\5D]_I?>>`.9D_BLGO\`
M2^\\`<S)_%9/?Z7WG@#F9/XK)[_2^\\`<S)_%9/?Z7WG@#F9/XK)[_2^\\`<
MS)_%9/?Z7WG@#F9/XK)[_2^\\!KFKF2YZ4^#"5%1I7V^E[E)_P"9\G`;'F9/
MXK)[_2^\\!$>Y+O;,,EVG0W*9P@Y+(Y?)LMK(Z3EGPG>Y2WQ:8G))1&/:)&C
MW)&.-PSI<RSXAFS8Z9*&(N=`#A36.QGZ.*5>+S34VSJ#O'5'CY^YE-QI)@NN
MRAEI>$,^<#/R"2\E#-'I5>773N()FR!DC"D1'@+V;?IP<;C6.,=OXV,'!&F'
M8BWPOPB6YF+#$T8TY,?\/<KD47<,QC`3TSG,8QR4$1$1KP#!WHWSV=V[23PC
M>B4AH5GGN.R"9HN;,_6C9G&W^4X5MG+)NW36,79)L_&]SXM!R"BA!2:.%71[
M6K9RLD$8Y+EW2#,8[E4H_)MSDD*ZF\2',"XLY?SCD)0&\X\@!F&&*1[B2;-V
ML,G+G>E.F1%&-3?D>@5`KDG`1G)2W0W&,3QKG;)CBZ#!/<"64@X+!-Q<75CK
M):?8Y>Y-&XIC;$&*SN5Q>4%H:A!4Y=TJT&PRQS`X\=R;HR'<7#H+%\?A$<S7
MR3'(7#21C3-F$,YF,8@DWD.#!P,:TQ5\T@V3%F=<URB19$K`5@,]*U$H7>B'
M,D$7'@$800Y-O0>?2[?6R]O8CZ/`5#WDV[Z2\%F6&8;J[586PFMULT6@UY]8
MJZ2F0S;V)F,EEPR=^U%!NI`C$0#EV_(],+)0K<HJ)G,0@`&S7ENELC[$LE5A
M,8.Y>0C22Q&1;)9&]8+0ZF\<+&Q\DT,PC',3JI[NYHU$BQ_;+8[]14PIM3+G
M`(S<91T-)SSJ6>XSCZ;R-ELJ7</7\+GQ<9%_C4-DQYM9(',)^*D@U(T@,@*S
MTRJH.'J$MRH'<G>"H$L["S>PDE)9:TV+AB-)2")A\=FZ#PV8L'K!)=S.O&#!
MZTS)HD\1EDWRCX\C:F#DSPYN:,=</-"(=N=T^AB)R'#9'"&,''9)FV5047BC
M]['YZH[F,TR%86;(!?3<2Y2/E9T)AD,@HX4!^W:.8OG!(F5B"8="^9D_BLGO
M]+[SP!S,G\5D]_I?>>`.9D_BLGO]+[SP$>[D.I3PC'Z1)#`.X>VP&'Q)$EA1
MSF!N4H9$;[0_@AVCP$@@ZE!$M8H@`(EN'Q!(;0$40,/L/;:!SC]6S_6[`YV=
M3^"_1_0FY+#<WJGQS&6FYC^-0SV$D):5W'EY-BSV;"!G'^78[$X>9VV@7T*R
MBFQY)PU0;N92,A0!US#-BH"`1'`QG01A^_>SL=L2_@4MWF&\N68T7'6^?;F/
M6$1);H;.YX7)62$/D#F5Q*)4)!XN@T0(W02Y-"#:12(I%12:%JIV=\>YK[>L
M:Z=9T^.FLQ^[!^3U<^NC'I@V_P`/6?[*[RCLAE_1)T"0"O2O!;FJ[W;P1NXR
M&^.6Y0&$YG@N1X/B^9L<2BGKA[D[-@Y>/FS522%&%<L8]N=74:_6?U`WWT<\
M8^DO!V\!WO*_[S=UGOER[7+3B]WM]KL<F+#;%&XWF/:TRY<]IGOIMNR+;6]]
MQ7+DMI6,FBVM>0S;_+^*K3\%6-(M'?6;6B9UTK-IB(^$V_?1$:1\KN[KX/\`
M1:0SJ;SZ3D,>9Y=D<=E>5Q:D-NYO@JG/9-L9/S\;,/%H/'\J=8](*8YG^#+H
M+(+,3^*2F-M"G(Z.Q9%1^=,GFWDN6DX[YL79:)B8_#;6.DQ,3U]G7X_"=?DV
MT;;#'72=?RV_LNB>W&UF%2&WV`OD\9>G1?8;B3LJS7</+EFQDW<'!+&4;J%G
M`!9`I72XD,'LA4`$*:@4]Q>;>28<=<./+AC'6L1'^+[:>D1I'6<,S/3YSJ3M
ML,SK,3K^6?[+=X-&N<7W/SB"B(!\TA!PC;25!-WF<A-H$DGTUGK5\X;M)9R^
M4:*JH-A34,F)`6+'IU`;BV[/R#?7Y?P_CN3WN7%?D_Q^]QS%<&/%/97'L[1$
MWQTI%XK-NZL3$S$Y;:::3K1BK[>XO2L3%.RL^LSUUM\_V=$T%=2@@6Z)(41L
MN#Q!(UMP-A/_`!(7:8JJA]72_P!8*0%E`'4H-*Q)`K;7X02&E02$W\2%;1.<
M/JV?5[`9N$/GYXZ8%%B5R`9AF9#&&7;KZ:I,EDRG;7DE)P"<N(6"341$@@)>
M7;TT2@\A=2M!I$D$:"(!XBD%1`%!`*Z/9<)2A]2[ZG`!G4J%UL20U`.)?A%(
M+A`'%@>P]EXIIA]34_U1J`9U*A?;$D-34L^$4BWV@\T^]$;=0440_P!76'U`
MU`.ZE`OLB2'MU;/A!(M]H/M(!JB-FJ*"'EMY@>_3&H(V+N3\/:&2BRJAR29B
M":30$3G!!X8I1.4711O.@@%VH<`UQ&HZ8W`L.ZE"ZED20]NKI_""1=2SG]*M
M4?,UM!OY;>8'[F-P!W4H%]D20]NK9\()%OM%[I5JB-NJ""'^SKC]S&H9,ZE`
MOMBB&H*EGP@D6^T7>F(^LC;J`DD/HTUO]0:@BDG<B5FY$T8!2`4P"<LB@4P%
M`ZH%-YYFI0N`A!]D+2_OJ7M!;S4I\5$[Q_X@EY3T'V'T0`!_=^IP&.:E.SX*
M)2H?\02[`J4!'V'T`$1_<^KP`#J4&E8D@5$M?A!(:`(H@8?8>VT#G'ZMG^L%
M`R5U*")+HHA0$27CX@D:P#"U`X]B/G6`JJ/U=(/5A0$*CN3%[&@>**0Q]4#%
M"30$"%,FP%<XEJF970UE0`"IGKI!Z6\!`%I'4H.G?$D)=I:GP@D;3OY#5I1$
M+]+7<>2[EP[M0+0".I0=.^)(2[2U*2*1M._P_5IZR%^CS#CR7<N'=J!:`1U*
M#9?$D)=I7_""1M._D-7N1"_2UU_]KEP[M0*`$=2@V71)"5T[OA!(UEP,]3N1
M"[3%9;_:T0]6%`0MGDF+UZ'A10&C$5`\30,"9CHHWE`H"<P6`<_>1.[3[*W5
M`%P.I2@5B2`-"U#Q!(:"()B8/8>VT3&#ZMOU>`.:E?BDG=7^D4N^G=[#Y>S@
M`74KVTB2#0#4^$4@J(`H)0]A[+A*4/J7?4X`,ZE0NMB2&I?:'B*076@YL#V$
M;;Q33_T:O^J-01M'DGI+Z4454".Y("&-)(!J&*[DA`H4%S8&HDD2@B`EU1J4
MM@EX!8=U*!?9$D/;JV?""1=2SG]+O1&S5T$/]GF![],:@'=2@:ED20]NKIUD
M4BZEGB&E7UD;-;EV_EMY@>_3&X`[J4#4LB2'MU=/X02+J6<_I5JB-FKH-_+;
MS`]^F-P?"[J3!-?X+*)0(XH8)!$HF*4'P)F[2$`HJ%01'M,%NN-1\P1$/!D\
ME!9-3%B2F]JI"6LD@8342<65.`+E&\$DNT#G#UT?.-8(B"L74H%:11!I?3X0
M2"M!7`G\3V7@0@_4U/\`5&H'-2GQ43O'_B"7=4P`/L/H@`#^[]3@*Q[%B8=T
M<^$Y-,P[0;1B8EP'L'YW^JRI;RT*:@^B'8/`6PX#G9M%F[B#Z"=GI3<K;$%L
M!B^F_:/QE%OEHOGLG%$P_%F3!1FV@8P[])T]U$7``"B7+@(W*%$E1#=[59'L
MHTW%2CMI]D,5C,WC(O)XUL\A5U(QG&,CRC9"5@F,HKCJ,(T3DS8R96/1;G!!
MU'1:BC,3-2%$X/C<O;B<WZ-N3M_.O]P]G'TAANUCZ&SC:+<U/&]PL6F(',\[
MFH6?QV=:13R/,HVD6@`NRD6CV,?-[V[MLX;JJ)CN.!YF_`\G3DJ;?:[JM8M6
MV'<8XRX<E+UFMJWKK$QK$]+4M6])TM2U;1$K>7'&6DTUM7[8G28_9^9-V"1D
M/B\/"XIA;%JI`XE$K8PW(7(59==%Q"ND&3]*4EG)';V4G0>)',_<.%572STR
MIG!C+BH/&'R&?=[O=WWF^B?Q.:>^?NQ6-+=8[:Q$16FFG9%8BL5TBL=NBJD5
MK6*U](Z'C)@H]C9!G+1,>K%.V+MM)I/9(H,U(]=NHD\3=B9I:#8[8Y@4KV6B
M/&&J<[8W/_HY,SQ>(S'P?IY:0F2LFN6L@DXI"!760AELLT^<C0Q=N=%>-7R2
M5,LP4*!TS28F42J[2%0'+CN1=!7XW)2^)I;'3N5(Q4ZV?Y!"RKC)Q80^(Q89
MW-263SR<5(,4$DF6'@]!Z]6%9\=@84CK"@I8"0I/H]8B,.@CC73VRB99KX:T
M0;-3E:G0EH[P1*.QQ%OC(E9*224VJT10C@345?F<))E%VBX*F&S&?Z#X/%Y7
M/H^(V$F,8!Y*0JZ^/`WRZ/D9;#THK)9"*C(>.@9-F^D`7-%KU01$'[Q:."]5
M91H`AIL]COH_W,S'8'F!]CXB:VR<&&0P=GEJD4YB6,:UC458+.H.'8$,KBB:
MZ488S21*+%9ZDQ*('4%`IPWHY[T.Q6UV(3IE]F(#`)U\[<80!IT^/NYF?VT>
M9`WD6,*0S!C+.\FQ>4F)-L[;@87*3IVY17#445*(>"N]_1>:&@]QP8X8>'CZ
M;'Q[Y.!RAHWA&"N&YS(Q6/R4*OBC1.*@G^*P\TSCGCIN1`.;58IJD.[41."7
M*9+Z/E10,GR9ETX+/TRP0)N5I*/&55,X0C,GQX$VR405TLLY8O4543B7SFBZ
MJ8FT3KD$))PS:CIGW9C,+S3;K#L4<LL!S9ED\'*89+RD"LVR5@3')])I-*MF
MD<ZE6+D\?#OEFJXK-'@LV:AP4(1/@+;\Q*?%B'RB'X)P!S$I\6(?*(?@G`',
M2GQ8A\HA^"<`<Q*?%B'RB'X)P!S$I\6(?*(?@G`',2GQ8A\HA^"<`<Q*?%B'
MRB'X)P!S$I\6(?*(?@G`',2GQ8A\HA^"<!KFKB3YZ4I&HUU&E:R`4_FA.[VK
MP&QYB4^+$/E$/P3@(PW4=X5"0;3<'<?"8:<1V_D&\GCSQ:&'*YV'G)Q9'%FQ
M\6:-8.2ED9>5-,@SJU(!U"+"4PV5X"E4TG]'/C><8YC\HEL5$9RY4))LX@N4
MNDYI5$F'3>6,5IUIRAGH-!Q8RT@UY@M1(W1.GYJ*=@7IV]-!M\8QM';Z+A2X
M(GAN(DPI.%?F+$)XF6-.&/DC`59)J@Q",T]*XH#92O;P%?\`J7SCI?Q^:PZ/
MZE<8P1_(N(J4D,17S*%5GD&D8^RO!=MIU1H_&`?MF!`DMRHT7A1.0Q([F'AP
MY9FX52#71LQTB.<-G&<%#;9RV*P,_@+;)VT.E,R3AAD.29<>,Q17(RHXZI,<
M^OELZY3DEW0F,@JN\"2,0!=!P$8Y!O9T23^/0L](8A#3D-^+LD\AG,/BF6K'
M;13UXX@FJ`*Q..I'C7T^ICYSQA%CI+F2**Z>F50YS`[('.^D4=RL3Q[&\'Q]
M',%\HQ['L5>Q$'.M,?/*XM"E"(/'3:,,VQ-W&8\W29(@JFLHW-(*1X$U7(-C
M$"[L0XDPBX^V-1$.3;]\B7[F7R-*<!57(>JCIDGLKD\`S2?PX)O%'&X+*3:9
M@C*,V<&KC;UWMWF/-O9#'19,4';:672*J<Y474:N94IQ1/<(>66[N]+^-0.)
MN)UAA2V/9%"K&Q!9I$R[R-?1,ON1C",FT8NB8N#1LN3<+D'CUH<Z;E!5F+E5
M,H("8`B]?<_HD3R]V[=X/BZ<VP4S;(7$J^Q3(T851+#FC^-GIALH]QQ.(F&J
MKJ-DVD<1LFX,[?H2(M4S',Z5.$P["9/LA-R&61VR>(H8_(XXGA\;F+9VQR&!
M=-TCN9U5I%K-<BC&[I1_'2`/0D3)IF-SQCE6447`UH5N9;S]`$,KC>7%PJ`B
M)$)Z.DH&7>8KF2<N3*8XY)XYEG:L`JY#)8MNYC'4H@X/SB3=U%%>$H1LFB%L
M-O>K7:[<B2)%1+TD*[7AL:FV8Y<Y+CC62;Y>NP;8\UBGCQ`6LJ^DEY9HFD1N
M=0JBZ^@0QG"3A)$/:.ZMMF7\=-S;C+H?'\>QZ&C)V6R7+QGL0Q]HQE#QJ29%
M)/(\=C4$W[)6<CR.VQ[5VBDBV(J4IU0+P#AVQZDMI=Y5R--L<ZPW,WJC;)7J
M;.#GU'3D[+$<F_$_('@%\+(F#9AD`@W$PF`3"8!`!"M`<^Y+F5"(@*12!J[A
M[:@;X3*6PHYS`W'[68WB4/X(4$?*'`2"#F5$0K%H`'FU'Q(!I44;J>U.VT#G
M\E;`]5V!#.XNPNV.[N1XSEFY&V<5E$]BD;*Q$([>Y#,)(LH[(#1H3""T:P<,
MXN4%1$BR9#ND5E$D#KI)&33>N2G"`\TZ7MFL;W;VAW2@MI6,?G,KOOCL]+RS
M7-<B3;+RL9M?N#&-IAW".GJ\`]<QZ4J]7M*U*=P^N=F-S2QE@#5].?0AA6Q_
MZX#.5BFN8P?6+U3YCU2YY%2,X^5;H91F#K$5`8))%9,CM6L(VQAH4B:2QR+*
MQ^J(EYD4TMUR^;@<U-M^I,&YPY*[>D9_=R5R1?/%*QDOB[:UFN.]XM:M+:S2
M+17NMIJMXXRQ-O<F)C6=-(TZ?")^TYMWNDG8;+8C*IF9V=CS9%'8_NGDS"4B
M<WR;'Y5*<W0-*S>=/$Y&'FV*P*R,[,R#M(54#(-72BBK?2.N<`TJXLGM0#QE
MMAMHR:P31@S:X%A35!FA)$.DQ;(X[`)`V1$K,A5$V::BY"4H!P;E[M3S`YI]
M1_6_.]`>^6:;R]<N>=,&SG1;FL?M1MILWDS68SN0WVS#<1_.2IG./2.)!S,6
M2*P0N2R4A,RK1!9L6(3;N#`V`KK2[1SFY^C%_HMQ&UX3-Y#/U?IR>ZOO,.:-
MK^K,>"],%8RX,E*1GO;+&''%,5IB<5JYIO:U9Q:Z[''(_K');)&+\!V5[9CN
M[YF)GI,>D::SU^/33XNA^8]0FT^W>'8QN'G>?X/C>"YHD"^)Y>ODR#W&\A;?
MB3+;C&>Q$U&M'<:^CQPG')*23<D4%!9HS%0AA`Y>.+MBBTW7ATJDF,8QX^\N
M(EF\S;X"OB\9IY2+N9-N>XAVV#LVB08O7Q2;/.-C\F>QVV05*LX212N.4)ZP
ME](*Q\R*#5)X4F99LB=0TTFXTU4,HE$CM@.67R73*W,2S3%5L9*EHM&@ARY`
M>(N9;MI%(#WT^$BA40!00_W0:5$I0^I=]3M`,YE@NMBT#4`]M9(`N$`<6`/M
M0;;Q33KY-0>^WM`,YE@OMBT#4U+*R0%OM!YI5]J#;J"DC7OMUA[[/.#)G,L%
M]D6@:FK962*6^WGM*OM0;-710KWVZYN_3\\$;)U)^'M#(QJ2H"S3,03RA*G/
MH/#%`5"E>E$#G10"[55[%Q&IM/SP6'<RH7V1:![=6RLD!+[>?T:^U#6:N@WK
MWVZYN_3\\`[F5"^R+0-35LK)%+?:+[2K[4-9J@BA7OMUS=^GYP!G,J`FMBT#
M`&I:(R12W6B[TQ'VH-NH"2->^W5'OL\X$4BZDBLW(GCDRI@4P"H233(<"WK`
M0X"?DBE$P$3$0UB4O$*C;YP+>9EOBM#T?^)!Y34_W3T0`/W_`*G:!S,KV?!:
M'>%?A(O8%2@(_P`T[:`(C^Y]7@`',KV5BT`]+6DD4:5%$#"'M0*V@<X_5L#U
M78`5S*C;=%H%KIWTDBFM`PM=2GM0+K`55IW7:0=U_F@B4=R?.1P*1J1#GU0$
MI90@@4IDV`N#B401%70U50+1)2[2#M3U*@"TCF5'3OBT"7:6I22`]EW(:U/:
MA;](%W%.Z[0+W:GF`$<RIM.^+0)=I:E)(I].[P_6I[4"_2UW%.Z[ER]VKY@8
M(YEALOBT"5TM2DD4UEW(ZM/:A;]+67IW7:!>[4\P`KF6&RZ*0+73OI)%-9<#
M/5I[4"[3%58`[KM$.Z_S00MG<H9Z\+X8C4`9"H'BI#@F8Z2(G*4@%4,%@'4&
MHII7V!2ZZH`N!S+=E8M`/2U#Q(!H(@E=_NG;:)C!]6T/+V`<S+4_HM"M.[Q(
MO?2M*\IY>S@`7,MVTBD![Z?"10K0%!+_`+IV5$I0^I</D[0#.98+K8I`U+[:
MR12W4!S8'\T&V\4TO]&H/J/.!(U=2>DOI1J2H%=R0%,>4)YYR.Y*A`$I7=A=
M1)(E!,`DU!\PFG9P"L[F6"^R+0/35TZR12WV\]I5]J&LU=%"O?;KF[]/SPR=
MS+!J61:![=73K)%)J6^(:-:M!LU=!O7OMY@W?I>>`=S*AJ61:![=73K)`2^W
MG]&OM0UFJ"#>O?;KF[]/SP^%W,H!%_@Q&PI%Z&\2*41*4'UANU`@$$X(H#Z8
M+=8>WUNI@\&;N6%DV,6+1-5JF)1&4(83^M+BF(G*DY`14!-*HZB@!JCYQK*F
M!4+F5"M(M`:74^$BA6@KVC_-!I<!"?Z+Q]3V@<S*]OP6@/?3X1+V]I@`?YKZ
M(``_N_4X"L>Q8F'='/A,6PP[0;1B8EP'M'YW^JRI;P``/0?1``KP%L.`YW;2
M9G(X_P!!.SDON-MA`RN!1G3AM%XQ'_C7(33B7B/Q.Q=FQ$D5%X0[7%R\!1%8
M4P&UL(C<J`$$_`2/@&<8=.9RR-@VTFW:&9DA\^:,).+?2\4H,1A\WAD9F#=I
M-'VL81*S1.2RN*,@)'!BO&R^NT%5N)E#`KW-VMD>H`^X^W69&RO;4TEANUK^
M+R[:3=B8Q3/\6F(#,\[F\?R;%<MB8%HK'2D9+LBG%%P@Z8N4BBBY0<-U541W
M'`\UN/'^3IR>WQ;;/-8M6V+<8ZYL.2EZS6],F.WK6U9F-8FMJSI:EJVB)BWE
MQQEI-)F8^V)TF/R2FW`XZ'QN(A<4PAA$EQS#XE7$V+9G.NY`C(V/N&\:Z8N9
M%TT<NI"3:.&YB/%EE57!W8*ZQQ6U!XQ.0S;S=;N^\W^OXK-/N3,Q$:]_WHF(
MC2(K,3K6(B(BNG;';HJI%:U[:_HQT.?(WZ;/'IUWD<?$_B\UAI1Q/<Z]6<,_
M!4&*ZLIS:!8E8R[7D2J:A`(<3$J%HUIQA*G.=]F707%9)F>19E@F!X5F$JS8
M8=N!B>9Q.1QQX-ADZ$1(M7\]B2&-OL/Q@N31C^,<K2Y"HK.4CLTUEQ7TD`"2
MF>3]$<"T@\QBX782,C\^<YCCL'D,2Q5;L9X[QLTB,W:IOH_"@;%9E;S0-7BQ
MS$01!RND)RB9P7@(W>Y=]'+.L4X$8O80R3!VP=1D5&I2\,[</<==X]),V^/D
M:8C&K/3(23!N11)J8Q#N"/$E0$_/%X"5<#R?HUS3(8G:[!<;V0D9-O/Y%D<'
MC$/&$(Q+E)6CPF5*1S4,0;QI9-JP@DU71/-3!$C-4MP<N8`L!+;&;4SV1/<N
MF=E-K9+*I-ZTD)3(W<'#*S<L\8M2LV2TK*&Q_G)/E6Z9`3*N=0I123,`7)D$
MH?3[8_:J30C&TELEM3(-H65?SL.W>X[`ND(F:E3QZDI+QB2^.'3824DK%-CN
M%T@(HLH@0QQ,8H#P"H-G=N/`U\9-M#MNKCKENX:.H->*BW$4Z:NH^?B7+=TQ
M7@5&[A%Q%Y5)MSE.4P&0D'!!\U4X&#0I].NRR34&9-B-IBMP>LY`">`PXFYN
M.?OY-@<51Q\51(S>RCDR28FTR`N<H%`AA*(2#B&&PF`Q[J)PG",7Q.+>2*\L
MYCH`R48R5D7*3=NLZ%LTB4D2J"V:))%H``1)(A"@!"%``=>M*_%[/Y24_J[@
M#6E?B]G\I*?U=P!K2OQ>S^4E/ZNX`UI7XO9_*2G]7<`:TK\7L_E)3^KN`-:5
M^+V?RDI_5W`&M*_%[/Y24_J[@#6E?B]G\I*?U=P!K2OQ>S^4E/ZNX#7-5I3G
MI2D>TKJ-*_"2E/YJ2E/@[@-CK2OQ>S^4E/ZNX"-]WY/&XW;3+Y'<K%F&08,P
MC"O<BB%$74\5VS;.VRQ!\+0AW"BYFKHB:P'M`$13U!,0""8`JIF^YO0JSW'\
M!SICTY)[KY(R;-'S.9CX\N=D8L<(+D$>A-@OA1,@BRML(QM,[9-;35(U:D*0
MH%(`%"W.WRT-^+..C@,7CR.#&P_$CX8A!.E&D*ABAHXXX^E%-O!VPH,"QNGI
M$TR6)T"@4H`0)U([G=-N%S6(1O47C6`/G[^+DI'%7698^;)&S..=97@^W$Z=
MH_6Q641CP(]W+8&>D`Q#EB@=NS@+9FX.F&IC=W.EC&<1FCXO#[=.,<A9+&8K
M(HK%X"8D'320!Y,9.P--1*.#\ZJYQMUCTG*2!EB&7CEX]T=P!7*9RB$7R>['
M1C!1)4W&TL$@U8)Y2OR+#;3)><8.I&3=8_)-C\KA1#M97(W&.&3:54`PHM0\
MY$B0@0'E`[G=*"VY&*8[CNWN($RUUDV/X[BLS#XD];P(26-PFC"KQ>4(XLVQ
MQ2*QUJHS9H+).!0%XY8)-]144!(%V(A:4\+C[6#00Y-"@C)*`(AIE[P\.&G`
M4)G-VNAB0W'RN#RK%=GFV>1TUF;G,Y')\159.2R>#Y)^+.0O,GFUL(.11NM(
M+`NFJZ5,V=M!*XN%.P>`>NXVZ_2PABV+%SG'-OYK$\JC%WN+D4QR7D(E\QD]
MP8*-F&R*JN$)LV3@<U>-W$HS5.DN0$%5G*=B9QX!E+[T]'".5/%W6`8<A,,%
M\TR5><>8-+MHM8</9NXF8G&;]UAB3.7%XO`OV,85L5=P^=L7O+)"!5E3!+>P
M^8[+Y&_RJ-V8P:+Q.0QE/#X[+6QH&3Q)PFCS$V#&&4;R>/LG#M>%?(O$GIDB
M'32>&.0RAU0.!0@<^Y70Z7'F>4N]IL*38KQ#')5P?;;SBDDRA%I#/V@RD^DI
MA"QFZ;=UA<F232<',Y;%*U3?)$$S9,`F7:#-]A-_<LGYS$MJL?=Y1CT1@,C)
MS.10D45TT0>Q\)DV$@S648OA3>M8YC&.2*H`&GRK8NH*C4I$0FYSLQMH];SC
M-[L]MJ\99,RAX[(6+N(BG3":8X^^2DX5K),5X!1J[2C9%!)=(#D&U5%,W>F0
M2A[8KM!MW@TRAD.%[2[>8E,MH9QCK>1QJ-CH1PA".EX]RZC$?#8-L1-JY7B6
MIE"@`7BW3K6PM`4[DKRP1$!2-9&KN'MJ!OA50MI1SF!`QP#PPUXE#^#V5\H<
M!((+RW96/9!Z6ZDFH-`$4KJ?!H5M`QZ=U;0[KO-`*O+");HYD4!LNI**&MJ+
M;4H'AI;K`.K3NNTR]UXV!$6Y[B:":V4I%,3W;O1Q5OAE0FBD?`<U!PL2L0;F
M#H`HN)4_,U-(OG$U!TPETB\N-E\<R+72U+910]EW(ZMM8TE^GJN+>Z[1)W:H
MZ85(ZB^K#9G91++<0W,RUMCV5J[2/,P&$1B-P)U-#&W[A_`EF'DICN&3,0Q9
M)231]JG4`JC=HQ4=K@FU*HHB&CZ?NM7IZW%<[9[,XAN%#S&YDABG)H8LV8YH
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M[([?8?DTIM'`X&SDVS=QN[C3G'(USDTIEF-L)]#)HZ#4E)A;(X%X:21?$<2"
MH-RMI(!2,5$/8M6?T9B7CH/A+N15CYD44&SH"YCFI#'4G#N1253R>4(=J4Y)
M3*P3(U,73T]9MHVV<FSMY9.H/$5Y:@TCV0C0:?"BH5$`4M`?@P:5$"_Z+A\G
M:`*\N%UL>Q&E]M914*T!Q97X+&VX2)U[Z7F[[`N\`9>7"ZR.9&IJ672BI;J`
M[TJTC#6WBFA7OMU3=^F%_H#KRX7V1S(U-73K**D`UO.Z-WP882:FDWN]-;K'
M]-I!J`C9.)06#0R+!HL`LTC$,I+'J<^@[,4#'(WD`$IU$T`$P*J]BQQJ;3#4
M!8=>7"^R.9&IJZ=THH2^WGM&ZD:>S4TF]WIK-8_IM(-4`R\N%]D<R-35LNE%
M276\YI74C#V:FFA7OMU3]^F&H`9>7"ZV.9&I?9645+=076G7X,-;>":->^W5
M-WV!>"20<216;D3LFJ:0%-50LH<ARE`RH$,`F18E*(@5,1]?)2\W:-H7@KUY
M?XN9>C_Q13RFI_PWT0`!_='R=H&O+U#X.94J%1\45[`J6HT\,]`!$?W/J]@`
M+RW9=',@#S;J2:HTJ*-U`\-"MH&/3NK8'==YH!5Y8;;HYD6HDOI)J&M`1:Z@
ME^#0NL!1:G==IE[KQL!$HXE.<CP48M"'."M2%ECB6T2,>9-04&YE10U%K`T5
M+M,M12U!$H+2+RXV7QS,M=+4ME%#V7<CK6UC2WZ>JXM]+=HD]+JCI`$7EQLO
MCF1:Z6I;**'LNY'6MK&DOT]5Q;Z6_1)Z75'2#!%Y<;+XUD6NEJ6RBA[+N2UK
M:QI+],57%O=?HD]+JCIADJ\N-E\<R+73OME%36U!IJVUC"WZ8J+T[KM(G=J#
MI@A;.947CTHL&=0!D*A?%E#@F8Z*(G`A>74$`*!E*"*2%]A>P;A$@+07EZ!6
M.9`-`J`2BHT$03N`/@P*T$QZ=U;0[KNP,Z\O\7,OE17OI_\`5GEX#`KR_;2.
M95[:5E%0J-%+:TC!I42D`?)</?3M`,O+A=;',C"%]M910H&$`<65'PTUMPD2
MKWTU#=]@7@E:N)04EM%BT5`KJ2`IE)4X7'([D@`@B5L_L*"B:1/3`)`.;ULF
MF"8@J.O+A?9&LC4U=.Z44)?;SNC=2-/9J"DWN[[-8_IM(-0,G7EPOLCF1J:N
MG=**$OMY[1NI&GLU-)O=Z:S6/Z;2#5`.O+A?9',S4U=.Z44)?;SVC=2--9J:
M3>[TUNL?TVD&J'PLO*`FM[09V`1>AO$U"F$I0>V&'VB0""<J:`CYX6ZI^WUL
M!4#Q9N)8638Q8]F>K9(2B,LH83^MKBF(G!FZ`;P(B(B"BM-0WG'L`5`4BO+=
MM(YD(>=;635"M!6LJ'AHTN`J=>^EX]]H7`:\M4:1S*E1H(R:@5"I@`?Z-&@B
M4`']WZG:%8MBQ,.Z.?"<H$..T&T8F(4^H!3?._U65*![27@`^C0*^3@+8<!S
MNVFS*7QOH'V;F<_VKQS(\&C.F_:#Q:%2R>4R%W-Q)L-Q9FR*6#9[>NQ4<NBJ
MI+F3J)&PUN5HF*G`2+M_O/#SN:1^,81M1A+>;499R+*3BI>1CF"3:%D<799.
MFVDPVO9E.QF54(M9-PC>Q?H-VJ@+&JT!0-CN3M4KU`+[B[;;AM9S"&TMA>V4
MA'9)M7NODV*YWB\UCN99Q-8YE6(YIC\/`2T#/PTTW(LD(:J!P2TUDUT554AW
M'!<WN_'^2IR>SI@RY*1:LX\V.N;#DI>LUOCR8[Q-;4M69B8Z3'K68M$3%O+C
MKEI-+:Q'SB=)C[8E/>+XZVPIE`8?B\%&1>/8SC+6&A(U&3>&291C#EFC5OJN
M&3ETNH1)N%RJIU%53B)SF,<1$=?N]UN-]NLF\W=ION<MYM:T_&UIUF=(Z1^2
M(B(](C176L5K%:^D-U.R2T;!S,C+1L<M%Q\5(O9)(SU9R55@T9K+O$S-S1)@
M7*=NF8!((#<`TH->,=ZYU1>\O05,8['L9#!=FX<"1K;*3X1-X<:4R")99)':
MC)]*QF-X-D[;6?PSQLJ4I5USMTG3,#@D=1N3@'DKU,=%!84F-D5V?DHG&&3E
MJEBC#%<CF#0K>;%N+^-#'6VU[A6/7DGJZ+=VW.DF<S]9-NN4'"A4S`V\?W=Z
M!(B5<&Q_&-C8M?&4I@BTRWPN39,HTB3LI<B*1^IMJF8$8YTU(:0<%*+9F8Z>
MNJF9=(%`M%M=MIL>9EC>X^U^TNUD0"RTC/8]/P.-HX](M'DLS<04JZ1(MB43
M+Q<@JP%5DNFJBBLFF)T3%*%Q>`GK5E?<+#Y37_JK@#5E?<+#Y37_`*JX`U97
MW"P^4U_ZJX`U97W"P^4U_P"JN`-65]PL/E-?^JN`-65]PL/E-?\`JK@#5E?<
M+#Y37_JK@#5E?<+#Y37_`*JX`U97W"P^4U_ZJX`U97W"P^4U_P"JN`-65]PL
M/E-?^JN`-65]PL/E-?\`JK@#5E?<+#Y37_JK@#5E?<+#Y37_`*JX#7-597GY
M2C%C74:5K)+@'\U)W?!8U_[.`V.K*^X6'RFO_57`1)OODNW^)[19UE.]T7BK
MG:W&XE.=RQ#(3*R\8JWBG[-]'E",&"=F?27C"#<6*1$S*G?`B"=%+1`*Q;A[
MU]#\1NL[PW<%GT^.-WYI,D?--I")0E\P.V8X9^,;$LQ)$P%U**H#AV.HJ,AU
M%14;(HZ-2`00"W>W3N&<8OC;G`(W'4,%<X=B*^%MX1=Q'PR&**QISP"44Q&"
M9F9L"1HIZ20HI"FG0HE+2@!I-WH?;XV)SF>[J[<81E\3MSC&4Y.JM.Q$=D[Z
M-B(Z"?.Y\L0E*0#@Z:SV*052,1,Q-8IK#=@\!7S']Q.FF7P2519[88.RQ;'W
MFUI,DQI7%RN!AI+-,I)'X,:59PV*2C%VHSFY7F'3M)9RW9E<*J++`;F`*$1F
MZA>B-CAL%(-=J<45Q%*$EG402.P)3E(&/FGB\0#%4OXL()8TME",(59NDJ9N
M5-@"*S@6R0E'@)`Q7>GI5F-P,+BL5VPQ@\[,SV+Q.'95&8,LP@=6,@$2XW),
MLA6Q2/:1\7#,G[!@S.H*(B\>LF[8BBEND%YHA64\+CZ,6(AR;>@C)K@/L9>\
M`BQIP%8-[T^GK;%YCF3;D[,;</Y#</-SQ9Y_\5L?>NQEV^/9!E<GD.423F`3
M=KQL?!X^\7<G$7*ZEH%(BJ<0#@&ON!O1TOM<.@WNX6+;?JX/.0CN6@EIS''J
ML&Z8/=T\7Q-W'H\WA(-FTE);B3D>LYCSZ;B@'<NDR$24,4-%.[O=*>.Y')/I
MG;#$&TS$2,K*24T?`WQDV\@A@N/9,UDP=&PD#/CY-BTVU)%+-R+`[7%5(HD4
MO$P2'L)GFS^5O\KC=GMNHS!WV+IXA'Y0@?'5<145;E<SB+2'3*,$W\4''9!L
M\;NU$-9LB\,=,%5%+[0C>,W;Z5YG"V,F&T6.(X['M\;F$HF7VZD2.(DT_/;L
MLH5*29*84X0C)!.<Q;(N9;N5"*,5GH%<E25>`0P/K;OJXV>G7KEFQC([;E66
MB<3R@%\R=Q>)-\F4R1MC>.XTVBUT$'09).*,G42Q3*WUREJBT*H*J)T4@^,E
MZ\NGW!\:QO)L_P`WQW;]+*PE!B(3,7LQ$9*<L#FKG;_(3KQ'XMN!33Q[)V2R
M3XP*&*W12,L8=,+A!_R'5+M?&8R&:.<AA1Q(F29OB3_(TU,I\*A9W;K%<GS+
M+F<XX5PU$8H(Z#Q!Z9,ZI0(Z6*FD@*AU2`(,B(ZF-O=]6Z,=MG(L<D4Q_--I
MGLTY:.),(^,\3GMK,A;L73]2"(V+*^%9XSJW`PF!P@[0,)5&JH%"W0+2W95@
MP#M+6DHN-`$4KJ?!05$`,>G=6T.ZX;0"K2_FW,&`5LNI*+FMJ+;4MK%%NM`Z
MM.Z[3)W7CIA$6Z"\T$ULI;&QIKMWHXJU9EP322-@.;<PHG\"FUU$0.O80;`4
MTR5,34'3"72*RXV7L(\M=+4ME'![:\EK65B27Z8*.+:VWZ2=;=4VD%3NH?II
MV:WE1R7,-R]H\/RC-H?;I-C$9(YEG24S&-,<DU<Q@R,G@,3D1/`98*[UFHJQ
M53!9,!-4JRB28)]D^F?8_%PV\W;@]H\#BMR!AXW*ELM9/CMW_P",N48+$XYD
M4V5G&P\9CY7[J&DI1`@MV39%,KMR*";?Q)X'`<4'W^6`Z$LGW^E>H#/,3@,N
MR7+]XY/=K/VDME&ZCN-RM3*\[',,Y@WD$.>(XV1MD3*7DH^J3-))`IDE4DDS
MU`G0\?.>![.T[WC..Y;!RU<-_:M7D*13'GG#-,>6.W:QE[<>;MS>W[NMHB<<
MWF)UC$G%NK?=O?'./7K]SUC7K'Z6G6.FNGVZ.H6P'0%TD-=H=B/%^G#:C)97
M;G"83'L=GLP%IE.1#&0N)8WMW'>.R[C&F(90Z1PO$V3+5?HJJG*R3.<QUU%5
MAVGG7F7E6T\NW^#9<EO<>VKGZ5IDRXZZ]M>Z8I.2_;K;69B+=NLS-:TKI2M&
MVV^"VWK-J5F=/E$_UD_[9]&O3#M`+TVW'3WM+BII.)@(1^+0%'HKQF.*2;B*
M:UDXYX)=!YD#]910MJKM=<RJYE%#W%B7^W'F4VB\\IO^Z(F-??R>DZ:_OOLC
M\R_^&V_\"OYH/7'=OL"GV\L]DL%P.=<I95E[(7<F=C)+H$99+*($CB+J/<P,
MD@P`NF5'7:Z-+.296\LGC;/RWRCC\7L;'D-YBPS:9[:9KUC6?6=(MZS\956P
M8+SK:E9G\D'`.T>V=!IM7MD(T&@<E'!4:'M`?@`:5$"U\E1\@5R_]N_-/]:\
MA_U^3^<I_"[?^!3\T(CWBG.EC8""8Y/O!CNU.$0$FO/M6$M(0#EZS5<8SA>7
M;A3":ZL-A\GR0ML0PM\[`5@("HHF12U%Q126?[=^:?ZUY#_K\G\X_"[?^!3\
MT(&ENKCZ.:#E8F%E9;:=A(3K;%G421U@&7)M7)<T8LY2!;JR9=N%(MJ_+&S4
M:XD&RBX+Q2#TIW9$@`FKY_MWYI_K7D/^OR?SC\+MOX%/S0C?I%W_`-^8YYOH
MXFHC8K?#920W)9RO3OF'2DHPQG%9K`LEP#$\S93DVMGNZ<PU%[(,,FCB*-HA
M(6:#M-^J5=>]-(GTA]3?&?I/YIX]XIS_`(-O^6V'.;G@HOR/ZZRVW=ISTW6Y
MP17;6V'&U[L46P9+4RY[^Y?%?!6<6/V[6OJ-EFWVWRY\6YKCMBC+]SVX[>G;
M6>O=?UZQTCIK$]9UZ7;B^HF4//XMC#G:++XU#(IAIC+'(I3(\(/&IRCB+EGZ
M!G[6-R>>GTFZQXP$KRH.#%.<XF\TA3*\5W/TR]GB=WR>#E^.SY=IMK9K8:4W
MD7M2MZTGMMDVM,6OWZVTG)'W9Z:VCM;&-[KDK2<=XBTZ:ZUT_J6F?ZCR?=9W
M3\PR&3Q-;<2!_&B*#=,SO'P9YJK,)DV:RB)PW<`XQS;"G#HY(;(\GBFY!3*H
M#\%W"C'FTF:RG'+F:>>T?43MIOR3)%=HLCC,P1Q12))++E1RB%1*3((UY*0;
MEHK.XI'DDV;M-N""JS05TFSY%XT4,#EDJD(3,9:6`36L&!@`3V",HN6X`%SI
MW4BC67@1&O?;J'[[`U`1R"\F5HY$[1DFD!354+*JD.4MRH%,%S>/*`FM3KZ^
MG2\WG#:%X+-:7]P1_H_\47[JFI_PGT0`!_='R=H&K+>X&'>%:2B_=4M1_HD*
MT`1_>#R]@`+2_95@P#TMU)1<:5%&ZGP4%;0,I3NK:7NN&T`JTL-MS!@6ME]L
MHN:T!%MJ6UBBW6`=6G==ID[KQTP1J+RG.1X*,V)#G!6I"2RQBB6QCS!@`S5L
M*ID-1:P-%6ZPE12U!$@+"*RXV7L(\M=/4ME'![*\EK65B2:FF"CBVMMVBG6W
M5-I`$5EQLO81Y:Z6I;*.#V5Y'6LK$DU-/4<VUMOT4ZVZIM$`JLN-E["/+73U
M+91P>VO):MM8DE^F*CBVMMVDG6W5-I`%6EQMO81Y:@G?;*.#6B(--4"UB27V
M"=>VMMVD2MNH.F"%NXEA>/2BR8U`&6H3Q=8X)F,BD)P(7E%1H`&4H(I(7V%[
M!N$2`N!:7[*L(\/2UI*+C01!*ZGP2%:")Z=U;0[KAM`UI?W!']WQJX[Z?_5'
M=7_L_>X#`K3';2/CQ[Z5E7`5&BEM?@@:5$"U[Z7#WT[0!6E_.MCX\1"^VLJN
M%:`O9<(1)K;A*E7OMO-WV!>"5HO*BBL*3-BJ`.I$"BI*K`(G([D@!,1*TD+"
M%431)Z>I`.?ULFF"1@5F5EPOL81YJ:EETHX)=3G=*ZD2>R_3;W4NMU5*7:1=
M4`ZLN%]C"/-35T[I1P2^G/:-](D^GJ:;:ZEUFLI2[2+K`'5EPOL81YJ:FG=*
M."7TYW1OI$GT]0$V]U+K=92EVD75#X76E037]I,;`(M:;Q1<IK0!Y88?@Y,"
M&,5-`1\\+15/YWK8"H'@T7EQ9MC$8L#@+9,2&-+KC>&DMIF,<&#NNH!41$=1
M6FH?SCV`*@*A6ENVC!@/::VLHN%0`5K*_!0VB8"IU[Z7&[[0N`U9;W`P[QI6
M47[JFH/]$C2H`'[X^3M"L.Q=P[HY\)RE*?YH-H[BE,)RE-\[_594"G$I!,`#
MZ-`KY.`MAP'/7:3+YG%N@G9J>S[;3#<MPB+Z;MGCR6/(SDYE+F>C#X;BC1F@
MOCAMLG:*ZRY%DU54A!9)`X#4XIE%8`>>!;LXQD>Y$>SQ#:';-IF<A#YE%QV8
MLWLFQ*M&XA*PYIN#0R@-HF;Q:/?GF$)!F")E&3YO[83.("03!.F/N<N5W.R@
MTQ#XXP7#`\(`B<;DDG*I'2_&#/Q(<RSG%8<R:@G$X"4"&```!J-1``D"^5\8
M#VK'5\-'LY]SW<T7T?#?+P'Q/2*L;!S,C+L(U>)81,B]E$3.5W)5HYJS67>I
M"W/&&(X!1LF8+!`0/6@]_`4::=4O2?*PY-P)#$<5C9_(XXR:\)-X,LIN%(1>
M+,8YRSUT6.'RC>2AFL'(,G#!PF]69*-7"!4%!.8J8!Y..HOHN:0AL@DL8VT9
M!F#M6(=1JNV\H[F)^;CT2N'V.N$8S;=^TFIJ)5:@BY1*NN#5VF"*ABK%L`-E
MC.XO11,'-'XQA&QZKEK"R.<<@RV[,@0L="Q4Q/KR[=Y\VB4,N=2-BY!9FJDX
M.5^5HY%J=8J*HE!^0O65TZ$=0N,QV;X?".Y:4:0\7#N6V7P")).95>K-$5#.
M<#9QK%&14;JJD<G.1JL4Y52J&(JF<X:XW7STTG#(2QVYV*SSG%5CLIMECP9G
M,.64N!Y--O`*BSP<[9'(7ZD*\!LS44376*T7.4HIH*G(#J+U>[2KR$#'1\[%
MRI\IV.F>HK&G4<ZDE&$[M;!@W4<2L8Y7@FXNI%VU7%PV:`746;(J*A0A!'@(
M8C/I->FB23@E?'G<>6>M*B648RC19@YT-RECL95`(I5=L_2/MH=(R12J&U)Z
M$I4DFF<H3).]6^W^'QT6[SIJ_P`+DI?</!MJFF,2I74OD0YUN/*R<-B,+H8;
M'Y3&+>(/H5X!UD72J2!6J@J"40`!"<\(S1/<'$,<S?'6R0PF41+29C/$#R,<
M^*T>DU$2O&+N)2=,W12"`*)*$*=,]2B%0KP#HU);W+'>_P!S_5O`&I+>Y8[W
M^Y_JW@#4EO<L=[_<_P!6\`:DM[ECO?[G^K>`-26]RQWO]S_5O`&I+>Y8[W^Y
M_JW@#4EO<L=[_<_U;P!J2WN6.]_N?ZMX`U);W+'>_P!S_5O`:YJ>6Y^4]JQU
M=1I4.?<]GM4G_P!&]O`;'4EO<L=[_<_U;P#%W.R1GBFWN89'EN,M,EQF'@GK
MR=@$#,Y)66BDR`#YF6.FT&4;("HV,;VNH>J]-,I3',4HA4O.^HKHO@MSW&!;
MAM=FD-W99)%CD./S>,^)Y@U3:X<7*VK#)C$P-^Y/9BT`B9ND"C@#D00*D`D!
M,0"VFW[^(D<;QZ1P%EC:6#R&'XF]PY"%YB*AT,6<QRBL$C%QH0;$&$>2.,31
M0T$=).A+"4M`(DW[ZH-J-BG<)BV\1VC-OG4+(.&Y'#5[*0;^'3RS!\&FVTA2
M(<)+E:&W#0?/&XIG,$(SD'5ITVBI>`0LNH+8F>C,OR**;XU-MXF?P2)SA1#&
M,H)((34]FC?%\9&<;2NW[!VZ5QW,#"1Z8X**0;ALMS`(*HF*`0`/4MT<N,8C
M)&/V;@9V"?1D[*,HZ%VG9R2R`9`]7CW3!6&2Q?593&;HPI'/+F(4ZC`$%GN@
MF8G`/^$WXZ9IC<K%H*#VUQMUD\KD\%"8UFD=A,>I!`^CH<J$'-,,T3@4VR$3
M%MI)G&Q[O53!=Q)-6[#6*H(D"Z40>6\+CZ-8X0Y-"@\^Y"OK9?0\-[.`I_.=
M;73B?-,BV\RR0C6TWAB^?LL@3R:$FW+&#+B,P?"LC5D56V,3)(YA+MGYE$5S
M@#9S%K"910H*`F8/#-^J+IBQ6,AR9C%X@EBT[CK4\4_DL:<)8^LAE^;/()/$
M%6<SB3)ZQFY;*,8>NG4>X:)%2"*6<.A3,D6H(W_4=T^.Y5U+O-K&LDMB3O+C
MJY4MAD8Y&*;8O#R$7*Y!''<17XQK1$BE@1X9LX:M3F679-FQRD259&5!][$[
MC;0YL^RF-VCVZC,"?8L7$6.3I#B37#CNFI'$VU:0J!V,.@2:3Q9\S=M5C(&7
M9-7)CI)JF-J``-[`=[NG_(X;'V&-[9QL)%SSK`HMO!.MOEHDD:XSG-=RH#&&
M,U&HXJ+*(<M<LQ:;,Z07,12-</2BN5)9X)1"S"FWN*+2CN<6V[V^6FG[=@U?
M2RL3'J2+QM%"S&,0<O3P!G"Z4>,:VT2F,()<NE;33):&N^:;;\6L$Q':C:TS
M/%T73;&FIL<ACM\>;O5CN7J,(B;&Q3BDGCE0RBI4`3!10PF-41$>`]H7:_",
M;*L3'MLMN(--PX%VNC$0T;'(*.S-I5D=X9NT@$4>;493CQ`RMNH=!RHF(B0X
ME$&QF.*1>.Q\&ZQW#,)@W2F:[7QBSJ*:-XQR,6VS7$446)5V,"FJ9LW;Q+4B
M:(F!,"-DB]A2%``F(%)FH7-(P`J6ZDBZ$0"J5U*Q85$`$].ZMI>ZX;0"J3'F
MW-(P`J2^V0=&H`BVU+:QA;A*!EK:TK82M+S6!$>YZD[XULI1G#]N[T<"]TH^
M"Q$<!S;F3(6PYM58@&7TRFTRG$B=QBWFTPEPBDP-FHTC`KIZEDBZ-;7D=:RZ
M+)?8!W-M;;M-*MNH;2!``R:SU1%RTBCD58-2+-AD7*R9DE54B/!%)1J4IR@!
MW!2U;E!0")@8X7F*D%`<@ZC_`*/S$,GRG!YV(VGCLEP..S-]E,+\STL1U%-M
MO):.@,C2;MC;:IFE%AD%W)8TC,%RRJ+,ZS45$`442!D9AU+]&LETY]0N].W4
M-L]!QVQ<#&&RS,\TV:0BX'`)3)&,:I'SV10F:0>WB\ICV*NGZHRY0>,DTS1[
MIL9RBX26*A)?#MMP>[\GV6'R:T4\>C-W;G7+.";8<<3DR8Z9HQ9YQY<E:SCP
MV]G+$9;4UQVC6)L[BV6N&TX?^5TZ=->L](F8UC6(]9ZQT^+E#TI?3$_1]8-L
MIB^.=4V\OT=6>;OLEI`LQ+[+RNV&+8`UBN<2)"1T8AF4S+Y#*/$8^JCIVORP
M*.#V%1(0HF#M_P!:-A]$?)OJ%O.8^DW+[C9>%Y8I[=>6MEW&^O>*_P"$ODMM
MMG3#2LV^[CQ4G)VTK69R3-M(UO'6Y+#M*X]]CBVXC77V](K]D1K;6?MGI^1V
M'V]WGV4W7PC$]RMM>E/`LWP#.H2.R3#\OQQ;8]_!9)`RB399A+Q#P'*?,L7:
M:XBF>A1$`"H`(F`L!P_3;B]QBC-A\@XZ<<QK$^QOOM^6U^R?ZWK#*G>7B=)Q
M7U_+7^<<X[C]/.,X5N=N%NAM5C+&"V\EHIQ.R<A@[#/9<B6>Y:Z@<9AXF.Q7
MYSIE\6-DC)L#(H&1*U$@@5DT0)IIQ#G_`!C-P.TVV]ON,.?!NLNXI6<<7C2=
MO>M+:]]*3I;NK:ND?HSI;2VM8R,6:,MIKI,36(GKI\?R&2IU:_1UJ-XYS"1F
MUN8(2TMGT)&K85LW,Y2U=R&VK\T3E%CV)VT<,21X3!T&K)X90&<DHY2%HJL1
M1,YXPO+*+;$=-N^^WV-2LIT\[0Y/A.7X\SRN$CLMVX80;X(_+\2DFB!Y.`E\
M.;2\%*K8YDJC9=!RDB[:<RL4Y"*IVB$<2OT;O1')MF*/ZH/3VU7A(F#B,>D6
MF&0";^#1Q.1E9G%'D>9?%';<LG"S+I-TFNJFN<RH^NZQ6Z13A4OHAZ9,DVO@
M-U=D=H.G:"Z0]C]LL_)';1XQEI8;<0<EB_Q&QR-DLC>2V';CFD$,AR7(H)*;
MDRR*1G)SS*QQ<KKWE2F'A_U8KN^+Q\/SW`;W:Y.,K?;X\M-[@I7<XYSY]Q7)
M;'7;YIIEC\1-+1-IB:UQVUFWN0ZQ]6_I;X7X+M."Y#POS'C_`";+RW&5W&\Q
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M#HM:"ZTKJ1AK;@*A=2MMYZ5L+>"215E0:.1.A'(I`0U50D70'*6Y6TWL$>`"
M8`3KZ^2EQNT;0O!7J3'N2,]'_B#KRGI_PSR6_OCY.T#4F:_S2,I4*_"+H1I4
MM?\`A85&E?W@\O8&2J3'9<TC0]+=;(.AIVHWTK&!6@"I3NJ)2]UPVA@JDQ4M
MS2,`/,OMD'1A`!%KJ6UC"W6@9:VM+K"5I>:P$:BLOSD>"B$:0QM6Y,LBZ$#%
MTV/,&*`MV^H9&Y:RJ*EUI*BE>82@M(I,#9>TC0KI:EDBZ-;7D=:RL62^R]S;
M6V[32K;J'T@P128&S4:1A:Z6I9(NC6UY'6LNBR7V7N;:VW::5;=0^D`129&R
M]I&%KI:EDBZ/;4&6M96+)?8)W-M;;M-.MNH;2`*I,^;>TC`]COMD71J5!IJV
MUBRW6B9>VM+K$ZTO-I@B;*RXO'@&;Q@B`,M0A9-T;2,9)'4`A1;*]@@*@E$4
MD+K2U`UPF("T%)GLJTC*]E:2#H:#1.ZGP8%:")Z=U:!W5&@&I,4_FD96GQBZ
MI6G_`-5]U?\`LX`%29[:-(RO;2L@Z"HT4MK\&#2H@2O?2H]]`J`929\ZQI&"
M/GVW2+H*B`.-.ZD6:VX2I5[Z7'I6T+P2-59?26%)"-6`'4B!!4D70#>5W)`"
M9A*V?VE*H1$HT,%I3'];(*94Q!6=29"^QI&&IJZ=\BZ)=0'NC?2+/9>)&UU+
MK=12EVF75`.I,!?IM(PU-73OD71;J<]HWVQ9[+[&UU+K=16EVF35#)U)@+[&
MD:--73OD71;J<]HWTBSV7V-KJ76ZBM+M,FJ'FLI+@FM[6C2D`B]#C(.@,!0!
M[IF,`,$P*(E(W$U#A:)U*&];**@>+-68%FV$K:,/5LD)3#).QO\`6E],QC\D
MZ'S[41$=16EY_./845`5&4F.VUI&CZ:VZ0=!7M6LK2,&E0!.O?03&[[0N#&I
M,U_FD92HT^$70#2IJ?\`"QH-*?OCY.T*Q[%W?.CGUX%`WS0;1W`0PF(`_._U
M65`IC%(8Q:]PB`#]3@+7\!SPVDRO(\3Z"=G,@SW;W!\UPJ*Z;]H%'^,-'<UD
MKK(8P^'8JU8-5\??84NS<+*HK)*KD,"R2:A3=HD#4`';@F^6%Y9NM%XCB.#[
M3L]T'V,Y](Q+TKU\UDCXCAL_B<7D#AM,([=H.S0,](Y*S<,!24,C(HH'7H`)
ME$0GS'E<R4W-RD9IAB[1P&"82":<7,2T@F9'\8,_$ASJNX.,$A[[P$H%,%``
M:]H@`2%=+^+AZU&W>&F_WAU2G-%[?YKP'E/R+F+@IJ3EF<:YBXZ)DG\DW`ZR
MXKL&C-9P\1T%6NDMJMTS%L-YIJT'L'@**H]5W2Q*1J&=S6"1$9FDM!K-AQR>
MVX76W)=8U"-(V0;D.JTQ:19KXR:&EF;IBJ:0Y%9%RD5(VJ;3`-3*]1G0Z$7'
M95D6";<!*S,J[8,XUYM"YE<E=90Q:BG*Q"+AM@#V.>3<6"7*NQ2>J$07+H'4
M`]"\!(&);]])TH,LSQ&(V^2</,:R#+YEM%X!-1B3V'1QJ?D)AVYE4\!:0[]2
M5QN+E00,#DX22#5T"!E2$4X"&('J>Z4MNEV>)073Z\@PPF8R6<7)&;?0\Q)X
M8XQETW:+Y[+$8>*Y,T-)K9.H9O*"51TX2644`QBJ@*@25MYOQTV[D9M/)0.R
MT4Q5A)_(XESN1.;:1L3!+Y"2%<Y7D;4TTK!C.,9>0B(8[I1%XV;NG(-Q$Y*I
MC0)"V(W*V%ZD&<?G.V>W.-+)-\#BI2!R+(,`;0CM7`]PIC/8DK.$<O(1-^G$
MRTEB\OS;8EB*FJ)C@;6-P$ZM]K<):%=$:;9[8-2OD"M7I6^,1*)7C8B\:Y(W
M=`G"E!P@1S#,U`(>I0.T1-2J1!*!$;78;C[=NT@]N=NHAFSD(Z78LHZ#9-&,
M=*1'-#%R$8R0BB-8QY'G?+G140(F9-1PJ<H@=4XF!Y,F;R-:-V$='03!BT3*
MBU9,M5JT;(E]*DW;H,TT44R^@4H``<`JNF?N49[X=?@O`%TS]RC/?#K\%X`N
MF?N49[X=?@O`%TS]RC/?#K\%X`NF?N49[X=?@O`%TS]RC/?#K\%X`NF?N49[
MX=?@O`%TS]RC/?#K\%X`NF?N49[X=?@O`:YJ:8YZ4HE&UU&E?;#KL]JD_P#1
M?1X#8W3/W*,]\.OP7@(^W4S-AM]M]DV:9G#L9G&\=9MY"1BT#,G#AX))!FFT
M3;HSRD=%*.BO5$S)`HL015*4"5/:'`5/S[JGZ-(7=)?;[<!/;@VZTVW;I9-#
MS6!3$EDS-L;"TLR8-LM,I@+IX<7&-1+;00$S@XF*W3`H53X"V^WTG$S.,XY,
M8`WQU/!I;#L2DL-1B4',5%(8L\CE%X%&.C"QC((]D2..GI(:*.B2A+"TM`-?
MNFEBL;B&1Y[N%A>*Y5%;>XME&4N"O85ED$FC%Q$$_?3"$.E*L1(5R_C4%4;`
M.F54#VF&T1X"#L0WLV63Q:7&$VXC,8CL8<;51>1XJAAQ(A:`>9YEK6'PMJZC
MF\`WBU6T%-.T7;E=LHLWC0$Q@-KI*ID".4>H#I-EL1C9N`VHQ#+<5?RFX4'`
M^!;?XTXC'V01V5$Q#*(1N,C&1\9&267/VS1P`.SM2.V"S==T9(`$I`V.,=1?
M39D>X6&PV.;4Q:DW.3V,1F*9LG@,(VBFIDH!%+&9LDXHR0DX2/CV4RRBXY1=
M-LJJO)HMF15"&5%,+OQ!I?PN/M2C!#DV]*N'5?8B]_M7OX"NN]<ML_M<MB\]
MGVT6'9`YS;,UV1I=EA,/-.HQ]&8QDN82V89"Y7AE9`&</!8\\4472*X=B8P$
M3(8QZ<!%.X'5)TW84AC4YDVW+"2999BKDK"6887$22K3%W^=NX>1BIYB[9-<
MB@HI3(F3I^[3=-$V8&;*F.87112X#:2O4UT^X?,38.MO6S!^=Q).9R49X8P(
M:262PG#,XC7NJDP3DY\^603Z*3CSHI.#J.&A$U]`J2)Q!X[#;G;5Y^^RJ.VH
MVUC]O'>,$P]ID('Q2&QDLDU3<3;)K$,'./(JM)UGB;YB[:'40568H.#'(@H>
MIQX"+,.ZONG,)?;;"(;;);$'^?RT#%XC#CA4%$I1DL.62C8&LPSCNS%9'$L@
MDA=.D716ZR"\J0R`*++G#@+_`-TS]QC/?#K\%X`NF?N49[X=?@O`%TS]RC/?
M#K\%X"/=R337A&/T1BJ?.'MK?<Y>`-GX\P-]EK0U5`#N`:`/HCP$@@::[*HQ
M=*ENHY=C0*HW4JT"H@45*>40+Y1H`4TUYMR,6':2^UR['LJUU+:M`J(`*UM>
M^A*]YK0B+<\T^,ULI:C"`/SO1W,:CN0H"'X@YKS7+Z;$;G!0,XT@/:0PE3N$
M+C6A+I#37K>HC%A[%JV.G8TKR&OIU:!=;<ZLK2MJ5:7'L!$D>9\1$%218#R3
M(3)$=O#4`5T.;.4IB@'FB+@$Q%$+K4ZG"XQ2!$\WTZ[,Y1/JY7DVR.T<WDSQ
MKD+*0G9'&XM_).F^9,&<7EQ%W;F!%9V,U&J.FZQE!$ZJ`V")2N%@*$.;N]"N
MQNZ?3OO%TU,]M,!P#;[?;%8+"MQ6F(L'D26;Q>%"':I0;DV/&QF5!@6'0>-$
MQ;/6BR(.#KI*)KKJJ!LN(W/';/D*;CEMK.\X^(M%\,9+89MW4M6LQDK%IK:E
MIB\?=M$S6(M6:S,31DK>U)C';MO\]-?ZG]1Q'+_E-_HS/-NVDQ+^+O`N4=4%
M.YIJ@2_J<,-`$%[:U[-.M1ONEOZ[^G?^HM]_\G'V_P"@_L_-I8]O=_TM?Y']
M\[$;-]$L]L%M5MWLIM9F6W6.[;[5XG"X3A$"MMUF4VK$8W`MF;6.CSR\YN[(
M3$D+=%`Q=9TNJN?S1.<1J([S;>?>*;/!&VVW$;^N&L:1'ZQI.GK\]A]JU.US
MVG6<E=?[3^^27@^PL-DN-;F0&YS3"]V<8SB5CX'(,9G(8IL<6/MOD,HHS,M'
MNLBSXBP!/E!VBDJNB=@***8((&2L+%?)O*<'/;+:;#;;:^WP;7+NLD3;+[MK
M3N<E;Z3,8\<1V5I6OI/=;NM]V)BL7\."<5K6F=9M%8]-/2/RSZGDOTK]/;C2
M`_3IL44B$KDTZDBC@^.M6WC690*N,Y7)G;ML9204>Y)!"5J^4,4QG"=+[A(4
M>(<R$\_#!"V(MHDA"%$J1.9=%*4"E<`D6A60`4OFH@-`[`$]*T+<'W=,W"&E
M&`6IZ&YAT)@+[;L$2<L`"/8A4*AZ93M\TMP<[L0^D(Z<6DWOG%JYBHI.X0YW
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MI\;RZ)2EXHDXUE829;%5YQ-1A-1#U@1W%RL<[1(W=('`3)+$6*`F`A1.#JD3
MS`,W(F+&))@4PZO-.P,4@'6L'LY*AA*"5?7B``F-VC0+@6737W&+]'_>7?E/
M3_=/);_V\`735?88NE0K[9=UI4M?]T[[:_NTX``TU4MR,72I;J.G8B`51OMJ
MT"H@`J4\M"^4:`%-->9>C%AVIWVN78T"K75LJT"H@`K6UI6TE:7&M!$H>9YR
M.!0D60PZMZ9';L;R:;#F1(`@C<9(3+6524K1.HIW&$`6D-->MZB,6'L6K8Z=
MC2O(:^G5H%UMSJRM*VI5I<>P`AIKUO41BP]BU;'3L:5Y#7T[F@76W.K*TK:E
M6EQ[`"&F_,U$8L!]:U+'3L:5Y'7LJT+=;<YMK2MJ5:7'L`*:;\V]&+#V.^UT
M[&E09ZUM6@5H(N+:TK:G6EQK00MCS(O'H"2+$0!EJ$!V\'2,**.I:`E5"T0%
M02^MHB-"UNJ(E!<!IJ@51BZ^;6CIW3N2NI[4[>V^GU`+Y1H&+INGL,56GNIW
M2M/_`.4[J_\`9P&1--]M$8JM#4JZ=]]%+:T:=@5LK_I'R!4`QIOSK4(NM#V7
M.G85&CFRZC,:`(@C6E:5/WT+<"1J>9%)<4B1:@<U(@F)W3RH&*[D@*F<0*\H
M!52HE&A@M*)Z$):4G`*SFF_/TT8L1]=T[W3L*TY[0OHT-;=:VNI6ERM*VDO`
M.::]<TT8L?9=*]T["M.?T-2UH-MUK6^E:7*TK:2\`YIKUS31BQ]ETKW3L*TY
M_0U*-!MNM:WTK2Y6E;27A\+FF=->B48!+%[3"Y=@8"4?:1C4;DH:TK<34,%!
M,I0?-*)@\&AYL6382I19Q%JF)3"[>"!_6E],PFTG(^=1&OKBGIC^<:THF!4)
MIKSK48OO-;5R[[JK674:#01`$Z_Z3>0*@"::[:(Q?>-*NG?=4U*^U![;:?NU
MX"L>Q=_SHY]J6`?YH-HK],3"G=\[_59=8)P*<25[J@`TX"V'`<[-ILLRS#N@
M;9_)<UP3!,UQ&(Z;MHU76+-%I><<9#%JX?BS1@S=1$ICAF"BBC9=-1P4VLF0
MY#`4#%H8`D'`^H1?--P&N#8O@F(L91>,RV483[AY)M81V:%E8N.D&T=(-L9%
M5=>?9Z4@WH!17CT2**`0P`0H37CJF9GW-RD9MIBS=P&"80"9(J1EWB9D?Q@S
MZPQU'<6Q$A[[P$`*;LMH/?P$AUE_%P\R,N\--V:KONYHOHZ/`*7GC(M'0<C%
MOJMEPY(RRH%>52,'*B+A$$`!QZ3SQ`G;V]E>`Y_M>LWIO?Z\M-84U9[GFP&(
MR*5P\F"AD>8IXLZA2Y)C\.OD\+&/\7?J##2+-0C-*55(V5DD$C6G,I8"Q7J4
MZ-Y:<$C[&\)5D%D9*27DIK:.2;N!"$*I&RK]563Q`CE5K#\@Z:.G513059*H
MW#0MP:Q?K&Z;(K&L=R^%P%B[VZW&D\Q3E<MBL'091C*.AW.!8SE>1Y8P-'-Y
M1-F9QNBT:N061%PJ0CI.TY]))<-IC'6=T;D:KABB\"R2F5CJNVD;M+F4<ZE7
M3M_'LESNV*>%H.G[MQDKEG'G$Y#G5DU4BA<7UT`=C3JLV8D,WP_`F.&2J^2Y
M%B6VN\35N7"R-V^.1^^N:--GL<ELD<.%&R,9D;Z0R@R,@F76<DCU%1JH`B0P
M6^CXE2)(1*+B,;C4DVK5BFG'MS,B$9,A7,R9D*W:)E*U:"Y5%),`L3%0UH!<
M-0V-9G[G&?RSK[QP!69^YQG\LZ^\<`5F?N<9_+.OO'`%9G[G&?RSK[QP!69^
MYQG\LZ^\<`5F?N<9_+.OO'`%9G[G&?RSK[QP!69^YQG\LZ^\<`5F?N<9_+.O
MO'`%9G[G&?RSK[QP!69^YQG\LZ^\<`5F?N<9_+.OO'`:YJ,QSTI0D974:5]=
M=^Y2?^9X#8UF?N<9_+.OO'`1/OIF^([;[19[GN[<3#3&WF(02D_D<4M$?C($
MBC'.6SADT2AWS?D73Q:3*B#<5A(BFXL.HHD0IE2!6K<'J]Z1\2W1<[3YBKB+
MS<%VW3:9)'$V[GYL6<:.&I9?%!,R*>)KM7\?*8ZQ:<D5)1P54RC1,H`*B("%
MLMO9J,R/&,<R'!$X(,*GL.Q&8Q%-BV<1;)+&)&-.Z@TFD<1JB1@W)'JDL1`A
M`2+0MH4IP"W<#)1PW`LWR_((UG*0.*8?DV2348U3.]<R43!0KV4D(]!FZ(DV
M=+/6C4Z14U#`0XFH;LKP%:UNJ?;Y#&LJR:4P5ZTD(%[MTTR[''D*VB\@-.YI
M*.28W%H$R@,=0R288+L[R(-U%G)G8@@W(HY*8A09C;K"V3S#!$<E2VSD)K'\
MH>Y5'&C)+%\:1(\R-!_&,)"$GB3DHUBF4AD[27CGI5GBI6JK!TFLX63+2H>F
M.=4.Q&5;C8;"PNUJ2DOD60XPPQK.%L.QU!DTU<>`F-SRC[7-D$&T1:3[2+C3
MKMVZBYY0$FH'0USD"\$0,QX7'VDC!#DV]/778?Q9?*B/`1'O7NW&[3M,.=97
MBJF2-,HR.0@-2)C'4T3'H]IAV3Y/DF12R";)RZ3AV&,X^[*MI)*&4U`3I0_`
M5SW`ZE-@(S\6I'(-HXO*4\AQ).9+(CB&*/UL;Q!IN(\@UW&7,)A5ODF,P$+D
M#5])+JKLP9I*-UA(<[HJA"@_)?J%VH:+.)V6VZ64=XTZRHK"65Q*)>/!<0NU
M&![CG-`+D76DM?*L'RF*;QY2$35<JMS-U2I$13$P+=@MV]N=RW^61^VNW;';
MYSBR6&-ILY\?@(A*89D6G&#6/C'V*.'T=.Q>+/8YTT*JBNJS*H8P-S&(83"$
M7XKU(]-:J6!.R[2Q6'R>895M'CN,,G>WF/,Y!EEF<;A[@89AS%=5B04HF4Q#
M(,2E'+L3J)\CS28-C+.'`I\!T`K,_<XS^6=?>.`*S/W.,_EG7WC@"LS]SC/Y
M9U]XX"/MR1FO"("B<3_[0]MKKUGOI/QY@;K+4/9`#NKYOEX"0`&;[+DXNE2W
M45=]U4;Z51[[=2GU0+Y1H`49KS;TXNE276K.Q[*M=2VJ`5$`%:VOD)7O-0(B
MW/'(/&ME+4X,!^=Z.YG56D::'X@YKS7+:;?M<@`N-*^A!$$[J5-0)=(,WYFH
MG%`'K6I8L['W!KV7(!6E75E>^B5:5/:"%(TUXD(*A%A[19"9--=X-*KH`[.4
M#"`=E7`)^M`(T3N/VF`H+2#-^9J)Q0>Q:EBKL:?S'7LN1"M!%S96E:)5I4]H
M!1FZ$O3BJ^MZEJSL0#L9ZUE4`K01<6U[Z)U[S4`*,WYMR<56A+[5G?8-&VI;
M5#M`!%:E?(3RFH``S?95.*_@W46=]]$KZ50\M]/J6_5H#.PI675CY@R2D<Y`
MN7YDF8ZCQXN)%$LDDDSHE,,I/"FFD8MI4]1'3`+>7;TT2`\1&;[:)Q5>VE5G
M?D4MKZQZJVOU*_4X`,,WYUJ<5_#MN6=^1QIW40'^$"5:>@)Z=P5`,,WYUB<5
M6BEERSL*C1WI740&@"((74K2JE*T+4*8Y-'[+[,8OO\`[SY]M1@TI%8]DN9M
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M;/.,^CMY^GR,EX#(NGY]+93,HP;"%R.7R1XQS.:B\K*FX0<`2,71(H1TD!2$
M('U]]*/+/HYS/A?*X_J?P_+Y>*O&[P[*FUY+)2?UAGV^WTONZQBQX\FTK&*D
MZ=ML],DZX[3-ITT&^P<ACW%)V63'%_NS:;4C]")G]'K,Q;K^28]5M'F2X;MC
MA>>RB'1ALXQQM)C*9[FS2(=80T4R5QB4'/.SS$E$M]M6<;(SJ<:1<J0JF`"'
M7<E*<I1,*G#N,^D?!\URVVXG9<YV;K>;G%AQQ;99.R+YLE<=(M;\1:W;%KUU
MMI:W;.NDST;*^_RX\<Y+8ONUK,S]Z/A&L_!*F8]7'3UTQYEC73F]AGV"DB6V
MW^/8TRQW;^3C=K\9ALO">C\324GHQDEBN*P#%2`*T'6.W!1P<$&:;A<#(DX6
MV:2<)ZG=O=U<D<8'B;B>;Y-X7NC)"TR+"<XQA-%'9S<*/VQSUJN\G(F$:)2<
M3EDRR3*W!QK*MERNB%%LHBJJ%B:S?W.+]'^-=^4]/XGR6_\`;P!6:[*IQ?>%
M?77?=4M:>L]]*_NTX``9KS;DXOO+=15WW51OMJCW@&I2OH@7RC0`HS7FWIQ=
M/6[[57?E:ZMM4>WL%>VOD)7O-0$2AIKG(X#A%E,.KJ$*L\$#$TV',"2ID@$Q
M!%>RY-3L`E;*F$`6D&:\S43B_P"*U+%G8T_F&O9<@%:`+JRM*T2KWGM`(,UZ
MWJ)Q8>Q:MBSL:?S#7T[D`K2KJRM*T2K2I[0P09OS-1.*#V+4L5=C3^8Z]ER(
M5H(N;*TK1*M*GM`(,WYEZ<4'L>I8L[&@T9ZUE4`KVBXMKY$Z]YJ`A;&F^=>W
M!%#0K&\A5WHZ9Q21U;;A4`"B`JV^MI"-"UK41`%P#-T"J<56A:T5=TK1*ZGK
M/==?3ZEOU>`*S=/8XJM/NKNE:?\`<]UW_9P`(S=!HG%5H:E5G=*T5MKZQW5L
MK]2[ZG`!AFZ&M3BJ^?;<L[I6CG3NH@-*B"-WDJ>G<6H)&IIL4EQ3"*4#FI$$
MA.L\J!@=20%(H("Y["JE1`:"%"B<`(02E+P"LXS?GZ:<4/LNG>L["O\`/M"^
MU`:5HVOIW55I6A+@R<9KS]-.+'V72O6=A7^?Z%]J`TK1K?2M*JTK0EP!QFO/
MTTXO^-T[UG85_G^A?:@-*@#6^E:55IW$N#X7&9TUZ%BP+8O:8RKL!`M'VD)J
M$)0;0;W4,%!%2@]A1$/!F:<%DU$"Q1A%JF(&%9X(&'27TS"-%Q$#!HU&\_>?
MSC4*)@5",UYUJ<7WFMJJ[[JK6741[Q#3K3T1-Y`J!6:[:)Q?>-/77?=4U*^L
M]]*?NUX"L>Q=_P`Z.?:EE_S0;1WZ=VG=\[_596R_S[:]U>VG`6PX#G9M'EF;
M8-T#[/99EN/8)E>,PO3?M(X6QAA%S$TYG(Q;#\69Q[%RREG#5BHH9FY3.Y$P
M'3`Y#`4@EH(`[\$ZAD<\W:0P3'L>Q!OFOXL9/)M,A?XW(-&2T)'Y`S8*MHZ=
M1>K.G#7)CLS2""1`N,U;)J.4T3G3*`;G=?=G/-DQW"W#DL0@LZ?Q&'[:()8[
MCN01^*E78/<GW#!X_=9#GDK$0,<C$-45G"NJJ`J$(!2>>(`:_ML>'+FC'N,L
M8<,ZZWFMK1'3^#2+6G6>G2/CK/1Y,S$:Q&LI"V'WC/OMB:&>1C&%A52/\IQ6
M8@DL@BLL5@L@Q'(5H2;AWTOC$@]AS2+"0;'36235,9$X"4W:`\9'(<9O^+R8
MZ;_%DQ>]AQYL7?6:^YARUB^+-2)ZSCRTF+TGXUF)>4O6\3-9B=)F)^R8]8_+
M$ICFY21@8:7G'8L5&L-%OY5RF@W<&7.WCFBKQ8B)5'229E3)HB!0,8H"/>(=
M_&`J401ZU>F'PS&\BSI&%Q.=E,=@<S-'/]MY2?DL=@%6^4(8U+/Y*+8KD+H,
M(N2(F1N*KAJ4YR`0"+%,H"X>L_I?G6L>Z6:JRD*\2;2;%^XV3RER@B!5G99"
M0<,W,?S3%I`N53$<.Q3T]=50J0J6G-P"-/KOZ3X_'&;F,=J!AMDVF1TSV<R*
M,Q]FC%-#3<HD1!^E&$7%06C$2HM4ECKK/6="B(G%(/A3JEZ0-N&./33B,QK%
MG&=QL?N7CR$1M$_?2$ZWE7\M@45.L30#5T"LFK'X^L02E,"S6,`A5-,%4TC@
MY6O67M&.Y..[2PF,RZN4S,5LG()(IXG!Q#&.9;Q$?3N$1H'?96T7E)J#8,59
M-_'QJ3Q5@U34<@!B)*'*#A6ZX]D&DE+PKW)GS::A%0*]B_Q,GUG`MG2A$X=^
MV.DX%!PRFU735%`Y3T*Y=E25TQ3<"B"&!Z^.G[*WZ\1BV824_,IXMFN8M8ME
MM[EZ+B1@\"C)>4FUVCA^5I&I+.4L??I,TW*[<SA=H<GF7(BJ&)?KUV)@L>@<
MQD\DE$,0GE,I;$GRX/D*Z<>^Q=OA+H6<A&MUU9<#3C?<&,%BHB@LF8RX%6,C
M:>P/',.OK8O"92`B96=G'"^4XC$9;`&CMO\`)W(R)<BBH&?QZ#!H8Z4@VFY*
M"R-L[.59%-!J0]JRI%0$A02A](+L*R1A"9)/SF-2\ZX68M8=WMYE\@H,DT]9
MD&*<C$)OHI<8N3418N5BK<LD\<$**FF"BJ8>D[U[[0X\EB!79LD<2F587B>Y
M"\''XFX>26,8'ES1P[;9%D!BS16"98HI$0>MFZR[I,':1TR*$$PE#8.>N3:E
MSMTCNCBSN1R+$3Y$\QYS)O,=?X4U9J0^%R.X60.3.<U>P:;L(G$HPZQ4F^LH
MZ74212`U5#I`SMK?I!L,WESC%,%V]P#<>;?9"S:O9=\EBS91CAA%IA*&D"Y*
M=ED;T&I<>,^9.GZUP-B,GJ1T5%E1T!!:P^D9Z>GQL?:!/SZ4W/-6;D\!^(LN
MM(PW/-Q6;)2JB,D9@4ZRJS1,@HK+%,,@V-4""L9$-@G](/T_I/&L3,9).8_.
M.U`TXF4VZR^XC)SD"./Q$PXDF17<,UAIQ1;FFSA1R0G*)J'4TS%`A@N!C,\\
MRO'8/)8X6B3*>BF,JV1=METW2";YLFX!!P1)XND"Z`G$AK#G((A4IA"@\!O*
M3/W2,_D77W_@"DS]TC/Y%U]_X#7-0F.>E**1E=1I7UIW[E)_Y[@-C29^Z1G\
MBZ^_\!&&\^Y[;9C;#+=S,K9*S$#C#)HH]B8"*/)R\D,I*,(1JR9,7,BS1<J.
M'<DF42B<*E$:`(]@A67-^MWI>QO<7YK\HEV3W-))DW4GV)-K\CF$H^+?X4EG
M$2>:DDFCF.>-9B`3:`V!)9<JBSAJD'G*H@8+88!/,,KQO'LIPI>(/B&28?B4
M[BQD(UQ'(!CLK''>PQ48\B]C%(K%8EJ04!,/-H%.`@7>[J^P#8_<*"VMSQA,
MN)#)\>8SQI",QWQ7'F<+*2<Y%*&E3C+IO/64,>?+J))MUCG00,!"G.)2"&DQ
MWJTV0W7B,CE\;C%\RQ^`<[3KS#Q]MXHQ(>0W'SMY@D"KX;E3^-?*K8C/-%59
M%4R0:"("=H+D1*!@CH_6QLFRQ9%%3;D[.'?1V2N)3'W4#@</'Q,H#M^DYQ>;
M;S>8Q,6>>FT6R*[E-#F44R/V@+J:CE$AP<L7U<;.2^[.&X'\W[YGEN4Y)&Q&
M-STCA./I)-W;*%;H-Y)Z]1R)S*8^6.1REK',N8325>>(*%8@N@FX.4+NQ`3'
MA<?:>,`.3;T]:=C_`!9?*N';P%$E?I$]A4LAR?'<R_&+%PQ#)'>(2$E,8%)S
M4>>;3>9#CCQ%DGCCZ;?J,2Y!A>4Q2S@R!$P<XU(%'S-(RH;[(>IG9U3%\9SF
M5VZ+*LLHQ^1D8`\KB6&-WR[+']VH7`A@$C3^6-;Y\V73B#YG&HF4.X,-4;G(
M@3@$*_77LZVG58"0@I]M/@]S-2'9#B#!VXF4\'@<A>.'[(S3)'')R,V.%KL8
MR/<Z$LY`&ZXMR,E".`![[`[\[=[Q26:1&VN)I8A)8(MA,7DY'&-PL4W=G65E
M6S**C)+&IJ389#%8\#8Y$G391:/-K"#90P7T"T4?`$B6J3&*BL7C&2!4RH,X
M^)!DU1*B[6?I%2;MA323*D^<*+%``"U4YCAYQA$0VM)G[I&?R+K[_P``4F?N
MD9_(NOO_``!29^Z1G\BZ^_\``1[N2$UX1`6J1/\`[0]M;KT7OI/QY@;[+5_9
M!#NKYH>CP$@@$WV7*1=*ENHD[[JHWTJMWVZE/JB7R#4`H37FWJ1=*DNM1=AV
M5:ZEM5QH(@"UM?*2O<:H1%N>&0!,[*6G@Q'YWH[F=5&1`-#\0<UYKEM->H.1
M`%]*^I`$4[JT-4)=($WYFHI%"'K6I8B[#W!KV7+C2M'5E>ZJ5:T/<"%()OQ,
M056BA#D60F(FB\`1'F$.;,43/1*`#1P"?K=0JG<8:&`06D";\S44BA]BU+$G
M85_F.O9<L-*B#FRM:52K6A[@"A-T)>I%5];U+478`/8SUK*KC2H@XMKW53KW
M&J`4)OS;E(JM"7VHN^T:-M2VJ_8`B"U*^4GD-4``F^RJD5_!NHB[[Z)7TJOY
M;Z?4M^K4&=A(S!XZ7%-Q&J6Y?F*9C'!ZK11/))(ARENEY(4TR&"A4[R6!YNF
ME2PH/$0F^VBD57MI5%WY%+:^O^JMK]2OU.`#!-^=:I%?P[;D7?D<:=U%P_A"
ME6GH`>G>%`#!-^=8I%?QEER+L>VCO2NHN%:"*%U.^BE*5+0(80PF*W$C=V,0
MS[%L!SC$Y3<457F,9=CB.38](&B8K%YF"6E(6<3>QKMU%S3"/=IF%(01<M]5
M*U0J9B:_8=W?N>[3_*)]/EV4_JIAY9[7X7A?:[]/U/CU[M/TOQ&ZUTT_>Z^F
MO73U>L7L-M0WQ-UC#/9[9-OC<\M(S,QCS?;/&&V/2TU/04_`3$G)0K=@:->O
M)6$FSL72IRG478N72!C"DL)>-@A[19EL&]G)>%D\0R6%V_:X_AJ6"1<#&87'
MOX)I`1KN1=0+1C'"[CDXI"*JS2*BWL1!!)0A"D$43HS[QKSFO`<-?A<^RINM
MO;=>_%IRY,=JVG'&.8^YTF)B->L:Z_9,Q.+FVWNY/<BTUGMT](GXZF/D_2UE
MF58[DV+/]W$"1640.08X]Y;;R'1>)QT]&SL2J*#@)0Y$W:31^UH?3$H'14$"
M@!TBH2?B_JUAXCE-KR^TXG%.[VFYQ9Z=VYSS6;X<E<E>Z-8F:]U?O1K$S$SU
MZS,V;["<E+8[9)[;1,3TCXQHF3(-BMK,IR1YF62;0[,9%E[UQ#NG.53^W6/2
M^1NW.,)R:&*N'LV^CEY-RXQUN\*1F<RHBU`ZP(V`8*<:;`YSXC&Q"KN9BL=P
MJ+E#%G[I9C`(-),2Y5*HS&2B+YJ9FY$^12K!FZ?CJEYMT@556\Y""4(TWZZC
ML3Z<(2'G-PV>4R260!FA81G@F$367/G[W!\`RG<I_#IHLG)"EFI7&\1>%CFY
MS%%Z[3!(@]IC$"O<1])=T[9#GN,[=P#C,IN9RZ8VOA(20B\4:/<>=N=UOQ:&
M&<-I='*11DV,(7,HHTFJR*Y*DD]%9OS*#1^HU>@EF5Z@-QF\_DD5#;;8C*1^
M.Y#(X\$D^W!EXAT_6BC-TWCCPQO@$VFS*=35!,@NE3"&F(B%X@'7-G]-^&R<
M=M-WO^5W&+<[G;8\W939UR5I&3K6.^V\Q3;2/6>RL>OR8%MYDB]JUI$Q6TQK
MW:>GV=L_ND8=0.[@"6[:?!!H)=2S=2>$1H*&IIUVJ\X1`JUE>\12]4-+_P#N
MW\9_UQN_^X8__P"P_9I/R>?C,W]'7^7/\P$WYW34%-9QMAAB;E`4RHH-MR9M
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MJ6).PK_,=>RY8:5$'-E:TJE6M#W`$";\R]2*'V/4L1=A4:,]:RJXT[0<6U\J
M=>XU00M@G.=?7+1(A:QN*5%Z`E-I(ZU+GJ@4-12WS"4J6MU!$07`$W0*J15:
M%K1)W2M$KJ>O=UU]/J6_5X`I-T]DBJT^Y.Z5I_WW==_V<`"$W0:*15:&I5%W
M2M%;:^O]U;*_4N^IP`8)NAK5(JOGVW(NZ5HYT[J+A6@BC=Y:'IWEH"-H$V*3
MC36BA#FY($KT7HB40=20$*H/.*W`571K:)?-`X`4M2@4%APF_/TU(H/9=.]%
MV-/Y]H7VKA6E6U].^BM*5):&3A->?IJ18>RZ5Z+L:?S_`$+[5PK2K6^E*T5I
M2I+0#A->?IJ1?\;IWHNQI_/]"^U<*T`6M]*5HK3O):'FN$UIKVJQ92V+V"9%
MV(E"C[2$]'*=1*46UU!+404H(5+:'BS"<Y)J(*Q1A%JE0=)Y01TE],1JZ5$0
M[4:^<8>P_:-2B`*A":\ZU2+[S6U2=]U5K+J+=X!IUIZ(&\H4`I-=M%(OO&GK
M3ONJ:E?7N^E/W:\!6/8N_P"='/K[+_F@VCNT[K+OG?ZK*V7>=;7NKV\!;#@.
M=.T^79]@'0+M!F60Q.WV40$%TV[2.AQE"*DW1YB-6P[%F;%B]\;FF<:408N2
M'=',!R7D,!$S5*'`29@N\&;;@9PPC,?Q/"4CFCL\IE3^*<M'#1GC<MB;9R<C
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M02BN+89!%ABESC!YS,7<[BZ2V6-G$Q#[>FQU2'EFR223A"7,1N0@@-W`,^;^
MEAZ=86%QS\8]H9+P?)8`V70[*+8;/Y8T!J\>,G@QKU"$W1>LH7.28O)C(O81
MZ+631>&)&$37?NFZ2P;7'?I4]A<Y@=RYS&=F,SG9#:;`HG*2P">%X,]F)]N&
MXV"XICV-8PA$Y]-.3NPFMQX5TVHD#8CWGF29AE(I\U2!\*_2A=*"*<DUE8O-
MR9%MSD!,:RK&V?3MG<J[P3-L=.XB7$$F[%%JT4?P$@PDF:2K4?-\-<B4"$`E
MX-$_TJ?04JQE'$.WF<B1;R3]&92C^F_)6B24B\1:,Y522?Y(I"0Z1ECY,Y9N
M%%7``.FZ*8=(Q#+`DQ3Z5GH,:KKI8ZBY@<7,ME+_`/&IOL@^:1$E)R\XBGFZ
M\>SC)%Q,O2O'";IU(.3-R%D`8B5MSBAT"'"3<@^D=Z-L9Q':*=EU'B+3>1WN
M(7;7%D]A,E7R:0F,=?L,>RALIC!#BYB'V2*9*DFBJJ!$7Z3D0.J%PE$-8A])
M'TX9/CBV?8-C">7X^RW5Q79QCD\SCF';;Q:[M';3(-X$Y4DUN;FF,(0D1C6,
MP;Y)@UD#,GSN8,1JT0]>!;@-`X^EJZ)I=I#NF@YCE,7)O5VC1XATZ9>#1!=T
MWF6;FU.?<1B[I9W'A8*+1-PY<)2:*94SBHL1,/1M]*?T?M5,K)FD;*8!-XI*
MM\&80T]M(9W-91&-(526OQQ*&FGX$QJ'<L'3!<'9VJ+-XU`IP(1=J=8'>3Z2
M/I.F,#P:>Q=ED.:X-G>XV8;<8@E#;$SJ3)QG^WB>*OS,RP$Z^B7Z17_XV,5(
M]\DT40)8L98[?EEA("7:KZ57I-W*W#P[`,1F))O+YUEN/;;Q,N7;:4;P@[A9
M*F[7:8B[ET),2-P.G'I@5\<.167620(<7`&2('1H^!P2A3$4Q7`SD.BX;G*?
M%&9BG0>+.'#M`Q3"(&1=.':IU"CYISJG,8!$PB(+7&*LWADCNX7$'1FZ944#
M.,>27,BD1PT=D22%14PIIE=,$%0*%`!1%,W>0H@&S8Q[R,9-(Z/3A6+!@V09
MLF31@LW:M&C9,J+=LV02=%31002(!2%*``4H``<`JMF/NT;[V=?A?`%LQ]VC
M?>SK\+X#7-2R_/RGKT;74:5'EG7;[5)_Z7V<!6+JLZM\9Z1X3"Y_<!D#Z-S2
M7R*%;O&<M@V/LX=Q`8A+Y;SDV\S[<'#FS.%73B!;K/BF4:L#*D.Y.D4R8*!"
M3OZ0'"\GRO;[;",VRG,XD-U<3V<R<D.FYVJ?!&1V[T]&P3B(R6#<;JK/$IO;
MI:42=3C(R`J`Q;NW#8'";4PF!DY-]*ST>1N<3N!2,AD<K)0N1;G;?YRZ^8O,
MC,X',MJ<?E<BR/#)0)(S=66D747B<FFS*U*Y1<O(X&9#&=+M$5@Z%[6YA$[B
MX5AVX.`OHEU@V=8#@^8X:X2B7,<DMBF2PH3&/G2CP>"#%,\6\2,"0#ZV`V^A
MP$4=2'4&TZ>#[<2F6XCX]C.:369Q4_ET>G$"AM]$X)M=F^\$Y/S$9)SC2:F8
M]+"MOYI0B,:DY<&<HII6`*Y3`$&X#U]],>:XUN7D^S8N<RA]L,_V:VTSU;%=
MJ'D"U;/]R<SC]NL,E6;_`"&7QR*R7&,9D%[W"S!=VHV8(:C9)8BC?5"OS_Z4
M_IV:XICD@ILW-KH2F);J9*ECZN/;51Y8-Y@KN?5RK$7"LYN9%Q"^2/FV*"Y=
M)QRCQ`BKJ/044,Y?-$U`E'#OI%MC<SWRQ79[']O9KQO(,OPS'8+,G6)X>T@D
M"3F%2LQB&0JF;9P]R6,8O(QP1C%7,BJ.4I'5;@+,%E2ATNB"R_A<?1:-`.3;
MT#EG0T];+Z(N^T>`J3U+]3&,=.^4;;8]EVVL]F;+-8/<W/Y;(L0P-?*V.`8W
MM*XPM.8R&>8LW"\H9V^F=U6C=@"25%7+E0HJD44(14*R[L?29]/FTT7MO&9;
MMY(.L?S7#(S*XN*98_MXH;$((^YDAMU;DF%26X;#((!C'/\`''KHCH(\8]86
M*B+=8ZR"X(`\,J^D@VBP#/)'!9C;O/&,]S>4OU^6PG%3N9Y]B^SF#[KQ4E#1
M[7<4\SD*N3X7E;-JU4(AS#!=$B4@5FFJV,H#]Z2NK[;KJG<YJSVPPIQA)\#8
M;7+R:DM#XLV;S+#(G66L(Y"#>X7EF1L):"QV5Q:0;(.BK`T<@`K-!.W4*H<+
MZ6S'W:-][.OPO@"V8^[1OO9U^%\`6S'W:-][.OPO@"V8^[1OO9U^%\!'NY)9
MKPC'[5XK_P!H>VM][5X(V?CS`W@2UX%%!#N$:@'H@/`2`!9JI:KQ=*ENHU=@
M-*HWVU>#VB4%*?5$OD&H!2S7FWKQ8A4E]K5V%0JUU+:O!H(@"UM:TN)6MIK@
MB+<\L^$ULI:M"#_XO1W,:C20"J`8#FO-<N";[S7!@*OI">XA1,G<!K37!^87
MZ1+_`#7F`?1]]7F\W2!+]'F9;GY3LID$!!S>7Q^Z$+B<#.%G<*Q#,TGD4Q=8
MQ/2+:Q#(SHBFM4`,4I@.8`$#!55/_.;(F9%FP^C#WM42460CQ53W)#PHP`D@
M[,*<K\VATQ>+%%82(:-2IB0^H8"B4P>!?\Z,CYM_T8>\`^DOMW6*%:<MJ6UV
MI&VZU:VM:7$K6TUX`?YT9+S;OHQ-X!'S+J;K%"M.7OMKM4:E:*T[Z7$[[1N`
M#_.C)=EWT8>\`^EK3=<H5[$;Z5VI&E1!2GDJ7OH-P`?YT9/L_P#U8>\`CV5I
MNN4*]A*T_P#"D:5&ZG^D/(-0D7<__-MDV&R*/Q`_T<6].1GR/"\!W:,]<Y\,
M(9B.\^%P6Z08X+13`9HRCC$0RSPMT?53`7C-8`23`MH!'(_YT9/T/HP]W_1[
M]UR^0U/_`+5(>C;^\/E[`R/^=&2[:?1A[P?PJ5W7*/H*VU_\*0K01)7RT-Y0
MH`/^=&2\ZWZ,/>`/3VUW7*-.Q>RZFU):T$4J]U;3=UP6AK&'^<?1QU68<D^C
M/W@=#E4JMDQ$QW-!`6',,4(E)DH([9+BZ,3PE)45`!(#E.8`(6H"&OV$ZWW'
M6)_QB?3^TIZ_;\TP\KK-=KPWW<E8GA\<_>C377<;GK7I'W9_>SUZ?&6\>?YS
M1.(6-&A]&#O>06J**90E-R/#7HW-E#I'<,!VS=F1`^HB8`U3WI@80$+RV;!#
MTB=-/^<9V]ZB.HG9GIW-T-9[A4WO7O!MYLW#3BN[<'.M\?FMQLT8X4QDYN,-
MAT$[590SR9;JN4D3ZRA$52D`IC$`H?L[.6:\_37BP]ET[VKL:=KW1OM>!=0#
M-KJ4K:I2EQ;`#%FO/L7B_P",LN:NQIVNM*^CP+J`*%U*5M/2EQ;01219D&;D
M=>,`MIO]U>7`2]6WM*^)YP%%.HU#M`WE``#5Y+A\?F<>>(S#'\*RN)4(]2/&
M9+C:$['G2D&#Z)?)G92AW38Q'T1(+-5@$M%6ZRJ9JD.8H@SS[&[8J2T+/*;4
M;-*3F.*X\MCTR?;7'S2T"KB7/!BJL+)&:B[BU<9++/`CC('(++FE=&S4/<$=
MRW3KDK^=R&7C]V7T(UR&<?3JL0WPS%))!DXD](7R35Y+,W;Y1%10RYR@J<]I
ME"AZ4IBGZILOJ9BV_'[79;GB=KGR[;;TPQDG/NJ3>N/]&;5QYJTB=(B/NUCI
M'SZL&VSF;VM7):(M,SII7X_E@B_5OS4U-3>Z2&M-2W;W`PJ!A3U@)?&'`+@6
M<VW74O3K=:J"U^/J?L8].#VG3_2=[]G_`$_V1^R(T\_!6_I;?FK_`&'B/3MF
MI%VJ2F]DD8RXF,H8FWV!E"U,&YG($*I%J]IQ7=6"836WIWWVJZR/J?L(C3]1
M[3X?YUO?AI_T_P!D>FFGP]*]K\%;^EM_)K_821CVQ\"RV]:;;YE'XGN="%D,
MLDY0N<8A%2S:5>9U.2<YE(J0SDB\0BV?&R:5;%2!(2\HLFD>\H*ZD%\I\@R^
M4<U?F,N''@FV'!BKCI-IK6FWV^+;8XB;S:TSV8JS:9F=;:S]C*P8HP8XQQ,S
MUF=9^<S,S_5DX8[:;"8QTB_8[>[6,'R;;$V1GD=@D2S=`SPEXSD<4:(N$4BK
M)ML3D#O5XE.X2QZRJ9T0(8IQ/'ET_P`A9KS-1>+'V+4L:NRUIR.M95X:VZUS
M;6M+DJUM/>`0LUYEZ\6/L>I8U=A4:,]:RKP;:B#BVM:7)UK::X$#8LWSKZYQ
M%"%&-P%:/0$#Z*.K03/SEM-12WL"E2UK01,"\"S?95>+K0M:-78=M$KJ>W![
M!$#T_P!)?(-0+9K[O%]WN5WWT\G.=UW_`&<!@2S?;1>*K0:5:.^^BEM?;G=<
M)*_4`?*%`#%F_.M7B@[#VW-78T&CC3NH\"H`(HU[JT/2E2V@C:%F])QIKQ5!
M=R6E>U>")1YJ2`FH//#>`*BB(TM\TIP"@B6T%IRS7GZ:\6'LNG>U=FI7GM&^
MCPMUMS:ZE*VJTI<2P,'+-^N::\4'LNE>U=C2OB&AJ6O"W6B9K?2E;%:4O)8&
M3EFO7-->+#V72O:NS4KS^AJ4>%NMN:WTI6U6E+B6!YN"S.FO:O%@6Q>RYJ[$
M0+1]I7T>$N$H&;W4$*VJ4I<6P/%D6;Y)KZ_%5Y5*@\H\I727L$0%\81`*H5[
M>VT_;YQ;05"6:J:U>+I4UM6KL1`*KV74>!40`4Z]W<;RA0`2S7;1>+[QI5J[
M[JFI7VYWVT_=KP%8]B[OG1SZ^V_YH-HK[`,!+OG?ZK+K`,(FMKW5[:<!;#@.
M=NTV8;B[:]`^SF=R0X'D,5CO3=M$^+CZ&+R6M(1ZV&XNT:,W;F9SV/C0,DR=
M%%RJ:A3&(<4TAJ5/@'=@G4ME><[KLMJ8]&&9RLACN5Y(C-2&W\JSB56>-3;&
M*;6J);FO'H%R-N[4>M`5127(@E:X216,9-,)K92<U`[C9"MFN5X)&&>XQMG#
M1CH6#R':/)&;RK/V$1#HA+92IS,O)2)@2;I)J"HX44*0A!-Z:[AP9]Q-JX*7
MO:M)M/;$SI6L:VM.FNE:QUF9Z1'67DS$>LZ'3#R<5N5&DD&#O'LJQ.99.4VS
MIQ!*.X#(FC&2(5*2CDW4DX;2\*NN2]J[)>W=$*59`QTCIJ&N;O:;C8YYVVZK
MV;BL1W5GUK,QKVVC][:/WU9ZUGI:(M$Q"MHM&M?0CS+;;;R8;)3V=87M?-(X
MC,-]PV<ED>`1<R>`R3&@=R#',6*CY1=5G/PHK++(/4A*Y1,<QB'*8PCQC/5)
M8CZ0;8Y[BC`9S&,FQIS'8T\F)G;^0VA<K2N#)XVZ:+/X>;A_QC;'B%8=P$:L
M54Z"3(3.FYTE3"DN+<'3"]=&R.=3A8F$:3,RM`)YSDCM[)[2OX@8)+!<8G,V
ME9-C'Y%D3&=>R+PL`NDF#)L=5%Y8#L6QEFVN&F<=='32PCX^8!)H+2578I1S
MA+;6'1%P[G)Z+D&2:IE\W;A'B]S!X54ZSH4$$G2(/EE"-UV;MR&^3ZU=E2X&
M;<+$HN1FFLCD>4X-#1;/:9YC<SD,[B3=CDRD:@WR+((95-L_E<M;BB"I=9)T
M\776123;OE4`5Y7UK;&X1N-F.V$LG+!FV+R0AEC5CLS.G:&DG#:/.U5:R[B9
M9LLG?RR<BV!N1B=V[52,944P;MW*J`:J7ZV=D8'`\3S*;@IA@;<R:S/&XS%#
M[+3;R>7RW!U6,'-PN1-H^2=IQAUEU6:#1VZHU?M5FZS<ZK91%0P:X>LS;=#;
MHFXJ.TV1(P++)D8J59*;:P)7<'$1V+[CYY%9T8D9FLFT>8U&.=MW:2YVIU7,
M8Y.+@4]!,RQ@72G7AT]MV+>4(:1F%6:\.TCDF&S4X]4;N<J;HN6K9!\2848L
ME%7C-9HY("H*D?QJ[<2&62*0P6+V3W#PO?7#'F4XA%Q"46CE*:<DREL-;L%B
M9/'Q\%.H/EFJ4T^(I(LTG[4Y5E!3=H+$`BA$EDC$*$P!C3<J942QV*E2(X%T
M1(,<("9'0N#.Q<E(#VTK@79A5O`+M01-6O;P#?S#:W#MPH61QO/<*VXS;'I=
MJ=A*P>68+&Y#$2;%1TU?*,W\=+*NVCQJH]8H*F34(8AE$2&$*E*(`X&^,MVB
M39!K&XJV09N%7;1%OC9$4FKM<ADUW39--Z4B#A9,XE,<H`8P"("-!X#Y3Q=J
MBHBLE&8FDLW>'D6ZJ>-)D40D#E5*=\B<KP#)/#E7.`JE$#B!S=O:/`;O3EO=
M4=[P<_UEP!IRWNJ.]X.?ZRX`TY;W5'>\'/\`67`&G+>ZH[W@Y_K+@#3EO=4=
M[P<_UEP&M:DEN?E/;4=[(TK[0<^Y2?\`TEV<!F0A!E@1"4;8Y)`W%<6X2$%S
MH("Y;JLW(H\P^4TA<-%SI'MI>F<Q1J41#@(SW.R*,V7P/(-QO`,<7"!0@VO+
MQL5%0BRQ7DXVA8Q%:6DIF-CHZ-8.I]10ZJZQ$FR1U3^B(&"KV;]<^Q^+9Z.U
MN0Q^1.\@<,6TGD:([)9$YAH5A,883/8]:>E5I48>^38.6B-HK"!7SQ!`Y@64
M(0P7!V[R-OFN,8WF6+.H_P#%K+,-Q#(\?*,,JQLA)F-._BTN21EUTF@ILUR`
M*93G*0?-`1`*\`T=\-R9#:R"QZ9?X['95"RN1J0L\8K4P'QZ##&<CG)K(.06
M<N3S)6L-".$^32L5<BJ"8&`##P$-X1U6[2Y='9\ZVS:'G6F`Y+MCB^3#$;:*
MPS)R;-,K:81C\K$O)')(YA/0V.F+S!U$#J&!@@!VA5@,D!PB57K5P#\7(U4^
MU#(6PP>8@I#.8W"F4?$2,:N[5D,.([D<L:Q,B\?M(UFXD#1HNV;<[YFD91=5
M1,H@],>ZOL/R/<S#\78[>G2<Y3DN-QT3ES^!@&9VB$YC(GA9YRS2RA]DK()!
ME,MV$<`-S&<MG2ZQ3$9MUU.`O)$$EO"X^CJ.`.30H'(.1IZV7T?$NW@*Q;K=
M3D)L]F>20FY[!G!XM#8YBLE%Y@WB7V4K9`YS`<M/^+K3&8YP642?H#M\]4,D
M4ZQW`%0TR',80(#'RWJHV_:87A>Y9,('),;S##6V8Q<W)X7$PY(S'F6XN*8Y
M(IR19C*5I9%>`?9"68*DV;.2NTV@F9BNN=(!!ONNM[$TLD59.=O9-64C9/+(
MV-,C"8V\R=RI%PL\[9@PQY/-39"S<Y6.$&0*BH1(R"#B*5<"5-^W``E'I_WR
MA-Y9#*XW&,1CL+/BB6#J.5TV,&NUGF[DTO&MO"GF+Y!(,GT#"JPBC=DX.H0K
MI+UQNF#>PYP9H]<L(EGVW^W[K$,C:R6X,U!0;)=6/A%DX%Y*Y7*XFY3RM.+S
M:4/!G;NF"2C0#:GB1'%4*D3$Y@O/IRWNJ.]X.?ZRX`TY;W5'>\'/]9<`:<M[
MJCO>#G^LN`CW<E.8\(@+7<9_[0]M;KH]V-2?CU`W@6DH6TXE[A&H!Y!X"0`3
MF.RYW&=Y;J1SH*A5*Z@C*#01`#T[Z")>^@W!DJ<QYM[N-'TE]L<Z+4`%MJ6U
ME#6W`5:VM:7DK6PUX5^Z@,I3P&-VYSC*Y_'8;&,1W#_&'))1^R<-V[>'B]N,
MY<R&BJI-I)IOG0)+)-"F%34<+H)@10_FJA^4;KYZY?\`+A[O?2/_`$?.\>_*
MN&;W;CRL!$9;([X8/&IN]C,3QS((>*?;+%ZOHI603<Y`XAIPZR[2.=-UWN*I
MG3\?0"/3Y=0/T@[Z_2'].O3G,0S?-,UBI=C+X;`Y,TF\.-ASW%RP+K<;%]O9
M-^>??[CQS5HT@'>1\\\JF*3:,*94JBRB(H*@U=LOI4.F7=/>"-V:@<B7:3<E
MF.;80CD$RIMTPQL93`<4G,QE'BQ4=V7^2LHJ5A\(G#-%5(V]($FYW1$$7+)5
M\%UB[R;94)?O)M`(AIWVY3CY0-0&FK8`Y4:VX2KVUK;>G6MAM0,!O)MGYMV\
MFSXCYE],JQ\*T!OJ6@.4FMN$JMM:TO)6M@W@!O)MG0*[R;/UH6ZF4X^`"-$K
MJ5RH:`(@>GDJ7OH-P-S&=S\$AVLLTD]T-L(AR;*<L<\M)S\0S743<9#)*)NT
MT7,\S4Y5R40,F-IP,2@@H</.$'&.\FV=!IO)L^`T&E<IQ\0`:*6U_P#6H*@`
MB6O=6@^4*`#O)MGYUN\FSX#Y]M<JQ\:5!?3N`,I"ZT3)5[JVF[K@L!^QK]2<
MCFTO!3F.2T5(M^:C).-1-(QSQLJ5T+9RV>LY@[9XW-<@-Z9K3@0]!"\NF#.P
MA*9&0W)H[B0_\09'1I&._,*.,06AK?"WKIR&,WO$M@'!-2@%O+IZ_8:^YN==
M/\HG^XHF'E?M_A>&]N+1'ZGQZZS$]?Q.ZUTTB-(U](ZS'QF3T8(R_A[33=19
M!Y-,"71CH0*?1=@2I0DTQ$I3F;U#S1$$U`[-0NEL$/<WH7Z(3H>QOKWF_I(8
M+9?#V74M-0"[$9'PQ8^'1V9N5I4K_>"*P\'I(F/W;G(ERU8R$RD4BJZ2*ZQ"
MI.WCERH'2XZ<SY]CN,"NIIWQSHUM1>:-])0MU@';W4I=IJ4IJ%TPR9.8\ZQW
M&AZ>RZ.=&I476G=24+=:!D;J4NL/2EY=,$,DG+\DY]M1PEL,-H1SJZV]6T*A
M)&\X"BG4;>T2F[`N"T%VG,>ZXWT?^'.O*:G_`!3R"'[P^7L`TYCW7&4[*_!S
MKNJ6O_%.SL`?WP\G:`"<QV7.XT>TMU(]T%0JC?2LF-!$`4IWT$Q>^T;@"IS'
MFW.XT0\R^V.=%K06VI:(RAK;@*M;6MMY*UL->"!5.8YZ.N=Q@T!;4$L<[+<0
M$V.N!*R1P(902K6"(C;>2H&L->"\B<P%E[N-&FEJ61SHMU.1UK*RA[+['-M;
MK=1*MVF?5#!$Y@+-1W&&II:ED<Z+=3D=:RZ4/9?8YMK=;J)5NTSZH!4YD++W
M<8:FEJ6QSHEU`9:UE90]EXD<VUNMU$ZW:9M4`J<SYM[N,&FG?;'.BUH#35MK
M*&MN$J]M:VWIUK8;4!`U3F0?/KW<8(48W6QKPHB8$4=40$TH(`!J*6AVVW%J
M(VC<"\$YCLJ[C.X*TCG05&B=U`\4&@"8#T[Z`(=]!J&=.8]UQOR<Z[Z?_6GE
MX#`IS';1W&=PTK'.AH-%+:AXH%0`PDKW5`![JA0`R<QYUKR,#T]MT<Z-01!Q
MIW4E"W6B9*O=6T]*7!8"-HG,"DOINXPH"\DM,#QSLPE'FY$""<0DD[P!0R(C
M0`J4AP`:G*8@+#)S(WV.XPM=73NCG1[:@]T;Z2A+[!.VNI;=IJ4MU"Z0!TY@
M;]-W&%KJZ=\<Z-;7GM&^V4)?9>VNI;=IJTMU":09.G,#?8[C0KJZ=\<Z-;7G
MM&^DH2^R]M=2V[35I;J$T@\G"<QI+VNHP`TU[`-'NC"`"5[I`80DPNM`[>Z@
M!=IJ4IJ%TP\F:<SR36CN,`>52MK&NZ`.DM94/%"B-MR->ZMA^Z\M@*A3F.VU
MW&AVFMK'NAH%5K*TDPJ(`*=>ZHE-W7!:!IS'NN,IVT^#G7=4U/\`BG;V"'[P
M^7L"L.Q=WSHY]>)1/\T&T=PD*8I!-\[_`%65$I3&.8I:]P"(C]7@+8<!SRVH
MR_<7:_H%V<W`6>X1D;/'.FS9]^ACX8>[8'=,UL,Q5L@U>R<QN>RC*-F3D.86
M-I%4$ACD3J)41!UX+U"Y[F^[$=MJ#"*BWDCC^93,=D4AM=-(-5(_&9F+8G5!
M,FZKMVQCYE!ZW<%YL&K@AUD$3H"MK@V!E]7S$R^W&],1NCMKM1U#XS-8)M='
MS>W&8DD\`PZ5AQR[<)ZN^D9I3YR9"-D,<Y$S]FX:-!=$=HHB@9%4I5@W/C_+
M;S@^7P\IL-WGV.ZQ3,US8H[KUZ3'2O=2+1;7MM69[9K,Q,3&L3;RXZY,<TM6
M+5GX3Z)TZ9MT3[P[>QF11T9B6(^`O<IV_?8GBZCZ<@<9DL"GAQA[!1TBK$86
MFLWC#QP(E!!BFW(4@`D8Y*#Q;Y?C>3X[<8[\I6\9-U@Q[FEK3$VR8<]?<Q99
MTM;2<E9B\Q:>Z)G2T1+W'>EXGL]*S,3]DQTF/VD^3S^3@X.9FCJM7A(B)D90
M[1",7UG18]FL[,V1K*B&JN"5I?JCQJE;FHWZ_-H(*1D9[<7:?*\'W/>035AE
MZ$7LY)9AD)8%&9%E%1<O)LG<3ECB.(WD"/R(/8]!%-LN)R7AYQ@<N6_2#8C@
M6;97A^8;;YM&KXQD.4XP\E6>&-G[:1>H2N,1V.&CSK95'-W;?.DGS]8;5S"Q
M+!+`N!@.D<`\GW7WLK)8[(34Q@^:*8W"2;5&85FMGTC-FLW'.$7<8@Q37S)9
MM*R+1YCY5D3)&`$Q8IF(;5%J14'8?K=Q]S@J.;P.*+N#L]QE,&G(*?C$\9DF
MD[\UT[N<L;&SA+S'XSSD[&Q@QD,RL9.)>3=IH7(@H!C`@A_I!=O)X';\<4W+
M0A63=Z\BY)QM!/N7SY[%L,AD91LE$MYY9:-<-H+'9!R4RB@&,FV72."2Y-$X
M3;LIU/8OO?+HPF-L\IAG[[$E\WCTLLP!UCY'V.M9=CCRTDBX)E4FB8H3*ZC5
M,AQ(=<6YUDKVVDJJ%E"-Y%,I2D<QA"E]*4D4N4I>_P!*`2H`'IA_?X#XY)Z!
M`3!6)TRJZX)^#JV`OK<QK`7Q2T%>8\^[OO\`.[^W@/HC612`P).8Q(#G.J<$
MXE8@&44,)U%#`$KYRBAAJ81[1'OX#[TI7W<P^3%_ZUX`TI7W<P^3%_ZUX`TI
M7W<P^3%_ZUX`TI7W<P^3%_ZUX`TI7W<P^3%_ZUX`TI7W<P^3%_ZUX`TI7W<P
M^3%_ZUX`TI7W<P^3%_ZUX`TI7W<P^3%_ZUX#6M4I7GY3V\QKJ-*_!J]/YJ3N
M#Q0!#]\>`V6E*^[F'R8O_6O`13OAN2MLUM7EVY,G&_C0RQMO&BK!QT<":[T9
M:;C(),5EG<KRS:/:J28+.ECU*@V344$IK+1"M&;]>>WV%[B*;7RF/;DR,LV9
MMWL])L-GL@6Q2(C)+"RYG&N7F0.LA0B3)231VS:`"BB14GKY%!42+&!,0MGM
M]DQ<[QK'<XQ]VBE"9CA^)91$)/(4[5RC%SD:>18)+M$IIPFU73;KE`Z955"D
M-4`,8`J(01U']5"73E,8?%3F'9-EC7+HV3D4Y/%,:<RR3$8;*<(B9=@X:I2H
M*@]:8?DDKD)`,)2.&F/.FY3`NJ@!@:R?65C*N#3V;X[B\P=I"S&%8^W:S,##
M8NWR=[E,T\QMBTQ2;)G$M#SAV3Z+710.10&#NU-5!R+!3GB!'\GUX,V4/SC;
M:EQ*I%#,F6FV>8PC$.7V/S;Z.?(1$X\R)&(F(9>/1;R,@_1-R[)L_0`P+J'`
MH@\X/K,99!N7BF%-<"?%:Y7D\!#QN6OF;:.TX^?@3R,)D+C'GDH&5-231))!
M..0%J+A5HJZ=+@U;LW`\!=:(2E/"X^U\QIR:%*QBXC[&7O$)0`'@*&S_`%]8
MOCNXV48!E&`9S'J8=-YE%/)I##2S+)5[BV1C#P@PUV21IYMUEL*8TDT09:KX
M$P,B5!0Y5!(&\S;K1AL*0A><V\S.0C)+%8W(BLX[!59&<A5#YU)86X:2V+P^
M02ZC&&Q5UCSEU(S!%E(UH4&J9#JJ.V]0^DNKN6=2F1A'[323X<6D,O3D0001
M-E"K2`8ND&+MI!I/5;93)I%E'M4X]P\;NDVDS%NAU$5S@@#WV)ZA?GQ?93'L
M,81Q$^(EPA<KL%(V693[:9=3+(%HIS"RZR:D`S<Q"A&3A84#2")M=%$J`E.<
M+4&8O#GU3JQ!E?6O7#0ZIE*MS*G0&\90350,L<2>I$XT[QX#VTI7W<P^3%_Z
MUX`TI7W<P^3%_P"M>`-*5]W,/DQ?^M>`CW<E&7&(@*2#`M-P]M1-\%+FN(&<
MP-Q`^%@L,8.XW;3R#P$@@C+=E7[`>TM:1:X5`!2NI\*C01`IZ=]+@[[1N`*C
M+^;<_8#2RZD6N6Z@MM2VLJ:VX"*T[[=0G?8.H&KF<>')(:3QW(#1<I"3D:ZA
MYN.5C'*:4A&2+=!G)M#&)+WI$=M3.B`(#<36(("(I#J!S5W+^AC^COW9WIZ8
M]]\OZ:=K0S#I+@XW%]J8F`Q=/'\&4QC'FL<EA6/9CA<>])!YE$[<O&SAWCR$
M@FNG'.5RC15,ATU@Z)RF'Q>0KI,LDA<.R!LV1C'"*4MB#5^@DJRDF$@!T$WS
MET1%5.1CA<("!AY=8$5`*8R-RH5"ZF^HK9SI#G\*ELLVTA,AS#-H?=K+8E[A
MT1M-`Y."6W^(8J]SA\93.MQ<2FE4YN+2:QRCQIS:)%5(YFY/JG9(O0C?%_I.
MMC\NW<PS:*%Q+.%WV;9'MW`164+XYB+7&RI;D8^RG<?G7A";A.\@8P\@H_:-
M&ASL;GSB1(9J#ANS=K@$REWTW5?R.1)PN&;2'BX7-LUP]LM,Y%E+&3>!A68/
M,/</W+)AB<JT9FD7$2NN1(KA;3(LD43&,4;^W_[M?%=MM=K;D.0Y/\9GV&TW
M-HQ;3!;'7\5ML>YBE;7WF.UNR,D5FTTKK,3,1I#6_C,\VMV4IVQ>T=;3K]VT
MQ_!GY/LN\N]0V5PS8_S@3K_ZV9J%1,#2M/\`U%&@"*QJ=_8)>^GG4S]/?"8U
M_P`?YGI_H6V^&O\`I_V'XO<_P<?\J?YJ-\EZSL*V"VYW@SG=EKCS)MMX\QG(
M%8.#DH!.=G2[I9T[@"+,/QWDMNXM!C&3;@1,LNN!%&H"H"RB@@4T:Y;Z=<EA
MXS:<IP&+?;_!N=QN\,]NWG[EMM>L1&N.V2-;TO%IB9B:SK6.Z(BUKV/=TF]J
M99K68BL^OS_+HAMU],CTG'1BUH)#))<LMD.Z6-HB_B<$P[EG.UH',[>OT<SW
M,@GS1GD315!\Q2,CSR46<SMZW:))K"EH/]AO-/\`5/(_]WR_S5W\3M_Z2GYX
M=!<7WNVZR7%L7R5[EN$X8\R7&8'(E\1RI]C!<DQA:>ATI7P*?)%98_C`EX@[
MU-%R#9PNAJHJ`FJ<IBG#ROA'F-XUIQ7(3&LQ_D^7UB=)C]'X3&CW\3M_X=/S
MP].GKQ!UL[B;EE,PSMLZ-DSEF]9Q"H,G+=SE>3K,W+8B<VJ0S8Z2[<P6J"!R
MIF$!#4+IQ_=[3=[#<WV>^Q9,.[QVTO3)6:7K/RM6T1:)^R8B5VMJVCNK,36?
MC!TX.C,\_N321CO.W"D11K$./6RFQB"T2J?#/KQDC*(7&"R_2/0"Z@:>GV&O
MN;G7_M$_W%$Q\KFD[3ANR)B/U/CUUG76?Q.ZUGTC2)^$==/G)[,D97D&H)/F
M*0<FF!`4BW!Q(?1=@03`$@U$0*=1N(A801!(X>;JE%+8(>6'1EQOL?L"UU=.
MZ+7/9=SVC?26)J:8*-[J6WZ*E+=4ND`9&7&^Q^P+75LNBUSVUYS1NI*DOTP4
M;W=UVD>ENH&D`9&7\ZU^P`!OLNBUS6U%UIW4E2WV`=&O==IG[M0-,$<@C*<H
MYN>,CIV&J0L8O>);E;2@;GG`7`!DZCIFK8;L"X+`6:,O[O8>C_PM?NJ:G_%?
M0`0_=#ZO8`",MZ+]@/:%?@M?NJ6H?TKV=@#^_P#4[0`1E^RK]@/I;J1:X5H*
M-U/A4:7`52G?2XO?:-P!49?S;G[`:67VQ:Y;@`6VI;65/;>!%:=]NH3OL'4!
M$HC*@\C]1ZQ.8-6XQ8M<I1*!&/,%#X05TS*V+6")PLU"U!33&\%I$9<++W[`
MU-+4MBUR7V\CK65ECZ>H";BVMUFLG6[2-J@$1EPLO?QYJ:6I;%KDOMY'6LK+
M'T]32<VUNLUDZW:1M4`J,N%E[]@:FEJ6Q:Y+J<EK6UECV:@IN+:W6ZQ*W:1M
M4,%1EPLOD&!J`G?;%+EN$`::HEK*GLO%->WOMU2=^F.H")NC+`\>B+YA6C(%
M!\*7*!S`DE>)!\1"@#:I0+E+;RU]*('!<",OV5?QX^EK2+7"H@"5U/A8:5$#
MT[Z7!WVC<&-&8^,(_N^*E^^E*_TMZKMX`%&8[:2$>'?2L4X&@T4MK\+A6@B6
MO=6T>ZO8`*,OYULA'@(WVUBEQI4%[+@"6+=:)DJ]UUANZ\+`2M49726TGS%,
M!=2-H*1:YQ*<7<D`',(2#:\NJ=$U*!4"&"X;P.0%1T9<;['\>6NIIW1:Y[:\
M[I74EB7Z>HWN]+=HG]+JET@R=&7&^Q_'EKJZ=T6N>R[GM&^DL34T]5M=2V_1
M4I;JET@#HRXWV/V!:ZNG=%KGLNY[1OI+$U-,%&]U+;]%2ENJ72#X71E137H^
M8V"1:THQBYA`H@]TRB/B8@82E40`1M\X4C]@:@`F'@T1E^3;`5^P+[63M`T4
MX&WUM;3`P>)HUL`R-?-)73/V%O`$P5"C+=M'[`.TUM8M<:`(K65^%0N$H&3K
MW5M-W7!:!HRWH/V%*C3X+7[JFH`_"OD$`_<^KV!6'8L#!NCGP',!C!M!M'<8
MI1(4P_._U65$""8XE`?)4:>7@+8<!SVVARS<W:WH*V9W!;2F'9*.-]-^STBP
M@38DZA==!7#<40;MWLP_W(29$*R9.?7EA!(%!3$Y2`(@D(+=F>J#<;>+<%UA
M+-EC$3&E;3KB/RH^%Y'IR)85Z#1420<AF["58^'KH*M94KHB)F#Y9FFGS23H
MK@H3/-[:&W%R[+<5W(E&\W&K8AMU(E_%8F8;>NTEH[)-PE&1DY;'<^+.)'35
M,I>";I--8A[#D$H#<$C85@;';QHSQ/%'+IO"L6CUPV2FI+)\L?E4?R/,N15F
M\JR:9FG!3+G$2E47,5,HVE`"@``#HG7DO"PDS,D5;OSQ,5(296*,<J"KTS!H
MLZ*T2$K\Y@4<BE86@"-1[AX"ASKZ0;'8YM%J2NV.[48\?0+7)';1[@44VY.(
M<-DEB.4EEMQB"Z.9=V@DFDH1LJ*BY2G*FH4Z90TB?TCD$J:/;DVNW-.]R!8[
MK&$0P=4J3['/@D[>:E!7R1!W'O%T9!82L6R#]0ZK0R*:BBRB1#`_"=;C:8C'
M;S%MO,X<G0,B"<AD^*H8]B"*!)2!83DI*Y-$9=EQX^&PUID;=]+N"LUBM$$G
M2-#/&;ILD#$)])%A2D'%N&N(YG,9)*OY&(:QF/86_E,>=/V+N99,9*/R52;9
M/GV)Y2$01W%/0BR.7,:_:.3M4BJ&`@;]SU^0V/1;]]F^W>X6/.V2K95.*88:
MVEWKV*DY1-A%2#)N[S.#?2"BK0XNWA&K=PC'`)&ZZX.UD$%`WFW_`%DP&;91
M"1C;;'/HO+<E/CD+).R[?Q+M"%CGTH5"*5R"<2SUL\/CD4[R.XBZ:*K9PLH^
M\/YKDWQT@7+]9*IH3.<HB]M\X?XY@DWB<`^=?BBNK+2LA/3&3Q\T2%Q^$R">
M?.C8JR@$%G*!Q3=E<O>271;.FZQ`!A/OI'<#\'?2>/XCGN0NF!<G37CF^(Q)
M&Q'F/E!%LFME#/<*3Q%!C/2@*,V;D7HD<N4%4$2K.BE;G!]*]7\^VW>0V@?;
M8RL7*/=R281$3DLV>,(/)H%6=>01,SQ=\8RD?)<LK#R*SJ,7<LW*"3'S5%#.
MX\KL&$I](]AK1UD;=_MEO>9+'W(T=8_M`YRPCR,%Y&1A)`48+-W+E!P25D#M
MW30I%EHY5`R+S0=`=LF$C[7];.)[K91C&+PV);FPZN4Y3+8:VE,DV[91,4PG
MXC'YK)EVD@N3<*0>%`\5"B8%$6SA)-1=--0Q#Z@$"Z&C*_&#/Y-4_K'@#1E?
MC!G\FJ?UCP!HROQ@S^35/ZQX`T97XP9_)JG]8\`:,K\8,_DU3^L>`-&5^,&?
MR:I_6/`&C*_&#/Y-4_K'@-<U1E.>E*2#2NHTK\&J4_FI*4^$>`V.C*_&#/Y-
M4_K'@(XW>SV5VFVPSG<@(.;SE3#L>>S:.(X=C$C,Y'/KM@*",?'1\>Z=.SZR
MAPU52IG*V1`ZYP$B9@$*QY_UR0>W^Y[K:]YMUO%,NXA,KK(<JB-GI@V%Q;!S
MB'XVQKPF1O,I:QJZ;X'#-D;54;`V>O4TEA(H!R`%J\!R93/<=@,YB'"C2,S/
M$<3RF/:RL(=G(M64]'J235N^9EF')6KQ)%P`*I@JH!%*@!C`%1!9GN03>$X+
MFN9-VQ<B<8EB.29,WQ]BP63>SCB!AGLJA$-#E=N3%<22K4$2""9QN.%`$>`K
M#(]5.706,SDK-[4ST;,XQ)8-#S$*ZCEV[)1_EZ4XY7)"S!7[D\@6-3ABL6Y3
MM6YW\V[;M`*DFLFZ,&NG^K?,8I^TB6NTL@J_>QN?JIH2OB+(#S6#RN41XP+4
ML2UR):3/)MH!JX.X0(9-J6;8@(*@=0Q`^X_JYR=?=6!VQD]KW$6:5S&*Q-U/
MG>ZB,:$E%J.D)4L<84W\@VE'IR%C>7*J+F/3=R"_*-V:H"%QXA&4\+CZ2#0`
MY-"E8U2OL9?_`*1X"*-Y]T,NVJ:X>[A\/>YZG/Y&_83I86/<"YQK&X;$,FRZ
M7R`&J;I0))<$L>*T;-C*-BKNW21!5)7@*Y;C=;DGM\WQQW\U\U/>,XJ.62L0
MV;K,\MQID.;2&%-V[K'`7D/&74C(1ATFI(YRZ46>*I%$A68J/T@VS?JWSQZ]
MR1"/V;D7:>,/LK1?LB&D_P`9G#2"9N_!Q:PJ;!6/).9%*%CDBQRT@DJBRG8]
MX4ZQ#KIMP?&Q/4'+;[O\HCE\63Q`N)!ALBU=D=DFV61HSCB:14>QJJ*K55*#
M!S"F%BNY2;K2+<P.2($2$HF"(LFZYLAQQ\HP^9Z7?NVL0$A)1R#D0F(Z0,_R
M1HTQT8U,''B,U/H8^*\41HJN1TF)]8S41:\X#PP?JTR>9S$,*SS;65PB5/"X
M#($2B8/)\_=MG^?/L9CV;*;88^R3-C3".<Y6B5=[(*-T[6SA0I3))'.0/`G6
M:JRA<ZR'(=NLK:1^WV(X'DN01.,8^XS7-F\CG<N$,TQHN),92.</7;999%;F
M&2[Q'ECBJMRY;-0'+L-U;Q6_&0ML598=N)@TX\Q[*LJ0;9[MZXQH/`L;RMAC
MC1TH5WDZL@FKD;.6:R+,IF@(J-%1HL8Q!`0G3<E"6\(@*23(M-P]MA-6*4-<
M4,Y@;B!\)EL$P?PNVGD'@)!!"6[*R#(?2W4C%`J`"E=3X2&EP%/3OI<'?;YP
M!4)8!+=(LC`%EU(M0MU!;:E!\2-;>!%:=]NH7OL&\`J$N%E\BR-04[[8M4MP
M!R>K;63-8*@)KT[[=4G?ICJ`$0EPLOD61J:6I;%J$OMY'5MK)'LU-)Q;WVZQ
M._2'4!$FWE0D!%1^T.?DF8&.6*43*8I%T1<E`1=GH984UA*&J;3!4M2&TQ%4
M$TCC+>;!`)]GC,X"*2J`>*8RB]L0>(L4))%`'3Y8$49!)%<IRT,!BJI@:X$A
M!4`,9;"\;R*C'%SR#8[)5-^&,I@\268M!8MU6[DTB==!1LR>OD4!`PBBD[L"
MI04!8.;W4MDF%=+^18@QF,FWQEW.\LUO-FD7C^W4/LN^*T?0"26X^8M8]'<!
MNPE'R\O*SJH,VQ7CKEFZZRZZB#-BLMQTN/J;OKX,&+=<=QV;)@VN#;Q>WXNM
MK8]OAI@Q=T8]U2G=&/'6)FM*ZS$VF-6'^"KK,UO>(FTSI]WUF=9]:Z^LH;8=
M1F%SF\$3LUBLMU)Y'.2,KM0P"42B>FZ+9C';EJ8WK9"V82+(LX[BL18RQGCP
MY&H@[;1TN+'FCQ3@AO/]Y.7_`%3QG\K??^,^W]G0_!Q_27_^W^:L'BC[-\(G
M=TH>!C<+RV/7RY7%91QN@]<-W4F&(N3BT?>"8SMSC<,BD^<3BCHXZ+C46.)R
M+J)`D;B;Y>(X3R;Q[C<G-9=UMY[,^XKCVNVK>E9W&>_=$WS[N;VT]FL5Z1I&
MFO=;NM;&C)DPY;QCBL]8C6T]>D1\(KI\4B);[98QRS`VVYD'LK#8UD^3S$(Y
MR=*3F7"V./3;;9OD*<FIXY&QK(4Y!#'"QJPF<HF,FZ,%PE\P=;G^EG#;[B>0
MW'C.;E-SS.SVM,U,-MKB_P`-%MWMMM:L3CSY+]T1N)R1I2VL4TG376*XWV2N
M2D9HI7':VFO=/3[LV^,1\M/VU=3?2\[+C,YO!HX-N*]<8C!9KD#*4BDMN9O$
M\JC\(W%)MO+/8C,X?=%]BS&(8R+LKAX_D7;)HT18/]0X`WO'B%XMC[HO$Q:N
MNL3ZQ,>L?EALHZ^BQ709OZ;J0V()F<#C\UB<1&Y-+Q$:[R9C"G'(T)5BUS9O
M)L6D'EDP=AX47,F\<_;.5"+HRD:\1I0`.67>=VI;RO=>W$Q6*X(TF=?\WP_'
M2-?S0Q]K_P`A77[?W963P=O,>(;E4E&/G;@R(HUB%`TBFQB"!$AZ2HZXHF40
M$QO,O!(_874#3@.PU]S<ZSK_`(Q/]Q3]FJ<>5S2=IPO96:Q^I\>NLZZS^)W6
ML^D:1/PKUT^<GLS;RG(M01?M$0Y-,I"J1:AA(?0=@43%!VS["J*(")=-,1!$
MX4+J!I[!#RLZ$N-]DBR+75T[HM0]EW/:-U)(E^GJM[O2WZ)_2ZH:0!D)<;[)
M%D6NK9=%JGMNYS2NI)DOT]1"O==I'[M0-,`R$N-ULBR+6^RL6J:VHNM.OPF6
MZP%$:]UVD;NO"P$D@A)BT<7O6QTQ*:J9(Q03B43*B0H#S+L!$`,F`CI'K8;L
M"X+05Z$O\8LO1_X6IY34_P")>@`@'[@^7L`T)>H?"+*E0J'A:O:%2U"OB?H@
M`A^[]3M`!"6[+I%D(>;=2,5"M!1NH/B0TN`IZ=]+P[[?.`*A+!;=(LC4$E](
MQ0MP`+74`OPD-MX)K4[[=0O?8-X(U$)3FX_4?-#G+J")R1:A2VE38\P7M=+B
MF*^FK8.H2S4+4%-,;@6$0EPLOD69J:6I;%J$OMY'6MK)&LU-)Q;Z:W6)Z;2'
M5`(A+A9?(LC4TM2V+4)?;R.M;62/9J:3BWTUFL3TVD.J&"(2X67R3(U-+4MB
MU"7V\EK6UDCV:@I.+>^S6)Z;2'4#)4)<++Y%D:FG?;%JENH#35MK)FLU!37I
MWVZI._3'4!$W;RH/'@B_:749`J;PI0I5#%11O,0>;)0#`52@:BMMY>T+:&!8
M"$O0*R+(1H%1"+5"H@"=PA\)C2HE/3OI<'?;VAG0E_C%E\EJ]]/_`*S\O`8%
M"7[:2+*O;2L6J-!HI;6DF%:"8@CY;1[J]@!D)<;K9%D41OMK%J&`HB#BRH>)
M%NM$Z5>ZNF;NO"P$S9"4TEM%\T2`74C:52+4.)3F=R5#C1VTO(*BB1O2U,"9
M@O-J`<H*3H2XWV23(M=73NBU#V7<[HW4DB7Z8JM[NZ_1/Z75#3#)T)<;[)%D
M6NKIW1:A[+N>T;J21+]/5;W>EOT3^EU0T@#H2XWV2+,M=73NBU#V7<]HW4DB
MWZ>JWN]+=HG]+JAI!\+(2@D6]OM+!(O0OABAC`4P/;"UY\P&$A5$`'S!N%(_
M9ZX`)AXM&\L#-L!9!F3VLF!`&*5`2!IKZ8&+SR':0#H@(6)UTS>:6\`("D4)
M;MI(L@#SK:QBHTJ*UE1\2"MH&3KW5L'NN"T#0EJC2194J-`&,4&@5,(!_205
M$"B`?N?5[`K'L6!@W1SX#F`Q@V@VCN,4M@&-\[_5940)<>T!'T*C3R\!:_@.
M>6S^1[G;7]!FS.X#2?@<I/CG3AM!)1V/FQ5O!ZZ*V'8JDV;/)9WEP-2)Q[!S
MZZL()"H*5]`$=,0>FS6^6Z&\4ZI&M$(Z$@E/G#Y'+3X7*"U.M@,GMY''CI*'
MEY^(FH28E#YTK[7<H$`AHIP**CE(2+<!.>.Q^5-]S<I+,9+'2:XX)A!DU&>-
M>%IE2'(,_`I#)GFY$QSE.4PU`Q0$#4IV5$)"Y>2\8#X22KX:;_AY:4YHO_I5
M:UX#XG74M#0DS,)K!(*145(21&"##U]Z=BT6=%:(VKJ&U7)DK"T*8:F[A[N`
MH3C_`%[+`L,#N!LKO#B&9-&I7<G&L,'+,0:*:[AX#!NRFI2:QES)2TDR:@9J
MS0:**O':A6;85G0Z?`;B.Z\H-]"Q\ZIM5ON@TF'V.(1B9=J`6$66323*$9/W
M;T,K)$I%"774(5-)PL9=,B9DKA73*(-[<3KJR[`LVR##&VR659HXBGN:1S<V
M*LI]XZ;/L?<91!XDVRA+\6C1T`;<?)X-AR1B.W16T+.M))6Y$%"@&XF^L/=K
M%-I,3W7R3ILSH$<MGI-HTQF!2<SV1-,8B\4;9ZYRU_%LXP9)BB7$HW(-)HY;
MH.'4C#H-4;C2C0P!]Q'65FSS<';K!)':L&SG-,OD,5R%./E95]*[<.8^?AL:
M4994V<8JRC!GSKR2DF#5F[=@6"2!Z<Y$#@?@+\<M)_&:7R>3\(X`Y:3^,TOD
M\GX1P'FDP?(%$B#YLB0RBRQB)1B2916<*G<.%1*1<`%1==4QSF[S',(CVB/`
M>G+2?QFE\GD_".`.6D_C-+Y/)^$<`<M)_&:7R>7\)X#/+R?QDC\GA^%<`<O)
M_&2/R>'X5P!R\G\9(_)X?A7`'+R?QDC\GA^%<`<O)_&2/R>'X5P!R\G\9(_)
MX?A7`'+R?QDC\GA^%<!KFK>2Y^4^$D:ZC2OP>7W*3N]M<!L>7D_C)'Y/#\*X
M"-]W<XE]K=N\CSM%JCD2T$2,TXHVI%MU1DYJ-AQ<OI%!M,+,8V.)("Y<JD;+
M&302,:T:4X"KV9=<;'#-P4MOG>T&_CYPTCFDKDV1L=I5AQ+'V<CA">9,`-D2
MV1I13I<57C2,<`95`C20=%24.!B*`4+8X#D:N>8[`9Q&+O&$?F6(XGE+)A,0
MY6<HQ:3L>I(MV<@T!ZJ#9ZW2<`55.\X$4`0`PAVB"S/9V<PS!<US!FW4R1YB
MF)9)DK/'6+,4GD\[@H9[*-H9JH0SLY'$FLU*@02I*&N.%"B/9P%8Y7JAS6`Q
M/)9><VKF8S)<7D-O(-7')2D:RR"?SQ^\:#&8UD202C58(P6Y41</4F34')Q,
MX5:LR\X(1_#=;F;9$PCG,9LC/LW,BQSCEDIP\RU0>S>&^*J#&0BD=B\J[FV+
MQ)FU(J^(@FD@XD4"IE<)W+`#PC^K',EMU8+;*4VJ?Q9)7,(O%'N0^(F61CDY
M**5=H2R<:K%MG4BUE'HD\.!N*HK1J+Q^YY1%HH40N/$-Y+PN/I)(TY-O3X/*
M'\67R.N`BC>;<K,]KFN'NX'#Y+<!.=R-^QR!.%:6NL;QJ&Q#)LMEI]-MJ&+)
M.A+CQ&35J95N"[MVD74+7M"N>XW6I/[?M\<<I[39'D!IC%1RN7A&Y5V66XVU
M'-W^%MFBL"5A(MYUW(OHTR35./>.%572R5R:;(3OBAMD.J[<=Z]R-"/V6EG)
M,8?94@]C^8E0R5TUA&;KP0&L67&CQ2<[D4KX:0(]60*9%A.L7A%5R\RFW![;
M%;_SN^3_`"EB_P`44PPF)DPZ19O"/2S;/)49Q::16?1RAF<6Y;PPN(418JND
M6Z[]L<K@J)$Q+4(@PCKAR7,,BPO'C[4+QZN22F+0\ZZ).+.T,3D<DR%]#%9'
M73Q[P_(U#-6IG+-Q'.'#!P5!<JR[4>6YD.@W+2?QFE\GD_".`.6D_C-+Y/)^
M$<`<M)_&:7R>7\)X"/MR6TH,1C])1$M-P]MA-\&$/>4,Y@;B=KL++@_A!40\
MG`2`#:5`0K*("%2U#PX`J`"C<`>V^RX"'\M+P]3V@%;2H6W2B)J67TCBEN`!
M:WT]M#;>":M.^FJ'?9YP!6TJ%E\H@:FG?2.*6^T66I3VT:S4!%>G?;K!WZ?G
M`$;2H:=\H@>W2U*1H$OMY'5I[;-9JZ+BG?;KE[]/SP1IM9,L@)CR*9S\FS`Q
MPC"$(8J:Z`N2`:HB!G`I+4#6'3!8/,\RXX+"-I4++Y1`UNEJ4C2EOMY'5I[;
M-9JZ+BG?;KE[]/SP"-I4++Y1`]-.\0C2EOM!GJT]MC;J"BM3OMU@[]/S@\#Q
MCM<[91VYCW:K4PG;JKPZ9SH**-TVKD[<PNQ%`SAN=P01+VV+VC4H"!@"1:Z:
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MUO[0=(^Q>R[%'*\GZRQR/:/(9V4W-4';V,W`R7'\8@\8E7&39)A3@^%K)8Y,
MHYNV.=O'1IN3U4TN6<*N%%$^7><^1\=Y5Y7R'DG$\3L.#XS=[G)EQ;'9^Y[&
MVI:9FN.MLU\F7)-8Z6R9+S:\]?NQI6,W;8;X,%,.3);+>L1$VMIK,_/I$1'Y
M(@X>EWKO)FL[BFQ>,;3YL>26RYE".,AF'..1BD?$YW#;E[FQ>6/X%QE$[*H-
M(_%\;%95LY<)N%P(`(7G5!%._P"?9*9?+=U;'6*4[<'2.W3_`";#/3MK2OQ^
M%8_KSYM8F,%=?M_=ET=PAK+^(;E4ET!NW!D12K$IET2GQB#!%,;7GKV@95`1
M,-HGT1J`:GF\_P!A$Q?<ZSK_`(Q/PT_>4Z?_`*IQY9:EMKPO97MB.'QQ/WIM
MK,;C=:VZQ&FOKV^D?.3V9M9+D&I4)%-`.33*0JD803)GT'A2B8@"Q"A%%D!M
MTDNQ`0H74&S8(>5G;2HWV2B!+M;3K&@>R\7^C7VV6_1!=O7NNT#=VIY@!FTJ
M-]DHB6NK96.*:RX7NE7VT%VD"R%>Z[0'NU/-`,VE1$ULH@6HJ6@,<4UMPN],
M!]M!=I@JC7NNTA[K_-!'(-9$S1P!Y!-1(2FJD2-()S%$ZHE(`B#X!H!TP'UD
M];![`N\T%G+2OQHAZ/\`PXOE-3_>O0`0_>^KP!RTKV?"B/?\7%[0J41#^=>0
M!#]WZG``-I7LK*(#VEK\'%"M!1$P![:&EP$.'U+P]3V@%;2H672B!J67TC2E
MOM%KJ4]MC;>"2M.^W5#OL\X$:C62YM@*DBF<Y=0;RQA`+85-@#@AA'6%,7&D
MK:(*I6ZH=BEE!!81M*A9?)H'MTM2D<!+[>0U:>VS6:N@XIWVZY>_3\\`C:5+
MIZDH@>W2U*1I2:EOA^K3VT:S5T'%.^WF"]^EYX!&TJ%E\H@>FE?2-*6^WD=6
MGMLUFKHKT[[=<O?I^>&"MI8++Y1`U-.^D:4M]H,P4I[;&W4%)80[[=8.^SS@
M1MVDF#QX/B2=U&0*F&+(4JIB)(W&(8!2'S@(H%-5:V\/2VT,"T&TK0*RB`CY
MM1\-*%:`G=3VWV7"4W^B[ZG:!RTK3^E$*TI7PTO?2E:<UY>W@,"VEJ#240`?
M.H/AI1I4%`+V<WVVB8H_5M^KV`&;2HW6RB!:WVUC2C;<#C3$?;076"HGY*Z8
M]UW8"5LUD])?1D4T0,ZD1*4\80;#F=R5#A06=Y!452/VE$3:8^>>^_@%9VTJ
M-]DH@2NK96-*:R[GM*OMLM^EK(5[KM`W=J>8`=M*FU+)1`EVKIUC2GLN\0TJ
M^VPOTM=O7NNY<W=J^8`=M*C?9)H$NU=.L<![+N?TJ^VRWZ6NWKW7:!N[4\P/
MA9M)B18?$DK!(O0@1Q3&`I@?6%`164`QB`L@'I#7:(]GKE"AXM&LJ#-L4DFD
M0.63`@&C"@)/6W&F!B@HU[4P42`0TTZZ0^:6^A04BVE1NME$0J)K:QQ1M`16
MM`?;05M`Y`^K8/JNP`6TKVTE$0[1I\'%&@5,(!_.NV@"`?N?5X"L>Q8&#='/
M@.?4,&T&T8&/8"=YOG?ZK*FL`1`EP^@`C3@+8<!SQV?F=U=M^@S9K.HC(8S+
M7T!TX[12<1C@XHUB@726P_%B-VCM_P"-K@9*,C7(WJ`5,RHHWB):B7@-EL]U
M!;M;L;@GPL6S;'8T6672",\^P7*HYV5KCDG#1C47T-DT=`)L7;MX]<MU&AG0
MNBJ-A62(LR,FZ5"RN.QN4MMS<I)+Y0TE%QP3"3)JML<1C"$2'(,^`J9B>)O3
M',4Y3#6X*W=W8'`2'RTCXN`>)EN\-$:\@EW<T7_SM>`^9I:9BH>6E&YW$NXC
M8U^_0B6$>B+Z469M57"4<R`RABB[>G3!).H"%Y@X"DL;UDY$=-O'#M%N%G$^
MHU3>"[VTQY\IB#E!9=8!692^?Q^#R8M&)"<LHX.R!NM)(N6R)SF;G'@&>G](
M0M)()OL<V"WUR"/?*RL7&.6V*1B38N0P:F0)R\5/2)'SJ/AEH\\'1PB51R];
M@*IC(41H<)!?=:2+'`8?/S[/;ZG0FOQXY?&AP>(2RA$,(FHV$5.X8&G3(IDD
ME),'`W*%,Q:-G*JX`"`W!J7W6=E&/8SCV59-L9NLW:9"KN@1.%C,<4=Y1'!@
MBV)^!#(PSMHRL#*FN1K**'34.E'D8+*W+H$44(&XQ_J_R')7<P1EL5O3%QK?
M:+(MTL<ELEQ)O$1V1.H)K(/6>#KO4%Y)''\JR5JP4.S;K@HH":2AE"E'1(L#
M/3Z]7D@9(D1T_=0-Y7`B[)+X.P9N/#47V1,5W$:S8R,FH]D3.($B1&BYF9Q6
M<B%P@V6'@'>QZT64BSW*!/;S<EGD6U#C$D,JP]U"P;K(Q5R>4G8XK6.CHN7>
MKKN5OQ<6-%BH"24P#EH9$Y4U[B`0764KDCK&V3/:3>2!4GI'&4%W67X:VBHY
MA%3)L2<RTTT=1[V7-/,L;BLF54<G;%$B:T<Y(<Q"D%0`TVX?5INM@F>Y7C4?
MLCDF>XYBTQ/-)6;Q*.RAS*P$)#8*WR1A/RL3^)J[*63RB;?IHLFT2\>N`CVC
MYP8IET$FC@%:G6?-PF#,LPR[8O>Z.?269;EXZTQ>)P<9&9)"8?%*9;A^3O$'
MIXI=!IGN$O8]R-$C(1+U5VV<+"+(YE`;I_I"L?(C/$#9SJ%5F(%.*56QQOMU
M%.9D"RC-V\.6420R!1OCRD2FV(=YS2@$2;/&JY3'(N%`<S[K76CC()/-BNH)
MJZ=NL=0;,5L%A`>F:Y3(-&<;*+(ER$R*#)FF[+XA5418O3HLCU67((!<##)B
M2R[$,6RH''A_XRX["SW(*-4ES,QEHYL_%MKU0UP1%>T#V%N`*T"M.`<O+2?Q
MH3W@E]^X`Y:3^-">\$OOW`'+2?QH3W@E]^X`Y:3^-">\$OOW`'+2?QH3W@E]
M^X#7-6TESTI23+74:5]H)>Y2?^=KP&QY:3^-">\$OOW`1IO%FTUM;MIEN>LT
M`R-[CS%LNR@RM)!(9-X\DF4:V:BK"P^2R*0**O`\\K0Z9/3*F22`ZI`K/F_6
M7-81N-\WJVP74#.%C&B+W*,V@=OVK_;Z-0=X83*FAHC+`DR,)Q/GW;6+64#0
M(@\<>?0J:PI!:O`<@=9QCF/YJU&3A4,OQ#$\G2B)V((TF(I*<CE)`D;*-3'(
M=M(,BKZ:Q!#S5`,'`+,]F,BQ'!<TRN*;K9/*XSB629#%XVR9@F[R"1A89[),
M81J=(KM4J\JZ;$0):DH:Y0*%$:!P%8I3J.W1Q_$LEDIO:2<9Y5C,AMY!EA'J
M2K6)R>=S>0>-737'YV$99<V1:0V@1%1V[!%BBJ857+ANU`JQ@8,/UB;M9"PC
MEV&PF21CN18YP5LG.)Y$1)].8B,H=%E#!'80]6D8E\1JS2.]4!J!%Y%/13<)
MD4.`/!AU.[H*[JP6W,IM%(QK"2S&+QB1R=)S(.D8]G(Q2KE":19.,7CDW[26
M?"4[+1<*&+%MGCQV5MRXHB%QHAM)#%QXA)D`.3;T#D$NSULO9V+>AP$3[SY]
MN)MPUP]WB&'26XA9?)'S7)T(AFW!W`8K#XCDN52<PW05<H(O9!RK`I,&:!E4
M]5V\3*%PT*(11F?4GGN)XMC^2_-9.F">@WDB+243DF2T7.M=QL=P=+$I/P?&
M<D29/)%A-J2#=^JHG'Z+8ZBJB38IW)0C5UUG;IM,W/AOZNN=/555<U28.8Y.
M15.H[@6,@OC$*]2<8JV;MYS)SL6[E8J"[MM&QLLQ<*K"8YTBA,>Q6^.9;SOL
MJ9Y!ACK!T<83PZ0BGQ#NI%GE",RM-HN7[$\G!X\^:QIUH@#L0<-4G#EHJ1<R
M9`,!0"/]K>J_<G<*5B(MUM!)1AUG.&,\F.BZEU/Q:5RO*9&`<.VZSO#&L5E,
M/$M6I')GD<[6;E3N%P9L84TS!>?EI/XT)[P2^_<`<M)_&A/>"7W[@#EI/XT)
M[P2^_<!'NY+64\(@*2Q"@&X>VPF#PU`UY0SF!N)4RWF7!_"#M#@)!!K*!2LJ
M0:"6OP>D%P`*(F#V7LN`AP^I?_J]H!6LH`DNE2&`++P\/2+?:+43]RHVW@DJ
M'U-7_4"H!&LH%E\J0]NE?\'I%OM%EJ=RPVZH(K?[.N'J`J`1K*!9?+$/;I7_
M``>B74LY#5[E1LU=!?\`V>8#[F%01),Y(L@)E)/4/R3(HG"-0(0Q4UT!<%O!
M&X#N!16$`Y@03!?L3\P#&!81K*!9?+$/;I7_``>D74MY#5I18;-44%_+;S`?
M<PJ`5K*!9=+$-33O^#T2WV@SU/XX;=445O\`9UP]0%0"M90+;I8AJ67?!Z07
M6@VO[ENS4%)4?J:O^J%0.6DR@`GE2F`H`)Z,$"7`4$KZ"*UI;K#]_8%_U.`X
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MX`S*ENTODN/[>Q4Q)KR$B\=+X`+B."0FBIL@>+-D4Q*8@\9_G7BG#<!PVRYK
MAYW48MUO-Y@FF>],DQ^%Q;')%HM3#A_3_%VB8[.G968GK*C;9\F7);'D[=:U
MK.L=/TIM'SG^":$-]*'BFS>W*K)[M1G.5H8MN[O1M:^EL.5QEZT7D,'FI5TF
MJU;*S'/GG7CR1536B%"%7:M(*4?`HLT;@H;3^?YZ[GR[=Y*QI';@^.O^;8?C
MI&OYES:QI@K'Y?W9=(^FC.G6\.V:&[<<=Y`,MT%8S.F4%)Q[)1_C[?)<)Q]\
MVB';ALL"#]>-!T@4ZY0`JXH"(`!5.SG^RK-<FXUG6?Q%O[FD?UDS\GS4S;3A
MYI7LK'#XOC,ZS.;<6F9U].MM-(Z1IT3TR9R(,&I49/1`&:1"%/&H`9,^@[*`
MB0$F`!IJ+(C;HI>P4$H7C;GHH6':RAM2R5(2[5T_@](VG?S^EWK!?HZZ'?Z;
MEQ^Z#0`[64&^R5(2NK9\'I&LN%[I]ZP7:0+H_P"UH#7TXT`,UE!NME2%J*EO
MP>D:T#"[%,/90NTP52#ZNC_KC0$D@TD#-'(*25Z8E,(IDCD3'$HG6$I``R+\
M!M`Z85T3UTQ&GG5`%?*RGQJ3O'_AZ7HB<0#V;T`$`_<^KP!RLIV?"I.\*_!Z
M7:%2B(>S=E0`0_=X`!K*!2LJ00"VOP>D%:"B)@[%>RX"'#ZE_P#JA4`K64"R
MZ5(:@DO^#TBW@46HG#L5\W4!)4/J:O\`J!4$2C.1YR/$\GJ')J")RQJ`%$I4
MV(+D,;16%+F-)6E%D1`5>X]@!P"TC64#3OEB'MTK_@]$NI9R&K2BHV:N@OY;
M>8#OTPJ`1K*!IWRI#VZ6I2/2+J6<AJ_QPV:W+K]WI>8#OTPJ&"-90++Y8A[=
M*_X/2+J6<CJ]RPV:N@O_`+/,!]S"H!6LH%ETL0]`3O\`@]$MXE!GJ#V*C;J"
MBM_LZW^H%01-V<D5X\-XIYP@R!4PQB!2JF(DB!C$,"*(C<!%`$!57MU.RVT`
M$%H-92@5EB"-`J/AZ05$`3`1IK#2HE,/U+OJ=H'*RE/Z6)6G?X>EWTI6FMY>
MW@`6LIVTEB!V&`/@](:"(*`4?9@K:)BC]6WZO`!FLH-ULL0M0/:/AZ(VB8'%
M@^S!=8*B?^G3_P!8:`E:LY'27TI/1`SJ1$I3QR'F'.ZDJ'*&DR$Y!462/VE,
M)M,?7%`.)Q!4=K*#?9+$)=JV?!Z1M._GM+O6"_2UT/\`:Y<?N@T#)VLH.I9*
MD)=JZ=8](VG?S^E_'!?H\PAW^FY<>[4&@!VLH.I9+$)=JV?!Z)M._G]*M50O
MTM=#R7<N/=J#0/A9K)&36^$PL,1>A"QZ)C`4X/K"A450,)"KHAVD-=H=H#>(
M`'@T9R8,VQ22H$`&R8$`T:B`D#2<`0!):U`!3!5*H:2?L0^:6X0*"H6LF(C2
M5(`#=0/#TAI45Q*%=7ML`Y`^K9_K#0#E93M^%2=XT^#TNP*F$`]E[:`(!^Y]
M7@*Q[%`8-T<^`Y]0X;0;1@8]H$O-\[_594UA1$I+A]`.P.`MAP'/#9Y]NCM[
MT&;-YQ"94ZRV4A.G#:.3A<:3QW'HM-8J^(8L5!FN[*PDEE&\7&.#`8P%*=71
M`YCEJ;@-IM%O=N_NAGJ>*N49[&H1TWS==M/R&'OF$@W#%7^.LV@S,!DNW^.A
M&<^M)NVYB"Z.<'#8ITP4:K-EW`;_`'KRS=W:-KN)E>%R<!F^9L\2VR+',\NA
MI".A31ZV2[C*2I%6^#0T[D+UZE'LU3-4V[<QE%S%*?S>TM_;?A?>C\;[D;;K
MK[<5F_ITTBTUKZZ:ZSZ/)[M/NZ:_:D'IQW(S#>#"4<KRQ`,>R5I,9GB<U'L<
M=GXB+Y[$LG7A%G4*7-(:)FI*'>';"HW>Z(-W:0@HB8Q!`PY?)\9FXO)BKEMB
MM7/M\6>G9DIDTQYJQ>E<G9,QCRQ68C+BMI?'?6MHB84TO%XG37I,QUB8ZQTG
M37UCY3\4YSIY:*A)B4:N7DFZC8J0?MHY!JT!:079M%G"+)$4V:ZFJ[43!,MI
M#C4W84>[C6JU%D.L3/HMPEB&7;$[O-MQDL1ALED4X7'F;_#$W\Y#NYQ#%V$R
MV:2)I'(F386J:C9$ZFH<S@0.F=JHCP&SP_JRS/(4,G@!V.W)AMPH3$IG-8C%
M7#>.9Q^01\4IBC5PB=VZQYM(P3^2R'+R-FA56BP.TT%W91`B+A-$$"_6Y+"C
MEAV/3YU%G-B3I&.?N)+%HF+C"2#Y@FK'G5='C%W80Z<FFY;OGB+=<C-)`JX%
M5(ND`A[-^M>8_%I&<>].W4US8%B><81^#PJR319_*0<.^9+/'Z4<#:7AY&>1
M279*D*L!P/01(DLHF$D)=1>2&S7$<->;3[K19LTPN`RZ/EG,?$N6T.XFXG(9
M1?&\D19PZA&$U!^#)$>)I+K"GKG&GK-%0C3#>LK,Y-%C&9KTY=0F.YNJIC+6
M2QN"Q!'(&+%Q.PV/E<O6D^_@\?:RN.,\SG"1X2!"$3(T4(\<%0*D]3:@[MD^
MI=_NWFJ4"KLMN]MPGD;1S*,<AS7%8F.(\0A&H%U)@Z,?8*S5RU.WJ5<XM#K,
MTS!>X$J07)Y-_P#&Z_O1C]XX`Y-_\;K^]&/WC@#DW_QNO[T8_>.`^`CW93G4
M+**%.I:"AP9,`.>P!`EY@;U-:`]E>[@/L6;X>P99<0'L$!:,>W_^!P&`9/B@
M!2RRQ2E``*4&C$```"@```A0``.`SR;_`.-U_>C'[QP!R;_XW7]Z,?O'`')O
M_C=?WHQ^\<`<F_\`C=?WHQ^\<`<F_P#C=?WHQ^\<!KFK1_STH'BRP44:=H-&
M51]J$[_6>`V/)O\`XW7]Z,?O'`1ON[E>1;<[=Y)F4,U<Y1)PR<9RL,":C=)7
MGYJ-BUWCM6'QW))0C"):O3NW`H,7"FB@:A?1`*PYEUAY1B.X"6#!TX=34NU8
MQ[63R;-&&$0RF&Q:$AA">5M4&,YH\O).6\F]:Q#P*$!J^6,!_,17,D%K\!G'
M6;8YC^9)>.0),MQ#$\F"%G8UJUFX@)N.4D`BY9JHS0.WD&&MI+$$A1*H40H'
M=P$%=1>_6XNR$QB3+&MH=PMW8W(HR2>OI'"(Q1ZM!NXC*L'0>QKQLRQJ3025
M<[?RF02K-19=`CA_"H,/-,^*LD#85ZI<T>8-+9C";*;JI#'2V,,&33(V#9JC
MD;296G$'LA`F@\8G9-R@=[!%:1AU&J23Y:5CUE3-FRQU$P;A>JO>.2(S"-Z?
M]PH!U(-=QBMHW.(^8CY<);#I?)FT*P,PB-OI)`Z$[#1D4Y6<@Y*W15G$R-3O
M4VZJPAOX_J1W:4W5@=O93:&;814AF,5C4GE*#E\\18,)")5<I3:+5?`HQJ]:
MRC\2J-=)X8R,6U>.794#H@B(7&B&CX8N/$)98`Y-OV`T8A_%E_\`,CP%%IKK
M$W%QG<;)\.F^G/>EU!X[,YE#M\IQ>$-)M<D5B<D!GAXXUS^+1T=+K99C!3O1
M33=40<D%`#G*`J\!OLVZI=R,4-#*1^P6[62A)8FRFWT)%1AG^30DB?.)/%)S
MG&D3ATG'.\<QF.ACOUG+9RJ_=%?,019"DN==(!'J+WO>R&2HQ^R<ZNGC4AEB
M1HU1>72FI5I%,W9<:0:+*;=)P2,_/R9XHYVP.5D4XV;27(NH=J[23!Y[&[T9
MUO`^RAGD^&26"H8X&$O860.+EZRR9*;=S#5Y(-!F,3Q9^T8'5BP59)KMB.%6
MBI%5"$$UA0M3R;_XW7]Z,?O'`')O_C=?WHQ^\<`<F_\`C=?WHQ^\<`<F_P#C
M=?WHQ^\<!'NY+.0\(@*3*Y:;A[:B;VDP->4,Y@1%/SD/,`WJ@[0]#@)!!G(`
M(5F%QI;4.38A=041-6B'9>!#!V=UXT[@H`5E(!9687-;9=5FQ"^T6HGK1$*:
M@(J`-.[6&E+2T`*SD"V73"Y[13OJS8AJ6"RU`&U`+=4&ZM:=W,#2EI*`$92!
M=.^874MTKZLV)=2SD-2MJ`6ZW++5I2G,FI2PEH(TF+XL@)CRCA0X,V0"J+%B
M4#E270%=,3ECB]KD4%1$`7\SF#6IEM(;@%A&4@6RZ874MTKZLV(:EG(ZE;4"
MVZW++5IW<R:E+"6A@K*0`"73*YQ+IW"+-B6^P&5XC:@%-46ZM:4IKC3TI*`%
M92(`6Z97-2RX19L0OM!L!Q&B`4U!14$:=VL-/2EH&.4?D+<:9<"!2@)AY-C4
M0*"5PT*W'M-IF'L#^&-.X.`_/1T^_3U["Y_])?N7]'!)8AN%BJ1H.+SK8O=Y
M#"\BD$MT'&5XB.\.1QV7;?I[88KEVURJ&.Y"FLQ7D&"Y'2C9R#QT1=1L9V%F
M]Q^OC$\_R^4VW4V%ZB,C1PK.]TU\+S[;9N\5@)V0VTVUR&;QU1EED?BP0T?D
M.Z$2Z=EC8APN<!B7K!^94Y7J:)-]X_Y'R/C6?-GXZ,-IW&WG#DKEQURTMCF^
M/)I-;=-8OBI:)CK$U^6JUEPTS1$7UZ3K&DZ==)C]R93ET)[A+;OJ;@9M'[?9
MS@;%_B.U*+;*LMW`4SXN3)ZNYK]"!BD)#"L72:,<<3F$Y5M(-S.DI>,GF2IQ
M16*NV2S/(/,.6\DV>WV&^KML>TVN7-EQUPX:8H]S<5PURVGMC6TS7;XHC6=*
M]O2(UG6G%M\>&TVKK-K1$3K.O2-=/W96QV.BGK;:['VZ4P<H%<904IDHR,;D
M`Q\JR<0.5NDAI%$AG"8T#L'0"OISUR_J'E]_R_=9=)C6F#I-IM/^3XH_2GK/
M[?Y%.TC3;UC\O[LMS@[&2Y[<@H3:P%'<&3%`I6$<4&Q%L;A3D3(`(B"@(JNR
M&N-VG%$+JWGNYUL(F+[B)G7_`!B?[BG1.?++4MMN&M2O;_Y/CB>LSK,;C<QW
M=?372.D=(TTCH>[-D]%@U*C*.&Y>33(4@LF-4C"@\*`@08YD`:9W"0@444P]
MK%`2A<<!V"'E9V4@:^V873NU;*,V)M._G].ER`W:/,HTKZ;EBU].>X`[*0-?
M;,+DNU;:,V(Z=XOM.ER(W:/,)4K6O+EK6\]0#,Y`1-;,+D`=2T`9L1LN%V)`
M"J`UTP73`*]^B%?3&J"1^R>BT<7R:ZJ8E,(H@R9'`Q1.L)24\.?&,!04('L1
MQ$$P[*B(\`KY*0[?AA?O&@<FQ[*B<0#V#MH!@#_R?]/`')R'9\,+]X5]IL>T
M*E&GL/94`$/W>``9R`4K,+C2VH"S8A6@HB8!H@%+@3.'U-0?(6@!6<@%M9A<
MU-.ZK-B%]HM;P&U`*:@(J5IW:PT]*6@(SLGH.X\3R:ZIR:@ZHLF-+2)L`7(8
M2QR@)\T*"@C15$0U1I=:4"@L(SD"Z=TPNI;I7U:,2ZEG(:E;4`MUN66K2EO,
MFI2PEH!&4@73OF%U+=*^K-B74L\/U*VHA;K<JM6E+>9-2EB=H8(RD"V73"Y[
M=*^K-B&I9R.I6U`+=;EEJTI3F#4](2T`K*1"RZ97/;IW59L0OL!G?6B(6ZHH
M*B-.[7&GI24!&W8O@=NQ\5<`:C(%5!8L"@N)$D;C`8(U&HF!,X#ZZM;J#2RA
M2@"P&4AV5F5QI;4>38A6@)`(^P?PA(8?_+'R!0#DI&G],+]W?R;'OI2OL/E[
M>`!92/;297"M:>TV/94%``?8.VT3E'_R`\HU`,RD1NI,KEK?;1FP&VX'($'M
M0&M@JD'M[](*^F-4$K9D^%)?2E'#<#NI$2DY)C0ASNI(-0H&CVHF`RBZ:@")
M37"D'GJ`8QS@J.RD#7VS"Y+M6RC-B.G?SVG2Y`;M'F4:5K7ERU].>X,G92!M
M2R873NU;*,V)M._Q#3I<B-VCS2-*^FY8M:WJ7`'9R!M2V873NU;*-&)M._G]
M.ER`W:/,HTK6[EBUK>>X/A9F^$BPC++B0Q5_6RLV(B!3@^M(41:K"(I@X2`*
ME/7ERU`UYP,'BT8O^3;`2673#EDP(7D6!13`4E["VBQ;`&D"R84TD_80J4MQ
M@X!2+.0&M)A<M;J>TV(VU%<2AVH=MH*$#ZNF'E-4#DY#M^&%P[Z>TV/9VF&G
ML/;0!`/W.`K'L6!@W1SX#'O,&T&T8&/:4EX_._U65-87S2U\@=@<!;#@.>&T
M([I81T&;-9AB>89#E601/3CM%)06-)X]BJ::PKX=B^FQ$([#)F2<MXN-7,``
M5,RRP(@)U"B)C@&XV@W3WVW&SQ+&IF!W:Q7%7+/<!XEG\QAV/0\8R<8M)X9'
MP6-3,'/[;PTRPR*:+-2JICF$K)5*.249J.TUE#(A-#_:Z(S;,<NQ7<U=MN5!
M.<-V]D#QF58UBCAAS#'),_48*"S1ADFYU&2Y3*)G$MY3''M[`H$CXE@./8"B
MTQ;!V++$L<8LG:[2$@(F'CHULJ]D.8='1:-V!$4S.%S"<]`"IAKW\>1$1Z!Q
MS8RT;#2\BQ6DYA\PC'[UG$M4XI)U*.FK55=O'-E5(]1--=\LF"1#&*8`,8!$
M!#CT4?8]4.[8D1C4-D-U,[F1:HNCS.+8Q,8;B3@JZJIU3(EW$V^8S+1LQ3HT
MO4*HHY?MW`$3(@"2J@,EOUO;D2K<LMC72YO]-LWZLM#L'I8B/:H-YK'E\D2D
MXO(9,,'<@R*Q<1``H#5%Z4ERVF9=4J:*H3!A/4?N-E4DM'OMA=]85O'1LTZE
M95W"0[1('\5C<O-LX>.CY#&VRCV4G7<(9!!--=1%,LC'"9<RKA5%L#?>]3>\
M37"XK+6_3]NO(N\CS]#&H'&F;,1DSXNVBL3=R>3/C+[>(JLE)%]+201)73=F
MU691IEG*[9:K7@%6(=2V[F63N5(_,#NO#8YCL1FA&;N803CYS(LOQ!155O$0
MC!YMV@P<PV4,%FXLWBCA$Y5BN":2FF6\-0/5MNBG)+PBO2YU''EV6-K9*^1:
M1$&O'Z307*[J+C9A3$FT?+32[`$.3;I'`SAXH=N84M$5#!XGZOMPD)UFR4Z>
M]^5H/))&31Q2?2Q9TDW0AXQ*'0)-9LDIMZHOCC66DEGX-BI$=+:"+4QTPYH1
M1!7%=5F[$VUCRL.FC?4DRF$:ADC)[&LF,5%RLM++1#6-CYR1PF/-*-FQ3(2#
MQZ5J"32-4$YR"KZT`(V'67DLYCY<FQ[9C>"7;1FXDYM[E^/,XUM(9AC;Z*P^
M)R<HKQ4/A$DV"5;NY([)XS56220.W5TW*JI2H*`8CU:[N9@>(,WZ:-ZH9%U+
M,0E&TVU*SE&>+N(IX[>SC9)QMPUC5GL=(($;\H9T4RQE"@0P7W$!RY#U1Y]C
M^:Y)B!^GGJ!>MH)>1!EE#&$AWD#D31F_R-JP/$+1^,/ECOLC;P156")RE2$5
M3%76;VHF<`VE>KO=%.7Q)N/35OJ6%GY!FU?R@Q(+.6C![,,8)/(F3!OMZ;5@
M2O%U5@YM1E(*,^74!H774Y8+_"S=U&DN\`*]@:$:-`\E>1[:<!CDGGQN\][Q
MOX%P!R3SXW>>]XW\"X`Y)Y\;O/>\;^!<`<D\^-WGO>-_`N`.2>?&[SWO&_@7
M`:YJS><]*!XL[[%&G;R\;4?:I._VEZ'`;'DGGQN\][QOX%P$;[NY%E>![=Y'
ME>+M9#*9V+)&<C#$9+.`5!]-1L<[>+M\?QJ>FUVD2Q>*NUB-6:ZQDD#`4`],
M`5;S'JJW5Q?<!+#&G2[U)SL2RCVDED.=QT#C3C$&:;_""9.BUBI!"'47F';.
M;>-H=X"2(BW=G5$2BD@NHD%L\`EY#,,<Q_+5T\BQIQE&(8GD3G'IY@R:SD$O
M,QQWRL-+M5XADLWD8PRNBL0Z*1BJ$,`E*/8`03U&;T;P;/3.(M<"V=S[>.)G
MHN1=RSW#F2;AS!/HG*\(*YCG:3?&))LB,AMX^R-\R4543!:6BVC(0H]%5(&T
M/4;NF^P2<RN/V7W,AY!E,87%X]'Y1'.!;Y87(YMY#R3YF6$VZ>341#L18ZZ;
M]^S;HIQ[E%VZ(A7EC!&4]U8]14?C".00G3[F.0G<LIX[-FC'Y1'N7;IE+N&K
M)95C*;5,GL#'1T2HT=R`296C@Y5CE;DU$ETT0?F/=1&^DSN)B6./-ELQ@L3R
M+(L>:/IF2C9@TM`P$]!!)-W<DT4V_C8<D@=XY**Y.>*$8T8O>:*5R"+<P74B
M&;P8N/$)9V%6:'8#>-H'K9>P*LJ\!1*:ZJ-\L<W%RC%9+IHWCE<:@)K,HIAE
M6+11GK;*`C\DY;"3XV9SA`,7A\EQ8IG*NHX3;H/"BES%E#G#=9UU';Q8VIC2
M<3M)F*CF6Q1.8FHN5B,E=N(*<5SU;#4(@LOB^U<S!/6CQ%DH[!<RJ)FC!4C]
MV1!#12>`UG75'U%M<U4Q4G3AN!(-E#YJ1G(,DGI$DW42QDE,.AY%^[VY0B4W
ML\HS:NGCI!5=@S8RS<H*&<(N$P"9=BMU=T-TW^4M<]PJ9P9I`)X>^QU\>/E$
M&^3%DUII"0?I!DV&XR\9)**QB:S5H=`[E-HN0[@2*'TB!7YMU<=1Q@@$S].^
M9/7#H\6TR4S&)RYNV@)!^YR$"^'B\VL,XRB&=(Q2*9'C%-0[4YP.X0*HL5JB
M$O\`3[OIO+NAF9,<SW;J?P>+'`7F0!.+8]+,FBV0QN2M(9=H5Q-0#1DE'2C-
MV*\:5-5T=RDW55%4HE.@B%RN2>?&[SWO&_@7`')//C=Y[WC?P+@(]W)9/?"(
M"DR]+3</;41#EHLUQ0SF!$Q!N8#:!@[*A0P>@/`2$#)X`A\,/1H):@+>,\Z@
MI"(#1B'I@3,`TIZ<:4H6@8*R>!;68>GH)*@+>,`#@46PF`;6!1#4!$X#2E-8
MU*4):`5D]+9=,O3VBG=<WC`U+.3O`UK`M-7EU*TI3F#TI:G8`1D]+9=,O3VZ
M5US>,#4LY*^ZQ@6FMRJEUM*<R>VEJ6F"--B[+(B8TJ]4,#%H45#-8P+P170%
M0ICDAR?S@4%!,`+>;S![2$HF8H+",GI;+IEZ>W2NN;Q@:EG)7W6,"TUN64NM
MI3F3VTM2TP"L7I;+IEZ>W3NN;Q8:EG)WW6L"TU>74K;2FN>E+4[``8O0MK,O
MC4`E1%O%A?:#<#"-K`*:@HG$:4IJFI2A+0`9/`I69>FI2HBWBP$:`D`B-&`!
MYPD,(T]6-.XM`J=M!TB[`8+OGO/U68IM=C&-]16\[I;$MR]V6^.L$<PRO'<.
MFG[2":JO'>*0')-W#1!MS9V;>R4Y-H=PZD.5;.`"5=B(Y\WV2VLU9YZ(_B!C
M2ZBHL8-M[-#I+F.9-O%)(W%%8!$XEN4$EQQ,8QQ,].L^CV(FTQ6O6TST<B/I
M+_ISMC?H^-F]],N;XMNMNANAMP[VXQO!L41P:6A\#RW)-X\2F,IP:2G]QC8T
MK%X?BC)I'.3NC/`2?O`9)D8(.N8U`CW&>2\=RW*[OA]I[OXK:5Q6M,TM%;5S
M5[J36TQI\XTG2>FL1-9U=@\Y^B'FGT^\`\?^HW/SLOU'Y%GW^##3'N<.3/BS
M\=G]C<8\V&EIM$1,TM&2DWI$VG'>U,M>R7;T0_2=8YU"?1<X=UN;=8)G;]Z6
M=:X7DFUV1LW>+K);C36XC+'\BAL2R]MMU.1N6X[%R.9IECYU!F6'4Y0"RCB+
M%&5,SZAYYDKE\JW5Z5BE=,,16)FVFF#%'K,S/PUG6>D].GI'%MK&F"O[?[LM
M*X^E#SC!\7R',V72YN?F[?)\VW?<(!C3^419H*8&2,AF24>M);+-'ZT6>+59
MRC]_)M8PK"/$%R%>ID4%6!;*LUON-9GKN)^&G3LI^S5,_)\V/-MN']NM8BO#
MXXG2TVUM&YW43KKZ3K&LUCI&O2(=G,/<O,AP_%ITJTU!>.8S#2P1#]E&(2,.
M>5BCO.0>MU(5D*+V./()D4(9!*U1H4#$"JI3YR*'(=D\-?;,/4[M6VUO&#IW
M\]9;>P-71YI.VZM>6)=6Y74`.R>FOMF7I+M2VUO&#9?SEEM[`U='F4[:UKRY
M*UN4O`,R>#=28>ENOMM;Q@V7"Z$M+F!JZ8+D`*UKH%K6I[P1R+)T+-R)I-VJ
M42F$41:QQRG`3JB"=H1#PYBEU"A[&<:)AZ(F$06<D\^.'O>/^[QG943"`?S#
MT`,`?N!]6H`,GGHS#T>T.SEXSRE&G\P[A`*?N_Z.``9/0I68>FI;4!;Q@74%
M$1`:,`$+M,P#2GL@T[BT#(,G@6UF'IK1)=5O&>?:+43`-K`*`H"!P&E*:QJ4
MH2T$*C%V#R/$TJ]5,35'4%K&5M(FQ!4AC%AS@0KKESW441'UXUM;2`F"TC)Z
M6RZ8>GMTKKF\8&I9R-]UC`M-;E5+K:4YD]M+4M,`C)X6RZ8>GMTKKF\8&I9R
M-]UC`E-;E5;K:4YD]M+4M,`C)Z6RZ9>GMTKKF\8&I9R5]UC`M-;EE+K:4Y@]
MM+4M,`K%Z6RZ9>GMT[KF\6%]@-+Q-:P+35Y=2M*4USTI:G8")NP=E>O1\5>U
MHR`QQ:QA=82(H@8PF"&0N$VD8!HHJ!=0U+*%`H+08O0I69?#0`K[7BPK0$P$
M1HPIYPD,(T]6-.X*`<B]^.7O^GEXOR4K_,/W>`P+%Z-:3+X*@-!!O%]@B"@`
M(58#Z43@(5]0%>\:ADS)X-U)EZ6M]!!O%U+<#@"B%S`P#8*Q1"M:Z1:UJ>X$
MC5B[%)>R5>MP.ZD;2$:Q@`0QW4B&H4%(A`3")UR*5,4X&,D4;E`,<R@*SLGI
MK[9EZ2[5MM;Q@Z=_.V6WL#5T>93MNK7ER75N5U`#LGAK[9AZ2[5MM;Q@Z=_/
M66WL#UT>:2MNK7EB75N5U`#LGIK[9AZ2[5MM;Q@Z=_/66WL#5T>:3MNK7EB7
M5N5U`^%V3L4U_A9[:8B]"`WC1``.#VTI:QRPFTP<I@%2GKRY*@:Y34#Q9L7@
M,VQ0EWJ?M9("E!K%DTZIKV@!!BD`+I`L0``4R>PEJ4*G`P*19/1K28>A6Z@`
MWC/-N%80`*L!$;-0H!6OL85K4UP9%D\]"8>AVCV<O&=G:8:=K#N`!`/W`^K4
M*P[%@)=T<^`QQ4,&T&T8"<P%*)Q#=_JLJ82D*4A1$?0``#@+8<!SRVA0W6Q'
MH,V7RG!LQR?*,JCNG+9]_CV-!CF+KHKJ+X=BMC`K:#V_FYQ\A'1RYRD(DDHN
ML"0"=0!$Z@`MV=W`ZD<]W%&#RUEN/AN"N8W*W,;D$Q@#"$F$W\+*1K5@RGF4
M[M?'0L<BNV6<`FJW?.SR)RIK-TBM@.H(6;QV%F&.YN4I/\PFII0V"82H5=W'
MXPU43(.09\4$2EC8)FD8A3$$P")1-4XU$0H`!(7)N?%P#Q9]7PT1KHQE?YT7
ML_H^G_9P'Q/%F&$',OHMW(2,DRB9%W'1Y4(XQGSYLS66:,RE3C#*"9RX(4@`
M4!'SNP.`H4XZJ.H1@VC.>Z4MZN=7@T9N1*TH_:H%5:HJ>&('BMII11.<!T[2
M3.U5IHB"M3G*D8_`:5+JSZD3'8MOU3M[@7G%57\<JI#G;-X2"'PA1NVR$GS>
MKH*9.8KEX31!RS0%PBD50Z"2IER!)C'J+WB<XQG&2N>G7>IF&+8R\EH2),DS
M/,9C.M9/'V7XMQL4IMBWEFPF0R`3"Z,V4**D:_%--1JBB[<AK&747O\`3#\6
M33IPW8@BGP;,<R:+9*1$1>N(O$I:;Q/&!Y#;<L=&9%,SC-M'OVCIXFY:K/$B
MM4WM5U&H?"/45OT1<T.QV(W/SERU`AS9<SQ^2VNQJ99BZ22"48P.;[>3,[$%
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M-NXUZZ?Y3-3;IPD@9LR71AV2BATA>)F9&!)#]3.\\E#Y)(R'2]O_`(VZQ^=V
MVAV[&9#$Q+D*&>/5&DK,PCB+Q&265BL$(W.I**+((@@0Z0GTRJ&,F#0#K"WH
M?(1\QC_2EU`3>.RJ$(]CG2*,0G(O8W)4(5[#2*::>WCB#(F#)\XYI/Q`QFRI
M$0.8I%%5$`D."Z@]Z7LV:&R/IYW<Q=(^+YQD;6;YF)FH;7Q:(6DH>#?NF^W#
M)-A*Y.NU.W33.>A%#H@F*YE1*F#!-U8[_.#BWCNE7>]2Q\^13EW+5F>+EHV-
MEFD<I*PR<=@+Q,WBS=R#ABDY=MTE4O.UQ3*=4`7S75-U`0KB-8'Z3=[WS]\J
MY75&'<,9>,;1;1ZV3$QI1#:U!L68?,DW8H-EA13*X!J"BI47"BS<']LEOSN[
MN?G#>#RW9G</:>`<8NG)IKYDW`)89FYV=VF)SX)"P:D2@V2;"30<KNP&00!T
MDS7!5H0+B<DZ^-W_`/(Q?]7<`<DZ^-W_`/(Q?]7<`<DZ^-W_`/(Q?]7<!KFK
M-US\I\+/@HHT[01C*C[5)WUCQ#]ZG`;'DG7QN_\`Y&+_`*NX!C;ENLU@L#RB
M7P4[F:S%C&&5QN(<QB$@VDY<5DDVC%TWCVS1V1LZ4/8HL50"MB&%8U2IF`0J
MAGG49OWANYSC`(SIDWNS>`A"$/-[I8\3%1PJ2*MB'C2"F+)!CSN;?D_&-TUC
M5DP;KKH*'5,)#)MUE4PM?@$E+97CD!D\DWR/%9+),1Q2>D<9G&K!&:QY]*QZ
MCQU!RR*\&P52D(I944%BG;H'!0@U(4?-`(&ZCMVM]MJ9K$&^UVT&8;QPTW&2
M+F<<XVBR%W!R,5E6$&58.+8)RV1)*[=N<D79*''SIMBP;&**;I0Y`:Y]^]^7
MV$S.2QFQ&XT7)L)C'&<3%S2)GRV11S]:?1E7S*(:;<1.1,2*NH1NW8G=MT#(
MIS#5[)),DD72"8-XF_/53))M>6V"S'%';IMN*EX?DL:GD#IO,8U,90CBB2SK
M%8DN/%C)N%9PRBK@T@FFX<2BP,CK)LE#'!P1V\O4J&ZD%ALOM1*I8BZS&+A)
MG+&<1..2-8%U&F-XZT7-AK>!.@_DE07.99\B$5'M%TW&H^5;(&"Y40S=#%QX
M^+/@]IM^P$8N@>ME[JQPCP%#9OJ4ZEL?W%RO&G/3+NA/8E`S&:1T5D^+M2'2
MRA%CDFE@Z\&=;"Y)J(3>)@95T=T=NR2?%$HNDDQ)J!OLYWXZ@X)3&R0.T&8K
MN)/%DI.>CG6+Y5D9(3(5<]7Q)"*0R+$MMEHIZQ<Q[%1^<ZJ39PRC%B/UT@*"
M+-X#6==175>VS13&D>G3+Y&-4/FA&DLV;O&[5!TP:28X1%2,P[P@L()Y=5FT
M=/Y!(XL$6TJ1ND8SMHY+P$R;%[C[Q[D/\I;[G85,8,RA"8@\Q9^:#F8I+).>
M7FD)-V9+*\4A'#(YU(Y%="/*1PX9MG!`=J%7/I$"(\+ZA.J"=E<683NS601)
M7<[@,/E9SX7GS-HT#(\R6A\C?8]*26WJ$>\AH#%2FDSNWYXX&Y6X$5)K/"(-
M`Z#<DZ^-W_\`(Q?]7<`<DZ^-W_\`(Q?]7<`<DZ^-W_\`(Q?]7<!'NY+)V,1C
M])F0+3</;4PT0B1O*&<P-2#6-&A3!WB%#>00X"009.PI68?C02U`48KSJ"D(
M@-(X/3:9@&E/3C2E"V@%9.PMK,/S4LK5&*"^T6PF`UL<6FIH&`:4]F/2E"6`
M%9.BV5F)`]NG=<C%!J6"SN`UD:6FKRQ[K:4Y@]*43TP",71;+IB04MTKKD8D
M-33Y*^^R-)36Y52ZVE.94MMHEI@B38N22(B:5?J"#%H`J';10"<$5T14*91.
M%3"CGESB<`5[.8.)"$HF)`6D8NRV73$@>W2NN1B0U-/DK[[(PE-;E5+K;:<R
MI;;1+3`*Q=EMK,2![=.HF1B0OL!H!KK(TM-7ESB:E*:YZ4HGIA77J=WGR/IV
MVS;[@PN$YENZ\-EV*XTIBF,HE\74;SKU%JL[:IPN&9(\<R*YFPM6#?EDD'4K
M(((+.&:!Q<MPI$[^D7WI=(0">/=&N\C>7GX;>1TWA\_4R?$7S>=VJR;*8:/Q
M]XW8[$Y"JV/ED9`12PNE"I-FSO*F22!GC9-P\1"<,X^<#-4-T]G&N9GVY@9.
M'<IS,EBT=+Q><MY+/I[-T):6Q7/<5G-GYG'96.5BRK,I-FV%R98VN#E41!0\
M;WO(<A3DLFUVU\5,./'CM]['-YF;]^O7W:1&G;&G27:_%_$?#]QX3M.>YG;;
M_<\GN]WO,<>UNZ;?'CKMHV_9]R=CN;7FTYK=T^Y2.D1$>LHVZ:-I-T>EC8;%
MMD8#J0S#=5AB,8^2/G^^D-+;G;FY`NZHJ9>6R>:W9%))NS27(@S9M6R#!FW1
M2320`H&!3&R[[EYBW;GP172?^8F9_/\`B/ZWYV[V'BWT\QY,49^,Y2^:+UUG
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MZ:;C=1VQWVMV1&GZ%=*5UTK6L.H#-F[48MA\7D4C':D"@(18"0QDG8`8"JPR
M`@9,SE,0`R9>UNG4O:J"FP1`K.Q=&OMF)`EVI;:C$CIW\[99?&GKH\TG;==7
MED[JU5U`#,G1KZ3$@2[4MM1BAT[^<LMOC35T>93MNK7ER75JKJ`&9.Q$U)A^
M2X3T`$8H;+A<V@6Z--73UR4K6NB2M:J7@CD6+D6;D1E'JI;3#HBWC#D,`G4$
M""4(=R<Q2ZA0#S##1,M:B)A,"SD7?QQ(>C_$Q7943#3^C?0`P!^X'U:@<DZ^
M.'_>'>C%=M!*(AV1H#V@`A^Z/U*``R=A2LP_&EM:HQ7G4%$1`:1P>GTS`-*>
MR&I2A;0"LG86UF'Y[;*W(Q07VBV$P&MC2TU`0.`TI36/2E"6`C48N0>1UTH^
M4,36-J&;Q=P@1-B"A!.2&$J97.@>^ATA]>/;Z5,$P6$8NBV73$@>W3NN1B0U
M+.2OOLC24UN54NMMIS*EM*):8!&+LMETQ(*6Z5UR,2&II\C??9&$IK<JI=;;
M3F5+;;4M(`K%T6RLQ('MT[KD8D-2SDKQ-9&EIK<LI=;2G,J6THEI@%8NRVUF
M)`]H)UN1B0OL!I<)K(TM-7ESW6TIKGI2B>F"%NP=`\>CXL_K1D!C\M%%%82(
MI`)C'"%2O$^D:M#G`NH:EE"@4%P,784K,R`TMJ(HQ7;0$@$1I&AVFL$1IZL:
M=Q:`<B[^.9#N^XQ/DI7^C.^O;_IX#`L78UI,R`5K000B>RH*``A6-'M+>`A7
MU`5[QJ`+%V-U)F0+6^@@C$^;<"X%$MT:(#IZQ1"M?8BUK4]P)6C%T*2]LJ_0
M`[J1M*FWBR@03.I$NH4%(=,3&$ZY5*F`X&,D7SCE,<5`5F8NS7TF)`EVI;:C
M$CIW\[9;?&&KH\RG;=6O+IW5JKJ`'8NS7VS$@G=JVVHQ(Z>ISUEE\8>NCS2=
MMUU>63NNN5U0#L71K[9B0)=J6VHQ(Z=_.V67QIZZ/-)VW75Y9.ZM5=0/A=DY
M%-<?%G]#$7H0$8LP`!RO;2@!HM43`F#D@!4#5Y<E0-534#P:,'?)M@"7?I^U
MD@`I6\44$ZI+6E*4T0C;I:Q``!3+["2I0J<#`J%D[&M)A^6HFH`(Q7FW"L(`
M%8X?2:A0"M?8RUK4UP').OCA_P!X]R,5V5$P@';&B/8`@'[@?5J%8=BP$NZ.
M?%$YE!#:#:,!.8"@8XAN_P!5E3&`A2D`1^H`!P%L.`Y[[0M=S<2Z"]F,GP#+
M<RR?+F/3ALZ]QW&UHG%G[91=QAV*#R:#+']LI:>?),&"QRI)D2764(F`'/<(
MK%#[V:W$ZE,]W/7QG-(#=C"]O5H;)7\;F4OB.-0;_P`2BYAFQ90DLPD]KT8^
M.73;D6,#A)VY2ER+HK,R$22<6A:+'X*18;G92FZR[(YDYL#P@Y5Y)'%TE4RF
MR#/RZ)2Q&-Q:(IE$@B`F*)JF&HB%``)`Y)?Q@`\5D?Z-$:TCO=1>S^CZ<!\3
MI)9A"3+Z*<R,C*,HJ0=QL?8P-SS]LT669L[21]YN9<$*2@=HW=G`4A9]3'4$
M4L*WFNEG=MB^D6D2X>+-799&+CADFZ:YU'2T5M1++-@CU1Y1RWHJ[0>N$*$5
MCR/Y)@'PCU/[\.W<@V8]+&]ZW,+L`Q<TFV;8\V<M@BWBT^KD4BZV_?)P9HR7
M:$;H`9&]\1TF=`BA"*J%"9W>YFZY\-<OFFUNX$=F)]J<LS9LTD2X_+8G'YI!
M.QC8O;^1<0\*EFLE(S:P@[0%G#"9=@41+:L()`%=V/5AU(I%8,Y+I`WW?N+H
MYK(9"R:0\)#*J+0ZCZ0ED(%7&,FGF,8@Y)4B&H\=Z!%""'B`M8]T%YMO'^2Y
M1@&#Y+E3:3Q;)\@Q'&YK(L9,0A38].2<.S>RT*8LG!1LD4T8_641$'#9NL`D
M\]),U2`#QY%?XUD?WH[^K^`.17^-9']Z._J_@#D5_C61_>COZOX`Y%?XUD?W
MH[^K^`.17^-9']Z._J_@#D5_C61_>COZOX`Y%?XUD?WH[^K^`.17^-9']Z._
MJ_@#D5_C61_>COZOX`Y%?XUD?WH[^K^`.17^-9']Z._J_@#D5_C61_>COZOX
M`Y%?XUD?WH[^K^`US5BOS\I\*R/LC2HTCNWVJ3_Z/X#8\BO\:R/[T=_5_`5!
MBMW=]GV18JR<;<Y$2"E]U]P<4FG2>(Y''2D9@L&0Z&&Y2FG.8PU@&83,D@N9
M=T[D2MEHY%)=NES#PC-$(D8=7^^Y79HV<Z4]YVSV17>-L94:E%E'RK_4F';"
M(56R3:V&>E<HP$49R\6106L,1;2141*DJL%X<!D97*\=@,GE&>1XE*Y'B.*3
MLIB\RFS3E\=D)2/4=NX.426A6*J<A%+*"@L!D$#:A!JF0?-`('ZC=UM_-K)G
M#V^TVSV2[QPLS&23F?<0HLRO861B\IPA0S!4PQAVR*4OMVKDJC)0P&'QQK'H
M'**+A42@W!WVW\?X/.Y$SV-SG'IQK-8=%XS%3;22R`N2H3LZ]B9B1<Q41MO"
MY3C4-&MV(.^;=M`7:Q[I-P[9IN"#''"-)WJ0ZO&>,-YS'^GN?G'CME."SC7&
M+YA%/5G:$NNA&N)"*<XGXECK..AEV;ER@N"KF3,=8C&BB2B20/O'M\.IB5W#
MQ&%D]E9^#PF>R''D)>3>0LTO,8]CDW!$>E6>.V^-I8P:21D'8"^,=TV1B&[!
MPBJ"SY=H@8+I1#%?PN/I*R(!R:'92.&GK9>SMCZ\!0!SU*]6<'D&4M9CI/W%
MGX"+RQ;'\?>X:[A@>3T4G*Y7`%R8`DH1V@W8JO=OGS],A@*0T3/02AUDU%U0
M$-W*=0/4XUA\<E(CI]S+(7\GA:N33V,,HZ0C74&X5W.7QAJBTGLLQ#%F<H[0
MP9FI+J0R[1A.*ZB1M%`I@2,&L?=075PUS=;&FO3GD4G$*JYJFRF46[YFU0<L
M6LI^(L;(3+G&309PE%&C)U(R*9P8IH28-4+GC)T`A,6QFXF\VXC[*FVZF#2>
M$,H0,0>XH_""G80N1"]7FD)1PX;Y3C\:LQ64.P172CD^9<,6SA,KQ4K@^D0(
M=PSJ!ZK9N>PF.G=E):*8/<APR'SUZ?#,]8I1C:>FYAA+R>).I/$&S67BHZ/;
MMG"SB2-$>'H7**D557(T0#H1R*_QK(_O1W]7\`<BO\:R/[T=_5_`'(K_`!K(
M_O1W]7\!'NY+!<8C'_A>4+3</;4PVA&!<!<Y@1L/=&F\PWHTH/D$.`D`(]P`
MA\,28T$HT$(VAK12$0&D:'8;3$!I3TYJ4\VT`L>X+;67DSVB01N"-\^P6PB!
MK8XO8IRYKJ4]F/2GF6`%CW!;*S$F>T4ZW!&^?9R=P'MCB^R\J:ZE/9U*4];T
MP",'!;*R\F>S3K>6,]<T^1NOMC2^S<F>ZVG\Y5MIZUI@D38KDD!`9.04$&;0
M16.G'7G!%=&],QR1)"VN.6,)P`_8*ZEI2>MB0%98]P6RLQ)GLTJW!&!J:8,@
M-?9&D]FY0]UM/YPI;3UO3`+'N"@2LQ)GMTZB8(RI[`:77VQI0]=Y8UU*>SJ4
MIZWIADK!P6WX8DC4`@")BQ8W6@W`UWP;2JF@:M*=JIZ4\RP,@Q<A3X8DAI;4
M12B.V@)`(C2*#M-IB(TIZ<U*>;:$$Q&SN)9([G\B?'RB,EW>09!&/%\?RC(L
M43?M(G*<@7C57;*#1Q=FX72/*+G!;EU!4U1'77`=4VOS\9L]QGG<Y(O&:U8B
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M_P`-Q_"<IGU"-D&II3Q1T5(SIJG.*-'*19?E\?XW@N9WD<=FWV><_L9K6W6?
M-N+T][!CM&*F3/,W]K'.M*:VM,Q6(M:VD2T'UW^IGDOU`Y7C\'-[/@./XSC-
MO;8[7'Q6TV.SKFC:VFMMQO:;*M*Y-_>+5OFF^/%%>^?:P8:6M5*6"]:6\[;J
M';;4->D[<I+#-TMW<;/*;B)1F11B6`1F=X)'28O<U:'V=8PJ4^W*=%SI>)K+
M)-&#CQ!1!=(Y5L384BE]SI$1KN;3Z1'K2G7I$:_EGK/QF7-_*]UDW.VX;W+6
MMV<+BK&MK7TB-SNH[8[K6[8C3]&NE:ZZ5K6.CK*R8KJ,&MLG(-@,T3*4B*<:
M0J54790%,BD202BF+H@@`D`*MTZEIJ`IL$0*SL'!KZ2\F2_5I86,];U.>MLO
MC3^P\X2VZ[^;)77>NZ@!H]P:^DQ)DNU*6A&^MZG.6V71QO8N:);6O\W3K7US
M4`-'N#74EY,EVI2T(WS+Q=4`MT<;V/F"VUK["2M?/O!*_8K@U<'&1?+!:8=!
M1./.D8#'5$"&(6*5.8I=4*=AA];+6OG"8%?(+_&\GZ/H1O943C3^CO0NI_Y(
M?5J&/#W%?Z8D^\!I2-H-!*-.R-[AMI^Z/U*!DK!P%/A>2-2VMP1OG6BB(@-(
MX/3Z0@-*=BAJ4\VT,%CW`"41EY,UME0,$;0]@M1$#6QQ?9.7,!J4]F/2GF6`
MD48K%=L"C)/U1#4'54)'BH`))L;R7$B;2%=<N;4H9,1U3V]Q`3!81@X+967D
MCV:5;RQGKFGR-U]L:7V;DSW6T_G*MM/6M,,$8."V5EY,]FE6\L9ZYI\C=?9&
MD]FY,]UMO\Y5MM]:TP"1[@ME9B3/9I5O",]<TP9`:^R-)[-RA[K:?SA2VWUO
M3`+'N"VUF),]NG6X(WS[`:7":V-+[+RQKJ4]G4I3UNP$;=@N#MV'B<A4@,RF
M4TXT#+B1)$1,J8(A,#&-I"`T,8`U#4M\T"@L"/<!3X8DQI3M$(WMH"8"(TC@
M#SK!$?\`;'ZE`/#W%*>,2?=2M(RO=2O]&]_H_P"G@`8]P-?AB3"M>T`C>RH*
M``A6.$/-O`0_V`^K4`T>X-=28DRUOI:6,\V\'``);HTWL>N40K7V(E:^?<"5
MLP7.DL)9.0;@9S(`!421Q2E$74B35*"D4414,9P52H@8!.D0:G`3BH"H\>X-
M?28DR7ZM+`C/6]0'H%LOC3^P\V2VZO\`-T[KO7-0`[!P:^DO)DOU:6%C/6]3
MGK;+XT_L/.$MNN_FR5UWKNH&3L'!KZ2\D2_5I86,];U.>MLNC3>P\X2VZO\`
M-DKJ^NZ@>:S!>Q8WBLC02+#IVQPD`#@]$"``QIS"4@.B@%;A$$$ZW>N:@>31
M@N+1M25D4[FR="D)&E*G<DO0I"&BD[02Y@H%`2!31)4/3@<%)F#@:_"\D6MU
M+0C?-N%80`*QP^DU0`*U[$RUKYUP8\/<5_IB3[Q&E(V@5$PT[8WN"ZG[@?5J
M%8]BP$NZ.?`)C'$-H-HP$Y[;S4W?ZK/.-84A;A]&@`'U.`M?P'/;:".W,Q;H
M,V9R7;K,<SR',V?3?L^]QN">QN-RK/F'&'8J<S5&.@]O7TT_28,%E"()%375
M.0A0,83U5`'1LW*]2>?9&H?-Y3/,(PXBF;)G:3>"X;`9(D$2\Q9KBI#OC0CM
M@L[DE7TL)SM4G3-RS8I."*('<<ND$^X_`/H_<W*$G.6Y-,G-@F$J%7D_Q=(H
MF4V09^72*$5CT6D)"BG<`F*8P"8W:(4``D#D%?%P#Q22KX:8:W,N[FB]E.2X
M#XG499E"3#V(<R$A+-(J0=1;`PLQ*]D6[195DT,`-"")7+DA2#VAZ;O#@*2Q
MF]O5ZP5/CDYTV2\_/16-8W*2>5QF8PV.87,3,ZP;/GT/`H'P?*WQ?`'#WDUA
M,X64%1DX4.5(IVI5P3K]1'5>?\9&S/I'S-JZ@$6XIOY+/(1S%3"RPM4%%8)&
M,VU,_F&J*KH5P*&BX,T;J`<B+D4VYPU<7U-]4SYS(NG'23N2UBR.'+*'CU)=
MHVEGJR#AP1LNZ=NMNP:M"3**13-Q4129MO/YMTA5N#@+387D6[4[-XHCE.)N
M,5A);",PDLE'Q-G*N\>S>`RZ!A82&;/R8]"I/8;)L?>/)%NJ=LDXL0`#D3&H
M"$R^'J_&LE]DR_`N`/#U?C62^R9?@7`'AZOQK)?9,OP+@#P]7XUDOLF7X%P!
MX>K\:R7V3+\"X`\/5^-9+[)E^!<`>'J_&LE]DR_`N`/#U?C62^R9?@7`'AZO
MQK)?9,OP+@#P]7XUDOLF7X%P!X>K\:R7V3+\"X`\/5^-9+[)E^!<`>'J_&LE
M]DR_`N`/#U?C62^R9?@7`:YJP5Y^4^%)+V1I4;F7;[5)_P"A<!L?#U?C62^R
M9?@7`1%N//[D8WE6U4;AT/(Y)CV2Y)+1V>/$&7-R4'%I0JCB+>M79F2>/Q3<
MLD6YPM(*I@=$@I(%5<*))B%1H[JMZFB.EF$UTD[G"X?*O"8XZ8216,:Y<BO,
M.6$7(*R^V)'R(M8.,U';LK>HK%/HMCIF0.L%WL!?3.48[`9+-L9_$)O(,1Q2
M;F<5DCLC26-RDG'J.GT"_'PII5Y$N%#(*#I)")R"-A?2@%?=[]R.IW"=R\<@
MMI]GWFY6W;F`CI/(\D3D(5G(M)524GO$81B#Y1NAS)8>(0TU#IBF1=^B(W%`
MY>`8D3O[U1Y!BN3S:FP&5X'-,#;6M<;QZ;CW^7N)-]ED[/M\L7DSQ>*XL+6"
MA(-FP=&<->:<1B3PPO&PNTQC@!O95OQUN1\`,G#].+]M-C^.;4,8D09Y(=-S
M%Y?,,8.16G,+6D&/A".%GBGRA4DUW4RZ5=I,DTM`I!!YX_N_U6R6XF(Q$UM$
M\@\'F\AQU*<=+0KUS,P&.S<"5Z(+2S%%;&E9-H_<F-(*G4:H1:4<JV]M/7;,
M@A=*(8*C%QXA*20>TV_9<R&GK9>P/:7=P%%)G?KJ[Q_<7*H(W31D.481$3.9
MQN/9#C\FQCU,H12R/_U!<,%EX?)>33>XF0P/U7Z+5F5\%_,H)BFDJ"W<S>OJ
MQQXF/*X/LA)SCY7%O%\IQQ:.=S)4)H,V?XTA#XSFL?%PL.]7D6#!-YIR#*/%
MC&O`?JJ'%'DE@TCO>_K3;YP?'6VP2TC#+JYJBUEBMSLFK1XU921\&CGDXLDM
M$N6CDR#!W)R92MVIB21V35,SMBX$0F/8O.=\,\?92AN]B#K$&$27#GF(/4("
M6QPTV+Q:;1DUW[2>;*"S>.>1;N21R*SM6-0<$3=*\P82%"*V6]G5XC%;=/Y?
M9=VX+,Y#@[#.UXB$ER+PT,^RG<V-W`DXB!>Q83R1(K'\=@G<4+Y!,RWB)Q<I
MIZB!`#[F=YNL%KCD],0.S)Y]ZSR++F,+'&B92*=2T<QS;"([#DTF,O'QC],9
MC%<D>\[(."-6;=W&.721562*8.@U&>;^=7$3+98UP'9B7RA@QEYM7%7LC@V6
M,64CB+>+B#Q[E^^-%LY`,M:.'BSQ2/1C3-I)`O)MG2;U)4O`7]ADI%_$13Z1
M<2T;(/8UB[?1RWAQ56#QPU26<LE2I-UTBJ-5CF3,!3G*`E[#"';P#/W)CE1B
M,?\`A:5+3</;4WFG8!=;G,"-AZL#53-Z(!0?JAP$@!'+`)1\7E!H)1H(L*&M
M%$1`U&`=AM(0'ZAS4IV4#(1RP6UEI,UHD$:F8>?8+81`U&`=BG+F`U*>RGI3
MS;0"1RQ;*RTF>T4ZWBP\_3%F(@>U@7V7E#74I[.I2GF6!@D<L6RLO*'LTJWF
M8^N:?(W7VL"^S<D:ZE/YPK2GK>F"1-@J1^)!DY%02LV9A5.#'4,""Z`&(8Y(
MX@"1QRIA.`&[UU+0+Y@D!62.6)967E#V:5;S,!U-/D:WVL"^R\F:ZE/YPK2G
MK>F`6.6+967E#V:=;C,/7-,&8")[6!?9>5-=2GLZE*>98`6.6*!0&7E#6@0!
MN,PJ:P&P")K6!>U3EQNI3V4]*>;:`$<L%/A>4&EO>9AVV@D`U]H!Z;3$1I3T
MYOJ4!H86Q.I'2]CQXS`N7YH4Q6R+)N"QAR:4,9RJ4T*S`ZZPFJ8X%,!Q[=12
MMY@J/U6=4&\VP&3L8';'IVW$ZAD%ML,@S=VGA3#*/$VDM'Y1"P;&,&18[93V
M)N@,PDG#LS!!^M/*I-1.FQ%,MRX1)%=5&]N[^_R_2]GW2'N=CNS>X$ON=@F0
M;M+N,UC8V/PQ/;[)92&5>RK3;R`CXZ=RINFS5`[&9,BR1EFB!7(R"#M'C*V.
M\S<?O<6_V\8ISX<E;UC)CQYL<S28M$9,.:E\66DS&EL>2E\=ZZUO6U9F%5,V
M;;Y*Y]O?)CW%+1:MZ6M2]+1,3%J7K,6K:L_>K:LQ-9B)B8F-5>-CMKX/H$P3
M>;+-KGO4GOWG;!U"89MABFZ&=[U[NL%&KS,\A(ZQZ*\`QC/TH^<3B-=VK)*Q
M)N4:,P4<*-F)GKA76>1^7;CZC?5/FOJ3S6#;;3G.7RXXG;[+%?;<=A]K%[?;
MM=I6UL&WF]</N7K2*UBTV]JF.ENV?JWZL\WS?^Y;QGP/8X>)KXYPF&^XW&>N
M#94Y7=7W%]M%<V]W5<=-[NL./+NHQ8];7C6:VSWRWQ4MBV9>OGJEP[$9[*8;
MH:W+FYB?W)WC1G\>CR90IX1,8JRAV40E'N(G9UPL^BS,7)9)S)R:4<1\SC%N
M4UESE25L[&D4ON-/CN)GX?P*?+_Z_.9?/OE.XR;C;<--]9[>&QUCK:?3<[J-
M/O3.FD1'2-*QKTK$='8+;E_+9?MS@>4RS2?PZ6R?",8GI/%7I6R4AB\C-P!7
M[V">I.81@LF_@W4IH*`HW0,"K,ER1!!0AL]$CT/'+'OI+RA+]6EAF/K>ISUM
MES`WL/.ELK7^;I5KZYJ!D\<L:^DM)DOU*6"P];U.=H!+F!O8N;+;6O\`-TZU
M\^\`T<L83"$M)ENU*`4S&A+Q="%MS`WL?,EMK7V$E:^?>"5^R5(U<*#(OUB@
M4PB@J#(Z)@,=8;3%+''.)2ZP4[!'ULO^M<"KPY;XVD^\?X3'LJ)QI_,.X+J?
MZ"A]6H'ARW9\+28TI_"8]M!*-!HP#OI3_0(\`!'+!;\+28TM[S,?.M%$1`U&
M`>FTA`?J*&I3S;0"QRP6UEI,UME;C,?/L%J(W6L"^R<L8#4IV+'I3S;01G8J
MD=L"#)2"H^N&U5`8BH`()L;R7%CK2E<\N.I02B.J>VGF6`K)'+%LK+RA[-*M
MYF'KFGR-U]K`OLW)&NI3^<*TIZWI@$CEB65EY0]FE6\S'US3Y&Z^U@7V;DC7
MTI_.%:4];TP"1RQ+*R\H>S2K>9@.II@Q`;[6!?9>3-=2G\X5I3UO3`+'+%LK
M+RA[-.HF,P\_3!F`WVL"^R\J:ZE/9U*4\RP$:#!7FW9?$Y$!3!F4QPY$#KVI
M(B)EC>'%`YC:(@-!$`!0U+?-`H+`CE@``\7E!H!0J)F%1H"0"(T8!VFTQ$?J
MG-]2@'ARU*>+RG=2MS"O=2O\P[_1_P!/``QRP@(>+R@5`P=AF%0J"@`(58#V
MEU`I_LA]6H`QRP@8/%Y0MP'`!`S"I;P<``EJP'M3UP$M:^Q$K7SK@3-F"JJ2
MULE(-ZN9`EJ'(E`HBZDB:I0/'>R"+D#B(@("=(@U,%UX*3QRQ[Z2\H2_5I89
M@&GJ`^`++F!O8N<+;6O\W2K7US4`/'+'OI+RA+]6EAF/K>ISUMES`WL/.ELK
M7^;I5KZYJ`'CEC7TEY0E^K2PS#UO4YZVRY@;V'G2VUK_`#=*M?7-0/E5@J!%
M3^*2(A:L;3'D1)0P/1`E.0,82D!T4`K4:()UKY]X>+6/6,T;B$K))@9LF(%)
MR!2I@=-<0*0HQP6@ES)0+YH=B)*AZ:X%(QRPW?"TF%;NXS'S;A6$`+5@/I=4
M`#ZB9:U\ZX#PY;M^%I,*U_A,>RHF&@58#W5I_H`.`K%L6%NZ.?%$QCB&T&T8
M7GM$YJ;O]5@7&$I2E$P^C0`#@+8<!SQV?@MPL9Z#-FLBVYRS-\@S1MTX[1/\
M;A)`[259\TZP_%ECMD8^$Q1:7>HL6*RI&Z)2K'%,A2C4P7@'WM!E'5#FFZ?X
MO9[C^XF';9N(3+7J622$?%0>0Q\Q%3,6RAHB0(6,FH!<BK7FC`X;NCED454%
MT$T@*Y2;A:3',<7C-S<I26RG*)@Q\$PA0%I5W&'43*;(,_+I$!C$L$["BG4*
M@(@)C=M![`D/P\WBX!XC)?T:8:ZZ7NHO93E^`\L@0E64#-O(5:0D)EI$23J)
M8'62$CZ3;LUE6#,X`FD(E<NB$(/G%[#=X=_`45ROJCWVQLN0OFW3#N=(XOC^
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M/QR;RF4MFF=3+,S-)F#<(7%EE5FZ13*HE=(@85UTCV`%SACS"(B$A(@`CV`"
MZ8@'U`N1$:!]41'@,>'&^,9+^72^\<`>'&^,9+^72^\<`>'&^,9+^72^\<`>
M'&^,9+^72^\<`>'&^,9+^72^\<`>'&^,9+^72^\<`>'&^,9+^72^\<`>'&^,
M9+^72^\<`>'&^,9+^72^\<`>'&^,9+^72^\<!KFL>;GY3X1DNQ1I_'I>Y2?^
MC]G`;'PXWQC)?RZ7WC@(BW(F]Q(#)MKHC"(>1GHS),CE&^;R"D>Z>-X3'V$.
MJ\34\8;.T&L!(/7P$2:'<M73==8=-04"7+D"HL9U0=4J;I=A.=(>?J+/U'B>
M./&&1N8Z,4=&7F'+&.E#R&#.7R"32$C0,[>`@0QURGT6QR*-Q4"[^`NYC)L=
M@,BGXZ=Q">GL1Q2:G,5?NTE7V-R\E'J.I"">*<HE>YB7)S('&PE3$$;2]P!!
M'49GG4EM[,XBGL?M0XW;A)2,DE\E.,FT8OH>4C,IPAVFT!=T_8H)M9O;TF3(
M-CE1<'2GAC#'*9MKD,#<5W=ZEY#`IR>9['RN,9*27PZ/Q&.DGDCEZ,XUFIM[
M&34M/0K&&Q'(L5A6+-FF].J8CE^Q8.RG68G=I&9&")Y+?+KL1Q)*78]/B)IX
MR.1M4XEPSF%DWCJ.EU6[6?6392ZLE`PK>'<-ETF2B+N1F#$6Y<B)B@EP$C8_
MNGU8R.XF(Q<YM(K!X-,Y%CI)]<T?).9F!QV:@0>G3/-,Y)YCKB28R#@YY%4_
M+(1J<<HU*+IV\:`8+IQ$>88N/'Q&2"K-O_'I#3ULO_H_`4#<;Y=;$!D&3I2?
M2U(Y=CC++58'%U,7RZ)AI"9@RRN5P2.2NEWBF1$;)+*8$K*%3.W13"-RF'(H
MJFND[`0>S'=#JD>IX,X#:PZ9YK$7&09=%K1DZW"`=I[LQ4`V8L)J16BA6D7N
MV"[J1)'.V#9\BZ3346*"9E$$@9CO>+K9;YP?'VFPR,E!KJYJBTEQYR/;-'K=
MC(GP5@[F595>-=L5-./=R<G8U14"059-4C.6*QA"8]BLRWRS=_E*.\6(KXFP
MC"8>[PYVVB)G'%)D7BTVE)JR;.:<R')OW(,F[DL>@X='C47!4G*HKB)0".-M
M-R>KS,)F`C,FP1#$D4GF(%RB1?X/D+2(>MG.12ALN6QV1D\K8.T(]/$(XP-C
MNV2;]K)K,RG:.47"RC4+V^&F^,I/WPG]XX`\--\8R?OA/[QP&?#C?&,E_+I?
M>.`CW<F-,,1C_P`)RI;=P]MC>8Y1+=3.8$;#^UAN3-Z(=E?+P$@!&&"GPG*#
M02]@N$>VT41H/M<.PVEV_P"V;RA0`L8<MOPG*&ML],NB-U@M1\[VN%;^6$#=
MU05/Y0H`2,,6SX3E#6"GZ==$;]/DJWT;@(ZG)C=W5UE.ZX+0"1AB6?"<H>S2
M].X1&_2Y&M]&X5U>2&_NKKJ]UP6@D38&(^%/Q"0/:T9GU#JHBH;EUD"B0Q@;
M!4CCE!%0/1%92E+@M!62,,2SX3E#6:7IW"(WZ7(UOHW"NKR0WTI775I2X+0"
MQAB@0/$Y0UFGZ9PB(FTP9AY]&X5U.4&[RZRG=<%H8+&'+;\*2IK;.TSA$;K`
M;`-U&P5OY<;N[V0_=4*!D(PP4^$Y0:`4*BX1[;02"H^U^T3:7;_M&\O8#0PQ
MD*\?+F*[=MK,OS1,2M3((E4,7)Y6JRH`T(!UU!&IC4\X>T1'O$(LZF-P=SMH
M-M$\JVDP>7W9S1SF.'8XRPTK+*I!-RRR*<1CI-^\=83A^72>/1\8R6,LO*.&
M:K&.2(*ZI%["MEPYQY+U[]?,7@N,9)&?1];C2,[-8YESB2Q\(W.U7C.;A,MF
M(=D](PB\'?O8G'U\>+'/4FK\Z<M(&DB"U(9-@_'@'_OIM'@;;>3*<[;X3GTM
ME6S.V$)O!MQCL--[M/\`&IS=/-)#=,&N.[G06#'FI++($^01[0T9&$CW!DG&
MNFD0R3A9`_/-SP/#[KRZD[G'EBNUKCRT[+Y(I;)EOFC3-I;MM36L32MND6FW
M[VTUG['X3ZL?4?@O^';<5X7><?;-SN;>\?N8W&VV5]SBV>QV_'9(R<9-\'NX
M-Q[>7)CW6;#/?DQ5PS,1EPX\M==(]5'5M@V'N<JQ/I$RW-<ARK<9G(Y=AL$M
M/24AC)<FV6VZS`N/`M%[=7QV31V2S$I#O59%$8^)<PZ";IRJJY#5F>QK6M]S
MVS$_XS/R]>S'\O\`Z_-\S^5YL^;:\+.>EJ3'"XXC7NZUC<[N(F.Z9]8B)Z:5
MZ](B'0KIZRG,]T=CML<_W!@)S;K-LMPZ.E,GPM<RS=?&IAR@_3=L"H243'R*
M!$5'0'1*Y0(X(1)$%0$Y3B?8(@F8\88]_P`)RA+]7TBZ(6:HOQ"RK<::7/!9
M6M-!+OM&X`\88U_PG*$OU?2.$0LU.=I95N--+G0M[Z:*=:VC<`:,,:_X3E"W
M"?L*X1"V\78T)5N-`)S06]]-)/R#4$SYB9)LX5%\_5`I3&TE54C(FN,MYIB<
MO42EU^P/_-E\@U!3X8;XSE/1_CT>RHG'W/Z%_9]0`X`\,-V?"<IV#7V='M[2
MC0?:_<-M/]`CP`$88!*/B<H-HE&@KHB!K11&AO:_:!M'M_VS>4*`%C#%M^$Y
M0UNGZ9PB-VF+4?.]KA74Y8;O+JG\H4!*=@9-RQ3Y^04K>?4451,H'+D8U(!P
M;A0CCEAU`[+M0]*5"T%1(PQ+/A.4/9I>G71&_2Y"M]&X5U>1&^E*ZZO=<%H!
M(PY-/X3E#V:7IUT1OTN0KJ4;!75Y$;Z4KKJ]UQ;0"1AB6?"<H:S2].X1&_2Y
M&M]&X5U>2&^E*ZZM*7!:`6,,6SX4E36:?IG"(WZ8,P\^C<*ZG*#=W5UE.ZH6
M@D08&%TZ)XA(>L@S*)P61`ZM$D1N6,#8+S#H]OU#G[JA0%81A@``\4E1H!0J
M+A&HT!(*C[7[QTZC]4QO+V!CPPU*>*2O=2O,(U[J5_F_?Z/^G@,C&&$!#Q25
M"H&"H.$:A4%0J'M?O#4J'U2E\G:`:,.8#!XI*%NO]*NB`EO!R'F^UA])S`"'
MDTR>0:@E;QYEDEA"0D4:N)!.B"R1``>:DDQ4`!;C101<W5]6F0>V@W`J/&&/
M?\*2I+]7TCA$+-7GJ65;C32YT+>^F@EWVC<`>,.>^DG*$OU:6+HA9J\_2RK8
MU-+G@LK6F@E6MIK@#QACW_"<H2_5](NB%FKS]+*MQII<\%E:TT$N^T;@^58\
MP%54\1DA"U8]@K(BG0W/&LM%N/F$YP``/(BGWVC<'BUC3*-&Y@DI-,#MR"!4
MUT2E)J)N!`$PY;S03YH`+Y`2)Y!J"@8PPW?"<H%PF'L71"VX5AH7VOV`76H'
MU"%\@U`&,-V_"<IVB/<NCV5$P]GM?N"ZG^@`X"L>Q1;-T<^+<<]NT&T87J&N
M4-3=_JL"XY@`H&./HC0*CP%L.`YX;/8GG$'T&;-S6VV29Q.9V3IPVC?8U&2<
M[(2#,KUWA^+.544(^+29N7"3)BJJFV0J<"D*4MIQ*'`*-H'/4_E.YGA>XN.Y
MOB>VKN-RYR24=RXQ>204A$RD4UAF$DJTR3)X.6-)$66%HHS$Z;MG<X5!JJ0&
MQ0M!CF,!%;FY2@.093)WX)A*NI*S)W2A+L@SXEA#$11H0NG4`&M!,;R\!(7A
MI?%P+SLG3PT1_GRWNHOU:^AP'S.,9!O"3"\*J_=S*$5(+1+59^MHN9--HL=@
MW5]?;^MK.BD*;UPG8/IB]X!2=GO%U>-2P;2;Z6E#.W;*)6E9&+W)<O&#`SY-
MN+PZK9'65!S&/3@R7;)J*F%1T#Q,YV;)T8P>;?>KJU>/9!%ITH3*24DJR-C"
MDYN.C',XUJUBW89$?*'31R]=`J$X@@1@1-!,[E!T)P+:@<PA,S[*-\EL-=&;
M[5/8C,E=J<LR%)^7,FV0XY%;F1;HS"`PSP,LI$9'-MII(0D$UR&1("!=`QP6
M&G`5VCM]NM-JE',G_1]*S!4_#6[[)S[I)0JCQ)6!<2#Z:_%9LA)JM@!TG>FT
M!<BY@2%HJFU>.44DPO%MV&3S.`8/+YTV=P&;2F(8W(9?!M'KLC6'R=Y#LW$]
M&-R+.GBQ$6,HHJD4IE53`!:"8P]O`/'PLGNV3]_K_7X`\+)[MD_?Z_U^`/"R
M>[9/W^O]?@#PLGNV3]_K_7X`\+)[MD_?Z_U^`/"R>[9/W^O]?@#PLGNV3]_K
M_7X`\+)[MD_?Z_U^`/"R>[9/W^O]?@#PLGNV3]_K_7X`\+)[MD_?Z_U^`/"R
M>[9/W^O]?@#PLGNV3]_K_7X#7-8P@OI0.=D^Q1I_OZWN4GU>`V/A9/=LG[_7
M^OP%0(K,NI)WDF*H/,#>%@'F[&X4-D)3L7\+)M]MV*2R&"RY7BF73L,T7<.V
MR[I=<53\VPY4A$T'BIVY0BF-ZANK]N\5CYWI&FG"DHL\2QQ^USF3BXXCM1>:
M=LF$P!4IYVBR80L8',O#%;G6<%'21M7;E,%WL"5F<AQS'YW)XF6Q#)9K$,3E
MLBQ5664=+8W.2$<=S*P2KDJRY5E(IXH9`3`<P&$E?1X"OV]^3]5F-;E8[';,
M;71>?;:*0$:^R67D\G3B9DDV,K/'DH:/.ZR:/(B`Q$:T(5<S-8J:S\IZ*`F<
MG`,6*W5ZOI_$<NFGFP:F!Y+'-=L@Q/%UIB1S()N2FI>>#,DWLB$_BH-8X(=M
M&B54$Q/"F>G*Z*N9%8R0>.YN>=;,$R,I@NU,'.ORM,L;%2,,NNQ7>,,MFFL5
M.'6;Y\=]'1J>%'BGB3,B+]Y*.S.TB`B*9$SAM<?SGJ^?;B8BRG]KVT)@LID6
M._C(5(7J\K!8]+P`N5VQ)YOFLK$NW\7(N%%))46Z2+4([E$#.5GJ"G`72B(T
MIHN/'G9/M9M_]_6^YE\@AP%6-^LYZC,`S1@IM-M9([LX>7!7;QU$-7RL8^<9
M?XA(II$<Y&XFVZ+5B@W29%!%%JHZJX.<J3E,%5&(,')-RNL5&'QN3@]GRDD9
M#!T9B:QY-I)S/AV7CELZT/CIY1;<6$%L!X5C%H"?EW"9?%%G]X(-#)E!"[W`
MZZ$<R6B(_9K'Y*#</,O;-'SB1?Q36+.E'2Z^)&?3!LY>(RT8G;#*.'*2#8[I
MS(/FI$D@C]90)=V*G]^,I?Y43>K%S8W&LB8<YPMRT;24"O)"X6FTI0TLQ=9+
MDA6TJ[(T:N3LT7:Q8\JY4#J&4`1$(1Q;<SK@=3^WT?-[2-2Q3K*,'BMQ91>,
MF8MJA!R>0RJ.4Y%B:Y,]?N^490:21A1DF+1=HH*?\X*8ZA@Z*^%D]VR?O]?Z
M_`'A9/=LG[_7^OP!X63W;)^_U_K\!'NY,608B`]ORQ:;A[:F\R17+=;G,"(%
M/WW)B/>7N'@)!"*(`@//2@T$H]K]<0&T41H/;V@.CV^4#&\H\`%BR%M]O2@V
MV>F?K&NL%J/G5'MNY4+O*!S^J'@`D40EGMZ4-8*8A>_7-=IBR$+ZCYP'Y(+J
M^FU%*^G'@`D40@D'GI0UFEZ=^N8#:0L!"^H^=J<@%]?3:JM?9#<`D2CRIOA1
MYR0.!6C)2X[U4Z@\NL@4"F.)KC$6Y(-0![#BHI7TYN`5DBB$L]O2AK-+T[]8
MUVD#$`OJ/G:G(!?ZK55K[(;@`L40MGMZ5-9I^FD%S7:8,P"^H^=?R075]-J*
M5]./`8+%$*!0YZ5&T"!YT@N(C8#8/.J/G";E@NKWWG]4/`9"*(%/;TH-+>^0
M7&MH)!V]O;72[?*)C>4>`:&&,R.F$N;FWB>GE^:(4:NQ2*.GD\K4R@(J*`=>
MIO.,80/4.T"TH`,KJ%R3/MMMD]RLZVIQY_GVX^-8RZDL-PQ9CEF2DR6<363*
MUAPA</.7(71GVL9,#-^Q`1!50033,(!1G=OJFZ[L+@X^0PSHT=YC*J9/N-%2
M,3'N\TEBC$1::;C`'K1Q'@R4:'DH=TZ?R+E4AVAW$9X4RO>/62HAH=WL$Q[?
M*4V%S7?;92?7W"'IJB]\IW`\=F<IQ7((W=O%Y'$G,1MU/RR$[&S2.!,,CSR2
M8NXQUJIBNHD=P2J(\<_\CX?B.6\CVF/E<,WQ4P^]W4FU;=V/+2M(O:MJS.&/
M<MW4G6LS,3,>KZ^^BWU&^HOT_P#HOY!O?`N2Q[7D-UR,<=[6XIBS8?8WFPW6
M7<WVV'-ARTQ\C;\'@C#NJ]F:F.EJ4MUK$1IA'5OUY(8WN8_C.CR0F)]O/X%-
M&:D@MS(IJD\R'Q7'\IQ\D:Y<#+*2)V++'I!LV1`RN+,IQ3Q@RBD2O?,-C6M;
M[B*SK_C$_'7]Y1\W^5Y,^7!P]\U9K,\-CF-:S777<[KKU]=?69^,S,NDW2MF
M>[&[6R\1F&]V!26TF?N9[.H5YB*$B\!).(Q_+LIQ_'IEH"Y$G`-YF$*BY06.
M1(SDA47()I`8B1-@B*QIXHA]3V]*%U-7TC]<MNKS]=.@^9I^(#93TNDE3V,O
M`!XHA[_;TH6_5](_7+;J\[6R@^;9SPV^ITD_4!P`:*(:[V]*!<*@^:_7+;J"
M[$;:#YH%YL;:=VFG3T@<`F>L"HMG"X.WYA*4QK%7BBB(W&6J!DSC8)2\P-`'
MNL)ZD.`4C%D'_?I3T>Y^MZ(F'R^A=^\`>3@#PLG9[>E.RG^_K>@)1[>WMK;^
M\(\`!%D"WV]*#:)1[7ZPUM%$:&[>T!T>WR@8WJAX`+%D*)1YZ4&VSTS]80-I
MBU'SNWSKN5"[RWG]6/`)31Y4G+%('D@<#7FO4>*'4]K$8T*!S&NM5Y4-0`#S
M[SU]./`*B11"6>WI0UFEZ=^L:[2Y"E]1\Z_P\+O5:JM?9#<`$BB$T_;TH;3T
MO3OUS7Z/(4U*CY^IX>%]?3:JM?9#<`$BB$L]O2AK-+T[]8UVD#$`OJ/G:G(!
M?ZK55K[(;@`L40EGMZ5-9I^FD%S7:8,P\^H^<)^3"ZOIM13U8\`D0CBBZ=)\
MY(^L%9E`P/E;U*)(&N6,!A,H8>7[1&E0.;U0\`K"*(%`YZ4&EH=K]?MM!,.T
M:U&NEV^43#Y1X`\*)[NE.ZG\_6\E.^M:_P#S\`#%$$!#GI3MN[I!<!\X%`[!
MKV4U.SR"`>3@,&BB&`P<]*A<!PJ607`0O!P`VT'L$O,C;Y+">I#@$[>/*X26
M,+R13JXD$:(/5$B@!74DC<4"&&BOMH3":M;R$$:"0``%!XHA[_;TJ6_5])(+
M%MU>>K90?-LY\;?4Z25/8R\!D\40^I[>E"ZFKZ1^N6S6Y^NG0?,T_$!LIZ72
M2I[&7@`\40]_MZ4+?J^D?K%MU>?K90?-L\0&WU.DE3V,O`?*L<0I55.<DNPJ
MQ[1?+6>=SQK;:T`A>=&@>@":?J`X#Q:QA%&C<W/29=1NF:B;Y4I2ZB;@:$`H
MB4H%YL;:=P)DIZ0.`4#%D&[V]*!<)A['ZP4N%8?-[>P"Z_9Y+2^I#@#PLG;[
M>E.VO^_K>B)A[.WLI=^\`<!6/8LMNZ.?%N.>W:#:,+E#7'-3=_JL"XYJ!<8?
M1'T1X"V'`<\-G\)S5AT&;-R>V.29W);@'Z<-HWN,M'V42+ULD_=X?BSI9)JP
M"1AVRA&K%19)LBHH*29`(%B@E`HAL]H(CJ=F]QI%GNG'9IC.W9F\FI$O`RQL
M$JFKIL%3-9-Y#Y[/)BYAI,3,61D69V\PR46>G.V.DF@(65QS%THG<S*4`G,I
MD0/@F$K7RT^]?*$$^09\2PASF*)2`"50#MH(C3O'@)#\-3\8`.;DJ>&F'^D7
M7HNBA]T^IP'Q.Q\@E"3*D&J]<3:<5('AVZTDY*BO*$:+&CT53'<H$!)5V!"F
M$3D"@]I@[^`I#%Y+UTQ8J8U(;.89E#R)QK&W:VX3C=!]'Q>29%*L4W<Y'LH&
M./#*,V\'(.SM`$R:0Z<>)ZK"[3.0/)?<'KI5_&)JVZ;L/CU89%H$=*K[MR,N
MVR%10C5!PXBXA+(HE0I`.X4=E07=I'(FV%L8XJJE6*&KBMT.NATY?O'W3#'M
MV7,N6<1"GW,(U<*`FY<E8N9.3#,WP($ED$BB=8B8IQM!`Z;K53,F%A\*?;X2
M.>XPPS7%S8YC!]M9I_ESJ-E%9.'#/T,R/%P[."F5,N=S12O,8:<^=LXCBHH)
M.B$!TNN"A&X6%\+3]UR7RB[^^\`>&)^ZY+Y1=??.`/#$_=<E\HNOOG`'AB?N
MN2^477WS@#PQ/W7)?*+K[YP!X8G[KDOE%U]\X`\,3]UR7RBZ^^<`>&)^ZY+Y
M1=??.`/#$_=<E\HNOOG`'AB?NN2^477WS@#PQ/W7)?*+K[YP!X8G[KDOE%U]
M\X`\,3]UR7RBZ^^<`>&)^ZY+Y1=??.`US6-3Y^4#FY+L4:4^$'7HM2?^<X#8
M^&)^ZY+Y1=??.`B#<<-SH_*MJDL"CG,UC#W))9ON4124.V=-H08548MRA*.9
M5$L>BVD@U5--LY6<6%1(*8G`3!4:.WCZX&CI5A-]+!'HRJCM&`DV^X#V.8LW
MBJ\T\9MYI*.R?*U4(R.B(\B:KM8[07+D`L*47*"(!=_`/'9K',?E\NBI'%<K
ME,1Q.1RC&0FEGH8]D+V..O,0H.TG[])R$8^.=$#E65*8"5`QJU$&KOR3="+V
MTF'VS"+Z5S]%["#&L57(.0<,AEV82R*97\DR9HJK1NHF58^L5&_4%,UM2A7%
MKG/6C-P&<NE-CV>%343DN-L<*C%\I3R1UD,*H^RLTU(/UD]RVL0W25%"#9+6
MKE,R;KO7Z(NQ*BW(#7F\FZ]TX4SJ!V\C5WR89>DW;R!FC=])MV4V^5AI)Z@C
MNJ\:8](+8XNS19-"&D$G+Y)P9<Y$`2.L#TQV9ZSW&X6((Y1A$3%X2\R''%,O
M0B)$KP8B$D(#5D6,;D;C.W:S_P`)EEUU'RYXTAJQZ+9MJ<YKE"ZD1&IC%QX\
MU)=K-O\`\1=?<R_^<#LX"L6ZI>J/'<ZEYO:N+CMP\&1A<8798/.2R&-K.Y$S
M'/"Y2SC<J1GFDBW?E>Q>/F0.[;J-"ED'(4/:440C+<K-.M4&V,2^V&SB2024
M/'NYS%Y[(&S]W$+_`(YY"B^25F"[ALBA,N<580Y4V9$%6R(RSI91V465`!&\
MG^O9+,%X^.VYQ1]C[EWEZ#9X^FU(YG#B,=,*XFJM(-]P'SR<BFAO!C*J%;LW
M#EXZDD=,B+5!0X2_L4[Z@)A_E)=\H4\/&H)X<MA"R!TXERZ.HM-HRH3#-CF.
M6$)-.TD&CE=%)SR[(5@03$XE,J8(6Q7)NNU:<P1M.X`R&*#(\(C<^=O!:1B3
MR%D,I?IY9DN-+L-RI9>-8Q&*IBHJR>M!><QRR2!E@UW"X=$?#$_=<E\HNOOG
M`'AB?NN2^477WS@#PQ/W7)?*+K[YP$>[DQ:8Q&/^W)4MNX>VIO,DWA`-;G,"
M-IZ*>>F-.TH]@^CP$@!%)`)1YR4&T2CVR3L0&T41\ZJG:`Z(5\H&-ZH>`"Q2
M1;?;DH-HD'SI)V:NF+40NJJ-P&Y4+J^FO/7TYJ@$B4B"2CR4&S3H!Y-V8#:0
MLA"^JHWW\B%U?3:BE?9#5`)%)$LH\E!LTJ7R3LUVER%+[E1OOY`M]?3:BM?9
M#U!(G'ID?"@#N1-:T9JU/(N3JCRZR!2@8PKB<Q%>2#4J6AQ.I41U#@(*R121
M+*/)0VGI4ODWA[M+D:7U5\^_D"W5]-J*U]D/4,$B4B6>W)4UFG2^3>&NT@9@
M%]5?.NY(+J^FU%*^R&J`6)2+;[<E1ML#SI-V-;`;`%PBK4UW*A=7TUYZ^G-4
M,A$I!3VY*#2T.V2=CZ4$@[:J=M=(*U[Q,;U0\`S\,:IO8^7.+QYZUE^9M@Y6
M15*7UG)Y0H@H*$B^`RY1[#"8Q#@(4%-(0TR@DW1=9-BFV>XN48)$2689QCF"
MY=.X=B9WTHL3)LIBL?E'V/P`H,W;9VN$O*D20L24(H83@!3%-00#E]^M?](F
MIC4B]8]&HR,^TGMKVZ#1U%[D8TR>1^7XI+/,ABRI/LE>22;IEE;=HW<3"95H
MW&VDR0SQ)RK%NRF!1N9@$CU>[!;#275ELW,8%N#D$J]<9=A.-OYG&LLC8V"W
M]Q#'HB/B)AU*KY-B4?GV)RB+YRR+)-'!3.FZ"RY>7L&!><<-QW-8\&UW^*;X
MYM76:3VY-(SX(FM;QI:L6BTQ.EJZ]-9Z/K3_`(6OJ7YC],=WRW/>([ZFUW=,
M&6*USU][9]]^+Y6U<V;:VB^+-?#;#2^.<F+/[<1>:XYFVL:J-ZE>KR`WSRK;
M+9OI&=Y3L>EFDQ"066+2D\S-#I,MJ(UMBT4_?(Y(I$P<0GDK=N=9\=(K1%DL
M=DB"C]@8PR?B)V\X<D;7IAC+I%=>M8C'2(C36=(C28B/LZ.&_4;'S->1V63G
M9]SD,FQF]\T5F*YKWW>ZR6R1?MK&2UHO6]K1$3K>.Z(F5A^C/>OJOWHF\PB^
MHC8=?:/%X?#,5E\/RY@?)H4^42\S*YK$S$8O'3$H[,S>1[!D@YY-,#*QI3-S
M+N%E%DTVNV<]=`CQ*1]2KR4#4U:V2;LENMS]=.U4++/$#64])II4]C)0`\4D
M>^KR4+?JULDG9+=47HC917S+.>-;3TNFG3V,M`#121K_`&Y*%OU*VR3LM-07
M0C917S+>;&VGI;"4](6@)GS!-%LX7!T_$2%,:U5^X.D-QEA$#$4733$H<P-`
M$0``*7U(<`I\)2[?;DIVU_XF[]$3CV>N_P"O_P!@>0.`/"D_=DIW@/\`23OT
M!*/=J4IYO[PCY>``BDBB`\Y*#:)1H,D[$!M%$>T!5[0'0"OEN-ZH>`"Q211*
M/.2@VZ=`-).S`.F+40N`5?.NY0+J^FO/7TYJ@D/'II.F"(.Y`U;SW*2#@Z@\
MJ1A0MQUP.)%.5#4"AK[SU].:H*R1*1-.CR4'3TJ7R;L]VER%-2Y4;[_#RWU]
M-J*U]D/4,$B4B:='DJ;3TJ7R;L]VCX?34N4&^_PXM]?3:JM?93U#)(I(EE'D
MH-FE2^3>'NTN1I?<J-]_(%NKZ;45K[(>H!(E(EGMR4-9I@%\F[-=I`S`+ZJ^
M>)^2"ZOIM12OLAJ@D0CDQ=.D^;D?6"LR@(2+D3FHDB8!6'F#&.8W+A43%+4#
M&[[A$05A$I!3VY*=@%#MDW8UM!(.VJO:(Z05\M3>4>`/"4O=DIW4_I-WY*=^
MK6O_`,_`8&)2&OMR5[0$.R3>!2X%`[/7>P0U1IY!`/('`!HE(UWMR5"X#AYL
MF[+2\'`#;17S1+S(TIW6$IZ0M`3MXY-PDJ87<B2KB01'0D7*8`!74FC<`)KG
M`JH`Z$:U`P'(0:`)"@4%)XI(]]7DH%^K6R3>$MU>>K9:J%EG/FMIZ732I[&2
M@8/$I'U*O)4NIJULDW9+=;Q"NG:H%EGB)K*>ETDJ>Q$H&3Q*1]2KR4#4U:V2
M;LENKS]=.U4++/$#64]+II4]C)0/E6-3`JJG-R7I5CVC(.M/SP?&$MHJE*!"
M\Z:@5``!-.E-,M`\6L8DHT;G%Y)AJ-TS#9).BE#53<"-EBYP*!>;&VAA``(2
M@^86@*!BDA$P\Y*!<)AH$D[``N%<?-HIV`&N-/):7U(4`&*2&OMR4[1$>R2=
MAWB8:!ZYV`%W[P!Y.`K'L66W='/BW&-;M!M$%QS"<YJ;O]5@7',/:8P^B/HC
MP%L.`YX[0X#E:'09LR]VOFLY>;A*]..T+S&V[K.LI=-R2+K#<6=.$VS%;+()
MB!$6BBQ&R)UR()%`A0(<I03$'ELWA^_,KDKH^ZK;*L=Q$X9ORJ1MQ\C4R-FY
M1':]7#VRCB&W/GXIZP!5_EC45@:@H[28-7*@MC*E0$)WQW%F<1N;E*"4GDSP
MI\$PE43RN43THJ4QL@SX@E35>OUE")@"0"!0&T!$1`*B-0D+PU#Q@`UY'^C3
M#_2DA[J+Z/,UX#RR&.D$X"</CYGB\\2'DCPB"\L^*@M+E9+#&I+&4?H)E24>
M`0#"8Y``![3!W\!0[,MW.KR`+D4G$]-4NZQ:%Q[%7K!Z\RJ2FLRG)U^Q8-)^
M(:8-A&X$VLL9ID;HYB*E<)HI,$SJ'$1+40<H9WUBCB>*2:_3G&M,FE9[/F65
M033=AQ-!BF/Q98T<+G$5%LQQYO/K2)EGH*-4G"2COE4J"R!T(MP\L.S7K.D]
MQ(MCE73Q%P.W3S*'L1*3!]W!-*1./,6DH\:Y$DUC\MF5'*TLJLW;B2BA$U&?
MFD`'=[<-6.:]=3[Q9%AT^8A%<KCK-_'2<WNA)+&?SB[9[S<22!89^<"\D_$B
M8&4D"%51;`K<47I4V0><GG76SC#*4R"4V,B<F8KQ<4=G`XOFDDL_QQRWT7^1
M23E%+-'4QDI"0SA<B,<T3.Z<2<>5%$^F]*HW#88MGG6=E6$I3BVPL#AN0NLU
MQ=G'P\]GT^N=UM],8?*O9?))1D.7QSS&Y:'R08XQV:HN'!"JKLC(F.CSI@S&
M9-UG2N,9\O+;1EPW(8V8P:&P%!IEL7E8S+1W-*DS#*)A(VY$>T2C8N,.F*R:
M2I7"B29C,T3+*`5$+X#&("(CK2(5'N"4D:?N>VN`QX8A]WD?E21_">`/#$/N
M\C\J2/X3P!X8A]WD?E21_">`/#$/N\C\J2/X3P!X8A]WD?E21_">`/#$/N\C
M\J2/X3P!X8A]WD?E21_">`/#$/N\C\J2/X3P!X8A]WD?E21_">`/#$/N\C\J
M2/X3P&M:QB'/RGK\CV*-/^*2'N4G_I/;P&R\,0^[R/RI(_A/`-7.H[)$\)S!
M7`S&7SA+%Y]3#4):1E%8I?*DXIV?'D9)(DY#&48*RP(E6+S;:J8B&J3TP!4;
M<[->KS%LZT<'V.:9IMVTC\;![)CG#YM(J.'C*+=Y/*(Z&>*3+CP=<S]!)@VA
MUE#<J0Q5')GB1$`M1MZ>7GL;Q^<RJ$D\0R::Q#%)?(<34R"0D%L8FI*/4>2.
M/.9`'5KUS"N%1;**E\Q0Z8F+V"'`,_?.$W=7QN'/LE++,\D;SBZ\FD^<MW31
M_#I8SD2S5BL,Q)-`;I.LG3CDE%&ZA7!43GM$H5.4(1=9#U@N\3R5!/:*,@\V
M@9S'FD0_99R:<@<UCUW>3!(/8J/D-P6"T-'K%8PP/!>N2N8]K)NC(`[7:$`X
M1:K-?2(GQ%B\#;[&VV5%99&F^C$9INY0=.6THZ<LG9'2^Y9"1BO@SELSC$P1
M=$=.VRZSLJ:)D05"1,=>=:2VX6($RC$8>.PEUD..JYBVAIA)V2+A'T"4TFPB
M\@>;@.W[LD1+.%U7JYXS44.P0;-;B.SN2!=:(C4!BX\17D:BS0_XI(_<R^1S
M0.`B3>F+WD!KARNRIF3ATUR5[(9FSGI]VS3E<9C\1R5XQ@63I4[DS1S/Y@E&
M-3K)E(=%NJH<%4:7@%=-Q9+KC8-\?7V_P/'Y.1''FR^113C(_@M3(/QMR)LY
M:L9MWN`V>,$5(A"%,4AFCDA(UV_4%?GD$0`-8[D.OI/+UV,=@^(/<><.LO10
M>O\`(5H]A$W1\R?$UQ=M]P7LK.Q+,W@QCF%NR=N'B\FF<A4$&IS!,.Q9NH*0
M?Y27?6)/&1A$\/5P=5%VWCG*R@KS24L68;1.;9:0)QTD@T<N2)KD:-#K:"&I
M898X0_ADGUSJ9+@33+,10+CIW<`CN!+:L.W5H&5N49%[#-6F[#M5I$26+J'5
M<D.DY>1BK5N1(CS757.'0GPQ#[O(_*DC^$\`>&(?=Y'Y4D?PG@#PQ#[O(_*D
MC^$\!'NY,4@,1`>V),+=P]M3>;+21:B7.H$0`U'07D&G:4>P?1X"0`BFX4]?
MDQH)1[9:3&MHI"%0%U00'1"M>\!-7TQJADL4W+;1>2&VP0NEI,U=,6PA=<Z&
MZO*ENK6ZX]:ZA[@P6*;DLHXDQL%,0NEI(]=(68EOO=&O`W)%NK6ZY2M=52X`
MD4W)91>3&S2I?+29ZZ7(VWWNQU+O#R75K?>K6NJI<"1..03D!2!Q(&`K-HH%
M\K(*'J@N@4EPGD#*&*IR);ZDHH)E+C&U%`$%9(IN2RB\F-FE2^6DSUT@8@6^
M]T;4NY`EUU;[U;JZJEP!8IN0"`#B3&S3I=+R9Q'3!H!;Q,[$3W<D6ZM;KE*U
MU5+@`BFY;0!>3&VRE9>3-6P&X!<(NQ$U>6+=6MUQZUO/<`$2W"E'$GV6]\O)
MC6T$@"M78UKI!6O>(FKZ8:@S\*;(O8Z7.9T\/HY?F;4!;R[L0*#?)I-/34,V
MGY8!62I::Y1)0HA:9%`0TB`[QB6X@(<Q*!4!#LEY,![0.`T$'=0'UP:4[J!Y
M`H')^>Z@/I(&V]FX&&8_TDQ4SMBP?;W,<!S=U(S\.G,*8TUE%-JE)-^?=11(
M(S(2%9J.7I6K,7BLN5LU01-%.ER@V4,[ZG=UMCNHN;ZM^G#$\&+MWB^WLKL_
M(O(V1,3*W.8K3Z.<)2&,Y3F^6MHMVSBR1*RK,Z^E&.9,6!W#E6-YDL8\OQX)
MX#<;C)CQY,F.FM>^L6CK,1/2W3K'3J[G_P`.>]Y.GU;XCB-EO=YL]GO=SVYI
MV^;)AM,4QY+TF;8OO_<M]Z.V)GUB(G726#MG.;]=.&ZTIT[=&G2?'2'2_#[I
M8N22<RN39`.6X^VS&$DXO/9J0RA3>#(AD$HO+<8FCE>.FR)FZ<>Q9MDG:;MF
MY96?$=APW#[3-Q'"89P;3%FFW9-N^?O?=M,SWWMK[F.\?>G]&*]NM.UL?^(C
MRWZD_4;R#COJ']3^1Q\KY!ON.IAG<4P3M\<QATS8JX\<;;:XHI&TW>UM,X:3
M'NVRQF[=Q&6%HND'>'K?W,W+DL:ZC=B8/`=KD]N,BEXS</&Y.:;*N\W8YHP@
M8_&TA+G^2L'+1>,DIO06;E$R[6&9R9E$"R#9FVEKY[=(SQ3<]]5Y,-35K9+2
M9*:W/766.PT[?$#VVTLL2MII)6@'BFY[ZN),+]2MDM)$IJB\$UEKH++>>/;2
MEEJ=*:2=H9-%-S757D@NOK;+29::@NA&VUV%E.;-;2EMI*4TR6@D?L$4&KA<
MJ[ZXA3'HI*/S)5,=41`2*/D4K0Y@:`)B@%"T](6@*_"F_P!WDO1'^EI+T1,/
MH.NSTX_N4\@4`\*;_=Y/LH/]+2?H"4>[FZ#VE_\`Q^4>``BFY:>OR0VB40K+
M21JVBB(5JZ&ZN@%:]X":OIC5`+%-RVB"\D-ME+I:3-73%L(7`9V('KRI;JUN
MN/6NH>X$9X]%)VQ2*X?B!M0WKDH_.<>6(QL`#*/P4,4W*EU`M.![CW^R'$P+
M"13<EE%Y(=/2I?+29ZZ7(VWW.QU+O#R775OO5NKJJW!@D4W)91>3'3TJ7RTF
M>NCR-M][L=2[P\EUU;[U;JZJMP!8IN2RCB3&S2I=+29ZZ0,@+?>Z-J7<@2ZM
M;[U+JZJEP!8IN2VCB3&S3I=+29ZZ8-`+=<Z&^[DRW5K=<I6NHI<"-O'("[=I
M\Q(""`,RA\+2`FH"2)@U1\04.<QN7"HF*43`)JW7F$06!%-PI[8D^P`#MEI,
M?2@F`5$751$=(*^41'U0U#/A3?[O)>3^EI/R4[^;X#`Q3<:^V)/M`0[):3#T
MP*`-!!U4!#5&GD$`]2%`#13<UU5Y,+KP&V7DRTO!P`VVNPMIS)J4]+:2E+"4
M!*VCD'"2QC.)`!%S(I#HRL@F``5W)(=@(OU"D4*#DW:`E,!BD&A3)D`@*C13
M<]]7$F%^K6V6DR4U0>@:RQT73MY\]M*66)VTTD[0#Q3<]]5Y,-35K9+29*:W
M/766.PT[?$#VVTLL2MII)6AD\4W/?5>2#4U:V2TF2FKSUUEKL-.WQ`]MM++$
MK::25H?"T8@!%E.8D:VK'H,K(`0!.#TP^;S9"%*`O34"I0*!4Z4!).T/%I&-
MU&C<XN)'UQLF81)+212^NI+B(DL?*%*`<V:VTQ@"TE!];((`I&*;FKZ_)!<)
MA&DM)%I<*PC2CH+::XTIW`!:>E+0#PIO]WD^VH_TM)^B)A[N;H':;_\`%Y`X
M"L.Q90)NCGQ0$P@7:#:,`$YS*'&F[_59VF.<1,<P^B(C4>`MAP'//:/;K*E.
M@O9A3:N<SL-Q'73CL\YQK4S_`"=RFE(N<.Q5VX3:LI?-L?A$R$:'63;IK.46
MR!;0`HE*!!!?L]@G4FZW)<%W7)G,+MX##(G;90F["\D8';G\6PAH4ZT)GZ\P
MNK%O2RO+/1:I)N(W1%TB1XH)6H69Q[%F$3N=E**#_)7)5,$PE43RF69)+*E,
M;(,^()4UI&4<JII@"8"!`$"@(B(!4PU"0?#&_C`!JR%/#3#_`$K)UKS1?1YN
MM.`\<ABW_@$Y^+RKP9_P>3\#!>7D`0&8Y)?PT%A5>E3!(7MEUP@6G?V<!2UO
M.];#W<W'FR.SL-%;6`TQY*8>Y+N(V)D+IZ[CHH,H5DU\:W2GP@T(F1(]49+1
M["4%8!204:"!Q=M@TTCD?7P:+=IL=D,+2F#S(,&JB6XZQF*4">7EVZF0E=O-
MW3*EDTH@K55)B=@JF)@U#J"98[)F"PN6=<32)PQ)[L9B;_*G\WGJF5LHC<>9
M6@V.)8](8*WQ=1+(7VXL2W8Y#DS"9FEFQ-!T#E:.0360C4EW"[,/D%>O`SQG
M/+83A+=@=LF1WA##+WD@X:&>R#A,[HTB^W$BO&)*"BFJ2G*DDXUH\<.S!S!"
M(45#5-<@^D&5>RCYSLM@+=D1TY9PT'\Y#PPK-2O'RS"3D9)/=-98#O6_*M7)
MD[?#TP5=ILY!0Q&)`DZ33ZIU'NUC`D*U9K/)MA\Y,GC,P9SCS*$;YG*I2[A9
MOE>>*RJ#9QA+5@9%O'+N)`7D@J8I[6IB"&GSU/K$<Q<&ZPK'(Z(E$\VW)C9R
M*892RDB.=O4W[=KMSE*4EE6:`BURI3'16?&C$T5&JDV*3-RX18$4>K!)&R2F
M^SDT5&[S8Z]B9%M$YN.0RS.<:.(&2?$RV(/@"N.GB,MEW:0+8@[=)/TW2#8Y
M'30!*!B'*HH%D/"V_P!VD?E:4_"^`/"V_P!VD?E:4_"^`/"V_P!VD?E:4_"^
M`/"V_P!VD?E:4_"^`/"V_P!VD?E:4_"^`/"V_P!VD?E:4_"^`/"V_P!VD?E:
M4_"^`/"V_P!VD?E:4_"^`/"V_P!VD?E:4_"^`/"V_P!VD?E:4_"^`US6,;\_
M*!K2'8HT_P"*R8#_`#4G>/-U'@-CX6W^[2/RM*?A?`1KO#'9T3;+,AVH&45W
M'\(,&'D))ME`\9%PW!`RQ<EFXR%Y4A;A6UERB"(&L`ZEI#!5K-)+KQ:[B\EA
M&U6UTGM?&LVKE2=D=U<I2RG(W;K"R'<L&\&K/,VC$8G.WQ4P$[ML1RQ9*J`J
M0RB21PMM@#?('^.0#W-XY6`S1WB.*.LOA(^?D7K*(R=Q'J*3D8T>DF)(KIJQ
MD!.FF<'+@#$*`@H>MP@LS^*R4V"9L7`'"Y,[/B.2%PH[Z5>BR)EIH9Z7'#O.
M9=BVY8LP*(J:GF6UN[*\!5J4@^L2.Q3(6$>ZQ^;R>/?82UQ>>0FE+YMH5M.J
M99(S#"1G,?BDDUYP(TC@$DF2J<*9QR:1GY$SJA%#IE](T;&&ZR,?BZ.2IHY*
MW%HVR&$7(^!O)N5XJ1DG3W)TF,5*2,4X10C4FJ;QHW404/(@J-NJ$@8XQZVA
MW"P];*6L*CA"N08XYS-A!S,>JR:PSN!3"8CXB8D<N/D@MH68<N%72BC!RY>+
MM&C=KIMG#MTD%V(B,;C%QXZTAVLT.Z5DP#V,O<`.P`.`B7>F`WB=-<./LM*-
M6;MADCZ3R]M.2[HC><QYCB.2K1N-IKKF<K-"S>9!%HKK-Q072:BJ)%DO3<!7
MW/&G6PD.$GPB,8++?BW,J;@-TYZ'&*-D:60R!L;)C2T]FJ4LD1\Q;M"22:]Z
M+6(<KG;KKR::1>`T#F/^D#)ERJ$>TPQ;&G3G+D@=2<^1O'0_,L)H<5=M199,
MXR29B8M4\10BR+9XL])*<Q<T&/#@)BV*8=0XO\J^?E-4D88N(&P80DH9N\27
M(O,I2Z,J7%\JG474XY039KO%"BU8HK*"BS(JF0ZQ@8&V<=UJ'EL?)N"1HE&-
M3XF3)W+U_`IC+)$S!XGD[R$:XOG,BK$.'>(."K';N#.TFJC9%)!1R=5=4H7I
M\+;_`':1^5I3\+X`\+;_`':1^5I3\+X`\+;_`':1^5I3\+X"/=R8IN,1`>O2
M7F[A[:G[)>5#M+G,"(`:CP`,01[RC4!]$.`D$(IL`@.M)#02B%9>5$!M%(0K
M5X-P#HA6O?4U?3&J&2Q;8MM%9$;;*72\J:M@MA"ZYX-U>5+6M;JGK74/<&"Q
M;8EE%9(;!3$+I>6/72Y02WWO3:@#R1+KJWW*75U5;P"138EE%9(;-.E\Q+'K
MI<E;?>]-J5Y`EUU;[E+JZRMX(TX]N20%(JS\0(R:*`!Y>34/5!=$I!-J2ASF
M*?D27U2HK52XQM54#`L)%-B645DALTJ7S$L>NER5M][TVI7D"775ON4NKK*W
M@%BFQ`(`*R0V:=+IB6.(Z8-`+>)WIA/7DB775ON4NKJJ7@%BFQ;0!62&VRET
MQ+&K8#<`N$ST1-7EBUK6ZIZUO/<`$4V"@:TEV6TK+RH^E!,`J(O!$?8@K7OJ
M-?3&J#/PIN@^CI<YGCQ;0R_,V8'1FGJ@%*VR:42!)0[?)YX-9"EA@,JBH2VT
MS=L(:"8/`8IL-?7I+MJ'9+RH=X'`:"#RH>R#3R=GD"@<P<[W5^D;CNH.>Q'`
M.G3$,FV4#*9V%@<OF9V8@W?A@X!(2$'-.YA/=)5-Y#)Y2X8\PN6,9.3J/'#!
M)`!C0?'#6[;9YUG;C[8]2[;JQV2QG;[%XC8-WD&#2#5!P12>R==AN.>58S^)
MRVX&YL.9>/;1[%XHQ,*[1H"S<ACN##I-M5ST1/";R9B)TVV6=)B+1K%+3&L6
MB8GK$=)B8GXQ*?\`TGODK]4?'*X[Y,??S>RI-L>3)BO%<FYQ4O%<F*^/)CF:
M6M'?CO2]==:VK.DDNV?3QBG3FGNABNQDEGVV<$XA"9FY8XW)Q0`]R"6=;CK+
M/7"S_")%PJD@9R!&B0""39,B":06HHE#G_%\%MO&XW6VX*V;;8)I[DQ7LG6]
MIRSK/=BMTCTK'I$:5CI$0^O///JMS7UKMP7.?57%QO-<I3<SLJWSQN:S3;XL
M>PI%*QAW^*(M:-;9;SK?)>;Y;S[EK7>F[G49UB%SK&(3ICVBB=V\198AC'SD
M*2,C%&FHK+73YD\.E"2T3O\`L6,A#97CV4HHK.4V2H8P`D?J'?BBFS1Z/L=]
MAWE)K6T>_28BU=:S:)[:VUTK:T=LQ:.L=->G28T?%WE/BO)>.;C'ESXKSQ>Z
MI;)@S1CSUQ6K&;-A[.[-BQVC)6^#)$TM'=-8B\=U;18]-E]R?I`\AZBR8=O+
ML5B>-;$*R&ZC61SR$DIF/DF2$(D)L,<1RP;H9&63:32\N@1LN5DU5=@LZ'EF
M013<5<Y%72(T6V/?562"_4K;+RQ*:O.":RQZ73ISQ[;:66IVTTDK`R:+;&NJ
MK(A<)Q&V7E2TU!<B:VUZ%@!S9K:4MM)2FFG:"1^P01:N%BK/BF*4QO/E9$4P
M$QU1&I%9)NE:&N:@"<H``%`/2%H"KPIM]VDO1_XO*^B)A]V=GIQ_[/(%`/"F
MWW:2\O\`2\KZ`@/=SE.\O_RJ/`9"+;!3UZ1&EM*R\J/I11$*U>>=71"M>\!-
M7TQJ@%BVQ;:*R0VV"%TO+&KIBV$MP&>B!ZBU+=6MUQZUU%+@1J,$$G;!(J[^
MTP*FH>6DCG,+8C&SM4DRJ'+[5+>%B@'N/?344$X*R1;8EE%9(;-.E\O+'KI<
ME;?>]-J5Y`EUU;[E+JZRMX9)%MB645DAT]*V^7ECUTN2MOO>FU*\@2ZZM]RE
MU=96\,%BFQ+**R0V:5+IB6/72Y,"WWO3:E>1)==6^Y2ZNLK>`6*;$MHK)#9I
MTNF)8]=,&@%NO>FOKR9+JUNN4K754N!&WCFXNWB>O(""`,RE#QB4,8`!%$0%
M3X44,<QN7"HF(035-6Z\XB"P(IL%`UI+LH`5F)4?2@F`5$7E1&B05KWB(B/:
M8U0/"FWW:3[J?TQ+>2G?SM:\`#%-AKZ])]M0[)B6#O!0!H(/0H/K@TIW=E/2
MEH`:*;&NJM)!=>`VS$L6EX.`&T2O0$M.9-2E+:$I2PEH)6L<W726,99_4SJ1
M2'2EY-,``KN10H4$9-4I#E*Y-V@)3`8I!M(9,A4P5'BFQ[ZJR07ZE;)B6)35
MYRZRQZ73ISQ[;:66IVTTDK`R>+;'OJK)!J:MUDO+$IJ\[=98]+ITY\]MM++4
M[::*5@8/%MCWU5D@OU*V2\L2FKSMUECTNG3GSVVTLM3MIHI6!\+1K<$UCZLA
M42+''X6E`*`G!X8:%YY,A2@+T]``2@4"ITII)V!Y-(QLHS;'%>1$5&R9A,28
ME``=1-8QA(*<DL4`]MFMM.8`H2AATTQ*"D8ML-1UI$*B81I+RH>F%81H`/`M
MIKC2E*`!:>E+0,#%MAKZ])=M1[)>5#O$P]E'@4[3?O4\@<!6+8LH$W1SXH7"
M!=H-HP`3F,<W9N_U6!YQSB8YC>41$1'@+7\!SWVAVYR$W07LP?:A]E[;<9YT
MW[/+XZK^/F7.RIR3K#<4>.N39SF>PL(W$R!EBHD.Y;MT0$"@&F&D(;':+`.H
M]?<41W7)E;';U5OEAS-?G9E9'ECJI8@KCC5)]"YOXP[682Q)E)LL9JB5S%&0
M4=E2>52`+)X_B<3$[G92BT/.J$/@F$*B:1RK*9A4#FR#/R"4B\O,OE4TQ!(!
ML*8"@-1`*B(B$@>%,_%P#VW3PTPU\2DJ_P`Z*%*\WW<!\3L2Z\$F?`#+EG?"
MI#P45Y-_HA+<HMX<*VHZ%/2!Y9==YM._LX"BL4R^D$Q>2Q_''C3;3<J.?-`<
MSVX<M*R$)^+[I9@T7\+2@('+\67G"Q[U)=N*Y&J/-"L18-`J0IJ!]9*QZ_FR
M&)91B[7`)60:X-!-\PVYD9Y:-A9'.W;[<LN1OV+\DZXE"QD.Q)C)VB9)QJ5V
M?5*<$M184@UL1DOTAF10:AS[3[8X9*NXZ6!N[E,BR"0"-D&B,BFBIX23=_5?
M:TBW;$CBJF03?M')W;P8Q1N6/=AT.+%M3%`Q^;`Y@`3@$E(@`&$*F``*\,4`
M`?((AP&?"6?E>?*4E^%\`>$L_*\^4I+\+X`\)9^5Y\I27X7P!X2S\KSY2DOP
MO@#PEGY7GRE)?A?`'A+/RO/E*2_"^`/"6?E>?*4E^%\`>$L_*\^4I+\+X`\)
M9^5Y\I27X7P!X2S\KSY2DOPO@#PEGY7GRE)?A?`'A+/RO/E*2_"^`/"6?E>?
M*4E^%\`>$L_*\^4I+\+X#7-8IGSTI_.^Q1IV^)251]JD[QYOMIP&Q\)9^5Y\
MI27X7P$<;O1FXY-L,Y^9(D(INP?'GJ>"?CE.3;/&TY\X%*V7DG#0L@L!6Q1,
MHF04A266*5-4Q$CG.4*RY^^Z[VVY[IOMWMSM$^VBC$RN6TG+[CY<;,LB,ZQ"
MXT<,6I,1L>U5B,V?$+>+ED1VR8J'O3,JFB(6IP)K/2&.P#W.HLD)F[K$<3<Y
MC#Q<U(.X^+RE:.4/.Q[)V66D`=-&<@)TTC\PO<F4!U#UN$%F>Q&1&P7-2;?K
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M9?0YOLX"*-YL>W@=-<//LK+L8MY'Y&^E<M0FW[D6T_`L<0R92*QH%5C.'#1*
M9S,8M-PLV,@X3:@J)%DQ\[@*X;E->NM-#&/FW80QY1OCB+C+M69@%<9E)[\?
M'P*,(=.<R=OD40L?#&C<QE#JNFJ*+LY2ZSQ,%`!QY)$=:*<Z9'&76*+Q;M25
M!BY>2)4XV'*_P#$N5_&#4F/'9%''=P%98S$S%,%'J*8%>%*B*(B#NV+C^HCG
M\J^?NJD8<,/4P6KN`2>-7":TTE+(2GXJ3LDW?3:R!6:[U4I&C!)PH*+(BB1#
M+&"(,.9]=I)_`6V6H*+08RV)M\ZE22&W:(#'MLID'&1RY(EID[UTBUF,4`K=
MRP;+N%V3@S51HX<6NRF#H+X2S\KSY2DOPO@#PEGY7GRE)?A?`'A+/RO/E*2_
M"^`CW<F'9&B(`1!Z-NX>VQPI*2@4,7.8$0$;7H7``^@-2CZ(<!((1+,*4%[Y
MMHA63DQ]**0A4!=C7V`M:]_;7TQJ@%B&1!*)1>^;92LG)F]C%L):@9X(&[6A
M*UK=YU:WGN`+$,B66B]\P4Q+=*29O8N3$EUSP;_YBG6M;O/K744N`)#LB66\
M[ZWI6W2<F?V'D;+KWAK_`.CDKKJW>?=755O!"G%,TY(2%.]H1BS,!#2TFH%6
M[A$$CBF>5.`B/()@8PH^N>>!CFU%"B"XD.R)9;SOK>E;=)R9_8>1`EU[PU_]
M'I775N\^ZNJK>`6(9$LM%[ZWIVW2DH?V+DP)=<\&_P#F*=;JW>?6NHI<&`AV
M1;:"]\T"`%924-[&#8"UN>#=V-"5K6OG5K>>X,A$,@```7O90`K*28^E!(`K
M5X(C["6M>_MKZ8U09N$-&KV.ESG=/'6AE^9,RG"=D'0ID:9+)-P;F43RW);3
MM[+!(99`Z8A:+5H(<NF#R&(9#4*O>T!`:2DF'I@4`:4>!0:*C_H[/(%`^ABV
MH@(:DB`#<'FR\L6EX+@-MKT+:<P:E*6T+2EA+0YS]1>2==;'?%OB6S&S>,[D
M].TO&X0VRM[E(0R3@YIB3R!GG<"D[E-Y(MR^@9#'7AA=.CPNI&*(-TD6CQ-8
M%"4WI3)2<>2(M2T3$Q,:Q,3TF)CXQ/QA>V^XW&SW&/=[2]\6ZQ7K>EZ3-;TO
M68M6U;1,36U9B)K,3$Q,1,3J@OIKPGJ1G-_MP(3J-Z:MB8#`4]L\K?2DWC$#
MC"#A+*V>4JQ^`\G'L\XS)\BTR:,F\L%!8Q6BKJ*8LW3E!FY6!`=3LN(XC)S=
ML=MMM[4M&#NB:4F.MLL3K$Q,=8TUB8ZQZNI[_P`_^H-?">,O;F.6K%=_R$4M
M^(SUUK&/CYZ6BT3:*WFW76>V>G332//IUV#PO;/%768;73^=8!/;Y,\;W(W/
MD<+FX*)_&_,9S&B+/)50J6`KI,43.,E74;M&>BS;KN2*II`M10_U+F\+^GWA
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M(YPK.?I1Y3#<W?Y3LUM7'YG"[A<GC$4X='8Q>:X&_P`:DC%>1HL-['BF-.8K
M)DB*K*O5ECJ-I(K=)$IVA5V_&&Q7VV5+N!/;2;?RV\\4I![HR.+Q[C.(IHX4
MC$VDVLBYYDJD9$91DL5%/5$W8G7:M9)^W:N#"DDX5(BDIP$C248T39N50.](
M8I3'N"5DDP*8QU3"-?%&92A5P;LU"``4#N*4`!9X0R[>U[VU_P")R?HB8?=G
M9VG'_1V>0.`/"&50&KVH"`A\*2?H"4WNSRE#_P"0CP`$0R+00%[YMM*RDF/I
M11$*@+P0'V`M:]_;7TQJ@%B&1;:"]\P2"6LG)C[&+42W5>#=VLR5K6[SJUO/
M<"%6+9D>QR93O0*&L<"C+R8WBV38@G>4TJ37`O*$N`R:P&$3":@J'$X+B0[(
MEEO.>MZ5MTG)G]AY&RZ]X:_^CDKKJW>?=755O`)#LB66\[ZWI6W2<F?V'D;+
MKWAK_P"CDKKJW^?=755O#!(=D2RWG?6]*VZ4DS^P\E9=>\-?_1Z=UU;_`#[J
MZJEX9+$,B66B]\S3MNE)0WL0-`)=<\&_^9)UK6[SZUU%+@0MHEF#UZ%[X=(&
M12E-,2B@$`B*(E\PTLL!1-RY1,(II"?SA&^XPB"T(=D``%7O8``%924'TH)@
M%:O!KV)%K7O[:]XU#/@[+RO?)_2LIY*=_.<!@8=D-0J][:@-)24#TP*`-*/`
MIV*C3R=E.X*`&AV1KJ\[YUX#24DRCYX.`-02O`$O8Z/2E*>;2EA+02-(IFLD
MN<YWQA4=R1#"67E*``.Y%N)262C@$K".3@`%,2TP%&Q,Q"%3!6>'9'ONYWUS
M5NME),GLW.WVV/"V?T@I;;2SS+::2=@9/#LCWW<[ZYJW6R<F3V;GK[;'A;/Z
M15MMI9YEM-)*P`\.R/?=SGKFK=;)R9/9N>OML>%L_I%6VVEOF6TTDK`\UXIG
MIKFN>E$Q%S")923)05`>F,);7R0)T%\I2AB6^902Z:=@>+.)9'9-1$ST][5(
M1-XM)F$VHDN)C7A).!$1%X>@@H>GFT,-A!`%0Q#(:B(O?.NK24DP].*PC0`>
M`!?9S4IW=E/2EH!X0R$1&KVHB(C23DP[1$QO0=]U3#_\@#@*Q[%E`FZ.?$`!
M`"[0;1E`#&,8P`&[_58``)CB8YA^J(B(\!:_@.>6S^U4DMT&;-!M2K/Q>XDA
MTX;0.,?=DRN?="WDWF'8J_>F9M9[+&,,W462,L5,#JH(I`>T+2>9P&ZVCVJZ
MCC;@G7W:5CR;5G9YI?%$W0R^3S)&==&V_4Q4C1S$FCXIWB,0LSR(C190[:47
M;/$!?(ZJ90*%C<=PZ"AMS<I08H2.FI@F$JF,\GL@DSWGR#/BF*563E'BA""5
M(OF@(``A6E1&H,+JD@MZW&S^:(=,KGP[>H6V+GQ%RJI!+5;HYI#+9,U3'-71
M<:;F>XP1VCK.`.*`J:B::JI2)F#G])9]],=B:[:/4Z>NG[/4'F1PL#'SL?ED
MR58YI7)LK.\E,B38;C8^WA\'AL5\*3<3";$)!%5`ZI(=TH[Y=L%FU(;K\FL#
MVYE5'6U>&;B.MK9,^YF+1":TMC;#=5ON_M4YB"P4G-Y#-/0B9;98N5M')`<.
M4&4H=!9,ZY@1$H5HZB\9^F%<Y[N.ATU2^U\;B2F22@X1)YI-X6O!)8F_Q#+X
M+%TX.&<XN^S%*;QN:FXB<F5)IZX2?RT*9JT(6,=G*`21$;2?2@/-LXQM*=0.
MVD)N?/;_`*LT^D1Q6#F(K;S81EC>?E2QI5)O`M&N;R<WDZ6.J&131:/6R!G"
M82U#&43!K2N9_2_QF0M8AML#TP9''NH@'Z<W$Y;F<=&I2#7#<6>RD7++S&[A
M'47=F$S(-(XR+5\9X:+*54&[1P=^W#XEY/Z8N2B<9:M-M>EW')&2QU9[E[^#
MR'(Y!SCN0)Y!!,6T%!#DNXK^/DB/H%*1>K.U6IDVH.$4DRKJMAYH+"]/[SK_
M`);<,B74=M[L+BVUJ3*3;JK8'D67R>8N9?V^=D^16=YM*Q18)HLS1;H7-"/)
M%L[!VNE&K$.P*%[/!X_[DK[[>?A'`'@\?]R5]]O/PC@#P>/^Y*^^WGX1P!X/
M'_<E??;S\(X`\'C_`+DK[[>?A'`'@\?]R5]]O/PC@#P>/^Y*^^WGX1P!X/'_
M`')7WV\_".`/!X_[DK[[>?A'`'@\?]R5]]O/PC@#P>/^Y*^^WGX1P!X/'_<E
M??;S\(X#7-8AASTH&DK34:4]MO.WVJ3_`-(]#@&3O%#9P.TVY@;.Z:&[`X'E
M@;;*O'#=1L3.!@WOXKBL6<7&%`HS.CYSP#-2#YRI3)@8HA0EW&_2>+Y%M0J+
M3;%AC".-].S+<QK`9/!NI"1SJ-S1J'4O-ORY%!W1^!9/A"KKP)&%=&E&BZ#4
MP))G5<ID#7Y,[^EK+F\ZZQW;SI5'`X3*MTHG&6*67YTYE\TPPT),I[2YA/-)
M3)8[PK("90PC#R<6VE&B!(N0?`"RSENU*8.A.V#7*Y'#,1?;HP<9`;EO,$PA
MUN)!X]+OI"!A\Y<0P*Y7%PT@=ZX.^BH^;.LDW6,H<RB)"F$QA&HAJ=^,:W-D
MMG=Q8[82588WO(_QA\SVZR&;,5[$P>3.0(BREW[*2*\8/&\=>984E4E"*"2T
M0&O`4HRG&OI-&V#Y0QQB<VD?YLRR3;^+PB<1*BU1D\6B\LW9B\HR'*X^<?OH
MY60R.!:X5+3*;0K`4V+N59Q"#9\@W65"$)O'_IGSX-CIH:5VC0S<D#N*A,$*
MO@ZJ3J1;9%)N<$>RIW[8T:TG9;'WD>U0\-*I&,.4>J/4G:IVUX3/B$'])F&^
M^+K9R]V]4V2/E^)NLNC<=<8T1$N,/,(DC91'1$B^.;-&K&"RI<E3*)/7\B\;
MMDT5&C!1TN4.E,1$,!BX\125`>3;_P"]O?N9?*X[.`Y`P;;Z9_&\JW+5?P?3
M9N'C+[*99EM8UGYYS$A#XJWRK<R6@Y?(C8I(8C()N7V(S>/QKHH'DU`=0"`)
MH)!)R,@U"?\`<6(^D<6P[%)';DVR2.>!@K=+.,<>R,I%XN?.HG>+$%WTEBTI
M)&S:311S'99&8;(L79U&L6_7(H+E54B8\!O9O%.O1)[D`8]EFW+QLY?Y^CC(
M2C%%JWBF<KLQM2?;QW(JMG2CY\EAV]Y,N3<)@059.,5:G5$"D(GP!TDPO6D1
MQFP]8:T*[8JM=L#;<EB7&(IO&+\JF3IYDVES82<$)&949A$*OW5&D>,BHX1C
MFQ6B)5UPOEX/'_<E??;S\(X`\'C_`+DK[[>?A'`'@\?]R5]]O/PC@#P>/^Y*
M^^WGX1P$?;D0L>:(@*H+&LW#VV4"CQ\%IB9S`B!AM<A4`\@U#RAP$@!#1X6T
M26\T2B'MU]WD%$2_[QVT%`O^F@^4:@%AH\MHE26\P2"6KUZ/:F+42UJX&Z@L
MDZUK6@U],:H!(:/3LM26#3T[*O7IJ:0LA)6YP-U/#TJUK6@UK>>X`D-'IV6I
M+!IZ5E7KXU-'D-.MSD;J>&(UK6ZT:UO/<")*)8IR(ID!P!",F1P2&1?F(!FR
MZ`('%$TF8HF`(Y(!,*`"<"F`QS7'*(+"0L<G9:DL&GI65>OC4T>0!.MSD;J!
M&HUK6ZT:UO/<`6%CB66I+>MZ=M7KXU-(&0$K<Y&Z@1Z5:UK0:UO/<`6%CBVV
MIK^;9;5Z^&FF#8"=[D:T!HGW]]!KZ8U0`A8X```26H%H![=?#Z4$@#O<]O8@
M7]X?*-09^%,FCZ/ESK++O!0R_,F13C,/'@IIM,EDFY6QE`RS)Q(9L!+!3%9N
M9(0M%HT$.73!X#"QPU`4ENVH#[=?!Z8%`'M!S4*@J/\`\@"@`PL<8#`*2WG`
M<!H]?!V'!P!NYR%*@Z/W=U0IZ4M`_+E_FA=[/I0.D_8'9/J%^CSSO.]OMKL/
ME]Q(GJNGL%B\8RJ1A8_*28DUVMR*7C,JQ_)WL/C+&25G&RTK'E;$9O'S0'!^
MUH9(.1_3YTP_YNKJ+VNQ#=B.ZTHS:B0W!Q&*RTV([U9-CF(;CM\(R!UDJ6%E
MRG&8O8?)"0;AXF62>),7"Q7C5N\1*NDBL0$4,'#K7D\UJZQ;VL4ZZ_QLOIUZ
M:?9IUZI5OKS;POC:S-9BO([^-(C28UQ<?/WI[8[IG7I,VM,1I'2(B#^>_13?
MYKF4/S3CK9Z1Y,7+5`HNP=8`H"J!V3M`J8*GZ2"&/HMY19*X*E[?-,(%(8)C
MC\Q\OPTC'BY7DJTCX1NL\>LZS^_^?7\J'SM]O/6:4_DQ_8;:'^C&_P`W#C)G
MRV,=>G3CC2T@4>>4Q?*,4QQ=\!5)1=,CA:'Z68\RP)+S+DR0'-1(ZMQ;1*42
MX'(\YS7,12O+;S=;JN/7MC-ER9(KKI$]L7M:(F8K6)T]8B(^$*Z8L>/_`).M
M:Z_*(A&'T,G41_F'MW_I8PZ8NK+<_>^8VBZ:<CGG'6CCN>X[M_#XWCT2^P_+
MT<"8)YG$X@P?2"F<9'(LG\`E"/Q),1J7.HBI'MSJIZM6_?T>'8*"83IKF$]]
MP\Z^"NIS5W<Y"@>W5*4[JA2EI;012$4Q3:.5B@NFH4IC@H60?)"41.J8P@8)
M)D!`JX/_`!I`H(!6@```L\&C_N2W>(_SU[WB)A'_`'CRG'_Y`'`'@T?]R6[Z
M_P`]>]X"4?='E('``0T>6E$EO-MI[=?#Z043%[W`UH+<G^F@^4:@%AH\MMJ2
MWF"02U>OA[4Q:B2M7(W4%DG6M:T&M;C5!&I%,4GD>F0'!2!J'T_$'UIS-4V`
M(B=,9)/6!,&:?>DL%0$1MO,)P6$AH].RQ)8-/2LJ]?&IH<AIUN<#=3PQ&M:W
M6C6MY[@"0T>GIV)+!I:5E7KXU-#P_3K<Y&ZGA:-:UNM-6MZEP8)"QR=EJ2P:
M>D!*O7QJ:(,03K<Y&Z@1J-:UK:-:WGN`+"QQ++4E_,TP+5Z^-32!F!*W.1K0
M&"5:]]!K6\]P(F\0PYQX6C@P(%8D3(,D_.5(I$D1*`)C)K`03"V((^M)">@B
M-]3"(+0A8X*`"2WFV@'MU]_!!,`[W/;V(E_TT^J-0/!8ZE-):E*?SU]W4M]T
M^3@`86.$!`4EO.`P#[=?=Q@4*/\`O/D5-_HK]0*`&A8XUU4EO/ON]NO@]D!R
M!Z4<A;4'9^[NJ%/2EH"5K$,5TES*@X4%1U(IF$9%^:A`=23>PE)%R"0$3=J%
M`I3%L$0\Q,2E(0%1X6.4ON26'4U0/1Z^+76!\"E+7(6U"26I2E+@I2PEH9/"
MQZFI>DN.IJWT>OBUU_$-2EKD+:^*+4I2VXM*6$M`/#1ZE]Z2PZFK?1Z^+77Y
M_4I:X"VOB:U*4MN"E+"6A\+1#&Q8X$7*<2+GN*^?$$#*`^$QBB5XE8-9!6E#
M%MJ%!"P@E#P:0\>HR;"8BYQ4;)B8XR#XQCBJFX$YA4Y]R)A,+U0:ZJG>%##:
M40!4,-'FN$4EO.NK1Z]#TXK&-2C@*5%P?N[JA3N"@`PT>/\`%+=HB/\`/7O>
M(F'W1V=IQX"L>Q9"I[HY\F0MI2;0;1E*6IAM`N[_`%6``5.)C#0`]$1'@+8<
M!SQV?V?<2'09LVVVO&3@]P)7IPVC7@I$N33HF:RCW#\6DGRC0LK-BP9*N2&6
M(00%(J8*6E$A>X-GM'LEORUW*<R6[4GSFWKB/R1)+'F>X,W)EBY!97&EHY=I
M(LT\?DI!,'Z$@1@#A$IDHE0H.1!V`Z@64QW#<?A=S<I1CV;LB2F"80J8SF8F
MY`^H?(,^(8"JR$BZ.0HE1+YH"`=E?1'@)#\(C_%P#0-3PTW;S#JM>:+V5UN`
M2Y+!NUL<R!'&12:Y(K"2J>/N7;AP9JWG#L%RQ*[DIS+D%ND_%,QP$APM`:E'
MNX#EA@D']+;C;#'8::;]/F5Q921JLG.YI.*36XS5L[FBI/F<I(X:PVUPJ=F6
M);SJF:Q+%JG`G)HJNY=(Q5P5R@?3#NX^1F(/%>C"&=DCW",9A,N[SZ665>IL
MF:`23C*F>2MFQ5E7RKIRV::`(&!!LBNN0JJZB8)YJ/\`IBDG[%Q%,^CYXB_5
MY5U'-TLM8Q,`V<9;$:\DLM)3C^<EW;'"V;KE2I+$3,\?FUDU`;(B<-O@D3]+
M0S?XM&Y:CTLOX5%W&/LOR*0')%\AD6`N7SR4BHME`R<3#Q\N]4#E#B"!F4>Q
M%JJW.Z<"Z(F'5#P>/^XG]\NOOW`'@\?]Q/[Y=??N`/!X_P"XG]\NOOW`'@\?
M]Q/[Y=??N`/!X_[B?WRZ^_<`>#Q_W$_OEU]^X`\'C_N)_?+K[]P!X/'_`'$_
MOEU]^X`\'C_N)_?+K[]P!X/'_<3^^77W[@#P>/\`N)_?+K[]P!X/'_<3^^77
MW[@#P>/^XG]\NOOW`'@\?]Q/[Y=??N`US6(C^>E/6#=BC2@\PZ[?:I/1UNW@
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M@KD:J'*!SH`01"H\!J-^,0W%R#9W<6#V.GF>&[N2V,/X_`,LE/;K#&\B=@1%
MI-.6;U)^T=ECBG,J"2B1RJ&*!>RM0"E65;<_22HX3E49BFXNT[K+V^2[?QV!
MY"5BC&BKB$+EN[,?/3.6LIZ.RJ/>2\]CGXDRTV1`B!ET?%H^-!FN5LZ4"#YS
M;3Z8];!L=)#[F[2-LT1@=Q6TL=-/#`2<O29%)/,#=2X/<(=LAGI*"?,&A58X
MR,?&E8.CN$7JJZ(\!,^(X#])2COOBTEG&;;<OMEBYAB;[+H/'S8ZV;KXXO@\
MD7*HR(.XQ5+,(]A#Y2N44P.Z>/))VDUM49LA<B`=*(B(CQBX\10.`BS;B/MA
MT'\47M]G]'@.0L%AOTS&+Y3N8Y5R+I?S_&YC*99KM@RRY:20+C6)HY/N?-0,
MC.EQ6&P]Z+UQC&1P<6[(5:14%QCS$2`0CR5<B$^[C87](L^Q#$G>W67;'QV?
M)8*W9YQ%/TG<9A[W-HC>#$))Q-XTZ=X[F\TP/FFS;*6CCMG!UF$8]=@HE54B
M:Y`WDYMUUT%>9!^+FYV`JM7K_/T\<"8AXA-O"LIS9C:EO@3IWR6.^(/RX+O<
MTRU;1,H8\A%/&PNCK"FFDD!TDX=UDP[C-3]7L_`Y$S>L]K_F]1B7>,*.X:0;
MJ903,&<FXQ''L:;RDDHP/$&?/C(H-5Y('(,FR30B9E0OEX/'_<3^^77W[@#P
M>/\`N)_?+K[]P!X/'_<3^^77W[@#P>/^XG]\NOOW`1[N3"1IXB`$6QSZ>X>V
MRA?;+SS#%SF!H?L7`!I]6H<!((0L:6E$#^:)1#VRZ&@E%$2]Z_H"@3_33ZHU
M`+"QI!()4#A99;[9=#33%J).]<:T%FGW]]O;WFJ`2%C266H'#3TK/;+H::(L
MA3[UQK;X>CW]]HU],:H!(6-3LL0.&GI6>V70TT>0T_3+C6WPQ'OK6P:UN/<"
M-.)8)R`I$35!,C-D<J0O79B`=JNB5!04C2!BB<I6"07"B`F`H@)S7&+P"LD+
M&IV6('#3TK/;+H::/(:=:KC=;X8CWUK8-:W&N`+"QI++4#A9IV^V70TT09@G
MWKC6GAZ7?WVC6MQJ@%A8TMMJ!PLLM]LNAII@V`G>N-:`S3_TV]O>:H`0L:``
M`('\VVGMET/I02`O>OVT!$O[WU1J#/PMDS?Q\N=<ZKPR&7YDR*H>4=/3))M,
MEDT"M=3\:<F%/EK1)I"LW%(0M%HT$.73!X#"QHUJ@?M`0'VRZ[C`H`_Q_94%
M3?O_`%`X`-"QI@,`H'$#`<#>V705!0'`'"H+@(5!TI_HN^H%`_+=_FBMQ/I.
M.GCI[V;WW^CYRK-,5VJQ)_N1#=6RF$0F+YE(-X7+$L3:;:Y#-8UE6-Y0Y3Q6
M*?*SK=U(,")`Q7D&YG`V:*B`<>NFSIJ_S1/4CCT#*MOI.]LMEMW,IQAIELUL
MAN]NNQQ_?O'L2DC2RN-M\[V]P[9'+G^*RS=F_=/E(YV<CV,:RK4CI-NO5NAH
M]OR''7YS/LL>?#.^C#CUQQDK-^DY-=:=W=&D377I'K$_&)GJ7,>'>9[7Z6<3
MY-O>+Y+'XO;D=[&/=WVF:FUGW*;**=NYG%&&\WOCRQ73):9G':L=:6K6U8_1
M>_YMIVF1;_XM6R*A7#=,UR>YV:`42*H.0M`R72T!!$I'Z@7%$0$:"`C:00WC
MEKY6^BX_S;HD6-_\63910QBK&TR;GYJF*AE`>B8A1'I;(0@G%^J`#4`+<6E+
M"6A6;Z'_`'%_S%^Y?TJ$QT\]36YN[J6VG3?/2;OK(-N?A>%N,-2CG6&9:AMS
M&AE,+"XS+YP.<R<FV>X^C#392R$407Q#&8MS&`/WK[?JIY=@.$Y3*LD$)+)\
M0Q[())!DK((LT7T[#%DGR31)=ZX72:D<2RX)E.H<Y2"`"81*`@#ED(IBDT<+
M)D524*4QRJ$>.TC%,<ZPF$#A(,K:BY/_`!I`H-*T``X!7X+&_<#>B/\`.70=
MXG$>Y;RG'@#P6-[!T#]@@(>V77>`E,'\?Y2AP`$+&EH(('"EHA[9==Y!1$O\
M=VT%N3][ZHU`+"QI++4#A8)!+[9=#04Q:B3O7&M!9)]_?;V^F-4$2D2P3=QZ
M1$U2)AJ*:8/7@%,9JFQ!`3I^()@MI<FG2Y);N$1MN,)@6DA8U/3L0.&GI6>V
M70TT.0TJW+C=;X8CWUK8-:W'N`)"QJ>G:@<-+2LJY=&IH<AI>F7&ZWPQ#OK6
MP:UN/<&"0L:G98@<-/2L]LNAIH\CI]ZXUM\-1[ZUL&M;C7`%A8TEEJ!PL!,"
M^V70T!(&8$[UQK0&"7?WV]OIC5!&WB(_FW9--42HE9%2(9Z\.5,I$D1*!4S2
M"P)U%L01]:2N$M1OJ(B"P(6-```$#]@``>V70]A03*'>OVT!$O[WU1J!X+&T
MIH'I2G\Y==U*4KKU[N`!A8T:@*!^T#`/MET'88%`'N7\BIOW_J!P`:%C37`*
M!_/`X&]LN@J"@.`/W+A2H.U.[NN^H%`2MHE@X27,LFJJ)W,BD(F>NST3!U)-
MP3(//N03*1-VH4"E,6VO81,2@0@*CPL:I?>@<=35O]LN@KK<]J=RX4N\26[J
M4O"E+2VAD\+&J:ER!QU=6^CET6NOS^KZ5<+;O$U^ZE+PI2TEH!X6-4U+T#CJ
M:M_MET%=?G]6EJX6W>)K=U*7A2EI+0^%HB/L6."*@'$BY[BNG1!`R@/C',4P
M.DK!ND%1`0,6EP4$+2B4/!I#1RC-L)T5#BHV3,<QGCLYCBJDX$YA/SKD3"87
MJHUU%/3>F&A1X!4,-&F$1%`]37"/MET'IQ7$W8"U`J+@_P"_]0*`>"QO;ZP?
MM$1'VRZ[Q$QA_C^SM./`5CV+(5+='/DREM*3:#:,A2U,-H%W?ZK``M3")AH`
M>B->`MAP'._9[99"4Z#-G&.VD<W@]P)GIPVD6A98[M0RS:5>X?BTH_705F#O
MVC)R\JL4JEA=/5$"B0O:`/W:38G==CD#A]O4_P!N)J&7/GVG!X*E+MHUHA(J
M;6+;?)MUI:,:Y#S&.$B\H;N5%'RO-%>HK'O,>QL$UXYA6,0>YN4HQ<.BU14P
M3"53AJNUP%4^09\4PW.5UJ")42]@4[N`D/P>,\7`.21M\--_!&E>:+]6E>`^
M)V`!Q"3"$(BS:32T5()1#I8@"BVE%&BQ&#A4#)KE%)%V8AC5(<*!Z4>[@.?T
M+BW7U"-H#%TF.TDTS-A*C67RS*I'F9-#*SK,4%919\R17D%717#QXX(BFB=J
M9BBV(045RK%4!;!X_P#2'2.'IR[Y3IW@<J+%.P1Q*8@%GI5I)1`"`>3F(55P
MV;`W='5.Q(@HJ44B-RNSF.+@1!X-,"ZR'T?-ERW)=JC'>XC%BSC\"C$,76;Y
M"CG$`XR2.8SLO"9`]CW,MMPS?-(Y^;629RKTRQTA*D@<@1VEB?TBCB`@X$$M
MA8DQ5WS:5GW<NXF<G3AW3B<7ARN)1OAD:PD9R`BG,8T=/TF+8LD]9.7`-44W
M)")AOG&%=>^/P[MA`S.R66RJJS!XSF,F2,D1`SJ50=3K%V@ACK<3H,F8"UCB
MH@F4&EZBYE'5EP.S`,0ZTFTWCC7.IK99SB[%Y".,F>I0YW613\>:39C-LFHM
M(V-81DFK&KOSJ*$3*V3528)M2$3YL1!ES;'Z0,DNTB\7Q[9`L.=CF+@^1SY&
MSM<LH1Q''@6LE'MCMCDCCHNWQ&!6UZASH-1=J))E7(J'T_QCZ1)JP`\3(=.$
MB\<#EAUFLM$.BJQQEVK5;%TF4BQBF#5XV8O7CA(-9H"ATF:(+"8RRBI0EW;+
M&>J)#*X%YNZ]VND,<?$67FHO!H8&",`93'9`5HTCR0`)"82+D:K0K5<`!0$$
M5!4I?P%J/!HOW"A]B/U^`/!HOW"A]B/U^`/!HOW"A]B/U^`/!HOW"A]B/U^`
M/!HOW"A]B/U^`/!HOW"A]B/U^`/!HOW"A]B/U^`/!HOW"A]B/U^`/!HOW"A]
MB/U^`US6'C.>E*LD::C2E0&G\T)W=O`;'P:+]PH?8C]?@(QWEQ++9K;++8O:
MMTW@<_=LFA<<E1Y$G+N$I1BX=)ZLDU>M4.;CD5D=04[R`I4AB'`IRA6K-L1Z
M[U=Q.<P:3Z:&>UT6S27:1$C#Y0YS&=?N<+*T?L9!XLU+%HM8W-WAW+-0#%,N
MQ9$(M8HX$S<+68#$31L<Q\,_809<Y+B&)AF98$#&A`RL(X_C_A)A0:7Q_B6I
MHCI$];IV!W<!!745M]U,3DSB3WIQRW`,7C6L7)-\LC,V:"L@]DT,KP?*81^S
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M*5J\.X6:F`3&.K<KP#@S;;WK'?FA2X3E>V$5*1^%)MIF3DFC0N+Y)D2.XH.E
MQ)CJ>'R<KC4O(;=,4D0D$W+YFF[=K$(R2TBK+@HR?:_JR6R`XXON%AS>'>JR
MW*KOX^"%#'4Y/`,3CQYF+3P<SR?2B<Z1E7D4472:B)#EYM1RF<J"(.O8K!=\
M<=D,I6WNFHS(H^23P[\3FP.(=^[@UVBTV208NG,)C6,M)%X=HHS,]>F:I@Y=
MWBD0J(%*`1WM[MGU?Q+F*6S',8*68P[;&CRC-5UBSQSF18W+))Y--Z$P-H7'
M9.;Q=;1<"BZ%N#@&PMU44@511#ZSO;3K"?SS)SA>:8['0II'-'CULY<XFW,6
M'ELI4?X%!HM_FU?:4CAS$S9*0<:RQ9.*07;E.F[4YI<+U##Q8B(BQ;U$:C0E
M`J/?0`&@!P&/!HOW"A]B/U^`CW<F#BCQ$!6/0-9N'MJH7S3>:8F<P(E/V&#M
M*/E[.`D$(2**("#%`!+;3L'LL%$2T[?X(MR?8AP`6$BBV6L4`LLLH!O-TA:B
MG3SOX`LDJ?[`<`%A(HEEC%`NF*8DH!O-%$60I"'G=Y!CD*?]V'`!(2*3T[&*
M!=+2TZ%'S-#D!2IV_P`7X8WI_P!T7@$*4-&)2(D3:)E(1DR,5,#GL*9JN@#8
MX)<V)0,D$<B`&T0&B10O&EH`N)"1*=EC%`NGI:=`$+=#D02IYW\7X8WI_P!T
M7@,%A(D@$`C%`H)Z8$H`^:"0,@3IYW\`(Y"G_=AP`6$B2`4"L4``E@%H!NS2
M!L"=/._@@S2I_L!P`$)$A2C%`+0*`>:/8!`2`OH^@"!/L0X!GX5'Q[R/ESKD
M*\%'+\R:$.J[5?"BDVR631(U!0^0Y$*1&P%L!+50!*EO*M::!`>`PD2-0%B@
M-:@/8;M`P*%$/3>B"IOW^`C'>:"W#5VXR$NR!\>C-SA7@5<?<Y#'M9"'401R
M:-=9$R=H/5"-T_%,;/(-R+=ID%'`*%*8Q0*(<O<H@OIBGN'((19]E39",QO*
MU<I#&;9+DE,=3?N'6V3Z;;2S56(9RDK%O'#5@DT,NDQ<\LI+\ZF#L%SR?3IZ
MI-BL9Q1UN<^W-W&QW$MM]Z<CV7VPQW/,IQ?*WNW\OE^0P^0;I8QG2AEX9U`R
M#F*/D4;I-4W*BRY&I&@GTC@4B7.<^+C9\AS\K-*;;>9-OCIWQ><>2\4RYZ3W
M36:S/6L1I,S.D5UT](^T.*WWFU/H]Q/@5=UN.;\;V7,;W<QM;;6N]V>UR;C8
M\7N,?LURUS4K,TS9+3:E:4F]LW;WQK>\IG3P_M26W'G[C)B02K;\9N542.$W
M8%"I\M*J`*)SA[![!`%TZ4M3T\VV?#:VMMS?6?\`2+Q_4B\?/^K'[48P<5R>
M+%%<7![><==>L\-MK^DSKK:VWM,Z36==9G3MM'IK%FQDCWJ@=X0Q#I@C(?,9
M)#J0QIK+3V8[B0\S#N-I%(@\GF[:=>YE#9!-.,:)(RRB-L&Z"<2,ZN:4324;
M'VO#;G=VPYO:K&?#7/,5M;-,S,=M9GK-;SI$S.G6?VM-$"^I/"^.X.3X^=]E
MMQG(9>+I?/AQ<=3'6N2,^:E9G'3-@K%[XZUFTQCKZ1,]TV[IB!ZC]*))[?LF
M`);/$W5B,29PV[;2,B,:=1$[DZDQ@AF.5XW-/X%B1]$Y%CB^2&E8PC4SAC'J
M'39'&34:6;G;;F^:^3%EQ^WDQS'Q[HF+1K$Q/;7\DQ\'->;X3:\9M=IO]ANX
MW>RWE,DQ,XXQ7I;%?LM6^.,N68B>EJVF8[HGTZ:NE6RT#$ALWM,0T>@%-LL%
M(8EIP`+L6:`<M#&N#^>J]_;YX\9:/)!D8B-3:.52-4TU"E,<%4SG14*8QUC'
M,"I'3,Q1,+E2M%2>G'MX!9X)$^X4/1]`?1$PC_"\IQ_?X`\%B@I[10[!`0[#
M=X"40_A>4H?O<`!"11:"#%`+;1"@&[+!1,6GG>@+8GV(<`%A(HMMK%`+-,24
M`WFBD+44Q#SOX(LDJ?\`=AP")2'C$WD<0C1,A"ZAP(4YRE$[5-@#<3$!TF53
M1!DE;5-6VP!\WO$%I(6*3T[&*!=+2TZ%'S=#D!1IV_Q8Q;>G_=%X`)"12>G8
MQ0+I:6G0#>9H>'Z-/._B_"F]/^Z+P&"0D2G98Q0+IZ6G0#>;H<CI4\[^!X8A
M3_NB\`%A(DEEK%`MFG90#>;H@S!*GG?P`CT:?]V'`(F\-%\X\+R:0E2!D1,H
MG4,5,J:2(D`B8NE2IT%LGW)I76!6[OX!:$)$A0`8H=EH!V#V`4$BE_A>@")?
ML0X`\$B:4Y%"E*=QNZEOJO)P`,)$C4!8H=M0'L-VW`H4W\+T06-]D/`!H.)-
M<!F"`WW@:H&[=0'('_A?P@=J_9CP"5K#QBZ2YE6B:HJ.I$AC',=01)S<D@*8
M"9TYM(";Q4MH&*!0.(6$](4%1X2)4OO8H&U-74J!O.U^>U:^=_#\37K_`-Z;
M@,GA(E34O8H&U=74J!O.U_$-:M#?QGBKBO\`WIN`#PL4IJ7L4#:NKJ5*/G:_
M/BM7M_C!E'%?^]-P'PO#1@D7/R:-YB+F$P7E,)E0?&.:X%4Q`3&D5QJ!B^R#
MVAW@'@SA(H[-L)F2)[VR8G,83J"<54G`J&,<SAP8XG%\J(B*AQ'4'SA[^`5#
M"11JU8H#=<(]ANV\5Q-_"]$7)_LAX`\%BAK[10[:B/8;T1,8?X7HB<?W^`K'
ML60J>Z.?)D+84FT&T92E"OF@7=_JL`"]HB/8'`6PX#GAL]L;'Y#T&;-1.W<;
M&XYG<]TX;1*Q$\*_+.&DH\P[%I1\Y2D'T=D)8]P]'6+K%:G,35$"6`-2AN]I
MNG/>&*W#5E=XY/;+)L/,TRE5NRPE"2AVB*DJ?%OQ>@QQF3A%G94<;+&OA+)G
MFW3QSS``8B8'6!0+&XYA>*P>YN4H1,$Q9(J8)A*QR)D.8IE3Y!GQ#&]=.>@B
M1(H#3R!P$A^$1?C`!R#6GAIA]B+W\T7ZG`?$[CY'<),M(=%DREW45(-XIZJB
M72:2*S19-BZ4]:7\QNY,4X^8?L#TH]W`<_87;+KO@6T!B[6:V:E8LF$J1\OD
MV4/GTQ)I90=5DFI+'?J8L;)'C_7=/G!`U#-#M"-D"`S51.9P"N%V\^D$?8DG
M)R69;`0.7A%N2)8R_P`29S#`\DJW*05I68BL=2`@(NCJJ,2-C*%13!N1T=V8
MJYU@>++:?JX<L)M/+]P=LI,7^*12;6-PZ';X3HSZ&<X^_P`B8L\A)A\G.PY9
MW;M@]C6DD15=6.D'ZCD$#V-Q1"/4]K_I!UX&$@!RCI]B4TEWS>4ES.)><R4D
M,[<SB\4U/.FVXBCRDMCD8\C62DF"+5:4<QZSM1%+F])(-TOM1UT04.[C\;S[
M93(9)==@\:S&61QS<L=Q)HO)]FY:EP)T=P@DW*+6-!!5JF@RO%4BKH2+`#KP
M';+K$CYS&TLWSK9V1Q:-?0CK(CM\;0>9!D;`LFQ/-1Q50Q");1CUQ&JR!E5D
M1(@9;D"-4F:23D%P:BNV?7=X]*/X?,]DFD6LU4;Q49DT.C(LF\@W=RKQ%\\9
M1>&C(>%2*;CEE4TY,71/::R8HIMW+-T'FMM=]((,-&IK;F=.BTX[6?#/+0>#
MC$L(M%&/=)Q@8Z:9Q'(5G`O'A4E'!7B9Q*H<2D.5,OG@K6VXZ^PF`:(YYTY&
M@%)5TD:9_$M9&8;PJD&R10=HQ9L;<LEI-"8!14A3*`E>"MX'2.BFB%H-G\3W
M#B(:89[NO<=R.=+,)"PF(2-8QS!['%A(A$SA"/9LV16!%'R2MZ1R`;F-4Y:)
M'3``ESP>+]P-?Y(OUN`/!XOW`U_DB_6X`\'B_<#7^2+];@#P>+]P-?Y(OUN`
M/!XOW`U_DB_6X`\'B_<#7^2+];@#P>+]P-?Y(OUN`/!XOW`U_DB_6X#6M8>+
MY^4]H->Q1I3UHO9[5)]3@-EX/%^X&O\`)%^MP$5[VX7FN2[6Y9![12<1BFX4
M@WC20$[()$*V:%1FXQU+H@OX?*"S<R$&@Y;(N`;JBW66*H`>;7@*UYKMEUQ/
M-Q/$\*S_`*=(S;&-:(+,,;?X5,JY9,2*^&!'R+:7ES1J\6BT:9F\5>LSE24$
M[1HBDL0%%SJMPM?@$),(XYC[?/6V/N,Y;XAB:.9.(%`"PCC*B1QRSZ\2`LHX
M?#EI(%#(^UT?6Q#S"^E`(*ZC-J>HK+9G$9#I[W!P;`V,=%R+7*(S+XQ5ZVDY
M%+*\&RR"D&A&V/RZAM5MB+V`?)F51(:(R%X<@<RFW.0&NKM7U;26#2[22SW;
M)GE[R7QEW`J0,2RBPA(U@I/)OVDI-!@KA*766,K$/)`$XY%&1,T>M$"L4'28
MI!KR;(]41\0.W5W+@V\Z27S(O(HOXM9P\Q.2F6DECK,V8*;7%7:9;',57K!*
M028$;H("@H+=4Y0*B&,<V5ZJV>X>(3V3;F8K+8RRR''97+H6.,WCHB5:!!`T
MG8V.AT<%;2+..CGZKQ1ND$D7Q!THS77TTFQVIPNM$1$6,7'B+!K46;<?8B_<
MR^6H\!1*:V;ZW&>XN4SF)[J;1O,(>3.:&Q''\HAE'3B-B\ER4)Z"/D2:>&&!
M\7#V1/#4$6SDBRC,P!S('`QSA(F:;3=3<CC$,GANYFW45F+/&W<7-/)/$V00
M$U+-]R,7F8Z93:,<9,[BI.5VZC)"*=K)B=JU</S*H,S&`BJ8+Y79_?A0DJ6&
MW-Q]JH_>9*+([R#A'#>&9SVU^%0<:=LW)AI'+D^)[F1LU+,457`@=L_(1PHM
M:1)`/K8O;+>3#7^4K[R91$Y9'S">')XDS!^A,KXZX8+S2;Z/,Z;X=B"3TYV:
MS,73Y5`ZS]V0ZE$DP32*$;8;L=U=L6A6N4;O80Z:,X?&V,81O%LW&1N7\=DN
M8/,FE,IR)_A#UC)OLG@IM@F4S)@P;,CQB"234J8.!=!X;9;,=7N*331]D&;;
M;Y&R)CD=#KL\O?Y%DS(FAG$8]=/DF3*&@EC90YPD'Z2CQ=RZ*#Y1`"#RI101
M#RR7:#KC6V\PN"V\W-V3QK+%E,S5W#FL_@9#/W<<9]/IO<-0PR6B<:Q#QAG%
MQ2RR+OG6;!10J:9411`]40M#LWCFZ3.$R)+>W\0Y"=4S"37QI7"FPD8(8:HP
MB0C6C_4A(,YY-O)$>`8XIG$Z(IF$Q3&%-,-WN3"1)HC'Q&.:&$FX>VJA:HE\
MTY,Y@1*<.SO*/`2`$+$A2D>U"T2B%$BU`2"D8HA_LB@3[$.`"PL22VV/:EL$
M@EHD7S13%L*8AY+!9)4\FF7R<`$A8E.RR/:ET].RB1?-T19"E;Y-,8Y"GDTB
M^3@`L)$DT[(YJ72TM.U(H6:'("C;Y-/PMO3R:)/('`(DX:*2D1(FQ;$*1DS,
M4A2T*46JZ`-S`GKB4!2"/0`HZ0"&D7SAH``"TD)$)V61S0NGI642*%F@#$$;
M>SLTPC&]/)HD\@<`%A(DEEL<U+IZ=E$BA;H@S!*G_=A'H4\FD7R<`%A(@MML
M<T+8!`+1$H6@F#8"`'9W$!FE3_NR^3@`(2("E(YH%MH!1(H4M!("T[/X((DI
M_LAP#.PF/CGD=+G601="EE^9-2&55,[%))MDLFD1L4ZDQ-BDFW`+`2!1$$Z6
M@W;TT2`\1A(@:UCF@U`0'UDM!`P*%$.[T05-^^/`!H2(-=='-#`<#@8!1*(&
M!0'`'J%.VX':M?\`;'R\!1;J_P`>ZU7,ICP=(R^,QL*.![E!DG/-]MS/CYTY
M9I_B"L0FX&/S":Y23;N\X)J(M!C32A7`&<JQYDPKCG&*?28899,8GBFQN6XN
MT).90XP-D6%E%?$Y;&,LFWN$'4E\+)D,W`/<TE3($49O&#L)!ZB85THI-X!H
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M;9<M;9LDUR3>LST[9?!6.T")#HHYT#<AQ5$Z+;J#SIJF<[CFS*F,BAN`B03+
M^)J5$0`1!P(=@#YF96W&1'W-S,5^S=Y8C^IE^V/SQ^UHKT\VRV]S/PV.]OG?
MQ[87G2/XUN/M.D:6^.G2WKU[D5N6*XIN[$;"O823R/)LCPYG%Y=+Y-)[I@16
M,@F>49C`2"4X7)WQFLY@B4HS252=*+MW<JF*+:\P5VG`Y\=-WFIAGW,&3)6.
M_P!VV68M&+OTF;3:=-(_A=)M'W4%^K7&;W=>/<;NN2I^"Y39;/-D_#?@,.QI
M;#DY",'?2N&N&ON=]NL>Q]^N*\SEF81]M'A_TB[OI]PX"99LU"Y,GC.[S#&4
MXS'8B2A7.*2NWF?273/.N"Y%C,5*Q\ACD_*8W&2<<Y1.HJV;NEW:JRBB@*2]
M\ZNHHQ*)(1)9^S:$E@8H'?*MP!,O/G(87IDE$E6=I#.'2U!`Q`$#CY:<!M_!
M(GXN:>C_`!)?1$XCZ'HBH;]\>`/!8GXO:]@@/L1:U`2F`?W!*'[W``0L2%*1
M[4+;:42*%+!1$M/]D6Z?V`>3@`L+$EMMCFA;!3$M$BA:*0M13IV=E@LD:?\`
M=E\G`(E(>+3>1Q",FY"%U3@0I;2B9LFP!N82`N0IQ0Y)&VI%+=,M+:5X!:6$
MB2:=D<U+I:6G:D4+-#D!1M\FGX6WIY-$GD#@`D)$)Z=D<T+I:6G:D4+-#D-&
MWR:?A;>GDT2>3@`D)$)Z8$CFA=+2TZ(E"S0Y'1M[.S3\,;T\FB3R!P`6$B"6
M61S4NGIV6I%"W1!F"5*=U@1Z%/\`NB^3@$+>&B0>/"@P;42!D5,MH"5,I$41
M(!":ZA4P#ED^XB=;`]-2O`+@A(@*4CF@4M`*)%[+02`OH>@")/L0X`\$B/BY
MIW4]A+2E+:=WDX`&$B!K6.:#4#`-4B]H&!4#?O@L?[(>`!A(@UP&CF@@<#@:
MJ)1N!0'!3@/9W&!VJ`_[8^7@$C6'BUTES*L6ZHG=229Q4*"E2<W)(B2IEEZ%
M!-XJ6VH``*&"TE;0!6>$B%-0#QS0VKJZE42C?K\]K7=G;J>)N*^76/Y1X`/"
M1"FI?'-#:NKJ7)%&_7Y_6N\NIXHXKY=8_EX`-"1)]2^.:FU=74N2*-^OSXK7
M>74\4<5\NL?RCP'PO#Q0IKG%@UN$BYQ-I%`PF4!\90UP&(-3FD5Q'M#V4W;V
M\!XLX6).R;"9@U/>V3$QC)@<3ZJ:XJ"8XJ+"83B]6$1O-74-VC6O`*1A8DUU
M8]J-PF$U4BC43BL)Q'_:%RH(_P"V/EX`&$B1K6/:]HB(^M%[1$3&']\3#^_P
M%8]BR%)NCGQ"%`I2;0;1%*4.XI2[O]5@``5[>P`X"V'`<[]H-CH3*^@S9B$V
M_A,6QS.9[IQV@4BI\K2,9.&TJYPW%I)\Z&3<8_DPLG+XP+%.N#-90IE1$MIO
M/*&ZVHZ9]SX'<(L]NU(;0Y5C!D\R%2.Q'%DL=C44)E/#QQ>(;XP]@'CDJN,.
MHN1`LFK-N'#E!U0Z0'.H80L?CN(8A";FY2WA\>@XY!3!,)6.DS8-$4SJFR#/
MB'4$I"``G$B1`$>^A0\@<!(?A<2,P!0CX\0\-,-H-FX]SHM1I9Z%>`)O'TW<
M-+M(9*+C9=U%OV\5(K1C5TC'R2S15-B]5:J)"1RDU=&*H9,0$#@6@]_`462V
M?ZQ8Y6(''\DVD9PL(HU>EQW+)Z8SR1FS6.D9.,F<WD=L&$VZYY5ZNX374(H@
MT*#)!)J`M%%W(//"]INJ]A/8X]SC<_:"<@TGT2^RJ&B]N8EB+M(B\4G-PT,Z
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MQ@VY=$&[-R^(H=).PEA#`%`I3@-SX5#_`!?'>]6_VG`'A4/\7QWO5O\`:<`>
M%0_Q?'>]6_VG`'A4/\7QWO5O]IP!X5#_`!?'>]6_VG`'A4/\7QWO5O\`:<`>
M%0_Q?'>]6_VG`'A4/\7QWO5O]IP!X5#_`!?'>]6_VG`'A4/\7QWO5O\`:<`>
M%0_Q?'>]6_VG`'A4/\7QWO5O]IP&N:Q<0+^4JPCQ`%&E`%LWH'M4G<%G9P&R
M")B![HZ/'_0U;C_^YP$:[Q8;DN1[:99!;:##0F<2C)LU@9=X[/!(1RII%D9V
M\&38P4^[050CBK&3*1L(K*`5/40`XKIA5_-]HNM1WN.>1P/=#8>.VLC&J!HG
M')W;XRN:3;P^&A%O2Y+.LX4T(D"67NU9%`[=F9(4FJ21D"BL8[<+88!"2C7'
M(!GGB.-/<W:8CB;;,7<&S0)"N\I2CU"SKJ*(:/C1+'N)$#G1#ET*)B`:9/2@
M%?=\-FNHK+=R\=R;9O=/"\'P:+@(UM*XA/8\$FG,Y`SE9Z1<O7(H1*ZHQSI$
M\:W.D1RB8Z)'`#:)B&X!@Q.RW64\Q?(4<OW,VO#+'0[>%@'.*1C2$AV00RN7
MKY.Y51+MR=RW6>.)2%.]()G:4V6)<()EB6[P$T@7M=@^IPF#LXMWNK`JY(Q7
MR-BY71<MB.<DQ]X^CG\6YD,I4VZ5<P^9C=(-B/&#!%E'M5&VFU5.D`E#TQW8
MOJA8[A8AD.2;IXM,8W'Y!CLOEL,Q%.+B9=H2"*SGHYE!-\%1<M(Y@^5>*-$"
M2:17SI5HY="0C,6BH75B(N(&+CQ%A'B(LT!$1;-Q$?6R]XV<!S_<;!]<45D.
M3RN-;W[0RD;)Y8LXQR'S3#EI-I!8>:3RAFA'."-H!`[J1#%X7%5U5-05!EGL
M\)%2(F:W@[<EV,ZI9';G&&<!NOB45N0T@95'('KUA$.(-]DCS<B(GX247<Q.
MW$*Z>H0>%D=,'"3=M&M7HE(B#9-!57@%N2;$=2;J<.MCF[>-,8IV>4M5>148
M)H`LK@&)PS@S6#0P@6\^1GFC&3D8Q-T[3&.!<IC*N=04$0>&Q>UF[F"R&4.-
MXLKA\PCILN'I8NR"0+.*XXO'KS2;Z/*Z-AF(%=ZC)=IS#]9-9S(NB'5,"!`3
M1*$:J[$=5!<ZPB2;[LXQ^*>/Y1ACO*6ZJS(76:8O&Y3/2N2,W<0VVT8,(B17
M@';1B46C@A7MAS+&(!&Q6X7Q\*A_B^.]ZM_M.`/"H?XOCO>K?[3@#PJ'^+X[
MWJW^TX"/=RHF%&(Q\31T:-NXFVIR5:MO-4+G,")#%\SL.4>[T>`D$(J&`0MC
MXX!`2B6C9O4!**0DI0G>442"'^R7R!P`6)A2VVQ\<42V64;-PM$@M13MH3LL
M%JC3R:9/4EH`6*A2661\:6S3%.UJV"S2%D*5E"=E@L6]M.[23IZ4M`"1,,2S
M3CHTNGI:=C5L%FB+#0LH3S=(6#:VG=HIT]*6@(4HN&3DA*G'QQ`(Q9B0I&[<
MH%Y=P@#42D`:`*/)-[!`@6Z2=!\TH`"XD3"DT[(Z-)IZ6E:U;%LT>1T+*$\W
M2!@VMIW:*=/2EH&"Q4*6P"1T:6S3LM:M@MTP9`E90G98#)O;3NTDZ>E+0`L3
M"E`MD=&@!;`):U;`!;`;`G;0G9:#5&GDTR>0.``B84*`$=&A2T`HV;=@%!("
M@'F=E`1(`?[(>0.`9^$L8MQ'3!EFK-P*67YBW(98J3@4T$<DDB)($,J]D131
M1(%I4P,F4@=@))!ZV4'@,3"C6L=&C4!`?:S;M`04`P#YGH@H8!_VA\O`!HF%
M,!KHZ-$#`>ZK5N(&`X.`4NJ3M`P.5:^4#F\H\!5[JLQ#J(G<2PUMTJRF'XQF
M!-PXY?,Y#(V6,KL5<"/"98C*HJM9_%LG2D0-,R2!S-FX,7:PF,!7:28K%4"K
M$AMC])DMMMMTK';D;8H;AEQDD9N-'.8S;\Z3B?:YCA1(W*49I3:Y^S6>3>+.
M,B<9(P11*Q!-VNSC3`NJ@_3&FO2?1N=P66UKS=S<Q+/LB9Q2Z&18HUBF#_=K
M)L"1_%]QM1@;Q4[2'B\T@&2S)U,S<J)W6F8RJZ[@#*F$AA1^G?%]IRE/!>'S
M<'QV'<1DV6>^7)'%[3>6G-&_WM8[\N7:Y[]T8<>+2DVTBD5F*Z7_`,)J\NYR
MUW%Z6W&:E8M$1$9\E(B.VL]*UO6/69ZZ>O\`48V=87U^9=L%L--]+KO9B%G7
MO3_A)<C1W'>Q,DXF,ZD)O:]^EE,P^G]F)^4,9;!G.4^+H<P(KK/SID`7)B.P
MYK]0>*\%V_U"Y_;XMQNL&UQ\UO:XZ8=AM[8JTC<9(BM/\>I$4KUI2(KI-*UM
MI77MKG[7D.5G9XM<F29G'769RWB==(]>FNOSZO'%,*ZL_P!<7#5,ZD=M#[4E
MS/*U]V,?B<8!PV<04YTL-$\?A(W(U=H<?9RK!AN6K.+`'/(NP:N+':[RI4$^
M:^0>-\?Q&YXWF.,SVW&SY'W;5[\6/%DQVP1?%:MZ8]QN.V+:1:EKSC[HUBM;
M1'=/3>.\AWW*>"\AQ&:U^W8[6D6[LU9B_O<AARU[*6FN2W9Z6[*WBLSW6FNK
MI%LO!PH;-[3D&)C:?-E@Q!*+-O2AL6:`<HAI]QN<6KY=4_JAKC.;I"D8J+*S
M<J%CV15`*8P*%;HD.!C'5$Q@.443`8PN%*C<%;S>4:@M\'B/BR/[1$?YHW[Q
M$YA_B^\3&,/[H\`>#Q(4^#(\!J`A[4;@-0$H@(>M^@8H?O!P&`AX@*4C(\+;
M1+1H@%+11$E/,[+103$/)87R!P`6'B"6B6-CRV"G91HW"T4Q;"G;0G98+1&W
MR:9/4A0$*L7#IO8XA&$<0"ZIB$*W;D`#MTV'+F`@"0!,CRB%@VF$NF2EM`X!
M:2)AB:>G'1I=/2TK&K8+-+D!1LH3S=,8]K;3NT4Z>E+0`D3#$T]..C2Z>EI6
M-6P6:/(:%E">;I^'M;:=VBE3TI:`%BH4EED=&EL!+3M:M@L!(&.C90G8"8,&
MUM.[13IZ4M`P6*A2V61T:6P$P3M:M@M!,&8)`2A.RP&3>VG=I$IZ4M`0MHJ&
MYUZ`1\=1,&()@#=N($*5%'3`A;C`0"\NG2A2>D+WT`>`7!$PH4`(Z-"EH!1L
MV[`*"0%`/,[*`B0`_P!D/('`'A,+3^C8RE*?S5M2E*>H[K>S_1P`,1"#4!CH
MP:W`-6K;M`P*@8!\ST05.`_[0^4>`#1,*(&NCHT0->!KFK:AKP<`I=4G;<#E
M6OEO/Y1X!(TC(=5)<56$<J)G<DF<5$&Z@F)S<FD8AQ.*HVZ3I8M*@`%4.%"@
M(EX!8>*A3WWQT:>_5U+FK8;]7GM:^I.W4!^YNKWZRE?3&J`>)ACZFI'1IM35
MU;VK8;];G]>^I/.U/$'5U>_65KZ8U0#Q,,?4U(Z--J:NK>U;#?J\^*U]2>=J
M#(.KJ]^LI7TQJAYKQD.*:YA81UQB+F,86S:X3*`^%0PFM*-3B^<"(U"HJJ=O
MG&X#Q9Q,*=DUNCXTU[5,3"+9N:[427%01$=03:@NEA$1,:NH>HC<81!4:)AA
MK='QPB83":K9OVB85Q.(U)VB8RZE?*)S>4>`/"H;XOC1$1$1]JMA$1$3"/\`
M`]$3#^^/`5CV+*0FZ.?$(4I"%V@VC*4I``"E*&[_`%6``%`.P"@'=P%L.`YY
M;1;+8[FO07LSC>"0V$XWFV1].&SY(_(&T?!1#M&35P[%9)^NM,(XQDCEJN\4
M25UEP9.5@.<Q@`%//*&]VGZ7=QL2W"_&;=/,ME\VPPS3.4UL2@=DXO$2%>Y&
M?;U;%U$7CF6F[&.&%QR5:MD37**)R2BZJJJRQ@1"Q6/8SAL/N;E",+C^,QC=
M3!,)5.E&144S2.L.09^0ZAB-4$RF.)"$`1$*B!0KW!P#"ZHMM=PMS-H<TPC8
MW+8_;?<^7:XNOCF6A*NL8(P)$9G#2TRU<3D'`9!-,F<Q"LEV:P-$".54ES)I
MKMC&!PD'/>7V8^E_QI=@RQO>WIJSF,?9-`QB;R1P['PE(*+=Y-E<E-Y5DHR>
MW<*>0Q:*@)*/8&A&"SN;=E8("C)(*"Z7<A.N:].76]DNT^W4<UWYPAAN\SVW
M>XQN=*XTFCMYB4KG3K=;;7(XW<7&EH;:J>E22N.[;P<_%\JJU;Q<FY?)%69I
M-5').`A?J+Z./I(<_P`YW%DMC.KG"-I<5R#)9=_C"JY\F>/V&,RV(9=B49`(
M8>3$7>)8:?!D,L2?-EX]5TO,3T*RE'JA37-2!(4/T3=6)MM8[&9[K>R-MF\M
MO\MN5E.90L-S9\9VR:XUG\=&[98(63737D2/9^5@7KLDD*<$!HX]L6=/50>`
MW\EZ>_I2GPLF<)U/=.+=FV5P*0<R!]N(V*E'TI"1D1(92V41CMJW"2>)R^3M
M7;5>.!874BP705!]'D1=1D@'M)[`_2A3:Z$DIU%=.&-.FTX]DT(.!Q)-SB1H
MQ;E'<1"2B)]HXO*)@T"Y:G;+.!E$$9=-P*QVK4B9F2X6LZ7MM^J+#U,R<=4>
MYVU>Y*<NVQHN'16"8=#P26)JQQ9=.;!_*M</Q%;)'<NBX9BNZ.V004=(*JMF
M<>BJ#1,+;\A#>XHSWLU^TX`Y"&]Q1GO9K]IP!R$-[BC/>S7[3@#D(;W%&>]F
MOVG`'(0WN*,][-?M.`.0AO<49[V:_:<`<A#>XHSWLU^TX`Y"&]Q1GO9K]IP!
MR$-[BC/>S7[3@#D(;W%&>]FOVG`'(0WN*,][-?M.`.0AO<49[V:_:<!KFK&'
MY^4#DHR@*-*>UFOHM2?ZG`0CU!;6;A[B0F.,]I,Y;8`]BG>=*SR*:PQ3/)&L
MYM!N)C.)-',K#PK_`"2+-C^Z<MCTT*T>X9K:$8J6Y0PD3$*@Y=TL];;W<_;N
M0P?J)B,=VSP0=B(:;;SV1.\FG-U8/`IY4=T<CS?&AVECHMGF6X&,(D`2,9<C
M5R_>.1?'7008$;AJLEZ>/I.GN;Y!.P/4YTYLL4:Y5NDG@V+AL^1@J;;[(X.:
M8[;$S%V?'9M@_P`WPJ>)#R3AP1HHU<I(OF:94P>$<H!T.VPA<CC\-Q&-W16Q
M&9W+CL#PACN%+XU'I-<<E,W;0P(Y5(P#5=A'+-H5]-$65:IF;H"1`Q2BF2EH
M!1KJHZ;>N/<'J!Q+<CIEZE<(VNVEA,'QUC.[4Y3"*R+&?SS'5]XM22,"&+S;
M-*&R5GN+$<^577`SG&8]0S=4B)T7`.;!-B.M_P#$O+6&ZN_FU4AF;W*=F)["
MI/!=O82$C<?B,0W$&7W3Q&:4_$=B[R"(W#V]:-H]94$V[@[Y5V=N:,;K(I-P
M;T3TO=:QMOSQ.3]4\"ON$6&ZC8@,JQ7$H:"AGCO.'DC+[#9,,'*X;DB\7+;;
M/GI6;A%-PNV2B4B))@Y7(1P4"-Z:^M-MU(L]Q)'J`Q5SLD3<J+RE[MB@N\:M
M#8<?')IG+8DG#(X`D/*1$E)$*Q2)-(I/E4D9!\)CMP8K!T3B&$.,7'B+*,J+
M-"OM9IWZ9>_S._@.3+KI1^DV@]PLOR7".L#:&5P^8S#*76-8CN/MZKD24#@[
MM[ER6*Q)E@QY8%)AA!,,7!PX"IQDU99R"AT#$:.@D3)>F+K??;8[91T%U%XV
MVW.@<#C(W<)XZ4198SE6?Q^[&,YD&1*2D'M2PR!W%O,(92$%)H-4(0)%FL1%
ML2+U%%R`U/U3OI`2YS/2*/5'BJ>,2>1[F+QJKA5P]/"XYE>'3,5BJ;3`C[8H
M0@R6+9&\BW+-$\L=K'>"*+D%PK,NTVX3+TA[%]5&TCG/U>J7>7%MXF&1J;;I
M;=L8T[M^M@Y(4)Y/(89T_D,0Q,9Y0Y'C,IYM9(9":51.X<I-1`B/`7X\.A?<
M,7[V:?:<!GD(;W%&>]FOVG`'(0WN*,][-?M.`.0AO<49[V:_:<!'NY,="#$8
M_<QB1MW#VU,2YJS&TX9S`V&)<GV*`/<(=H#W<!(`1T(`EHPB@$!*):-6@"`E
M%$26T)W@9).GU2E\@<!DL="%ML8Q9;13$EK5H%HD%J*5M"=@E%NC;3NTR4]*
M6@8)'0A;--A%%L%,4[&K0+13%EHV4)V"06C:VG=I)T]*6@!(Z$)9IL8HMFEI
MV-6A;=/D-"RT@6Z?)M;*=VDE3TI*`A2CX0DD.DQBB`5BS$EC9H4`%%PARMMI
M>S2Y1OIT#S=).GI2T!<2.A"V:;&*+9I:=C5H%FF##0LM)YNF#-K93NTDJ>E)
M0`L="%`@$8110+IZ=K5H`%TP9`C90G98#5O;3NTTZ>E+0`L="`!;6$4`%`EE
MK5H`%`@-@3MH3L`H-T;:=UA*=Q:`!&P?9:PBJ!:`4:L^P`!("@%$^RA4R4^H
M4OD#@&=A3&)4CY@5VD>H),OS),@K((*"1`F2214DR"J982HD)V%*`E*4O8!2
MAV`#Q&-@Q`:L(H0H(#5JSI004`U?,[A*<]?J"/E'@`8Z$$#7,(H0&\#U:M!`
M;P<`I=4G;<"ZM:]]YZ]X\`'C8,]]["*-=J:E[5F:Z\'@+7U3&MX.G%U>\%%*
M^F-4`\9!GOU(^*-?JZE[1F-VIS^O?<F-VISKJZO?K*U],>H(649!G8--:/B3
MB9FF!Q4:,S7$.B\!0#7D,(E.1VYNJ(U!56OICU]BUHZ1,Z#4YIC#;(,1RV#B
M#143-3F.9!$QLN9NB`QLG*1DRT;2)C(DUZM7<FX5,)?/\]6G:8U?!_-)Z<OH
MQO\`,&[_`'5]OGTO[I=774UL,XVD*YCLXZB<WWKWGE-L\E<NHN3E<03V]EX>
M?:/MR"YYAQWCE,[>SD(Q5=.2Y9R8&2L@\DR3DX#QO':9F,=M]I$Q.D=U[:Z3
MZ==.NFO6/RI/X]FR8^!\@PUM,8\FWVO=&O2>W=89B9CKKI,])G2(U]=9B)Z9
M8/\`Y<KZ:";PC$)B'^G+W)B(>7Q6!DHR(1W"ZFTD(R,DHDKII&I)([@(HIHM
M&L@HD!2D(0"F.`%`#"'$?1@\$/\`+A?37-%@=./IZ=W&)$P6.=VPW#ZH57I#
M'(Z#ULH[H,1-K*.5"G'5+0JIQ\ZHE,'A_P#@W'TV?_\`W=W/]'_[8W5!WB)A
M'_[8O>(G-7ZHCY>`/_P;CZ;/O_\`CN[G=E!#_P`1NJ#O`2B`_P#M%]`2`/[@
M<`!_EN/ILPI;].[N<`E$HEIN-U0!02BB)!"FXO8)3()T\@D+Y`X#F+UN?1;?
MYCOHYW=V'P':WK5ZN>K2%WYFVN%XON'M!OIOHU@L.SM0XJ*8_N:TR++E$L!B
M$86-3D4IQ\L2(%JU5$5TU&IB`']#/I<VPR_:?ISZ:]L-X,BB]P-V]O=EMM\/
MW/SPKAQ+_CIN1BN$XO$9;EWB\RBA,2RT[D<89V#MV0KM<3$44`J@T`+#$CH0
MEFFQBBV:6G8V:!9I\AH64)YNGR36RG=I)4]*2@!(Z$)IZ;&*+9I:5C9H%FGR
M&AIVD\W3Y)K93NTDJ>E)0`D="%LTV$46S2T[&K0+=,&&A9:3S=,&;:RG=I)4
M]*2@!8Z$+98PBBVZ8)VM6@6Z8,P2LH3LL!JWMIW::=/2EH"%M'0@/7MK"*`"
M@Q`EK9H%I2(H:8%H7L*712MH``%A*=P4!<$="``48Q0``%I1JTH``"0%IYG8
M``F2GU"E\@<`>'0E/YC%4I[E:4I2GJ.ZG_9P`,=""`U8Q0@(&K5JTH(""H&K
MYG:`@H>OU#&\H\`&CH0P&O810@8#WW-6@@('!R"EU2=H&!=:ZO?>>O>;@$C2
M/A5$EQ58Q9Q,[D2J"HV:&$Q!=21#`<3%,(E%)PN`@/\`!.<.X3!P"L\="&OU
M&$4:_5U+VK0;M0'^O?<3SM0'CF^O?JJU],>H!XZ$/J:C&*-?JZM[9H-^IS^O
MJ7$\[4YUU?7OU5:^F/4`\="'OU&,4:_5U+VS0;]3G]>^I/.U.==7U[]56OIC
MU#X7CX84UQ%C&"8Q%Q,(MF@F$QP?"J)A$E1$YG;FZO>*JE?3&J'BSCH063:Y
MC%#<U2$]6K0:WI.!4NJ0:W<RO6M:ZAZ^F-4%0QT*-US&+$1$UU6S0:B85A/=
M4G:)C*J5\HF-Y1X#'AT((C[0BJU$1]JM*U$3"-?,[Q,8?W1'@*R;%E*7='/B
MD*4I`V@VC`I2`4I`+\[_`%64`H%H4"@'=3LX"V'`<Z-H=J,(SGH+V;Q;#$,`
MQG+LDZ<=HF[6>8)X_"/494V'XM(2!UIAC!S+QHX=.6ZH.%BM5U@4,8PEO[0#
M<[3],D]A.Y"V6[D;A;8;C8^Z8Y0@K%-L&A</B&7C*F,.8B/CL/`\XP*>#<Q3
MDB4@>2%0&AP2%L=999R`63QN%P:.W-RE*!B<28MSX+A*BJ<0PAFJ1U_'\^*<
MYR,TB%,H*92`81[:`6OH<!(@MH3Q<`Y>*M\-$::+/OYHO^K7@$N2PS64QR?C
M(9>*B)B1A)5C$RP(MJQDD[8KMV,B&F4%*LG2A%/-\[S>SMX#CCA/1_\`2BX=
MBV(XX3KCVQE4L5@US*N)_&4<MR+(\G>269+.#9'F^8[?3TU+1+>-GVB3;614
M1148MC"S,#4P/`MKMYT[=3<1#2+3/^I..R1^KOMMUNE".HV#A6"\5@D;N0ZR
M7<S:!W),<6AUYK#\HPQ1..9)F21%JN!K#(L])HD%]N1A?<<7[W:?:<`<C"^X
MXOWNT^TX#YY2##L%K$U#O#19]G_[/`'*08=S:)_D6?VO`9Y6$]SQ7\BT^UX`
MY6$]SQ7\BT^UX`Y6$]SQ7\BT^UX`Y6$]SQ7\BT^UX`Y6$]SQ7\BT^UX`Y6$]
MSQ7\BT^UX`Y6$]SQ7\BT^UX`Y6$]SQ7\BT^UX`Y6$]SQ7\BT^UX`Y6$]SQ7\
MBT^UX`Y6$]SQ7\BT^UX`Y6$]SQ7\BT^UX#7-6T)STI[7BJ`HTIZTS[/:I/\`
M5X"#NH7:G+]S83&F6VNX2>WCR'=YVO,)-WS^)C\F;Y!L_N)B.,LY%[C)V61M
M"8YN5.P,\"C)XT7`L28I3WF)0(&R'IFZB%)C;[\1>IA''\8P];IMC,CB<HCE
MLWE=Q,:V7W-G9K<9S*SH&QY[$9=OWMX[8,\B>5?D<N69D+0;JF4$(HR3IG^D
M<?9O/9)"]:&T;/'FN5;I?B)BA-D<9C"-MO\`*H.9C<`CLL=%A)B+F\QP69"(
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M<:W2?M&RYR(R+\'"[5-HJ'1B(;0HQ<>(MXJO)MZ^M,^_3+Y"]_`4%W?Z<NJM
M7/\`<[.>G'J`PW#C;D2N(E9PVZS3(MR<5P&$@\23CY-SA^%3"LMC47(R62H"
MNJV8)QB3M%R8RJX'03(<-?F_3/UB9/M_@+>#ZK<7Q;=2)VP@\?W`G6^$-?Q.
MRW/H?=+!LW<Y)'P&/M\3&%4R#$8.4QQ^\2*3482!M)B@*AK`CD>COK9#/9^5
M0ZO&+?&)?)MSG;%11]D;]U!XWF.&R\/CC9AA"\:3$PDL9GY*/<,B<P#:+_%X
MJ[<%%I=^"03+T@;`=1^RCG<!3J2WZB-[F.5&VU3P./%S+2)L!\"+/IS\$D]G
MF+)>90$C]HGXPY`\K-'0,X>Z1[$@"_W)PWN2,_D&OVO`')PWN2,_D&OVO`')
MPWN2,_D&OVO`')PWN2,_D&OVO`1YN4S@PB,?O:Q`#\X>VPIZB#'L4#.8$2BG
M>7L5`0[+?.\G`/\`!I`!2UM$5`2"6B++L$!0$E*%[P,1.GU0+Y`X`*T@0$EC
M:(`2BF)+46=0$HM!2LH7L$!20MIZE.G<7@`C2!"S3;1`4%+3L19!02BPT++2
M]@E%%K93NL2IW$X`(U@0T]-M$!;HZ5B+(*6>'<OIVE[+>7:64[K$:>E)0$*3
M."+)"*36(``8L@(*:#(*"FNV%F!1*GV6:+;3H/98E3N)P"XC6`+IZ;:'"W1T
MK$604M\.T-.TO9;R[2RG=8C3TI*`$:0`:>FVAPII:5B+(*`4&.AIT+V6@BVL
MIW6)4[B<!@K2`"VQM#A0$[+4604`H-02MH7L`H)(6T[K24[B\``T@*!1M#TH
M6VB+*E`!$"4H7N`"IT_T%^IP#/PII#>'RX+M8P#!EV8E3!9!L`@A^,DD"0$!
M1!(=&STE`$MOI1$.W@'@+2`[:MH>@@(#5%EV@(*7`/F]PE,>OU!'ZO`!FD`-
MU[:'$!O`]R+(:@8'.H!JE]$JBUU?0,>O>;@`[2`&^]M#C75U+T60U`X/=:^I
M>VX%G-U>^]2O>;@`[2`-J:C:'&[6U;T60UO\0!QJ7%[;@7=WU[[U:]Y^`2L&
M,(=@U*HSBC"+-,#E,W:#YATGI3@8!3#S3%<N@&H!4%%:^F/P&JS/&6V0XCEL
M%%*1L3+SF.9!$Q\N+=&Z,D96,F&:$D840*N(M74DNJ:T0.-RO;4QJA_*9VLV
M5^D=ROK(ZC>E3JB^E=W*Z8E.GTF;1VZ._F8]0.^>88S(GQ!.4,)L-BH?)HG(
MLN:36.\VNHLXY%-G#JN#N#%,(-ENJ?5+Z?><>#?3KP;R[S/CMSL/%N8R[NG&
MY\TU[-U?-W9=-M6+VO/W([LDQ2(KT[YB9=#^FW`>1^8^/^9U\4VV;>;3BN,V
M^ZY"U)[<6UP8]UBTR;B]IKCKK:-,5;6[\EM8Q5M,3#M%TQ_0)=?/4_L?@F\N
MPG^8;W8RO:S*8<A,?D\9D>I,N/)A'E=1TC$11W.^\25RSA7PNV=Z2!$!,14"
M@`7!QRMSN)B>L=8_L+`I_P"6>^E=9*"\-_F`>H!J*0+'%RTE.HTSHASE=%-9
M;U'H'JJ=PJ4X@<!HH<>VH@)Z\/\`\&8^E9[:_3^;Y^C7X7ZB>\1.(U__`#BO
M1,8W[HC]7@#_`/!F/I6:_P#^_P`WSJ`A3X7ZB:@-Q1#_`/R*[[@+^Z`<!@/\
MLO\`2L@);?I_-\@$!);27ZB0$!`6XIVTZBNP0,FE3ZI24[@X#EGU<?1)?YB#
MI?ZE]C]CMENM_JMZGL4W_>H0&([WX1U`;WXOA6&33)NU?9(UWD9R>?3QML8W
M'HQDF_1D%UW+63:(D(R,J^(+$@?T:-I\,6P?;7:#"\NEXK+,LP[;W#\8R;*A
M#7-DF3X[B^.Q,ED(.'Y3OU59>2CB."'6-KFN3$PB8`X"3TVD"&GI-H@+='2T
MT606V>'<OIVE[+>7:64[K$:=Q*`$:0)=/3;1`6Z.E8BS"VSP[E].TO9;R[2R
MG=8C3N)P&"-(`-/3;0X6Z.E8BR"VWP\$-.TO9:#=I93NL2IW$H`1I`!IZ;:'
M``TM*Q%D%+08Z&G:7LM!%M93NL2IW%X!"V9P`/7HE:PX>:Q!,009!YA$FX)`
M003#S2"FE;01`+24[B\`O!K`4"C:(H`%MHBRI0`2`M*%[@*1.GU`+]3@,<K`
M4_FT/2GW%E2E*>I[K?\`LX`%I`#6YM#B%#5JBR[A!6ZM2]PE,>OU!-]7@,F:
M0`@:YM#T$%+[D65!`P.@5NJ7M`046NKZ!CU[S<`C:M((4G&LVB!$[N2%7409
M5,07,F4PJ7$`3`**JX#7O*93O`35!6=I`#J:C:'&[6U;T60W7>(`OJ7%[;@<
M.[Z]]ZM>\]0R=I`FU-1M$#=K:MZ+(;K_`!'F-2XO;=S#N^O?>M7O/4!1I`CJ
M:K:(&[6U=1%D-U_B/,:EQ>V[F'=]>^]:O>>H?"[2",FO5M$B<Q%[[D68F$QP
MD-6ZI!$1,9=U=7O$ZM>\_`>#-I`<DV`S:'IRJ=P"@RIVIN=6H"0.P15<7=G\
M)2O>;@%0M8'SKFT16IKJHL^\17$]U2]XF.K7ZHF\H\`"U@>VK:(K4:U19]XB
M81KYO>)A']VO`5FV*`@;H9Z"=@)AL_M$!`3MTP)\[_59;99YEE.ZG93@+8<!
MSJV@V\P;.>@S9O$\1=X%B^59)TX[1LT)Z.7@H1\WE!P_%G\CK2T=&R+UJNY=
MME"N%"H+*@H8PB43@(\!L=I^G3)L(W4=9EN-O9MUN?B#R)R%M^*WXCP.(1T6
M_EW,`Y9DCX1&4FX]1!@,:=)!51<!:MT@*1(ZKMTXX"S6-L<':;FY22!9XFU;
MGP7"3JEB&\,BF9;\8,^*<QP9D*`GTP(`B/H6_4X"1+(;Q</-B[?#3>@T[^:+
M]2O=P&RLA?4Q?V+3ZW`%D+ZF+^Q:?6X#GA+]-W50SSN=R7">K*(8P,KF&6R$
M;`9'C1)X(+#<KS_(LZ\%(686FHR2DH-/)E(I@L9LARL6P8-TQ*DV%-0-E/[%
M]6[P'3B%ZH\-:RT/S$?A<@]PB&,V6BY#)&LPX?9M"LXQ")G9UE#1S>*2-I"1
M1#F52F;J/#Z8;!ELOU9)R2PFZF\2:14HXBGLD=7#\:R*1BUXJ+.Q798XB]Q>
M+CFT5D3[2=NDS%*9$4S)IB)E3K\!:[:R$R'']O,2A-S<K@\ZSR,B4VV396TC
MXJ,;3,CK+*'<(,6;*.;(ID34*2I4$14$MYB@8P\`_P"R%]3%_8M/K<`60OJ8
MO[%I];@"R%]3%_8M/K<`60OJ8O[%I];@"R%]3%_8M/K<`60OJ8O[%I];@"R%
M]3%_8M/K<`60OJ8O[%I];@"R%]3%_8M/K<`60OJ8O[%I];@"R%]3%_8M/K<`
M60OJ8O[%I];@"R%]3%_8M/K<!KFI(7GI3S8OV1I3S6GN4GU*]_`;&R%]3%_8
MM/K<!&>\>*RF:;9Y;BN"3D-B^53C%LRBY]9_*118RLDR6>N$Y#&';&;;.2QZ
M2H(F24MUA*"A3I7D,%9<XV-ZHI?<4<BPSJLQS&MOHEHC^+FWKS;7%)%^J]-A
M9,??_C+FAFPKRY5<@=.)5%51BIHJI-R"D8`5O"UN`1[V+QS'XO-9>"R/,(O$
M,4CLJR!DT:,V<YD;./41FI9JT`B?+(2+\IU2DM*!`/0`"E`"".HW93='="9Q
M"5VBWV0V=3@XR293;!.-/*LIUR.4X1F<%)&9H2;!H5TQD\$)'.!636*Z@I:3
M9&+8Z-P&<8VBWE3Q>:CLWWY83,[)2V!2L2\C82$C$\9;XMFK6>FH%)]#1F.O
MIYAD^+M"14@JY(GSXBJL*2!%S-RAH(_I\W:+B[V*GNI-Y+Y,NSWFCDLJBV"V
M,`9#/PFGN"R!X9K./T&TSMU,3/M95%4J:3)LBW;D1(0``/)#8'=A+=^,SU3>
MY-SBS?.F65OL2\7FT(EQ&*,5T'\!^+PJN8?PV(!PNA'((G:$4.Z(]=BLLQ11
M5"X402&\+CZEBZ\FWKYK/OTR^0._@*)S73IU+)[C93E^(=5+"-QZ8F<R7QW&
M)K'D)U#&8O,,D#)2`X+-J34=/J8NLF#6/;\NT!-B?ER+I)%$B@>^Z/3OU`Y@
MGC),6ZBF>//,?QQM'NL@0=RD(_R:6;9V[FTG&1P<`5'$G2!,838-U5FS)H]=
MK(+)G4(BN70"29+8S/7*<D2/WVD(Y24>9&87("JX+%M,EVOPG#U!B6*T@9L@
MO`YI`24_%D$=)FO*'*0`-<<0]-B=ILZVO?Y2[W"W*;YRUR0F'HPS!S.S&0(X
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MV29L"/+PHDE9!OG(8=C,CC$FV,\C'N*.]LVF8J+%EY`(OGS*2RU]UC5,%P<6
M/;99OA2>).]Q,[B\M2CXC8_;X$PR%_)(2L_`;K0LJ?,'49,1:!2Y-)(/5&[I
M_P`RHN[2:MP$A+1``N<!(+LM)$UJ6VA6?>`HV4H'>!@3I]6WZG`!207FV$B>
MS3LM*S[!JTTK:!ZHJ%M/1!.G\'@`A(+S-,D34!2T["L^P0Y'1LH'>%K:VGD2
MI_`X`(2"#3TR1(>PZ5A6?H>'Z&G:'H6M;*>1*G\#@$*2,&$D*B2433DF12G3
M39]Y5VXM"E.5+T+6PI@!^RB5`#S1X!<0D%ZWIDB>S1TK"L^RGA^AIVAZ%K6R
MGD2I_`X`(2""RPD1_%:=A6?H`RT;*!Z`%;6T\B=/X/`8*G`T+82(I1,26E9T
MH`-=*V@=U`0MIY"4_@\``2!H%I8BE"VT*SI0`2LI0.X`!.G_`)/U.`9V%(0Z
M4?,%6;QJ0_C?F)B%6;MD!%$V226D<A5&$>)D3D[2&`JA3%[055#SS`\1)`]M
M21'<-:E9]U%+J]G=2^OU*_5X`,2!\ZXD100/=<5GVA1SJ75#NH9:ZOE/7^%P
M`8D#YX')$4'5U+BL^WL>ZU]0\AG%U?*I7^%P`<D".IJ$B/XW5O*S]$'^OJ7!
MZ(&=75\JM?X?`0_NGB6591@T!';99G$[?91'9CMID+J2=,8QW&RF)8_F,?,9
MUB<TQ6BG#EQ%Y7AJ$NR43;&CW!S+F*#IN0RI^`I]`=.W6Z7;>+B,JZM(&0W*
M8X+NWC4ME4#!0L=!S>52N<XA/[89HO%RF"S3MC(1&/Q>214NB14R)6DN=-N4
MZI1=D!W;NX!L8YWQS#(,YP3;QU)R6,X3JSLWB<<Z=2!#-<^AI<'4J#(3.C'A
MQ,S=`JH)S,ATE/6:`6+\[N\F]W^';<MDR9MGL<4?A:9+7OCV_NVR6S?AZS,U
MP^[;2<OMQ6;SI-]>DQ]-?3W?>1[/Z:QL/&-QFPXM]N]W7>8L.6M/Q$8XV=MO
M&XI,Q.6M)B]L,7BU:WB]J:6[M:-.'V[V_++"^FSHHW\VUV-R7ITV0B<=S;%(
MM7,L04@5)-'$V&-P,UAZ^RTU!0P0D+#R0$=H.T5RJ."%8D,U/(`KB>*^1\?R
M&O!TRUMR>TPXO<I$9(M76O\`SG?6-+:QKZS%M=8UTE3]?OHOY?X?&/ZI[K89
ML'@WD/)[V-GN+Y-I;#GG'EF==I.WS9._!VV[=.VML/;%,D5FU8GH3!;.=2$;
MFV.Y1E._3";Q=OE6)9!F&%-V$*G%2$:&SFX^+Y]BL0!,%2E$H%QNY.PL]&$4
M=\P"+!P5PM:8C8)F^9UT+(+U$3Z/\%GY3U]#RW?]O`%D%ZB)K4*>:S[ZEIZ'
M?=3]VG``$@JEH2)K4MM"LZUJA9;0.^H)4^K;]3@,D+!A;IA%!['98#,.X6FE
M;;Y!*A;3R)T_@\`A41@Q>QQDTHD2DU+#$39B!#F3CP:V&!(UIA`J%E#%$:)T
MK0M`6D)!!IZ9(D*:.E85GZ'A^AIVAZ%K2RGD2I_`X`(2"#3TB1(4T=*PK/LI
MX=H:=H>A8TLIY$:=Q.`"$@O6],D3V:6E85GV4\/T-.T/0`K6RGD2I_`X`(2"
M\RPD1_%:=A6?H`RT;*!Z`%;6T\B=/X/`(&R,$5Z],5*(+<#+3,5-D`F*5%`$
M[3`D03E+1("^<:GF4IV!P"X"05`H2(IYH%H5G2E$@*`4#U($I]2WZG`9L@J>
MDB*4]2SI2E/)W6_]G`8$D#0:DB*4,`U*SI2BH&KV=UHGK]2[ZO`!B07G7$B*
M>??<5GY'.I=4/4F6NKZ`GK_"X!(U1@RI.-5*)*)G<B93439E$Q3.9.XRER:8
MF`R(KU$0&I1/VF"X1!8<D%ZYJ$B>W5U;RL^VOB&OJ7!Z-SJ^OE5K_#X`.2"'
M4U21(UUM6\K/MKXCKZEP>C>[OKY5J]Y^`#D@AU-0D2-=;5O*S]'Q#7U+@]&Y
MW?7RJU_A\!\+I0ADURBG%&.8C@#%,1F8PF,#_5`P"4PB)C'<W5`:B*M0[3\!
MX,TH$K)L44X@H%:I@8HD9%`OK3D%`$MB8%[17N"TO\94`\[@%0D@O.N)$UJ8
M35*S[ZKWB:H=]PJU^K=]7@`207HDB>\>\K/OJ:OH=]UW[M>`K+L59\Z&>Z=F
MG\T&T5FG;IV_._U66V6>993NIV4X"V'`<X=HL1VOSSH,V>PN`R';;%,AR7IR
MVDCC3;)]C\8Z:R9<1Q=[(D=NXLQ'R:KA^T4(ZI<?4,>\IC5`0=VTFQV'81EC
MC*]P=Z<#W7?F5R]1D=S$XYBS=JAE),*!M$>!Q^2/\;\'Q4V,//#DB-""D644
MJ(J$U%`L!C`X`3<O*OQ='#2M38-A.KX*,&5(7`3^>WZ@,:%%0$Q3K7MI;]3@
M)(U8/Q</7(BWPXW\-EW\T7ZM>[@-CJ0/W2(^R9_7X`U('[I$?9,_K\!1/(>F
M_=F,GY+(-J>J1_C2V6[@;@9EGD3DB;6=B'L//S4R^Q3$L5;G5,?$4<?B9CDE
M9!,5G@G;-ED13*V1;E!:.PF]HX0RPQ7JU,XUL@RMQ-S2>-Q$9-+8OE!G3E"&
M9RK*1&3%;&B/EX]FH*R0B@9%X<P/6Q3J!:O;['X;"L*QK%'F1M\F=P,4WCW.
M03#]-]*2ZZ(#JOWSMZZ=NUW"YS")C'4.;ZO`/'F,=^[PO\JQ^VX#(+X^;TJT
M,:G?11D-/WAX#ZU('[I$?9,_K\`:D#]TB/LF?U^`-2!^Z1'V3/Z_`&I`_=(C
M[)G]?@#4@?ND1]DS^OP!J0/W2(^R9_7X`U('[I$?9,_K\`:D#]TB/LF?U^`-
M2!^Z1'V3/Z_`&I`_=(C[)G]?@#4@?ND1]DS^OP!J0/W2(^R9_7X#7-5(+GI.
MJD134:4\YE[E)7T?+P&QU('[I$?9,_K\`ULXA6&585E^,160M\7D\CQ>?@8[
M)8IT5K)X\_F(IW'M)N.<L73)ZW?13AP5=(Z*R2I3I@)3E&A@"I&YFS/4#,YZ
M&7;;=3D5BD.SC<:8-<1<1;5PV=MXMI&#/,CBNN^B6[C()..75,^59NG`!(6C
MYC-(JH6HP!!Y'XWCT?G,_CV2YHPQ#%&>7Y#'MV+".F\H0CU"S\K&L2@0&4<^
MDQ44;HTJDB8I/0KP$$]1FQV:[MS&)2^VO4"YV7_%^+DF$JTBF?B;.=5-E6#Y
MQ!R"K1+((AFD\BI[`&S=4ZJ:X.H5_(L#AHO50$&XKLAN_(X'-X[/=2:$_/3D
MQACU"04(X@R8G%P,V\?2['&I3%I:%FEY)Y#G;-RO7QG";ATTYMTV4,J9(H:O
M$.FG/HG`QQK(NIJ<E<A")W4A$LD9R\TT73;9S$.4<;D%!3R9!5Q-8;DCY:0;
M.1L610.1HD8@)BNJ&S1Z>LW)N_&;BJ;]"[A6N=L\P=XH>0FO"W;51@Z:R$)X
M&KD3K'R1T<1TNVBTD6Z!4BO1=+ZSEJA<%PHE2"\+C[E(BO)MZ^<R[](O?0>_
M@*S[I[-9E,YG/YWM!O+#;6Y#E$)A^-2+J1B?QN9,6./AFAY"4C,?E9S\723$
MB::B0\QJ@"A(DH+'4*8`*$2YKTV;VYE"X,W4ZI$XW*<9P",@9?-(M25BGL_F
M*>5+2K[()?'X>=C\4F6#.%.B1FD9DV=J/F::KM==,2I)!*TEL7/NTI))AU`3
MD::4=Y&=1T23>N5&#7)]K\)P9UX6U6R(6#5U%Y/C3Z?C:)@DP=RJH($(83J*
M!Z;$[19%M,_RI]F&Z3;.T<H3PYO',7$E,2B&-.(5::*HSB5\GF9F21B&S-^@
M@F*CA5PZ%`5USZIAJ$-XITJ;P0$_MS*NNK21DX#"YO"G+W`%47"D7)Q&+Y-E
M$V_)(9&:?"6R.5R)ID8$=K/6][E5LWU3G1;I(\!T,U('[I$?9,_K\`:D#]TB
M/LF?U^`-2!^Z1'V3/Z_`1[N2KCX1&/W*0H#\X>VH$O.P`=0<Z@0("=XUU1-Z
M6WSO)P$@@KC]2VJ0]:DMH=E6MR%EM![[A2I3T1+]3@,%5Q\;+%88>U.RT[+O
M$6>E90>\1.WMIZ(IT[R\`$6QX=/35AAKI:5AV/;48_0T[1[:B=K93RI4[R<`
M$5QX=/35ANW1TK#LNVOAO+Z=H^CJ,[*>J1IWDX!"D;'_`!+52&&H+%BF11/D
M>T3+M3,B$4*E4:ZC44@!0?3)"4O:01!<17'AT]-6&&NCI6'8C6OAO+Z=H^CJ
M,[*>J1IWDX`(MCPV::L-VZ6G8=CZ(,-"RT?1`[6RGE2IWDX`*KCU"6*PU*)Z
M=IV-*"#32LH/<)3(6T]`4Z?P>``5QZ@45AJ4*):'8TH((B2E![K13I]02_4X
M!G842%:QTN1PG%M3'R[,5DR+(-6@G04R22%)=,BD1"BH@J3SB*`FL50OG`X<
M`(+'!XBKCU!JI#4H:ZIV-*`"HFK4>ZT#U^I=]7@`RN/>=>K#4`%+[CL>P`!U
MJW5'L`"E6NKZ`'K_``N`#K8\`'U%88`#5U;SL0```'VO?</90".;Z^16O<?@
M`ZN/!J:BD,%-;5O.Q[*!(\QJ7#V4!-W?7U*U>X_`(V1H!&/:IK&ADK&1-0BG
M(I@1,$'YE+R&2;@0@)D=B8!3(``"U0"A^`Y]]8FQO5WNMGD%-=,G4#BFS.-0
M^(,8^792.63;<D]E+;<!2=E!D\8883D$4G'%Q^.<(*/$7B,@[O<LE03:&7,J
M$MX=M)OAC^YL7EF4=089%A37.,EGYW"W81";!WC$YL7AV)_BVD5/&VKI%#'=
MZ<=GI]B!WGK3*5<)K'74[$CS2-==.KFL^G]V-]<@2Z;.GC?2)V/WMVSA=W<D
MW/4<&W1PK)9E+)IG)HO;QEEG-;53V-Y#"QJ+9)?Q4DBBZ28O@\$5(J519.`>
M(<]L<NZS>/7G3FL,3>]?;R5OVSDR=ON6M2(G2O9-+1::VK;[G2KZ\_XB_I+Y
M7L>`XSZQ[:G?],>2O3;;7+&[V67;QGQ[+9SFC:XL&XODI-LT[BFYQ6PX\N#+
M@F=Q][)$1?2#V.ZF8V3PV8R?J=3R(D:39=UGT(W8Q#"$R>1Q)GOC&;Q,HR-1
MQ-=W'P>XY,OQAT1OKB=-]`*F.8B!A15G[Y$7K,I`%&TQX<H]HB!C,@'O/7L$
M?*!OW:_5X`!7'ZA12'K4`"AV5:U*`4[>^X2_NTX#!5L?J6U6&J(DMM.RJ(U;
MV6T'ON,E3ZHD^IP&2K8^(DL5AQ$12T[3LJB(BST;*#VB(G;VT]$4Z=Y>`0J#
M`'>1RB8PYRDO!,Y.2,!5%$XX&H)G!$]IU`,WTZ'((@*=+O-H"U-;'AT])6&&
MNCHZ9V/;7PWE].T>VNHSLIZI&G>3@!-;'AT])6&&NCHZ9V/;7PP6^G:/;4%6
M=E/5(T[R<`$5QX=/25AAKHZ5AV(UJ$;R^G:/H@HSLIZI&G>3@`BN/#9IJPW:
M"0IV'8]H"##0LM'N$#M;*>5*G>3@$+8V/@]>'*,*&J5B*9R\B&H0J3<J5IP2
M(*A2B9$"^>I2I*4J4.`7`MCW9:K#=Q:4.Q[J(V4H/=04Z?4$OU.`-7'J>R0U
M*>K8TI;_`*>ZW_LX`%;'NVJL-2AJU.Q[J*B:O;W6@I7Z@&^KP`9;'@NO5A@#
MUR^X['N`'>K=4?0*5>ZOH`I7^%P"1J:`32<:PPZ9C.I)14%.23$2&=2IC**`
M9)`1*9`C@1,(#4@*#<8+C""LZN/!J:JL,%-;5O.Q"E`DN8U+A]`$WE]?4K5[
MC\`*+8\&IJJPP4UM;4.Q[*>)BXU+A[*`D\OKZE:O<?@!1;'@U-56&"FMK:AV
M/93Q+F-2X>RFF\OKZE:O<?@/A<\`9-<ACPXG$C@IRF,R$1-21*L4Y1`XB-Q'
M0&`2CV@K4!H?@/!FICQ&38ACPQ`(U3*8HBQ(!+4G0*E,6Q$"6BFXN"PE+5*@
M%#``*C*X_P"=<I#5`3W7'9=@U<7W5'ON*K7ZH'^KP&15Q_MJK#UJ-:G9=]3@
M->WONN_=KP%9]BK/G0SW3LT_F@VBLT[=.WYW^JRVRSS+:=U.RG`6PX#G)M"Q
MVOSKH*V=P>&S_;K#YG(NG':2*4FF4_"1KAC(IXCBSJ02=KQ$BR?IJ*R#,Z;H
MH'`]XG`X&&XH@JVFVG9X3NP?/LQZN,7W8A'$1E3)7%97\4X2/2<Y$YQIT@1O
M%1N1.X)-E#J8^(,RI-D`:(>M`10QSK\!:7&9;!7&YF4GQZ2Q%=L&"X254T,\
MAE407+/YZ)RJ&8J&+J`F<@B`]M!+Y0X"1N=AO&`'FXNGAI@KS#3OYHO^OY.`
MV7/0ONR+]\-/M^`.>A?=D7[X:?;\!0]UTXYRIN](Y\.^6+.L84R5_.ML0DSY
MZ8'#R4S20R='*9P\?NI',G&6;<02R..XV1N@VC"1FMSK=P/*IM`5S?3YN2_?
M96K$]8N00,;/S^32L9!M&D8M'Q+#)9IQ(FCEA7G#/'ZT:P<BV:K%50Y<")F2
M(0$RE`-)CO3]OJT?UR[K5D\IB&T5FS&)8$3\$>Q+K(-O9K"H-^$M%9"VD)9W
M"OYE&1!=\=RX1=Q::S<Z:[MRH`:TG3SU(N@21FNNQW(D0=.WC>R`BV6@Z&2D
M58X3-XV;8(R31DR>@8[9_P`VBJNDD``0B):A.^R>+;H8-F6X1=RMZXO<[!';
M'&4-NEY.6:_C$T.U6G5YH)N.39-XYLJV2>M6Y'23ERM(%2%1<$C%*7@++%E,
M?.-"2,,<?(5VR,/=7N!01[N`]>>A?=D7[X:?;\`<]"^[(OWPT^WX`YZ%]V1?
MOAI]OP!ST+[LB_?#3[?@#GH7W9%^^&GV_`'/0ONR+]\-/M^`.>A?=D7[X:?;
M\`<]"^[(OWPT^WX`YZ%]V1?OAI]OP!ST+[LB_?#3[?@#GH7W9%^^&GV_`:UJ
M]A>?E/;<7VJ-*>V&G;[5)_K\!LN>A?=D7[X:?;\`"^A``1%Y%@`=XBX:4"H@
M`5&_RCP%,]U=D]SLSQ)MBFWG6%-;3IN,KW9E\GF&,5"9=.3&-[D9))R\-C3"
M3R:<<N\?-M_&RRC.,<('$J0)H`5(B*)4.`LYA@!%0\3%9%EL?ET]%8SC49,Y
M6LG'1ZN32C%FLW?3RK%NNJV9*RS@@KG12,*:1CB4GF@'`,O>G;V.W1A<>:QV
M;-<-E\5R7\;(:;;.#*:$LUQZ?BXI1=HTF(I%^A'RLL@^T'(KME3M"E.F-0,4
M*^$V5WOF,;SV&S?JR890YR_(L%EH8\?'JX:E@4/!2;V1RB)Q5YBF3QLR1]((
M.$4&3UVX=II&9IN%VRRHB'`>V+]..616%+8W-]4F32DVK';JP[><:9!-1YX^
M/SV'<-,7T2MLQ1<NI3!IET>0;OU5!>'.H*2:B).T07H[`9;\[\9N0?J&7>1C
M;/&>9.L64DIL\8]1.P<LY"&&'4RUQCA6#(KI=M%IILTBMDWQUU-9TW0/P%P8
MA]#>%Q]7<77DT*^V&G?IE_U^`K-NIM!E,UFF09WM-OE&[29+E4'A^-2KY>-2
MRE)K'XZ&9G>R,;#2F0(P1)>1&=B^WEDRF)$D!852F*!`B/,>F[=_+HK;W_\`
M.^=M,HQ/%,;B,CGT1=MTLREX*?FYE=26AXC*8J'5B)#Q-DHX'ERR3E2`:)G=
M`@NZ(8'CDVP&5S,VW7CNI&3BH=PMDKM\NG/9-^,4>ZR+;;"<$5_%Q4,Z''VD
M8$KC\G,@T.Q,5"0E"G;G1T5`=`[-BMIIK:-_E3[)]VTL]3RE/#FS-@XDYF0;
MXRX@UIHIFD0MD^2Y%(MH9LSDD6Z)3.#K*Z`K+F,L<QA"/]M^F3(\9DL;5S+J
M6E<U@\<6PA2,P]5T^;HQ*N#9;E&7MWK+(29:25EY;*7<ZW;S3J42>K2#%N+=
M0QDA2*D%Z>>A?=D7[X:?;\`<]"^[(OWPT^WX`YZ%]V1?OAI]OP$>[DOX,(C'
M[GL0%=P]M2DO<,@$5#9S`@0"7'[5!$>RG;P$@`_@A$MKV)$1$H%HY9B(B(H@
M2VA^\3*)T^J8OE#@`K^",);'D2(F%.RUPS$1$XM`2MH?M$PKH6T[[TZ=Y>`"
M/X(PDTWL283"EIV.&8B83BQT;+3]HG%RVMIWZB5/3$J`1_!&T]-[$FNT=*QR
MS&Z_P_0T[3]MXNVEE._52IZ8E01).X0TB*J3F*,0S)DF11-5F)3&47;F:$*H
M5&@BH#ML*906&NHF($"XIC`M(_@C:>F]B37:.E8Y9C=J!'BAIVG[;P=M;*=^
MJE3TQ*A@C^!-8*;V($#:6F)'+,;KP9"C9:?MO!RVMIWZB=/3%J`5_!#:)'L0
M-P)V"5PS[0.#44K:'[0,"Z%M.^\E.\O``/X$0"U[$"`@40HY9T$!!$24H?M`
M2J)T^H8OE#@&?A2D0SCY<BYHUF97+\R<D(LFV8BJBODLFHFZ(FI!XX*R3@OG
M%6!)<JP#>#IT`ZYP>`OX$`&KV(`*&$U7+.E`!035\_N`I#U^H`^0>`#/X(`-
M<]B``M]USAG0`*#D5+JG[+016NKW`4]>XW`9._@@OO>Q(6:FI>X9A:!`>ZU]
M3]E@-W%U>[34KZ4U`#OX(NIJ/8DH$!75O<LPM!/G]?4J?L`G*NKZ]VFK7TIZ
M`C9.X1!@U(NYBD=-FG>155HEIIE0>F/<0Z333(5-JZ$:I)@!4U:E"TX`%%.M
M+9#J+WL?8U^KOU)M]@DH3$,YCI1Y'YKE4*N_RN6DX5:">24%`IN(66A(9ICT
MNHX,;E9<KE,A&[QNV\11=@\\2V8WE@MQ\9R[)>IV5R;'H[*\>R/+<.>/B(0L
M\W;;&[GX#F\`C%D(1K'0,ENE*1F3,V8"*;)2%6*83"!03/)U^"FO4%O1A_3^
MAN4\<9$;:;,-W7^\FTL7G:.V.Z#B87S3.]XLG9[=NVV88)!+NPF(>#<O9&%5
M$5S*)MCI,SD4$`XYIDY7;^.\G^-W.'-%=QN<F&UJ[7<7G);)NIC%2+X\<Q:_
M9:9Q5M,]T:5KIW0^Z>)^F/E'UR\*CQ7Q;<[7=9N*X;9\AAQ7YGC,&+:X]MP-
M/QN6=MNMS2^/%.ZICQ;VV**7Q6GW\U;1CD]]H.G3J[Q_')MKN+URKYI**YWM
MSFV)JH3<RRDDH6$?P"V;;>9.4R[Y0(!]BL$XAT2-2'=*O.8EWBZKETJW1ZA&
MWW$TB\X\D5F->M9CU^?VOAK+2,.6V&;4M-;3&M9UK.DZ:UF8B9K/K$S$:Q\(
M7HZ;L>R;`=DMOL*W6W%B-R-R,=AUVN7Y>3*)3*4I637E9)[1I-Y6HIE3Z-8H
M."MFHR:KE^5N@4KAPY5*=PI3?%DQ],E;5F?G$Q^ZMQ,3Z)QYR%[@=1?>`4UV
MG?4H!_"[ZB'[HAQ0]?(/H.H`#R)J(E`M'#.HB(H`0`H>M1,HF`?5,7RAP`5_
M!");'L2(FT[+7#,1,)Q:`E;0_;<*Z%M.\3IT[R\`B4=0AWD<HFXBCD)J`50B
MC0Y2'<)QX-0*H5%4"'7!=`$P!1,3WIT`]2AP"TC^"-IZ;R)-=HZ5CAF-VIX=
MH:=I^V_FVEE._51IZ8E0P1_!&T]-Y$&OT=*QPS&[4\.Y?3M/VW\VTLIWZJ-/
M3$J&2/X(UFF]B37Z.E8Y9C=J>'Z%EI^V\'36RG?J)4],2H!'\$:S3>Q(W:0I
MV.68W7@R%&RT_;>#EM;3OU$Z>F+4$+9W!@\>'*YB0!8K(4C@JS`%2:2`)B0X
M))ZI:K)`6BBM+R4MJ`""X'\$(!1Y$B%"B6CAG2@@D):>?W"4Y*?4$OE#@#GX
M+OYV)[N_F&?=2OJ^ZW_LX`%_!``U>1(!0PFJX9TH`*B:OG]P%(>OU`-Y!X#!
MG\"`&O>Q``4#B>YRS```H.14NJ?L`H(K75[K#U[C<`E;.X1%)8%G,4B/-2*I
MP55:)#89U)J"J<ITFPVF107,)A*("4AQO.`&.(*SOX(M^H]B2V:VK>Y9A;I^
M(:]]Q^RP&KJ^O=IJU]*>@8._@BZFH\B"V:VK>X9A;I^(\QJ7'[+.4=WU[M):
MOI3T#)W\$74U'D26W6U;W#,+=/Q'7U+C]EG*.[Z]VDM7TIZ!\+O802+D%W%"
MI8N4Q!7:":\H/RJE,4;QJ!FSD#!:/:FK4/-.'`>#1[!)LVQ3.XE/3;)E,45F
M9-/32<`H4Q!(WLL%NN!@%-.EBE2EM,``J,^@@$USR)`0$UUSAF`@)17`]U3]
M@@*:E?\`9-Y!X`%_!=M7L36HUJY9]X"8!KY_?<4W[H#P%9=BA(;=#/13$ADQ
MV?VB$@IB44Q+\[_59:)!)4HEIW4[*<!;#@.=VT(;8;A]!>S6`MMS<"Q1]D'3
MAM!$N)AMDD:V7C7K;#L56=I._!<B@)0#"^9F1<IE=HG$PF*>OG%$%NT^UN.8
M%NB.X60]8+3=-!=CE2#N`R.7PULV65R/\656:+=O%31(.,AH-2$6.W:M&#<M
M%4"F,(-BB<+.XYD6%O\`<W*58*=Q=ZW+@F$)JJ1,G$N42KER#/C&(H=FN<@*
ME34((@/:`&#RAP$A^)Q/C`#XA'4\-,%>;:TKS1:A74[Z<!LO$X?XPC??;7[Y
MP!XG#_&$;[[:_?.`HDZZ9I@V[C_<0V^>*KPALADIQKA\M!3[I,[^6S>1RXN4
MSSM'==BTE,\P*->(P&*O4VC9I%PQ54EVKO40*U#79'TX;M2L_E#R-ZX\QA<6
MR"?GY)ABA5%5"0D//*Y@X&$9SK;-F$\`QRN1H<JNDX1!`K<H$3`B#--N&U@]
MEMX<8S;%7;/JS<9'@Z,+E[3)XJ?DE&;QK*R6+93!XTXQ>,82+J+68L'TO%.#
M(O%0*T-!$4;%!9Z\.8&M^K-O"[,"4EURY($49T[<EQYNBF5A&('D(%W%1#-P
MRRV'4D8Z$:QR[:UZDLD\2.&JB747*H&QFNFS=MTM%(0O7?G,?'-7:DC)(OK9
M&2>O]9)R@*,@7-6HH1J#AHW.#(Z:C<01.F8ID7+E)0'CLULIG>WF=Q679WU3
M/MX"-<?3@G3>?<*QQE$2-I83)$CT\HD8`Y#R,@@IS!6B+\Y&"7,KNE!U"!<H
MDW`*#:27ASCW4(_9&'T?0!41]#@/;Q.'^,(WWVU^^<`>)P_QA&^^VOWS@#Q.
M'^,(WWVU^^<`>)P_QA&^^VOWS@#Q.'^,(WWVU^^<`>)P_P`81OOMK]\X`\3A
M_C"-]]M?OG`'B</\81OOMK]\X`\3A_C"-]]M?OG`'B</\81OOMK]\X#7-9.(
M!_*#XA'4%1I0>;;4&C4E:>N=O`;'Q.'^,(WWVU^^<!&.\N)L=TMLLMP)EF+7
M%761,VC="?;/7!5(Y1K*,)$AS!$3<$^517,S!)1,KI,BJ9Q(H!TS&3.%8<VZ
M?-T\HW%'-XGKHS+&8%BT0\$V[CX;$BXVRDS88&*RCQZ\;2K.3>-Y*1=.Y5-$
MAD.3=J($2-H(&37"V6WZ9L?QO'X'(LS9YC/0>(8G#367.#H-5LHEHV.4:R$^
MJW4?R!T599T0RYBBNL)3'$!.8>T0:N].WD#NO"XZR#-&>)2F*9+^-L!/-Q:/
M'$?.-<?GXB*>)(FDF"9CQ<A,I/B`<QR&5:$*)>VXH5W#I^W+E\=SF'S3K'E<
MF>97D>*S\*Y08(0+#!DX,D^9^PQ]E#Y@V?J)).YAL\8&7>'!-Y#,E'97@`L1
M4$T?TMS;';9+#''4])S4\T9Y?#)Y'-*RZ[5[#9:+-33R"%8[B1P34TV?"]>E
M>K+B;F7PD*F#4AFZH;*#Z8W\7N1BV>FZAY&61@\G@\E7AY"1GI$DPHPAO!WS
M1X5]N`\B7J8HJ+H,#KLE3LDI%PJ85WH(NB!=*(DX@(N/`9".`09H`("[;`(>
MME[PU.`K)NKLJ_R3,\ASW;7?1MLUEF5P>(8U-3$?#Q<Z["+Q@,R45<LTI"=9
ML0E9$<DCQ`ZJ"B121"(*D7*)03!L9%T_Y#DV#8-`ONJ":<Y;BV'KXQ,Y8Y?/
M^7RN25R*'R!EDLC"Q.;PQ/%\:/%U8*F64<**D1,Z6<)%617#SC^FQRS/E!AZ
MELJ`N2/,O4,Z;3LFF]!MFT4_CI!XMK9FXB_QC8F?D28.T&J"3)I',R(()JE6
M66!R[";+/ME)/,Y":WK<;D-\Q/B"$=$/E'9(_!BP1Y<!B,;\6RO)7C?&4`DP
M!JBJJ=PG0PK+KF,42!$&-](640<[MS(?K=Y6^AL!G\$D@P<5#%@'+#",MRG)
MO#BNC9:M//G.1I94HWDW4LXE'3X2)BLHHFD@BD'1'Q.'^,(WWVU^^<`>)P_Q
MA&^^VOWS@#Q.'^,(WWVU^^<!'NY,I#!$8_=(Q87;A[:D+<[:><<V<P($*6JG
M:<P]P!VCP$@A*PPT`LC&#42@4`>-1J)A1`M**=HF%9.GE$Q?*'`!92'-;;(Q
M@W6`2UVU&Z\6P)VT4[;Q=(@6G?J$IZ8M0"RD,>RR1C#7BF"=KMJ:\519@E91
M0;A4%ZWMIWZR=/3EJ`25ACV:<E&'OTM.QXU-?J\CHV6J#=J<^VMIWZR5/3DJ
M").1B#R(JIO8XY3LF:95B.&IBG%==`S5,JI4:&,J#YN*906&NLF($"\IC`M)
M*PQ[+)*,/?I:=CQJ:_5Y'0LHH-VJ#YM;3TVLE3TY:@$E88P$$DE%F`^G98\:
M"!]0&8I644\[4!ZWMIWZJ=/3%J`65AC6B62C#`:P2"5XU&Z\&PIVT4[;P<HT
MIWZA*>F+4`)6&$`I(Q@@-HEH\:B`W`D):>N=MP*DIY;B^4.`9V$N(QC'S":Z
MC%@97,,S=D36(A'"LDYR635(\*DIC^+BNDZ`;RK@BY*L`W@[>5YA0'B,I#!4
M1D8SL`1$1=M>P"@H(U]<[``$S5^H4?(/`!I6&+<)I*,`"WB:YXU"T"`X%035
M4[+0;JB/DL/ZD:`&E88H'ODHLH$!34N>-``H)@[%6^JGF@0&:]U>[24KZ4U`
MP:4AB7WR,66S5U+GC0MFESNM?50+=/D7-U>[14KZ0U`2,I&(;L&I%GL<W%)F
MF)TU5VR`I$(@[,>],Z3(4RD38N!&J25`14J4MA@`(QWZQZ8W$V@W"PC`]PF6
MW^99!`NF$)EB4S)11XAZDNNNN5:4QF5A\FB$'B$4\:KNX]TW?M$M=5!0JR-0
M"B.`=)?5%B>$2T%F77=/;@Y4PW$D,N@,EDY?+\?++0SO$,KQ^9Q?.4,>S:.=
MDAEY1-JY;M(Q9J6&&)65;JBZ.9=(,[QXBUPG#>EC$MW7R.[LW@VW:>'Y/FCW
M%,GW02E\V:9CLD@]D5UW+/*IQL_R$V-RBC<9%=1\Y3;+D%595-4_'5?"-]N=
MIXIO-OL][7:[W+Y!PTUB=WCVMKQ2=[K-9R9,?=&.;T[K1.F.;4FTQK&N]\8V
MV;<<KN[XJ6OCIP/*S?3X4G99(G7YQ,S$=O7N^4Z/1C"[,K/B(Q>T\:21,9R5
M`6_39E;%P!B)R8J@1T;!6I43:38X#YY:@40#T`#LN?F/,:X9G=<Y><'36)YW
M;7CUKI]W\7;7K]DZ>OSE`XQ[?72N*-?_`.*8_P#VJ]S'45M?@6XS?I-@<YS/
M87-^HS=W$LNVF_$/I_W/Q5TZ+MM&;)2^5*CDW+XM@S/%IQKB<E"SC.1%H5%!
MT=P[5,S4,4=WY;]%_/?J;],\OU1V.7:[W9>+<?2F_P!UEYK8Y_:KFW^^O3%.
M"N3+N\F6U+TM@G%.2N7_`)"F.<M9A;P<CM=EO(V5HM6V>\S2L8[1KI6O772*
MQ'2===-/771(,?TA]3(P^/1LM](Q-%=,,)WEQAZ^ALWSI!RC*YE#3[?;Z>9N
MGFXCAU,OX+*I]&1=KR9EW31*-;,HQ1JB)A#XU_`;_P#H,W\BW]A(>^OSAUS)
MEN("!`_&?&SF$"=H3,6-YC:(`(>V1J)S+)T\MY?*'#]7[_\`H,W\BW]@[Z_.
M'NWR;%G:A$6N00#E92T$DF\K'+**";E[+")N#&-=S*5*!VZA/5!6C)M-WBKW
MY<62M/G-9B/SS#V+5GI$QJ%'\4J]CU$WD<H4`6`JA%VQR@9P1@#<H*`BJ!3.
M.:1L#53$^H2@'N*'&.]+2RD.;3LD8T=32TK7;4;]46((Z=%/.U!?-K:=^LE3
MTY*A@DK#'LTY*,/J:6G8\:FOU>1T++5!NU.?;64[]9*GIR5#!96&/99)19[]
M+3M>-#7ZH,=&RB@W:H/FUM/3:R5/3EJ&22L,:VR1C#7Z8DL>-1NU`:"E;13S
MM0'J%M._53IZ8M00MI*'!X\4!]&@5<&1DE`<-2@L4440(9-312!8*N$@`056
MI>4/-N`!!<$K##00DHL:@%!!XT[0,"8EIZYV@)524^H8/*'`'BL-W^)1=*5_
MGC3NI6OLG=3MX#`RL*%1&2BPH`U$7C3L`H*":OKG8`%3/7ZA1\@\`&EH8MPF
MDHL`+>)KGC0+0(#@5!-53LL!LJ(U[M,]?2C0$K60B$$EBK/8Y`0=22IBJKMD
M1L%W)*BL8ITF@V&2:K'NM$#%3.:]0`,<05'E84E]\E%DLU=2]XT+9I`^UKZJ
M!;I@Q<W5[M%6OI#4#)Y6&)?J24833U=2]XU+9I<]KWW*!;I\@YOKW:*M?2'H
M`>5AB7ZDE&$LU=2]XU+9I<]K7W*!;I\@YNKW:*M?2'H'FO)0XIK)\_&B>Q<A
MB<RU$UQ`>E4()*J")BF9.`$+3#5)0!`;3``>+.3ADV34II",3TVJ13D,Y:IZ
M>DDN50IB"5MIZ8M%@$!33MTC@)2VF``5#*0X5`TC&!:)@,`NVH4$HK`>M5.P
M2BBI7R"0WD'@`92'"M9&,"E0&KQJ%!`3`(#ZYZ`E$/\`2`\!6+8HQ#[HY\<A
MBF(;:#:,Q#$$!(8H[O\`58("42^:)1#NIP%L.`YW[/K;6;G]!>S6WGSG81C:
MDYTX;013^6)-LP-$N&>(8H+L'R,7D>-/C`20::"Z7.MKSF$AS#42F!5LMM)M
MWM1G[O.'?4[C6=IN4)_4AGTG!HZ;G))$\I).TW)<RDR%3FI-P+N01Y84#N6S
M(K(K!FS3:&"SV.99ALKN;E*L'D&/2+<F"82FJI%2+!TD18N09\<R:AVJAR%4
M`BI!H(UH8/+P$A^+1/C`#S[.GAI@]G3I7FBCY:5IP&S"6B1$`"09=HT]G2#_
M`+1-3@,&EX<@B4TI&%,4`$P&>M0$H#2@B`J@(`-P?O\``43?=)*\INXAN.CU
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M3=E!@K=).Y+[F4GO6GN22*>&;`IC+<\@G"M6[6)BV96S0S#,HAQ:O*QO.*B>
MH*ZITS@8YUUUPV$WTGY_(,64=&]:^[\:T,X36R%-S*2[\9M((M6,78M#-LVB
MC8Y'NP=+*'09V(D.9,R14S()&*#BVQZ;\TP;<+$LYRWJHS/=LN-'R,GA^8'?
M(5:9$V5(NW;)-\K=P.DBN@@8M\>+DHJN"@Y!L5DS9A=CQ>(^,&7\NE]MP!XO
M$?&#+^72^VX`\7B/C!E_+I?;<`>+Q'Q@R_ETOMN`/%XCXP9?RZ7VW`'B\1\8
M,OY=+[;@#Q>(^,&7\NE]MP!XO$?&#+^72^VX`\7B/C!E_+I?;<`>+Q'Q@R_E
MTOMN`US66B>?E!Y]E05&E!UD^VC4G=V\!L_%8FVX9!B4M;0,=R@0HC4H4`3'
M`!$!.7[(/*'`15O;AD=O!M9F.VS;.DL,<90Q19I91'';/7D,LQDF,H+E)EXC
M'INQ)R0%.DHJ"1B&$%"G()B&"M.9=,&:91N$7-XOK:W;QR&C&+-MCV"-9"%<
MX[&/2823#9"1D'2;YC-2BTNJN\DSVN&RB<@LF9-0J2(IJ!;+`D@QC'H#&YS,
MOQPF,?Q'$X24RZ1,5%]E,A&1RC5YD+M-1[('*YF%DQ74`7"YKSC50X^<(-;>
M;;7&]X(3'V3C)VV.O\3R4<MQ_($$(]Z[B)]MCT]#1DDRYQ9$B#N(>3B;U(Y3
M7%6;)]U;@"(,3V#RMK&9_'9UU6YKN&OF>0;?9)%+:Z./I8&K@N6HY<Z8XHT9
M9(^.WBIQ5NFT4245/[32*1R+P;S'!B,NC%LFV;,GG4'D3C0QS-\7*+!:2BEH
M]EF&/R<8W4Q]5#.5G,0\+*S+B6D5#G<J2;PQ+#-$R%+P#C#I5'YYH3>$F_\`
MD%L;FH9O)8K:92(R-PLT3:/&DH4<H%BHA'U70AK6FG$LY)ZEIKK*HN&P7&B)
M:)"*CP%^R`09H5#72^YE^KP%:=U=AOQOS#(L^V_WJ5V8R[+(3$,9GLAQJ*A'
MLNXB,5'-1'1=NI)F4))ZIDS2U1P1RBD$0@4Z"P6@D&@G.FJ1R7`\2Q=[U/;B
MHY7C6$!B,EN%'RK09K*'*&=XEN`A*34?*R4NR43!3$^07*(G?.HQRHBJ\,4R
MFH#1=='*;C(GTTGU#9$R8RLOE4F]%D+I'(E4<TB<DB)9%'(CYHHR;NGB62"D
M+@D<%&L1$I(D2,R,JX"1MA]AB;"R.9R;S=V0SU'-UL1;-XM^BJTB\._%\\N4
M(S&$7>2Y`I&8ND$K1FP`][0`/J+.#'`Q`B7&NBP^/3&WTH'4]GCMG@4S@+]I
MBPIMBXL2,P3-,BRXL5%-G,R^FDG.2$R)5G)2,J_FI!PD8XBKVHE;AT(\7B/C
M!E_+I?;<`>+Q'Q@R_ETOMN`/%XCXP9?RZ7VW`1[N5,PQ8C'P-(L0NW$VU(6J
MZ7G'-G,"!2AV]IA'NX"0@F(@1"V09")A*!:+I5$3"D!:>=WF%<@!_MAY>`P6
M9B#B4"2+(PGL`@`X2\[4%J"=OG=MXO$:>74+Y0X#)9F(/99(L3:@I@2UPD-X
MJ\F"0%H;M%07Z%OEU2>J#@,$FHA2RR19&U-+3M73&_6Y'1MH;MU/$FUOEUB>
MJ#@$24M$J2(JIO6ARG9,TRJE,02F,Y71,V3!8&U!,L$@@)"ZXB.L003"X#&!
M:2:B%++)%D;4TM.U=,;];D11MH;MU`DF]OEUB>J#@`LS#GLLDF)M33T[7"0W
MZO)BE;0W;J`_0IY=4GJ@X`":AS6VR3$;@():.$AN!0&PITH;MO!VE3_O"^4.
M``F8<0`0D6(@-!"CA(:@8$A+2ANVH+DI_M!Y>`9V$NXUC'S":QVK`RV89F\(
MFJW)'"LDZR636(\*D;&\6%<CH#7@OHN06K?SCRO,*`\1F8<*B,BQ```1&JZ0
M4`H*&,(^=W`"1A_\D>`!FH<M;I)B`%ONJX2\T"`X$]?.[+0;*U_V#>0>`#3,
M02Z^28ELU!/<X2"W2!V*MU3=E@,5Z^32/Y!X`/-0Y+[Y%D73U14N<)!8"//"
MM=YW9I^'.+O)HG]2/`(V4K$MH]H15ZT;BDS2,=-0Y$!2(1!V<]R1F[(4BD)'
MN!$-%*@(G\T+1``6'FHA.^^19$T]74N73"S1Y[6NJ;LT_#7-WDT3^I'@`TS$
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MBJU,)?/`P_2OB'.[O!X7Q>TXGE:;2V*-Q&7''(XMI,9)W5KUFV.^;'-IG'-9
MB^DQV](G[NC3[C%6=S>V2G=KII/9-NG;IZZ3\?@90FZ?1$P!@6&C45`+_P"!
M;[O,9P0H?_VJ'>*Z8?\`E!Y!IOH\D\GZ?_Z"?A_ZY@_B_P"E?9/[/6U[.'^B
M_P#Q3_-`FZ?3U`N!8:;5J!*;%/\`SA5$Y4P[<5``N&11[Z>R!6E#6H\E\FC3
M7R"W33_US!_%_P!*^R?V::O9P_T7_P"*?YIW[6K[5M]Y-L)7$8+&<:".>9<O
M-3#7`3X$FG%OL-E&C1)W+OXJ(1<).Y6<8`1M>8YU52&`E2'$ND\L\BWNX\(Y
M79<QR\;NV;'MHQ8K<EBWDSDKN<-K37'3-DF)KCI>9OI$176-?O5UNX,58W-+
M8\?;I,ZSV37IVS\=(^.G0SL@Z.>HN>B\E:8[]()FCF&R#!(C%<78+O<V4)&2
MT-NUD>>,I9_GL!N@UR!XME&+YNG`2+A-1O*.F[1@1-R+=NDV#YI;A<7I=VVS
M'9?#<IQS<K>D^\$MD&XTUE<'.2$MDDDM%X_+Q>(Q[2&27RW*,LDT_$9=-28.
MW1<E8-',X+=HF5N1(3!9,DU$*662+(^II:=JZ8WZW(Z-M#=NIXDVM\NL3U0<
M`$FH=2RR19&U-+3M73&_6Y$4;:&[=0))O;Y=8GJ@X`+-0Y[+))B:_3$EKA(;
MM4&8I6T-VZ@/D+?+JD\H<`B;2T3SKTX/68`L#(R:EZ92K%,B@!!(KRZ0+![9
M3`**K4O*'FU`.`6!,PP@`A(L1`0`0HX2&H&!,2B'G=M06((?[0>7@,^,P_?X
MBQ\O\X1[J5KZ;R=O`8&9A@J(R+$`"HC5PD%`*"AC"-3>@")Q'_9'R<!DTU#E
MN$TBR*!;Q,(N$@`H$!P)Z^=V6@U5KY+#>0>`2-96*;I+E6>M$!*[DE3E4.F@
M-@NY)851*9NTJ0R;18]]I@,"9C7J4$Y@5GFH=.^^19%T]74N73"S1YX5KJF[
M-,(UQ=Y-$_J1X`/-1"=]\BR)IZNI<NF%FCSVM=4W9I^&N;O)HG]2/`!YF()?
M?(LBZ>KJ7+IA9H\]K75'LT_#7-WDT3^I'@/A>6BA373Y]F)P(N04]9,QKDP?
M%4+9:J(B4S!<!"TW:D?L&T0X#Q9R\0FR:E,_9)Z;5(IB&533%/237*H4R8I-
M13%,62P"`I)VZ1@M+00`%(S,0`C=(L0$MP&JX2J%@K`>OG=EHMU*_P"P/D'@
M#QB(`1`9!B`@(@-5TN\!,40]-W@8@A^YP%8]BS%/NCGQR&`Y#;0;1&*8HU*8
MH[O]5@@8!]$!#@+8<!STVAD]M-TN@K9K;M;=+%H#Q?IOV@B9"6&:`0A5H[#L
M4(ZYXC#(,<>@FB^:<NLF#UM<(BF8P@82F!V;)83MEM+.*SZG49%YPYOW).JV
M=9)&)M53[C2^W4W(OWS-/(Y1->5:RN%J+:P$312&761:HLVA46I0GK'\TQ.:
MW.RA>'R.'E$"8)A*2BC!^@[3(J3(,_.8ASH'.0IRD6*-!&M#!P$@>,Q?BX#S
M[>WPTP>R!2O-%_[:<`FR48O(L<R#'RSI8PT["2L,62:J!S4>,FP79`];4.GZ
M^T%?4)YQ?.*':'?P''?"/HP-V-OL7Q'#\7^DGWPA\>P>#<,L=@XEC-Q$,WFW
M\EF3Z2G'#:.W6;OG!7J&9+-]'FBJI$*!B+E429'9!8>&Z*9B)AF,#(=6F7Y4
MW;]2.W_4.]2S/Q:?,P=X?EF3Y7DF(X<H[W(++8>PS20FFB*ZAG+U%L1DH86R
MSEVLOP'1L9R&`;1EHT#=OFB^;5\T!$W9J5[`#MX#(S4.%!&5C@J`B%7K<*@'
M8(AZYV@`AP'T,O%EI5^VH8*E$%2B4P5$HB4P5*8`,40J'H@(<!\^,Q7N]M_*
M!P!XS%>[VW\H'`'C,5[O;?R@<`>,Q7N]M_*!P!XS%>[VW\H'`'C,5[O;?R@<
M`>,Q7N]M_*!P!XS%>[VW\H'`'C,5[O;?R@<`>,Q7N]M_*!P!XS%>[VW\H'`'
MC,5[O;?R@<`>,Q7N]M_*!P&N:S,7STH(OVU!4:4]<#W*2M.`@SJ&V=8;]PF-
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M[VZBW;('<E%@*N-3^4Q^1H)E.(JR,"U"I!`%4PJF\Z$=T,FV]W!PO<#Z0O=[
M-)+-]Q-O\]B,C6;MX@-NR8@AD:4C!8-%L,TNCF[M_D2+^+54=*^&R<+%.7))
M-1NOS8(DOHZUD=D8[:E7JZRV7FX>`W*Q)'-<A0DY-FYQO<1["O\`EIS$T-S8
M]M/3&//HQZ];R;UXL\-(2"IQ.5N46I@<&+=`Q\:W\QG>Y3JMS":"#S?%<Q4P
MV34F)%G+/8?#)3%)..<*R>Y$FQ?>*FDU^24>1[YQ&,EEDDC*/3$D4@Z41$S%
MA%QX"_;5!FWK50/N1>`Y*N/HW<BB]R,SSC;OZ0[?G;F0RG+<FR57&HR3CGL=
M"060N\K6B\29,7D^DNG!P,+(8W'(7`!%&N.$6`A7CH'3<)&R;H)4R';#;'!T
MNJ_-&&3;=X'%X>\S1=Y/S">32D1NWB^[,=F,GC$IN:LV>3D9*02C1$91S+@Z
M0=@23-)(IZ"@-/\`^'"L7.Y[+4NL3/6C#(LDW.FW"#0\BGE*$;N=ALQB,E$,
M<I5W'7C6RB!Y@JYW:<050Y(6&21*V&/45=A,W1]TE*])SO<!Q(=1.2;V!N$.
MVB",=D*"Z#'!RX>$^@$=B:#K+<L<1.&*IS`(QL;J>T&[8"G7>*&,MP%^RS4.
M<`$DK''N.*9;'C<]R@#:)"@501,<#=E`[:\`>,Q7N]M_*!P!XS%>[VW\H'`'
MC,5[O;?R@<!'NY,Y$DB("LBV+?N'MJF7UVEYCYS`@4G9WB8>`D$)N)$0`)!J
M(FM`/72]MXHE+3_:%<E/]H.`R6:B36VR#4;Q(!:*E\X5!:E3I_MB]2IY=0OE
MX#!9J)/99(-3:FE914OG:PLP2IY=09!"G_>E\O`!)N)4LLD&IM32TZ*E&_7Y
M'1M\NIXFWIY=8OEX!$G,1:DB)TWK<Q#LF92JE](8SI=$6Y`6Y4"B94)!`2EU
MQ&BI1L"MP@M)-Q*EED@U-J:6G14HWZW(Z5OEU/$V]/+K%\O`!9N)/99(-3:@
M)B2BI1N!8&8I"'EO"00I_P!Z7R\`%FXDX%$L@U,![!+14HW:@-C$I_M`\2I_
MW@>7@`)N(-2DBU&H%$**E[0."0E$/](+D^R#@&=A+^.91\P191%B9;,,S>%3
M4;>'BLFZR:36*[!,<;Q?6*ZN$^MHN=:MXNW8CS"@/$9N("M9%J%M1'UTO8!0
M4$W[P)&_>'@`9N)*!A-(-0`@'$PBJ7L!,'`GK_L@T4K_`+`^3@`TW$DOND&I
M;-2^JI?-T@=BI7R6`P6K_P!T;R<`'FXE.^^0:ET]74JJ4+-#GA6KY-,(UQ7R
M:)O)P"1E+Q:#!H59Z@@*;-,QR*>LF3(F@[.<3)&;,A3`A(U<::*5`2-YH4IP
M"[Q>+O%/GFUY3*$$NJ4!`R0O@5`?(*8QCBODT3>3@/4T@Q()@.[;E$MXF`5B
M!;IBY`]>WLL%DM7R:1O4CP'\S[Z1GZ`/>3#?I4\TS;=C=R30Z(^J7>S.=QC;
MYX;"/<RSS$'^]&79/-2.T".U;)XYE#YO&S+U9FQDS`$`LS*BZ56(Y$T:6*>6
M>1<9X_M\%^1]W3+N<5:Q3';).L9*SI,5B9C7K$3,:3/36)F'T#_P_?1GS?ZP
M<SRNU\-C8Q;8\)OLN:VZW6':4C';:YJ3:E\]Z5R329K;)CI:<E<<SD[+5K;3
MJEC'^3,Z%YM!&89=='4QDD6!506;XVVVF%X#D$G!!:<^RQ[(T$';-TD(+I@@
ML8`3.3S1\\LFPY\6XQQEPVK:D_*8GK\ITF8UCXPX=R?%\AP^[ML>2PY,.XKU
MTO2])FLZZ7K%ZUM-;::UMIUAL`_R4_1Y42AUR]2M0NJ`0&V-0$MX&J'AM0$N
MF:ODM'R<76O>(_Y+'HU*82FZZNI0I@-:)1@-L@,!KBEM$HQM0$#&`*>4>`P'
M^2RZ-#6V]=?4F-PE`M(#;+M$XH@2GP;_``A<$^R#R\!S+ZUO\H+U$;<[M[$1
M70AO>?>W:O<R=:8CN;E6Z<A#X9D6Q+M83.U\\R!*"4*GE6W:\,LF4I8MNI+I
MR`IM^76*Y24*']!+IDVLB>G+IYZ;^GUOF2F<(;&;+[;;/)YH]9%8NLH_$+",
M7Q%M/NV:?B:<6XGP:HN-#G!`@N`(!UJ5X"P!)N)4LLD&IM72TZ*E&_7Y'1M\
MNIXFWIY=8OEX`)-1*FG9(-3:NEIT5`;]?D-&WRZGBC>GEUB>7@`DW$J662#4
MVKI:=%2C?K<B*5OEU`DV]/\`OB^7@`LW$GLLD&IM0$Q)14HW`L#,4J>6\)!"
MG_>E\O`(FTQ%B\>&!ZW`JP,C)']*54ITD0*)%!:I`J%728=BJU!.`>;6G`+0
MFXD:"$@U$!`HAZZ7M`P)F*/[H+%'_P`H.`QXY$4KXBUI2OLI>ZE:_O=O`9&;
MB0J(R#4``#"/KI>P"@H8P_N`B8?_`"1X`--Q!;KI!J%H'$U50[`3!R)Z_P"R
M#16O_=CY.`2-9B+027*L];HBFZDE#%4]:HGS<FN*E#-FMQ#),UCW`4P&!,PW
MJ>G,"L\W$IWWR#4NEJZE52A9H\\*MWDTPC'%?^Y-Y.`#S42GJ7R#4NEJZE50
M"S0Y_6N\FGX6XKY-$_DX`/-Q*=]\@U+I:NI54H6:'/:UWDT_#'%?)HF\G`?"
MTQ%Z:Y.>;B<I%B"0#@8UR8/BG+8!%1,8IHY<*6F]B-V#2G`>#.:B4V34#/VR
M=C9,#%,8$Q(*2:X*%,04&PIBF+)8!#33MTS!:6E`!4,U$ENND&H6W`:JI0H)
M!6*:O^R+<]?]D>`/&HGM^$&O8-!]=+WU,6G[Y!_>X"L>Q9RJ;HY\H0P'*?:#
M:(Y3@-0,4V[_`%6"!@'T0$!X"V'`<[]H)?;#=7H*V;V[?Y]%Q+>7Z<-HHF4D
MCED5$XE6+P_%B.3O2-WD(OH(2#+14#FFY3UMOH8*@NV9VNVMVGW`4SE+?Q',
M2)-,S2)$R+)AS*4IF<O$2L]-N9QHZ7DUW3]VT!9TU,`1G-NC*MVS0NBDF%F\
M=S7%IS<W*5HB;:2"">"82DH9MK'(14F09\<Q3#I`4#`18O[_`/IX"0_&([Q<
M!YLM/#3?P%:5YHO;['3@-CXS&>ZR?8J_:<`>,QGNLGV*OVG`<\)#HFBW>=Y'
MFN%]4&\&&.Y7-\MFY"*QN5210AF>:9[/[F9)AC!=@HPD(]D\RS,Y-P)5SK'(
M#T``H:2&F&UGND&2F4WBK7JVWKC'K$KEIA<ZG,NGLS@\`^R5KDLK&,I1W)G6
MD#JNXUFU(Y<><5@P006!<`5%8%S#I2ET)%9X7JOWI;Q\LXBI#(&<%/9`R5F)
M&"BSP\<\1EG^13CF/(JD)5GJ2=R3QR@D(@5(FB(6LVK@T]N=O,3P>3SJ>SY_
MC<4G'.\PRI=Z\GYY8JJJIGDBX=KOG)SAJV$`ZRIBI$*43FI40D#QF,]UD^Q5
M^TX`\9C/=9/L5?M.`/&8SW63[%7[3@#QF,]UD^Q5^TX`\9C/=9/L5?M.`/&8
MSW63[%7[3@#QF,]UD^Q5^TX`\9C/=9/L5?M.`/&8SW63[%7[3@#QF,]UD^Q5
M^TX`\9C/=9/L5?M.`/&8SW63[%7[3@#QF,]UD^Q5^TX#7-9B-!]*5=EH*C2G
MF*^Y2?\`FZ=O`;'QF,]UD^Q5^TX"--X<2C=V]MLJVY_&,D"3*F;5@M*^"MIX
M6S9*19/712Q<B!&BYW3=J9$IQ,4Z(J`J00.0H\!6?-NDQ3,-QOG`8]56_N*M
MF+))+%<`@LN<DP+&%D\,3PIZX8QQC!-+(OVZ[EVJ`ORK%>N"J$6+HIAP%K,!
M:I8ACF/XK(Y3(94]QG$<3Q]WE$T549;(W,1'*,EYV2-Z[<^E5$A65&\XBH<U
M3#WB#3WHP7"-UX7'8K(,C)CSN!R8,AQ>:10CC24;DX8]D$#%/X9:4;*\K+QJ
MDZ+MLJA8X(X;D$I@H/`5]'I/<R.-YO!YMU-;IYR?-LBQ/(4WF2..;98JZ@@G
M4';;$8=P\<,(=-=;(=:-.2JT:^CXYP8[I5H43@A8=&N)QVVB6"!O'DD@ZCF6
M8Q+/)IV.CYO2QW+C-!?14I%22J[6:TW+)T\.Y>**KJR+Q=>XA2IHIALH3I'P
MS']RL6W#;[HS"LCCN40&0),G355PL^D6$&:&>MEGBTLHL^%^U25;L^=3?*1L
M>[?(H567*Z1"Z$1,1H1<>`NR5!FW`?-5]!,OE)P%;=TMAXG<'+)S-L.W;R3:
M++LHA,2QS(LDV^:Q;/(G^/8G^.BA&Y9C0(]YMRIF:)@5<"Y10\.;41-0+0BS
M)NCF+R]C@+2<WVRB8D\`V_)A[;()F,1FLDDWZ<Y*2+_)I:9?R2LG)G:(RI"Q
M[5\J\1BG[%F^3,9TA<<''DG2;A>0339[\Z&1L(MPODKV49I)(&G7S[)=M<(V
MRE7\3EA5492$5<Q.'*N7*:15&KIY)+*JI"=)N9('7L3L7C>Q+_*GD5G"V2J9
MDEAJ#]FG%C&M(]6&6FQ;+Q[!"0D6D7#@WDP;1[)JFW0:-6Y2"*YQ,KP$*8UT
M/X5!SVW$VTW^S]X.WL]@,K'XF#AF.&%9;?9?E>1PD1#Q13JY$P*X=Y2[0<*.
MY63YHYSF6(J8$BH!T3\9C/=9/L5?M.`/&8SW63[%7[3@#QF,]UD^Q5^TX"/=
MR9N++$0`"]*6_</;9,OF+C>8^<P-I/-2'TPAZ-`X"00FHLU*.R#<)0#S%>\P
MH@7^+[*BX)]EP`6:BSB0"NR")[+/,5[=06H$[T^RX7J7V?U!H`2:BSV6.R#J
M:5GF*A=K"R!/O3"EPR"/\H'D&@!)N+4LL=D-J:5GF+>=K<AI=Z84O\30_E`\
M@T!"G,QBDD)B.`,4[%F4IP;KVF%TN@+<FL+("W*!((B!=81#4J)`[3<`M)-Q
M:EECLAM72L\Q4+M;D!2I5,/3A)H?R@>0:`%FXL]EKL@WZ=GF+=NL#,4_XO\`
MAA((_9AY!H`6;BS6VNR#?9;YBO;J`V$G>GV7`\2^S^H-``FXLP`(.R"!K:>8
MKVW`D)?XOT06+^_P#-PB1CVD?,D5'E!5S#,W92&8*LA5(ZR637*YTPQS'=7F
M;[Q5TEQ5$;A=.A$5S@\AFXL*U=D[`$1\Q7L`H*"/\7Z`)&_>X`--Q90,)G9`
M`H'$PV*]@)@X$_\`%_P0:*?8_P"BH!IN+)?<[(&GJ7^8KYND#P5*T3_@@P6^
MP'RA4,GFXM.^]V0-/5O\Q8;=$'PJ]R8UL"-7_DQ\H5!$QF(U&/:`JX!+39)F
M,4Z"Z0D(F@\.:J9F;026DC5NS23[$^PH5`!",]^,3/NSM%N#MK"9PM@DOED$
M[B&N4MT9I7PI0B[A9P5TE!3>+32T:]2AG+5X1G)L'1VIE02<)'$AP"C>WG0;
MN;AF#R^-S76ONGN!-$W$D,X@LMRC\=6[A3G<1R3&)Z`SM/']U(-SFD9)N#-'
M!T"NV23$L.D+(C9<P.4PF13`9+:[#^G_``B45R'=1;;79N>V]F\PCL6R+(EY
M2;CR;>-E'[IBK(Y-,1PSA<4?*$25>.S$*W%$53F!,#QWFL62V[PY8Q7R8XQ9
M:S-:3;2;6Q3$=/G%9_-^37LOTSW^TP>/<GL,F^VVTWF3D-AEK7+N*X)O3%BY
M"MK1-YTGV[9<<?9WQ,=(M-::[F'R/?7/8OI+Q.=WUV6?J9S.;S'SS&=D-P64
M?"P\5CKZ!;HQ^XV,[F8*P@'R\Y(G5=-Y-%VN<4TT"L3D>HO2Z3A><C!SE_'[
M;?=ZY._)%O8F,5(CMZVR]W;&LZQ-;1%XM-=(F)B9ZA]3/I7;D_I7@^K^+E^`
MG'LOPVROBGE:9-]N+V]^>W%L?:]V_;7V[8\V*]]O;%7+W7I>EJ5F\_0AGQL!
MP+%2=6V:.)_&8>)Q[(9)TON<:$EHZ'W1PG/(P,>@6&]K%[CDOCF-86MCL9(N
M'LH^(U=<P[.[5;IEXGKY*=-1F8P#6BZ*!@-:("FK4#7%+0?6^SSC`'`8":BS
M4`'9*FM`/,5[;Q1`O>GZ(N"?9?Z>`"S46>RUV0=02`3S%>T5!:@3O3_A"]2^
MS_TT!"I,1JCV..1P!RGU2%.""YB@9RFP%`#*<DH"6KSJ5*J)5N_A4$"@N)-Q
M:FG8[(;5TK/,6\[7Y#2I5,/3^)H?R@>0:`$FHM33L=D-JZ6G0BOG:_(:7\7V
M7^*(=_W0/(-`P2;BU++'9#:FE9YBOG:_(Z7>F%+_`!-#^4#R#0`LW%GLM=D&
M\$Q)YBWG`J#,4Q[4_P"$$@C]G]0:`A;348+UZ(.0]=!B<AA;KE*<JB*($$B@
MLD@4J+DE:**VW=MG:'`+@FXL0`0=D$!`!#S%>T#`F8/XOT06+^_P!XW%TKS9
M*4K6Q7NI7[GY.`!FXL*B+L@4`PCYBO<4%#&_B_0!$W[W`!IN++<)G9`L`XF\
MQ;L!,'`G_B_0!HI]C_HJ"1I,QJ*3@JC@$Q2=R1S@9NNG0H.Y)<3@`LVP'**;
M-4UP%,!K1&\]0.8%9YN+3OO=D+IZM_F*^;H<]J]R8UL\,7_DQ\H5#)YJ+3U+
MW9"Z6KJ5(KYNAS^K_%]MGA:_=]S'RA4`\W%IZE[LA=+5O\Q;S=#G]6M$Q])X
M8O\`R8^4*AYKS$:"2Y>:+<4BY1*"2QQN3!\4X`4J"HF$#1RP4`IJV=@#4*AX
MLYN+(R:W.BDL:I`8HHK$$NFDN!P$@M6XD$G)*U#33I8/FAV!P"H9J,*(@+L@
M"6X!"Q7LL%<#?Q?H"V/]C_HX`\:B^WVV3L$0'S%>P0$Q1_B_*0?WN`K'L4<J
MFZ.?*$-<0^T&T9RF[0N*;=_JL$#4,`&[0'T>W@+8<!SLVCFMLMT.@C9[`9?+
M%XV/D^F_:2,F)<<?R==M%&B</Q8CEP[,BWC;F;>19`F<W,HIG`:`I0P"(+]F
M-L-I]KLY#.XS=Z?RPS$<];*MGN*O3+"_S>1@).=5DIEI&J.U5W$C&@]=MS`1
MOXD[,JW29I&Y<P6=QS-,<G-S,I7BWZSI%/!,(2/\&2Z(E4)D&?''S'#%(1H5
M8O;3MKV=PT"0_%V/BX#JK4\--V<F]K7FB]M.7X#8^,,/5K^\GWX-P!XPP]6O
M[R??@W`4$RSI6V\<9$]F<)WWW`VOR*6W+S/(L_+`S<F4N;Y#N%+3F1PN%9)'
M)/XWEXJ);Y(\09L&W+.W3-P8X*`L":Y`W'ZIT&K@[7"AW_WO>XPSR;+9*<3>
MS$BX1?,LO,NO.8PNJV;-`;LD';]=NV3<F<D;13M5H*1CBDX2"VN!P6/;<8;C
M&#0PR816.QK>%C#/6$F+I=-N10Y=0YVMRS@Y2G.;O$:"/H#P#O4EF2)!45YM
M),!*`J*QTBF0!.8"$`3G:E+4QC``>41X#Z-*-"A4X/"!6E3QLB0!'M[`$[4*
MCV<!\>,,/5K^\GWX-P!XPP]6O[R??@W`'C##U:_O)]^#<`>,,/5K^\GWX-P!
MXPP]6O[R??@W`'C##U:_O)]^#<`>,,/5K^\GWX-P!XPP]6O[R??@W`'C##U:
M_O)]^#<`>,,/5K^\GWX-P!XPP]6O[R??@W`'C##U:_O)]^#<!KFLNQYZ4'46
M]D:=G)O1$/:I/0Y?LX#8^,,/5K^\GWX-P#5SF*@L]PG,,&E'4@VC,SQ;(,4D
M'#-H\([;L<AB7<0Z7:F.U,0KE)!X8Q!$!`#`%0X"IFY?2NZSC.S[B0O4'N]@
MSQC'8U'-V$(6<1C&S'%VD<FO&.%6SIB=O#RCN(YERDWY8PK/'AE#JBHCRP6F
MP)LKB>.P&,3>2SF7S&.XCBL)*Y;.,'I)G*9.,8*M9'))1$$3E1?3CQ,[E4A1
M$A%%!*7S0#@&MO'@>%[MQ$%"STN\AWF/SHY1CLJQC$E9>(GA@9_&XV7B5)"-
M='82,:M/F<-7"&FNFZ03$IP[0$*[*]*1%,9S_',XZB-U\V)N#D.!SLFKG;5>
M5:0:6.RSUPZA\1C7H`AB3/)7<ARJ#AB9"28IHH`@Y%PB18`^#]'^!,L"<8H?
M<;(V[ELURUHG//<6BUF$;`Y,TBV<G%GQQY&&@^1*:%7>K'4"Y26>.G@F*H8`
M('I"=)VW..[FXMGS?<>>"9QW*L>FV[!U&J"Y=R[6!4BG+-9XJH+QX>59-5D6
MA7@/%&$:X?(MZ'6YA$+KQ$NQ"+CP%1<1!FW"O)/A_BB^CRWH<!0`W0YA@Y)D
M^0X5U"[]8?-Y5EJN62)L2G%62S-N>4R5Z:&C#1<6T=M8IOC\YC<4F10ZJ(,,
M3BA4(HH9918'>SZ5<'8CAR$GN9/.U,-PY#'XQ9:"(WERS*&\K3=!7(BS#H'<
MVY;CD96\:6/>KOD$4@+0W-*'54!5D_2EMYD$\V=JY_E$='O'&4/I2+;Q21)>
M2?S^V>#[;3;^*R<&*4W#+J06'F<.TT3';.',DLLND8Z;8Z(.G839+#]D'^5N
M\=S-[DR^8H8465:(POAK1D:-5G#,7K"-8"NRC(A9O(BWCFC9)NV;-&Q2%UC`
M*G`0Q@W1QMQBF087)0V[SYXVQJ?P69#'_P`7&CUI+IX1D4S)8S$H.'KF2EH=
MM&/EE$6*S-=-X!N<3<K/$ES(I!T5\88>K7]Y/OP;@#QAAZM?WD^_!N`/&&'J
MU_>3[\&X"/MR)J/+$0`"LN6_</;9,/:,AYQCYS`@!?-:C0!]$1H4/1'@)`"9
MCQH`*+^=;3VB^#TXH@6M6W9VKE[^ZHU[AH`69CS6T47\\2`6K%\'L@M0+6K8
M+>UXG6M*5&M+34`),QY[+5%_7!3`M6+XM=;D@3K<V"VOB"5:TMJ:M+#V@$F8
M]33M47'5TK*L7Q:Z_(:=;FP65\21K6EMQJTL/:"!*9CU),;#.1O8,Z&&-D"$
M'FG"&@45C1Q2`8?$$ZE%6I`$PF(6PX@"\DS'J66J+^N:5E6+XM=;D-.MS8+:
M^)(UK2VXU:6'M`+-1YP()5%_/TQ+5B_+[*#,25N;!;7GTJUI2HUI8>T`LU'F
MMHHOYX$$M6+\/9`;"6M6P4[':=:]U1K2TU`P$U'C2BB_:!1#VB_#TX)"7O;=
ME06+_H[?(-`9F#R3%M'3!3D<-Q5S#,W0$&)>-A.5QDDDN"PIEQZ%$QE@/<)C
M)JG.(U,NN:JI@>@S,>`"(J+]@"(^T7P]A04$>YMY$A_T_NA4,&FH\MU5%_-`
MXC1B_'V,'`GI1L-:`U/W=]`IZ8M0R::CR7W*+^9J748OQII`\$]*-ANH#%6E
M*W4"E;R7`'F8\E]RBX:>K?1B^-31YX5*6MANIX<M2E;J%I6\EP(F$RP3CF@G
M,Y)8S3.)31T@0Q2IHO##ZUX>V,%"QJM`!,E:%H7STP,"T\S'IWW*+AIZM]&+
MXU-#G]2EK8;J>&+4I6ZTM*WIW!3OJ_Z8WO5;&8-#Q&[4UM43!I3*I5Z[@\:R
MF0DYM68QZ4QQI'&?P>:X2HS@TW22HR38>9\79"9D)T47)Q6"*VW0;+M%MHG?
MZQ6?R[O;F0Z?W64+9#$9E,)9J38#,<ZRAN>*9([A,6&&S&4,I]I#N7B:4@8T
M9%))KD>'6*<AY,:QHAS>O)%<WZET.E)TON3`&S/?+&NH9MDV-8"M/0I,9VO@
MMOUG40ME^-[GX;DN%/<@=0;MJJJY:+.T$Q078H*E537"!;?GIV'E^3Q[+BSV
MMO+WRTM6E9QUBN+#&MKQ?6OZ-HFMJ1,_=FFM9UGZUYGZ35\N_P"'/9?6/C^0
MXK!@\<VNWV&XPY=QGIN\V3-ON1O&/!MK;;V\VD9<-JYL&XM2D1GIN.S+6*UE
M7.OH_)+*]M(K`F/49N,RD(S`\CVV+D.0,,ZR=![C<YENU.2M7+^&2W(@#O<L
MQMOML[1CIE9XI(HKS:K@5#:14E)Z^2W2@9%HW*DFJ9R`VE*4QV;\PGI82HF,
M@<PB(F"HB(CV]H\!\A,QYJ447\ZT`]HO@],*`!6K8*=K@G^BH^0U`"S,>>RU
M1?SQ3`M6+X*BJ+4"5JV"E1>IUKW5&OI34!`K,,#O8TQ3.!!35(4WATA:!G"3
M`R0'.,><$;@>)^F42`*B`UL.!07DF8]33M47'4TK*L7Q:Z_(`G6YL%M?$T:U
MI;<:M+#V@$F8]33M47'4TK*L7Q:Z_(:=;FP6U\31K6EM35IIJ6@$F8\]EJB_
MKFE95B^+76!B*=;FP6U"21K6EM35I8>T`LS'GMM47&_3$M6+X/909B2MS8+:
M@_2K6EM1K2P]H(&TS'B^?4,Z"\&)RB:-D2%,51%$""50T<D52G,$J&HI8(B`
MVVF``7!-1XT'47[0*(>T7X=A@2$.]MV=BQ?^WR#0,^,Q]*ZB_O%]Y+O<WDX#
M`S4>`"(J+T`!$?:+[N*"@C_NW;V(F_T]GE"H!IJ/+=51?S;[J,7XTL!R)NYL
M->QH?N[Z!3TQ:@C9S#!-)P4YG)!2>20F#PZ0*%`=R2PF)1@B"@&(T4$!*!@,
M(!0QQ,4QP6GF8\E]RB_K>K?1B^-31!\*E+6PW4"-6I2MU"TK>2X`\S'IWW*+
MAIZM]&+XU-#G]2EK8;J>&+4I6ZA:5O3N`/,QZ>I<HN&GJWT8OC4T.?!2EK8;
MJ>&+4I6ZTM*WDN#S<3#`J;@M[@3$37`0*P?G$12*^`X%`K134&L>K2T#74+0
M!O)<'BRFH\&341.X*!6J=0&/?D,7327O`4^11$HEY-3LL)W!0H7%`05#,QY:
MU47\VX!]HOA]**X#2C8:]K<_^F@>4M0/&&`?QB_97_<GWH"8!_W;RD'@*Q[%
MG*INCGQRC<4^T&T9BFH8+@'=_JL$!H8"F"OU0`>`MAP'.W:2=VLW(Z"=G<&R
M7(Y&,@W_`$W[11\Y,CBN2J-HGPG#\6*J\77=0I&0M6LFR*45#'*D;L$I^TIN
M`5;,;>]/^V&X:6:8_O#N/E60,6.Y4:VQ^2"7>022&=SN&3.;R3O'F6*D$V2N
ML@QEBO(R"9D#+.UQUB`!D4TPM#CF8P$YN9E*\8Y>KI)X)A*)P4A)UH8%"Y!G
MQS#IO(UN82VJE[0"@]H!W#0)#\59^+@-SFGAI@IX?(5_G1>VG*]W`;+Q9EY7
M7R?(?@O`'BS+RNOD^0_!>`H"[Z==GF^\4EN,.]#EG-DRQW%)8L]QC;>0;14K
MGN:R6Y<W`N$Y;#74A(YS.S+D"PC]Z*TQ#Q:)T(X2E<.SK@X9WHTVSGI#)Y5;
M<'?)B;))O)IM9O&2\RQC(L<IFG,S.Q\?'(P01X,72KM=$^NFLJ**A@,<3><`
M-O%NA_`H=P5^MN_OCE\2K!YG%1T3D3F0FH*-C\XV^EMO#FQQ!6&.A$(-L?R!
M:T&UI'`-V(&\QJ`*AJ4NAC"4VZ3R2Z@NHN58(*.Y1H\EIZ1>IL5WKZ1>MY:*
M>OH9PA$N&3.65306:Z1;E#*FO$2@0)^V2V4'9;,MPIE'<+.,LQ+*F.,,,8QG
M*(S*I)]B)8AQ..'C<)U^X=$D6*Z\R1-DB1JV,T02L,=<37%"R(Y#%%<D9&5<
MD>*(G<IM5(Z23<';IG(FHN5%1H5042**%*)Z6@8P!6HAP"CQ9EY77R?(?@O`
M'BS+RNOD^0_!>`/%F7E=?)\A^"\`>+,O*Z^3Y#\%X`\69>5U\GR'X+P!XLR\
MKKY/D/P7@#Q9EY77R?(?@O`'BS+RNOD^0_!>`/%F7E=?)\A^"\`>+,O*Z^3Y
M#\%X`\69>5U\GR'X+P&N:RK+GY0:N>U1I_P^0K_-2=_M7LX#8^+,O*Z^3Y#\
M%X!*^R2%C&;F0DG@L&#-/6=O7K9VU:-DKBD%5=PL@1)%,#&`!,80`*\!3S=7
MI.VZW2Q:+PI;<W?7`L>4RW=?*'L=MK/RN'%R\=X<@E,LRR!FN1Q\PR<.B>5>
M%:E3M7016.IJ"H`*@%G<,:,L2AXG%BRF1S2>-XSC4"E,9&C)/L@EDHEFLR3D
MIQZ9@@9[+/2)`=PL)"BLL)CB`":G`5LWSZ;-G=Y=T,;W$RW.=P<8RZ`@(N"A
M&F+2@0R946<O.OH^0107@'KT94TQ.%,15-0!UF;:P`,0;@8D;T?[>8IBV2XW
M-[Q;E3I,E':1O+R^XK1MDDD>,P&=G'41!F>Y)".'*##(9/(W+%N9-1)VS:@D
MV9+)G)>8'3D_3GLG-XBX8(9I*PS5JAN*#&?\*@I)K"P&;S[V:R6(*C+8TYA@
M@HZ6,]%.\A3-EC'.*@+(IG3#3P72WLECFYV+9LPS^<0R;&LJQ^48QQVD>BZ6
MFDX%:/5CU5_""3"QY^/CE")(KJ+&;1IGS=J!$ESG3"[D1*LPBX\!,Y'VFW[0
M82`A[$7T>5[>`Y[FZ'=EG^2Y/.8=O/OEC4]E&6JYA,FPG*%V#I$QI+(Y0\:P
M-$8^B[9Q:$'EL!&)%.=4I(K&H,I@,8BBC@/O*^BC:/+(C"\4D=T<R;&PK%SQ
MD2+&!A6LT5TGN1)97)Y"F\)CH2^F6?G!8D:*JKQ[0Z2)03U#N0=`\LBZ9MC\
MFR`JJN=SC9LL]RM2>@6C&&+(2LQ*;7X)M]D+L)M/'29+%2B>(XFDX>E17!-4
M\FNNX2$1:G0![;![-;<[,O,H?X3ETEDRN;-\,7FD4XIBS8DY1>=-'S+*.Q^*
M:1S-@^3?*(,444DVJ#1J5)(#%((@$.8'TA;)04QC3[&]TIV2+C4OMS.HQ32+
M@GC14F!9NM,8DW3,2$<OHEBSE$!BV2C55%0C=9^U%14KHR:0=$?%F7E=?)\A
M^"\`>+,O*Z^3Y#\%X`\69>5U\GR'X+P$>[DS#$L1CX"9V%^X>VQ"_!TF-QC9
MS`@!1M:#0/*(T*'HCP$@!,,1I077G"4`K'2(!4PI%"HBU``[5R]_=VU]*:@!
M9AB>VT77GB0"UCI$OL@M@+6YH%O\\)6M+?.K2P]H!)AB>RT77KFG;6.D2^RB
MR`EUS0+/Y^E6M+?.K334M`+,L3Z=HNO7-*RZ.D2^S<@"=US0+/Z22K=2WSZT
MTU+`0)S+!23$2<WY[!G0QHN3('MEPAH@*AX\H%$>?3N*)ZD\X3%+IJ"4%Y)E
M@I9:+OUS2MK&R1?9@8BG=<T+9_225:TM\^M--2P`LRQ/9077GZ=M8Z1+[*#,
M25N:!;V/TZUI;YU:::EH!9E@:V@N_/`@EK&R1?9`;"6MS0+1H[)6M*>=6EA[
M0`F6`T[7?G6TK&R0>F!(0K5H%.Q8M:]W;7N&@,S!Y)DA'3`&(Y2U,PS)P!2Q
M3Y*XJ^2R2H*&*2&C_7%+KC"8ASB(^<HH-3F!YC,L`K47?8`B/P;)"-"@H8>P
M&E1[$Q_T]GE"H!IE@6ZHN_-O$:1LD/I`<":@`T&O8U/2G?V4],6H!IE@2^X7
M7F`H)J1TB;V,'8GM`K0;NQBI2E;O-I6\EP!YABG?<+OUO5NI&R)O8>>U+;6@
MW_T<K2E;O-I743N!"PF6"<<T$W-E`K-,XAX7)@(%(B\.:B8,$C5MCE:`!`$?
M,H'KB8&!<>98$ON%UZWJW6QTB;V'G]2VUH-_]&JTI6ZA*5U$[PKOU#;*1.__
M`,TC)_DS^`CML=X('<^29-<9EWKO*D,<C,ICAQAK-1[^$E\4YY=P90\@P6%=
M1%'E3%4:O54E@K1._1ZPDECVVL*WWESX'^`8GM?A$G+3D%+9$&70.T^58#/0
MR[I@::8)1.3K1VVA6!9AF<L@B$@LY35%P9LH02].IK<.:V*E,XW<<8CN(]@X
M#/7.=-W6(X[C\TM+,F_3:ZPT$V$5/3$>XFW2<]&*D<M&J*D@#%%1=(!3`##S
MSR/>Y^!RYN:OASVVV+<>[KCK2TVB-G[?2MKUFTQ>.M:QW=L3,=(?9'T9\7XG
MZM<?QOTRVO(\5@YO?<1&PFN\R;K!3%DMY%&\_P`)GQ;;+CP4MM[1-,N6\8/>
MOCQW^_:(4TV1Z/\`8AQ`Y9FDYUA9+$,M]=D<HQ&5V]D0@]M9'#GF?.\FGXN>
M)C\3N!D*6'3F&/<E,Z;13-=(B+XAS.#&,<R:<IV?D/$[S:X]U.;'A]RD6[,E
MZ5O76-=+1%ITM\XUG3TGJX+Y)]'OJ!XYS^\X"O';OD?P>YR89W.SVVZR[7-.
M.TUF^#);!CG)BF8GMOV5B\?>KK68F>G/2GB>`;:MMVX?&-WH'=>2W#WDS+>6
M2''6+9K^+B.9IQ$>P@U(N(F)Y#3CVL`0AY`0;'DW.JZ7(9THNJIL-OOMEN[3
M7:YL62T1K,5M6TQ'VZ3.B'<OXOY-P&*F?G>.WVRPY+36EL^#+BK:T1$S%9R5
MK%IB)B9B-9B)B5M@>HB(!8[[;>]@^#TPD`*U;!3V0*U[J#7TIJ931/(THT()
M"FYLHGLMK'2``-YVZ91KRM`"]T0!KW>=6EA[0UJLPQ.^C1+S8@?6(41BY+L,
MNDQ%,#&&/'2`0>$J)C$`/.KZ0X%!<698GT[1=>N:5ET=(E]FY`$[KF@6?TDE
M6ZEOGUIIJ6`$F6"FG:9WZYI671LD3V;D-.Z]H6S^DDJW4MJ>ZFFI8`288J:8
ME%WZYI65C9(OLW(Z=US0+/Z12K=2WSZTTU+`"S+`]EHNO/T[;HZ1+[*#,25N
M:!;V/DZUI;YU:6'M!`VF6`OGU.<"\&)P$T5)D`P*HHV>>:/3`PAS!:A<82=H
M#;:8`!>$RP&G:[[;:5C9(/3`D(=[3L[%B_Z.WR#0#QEAY7?=7^C9*M*7=W*5
M[N`!F6`5[7?8!A&D=(CZ4%1'N:=O8B;_`$]GE"H`S+`MPB+OS`.)J1LD;V,'
M`FI:T&X:-3TI6O92MQ:@B9S#%-)P4W-E%)Y)"<`C)+N!W)+")+6!`5`2-3C4
MH&N&@`)A.03`M/,,4]03"[];U;Z1LD;V'GM2VUH-_P#1RM+:W>92NHG>`>98
M)ZEQG?K>K?;&R1_8>?U+;&AK_P"C5:6UNH2VNHG>`:98DU+A=>MZM]L=(F]A
MY\%+;6@W_P!&JTMK=YE*ZB=X>;B78E27*(NQ$I%RB`1LD>HI`^`X%`K,]_:P
M5I0#7>;2NHG<'BRF6`,6HU=@!6J50\,D@III+@8+>13$!#DS]EI?X-`\\@""
MH9AB%U1=>:)@&D=(CZ05@-00:"`]K<U*=_93TQ:@#,,0KVNNP1#^CI$>T!,`
M]S3M[2C_`/(0X"LFQ9@/NCGQRB(E/M!M&8!$#%$0-N_U6"`B!@`P5`?1`!X"
MU_`<\-I)O:[<'H*V:PK,Y#)XW&Y#IPV@CYZ6^;_+5$(XL7AN+"9[KRV'OH=1
MLVD61!*L<AT#E`#D-02GX!7LMMYT[[8;@FS'"\YW)G<A%GF<:Y9R&)3SP7*<
MM+Q$ED8/3QFWS&177;SRA7D@!U1UI9^+IR47*H&,%H,=RV'F=S<I78!-"FG@
MF$I&!WC&3QJ@'+D&?'$2HR4.T5.02JA0P`)1&H`-0&@2#XFV\7`;'U/#1"GA
M<G7^=%_@\G7@-EXHU]0_^2I3\#X`\4:^H?\`R5*?@?`46#IZV74WAD\_8[N9
M03*V4[,0Q,71B=OI-KCRV>YE+;K97C`LGNW3^86G<JG53N6CMZLO-1K!J*<:
MNV2.[,N#0>]&W3_G^39M+1>[N[;XLSEN4O<CQ+',A+*8S$2<HOEILGQM;&BX
MS(L6*2;[.%1<-W"8N4E3F$QBJ.53'!VQW2+A>(YMC>8P>Z&Z\="1,3F$=DD)
MD#.;ERS[S+,:RC%6TLUF5V3!'&WC%#+`%32;*\X$7%I&$A62=0;3?H0VD?+E
MDG6Z._<N"D@_E#(DD'[J%2DG,I!R%\,S>XO*IPJ4,[@=-D5LH55J02D%0XH)
MT#WFNA?9*4)%NFNX^_,+"Q;AQ*+-&$V^/$OI,5DUO&G3EYB3E1*1;NFB"I5D
MU2`1PR;*E`JB!3<`_=E^E/;O9/+HS.('-=ULG>L8)"',XSAJ^GG+B/;,9E%%
M'QX,<9R01*:D\NLFT455:-K$2MRHIIVF"WYLEB".FK)55XB\>@N+-JO%2R"[
ML&I"J.1;)+,2'7*W3,`J"4!`@"`C2H<`M\4:^H?_`"5*?@?`'BC7U#_Y*E/P
M/@#Q1KZA_P#)4I^!\`>*-?4/_DJ4_`^`/%&OJ'_R5*?@?`'BC7U#_P"2I3\#
MX`\4:^H?_)4I^!\`>*-?4/\`Y*E/P/@#Q1KZA_\`)4I^!\`>*-?4/_DJ4_`^
M`US63:@_E/,?=JC3NBY,1_FI.\`9U#]W@-CXHU]0_P#DJ4_`^`C#>+&L,W0V
M^R/;G+WDE'0^3LDQ<N48915TV3AI&/ER/VZ<K#2#$!CWC1%05%$C`D-I@$IK
M3`%8\XZ+]I,UW&-N3+[F=23+)'#5%E#Q;7-,I0QB/>(89^*+Q]&8PMCIVCB0
ME88KMR^!36*L[=+.K2*D0.@%LMOXJ/P?&\?PMJ^R27:8CB&)XPTEIV/?+3<H
MV@XY2.1D)91"*9I'D79&X'6,1%(IE!$0*4.P`KSOETX[$;Q[FXWGV>9)G4)F
MT'`1D!`H8Y,NH`2M&TM.NH]VW:^!N'PR9YB?$4UDE"FUVS:P`,F%P,*+Z/ME
ML,Q/*,7D=RMSW3+*?FL:3TEFZ43+R2L;A4Y.K0,"I(9'A#A<D3D<GDCMBFF8
M^H@U$C&..W3)IF#XBND_ISQ_;0,48YYEB,9'HYPJTS)X3'G[V(A,G6;I90P1
M>RF%NX="%0>1*ZBHF3J@_5<+ZA%B)"@&W@NF3IZQ[<S%\QC,SG6N68SE$#(Q
M49HP;=SX[X(9H9@)BXJC.D-DT=#FN;@N`ECR.V[4$FBRZ?`77B)1L$7'@)'P
MCR;?M"+E!#V,OH@S$!X#GTMT/]-\UD63R^-;B[SPT_DV6K9G/#A.82#)V5V:
M2R6;.U:A$X[S3*-0B\ZB6"0")]*)@8%,!'0%1R#T1Z7]@8!ABOB65Y*DTQ#'
MHS&X]W(1T#&I%>PNZSO/HR437+A;5&/=L<[FU&R;-OI,2J';D!#FD$%"@WE>
MDSIN=9/).3YSE"B;]SF:4OB94L<+S*\PR?/LF*[D4<+3S`):/;Y9(++K&?:Z
M;*3*1:J*+(4`DW8'93:39B3S.8VWRO),I=[B&PZ4R0CLK)PQ3%`\P#";AX_'
M\=BV,1%RP.%@;MFR9(],J)@:ID#4J$.XGTI]+6-RF)RD=NAEBGXL9%MWDD%&
MQF01D+#NY7`\O=SV$M)&+Q_'F#2>@V3Q@NQCH]<JJ#1,'8,P27,91,+Y0NY&
M"Y&X3:X_D\9..5HTLRBWB%#R*RT.9T=B6522:)K'5C3/DS(@N4!2%4HDNN`0
M`'-XHU]0_P#DJ4_`^`/%&OJ'_P`E2GX'P$>[DRS0(C'ZDD/.W#VU(%(B6'SC
M9S`@%:,AM+7O$:%#T1#@)!"5:#2A'_:)0"L3*AZ84@"HBR"GLQ:U[NVOI34`
M++-#6T(_\ZRE8F5+Z<6P%NN9!;3FBUK2VAZTTSV@%E6I[*$D//T[;HF5)[*+
M,"W7LBV4YXEUU+:'K324L`)*M3V6DD/7-*VZ(EB4UN2LOO9%TZ<^G==2RBEU
M-)6P$"<LT4E!M(_`3,&E+XB53&CAPCIW"HR*);1>DOK33H>^W24L!>25:'LM
M3D/7-*VZ(EB4UN2LOO9%TZ<^G==2RBEU-)6P`LLT-:($D`OTZ71$L2FH#02W
M7LBV4YTEU:6T/6FDI8&"RS0UH@20\ZRET1+%].#<2W`9D`EIS1:UI;0U:6'M
M#(2S0:4)(=MHA6)E0],"0A4!9!0?70K7N[:^E-0&7@LDT3C9FB;RA\QS17UJ
M+?G#US)I,XWZ#0P$5J/G%-10#>F`#5X!Z#+-`K4DAV`(_P!$RH]P*"-`!E4>
MQ,:>7L\H5#`RS0MU22'FWB-(F5-Z0%Q&@%9")OYL:E*W5+2MY+@R:6:%`PB2
M0&S4NMB)8_L8.A-:!&1A/4&9[:5NJ2E=1.X`TJT)?5.0\S4NMB)8_L7.WVV,
MC7UY!2VVM]4[:ZJ5X(H^5:$CF@B20H5FF8;(B5/YI$79A`H)LC7&HP4H`5$P
MBF`5U4KP6GE6I+[B2'K>I=;$2QZZ7.WV6,C:E?#U+;:WU3MKJI7AXNWS5=NZ
M;6ORBJBZ0$X0TJL!1L?)F,!"M`!8`%F<2@`^N5):(ZJ5X<CMJ?HL<(V^9[AL
M9'?W<[*F>X.W4!B3EC$XO^*47"S.//95[%YSC<9`J+LXA1HZ-(*L(UB5O$MS
MOE2IHF;F9H(`^,,VZ4V0VVQB2<9W*9?'2?4WO=GCN+:8]BN'1D<XS".WMCDH
MZ")((8J+E>#5.1%0.83<N"%5=.457!EEU(=R&3-DP[;?9LNN.-UDCM_P=8C3
M'N*1I-HQVF8Z=)G736=)T?2'AVRXW9<ESGBO';**[S)P.SM&?3=Y\EYMN^'W
M.2,E,%]YAI2VEYBU*=D6[,<7K-HB76;?O"Q$]3S=1%2HC+8+6X1=@-?_`%_$
M1&IO+]<=;/,[3YV_EX?M_P"F3:OTT\@B(TIBTZ?YMR/\7_V[["!]ENV.ZD'N
MYA>19XWV_B-P]FI[;0L_-O,7D%F[K)G$P@HX;13#(9="209-7Y3KH.#H).""
M*=:"<2YO&<OQ]=];/FRTQX_9BL=]\?6>Z9Z=M[?#YZ?8C/G7T[\NR^*X.+XS
M8;K>;S]8VS6C;[7>?=I&"E(FTY=MA];1,1%>[TGNTUC6`)WI(Z8I?%,7Q9GU
MAS+$F-9QA.>-G3R1C9A-Q-8YM-MOM/+KF9OG)4VRV1I;>Q\D4Y#@6,=K.@0(
M!%#VR#]>\+_VK;_RZ_V7'_\`=1]3?]0<O_W7-_,7ZZ7I'9W:G:O:_8+%MW,>
MW`E<6ACPC!XP;-8N0R1T4SJ=?O&N+Q:KIE$%TGBJXLF0$9,6Z2A4$D&R&DC=
MP<OQ>YRUP;?<8;YK:Z5K>LS.D3,Z1$]=(B9_)&K`Y3Z>>=\)L,G*\QP_);;C
M<,5G)ER[?+3'2+7KCK-K6K$5BU[5I$S,:VM%?68A9AQ,,0?L`-SA!*BY5-?%
MR9-%$Y&0:RYCLP!L@47)0,<XE(40.!A`4U+=BAQ>279J"`$!Z81,0@AX7)A8
M=3D:$5JS#1,7Q%,3`>T2`!Q-0$E;`R25:'LM3D/7-*VZ(EB4UN1LOO9%TZ>(
M)W74LHI=315L`+*M3V4)(>?IVW1$L3V7DK+KV1;*<^G==2RBEU-)6P`LLT-;
M0D@%X)B%T1+$IJ`T$MU[(ME.=)==2VAZTTU+`U[:69B^?T(_J8&)NV'EB]BB
M*5MPBR"@AKEJ`]I?.K2PUH;`)9H-*$D.VT0K$RH>F!(0J`L@H/KH5KW=M?2F
MH!XLT^YR'=7^B);R5]Q=]/\`M[.`P,NT"M22'941I$2P^E!01H`,AJ/K0TIW
M]E/3!4`99H6X1)(>;?6D1+&]("XFM`K(1-7EC4I6ZI:5O)<"-G*M").`$C\=
M-Y)":R)E5`\UW(JFL%-D8JAK6I^PM1$PE#TRA`,"TTJT)?5.0\S4NMB)8_L7
M.WVV,C7UY!2VVM]4[:ZJ5X!Y5H2^Y.0];U;K8B6/71YZ^RQD;4KX>I;;6^J=
MM=9*\`\JU)?<20];U+K8B6/72YV^RQD;4KX>I;;6^J=M=5*\/-Q*M2I.`$C_
M`,Q-<!I$RI@];*]`UHE9"!P]HGI2MU24KJIWAX,I=F#%H-DA0&J7=$2P]A$E
MJT`K(:UY4U*=]24KJ$N!6,JT"M2/_-$P#2)E1]**P#009#=[`:E._P`VGIBU
M`\5:^H?]@B'9$RH]PF`>T&5![2C_`-GE#@*P[%F`^Z.?'"ZAMH-HS!<4Q#4'
M=_JL$+B'`IRC]00`0X"V'`<\=J)S:O-^@?9K$,^>95$8F\Z;]GF.0S"FW>5B
MVC21N&XJ(/2N9W"9."500D69!364260.4`.F(@)3\`@V3P/I7VRW;/F.![A;
ME3F=.X?+(16`D87)9!-TV5G"2>2+C#,,`8O#2C2?757E7!1UW<BY,O("LY`A
MRA;K'LJBIC<[*5V24\":>"82D8'V*93%*7ER#/CB)496&9+'()50H<I1*(@(
M`-2B`!(/B3?Q@!TY"GAIO^%2G?S1?0Y.O`;+Q-M]SD/DF5_`N`/$VWW.0^29
M7\"X"B2_2_L#E^[#3/3[C;B3>08KF,AGV*8I`2,>VBL.RZ*W7RO)IZ;(VQ?#
MVL[D9VN?34Y%.$YYW*MFB:[I@5-(X*``:;.^BG9[*EY1%'<O>7$LNR`F5NX%
MW#)M8URQ9O9?*)TZ#6$9X1'CD$=C<YN(Z/S+D5Y+2=)HK/1*#?3#R/T,;):)
MO$-Q]]UV<>61++(&>D9QYFDE#.FLBPDFS;`D6[2+382-&K>B:4;'$19M`08)
MD0`';B/2?LAM;*16=?CANSR^$<C.1R^0OG;3'81.#59/E7[L[;%(MN+`C&..
MUJX5%%E%.%VC?0;*&)P#$8]#.Q&3-T<@3W)WJR2.G$F$@BM'2*\GB<BT1A(B
M,BUHMDXQ.9BP9D"'0=IJ(G,;6*4"'!$B:10V\WT#[$3+5DR)DV^T:T1?)R$L
MV:O9!PAE#I.+7B!4R5.3PI^$D9=H[7!;T@+@Y6!0#`?L!9MITS;#;,[M8;)Q
MFZ.XDIN"R1R%]!XSN!*%GLEE8J90DC2QHI%WCK/+1C=5H#A0C=0['5;NUS(\
MPZ>+G"]:N0QJ"2BRY91%%%,ZJRRT#.I(I))E$ZBJJJD:4B::9`$3&,(``!4>
M`5A)MA`!!.0$![0'PF5[A_\`Z+@#Q-M]SD/DF5_`N`/$VWW.0^297\"X`\3;
M?<Y#Y)E?P+@#Q-M]SD/DF5_`N`/$VWW.0^297\"X`\3;?<Y#Y)E?P+@#Q-M]
MSD/DF5_`N`/$VWW.0^297\"X#6M9)OS\IZU(=JC2GP5*#_NI/0!G4/W>`V7B
M;;[G(?),K^!<!#.[VV&V&YS)9_N$C))L8S!=P\0<OACCMT&6+[@,H9+*5EW$
MA".R(`V)CK5RFH(@B@HW*JH4VF42A`&Y'1ULEN+NP^W9G\VWZB\LGU%?"86)
MRW*X_$HQ\.)GQN06QS#UX)Q&F5>P8NUG*1RN$S+.5G-A5"(G1"U>W\1&8+CF
M/X4P=9))L,0Q#%,882<Y'OG$U(LX*/4C6[V65;Q3))20<)MP,L8J*13*5$"%
M#L`*Y;[=/O3ONYNCC6;;C9+ED+G\3`1<!CK2$GWN.N18I2\\M&N&3`L6I('D
M5IK(#::R1@.*Z#8"4.F%09T%T=[%8?C6488;.]TG*&4%VM1R!;*$HJ7F%XK#
MYW(#8W!KNYO`'+H83)I;(7K`J*@F$C82Q\<9J@31$-'%].G29C>W33$&.Z<L
MQC2-<^?0V6.I;%%Y9I`3BK1#,T(I_)8@O$_B^P>1*IW!R("#9ZLNN=0C@$SI
M`Y\>Z=>F>%W-QK*83-I5',<5RB`?Q<0B?'4G24^I"F0*Q$B.))3S8^5QD(8Y
MVZ:Z8F8).F[4$F*KE$P7<AY)N$5'@*;_`+&;?NBI00]C+Z(,Q`>`YY'Z*NE?
M)LDRJ0QK/]UF619%EBV9Y$3!<UDD'R;\TCDF0&0(E$02CJ/CT(O<:*9I%K<E
M#P\`F4P%0*=<'I-=.7387`,3Q&1R^:A6F)0;_&H3*2ML<B9A)*3W6@,P.Y9*
MGPI*%C9..W'CFR$89DU;EBWJI4VQ$W.D(`VUNF'I2>Y$_!3<&<444E<M5E,8
M0?X\DNHLYA<C/F$9(OF^(DS`P),-P)-W)%4>Z^@^1Y@PH-F14`E/I\V@V3VD
MDLUF=J,OG<N>;A&PZ8RO5<1TDS"AYCPW((YCCF/13*)8395EM!%N0D>!4!!H
MDF`*`(0(PZ4NC]-LR%ANO+@R8IP:C06+[!DFK=%NMD;*#%F5K@Q6K5L5BXD8
MR.*D4J;=B+YJV`J3EZFH$Q=..T?3[@>9.LHVGW/FLZF$,,5@)"/1DH699$A9
MR98SC)^\;8WCC)R*38T<FA$ZJAD&C(QTD`TS`!0NIXFV^YR'R3*_@7`'B;;[
MG(?),K^!<!'NY,HV"(Q_UJ2&[</;4G9#RPT$V=0(`)J,AM(`]YAH4/1'@)!"
M4;#3UJ2[1*`5B)8/3"D`5$606TU@K7NH:OI34`+*-C6T2D0NLI=$2I:7BV`+
MKF86TYHM:TMH>M-,]H8+*-CV42D@O%,`NB)8E-7E`+?>R+I@'.DNNI9:I=32
M5L`)*MCV42D@OTZ7P\L2FKR5M][(NG3GR774LM4NIHJV`A3E6RDF(%2D0N8M
M!`#Q,JF(<PX1L$P*-2B0"\Z2\1*&G:I<(:2H$!<25;'LHE)!?I4OAY8E-7DK
M;[V1=.G/DNNI9:I=315L`+*MC@002D@OTZ70\L00U`:"6\#LBB2G.DNNI9:I
M=324L`+*MC6B"4D%UE+H>6+2\&XA<!F0"6G,EK6EM#UI8>T`)5L-!TI+MM[X
M>6#TP)"%0%E4*:H5KW4-7TIJ`S,'DVX1TQ4CY2N8YF8!2CW[@"@.2R?F'%'G
M@35)W&3,8AR#V&33'S`!YC*-@KZU)=E1[(B6'N!01H`,JC73&GEJ'E"H`RC8
MMU4I+S;Q&D1+&K8"XC:!60B:O+FI2MU2TK>2X`TJV+=5*2&R^ML/+'KI@Z$U
MMK(;Z\F:VE;KB4KJ)W`&E6Q+ZI20V:E;8>6/72YRZRQD;4KR)[;:WW)VUU4K
MP1L)5L6.:"*4B:UFF<;(F45J!$71AM%-JM>(@Q/:`"83"9,`J*J5X+#RK8E]
M4I(=/4NLAY92NESMUEC(VI7D#VVUON3MKK)7AXO'S59L[;'3D0!5!T@<P0LF
MN`!8^3.8J?(G(N'M,]I:&!2Y.E052O#DWMC]%%L_MRVW$9/MTMU\I9[A8!#8
M;*L?Q4@L:BX^7QQ[(OF6;P</BV)L8>*F6;OG%F35B@WC&JS]71;Z2C))`3UC
M1]8?T39WT^;L.-R</W1W+W&V^DLKSS()3:%GC^&XU&CD>X;C>*=?YJ=FJRP?
M&&!L0=9>A!QI&RO-N8Y=1=VLY.9(O$#W_CO*4\@Q\SML^;)QU:33\-$T[>ZT
M;B9RSW=D1-9R12L1,V[;6FTS$1$?67BGUD\%W'T@W7TUYKB>-VGF.7<5W$<U
M>FY]WVL5^)QUX^L8?Q-K4S8]E;<Y[WI7%&;#BKBQX[6R9+VF6E,\13456VHW
M;21*58YU5/F[(0A2`Z,<YS#N51,A"FJ)C"!:=M1#MXSM.1_[+NOSX?M_Z9%^
M[PR-)_7W!=/XG)QZ=OSXR/E+Q&>S,QBD#;#=6Y?2T2BKMP`J<X+SE!)7<L`,
M#GML&M#`4P@/FB)6G(_]EW7Y\/V_],IB_AG3_P`_X+X?O>2_B_\`MOV3^SUC
M66Z@L9A)21A)AIET;,1;M1A)QKM_@!'4>]`MYFCLA=P1!!<A'R0F*(@)0-4:
M4$22W:>`?4G?[7'OMEX_S&799J=^.]:89K>DZQ%JS[_6)TGK]D_+IC6W_@>.
M_MW\AX"+UGK$QR$3^]]8GCM?A/K'Y_WWOB>[6.[D;C[68]!3>0P,B7,Y651>
MG<8*Z>J)H[9;CME&D4P"6RXSU\=.9(HHGR)M)FDY6$R96YQ3IW?T\^HNSK3D
MN3X7E=EQFUR>YESY,>+LQUM6^"LVF+Y=(MES8\<3-=.Z\1K$S#S/Y-X+QG`\
MMCP\EPW*;S=\?3!BVV/\?$Y+QOMAN)FT^QM)BM,6VRWUC-$]U:QVVB9U@P_T
M>FTVX,IND]D=S,_@`R-MN_@KV/:PT<]9N&$SO_D6^S*9RUG-X4PCW&/X[GF9
MJ"$25N6(6;<P@[7<$,HFWP^/RY<N/)&:W=:F:]8GXS%;=-=*TC73ITB8^V9U
M<M\OV''['>[2_&XO8P;GC=KGMCC6:TR9<43>*3;/N,DUFWWH]R]+QK,>W2L5
MUNMTG].>&=+>-9OBV)95E.7M,QS6,R=TXF\<:,'<<[CMO-N=O$&SWP&#C$'<
MN[C<7:/)-ZY3*Z=OUW3A>BA5S!GHFM224;'LHE)!J:5M\1+$IJ\E;?>R+ITY
M\EUU++5+J:*M@8+*MCV42D@OTJ70\L2FKR8EOO9%TZ<\2ZZEEJEU-%6P`LJV
M/;1*2"_3I=#RQ*:@-!+=>R+93G"75I;:I6FDI:"!M+-3/7P`E)><#(P`,1+!
M:"B*-H&`6HBF8.8"X!`HEH:OI#T!>$JV&@Z4EVT'MAY8/3`F(5`650$`5"M>
MX0$.\HT`\5;?<9+NK_0\MY*]W)5K_P#/P`,JV"OK,EV5'LAY8?2@H(T`&7:(
MZ0T\M0]4%0#2K8MU49(;;Q&V'EC5L!P(V@5D(FKRQJ4K=4E*WDN!&SE&Q$EP
M,G(FL=R0B*<3**A0KN1.)2BFU5`Y@!J8*`-;A(6@&4(406'E6Q+ZI20V:E;(
M>6/72YRZRQD;4KR)[;:WW)VUU4KPR>4;$OJE)#IZMUD1+'KI<[=98R-J5Y`]
MMM;[D[:ZR5X8/*-B7U2DALU*V1$L>NESMUEC(VI7D#VVUON3MKK)7AYN)1L5
M)<!2D:E37`1")E1+5,KT#"4P,[3`(LCVB`T,!DZ".JE>'BSE6P,FHZ4D-&J0
MB(0\L:MB2U;;6A[J\J:E!-=<2@CJ$N!6,HV"M4I'S1,`TB)4?2BL`T$&8W5T
M!I3OJ6GIBU`&4;!7UJ1&@B'9$2H]PF#LHS[0\W]ZGE#@*P[%F`^Z.?&"X`-M
M!M&(`<IB&[=W^JP?.(<"G*;R@(`(<!:_@.>NT4UMKFG07LSB>X9,U@L.<].&
MSS3(IIYM[D*+5@WC<.Q2Q^W<9!A\O!N$BOVJ9T%3MW*)R6JE`2T.`.G9.)Z<
M-MYYR&WF0[@9//$4SE9*)?X_E\PYCU9>6Q9+.W+2,:8;'B,B$Q!L2RCQ0JCY
M5ZHHH\54=.%E%`GW'\I8RVYN4+MH[)D")X)A*1BR>*9%#J7%R#/SU(C*QK-5
M0A@4"ABE$HB`A6I1``<>39YB.$I/,IS6=C\.QF.8-$9#(LJ<)X_!L59*7;1T
M<DZE)0S5F@H_D723=$IC@*BRA"%J8Q0$-.YWXV791CV:>;I8,TAHUS%,I*7<
MY)&(1D<\G55$(-F_?JN"-&;N:61.1FFH<IW1B&!(#"4:`\FV98V])'J,Y,KL
MDM'*S$4=JU>N"2D0AR6O*QQD6QP?1J/B3>]=*Y(O,)U-ZX2H4"R'HHZ2\IS%
MOF/XW9U&3>Y^4Y#GT(V@<R%LTS!;()B5W+R1OAK)6$>*R.//Y'()&6=)Q9AO
M3DG*RB@D6,800CTE=(6<P65N83=7,'L!&+R:3R5Q+<&+<M=M&49D:F63\)$3
M;""=FPV+93Z!5URJK%48@T1(FH@DV1(F&U:=)/2FURDL6;<'*U9M5>`D)3"B
MY#CT6.0OHV+,QQ61G,<@\2B7TBZ1C7X"W/:4'ACD65!=2Q0`3QW31TRX;N=,
M8LVW7=QDA/[(9/`R^S\U(04CE;O&9PD=&3VY1V.11CV?-#'1@A%V)V1X=U)G
M6=NP56$:!O&/11TVO5TX]WD^Z&7N&4.RDHF/E\E=RSF!82CER=IDT.BUQY%X
MT\5D&:XMGHW)IBD=%H*2*0)$#4Q72'TA9#D\4MBN63DJ\Q&7DWLAA,#E*,Q!
MRDHQ4CB3Z&;XY'Q2T@]2^$F"4H@95N*B:K4JX^<@/`.+).BWI[R;&<'P?-IW
M<>1RB(PJ&Q"+RH\_/1^;Y&ABI\QDIJ7.FY9.DYA],OMQ9%Q+"H@Y(<C@B9P!
M$3%4!LXM]'WT\^!-TG60[FY[$/FLH4%'KU@\A)>,E#R8QY5DD<:.6429,Y.B
MQUE5@F7#=L[D^=<LV2K8.A;=ZW;-T&R;:3$C=%)`@C%NBB)$B%3*(E2;)IE$
M0+W%*4H>@`!V<![>*)>YI+Y->_>>`/%$O<TE\FO?O/`'BB7N:2^37OWG@#Q1
M+W-)?)KW[SP!XHE[FDODU[]YX`\42]S27R:]^\\`>*)>YI+Y->_>>`/%$O<T
ME\FO?O/`:YK)I<_*#RLEVJ-*?!KWT&I/_,\!L@DTA$`Y:1"H@';'/`#M[.T1
M1``#ZO`0=NV\V(W<V]R#:K<+,HL<5W+;-\.=-6&6.<;DY=:=D7L;&Q4-)1KQ
ME(*R4I,0CEJ@W1,<7JS1PV%-4"+I<!!.X'1=TY9]NPON-DTWNNWW`R%DNI%Q
MS?-<K:L4BQN+L\-EY2"P]XS<1SM0\*^,$@=1LY1.XDCKK%UE$CD"U^!0L5@.
M/0&#Q/XQ/8G#L1Q3%XIY+-7+N5=QT#'J1K-Q).$F+1-5\J@W**I@12`3U$"%
M[@"N6^FQG3%NONEC.4[JS[^)W(80$-C^-QK;,G>+RJL:M-9"E"GCX=`4WZSQ
M_/SZZ:"J0:BSI%$I*G2('`:#$.FGI>V/ALEQ]SE<TU99`MLL23/N#.1R,@U=
MX7G;^?VM!.3=P$2_*M,YR5RG&IN%%27I"RBRMT4"()@R`Z;^CUQ#1#&/WDD&
MJ*T9E#J$DHG-<((=7&XI\X)+I8ZF3%U8:-Q?"7KE^F<D6W;M&2[YT9U<N)3I
M@ZXKISZ3HO=K$LGB\U=M]Q\`REAX)C;7)8%F[:Y*[@D5G4*ZQQM"-I$KW*XS
M#RO%&E$UBMF"Y&0-V)WJ"H7>B)-((N/`6TEV,V__``U[]S+W>L]H<!SW_4SZ
M-LZR/*W&.Y9ECG))S*ELXR9M@NXL@M(IR9YG+<@4%5I$(/'$:P20W,:M"6E3
M,C%QD(@FH5-JB)P>TML#TL'P'#,,>YJ>*CH"#<8YB^1HR.)0\RJVR#=.!R=-
M>)7+BR$&SD#;E1[5O&*QC-KX<_5*E'@W=:(D!N*]._1S(Y,\:'W'.Y=A*9>K
M*82EFF/`)EDH:;6S2+DD&\07+@2C&&Y,B]E"*.P733F2F=G%N1D1`)+Z?-L=
M@-LY+-YS9?-'6<O\^5PF9S99KD$-DR:AW1)-S"Y0+?&HMDWCRY2V=**(Z921
MZB20"S22)J`<(_6^CTZ>'!8XBJFZ1"12:23--BXC(9%)%-&59%0*W@\.C6Y$
M&\5+K,F9"%*6):'43CP:`Y=BX"T&V.T6V.SZ^0.<"QJ5B5LF)C:,F8Z4P[JT
MQ/%X;$8-DW*X*<J+=K%PB9A[SG644,8P@8"E"6_%$O<TE\FO?O/`'BB7N:2^
M37OWG@(]W)E4@B,?]J2HW;A[:E\V*?FMNSF!"XX@AYB85[3#V!P$@!*HB)0Y
M64\X2AVQ;\`"X40"ZJ`4`-8*^0`-7THT#(2J)K:-9,+Q(`5BWY::@M@"ZJ`6
M@7FBW5]+:>OI#4`)*HGLHUDRWBF`7Q;\E-468!?<@%EO.ENKZ6Q2M-,]H8)+
M(GLHUE`OTJ7Q;XENKR-M]R`66^(%NK2S35K324M!&G*)*2`G!M)`4S-F6T\<
M\(<HN5T1*)DCT.4I`>%U#"F`)V*`8U4S@4%A)9$]E&LH6_2I?%OR6ZO(TON0
M"RSGRW5I;IJUII*6@%ED364:R@7Z=+HM^6W5!F(7W(!9;SI;JTML4K33/0`L
MLB8"B#64"X""`&BGY1"\&PA=<@%HEYH+J^EM/7TAJ`!+(B`#RLH%;>^+?@(7
M`D(5#0[*:H5\E#>I&@,["I-)./F`$CYP(YAF8W(-W+X"6Y-)D%`ZB#^9*BLB
M)!*9$5$C)B%HH(>Q%!X^+(T$>5E.P!'^BG]1H"@]GK':(Z8T\M0\H<`&ED2W
M5:R@VWCYL4_-6P'`C;:@-U>7&E.^XE/3EJ`:61+=5K*#9J5MBGYJZ0.Q&VU`
M;KN3-;3TUZ=/9"5`/+(DOJUE!LU:V13\]VESMUEK<;[N0-;2M]Z=*ZI+@2,I
M1)%@U`S:24$K-(XBC'O'`&`$':E"*)`Y*J809&`*'/43I@`B*A+@5GED27U:
M2@Z>K6R+?'NT>>NLM0&^_P`/-92M^HE2NJG<&3RJ)+ZM9,;-2MD6_/=I<[6R
MU`;[N1-;2MUZ=*ZI+@#2J)1,`M9,;-2HEBWQ@'3%T`VB5`;[N4-;3TUY*>R$
MJ"20DDCM7"8-Y`IA*8H'.P=HI@)3K`(BNIRR9"^UQ$!%0H#<6@^>6H4HZ]\4
MZ8LHV?+EG5-N9%;);<8,;+(YQN3FJ\9CF(QGSN8'E6RSF(R67RELG$EBIQ/.
M0(1N==MS;XC5,#C>!#AQ]C]SOH2H/=3!]SP^EIV'D)_")W9F:?M\DW?Z>9T^
M526RZD+X8>7F'$`2;BQD%L7BE`-%N6)H\R+PK44V\G)(./)ZQH)PD/I9_HZ6
M.0YF+'K9Z8)9A+YID$Y&2,5U*]/S=DX8S2R2S8PHS>YD-)MU2"[`%2JH$$AB
M*"`B!+B]YVO/>*;GC-A[_([7#N,.QPXKTR8MW-ZWQQVVZX]MDI,?&)K:=8TU
MB)UB=9;%GK>VE+3$VF8TFOQ_+,2@+J,^D;Z$][MN%L/Q3Z2#8[9"7;NYC(T=
MP\=ZCNGU]/QY6FWV<Q[>"C8Z$S_(99^.8R.3M(=Z@W206&.=O;%DS)``59LG
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MXUTS6C]O]NMN622WXO!`MGKYS$XJS<R+]RD+MX_4=N'!A5*X,6VUJT)/IH?H
MF3V4^D5Z/PU-*E^^V`)TUN1MOOFBZ=OB)+[J66*W4T5;`"?30_1,GLI](KT?
MAJ:5+]]L`3IK<C;??-%T[>?)==2RQ6ZFBK8`7Z:'Z)@]E/I%NC\+].EV^N`D
MIJ@T$M]TR%EO.DNK2VU2M-)2T/!+Z9CZ)]-99P?Z13H^!%X#8S<1WZV]$1`I
M$"'O3_&$YT!*=R`"!R)"%IZUL.)0]P^FA^B9&G_ZQ7H_[0`>W?7`0],"8A6L
MR%!`%0K7N$!#^":@'_QH?HF*5_\`B+='_=7_`-NN`U[J]WC-:T]#R\`#]-#]
M$R%?_P!8KT?]@"/9OK@(^E!01I29&HB"0TIWB(!_"+4`?IH?HF0NK](KT?\`
MF@<1IOM@)JV`X$;0+,B)A'EC6TK=4E*WDN#S3^F8^B>9I&*O](KT>7&4>NB@
MEOYMXY$45',DLG[!D+FBADVAJ)B('\Y,+"ZJ93!Z'^FA^B9)?7Z17H_'3U:V
M;[8`I72YZZRR:-J7<@>VVM]Z5M=9*\`_TT/T3)+Z_2*]'XZ>K6S?;`%*Z//7
M6631M2[PX]EM;[TK:ZR5X!_IH?HF27U^D5Z/QT]6MF^V`'KI<]=99-&U+O#S
MVVUOO2MKK)7@'^F;^B<4O0)](KT>BH?42)_X];>@4QPYT@45&=(G0QF1K37`
M40,F(#15,3!Y(_3._1-MVZ22OTBO1_J((E34`N^^`*^>@1P0X%.G.KE4J9F>
M@E.<#7$$!-J)B8/4?IH?HF0J'_Q%>C_S;JTWVP`:V"L`T$)H0-70&E.^I:>G
M+4#_`.-#]$SVA_\`$6Z/^RH?^W;`1[A,'8(3/;Z7]ZGE#@)IZ8LJQG.LKG,W
MPN>B<JP[,=@]C,IQ3)X%\WE(+(\;G]T.J65@YZ%DFAU6LC$R\8[2<-ETC&36
M14*<HB40'@+F\!SMVER';O*^@C9S&=R([-\>PE;IPV@9Y).2&&+-6C%M'8CB
MJ:<B@XR&&E81=([]NDHW.=NX(H0Q5"E$.T`\=F\!Z6-O-V@S';N6W%G=Q&\-
MF4(6"72?3"Z,<YFXY?*[85"";2`.V<V=,TDX$PN';Y<SB2,Y>47*%L<=RE"6
MW-RE=&%REH5/!,(2$LKCLE%J&$N09\>XB;Y)$YR&!2@&`!`1*8*U#@&IU%8A
ML[N9M^_QK?E!1#:]">VSRR8-*NCPD:K,X'N=C&:X8S?O;R'.U>YE!,$SH$,!
MG)3:("`G#@*PX5]'ST;1T9-(1+?*\N@,QW*VVW3D6\AEZT]&265;2R.:2V&D
M1<LFZ:BD:R>Y0_.JW*J(J@V(43`5$X"$0SOT9G0GCXLV<EG^Z^'R2LGB<NW<
M*[NHQ4P]DCYVTG,3D/A.-.9PXDIV%2C&3@$]15HT*T0/ZR%@2CC_`$7='V#R
M'3M.8MFN=8JCT993N!F6WD?%9XT91$.MN.Y<8AF<1EC,8LQC8Y(2&)OV"K-(
MS(IETWB*HG,!RE"&<B^BHZ$YU21=2&=[MQR1<@%O+MH?/<9QYF1T[04=QN&"
MRB\.9IQ$<U1R4RJ48S*V,[._,JZ!RHN8YP79!]%KT.8IC1L@GLEW'8M\:;P3
ME#)<PRQB\@8MZQE&S?&7;F&+!Q<`S8%G$BMV3)@G'MVYCBWCBM#%2T@L6CT5
M]-.98#M+CDQ(9AG[/!=G\1VPBLH5G0D)+/,?A)_#-R29-DLDBT<_C'.9/DV-
MLIAZYO%-R9T=2VU4IN`C/;3Z,/I6VMSS#]QL;R_?EYEF`;F-]S(Y[-[A!*%4
MG6#6?3&#ET@QY#6QY5E,/>9:%%)5<NHHJH8PJG,#(8?1:]$L9D+?,RYAN@SR
MN5=,<6RB2@\_:P[/<<C6/A,9'$LG@&T8XC'[^4QK"6L8_4:)MY9RW9&JN042
M"B&Q1^B'Z/G0R2[3(NHI^^DD(-1S*.MUI+(WXG;1B#0TDH?(8J81?+9&F@9T
ML=RFNF#M07+0&ZI4CIATHVLP^,VIP.`P&)'(I1C`ED1(_DVICO'*\K+OYMZH
MH)``I$@>R2@)$[132`I1,80N$)!\3+[AD_>2GU^`/$R^X9/WDI]?@#Q,ON&3
M]Y*?7X`\3+[AD_>2GU^`/$R^X9/WDI]?@#Q,ON&3]Y*?7X`\3+[AD_>2GU^`
M/$R^X9/WDI]?@#Q,ON&3]Y*?7X#7-9(H/I0>1D^U1I_N*GN4GU>`V/B9?<,G
M[R4^OP'/W).ASI:QA&%S!\MDFW,)@>2XEF,@^*YQ"(QQZVPO>+<S>G',>R@T
M]BSQE^*3/<7=^143;(F:G(B1LBFH0J9]0(NR7Z+;HUF<NF\LDYK>]IDFX.8[
MF9>RNW5GUVC=UN;C.30N90&(PDRWD8E#$B8ID3HC6-*@LW8E0;.4@(X9MET@
MZ&[6XU"[983AVW./&RB6Q_`<"P?"H&4G5#2\Y)PN+0H0L9(S$J1%L21DW;-D
M0[A<$TP55$QP*4!H`4TZL^C[HUZEMU,5RG?F5R&&W08X6EA6+-X7<!?"II:$
M?2F1)Q#AC%ME`=O)%KD63+J,EBE-1X1+S36`408\#]'=TA8-B>X>WS'.]SF\
M5N#)=/\`)9D6?RW$YJ4<Q^W4QD#+;+&W3[(\.D%UL:SB9R5\P%JZUA?MU2Q3
M`Z#!-%D0&6ET/?1V,(/&DY?<9W)0#7`=X8*))D&?X26%E<'SEOE\#/JQK%.`
M80[&!V_<Y5-C#IPZ3*-CGKI0ZJ2RB*&B$A1O1QT2I]3\'OS'9]D*V^$%G[3(
M8Z*1W$@CWY;/0#D9%@ZA$XXLN[5SE.+&3=$.N+A7EU$VZB,>N\:N`Z51$D4L
M7'AR4GV,V_;R*OW,O`<E77T9WT?VX>XN8Y1CN3;B(YYD&:Y1F^3H8!NZ\;N6
M\YE2^2Y!)-CQ4>FZ\,9-VV[;(K="PIDXMK$M:F9%,BX!YYKT0="F1;3;9[;9
M/E4A'XSM[@;3;O%<D;9?BF.Y$^Q)ONSC<\=N>:90;)L1%QG[`D4`QR+-!J$D
MY9-"MSN*`#?-T.]`KO.LAD!W$G%WTCDFZ,UDF%(Y_B:;$KF7PZ<A]P8B3%I`
MI9>TB(2$W!E73M%21**:DN)GAU$T&";4)HZ/.F3IBZ=)'<.:Z=\QR//)'<M/
M;1_G3F0RS'<L+HQ#C*W4#/HHX[$P[:++DCN<D5C%(4K*I;&:+=!,$@"V3/?_
M`&9D#QZ;#<C$'II9S`LXP&L]%K`_=Y4_<Q6,-FITW1B++9'),U4&!0&KM5,2
MI7"%.`D[Q,ON&3]Y*?7X`\3+[AD_>2GU^`/$R^X9/WDI]?@(]W)E"A$0'P?+
M#7</;4OF1ZI[;LY@0O/0?,3+Z)O0X"00E2B(!R,H%;>]@J`!<*(=ODIK=ODM
M-Y!X`+*E-9[0E`OL],P5"W4%J'GU]+9S07>0$S^I'@`DJ4XD#D)0M^GZ=@J4
M"ZO)>GKZ6SG0NKZ724]0/`!)4I[/:$J6_2].P5+;J\A2^OI=/GPO]3I*_<QX
M!$G)@I("/)292F9,@M.U.4Q1<KH4,9$7`G*"(/`U#:0`724`3C8)0!825*>S
MVA*EOTO3L%2VZO(TO]1I\^%]?2Z2M?8QX#))4I[/:$J6_3].P6+;J@S'SZ^E
MLYP+O4Z:GJ!X#!94I@*/(2H76>F8+%$+P;#YU?2V\SYWDL/ZD>``E2C3VA*A
M6T>U@L%+@2'M\ENKV^2TWDX!GX5*`6/EZHOW0_C?F87(@,@"5F2R9!;'52G<
M@*@JV$@D,B*J`HB%HMFU-$@/`94H5]H2HT`1[&"PUH"@]GE$=/L_TAY>`#2I
M2W>T)4;0./FL%AK8#@?-IWB;E^SRWD]4'`!I4I0./(2IK-3L*P6$3:8/!\SU
M0GY,;?+J)^K#@,GE2DO]H2IK-7TC!8UVESWI*>FOY$;?5:J7JPX!(SDP28-;
MF4FJ)6:2@BDU.X`]$'BE"*)N'953'!B(!152HJI!<-X<`K/*E)?[0E3:>KZ1
M@J:[2%^`V>KU.0&RGIM5+[H'`!Y4I+_:$J:S5](P6-=I"]`;*>FOY$;?5:J=
M/3AP`:5*43!R$H:T5`\U@J(&TQ=AYOJ@/R@VT[]1/U8<`DD)(#-')`9R)1M,
M4#F;&13"PZP7"L=RT(0HZ`T$5"5N+V^<`<!2'Z2;HHP7Z27HSWDZ/<^F\QP>
M*W.80KF)S+'8LCM_C&88;D4;F&&S2L8[,DVFXEIDL"V%ZQ,JW,\9&42(NW4.
M1=,/S%?1W_Y/GIDPS:B9=?20O<IWCWMGLF>^%PVSV9Y5ANW.!8E&O7;&'3:R
MS!O$S>53V3M3)OWRSLB#=B!DVB*(F16=.0NLY_RN_P!`TS*].]Q#/&2<:R;R
M<DH\ZFLQ:IQL8Z=J,&TE(G7G4RL(]=\@LB1=42)&5;JD`PF2.!0@CJ=_RY'T
M+NR6P^;;L;9]->_&^F60*DE#8QMYM[U&9NZR;*,QBDEUY3%X$O-2;1UEL"T9
M.W*D8J0JQQCUT3`50HEXZ_\`0GPO:>=_5'BN%Y+DMKP_$UW6++GWVZK>VUVU
M*9<<5ON9I?'>F&V6V/%;)6T33W(MTB-8P.3W%MKLKY*4MDR=LQ%:_I6F8GI&
ML3K.FLZ?'1X[/?Y?SZ"?-=J\8RC<3I<ZC=J<TRZ`B)B>P3*-U^H2?RS;-ZZ5
M1<!!N9+%DF^,2DOR[DJ<F"3>01:G36*F<FB98V9YY]'^:X?S3D>*\:W&RYCA
M,>\R5P[W!FQ8=ON*Q.ON8J;G<VS4PS,Z8ISV]R].VUOO3,13M>0QY-M2^:+8
M\DUC6LQ,S'V3I&FOSTZ0>A?\N9_E]#6_^&_466ZST^7=2Y;;^6]/7'_-LYGS
MJ^ETE*^QFI%X^E?G$_YKM_\`OFR^S_2/MA>_';;^%/\`)M_8;[%_\M1]`7F4
MZPQK']L]_EYN43758L9#<??V!Y@C1)FN\L=3\?&,A.S0>7J%U+RE25&@Z9J:
M[EO`/*^$XZ_*\CML==ABFL7M3<;;+VS>=*ZUQ9KVB)F=(G337XJ\>ZP9+Q2D
MSW3]DQZ?EB#K7_RN_P!`VT2?.'F&[@,F\6SCI"57>]2^:-$8IA+.%6D:^DU7
M$VF2/:/7;5RDDHL)"'59.B%$3-U@)#60W,5_E5/H/YU)=>"VKW=FD&DBZB'J
MT3U`[@R"3"6CUVK62BGYVLJJ#.2C'#FQR@I:J@=)0IRE,0P<!MS?Y4KZ%1RB
MV8DZ?MY&BK$HF5DD-]MV#OY,'YFZJ82B*^3/&C8T<56Q,$6K.I`.)]4Q;P#Q
M#_*=_0LB`#\R.^@5M'MWPW,`0N!(>WX0[*:O;Y!*;R<!C_\`!._H6:5^9#?7
MNK_[<-S*]U:?TCW_`/S\!D?\IW]"R`"/S([Z#2X>S?#<P1&T%1[/A#MKI=GE
M$Q?+P`;_`"G?T+);O_!'?0;;_2[X;F#6P'(^;\(=MW+#;Y1.3U0<`H<_Y4GZ
M%1VF@*73]O&P%BV59+&B]]]V7(2BK)>4`TDZ%WD\L4DDY(T`BB:`MD0-I@""
M1CB`@G/_`)3OZ%DE_P#X([Z&LU?2;X;F&NTN>K920\[4Y`;/5:J7JPX`/_E.
M_H64]3_P0WT/IZOI-\-S#7Z7B%=.DCY^IX>-GJM9+[H'`!_\IU]"R2__`,$=
M]#:>KZ3?#<PUVES];*2/GZG(#9ZK52^Z!P'NC_E0/H5FKE)=38?>M^FV7U5&
M;K?3=--F](V4>&.V<*M9MBY(V=E8"43)KHGL63$IR"<I@#Q/_E0_H5W8G>$V
M(WL9D<BHY*S9[Y[HJM6I5!=*`V:*+SD@NJW2!O:D)W"YS%,F(J'$]PA@?\IU
M]"R%W_@COH-HF#LWPW,&MHKAYOPCVW:'9Y0,7U0<`?\`X)U]"SV_^".^G97_
M`.WAN9Z`F#L^$?1M_>$/+P'8;HWVWQ'9L[?:';^/>1&![5],O3KMQA,5(OG<
MF_C,2PC<#J=QG'(]])2"JS^0=LX>,13477.=94Y1,<1,(CP%[.`YU[29;M_-
M]!&SD-N5"9U`8.7IRVA:9)-O\4!JV:-F&)8JW0D&JDPTD(]T1:111.UJW<:Q
M3D,"8@/8!L3CW2SMEG=NT+K<:1R)FQS5LWPH[V6R5M'D--Q".7OF\*_!=X69
MCY(K=J[?&4,^4$YRN553F5-P%K,<RA.6W-RE=.!RIB">"82D))6!<QRAA+D&
M?'O(1R)3'(;4H`@`A4HAZ'`:;?EOMUD.WV31&[#R0QW`GK;'TY>8$6C%1J\+
ME48:`3;*O4'Z(O7D[RZ2!0044,L<H)@"@E,`4Y=]"/2'F#EM.PF79@2+?N&K
M)^UA-Q<?E8V=CV;V4EDH('STDG),G9I)JY6.]9N49@Y$79!<B15X!PG&8V=Z
M9V<%B&$R$FM#-<1PO;+&HQ`F7QS%_(X.SSAL3`6DB(N:/(O*,[43:LUT2)"Z
M?G!%D<BMH`#(G=@NCK>;.<KD1DW[O*H+<R<R+,XB&SU>,Y3.)J-CL(E&+N-5
MD"JLF:KS&W!`;--)N,RYDCA5TX<U!C*='/0\REG;][+3B3C%D)A608N]Q$&A
M(MK'+!&R8NTRK-GZ3R.2P\6ZKO4"1-R"CA5<[DBCC@)'Q[9/I+PV(R=#'LF6
M@I%5;&QGLF:YU#L\HCI)GD6`YIAX>S)MF+]C-8_"*LFG*`6]S31,H^5%<-!)
M=)O2'B$7.9*,MD>+QD7&JOY*49YRT65@X^-G2.SR)'3@9*2;KL\M37%5T8QW
M*SA8S%=15L@U9MPUZ?2;T'R3'#YAHA'EC8R/)DL49OG[=-O/Q2<3%,O$IMLK
M+"K.$Y678&.X6*+D1=ID,IIO%$UPW[+H*Z4I]RAF$/"Y?(Q<S'/%(LT#EJA\
M>-&3SAX_<+0KF(4!1`KM617,1=!P"I"KG`AP*<P"%C]G-D=M-BTIHN`8Y/-'
M62%8?C#(O@!P\F%HU627:KN"H$:LV^BI++@FBW11;-TC`D@DDB0B90FWQ,/<
M$G[T'[?@#Q,/<$G[T'[?@#Q,/<$G[T'[?@#Q,/<$G[T'[?@#Q,/<$G[T'[?@
M#Q,/<$G[T'[?@#Q,/<$G[T'[?@#Q,/<$G[T'[?@#Q,/<$G[T'[?@#Q,/<$G[
MT'[?@-<UDJ/I0>0D^U1I_N@^Y2?Z_`;'Q,/<$G[T'[?@(BWYAMMLXVCS7&-W
MCNX?;B28L1RB2=.&D0W:-6<Q'/V9U7L@"K("FE&J!13534(M73,0P&$!"M&:
M]'_1]F&X:.X^2Q\O^/>3QS9C"R/SC2R:2B47@Q,:YV&AG$\M"+KJX8V7YE4[
M=8CHCEPLL!SK'.(6ZV^BH3"L:QW$,:;S#K&\6P[$L=QYRNJ$LNY@X:-.PBW"
MTF14Y9!15F@416`:*#YP=@\!7/?7:_I0W#W1QF5WF410W-#'XR"QB/=9J\QF
M7<PJDM/MHTL=#-)M@JZ,XF<C<D*J1,3G6TPJ(I)VAIMOM@.D_9^*RG%X![I1
M\N79=Q.MI7,8IP=J>)S9Q-[4.1>(.6JS0^4YXX5/'E.<2.EE`;,2D0!)`H1R
MXVUZ'(Z!:5W.+&,7<7ESUM)-=Q8!N5["F<R$,_*S8I5A@A<<=K2"#5HU:$::
MSQT*B2RBZAA!V0NSG1O&[L82]A\B.3<O;[(XICBV/CGR+F789"M!-N<C%8MT
M^6EEI'*6F'M7DH"AA<.#L``QB)+.4G`7HB)*V+CPY"3[&;?_`',?N1?]?NX#
MGDITN="&Y.294WC5"R.3R>7J97EC*"W,=B^_&)23RC,5$7;(DZKX:J8N])`3
M13(BNG'EBD$A(BR:E(#T>[9](+K$,-P9?*VK=CCF&Y,VQF599O!Q<FOB>0YT
M@URQVW>QZ[6+68366&5C!%NB1!(SE5NT*D:VP&RKM+T//<M?%4R=HYDX\^=(
M2^-)YTQ%!C$1C1U)Y[`R@(.@EX[%HQWDSQ_*('=)('=R)P=BH":"2`2KT]83
MT]8;)YQ-;&3SC+97-5,-FMP7B&4L<G5>.G)IDT=DTF+18H-I7(0UQ4$UJ8@@
M`))I%`P&!A;58CT;8?,X]*X1G;60=R3C#0@F`YE"ECYMV^R"94P821$5X6UE
M$'4\U$T.V,0[)NHQ248I)"=4ZX7X\3#W!)^]!^WX`\3#W!)^]!^WX`\3#W!)
M^]!^WX"/=R)/X(Q\/#I8UVX>VQ:D9"8"W9S`A>H.H%B9?1'MIP$@A*5I\'2@
M5$H=K,0I<*(5'S^P"ZU1\@%-Y.`"REUOP?*!<*8><S$+;Q:AYWG]@$YKSO)I
MG]3V@$E+[/@Z4+?I^G9B%NIR7I_7/-LYWSO)I*>H[0"2E^G\'2I;]+T[,2V:
MO(>R>?YNGS_G^IT5?4=H(DI05)`1Y"4(463/S5$`*)1<+H><9'GA.4$0=^N&
MT``NDH%XV6\`L)*7V?!TJ6_2].S$MFKR'I_7/-T^?\_R:*OJ.T`LI=9\'2I;
M]/TS.ENH#,?/]<\VSG/.\FDIZGM`+*76_!TJ6X"#YS,0MO!L-#>?YHDYGSO)
MIG]3V@!*U`!\.E0K;WL^T+@2'M]<]#5[?]DWDX!G85*B,?,"*$@['\<,S+<B
MH21!'3R:33%H=5/)LE*@JT,04S(:S<41+9RK6F@0'B,K2OP=*C0!'L9B-:`H
M-`\_M$=/L^J8/+P`:5MK\'2HT`X^:SK6P'`]GKG:)N7[/*)R>JX`-*6W_!TJ
M:S4'S68C=I@\'S/7`NU.3\WRZJ?JNP`\K9?\'2IK-7TC,37Z0/A\SS_.U.1\
MWRZR7J^P$C*3%-@UN82:H@S24$4T"N+Z(.U*%5(]>%5,<&=`HJI45D_.&^H`
ML/*6:GP=*FLU?2,Q-?I<_P"Q^?YVIR'F>JUDO5]@!Y2R_P"#I0U@J^D9B:_2
MYWTGKGG`IR7F>753]7V`&E+;_@^4-9J>E9B-VF+L/,\_MOY7S?+J)^J[`22$
MD(M'!"L9(HVF`%!1*@0+3K`)A7.^8D(4=#L$525`Y>WSJ<`K\4_^CY3T?]S'
MT!,'J_1M_>$/+P!XI7L\.E.V@=K,:=HE#M\_N\[]X!X#FE+_`$773%,(9.R2
M)NS!QF4XY#XXI$0;C$&$/%!!9Z\W!@)9K%GPEPPD9''I6=<MF!)1.191\<LX
M0;H)@JL)P?$;TL1VQ^`0V*[(P.998W^?*2W<FXW(7N'1#XAIG::2VS(SB5F\
M1B^/I,XINO%@8%4S/'&@Z<KKN'9CG4Z'].N9X?B-WR.+F<\[;!O..C#7)[=\
MD1>-YL]Q]ZN/6^DTP7B)B)^]VQ/298F[QY,E:3CC6:WUTUB/WMH^/VS!2:'W
M>*)=39;(4`4`3`9?--KD@3)0AC*JAXU>"3<KL@JB0#:=BGJ"5GEN>\+K:M?U
MO28GUF-KN]*Z17UUB)Z_>B-(GTZZ1.LXOM;C^CG^54SQRZ5`BJIL>A$TD'6.
M,G"RN[>SJ:31[F2+)WB3-XJ$_8V=Y*VDT56"0B"CQ,JAFX*`1,3(Y_PJ=->7
MI\/\UW?\7[/MG\WVR>UN?Z/_`.ZJO_4=O%O#M1MSCN^NV.QN<[KR..RF3(8A
MC>TVX>W\QDF;3[B#D(=U$XPVQYCES/)WF+J-G;N4BE^4(=O#OB`L*S=)NMUW
MZ.<'].OJ5SF?PSF/(N.X[A][CP_B-WO-KN/PNUQTSX[3;/DOFPS@C):U<&//
M3W9QYLF/OI%+VR5P.0R[O9XHW&/#>^2LSI6MH[K3,3Z1I.NGK,3IK$3U^#7X
M%T2]%FYFWL]F>0%W)V3--XY@V.YQA,U/8W!P.S>52\YA>80N/M)'+-N(N`E)
MEN]>1<8V34))0J9"J)L$2JN5EG'ROYUX5G\'YJ_&_B*;WB;7R?A=W6<<5W>'
M'DMB]^N.F3)..+VI;2F2:WCTM6LQ,1O-MN8W./OT[<G3NKU^[,QKIK,1K^6.
MB_/3_A/3IT@X"^VWPS<!I%XQ(Y9G6;D;9ME^)-CQKMNJU;9LUC4FZ6/,VL7B
MSJ+6-*F%$SA*02?.9%91X=TJ:%LA:)G,)+N'"Z#9\X;.4V"S==`B;A$Z*Z"!
MB*$%)^N!4S%<`8!TT@,4IA"\`NX#8!*5I\'2H5`H]K,>RX$A[?7.P0U.W_9-
MY.`/%.ROATKW5_F8U[JTI?W_`/S\`#*4`1\.E1H`C0&=1&@*#V>N=HCI]G^T
M'EX`-*4`P^'2HVW^E9B(FL!R/F^?VW<OV>6\GJN`2M9,4TEP%A)JV.I$0,F@
M5<#E*ZDC@4ABO75#!RME@F()3G(6Q.MA05'E++_@Z5-9J^D9B:_2!^/F>>%V
MIR/F^762]7V!D\I9J?!TJ:S5](S$U^ES_L?G^=J<AYGJM9+U?8`>4LU/@Z5-
M9J^D9B:_2Y_V/S_.U.0\SU6LEZOL#X7DO,6(#"3J!%R@8&P%*(D!\`&`YET2
M@4_)^:(F*'KJ?:%U0#P:2M&;81CY0P@V3$1*V!6\2)N*B50'3DJE_*U*.HH!
MM0@W&NKP"H92E?@Z4&EW<SK6T5@[/7.V[1[/*!R^7@`92G_#I3L$0[&GD$P5
M]D[0&W]X0X"L>Q1K]T,]-:<EVT&T1K%"V*%KN_U6#:<M1M,'HAZ`\!;#@.=V
MT.889)=!6SD=N5B>=PV!)]..T+7(YE\SA(ANDR:8CBK1N_:N7TV(*%=/TT3M
M0!,YUBG(.F-1*`;#9#&^FG;_`"=HML[C&<'DXP^XS*,QMKE32?:LEV[[#V&X
M)X^!>9D\64=P#EQ$-)%<I3J$4=(\V<ZQDS@%FL<R165W,RE8<9RF,$F"82EH
MRS!DU4,!<@SX^H0"2:P&(85*!V]Y1K3LJ&GWV)MU,[?Y-&;NB^AMOGK2`;33
M\[MK'F(Z5RB-)`MT%@<+&5=/YTS=%)$J:AE5#E(!1$P<!3F0Z)NC#-7C*>B)
MB7)'O';2.E6D/NW`2T9D\6S=RDNAB;EU)S\N_:D"6BUG)U6;AO)F%FX**]IG
M-P3/D.V72/&16V>%Y3'Q14,4BMIXG;F+6SHC>4,UBLM/(;5/HY*&RMJ_D3O<
MN8+&9N"E,DZ536+4R93E*&BG=I.B3=Y_DN//,?Q!]D&/;C3TEEP,LAB(+)?Q
M\R/<3Q^<3FG?CC*0F32&:Q:S$I3F713,FLR0$ADQ(0-IFG37TFY_*'G)R'3*
M[>9)`9:Y-%[G(QK1[*8WC2^)PP\JVS,K9)DC"P#HIDD"I%652=JGN4.Y,8([
M7Z1^B)ODT:5PS=MIIHLBO%1B^Z@IHE3E8]BO'E;-U\JL<-W3`R1FZXF.HMJ$
M]=.<J-@;_']G>B2(Q[*8:'6@&S/-,$?H3K]WN5#EE%-OEUV*B*XNY/*`.U@8
MXN&(`V64+IG38**',J87*B@(H'H[Z-PD/%X&.D57LF@BB6S=%)THLQ98\DJY
M9(-764++-FBN+.M15-,I-!BL4Z6BF1`4@LSMAGFR$'@D>PVYE\>C\&BS22L>
MD6?@6+-FE(SCETX513E9ELLC'.I:3,+8]H-U"*IZ(BF9.H2(?<K$"`41FHDU
MSCE"@ED&,+'%P!H\ITK$9LYP,CXJV%3LHD1=,Q[2F`1#:1.70\\192$7;S)&
MX-3+FB)2"E01*^;@Z9G5&.EG.D1TU,"B8FH"A!`Q:@->`VWB"GQ9)?8-?PO@
M#Q!3XLDOL&OX7P!X@I\627V#7\+X`\04^+)+[!K^%\`>(*?%DE]@U_"^`/$%
M/BR2^P:_A?`'B"GQ9)?8-?PO@#Q!3XLDOL&OX7P!X@I\627V#7\+X#7-9!3G
MY3X,DO9&E0TVO9[5)_Z7P&Q\04^+)+[!K^%\!#F]LUMB]PJ9PW=3(%L2@LDA
MGCY[3+(_$IES!8])P1YARR7),-9%>+;O))BV?`F51%1-\1NL!BN`(<*[YSTK
M=&69;C?.7EV)QRFXV7LD4(Z<+N(1@HNG'X26!*[@H=MF*4`V,&$MEDU3HM`2
M6;+N#*`;75$X6QV_C(3$,:QW%<4CY-3%L:P_$H'&5#/V\R93'XF-.RB%32YY
M-T:3$[%(@ZXJ'%7TU1K7@*];Y;?])F<[FXX[WL8PY]SE<?C83&6,MFYL=F74
M$M*SS*-1CX=ME49S9%YC(WB95`2,8ZIR@)A%,EH-;$-H^C?97&LOQ^)&*C<;
M?L]IW.5LY'<*,?MFK5CDLADFW3YTH7)3'CT,BR@'CXA[B).Q!82T;)B4@-;(
MMN.AV"C^1R')V3`AFV2.%G$ANHP>KR">-R#C#7!W97>1OF\H;`I>`<QK)$Z2
M@,WB#A("'6U0X!P0^V/1FPW5PQ2*>MB[GX'D<9'8G"'W)!]-Q>0C"MCNXTL6
M[R=U(+R.1-<39O)?4`[AXO')&<&'44(N%X(A^H$7'AX9)#1FW[=-J%?6R_\`
MI?=P'/E?ITZ!-R\CR=HVB8&8R5]F"F2Y:SC=SC`]/DZTIE&;*IR+3\<_@]PJ
MMO<JH5`A45"-%V"*8%18M$T`WDWM-T6R&,XI&Y/+MIG$V6+DB<49/-VT`CE4
M2[K%>%R^`\)R]FHED*NZ4NFV&5CS):C@46PB*:**:8)G.`]#4AECU1Y-0+F6
M8O<T3DH%?="/!FV0BV$E,9M".F8Y251O`1JDS)R+YJ"A6YG3UV98#B2Q$)/Z
M?\5Z=\9E,VF-B'H9%,98IALMN(^:9FTRQV_<N33!XW(IQ09MTHC.3H`X,NHI
M8<^B'F$`*"$,X%MKT-163XKDV!Y45*=D\BP";BBQFZ*`,LNFG$N^0P09."3G
MBQ<\TEGT.FG'MU&YFU8]NLU(FH(+*AT;\04^+)+[!K^%\`>(*?%DE]@U_"^`
M/$%/BR2^P:_A?`1[N3(J!$8_\%2IJ[A[:E\Q)F(%NSF!`3GJ]+:F4.T1"H^0
M!X"0`DE1$H>%2@5$H5%-I0+A1"IJ/!H!=41'ZA#?4J`625-;\$RA;A('G)M/
M-O%J`B:CP>Q/F1NI7V(]*T+<`225,)`&)E"7Z=;TV@`34%D`WT>FII<V-U*^
MP*4K0MX!))4UE8J4)?I5O3:>9J\A6^UX:FESIKZ5IRZM*T)>"-.25._$1C9(
M@&9LJI'%F!R"X70N.9`)8P@5`'1@4."/\0H`'-0A3`L))*GLK$RA+]*MZ;,+
M-3D:WT>FII<Z:ZE:<NK2M"7A@DDJ:SX)E27:=;TV86:@,Q&^CT::7-C=2OL"
ME*T+>`625-;\$RI;K.PR;0+;P;"(&H]$/6^8$#4K[$>E:%N#(22HT^"90*V]
MZ;0*7`D-!]N#Z75$!^J0WU*@S\+E%!CY<0;OWXAEV9%$Z#MK(`W,EDLFD+%1
M4V79*"*K,2:9D060*B(6`U:`'+I@\!DE0`1\)E!H`C0$VE1H"@T#VYVB.G0/
MJF#ZM`#22I0,/A,H:V^EJ;2IK`<"%M7@>GT``M:>R$K2HV@'DE2@<0B94]NI
M0")M!$^F#P0LJ]+[)RH6UI[,G6E36@&DE2WTBI0]FK2U-IY^GSU++GA:ZO)%
MMK3V=*M*GL!(SD54V#7X-DG%&::@'1Y-<%:(/%`L5&5=`H97DR@4154J+A*I
MAJ<2`K/)*EU*1,H>S5I8FT]<TN?IIW/2UUN2+96G\X2K2I[`#R2I+Z1,H>S5
MI8FT&_3%Z`"2KPM=7DRVUI773K2IK`#22I;_`()E#6ZE+4V@WV"Z`!)5X'LG
M+!;6GLQ*TJ:T$C^05%HX+X?(H^:8-8XM44RVF6"\50E&@D*8$0$!U"=BA?*(
M`"OQ)7M^"93LK_%M/0$X=GMWT;:_NA]6@'B2GQ5*=X![&T]$2A7^>5H%U?\`
M0`\`!)*B(!X3*%J)0J*;2A;A1"HT>#V%UA$?]@WU*@%DE3"4/"I0MVG43)M*
M%O%J`W4>#['S(W4K[$>E:%N#7.W)'JC9LZAGBK9XBY:NF3M-B=-=N\19$7(X
M:J2@)N6Y$W9BK`*2X`":@=@6Z@<L<@^C'Z*<6QTT?E<QGN$8[DCS:##(,<BW
M#PC'63*3Q2`:8-BV-8VK)QB*3F<RZ%E7L<=,PNWQ1<N21)F:A6>F#W=8YLAL
M3M/LKMCM3N/MTXQK;O,-PMPFK+<#>7:W&%C8ODYMPX'('L2Y8H(0*4%B^X>Y
M"<<5)I'H,V9$#-P/S!4B..A_3[G>%X2W)X>:S9L&+>[''BI?'BG-,7KO-IGG
MNK&3%I6<>&\:Q:9[IK';,3:U<3=XLF3LG'$3-;3,ZSIT[;1\I^,J@=1[S=PV
MZ\'T\9-T][K9#M+OGE^&2.^.9[6;A-)N&VCPW%,=QM['?C[B9=C,VCI5',9;
M&#HIA'*J/)%NT7CE0:I.$G)_IC9>"?3?ZF?2#?<[N/)=KQW.\1M[5X[;;G9X
M<6YY3<9-Y.2^/:[G+R=8ICPTS17<QGQ13'7).?';+-+4::VZWFSW]<48;7Q9
M)^_:+3,4B*Z1-HBG69TZ:3K.FDZ>IVS71-]'U.PK*`59=4Z$8SD-SI%N@]V^
MW4RPY3[M9`ZRZ;;.5\]VDR]9ZRALLR60DF::QE;GCEP=V+P!3#CYF_W7^6_+
MC/\`Y3C/_&?;^[\ITW/XW!_'_D7_`)KI9CF_FUF+PL-$-4MW'4;'Q$/#1JC_
M`&FWAF)D6T,Q91I%9I0^+.Y`'ZI1*919PDB=R8#J`*E;AMU^F?EMKVIV\?$U
MTZSR7&Q$Z]?NVG=Q6VGQ[9GMGI.DO?QF#U^__(O_`#6Z#J@VP&GM#=?MM[]C
M=Y/X0)"'_P"0_H:P?O#]2MS_`'7^6_+C/_E.,_\`&//QN#^/_(O_`#2N.ZE=
MLI.1BXI%'<)H[F9)C#QQYK:?<O'8]63E%DFT<S5F)_%8R'9JOG2Y$DA773*=
M4Y2`-Q@`;.Y^FOENUVN;>7Q[*^'!BOEO&+?[#->,>.)M>T8\6YODM%*Q-K=M
M9F*Q,^D2]KO,%K176T3,Z=:VB-9].LUB#S>;P;91[QY'O\\PIE(1R.0KOV#O
M-</;/6*.)&9$RI5XV6GB+-D\:4DVI9`QP*5D9TB"PDU"U@;**,5W4P'/$WJN
M`Y5C>>IQJ48O(FPK*,7R@&",Y&'F8)9Z,--O`:)3L4!'#,REI7**Q%"")!$P
M`Y&TBJFDM\&R2]KF0,!DN36`]KJ2-I$,,JX$#E%J"=HF):=0@6)A<5,%1Y)4
MM](F4/9JTL39^?I\]2RYZ7V7DBVUI_.$JTJ>P,'DU2:E(F5/9JTL3:#J:7B%
M-.YX6NMR);*TKS"5:5/8&3R2I=2D3*'LU:6)M/7-+GZ:=STM=7DBV5I7F$JT
MJ>P/E:05L6*$9)=A5R@>UH4@V`^`#`<S]&TI^4*)1$Q.Q=.HEJ>P/!I)*@S;
M?!<FI1LGYY`:*`I:FX\XB@R;B\%.6`2B*AZZQ!N&IA*"D9)4!,'A4H-!,%03
M:4-:*X5+5X'8;1"G=[(7ZM`!DE0K\%2@T$0[$VG;03!4/;G<-M?]`AP%8]BS
M7;HY\:TQ+MH-HAM.`%.6N[_58-IP`3`!@]$*CV\!;#@*%=/KYCGG17L)A.0[
M8[G/(*7Z>]HHIZ+5I!,E7*+3!\<TGK)?\9R+)HK*M"+H&,4!,F)1,4*B7@'%
MM9L?LGLSD;;+=O.GO<2"R)E&ST)'RAG2;]6/@<D=P[Z5@VZ+W/7+8T<L\@6J
MI04344*J0RE]ZBICA,3;)YI+.)K(#[:[AA'OL4QB';F!CC0J&>14QESUX4Z0
M93J$(5"80$IA"TPB(`-2CP&KW&;Q>Z6,3.'9=MAN8[QN>:LVT@T9I0C%X<T?
M)MY1L8CA'*"T2!PW+<41$#`%!`0'@*AY%T-=..0RJ$G\SN_$6F8[5O.1;/(F
M;QADL`R>FE&^+R9IO+9=^UBB2X).159+M7ICI4%>U10#A.CC9S:1SCF(XJ?8
MK<Y.'P>!QC&,?2;N63=5O`XE(C*Q4>JNCFQ#JE%XH<RJO8N;4-0Y1H(`CRO8
MC8G,T7B<UTV9D5>2F\OR"4DHMI$0\S+26?SHY!F:DI,1F9-I&0+D#E11!0%5
M#"BT5,B@*1`*!0CEST;],[R0/+.NGK=I>44:L62T@I.F,Z6:1T/(P#9JHJ.>
M=K7P:0*V52"B2Z3=(JI3AJ`H#SS#IVV-SJ"C<?R38?=MZUB=O<6VL9NB3SAO
M(AA&&RZ$[!1*[Q'<,IW2R$FW*H=TH!G:H>:902@``#,DNC?IGE'!'"_3YO`F
M";UO()MV^3O4VA7J!RJF<"W'<0Y%5'*R*1E+[@JB4"VE,H!P?.(]/6Q&$S7X
MP0?3SN/XJ0KQ)LXD7:,J#)M))OBRK-HD_P`[732:2R\L\6<DH(*J.E`'UL"$
M(&C==+NPLK.1.19)L?O7F$I"0"F,1ZN898_R5%&"'UMM&@TEMQ'+8&T<U(FD
MW*!0*0$BG$!6$ZIP8P=#_3=I#?LKOB=Z@_RY]$2!LB0`T$.5OYJ02:QT<3,B
M0QV>-JSRQ6)'#9<1*!0<BXM#@+"[&[>X3T_8^>#P3:G=473]JR2R/(Y=#&G4
MWE;UF_FY3Q>:,VR)I'>(.)'(WBAN7;-TBE5!,A"IIID*$X?.`^_-MN-\G8[^
M4_`'S@/OS;;C?)V._E/P!\X#[\VVXWR=COY3\`?.`^_-MN-\G8[^4_`'S@/O
MS;;C?)V._E/P!\X#[\VVXWR=COY3\`?.`^_-MN-\G8[^4_`'S@/OS;;C?)V.
M_E/P!\X#[\VVXWR=COY3\`F1S>02<.UQVYW#$'1T3%(6.Q^\@)($3&^N3`7S
MA#LH(]G?P"GYP'WYMMQOD['?RGX"+]S8#%MV623+,-JMVU="-E(EL]A7K3'Y
M!O'3CJ&=3#,CN(S5FJ=M*&@&R;A,]Z:S<#HG`R2JA#!"F8=*W37GF?RFZ>3]
M,NX#_<&6:M6SC)R/A:.D>3QI'#T%V#%IN"C#Q[C\6DSM%#(MB`LDX7!0#<PM
M>%D,,?-\"QV`Q+'MLMRF^.XQC6/XK`M'*41(/&L3CC(T:P1=OGV5KNGBQ6I"
M`*IU#G.(5,-U>`BW<[:+9S>+*F&:[C]/>X&39-%PJ&/,9159-B9"';JSJZ3(
MK>,SYBU,4JV2/#"8R8G,*@5$;"6@R<6Z:=CL)QJ6Q'$]DMY8*"G%\.7E&;#(
M!2*\'")23G(MNX_]>Q*O'OYJ:>.I%H<#-7ZC@P+)F3`I"AZATT[`H1:<)%]/
MFZ$+$(GFU48Z+E1(R36G'[N64/RKK/W:!THR5DG;E@@8IFS%9VN**9`4,`AL
M8WI_V3B,LP_-(_8?=9"?P)TR=XFZ/+\R2'6;,8MDZ,BF[SYQJ#.#`QR\F8XF
M4D7#!%1P90=0%`LHRS>09LVC4^W.X:AT&R*9S)QV/V7E3*!P*)LF*(@4W96E
M!X"H>0])/3%E#V7D)?IBW!6=Y!DRF73:J<DJEXE.+Y!N#DZ[E8A=Q--(BLON
M?+&L2!,"HF;($M18LTT`=TUL3LUD.%XW@<QL7NL\A<29OF4&N:212F&993)6
M>72KDLLAG*;OGY"=9`L9P!@52`YRHF3`W8&H>=-6P,ADS?*WW3WN@ZD6I95N
MW;KRNI%I1LWX@K)PJ4<;/A;HPKV0FI!VLV(!4UW,@X,J!P.!2@_-L-M\"V?D
M<IF=O]H-TXV6S=Q#O,QD)1XUF7>1R$4H\,:9?+R.9NSK3\ASQQ<.3"`JB4M1
M`"@'`,#&^FO8W$IM+(8#8_>*/E`F<:R!XJC/6MIB6Q*;8Y#!N9J.+G98Z3*S
ME(:..1-1(4T_#D-,I/715"V/S@/OS;;C?)V._E/P!\X#[\VVXWR=COY3\`?.
M`^_-MN-\G8[^4_`-3,,GFIR/BVS';7<(RK3+,-F%0498TD7DX3)XJ5?F`Q\I
M*`G(S:'$I0J8Q@`H!4>`=?S@/OS;;C?)V._E/P!\X#[\VVXWR=COY3\`?.`^
M_-MN-\G8[^4_`'S@/OS;;C?)V._E/P'@&=2/-&7^;G<;3%N1(">'P/IP54,)
MK?QN%*MHAVZ0&_UA#L`/?YP'WYMMQOD['?RGX`^<!]^;;<;Y.QW\I^`/G`??
MFVW&^3L=_*?@#\?WWYM]QOD['?RGX!O8UE\W&M)%)_MUN6=1QD62/D!59PRQ
MN1?33UTQL,ZW%R$Y$>45)ID*JW(0E"E:M`#ETP</S@/OS;;C?)V._E/P!\X#
M[\VVXWR=COY3\`?.`^_-MN-\G8[^4_`'X_OOS;[C?)V._E/P'@USN10;-TE-
MN=QCJ)H)$.;P^!$1.4@`:HJY:X4$0'T144_VC=_`>_S@/OS;;C?)V._E/P!\
MX#[\VVXWR=COY3\`?.`^_-MN-\G8[^4_`)W6=2*[=9)/;G<8ASD$"F\/@0$!
MJ`]@I9<V.`C3T%"?Z>`4?C^^_-ON-\G8[^4_`'S@/OS;;C?)V._E/P!\X#[\
MVVXWR=COY3\`?.`^_-MN-\G8[^4_`)U,ZD3N&ZH;<[C`1(JX'+X?`A<)RD`O
M87+B)C2@TN34^H)?1"']]<+QSJ$P^-P7.\!WJ0QUAE^-9BX:XV;%8LTRYQ9Z
M+]E"S2CB;>\YCSUP)1=-R@F98I`"\H5J%*YGZ,WI*EH&"QI/9[J-C8C&HB=A
M(5%',(V8<LF,QDD_DS(2R&69'D<@H[Q-WE\RG#+G5,JP)**JE,+I%FX;!87/
MV&[3K<G)<FQ79#(,AA)Z$PQHDM+Y5C>-R+1WCI)M%V@HT68Y1S**B3](Q%N8
M()CW%$@6WF[3XQY1XE@\3V?$<MO=UMM_ML^YM,4VLYZVKF]J:SW_`(K!I:)I
M:)KVVZ:3W3,S6NNS8<\Y[9,=:VK:(];:>FO\6?F;0-=_`MKTX/NRWNW+Q3^"
M*(C3_P!3`^Y#^^'U:;>?)O`?];;[_P".M]O_`+C]O[/C;]G=?T=?Y?\`>,@T
MWZ`"4Z<I`3!;<'SD8F4H6BVH)#_B@83U!$>\I*=G?Z%$>4>"6O:L\GOHI'I/
MZOF>[7NUZ?K#6--8CKZ]7OL[K3]"NO\`;_WCY*UW]"VO3@^&EG_VS,5_@\M7
M_P#(ST=$?WPXN3Y-X!.NG+;[X_\`IUOXW_N/VO/9W7]'7^7_`'CT9PF]LA-8
MCXKL-*P<7$9IAV22,FUS;&9QTDSQF=BIE=)M%)0,(9VN[+&BD4.:2`HG`PU`
MMHT9_,/"=ML-[^#W^\W&[S;#<X*8[;*<59MGPY,59G).\R]L5F_=/^#MKIIT
MUUA&WW-K5[JUBL6K,SW:^DQ/IVQ\OFTN<]$73AN#N-DNZ$[LMO@AD>9L]P&>
M5MX:8AHB&GR;D1K6/G32,<SR0@*BBJV%Z@0#E1-)'!TX(NNBV.AP%M3]Z7.F
MW:;I#7W%<[2;:;[<SNF[QR2S%QEDECN0*/93&V\L1.10^'6@-74J]GWKMT!0
MT@57!)`J#5%NW2"U[?.Y%),2GVYW&,8R[I7^CX$1*15TLHF414RU<>Q,P4H8
M"@%``I/2%#W^<!]^;;<;Y.QW\I^`/G`??FVW&^3L=_*?@#YP'WYMMQOD['?R
MGX#Y/GS\Y#$#;C<8HF*8H&\.Q_L$0$`'S<I(;L^H(#]4.`^&^>2"2""9]N-Q
MC'312(<PQ^/B)C%(4#"(GRQ<XB(AZ)SCY3#W\!Z_.`^_-MN-\G8[^4_`'X_O
MOS;[C?)V._E/P$1[.1S^*W:SYG)M%6#WYE]E7:K)<R!W#4LCNCU22""+@6RS
MAN#@C=T0%"D4.4IZ@!AI7@+1<!7?I#_]T_IB_P#T>]F/_O<XYP%B.`.`.`.`
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`A2!_]XS=3_[BFP/_`-G74IP$
MU\!7?I#_`/=/Z8O_`-'O9C_[W..<!8C@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@(4@?\`WC-U/_N*;`__`&==2G`37P%=^D/_`-T_IB__`$>]
MF/\`[W..<!8C@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#
M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#
M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@(4@?_
M`'C-U/\`[BFP/_V==2G`37P%=^D/_P!T_IB__1[V8_\`O<XYP%B.`.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`A2!_]XS=3_P"XIL#_`/9UU*<!
M-?`<M^GQS)8ML)TT8]/]6&Z^(KR72K@.X3)`VV^S9L8C\6QS!,3+,-F^2O=F
M7S55>$3D$0Y=9VL^%$Q#GN,H03A+>`Y2;<W)E<3POK$WFEI(D;/2S5T;:?9Q
MA"2K'%YF,@,A6A9V0V*:Q4OX1+3+5%<&ZJ@D,N7ZM`FOYI-UOVJ-V/[$=/G]
MSG`'S2;K?M4;L?V(Z?/[G.`/FDW6_:HW8_L1T^?W.<`?-)NM^U1NQ_8CI\_N
M<X`^:3=;]JC=C^Q'3Y_<YP!\TFZW[5&[']B.GS^YS@#YI-UOVJ-V/[$=/G]S
MG`'S2;K?M4;L?V(Z?/[G.`/FDW6_:HW8_L1T^?W.<`?-)NM^U1NQ_8CI\_N<
MX`^:3=;]JC=C^Q'3Y_<YP!\TFZW[5&[']B.GS^YS@#YI-UOVJ-V/[$=/G]SG
M`'S2;K?M4;L?V(Z?/[G.`/FDW6_:HW8_L1T^?W.<`?-)NM^U1NQ_8CI\_N<X
M`^:3=;]JC=C^Q'3Y_<YP!\TFZW[5&[']B.GS^YS@#YI-UOVJ-V/[$=/G]SG`
M'S2;K?M4;L?V(Z?/[G.`/FDW6_:HW8_L1T^?W.<`?-)NM^U1NQ_8CI\_N<X`
M^:3=;]JC=C^Q'3Y_<YP!\TFZW[5&[']B.GS^YS@#YI-UOVJ-V/[$=/G]SG`'
MS2;K?M4;L?V(Z?/[G.`/FDW6_:HW8_L1T^?W.<`?-)NM^U1NQ_8CI\_N<X`^
M:3=;]JC=C^Q'3Y_<YP!\TFZW[5&[']B.GS^YS@#YI-UOVJ-V/[$=/G]SG`'S
M2;K?M4;L?V(Z?/[G.`/FDW6_:HW8_L1T^?W.<`?-)NM^U1NQ_8CI\_N<X`^:
M3=;]JC=C^Q'3Y_<YP!\TFZW[5&[']B.GS^YS@(VW33R79O&4LNSCJQWG:0JT
MS&01%H_;38F4.1]*J*%0,X*TV7.1FT3(B<YUEC)IA:!"B94Z:9PC9?>3;UD\
M=LY/Z0W(X4S0T:474]C/3]!QCLLL=0C):-E9;99G&R;<Q4A5.H@JH1)N)5SB
M5`Y%#!X?/9MX1E'R+OZ0;+HUE)2F10R#B8P_82'*C(XO*HPLNW?IR>RC5:-,
M1^Y2!+7*GK)JE4)<F-W`/G)YU7#HW.)?(^LO=J-8[<RS^#RY9?;'94GA\G&;
M=$W8?(MP/L87Q1%'`#^(:[760,4IDBG%8ADP!C-=[MM74:TEO_B*3S1F\A6V
M0IGD<=Z>X\Z42ZCV4BBY<D=[,)"WN"01;6GH89!0K,`%V.CP'HOO-@"3F):-
M_I!LLDU9J3+%M#Q&)[`2;5)0S-Z_!Z_?--EU64=$';1KG3=K*$;KJ-EDTCG4
M14(4'NC-.7.5XMA[7K'W==R&;0$9DV)R37;+9)QB\_#S)3GBW,;E2.QY\?<<
M\0""D`./7-9,"U$X!P$O?-)NM^U1NQ_8CI\_N<X`^:3=;]JC=C^Q'3Y_<YP!
M\TFZW[5&[']B.GS^YS@#YI-UOVJ-V/[$=/G]SG`'S2;K?M4;L?V(Z?/[G.`/
MFDW6_:HW8_L1T^?W.<`?-)NM^U1NQ_8CI\_N<X`^:3=;]JC=C^Q'3Y_<YP!\
MTFZW[5&[']B.GS^YS@#YI-UOVJ-V/[$=/G]SG`'S2;K?M4;L?V(Z?/[G.`/F
MDW6_:HW8_L1T^?W.<`?-)NM^U1NQ_8CI\_N<X`^:3=;]JC=C^Q'3Y_<YP!\T
MFZW[5&[']B.GS^YS@#YI-UOVJ-V/[$=/G]SG`'S2;K?M4;L?V(Z?/[G.`/FD
MW6_:HW8_L1T^?W.<`?-)NM^U1NQ_8CI\_N<X`^:3=;]JC=C^Q'3Y_<YP!\TF
MZW[5&[']B.GS^YS@#YI-UOVJ-V/[$=/G]SG`'S2;K?M4;L?V(Z?/[G.`/FDW
M6_:HW8_L1T^?W.<`?-)NM^U1NQ_8CI\_N<X`^:3=;]JC=C^Q'3Y_<YP!\TFZ
MW[5&[']B.GS^YS@#YI-UOVJ-V/[$=/G]SG`'S2;K?M4;L?V(Z?/[G.`/FDW6
M_:HW8_L1T^?W.<`?-)NM^U1NQ_8CI\_N<X`^:3=;]JC=C^Q'3Y_<YP!\TFZW
M[5&[']B.GS^YS@#YI-UOVJ-V/[$=/G]SG`'S2;K?M4;L?V(Z?/[G.`/FDW6_
M:HW8_L1T^?W.<`?-)NM^U1NQ_8CI\_N<X`^:3=;]JC=C^Q'3Y_<YP#>VIQC)
ML7Z@-X6^3;DY-N2NYV=Z?EFS[)H;!8=Q&I%S7J4(=HV3P;%,4:KHJG"\1735
M4`WI3`'9P%H^`Y@;3.XB)V<V1B\JQ'I<RF4C>D;"V#?)YC>/.HMSD>S+/#8=
MN_GD8S(.G%G,1V/RZ29G&@X12>(D4.0Q"B"H`$M[934-^-3?YIMM.E3\;OQ(
M#E_Q2WQR'Q/\2?%&_,6\GT]5Y;Q?0YNOKVMHZ_;I\!83QK?W\VFS_P"G'-/\
M/7`'C6_OYM-G_P!..:?X>N`/&M_?S:;/_IQS3_#UP!XUO[^;39_]..:?X>N`
M/&M_?S:;/_IQS3_#UP!XUO[^;39_]..:?X>N`/&M_?S:;/\`Z<<T_P`/7`'C
M6_OYM-G_`-..:?X>N`/&M_?S:;/_`*<<T_P]<`>-;^_FTV?_`$XYI_AZX`\:
MW]_-IL_^G'-/\/7`'C6_OYM-G_TXYI_AZX`\:W]_-IL_^G'-/\/7`'C6_OYM
M-G_TXYI_AZX`\:W]_-IL_P#IQS3_``]<`>-;^_FTV?\`TXYI_AZX`\:W]_-I
ML_\`IQS3_#UP!XUO[^;39_\`3CFG^'K@#QK?W\VFS_Z<<T_P]<`>-;^_FTV?
M_3CFG^'K@#QK?W\VFS_Z<<T_P]<`>-;^_FTV?_3CFG^'K@#QK?W\VFS_`.G'
M-/\`#UP!XUO[^;39_P#3CFG^'K@#QK?W\VFS_P"G'-/\/7`'C6_OYM-G_P!.
M.:?X>N`/&M_?S:;/_IQS3_#UP!XUO[^;39_]..:?X>N`/&M_?S:;/_IQS3_#
MUP!XUO[^;39_]..:?X>N`/&M_?S:;/\`Z<<T_P`/7`'C6_OYM-G_`-..:?X>
MN`/&M_?S:;/_`*<<T_P]<`>-;^_FTV?_`$XYI_AZX`\:W]_-IL_^G'-/\/7`
M'C6_OYM-G_TXYI_AZX"*]XIK(/Q./\]FVG3M^)/B+74_&_?'+O">>TG-NIK=
M/5NGX?S/,U]:Y'7U_:^MP%?9":V"\!A_%MM.A7\7?QD5\#\5WQ7\/\=N;:GA
MW/=/5G*<EH>D]I^&:=/:=G`-A*:Z6[%__#3H.NOB-;G=\7_/<WXJCR7\^Z>N
M>\4\6LYJGMF_^<]G`6+W!F@%)U\XFVG3.#?YPX'QKQ;?'*N4^<$,0;^"!E5O
M3R+?FQP71_I'UCPS3O\`6K.`IPVF>C,,FG!#;?HO&4!UNOXT62WPS[\6Q6-/
M0)L]$GB73N&)\JGDH-@B^7'0Y\5O"JK\R/`37(36Q?B..^(;:=#/B'@O_J]J
M[XK_`-":LMR^G3IZT-#6\2Y75\Z[GM'_`'K@'A%36)#GN)_BYMKTN!G(8YM\
M.+AC.^.87&P[P_)@VL`/!>GD8O\`%?E1D1@M:C34`>5\^S@+/>-;^_FTV?\`
MTXYI_AZX`\:W]_-IL_\`IQS3_#UP!XUO[^;39_\`3CFG^'K@#QK?W\VFS_Z<
M<T_P]<`>-;^_FTV?_3CFG^'K@#QK?W\VFS_Z<<T_P]<`>-;^_FTV?_3CFG^'
MK@#QK?W\VFS_`.G'-/\`#UP!XUO[^;39_P#3CFG^'K@#QK?W\VFS_P"G'-/\
M/7`'C6_OYM-G_P!..:?X>N`/&M_?S:;/_IQS3_#UP!XUO[^;39_]..:?X>N`
M/&M_?S:;/_IQS3_#UP!XUO[^;39_]..:?X>N`/&M_?S:;/\`Z<<T_P`/7`'C
M6_OYM-G_`-..:?X>N`/&M_?S:;/_`*<<T_P]<`>-;^_FTV?_`$XYI_AZX`\:
MW]_-IL_^G'-/\/7`'C6_OYM-G_TXYI_AZX`\:W]_-IL_^G'-/\/7`'C6_OYM
M-G_TXYI_AZX`\:W]_-IL_P#IQS3_``]<`>-;^_FTV?\`TXYI_AZX`\:W]_-I
ML_\`IQS3_#UP!XUO[^;39_\`3CFG^'K@#QK?W\VFS_Z<<T_P]<`>-;^_FTV?
M_3CFG^'K@#QK?W\VFS_Z<<T_P]<`>-;^_FTV?_3CFG^'K@#QK?W\VFS_`.G'
M-/\`#UP!XUO[^;39_P#3CFG^'K@#QK?W\VFS_P"G'-/\/7`'C6_OYM-G_P!.
M.:?X>N`/&M_?S:;/_IQS3_#UP!XUO[^;39_]..:?X>N`/&M_?S:;/_IQS3_#
MUP#9V\'+G.^.Z<AFC'"8.65VIV/9H0.)9=E&8.$8YIE_4`NC+RCZ;VUP&-:H
5R;E\LBV2;*O5[F2QERMRF;BN'__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
